{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "nVA9y676w7oE"
   },
   "source": [
    "# Custom Named Entity Recognition model with spaCy(clinical named entity recognition)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "3TDI0u8BxmOS"
   },
   "source": [
    "![download.jpg](data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wCEAAkGBxISEhUSExIREBUXFhcWFxYVFRUYFRYVFxgXFhUXFRUaHSggGRolGxYXITEiJSkrLi4uFx8zODMtNygtLisBCgoKDg0OGxAQGi0lHyUrLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tKy0tLS0tLS0tLS0tLS0tLS0tLf/AABEIAKQBMgMBIgACEQEDEQH/xAAbAAABBQEBAAAAAAAAAAAAAAAFAAIDBAYBB//EAEUQAAIBAgMEBwQHBQYGAwAAAAECAAMRBBIhBTFBcQYTIlFhgbEycpGhFCMzQlLB0QdikuHwFUNjgqLCFjRTg7LSJHOT/8QAGwEAAgMBAQEAAAAAAAAAAAAAAgMAAQQFBgf/xABBEQABAwIDAwkEBwYHAQAAAAABAAIRAzEEEiFBUXEFMmGBkaGx0fATIsHhFDNCUpKi4hUWQ2OC8SMlRFNicsIG/9oADAMBAAIRAxEAPwDJVlszD95vUxkmxf2j++3qZFNwWZS4QfWJ749ZpZndn/aLzmilrDiecOCU4Z2cMF1lmSiiii1aUhffJpE++A+yZTumyti945S1KWK9rylMunhRSP8AvU5r6ySRoPrU5j1jhdENJ4HwR2cfceRnRONGLCssIQpDsjkIPhJYt66daw4p0UUUBZ0ooopFIUVbhI5JWkUsFOZZWsN7PnJpFh/ZksNKdcqrit45S3s1eyfFj6CVcVvHKXsCOwPP1MU+yJ3MCsLHxqzsFtlgq85dinIoSWuxTkUiiAY1frWH7/rY/nLUj2gv1w8bH+vhJIRK6jjLGcAlLKUs1IjnbmN0rS/gvZHnLZdZ6lkGnYRfZ4uYpMqrOEIxf2j++3qZHJcX9o/vt6mQwwV0VZ2aPrV5n0M0MA7KH1q+foYekWLE84cEpwzs4ZTrLNCUUUUWrSkT75LIn3wH2TKd0pQxHtGX4PrHtHnKZdPCbG0R9cn9d87Fh/tk8/Qxzboth4FGZydihrDCyyiE4OTeOcIQHro1rhdiiii0lKKKKRRR1t0hk1bdIpYTmWVrD+yP64yaR4f2RHwwkm5VfF7xL+FHYHKUMXw84RoDSLqK3c0KQR0QigtssVXnJRRRQpS0ooopJUQzaK/Wof3fS/6xss49dUPvf7ZWkW5hljeHxKUv4P2B5+soQlhR2B/XGGy6GpZTxTsUNKhZfF/aP77epkckxf2j++3qZFKXVV3ZA+sHI+kOQJsYfWf5D6iG5aw4nn9SUW/QXJO4DeYjNZ0X2aFUVmHabVb/AHRwt4n0guOimHw7qz8o6/XrskrL4nDvTNnRkJF7MLaR1fDVEALoyBtxIIvD3Tz2qPJ/VJptoUFqKUcZgd4/PnEhyfTwge9zAbRHZK81kL75e2hhDRqNTOttQe8Hcf67pRffI+yzNaWuLTcSuQe+88zCMGSqe1PC7FhR9cvI+hnI7B/bD3T+ccLqGx4FF4o6KGsSy6e15wiiFiFUFidAALknwEH8fjPT+h+xxRRarD6xxfXeqnco7j3/AMoqoYXVFE1XwNg1WExWFqUmyVEZG7iLGx3W753F4KrSt1lN6dxcZgRflDn7QtrUaeLo3bMUVSyrYsLOWsRwNuB75efprs7GDqahekG3GqoUA8CHBIU+JtAkoW0WlxbmjisdFJ8fhGo1GptqVO/gQdQRzBBkEtIILTBumVt0hk9XdIJYTKdldoeyJLI6W4cpJDBSjdV8QNV5/pCFHdKVQdpfOXaO6KqKzYKRY6NWXdk4E1qgTcN7HuA/M7vOU2yyupl9QNbcwoaWGqMpdUZlXewBsPOLD4Z6l8iM9hc5QTYT0OnSVaTKoCqFIAHdaAOgfsVfeX0MkrVUwQZUDCd/duWVnZpulGzQQa6ixHt24jv5j05TMCQGVmxOGdQfkd/dVsfuHOUpcx53ef5SnCTKXMCUJ4b2RygyFMP7I5Q2XUqWU0UdFDS1gsQlbO3te03HxPjI8lb974/zhjF/aP77epkUABdA0ukqlhqWJJ7HWXtwYDT4yz1GO/xv4x+sLbEHabl+cMy4WWqcroWSTC49iFHXEkgAZxqToPvQyMBt0aA4kf8AeT/3h7Y329L3hN3BK34GiKjS6SNY009XXjG1sJtVSvXnEX1y5qqnuvazcoQfAbe4nFf/ALL/AO82nTrfR5P6pNRiN8AGVVCiHVXNkiIseheJ7SwG1RZq30juBaop7zb2ucLoDYX32F+dhebbpb9iPfHoZjX3yn2SsTTFOtEzpOt019x5QfL1b2TylGUyyWEo7Bfaj3DGyTAD63/tn1Ea06qnc08EViiijFjQTY2G63E06Z1DNr7oN2+QM9I6WbVOFwtSsvtgBU8GYhQbeF7+UwnRAf8AzqfvVP8AwebXpvs5q+Cqoguws6gbyUIYgeJAMRUuF6HDz7J5bf5fNeUbF2Z1zq9XMyvUAJubuSwzktv475uOl/7PqCUWqYUNTZFLFCzMrqNSO1chrA21mM6O7UVWpI7BVWoCGO4AsC1zw756L0y6Z4ZKLrRqpXqOpVRTIYLmuCzMNBa+7eZRmViw4pEOz2j4Lz3Y+OZ1CMb9WAFJ35LkhfI3t4EDhCEo7C2cy0PpB0V2yJ4hQSx5XsPIy/LN1nIIid39kypukMnqbjIJAm07K5S3DlJIynuHIR0YklNI7Q85aoyuBr5H8pZocYl51VFKsDla2/Ibc7aQPs3Z+1iC1H6RY6Eiqovbh7XjDgmz6Lf8uvNvWRhTMJTFSuWkxpOl9gXnhwG3bHXFWtr9cu7j9+U9k4TaxDfRzibXGbLVUa8L3aezn2H90+hme6DfZ1ea+hlkrRWpBtdrJOs7ddiwb7O24QQfpJB0INZbEfxwMcNjgSPrgRoe2N4857lMBj/tanvt6mUHKuUaIota4EnjqsRVo4z73W+bj9ZH1WK/xP4h+s0+N9ryleFKxs1EoB1WK/xP4h+snWhjradbb3x+sMwnS9kch6Qm6oXmFmOox3+N/GP1imtihQhzrM4v7R/fb1Mgk+L+0f329TIpF00R2GNW5D84XgrYY9vy/OFpFzq/1hU2AfLVpt3MPhcX+U9Anm7T0PCVc6K4+8oPxF5RXT5Ldo5vA+u5Z/pzvocn/wBk1NffAXSrZdat1XVpmyhr6qLXy23nwMO1xrFtumYYEV3nh4LN9MH7FNe9ifgLfnMm++aDpdWvVVPwi/mx/QCZ998GoseKdOId0adgUOJ9k/1xlKW8X7PnKctlksBdkuzx9Yf/AK/9wkMsbOHbPufnDF1Tx7pRGKdihrGh3RyplxlM/wCLl/iuv5z1SeO5yrlhvWoSOYNxPYaNQOqsuoYBhyIuIp916LAu5w4Hu+S876e9G6JxdPqx1JqgFyoupZnKlsvA8rXl3Bfsxo02+urPXA+6q9WDz1J+BENdJ9j162JoVKaZlQLmOZRaz5joTc6TR1xrBzFIw9BjqpzBYrpuFRaFJFCqM1lAsABlAAHxmVh3pnXzYnL+BVXzPaPqIDkBWfFGazuzsTKm4yCWHGhleECgpq8u4co6IRQwUpdUSahxkQ3SWjxiX3VFTCa7ok96JHcx+YBmRE0PQ+tZqid4BHkbH1Hwl0ymYJ2XFDpBHctQ3sv7p9Jnug/2dbmvoZospKsAN6kDnaCOi2zatFKgqLlJy21U3sDfcTLfdbq7T9KYeKJieeVHzMzd5v8AEkzd7SrZKVRu5T8ToPmRMCsEJPLD9WN4nw+ao4s9o+XpIZLiPaPORwpWNo90LkKINByEGQoo0hsQVdikinOtXvEUKUqFmcX9o/vN6mRTge+vifjfWOkXWRbYe5uY/OE4N2IOy3vflCMi59b6wqXDYZqrrTQXZjYfmT4Aaz0bZ+zuoprT1NhvI363PlrAv7OcGpapVPCyKe6+r/7Ye6PYnGVFrfTcPTwxWsy0gjZs9Eeyx7R18dL9wi3mVrwtPK3Nv8FLlnQnnIK20qKMVaooI3jXSEdl1UcZlIYHiP674kVGOMAgniFsdSeBmLSBwMeSwvTDYrIxxAuVYgN+6bWH+U2+POZV989L6KYrH4hcQu0cLSw4D5aYXc6G4YHtNcDTtaXvu0nm2JTK7KODEa79DbWE+ywVacPzDb4qpjNw5yrLOM4ecrS2WQhKWNnDtt7o9TK8tbO9puS+rRguqqc0q/OxsUNZEM2ds58RX6mn7TVG14KAdWPgBPX9n7PFCklIZiFULdt5sLawD+ynAKBXrkDM1Q0we5V7Rt3XJH8Ih/ZuJxr18UmJw9KjRRwMM6Ndqqa6sMx1sFO5bZiNbXinGSutTECd6nyzop30teV6u1KCkqaigg2I10MKbNdHAYEMDuI4iKbUY4wCD1hPdSe0AuaQOkHivL+nGwXo1DXGZqdRtSfuOeBPceHwmYntDivWfFUcRhqaYayrRcOGaqrKc5ZPukG1t3nvniyw1irNgzvSbcZWlsysJYUpq/FOxQ0hOA0Eko7407hH0d8U+6gUomq6HbHYn6Q1wuoUD73Ak+EzNCkXdUG9iF/iIH5z03C4nEJjFwq4QDBrRuMRnGjDQJl/rvlNR0KU1M52eKlyxZZPtKslPtMwUbrn5SnhtoUXYKtRWJ4a698o1GA5SRPFdFtJ5bmDTG+DHbZRbW2T9IpMmqk2sfEG4v3ieb16LU2ZHGVlNiD3z1/A1Kpq1VelTWkoTqqgfMz3Bzhkt2LGwGpvMf8AtJoKGpOBqc6k94GUi/K5hrBjKUtz7R4LzqodTzMbFFIlwuwsIKEt7Tr9XSd+5TbmdB8yIbEqpsWVxG03LsQdCxtrwvpFBoMUYrhEsDUuWHcxPxMtQaGyVm7szDyJ0/KEXMErZSd7uuxGNjtZD7/5CaPYexquKaydlB7TncPAd58PSBsDhhTQAanedTvPKG9n7erUVCIwCjcCAQPlEe2C7H7t4h3vuc3XZrPCYjj8V6DsrZSYZOrpljrmJbeWIAJ8NANJdYkzB4XpnVUAOiPYWvchj4k3Iv5QnQ6a0vv0nHu5T62le0aVbuSMWwaM06CPC/cu9KcDTDUqhOTrKq0mOlhcMc5vusFt8IW2RjMMw6vD1qNTINVp1EcjvLWPf6zM0toYXE1Wq4s5grEUKDKWo01G6o62KvWbfc3CiwHEnUYTHYQm9N6AO7TIrW7uB8oDKVJry9oGZ1z674vtQV24vI2nUa6G2007dvRuRFnJnn3TPo/1LfSKdzTc9ob8jk6/5SfgdO6egqwO4g8pXxT03vh3scyE5T95b5TbkbfERpErnOAcIXiuLOo5SvCfSTZ7Yeu1M6i10b8SG9jz4HxBgy8gss0QlLmzt7cl/OUWaXMCji5tvtx5wgQDqiFGpVBFNpcegE+Cvw10d6OPijmJ6ukDYtbVjxCD893OB8DSzVFFRsiX7TXG7ja3E7vOa/bPSdadEU8IRmtlBFgKajuB3nu+MsvGwoqfJuI5zqT4/wCjte5aTZmy6eFTqqWbKCTdiCSWNzfQcZaYkwRS6RYRVC9dewAucxJsLXJI1j/+JcL/ANYfBv0i8w3roDB4j/ad+F3khPSTA0lr0GZurWtUZHNwFBWm9UsSTYXFMjmQYd2VjsO65cPVo1AlgRTdXy88pNpmcJisLWc4jGulR8x6qi13pYdASEyrbKapFiz6m5sNBDdPb2BXVXpqTvspF/gsWyjRpuc5gALr+vHftT6jMZUY1jmPIbb3T5btEaZyZhOkXQCymrhWZjvNJyCTxORtNfA/GaX/AIlwv/WHwb9IDbpT1eMOVjVw1RVub/ZPaxKg620Fx43Gt7szDesz8FXI1pO/C7yXnJG8HQ7iDvB4giV1mv6a06FWoK2HZWZtKijS54PqByPl4zKrg6t/Z/1L+sgcN6U3A4lpI9m78LvJW4rSMNwOk6WjVzy0jQqw+4R2FpszBVBZm0AG8mRurncPnNT0NrUMODVqvaqbgCxJReO4bz6W8YkkE3WijgsQ+1N34T5I7sLoctLLWrOTUBDBVtlUjdc/e+X5zTBjMdg+loNd3qllpBctJFsb3Nyza+1YDlew43v1OmeH4LWPkg/3SBzQuhT5NxMe7ScOIjxRrGYRaqlHFwfiDwI8YD6J7PWz1dSy1atIEjd1bmmxHMr8JUxfTJWRlVaqEqQHDIGUkWDLcEXG/UGA8HtDC0SrUsIA6m/WGrUNRm4mo+9yTqc1wYp1Oi6oKjhJFj67ty3U8FygKbqbWkNNxLfPbt3r0sORKO1tjU8WoSoXW1ypUi4NrcRqJlX6bVfu0qXnm/8AYSpiuluIdSvYS/FAwYWN9CWMZ7UIP2JiXCHAdZ8pQLpJ0eq4N7N26bexUA0Pgw+63h8IGzzV7Q27XroadQo6HeMg4ajW2hggYdPwD4mUagU/dvEE85o7T/5Q1DqOcrdLsTZFpj7xzHku75n5QhiqAVlYbibW8ZmtpVuvxB7r5R7q7z6nzj6RkSuDjcK/DVjTfcbra2UVLZrEA94B+M7C87GSskoHtNO2x/eYfMy9gGzhRxuFPxjsVgHLP2d7NxHefGVtjP1ddVfTtWN+B4fP1gFwI0W6g0e3a11nEA9ZhemdF8CtbFIjjMnaJGuoAJ4eNoS2zsimMO1bqKmFdagRVZmIqA8QG1GmvkYH2HtP6NUd8uYtTZBrbKWtZt2u7d4yCjiSzp1ruaYZb3Jay3F7A+Ew7F9BfTqur55hojTXXUkiJjWQNRay0G0OjeHpkK+JqUWyqTnpFluRuzrYb4N2fsA1abVRWooq1OrBqMUzGwIsbW1Bmh2ntsVBUejj8gKn6p6X7tsqkjefUyPYOIw4w+Ho1OrqCrVYlSblD7ClgDpfQa/illYmV8QyiHOku0kRqNCToWs2D7zhMQbTm22FiOtNEUmZ1FyBYjLwbNusZTxGHdGKOrqw0II18NJs6NbENWrLWol6bsMO/Ug3TL7BUXuFs17nTXyjVpnDLjKwc1qtNhSV37TKpt2teIBt/k8pSc3GPByugmGxBuXZReTADjYiY1BMrGpUdDoXQ+BIN/KT/wBpVsyv1jlkvlLMzEX3gXvoZqq9AV/7PqVVDVaj2c5QOspq1+0OPZ/8oto7EoZ61YKDS+js6AAqq1lIQAW7iL2/eksrdiaTyG1WgnW4BEh2WASNZIMcFktrYxsSFFWxK3swADa7xpw0HwgTE4YpqDcfMTbY3ZGHpYem569mekHWomU0usb+7I3jne/pMtjKTMhCi5uP6+cIVCDqVhxuDwlTDPqU2QRMECNR4jYhtAXdQfCHsPhqlU2RHqG17KpY277CCqGAqK4JUgA66j9Zrdh4pepqUhW+jOXVxUJZQyrcFCV1Ficw75HuDuaZSuQiWYd5j7Q2G0DWBqY1PqUKw+zqz3yUqj2NjlRjY9xsNDG0MDVe+SnUfL7WVWOXnYaTYU9t4UvUYnRsSjLYlSLJbrSBYlcwuR3NIsJtOmdHrrSK1qzVMj1UFXrGv1lJkFyQLgKYC6n0qrqTTOzvEnjrpsgmbLI06DMGKqzBRdiASFB3FjwEdTwdQ5bU3Oe+Wyk5re1l/Fbwmo2Vj8Kilc7KtarUuLXIpFWpoKpJBHtltLybYe16FNKFKo6kI1Rs4v2HV2yn3WRm+UtFUxT2hxawmLaX0dO+xbGlwRGqyVHBVXy5abtmuVyqTmC+1lsO1bjHnZ1bP1fVVM9r5MjZrd+W17aQ1ga9FkwavWFMU+tNQ3IIBcsFuPxDTkTLVHaCUq1bEVK6u7ZQvUgvYFwWUBsugVAvJuMpE+u9ri1o3xodTnLR1EDMfmIzmH2XXqKGSjVdTuZUYg20NiBIvoj9kZH7Xs9k9qxscvfrppNBU2glMYtadY5TlNGzMPafOQo4EXIPKS7P2rSVaANTK30etTzi5NKpUa6uba7uI75FXt6kTl4XmMubXr0MC8i8LOHA1QxU0nDKCzKVa6qN5ItoPGJMBVYgLSqMWXMAFckr+IADUeM1NDbFOkyk1VqvTwtRTUOZlqPnDLTuwuwAuL+Mc206PWoKdSktI4dEYOaikDrGbIroLh1BHgbfCITiag+xsvr4XE6EAxuJESsFtFbFbix7QN9+ltDIcKt3Hn6Ewjtmlnqnqs1Rcz2Zj2iCdCxPEyrSwjq4JWw17vwxwqNDcpIncvN4tv8AmwJGmans6GT8USwOCqVmK01zEKWIuB2RvOvOLZ+Beu606YzMfIAbySeAhboM9sUoOgZXU8spP5S/sXZ7YSoWrPSVKqNRzBwxUuLhiBuHZtfxEUvS18UWOe3ScoLRtJOadNsRb5IPjejtWnksadZajBA1JsylzoFJ0sY7amxVoKQcRSaqtr0lBuL2vZtxIvuhdK64KgiGpSrv9JSqBSbMAiZbkngSBbzlLbOFwtRqldcUv1hzCnlOfMx1DdwFybyIWVnueJJyyYIaTm1HQYGp1ESdQq2K2AUwyYjODmCMyBbFEqXyMTfW9u4b5ffZeAWh9Iz4pgXNIWFIdvKWFwRu075cxG3cIWejZ+raitLrLkqAq/V2p2uLMTr3wAu0k+hth7NnNbrFNhlC5Qhub3vv4SIKZr1GjNmGo3D3T26tiNhAjMJVylsFHXB5WYGuXDk2IAUj2Rbuzb/CWK2z8LVXEJRpvSfDhmzFiRUVCQ1wfZOnDw5Qeu28tHDIgIqUajNmNspu1wN9+csY3pFTK1eqoCk9f7R8xNwdXCi2l7m/ORE5uILwdbmNYHPmXCRILIA0O4RIRzD7CoM2FdUQ9ik1WmQCGWopAqZTv7Wh/lKexQmR6FP6OtcVXBFdAwqJqoQMfHh+sD0+kdVXpVFCqadJaWtyHVb7xp3/ACE5hekNRGdhToMz1GqAtTDFHbeUJNx53kS/otctIJm0a7QXaG8jXsgXAWY6TsaVNgey4e1uIYXB+GszOyKO9/IfnLHSXGtiK9gS1ide9mN3b4+ktUcOVAAG6a6cMbBK8hy1XGIxbnMsPdkbSLntkDoAKfFH9S3dFCzt3hczK7crdX2jzPrAm3sJ/eDk3Lgfyhur7R5n1jHUEEHUHQ8pz2PLHArU9ocIKtdHMWK9LtG7po3j3N5+oMKHDHu+f8phMLiGweIDr2l4j8SHeOf5gTe09qI6hkBYEXB3RWKFSm6Wc026Oj1w2Lp4blfEhuU1DI3wfEJtLBljYWvwubXj32ZWG9GPLX0jGxp/CB8ZuemB+j0lqU1W5cKb3tYhjuB33AjMO/Mwmps3LcOXMQ3Y09RHgfgsPRr1qJJVqtMnQ2LLccAZJs3atagxZGIzaMCAQ3vA79518Za/4hbjSU/5j+khO0+sdF6il2mVdRc6kDQ6RhfS2O7injlxjwRVpXvqDPUQPFSp0gq/SExD2qFLhQdAAQRYAbt8dR28wwtTDEFszXD33AspItbiQT5wj022TSw6I1JApZ8p3kWCk7vhMiap/D/qlPcGuylPbylgHRLS2IjT7skc0m0njOs7NQ+18OmGqUqXXnrAo6uplKUyNWIPEnThwECYQa/H8pTWovG4/rlCWBy8CD6/CZ8RUGSEvGYvDfR3MpOkuImZ2ReQNwG+esp+IS4g9k84aKSJsOJko4j2YIhYsFj3YUEZZB6Y17/BCsp7jFY9xl2o9Mcb8tZA2IXgvxM0jEk/Z71tPL38v836VBkPjO5G7mljCV71KYygAugO/dmF5semLfRlpuiL2mKte9t1xax0O+aKTg5pc7SOvyQn/wCgOyl+b9K8421iWo0i6rrcDtA21i2LiWr0g7LrcjQG2km6a7WNXClCgXtobgnge60l/Z5jnFOjRCqVatYnW9mYXtrppNH+HkkHbeO5ZP27V+lZsvu5YyZtJmZnL8E7IfGdynuM13T2mKQoBVUX6z4DJMquJ71HxmSrULHFoE9a2Dl/+X+b9Kjse4xZT4yyldOII+csUkVtxB9fhEnFEXb67EQ5en+H+b9Kr4Smd/P8pNiU0llKdo50vMb6pc/MuTWxDqlY1jeQeyI8EEKnxMWU+MJVaSjUkCV2rINwJmwYubN9di655fgfV/m+SrZD3GTUsDUbVUYjvsbfGI4nuX4mavoLTWqlbMo0ZPhYx1Coaj8pEdaS7l9/2WDrJPks0ux6x3IPMqPWWl6OVeLUhzqA+l5LiduulSohRCFd1GpBsrEC+/XSMPSNuFNf4j+k0e0ofePZ8lnPLuKNmtHUfi5NPR6p+OmeRb81Ep18AVNs2bvsdAe69ps+hlQ4hHqOq3V8q2Bt7IPE+MxlTGkMwspGY237r6RWJflYDS27/JAOWcWbuA4AfGUwYU/0f5QT0kxfUU7D23uF8Bxby9SIXq7VRFLOtgBckGYPFYhsXiC7dlf/ABUbhz/MmLwvtajsz+aL216FnxHK+Ky5RUMnoA8An7Cwf94eOi8uJhoCJFAAAtbhaOjKlQvdmXLY0NEBSicnRORaNMq+0eZ9ZDXUkaSar7R5n1nJcwqIQjGYbOtjoeHOM2DtPqWNN9EJ4/cbv5H+cMkQZtbZ2cZkHaHD8Q/WaGPa4ZH2PcklpHvNWlIms2x0npV8EKJR+t7AJsMoKEXYG/EA/Gec9FNqoSKFYkcEa/8Aoa/y+HdNednL3t8v0mGq84dxY7b3jo9aLVTOcSELlvZeIWlWp1GXOqOrEDfoeHjx8pP/AGaPxH5Rf2aPxH5RArNBn4I8jlf6Y7dTFNTFMMEQH2hYlmtfTuAHzMz9oUGzl72+X6R64FO4nzlvxIcZKmQoPlklGgzeyDz4fGGEw6Dco+EkijX3BEGJtMEAAm5tvlfH0mYDL5jvlqKJBgyjIkQgTKRvBHONh5lB3gHnIWwiH7o8tI8VxtCXkQe53jQ8Oc1XSXpNSxOGSmEYVMys17ZVIBDZTfW9yORgk7PT94ecadnL3t8o1uJABA29CrIVlulH2B95fWX/ANneMSiaVV1LKruSBv1BAI5E38ozplgwuGJuT219Z3obgw+GBJI7T+s1Cq0YbN/y+CTlPto6Fpel22lxVVSgYIi2GYWJJN2NuHAeUBwqNnL3t8v0jlwKdxPMzI/EBxzFOyFCJNRoMx7IPPcPjCyUFG5R8JJFGvuCsMXF+M7FFM6YhGLoOCSbt4/1ulaaCNeip3qD5TQ2tvCAs3IFDvRDba4Wo/WBijqAcouQyk5Tbu1MgbBJ3W5Exp2cne3xH6RrcQGnMEOQqvtnFrWxFSqilVdrgHfuAJPiTc+cpQn/AGav4j8pz+zh+I/KUa7SZUyFGuj/AEnpYbCtTyP1oLFSAMrFvZJN9LaDymTEJjZq97fKZDpXtVATQokng7X/ANC2+fwj6TjiHBjdncOn1qgecgkoft7aRrMKaaoDw+83fyH84/CYfItt54+JkmytmhBmcdo8Pwju5wiAB4Tc6o1oyMsO9Zg0n3nKHDoRv0HdLEUUzkyZTQIUonJ0TkpWmVfaPM+s5FFLVJRRRSlEA2/h1UhgLFt/cfHnNl0Kx9StQPWHMUfIDxIA+8eJ8YooeM1woJVUdKpR+KKKcRbUooopFEooopFEooopFEooopFEooopFEA6c/8AKn309ZzoN/yi++/rOxTd/ov6/gs/8f8ApR+KKKYVoSiiikUSiiikUSiiikUSiiikUSiiikUWf6b4+pSofVnKXIUkbwDvseEx3R7DqxZiLld3cPHnOxTt4PTCEhYa+tVHooooCJKKKKRRSiciikVr/9k=)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {
    "id": "1Q4mgwceXKic"
   },
   "outputs": [],
   "source": [
    "#Import all required libraries\n",
    "import spacy\n",
    "import random\n",
    "import time\n",
    "import numpy as np\n",
    "from spacy.util import minibatch, compounding\n",
    "import sys\n",
    "from spacy import displacy\n",
    "from itertools import chain\n",
    "import matplotlib.pyplot as plt \n",
    "from matplotlib.ticker import MaxNLocator"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {
    "id": "KF5xhNJWZtbf"
   },
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "fjQjt0MJcMVC"
   },
   "source": [
    "  below code is  inpsired from: https://aihub.cloud.google.com/u/0/p/products%2F2290fc65-0041-4c87-a898-0289f59aa8ba"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "4u3v352qxzHq"
   },
   "source": [
    "## Convert data in spacy NER formte"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {
    "id": "IKNYbvzEcIqM"
   },
   "outputs": [],
   "source": [
    "def load_data_spacy(file_path):\n",
    "    file = open(file_path, 'r')\n",
    "    training_data, entities, sentence, unique_labels = [], [], [], []\n",
    "    current_annotation = None\n",
    "    start =0\n",
    "    end = 0 # initialize counter to keep track of start and end characters\n",
    "    for line in file:\n",
    "        line = line.strip(\"\\n\").split(\"\\t\")\n",
    "        # lines with len > 1 are words\n",
    "        if len(line) > 1:\n",
    "            label = line[1]\n",
    "            if(label != 'O'):\n",
    "                label = line[1]+\"_Disease\"     # the .txt is formatted: label \\t word, label[0:2] = label_type\n",
    "            #label_type = line[0][0] # beginning of annotations - \"B\", intermediate - \"I\"\n",
    "            word = line[0]\n",
    "            sentence.append(word)\n",
    "            start = end\n",
    "            end += (len(word) + 1)  # length of the word + trailing space\n",
    "           \n",
    "            if label == 'I_Disease' :  # if at the end of an annotation\n",
    "                entities.append(( start,end-1, label))  # append the annotation\n",
    "                              \n",
    "            if label == 'B_Disease':                         # if beginning new annotation\n",
    "                entities.append(( start,end-1, label))# start annotation at beginning of word\n",
    "                \n",
    "           \n",
    "           \n",
    "            if label != 'O' and label not in unique_labels:\n",
    "                unique_labels.append(label)\n",
    " \n",
    "        # lines with len == 1 are breaks between sentences\n",
    "        if len(line) == 1:\n",
    "            if(len(entities) > 0):\n",
    "                sentence = \" \".join(sentence)\n",
    "                training_data.append([sentence, {'entities' : entities}])\n",
    "            # reset the counters and temporary lists\n",
    "            end = 0 \n",
    "            start = 0\n",
    "            entities, sentence = [], []\n",
    "            \n",
    "    file.close()\n",
    "    return training_data, unique_labels"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "LtYLzv2bx5eR"
   },
   "source": [
    "## Train Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "BO7Kbrnddppy",
    "outputId": "c539c8cd-b78d-4df3-e8a0-227b33171a9e"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[\"Selegiline - induced postural hypotension in Parkinson ' s disease : a longitudinal study on the effects of drug withdrawal .\", {'entities': [(21, 29, 'B_Disease'), (30, 41, 'I_Disease'), (45, 54, 'B_Disease'), (55, 56, 'I_Disease'), (57, 58, 'I_Disease'), (59, 66, 'I_Disease')]}], [\"OBJECTIVES : The United Kingdom Parkinson ' s Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson ' s disease ( PD ) randomized to receive 10 mg selegiline per day and L - dopa compared with those taking L - dopa alone .\", {'entities': [(32, 41, 'B_Disease'), (42, 43, 'I_Disease'), (44, 45, 'I_Disease'), (46, 53, 'I_Disease'), (132, 141, 'B_Disease'), (142, 143, 'I_Disease'), (144, 145, 'I_Disease'), (146, 153, 'I_Disease'), (156, 158, 'B_Disease')]}], ['Recently , we found that therapy with selegiline and L - dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline .', {'entities': [(92, 100, 'B_Disease'), (101, 112, 'I_Disease'), (113, 124, 'I_Disease')]}], ['The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension .', {'entities': [(274, 285, 'B_Disease'), (286, 297, 'I_Disease')]}], ['METHODS : The cardiovascular responses to standing and head - up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn .', {'entities': [(97, 99, 'B_Disease')]}], ['RESULTS : Head - up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline , one of whom lost consciousness with unrecordable blood pressures .', {'entities': [(32, 40, 'B_Disease'), (41, 52, 'I_Disease'), (53, 64, 'I_Disease'), (95, 97, 'B_Disease')]}], ['A lesser degree of orthostatic hypotension occurred with standing .', {'entities': [(19, 30, 'B_Disease'), (31, 42, 'I_Disease')]}], ['Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug .', {'entities': [(0, 11, 'B_Disease'), (12, 23, 'I_Disease')]}], ['Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action .', {'entities': [(39, 46, 'B_Disease'), (47, 50, 'I_Disease'), (51, 57, 'I_Disease'), (58, 66, 'I_Disease'), (67, 70, 'I_Disease'), (71, 80, 'I_Disease'), (81, 86, 'I_Disease'), (87, 96, 'I_Disease')]}], ['CONCLUSION : This study confirms our previous finding that selegiline in combination with L - dopa is associated with selective orthostatic hypotension .', {'entities': [(128, 139, 'B_Disease'), (140, 151, 'I_Disease')]}], ['The results have shown that the degradation product p - choloroaniline is not a significant factor in chlorhexidine - digluconate associated erosive cystitis .', {'entities': [(149, 157, 'B_Disease')]}], ['A high percentage of kanamycin - colistin and povidone - iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage .', {'entities': [(105, 113, 'B_Disease')]}], ['Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures .', {'entities': [(70, 78, 'B_Disease')]}], ['Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation .', {'entities': [(57, 67, 'B_Disease'), (86, 94, 'B_Disease'), (95, 106, 'I_Disease')]}], ['The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .', {'entities': [(95, 105, 'B_Disease'), (164, 172, 'B_Disease'), (173, 184, 'I_Disease'), (189, 194, 'B_Disease'), (195, 206, 'I_Disease')]}], ['In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and FAN in mice showed the inhibition of thrombosis by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .', {'entities': [(115, 125, 'B_Disease')]}], ['In the vitro human platelet aggregations induced by the agonists used in tests , TET and FAN showed the inhibitions dose dependently .', {'entities': [(19, 27, 'B_Disease'), (28, 40, 'I_Disease')]}], ['Angioedema due to ACE inhibitors : common and inadequately diagnosed .', {'entities': [(0, 10, 'B_Disease')]}], ['The estimated incidence of angioedema during angiotensin - converting enzyme ( ACE ) inhibitor treatment is between 1 and 7 per thousand patients .', {'entities': [(27, 37, 'B_Disease')]}], ['Cocaine - induced mood disorder : prevalence rates and psychiatric symptoms in an outpatient cocaine - dependent sample .', {'entities': [(18, 22, 'B_Disease'), (23, 31, 'I_Disease'), (55, 66, 'B_Disease')]}], ['This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance - induced and other mood disorders .', {'entities': [(118, 122, 'B_Disease'), (123, 132, 'I_Disease')]}], ['243 cocaine - dependent outpatients with cocaine - induced mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .', {'entities': [(59, 63, 'B_Disease'), (64, 72, 'I_Disease'), (75, 79, 'B_Disease'), (90, 94, 'B_Disease'), (95, 104, 'I_Disease'), (113, 117, 'B_Disease'), (118, 126, 'I_Disease'), (156, 167, 'B_Disease')]}], ['The prevalence rate for CIMD was 12 % at baseline .', {'entities': [(24, 28, 'B_Disease')]}], ['Introduction of the DSM - IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders .', {'entities': [(42, 46, 'B_Disease'), (95, 105, 'B_Disease'), (106, 115, 'I_Disease')]}], ['Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder .', {'entities': [(14, 18, 'B_Disease'), (92, 96, 'B_Disease'), (97, 105, 'I_Disease')]}], ['These findings suggest some validity for the new DSM - IV diagnosis of CIMD , but also suggest that it requires further specification and replication .', {'entities': [(71, 75, 'B_Disease')]}], ['Effect of fucoidan treatment on collagenase - induced intracerebral hemorrhage in rats .', {'entities': [(54, 67, 'B_Disease'), (68, 78, 'I_Disease')]}], ['Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke .', {'entities': [(57, 62, 'B_Disease'), (63, 69, 'I_Disease'), (80, 88, 'B_Disease'), (89, 95, 'I_Disease')]}], ['Intracerebral hemorrhage is associated with more inflammation than ischemic stroke .', {'entities': [(0, 13, 'B_Disease'), (14, 24, 'I_Disease'), (49, 61, 'B_Disease'), (67, 75, 'B_Disease'), (76, 82, 'I_Disease')]}], ['We tested the sulfated polysaccharide fucoidan , which has been reported to reduce inflammatory brain damage , in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus .', {'entities': [(96, 101, 'B_Disease'), (102, 108, 'I_Disease'), (129, 142, 'B_Disease'), (143, 153, 'I_Disease')]}], ['The hematoma was assessed in vivo by magnetic resonance imaging .', {'entities': [(4, 12, 'B_Disease')]}], ['Fucoidan - treated rats exhibited evidence of impaired blood clotting and hemodilution , had larger hematomas , and tended to have less inflammation in the vicinity of the hematoma after three days .', {'entities': [(46, 54, 'B_Disease'), (55, 60, 'I_Disease'), (61, 69, 'I_Disease'), (74, 86, 'B_Disease'), (100, 109, 'B_Disease'), (136, 148, 'B_Disease'), (172, 180, 'B_Disease')]}], ['They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test .', {'entities': [(95, 105, 'B_Disease')]}], ['Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups .', {'entities': [(6, 11, 'B_Disease'), (12, 18, 'I_Disease'), (19, 24, 'I_Disease'), (38, 46, 'B_Disease'), (47, 51, 'I_Disease'), (84, 92, 'B_Disease')]}], ['Investigation of more specific anti - inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage .', {'entities': [(99, 112, 'B_Disease'), (113, 123, 'I_Disease')]}], ['A respiratory arrest with severe desaturation and bradycardia occurred .', {'entities': [(2, 13, 'B_Disease'), (14, 20, 'I_Disease'), (33, 45, 'B_Disease'), (50, 61, 'B_Disease')]}], ['Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur , following the administration of a small dose of relaxant , are discussed .', {'entities': [(66, 79, 'B_Disease'), (80, 88, 'I_Disease')]}], ['We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response .', {'entities': [(114, 125, 'B_Disease')]}], ['The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study .', {'entities': [(89, 100, 'B_Disease')]}], ['However , marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients , occasionally reaching high levels in individual patients .', {'entities': [(17, 28, 'B_Disease')]}], ['Due to the risk of this tachycardia inducing myocardial ischemia , we would not recommend the use in elderly patients of any of the ephedrine / propofol / mixtures studied .', {'entities': [(24, 35, 'B_Disease'), (45, 55, 'B_Disease'), (56, 64, 'I_Disease')]}], ['Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin .', {'entities': [(32, 40, 'B_Disease'), (41, 45, 'I_Disease'), (46, 50, 'I_Disease'), (51, 60, 'I_Disease')]}], ['BACKGROUND : Although the prevalence of nonsmall cell lung carcinoma ( NSCLC ) is high among elderly patients , few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients .', {'entities': [(40, 48, 'B_Disease'), (49, 53, 'I_Disease'), (54, 58, 'I_Disease'), (59, 68, 'I_Disease'), (71, 76, 'B_Disease'), (162, 170, 'B_Disease')]}], ['Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable toxicity and improvement in symptoms and quality of life .', {'entities': [(176, 184, 'B_Disease')]}], ['In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .', {'entities': [(38, 46, 'B_Disease'), (115, 120, 'B_Disease')]}], ['METHODS : Forty - nine patients with advanced NSCLC were included , 38 of whom were age > / = 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin .', {'entities': [(46, 51, 'B_Disease')]}], ['All patients were evaluable for response and toxicity .', {'entities': [(45, 53, 'B_Disease')]}], ['Toxicity was mild .', {'entities': [(0, 8, 'B_Disease')]}], ['Six patients ( 12 % ) had World Health Organization Grade 3 - 4 neutropenia , 2 patients ( 4 % ) had Grade 3 - 4 thrombocytopenia , and 2 patients ( 4 % ) had Grade 3 neurotoxicity .', {'entities': [(64, 75, 'B_Disease'), (113, 129, 'B_Disease'), (167, 180, 'B_Disease')]}], ['Three patients with severe neutropenia ( 6 % ) died of sepsis .', {'entities': [(27, 38, 'B_Disease'), (55, 61, 'B_Disease')]}], ['The median age of those patients developing Grade 3 - 4 neutropenia was significantly higher than that of the remaining patients ( 75 years vs . 72 years ; P = 0 . 047 ) .', {'entities': [(56, 67, 'B_Disease')]}], ['This age group had an increased risk of myelosuppression .', {'entities': [(40, 56, 'B_Disease')]}], ['New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC .', {'entities': [(61, 69, 'B_Disease'), (116, 121, 'B_Disease')]}], ['NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine ( MAP ) in mice .', {'entities': [(44, 57, 'B_Disease')]}], ['NRA0160 and clozapine significantly induced catalepsy in rats , although their effects did not exceed 50 % induction even at the highest dose given .', {'entities': [(44, 53, 'B_Disease')]}], ['Warfarin - induced artery calcification is accelerated by growth and vitamin D .', {'entities': [(19, 25, 'B_Disease'), (26, 39, 'I_Disease')]}], ['The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma - carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .', {'entities': [(90, 96, 'B_Disease'), (97, 110, 'I_Disease'), (213, 226, 'B_Disease')]}], ['The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin - treated rats .', {'entities': [(83, 89, 'B_Disease'), (90, 103, 'I_Disease')]}], ['Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20 - day - old rats and less extensive focal calcification in 42 - day - old rats .', {'entities': [(57, 70, 'B_Disease'), (71, 73, 'I_Disease'), (74, 77, 'I_Disease'), (78, 84, 'I_Disease'), (139, 152, 'B_Disease')]}], ['In contrast , no artery calcification could be detected in 10 - month - old adult rats even after 4 weeks of Warfarin treatment .', {'entities': [(17, 23, 'B_Disease'), (24, 37, 'I_Disease')]}], ['To directly examine the importance of growth to Warfarin - induced artery calcification in animals of the same age , 20 - day - old rats were fed for 2 weeks either an ad libitum diet or a 6 - g / d restricted diet that maintains weight but prevents growth .', {'entities': [(67, 73, 'B_Disease'), (74, 87, 'I_Disease')]}], ['Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum - fed rats but no detectable artery calcification in the restricted - diet , growth - inhibited group .', {'entities': [(81, 94, 'B_Disease'), (95, 97, 'I_Disease'), (98, 101, 'I_Disease'), (102, 108, 'I_Disease'), (162, 168, 'B_Disease'), (169, 182, 'I_Disease')]}], ['Although the explanation for the association between artery calcification and growth status cannot be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .', {'entities': [(53, 59, 'B_Disease'), (60, 73, 'I_Disease'), (216, 222, 'B_Disease'), (223, 236, 'I_Disease'), (391, 397, 'B_Disease'), (398, 411, 'I_Disease')]}], ['This observation suggests that increased susceptibility to Warfarin - induced artery calcification could be related to higher serum phosphate levels .', {'entities': [(78, 84, 'B_Disease'), (85, 98, 'I_Disease')]}], ['The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification .', {'entities': [(94, 100, 'B_Disease'), (101, 114, 'I_Disease')]}], ['High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days .', {'entities': [(43, 56, 'B_Disease'), (57, 59, 'I_Disease'), (60, 63, 'I_Disease'), (64, 70, 'I_Disease')]}], ['High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media , but at treatment times of 2 weeks or longer yet not at 1 week .', {'entities': [(72, 85, 'B_Disease'), (86, 88, 'I_Disease'), (89, 92, 'I_Disease'), (93, 99, 'I_Disease')]}], ['In the current study , we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D - treated rats at 3 and 4 days .', {'entities': [(165, 178, 'B_Disease')]}], ['There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .', {'entities': [(67, 73, 'B_Disease'), (74, 87, 'I_Disease'), (198, 204, 'B_Disease'), (205, 218, 'I_Disease')]}], ['Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor .', {'entities': [(250, 263, 'B_Disease')]}], ['High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not gamma - carboxylated .', {'entities': [(56, 62, 'B_Disease'), (63, 76, 'I_Disease')]}], ['These observations indicate that although the gamma - carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor , they are not required for its accumulation at calcification sites .', {'entities': [(148, 161, 'B_Disease'), (220, 233, 'B_Disease')]}], ['Apomorphine , a nonselective dopamine agonist , was selected due to its biphasic behavioral effects , its ability to induce hypothermia , and to produce distinct changes to dopamine turnover in the rodent brain .', {'entities': [(124, 135, 'B_Disease')]}], ['In rats , detection of apomorphine - induced hyperactivity was facilitated by a period of acclimatization to the test conditions .', {'entities': [(45, 58, 'B_Disease')]}], ['Moreover , test conditions can impact upon other physiological responses to apomorphine such as drug - induced hypothermia .', {'entities': [(111, 122, 'B_Disease')]}], ['Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure .', {'entities': [(0, 9, 'B_Disease')]}], ['Tamoxifen ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .', {'entities': [(90, 96, 'B_Disease'), (97, 103, 'I_Disease'), (166, 175, 'B_Disease'), (176, 182, 'I_Disease')]}], ['This work evaluates the effects of TAM on isolated human erythrocytes , attempting to identify the underlying mechanisms on TAM - induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms .', {'entities': [(138, 147, 'B_Disease'), (148, 154, 'I_Disease')]}], ['TAM induces hemolysis of erythrocytes as a function of concentration .', {'entities': [(12, 21, 'B_Disease')]}], ['The extension of hemolysis is variable with erythrocyte samples , but 12 . 5 microM TAM induces total hemolysis of all tested suspensions .', {'entities': [(17, 26, 'B_Disease'), (102, 111, 'B_Disease')]}], ['The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .', {'entities': [(4, 13, 'B_Disease'), (212, 221, 'B_Disease')]}], ['This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM - induced hemolysis .', {'entities': [(132, 141, 'B_Disease')]}], ['Hemolysis caused by TAM was not preceded by the leakage of K ( + ) from the cells , also excluding a colloid - osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .', {'entities': [(0, 9, 'B_Disease'), (137, 146, 'B_Disease')]}], ['These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .', {'entities': [(47, 56, 'B_Disease')]}], ['Therefore , TAM - induced hemolysis results from a structural perturbation of red cell membrane , leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane .', {'entities': [(26, 35, 'B_Disease')]}], ['These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM , resulting in hemolytic anemia .', {'entities': [(119, 128, 'B_Disease'), (129, 135, 'I_Disease')]}], ['Changes of sodium and ATP affinities of the cardiac ( Na , K ) - ATPase during and after nitric oxide deficient hypertension .', {'entities': [(112, 124, 'B_Disease')]}], ['Inhibition of NO synthesis induces sustained hypertension .', {'entities': [(45, 57, 'B_Disease')]}], ['In several models of hypertension , elevation of intracellular sodium level was documented in cardiac tissue .', {'entities': [(21, 33, 'B_Disease')]}], ['To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient hypertension induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .', {'entities': [(159, 171, 'B_Disease')]}], ['After recovery from hypertension , the activity of ( Na , K ) - ATPase increased , due to higher affinity of the ATP - binding site , as revealed from the lowered Km value for ATP .', {'entities': [(20, 32, 'B_Disease')]}], ['Inhibition of NO - synthase induced a reversible hypertension accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .', {'entities': [(49, 61, 'B_Disease'), (77, 86, 'B_Disease')]}], ['Effects of long - term pretreatment with isoproterenol on bromocriptine - induced tachycardia in conscious rats .', {'entities': [(82, 93, 'B_Disease')]}], ['It has been shown that bromocriptine - induced tachycardia , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5 - day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .', {'entities': [(47, 58, 'B_Disease')]}], ['This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine - induced tachycardia in conscious rats .', {'entities': [(124, 135, 'B_Disease')]}], ['Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate .', {'entities': [(46, 53, 'B_Disease'), (54, 65, 'I_Disease')]}], ['In control rats , intravenous bromocriptine ( 150 microg / kg ) induced significant hypotension and tachycardia .', {'entities': [(84, 95, 'B_Disease'), (100, 111, 'B_Disease')]}], ['Bromocriptine - induced hypotension was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i . v . domperidone ( 0 . 5 mg / kg ) .', {'entities': [(24, 35, 'B_Disease'), (89, 100, 'B_Disease'), (129, 140, 'B_Disease')]}], ['These results show that 15 - day isoproterenol pretreatment not only abolished but reversed bromocriptine - induced tachycardia to bradycardia , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .', {'entities': [(116, 127, 'B_Disease'), (131, 142, 'B_Disease')]}], ['They suggest that , in normal conscious rats , the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors .', {'entities': [(59, 70, 'B_Disease'), (127, 138, 'B_Disease')]}], [\"Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that clonidine induces sympathetic withdrawal and bradycardia , we hypothesized that clonidine ' s developmental effects on cardiac rate and ultrasound production would mirror each other .\", {'entities': [(143, 154, 'B_Disease')]}], ['Age - related changes in ultrasound production corresponded with changes in cardiovascular variables , including baseline cardiac rate and clonidine - induced bradycardia .', {'entities': [(159, 170, 'B_Disease')]}], ['Recurrent use of newer oral contraceptives and the risk of venous thromboembolism .', {'entities': [(59, 65, 'B_Disease'), (66, 81, 'I_Disease')]}], ['The epidemiological studies that assessed the risk of venous thromboembolism ( VTE ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .', {'entities': [(54, 60, 'B_Disease'), (61, 76, 'I_Disease'), (79, 82, 'B_Disease')]}], ['Data from a Transnational case - control study were used to assess the risk of VTE for the latter patterns of use , while accounting for duration of use .', {'entities': [(79, 82, 'B_Disease')]}], ['Over the period 1993 - 1996 , 551 cases of VTE were identified in Germany and the UK along with 2066 controls .', {'entities': [(43, 46, 'B_Disease')]}], ['The adjusted rate ratio of VTE for repeat users of third generation OC was 0 . 6 ( 95 % CI : 0 . 3 - 1 . 2 ) relative to repeat users of second generation pills , whereas it was 1 . 3 ( 95 % CI : 0 . 7 - 2 . 4 ) for switchers from second to third generation pills relative to switchers from third to second generation pills .', {'entities': [(27, 30, 'B_Disease')]}], ['We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills .', {'entities': [(92, 95, 'B_Disease')]}], ['Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans .', {'entities': [(95, 107, 'B_Disease')]}], ['We have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin .', {'entities': [(111, 115, 'B_Disease'), (149, 161, 'B_Disease')]}], ['The following were measured : spontaneous pain , pain evoked by punctate and brush stimuli ( VAS ) , and areas of brush - evoked and punctate - evoked hyperalgesia .', {'entities': [(42, 46, 'B_Disease'), (49, 53, 'B_Disease'), (151, 163, 'B_Disease')]}], ['Ketamine reduced both the area of brush - evoked and punctate - evoked hyperalgesia significantly and it tended to reduce brush - evoked pain .', {'entities': [(71, 83, 'B_Disease'), (137, 141, 'B_Disease')]}], ['Lidocaine reduced the area of punctate - evoked hyperalgesia significantly .', {'entities': [(48, 60, 'B_Disease')]}], ['It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain .', {'entities': [(46, 50, 'B_Disease'), (79, 83, 'B_Disease')]}], ['The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .', {'entities': [(73, 85, 'B_Disease'), (116, 128, 'B_Disease')]}], ['Development of apomorphine - induced aggressive behavior : comparison of adult male and female Wistar rats .', {'entities': [(37, 47, 'B_Disease'), (48, 56, 'I_Disease')]}], ['The development of apomorphine - induced ( 1 . 0 mg / kg s . c . once daily ) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets .', {'entities': [(78, 88, 'B_Disease'), (89, 97, 'I_Disease')]}], ['In male animals , repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent .', {'entities': [(82, 92, 'B_Disease'), (93, 101, 'I_Disease'), (145, 159, 'B_Disease')]}], ['In female rats , only a weak tendency toward aggressiveness was found .', {'entities': [(45, 59, 'B_Disease')]}], ['In conclusion , the present study demonstrates gender differences in the development of the apomorphine - induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method .', {'entities': [(114, 124, 'B_Disease'), (125, 133, 'I_Disease')]}], ['Intracranial aneurysms and cocaine abuse : analysis of prognostic indicators .', {'entities': [(0, 12, 'B_Disease'), (13, 22, 'I_Disease'), (27, 34, 'B_Disease'), (35, 40, 'I_Disease')]}], ['OBJECTIVE : The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor .', {'entities': [(27, 39, 'B_Disease'), (40, 50, 'I_Disease'), (67, 74, 'B_Disease'), (75, 80, 'I_Disease')]}], ['METHODS : A review of admissions during a 6 - year period revealed 14 patients with cocaine - related aneurysms .', {'entities': [(102, 111, 'B_Disease')]}], ['This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse .', {'entities': [(66, 74, 'B_Disease'), (75, 84, 'I_Disease'), (103, 110, 'B_Disease'), (111, 116, 'I_Disease')]}], ['Age at presentation , time of ictus after intoxication , Hunt and Hess grade of subarachnoid hemorrhage , size of the aneurysm , location of the aneurysm , and the Glasgow Outcome Scale score were assessed and compared .', {'entities': [(80, 92, 'B_Disease'), (93, 103, 'I_Disease'), (118, 126, 'B_Disease'), (145, 153, 'B_Disease')]}], ['In patients in the study group , all aneurysms were located in the anterior circulation .', {'entities': [(37, 46, 'B_Disease')]}], ['The majority of these aneurysms were smaller than those of the control group ( 8 + / - 6 . 08 mm versus 11 + / - 5 . 4 mm ; P = 0 . 05 ) .', {'entities': [(22, 31, 'B_Disease')]}], ['Hunt and Hess grade ( P < 0 . 005 ) and age ( P < 0 . 007 ) were significant predictors of outcome for the patients with cocaine - related aneurysms .', {'entities': [(139, 148, 'B_Disease')]}], ['CONCLUSION : Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms .', {'entities': [(37, 47, 'B_Disease'), (48, 55, 'I_Disease'), (107, 116, 'B_Disease')]}], ['Effect of intravenous nimodipine on blood pressure and outcome after acute stroke .', {'entities': [(69, 74, 'B_Disease'), (75, 81, 'I_Disease')]}], ['BACKGROUND AND PURPOSE : The Intravenous Nimodipine West European Stroke Trial ( INWEST ) found a correlation between nimodipine - induced reduction in blood pressure ( BP ) and an unfavorable outcome in acute stroke .', {'entities': [(66, 72, 'B_Disease'), (139, 148, 'B_Disease'), (149, 151, 'I_Disease'), (152, 157, 'I_Disease'), (158, 166, 'I_Disease'), (204, 209, 'B_Disease'), (210, 216, 'I_Disease')]}], ['We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction .', {'entities': [(157, 159, 'B_Disease'), (160, 169, 'I_Disease')]}], ['METHODS : Patients with a clinical diagnosis of ischemic stroke ( within 24 hours ) were consecutively allocated to receive placebo ( n = 100 ) , 1 mg / h ( low - dose ) nimodipine ( n = 101 ) , or 2 mg / h ( high - dose ) nimodipine ( n = 94 ) .', {'entities': [(48, 56, 'B_Disease'), (57, 63, 'I_Disease')]}], ['Nimodipine treatment resulted in a statistically significant reduction in systolic BP ( SBP ) and diastolic BP ( DBP ) from baseline compared with placebo during the first few days .', {'entities': [(61, 70, 'B_Disease'), (71, 73, 'I_Disease'), (74, 82, 'I_Disease'), (83, 85, 'I_Disease')]}], ['In multivariate analysis , a significant correlation between DBP reduction and worsening of the neurological score was found for the high - dose group ( beta = 0 . 49 , P = 0 . 048 ) .', {'entities': [(61, 64, 'B_Disease'), (65, 74, 'I_Disease')]}], ['Patients with a DBP reduction of > or = 20 % in the high - dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency ( Barthel Index < 60 ) ( n / N = 25 / 26 , OR 10 . 16 , 95 % CI 1 . 02 to 101 . 74 ) and death alone ( n / N = 9 / 26 , OR 4 . 336 , 95 % CI 1 . 131 16 . 619 ) compared with all placebo patients ( n / N = 62 / 92 and 14 / 92 , respectively ) .', {'entities': [(16, 19, 'B_Disease'), (20, 29, 'I_Disease'), (146, 151, 'B_Disease'), (255, 260, 'B_Disease')]}], ['CONCLUSIONS : DBP , but not SBP , reduction was associated with neurological worsening after the intravenous administration of high - dose nimodipine after acute stroke .', {'entities': [(156, 161, 'B_Disease'), (162, 168, 'I_Disease')]}], ['Neonatal pyridoxine responsive convulsions due to isoniazid therapy .', {'entities': [(31, 42, 'B_Disease')]}], ['A 17 - day - old infant on isoniazid therapy 13 mg / kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits .', {'entities': [(93, 105, 'B_Disease'), (135, 141, 'B_Disease'), (142, 146, 'I_Disease')]}], ['The fits ceased within 4 hours of administering intramuscular pyridoxine , suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication .', {'entities': [(4, 8, 'B_Disease')]}], [\"Ketamine sedation for the reduction of children ' s fractures in the emergency department .\", {'entities': [(52, 61, 'B_Disease')]}], [\"The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children ' s fractures in the emergency department .\", {'entities': [(130, 139, 'B_Disease')]}], ['METHODS : One hundred and fourteen children ( average age , 5 . 3 years ; range , twelve months to ten years and ten months ) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level - I trauma center were prospectively evaluated .', {'entities': [(172, 180, 'B_Disease'), (184, 195, 'B_Disease'), (239, 245, 'B_Disease')]}], [\"Any pain during the reduction was rated by the orthopaedic surgeon treating the patient according to the Children ' s Hospital of Eastern Ontario Pain Scale ( CHEOPS ) .\", {'entities': [(4, 8, 'B_Disease'), (146, 150, 'B_Disease')]}], ['RESULTS : The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty - six seconds ( range , twenty seconds to five minutes ) , and the average time from intramuscular administration to manipulation was four minutes and forty - two seconds ( range , sixty seconds to fifteen minutes ) .', {'entities': [(94, 102, 'B_Disease'), (106, 117, 'B_Disease')]}], [\"The average score according to the Children ' s Hospital of Eastern Ontario Pain Scale was 6 . 4 points ( range , 5 to 10 points ) , reflecting minimal or no pain during fracture reduction .\", {'entities': [(76, 80, 'B_Disease'), (158, 162, 'B_Disease'), (170, 178, 'B_Disease')]}], ['Adequate fracture reduction was obtained in 111 of the children .', {'entities': [(9, 17, 'B_Disease')]}], ['Minor side effects included nausea ( thirteen patients ) , emesis ( eight of the thirteen patients with nausea ) , clumsiness ( evident as ataxic movements in ten patients ) , and dysphoric reaction ( one patient ) .', {'entities': [(28, 34, 'B_Disease'), (59, 65, 'B_Disease'), (104, 110, 'B_Disease'), (115, 125, 'B_Disease'), (139, 145, 'B_Disease'), (146, 155, 'I_Disease'), (180, 189, 'B_Disease'), (190, 198, 'I_Disease')]}], ['No long - term sequelae were noted , and no patients had hallucinations or nightmares .', {'entities': [(57, 71, 'B_Disease')]}], [\"CONCLUSIONS : Ketamine reliably , safely , and quickly provided adequate sedation to effectively facilitate the reduction of children ' s fractures in the emergency department at our institution .\", {'entities': [(138, 147, 'B_Disease')]}], ['Cyclosporine and tacrolimus - associated thrombotic microangiopathy .', {'entities': [(41, 51, 'B_Disease'), (52, 67, 'I_Disease')]}], ['The development of thrombotic microangiopathy ( TMA ) associated with the use of cyclosporine has been well documented .', {'entities': [(19, 29, 'B_Disease'), (30, 45, 'I_Disease'), (48, 51, 'B_Disease')]}], ['As a result , switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine - induced TMA .', {'entities': [(131, 134, 'B_Disease')]}], ['With the more widespread application of tacrolimus in organ transplantation , tacrolimus - associated TMA has also been recognized .', {'entities': [(102, 105, 'B_Disease')]}], ['However , literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited .', {'entities': [(66, 69, 'B_Disease')]}], ['We report a case of a living donor renal transplant recipient who developed cyclosporine - induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .', {'entities': [(99, 102, 'B_Disease')]}], ['Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft .', {'entities': [(99, 102, 'B_Disease')]}], ['Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA .', {'entities': [(140, 143, 'B_Disease')]}], ['Analgesic effect of intravenous ketamine in cancer patients on morphine therapy : a randomized , controlled , double - blind , crossover , double - dose study .', {'entities': [(44, 50, 'B_Disease')]}], ['Pain not responsive to morphine is often problematic .', {'entities': [(0, 4, 'B_Disease')]}], ['Animal and clinical studies have suggested that N - methyl - D - aspartate ( NMDA ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult pain syndromes , such as neuropathic pain .', {'entities': [(177, 181, 'B_Disease'), (202, 213, 'B_Disease'), (214, 218, 'I_Disease')]}], ['A slow bolus of subhypnotic doses of ketamine ( 0 . 25 mg / kg or 0 . 50 mg / kg ) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized , double - blind , crossover , double - dose study .', {'entities': [(99, 105, 'B_Disease'), (121, 125, 'B_Disease')]}], ['Pain intensity on a 0 to 10 numerical scale ; nausea and vomiting , drowsiness , confusion , and dry mouth , using a scale from 0 to 3 ( not at all , slight , a lot , awful ) ; Mini - Mental State Examination ( MMSE ) ( 0 - 30 ) ; and arterial pressure were recorded before administration of drugs ( T0 ) and after 30 minutes ( T30 ) , 60 minutes ( T60 ) , 120 minutes ( T120 ) , and 180 minutes ( T180 ) .', {'entities': [(0, 4, 'B_Disease'), (46, 52, 'B_Disease'), (57, 65, 'B_Disease'), (81, 90, 'B_Disease'), (97, 100, 'B_Disease'), (101, 106, 'I_Disease')]}], ['Ketamine , but not saline solution , significantly reduced the pain intensity in almost all the patients at both doses .', {'entities': [(63, 67, 'B_Disease')]}], ['Hallucinations occurred in 4 patients , and an unpleasant sensation ( \" empty head \" ) was also reported by 2 patients .', {'entities': [(0, 14, 'B_Disease')]}], ['Ketamine can improve morphine analgesia in difficult pain syndromes , such as neuropathic pain .', {'entities': [(53, 57, 'B_Disease'), (78, 89, 'B_Disease'), (90, 94, 'I_Disease')]}], ['Paclitaxel , cisplatin , and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma .', {'entities': [(128, 136, 'B_Disease'), (137, 141, 'I_Disease'), (142, 146, 'I_Disease'), (147, 156, 'I_Disease')]}], ['BACKGROUND : Cisplatin - based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma ( NSCLC ) .', {'entities': [(106, 114, 'B_Disease'), (115, 119, 'I_Disease'), (120, 124, 'I_Disease'), (125, 134, 'I_Disease'), (137, 142, 'B_Disease')]}], ['METHODS : The objective of this study was to determine the feasibility , response rate , and toxicity of a paclitaxel , cisplatin , and gemcitabine combination to treat metastatic NSCLC .', {'entities': [(93, 101, 'B_Disease'), (180, 185, 'B_Disease')]}], ['Thirty - five consecutive chemotherapy - naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of paclitaxel ( 135 mg / m ( 2 ) given intravenously in 3 hours ) on Day 1 , cisplatin ( 120 mg / m ( 2 ) given intravenously in 6 hours ) on Day 1 , and gemcitabine ( 800 mg / m ( 2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .', {'entities': [(70, 75, 'B_Disease')]}], ['Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second - line chemotherapy after disease progression , the response and toxicity rates reported refer only to the chemotherapy regimen given .', {'entities': [(190, 198, 'B_Disease')]}], ['RESULTS : All the patients were examined for toxicity ; 34 were examinable for response .', {'entities': [(45, 53, 'B_Disease')]}], ['World Health Organization Grade 3 - 4 neutropenia and thrombocytopenia occurred in 39 . 9 % and 11 . 4 % of patients , respectively .', {'entities': [(38, 49, 'B_Disease'), (54, 70, 'B_Disease')]}], ['There was one treatment - related death .', {'entities': [(34, 39, 'B_Disease')]}], ['Nonhematologic toxicities were mild .', {'entities': [(15, 25, 'B_Disease')]}], ['CONCLUSIONS : The combination of paclitaxel , cisplatin , and gemcitabine is well tolerated and shows high activity in metastatic NSCLC .', {'entities': [(130, 135, 'B_Disease')]}], ['Serotonergic antidepressants and urinary incontinence .', {'entities': [(33, 40, 'B_Disease'), (41, 53, 'I_Disease')]}], ['Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature .', {'entities': [(9, 16, 'B_Disease'), (17, 29, 'I_Disease')]}], ['This concerns 2 male patients who experienced incontinence while taking venlafaxine .', {'entities': [(46, 58, 'B_Disease')]}], ['In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on venlafaxine .', {'entities': [(74, 86, 'B_Disease')]}], ['In 2 of the 3 cases the patients were also taking lithium carbonate and beta - blockers , both of which could have contributed to the incontinence .', {'entities': [(134, 146, 'B_Disease')]}], ['Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder .', {'entities': [(28, 40, 'B_Disease')]}], ['Acute cocaine - induced seizures : differential sensitivity of six inbred mouse strains .', {'entities': [(24, 32, 'B_Disease')]}], ['Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine .', {'entities': [(96, 104, 'B_Disease')]}], ['Seizure end points included latency to forelimb or hindlimb clonus , latency to clonic running seizure and latency to jumping bouncing seizure .', {'entities': [(0, 7, 'B_Disease'), (95, 102, 'B_Disease'), (135, 142, 'B_Disease')]}], ['Additional studies of these murine strains may be useful for investigating genetic influences on cocaine - induced seizures .', {'entities': [(115, 123, 'B_Disease')]}], ['Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension .', {'entities': [(0, 11, 'B_Disease'), (132, 144, 'B_Disease')]}], ['Centrally acting alpha - 2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system .', {'entities': [(112, 122, 'B_Disease'), (134, 143, 'B_Disease'), (144, 146, 'I_Disease'), (147, 150, 'I_Disease'), (151, 158, 'I_Disease'), (159, 166, 'I_Disease'), (167, 173, 'I_Disease')]}], ['In addition to their effects on spasticity , certain adverse cardiorespiratory effects have been reported .', {'entities': [(32, 42, 'B_Disease')]}], ['Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked .', {'entities': [(114, 125, 'B_Disease')]}], ['The authors present a 10 - year - old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .', {'entities': [(136, 148, 'B_Disease'), (163, 174, 'B_Disease'), (258, 268, 'B_Disease')]}], ['The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients .', {'entities': [(137, 149, 'B_Disease'), (153, 163, 'B_Disease')]}], ['Two mouse lines selected for differential sensitivities to beta - carboline - induced seizures are also differentially sensitive to various pharmacological effects of other GABA ( A ) receptor ligands .', {'entities': [(86, 94, 'B_Disease')]}], ['Two mouse lines were selectively bred according to their sensitivity ( BS line ) or resistance ( BR line ) to seizures induced by a single i . p . injection of methyl beta - carboline - 3 - carboxylate ( beta - CCM ) , an inverse agonist of the GABA ( A ) receptor benzodiazepine site .', {'entities': [(110, 118, 'B_Disease')]}], ['We measured diazepam - induced anxiolysis with the elevated plus - maze test , diazepam - induced sedation by recording the vigilance states , and picrotoxin - and pentylenetetrazol - induced seizures after i . p . injections .', {'entities': [(192, 200, 'B_Disease')]}], ['Propylthiouracil - induced perinuclear - staining antineutrophil cytoplasmic autoantibody - positive vasculitis in conjunction with pericarditis .', {'entities': [(101, 111, 'B_Disease'), (132, 144, 'B_Disease')]}], ['OBJECTIVE : To describe a case of propylthiouracil - induced vasculitis manifesting with pericarditis .', {'entities': [(61, 71, 'B_Disease'), (89, 101, 'B_Disease')]}], ['METHODS : We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis , fever , and glomerulonephritis developed .', {'entities': [(59, 74, 'B_Disease'), (127, 139, 'B_Disease'), (142, 147, 'B_Disease'), (154, 172, 'B_Disease')]}], [\"RESULTS : A 25 - year - old woman with Graves ' disease had a febrile illness and evidence of pericarditis , which was confirmed by biopsy .\", {'entities': [(39, 45, 'B_Disease'), (46, 47, 'I_Disease'), (48, 55, 'I_Disease'), (62, 69, 'B_Disease'), (70, 77, 'I_Disease'), (94, 106, 'B_Disease')]}], ['A literature review revealed no prior reports of pericarditis in anti - MPO pANCA - positive vasculitis associated with propylthio - uracil therapy .', {'entities': [(49, 61, 'B_Disease'), (93, 103, 'B_Disease')]}], ['CONCLUSION : Pericarditis may be the initial manifestation of drug - induced vasculitis attributable to propylthio - uracil therapy .', {'entities': [(13, 25, 'B_Disease'), (77, 87, 'B_Disease')]}], ['Repeated transient anuria following losartan administration in a patient with a solitary kidney .', {'entities': [(19, 25, 'B_Disease')]}], ['We report the case of a 70 - year - old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration .', {'entities': [(40, 52, 'B_Disease'), (84, 91, 'B_Disease'), (92, 97, 'I_Disease'), (98, 111, 'I_Disease'), (152, 158, 'B_Disease')]}], ['He was hospitalized for a myocardial infarction with pulmonary edema , treated with high - dose diuretics .', {'entities': [(26, 36, 'B_Disease'), (37, 47, 'I_Disease'), (53, 62, 'B_Disease'), (63, 68, 'I_Disease')]}], ['Due to severe systolic dysfunction losartan was prescribed .', {'entities': [(14, 22, 'B_Disease'), (23, 34, 'I_Disease')]}], ['Surprisingly , the first dose of 50 mg of losartan resulted in a sudden anuria , which lasted eight hours despite high - dose furosemide and amine infusion .', {'entities': [(72, 78, 'B_Disease')]}], ['One week later , by mistake , losartan was prescribed again and after the second dose of 50 mg , the patient developed a second episode of transient anuria lasting 10 hours .', {'entities': [(149, 155, 'B_Disease')]}], ['During these two episodes , his blood pressure diminished but no severe hypotension was noted .', {'entities': [(72, 83, 'B_Disease')]}], ['Ultimately , an arteriography showed a 70 - 80 % renal artery stenosis .', {'entities': [(49, 54, 'B_Disease'), (55, 61, 'I_Disease'), (62, 70, 'I_Disease')]}], ['In this patient , renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin - angiotensin system ( RAS ) .', {'entities': [(18, 23, 'B_Disease'), (24, 30, 'I_Disease'), (31, 39, 'I_Disease'), (54, 59, 'B_Disease'), (60, 67, 'I_Disease')]}], ['This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting .', {'entities': [(150, 162, 'B_Disease'), (163, 170, 'I_Disease')]}], ['Calcineurin - inhibitor induced pain syndrome ( CIPS ) : a severe disabling complication after organ transplantation .', {'entities': [(32, 36, 'B_Disease'), (48, 52, 'B_Disease')]}], ['Bone pain after transplantation is a frequent complication that can be caused by several diseases .', {'entities': [(5, 9, 'B_Disease')]}], ['Treatment strategies depend on the correct diagnosis of the pain .', {'entities': [(60, 64, 'B_Disease')]}], ['Nine patients with severe pain in their feet , which was registered after transplantation , were investigated .', {'entities': [(26, 30, 'B_Disease')]}], ['Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones .', {'entities': [(40, 44, 'B_Disease'), (45, 51, 'I_Disease'), (52, 58, 'I_Disease')]}], [\"Pain was not explained by other diseases causing foot pain , like reflex sympathetic dystrophy , polyneuropathy , Morton ' s neuralgia , gout , osteoporosis , avascular necrosis , intermittent claudication , orthopaedic foot deformities , stress fractures , and hyperparathyroidism .\", {'entities': [(0, 4, 'B_Disease'), (54, 58, 'B_Disease'), (66, 72, 'B_Disease'), (73, 84, 'I_Disease'), (85, 94, 'I_Disease'), (97, 111, 'B_Disease'), (114, 120, 'B_Disease'), (121, 122, 'I_Disease'), (123, 124, 'I_Disease'), (125, 134, 'I_Disease'), (137, 141, 'B_Disease'), (144, 156, 'B_Disease'), (159, 168, 'B_Disease'), (169, 177, 'I_Disease'), (180, 192, 'B_Disease'), (193, 205, 'I_Disease'), (220, 224, 'B_Disease'), (225, 236, 'I_Disease'), (239, 245, 'B_Disease'), (246, 255, 'I_Disease'), (262, 281, 'B_Disease')]}], ['The reduction of cyclosporine - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain .', {'entities': [(128, 132, 'B_Disease')]}], ['The Calcineurin - inhibitor Induced Pain Syndrome ( CIPS ) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .', {'entities': [(36, 40, 'B_Disease'), (52, 56, 'B_Disease')]}], ['Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS .', {'entities': [(116, 120, 'B_Disease')]}], ['Brain natriuretic peptide is a predictor of anthracycline - induced cardiotoxicity .', {'entities': [(68, 82, 'B_Disease')]}], ['Anthracyclines are effective antineoplastic drugs , but they frequently cause dose - related cardiotoxicity .', {'entities': [(93, 107, 'B_Disease')]}], ['The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction .', {'entities': [(4, 18, 'B_Disease'), (149, 156, 'B_Disease'), (157, 168, 'I_Disease')]}], ['We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline - induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin ( DNR ) - containing regimen .', {'entities': [(163, 177, 'B_Disease'), (195, 200, 'B_Disease'), (201, 209, 'I_Disease')]}], ['Thirteen patients with acute leukemia were treated with a DNR - containing regimen .', {'entities': [(23, 28, 'B_Disease'), (29, 37, 'I_Disease')]}], ['Three patients developed congestive heart failure after the completion of chemotherapy .', {'entities': [(25, 35, 'B_Disease'), (36, 41, 'I_Disease'), (42, 49, 'I_Disease')]}], ['Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy .', {'entities': [(51, 56, 'B_Disease'), (57, 64, 'I_Disease')]}], ['The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit ( 40 pg / ml ) before the detection of clinical or subclinical heart failure by radionuclide angiography .', {'entities': [(75, 80, 'B_Disease'), (81, 88, 'I_Disease'), (185, 190, 'B_Disease'), (191, 198, 'I_Disease')]}], ['On the other hand , BNP did not increase in the patients without heart failure given DNR , even at more than 700 mg / m ( 2 ) .', {'entities': [(65, 70, 'B_Disease'), (71, 78, 'I_Disease')]}], ['The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure .', {'entities': [(98, 103, 'B_Disease'), (104, 111, 'I_Disease')]}], ['These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline - induced cardiotoxicity .', {'entities': [(120, 134, 'B_Disease')]}], ['Nephrotoxicity of combined cephalothin - gentamicin regimen .', {'entities': [(0, 14, 'B_Disease')]}], ['Two patients developed acute tubular necrosis , characterized clinically by acute oliguric renal failure , while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy .', {'entities': [(23, 28, 'B_Disease'), (29, 36, 'I_Disease'), (37, 45, 'I_Disease'), (82, 90, 'B_Disease'), (91, 96, 'I_Disease'), (97, 104, 'I_Disease')]}], ['Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity .', {'entities': [(94, 108, 'B_Disease')]}], ['Patients with renal insufficiency should not be given this regimen .', {'entities': [(14, 19, 'B_Disease'), (20, 33, 'I_Disease')]}], ['In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .', {'entities': [(58, 66, 'B_Disease'), (110, 124, 'B_Disease'), (148, 152, 'B_Disease'), (153, 161, 'I_Disease'), (188, 202, 'B_Disease')]}], ['This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .', {'entities': [(129, 143, 'B_Disease'), (175, 179, 'B_Disease'), (180, 188, 'I_Disease'), (225, 239, 'B_Disease')]}], ['Histopathological examination of kidney , heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence .', {'entities': [(95, 101, 'B_Disease'), (102, 108, 'I_Disease')]}], ['Interestingly , all the drugs , such as , AAP , AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE .', {'entities': [(99, 107, 'B_Disease')]}], ['Antidepressant - induced mania in bipolar patients : identification of risk factors .', {'entities': [(25, 30, 'B_Disease'), (34, 41, 'B_Disease')]}], ['BACKGROUND : Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression .', {'entities': [(59, 64, 'B_Disease'), (179, 186, 'B_Disease'), (187, 197, 'I_Disease')]}], ['METHOD : The response of 44 patients meeting DSM - IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery - Asberg Depression Rating Scale and the Bech - Rafaelson Mania Rating Scale .', {'entities': [(67, 74, 'B_Disease'), (75, 83, 'I_Disease')]}], ['Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM - IV bipolar I vs . bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs . antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs . anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi - structured Affective Temperament Interview .', {'entities': [(27, 32, 'B_Disease'), (36, 45, 'B_Disease'), (145, 148, 'B_Disease'), (149, 150, 'I_Disease'), (151, 153, 'I_Disease'), (154, 161, 'I_Disease'), (162, 163, 'I_Disease'), (169, 176, 'B_Disease'), (177, 179, 'I_Disease'), (203, 208, 'B_Disease')]}], ['RESULTS : Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with SSRIs [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .', {'entities': [(22, 31, 'B_Disease'), (35, 40, 'B_Disease'), (188, 193, 'B_Disease'), (236, 245, 'B_Disease')]}], ['Sex , age , diagnosis ( bipolar I vs . bipolar II ) , and additional treatment did not affect the risk of switching .', {'entities': [(24, 31, 'B_Disease'), (32, 33, 'I_Disease'), (39, 46, 'B_Disease'), (47, 49, 'I_Disease')]}], ['The number of previous manic episodes did not affect the probability of switching , whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching ( p = . 008 ) .', {'entities': [(23, 28, 'B_Disease')]}], ['Peritubular capillary basement membrane reduplication in allografts and native kidney disease : a clinicopathologic study of 278 consecutive renal specimens .', {'entities': [(79, 85, 'B_Disease'), (86, 93, 'I_Disease')]}], ['BACKGROUND : An association has been found between transplant glomerulopathy ( TG ) and reduplication of peritubular capillary basement membranes ( PTCR ) .', {'entities': [(51, 61, 'B_Disease'), (62, 76, 'I_Disease'), (79, 81, 'B_Disease')]}], ['In addition to renal allografts with TG , we also examined grafts with acute rejection , recurrent glomerulonephritis , chronic allograft nephropathy and stable grafts ( \" protocol biopsies \" ) .', {'entities': [(37, 39, 'B_Disease'), (99, 117, 'B_Disease'), (120, 127, 'B_Disease'), (128, 137, 'I_Disease'), (138, 149, 'I_Disease')]}], ['Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy , malignant hypertension , acute interstitial nephritis , and acute tubular necrosis .', {'entities': [(49, 65, 'B_Disease'), (86, 96, 'B_Disease'), (97, 112, 'I_Disease'), (115, 124, 'B_Disease'), (125, 137, 'I_Disease'), (146, 158, 'B_Disease'), (159, 168, 'I_Disease'), (175, 180, 'B_Disease'), (181, 188, 'I_Disease'), (189, 197, 'I_Disease')]}], ['RESULTS : We found PTCR in 14 of 15 cases of TG , in 7 transplant biopsy specimens without TG , and in 13 of 143 native kidney biopsy specimens .', {'entities': [(45, 47, 'B_Disease'), (91, 93, 'B_Disease')]}], ['These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and cocaine - related acute renal failure .', {'entities': [(27, 36, 'B_Disease'), (37, 49, 'I_Disease'), (52, 62, 'B_Disease'), (63, 78, 'I_Disease'), (81, 86, 'B_Disease'), (87, 96, 'I_Disease'), (99, 105, 'B_Disease'), (106, 107, 'I_Disease'), (108, 117, 'I_Disease'), (118, 127, 'I_Disease'), (141, 159, 'B_Disease'), (184, 189, 'B_Disease'), (190, 195, 'I_Disease'), (196, 203, 'I_Disease')]}], ['Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow - up periods of between 3 months and 1 year .', {'entities': [(32, 34, 'B_Disease'), (51, 56, 'B_Disease'), (57, 64, 'I_Disease'), (80, 91, 'B_Disease')]}], ['CONCLUSIONS : We conclude that in transplants , there is a strong association between well - developed PTCR and TG , while the significance of mild PTCR and its predictive value in the absence of TG is unclear .', {'entities': [(112, 114, 'B_Disease'), (196, 198, 'B_Disease')]}], ['PTCR also occurs in certain native kidney diseases , though the association is not as strong as that for TG .', {'entities': [(35, 41, 'B_Disease'), (42, 50, 'I_Disease'), (105, 107, 'B_Disease')]}], ['We suggest that repeated endothelial injury , including immunologic injury , may be the cause of this lesion both in allografts and native kidneys .', {'entities': [(25, 36, 'B_Disease'), (37, 43, 'I_Disease'), (56, 67, 'B_Disease'), (68, 74, 'I_Disease')]}], ['Caffeine - induced cardiac arrhythmia : an unrecognised danger of healthfood products .', {'entities': [(19, 26, 'B_Disease'), (27, 37, 'I_Disease')]}], ['We describe a 25 - year - old woman with pre - existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a \" natural energy \" guarana health drink containing a high concentration of caffeine .', {'entities': [(56, 62, 'B_Disease'), (63, 68, 'I_Disease'), (69, 77, 'I_Disease'), (104, 115, 'B_Disease'), (116, 128, 'I_Disease')]}], ['In behavioral studies , pre - treatment of mice with BD1018 , BD1063 , or LR132 significantly attenuated cocaine - induced convulsions and lethality .', {'entities': [(123, 134, 'B_Disease')]}], ['In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral toxicity of cocaine .', {'entities': [(320, 328, 'B_Disease')]}], ['To further validate the hypothesis that the anti - cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine .', {'entities': [(234, 244, 'B_Disease')]}], ['Ranitidine - induced acute interstitial nephritis in a cadaveric renal allograft .', {'entities': [(27, 39, 'B_Disease'), (40, 49, 'I_Disease')]}], ['This drug occasionally has been associated with acute interstitial nephritis in native kidneys .', {'entities': [(54, 66, 'B_Disease'), (67, 76, 'I_Disease')]}], ['We report a case of ranitidine - induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug .', {'entities': [(47, 59, 'B_Disease'), (60, 69, 'I_Disease')]}], ['Liver disease caused by propylthiouracil .', {'entities': [(0, 5, 'B_Disease'), (6, 13, 'I_Disease')]}], ['This report presents the clinical , laboratory , and light and electron microscopic observations on a patient with chronic active ( aggressive ) hepatitis caused by the administration of propylthiouracil .', {'entities': [(115, 122, 'B_Disease'), (123, 129, 'I_Disease'), (130, 131, 'I_Disease'), (132, 142, 'I_Disease'), (143, 144, 'I_Disease'), (145, 154, 'I_Disease')]}], ['This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease .', {'entities': [(94, 99, 'B_Disease'), (100, 107, 'I_Disease')]}], ['Withdrawal - emergent rabbit syndrome during dose reduction of risperidone .', {'entities': [(0, 10, 'B_Disease'), (11, 12, 'I_Disease'), (13, 21, 'I_Disease'), (22, 28, 'I_Disease'), (29, 37, 'I_Disease')]}], ['Rabbit syndrome ( RS ) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication .', {'entities': [(0, 6, 'B_Disease'), (7, 15, 'I_Disease'), (18, 20, 'B_Disease')]}], ['Here we present a case of withdrawal - emergent RS , which is the first of its kind to be reported .', {'entities': [(26, 36, 'B_Disease'), (37, 38, 'I_Disease'), (39, 47, 'I_Disease'), (48, 50, 'I_Disease')]}], ['The patient developed RS during dose reduction of risperidone .', {'entities': [(22, 24, 'B_Disease')]}], ['The underlying mechanism of withdrawal - emergent RS in the present case may have been related to the pharmacological profile of risperidone , a serotonin - dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .', {'entities': [(28, 38, 'B_Disease'), (39, 40, 'I_Disease'), (41, 49, 'I_Disease'), (50, 52, 'I_Disease'), (267, 269, 'B_Disease')]}], ['Torsades de pointes ( TDP ) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration ( MAPD ) .', {'entities': [(0, 8, 'B_Disease'), (9, 11, 'I_Disease'), (12, 19, 'I_Disease'), (22, 25, 'B_Disease'), (51, 62, 'B_Disease'), (63, 74, 'I_Disease')]}], ['TDP is a side - effect that has led to withdrawal of several drugs from the market ( e . g . terfenadine and terodiline ) .', {'entities': [(0, 3, 'B_Disease')]}], ['The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog .', {'entities': [(36, 39, 'B_Disease')]}], ['Four compounds known to increase QT interval and cause TDP were investigated : terfenadine , terodiline , cisapride and E4031 .', {'entities': [(55, 58, 'B_Disease')]}], ['For compounds that have shown TDP in the clinic ( terfenadine , terodiline , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10 - fold ) reflecting their limited safety margins .', {'entities': [(30, 33, 'B_Disease')]}], ['These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic / pharmacodynamic studies .', {'entities': [(80, 83, 'B_Disease')]}], ['Bladder retention of urine as a result of continuous intravenous infusion of fentanyl : 2 case reports .', {'entities': [(8, 17, 'B_Disease'), (18, 20, 'I_Disease'), (21, 26, 'I_Disease')]}], ['Sedation has been commonly used in the neonate to decrease the stress and pain from the noxious stimuli and invasive procedures in the neonatal intensive care unit , as well as to facilitate synchrony between ventilator and spontaneous breaths .', {'entities': [(74, 78, 'B_Disease')]}], ['Various reported side effects of fentanyl administration include chest wall rigidity , hypotension , respiratory depression , and bradycardia .', {'entities': [(65, 70, 'B_Disease'), (71, 75, 'I_Disease'), (76, 84, 'I_Disease'), (87, 98, 'B_Disease'), (101, 112, 'B_Disease'), (113, 123, 'I_Disease'), (130, 141, 'B_Disease')]}], ['Here , 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported .', {'entities': [(18, 25, 'B_Disease'), (26, 33, 'I_Disease'), (34, 43, 'I_Disease'), (96, 110, 'B_Disease')]}], ['Fatal myeloencephalopathy due to accidental intrathecal vincristin administration : a report of two cases .', {'entities': [(6, 25, 'B_Disease')]}], ['We report on two fatal cases of accidental intrathecal vincristine instillation in a 5 - year old girl with recurrent acute lymphoblastic leucemia and a 57 - year old man with lymphoblastic lymphoma .', {'entities': [(118, 123, 'B_Disease'), (124, 137, 'I_Disease'), (138, 146, 'I_Disease'), (176, 189, 'B_Disease'), (190, 198, 'I_Disease')]}], ['Clinically , the onset was characterized by the signs of opistothonus , sensory and motor dysfunction and ascending paralysis .', {'entities': [(57, 69, 'B_Disease'), (70, 71, 'I_Disease'), (72, 79, 'I_Disease'), (80, 83, 'I_Disease'), (84, 89, 'I_Disease'), (90, 101, 'I_Disease'), (116, 125, 'B_Disease')]}], ['Histological and immunohistochemical investigations ( HE - LFB , CD - 68 , Neurofilament ) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine , accompanied by secondary changes with numerous prominent macrophages .', {'entities': [(100, 112, 'B_Disease'), (113, 115, 'I_Disease'), (116, 122, 'I_Disease'), (123, 126, 'I_Disease'), (127, 132, 'I_Disease'), (144, 156, 'B_Disease'), (157, 171, 'I_Disease')]}], ['Palpebral twitching in a depressed adolescent on citalopram .', {'entities': [(0, 9, 'B_Disease'), (10, 19, 'I_Disease'), (25, 34, 'B_Disease')]}], ['Current estimates suggest that between 0 . 4 % and 8 . 3 % of children and adolescents are affected by major depression .', {'entities': [(103, 108, 'B_Disease'), (109, 119, 'I_Disease')]}], ['We report a favorable response to treatment with citalopram by a 15 - year - old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment .', {'entities': [(90, 95, 'B_Disease'), (96, 106, 'I_Disease'), (121, 130, 'B_Disease'), (131, 140, 'I_Disease')]}], ['A 34 - year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral sulphasalazine for sero - negative rheumatoid arthritis .', {'entities': [(52, 62, 'B_Disease'), (65, 70, 'B_Disease'), (73, 88, 'B_Disease'), (93, 102, 'B_Disease'), (186, 196, 'B_Disease'), (197, 206, 'I_Disease')]}], ['Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis , associated with erythrophagocytosis and prominent eosinophilic infiltrates , without viral inclusion bodies , suggestive of an adverse drug reaction . A week later , fulminant drug - induced hepatitis , associated with the presence of anti - nuclear autoantibodies ( but not with other markers of autoimmunity ) , and accompanied by multi - organ failure and sepsis , supervened .', {'entities': [(84, 97, 'B_Disease'), (227, 234, 'B_Disease'), (235, 239, 'I_Disease'), (240, 248, 'I_Disease'), (276, 280, 'B_Disease'), (281, 282, 'I_Disease'), (283, 290, 'I_Disease'), (291, 300, 'I_Disease'), (397, 409, 'B_Disease'), (433, 438, 'B_Disease'), (439, 440, 'I_Disease'), (441, 446, 'I_Disease'), (447, 454, 'I_Disease'), (459, 465, 'B_Disease')]}], ['She subsequently died some 5 weeks after the commencement of her drug therapy . Post - mortem examination showed evidence of massive hepatocellular necrosis , acute hypersensitivity myocarditis , focal acute tubulo - interstitial nephritis and extensive bone marrow necrosis , with no evidence of malignancy .', {'entities': [(125, 132, 'B_Disease'), (133, 147, 'I_Disease'), (148, 156, 'I_Disease'), (182, 193, 'B_Disease'), (230, 239, 'B_Disease'), (254, 258, 'B_Disease'), (259, 265, 'I_Disease'), (266, 274, 'I_Disease'), (297, 307, 'B_Disease')]}], ['Intravenous administration of prochlorperazine by 15 - minute infusion versus 2 - minute bolus does not affect the incidence of akathisia : a prospective , randomized , controlled trial .', {'entities': [(128, 137, 'B_Disease')]}], ['STUDY OBJECTIVE : We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2 - minute bolus or 15 - minute infusion .', {'entities': [(51, 60, 'B_Disease')]}], ['Patients aged 18 years or older treated with prochlorperazine for headache , nausea , or vomiting were eligible for inclusion .', {'entities': [(66, 74, 'B_Disease'), (77, 83, 'B_Disease'), (89, 97, 'B_Disease')]}], ['The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration .', {'entities': [(67, 76, 'B_Disease')]}], ['Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient - reported akathisia rating scale and a change of at least 1 in the investigator - observed akathisia rating scale .', {'entities': [(72, 81, 'B_Disease'), (133, 142, 'B_Disease'), (214, 223, 'B_Disease')]}], ['The intensity of headache and nausea was measured with a 100 - mm visual analog scale .', {'entities': [(17, 25, 'B_Disease'), (30, 36, 'B_Disease')]}], ['Seventy - three percent ( 73 / 99 ) of the study participants were treated for headache and 70 % ( 70 / 99 ) for nausea .', {'entities': [(79, 87, 'B_Disease'), (113, 119, 'B_Disease')]}], ['In the bolus group , 26 . 0 % ( 13 / 50 ) had akathisia compared with 32 . 7 % ( 16 / 49 ) in the infusion group ( Delta = - 6 . 7 % ; 95 % confidence interval [ CI ] - 24 . 6 % to 11 . 2 % ) .', {'entities': [(46, 55, 'B_Disease')]}], ['The difference between the bolus and infusion groups in the percentage of participants who saw a 50 % reduction in their headache intensity within 30 minutes was 11 . 8 % ( 95 % CI - 9 . 6 % to 33 . 3 % ) .', {'entities': [(121, 129, 'B_Disease')]}], ['The difference in the percentage of patients with a 50 % reduction in their nausea was 12 . 6 % ( 95 % CI - 4 . 6 % to 29 . 8 % ) .', {'entities': [(76, 82, 'B_Disease')]}], ['CONCLUSION : A 50 % reduction in the incidence of akathisia when prochlorperazine was administered by means of 15 - minute intravenous infusion versus a 2 - minute intravenous push was not detected .', {'entities': [(50, 59, 'B_Disease')]}], ['The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .', {'entities': [(53, 61, 'B_Disease'), (66, 72, 'B_Disease')]}], ['Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice .', {'entities': [(39, 53, 'B_Disease'), (96, 100, 'B_Disease')]}], ['Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .', {'entities': [(64, 78, 'B_Disease'), (81, 83, 'B_Disease'), (127, 131, 'B_Disease'), (154, 167, 'B_Disease'), (168, 179, 'I_Disease')]}], ['To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic AIDS mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of zidovudine , lamivudine , and indinavir or vehicle control for 10 days or 35 days .', {'entities': [(92, 96, 'B_Disease')]}], ['At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of CM ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic calcium ATPase [ SERCA2 ] ) , and determination of plasma LA .', {'entities': [(120, 122, 'B_Disease')]}], ['Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice .', {'entities': [(56, 58, 'B_Disease'), (79, 83, 'B_Disease')]}], ['A Phase II trial of cisplatin plus WR - 2721 ( amifostine ) for metastatic breast carcinoma : an Eastern Cooperative Oncology Group Study ( E8188 ) .', {'entities': [(75, 81, 'B_Disease'), (82, 91, 'I_Disease')]}], ['BACKGROUND : Cisplatin has minimal antitumor activity when used as second - or third - line treatment of metastatic breast carcinoma .', {'entities': [(116, 122, 'B_Disease'), (123, 132, 'I_Disease')]}], ['Although a dose - response effect has been observed with cisplatin , the dose - limiting toxicities associated with cisplatin ( e . g . , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .', {'entities': [(89, 99, 'B_Disease'), (138, 152, 'B_Disease'), (155, 166, 'B_Disease'), (173, 186, 'B_Disease'), (229, 235, 'B_Disease'), (236, 245, 'I_Disease')]}], ['Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin - induced nephrotoxicity , ototoxicity , and neuropathy were reduced .', {'entities': [(111, 125, 'B_Disease'), (128, 139, 'B_Disease'), (146, 156, 'B_Disease')]}], ['METHODS : A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one , but not more than one , chemotherapy regimen for metastatic disease .', {'entities': [(129, 135, 'B_Disease'), (136, 145, 'I_Disease')]}], ['Neurologic toxicity was reported in 52 % of patients .', {'entities': [(0, 10, 'B_Disease'), (11, 19, 'I_Disease')]}], ['Seven different life - threatening toxicities were observed in patients while receiving treatment .', {'entities': [(35, 45, 'B_Disease')]}], ['Neither a tumor - protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial .', {'entities': [(10, 15, 'B_Disease'), (48, 56, 'B_Disease')]}], ['Oral contraceptives and the risk of myocardial infarction .', {'entities': [(36, 46, 'B_Disease'), (47, 57, 'I_Disease')]}], ['BACKGROUND : An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some , but not all , studies .', {'entities': [(83, 93, 'B_Disease'), (94, 104, 'I_Disease')]}], ['We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .', {'entities': [(451, 461, 'B_Disease'), (462, 472, 'I_Disease'), (535, 545, 'B_Disease'), (546, 556, 'I_Disease')]}], ['An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS : The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive , as compared with nonusers , was 2 . 0 ( 95 percent confidence interval , 1 . 5 to 2 . 8 ) .', {'entities': [(157, 167, 'B_Disease'), (168, 178, 'I_Disease')]}], ['Among women who used oral contraceptives , the odds ratio was 2 . 1 ( 95 percent confidence interval , 1 . 5 to 3 . 0 ) for those without a prothrombotic mutation and 1 . 9 ( 95 percent confidence interval , 0 . 6 to 5 . 5 ) for those with a mutation CONCLUSIONS : The risk of myocardial infarction was increased among women who used second - generation oral contraceptives .', {'entities': [(277, 287, 'B_Disease'), (288, 298, 'I_Disease')]}], ['The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation .', {'entities': [(12, 22, 'B_Disease'), (23, 33, 'I_Disease')]}], ['End - stage renal disease ( ESRD ) after orthotopic liver transplantation ( OLTX ) using calcineurin - based immunotherapy : risk of development and treatment .', {'entities': [(0, 3, 'B_Disease'), (4, 5, 'I_Disease'), (6, 11, 'I_Disease'), (12, 17, 'I_Disease'), (18, 25, 'I_Disease'), (28, 32, 'B_Disease')]}], ['BACKGROUND : The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic .', {'entities': [(89, 100, 'B_Disease')]}], ['Recently , however , we have had an increase of patients who are presenting after OLTX with end - stage renal disease ( ESRD ) .', {'entities': [(92, 95, 'B_Disease'), (96, 97, 'I_Disease'), (98, 103, 'I_Disease'), (104, 109, 'I_Disease'), (110, 117, 'I_Disease'), (120, 124, 'B_Disease')]}], ['This retrospective study examines the incidence and treatment of ESRD and chronic renal failure ( CRF ) in OLTX patients .', {'entities': [(65, 69, 'B_Disease'), (74, 81, 'B_Disease'), (82, 87, 'I_Disease'), (88, 95, 'I_Disease'), (98, 101, 'B_Disease')]}], ['Patients were divided into three groups : Controls , no CRF or ESRD , n = 748 ; CRF , sustained serum creatinine > 2 . 5 mg / dl , n = 41 ; and ESRD , n = 45 .', {'entities': [(56, 59, 'B_Disease'), (63, 67, 'B_Disease'), (80, 83, 'B_Disease'), (144, 148, 'B_Disease')]}], ['Groups were compared for preoperative laboratory variables , diagnosis , postoperative variables , survival , type of ESRD therapy , and survival from onset of ESRD .', {'entities': [(118, 122, 'B_Disease'), (160, 164, 'B_Disease')]}], ['RESULTS : At 13 years after OLTX , the incidence of severe renal dysfunction was 18 . 1 % ( CRF 8 . 6 % and ESRD 9 . 5 % ) .', {'entities': [(59, 64, 'B_Disease'), (65, 76, 'I_Disease'), (92, 95, 'B_Disease'), (108, 112, 'B_Disease')]}], ['Compared with control patients , CRF and ESRD patients had higher preoperative serum creatinine levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum creatinine .', {'entities': [(33, 36, 'B_Disease'), (41, 45, 'B_Disease'), (143, 154, 'B_Disease'), (155, 163, 'I_Disease')]}], ['Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year , 3 months , and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2 . 6 , 2 . 2 , and 1 . 6 , respectively .', {'entities': [(272, 275, 'B_Disease'), (279, 283, 'B_Disease')]}], ['Overall survival from the time of OLTX was not significantly different among groups , but by year 13 , the survival of the patients who had ESRD was only 28 . 2 % compared with 54 . 6 % in the control group .', {'entities': [(140, 144, 'B_Disease')]}], ['Patients developing ESRD had a 6 - year survival after onset of ESRD of 27 % for the patients receiving hemodialysis versus 71 . 4 % for the patients developing ESRD who subsequently received kidney transplants .', {'entities': [(20, 24, 'B_Disease'), (64, 68, 'B_Disease'), (161, 165, 'B_Disease')]}], ['CONCLUSIONS : Patients who are more than 10 years post - OLTX have CRF and ESRD at a high rate .', {'entities': [(67, 70, 'B_Disease'), (75, 79, 'B_Disease')]}], ['The development of ESRD decreases survival , particularly in those patients treated with dialysis only .', {'entities': [(19, 23, 'B_Disease')]}], ['Patients who develop ESRD have a higher preoperative and 1 - year serum creatinine and are more likely to have hepatorenal syndrome .', {'entities': [(21, 25, 'B_Disease'), (111, 122, 'B_Disease'), (123, 131, 'I_Disease')]}], ['However , an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD .', {'entities': [(116, 119, 'B_Disease'), (123, 127, 'B_Disease')]}], ['Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats .', {'entities': [(0, 9, 'B_Disease'), (10, 18, 'I_Disease')]}], ['However , tAMCA has been shown to cause epileptic seizures .', {'entities': [(40, 49, 'B_Disease'), (50, 58, 'I_Disease')]}], ['We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS .', {'entities': [(45, 55, 'B_Disease')]}], ['FINDINGS : FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours .', {'entities': [(99, 109, 'B_Disease')]}], ['The degree of these seizures increased with increasing concentration of tAMCA .', {'entities': [(20, 28, 'B_Disease')]}], ['Thus , FS containing 47 . 5 mg / ml tAMCA evoked generalized seizures in all tested rats ( n = 6 ) while the lowest concentration of tAMCA ( 0 . 5 mg / ml ) only evoked brief episodes of jerk - correlated convulsive potentials in 1 of 6 rats .', {'entities': [(49, 60, 'B_Disease'), (61, 69, 'I_Disease'), (205, 215, 'B_Disease')]}], ['INTERPRETATION : Tranexamic acid retains its convulsive action within FS .', {'entities': [(45, 55, 'B_Disease')]}], ['Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system : analysis of the mechanism of transformation from exencephaly to anencephaly .', {'entities': [(27, 38, 'B_Disease'), (165, 176, 'B_Disease'), (180, 191, 'B_Disease')]}], ['Anencephaly has been suggested to develop from exencephaly ; however , there is little direct experimental evidence to support this , and the mechanism of transformation remains unclear .', {'entities': [(0, 11, 'B_Disease'), (47, 58, 'B_Disease')]}], ['We observed the exencephaly induced by 5 - azacytidine at embryonic day 13 . 5 ( E13 . 5 ) , let the embryos develop exo utero until E18 . 5 , and re - observed the same embryos at E18 . 5 .', {'entities': [(16, 27, 'B_Disease')]}], ['We confirmed several cases of transformation from exencephaly to anencephaly .', {'entities': [(50, 61, 'B_Disease'), (65, 76, 'B_Disease')]}], ['However , in many cases , the exencephalic brain tissue was preserved with more or less reduction during this period .', {'entities': [(30, 42, 'B_Disease')]}], ['To analyze the transformation patterns , we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13 . 5 and E18 . 5 .', {'entities': [(59, 70, 'B_Disease'), (96, 108, 'B_Disease')]}], ['It was found that the transformation of exencephalic tissue was not simply size - dependent , and all cases of anencephaly at E18 . 5 resulted from embryos with a large amount of exencephalic tissue at E13 . 5 .', {'entities': [(40, 52, 'B_Disease'), (111, 122, 'B_Disease'), (179, 191, 'B_Disease')]}], ['Microscopic observation showed the configuration of exencephaly at E13 . 5 , frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15 . 5 , and multiple modes of reduction in the exencephalic tissue at E18 . 5 .', {'entities': [(52, 63, 'B_Disease'), (86, 98, 'B_Disease'), (163, 175, 'B_Disease'), (233, 245, 'B_Disease')]}], ['From observations of the vasculature , altered distribution patterns of vessels were identified in the exencephalic head .', {'entities': [(103, 115, 'B_Disease')]}], ['These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels , subsequent peripheral circulatory failure and / or hemorrhaging in various parts of the exencephalic head , leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly .', {'entities': [(46, 58, 'B_Disease'), (149, 160, 'B_Disease'), (161, 168, 'I_Disease'), (178, 190, 'B_Disease'), (215, 227, 'B_Disease'), (312, 323, 'B_Disease'), (327, 338, 'B_Disease')]}], ['99mTc - glucarate for detection of isoproterenol - induced myocardial infarction in rats .', {'entities': [(59, 69, 'B_Disease'), (70, 80, 'I_Disease')]}], ['Infarct - avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction .', {'entities': [(0, 7, 'B_Disease'), (90, 100, 'B_Disease'), (101, 111, 'I_Disease')]}], ['The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol .', {'entities': [(33, 43, 'B_Disease')]}], ['A new infarct - avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ .', {'entities': [(6, 13, 'B_Disease')]}], ['99mTc - glucarate was easy to prepare , stable for 96 h and was used to study its biodistribution in rats with isoproterenol - induced acute myocardial infarction .', {'entities': [(141, 151, 'B_Disease'), (152, 162, 'I_Disease')]}], ['Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration .', {'entities': [(61, 68, 'B_Disease')]}], ['The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect , in patients , early cardiac infarction .', {'entities': [(163, 170, 'B_Disease'), (171, 181, 'I_Disease')]}], ['Bupropion ( Zyban ) toxicity .', {'entities': [(20, 28, 'B_Disease')]}], [\"In the initial 6 months since it ' s introduction , 12 overdose cases have been reported to The National Poisons Information Centre .\", {'entities': [(55, 63, 'B_Disease')]}], ['8 patients developed symptoms of toxicity .', {'entities': [(33, 41, 'B_Disease')]}], ['Common features included tachycardia , drowsiness , hallucinations and convulsions .', {'entities': [(25, 36, 'B_Disease'), (52, 66, 'B_Disease'), (71, 82, 'B_Disease')]}], ['Two patients developed severe cardiac arrhythmias , including one patient who was resuscitated following a cardiac arrest .', {'entities': [(30, 37, 'B_Disease'), (38, 49, 'I_Disease'), (107, 114, 'B_Disease'), (115, 121, 'I_Disease')]}], ['Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine .', {'entities': [(10, 18, 'B_Disease'), (64, 75, 'B_Disease')]}], ['Zyban caused significant neurological and cardiovascular toxicity in overdose .', {'entities': [(25, 37, 'B_Disease'), (38, 41, 'I_Disease'), (42, 56, 'I_Disease'), (57, 65, 'I_Disease'), (69, 77, 'B_Disease')]}], ['GLEPP1 receptor tyrosine phosphatase ( Ptpro ) in rat PAN nephrosis .', {'entities': [(58, 67, 'B_Disease')]}], ['To better understand the utility of GLEPP1 as a marker of glomerular injury , the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry , Western blot and RNase protection assay in a model of podocyte injury in the rat .', {'entities': [(58, 68, 'B_Disease'), (69, 75, 'I_Disease')]}], ['Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside ( PAN , 20 mg / 100g BW ) .', {'entities': [(26, 35, 'B_Disease')]}], ['Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement ( days 5 - 11 ) and the chronic phase of proteinuria associated with glomerulosclerosis ( days 45 - 126 ) .', {'entities': [(129, 140, 'B_Disease'), (222, 233, 'B_Disease'), (250, 268, 'B_Disease')]}], ['Antithymocyte globulin in the treatment of D - penicillamine - induced aplastic anemia .', {'entities': [(71, 79, 'B_Disease'), (80, 86, 'I_Disease')]}], ['A patient who received antithymocyte globulin therapy for aplastic anemia due to D - penicillamine therapy is described .', {'entities': [(58, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['Use of antithymocyte globulin may be the optimal treatment of D - penicillamine - induced aplastic anemia .', {'entities': [(90, 98, 'B_Disease'), (99, 105, 'I_Disease')]}], ['Metamizol potentiates morphine antinociception but not constipation after chronic treatment .', {'entities': [(55, 67, 'B_Disease')]}], ['This work evaluates the antinociceptive and constipating effects of the combination of 3 . 2 mg / kg s . c . morphine with 177 . 8 mg / kg s . c . metamizol in acutely and chronically treated ( once a day for 12 days ) rats .', {'entities': [(44, 56, 'B_Disease')]}], ['On the 13th day , antinociceptive effects were assessed using a model of inflammatory nociception , pain - induced functional impairment model , and the charcoal meal test was used to evaluate the intestinal transit .', {'entities': [(100, 104, 'B_Disease')]}], ['In independent groups , morphine inhibited the intestinal transit in 48 + / - 4 % and 38 + / - 4 % after acute and chronic treatment , respectively , suggesting that tolerance did not develop to the constipating effects .', {'entities': [(199, 211, 'B_Disease')]}], ['The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that metamizol did not potentiate morphine - induced constipation .', {'entities': [(184, 196, 'B_Disease')]}], ['These findings show a significant interaction between morphine and metamizol in chronically treated rats , suggesting that this combination could be useful for the treatment of chronic pain .', {'entities': [(177, 184, 'B_Disease'), (185, 189, 'I_Disease')]}], ['Ifosfamide encephalopathy presenting with asterixis .', {'entities': [(11, 25, 'B_Disease'), (42, 51, 'B_Disease')]}], ['We report a case of a 51 - year - old man who developed severe , disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma .', {'entities': [(84, 93, 'B_Disease'), (166, 178, 'B_Disease')]}], ['Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities .', {'entities': [(85, 95, 'B_Disease'), (96, 103, 'I_Disease'), (104, 106, 'I_Disease'), (107, 110, 'I_Disease'), (111, 116, 'I_Disease'), (121, 130, 'B_Disease'), (131, 144, 'I_Disease')]}], ['An electroencephalogram showed continuous , generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy .', {'entities': [(135, 149, 'B_Disease')]}], ['The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely .', {'entities': [(70, 79, 'B_Disease')]}], ['In the patient described , the presence of asterixis during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX .', {'entities': [(43, 52, 'B_Disease'), (227, 236, 'B_Disease')]}], ['Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine - induced anemia and in bone marrow endothelial cells .', {'entities': [(90, 96, 'B_Disease')]}], ['Azidothymidine ( AZT ) - induced anemia in mice can be reversed by the administration of IGF - IL - 3 ( fusion protein of insulin - like growth factor II ( IGF II ) and interleukin 3 ) .', {'entities': [(33, 39, 'B_Disease')]}], ['The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure - prone and withdrawal seizure - resistant selected mouse lines .', {'entities': [(112, 119, 'B_Disease'), (143, 150, 'B_Disease')]}], ['METHODS : Cholinergic convulsant sensitivity was examined in alcohol - na ve Withdrawal Seizure - Prone ( WSP ) and - Resistant ( WSR ) mice .', {'entities': [(88, 95, 'B_Disease')]}], ['Animals were administered nicotine , carbachol , or neostigmine via timed tail vein infusion , and the latencies to onset of tremor and clonus were recorded and converted to threshold dose .', {'entities': [(125, 131, 'B_Disease')]}], ['Hippocampal ACh also was measured during testing for handling - induced convulsions .', {'entities': [(72, 83, 'B_Disease')]}], ['RESULTS : Sensitivity to several convulsion endpoints induced by nicotine , carbachol , and neostigmine were significantly greater in WSR versus WSP mice .', {'entities': [(33, 43, 'B_Disease')]}], ['When hippocampal ACh was measured during testing for handling - induced convulsions , extracellular ACh was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .', {'entities': [(72, 83, 'B_Disease')]}], ['CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal .', {'entities': [(121, 132, 'B_Disease')]}], ['Specifically , WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons .', {'entities': [(66, 77, 'B_Disease')]}], ['Capsaicin - induced muscle pain alters the excitability of the human jaw - stretch reflex .', {'entities': [(20, 26, 'B_Disease'), (27, 31, 'I_Disease')]}], ['The pathophysiology of painful temporomandibular disorders is not fully understood , but evidence suggests that muscle pain modulates motor function in characteristic ways .', {'entities': [(31, 48, 'B_Disease'), (49, 58, 'I_Disease'), (112, 118, 'B_Disease'), (119, 123, 'I_Disease')]}], ['This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw - stretch reflex and whether this process would be sensitive to length and velocity of the stretch .', {'entities': [(52, 63, 'B_Disease'), (64, 70, 'I_Disease')]}], ['Capsaicin ( 10 micro g ) was injected into the masseter muscle to induce pain in 11 healthy volunteers .', {'entities': [(73, 77, 'B_Disease')]}], ['Short - latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before , during , and after the pain .', {'entities': [(180, 184, 'B_Disease')]}], ['The normalized reflex amplitude was significantly higher during pain , but only at faster stretches in the painful muscle .', {'entities': [(64, 68, 'B_Disease'), (107, 114, 'B_Disease'), (115, 121, 'I_Disease')]}], ['Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings .', {'entities': [(59, 65, 'B_Disease'), (66, 70, 'I_Disease')]}], ['Effects of 5 - HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine - induced locomotor hyperactivity in rats .', {'entities': [(108, 117, 'B_Disease'), (118, 131, 'I_Disease')]}], ['The present study was designed to examine the effect of 5 - HT1B receptor ligands microinjected into the subregions of the nucleus accumbens ( the shell and the core ) on the locomotor hyperactivity induced by cocaine in rats .', {'entities': [(175, 184, 'B_Disease'), (185, 198, 'I_Disease')]}], ['GR 55562 ( 0 . 1 - 10 microg / side ) , administered intra - accumbens shell prior to cocaine , dose - dependently attenuated the psychostimulant - induced locomotor hyperactivity .', {'entities': [(156, 165, 'B_Disease'), (166, 179, 'I_Disease')]}], ['Our findings indicate that cocaine induced hyperlocomotion is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( GR 55562 ) and agonist ( CP 93129 ) , respectively .', {'entities': [(43, 58, 'B_Disease')]}], ['Cocaine related chest pain : are we seeing the tip of an iceberg ?', {'entities': [(16, 21, 'B_Disease'), (22, 26, 'I_Disease')]}], ['In particular , the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk .', {'entities': [(51, 56, 'B_Disease'), (57, 61, 'I_Disease'), (143, 148, 'B_Disease'), (149, 153, 'I_Disease')]}], ['The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed .', {'entities': [(17, 22, 'B_Disease'), (23, 27, 'I_Disease')]}], ['Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine / caffeine in migraine .', {'entities': [(102, 110, 'B_Disease')]}], ['Rizatriptan is a selective 5 - HT ( 1B / 1D ) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine .', {'entities': [(142, 150, 'B_Disease')]}], ['This randomized double - blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg / caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy .', {'entities': [(194, 202, 'B_Disease')]}], ['Faster relief of headache was the most important reason for preference , cited by 67 . 3 % of patients preferring rizatriptan and 54 . 2 % of patients who preferred ergotamine / caffeine .', {'entities': [(17, 25, 'B_Disease')]}], ['The co - primary endpoint of being pain free at 2 h was also in favor of rizatriptan .', {'entities': [(35, 39, 'B_Disease')]}], ['Forty - nine percent of patients were pain free 2 h after rizatriptan , compared with 24 . 3 % treated with ergotamine / caffeine ( p < or = 0 . 001 ) , rizatriptan being superior within 1 h of treatment .', {'entities': [(38, 42, 'B_Disease')]}], ['Headache relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for ergotamine / caffeine ( p < or = 0 . 001 ) , with rizatriptan being superior to ergotamine / caffeine within 30 min of dosing .', {'entities': [(0, 8, 'B_Disease')]}], ['Almost 36 % of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on ergotamine / caffeine ( p < or = 0 . 001 ) .', {'entities': [(48, 52, 'B_Disease')]}], ['Rizatriptan was also superior to ergotamine / caffeine in the proportions of patients with no nausea , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .', {'entities': [(94, 100, 'B_Disease'), (103, 111, 'B_Disease'), (114, 125, 'B_Disease'), (129, 140, 'B_Disease')]}], ['The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and ergotamine / caffeine , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .', {'entities': [(135, 144, 'B_Disease'), (169, 175, 'B_Disease'), (202, 212, 'B_Disease')]}], ['Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas .', {'entities': [(7, 13, 'B_Disease'), (14, 17, 'I_Disease'), (18, 25, 'I_Disease'), (26, 34, 'I_Disease'), (93, 106, 'B_Disease')]}], ['BACKGROUND : Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood .', {'entities': [(13, 25, 'B_Disease'), (31, 40, 'B_Disease'), (41, 46, 'I_Disease')]}], ['Therefore , patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen .', {'entities': [(26, 38, 'B_Disease')]}], ['Generally , carboplatin is said to have milder side effects than cisplatin , whose ocular and orbital toxicity are well known .', {'entities': [(83, 89, 'B_Disease'), (90, 93, 'I_Disease'), (94, 101, 'I_Disease'), (102, 110, 'I_Disease')]}], ['However , we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin , which is infrequently reported .', {'entities': [(42, 48, 'B_Disease'), (49, 52, 'I_Disease'), (53, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['CASE : A 58 - year - old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe .', {'entities': [(93, 106, 'B_Disease')]}], ['He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection .', {'entities': [(17, 21, 'B_Disease'), (22, 25, 'I_Disease'), (26, 32, 'I_Disease'), (33, 44, 'I_Disease'), (45, 47, 'I_Disease'), (48, 51, 'I_Disease'), (52, 63, 'I_Disease'), (64, 67, 'I_Disease')]}], ['Various ocular symptoms and findings caused by carboplatin toxicity were seen .', {'entities': [(59, 67, 'B_Disease')]}], ['Although the intraocular pressure elevation caused by secondary acute angle - closure glaucoma decreased and ocular pain diminished , inexorable papilledema and exudative retinal detachment continued for 3 weeks .', {'entities': [(86, 94, 'B_Disease'), (109, 115, 'B_Disease'), (116, 120, 'I_Disease'), (145, 156, 'B_Disease'), (171, 178, 'B_Disease'), (179, 189, 'I_Disease')]}], ['Finally , 6 weeks later , diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost .', {'entities': [(34, 47, 'B_Disease'), (48, 55, 'I_Disease'), (61, 66, 'B_Disease'), (67, 74, 'I_Disease')]}], ['CONCLUSION : When performing intracarotid injection of carboplatin , we must be aware of its potentially blinding ocular toxicity .', {'entities': [(114, 120, 'B_Disease'), (121, 129, 'I_Disease')]}], ['Visual hallucinations associated with zonisamide .', {'entities': [(0, 6, 'B_Disease'), (7, 21, 'I_Disease')]}], ['Zonisamide is a broad - spectrum antiepileptic drug used to treat various types of seizures .', {'entities': [(83, 91, 'B_Disease')]}], ['Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased .', {'entities': [(9, 15, 'B_Disease'), (16, 30, 'I_Disease'), (142, 148, 'B_Disease'), (149, 163, 'I_Disease')]}], ['All three had been diagnosed earlier with epilepsy , and their electroencephalogram ( EEG ) findings were abnormal .', {'entities': [(42, 50, 'B_Disease')]}], ['During monitoring , visual hallucinations did not correlate with EEG readings , nor did video recording capture any of the described events .', {'entities': [(20, 26, 'B_Disease'), (27, 41, 'I_Disease')]}], ['None of the patients had experienced visual hallucinations before this event .', {'entities': [(37, 43, 'B_Disease'), (44, 58, 'I_Disease')]}], ['Anti - epileptic drugs - induced de novo absence seizures .', {'entities': [(7, 16, 'B_Disease'), (41, 48, 'B_Disease'), (49, 57, 'I_Disease')]}], ['The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin .', {'entities': [(48, 55, 'B_Disease'), (56, 64, 'I_Disease')]}], ['Despite the underlying diseases , the prognosis for drug - induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs .', {'entities': [(75, 82, 'B_Disease'), (83, 90, 'I_Disease')]}], ['The gamma - aminobutyric acid - transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy .', {'entities': [(137, 144, 'B_Disease'), (145, 153, 'I_Disease')]}], ['Because drug - induced de novo absence seizure is rare , pro - absence drugs can only be considered a promoting factor .', {'entities': [(31, 38, 'B_Disease'), (39, 46, 'I_Disease')]}], ['The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure .', {'entities': [(136, 143, 'B_Disease'), (144, 151, 'I_Disease')]}], ['The possibility of drug - induced aggravation should be considered whenever an unexpected increase in seizure frequency and / or new seizure types appear following a change in drug treatment .', {'entities': [(102, 109, 'B_Disease'), (133, 140, 'B_Disease')]}], ['By understanding the underlying mechanism of absence epilepsy , we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug - induced absence seizures .', {'entities': [(45, 52, 'B_Disease'), (53, 61, 'I_Disease'), (135, 143, 'B_Disease'), (171, 178, 'B_Disease'), (179, 187, 'I_Disease')]}], ['Prenatal dexamethasone programs hypertension and renal injury in the rat .', {'entities': [(32, 44, 'B_Disease'), (49, 54, 'B_Disease'), (55, 61, 'I_Disease')]}], ['The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats .', {'entities': [(101, 109, 'B_Disease'), (110, 112, 'I_Disease'), (113, 118, 'I_Disease'), (119, 127, 'I_Disease'), (132, 137, 'B_Disease'), (138, 144, 'I_Disease')]}], ['Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20 % reduction in glomerular number compared with control at 6 to 9 months of age ( 22 527 + / - 509 versus 28 050 + / - 561 , P < 0 . 05 ) , which was comparable to the percent reduction in glomeruli measured at 3 weeks of age .', {'entities': [(84, 93, 'B_Disease'), (94, 96, 'I_Disease'), (97, 107, 'I_Disease'), (108, 114, 'I_Disease')]}], ['Male rats that received prenatal dexamethasone on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had elevated blood pressures at 6 months of age ; the latter group did not have a reduction in glomerular number .', {'entities': [(110, 118, 'B_Disease'), (119, 124, 'I_Disease'), (125, 134, 'I_Disease'), (188, 197, 'B_Disease'), (198, 200, 'I_Disease'), (201, 211, 'I_Disease'), (212, 218, 'I_Disease')]}], ['Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats .', {'entities': [(86, 104, 'B_Disease')]}], ['This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number , glomerulosclerosis , and hypertension when administered at specific points during gestation .', {'entities': [(66, 75, 'B_Disease'), (76, 78, 'I_Disease'), (79, 89, 'I_Disease'), (90, 96, 'I_Disease'), (99, 117, 'B_Disease'), (124, 136, 'B_Disease')]}], ['Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number , suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension .', {'entities': [(0, 12, 'B_Disease'), (113, 122, 'B_Disease'), (123, 125, 'I_Disease'), (126, 136, 'I_Disease'), (137, 143, 'I_Disease'), (164, 173, 'B_Disease'), (174, 176, 'I_Disease'), (177, 187, 'I_Disease'), (188, 194, 'I_Disease'), (240, 252, 'B_Disease')]}], ['These are nephrotoxic , but SRL seems to act differently displaying only minor nephrotoxic effects , although this question is still open .', {'entities': [(10, 21, 'B_Disease'), (79, 90, 'B_Disease')]}], ['In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described .', {'entities': [(116, 127, 'B_Disease')]}], ['The morphological analysis of the kidneys included a semi - quantitative scoring system analysing the degree of striped fibrosis , subcapsular fibrosis and the number of basophilic tubules , plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red .', {'entities': [(120, 128, 'B_Disease'), (143, 151, 'B_Disease'), (255, 263, 'B_Disease')]}], ['The semi - quantitative scoring was significantly worst in the group treated with CsA plus SRL ( P < 0 . 001 compared with controls ) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls ( P < 0 . 02 ) .', {'entities': [(173, 181, 'B_Disease')]}], ['The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls ( P = 0 . 05 ) .', {'entities': [(73, 81, 'B_Disease')]}], ['CONCLUSION : This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL , whereas FK506 plus SRL was better tolerated .', {'entities': [(55, 66, 'B_Disease')]}], ['Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin - induced cardiomyopathy rats , and their relationship with echocardiographic and histological findings .', {'entities': [(60, 70, 'B_Disease'), (71, 77, 'I_Disease'), (103, 117, 'B_Disease')]}], ['BACKGROUND : Cardiac troponins I ( cTnI ) and T ( cTnT ) have been shown to be highly sensitive and specific markers of myocardial cell injury .', {'entities': [(120, 130, 'B_Disease'), (131, 135, 'I_Disease'), (136, 142, 'I_Disease')]}], ['We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ( DOX ) - induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .', {'entities': [(75, 85, 'B_Disease'), (86, 92, 'I_Disease'), (141, 155, 'B_Disease'), (244, 251, 'B_Disease'), (252, 261, 'I_Disease')]}], ['RESULTS : Eighteen of the DOX rats died prematurely of general toxicity during the 9 - week period .', {'entities': [(63, 71, 'B_Disease')]}], ['Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis .', {'entities': [(127, 135, 'B_Disease')]}], ['Only five of the controls exhibited evidence of very slight perivascular fibrosis .', {'entities': [(73, 81, 'B_Disease')]}], ['CONCLUSIONS : Among markers of ischemic injury after DOX in rats , cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes .', {'entities': [(31, 39, 'B_Disease'), (40, 46, 'I_Disease'), (110, 120, 'B_Disease'), (121, 127, 'I_Disease')]}], ['Although there was a discrepancy between the amount of cTnI and cTnT after DOX , probably due to heterogeneity in cross - reactivities of mAbs to various cTnI and cTnT forms , it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments .', {'entities': [(370, 384, 'B_Disease')]}], ['Octreotide - induced hypoxemia and pulmonary hypertension in premature neonates .', {'entities': [(21, 30, 'B_Disease'), (35, 44, 'B_Disease'), (45, 57, 'I_Disease')]}], ['The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis .', {'entities': [(73, 80, 'B_Disease'), (94, 105, 'B_Disease'), (106, 119, 'I_Disease')]}], ['Pulmonary hypertension developed after administration of a somatostatin analogue , octreotide , to enhance resolution of the fistula .', {'entities': [(0, 9, 'B_Disease'), (10, 22, 'I_Disease'), (125, 132, 'B_Disease')]}], ['The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol : a nested cohort analysis and case - control study .', {'entities': [(12, 18, 'B_Disease'), (19, 34, 'I_Disease')]}], ['BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .', {'entities': [(132, 136, 'B_Disease'), (141, 150, 'B_Disease'), (186, 196, 'B_Disease'), (197, 202, 'I_Disease'), (203, 211, 'I_Disease'), (214, 218, 'B_Disease')]}], ['Previous studies have demonstrated an increased risk of venous thromboembolism ( VTE ) associated with CPA / EE compared with conventional combined oral contraceptives ( COCs ) .', {'entities': [(56, 62, 'B_Disease'), (63, 78, 'I_Disease'), (81, 84, 'B_Disease')]}], ['METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of VTE associated with CPA / EE .', {'entities': [(181, 185, 'B_Disease'), (188, 197, 'B_Disease'), (201, 205, 'B_Disease'), (230, 233, 'B_Disease')]}], ['CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of CPA / EE in women with acne , hirsutism or PCOS although residual confounding by indication cannot be excluded .', {'entities': [(56, 59, 'B_Disease'), (110, 114, 'B_Disease'), (117, 126, 'B_Disease'), (130, 134, 'B_Disease')]}], ['The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats : a preliminary study .', {'entities': [(54, 68, 'B_Disease')]}], ['In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin ( GM ) nephrotoxicity .', {'entities': [(83, 88, 'B_Disease'), (89, 94, 'I_Disease'), (95, 102, 'I_Disease'), (132, 146, 'B_Disease')]}], ['Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .', {'entities': [(0, 14, 'B_Disease')]}], ['The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .', {'entities': [(362, 369, 'B_Disease'), (370, 378, 'I_Disease')]}], ['It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity .', {'entities': [(139, 153, 'B_Disease')]}], ['Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure , and on the mechanism ( s ) involved .', {'entities': [(99, 106, 'B_Disease'), (107, 112, 'I_Disease'), (113, 120, 'I_Disease')]}], ['Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen - independent prostate cancer .', {'entities': [(23, 29, 'B_Disease'), (30, 45, 'I_Disease'), (147, 155, 'B_Disease'), (156, 162, 'I_Disease')]}], ['STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( VTE ) in patients with advanced androgen - independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide .', {'entities': [(47, 53, 'B_Disease'), (54, 69, 'I_Disease'), (72, 75, 'B_Disease'), (127, 135, 'B_Disease'), (136, 142, 'I_Disease')]}], ['PATIENTS : Seventy men , aged 50 - 80 years , with advanced androgen - independent prostate cancer .', {'entities': [(83, 91, 'B_Disease'), (92, 98, 'I_Disease')]}], ['This 4 - week cycle was repeated until there was evidence of excessive toxicity or disease progression .', {'entities': [(71, 79, 'B_Disease')]}], ['MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus thalidomide developed VTE ( p = 0 . 025 ) .', {'entities': [(91, 94, 'B_Disease'), (181, 184, 'B_Disease')]}], ['CONCLUSION : The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE .', {'entities': [(74, 82, 'B_Disease'), (83, 89, 'I_Disease'), (131, 134, 'B_Disease')]}], ['Ticlopidine - induced cholestatic hepatitis .', {'entities': [(22, 33, 'B_Disease'), (34, 43, 'I_Disease')]}], ['OBJECTIVE : To report 2 cases of ticlopidine - induced cholestatic hepatitis , investigate its mechanism , and compare the observed main characteristics with those of the published cases .', {'entities': [(55, 66, 'B_Disease'), (67, 76, 'I_Disease')]}], ['CASE SUMMARIES : Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty , with complete remission during the follow - up period .', {'entities': [(50, 61, 'B_Disease'), (62, 71, 'I_Disease')]}], ['DISCUSSION : Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine ; several cases have been reported but few in the English literature .', {'entities': [(13, 24, 'B_Disease'), (25, 34, 'I_Disease')]}], ['Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis , which resolved after discontinuation of the drug .', {'entities': [(23, 31, 'B_Disease'), (127, 138, 'B_Disease'), (139, 148, 'I_Disease')]}], ['Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course , but complete remission was observed in all reported cases .', {'entities': [(0, 9, 'B_Disease')]}], ['The mechanisms of this ticlopidine - induced cholestasis are unclear .', {'entities': [(45, 56, 'B_Disease')]}], [\"Immune mechanisms may be involved in the drug ' s hepatotoxicity , as suggested by the T - cell stimulation study reported here .\", {'entities': [(50, 64, 'B_Disease')]}], ['CONCLUSIONS : Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated .', {'entities': [(14, 25, 'B_Disease'), (26, 35, 'I_Disease')]}], ['Epithelial sodium channel ( ENaC ) subunit mRNA and protein expression in rats with puromycin aminonucleoside - induced nephrotic syndrome .', {'entities': [(120, 129, 'B_Disease'), (130, 138, 'I_Disease')]}], ['In experimental nephrotic syndrome , urinary sodium excretion is decreased during the early phase of the disease .', {'entities': [(16, 25, 'B_Disease'), (26, 34, 'I_Disease')]}], ['We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside ( PAN ) - induced nephrotic syndrome .', {'entities': [(108, 117, 'B_Disease'), (118, 126, 'I_Disease')]}], ['The time courses of urinary sodium excretion , plasma aldosterone concentration and proteinuria were studied in male Sprague - Dawley rats treated with a single dose of either PAN or vehicle .', {'entities': [(84, 95, 'B_Disease')]}], ['The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously .', {'entities': [(63, 74, 'B_Disease')]}], ['In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of PAN - induced nephrotic syndrome in rats , but appears to escape from the regulation by aldosterone after day 3 .', {'entities': [(142, 151, 'B_Disease'), (152, 160, 'I_Disease')]}], ['OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .', {'entities': [(56, 65, 'B_Disease'), (66, 71, 'I_Disease'), (98, 104, 'B_Disease'), (105, 110, 'I_Disease'), (111, 118, 'I_Disease'), (121, 124, 'B_Disease')]}], ['MR imaging with quantitative diffusion mapping of tacrolimus - induced neurotoxicity in organ transplant patients .', {'entities': [(71, 84, 'B_Disease')]}], ['Brain MR studies , including DW imaging , were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications .', {'entities': [(138, 148, 'B_Disease'), (149, 162, 'I_Disease')]}], ['Of the 14 patients , 5 ( 35 . 7 % ) had white matter abnormalities , 1 ( 7 . 1 % ) had putaminal hemorrhage , and 8 ( 57 . 1 % ) had normal findings on initial MR images .', {'entities': [(40, 45, 'B_Disease'), (46, 52, 'I_Disease'), (53, 66, 'I_Disease'), (87, 96, 'B_Disease'), (97, 107, 'I_Disease')]}], ['Among the 5 patients with white matter abnormalities , 4 patients ( 80 . 0 % ) showed higher than normal ADC values on initial MR images , and all showed complete resolution on follow - up images .', {'entities': [(26, 31, 'B_Disease'), (32, 38, 'I_Disease'), (39, 52, 'I_Disease')]}], ['The remaining 1 patient ( 20 . 0 % ) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis .', {'entities': [(110, 118, 'B_Disease'), (119, 126, 'I_Disease'), (127, 135, 'I_Disease')]}], ['Diffusion - weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus - induced neurotoxicity .', {'entities': [(109, 122, 'B_Disease')]}], ['L - arginine transport in humans with cortisol - induced hypertension .', {'entities': [(57, 69, 'B_Disease')]}], ['A deficient L - arginine - nitric oxide system is implicated in cortisol - induced hypertension .', {'entities': [(83, 95, 'B_Disease')]}], ['We conclude that cortisol - induced increases in blood pressure are not associated with abnormalities in the l - arginine transport system .', {'entities': [(36, 45, 'B_Disease'), (46, 48, 'I_Disease'), (49, 54, 'I_Disease'), (55, 63, 'I_Disease')]}], ['Amount of bleeding and hematoma size in the collagenase - induced intracerebral hemorrhage rat model .', {'entities': [(10, 18, 'B_Disease'), (23, 31, 'B_Disease'), (66, 79, 'B_Disease'), (80, 90, 'I_Disease')]}], ['The aggravated risk on intracerebral hemorrhage ( ICH ) with drugs used for stroke patients should be estimated carefully .', {'entities': [(23, 36, 'B_Disease'), (37, 47, 'I_Disease'), (50, 53, 'B_Disease'), (76, 82, 'B_Disease')]}], ['We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration .', {'entities': [(77, 80, 'B_Disease'), (104, 107, 'B_Disease')]}], ['In ICH intrastriatally induced by 0 . 014 - unit , 0 . 070 - unit , and 0 . 350 - unit collagenase , the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume .', {'entities': [(3, 6, 'B_Disease'), (115, 123, 'B_Disease'), (246, 254, 'B_Disease')]}], ['The blood amounts and hematoma volumes were significantly correlated , and the hematoma induced by 0 . 014 - unit collagenase was adequate to detect ICH deterioration .', {'entities': [(22, 30, 'B_Disease'), (79, 87, 'B_Disease'), (149, 152, 'B_Disease')]}], ['In ICH induction using 0 . 014 - unit collagenase , heparin enhanced the hematoma volume 3 . 4 - fold over that seen in control ICH animals and the bleeding 7 . 6 - fold .', {'entities': [(3, 6, 'B_Disease'), (73, 81, 'B_Disease'), (128, 131, 'B_Disease'), (148, 156, 'B_Disease')]}], ['Data suggest that this sensitive hemoglobin assay is useful for ICH detection , and that a model with a small ICH induced with a low - dose collagenase should be used for evaluation of drugs that may affect ICH .', {'entities': [(64, 67, 'B_Disease'), (110, 113, 'B_Disease'), (207, 210, 'B_Disease')]}], ['Estradiol reduces seizure - induced hippocampal injury in ovariectomized female but not in male rats .', {'entities': [(18, 25, 'B_Disease'), (36, 47, 'B_Disease'), (48, 54, 'I_Disease')]}], ['Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid - induced status epilepticus ( SE ) .', {'entities': [(43, 54, 'B_Disease'), (55, 61, 'I_Disease'), (95, 101, 'B_Disease'), (102, 113, 'I_Disease'), (116, 118, 'B_Disease')]}], ['We compared the effects of 17beta - estradiol in adult male and ovariectomized female rats subjected to lithium - pilocarpine - induced SE .', {'entities': [(136, 138, 'B_Disease')]}], ['SE was induced 20 h following the second injection and terminated 3 h later .', {'entities': [(0, 2, 'B_Disease')]}], ['The extent of silver - stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE .', {'entities': [(90, 92, 'B_Disease')]}], ['These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex - related differences in the hormonal environment .', {'entities': [(56, 63, 'B_Disease')]}], ['Pseudoacromegaly induced by the long - term use of minoxidil .', {'entities': [(0, 16, 'B_Disease')]}], ['Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland .', {'entities': [(0, 10, 'B_Disease'), (17, 26, 'B_Disease'), (27, 35, 'I_Disease')]}], ['Significant disfiguring changes occur as a result of bone , cartilage , and soft tissue hypertrophy , including the thickening of the skin , coarsening of facial features , and cutis verticis gyrata .', {'entities': [(88, 99, 'B_Disease'), (177, 182, 'B_Disease'), (183, 191, 'I_Disease'), (192, 198, 'I_Disease')]}], ['Pseudoacromegaly , on the other hand , is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin - like growth factor levels .', {'entities': [(0, 16, 'B_Disease')]}], ['We present a patient with pseudoacromegaly that resulted from the long - term use of minoxidil at an unusually high dose .', {'entities': [(26, 42, 'B_Disease')]}], ['This is the first case report of pseudoacromegaly as a side effect of minoxidil use .', {'entities': [(33, 49, 'B_Disease')]}], ['Combined androgen blockade - induced anemia in prostate cancer patients without bone involvement .', {'entities': [(37, 43, 'B_Disease'), (47, 55, 'B_Disease'), (56, 62, 'I_Disease')]}], ['BACKGROUND : To determine the onset and extent of combined androgen blockade ( CAB ) - induced anemia in prostate cancer patients without bone involvement .', {'entities': [(95, 101, 'B_Disease'), (105, 113, 'B_Disease'), (114, 120, 'I_Disease')]}], ['PATIENTS AND METHODS : Forty - two patients with biopsy - proven prostatic adenocarcinoma [ 26 with stage C ( T3N0M0 ) and 16 with stage D1 ( T3N1M0 ) ] were included in this study .', {'entities': [(65, 74, 'B_Disease'), (75, 89, 'I_Disease')]}], ['All patients received CAB [ leuprolide acetate ( LHRH - A ) 3 . 75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post - CAB ) .', {'entities': [(166, 172, 'B_Disease')]}], ['Severe and clinically evident anemia of Hb < 11 g / dl with clinical symptoms was detected in 6 patients ( 14 . 3 % ) .', {'entities': [(30, 36, 'B_Disease')]}], ['This CAB - induced anemia was normochromic and normocytic .', {'entities': [(19, 25, 'B_Disease')]}], ['At six months post - CAB , patients with severe anemia had a Hb mean value of 10 . 2 + / - 0 . 1 g / dl ( X + / - SE ) , whereas the other patients had mild anemia with Hb mean value of 13 . 2 + / - 0 . 17 ( X + / - SE ) .', {'entities': [(48, 54, 'B_Disease'), (157, 163, 'B_Disease')]}], ['The development of severe anemia at 6 months post - CAB was predictable by the reduction of Hb baseline value of more than 2 . 5 g / dl after 3 months of CAB ( p = 0 . 01 ) .', {'entities': [(26, 32, 'B_Disease')]}], ['The development of severe CAB - induced anemia in prostate cancer patients did not correlate with T baseline values ( T < 3 ng / ml versus T > or = 3 ng / ml ) , with age ( < 76 yrs versus > or = 76 yrs ) , and clinical stage ( stage C versus stage D1 ) .', {'entities': [(40, 46, 'B_Disease'), (50, 58, 'B_Disease'), (59, 65, 'I_Disease')]}], ['Severe and clinically evident anemia was easily corrected by subcutaneous injections ( 3 times / week for 1 month ) of recombinant erythropoietin ( rHuEPO - beta ) .', {'entities': [(30, 36, 'B_Disease')]}], ['CONCLUSION : Our data suggest that rHuEPO - beta correctable CAB - induced anemia occurs in 14 . 3 % of prostate cancer patients after 6 months of therapy .', {'entities': [(75, 81, 'B_Disease'), (104, 112, 'B_Disease'), (113, 119, 'I_Disease')]}], ['Delirium during clozapine treatment : incidence and associated risk factors .', {'entities': [(0, 8, 'B_Disease')]}], ['BACKGROUND : Incidence and risk factors for delirium during clozapine treatment require further clarification .', {'entities': [(44, 52, 'B_Disease')]}], ['METHODS : We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of delirium , and tested associations with potential risk factors .', {'entities': [(70, 81, 'B_Disease'), (198, 206, 'B_Disease')]}], ['Delirium was diagnosed in 14 ( 10 . 1 % incidence , or 1 . 48 cases / person - years of exposure ) ; 71 . 4 % of cases were moderate or severe .', {'entities': [(0, 8, 'B_Disease')]}], ['CONCLUSIONS : Delirium was found in 10 % of clozapine - treated inpatients , particularly in older patients exposed to other central anticholinergics .', {'entities': [(14, 22, 'B_Disease')]}], ['Delirium was inconsistently recognized clinically in milder cases and was associated with increased length - of - stay and higher costs , and inferior clinical outcome .', {'entities': [(0, 8, 'B_Disease')]}], ['Neuroprotective action of MPEP , a selective mGluR5 antagonist , in methamphetamine - induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats .', {'entities': [(107, 120, 'B_Disease'), (189, 201, 'B_Disease')]}], ['Moreover , it transiently diminished the methamphetamine ( 10 mg / kg sc ) - induced hyperthermia and reduced basal body temperature .', {'entities': [(85, 97, 'B_Disease')]}], ['The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine - induced toxicity .', {'entities': [(138, 146, 'B_Disease')]}], ['Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine - induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in hyperthermia .', {'entities': [(204, 216, 'B_Disease')]}], ['Protective efficacy of neuroactive steroids against cocaine kindled - seizures in mice .', {'entities': [(70, 78, 'B_Disease')]}], ['Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders .', {'entities': [(91, 103, 'B_Disease'), (104, 107, 'I_Disease'), (108, 119, 'I_Disease'), (120, 129, 'I_Disease')]}], ['They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments .', {'entities': [(30, 38, 'B_Disease'), (98, 102, 'B_Disease'), (103, 113, 'I_Disease')]}], ['The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma - aminobutyric acid ( GABA ( A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( seizure kindling ) .', {'entities': [(296, 303, 'B_Disease')]}], ['Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled seizures in male , Swiss - Webster mice .', {'entities': [(408, 416, 'B_Disease')]}], ['Kindled seizures were induced by daily administration of 60 mg / kg cocaine for 5 days .', {'entities': [(8, 16, 'B_Disease')]}], ['All of these positive GABA ( A ) modulators suppressed the expression of kindled seizures , whereas only allopregnanolone and ganaxolone inhibited the development of kindling .', {'entities': [(81, 89, 'B_Disease')]}], ['Effect of humoral modulators of morphine - induced increase in locomotor activity of mice .', {'entities': [(51, 59, 'B_Disease'), (60, 62, 'I_Disease'), (63, 72, 'I_Disease'), (73, 81, 'I_Disease')]}], ['The effect of humoral modulators on the morphine - induced increase in locomotor activity of mice was studied .', {'entities': [(59, 67, 'B_Disease'), (68, 70, 'I_Disease'), (71, 80, 'I_Disease'), (81, 89, 'I_Disease')]}], ['The subcutaneous administration of 10 mg / kg of morphine - HC1 produced a marked increase in locomotor activity in mice .', {'entities': [(82, 90, 'B_Disease'), (91, 93, 'I_Disease'), (94, 103, 'I_Disease'), (104, 112, 'I_Disease')]}], ['The morphine - induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine .', {'entities': [(23, 36, 'B_Disease')]}], ['In contrast , both methscopolamine and neostigmine , which do not penetrate the blood - brain barrier , had no effect on the hyperactivity produced by morphine .', {'entities': [(125, 138, 'B_Disease')]}], ['On the other hand , pretreatment with p - chlorophenylalamine ( 3 X 320 mg / kg i . p . , 24 hr ) , a serotonin depletor , caused no significant change in the hyperactivity .', {'entities': [(159, 172, 'B_Disease')]}], ['Effects of uninephrectomy and high protein feeding on lithium - induced chronic renal failure in rats .', {'entities': [(72, 79, 'B_Disease'), (80, 85, 'I_Disease'), (86, 93, 'I_Disease')]}], ['Rats with lithium - induced nephropathy were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of renal failure .', {'entities': [(28, 39, 'B_Disease'), (216, 221, 'B_Disease'), (222, 229, 'I_Disease')]}], ['Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis .', {'entities': [(20, 31, 'B_Disease'), (45, 57, 'B_Disease'), (72, 90, 'B_Disease')]}], ['HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats .', {'entities': [(40, 45, 'B_Disease'), (46, 53, 'I_Disease')]}], ['The results indicate that Li - induced nephropathy , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic hypertension .', {'entities': [(39, 50, 'B_Disease'), (117, 128, 'B_Disease'), (151, 163, 'B_Disease')]}], ['In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow , which may be the functional expression of the formation of nonfiltrating atubular glomeruli .', {'entities': [(17, 24, 'B_Disease'), (25, 30, 'I_Disease'), (31, 38, 'I_Disease')]}], [\"Treatment of Crohn ' s disease with fusidic acid : an antibiotic with immunosuppressive properties similar to cyclosporin .\", {'entities': [(13, 18, 'B_Disease'), (19, 20, 'I_Disease'), (21, 22, 'I_Disease'), (23, 30, 'I_Disease')]}], [\"Because of the need for the development of new treatments for Crohn ' s disease , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active , therapy - resistant patients .\", {'entities': [(62, 67, 'B_Disease'), (68, 69, 'I_Disease'), (70, 71, 'I_Disease'), (72, 79, 'I_Disease')]}], [\"Eight Crohn ' s disease patients were included .\", {'entities': [(6, 11, 'B_Disease'), (12, 13, 'I_Disease'), (14, 15, 'I_Disease'), (16, 23, 'I_Disease')]}], ['There were no serious clinical side effects , but dose reduction was required in two patients because of nausea .', {'entities': [(105, 111, 'B_Disease')]}], [\"The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn ' s disease patients in whom conventional treatment is ineffective .\", {'entities': [(103, 108, 'B_Disease'), (109, 110, 'I_Disease'), (111, 112, 'I_Disease'), (113, 120, 'I_Disease')]}], ['Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease , we suggest that the role of this treatment should be further investigated .', {'entities': [(105, 117, 'B_Disease'), (118, 123, 'I_Disease'), (124, 131, 'I_Disease')]}], ['Changes in depressive status associated with topical beta - blockers .', {'entities': [(11, 21, 'B_Disease')]}], ['Depression and sexual dysfunction have been related to side effects of topical beta - blockers .', {'entities': [(0, 10, 'B_Disease'), (15, 21, 'B_Disease'), (22, 33, 'I_Disease')]}], ['Eight glaucomatous patients chronically treated with timolol 0 . 5 % / 12h , suffering from depression diagnosed through DMS - III - R criteria , were included in the study .', {'entities': [(6, 18, 'B_Disease'), (92, 102, 'B_Disease')]}], ['During the six - month follow up , depression was quantified through the Beck and Zung - Conde scales every two months .', {'entities': [(35, 45, 'B_Disease')]}], ['In a double blind cross - over study with control group , the patients under timolol treatment presented higher depression values measured through the Beck and the Zung - Conde scales ( p < 0 . 001 vs control ) .', {'entities': [(112, 122, 'B_Disease')]}], ['These results suggest that betaxolol could be less of a depression - inducer than timolol in predisposed patients .', {'entities': [(56, 66, 'B_Disease')]}], ['Protection against amphetamine - induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614 , an excitatory amino acid antagonist .', {'entities': [(41, 54, 'B_Disease')]}], ['The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long - lasting in vivo effects in rats .', {'entities': [(42, 52, 'B_Disease')]}], ['Ketoconazole - induced neurologic sequelae .', {'entities': [(23, 33, 'B_Disease'), (34, 42, 'I_Disease')]}], ['A 77 - y - old patient developed weakness of extremities , legs paralysis , dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life .', {'entities': [(33, 41, 'B_Disease'), (42, 44, 'I_Disease'), (45, 56, 'I_Disease'), (59, 63, 'B_Disease'), (64, 73, 'I_Disease'), (76, 86, 'B_Disease'), (91, 97, 'B_Disease')]}], ['This case illustrates the need for close vigilance in adverse drug reactions , particularly in the elderly .', {'entities': [(54, 61, 'B_Disease'), (62, 66, 'I_Disease'), (67, 76, 'I_Disease')]}], ['Development of levodopa - induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and / or duration of symptoms .', {'entities': [(34, 45, 'B_Disease'), (49, 61, 'B_Disease')]}], [\"Levodopa - induced dyskinesias ( LIDs ) present a major problem for the long - term management of Parkinson ' s disease ( PD ) patients .\", {'entities': [(19, 30, 'B_Disease'), (33, 37, 'B_Disease'), (98, 107, 'B_Disease'), (108, 109, 'I_Disease'), (110, 111, 'I_Disease'), (112, 119, 'I_Disease'), (122, 124, 'B_Disease')]}], ['Due to the interdependence of risk factors in clinical populations , it is difficult to independently examine factors that may influence the development of LIDs .', {'entities': [(156, 160, 'B_Disease')]}], ['Using macaque monkeys with different types of MPTP - induced parkinsonism , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of levodopa therapy may be involved in the development of LIDs .', {'entities': [(61, 73, 'B_Disease'), (260, 264, 'B_Disease')]}], ['Monkeys with acute ( short - term ) MPTP exposure , rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration .', {'entities': [(149, 159, 'B_Disease')]}], ['In contrast , monkeys with long - term MPTP exposure , slow symptom progression and / or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs ( e . g . , dyskinesia developed no sooner than 146 days of chronic levodopa administration ) .', {'entities': [(185, 189, 'B_Disease'), (202, 212, 'B_Disease')]}], ['These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs .', {'entities': [(69, 73, 'B_Disease'), (254, 258, 'B_Disease')]}], ['A diet promoting sugar dependency causes behavioral cross - sensitization to a low dose of amphetamine .', {'entities': [(17, 22, 'B_Disease'), (23, 33, 'I_Disease'), (41, 51, 'B_Disease'), (52, 57, 'I_Disease'), (58, 59, 'I_Disease'), (60, 73, 'I_Disease')]}], ['Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency .', {'entities': [(170, 174, 'B_Disease'), (175, 185, 'I_Disease')]}], ['The present study examined whether female rats on various regimens of sugar access would show behavioral cross - sensitization to a low dose of amphetamine .', {'entities': [(94, 104, 'B_Disease'), (105, 110, 'I_Disease'), (111, 112, 'I_Disease'), (113, 126, 'I_Disease')]}], ['The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .', {'entities': [(62, 73, 'B_Disease')]}], ['Reversible dilated cardiomyopathy related to amphotericin B therapy .', {'entities': [(11, 18, 'B_Disease'), (19, 33, 'I_Disease')]}], ['We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B ( AmB ) for disseminated coccidioidomycosis .', {'entities': [(36, 43, 'B_Disease'), (44, 58, 'I_Disease'), (83, 88, 'B_Disease'), (89, 96, 'I_Disease'), (168, 186, 'B_Disease')]}], ['His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB .', {'entities': [(40, 45, 'B_Disease'), (46, 53, 'I_Disease')]}], ['It is important to recognize the rare and potentially reversible toxicity of AmB .', {'entities': [(65, 73, 'B_Disease')]}], ['NO - induced migraine attack : strong increase in plasma calcitonin gene - related peptide ( CGRP ) concentration and negative correlation with platelet serotonin release .', {'entities': [(13, 21, 'B_Disease')]}], ['The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin .', {'entities': [(214, 222, 'B_Disease'), (247, 255, 'B_Disease')]}], ['Fifteen female migraineurs ( without aura ) and eight controls participated in the study .', {'entities': [(15, 26, 'B_Disease'), (27, 28, 'I_Disease'), (29, 36, 'I_Disease'), (37, 41, 'I_Disease'), (42, 43, 'I_Disease')]}], ['Blood was collected from the antecubital vein four times : 60 min before and after the nitroglycerin application , and 60 and 120 min after the beginning of the migraine attack ( mean 344 and 404 min ; 12 subjects ) .', {'entities': [(161, 169, 'B_Disease')]}], ['In those subjects who had no migraine attack ( 11 subjects ) a similar time schedule was used .', {'entities': [(29, 37, 'B_Disease')]}], ['Plasma CGRP concentration increased significantly ( P < 0 . 01 ) during the migraine attack and returned to baseline after the cessation of the migraine .', {'entities': [(76, 84, 'B_Disease'), (144, 152, 'B_Disease')]}], ['In addition , both change and peak , showed significant positive correlations with migraine headache intensity ( P < 0 . 001 ) .', {'entities': [(83, 91, 'B_Disease'), (92, 100, 'B_Disease')]}], ['However , plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack .', {'entities': [(71, 79, 'B_Disease'), (108, 116, 'B_Disease')]}], ['Basal CGRP concentration was significantly higher and platelet 5 - HT content tended to be lower in subjects who experienced a migraine attack .', {'entities': [(127, 135, 'B_Disease')]}], ['Platelet serotonin content decreased significantly ( P < 0 . 01 ) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack .', {'entities': [(106, 114, 'B_Disease'), (177, 185, 'B_Disease')]}], ['In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine .', {'entities': [(101, 109, 'B_Disease'), (110, 118, 'B_Disease'), (167, 175, 'B_Disease')]}], ['In contrast , serotonin release from platelets does not provoke migraine , it may even counteract the headache and the concomitant CGRP release in this model .', {'entities': [(64, 72, 'B_Disease'), (102, 110, 'B_Disease')]}], ['Hyperbaric oxygen therapy for control of intractable cyclophosphamide - induced hemorrhagic cystitis .', {'entities': [(80, 91, 'B_Disease'), (92, 100, 'I_Disease')]}], [\"We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener ' s granulomatosis .\", {'entities': [(32, 43, 'B_Disease'), (44, 52, 'I_Disease'), (89, 96, 'B_Disease'), (97, 98, 'I_Disease'), (99, 100, 'I_Disease'), (101, 115, 'I_Disease')]}], ['Conservative treatment , including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha , failed to totally control hemorrhage .', {'entities': [(151, 161, 'B_Disease')]}], ['The bleeding ceased completely by the end of treatment and the patient remained free of hematuria thereafter .', {'entities': [(4, 12, 'B_Disease'), (88, 97, 'B_Disease')]}], ['In future , this form of therapy can offer a safe alternative in the treatment of cyclophosphamide - induced hemorrhagic cystitis .', {'entities': [(109, 120, 'B_Disease'), (121, 129, 'I_Disease')]}], ['Acute psychosis due to treatment with phenytoin in a nonepileptic patient .', {'entities': [(0, 5, 'B_Disease'), (6, 15, 'I_Disease')]}], ['The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs .', {'entities': [(19, 28, 'B_Disease'), (122, 131, 'B_Disease')]}], ['The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described .', {'entities': [(49, 58, 'B_Disease'), (93, 103, 'B_Disease'), (104, 113, 'I_Disease')]}], ['This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication , unrelated to seizures .', {'entities': [(28, 37, 'B_Disease'), (38, 46, 'I_Disease'), (96, 105, 'B_Disease'), (169, 177, 'B_Disease')]}], ['Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy , quinine is widely available in beverages including tonic water and bitter lemon .', {'entities': [(75, 84, 'B_Disease'), (85, 88, 'I_Disease'), (89, 95, 'I_Disease')]}], ['Numerous anecdotal reports suggest that products containing quinine may produce neurological complications , including confusion , altered mental status , seizures , and coma , particularly in older women .', {'entities': [(80, 92, 'B_Disease'), (93, 106, 'I_Disease'), (119, 128, 'B_Disease'), (155, 163, 'B_Disease'), (170, 174, 'B_Disease')]}], [\"Transient platypnea - orthodeoxia - like syndrome induced by propafenone overdose in a young woman with Ebstein ' s anomaly .\", {'entities': [(10, 19, 'B_Disease'), (20, 21, 'I_Disease'), (22, 33, 'I_Disease'), (34, 35, 'I_Disease'), (36, 40, 'I_Disease'), (41, 49, 'I_Disease'), (73, 81, 'B_Disease'), (104, 111, 'B_Disease'), (112, 113, 'I_Disease'), (114, 115, 'I_Disease'), (116, 123, 'I_Disease')]}], [\"In this report we describe the case of a 37 - year - old white woman with Ebstein ' s anomaly , who developed a rare syndrome called platypnea - orthodeoxia , characterized by massive right - to - left interatrial shunting with transient profound hypoxia and cyanosis .\", {'entities': [(74, 81, 'B_Disease'), (82, 83, 'I_Disease'), (84, 85, 'I_Disease'), (86, 93, 'I_Disease'), (133, 142, 'B_Disease'), (143, 144, 'I_Disease'), (145, 156, 'I_Disease'), (247, 254, 'B_Disease'), (259, 267, 'B_Disease')]}], ['This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure , and was probably precipitated by a propafenone overdose .', {'entities': [(26, 32, 'B_Disease'), (33, 40, 'I_Disease'), (41, 46, 'I_Disease'), (159, 167, 'B_Disease')]}], ['This drug caused biventricular dysfunction , due to its negative inotropic effect , and hypotension , due to its peripheral vasodilatory effect .', {'entities': [(17, 30, 'B_Disease'), (31, 42, 'I_Disease'), (88, 99, 'B_Disease')]}], ['Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino - parasympathetic reflex - - an experimental model for vascular dysfunctions in cluster headache .', {'entities': [(159, 167, 'B_Disease'), (168, 180, 'I_Disease'), (184, 191, 'B_Disease'), (192, 200, 'I_Disease')]}], ['Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease'), (89, 101, 'B_Disease'), (102, 110, 'I_Disease'), (111, 123, 'I_Disease')]}], ['Capsaicin ( 0 . 01 - 1 mm ) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation .', {'entities': [(68, 77, 'B_Disease'), (78, 80, 'I_Disease'), (81, 86, 'I_Disease'), (87, 90, 'I_Disease'), (91, 99, 'I_Disease'), (100, 105, 'I_Disease'), (106, 110, 'I_Disease')]}], ['The evoked increases in dural blood flow were also abolished by topical pre - administration of atropine ( 1 mm ) and [ Lys1 , Pro2 , 5 , Arg3 , 4 , Tyr6 ] - VIP ( 0 . 1 mm ) , a vasoactive intestinal polypeptide ( VIP ) antagonist , onto the exposed dura mater .', {'entities': [(11, 20, 'B_Disease'), (21, 23, 'I_Disease'), (24, 29, 'I_Disease'), (30, 35, 'I_Disease'), (36, 40, 'I_Disease')]}], ['Similar mechanisms may be involved in the pathogenesis of cluster headache .', {'entities': [(58, 65, 'B_Disease'), (66, 74, 'I_Disease')]}], ['Organophosphate - induced convulsions and prevention of neuropathological damages .', {'entities': [(26, 37, 'B_Disease'), (56, 73, 'B_Disease'), (74, 81, 'I_Disease')]}], ['The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( ACh ) levels .', {'entities': [(10, 18, 'B_Disease')]}], ['The rats treated with DFP - atropine showed severe typical OP - induced toxicity signs .', {'entities': [(72, 80, 'B_Disease')]}], ['When CPA , diazepam or 2PAM was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of poisoning .', {'entities': [(158, 167, 'B_Disease')]}], ['Atropine - MK801 did not offer any additional protection against DFP toxicity .', {'entities': [(69, 77, 'B_Disease')]}], ['In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat .', {'entities': [(114, 123, 'B_Disease'), (145, 153, 'B_Disease')]}], ['A pyridoxine - dependent behavioral disorder unmasked by isoniazid .', {'entities': [(25, 35, 'B_Disease'), (36, 44, 'I_Disease')]}], ['A 3 - year - old girl had behavioral deterioration , with hyperkinesis , irritability , and sleeping difficulties after the therapeutic administration of isoniazid .', {'entities': [(26, 36, 'B_Disease'), (37, 50, 'I_Disease'), (58, 70, 'B_Disease'), (73, 85, 'B_Disease'), (92, 100, 'B_Disease'), (101, 113, 'I_Disease')]}], ['Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis .', {'entities': [(68, 80, 'B_Disease')]}], ['Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy .', {'entities': [(63, 71, 'B_Disease'), (72, 76, 'I_Disease'), (77, 85, 'I_Disease')]}], ['Similar to rats , systemic pilocarpine injection causes status epilepticus ( SE ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL / 6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .', {'entities': [(56, 62, 'B_Disease'), (63, 74, 'I_Disease'), (77, 79, 'B_Disease'), (126, 134, 'B_Disease')]}], ['In Mg ( 2 + ) - free bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine - treated mice that did not experience SE .', {'entities': [(286, 288, 'B_Disease')]}], ['In SE survivors , similar stimulation resulted in a population spike followed , at a variable latency , by negative DC shifts and repetitive afterdischarges of 3 - 60 s duration , which were blocked by ionotropic glutamate receptor antagonists .', {'entities': [(3, 5, 'B_Disease')]}], ['Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1 - 30 s duration in slices from SE survivors but not other groups .', {'entities': [(172, 174, 'B_Disease')]}], ['These data support the hypothesis that SE - induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains , resembling rat models of human temporal lobe epilepsy .', {'entities': [(39, 41, 'B_Disease'), (134, 141, 'B_Disease'), (211, 219, 'B_Disease'), (220, 224, 'I_Disease'), (225, 233, 'I_Disease')]}], [\"Urinary bladder cancer in Wegener ' s granulomatosis : risks and relation to cyclophosphamide .\", {'entities': [(0, 7, 'B_Disease'), (8, 15, 'I_Disease'), (16, 22, 'I_Disease'), (26, 33, 'B_Disease'), (34, 35, 'I_Disease'), (36, 37, 'I_Disease'), (38, 52, 'I_Disease')]}], [\"OBJECTIVE : To assess and characterise the risk of bladder cancer , and its relation to cyclophosphamide , in patients with Wegener ' s granulomatosis .\", {'entities': [(51, 58, 'B_Disease'), (59, 65, 'I_Disease'), (124, 131, 'B_Disease'), (132, 133, 'I_Disease'), (134, 135, 'I_Disease'), (136, 150, 'I_Disease')]}], [\"METHODS : In the population based , nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener ' s granulomatosis , 1969 - 95 , was identified .\", {'entities': [(105, 112, 'B_Disease'), (113, 114, 'I_Disease'), (115, 116, 'I_Disease'), (117, 131, 'I_Disease')]}], ['Through linkage with the Swedish Cancer Register , all subjects in this cohort diagnosed with bladder cancer were identified .', {'entities': [(33, 39, 'B_Disease'), (94, 101, 'B_Disease'), (102, 108, 'I_Disease')]}], ['Nested within the cohort , a matched case - control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios ( ORs ) as relative risk .', {'entities': [(129, 136, 'B_Disease'), (137, 143, 'I_Disease')]}], [\"In the cohort the cumulative risk of bladder cancer after Wegener ' s granulomatosis , and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener ' s granulomatosis , were also estimated .\", {'entities': [(37, 44, 'B_Disease'), (45, 51, 'I_Disease'), (58, 65, 'B_Disease'), (66, 67, 'I_Disease'), (68, 69, 'I_Disease'), (70, 84, 'I_Disease'), (131, 138, 'B_Disease'), (139, 145, 'I_Disease'), (174, 181, 'B_Disease'), (182, 183, 'I_Disease'), (184, 185, 'I_Disease'), (186, 200, 'I_Disease')]}], ['The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide ( OR = 2 . 0 , 95 % confidence interval ( CI ) 0 . 8 to 4 . 9 ) .', {'entities': [(12, 19, 'B_Disease'), (20, 26, 'I_Disease')]}], [\"The absolute risk for bladder cancer in the cohort reached 10 % 16 years after diagnosis of Wegener ' s granulomatosis , and a history of bladder cancer was ( non - significantly ) twice as common as expected at the time of diagnosis of Wegener ' s granulomatosis .\", {'entities': [(22, 29, 'B_Disease'), (30, 36, 'I_Disease'), (92, 99, 'B_Disease'), (100, 101, 'I_Disease'), (102, 103, 'I_Disease'), (104, 118, 'I_Disease'), (138, 145, 'B_Disease'), (146, 152, 'I_Disease'), (237, 244, 'B_Disease'), (245, 246, 'I_Disease'), (247, 248, 'I_Disease'), (249, 263, 'I_Disease')]}], [\"CONCLUSION : The results indicate a dose - response relationship between cyclophosphamide and the risk of bladder cancer , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before Wegener ' s granulomatosis .\", {'entities': [(106, 113, 'B_Disease'), (114, 120, 'I_Disease'), (231, 238, 'B_Disease'), (239, 240, 'I_Disease'), (241, 242, 'I_Disease'), (243, 257, 'I_Disease')]}], ['Differential modulation by estrogen of alpha2 - adrenergic and I1 - imidazoline receptor - mediated hypotension in female rats .', {'entities': [(100, 111, 'B_Disease')]}], ['We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine ( mixed alpha2 - / I1 - receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .', {'entities': [(62, 73, 'B_Disease')]}], ['In sham - operated rats , rilmenidine or alpha - methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .', {'entities': [(77, 88, 'B_Disease')]}], ['Ovx significantly enhanced the hypotensive response to alpha - methyldopa , in contrast to no effect on rilmenidine hypotension .', {'entities': [(31, 42, 'B_Disease'), (116, 127, 'B_Disease')]}], ['The enhanced alpha - methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity .', {'entities': [(32, 43, 'B_Disease'), (106, 107, 'B_Disease'), (108, 115, 'I_Disease'), (116, 125, 'I_Disease'), (126, 134, 'I_Disease')]}], ['These findings suggest that estrogen downregulates alpha2 - but not I1 - receptor - mediated hypotension and highlight a role for the cardiac autonomic control in alpha - methyldopa - estrogen interaction .', {'entities': [(93, 104, 'B_Disease')]}], ['Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose .', {'entities': [(18, 22, 'B_Disease'), (23, 34, 'I_Disease'), (35, 43, 'I_Disease'), (44, 47, 'I_Disease'), (48, 57, 'I_Disease'), (58, 69, 'I_Disease'), (111, 119, 'B_Disease')]}], ['Catecholamine - induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon .', {'entities': [(24, 38, 'B_Disease')]}], ['In contrast , reports of myocardial dysfunction due to acute iatrogenic overdose are rare .', {'entities': [(25, 35, 'B_Disease'), (36, 47, 'I_Disease'), (72, 80, 'B_Disease')]}], ['A 35 - year - old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise , profound , albeit transient , left ventricular systolic and diastolic dysfunction , and only modestly elevated biochemical markers of myocardial necrosis .', {'entities': [(105, 115, 'B_Disease'), (116, 124, 'I_Disease'), (213, 217, 'B_Disease'), (218, 229, 'I_Disease'), (230, 238, 'I_Disease'), (239, 242, 'I_Disease'), (243, 252, 'I_Disease'), (253, 264, 'I_Disease'), (317, 327, 'B_Disease'), (328, 336, 'I_Disease')]}], ['Cardioprotective effect of tincture of Crataegus on isoproterenol - induced myocardial infarction in rats .', {'entities': [(76, 86, 'B_Disease'), (87, 97, 'I_Disease')]}], ['The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats .', {'entities': [(97, 107, 'B_Disease'), (108, 118, 'I_Disease')]}], ['Treatment of tinnitus by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through ventilation tubes .', {'entities': [(13, 21, 'B_Disease')]}], ['Idiopathic subjective tinnitus ( IST ) is one of the most obscure otological pathologies .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (22, 30, 'I_Disease'), (33, 36, 'B_Disease')]}], ['This paper presents the results of treating IST by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through a grommet , for five weekly courses .', {'entities': [(44, 47, 'B_Disease')]}], ['Fifty - two patients suffering from intractable tinnitus entered this therapeutic trial , but only nine finished all five courses .', {'entities': [(48, 56, 'B_Disease')]}], ['In one patient , the tinnitus was almost completely abolished , but in all the nine patients the decompensated tinnitus changed to a compensated one .', {'entities': [(21, 29, 'B_Disease'), (111, 119, 'B_Disease')]}], ['Patients should be warned about the side effects of vertigo and vomiting , which subsides gradually with every new instillation , and that the tinnitus may not disappear but will be alleviated , enabling them to cope more easily with the disease and lead a more normal life .', {'entities': [(52, 59, 'B_Disease'), (64, 72, 'B_Disease'), (143, 151, 'B_Disease')]}], ['The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine - induced seizures and hypolocomotion in mice .', {'entities': [(100, 108, 'B_Disease'), (113, 127, 'B_Disease')]}], ['Binding of nicotine to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and death .', {'entities': [(165, 172, 'B_Disease'), (178, 186, 'B_Disease'), (191, 196, 'B_Disease')]}], ['We examined the role of the beta4 subunits in nicotine - induced seizures and hypolocomotion in beta4 homozygous null ( beta4 - / - ) and alpha3 heterozygous ( + / - ) mice .', {'entities': [(65, 73, 'B_Disease'), (78, 92, 'B_Disease')]}], ['beta4 - / - mice were less sensitive to the effects of nicotine both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to nicotine - induced seizures .', {'entities': [(203, 211, 'B_Disease')]}], ['alpha3 + / - mice were partially resistant to nicotine - induced seizures when compared to wild - type littermates .', {'entities': [(65, 73, 'B_Disease')]}], ['Together , these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine - induced seizures and hypolocomotion .', {'entities': [(108, 116, 'B_Disease'), (121, 135, 'B_Disease')]}], ['The effects of sevoflurane on lidocaine - induced convulsions .', {'entities': [(50, 61, 'B_Disease')]}], ['The influence of sevoflurane on lidocaine - induced convulsions was studied in cats .', {'entities': [(52, 63, 'B_Disease')]}], ['The convulsive threshold ( mean + / - SD ) was 41 . 4 + / - 6 . 5 mg .', {'entities': [(4, 14, 'B_Disease')]}], ['There was no significant difference in the convulsive threshold between sevoflurane and enflurane .', {'entities': [(43, 53, 'B_Disease')]}], ['The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1 . 6 % sevoflurane , and in 0 . 8 % and 1 . 6 % enflurane .', {'entities': [(145, 156, 'B_Disease')]}], ['Apamin ( 10 ng ) had a tendency to decrease the convulsive threshold ( 21 . 6 + / - 2 . 2 to 19 . 9 + / - 2 . 5 mg . l ( - 1 ) ) but this was not statistically significant .', {'entities': [(48, 58, 'B_Disease')]}], ['It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression .', {'entities': [(45, 55, 'B_Disease'), (76, 84, 'B_Disease'), (126, 136, 'B_Disease')]}], ['Cardiac toxicity observed in association with high - dose cyclophosphamide - based chemotherapy for metastatic breast cancer .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease'), (111, 117, 'B_Disease'), (118, 124, 'I_Disease')]}], ['In high doses , its nonhematological dose - limiting toxicity is cardiomyopathy .', {'entities': [(53, 61, 'B_Disease'), (65, 79, 'B_Disease')]}], ['STUDY DESIGN : We combined paclitaxel , melphalan and high - dose cyclophosphamide , thiotepa , and carboplatin in a triple sequential high - dose regimen for patients with metastatic breast cancer .', {'entities': [(184, 190, 'B_Disease'), (191, 197, 'I_Disease')]}], ['Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left - sided chest irradiation .', {'entities': [(77, 83, 'B_Disease'), (84, 90, 'I_Disease'), (244, 254, 'B_Disease'), (255, 260, 'I_Disease'), (261, 268, 'I_Disease'), (271, 274, 'B_Disease'), (386, 398, 'B_Disease'), (435, 443, 'B_Disease'), (444, 452, 'I_Disease')]}], ['RESULTS : Six of 61 women ( 10 % ) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31 % .', {'entities': [(75, 78, 'B_Disease')]}], ['Incidence of transient cyclophosphamide - related cardiac toxicity ( 10 % ) is comparable to previous recorded literature .', {'entities': [(50, 57, 'B_Disease'), (58, 66, 'I_Disease')]}], ['Older age was significantly correlated with the CHF development ; with median ages for the entire group and for patients developing CHF of 45 and 59 , respectively .', {'entities': [(48, 51, 'B_Disease'), (132, 135, 'B_Disease')]}], ['Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development .', {'entities': [(74, 77, 'B_Disease')]}], ['Tremor side effects of salbutamol , quantified by a laser pointer technique .', {'entities': [(0, 6, 'B_Disease')]}], ['OBJECTIVE : To study tremor side effects of salbutamol an easily applicable , quick and low - priced method is needed .', {'entities': [(21, 27, 'B_Disease')]}], ['METHODS : Tremor was measured using a laser pointer technique .', {'entities': [(10, 16, 'B_Disease')]}], ['To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol .', {'entities': [(37, 43, 'B_Disease'), (64, 75, 'B_Disease'), (76, 80, 'I_Disease'), (81, 88, 'I_Disease')]}], ['In another series of measurements , reproducibility and reference values of the tremor was assessed in 65 healthy subjects in three sessions , at 9 a . m . , 4 p . m . and 9 a . m . , respectively , 1 week later .', {'entities': [(80, 86, 'B_Disease')]}], ['Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2 - kg weight until exhaustion .', {'entities': [(9, 15, 'B_Disease'), (73, 79, 'B_Disease'), (129, 135, 'B_Disease')]}], ['Tremor was measured simultaneously by two independent observers .', {'entities': [(0, 6, 'B_Disease')]}], ['RESULTS : Salbutamol significantly increased tremor severity in patients in a dose - dependent way .', {'entities': [(45, 51, 'B_Disease')]}], ['There was no agreement between the questionnaire and tremor severity ( r = 0 . 093 ; P = 0 . 53 ) .', {'entities': [(53, 59, 'B_Disease')]}], ['Postural tremor showed no significant difference between the first and third session ( P = 0 . 07 ) .', {'entities': [(9, 15, 'B_Disease')]}], ['Support of the arm decreased tremor severity , exhaustion increased tremor severity significantly .', {'entities': [(29, 35, 'B_Disease'), (68, 74, 'B_Disease')]}], ['DISCUSSION : Quantifying tremor by using an inexpensive laser pointer is , with the exception of children ( < 12 years ) a sensitive and reproducible method .', {'entities': [(25, 31, 'B_Disease')]}], ['METHODS : The Multiple Outcomes of Raloxifene Evaluation , a multicenter , randomized , double - blind trial , enrolled 7 , 705 postmenopausal women with osteoporosis .', {'entities': [(154, 166, 'B_Disease')]}], ['Outcomes included venous thromboembolism , cataracts , gallbladder disease , and endometrial hyperplasia or cancer .', {'entities': [(18, 24, 'B_Disease'), (25, 40, 'I_Disease'), (43, 52, 'B_Disease'), (55, 66, 'B_Disease'), (67, 74, 'I_Disease'), (81, 92, 'B_Disease'), (93, 104, 'I_Disease'), (105, 107, 'I_Disease'), (108, 114, 'I_Disease')]}], ['RESULTS : During a mean follow - up of 3 . 3 years , raloxifene was associated with an increased risk for venous thromboembolism ( relative risk [ RR ] 2 . 1 ; 95 % confidence interval [ CI ] 1 . 2 - 3 . 8 ) .', {'entities': [(106, 112, 'B_Disease'), (113, 128, 'I_Disease')]}], ['Raloxifene did not increase risk for cataracts ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , gallbladder disease ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , endometrial hyperplasia ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or endometrial cancer ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .', {'entities': [(37, 46, 'B_Disease'), (86, 97, 'B_Disease'), (98, 105, 'I_Disease'), (145, 156, 'B_Disease'), (157, 168, 'I_Disease'), (211, 222, 'B_Disease'), (223, 229, 'I_Disease')]}], ['CONCLUSION : Raloxifene was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or endometrial cancer .', {'entities': [(66, 72, 'B_Disease'), (73, 88, 'I_Disease'), (127, 136, 'B_Disease'), (139, 150, 'B_Disease'), (151, 158, 'I_Disease'), (161, 172, 'B_Disease'), (173, 184, 'I_Disease'), (190, 201, 'B_Disease'), (202, 208, 'I_Disease')]}], ['While there is no single correct starting dose for levodopa therapy , many individuals can be started on either the 25 / 100 or controlled - release formula , following the general rule not to attempt to titrate carbidopa - levodopa to the point of \" normality , \" which can lead to toxicity .', {'entities': [(283, 291, 'B_Disease')]}], ['Other possible adverse effects - - such as gastrointestinal disorders , orthostatic hypotension , levodopa - induced psychosis , sleep disturbances or parasomnias , or drug interactions - - also require carefully monitored individual treatment .', {'entities': [(43, 59, 'B_Disease'), (60, 69, 'I_Disease'), (72, 83, 'B_Disease'), (84, 95, 'I_Disease'), (117, 126, 'B_Disease'), (129, 134, 'B_Disease'), (135, 147, 'I_Disease'), (151, 162, 'B_Disease')]}], [\"Nonpharmacologic concerns can help the Parkinson ' s disease patient achieve and maintain optimal functioning , including daily exercise , physical therapy , and involvement with support groups .\", {'entities': [(39, 48, 'B_Disease'), (49, 50, 'I_Disease'), (51, 52, 'I_Disease'), (53, 60, 'I_Disease')]}], ['Long term audiological evaluation of beta - thalassemic patients .', {'entities': [(37, 41, 'B_Disease'), (42, 43, 'I_Disease'), (44, 55, 'I_Disease')]}], ['OBJECTIVE : The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta - thalassemia major .', {'entities': [(104, 111, 'B_Disease'), (112, 116, 'I_Disease'), (151, 155, 'B_Disease'), (156, 157, 'I_Disease'), (158, 169, 'I_Disease')]}], ['RESULTS : Overall , 21 out of 104 patients ( 20 . 2 % ) presented with high frequency sensorineural hearing loss ( SNHL ) , either unilateral or bilateral .', {'entities': [(86, 99, 'B_Disease'), (100, 107, 'I_Disease'), (108, 112, 'I_Disease'), (115, 119, 'B_Disease')]}], ['No ototoxic factor , other than DFO , was present in any of the patients .', {'entities': [(3, 11, 'B_Disease')]}], ['Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing , however , no statistically significant difference was observed .', {'entities': [(14, 18, 'B_Disease')]}], ['Subjects with SNHL were submitted to DFO reduction or temporary withdrawal .', {'entities': [(14, 18, 'B_Disease')]}], [\"CONCLUSION : The findings are indicative of DFO ' s contributing role in the development of hearing impairment .\", {'entities': [(92, 99, 'B_Disease'), (100, 110, 'I_Disease')]}], ['Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment .', {'entities': [(51, 62, 'B_Disease'), (185, 192, 'B_Disease'), (193, 203, 'I_Disease')]}], ['Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin - induced renal damage .', {'entities': [(108, 113, 'B_Disease'), (114, 120, 'I_Disease')]}], ['Therefore , we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats .', {'entities': [(87, 92, 'B_Disease'), (93, 99, 'I_Disease')]}], ['After 1 week of recovery , proteinuria was induced by adriamycin [ 1 . 5 mg / kg intravenously ( i . v . ) n = 18 ; controls , saline i . v . n = 9 ] .', {'entities': [(27, 38, 'B_Disease')]}], ['Proteinuria was measured every 2 weeks .', {'entities': [(0, 11, 'B_Disease')]}], ['RESULTS : As anticipated , adriamycin elicited nephrotic range proteinuria , renal interstitial damage and mild focal glomerulosclerosis .', {'entities': [(47, 56, 'B_Disease'), (63, 74, 'B_Disease'), (77, 82, 'B_Disease'), (83, 95, 'I_Disease'), (96, 102, 'I_Disease'), (112, 117, 'B_Disease'), (118, 136, 'I_Disease')]}], ['Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin ( r = 0 . 62 , P < 0 . 01 ) , renal interstitial alpha - smooth muscle actin ( r = 0 . 49 , P < 0 . 05 ) , interstitial macrophage influx ( r = 0 . 56 , P < 0 . 05 ) , interstitial collagen III ( r = 0 . 53 , P < 0 . 05 ) , glomerular alpha - smooth muscle actin ( r = 0 . 74 , P < 0 . 01 ) and glomerular desmin ( r = 0 . 48 , P < 0 . 05 ) .', {'entities': [(67, 78, 'B_Disease')]}], ['Baseline renal ACE did not correlate with focal glomerulosclerosis ( r = 0 . 22 , NS ) .', {'entities': [(42, 47, 'B_Disease'), (48, 66, 'I_Disease')]}], ['CONCLUSION : Individual differences in renal ACE activity predict the severity of adriamycin - induced renal damage in this outbred rat strain .', {'entities': [(103, 108, 'B_Disease'), (109, 115, 'I_Disease')]}], ['This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage .', {'entities': [(110, 115, 'B_Disease'), (116, 122, 'I_Disease')]}], ['Recurrent acute interstitial nephritis induced by azithromycin .', {'entities': [(16, 28, 'B_Disease'), (29, 38, 'I_Disease')]}], ['A 14 - year - old girl is reported with recurrent , azithromycin - induced , acute interstitial nephritis .', {'entities': [(83, 95, 'B_Disease'), (96, 105, 'I_Disease')]}], ['Although most cases of antibiotic induced acute interstitial nephritis are benign and self - limited , some patients are at risk for permanent renal injury .', {'entities': [(48, 60, 'B_Disease'), (61, 70, 'I_Disease'), (143, 148, 'B_Disease'), (149, 155, 'I_Disease')]}], ['Spironolactone - induced renal insufficiency and hyperkalemia in patients with heart failure .', {'entities': [(25, 30, 'B_Disease'), (31, 44, 'I_Disease'), (49, 61, 'B_Disease'), (79, 84, 'B_Disease'), (85, 92, 'I_Disease')]}], ['BACKGROUND : A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia ( 2 % ) and renal insufficiency ( 0 % ) .', {'entities': [(92, 97, 'B_Disease'), (98, 105, 'I_Disease'), (138, 150, 'B_Disease'), (163, 168, 'B_Disease'), (169, 182, 'I_Disease')]}], ['Because treatments for heart failure have changed since the benefits of spironolactone were reported , the prevalence of these complications may differ in current clinical practice .', {'entities': [(23, 28, 'B_Disease'), (29, 36, 'I_Disease')]}], ['We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone .', {'entities': [(77, 89, 'B_Disease'), (94, 99, 'B_Disease'), (100, 113, 'I_Disease'), (117, 122, 'B_Disease'), (123, 130, 'I_Disease')]}], ['METHODS : We performed a case control study of heart failure patients treated with spironolactone in our clinical practice .', {'entities': [(47, 52, 'B_Disease'), (53, 60, 'I_Disease')]}], ['Cases were patients who developed hyperkalemia ( K ( + ) > 5 . 0 mEq / L ) or renal insufficiency ( Cr > or = 2 . 5 mg / dL ) , and they were compared to 2 randomly selected controls per case .', {'entities': [(34, 46, 'B_Disease'), (78, 83, 'B_Disease'), (84, 97, 'I_Disease')]}], ['RESULTS : Sixty - seven of 926 patients ( 7 . 2 % ) required discontinuation of spironolactone due to hyperkalemia ( n = 33 ) or renal failure ( n = 34 ) .', {'entities': [(102, 114, 'B_Disease'), (129, 134, 'B_Disease'), (135, 142, 'I_Disease')]}], ['Patients who developed hyperkalemia were older and more likely to have diabetes , had higher baseline serum potassium levels and lower baseline potassium supplement doses , and were more likely to be treated with beta - blockers than controls ( n = 134 ) .', {'entities': [(23, 35, 'B_Disease'), (71, 79, 'B_Disease')]}], ['Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine , required higher doses of loop diuretics , and were more likely to be treated with thiazide diuretics than controls .', {'entities': [(23, 28, 'B_Disease'), (29, 42, 'I_Disease')]}], ['CONCLUSIONS : Spironolactone - induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously .', {'entities': [(39, 51, 'B_Disease'), (56, 61, 'B_Disease'), (62, 75, 'I_Disease')]}], ['Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats .', {'entities': [(108, 117, 'B_Disease'), (118, 128, 'I_Disease')]}], ['Reserpine - and haloperidol - induced orofacial dyskinesia are putative animal models of tardive dyskinesia ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .', {'entities': [(38, 47, 'B_Disease'), (48, 58, 'I_Disease'), (89, 96, 'B_Disease'), (97, 107, 'I_Disease'), (110, 112, 'B_Disease')]}], ['In the present study , the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats .', {'entities': [(43, 52, 'B_Disease'), (53, 63, 'I_Disease')]}], ['Importantly , a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia .', {'entities': [(104, 113, 'B_Disease'), (114, 124, 'I_Disease')]}], ['Ceftriaxone - associated biliary pseudolithiasis in paediatric surgical patients .', {'entities': [(25, 32, 'B_Disease'), (33, 48, 'I_Disease')]}], ['It is well known that ceftriaxone leads to pseudolithiasis in some patients .', {'entities': [(43, 58, 'B_Disease')]}], ['Clinical and experimental studies also suggest that situations causing gallbladder dysfunction , such as fasting , may have a role for the development of pseudolithiasis .', {'entities': [(71, 82, 'B_Disease'), (83, 94, 'I_Disease'), (154, 169, 'B_Disease')]}], ['In this study , we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment , who often had to fast in the post - operative period .', {'entities': [(84, 99, 'B_Disease')]}], ['Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age , sex , duration of the treatment and starvation variables .', {'entities': [(43, 58, 'B_Disease')]}], ['After cessation of the treatment , pseudolithiasis resolved spontaneously within a short period .', {'entities': [(35, 50, 'B_Disease')]}], ['The incidence of pseudolithiasis is not affected by fasting .', {'entities': [(17, 32, 'B_Disease')]}], ['Coronary aneurysm after implantation of a paclitaxel - eluting stent .', {'entities': [(0, 8, 'B_Disease'), (9, 17, 'I_Disease')]}], ['Formation of coronary aneurysm is a rare complication of stenting with bare metal stents , but based on experimental studies drug - eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition , aneurysm formation and with the potential of stent thrombosis or vessel rupture .', {'entities': [(13, 21, 'B_Disease'), (22, 30, 'I_Disease'), (226, 234, 'B_Disease'), (277, 287, 'B_Disease'), (291, 297, 'B_Disease'), (298, 305, 'I_Disease')]}], ['We present a 43 - year - old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel - eluting stent .', {'entities': [(49, 57, 'B_Disease'), (58, 66, 'I_Disease')]}], ['The patient was asymptomatic and the aneurysm was detected in a routine control .', {'entities': [(37, 45, 'B_Disease')]}], ['Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15 - mm long segment with maximal aneurysm diameter of 6 . 0 mm .', {'entities': [(139, 147, 'B_Disease')]}], ['Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation .', {'entities': [(16, 26, 'B_Disease'), (27, 42, 'I_Disease')]}], ['OBJECTIVES : Thrombotic microangiopathy is a well - known problem in patients following renal transplantation .', {'entities': [(13, 23, 'B_Disease'), (24, 39, 'I_Disease')]}], ['In postrenal transplantation , thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome .', {'entities': [(31, 41, 'B_Disease'), (42, 57, 'I_Disease'), (83, 92, 'B_Disease'), (93, 99, 'I_Disease'), (100, 108, 'I_Disease')]}], ['We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature .', {'entities': [(36, 46, 'B_Disease'), (47, 62, 'I_Disease')]}], ['MATERIALS AND METHODS : We investigated the causes of thrombotic microangiopathy during a 1 - year period , from June 2003 to June 2004 , at the King Fahad National Guard Hospital in Riyadh , Saudi Arabia , by reviewing the slides of all transplant biopsies ( n = 25 ) performed during this interval .', {'entities': [(54, 64, 'B_Disease'), (65, 80, 'I_Disease')]}], ['RESULTS : Five cases of thrombotic microangiopathy were found .', {'entities': [(24, 34, 'B_Disease'), (35, 50, 'I_Disease')]}], ['The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus .', {'entities': [(31, 41, 'B_Disease'), (42, 57, 'I_Disease'), (72, 88, 'B_Disease'), (89, 97, 'I_Disease'), (116, 124, 'B_Disease'), (125, 130, 'I_Disease'), (131, 144, 'I_Disease')]}], ['CONCLUSIONS : In the literature , the most - frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome .', {'entities': [(63, 72, 'B_Disease'), (73, 79, 'I_Disease'), (80, 88, 'I_Disease'), (154, 163, 'B_Disease'), (164, 170, 'I_Disease'), (171, 179, 'I_Disease')]}], ['Other causes include drug - related ( cyclosporine , tacrolimus ) toxicity , procoagulant status , and antibody - mediated rejection .', {'entities': [(66, 74, 'B_Disease')]}], ['We found that the most - frequent cause of thrombotic microangiopathy was drug related , secondary mainly to cyclosporine .', {'entities': [(43, 53, 'B_Disease'), (54, 69, 'I_Disease')]}], ['In the current study , the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature ( 20 % ) .', {'entities': [(40, 50, 'B_Disease'), (51, 66, 'I_Disease')]}], ['Comparison of developmental toxicity of selective and non - selective cyclooxygenase - 2 inhibitors in CRL : ( WI ) WUBR Wistar rats - - DFU and piroxicam study .', {'entities': [(28, 36, 'B_Disease')]}], ['Unlike general toxicity data , their prenatal toxic effects were not extensively studied before .', {'entities': [(15, 23, 'B_Disease')]}], ['The aim of the experiment was to evaluate the developmental toxicity of the non - selective ( piroxicam ) and selective ( DFU ; 5 , 5 - dimethyl - 3 - ( 3 - fluorophenyl ) - 4 - ( 4 - methylsulphonyl ) phenyl - 2 ( 5H ) - furanon ) COX - 2 inhibitors .', {'entities': [(60, 68, 'B_Disease')]}], ['The pooled statistical analysis for ventricular septal ( VSD ) and midline ( MD ) defects was performed for rat fetuses exposed to piroxicam , selective and non - selective COX - 2 inhibitor based on present and historic data .', {'entities': [(36, 47, 'B_Disease'), (48, 54, 'I_Disease'), (55, 56, 'I_Disease'), (57, 60, 'I_Disease'), (61, 62, 'I_Disease'), (63, 66, 'I_Disease'), (67, 74, 'I_Disease'), (75, 76, 'I_Disease'), (77, 79, 'I_Disease'), (80, 81, 'I_Disease'), (82, 89, 'I_Disease')]}], ['RESULTS : Maternal toxicity , intrauterine growth retardation , and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam .', {'entities': [(19, 27, 'B_Disease'), (30, 42, 'B_Disease'), (43, 49, 'I_Disease'), (50, 61, 'I_Disease'), (68, 76, 'B_Disease'), (77, 79, 'I_Disease'), (80, 88, 'I_Disease'), (89, 92, 'I_Disease'), (93, 101, 'I_Disease'), (102, 112, 'I_Disease')]}], ['Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose .', {'entities': [(69, 77, 'B_Disease')]}], ['Prenatal exposure to selective COX - 2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non - selective drugs and historic control .', {'entities': [(80, 91, 'B_Disease'), (92, 98, 'I_Disease'), (99, 102, 'I_Disease'), (103, 110, 'I_Disease'), (111, 118, 'I_Disease')]}], ['Lone atrial fibrillation associated with creatine monohydrate supplementation .', {'entities': [(5, 11, 'B_Disease'), (12, 24, 'I_Disease')]}], ['Atrial fibrillation in young patients without structural heart disease is rare .', {'entities': [(0, 6, 'B_Disease'), (7, 19, 'I_Disease'), (57, 62, 'B_Disease'), (63, 70, 'I_Disease')]}], ['Therefore , when the arrhythmia is present in this population , reversible causes must be identified and resolved .', {'entities': [(21, 31, 'B_Disease')]}], ['Thyroid disorders , illicit drug or stimulant use , and acute alcohol intoxication are among these causes .', {'entities': [(0, 7, 'B_Disease'), (8, 17, 'I_Disease'), (56, 61, 'B_Disease'), (62, 69, 'I_Disease'), (70, 82, 'I_Disease')]}], ['We report the case of a 30 - year - old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response .', {'entities': [(94, 100, 'B_Disease'), (101, 113, 'I_Disease')]}], ['His medical history was unremarkable , except for minor fractures of the fingers and foot .', {'entities': [(56, 65, 'B_Disease')]}], ['Previous anecdotal reports have linked creatine to the development of arrhythmia .', {'entities': [(70, 80, 'B_Disease')]}], ['Seizures induced by the cocaine metabolite benzoylecgonine in rats .', {'entities': [(0, 8, 'B_Disease')]}], ['The half - life ( t1 / 2 ) of cocaine is relatively short , but some of the consequences of its use , such as seizures and strokes , can occur hours after exposure .', {'entities': [(110, 118, 'B_Disease'), (123, 130, 'B_Disease')]}], ['We evaluated the potential of the major metabolite of cocaine , benzoylecgonine ( BE ) , to cause seizures .', {'entities': [(98, 106, 'B_Disease')]}], ['Treated rats were then evaluated for incidence , latency , and seizure pattern or for locomotor activity in animals without seizures .', {'entities': [(63, 70, 'B_Disease'), (124, 132, 'B_Disease')]}], ['BE - Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine .', {'entities': [(13, 21, 'B_Disease')]}], ['Whereas cocaine - induced seizures were best characterized as brief , generalized , and tonic and resulted in death , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in death .', {'entities': [(26, 34, 'B_Disease'), (110, 115, 'B_Disease'), (213, 218, 'B_Disease')]}], ['Electrical recordings from the hippocampus showed a rhythmic progression in EEG frequency and voltage with clinical seizure expression .', {'entities': [(116, 123, 'B_Disease')]}], ['BE - Injected rats that did not have seizures had significantly more locomotor activity than cocaine - injected animals without seizures .', {'entities': [(37, 45, 'B_Disease'), (128, 136, 'B_Disease')]}], ['The finding that cocaine - and BE - induced seizures differ in several respects suggests more than one mechanism for cocaine - induced seizures and emphasizes the importance of a cocaine metabolite , BE .', {'entities': [(44, 52, 'B_Disease'), (135, 143, 'B_Disease')]}], ['The selective 5 - HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat .', {'entities': [(122, 128, 'B_Disease'), (129, 139, 'I_Disease')]}], ['Both , Ro4368554 ( 3 and 10 mg / kg , intraperitoneally ( i . p . ) ) and metrifonate ( 10 mg / kg , p . o . , respectively ) reversed memory deficits induced by scopolamine and TRP depletion ( 10 mg / kg , i . p . , and 3 mg / kg , p . o . , respectively ) .', {'entities': [(135, 141, 'B_Disease'), (142, 150, 'I_Disease')]}], ['In conclusion , although Ro4368554 did not improve a time - related retention deficit , it reversed a cholinergic and a serotonergic memory deficit , suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and , possibly , other 5 - HT ( 6 ) receptor antagonists .', {'entities': [(133, 139, 'B_Disease'), (140, 147, 'I_Disease')]}], ['Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose .', {'entities': [(82, 89, 'B_Disease'), (90, 98, 'I_Disease')]}], ['The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive .', {'entities': [(79, 86, 'B_Disease'), (87, 95, 'I_Disease')]}], ['The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose .', {'entities': [(92, 99, 'B_Disease'), (100, 108, 'I_Disease')]}], ['Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .', {'entities': [(32, 40, 'B_Disease'), (156, 164, 'B_Disease'), (180, 185, 'B_Disease')]}], ['Importantly , GNC92H2 prevented death even post - cocaine injection .', {'entities': [(32, 37, 'B_Disease')]}], ['The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose .', {'entities': [(85, 92, 'B_Disease'), (93, 101, 'I_Disease')]}], ['Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers .', {'entities': [(33, 43, 'B_Disease'), (44, 50, 'I_Disease')]}], ['The electrocardiograms ( ECG ) of 99 cocaine - abusing patients were compared with the ECGs of 50 schizophrenic controls .', {'entities': [(98, 111, 'B_Disease')]}], ['Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , ischemia , and bundle branch block .', {'entities': [(87, 97, 'B_Disease'), (98, 104, 'I_Disease'), (116, 126, 'B_Disease'), (127, 137, 'I_Disease'), (140, 148, 'B_Disease'), (155, 161, 'B_Disease'), (162, 168, 'I_Disease'), (169, 174, 'I_Disease')]}], ['Intracerebroventricular ( i . c . v . ) injection of U - II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion .', {'entities': [(67, 79, 'B_Disease'), (84, 95, 'B_Disease')]}], ['Whatever was the dose , the central administration of U - II had no effect on body temperature , nociception , apomorphine - induced penile erection and climbing behavior , and stress - induced plasma corticosterone level .', {'entities': [(133, 139, 'B_Disease'), (140, 148, 'I_Disease')]}], ['These data suggest that U - II may be involved in some aspects of psychiatric disorders .', {'entities': [(66, 77, 'B_Disease'), (78, 87, 'I_Disease')]}], ['Learning of rats under amnesia caused by pentobarbital .', {'entities': [(23, 30, 'B_Disease')]}], ['Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital ( 15 mg / kg , ip ) was carried out .', {'entities': [(66, 73, 'B_Disease')]}], ['It was shown that memory dissociation occurred in both groups .', {'entities': [(18, 24, 'B_Disease'), (25, 37, 'I_Disease')]}], ['METHODS : Thirty - nine postmenopausal women with osteopenia or osteoporosis were included in this prospective , controlled clinical study .', {'entities': [(50, 60, 'B_Disease'), (64, 76, 'B_Disease')]}], ['A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea ( P < 0 . 05 ; r = 0 . 33 ) .', {'entities': [(101, 111, 'B_Disease')]}], ['CONCLUSION : We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels , but not TAFI levels .', {'entities': [(51, 57, 'B_Disease'), (58, 73, 'I_Disease')]}], ['Valproate - induced encephalopathy .', {'entities': [(20, 34, 'B_Disease')]}], ['Valproate - induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals .', {'entities': [(20, 34, 'B_Disease'), (92, 101, 'B_Disease')]}], ['It is usually but not necessarily associated with hyperammonemia .', {'entities': [(50, 64, 'B_Disease')]}], ['A case of valproate - induced encephalopathy is presented .', {'entities': [(30, 44, 'B_Disease')]}], ['Recurrent dysphonia and acitretin .', {'entities': [(10, 19, 'B_Disease')]}], ['We report the case of a woman complaining of dysphonia while she was treated by acitretin .', {'entities': [(45, 54, 'B_Disease')]}], ['To our knowledge , this is the first case of acitretin - induced dysphonia .', {'entities': [(65, 74, 'B_Disease')]}], ['Nitro - L - arginine methyl ester : a potential protector against gentamicin ototoxicity .', {'entities': [(77, 88, 'B_Disease')]}], ['The nitric oxide ( NO ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against high - frequency hearing loss caused by gentamicin , but further studies are needed to confirm this . Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .', {'entities': [(117, 121, 'B_Disease'), (122, 123, 'I_Disease'), (124, 133, 'I_Disease'), (134, 141, 'I_Disease'), (142, 146, 'I_Disease')]}], ['Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .', {'entities': [(6, 17, 'B_Disease'), (61, 69, 'B_Disease'), (202, 215, 'B_Disease'), (216, 223, 'I_Disease'), (224, 228, 'I_Disease')]}], ['Its effect was determined in terms of attenuation of hearing loss , measured by shifts in the auditory brainstem response threshold .', {'entities': [(53, 60, 'B_Disease'), (61, 65, 'I_Disease')]}], ['L - NAME reduced gentamicin - induced hearing loss in the high - frequency range , but gave no protection in the middle or low frequencies .', {'entities': [(38, 45, 'B_Disease'), (46, 50, 'I_Disease')]}], ['METHODS : This was a multicenter , randomized , open - label study in adult smokers with heart disease , hypertension not controlled by medication , and / or diabetes mellitus .', {'entities': [(89, 94, 'B_Disease'), (95, 102, 'I_Disease'), (105, 117, 'B_Disease'), (158, 166, 'B_Disease'), (167, 175, 'I_Disease')]}], ['The most common adverse events were nausea ( 17 . 2 % and 16 . 1 % ; 95 % CI , - 3 . 7 to 6 . 0 ) , hiccups ( 10 . 7 % and 6 . 6 % ; 95 % CI , 0 . 5 to 7 . 8 ) , and headache ( 8 . 7 % and 9 . 9 % ; 95 % Cl , - 5 . 0 to 2 . 6 ) .', {'entities': [(36, 42, 'B_Disease'), (100, 107, 'B_Disease'), (166, 174, 'B_Disease')]}], ['Pharmacological modulation of pain - related brain activity during normal and central sensitization states in humans .', {'entities': [(30, 34, 'B_Disease')]}], ['Abnormal processing of somatosensory inputs in the central nervous system ( central sensitization ) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury ( secondary hyperalgesia ) .', {'entities': [(145, 149, 'B_Disease'), (186, 192, 'B_Disease'), (193, 199, 'I_Disease'), (202, 211, 'B_Disease'), (212, 224, 'I_Disease')]}], ['Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain .', {'entities': [(0, 9, 'B_Disease'), (10, 22, 'I_Disease'), (60, 70, 'B_Disease'), (71, 83, 'I_Disease'), (101, 112, 'B_Disease'), (113, 117, 'I_Disease')]}], ['Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization .', {'entities': [(83, 95, 'B_Disease')]}], ['The aim of this study was to assess the effects of gabapentin , a drug effective in neuropathic pain patients , on brain processing of nociceptive information in normal and central sensitization states .', {'entities': [(84, 95, 'B_Disease'), (96, 100, 'I_Disease')]}], ['Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the gabapentin - induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin - induced secondary hyperalgesia .', {'entities': [(230, 239, 'B_Disease'), (240, 252, 'I_Disease')]}], ['Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine .', {'entities': [(72, 80, 'B_Disease')]}], ['Mitochondrial abnormalities have been associated with several aspects of epileptogenesis , such as energy generation , control of cell death , neurotransmitter synthesis , and free radical ( FR ) production .', {'entities': [(0, 13, 'B_Disease'), (14, 27, 'I_Disease'), (135, 140, 'B_Disease')]}], ['In this study , we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase ( CCO ) , complex IV of the respiratory chain , in the chronic phase of the pilocarpine model of temporal lobe epilepsy .', {'entities': [(74, 80, 'B_Disease'), (81, 92, 'I_Disease'), (303, 311, 'B_Disease'), (312, 316, 'I_Disease'), (317, 325, 'I_Disease')]}], ['Although evidences of mitochondrial abnormalities were found in previously published studies , our results do not suggest that the FRs , generated during the acute phase , determined important abnormalities in mtDNA , in expression of CCO - I , and in CCO activity .', {'entities': [(22, 35, 'B_Disease'), (36, 49, 'I_Disease')]}], ['Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension .', {'entities': [(62, 77, 'B_Disease'), (91, 103, 'B_Disease'), (104, 116, 'I_Disease')]}], ['The effect of a 6 - week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip renovascular hypertension .', {'entities': [(158, 169, 'B_Disease'), (282, 294, 'B_Disease'), (295, 307, 'I_Disease')]}], ['Six weeks after clipping of one renal artery , hypertensive rats ( 178 + / - 4 mm Hg ) were randomly assigned to three groups : untreated hypertensive controls ( n = 8 ) , enalapril - treated ( n = 8 ) , or nitrendipine - treated ( n = 10 ) .', {'entities': [(47, 59, 'B_Disease'), (138, 150, 'B_Disease')]}], ['Renal plasma flow increased , but albumin excretion and glomerulosclerosis did not change after enalapril treatment .', {'entities': [(56, 74, 'B_Disease')]}], ['In contrast , in the nitrendipine - treated group albuminuria increased from 12 . 8 + / - 2 progressively to 163 + / - 55 compared with 19 . 2 + / - 9 mg / 24 hr in the hypertensive controls .', {'entities': [(50, 61, 'B_Disease'), (169, 181, 'B_Disease')]}], ['Furthermore , glomerulosclerosis index was significantly increased in the nitrendipine - treated group compared with the hypertensive controls ( 0 . 38 + / - 0 . 1 versus 0 . 13 + / - 0 . 04 ) .', {'entities': [(14, 32, 'B_Disease'), (121, 133, 'B_Disease')]}], ['In addition , glomerular size was higher in the nitrendipine - treated group ( 14 . 9 + / - 0 . 17 10 ( - 3 ) mm2 ) but lower in the enalapril - treated group ( 11 . 5 + / - 0 . 15 10 ( - 3 ) mm2 ) compared with the hypertensive controls ( 12 . 1 + / - 0 . 17 10 ( - 3 ) mm2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )', {'entities': [(216, 228, 'B_Disease')]}], ['Ketoconazole induced torsades de pointes without concomitant use of QT interval - prolonging drug .', {'entities': [(21, 29, 'B_Disease'), (30, 32, 'I_Disease'), (33, 40, 'I_Disease')]}], ['We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking ketoconazole for treatment of fungal infection .', {'entities': [(23, 31, 'B_Disease'), (32, 38, 'I_Disease'), (39, 46, 'I_Disease'), (72, 81, 'B_Disease'), (82, 84, 'I_Disease'), (85, 93, 'I_Disease'), (98, 106, 'B_Disease'), (107, 109, 'I_Disease'), (110, 117, 'I_Disease'), (120, 123, 'B_Disease'), (169, 175, 'B_Disease'), (176, 185, 'I_Disease')]}], ['We postulate that by virtue of its direct blocking action on IKr , ketoconazole alone may prolong QT interval and induce TdP .', {'entities': [(121, 124, 'B_Disease')]}], ['This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome .', {'entities': [(102, 106, 'B_Disease'), (107, 109, 'I_Disease'), (110, 118, 'I_Disease')]}], ['Cerebral vasculitis following oral methylphenidate intake in an adult : a case report .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease')]}], ['Cerebral vasculitis associated with amphetamine abuse is well documented , and in rare cases ischaemic stroke has been reported after methylphenidate intake in children .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease'), (36, 47, 'B_Disease'), (48, 53, 'I_Disease'), (93, 102, 'B_Disease'), (103, 109, 'I_Disease')]}], ['We report the case of a 63 - year - old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes .', {'entities': [(91, 104, 'B_Disease'), (132, 141, 'B_Disease'), (142, 149, 'I_Disease')]}], ['We consider drug - induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work - up .', {'entities': [(27, 35, 'B_Disease'), (36, 46, 'I_Disease'), (85, 94, 'B_Disease'), (95, 102, 'I_Disease')]}], ['We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy .', {'entities': [(42, 52, 'B_Disease')]}], ['MDMA polydrug users show process - specific central executive impairments coupled with impaired social and emotional judgement processes .', {'entities': [(87, 95, 'B_Disease'), (96, 102, 'I_Disease'), (103, 106, 'I_Disease'), (107, 116, 'I_Disease'), (117, 126, 'I_Disease'), (127, 136, 'I_Disease')]}], ['In recent years working memory deficits have been reported in users of MDMA ( 3 , 4 - methylenedioxymethamphetamine , ecstasy ) .', {'entities': [(24, 30, 'B_Disease'), (31, 39, 'I_Disease')]}], ['Phase II study of the amsacrine analogue CI - 921 ( NSC 343499 ) in non - small cell lung cancer .', {'entities': [(68, 71, 'B_Disease'), (72, 73, 'I_Disease'), (74, 79, 'I_Disease'), (80, 84, 'I_Disease'), (85, 89, 'I_Disease'), (90, 96, 'I_Disease')]}], ['It was administered by 15 min infusion to 16 evaluable patients with non - small cell lung cancer ( NSCLC ) ( 7 with no prior treatment , 9 patients in relapse following surgery / radiotherapy ) at a dose ( 648 mg / m2 divided over 3 days , repeated every 3 weeks ) determined by phase I trial .', {'entities': [(69, 72, 'B_Disease'), (73, 74, 'I_Disease'), (75, 80, 'I_Disease'), (81, 85, 'I_Disease'), (86, 90, 'I_Disease'), (91, 97, 'I_Disease'), (100, 105, 'B_Disease')]}], ['The histology comprised squamous carcinoma ( 11 ) , adenocarcinoma ( 1 ) , mixed histology ( 2 ) , bronchio - alveolar carcinoma ( 1 ) and large cell undifferentiated carcinoma ( 1 ) .', {'entities': [(24, 32, 'B_Disease'), (33, 42, 'I_Disease'), (52, 66, 'B_Disease'), (99, 107, 'B_Disease'), (108, 109, 'I_Disease'), (110, 118, 'I_Disease'), (119, 128, 'I_Disease'), (150, 166, 'B_Disease'), (167, 176, 'I_Disease')]}], ['Neutropenia grade greater than or equal to 3 was seen in 15 patients , infections with recovery in 3 , and grand mal seizures in 1 patient .', {'entities': [(0, 11, 'B_Disease'), (71, 81, 'B_Disease'), (117, 125, 'B_Disease')]}], ['Grade less than or equal to 2 nausea and vomiting occurred in 66 % courses and phlebitis in the infusion arm in 37 % .', {'entities': [(30, 36, 'B_Disease'), (41, 49, 'B_Disease'), (79, 88, 'B_Disease')]}], ['1 patient with squamous cell carcinoma achieved a partial response lasting 5 months .', {'entities': [(15, 23, 'B_Disease'), (24, 28, 'I_Disease'), (29, 38, 'I_Disease')]}], ['Further testing in this and other tumour types using multiple daily schedules is warranted .', {'entities': [(34, 40, 'B_Disease')]}], ['Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and headache ) have been reported for patients treated with either desipramine or cinacalcet .', {'entities': [(180, 186, 'B_Disease'), (191, 199, 'B_Disease')]}], ['We report an interesting case investigating a ( near ) fatal poisoning .', {'entities': [(61, 70, 'B_Disease')]}], [\"METHODS : The son of an 84 - year - old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer ' s disease .\", {'entities': [(123, 132, 'B_Disease'), (133, 134, 'I_Disease'), (135, 136, 'I_Disease'), (137, 144, 'I_Disease')]}], ['RESULTS : Minutes after oral administration , the patient developed nausea , sweating and hypotension , and finally collapsed .', {'entities': [(68, 74, 'B_Disease'), (90, 101, 'B_Disease')]}], ['Bradycardia , cholinergic symptoms and asystole occurred .', {'entities': [(0, 11, 'B_Disease'), (39, 47, 'B_Disease')]}], ['Further signs were hyperhidrosis , hypersalivation , bronchorrhoea , and severe miosis ; the electrocardiographic finding was atrio - ventricular dissociation .', {'entities': [(19, 32, 'B_Disease'), (35, 50, 'B_Disease'), (53, 66, 'B_Disease'), (80, 86, 'B_Disease'), (126, 131, 'B_Disease'), (132, 133, 'I_Disease'), (134, 145, 'I_Disease'), (146, 158, 'I_Disease')]}], ['However , increased dyspnoea and bronchospasm necessitated reintubation .', {'entities': [(20, 28, 'B_Disease'), (33, 45, 'B_Disease')]}], ['Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction .', {'entities': [(0, 11, 'B_Disease'), (12, 25, 'I_Disease'), (50, 57, 'B_Disease'), (58, 67, 'I_Disease'), (68, 77, 'I_Disease')]}], ['On the next day he died , probably as a result of heart failure .', {'entities': [(50, 55, 'B_Disease'), (56, 63, 'I_Disease')]}], ['Especially in old patients , intensivists should consider intoxications ( with cholinergics ) as a cause of acute cardiovascular failure .', {'entities': [(108, 113, 'B_Disease'), (114, 128, 'I_Disease'), (129, 136, 'I_Disease')]}], ['Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions .', {'entities': [(81, 90, 'B_Disease'), (91, 103, 'I_Disease')]}], ['Diazepam - , scopolamine - and ageing - induced amnesia served as the interoceptive behavioral models .', {'entities': [(48, 55, 'B_Disease')]}], ['Furthermore , DCE reversed the amnesia induced by scopolamine ( 0 . 4 mg / kg , i . p . ) and diazepam ( 1 mg / kg , i . p . ) .', {'entities': [(31, 38, 'B_Disease')]}], ['Therefore , DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as , memory improving property , cholesterol lowering property and anticholinesterase activity .', {'entities': [(70, 79, 'B_Disease'), (80, 92, 'I_Disease')]}], ['Valproic acid induced encephalopathy - - 19 new cases in Germany from 1994 to 2003 - - a side effect associated to VPA - therapy not only in young children .', {'entities': [(22, 36, 'B_Disease')]}], ['Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , VPA - induced hepatotoxicity and VPA - induced encephalopathy .', {'entities': [(79, 91, 'B_Disease'), (94, 98, 'B_Disease'), (99, 105, 'I_Disease'), (106, 117, 'I_Disease'), (134, 148, 'B_Disease'), (167, 181, 'B_Disease')]}], ['The typical signs of VPA - induced encephalopathy are impaired consciousness , sometimes marked EEG background slowing , increased seizure frequency , with or without hyperammonemia .', {'entities': [(35, 49, 'B_Disease'), (54, 62, 'B_Disease'), (63, 76, 'I_Disease'), (131, 138, 'B_Disease'), (167, 181, 'B_Disease')]}], ['There is still no proof of causative effect of VPA in patients with encephalopathy , but only of an association with an assumed causal relation .', {'entities': [(68, 82, 'B_Disease')]}], ['We report 19 patients with VPA - associated encephalopathy in Germany from the years 1994 to 2003 , none of whom had been published previously .', {'entities': [(44, 58, 'B_Disease')]}], ['Cerebral haemorrhage induced by warfarin - the influence of drug - drug interactions .', {'entities': [(0, 8, 'B_Disease'), (9, 20, 'I_Disease')]}], ['PURPOSE : To evaluate the frequency , severity and preventability of warfarin - induced cerebral haemorrhages due to warfarin and warfarin - drug interactions in patients living in the county of Osterg tland , Sweden .', {'entities': [(88, 96, 'B_Disease'), (97, 109, 'I_Disease')]}], ['METHODS : All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000 - 2002 were identified .', {'entities': [(40, 48, 'B_Disease'), (49, 60, 'I_Disease')]}], ['Medical records were studied retrospectively to evaluate whether warfarin and warfarin - drug interactions could have caused the cerebral haemorrhage .', {'entities': [(129, 137, 'B_Disease'), (138, 149, 'I_Disease')]}], ['RESULTS : Among 593 patients with cerebral haemorrhage , 59 ( 10 % ) were assessed as related to warfarin treatment .', {'entities': [(34, 42, 'B_Disease'), (43, 54, 'I_Disease')]}], ['A warfarin - drug interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .', {'entities': [(60, 71, 'B_Disease'), (143, 151, 'B_Disease')]}], ['CONCLUSIONS : Warfarin - induced cerebral haemorrhages are a major clinical problem with a high fatality rate .', {'entities': [(33, 41, 'B_Disease'), (42, 54, 'I_Disease')]}], ['A significant proportion of warfarin - related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin .', {'entities': [(47, 55, 'B_Disease'), (56, 68, 'I_Disease')]}], ['Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia .', {'entities': [(107, 120, 'B_Disease')]}], ['The present study was designed to study the effect of histamine H ( 3 ) - receptor ligands on neuroleptic - induced catalepsy , apomorphine - induced climbing behavior and amphetamine - induced locomotor activities in mice .', {'entities': [(116, 125, 'B_Disease')]}], ['Catalepsy was induced by haloperidol ( 2 mg / kg p . o . ) , while apomorphine ( 1 . 5 mg / kg s . c . ) and amphetamine ( 2 mg / kg s . c . ) were used for studying climbing behavior and locomotor activities , respectively .', {'entities': [(0, 9, 'B_Disease')]}], ['( R ) - alpha - methylhistamine ( RAMH ) ( 5 microg i . c . v . ) and thioperamide ( THP ) ( 15 mg / kg i . p . ) , per se did not cause catalepsy .', {'entities': [(137, 146, 'B_Disease')]}], ['Administration of THP ( 3 . 75 , 7 . 5 and 15 mg / kg i . p . ) 1 h prior to haloperidol resulted in a dose - dependent increase in the catalepsy times ( P < 0 . 05 ) .', {'entities': [(136, 145, 'B_Disease')]}], ['On amphetamine - induced hyperactivity , THP ( 3 . 75 and 7 . 5 mg / kg i . p . ) reduced locomotor time , distance traveled and average speed ( P < 0 . 05 ) .', {'entities': [(25, 38, 'B_Disease')]}], ['THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced catalepsy , reducing amphetamine - induced hyperactivity and reducing apomorphine - induced climbing in mice .', {'entities': [(84, 93, 'B_Disease'), (127, 140, 'B_Disease')]}], ['Findings suggest a potential for H ( 3 ) - receptor antagonists in improving the refractory cases of schizophrenia .', {'entities': [(101, 114, 'B_Disease')]}], ['Cauda equina syndrome after epidural steroid injection : a case report .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease'), (13, 21, 'I_Disease')]}], ['OBJECTIVE : Conventional treatment methods of lumbusacral radiculopathy are physical therapy , epidural steroid injections , oral medications , and spinal manipulative therapy .', {'entities': [(58, 71, 'B_Disease')]}], ['Cauda equina syndrome is a rare complication of epidural anesthesia .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease'), (13, 21, 'I_Disease')]}], ['The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine .', {'entities': [(34, 39, 'B_Disease'), (40, 46, 'I_Disease'), (47, 55, 'I_Disease')]}], ['CLINICAL FEATURES : A 50 - year - old woman with low back and right leg pain was scheduled for epidural steroid injection .', {'entities': [(49, 52, 'B_Disease'), (53, 57, 'I_Disease'), (58, 61, 'I_Disease'), (62, 67, 'I_Disease'), (68, 71, 'I_Disease'), (72, 76, 'I_Disease')]}], ['Three hours later , she complained of perineal numbness and lower extremity weakness .', {'entities': [(47, 55, 'B_Disease'), (60, 65, 'B_Disease'), (66, 75, 'I_Disease'), (76, 84, 'I_Disease')]}], ['The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg .', {'entities': [(35, 39, 'B_Disease'), (40, 42, 'I_Disease'), (43, 52, 'I_Disease')]}], ['Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important .', {'entities': [(49, 59, 'B_Disease'), (60, 73, 'I_Disease')]}], ['High - dose testosterone is associated with atherosclerosis in postmenopausal women .', {'entities': [(44, 59, 'B_Disease')]}], ['OBJECTIVES : To study the long - term effects of androgen treatment on atherosclerosis in postmenopausal women .', {'entities': [(71, 86, 'B_Disease')]}], ['METHODS : In a population - based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self - reported intramuscularly administered high - dose estrogen - testosterone therapy ( estradiol - and testosterone esters ) and aortic atherosclerosis .', {'entities': [(274, 289, 'B_Disease')]}], ['Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta , which have been shown to reflect intima atherosclerosis .', {'entities': [(7, 22, 'B_Disease'), (150, 165, 'B_Disease')]}], ['In almost half of these women severe atherosclerosis of the aorta was present ( n = 11 ) , while in women without hormone use severe atherosclerosis of the aorta was present in less than 20 % ( OR 3 . 1 ; 95 % CI , 1 . 1 - 8 . 5 , adjusted for age , years since menopause , smoking , and body mass index ) .', {'entities': [(37, 52, 'B_Disease'), (133, 148, 'B_Disease')]}], ['The association remained after additional adjustment for diabetes , cholesterol level , systolic blood pressure , or alcohol use .', {'entities': [(57, 65, 'B_Disease')]}], ['CONCLUSION : Our results suggest that high - dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless .', {'entities': [(92, 107, 'B_Disease')]}], ['Optimising stroke prevention in non - valvular atrial fibrillation .', {'entities': [(11, 17, 'B_Disease'), (47, 53, 'B_Disease'), (54, 66, 'I_Disease')]}], ['Atrial fibrillation is associated with substantial morbidity and mortality .', {'entities': [(0, 6, 'B_Disease'), (7, 19, 'I_Disease')]}], ['Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62 % , and that aspirin alone reduces the risk by 22 % .', {'entities': [(117, 123, 'B_Disease')]}], ['Overall , in high - risk patients , warfarin is superior to aspirin in preventing strokes , with a relative risk reduction of 36 % .', {'entities': [(82, 89, 'B_Disease')]}], ['Ximelagatran , an oral direct thrombin inhibitor , was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events , but has been recently withdrawn because of abnormal liver function tests .', {'entities': [(131, 138, 'B_Disease'), (139, 145, 'I_Disease'), (191, 199, 'B_Disease'), (200, 205, 'I_Disease'), (206, 214, 'I_Disease')]}], ['The ACTIVE - W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .', {'entities': [(17, 23, 'B_Disease'), (24, 36, 'I_Disease'), (226, 233, 'B_Disease'), (234, 240, 'I_Disease')]}], ['Idraparinux , a Factor Xa inhibitor , is being evaluated in patients with atrial fibrillation .', {'entities': [(74, 80, 'B_Disease'), (81, 93, 'I_Disease')]}], ['Angiotensin - converting enzyme inhibitors and angiotensin II receptor - blocking drugs hold promise in atrial fibrillation through cardiac remodelling .', {'entities': [(104, 110, 'B_Disease'), (111, 123, 'I_Disease'), (132, 139, 'B_Disease'), (140, 151, 'I_Disease')]}], ['Anti - oxidant effects of atorvastatin in dexamethasone - induced hypertension in the rat .', {'entities': [(66, 78, 'B_Disease')]}], ['Dexamethasone ( Dex ) - induced hypertension is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( O2 - ) production .', {'entities': [(32, 44, 'B_Disease')]}], ['Atorvastatin ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2 - production in various forms of hypertension .', {'entities': [(195, 207, 'B_Disease')]}], ['Severe citrate toxicity complicating volunteer apheresis platelet donation .', {'entities': [(15, 23, 'B_Disease')]}], ['We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection .', {'entities': [(35, 43, 'B_Disease')]}], ['Past medical history was remarkable for hypertension , hyperlipidemia , and depression .', {'entities': [(40, 52, 'B_Disease'), (55, 69, 'B_Disease'), (76, 86, 'B_Disease')]}], ['She then very rapidly developed acute onset of severe facial and extremity tetany .', {'entities': [(75, 81, 'B_Disease')]}], ['Empirical treatment with intravenous calcium gluconate was initiated , and muscle contractions slowly subsided over approximately 10 to 15 minutes .', {'entities': [(75, 81, 'B_Disease'), (82, 94, 'I_Disease')]}], ['The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia .', {'entities': [(136, 148, 'B_Disease')]}], ['Upon additional retrospective analysis , it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia .', {'entities': [(116, 128, 'B_Disease')]}], ['We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity .', {'entities': [(93, 105, 'B_Disease'), (169, 177, 'B_Disease')]}], ['Sirolimus - associated proteinuria and renal dysfunction .', {'entities': [(23, 34, 'B_Disease'), (39, 44, 'B_Disease'), (45, 56, 'I_Disease')]}], ['Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy .', {'entities': [(124, 135, 'B_Disease')]}], ['Its role in the therapy of glomerulonephritis , autoimmunity , cystic renal diseases and renal cancer is under investigation .', {'entities': [(27, 45, 'B_Disease'), (48, 60, 'B_Disease'), (63, 69, 'B_Disease'), (70, 75, 'I_Disease'), (76, 84, 'I_Disease'), (89, 94, 'B_Disease'), (95, 101, 'I_Disease')]}], [\"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors , it has been designated a ' non - nephrotoxic drug ' .\", {'entities': [(140, 151, 'B_Disease')]}], ['However , clinical reports suggest that , under some circumstances , sirolimus is associated with proteinuria and acute renal dysfunction .', {'entities': [(98, 109, 'B_Disease'), (114, 119, 'B_Disease'), (120, 125, 'I_Disease'), (126, 137, 'I_Disease')]}], ['A common risk factor appears to be presence of pre - existing chronic renal damage .', {'entities': [(62, 69, 'B_Disease'), (70, 75, 'I_Disease'), (76, 82, 'I_Disease')]}], ['The mechanisms of sirolimus - associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal .', {'entities': [(41, 52, 'B_Disease')]}], ['The acute renal dysfunction associated with sirolimus ( such as in delayed graft function ) may be due to suppression of compensatory renal cell proliferation and survival / repair processes .', {'entities': [(4, 9, 'B_Disease'), (10, 15, 'I_Disease'), (16, 27, 'I_Disease')]}], ['Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .', {'entities': [(237, 248, 'B_Disease'), (359, 370, 'B_Disease')]}], ['Proteinuria after conversion to sirolimus in renal transplant recipients .', {'entities': [(0, 11, 'B_Disease')]}], ['More recently , proteinuria has been reported as a consequence of sirolimus therapy , although the mechanism has remained unclear .', {'entities': [(16, 27, 'B_Disease')]}], ['We retrospectively examined the records of 25 renal transplant patients , who developed or displayed increased proteinuria after SRL conversion .', {'entities': [(111, 122, 'B_Disease')]}], [\"The patient cohort ( 14 men , 11 women ) was treated with SRL as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi ' s sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .\", {'entities': [(93, 100, 'B_Disease'), (101, 110, 'I_Disease'), (111, 122, 'I_Disease'), (125, 128, 'B_Disease'), (142, 151, 'B_Disease'), (164, 170, 'B_Disease'), (171, 172, 'I_Disease'), (173, 174, 'I_Disease'), (175, 182, 'I_Disease'), (190, 194, 'B_Disease'), (195, 202, 'I_Disease'), (209, 219, 'B_Disease'), (220, 226, 'I_Disease'), (233, 238, 'B_Disease'), (239, 243, 'I_Disease'), (244, 252, 'I_Disease'), (267, 278, 'B_Disease')]}], ['Proteinuria increased from 0 . 445 ( 0 to 1 . 5 ) g / d before conversion to 3 . 2 g / dL ( 0 . 2 to 12 ) after conversion ( P = 0 . 001 ) .', {'entities': [(0, 11, 'B_Disease')]}], ['Before conversion 8 ( 32 % ) patients had no proteinuria , whereas afterwards all patients had proteinuria .', {'entities': [(45, 56, 'B_Disease'), (95, 106, 'B_Disease')]}], ['In 28 % of patients proteinuria remained unchanged , whereas it increased in 68 % of patients .', {'entities': [(20, 31, 'B_Disease')]}], ['Twenty - eight percent of patients showed increased proteinuria to the nephrotic range .', {'entities': [(52, 63, 'B_Disease'), (71, 80, 'B_Disease')]}], ['Biopsies performed in five patients revealed new pathological changes : One membranoproliferative glomerulopathy and interstitial nephritis .', {'entities': [(76, 97, 'B_Disease'), (98, 112, 'I_Disease'), (117, 129, 'B_Disease'), (130, 139, 'I_Disease')]}], [\"Five patients displayed CAN and Kaposi ' s sarcoma .\", {'entities': [(24, 27, 'B_Disease'), (32, 38, 'B_Disease'), (39, 40, 'I_Disease'), (41, 42, 'I_Disease'), (43, 50, 'I_Disease')]}], ['Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation .', {'entities': [(6, 17, 'B_Disease')]}], ['Therefore , conversion should be considered for patients who have not developed advanced CAN and proteinuria .', {'entities': [(89, 92, 'B_Disease'), (97, 108, 'B_Disease')]}], ['Long - term follow - up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors : an International Society of Pediatric Oncology report .', {'entities': [(38, 43, 'B_Disease'), (44, 52, 'I_Disease'), (77, 86, 'B_Disease'), (87, 98, 'I_Disease'), (99, 105, 'I_Disease')]}], ['The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol ( International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .', {'entities': [(39, 48, 'B_Disease'), (49, 60, 'I_Disease'), (61, 67, 'I_Disease'), (200, 209, 'B_Disease'), (210, 221, 'I_Disease'), (222, 227, 'I_Disease')]}], ['The most common primary tumor site was the head and neck .', {'entities': [(24, 29, 'B_Disease')]}], ['Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , aminoaciduria , urinary pH , osmolarity , creatinine clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .', {'entities': [(79, 89, 'B_Disease'), (92, 103, 'B_Disease'), (106, 119, 'B_Disease')]}], ['Fifty - eight patients ( 78 % ) had normal renal tests , whereas 16 patients ( 22 % ) had renal abnormalities .', {'entities': [(90, 95, 'B_Disease'), (96, 109, 'I_Disease')]}], [\"Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in Fanconi ' s syndrome ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption .\", {'entities': [(150, 158, 'B_Disease'), (172, 179, 'B_Disease'), (180, 181, 'I_Disease'), (182, 183, 'I_Disease'), (184, 192, 'I_Disease'), (195, 199, 'B_Disease')]}], ['Severe toxicity was correlated with the higher cumulative dose of 60 g / m2 of ifosfamide , a younger age ( less than 2 1 / 2 years old ) , and a predominance of vesicoprostatic tumor involvement .', {'entities': [(7, 15, 'B_Disease'), (178, 183, 'B_Disease')]}], ['This low percentage ( 5 % ) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children .', {'entities': [(117, 128, 'B_Disease'), (129, 135, 'I_Disease')]}], ['Progressive myopathy with up - regulation of MHC - I associated with statin therapy .', {'entities': [(12, 20, 'B_Disease')]}], ['Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug .', {'entities': [(32, 40, 'B_Disease'), (45, 57, 'B_Disease')]}], ['What is less well known is a phenomenon whereby statins may induce a myopathy , which persists or may progress after stopping the drug .', {'entities': [(69, 77, 'B_Disease')]}], ['All had myofibre necrosis but only 3 had an inflammatory infiltrate .', {'entities': [(17, 25, 'B_Disease')]}], ['In all cases there was diffuse or multifocal up - regulation of MHC - I expression even in non - necrotic fibres .', {'entities': [(97, 105, 'B_Disease')]}], ['These observations suggest that statins may initiate an immune - mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy .', {'entities': [(74, 82, 'B_Disease')]}], ['The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up - regulation of MHC - I expression and antigen presentation by muscle fibres .', {'entities': [(22, 30, 'B_Disease')]}], ['Use of chromosome substitution strains to identify seizure susceptibility loci in mice .', {'entities': [(51, 58, 'B_Disease')]}], ['Seizure susceptibility varies among inbred mouse strains .', {'entities': [(0, 7, 'B_Disease')]}], ['Chromosome substitution strains ( CSS ) , in which a single chromosome from one inbred strain ( donor ) has been transferred onto a second strain ( host ) by repeated backcrossing , may be used to identify quantitative trait loci ( QTLs ) that contribute to seizure susceptibility .', {'entities': [(258, 265, 'B_Disease')]}], ['QTLs for susceptibility to pilocarpine - induced seizures , a model of temporal lobe epilepsy , have not been reported , and CSS have not previously been used to localize seizure susceptibility genes .', {'entities': [(49, 57, 'B_Disease'), (71, 79, 'B_Disease'), (80, 84, 'I_Disease'), (85, 93, 'I_Disease'), (171, 178, 'B_Disease')]}], ['We report QTLs identified using a B6 ( host ) x A / J ( donor ) CSS panel to localize genes involved in susceptibility to pilocarpine - induced seizures .', {'entities': [(144, 152, 'B_Disease')]}], ['Three hundred fifty - five adult male CSS mice , 58 B6 , and 39 A / J were tested for susceptibility to pilocarpine - induced seizures .', {'entities': [(126, 134, 'B_Disease')]}], ['B6 mice were resistant to seizures and slower to reach stages compared to A / J mice .', {'entities': [(26, 34, 'B_Disease')]}], ['CSS mapping suggests seizure susceptibility loci on mouse Chromosomes 10 and 18 .', {'entities': [(21, 28, 'B_Disease')]}], ['This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy .', {'entities': [(106, 114, 'B_Disease'), (115, 119, 'I_Disease'), (120, 128, 'I_Disease')]}], ['In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide - induced cystitis in the rat .', {'entities': [(101, 109, 'B_Disease')]}], ['In cyclophosphamide - induced cystitis in the rat , detrusor function is impaired and the expression and effects of muscarinic receptors altered .', {'entities': [(30, 38, 'B_Disease')]}], ['Whether or not the neuronal transmission may be affected by cystitis was presently investigated .', {'entities': [(60, 68, 'B_Disease')]}], ['Thus , in cystitis substantial changes of the efferent functional responses occur .', {'entities': [(10, 18, 'B_Disease')]}], ['BACKGROUND : Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease , including arrhythmia , coronary heart disease , and chronic heart failure .', {'entities': [(102, 116, 'B_Disease'), (117, 124, 'I_Disease'), (137, 147, 'B_Disease'), (150, 158, 'B_Disease'), (159, 164, 'I_Disease'), (165, 172, 'I_Disease'), (187, 192, 'B_Disease'), (193, 200, 'I_Disease')]}], ['Clonidine - induced bradycardia in conscious alpha2ABC - / - mice was 32 . 3 % ( 10 microg / kg ) and 26 . 6 % ( 100 microg / kg ) of the effect in wild - type mice .', {'entities': [(20, 31, 'B_Disease')]}], ['Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid .', {'entities': [(0, 13, 'B_Disease'), (14, 23, 'I_Disease')]}], ['We report the case of a patient with amoxicillin - clavulanic acid - induced hepatitis with histologic multiple granulomas .', {'entities': [(77, 86, 'B_Disease'), (112, 122, 'B_Disease')]}], ['This type of lesion broadens the spectrum of liver injury due to this drug combination , mainly represented by a benign cholestatic syndrome .', {'entities': [(45, 50, 'B_Disease'), (51, 57, 'I_Disease'), (120, 131, 'B_Disease'), (132, 140, 'I_Disease')]}], ['The association of granulomas and eosinophilia favor an immunoallergic mechanism .', {'entities': [(19, 29, 'B_Disease'), (34, 46, 'B_Disease')]}], ['Dobutamine stress echocardiography : a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin - treated long - term survivors of childhood cancer .', {'entities': [(166, 172, 'B_Disease')]}], ['Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy .', {'entities': [(95, 109, 'B_Disease')]}], ['To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long - term survivors of childhood cancer treated with doxorubicin from healthy control subjects .', {'entities': [(65, 72, 'B_Disease'), (73, 79, 'I_Disease'), (221, 227, 'B_Disease')]}], ['The influence of smoking during pregnancy on the developing cochlea has not been estimated , although smoking has been positively associated with hearing loss in adults .', {'entities': [(146, 153, 'B_Disease'), (154, 158, 'I_Disease')]}], ['METHODS : This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns .', {'entities': [(70, 77, 'B_Disease'), (78, 88, 'I_Disease')]}], ['However , by comparing each subgroup to control group , we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups .', {'entities': [(91, 100, 'B_Disease'), (101, 103, 'I_Disease'), (104, 110, 'I_Disease'), (111, 121, 'I_Disease')]}], ['Simvastatin - induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism .', {'entities': [(36, 47, 'B_Disease'), (48, 56, 'I_Disease'), (61, 72, 'B_Disease'), (89, 103, 'B_Disease')]}], ['A 54 - year - old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis .', {'entities': [(18, 29, 'B_Disease'), (97, 108, 'B_Disease'), (109, 117, 'I_Disease'), (122, 133, 'B_Disease')]}], ['It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients .', {'entities': [(131, 144, 'B_Disease')]}], ['Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats : implications for autism .', {'entities': [(0, 17, 'B_Disease'), (22, 32, 'B_Disease'), (33, 46, 'I_Disease'), (111, 117, 'B_Disease')]}], ['Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors .', {'entities': [(0, 6, 'B_Disease'), (12, 30, 'B_Disease'), (31, 39, 'I_Disease'), (78, 86, 'B_Disease'), (87, 89, 'I_Disease'), (90, 103, 'I_Disease'), (104, 107, 'I_Disease'), (108, 114, 'I_Disease'), (115, 121, 'I_Disease'), (126, 136, 'B_Disease'), (137, 146, 'I_Disease')]}], ['In addition to genetic influences , recent studies suggest that prenatal drug or chemical exposures are risk factors for autism .', {'entities': [(121, 127, 'B_Disease')]}], ['Terbutaline , a beta2 - adrenoceptor agonist used to arrest preterm labor , has been associated with increased concordance for autism in dizygotic twins .', {'entities': [(60, 67, 'B_Disease'), (68, 73, 'I_Disease'), (127, 133, 'B_Disease')]}], ['Our findings indicate that beta2 - adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities , similar to those described in autism .', {'entities': [(183, 193, 'B_Disease'), (194, 207, 'I_Disease'), (240, 246, 'B_Disease')]}], ['This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders .', {'entities': [(103, 109, 'B_Disease'), (110, 118, 'I_Disease'), (119, 128, 'I_Disease')]}], ['Upregulation of brain expression of P - glycoprotein in MRP2 - deficient TR ( - ) rats resembles seizure - induced up - regulation of this drug efflux transporter in normal rats .', {'entities': [(97, 104, 'B_Disease')]}], ['A comparable overexpression of Pgp in the BBB was obtained after pilocarpine - induced seizures in wild - type Wistar rats .', {'entities': [(87, 95, 'B_Disease')]}], ['Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds , the present data substantiate the concept that MRP2 performs a protective role in the BBB .', {'entities': [(67, 73, 'B_Disease'), (74, 76, 'I_Disease'), (77, 80, 'I_Disease'), (81, 86, 'I_Disease')]}], ['Furthermore , our data suggest that TR ( - ) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain , without the need of inducing seizures or other Pgp - enhancing events for this purpose .', {'entities': [(195, 203, 'B_Disease')]}], ['Role of xanthine oxidase in dexamethasone - induced hypertension in rats .', {'entities': [(52, 64, 'B_Disease')]}], ['Glucocorticoid - induced hypertension ( GC - HT ) in the rat is associated with nitric oxide - redox imbalance .', {'entities': [(25, 37, 'B_Disease'), (45, 47, 'B_Disease')]}], ['We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone - induced hypertension ( dex - HT ) .', {'entities': [(143, 155, 'B_Disease'), (164, 166, 'B_Disease')]}], ['Dex increased SBP ( 110 + / - 2 - 126 + / - 3 mmHg ; P < 0 . 001 ) and decreased thymus ( P < 0 . 001 ) and bodyweights ( P \" < 0 . 01 ) .', {'entities': [(4, 13, 'B_Disease'), (14, 17, 'I_Disease'), (71, 80, 'B_Disease'), (81, 87, 'I_Disease'), (88, 89, 'I_Disease'), (90, 91, 'I_Disease'), (92, 93, 'I_Disease'), (94, 95, 'I_Disease'), (96, 97, 'I_Disease'), (98, 101, 'I_Disease'), (102, 103, 'I_Disease'), (104, 107, 'I_Disease'), (108, 119, 'I_Disease')]}], ['Allopurinol did not prevent dex - HT .', {'entities': [(34, 36, 'B_Disease')]}], ['This , together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension , suggests that XO activity is not a major determinant of GC - HT in the rat .', {'entities': [(115, 127, 'B_Disease'), (191, 193, 'B_Disease')]}], [\"PURPOSE : To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub - Tenon ' s space at the end of routine cataract surgery .\", {'entities': [(196, 204, 'B_Disease')]}], ['Postoperatively , all patients were assessed for symptoms of nausea , vomiting , and headache .', {'entities': [(61, 67, 'B_Disease'), (68, 69, 'I_Disease'), (70, 78, 'I_Disease'), (85, 93, 'B_Disease')]}], ['RESULTS : Sixty percent in Group A developed postoperative emetic symptoms , headache , or both ; 1 patient in Group B developed symptoms .', {'entities': [(45, 58, 'B_Disease'), (59, 65, 'I_Disease'), (66, 74, 'I_Disease'), (77, 85, 'B_Disease')]}], [\"CONCLUSIONS : The administration of methylprednisolone and gentamicin in the posterior sub - Tenon ' s space was related to a high incidence of side effects including nausea , vomiting , and headache .\", {'entities': [(167, 173, 'B_Disease'), (174, 175, 'I_Disease'), (176, 184, 'I_Disease'), (191, 199, 'B_Disease')]}], ['Assessment of a new non - invasive index of cardiac performance for detection of dobutamine - induced myocardial ischemia .', {'entities': [(102, 112, 'B_Disease'), (113, 121, 'I_Disease')]}], ['BACKGROUND : Electrocardiography has a very low sensitivity in detecting dobutamine - induced myocardial ischemia .', {'entities': [(94, 104, 'B_Disease'), (105, 113, 'I_Disease')]}], ['OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting dobutamine - induced myocardial ischemia , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .', {'entities': [(229, 239, 'B_Disease'), (240, 248, 'I_Disease'), (392, 400, 'B_Disease')]}], ['In 19 of the 40 patients perfusion defects compatible with ischemia were detected on SPECT .', {'entities': [(59, 67, 'B_Disease')]}], ['CONCLUSIONS : If ECG alone is used for specificity , the combination with dP / dtejc improved the sensitivity of the test and could be a cost - savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia , especially in patients unable to exercise .', {'entities': [(214, 224, 'B_Disease'), (225, 233, 'I_Disease')]}], ['Cocaine - induced myocardial infarction : clinical observations and pathogenetic considerations .', {'entities': [(18, 28, 'B_Disease'), (29, 39, 'I_Disease')]}], ['Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction .', {'entities': [(116, 121, 'B_Disease'), (122, 132, 'I_Disease'), (133, 143, 'I_Disease')]}], ['In individuals with preexisting , high - grade coronary arterial narrowing , acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine - induced increase in rate - pressure product .', {'entities': [(77, 82, 'B_Disease'), (83, 93, 'I_Disease'), (94, 104, 'I_Disease')]}], ['In other individuals with no underlying atherosclerotic obstruction , coronary occlusion may be due to spasm , thrombus , or both .', {'entities': [(40, 55, 'B_Disease'), (56, 67, 'I_Disease'), (70, 78, 'B_Disease'), (79, 88, 'I_Disease'), (103, 108, 'B_Disease'), (111, 119, 'B_Disease')]}], ['With regard to spasm , the clinical findings are largely circumstantial , and the locus of cocaine - induced vasoconstriction remains speculative .', {'entities': [(15, 20, 'B_Disease')]}], ['Although certain clinical and experimental findings support the hypothesis that spasm involves the epicardial , medium - size vessels , other data suggest intramural vasoconstriction .', {'entities': [(80, 85, 'B_Disease')]}], ['Diffuse intramural vasoconstriction is not consistent with reports of segmental , discrete infarction .', {'entities': [(91, 101, 'B_Disease')]}], ['Finally , the contribution of a primary , thrombotic effect of cocaine has not been excluded .', {'entities': [(42, 52, 'B_Disease')]}], ['Proteomic analysis of striatal proteins in the rat model of L - DOPA - induced dyskinesia .', {'entities': [(79, 89, 'B_Disease')]}], [\"L - DOPA - induced dyskinesia ( LID ) is among the motor complications that arise in Parkinson ' s disease ( PD ) patients after a prolonged treatment with L - DOPA .\", {'entities': [(19, 29, 'B_Disease'), (32, 35, 'B_Disease'), (85, 94, 'B_Disease'), (95, 96, 'I_Disease'), (97, 98, 'I_Disease'), (99, 106, 'I_Disease'), (109, 111, 'B_Disease')]}], ['To this day , transcriptome analysis has been performed in a rat model of LID [ Neurobiol . Dis . , 17 ( 2004 ) , 219 ] but information regarding the proteome is still lacking .', {'entities': [(74, 77, 'B_Disease')]}], ['In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6 - hydroxydopamine - lesion rat model of PD treated with saline , L - DOPA or bromocriptine using two - dimensional difference gel electrophoresis and mass spectrometry ( MS ) .', {'entities': [(175, 177, 'B_Disease')]}], ['Rats treated with L - DOPA were allocated to two groups based on the presence or absence of LID .', {'entities': [(92, 95, 'B_Disease')]}], ['Out of these 67 proteins , LID significantly changed the expression level of five proteins : alphabeta - crystalin , gamma - enolase , guanidoacetate methyltransferase , vinculin , and proteasome alpha - 2 subunit .', {'entities': [(27, 30, 'B_Disease')]}], ['In conclusion , this study provides new insights into the protein changes occurring in LID .', {'entities': [(87, 90, 'B_Disease')]}], ['Cardiac Angiography in Renally Impaired Patients ( CARE ) study : a randomized double - blind trial of contrast - induced nephropathy in patients with chronic kidney disease .', {'entities': [(122, 133, 'B_Disease'), (151, 158, 'B_Disease'), (159, 165, 'I_Disease'), (166, 173, 'I_Disease')]}], ['METHODS AND RESULTS : The present study is a multicenter , randomized , double - blind comparison of iopamidol and iodixanol in patients with chronic kidney disease ( estimated glomerular filtration rate , 20 to 59 mL / min ) who underwent cardiac angiography or percutaneous coronary interventions .', {'entities': [(142, 149, 'B_Disease'), (150, 156, 'I_Disease'), (157, 164, 'I_Disease')]}], ['In 414 patients , contrast volume , presence of diabetes mellitus , use of N - acetylcysteine , mean baseline SCr , and estimated glomerular filtration rate were comparable in the 2 groups .', {'entities': [(48, 56, 'B_Disease'), (57, 65, 'I_Disease')]}], ['In patients with diabetes , SCr increases > or = 0 . 5 mg / dL were 5 . 1 % ( 4 of 78 patients ) with iopamidol and 13 . 0 % ( 12 of 92 patients ) with iodixanol ( P = 0 . 11 ) , whereas SCr increases > or = 25 % were 10 . 3 % and 15 . 2 % , respectively ( P = 0 . 37 ) .', {'entities': [(17, 25, 'B_Disease')]}], ['Mean post - SCr increases were significantly less with iopamidol ( all patients : 0 . 07 versus 0 . 12 mg / dL , 6 . 2 versus 10 . 6 micromol / L , P = 0 . 03 ; patients with diabetes : 0 . 07 versus 0 . 16 mg / dL , 6 . 2 versus 14 . 1 micromol / L , P = 0 . 01 ) .', {'entities': [(175, 183, 'B_Disease')]}], ['CONCLUSIONS : The rate of contrast - induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or iodixanol to high - risk patients , with or without diabetes mellitus .', {'entities': [(45, 56, 'B_Disease'), (230, 238, 'B_Disease'), (239, 247, 'I_Disease')]}], ['A novel compound , maltolyl p - coumarate , attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models .', {'entities': [(55, 64, 'B_Disease'), (65, 73, 'I_Disease'), (129, 137, 'B_Disease')]}], ['In the present study , we investigated whether maltolyl p - coumarate could improve cognitive decline in scopolamine - injected rats and in amyloid beta peptide ( 1 - 42 ) - infused rats .', {'entities': [(84, 93, 'B_Disease'), (94, 101, 'I_Disease')]}], ['Maltolyl p - coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide ( 1 - 42 ) - infused rats .', {'entities': [(46, 55, 'B_Disease'), (56, 64, 'I_Disease')]}], [\"Taking these in vitro and in vivo results together , our study suggests that maltolyl p - coumarate is a potentially effective candidate against Alzheimer ' s disease that is characterized by wide spread neuronal death and progressive decline of cognitive function .\", {'entities': [(145, 154, 'B_Disease'), (155, 156, 'I_Disease'), (157, 158, 'I_Disease'), (159, 166, 'I_Disease'), (204, 212, 'B_Disease'), (213, 218, 'I_Disease'), (235, 242, 'B_Disease'), (243, 245, 'I_Disease'), (246, 255, 'I_Disease'), (256, 264, 'I_Disease')]}], ['Attenuation of methamphetamine - induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment .', {'entities': [(68, 81, 'B_Disease')]}], ['Immunological activation has been proposed to play a role in methamphetamine - induced dopaminergic terminal damage .', {'entities': [(87, 99, 'B_Disease'), (100, 108, 'I_Disease'), (109, 115, 'I_Disease')]}], ['In this study , we examined the roles of lipopolysaccharide , a pro - inflammatory and inflammatory factor , treatment in modulating the methamphetamine - induced nigrostriatal dopamine neurotoxicity .', {'entities': [(186, 199, 'B_Disease')]}], ['Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine - elicited hyperthermia three days later .', {'entities': [(104, 116, 'B_Disease')]}], ['We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine - induced nigrostriatal dopamine neurotoxicity .', {'entities': [(171, 184, 'B_Disease')]}], ['Acute myocarditis associated with clozapine .', {'entities': [(6, 17, 'B_Disease')]}], ['OBJECTIVE : A case of acute myocarditis associated with the commencement of clozapine is described , highlighting the onset , course and possible contributing factors .', {'entities': [(28, 39, 'B_Disease')]}], ['RESULTS : A 20 - year - old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine .', {'entities': [(38, 51, 'B_Disease'), (80, 91, 'B_Disease')]}], ['CONCLUSIONS : Myocarditis is an increasingly recognized complication associated with the use of clozapine .', {'entities': [(14, 25, 'B_Disease')]}], ['Considering that clozapine remains the gold standard in treatment of resistant psychosis , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients .', {'entities': [(79, 88, 'B_Disease')]}], ['Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin , amiodarone , and atazanavir .', {'entities': [(7, 21, 'B_Disease'), (26, 31, 'B_Disease'), (32, 37, 'I_Disease'), (38, 45, 'I_Disease')]}], ['OBJECTIVE : To report a case of a severe interaction between simvastatin , amiodarone , and atazanavir resulting in rhabdomyolysis and acute renal failure .', {'entities': [(116, 130, 'B_Disease'), (135, 140, 'B_Disease'), (141, 146, 'I_Disease'), (147, 154, 'I_Disease')]}], ['BACKGROUND : A 72 - year - old white man with underlying human immunodeficiency virus , atrial fibrillation , coronary artery disease , and hyperlipidemia presented with generalized pain , fatigue , and dark orange urine for 3 days .', {'entities': [(57, 62, 'B_Disease'), (63, 79, 'I_Disease'), (80, 85, 'I_Disease'), (88, 94, 'B_Disease'), (95, 107, 'I_Disease'), (110, 118, 'B_Disease'), (119, 125, 'I_Disease'), (126, 133, 'I_Disease'), (140, 154, 'B_Disease'), (182, 186, 'B_Disease'), (189, 196, 'B_Disease')]}], [\"Simvastatin , amiodarone , and the patient ' s human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis .\", {'entities': [(47, 52, 'B_Disease'), (53, 69, 'I_Disease'), (70, 75, 'I_Disease')]}], ['DISCUSSION : The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism .', {'entities': [(25, 39, 'B_Disease')]}], ['We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin .', {'entities': [(29, 37, 'B_Disease')]}], ['Mutations associated with lamivudine - resistance in therapy - na ve hepatitis B virus ( HBV ) infected patients with and without HIV co - infection : implications for antiretroviral therapy in HBV and HIV co - infected South African patients .', {'entities': [(69, 78, 'B_Disease'), (79, 80, 'I_Disease'), (81, 86, 'I_Disease'), (87, 88, 'I_Disease'), (89, 92, 'I_Disease'), (93, 94, 'I_Disease'), (95, 103, 'I_Disease'), (130, 133, 'B_Disease'), (134, 136, 'I_Disease'), (137, 138, 'I_Disease'), (139, 148, 'I_Disease'), (194, 197, 'B_Disease'), (198, 201, 'I_Disease'), (202, 205, 'I_Disease'), (206, 208, 'I_Disease'), (209, 210, 'I_Disease'), (211, 219, 'I_Disease')]}], ['This was an exploratory study to investigate lamivudine - resistant hepatitis B virus ( HBV ) strains in selected lamivudine - na ve HBV carriers with and without human immunodeficiency virus ( HIV ) co - infection in South African patients .', {'entities': [(68, 77, 'B_Disease'), (78, 79, 'I_Disease'), (163, 168, 'B_Disease'), (169, 185, 'I_Disease'), (186, 191, 'I_Disease'), (192, 193, 'I_Disease'), (194, 197, 'I_Disease'), (198, 199, 'I_Disease'), (200, 202, 'I_Disease'), (203, 204, 'I_Disease'), (205, 214, 'I_Disease')]}], ['Thirty - five lamivudine - na ve HBV infected patients with or without HIV co - infection were studied : 15 chronic HBV mono - infected patients and 20 HBV - HIV co - infected patients .', {'entities': [(33, 36, 'B_Disease'), (37, 45, 'I_Disease'), (71, 74, 'B_Disease'), (75, 77, 'I_Disease'), (78, 79, 'I_Disease'), (80, 89, 'I_Disease'), (116, 119, 'B_Disease'), (120, 124, 'I_Disease'), (125, 126, 'I_Disease'), (127, 135, 'I_Disease'), (152, 155, 'B_Disease'), (156, 157, 'I_Disease'), (158, 161, 'I_Disease'), (162, 164, 'I_Disease'), (165, 166, 'I_Disease'), (167, 175, 'I_Disease')]}], ['HBV lamivudine - resistant strains were detected in 3 of 15 mono - infected chronic hepatitis B patients and 10 of 20 HBV - HIV co - infected patients .', {'entities': [(84, 93, 'B_Disease'), (94, 95, 'I_Disease'), (118, 121, 'B_Disease'), (122, 123, 'I_Disease'), (124, 127, 'I_Disease'), (128, 130, 'I_Disease'), (131, 132, 'I_Disease'), (133, 141, 'I_Disease')]}], ['To the best of our knowledge , this constitutes the first report of HBV lamivudine - resistant strains in therapy - na ve HBV - HIV co - infected patients .', {'entities': [(122, 125, 'B_Disease'), (126, 127, 'I_Disease'), (128, 131, 'I_Disease'), (132, 134, 'I_Disease'), (135, 136, 'I_Disease'), (137, 145, 'I_Disease')]}], ['It remains to be seen whether such pre - existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine - containing highly active antiretroviral ( ARV ) treatment ( HAART ) regimens become widely applied in South Africa , as this is likely to have potential implications in the management of HBV - HIV co - infected patients .', {'entities': [(337, 340, 'B_Disease'), (341, 342, 'I_Disease'), (343, 346, 'I_Disease'), (347, 349, 'I_Disease'), (350, 351, 'I_Disease'), (352, 360, 'I_Disease')]}], ['Rabbit syndrome , antidepressant use , and cerebral perfusion SPECT scan findings .', {'entities': [(0, 6, 'B_Disease'), (7, 15, 'I_Disease')]}], ['The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy .', {'entities': [(4, 10, 'B_Disease'), (11, 19, 'I_Disease')]}], ['Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present , and a return to normal perfusion when the rabbit syndrome resolved .', {'entities': [(49, 58, 'B_Disease'), (59, 64, 'I_Disease'), (65, 72, 'I_Disease'), (73, 82, 'I_Disease'), (93, 101, 'B_Disease'), (102, 110, 'I_Disease'), (167, 173, 'B_Disease'), (174, 182, 'I_Disease')]}], ['Many patients , however , develop negative long - term side effects such as premature atherosclerosis .', {'entities': [(76, 85, 'B_Disease'), (86, 101, 'I_Disease')]}], ['We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice .', {'entities': [(67, 82, 'B_Disease'), (83, 89, 'I_Disease')]}], ['Acute hepatitis attack after exposure to telithromycin .', {'entities': [(6, 15, 'B_Disease')]}], ['INTRODUCTION : Antibiotic - associated hepatotoxicity is rare .', {'entities': [(39, 53, 'B_Disease')]}], ['With widespread use of antimicrobial agents , however , hepatic injury occurs frequently , and among adverse drug reactions , idiosyncratic reactions are the most serious .', {'entities': [(56, 63, 'B_Disease'), (64, 70, 'I_Disease'), (101, 108, 'B_Disease'), (109, 113, 'I_Disease'), (114, 123, 'I_Disease')]}], [\"CASE SUMMARY : A 25 - year - old male patient , with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department , Istanbul , Turkey , with 5 days ' history of jaundice , malaise , nausea , and vomiting .\", {'entities': [(201, 209, 'B_Disease'), (222, 228, 'B_Disease'), (235, 243, 'B_Disease')]}], ['He had been prescribed telithromycin 400 mg / d PO to treat an upper respiratory tract infection 7 days prior .', {'entities': [(63, 68, 'B_Disease'), (69, 80, 'I_Disease'), (81, 86, 'I_Disease'), (87, 96, 'I_Disease')]}], ['The patient had suffered a previous episode of \" acute hepatitis of unknown origin , \" that occurred after telithromycin usage .', {'entities': [(55, 64, 'B_Disease')]}], ['It has been associated with infrequent and usually reversible severe hepatic dysfunction .', {'entities': [(69, 76, 'B_Disease'), (77, 88, 'I_Disease')]}], ['Based on a score of 8 on the Naranjo adverse drug reaction probability scale , telithromycin was the probable cause of acute hepatitis in this patient , and pathological findings suggested drug - induced toxic hepatitis .', {'entities': [(37, 44, 'B_Disease'), (45, 49, 'I_Disease'), (50, 58, 'I_Disease'), (125, 134, 'B_Disease'), (204, 209, 'B_Disease'), (210, 219, 'I_Disease')]}], ['Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time .', {'entities': [(14, 23, 'B_Disease')]}], ['CONCLUSION : Here we report a case of acute hepatitis probably associated with the administration of telithromycin .', {'entities': [(44, 53, 'B_Disease')]}], ['A study on the effect of the duration of subcutaneous heparin injection on bruising and pain .', {'entities': [(75, 83, 'B_Disease'), (88, 92, 'B_Disease')]}], ['AIM : This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin .', {'entities': [(82, 90, 'B_Disease'), (95, 99, 'B_Disease')]}], ['BACKGROUND : Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described , the effect of injection duration on the occurrence of bruising and pain is little documented .', {'entities': [(51, 59, 'B_Disease'), (64, 68, 'B_Disease'), (212, 220, 'B_Disease'), (225, 229, 'B_Disease')]}], ['Injections areas were assessed for the presence of bruising at 48 and 72 hours after each injection .', {'entities': [(51, 59, 'B_Disease')]}], ['Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper .', {'entities': [(18, 26, 'B_Disease')]}], ['The visual analog scale ( VAS ) was used to measure pain intensity and a stop - watch was used to time the pain period .', {'entities': [(52, 56, 'B_Disease'), (107, 111, 'B_Disease')]}], ['RESULTS : The percentage of bruising occurrence was 64 % with the injection of 10 seconds duration and 42 % in the 30 - second injection .', {'entities': [(28, 36, 'B_Disease')]}], ['It was determined that the size of the bruising was smaller in the 30 - second injection .', {'entities': [(39, 47, 'B_Disease')]}], ['Pain intensity and pain period were statistically significantly lower for the 30 - second injection than for the 10 - second injection .', {'entities': [(0, 4, 'B_Disease'), (19, 23, 'B_Disease')]}], ['CONCLUSIONS : It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin .', {'entities': [(73, 81, 'B_Disease'), (86, 90, 'B_Disease')]}], ['Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage .', {'entities': [(0, 5, 'B_Disease'), (6, 11, 'I_Disease'), (12, 19, 'I_Disease')]}], ['BACKGROUND : The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol ( acetaminophen ) is currently debated .', {'entities': [(64, 78, 'B_Disease')]}], ['CASE REPORT : We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3 - 5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol / day .', {'entities': [(93, 98, 'B_Disease'), (99, 106, 'I_Disease')]}], ['Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed .', {'entities': [(45, 59, 'B_Disease')]}], ['CONCLUSION : In patients with risk factors , e . g . regular consumption of alcohol , liver failure is possible when therapeutic doses are ingested .', {'entities': [(86, 91, 'B_Disease'), (92, 99, 'I_Disease')]}], ['Long - term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS , which tended to be related to diagnosed dementia .', {'entities': [(164, 172, 'B_Disease')]}], ['However , use of BZDs / RDs was associated with dizziness , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .', {'entities': [(48, 57, 'B_Disease'), (60, 69, 'B_Disease'), (70, 72, 'I_Disease'), (73, 78, 'I_Disease'), (106, 115, 'B_Disease'), (185, 195, 'B_Disease'), (196, 204, 'I_Disease')]}], ['Acute vocal fold palsy after acute disulfiram intoxication .', {'entities': [(6, 11, 'B_Disease'), (12, 16, 'I_Disease'), (17, 22, 'I_Disease')]}], ['Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy .', {'entities': [(6, 16, 'B_Disease'), (17, 27, 'I_Disease'), (51, 59, 'B_Disease'), (113, 118, 'B_Disease'), (119, 123, 'I_Disease'), (124, 129, 'I_Disease')]}], ['A 49 - year - old woman was transferred to our department because of quadriparesis , lancinating pain , sensory loss , and paresthesia of the distal limbs .', {'entities': [(69, 82, 'B_Disease'), (97, 101, 'B_Disease'), (104, 111, 'B_Disease'), (112, 116, 'I_Disease'), (123, 134, 'B_Disease')]}], ['For the first few days after ingestion , she was in a confused state and had mild to moderate ataxia and giddiness .', {'entities': [(94, 100, 'B_Disease'), (105, 114, 'B_Disease')]}], ['She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state .', {'entities': [(12, 22, 'B_Disease')]}], ['A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy .', {'entities': [(72, 86, 'B_Disease')]}], ['This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high - dose disulfiram intoxication .', {'entities': [(25, 30, 'B_Disease'), (114, 128, 'B_Disease')]}], ['Encephalopathy induced by levetiracetam added to valproate .', {'entities': [(0, 14, 'B_Disease')]}], ['BACKGROUND : We report on the manifestation of a levetiracetam ( LEV ) - induced encephalopathy .', {'entities': [(81, 95, 'B_Disease')]}], ['FINDINGS : A 28 - year - old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .', {'entities': [(48, 58, 'B_Disease'), (59, 67, 'I_Disease'), (85, 93, 'B_Disease')]}], ['Frequency of generalized tonic - clonic seizures increased from one per 6 months to two per month .', {'entities': [(25, 30, 'B_Disease'), (31, 32, 'I_Disease'), (33, 39, 'I_Disease'), (40, 48, 'I_Disease')]}], ['Neuropsychological testing showed impaired word fluency , psychomotor speed and working memory .', {'entities': [(34, 42, 'B_Disease'), (43, 47, 'I_Disease'), (48, 55, 'I_Disease'), (56, 57, 'I_Disease'), (58, 69, 'I_Disease'), (70, 75, 'I_Disease'), (76, 79, 'I_Disease'), (80, 87, 'I_Disease'), (88, 94, 'I_Disease')]}], ['OUTCOME : Following discontinuation of LEV , EEG and neuropsychological findings improved and seizure frequency decreased .', {'entities': [(94, 101, 'B_Disease')]}], ['Norepinephrine signaling through beta - adrenergic receptors is critical for expression of cocaine - induced anxiety .', {'entities': [(109, 116, 'B_Disease')]}], [\"While the mechanisms underlying cocaine ' s rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by cocaine , such as anxiety .\", {'entities': [(188, 195, 'B_Disease')]}], ['METHODS : In this study , we evaluated the performance of dopamine beta - hydroxylase knockout ( Dbh - / - ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine - induced anxiety .', {'entities': [(261, 268, 'B_Disease')]}], ['RESULTS : We found that cocaine dose - dependently increased anxiety - like behavior in control ( Dbh + / - ) mice , as measured by a decrease in open arm exploration .', {'entities': [(61, 68, 'B_Disease')]}], ['Cocaine - induced anxiety was also attenuated in Dbh + / - mice following administration of disulfiram , a dopamine beta - hydroxylase ( DBH ) inhibitor .', {'entities': [(18, 25, 'B_Disease')]}], ['In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist propranolol blocked cocaine - induced anxiety - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist prazosin and the alpha ( 2 ) antagonist yohimbine had no effect .', {'entities': [(167, 174, 'B_Disease')]}], ['CONCLUSIONS : These results indicate that noradrenergic signaling via beta - adrenergic receptors is required for cocaine - induced anxiety in mice .', {'entities': [(132, 139, 'B_Disease')]}], ['Hypothalamic prolactin receptor messenger ribonucleic acid levels , prolactin signaling , and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol .', {'entities': [(94, 112, 'B_Disease')]}], ['Hyperprolactinemia can reduce fertility and libido .', {'entities': [(0, 18, 'B_Disease')]}], ['We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility : pulsatile LH secretion and the estrogen - induced LH surge .', {'entities': [(32, 50, 'B_Disease')]}], ['Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .', {'entities': [(8, 26, 'B_Disease')]}], ['These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid - dependent manner .', {'entities': [(66, 84, 'B_Disease')]}], ['Clonidine for attention - deficit / hyperactivity disorder : II .', {'entities': [(14, 23, 'B_Disease'), (24, 25, 'I_Disease'), (26, 33, 'I_Disease'), (34, 35, 'I_Disease'), (36, 49, 'I_Disease'), (50, 58, 'I_Disease')]}], ['OBJECTIVE : To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention - deficit / hyperactivity disorder ( ADHD ) .', {'entities': [(116, 125, 'B_Disease'), (126, 127, 'I_Disease'), (128, 135, 'I_Disease'), (136, 137, 'I_Disease'), (138, 151, 'I_Disease'), (152, 160, 'I_Disease'), (163, 167, 'B_Disease')]}], ['METHOD : In a 16 - week multicenter , double - blind trial , 122 children with ADHD were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .', {'entities': [(79, 83, 'B_Disease')]}], ['RESULTS : There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine ( 17 . 5 % versus 3 . 4 % ; p = . 02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .', {'entities': [(39, 50, 'B_Disease')]}], ['Drowsiness was common on clonidine , but generally resolved by 6 to 8 weeks .', {'entities': [(0, 10, 'B_Disease')]}], ['CONCLUSIONS : Clonidine , used alone or with methylphenidate , appears safe and well tolerated in childhood ADHD .', {'entities': [(108, 112, 'B_Disease')]}], ['Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness .', {'entities': [(52, 63, 'B_Disease'), (121, 131, 'B_Disease')]}], ['Renal Fanconi syndrome and myopathy after liver transplantation : drug - related mitochondrial cytopathy ?', {'entities': [(0, 5, 'B_Disease'), (6, 13, 'I_Disease'), (14, 22, 'I_Disease'), (27, 35, 'B_Disease'), (81, 94, 'B_Disease'), (95, 104, 'I_Disease')]}], [\"We describe a 15 - yr - old girl who had orthotopic liver transplantation because of Wilson ' s disease .\", {'entities': [(85, 91, 'B_Disease'), (92, 93, 'I_Disease'), (94, 95, 'I_Disease'), (96, 103, 'I_Disease')]}], ['Lamivudine was added because of de nova hepatitis B infection during her follow - up .', {'entities': [(40, 49, 'B_Disease'), (50, 51, 'I_Disease'), (52, 61, 'I_Disease')]}], ['Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis , hypophosphatemia , glycosuria , and aminoaciduria .', {'entities': [(45, 50, 'B_Disease'), (51, 58, 'I_Disease'), (59, 67, 'I_Disease'), (80, 89, 'B_Disease'), (90, 98, 'I_Disease'), (101, 117, 'B_Disease'), (120, 130, 'B_Disease'), (137, 150, 'B_Disease')]}], ['Although tacrolimus was suspected to be the cause of late post - transplant renal acidosis and was replaced by sirolimus , acidosis , and electrolyte imbalance got worse .', {'entities': [(82, 90, 'B_Disease'), (123, 131, 'B_Disease')]}], ['Proximal muscle weakness has developed during her follow - up .', {'entities': [(9, 15, 'B_Disease'), (16, 24, 'I_Disease')]}], ['Fanconi syndrome , as well as myopathy , is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease'), (30, 38, 'B_Disease'), (77, 90, 'B_Disease'), (91, 100, 'I_Disease')]}], [\"We suggest that our patient ' s tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine .\", {'entities': [(32, 39, 'B_Disease'), (40, 51, 'I_Disease'), (56, 64, 'B_Disease'), (88, 101, 'B_Disease'), (102, 113, 'I_Disease')]}], ['Higher optical density of an antigen assay predicts thrombosis in patients with heparin - induced thrombocytopenia .', {'entities': [(52, 62, 'B_Disease'), (98, 114, 'B_Disease')]}], ['OBJECTIVES : To correlate optical density and percent inhibition of a two - step heparin - induced thrombocytopenia ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .', {'entities': [(99, 115, 'B_Disease'), (118, 121, 'B_Disease'), (143, 153, 'B_Disease')]}], ['PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or thrombocytopenia ( < 150 x 10 ( 9 ) / L ) after exposure to heparin , who had a positive two - step antigen assay [ optical density ( OD ) > 0 . 4 and > 50 inhibition with high concentration of heparin ] were included in the study .', {'entities': [(82, 98, 'B_Disease')]}], ['RESULTS : Forty of 94 HIT patients had thrombosis at diagnosis ; 54 / 94 had isolated - HIT without thrombosis .', {'entities': [(22, 25, 'B_Disease'), (39, 49, 'B_Disease'), (88, 91, 'B_Disease'), (100, 110, 'B_Disease')]}], ['Eight of the isolated - HIT patients developed thrombosis within the next 30 d ; thus , a total of 48 patients had thrombosis at day 30 .', {'entities': [(24, 27, 'B_Disease'), (47, 57, 'B_Disease'), (115, 125, 'B_Disease')]}], ['At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated - HIT .', {'entities': [(63, 66, 'B_Disease'), (81, 91, 'B_Disease'), (118, 121, 'B_Disease')]}], ['However , OD was significantly higher in all patients with thrombosis ( n = 48 , 1 . 34 + / - 0 . 89 ) , including isolated - HIT patients who later developed thrombosis within 30 d ( n = 8 , 1 . 84 + / - 0 . 64 ) as compared to isolated - HIT patients who did not develop thrombosis ( 0 . 96 + / - 0 . 75 ; P = 0 . 011 and P = 0 . 008 ) .', {'entities': [(59, 69, 'B_Disease'), (126, 129, 'B_Disease'), (159, 169, 'B_Disease'), (240, 243, 'B_Disease'), (273, 283, 'B_Disease')]}], ['The Receiver Operative Characteristic Curve showed that OD > 1 . 27 in the isolated - HIT group had a significantly higher chance of developing thrombosis by day 30 .', {'entities': [(86, 89, 'B_Disease'), (144, 154, 'B_Disease')]}], ['Multivariate analysis showed a 2 . 8 - fold increased risk of thrombosis in females .', {'entities': [(62, 72, 'B_Disease')]}], ['Similarly , thrombotic risk increased with age and OD values .', {'entities': [(12, 22, 'B_Disease')]}], ['CONCLUSION : Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated - HIT ; percent inhibition , however , was not predictive .', {'entities': [(73, 83, 'B_Disease'), (112, 115, 'B_Disease')]}], ['Thalidomide has limited single - agent activity in relapsed or refractory indolent non - Hodgkin lymphomas : a phase II trial of the Cancer and Leukemia Group B .', {'entities': [(83, 86, 'B_Disease'), (87, 88, 'I_Disease'), (89, 96, 'I_Disease'), (97, 106, 'I_Disease'), (133, 139, 'B_Disease'), (144, 152, 'B_Disease')]}], ['Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma , mantle cell lymphoma and lymphoplasmacytic lymphoma .', {'entities': [(71, 79, 'B_Disease'), (80, 87, 'I_Disease'), (90, 96, 'B_Disease'), (97, 101, 'I_Disease'), (102, 110, 'I_Disease'), (115, 132, 'B_Disease'), (133, 141, 'I_Disease')]}], ['Its activity is believed to be due modulation of the tumour milieu , including downregulation of angiogenesis and inflammatory cytokines .', {'entities': [(53, 59, 'B_Disease')]}], ['Between July 2001 and April 2004 , 24 patients with relapsed / refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1 - 2 weeks as tolerated , up to a maximum of 800 mg daily .', {'entities': [(83, 92, 'B_Disease')]}], ['Grade 3 - 4 adverse effects included myelosuppression , fatigue , somnolence / depressed mood , neuropathy and dyspnea .', {'entities': [(37, 53, 'B_Disease'), (56, 63, 'B_Disease'), (66, 76, 'B_Disease'), (79, 88, 'B_Disease'), (89, 93, 'I_Disease'), (96, 106, 'B_Disease'), (111, 118, 'B_Disease')]}], ['Of concern was the occurrence of four thromboembolic events .', {'entities': [(38, 52, 'B_Disease')]}], ['Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent , lenalidomide .', {'entities': [(101, 110, 'B_Disease')]}], ['Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain : comparisons to two models of acute pain .', {'entities': [(111, 115, 'B_Disease'), (147, 152, 'B_Disease'), (153, 157, 'I_Disease')]}], ['In acute pain models , N - methyl - D - aspartate ( NMDA ) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females .', {'entities': [(3, 8, 'B_Disease'), (9, 13, 'I_Disease')]}], ['The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated , neurochemical substrates , and duration of the nociceptive stimulus .', {'entities': [(79, 83, 'B_Disease'), (124, 129, 'B_Disease'), (130, 134, 'I_Disease')]}], ['To this end , persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats , following which the tail was immersed in a mildly noxious thermal stimulus , and tail - withdrawal latencies measured .', {'entities': [(25, 37, 'B_Disease')]}], ['For comparison , tests were conducted in two acute pain models , the hotplate and warm water tail - withdrawal procedures .', {'entities': [(45, 50, 'B_Disease'), (51, 55, 'I_Disease')]}], ['Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models , with the magnitude of this effect being greater in males .', {'entities': [(102, 107, 'B_Disease'), (108, 112, 'I_Disease')]}], ['These findings demonstrate a sexually - dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models .', {'entities': [(116, 120, 'B_Disease'), (176, 181, 'B_Disease'), (182, 186, 'I_Disease')]}], ['Development of proteinuria after switch to sirolimus - based immunosuppression in long - term cardiac transplant patients .', {'entities': [(15, 26, 'B_Disease')]}], ['Calcineurin - inhibitor therapy can lead to renal dysfunction in heart transplantation patients .', {'entities': [(44, 49, 'B_Disease'), (50, 61, 'I_Disease')]}], ['The novel immunosuppressive ( IS ) drug sirolmus ( Srl ) lacks nephrotoxic effects ; however , proteinuria associated with Srl has been reported following renal transplantation .', {'entities': [(63, 74, 'B_Disease'), (95, 106, 'B_Disease')]}], ['In cardiac transplantation , the incidence of proteinuria associated with Srl is unknown .', {'entities': [(46, 57, 'B_Disease')]}], ['Before the switch , 11 . 5 % of patients had high - grade proteinuria ( > 1 . 0 g / day ) ; this increased to 22 . 9 % postswitch ( p = 0 . 006 ) .', {'entities': [(58, 69, 'B_Disease')]}], ['ACE inhibitor and angiotensin - releasing blocker ( ARB ) therapy reduced proteinuria development .', {'entities': [(74, 85, 'B_Disease')]}], ['Patients without proteinuria had increased renal function ( median 42 . 5 vs . 64 . 1 , p = 0 . 25 ) , whereas patients who developed high - grade proteinuria showed decreased renal function at the end of follow - up ( median 39 . 6 vs . 29 . 2 , p = 0 . 125 ) .', {'entities': [(17, 28, 'B_Disease'), (147, 158, 'B_Disease')]}], ['Thus , proteinuria may develop in cardiac transplant patients after switch to Srl , which may have an adverse effect on renal function in these patients .', {'entities': [(7, 18, 'B_Disease')]}], ['Srl should be used with ACEi / ARB therapy and patients monitored for proteinuria and increased renal dysfunction .', {'entities': [(70, 81, 'B_Disease'), (96, 101, 'B_Disease'), (102, 113, 'I_Disease')]}], ['Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats .', {'entities': [(29, 39, 'B_Disease'), (40, 42, 'I_Disease'), (43, 51, 'I_Disease')]}], ['Rg1 , as a ginsenoside extracted from Panax ginseng , could ameliorate spatial learning impairment .', {'entities': [(79, 87, 'B_Disease'), (88, 98, 'I_Disease')]}], ['The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect .', {'entities': [(62, 70, 'B_Disease'), (71, 81, 'I_Disease')]}], [\"SAR studies led to compound 14 with excellent potency ( K ( i ) = 0 . 4 nM ) , selectivity ( A ( 1 ) / A ( 2A ) > 100 ) , and efficacy ( MED 10 mg / kg p . o . ) in the rat haloperidol - induced catalepsy model for Parkinson ' s disease .\", {'entities': [(195, 204, 'B_Disease'), (215, 224, 'B_Disease'), (225, 226, 'I_Disease'), (227, 228, 'I_Disease'), (229, 236, 'I_Disease')]}], ['Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine - induced hyperactivity in rats .', {'entities': [(92, 105, 'B_Disease')]}], ['Nicotine ( 1 . 0 mg / kg ) caused a significant increase in locomotor activity in rats that were habituated to the test environment , but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment .', {'entities': [(48, 56, 'B_Disease'), (57, 59, 'I_Disease'), (60, 69, 'I_Disease'), (70, 78, 'I_Disease')]}], ['Nicotine - induced hyperactivity was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1 / D2 antagonist fluphenazine .', {'entities': [(19, 32, 'B_Disease')]}], ['Pretreatment with the D2 agonist PHNO enhanced nicotine - induced hyperactivity , whereas the D1 agonist SKF 38393 had no effect .', {'entities': [(66, 79, 'B_Disease')]}], ['The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment .', {'entities': [(72, 85, 'B_Disease')]}], ['Central retinal vein occlusion associated with clomiphene - induced ovulation .', {'entities': [(8, 15, 'B_Disease'), (16, 20, 'I_Disease'), (21, 30, 'I_Disease')]}], ['OBJECTIVE : To report a case of central retinal vein occlusion associated with clomiphene citrate ( CC ) .', {'entities': [(40, 47, 'B_Disease'), (48, 52, 'I_Disease'), (53, 62, 'I_Disease')]}], ['PATIENT ( S ) : A 36 - year - old woman referred from the infertility clinic for blurred vision .', {'entities': [(58, 69, 'B_Disease'), (81, 88, 'B_Disease'), (89, 95, 'I_Disease')]}], ['MAIN OUTCOME MEASURE ( S ) : Central retinal vein occlusion after ovulation induction with CC .', {'entities': [(37, 44, 'B_Disease'), (45, 49, 'I_Disease'), (50, 59, 'I_Disease')]}], ['RESULT ( S ) : A 36 - year - old Chinese woman developed central retinal vein occlusion after eight courses of CC .', {'entities': [(65, 72, 'B_Disease'), (73, 77, 'I_Disease'), (78, 87, 'I_Disease')]}], ['A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication , although mild visual disturbance after CC intake is not uncommon .', {'entities': [(34, 48, 'B_Disease'), (138, 144, 'B_Disease'), (145, 156, 'I_Disease')]}], ['CONCLUSION ( S ) : This is the first reported case of central retinal vein occlusion after treatment with CC .', {'entities': [(62, 69, 'B_Disease'), (70, 74, 'I_Disease'), (75, 84, 'I_Disease')]}], ['Extra caution is warranted in treating infertility patients with CC , and patients should be well informed of this side effect before commencement of therapy .', {'entities': [(39, 50, 'B_Disease')]}], ['Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease .', {'entities': [(73, 80, 'B_Disease'), (81, 92, 'I_Disease'), (93, 102, 'I_Disease'), (103, 110, 'I_Disease')]}], ['The bronchodilator effects of a single dose of ipratropium bromide aerosol ( 36 micrograms ) and short - acting theophylline tablets ( dose titrated to produce serum levels of 10 - 20 micrograms / mL ) were compared in a double - blind , placebo - controlled crossover study in 21 patients with stable , chronic obstructive pulmonary disease .', {'entities': [(304, 311, 'B_Disease'), (312, 323, 'I_Disease'), (324, 333, 'I_Disease'), (334, 341, 'I_Disease')]}], ['While side effects were rare , those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems .', {'entities': [(88, 102, 'B_Disease'), (103, 106, 'I_Disease'), (107, 123, 'I_Disease'), (124, 131, 'I_Disease')]}], ['These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction .', {'entities': [(108, 115, 'B_Disease'), (116, 123, 'I_Disease'), (124, 135, 'I_Disease')]}], ['Methamphetamine - induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling .', {'entities': [(26, 39, 'B_Disease')]}], ['[ Nat . Neurosci . 9 ( 2006 ) , 917 ] recently identified the microglial - specific fractalkine receptor ( CX3CR1 ) as an important mediator of MPTP - induced neurodegeneration of DA neurons .', {'entities': [(159, 176, 'B_Disease')]}], ['Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .', {'entities': [(12, 15, 'B_Disease'), (16, 22, 'I_Disease'), (113, 126, 'B_Disease'), (192, 205, 'B_Disease')]}], ['Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein ( eGFP ) were treated with METH and examined for striatal neurotoxicity .', {'entities': [(174, 187, 'B_Disease')]}], ['We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation .', {'entities': [(76, 89, 'B_Disease')]}], ['Nicotine - induced nystagmus correlates with midpontine activation .', {'entities': [(19, 28, 'B_Disease')]}], ['The pathomechanism of nicotine - induced nystagmus ( NIN ) is unknown .', {'entities': [(41, 50, 'B_Disease'), (53, 56, 'B_Disease')]}], ['The aim of this study was to delineate brain structures that are involved in NIN generation .', {'entities': [(77, 80, 'B_Disease')]}], ['NIN correlated with blood oxygen level - dependent ( BOLD ) activity levels in a midpontine site in the posterior basis pontis .', {'entities': [(0, 3, 'B_Disease')]}], ['NIN - induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis , structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements .', {'entities': [(0, 3, 'B_Disease')]}], ['Acute effects of N - ( 2 - propylpentanoyl ) urea on hippocampal amino acid neurotransmitters in pilocarpine - induced seizure in rats .', {'entities': [(119, 126, 'B_Disease')]}], ['VPU was more potent than VPA , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against pilocarpine - induced seizure whereas the corresponding value for VPA was 322 mg / kg .', {'entities': [(145, 152, 'B_Disease')]}], ['Based on the finding that VPU and VPA could protect the animals against pilocarpine - induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .', {'entities': [(94, 101, 'B_Disease')]}], ['Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced seizure in experimental animals .', {'entities': [(229, 236, 'B_Disease')]}], ['Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats .', {'entities': [(34, 41, 'B_Disease'), (42, 53, 'I_Disease'), (54, 60, 'B_Disease'), (71, 86, 'B_Disease')]}], ['Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking .', {'entities': [(40, 47, 'B_Disease'), (48, 58, 'I_Disease'), (94, 109, 'B_Disease')]}], ['The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .', {'entities': [(197, 204, 'B_Disease'), (205, 215, 'I_Disease'), (220, 225, 'B_Disease'), (239, 254, 'B_Disease')]}], ['Additionally , the protective effect of verapamil on this ulcer model was evaluated .', {'entities': [(58, 63, 'B_Disease')]}], ['Male Wistar rats were challenged intragastrically once daily for 9 days with 1 . 0 ml / kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis .', {'entities': [(151, 166, 'B_Disease')]}], ['Gastric acid back - diffusion , mucosal LPO generation , histamine concentration , microvascular permeability , luminal hemoglobin content and ulcer areas were determined .', {'entities': [(143, 148, 'B_Disease')]}], ['Elevated atherosclerotic parameters , such as serum calcium , total cholesterol and low - density lipoprotein concentration were obtained in atherosclerotic rats .', {'entities': [(9, 24, 'B_Disease'), (141, 156, 'B_Disease')]}], ['Severe gastric ulcers accompanied with increased ulcerogenic factors , including gastric acid back - diffusion , histamine release , LPO generation and luminal hemoglobin content were also observed in these rats .', {'entities': [(15, 21, 'B_Disease')]}], ['Moreover , a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats .', {'entities': [(50, 57, 'B_Disease'), (58, 68, 'I_Disease'), (76, 81, 'B_Disease'), (101, 116, 'B_Disease')]}], ['This hemorrhagic ulcer and various ulcerogenic parameters were dose - dependently ameliorated by daily intragastric verapamil .', {'entities': [(5, 16, 'B_Disease'), (17, 22, 'B_Disease')]}], ['Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back - diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by verapamil in rats .', {'entities': [(0, 15, 'B_Disease'), (30, 37, 'B_Disease'), (38, 49, 'I_Disease'), (50, 55, 'B_Disease')]}], ['Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis - B surface antigen ( HBSAG ) seropositive cancer patients undergoing cytotoxic chemotherapy .', {'entities': [(33, 42, 'B_Disease'), (43, 44, 'I_Disease'), (120, 126, 'B_Disease')]}], ['Hepatitis B virus ( HBV ) is one of the major causes of chronic liver disease worldwide .', {'entities': [(0, 9, 'B_Disease'), (10, 11, 'I_Disease'), (64, 69, 'B_Disease'), (70, 77, 'I_Disease')]}], ['Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy ( CT ) and this has mainly been attributed to HBV reactivation .', {'entities': [(0, 6, 'B_Disease'), (62, 69, 'B_Disease'), (70, 82, 'I_Disease')]}], ['In this study , cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine .', {'entities': [(16, 22, 'B_Disease'), (51, 64, 'B_Disease'), (65, 77, 'I_Disease'), (91, 94, 'B_Disease'), (95, 104, 'I_Disease')]}], ['Of our control group ( n = 50 ) , 21 patients ( 42 % ) were established hepatitis .', {'entities': [(72, 81, 'B_Disease')]}], ['Twelve ( 24 % ) of them were evaluated as severe hepatitis .', {'entities': [(49, 58, 'B_Disease')]}], ['In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient ( 2 . 7 % ) of 37 patients ( p < 0 . 006 ) .', {'entities': [(44, 53, 'B_Disease')]}], ['Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy .', {'entities': [(131, 137, 'B_Disease')]}], ['Recovery of tacrolimus - associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient - - case report and review of the literature .', {'entities': [(36, 44, 'B_Disease'), (45, 53, 'I_Disease')]}], ['Neurotoxicity is a potentially serious toxic effect .', {'entities': [(0, 13, 'B_Disease')]}], ['It is characterized by encephalopathy , headaches , seizures , or neurological deficits .', {'entities': [(23, 37, 'B_Disease'), (40, 49, 'B_Disease'), (52, 60, 'B_Disease'), (66, 78, 'B_Disease'), (79, 87, 'I_Disease')]}], ['MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis .', {'entities': [(113, 121, 'B_Disease'), (132, 140, 'B_Disease'), (141, 149, 'I_Disease')]}], ['Omitting fentanyl reduces nausea and vomiting , without increasing pain , after sevoflurane for day surgery .', {'entities': [(26, 32, 'B_Disease'), (37, 45, 'B_Disease'), (67, 71, 'B_Disease')]}], ['BACKGROUND AND OBJECTIVE : Despite advantages of induction and maintenance of anaesthesia with sevoflurane , postoperative nausea and vomiting occurs frequently .', {'entities': [(109, 122, 'B_Disease'), (123, 129, 'I_Disease'), (130, 133, 'I_Disease'), (134, 142, 'I_Disease')]}], ['METHODS : This double - blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients .', {'entities': [(75, 88, 'B_Disease'), (89, 95, 'I_Disease'), (96, 99, 'I_Disease'), (100, 108, 'I_Disease'), (113, 117, 'B_Disease')]}], ['RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .', {'entities': [(71, 84, 'B_Disease'), (85, 91, 'I_Disease'), (92, 95, 'I_Disease'), (96, 104, 'I_Disease'), (139, 147, 'B_Disease'), (176, 182, 'B_Disease')]}], ['Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting .', {'entities': [(72, 85, 'B_Disease'), (86, 92, 'I_Disease'), (93, 96, 'I_Disease'), (97, 105, 'I_Disease')]}], ['Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids , reducing postoperative nausea and vomiting and nausea prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0 . 049 and P = 0 . 035 ) , respectively , while nausea in the first 24 h was decreased from 42 % to 27 % ( P = 0 . 034 ) .', {'entities': [(113, 126, 'B_Disease'), (127, 133, 'I_Disease'), (134, 137, 'I_Disease'), (138, 146, 'I_Disease'), (151, 157, 'B_Disease'), (268, 274, 'B_Disease')]}], ['Pain severity and analgesic requirements were unaffected by the omission of fentanyl .', {'entities': [(0, 4, 'B_Disease')]}], ['Fentanyl did reduce minor intraoperative movement but had no sevoflurane - sparing effect and increased respiratory depression , hypotension and bradycardia .', {'entities': [(104, 115, 'B_Disease'), (116, 126, 'I_Disease'), (129, 140, 'B_Disease'), (145, 156, 'B_Disease')]}], ['CONCLUSION : As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery .', {'entities': [(37, 50, 'B_Disease'), (51, 57, 'I_Disease'), (58, 61, 'I_Disease'), (62, 70, 'I_Disease'), (97, 110, 'B_Disease'), (111, 115, 'I_Disease')]}], [\"Valvular heart disease in patients with Parkinson ' s disease treated with pergolide .\", {'entities': [(0, 8, 'B_Disease'), (9, 14, 'I_Disease'), (15, 22, 'I_Disease'), (40, 49, 'B_Disease'), (50, 51, 'I_Disease'), (52, 53, 'I_Disease'), (54, 61, 'I_Disease')]}], [\"Valvular heart abnormalities have been reported in patients with Parkinson ' s disease ( PD ) treated with pergolide .\", {'entities': [(0, 8, 'B_Disease'), (9, 14, 'I_Disease'), (15, 28, 'I_Disease'), (65, 74, 'B_Disease'), (75, 76, 'I_Disease'), (77, 78, 'I_Disease'), (79, 86, 'I_Disease'), (89, 91, 'B_Disease')]}], ['OBJECTIVES : To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case - control study .', {'entities': [(55, 63, 'B_Disease'), (64, 69, 'I_Disease'), (70, 81, 'I_Disease')]}], ['METHODS : All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography .', {'entities': [(14, 16, 'B_Disease')]}], ['Thirty PD patients participated in the study .', {'entities': [(7, 9, 'B_Disease')]}], ['Controls were age - and sex - matched non - PD patients referred to the cardiology department .', {'entities': [(44, 46, 'B_Disease')]}], ['RESULTS : Compared to controls , aortic regurgitation ( OR : 3 . 1 ; 95 % IC : 1 . 1 - 8 . 8 ) and mitral regurgitation ( OR : 10 . 7 ; 95 % IC : 2 . 1 - 53 ) were more frequent in PD patients ( tricuspid : NS ) .', {'entities': [(33, 39, 'B_Disease'), (40, 53, 'I_Disease'), (99, 105, 'B_Disease'), (106, 119, 'I_Disease'), (181, 183, 'B_Disease')]}], ['A restrictive pattern of valvular regurgitation , suggestive of the role of pergolide , was observed in 12 / 30 ( 40 % ) patients including two with heart failure .', {'entities': [(25, 33, 'B_Disease'), (34, 47, 'I_Disease'), (149, 154, 'B_Disease'), (155, 162, 'I_Disease')]}], ['Pergolide was discontinued in 10 patients with valvular heart disease , resulting in a lower regurgitation grade ( p = 0 . 01 ) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination .', {'entities': [(47, 55, 'B_Disease'), (56, 61, 'I_Disease'), (62, 69, 'I_Disease'), (199, 204, 'B_Disease'), (205, 212, 'I_Disease')]}], ['This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non - ergot dopamine agonists .', {'entities': [(54, 59, 'B_Disease'), (60, 73, 'I_Disease'), (77, 79, 'B_Disease')]}], ['Adriamycin - induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure .', {'entities': [(46, 51, 'B_Disease'), (94, 99, 'B_Disease'), (100, 107, 'I_Disease')]}], ['BACKGROUND : The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear .', {'entities': [(39, 44, 'B_Disease'), (45, 52, 'I_Disease')]}], ['The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin , so that we can develop a novel treatment strategy for heart failure .', {'entities': [(94, 99, 'B_Disease'), (100, 107, 'I_Disease'), (186, 191, 'B_Disease'), (192, 199, 'I_Disease')]}], ['METHODS : 3 - methyladenine ( 3MA ) , a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin .', {'entities': [(86, 91, 'B_Disease'), (92, 99, 'I_Disease')]}], ['CONCLUSION : Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin .', {'entities': [(38, 43, 'B_Disease'), (91, 96, 'B_Disease'), (97, 104, 'I_Disease')]}], ['Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway .', {'entities': [(59, 64, 'B_Disease'), (65, 72, 'I_Disease')]}], ['mToR inhibitors - induced proteinuria : mechanisms , significance , and management .', {'entities': [(26, 37, 'B_Disease')]}], ['Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin ( mToR ) inhibitors , especially sirolimus , in renal transplant recipients with chronic allograft nephropathy .', {'entities': [(211, 218, 'B_Disease'), (219, 228, 'I_Disease'), (229, 240, 'I_Disease')]}], ['Because proteinuria is a major predictive factor of poor transplantation outcome , many studies focused on this adverse event during the past years .', {'entities': [(8, 19, 'B_Disease')]}], ['Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo .', {'entities': [(8, 19, 'B_Disease'), (135, 146, 'B_Disease')]}], ['Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients , but the pathways underlying these lesions remain hypothetic .', {'entities': [(36, 54, 'B_Disease')]}], ['We discuss herein the possible mechanisms and the significance of mToR blockade - induced proteinuria .', {'entities': [(90, 101, 'B_Disease')]}], ['Reactions consisted mainly of seizures , acute psychoses , anxiety neurosis , and major disturbances of sleep - wake rhythm .', {'entities': [(30, 38, 'B_Disease'), (47, 56, 'B_Disease'), (59, 66, 'B_Disease'), (67, 75, 'I_Disease'), (88, 100, 'B_Disease'), (101, 103, 'I_Disease'), (104, 109, 'I_Disease'), (110, 111, 'I_Disease'), (112, 116, 'I_Disease'), (117, 123, 'I_Disease')]}], ['Therefore , certain limitations for malaria prophylaxis and treatment with mefloquine are recommended .', {'entities': [(36, 43, 'B_Disease')]}], ['Epidemiological evidence indicates that prenatal nutritional deprivation may increase the risk of schizophrenia .', {'entities': [(98, 111, 'B_Disease')]}], ['The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia .', {'entities': [(160, 173, 'B_Disease')]}], ['No changes in haloperidol - induced catalepsy or MK - 801 - induced locomotion were seen following PD .', {'entities': [(36, 45, 'B_Disease')]}], ['This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse .', {'entities': [(76, 87, 'B_Disease'), (88, 98, 'I_Disease'), (117, 130, 'B_Disease')]}], ['BACKGROUND : Papaverine hydrochloride is a direct - acting vasodilator used to manage vasospasm during various neurosurgical operations .', {'entities': [(86, 95, 'B_Disease')]}], ['Transient cranial nerve dysfunction has been described in a few cases with topical papaverine .', {'entities': [(10, 17, 'B_Disease'), (18, 23, 'I_Disease'), (24, 35, 'I_Disease')]}], ['METHODS : We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm .', {'entities': [(166, 175, 'B_Disease')]}], ['Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .', {'entities': [(69, 78, 'B_Disease')]}], ['One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss .', {'entities': [(69, 82, 'B_Disease'), (83, 90, 'I_Disease'), (91, 95, 'I_Disease')]}], ['CONCLUSIONS : Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway .', {'entities': [(54, 63, 'B_Disease')]}], ['The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve .', {'entities': [(98, 105, 'B_Disease'), (106, 112, 'I_Disease'), (113, 115, 'I_Disease'), (116, 119, 'I_Disease'), (120, 128, 'I_Disease'), (129, 135, 'I_Disease'), (136, 141, 'I_Disease')]}], ['Recommendations to avoid potential cranial nerve deficits from papaverine are provided .', {'entities': [(35, 42, 'B_Disease'), (43, 48, 'I_Disease'), (49, 57, 'I_Disease')]}], ['Simvastatin - ezetimibe - induced hepatic failure necessitating liver transplantation .', {'entities': [(34, 41, 'B_Disease'), (42, 49, 'I_Disease')]}], ['However , hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin - ezetimibe .', {'entities': [(10, 21, 'B_Disease')]}], ['We describe a 70 - year - old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg / day to simvastatin 10 mg - ezetimibe 40 mg / day .', {'entities': [(59, 68, 'B_Disease'), (69, 76, 'I_Disease'), (77, 84, 'I_Disease')]}], [\"The patient ' s lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity .\", {'entities': [(121, 135, 'B_Disease')]}], ['Simvastatinezetimibe and escitalopram ( which she was taking for depression ) were discontinued , and other potential causes of hepatotoxicity were excluded .', {'entities': [(65, 75, 'B_Disease'), (128, 142, 'B_Disease')]}], ['A repeat work - up revealed further elevations in aminotransferase levels , and liver biopsy revealed evidence of moderate - to - severe drug toxicity .', {'entities': [(137, 141, 'B_Disease'), (142, 150, 'I_Disease')]}], ['Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased simvastatin exposure and subsequent hepatotoxicity .', {'entities': [(261, 275, 'B_Disease')]}], ['To our knowledge , this is the first case report of simvastatin - ezetimibe - induced liver failure that resulted in liver transplantation .', {'entities': [(86, 91, 'B_Disease'), (92, 99, 'I_Disease')]}], ['We postulate that the mechanism of the simvastatinezetimibe - induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes .', {'entities': [(70, 84, 'B_Disease')]}], ['Clinicians should be aware of potential hepatotoxicity with simvastatin - ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage .', {'entities': [(40, 54, 'B_Disease')]}], ['Massive proteinuria and acute renal failure after oral bisphosphonate ( alendronate ) administration in a patient with focal segmental glomerulosclerosis .', {'entities': [(8, 19, 'B_Disease'), (24, 29, 'B_Disease'), (30, 35, 'I_Disease'), (36, 43, 'I_Disease'), (119, 124, 'B_Disease'), (125, 134, 'I_Disease'), (135, 153, 'I_Disease')]}], ['A 61 - year - old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy .', {'entities': [(36, 45, 'B_Disease'), (46, 54, 'I_Disease'), (62, 67, 'B_Disease'), (68, 77, 'I_Disease'), (78, 96, 'I_Disease')]}], ['Within 14 days of the oral bisphosphonate ( alendronate sodium ) administration , the amount of daily urinary protein increased rapidly up to 12 . 8 g with acute renal failure .', {'entities': [(156, 161, 'B_Disease'), (162, 167, 'I_Disease'), (168, 175, 'I_Disease')]}], ['This report demonstrates that not only intravenous , but also oral bisphosphonates can aggravate proteinuria and acute renal failure .', {'entities': [(97, 108, 'B_Disease'), (113, 118, 'B_Disease'), (119, 124, 'I_Disease'), (125, 132, 'I_Disease')]}], ['Serum - and glucocorticoid - inducible kinase 1 in doxorubicin - induced nephrotic syndrome .', {'entities': [(73, 82, 'B_Disease'), (83, 91, 'I_Disease')]}], ['Doxorubicin - induced nephropathy leads to epithelial sodium channel ( ENaC ) - dependent volume retention and renal fibrosis .', {'entities': [(22, 33, 'B_Disease'), (90, 96, 'B_Disease'), (97, 106, 'I_Disease'), (117, 125, 'B_Disease')]}], ['The aldosterone - sensitive serum - and glucocorticoid - inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess .', {'entities': [(157, 165, 'B_Disease')]}], ['The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome .', {'entities': [(69, 75, 'B_Disease'), (76, 85, 'I_Disease'), (90, 98, 'B_Disease'), (106, 115, 'B_Disease'), (116, 124, 'I_Disease')]}], ['Doxorubicin treatment resulted in heavy proteinuria ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe nephrotic syndrome with ascites , lipidemia , and hypoalbuminemia in both genotypes .', {'entities': [(40, 51, 'B_Disease'), (165, 174, 'B_Disease'), (175, 183, 'I_Disease'), (189, 196, 'B_Disease'), (199, 208, 'B_Disease'), (215, 230, 'B_Disease')]}], ['Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1 ( + / + ) mice .', {'entities': [(39, 48, 'B_Disease')]}], ['Urinary sodium excretion reached signficantly lower values in sgk1 ( + / + ) mice ( 15 + / - 5 mumol / mg crea ) than in sgk1 ( - / - ) mice ( 35 + / - 5 mumol / mg crea ) and was associated with a significantly higher body weight gain in sgk1 ( + / + ) compared with sgk1 ( - / - ) mice ( + 6 . 6 + / - 0 . 7 vs . + 4 . 1 + / - 0 . 8 g ) .', {'entities': [(224, 230, 'B_Disease'), (231, 235, 'I_Disease')]}], ['During the course of nephrotic syndrome , serum urea concentrations increased significantly faster in sgk1 ( - / - ) mice than in sgk1 ( + / + ) mice leading to uremia and a reduced median survival in sgk1 ( - / - ) mice ( 29 vs . 40 days in sgk1 ( + / + ) mice ) .', {'entities': [(21, 30, 'B_Disease'), (31, 39, 'I_Disease'), (161, 167, 'B_Disease')]}], ['In conclusion , gene - targeted mice lacking SGK1 showed blunted volume retention , yet were not protected against renal fibrosis during experimental nephrotic syndrome .', {'entities': [(65, 71, 'B_Disease'), (72, 81, 'I_Disease'), (121, 129, 'B_Disease'), (150, 159, 'B_Disease'), (160, 168, 'I_Disease')]}], ['Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin : a case report with fatal outcome .', {'entities': [(7, 23, 'B_Disease'), (28, 38, 'B_Disease'), (39, 46, 'I_Disease')]}], ['A 30 - year old Caucasian man reported with abdominal pain and jaundice after 3 - day administration of oral ciprofloxacin for a suspect of urinary tract infection .', {'entities': [(44, 53, 'B_Disease'), (54, 58, 'I_Disease'), (63, 71, 'B_Disease'), (140, 147, 'B_Disease'), (148, 153, 'I_Disease'), (154, 163, 'I_Disease')]}], ['Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis .', {'entities': [(62, 78, 'B_Disease'), (83, 93, 'B_Disease')]}], ['The patient progressively developed petechiae and purpura on thorax and lower limbs .', {'entities': [(36, 45, 'B_Disease'), (50, 57, 'B_Disease')]}], ['An accurate autopsy revealed most organs with diffuse petechial haemorrhages .', {'entities': [(64, 76, 'B_Disease')]}], ['No signs of bone marrow depression were found .', {'entities': [(12, 16, 'B_Disease'), (17, 23, 'I_Disease'), (24, 34, 'I_Disease')]}], ['No thrombi or signs of microangiopathies were observed in arterial vessels .', {'entities': [(3, 10, 'B_Disease'), (23, 40, 'B_Disease')]}], ['This case report shows that ciprofloxacin may precipitate life - threatening thrombocytopenia and haemolytic anaemia , even in the early phases of treatment and without apparent previous exposures .', {'entities': [(77, 93, 'B_Disease'), (98, 108, 'B_Disease'), (109, 116, 'I_Disease')]}], ['Alpha - lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy .', {'entities': [(29, 42, 'B_Disease'), (43, 49, 'I_Disease'), (54, 67, 'B_Disease'), (97, 107, 'B_Disease')]}], ['The study investigates if alpha - lipoic acid is neuroprotective against chemotherapy induced neurotoxicity , if mitochondrial damage plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of alpha - lipoic acid depend on mitochondria protection .', {'entities': [(94, 107, 'B_Disease'), (113, 126, 'B_Disease'), (127, 133, 'I_Disease'), (159, 164, 'B_Disease'), (165, 182, 'I_Disease'), (183, 190, 'I_Disease')]}], ['We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion ( DRG ) sensory neurons to paclitaxel and cisplatin , two widely used and highly effective chemotherapeutic drugs .', {'entities': [(50, 60, 'B_Disease'), (61, 71, 'I_Disease')]}], ['This approach allowed investigating the efficacy of alpha - lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha - lipoic acid .', {'entities': [(86, 92, 'B_Disease'), (93, 99, 'I_Disease')]}], ['Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons .', {'entities': [(71, 84, 'B_Disease'), (85, 95, 'I_Disease')]}], ['Alpha - lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons : it rescues the mitochondrial toxicity and induces the expression of frataxin , an essential mitochondrial protein with anti - oxidant and chaperone properties .', {'entities': [(80, 93, 'B_Disease'), (130, 143, 'B_Disease'), (144, 152, 'I_Disease')]}], ['In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity .', {'entities': [(14, 27, 'B_Disease'), (28, 36, 'I_Disease'), (103, 116, 'B_Disease')]}], ['These findings suggest that alpha - lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials .', {'entities': [(84, 94, 'B_Disease'), (95, 100, 'I_Disease'), (101, 109, 'I_Disease')]}], ['Toxicity in rhesus monkeys following administration of the 8 - aminoquinoline 8 - [ ( 4 - amino - l - methylbutyl ) amino ] - 5 - ( l - hexyloxy ) - 6 - methoxy - 4 - methylquinoline ( WR242511 ) .', {'entities': [(0, 8, 'B_Disease')]}], ['INTRODUCTION : Many substances that form methemoglobin ( MHb ) effectively counter cyanide ( CN ) toxicity .', {'entities': [(98, 106, 'B_Disease')]}], ['Although MHb formers are generally applied as treatments for CN poisoning , it has been proposed that a stable , long - acting MHb former could serve as a CN pretreatment .', {'entities': [(64, 73, 'B_Disease')]}], ['RESULTS : The selected doses of WR242511 , which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere , produced very little MHb ( mean < 2 . 0 % ) in the rhesus monkey .', {'entities': [(70, 87, 'B_Disease')]}], ['Furthermore , transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 ( 3 . 5 or 7 . 0 mg / kg ) , and 2 lethalities occurred ( one IV and one PO ) following the 7 . 0 mg / kg dose .', {'entities': [(24, 38, 'B_Disease')]}], ['Myoglobinuria was also observed following the 7 . 0 mg / kg dose .', {'entities': [(0, 13, 'B_Disease')]}], ['Histopathology analyses in the 2 animals that died revealed liver and kidney toxicity , with greater severity in the orally - treated animal .', {'entities': [(60, 65, 'B_Disease'), (66, 69, 'I_Disease'), (70, 76, 'I_Disease'), (77, 85, 'I_Disease')]}], ['CONCLUSIONS : These data demonstrate direct and / or indirect drug - induced toxicity .', {'entities': [(77, 85, 'B_Disease')]}], ['It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti - CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity .', {'entities': [(77, 86, 'B_Disease'), (206, 214, 'B_Disease')]}], [\"Repetitive transcranial magnetic stimulation for levodopa - induced dyskinesias in Parkinson ' s disease .\", {'entities': [(68, 79, 'B_Disease'), (83, 92, 'B_Disease'), (93, 94, 'I_Disease'), (95, 96, 'I_Disease'), (97, 104, 'I_Disease')]}], ['In a placebo - controlled , single - blinded , crossover study , we assessed the effect of \" real \" repetitive transcranial magnetic stimulation ( rTMS ) versus \" sham \" rTMS ( placebo ) on peak dose dyskinesias in patients with Parkinson \\' s disease ( PD ) .', {'entities': [(200, 211, 'B_Disease'), (229, 238, 'B_Disease'), (239, 240, 'I_Disease'), (241, 242, 'I_Disease'), (243, 250, 'I_Disease'), (253, 255, 'B_Disease')]}], ['Ten patients with PD and prominent dyskinesias had rTMS ( 1 , 800 pulses ; 1 Hz rate ) delivered over the motor cortex for 4 consecutive days twice , once real stimuli and once sham stimulation were used ; evaluations were done at the baseline and 1 day after the end of each of the treatment series .', {'entities': [(18, 20, 'B_Disease'), (35, 46, 'B_Disease')]}], ['Direct comparison between sham and real rTMS effects showed no significant difference in clinician - assessed dyskinesia severity .', {'entities': [(110, 120, 'B_Disease')]}], ['However , comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo .', {'entities': [(81, 91, 'B_Disease')]}], ['The major effect was on dystonia subscore .', {'entities': [(24, 32, 'B_Disease')]}], ['Similarly , in patient diaries , although both treatments caused reduction in subjective dyskinesia scores during the days of intervention , the effect was sustained for 3 days after the intervention for the real rTMS only .', {'entities': [(89, 99, 'B_Disease')]}], ['Following rTMS , no side effects and no adverse effects on motor function and PD symptoms were noted .', {'entities': [(78, 80, 'B_Disease')]}], ['The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low - frequency rTMS on dyskinesias in PD .', {'entities': [(140, 151, 'B_Disease'), (155, 157, 'B_Disease')]}], ['Intracavernous epinephrine : a minimally invasive treatment for priapism in the emergency department .', {'entities': [(64, 72, 'B_Disease')]}], ['Priapism is the prolonged erection of the penis in the absence of sexual arousal .', {'entities': [(0, 8, 'B_Disease')]}], ['A 45 - year - old man , an admitted frequent cocaine user , presented to the Emergency Department ( ED ) on two separate occasions with a history of priapism after cocaine use .', {'entities': [(149, 157, 'B_Disease')]}], ['Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders .', {'entities': [(74, 87, 'B_Disease'), (88, 97, 'I_Disease')]}], ['The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen ( HBs Ag ) positive patients with rheumatologic disease .', {'entities': [(206, 219, 'B_Disease'), (220, 227, 'I_Disease')]}], ['From June 2004 to October 2006 , 11 HBs Ag positive patients with rheumatologic diseases , who were on both immunosuppressive and prophylactic lamivudine therapies , were retrospectively assessed .', {'entities': [(66, 79, 'B_Disease'), (80, 88, 'I_Disease')]}], ['Liver function tests , hepatitis B virus ( HBV ) serologic markers , and HBV DNA levels of the patients during follow - up were obtained from hospital file records .', {'entities': [(23, 32, 'B_Disease'), (33, 34, 'I_Disease')]}], ['Shortly after treatment their tests normalized and during follow - up period none of the patients had abnormal liver function tests .', {'entities': [(102, 110, 'B_Disease'), (111, 116, 'I_Disease'), (117, 125, 'I_Disease')]}], ['Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats .', {'entities': [(71, 81, 'B_Disease'), (82, 92, 'I_Disease')]}], ['The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol ( ISO ) - induced myocardial infarction in rats .', {'entities': [(253, 263, 'B_Disease'), (264, 274, 'I_Disease')]}], ['These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats .', {'entities': [(104, 114, 'B_Disease'), (115, 125, 'I_Disease')]}], ['Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats .', {'entities': [(76, 87, 'B_Disease')]}], ['Renal papillary necrosis ( RPN ) and a decreased urinary concentrating ability developed during continuous long - term treatment with aspirin and paracetamol in female Fischer 344 rats .', {'entities': [(0, 5, 'B_Disease'), (6, 15, 'I_Disease'), (16, 24, 'I_Disease'), (27, 30, 'B_Disease')]}], ['This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN .', {'entities': [(183, 186, 'B_Disease')]}], ['Testosterone - dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt - sensitive rats .', {'entities': [(25, 37, 'B_Disease')]}], ['In this study , the hypothesis was tested that there is a sexual dimorphism in HS - induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury .', {'entities': [(197, 202, 'B_Disease'), (203, 209, 'I_Disease')]}], ['HS diet for 4 wk caused a progressive increase in BP , protein and albumin excretion , and glomerular sclerosis in male DS rats , which were attenuated by castration .', {'entities': [(91, 101, 'B_Disease'), (102, 111, 'I_Disease')]}], ['Testosterone replacement in castrated DS rats increased BP , renal injury , and upregulation of renal angiotensinogen associated with HS diet .', {'entities': [(61, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin - angiotensin system .', {'entities': [(47, 59, 'B_Disease'), (64, 69, 'B_Disease'), (70, 76, 'I_Disease')]}], ['Explicit episodic memory for sensory - discriminative components of capsaicin - induced pain : immediate and delayed ratings .', {'entities': [(88, 92, 'B_Disease')]}], ['Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions .', {'entities': [(0, 4, 'B_Disease'), (40, 44, 'B_Disease'), (89, 93, 'B_Disease')]}], ['Systematic investigations of the human capacity to remember sensory features of experimental pain are sparse .', {'entities': [(93, 97, 'B_Disease')]}], ['In order to address long - term pain memory , nine healthy male volunteers received intradermal injections of three doses of capsaicin ( 0 . 05 , 1 and 20 microg , separated by 15 min breaks ) , each given three times in a balanced design across three sessions at one week intervals .', {'entities': [(32, 36, 'B_Disease')]}], ['Pain rating was performed using a computerized visual analogue scale ( 0 - 100 ) digitized at 1 / s , either immediately online or one hour or one day after injection .', {'entities': [(0, 4, 'B_Disease')]}], ['Subjects also recalled their pains one week later .', {'entities': [(29, 34, 'B_Disease')]}], ['The strong burning pain decayed exponentially within a few minutes .', {'entities': [(19, 23, 'B_Disease')]}], ['Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses ( both p < 0 . 001 ) , regardless of whether first - time ratings were requested immediately , after one hour or after one day .', {'entities': [(44, 48, 'B_Disease')]}], ['Pain recall after one week was similarly precise ( magnitude : p < 0 . 01 , duration : p < 0 . 05 ) .', {'entities': [(0, 4, 'B_Disease')]}], ['These results indicate a reliable memory for magnitude and duration of experimentally induced pain .', {'entities': [(94, 98, 'B_Disease')]}], ['Severe and long lasting cholestasis after high - dose co - trimoxazole treatment for Pneumocystis pneumonia in HIV - infected patients - - a report of two cases .', {'entities': [(24, 35, 'B_Disease'), (85, 97, 'B_Disease'), (98, 107, 'I_Disease'), (111, 114, 'B_Disease'), (115, 116, 'I_Disease'), (117, 125, 'I_Disease')]}], ['Pneumocystis pneumonia ( PCP ) , a common opportunistic infection in HIV - infected individuals , is generally treated with high doses of co - trimoxazole .', {'entities': [(0, 12, 'B_Disease'), (13, 22, 'I_Disease'), (25, 28, 'B_Disease'), (42, 55, 'B_Disease'), (56, 65, 'I_Disease'), (69, 72, 'B_Disease'), (73, 74, 'I_Disease'), (75, 83, 'I_Disease')]}], ['Here , we report two cases of severely immunocompromised HIV - infected patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking liver abscess formation on radiologic exams , during co - trimoxazole treatment for PCP .', {'entities': [(57, 60, 'B_Disease'), (61, 62, 'I_Disease'), (63, 71, 'I_Disease'), (102, 114, 'B_Disease'), (115, 126, 'I_Disease'), (166, 171, 'B_Disease'), (172, 179, 'I_Disease'), (250, 253, 'B_Disease')]}], ['Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model .', {'entities': [(112, 124, 'B_Disease'), (145, 153, 'B_Disease'), (154, 164, 'I_Disease')]}], ['PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy was investigated .', {'entities': [(527, 535, 'B_Disease'), (536, 537, 'I_Disease'), (538, 552, 'I_Disease'), (553, 554, 'I_Disease'), (555, 562, 'I_Disease'), (563, 564, 'I_Disease'), (565, 568, 'I_Disease'), (569, 574, 'I_Disease'), (575, 576, 'I_Disease'), (577, 588, 'I_Disease'), (589, 590, 'I_Disease'), (591, 598, 'I_Disease'), (599, 600, 'I_Disease'), (601, 611, 'I_Disease')]}], ['METHODS : The changes in pain thresholds were determined using mechanical stimuli - - the modification of the classic paw withdrawal test described by Randall - Selitto .', {'entities': [(25, 29, 'B_Disease')]}], ['RESULTS : The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia .', {'entities': [(156, 164, 'B_Disease'), (165, 177, 'I_Disease')]}], ['It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine .', {'entities': [(136, 148, 'B_Disease')]}], ['Moreover , L - NOArg and 7 - NI but not L - NIL intensify antihyperalgesic activity of HOE 140 or des - Arg10HOE 140 in toxic neuropathy .', {'entities': [(120, 125, 'B_Disease'), (126, 136, 'I_Disease')]}], ['CONCLUSIONS : Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy .', {'entities': [(131, 139, 'B_Disease'), (140, 143, 'I_Disease'), (144, 149, 'I_Disease'), (150, 160, 'I_Disease')]}], ['In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .', {'entities': [(28, 40, 'B_Disease'), (154, 166, 'B_Disease')]}], ['Therefore , concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain , even in hospital care .', {'entities': [(151, 162, 'B_Disease'), (163, 167, 'I_Disease')]}], ['Confusion , a rather serious adverse drug reaction with valproic acid : a review of the French Pharmacovigilance database .', {'entities': [(0, 9, 'B_Disease')]}], ['INTRODUCTION : Confusion is an adverse drug reaction frequently observed with valproic acid .', {'entities': [(15, 24, 'B_Disease')]}], ['METHODS : Using the French Pharmacovigilance database , we selected the cases of confusion reported since 1985 with valproic acid .', {'entities': [(81, 90, 'B_Disease')]}], ['RESULTS : 272 cases of confusion were reported with valproic acid : 153 women and 119 men .', {'entities': [(23, 32, 'B_Disease')]}], ['Confusion mostly occurred during the two first weeks following valproic acid exposure ( 39 . 7 % ) .', {'entities': [(0, 9, 'B_Disease')]}], ['CONCLUSION : This work shows that confusion with valproic acid is a serious , rather frequent but reversible adverse drug reaction .', {'entities': [(34, 43, 'B_Disease')]}], ['Reversible inferior colliculus lesion in metronidazole - induced encephalopathy : magnetic resonance findings on diffusion - weighted and fluid attenuated inversion recovery imaging .', {'entities': [(11, 19, 'B_Disease'), (20, 30, 'I_Disease'), (31, 37, 'I_Disease'), (65, 79, 'B_Disease')]}], ['OBJECTIVE : This is to present reversible inferior colliculus lesions in metronidazole - induced encephalopathy , to focus on the diffusion - weighted imaging ( DWI ) and fluid attenuated inversion recovery ( FLAIR ) imaging .', {'entities': [(42, 50, 'B_Disease'), (51, 61, 'I_Disease'), (62, 69, 'I_Disease'), (97, 111, 'B_Disease')]}], ['MATERIALS AND METHODS : From November 2005 to September 2007 , 8 patients ( 5 men and 3 women ) were diagnosed as having metronidazole - induced encephalopathy ( age range ; 43 - 78 years ) .', {'entities': [(145, 159, 'B_Disease')]}], ['They had been taking metronidazole ( total dosage , 45 - 120 g ; duration , 30 days to 2 months ) to treat the infection in various organs .', {'entities': [(111, 120, 'B_Disease')]}], ['All the lesions in dentate , inferior colliculus , pons , and medullas had been resolved completely on follow - up MRIs in 5 patients , but in 1 patient of them , corpus callosal lesion persisted .', {'entities': [(170, 178, 'B_Disease'), (179, 185, 'I_Disease')]}], ['CONCLUSIONS : Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole - induced encephalopathy , next to the dentate nucleus involvement .', {'entities': [(25, 33, 'B_Disease'), (34, 44, 'I_Disease'), (45, 52, 'I_Disease'), (123, 137, 'B_Disease')]}], ['Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients .', {'entities': [(23, 34, 'B_Disease')]}], ['BACKGROUND : Sirolimus is the latest immunosuppressive agent used to prevent rejection , and may have less nephrotoxicity than calcineurin inhibitor ( CNI ) - based regimens .', {'entities': [(107, 121, 'B_Disease')]}], ['To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus .', {'entities': [(70, 81, 'B_Disease')]}], ['We have encountered several patients who developed substantial proteinuria associated with sirolimus use .', {'entities': [(63, 74, 'B_Disease')]}], ['In each patient , the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria .', {'entities': [(99, 110, 'B_Disease'), (167, 178, 'B_Disease')]}], ['In these patients , the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein : creatinine ratios , an estimate of grams of proteinuria / day .', {'entities': [(37, 48, 'B_Disease'), (186, 197, 'B_Disease')]}], ['RESULTS : Twenty - eight patients ( 24 % ) developed increased proteinuria from baseline during their post - transplantation course .', {'entities': [(63, 74, 'B_Disease')]}], ['In 21 patients an alternative cause of proteinuria was either obvious or insufficient data was available to be conclusive .', {'entities': [(39, 50, 'B_Disease')]}], ['In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic - range proteinuria .', {'entities': [(125, 134, 'B_Disease'), (143, 154, 'B_Disease')]}], ['Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables .', {'entities': [(0, 11, 'B_Disease')]}], ['In most patients , discontinuation of sirolimus resulted in a decrease , but not resolution , of proteinuria .', {'entities': [(97, 108, 'B_Disease')]}], ['CONCLUSIONS : Sirolimus induces or aggravates pre - existing proteinuria in an unpredictable subset of renal allograft recipients .', {'entities': [(61, 72, 'B_Disease')]}], ['Proteinuria may improve , but does not resolve , when sirolimus is withdrawn .', {'entities': [(0, 11, 'B_Disease')]}], ['Components of lemon essential oil attenuate dementia induced by scopolamine .', {'entities': [(44, 52, 'B_Disease')]}], ['The anti - dementia effects of s - limonene and s - perillyl alcohol were observed using the passive avoidance test ( PA ) and the open field habituation test ( OFH ) .', {'entities': [(11, 19, 'B_Disease')]}], ['These lemon essential oils showed strong ability to improve memory impaired by scopolamine ; however , s - perillyl alcohol relieved the deficit of associative memory in PA only , and did not improve non - associative memory significantly in OFH .', {'entities': [(60, 66, 'B_Disease'), (67, 75, 'I_Disease'), (137, 144, 'B_Disease'), (145, 147, 'I_Disease'), (148, 159, 'I_Disease'), (160, 166, 'I_Disease')]}], ['Attentional modulation of perceived pain intensity in capsaicin - induced secondary hyperalgesia .', {'entities': [(36, 40, 'B_Disease'), (84, 96, 'B_Disease')]}], ['Perceived pain intensity is modulated by attention .', {'entities': [(10, 14, 'B_Disease')]}], ['However , it is not known that how pain intensity ratings are affected by attention in capsaicin - induced secondary hyperalgesia .', {'entities': [(35, 39, 'B_Disease'), (117, 129, 'B_Disease')]}], ['Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task .', {'entities': [(28, 32, 'B_Disease'), (56, 68, 'B_Disease')]}], ['Furthermore , it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin - untreated , control condition .', {'entities': [(85, 97, 'B_Disease')]}], ['Our findings , showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms .', {'entities': [(136, 148, 'B_Disease'), (187, 191, 'B_Disease')]}], ['Cardioprotective effect of salvianolic acid A on isoproterenol - induced myocardial infarction in rats .', {'entities': [(73, 83, 'B_Disease'), (84, 94, 'I_Disease')]}], ['The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol - induced myocardial infarction in rats .', {'entities': [(123, 133, 'B_Disease'), (134, 144, 'I_Disease')]}], ['In addition , mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP / O was observed in isoproterenol - treated rats .', {'entities': [(28, 39, 'B_Disease'), (40, 51, 'I_Disease')]}], ['Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol - induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function .', {'entities': [(109, 116, 'B_Disease'), (117, 128, 'I_Disease'), (133, 143, 'B_Disease'), (144, 150, 'I_Disease')]}], ['The protective role of salvianolic acid A against isoproterenol - induced myocardial damage was further confirmed by histopathological examination .', {'entities': [(74, 84, 'B_Disease'), (85, 91, 'I_Disease')]}], ['The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol - induced myocardial infarction .', {'entities': [(157, 167, 'B_Disease'), (168, 178, 'I_Disease')]}], ['Long - term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel .', {'entities': [(64, 74, 'B_Disease'), (75, 88, 'I_Disease')]}], ['Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .', {'entities': [(6, 16, 'B_Disease'), (17, 27, 'I_Disease'), (205, 218, 'B_Disease')]}], ['This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC - induced peripheral neuropathy in a randomized , placebo - controlled , double - blinded clinical and electro - diagnostic study .', {'entities': [(102, 112, 'B_Disease'), (113, 123, 'I_Disease')]}], ['Forty - three ovarian cancer patients were available for analysis following six cycles of the same PAC - containing regimen : 23 had been supplemented by glutamate all along the treatment period , at a daily dose of three times 500 mg ( group G ) , and 20 had received a placebo ( group P ) .', {'entities': [(14, 21, 'B_Disease'), (22, 28, 'I_Disease')]}], ['There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G .', {'entities': [(106, 119, 'B_Disease')]}], ['However , this difference reached statistical significance only with regard to reported pain sensation ( P = 0 . 011 ) .', {'entities': [(88, 92, 'B_Disease')]}], ['This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC .', {'entities': [(119, 129, 'B_Disease'), (130, 143, 'I_Disease')]}], ['Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C .', {'entities': [(15, 21, 'B_Disease'), (22, 32, 'I_Disease'), (89, 96, 'B_Disease'), (97, 106, 'I_Disease'), (107, 108, 'I_Disease')]}], ['A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha - 2b and ribavirin for chronic hepatitis C ( CHC ) .', {'entities': [(42, 50, 'B_Disease'), (144, 151, 'B_Disease'), (152, 161, 'I_Disease'), (162, 163, 'I_Disease'), (166, 169, 'B_Disease')]}], ['Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs .', {'entities': [(35, 41, 'B_Disease'), (42, 44, 'I_Disease'), (45, 48, 'I_Disease'), (49, 54, 'I_Disease'), (55, 60, 'I_Disease'), (61, 64, 'I_Disease'), (69, 79, 'B_Disease'), (80, 85, 'I_Disease'), (86, 89, 'I_Disease'), (90, 98, 'I_Disease')]}], ['The ocular myasthenia associated with combination therapy of pegylated IFN alpha - 2b and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .', {'entities': [(4, 10, 'B_Disease'), (11, 21, 'I_Disease'), (104, 107, 'B_Disease')]}], ['Learning and memory deficits in ecstasy users and their neural correlates during a face - learning task .', {'entities': [(0, 8, 'B_Disease'), (9, 12, 'I_Disease'), (13, 19, 'I_Disease'), (20, 28, 'I_Disease')]}], ['It has been consistently shown that ecstasy users display impairments in learning and memory performance .', {'entities': [(58, 69, 'B_Disease'), (70, 72, 'I_Disease'), (73, 81, 'I_Disease'), (82, 85, 'I_Disease'), (86, 92, 'I_Disease')]}], ['To address the potential confounding effects of the cannabis use of the ecstasy using group , a second analysis included 14 previously tested cannabis users ( Nestor , L . , Roberts , G . , Garavan , H . , Hester , R . , 2008 . Deficits in learning and memory : parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users . Neuroimage 40 , 1328 - 1339 ) .', {'entities': [(228, 236, 'B_Disease'), (237, 239, 'I_Disease'), (240, 248, 'I_Disease'), (249, 252, 'I_Disease'), (253, 259, 'I_Disease'), (278, 291, 'B_Disease')]}], ['A conjunction analysis of the encode and recall phases of the task revealed ecstasy - specific hyperactivity in bilateral frontal regions , left temporal , right parietal , bilateral temporal , and bilateral occipital brain regions .', {'entities': [(95, 108, 'B_Disease')]}], ['These ecstasy - specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy .', {'entities': [(116, 126, 'B_Disease')]}], ['In less than 1 hour after the ingestion of alcohol , he developed malaise with flushing of the face , tachycardia , and dyspnea .', {'entities': [(79, 87, 'B_Disease'), (88, 90, 'I_Disease'), (91, 94, 'I_Disease'), (95, 99, 'I_Disease'), (102, 113, 'B_Disease'), (120, 127, 'B_Disease')]}], ['Five hours after exposure , he developed disulfiram - like syndrome with flushing , tachycardia , and arterial hypotension after consuming three glasses of wine .', {'entities': [(73, 81, 'B_Disease'), (84, 95, 'B_Disease'), (102, 110, 'B_Disease'), (111, 122, 'I_Disease')]}], ['Sulpiride - induced tardive dystonia .', {'entities': [(20, 27, 'B_Disease'), (28, 36, 'I_Disease')]}], ['Although initially thought to be free of extrapyramidal side effects , sulpiride - induced tardive dyskinesia and parkinsonism have been reported occasionally .', {'entities': [(91, 98, 'B_Disease'), (99, 109, 'I_Disease'), (114, 126, 'B_Disease')]}], ['We studied a 37 - year - old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy .', {'entities': [(68, 76, 'B_Disease')]}], ['We could not find any previous reports of sulpiride - induced tardive dystonia .', {'entities': [(62, 69, 'B_Disease'), (70, 78, 'I_Disease')]}], ['This study measured the objective and subjective neurocognitive effects of a single 10 - mg dose of immediate - release oxycodone in healthy , older ( > 65 years ) , and middle - aged ( 35 to 55 years ) adults who were not suffering from chronic or significant daily pain .', {'entities': [(267, 271, 'B_Disease')]}], ['Significant declines in simple and sustained attention , working memory , and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose .', {'entities': [(12, 20, 'B_Disease'), (21, 23, 'I_Disease'), (24, 30, 'I_Disease'), (31, 34, 'I_Disease'), (35, 44, 'I_Disease'), (45, 54, 'I_Disease'), (55, 56, 'I_Disease'), (57, 64, 'I_Disease'), (65, 71, 'I_Disease'), (72, 73, 'I_Disease'), (74, 77, 'I_Disease'), (78, 84, 'I_Disease'), (85, 91, 'I_Disease')]}], ['This study suggests that for healthy older adults who are not suffering from chronic pain , neurocognitive and pharmacodynamic changes in response to a 10 - mg dose of immediate - release oxycodone are similar to those observed for middle - aged adults .', {'entities': [(77, 84, 'B_Disease'), (85, 89, 'I_Disease')]}], ['Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission .', {'entities': [(0, 13, 'B_Disease')]}], ['However , the observation that antagonists of the glutamate N - methyl - D - aspartate ( NMDA ) receptor produce schizophrenic - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .', {'entities': [(113, 126, 'B_Disease')]}], ['This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of hyperactivity , involving either drug challenge ( ie , amphetamine and MK - 801 ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .', {'entities': [(132, 145, 'B_Disease')]}], ['Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .', {'entities': [(66, 79, 'B_Disease'), (184, 197, 'B_Disease')]}], ['In contrast , SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg p . o . ) .', {'entities': [(41, 54, 'B_Disease')]}], ['Importantly , both classical ( haloperidol ) and atypical ( olanzapine , clozapine and aripiprazole ) antipsychotics were effective in all these models of hyperactivity .', {'entities': [(155, 168, 'B_Disease')]}], ['However , unlike these latter , SSR103800 did not produce catalepsy ( retention on the bar test ) up to 30 mg / kg p . o .', {'entities': [(58, 67, 'B_Disease')]}], ['Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model .', {'entities': [(76, 82, 'B_Disease'), (83, 94, 'I_Disease')]}], ['Both , production of reactive oxygen species as well as activation of NF - kappaB have been implicated in severe neuronal damage in different sub - regions of the hippocampus as well as in the surrounding cortices .', {'entities': [(113, 121, 'B_Disease'), (122, 128, 'I_Disease')]}], ['The effect of PDTC on status epilepticus - associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model .', {'entities': [(22, 28, 'B_Disease'), (29, 40, 'I_Disease')]}], ['Treatment with 150 mg / kg PDTC before and following status epilepticus significantly increased the mortality rate to 100 % .', {'entities': [(53, 59, 'B_Disease'), (60, 71, 'I_Disease')]}], ['Administration of 50 mg / kg PDTC ( low - dose ) did not exert major effects on the development of a status epilepticus or the mortality rate .', {'entities': [(101, 107, 'B_Disease'), (108, 119, 'I_Disease')]}], ['In vehicle - treated rats , status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons .', {'entities': [(28, 34, 'B_Disease'), (35, 46, 'I_Disease'), (65, 73, 'B_Disease'), (74, 80, 'I_Disease')]}], ['A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle - and PDTC - treated rats following status epilepticus .', {'entities': [(140, 146, 'B_Disease'), (147, 158, 'I_Disease')]}], ['In conclusion , the NF - kappaB inhibitor and antioxidant PDTC protected the piriform cortex , whereas it did not affect hilar neuronal loss .', {'entities': [(127, 135, 'B_Disease'), (136, 140, 'I_Disease')]}], ['These data might indicate that the generation of reactive oxygen species and activation of NF - kappaB plays a more central role in seizure - associated neuronal damage in the temporal cortex as compared to the hippocampal hilus .', {'entities': [(132, 139, 'B_Disease'), (153, 161, 'B_Disease'), (162, 168, 'I_Disease')]}], [\"Anaesthetists ' nightmare : masseter spasm after induction in an undiagnosed case of myotonia congenita .\", {'entities': [(28, 36, 'B_Disease'), (37, 42, 'I_Disease'), (85, 93, 'B_Disease'), (94, 103, 'I_Disease')]}], ['We report an undiagnosed case of myotonia congenita in a 24 - year - old previously healthy primigravida , who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia .', {'entities': [(33, 41, 'B_Disease'), (42, 51, 'I_Disease'), (138, 146, 'B_Disease'), (147, 152, 'I_Disease')]}], ['Twin preterm neonates with cardiac toxicity related to lopinavir / ritonavir therapy .', {'entities': [(27, 34, 'B_Disease'), (35, 43, 'I_Disease')]}], ['We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection .', {'entities': [(92, 97, 'B_Disease'), (98, 114, 'I_Disease'), (115, 120, 'I_Disease'), (121, 130, 'I_Disease')]}], ['One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir / ritonavir therapy , a boosted protease - inhibitor agent , while the other twin developed mild bradycardia .', {'entities': [(36, 41, 'B_Disease'), (42, 47, 'I_Disease'), (52, 59, 'B_Disease'), (60, 74, 'I_Disease'), (193, 204, 'B_Disease')]}], ['Twenty - three hours after heart transplantation , life - threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration ( CVVHDF ) .', {'entities': [(76, 81, 'B_Disease'), (82, 87, 'I_Disease'), (88, 95, 'I_Disease')]}], ['However , a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis .', {'entities': [(85, 97, 'B_Disease')]}], ['Lithium - induced polyuria seems to be related to extrarenal as well as to renal effects .', {'entities': [(18, 26, 'B_Disease')]}], ['Antibacterial medication use during pregnancy and risk of birth defects : National Birth Defects Prevention Study .', {'entities': [(58, 63, 'B_Disease'), (64, 71, 'I_Disease'), (83, 88, 'B_Disease'), (89, 96, 'I_Disease')]}], ['OBJECTIVE : To estimate the association between antibacterial medications and selected birth defects .', {'entities': [(87, 92, 'B_Disease'), (93, 100, 'I_Disease')]}], ['DESIGN , SETTING , AND PARTICIPANTS : Population - based , multisite , case - control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states ( n = 13 155 ) and control women randomly selected from the same geographical regions ( n = 4941 ) .', {'entities': [(166, 171, 'B_Disease'), (172, 179, 'I_Disease'), (195, 200, 'B_Disease'), (201, 207, 'I_Disease')]}], ['MAIN OUTCOME MEASURE : Odds ratios ( ORs ) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders .', {'entities': [(108, 113, 'B_Disease'), (114, 121, 'I_Disease')]}], ['Sulfonamides were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .', {'entities': [(34, 45, 'B_Disease'), (130, 141, 'B_Disease'), (142, 146, 'I_Disease'), (147, 152, 'I_Disease'), (153, 161, 'I_Disease'), (206, 217, 'B_Disease'), (218, 220, 'I_Disease'), (221, 224, 'I_Disease'), (225, 230, 'I_Disease'), (275, 282, 'B_Disease'), (283, 290, 'I_Disease'), (336, 346, 'B_Disease'), (347, 351, 'I_Disease'), (352, 362, 'I_Disease'), (411, 424, 'B_Disease'), (425, 431, 'I_Disease')]}], ['Nitrofurantoins were associated with anophthalmia or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .', {'entities': [(37, 49, 'B_Disease'), (53, 67, 'B_Disease'), (113, 124, 'B_Disease'), (125, 129, 'I_Disease'), (130, 135, 'I_Disease'), (136, 144, 'I_Disease'), (189, 195, 'B_Disease'), (196, 202, 'I_Disease'), (203, 210, 'I_Disease'), (259, 264, 'B_Disease'), (265, 268, 'I_Disease'), (274, 279, 'B_Disease'), (280, 286, 'I_Disease')]}], ['CONCLUSIONS : Reassuringly , penicillins , erythromycins , and cephalosporins , although used commonly by pregnant women , were not associated with many birth defects .', {'entities': [(153, 158, 'B_Disease'), (159, 166, 'I_Disease')]}], ['Sulfonamides and nitrofurantoins were associated with several birth defects , indicating a need for additional scrutiny .', {'entities': [(62, 67, 'B_Disease'), (68, 75, 'I_Disease')]}], ['Immune escape variants of the hepatitis B virus ( HBV ) represent an emerging clinical challenge , because they can be associated with vaccine escape , HBV reactivation , and failure of diagnostic tests .', {'entities': [(30, 39, 'B_Disease'), (40, 41, 'I_Disease')]}], ['Hemolytic anemia associated with the use of omeprazole .', {'entities': [(0, 9, 'B_Disease'), (10, 16, 'I_Disease')]}], ['It has been shown to be extremely effective in the treatment of peptic ulcer disease , reflux esophagitis , and the Zollinger - Ellison syndrome .', {'entities': [(64, 70, 'B_Disease'), (71, 76, 'I_Disease'), (77, 84, 'I_Disease'), (87, 93, 'B_Disease'), (94, 105, 'I_Disease'), (116, 125, 'B_Disease'), (126, 127, 'I_Disease'), (128, 135, 'I_Disease'), (136, 144, 'I_Disease')]}], ['We report the first case of a serious short - term adverse reaction with the use of omeprazole : hemolytic anemia .', {'entities': [(97, 106, 'B_Disease'), (107, 113, 'I_Disease')]}], ['The patient developed weakness , lethargy , and shortness of breath 2 days after starting therapy with omeprazole .', {'entities': [(33, 41, 'B_Disease'), (48, 57, 'B_Disease'), (58, 60, 'I_Disease'), (61, 67, 'I_Disease')]}], [\"The mechanism by which omeprazole caused the patient ' s hemolytic anemia is uncertain , but physicians should be alerted to this possible adverse effect .\", {'entities': [(57, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia - induced hypotension .', {'entities': [(32, 39, 'B_Disease'), (40, 47, 'I_Disease'), (48, 52, 'I_Disease'), (53, 64, 'I_Disease'), (96, 107, 'B_Disease')]}], ['BACKGROUND : Vasopressor agents are used to correct anesthesia - induced hypotension .', {'entities': [(73, 84, 'B_Disease')]}], ['We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced hypotension .', {'entities': [(133, 144, 'B_Disease')]}], ['Heart rate ( HR ) , MAP , stroke volume ( SV ) , cardiac output ( CO ) , and frontal lobe oxygenation ( S ( c ) O ( 2 ) ) were registered .', {'entities': [(26, 32, 'B_Disease')]}], ['RESULTS : Induction of anesthesia was followed by a decrease in MAP , HR , SV , and CO concomitant with an elevation in S ( c ) O ( 2 ) .', {'entities': [(50, 51, 'B_Disease'), (52, 60, 'I_Disease'), (61, 63, 'I_Disease'), (64, 67, 'I_Disease'), (68, 69, 'I_Disease'), (70, 72, 'I_Disease'), (73, 74, 'I_Disease'), (75, 77, 'I_Disease'), (78, 79, 'I_Disease'), (80, 83, 'I_Disease'), (84, 86, 'I_Disease')]}], ['CONCLUSIONS : The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO .', {'entities': [(58, 69, 'B_Disease')]}], ['Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin - induced thrombocytopenia with thrombosis .', {'entities': [(119, 135, 'B_Disease'), (141, 151, 'B_Disease')]}], ['BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of heparin - induced thrombocytopenia ( HIT ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .', {'entities': [(147, 163, 'B_Disease'), (166, 169, 'B_Disease'), (175, 178, 'B_Disease'), (184, 194, 'B_Disease'), (197, 201, 'B_Disease')]}], ['In the following report , a 65 - year - old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation .', {'entities': [(44, 54, 'B_Disease'), (55, 58, 'I_Disease'), (95, 99, 'B_Disease')]}], ['The patient required massive transfusion support ( 55 units of red blood cells , 42 units of fresh - frozen plasma , 40 units of cryoprecipitate , 40 units of platelets , and three doses of recombinant Factor VIIa ) for severe intraoperative and postoperative bleeding .', {'entities': [(227, 241, 'B_Disease'), (242, 245, 'I_Disease'), (246, 259, 'I_Disease'), (260, 268, 'I_Disease')]}], ['RESULTS : Unexpectedly high concentrations of argatroban were measured in these samples ( range , 0 - 32 microg / mL ) , and a prolonged plasma argatroban half life ( t ( 1 / 2 ) ) of 514 minutes was observed ( published elimination t ( 1 / 2 ) is 39 - 51 minutes [ < or = 181 minutes with hepatic impairment ] ) .', {'entities': [(290, 297, 'B_Disease'), (298, 308, 'I_Disease')]}], [\"CONCLUSIONS : Correlation of plasma argatroban concentration versus the patient ' s coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient ' s extended coagulopathy .\", {'entities': [(235, 247, 'B_Disease')]}], ['This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy .', {'entities': [(103, 115, 'B_Disease')]}], ['The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor : a double - blind placebo - controlled and randomized study .', {'entities': [(48, 54, 'B_Disease'), (55, 66, 'I_Disease')]}], ['OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .', {'entities': [(108, 114, 'B_Disease'), (115, 126, 'I_Disease'), (129, 131, 'B_Disease'), (200, 202, 'B_Disease')]}], ['Efficacy was evaluated using the Clinical Global Impression - Sexual Function ( CGI - SF ; the primary outcome measure ) , the International Index of Erectile Function ( IIEF ) , Arizona Sexual Experience Scale ( ASEX ) , and Erectile Dysfunction Inventory of Treatment Satisfaction ( EDITS ) ( secondary outcome measures ) .', {'entities': [(226, 234, 'B_Disease'), (235, 246, 'I_Disease')]}], ['In linear regression analyses the CGI - SF score was not affected significantly by the duration of SD , type of SSRI used and age .', {'entities': [(99, 101, 'B_Disease')]}], ['CONCLUSIONS : Bupropion is an effective treatment for male SD induced by SSRIs .', {'entities': [(59, 61, 'B_Disease')]}], ['Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy .', {'entities': [(14, 22, 'B_Disease'), (142, 150, 'B_Disease')]}], ['In this study , we investigated the therapeutic potential of bone marrow mononuclear cells ( BMCs ) in a model of epilepsy induced by pilocarpine in rats .', {'entities': [(114, 122, 'B_Disease')]}], ['BMCs obtained from green fluorescent protein ( GFP ) transgenic mice or rats were transplanted intravenously after induction of status epilepticus ( SE ) .', {'entities': [(128, 134, 'B_Disease'), (135, 146, 'I_Disease'), (149, 151, 'B_Disease')]}], [\"Spontaneous recurrent seizures ( SRS ) were monitored using Racine ' s seizure severity scale .\", {'entities': [(0, 11, 'B_Disease'), (12, 21, 'I_Disease'), (22, 30, 'I_Disease'), (33, 36, 'B_Disease'), (71, 78, 'B_Disease')]}], ['All of the rats in the saline - treated epileptic control group developed SRS , whereas none of the BMC - treated epileptic animals had seizures in the short term ( 15 days after transplantation ) , regardless of the BMC source .', {'entities': [(40, 49, 'B_Disease'), (74, 77, 'B_Disease'), (114, 123, 'B_Disease'), (136, 144, 'B_Disease')]}], ['Over the long - term chronic phase ( 120 days after transplantation ) , only 25 % of BMC - treated epileptic animals had seizures , but with a lower frequency and duration compared to the epileptic control group .', {'entities': [(99, 108, 'B_Disease'), (121, 129, 'B_Disease'), (188, 197, 'B_Disease')]}], ['At hippocampal Schaeffer collateral - CA1 synapses , long - term potentiation was preserved in BMC - transplanted rats compared to epileptic controls .', {'entities': [(131, 140, 'B_Disease')]}], ['The donor - derived GFP ( + ) cells were rarely found in the brains of transplanted epileptic rats .', {'entities': [(84, 93, 'B_Disease')]}], ['In conclusion , treatment with BMCs can prevent the development of chronic seizures , reduce neuronal loss , and influence the reorganization of the hippocampal neuronal network .', {'entities': [(75, 83, 'B_Disease'), (93, 101, 'B_Disease'), (102, 106, 'I_Disease')]}], ['OBJECTIVE : The purpose of the present study was to determine the effect of morning - dosed modafinil on sleep and daytime sleepiness in chronic cocaine users .', {'entities': [(115, 122, 'B_Disease'), (123, 133, 'I_Disease')]}], ['Modafinil was associated with increased daytime sleep latency , as measured by the Multiple Sleep Latency Test , and a nearly significant decrease in subjective daytime sleepiness .', {'entities': [(161, 168, 'B_Disease'), (169, 179, 'I_Disease')]}], ['CONCLUSIONS : Morning - dosed modafinil promotes nocturnal sleep , normalizes sleep architecture , and decreases daytime sleepiness in abstinent cocaine users .', {'entities': [(113, 120, 'B_Disease'), (121, 131, 'I_Disease')]}], ['Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( MP ) , duration of the test , mitral regurgitation ( MR ) and the MZ dose .', {'entities': [(104, 110, 'B_Disease'), (113, 127, 'B_Disease'), (130, 132, 'B_Disease'), (160, 166, 'B_Disease'), (167, 180, 'I_Disease'), (183, 185, 'B_Disease')]}], ['Mild hypoxia ( SO2 < 90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 ( 5 . 8 % ) due to hypoxia caused by MZ use .', {'entities': [(5, 12, 'B_Disease'), (111, 118, 'B_Disease'), (132, 138, 'B_Disease'), (139, 150, 'I_Disease'), (198, 205, 'B_Disease')]}], ['Transient hypotension ( SAP < 90mmHg ) occurred in 1 patient ( 0 . 7 % ) .', {'entities': [(10, 21, 'B_Disease')]}], ['The multivariate analysis showed that severe MR , MP ( EF < 45 % ) and high doses of MZ ( > 5mg ) were associated with events ( p < 0 . 001 ) .', {'entities': [(45, 47, 'B_Disease'), (50, 52, 'B_Disease')]}], ['The EF was 40 % , in the group with MP and 44 % in the group with severe MR and it can be a factor associated with clinical events in the last group .', {'entities': [(36, 38, 'B_Disease'), (73, 75, 'B_Disease')]}], ['Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina .', {'entities': [(95, 102, 'B_Disease'), (103, 109, 'I_Disease')]}], ['The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris ( control group ) .', {'entities': [(97, 104, 'B_Disease'), (105, 111, 'I_Disease'), (142, 147, 'B_Disease'), (148, 152, 'I_Disease'), (175, 181, 'B_Disease'), (182, 190, 'I_Disease')]}], ['In all patients with variant angina , coronary spasm was provoked at a mean dose of 28 + / - 13 micrograms ( mean + / - SD ) .', {'entities': [(21, 28, 'B_Disease'), (29, 35, 'I_Disease'), (38, 46, 'B_Disease'), (47, 52, 'I_Disease')]}], ['In the control group neither ischemic ST change nor localized spasm occurred .', {'entities': [(62, 67, 'B_Disease')]}], ['These results suggest that spasm provocation tests , which use an intracoronary injection of a relatively low dose of methylergonovine , have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries .', {'entities': [(27, 32, 'B_Disease'), (164, 171, 'B_Disease'), (172, 178, 'I_Disease')]}], ['Oral manifestations of \" meth mouth \" : a case report .', {'entities': [(25, 29, 'B_Disease'), (30, 35, 'I_Disease')]}], ['AIM : The aim of the documentation of this clinical case is to make clinicians aware of \" meth mouth \" and the medical risks associated with this serious condition .', {'entities': [(90, 94, 'B_Disease'), (95, 100, 'I_Disease')]}], ['BACKGROUND : Methamphetamine is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , hypertension , hallucinations , and violent behavior .', {'entities': [(157, 164, 'B_Disease'), (165, 177, 'I_Disease'), (180, 192, 'B_Disease'), (195, 209, 'B_Disease'), (216, 223, 'B_Disease'), (224, 232, 'I_Disease')]}], ['Dental patients abusing methamphetamine can present with poor oral hygiene , xerostomia , rampant caries ( \" meth mouth \" ) , and excessive tooth wear .', {'entities': [(77, 87, 'B_Disease'), (98, 104, 'B_Disease'), (109, 113, 'B_Disease'), (114, 119, 'I_Disease'), (140, 145, 'B_Disease'), (146, 150, 'I_Disease')]}], ['CASE DESCRIPTION : A 30 - year - old Caucasian woman presented with dental pain , bad breath , and self - reported poor esthetics .', {'entities': [(75, 79, 'B_Disease'), (82, 85, 'B_Disease'), (86, 92, 'I_Disease')]}], ['A comprehensive examination including her medical history , panoramic radiograph , and intraoral examination revealed 19 carious lesions , which is not very common for a healthy adult .', {'entities': [(121, 128, 'B_Disease'), (129, 136, 'I_Disease')]}], ['She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug .', {'entities': [(89, 96, 'B_Disease'), (97, 105, 'I_Disease')]}], ['SUMMARY : The patient \\' s medical and dental histories along with radiographic and clinical findings lead to a diagnosis of \" meth mouth . \" Although three different dental treatment modalities ( either conventional or implant - supported ) have been offered to the patient since August 2007 , the patient has yet to initiate any treatment .', {'entities': [(126, 130, 'B_Disease'), (131, 136, 'I_Disease')]}], ['CLINICAL SIGNIFICANCE : This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines .', {'entities': [(74, 78, 'B_Disease'), (79, 84, 'I_Disease')]}], ['Antituberculosis therapy - induced acute liver failure : magnitude , profile , prognosis , and predictors of outcome .', {'entities': [(35, 40, 'B_Disease'), (41, 46, 'I_Disease'), (47, 54, 'I_Disease')]}], ['Antituberculosis therapy ( ATT ) - associated acute liver failure ( ATT - ALF ) is the commonest drug - induced ALF in South Asia .', {'entities': [(46, 51, 'B_Disease'), (52, 57, 'I_Disease'), (58, 65, 'I_Disease'), (74, 77, 'B_Disease'), (112, 115, 'B_Disease')]}], ['Prospective studies on ATT - ALF are lacking .', {'entities': [(29, 32, 'B_Disease')]}], ['The current study prospectively evaluated the magnitude , clinical course , outcome , and prognostic factors in ATT - ALF .', {'entities': [(118, 121, 'B_Disease')]}], ['From January 1986 to January 2009 , 1223 consecutive ALF patients were evaluated : ATT alone was the cause in 70 ( 5 . 7 % ) patients .', {'entities': [(53, 56, 'B_Disease')]}], ['Another 15 ( 1 . 2 % ) had ATT and simultaneous hepatitis virus infection .', {'entities': [(48, 57, 'B_Disease'), (58, 63, 'I_Disease'), (64, 73, 'I_Disease')]}], ['In 44 ( 62 . 8 % ) patients , ATT was prescribed empirically without definitive evidence of tuberculosis .', {'entities': [(92, 104, 'B_Disease')]}], ['ATT - ALF patients were younger ( 32 . 87 [ + / - 15 . 8 ] years ) , and 49 ( 70 % ) of them were women .', {'entities': [(6, 9, 'B_Disease')]}], ['Most had hyperacute presentation ; the median icterus encephalopathy interval was 4 . 5 ( 0 - 30 ) days .', {'entities': [(46, 53, 'B_Disease'), (54, 68, 'B_Disease')]}], ['The median duration of ATT before ALF was 30 ( 7 - 350 ) days .', {'entities': [(34, 37, 'B_Disease')]}], ['At presentation , advanced encephalopathy and cerebral edema were present in 51 ( 76 % ) and 29 ( 41 . 4 % ) patients , respectively .', {'entities': [(27, 41, 'B_Disease'), (46, 54, 'B_Disease'), (55, 60, 'I_Disease')]}], ['Gastrointestinal bleed , seizures , infection , and acute renal failure were documented in seven ( 10 % ) , five ( 7 . 1 % ) , 26 ( 37 . 1 % ) , and seven ( 10 % ) patients , respectively .', {'entities': [(0, 16, 'B_Disease'), (17, 22, 'I_Disease'), (25, 33, 'B_Disease'), (36, 45, 'B_Disease'), (52, 57, 'B_Disease'), (58, 63, 'I_Disease'), (64, 71, 'I_Disease')]}], ['Compared with hepatitis E virus ( HEV ) and non - A non - E - induced ALF , ATT - ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes .', {'entities': [(14, 23, 'B_Disease'), (24, 25, 'I_Disease'), (70, 73, 'B_Disease'), (82, 85, 'B_Disease')]}], ['The mortality rate among patients with ATT - ALF was high ( 67 . 1 % , n = 47 ) , and only 23 ( 32 . 9 % ) patients recovered with medical treatment .', {'entities': [(45, 48, 'B_Disease')]}], ['In multivariate analysis , three factors independently predicted mortality : serum bilirubin ( > or = 10 . 8 mg / dL ) , prothrombin time ( PT ) prolongation ( > or = 26 seconds ) , and grade III / IV encephalopathy at presentation .', {'entities': [(201, 215, 'B_Disease')]}], ['CONCLUSION : ATT - ALF constituted 5 . 7 % of ALF at our center and had a high mortality rate .', {'entities': [(19, 22, 'B_Disease'), (46, 49, 'B_Disease')]}], ['Design and analysis of the HYPREN - trial : safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure .', {'entities': [(125, 135, 'B_Disease'), (136, 141, 'I_Disease'), (142, 149, 'I_Disease')]}], ['Since the introduction of angiotensin converting enzyme ( ACE ) inhibitors into the adjunctive treatment of patients with congestive heart failure , cases of severe hypotension , especially on the first day of treatment , have occasionally been reported .', {'entities': [(122, 132, 'B_Disease'), (133, 138, 'I_Disease'), (139, 146, 'I_Disease'), (165, 176, 'B_Disease')]}], ['To assess the safety of the ACE inhibitor enalapril a multicenter , randomized , prazosin - controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment .', {'entities': [(178, 189, 'B_Disease')]}], ['Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension ( 5 . 2 % ) than the patients who received prazosin ( 12 . 9 % ) .', {'entities': [(104, 115, 'B_Disease')]}], ['Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution .', {'entities': [(0, 7, 'B_Disease'), (8, 15, 'I_Disease'), (16, 22, 'I_Disease'), (23, 36, 'I_Disease'), (57, 62, 'B_Disease'), (63, 76, 'I_Disease'), (77, 85, 'I_Disease')]}], ['Central nervous system ( CNS ) complications during treatment of childhood acute lymphoblastic leukemia ( ALL ) remain a challenging clinical problem .', {'entities': [(0, 7, 'B_Disease'), (8, 15, 'I_Disease'), (16, 22, 'I_Disease'), (23, 24, 'I_Disease'), (25, 28, 'I_Disease'), (29, 30, 'I_Disease'), (31, 44, 'I_Disease'), (75, 80, 'B_Disease'), (81, 94, 'I_Disease'), (95, 103, 'I_Disease'), (106, 109, 'B_Disease')]}], ['This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution , focusing on clinical , radiological , and electrophysiological findings .', {'entities': [(37, 49, 'B_Disease'), (50, 63, 'I_Disease'), (71, 74, 'B_Disease')]}], ['Exclusion criteria included CNS leukemic infiltration at diagnosis , therapy - related peripheral neuropathy , late - onset encephalopathy , or long - term neurocognitive defects .', {'entities': [(32, 40, 'B_Disease'), (41, 53, 'I_Disease'), (87, 97, 'B_Disease'), (98, 108, 'I_Disease'), (124, 138, 'B_Disease'), (156, 170, 'B_Disease'), (171, 178, 'I_Disease')]}], ['During a 9 - year period , we retrospectively collected 27 neurological events ( 11 % ) in as many patients , from 253 children enrolled in the ALL front - line protocol .', {'entities': [(144, 147, 'B_Disease')]}], ['CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose methotrexate toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .', {'entities': [(48, 67, 'B_Disease'), (90, 96, 'B_Disease'), (109, 117, 'B_Disease'), (118, 122, 'I_Disease'), (123, 131, 'I_Disease'), (169, 177, 'B_Disease'), (202, 215, 'B_Disease'), (216, 228, 'I_Disease'), (229, 236, 'I_Disease'), (237, 246, 'I_Disease')]}], ['In conclusion , CNS complications are frequent events during ALL therapy , and require rapid detection and prompt treatment to limit permanent damage .', {'entities': [(61, 64, 'B_Disease')]}], ['Cocaine causes memory and learning impairments in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by topiramate .', {'entities': [(15, 21, 'B_Disease'), (22, 25, 'I_Disease'), (26, 34, 'I_Disease'), (35, 46, 'I_Disease')]}], ['Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced - behaviour is poorly understood .', {'entities': [(53, 61, 'B_Disease')]}], ['Nuclear factor kappa B ( NFkappaB ) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms .', {'entities': [(136, 144, 'B_Disease')]}], ['Therefore NFkappaB activity , oxidative stress , neuronal nitric oxide synthase ( nNOS ) activity , spatial learning and memory as well as the effect of topiramate , a previously proposed therapy for cocaine addiction , were evaluated in an experimental model of cocaine administration in rats .', {'entities': [(200, 207, 'B_Disease'), (208, 217, 'I_Disease')]}], ['Efficacy and safety of asenapine in a placebo - and haloperidol - controlled trial in patients with acute exacerbation of schizophrenia .', {'entities': [(122, 135, 'B_Disease')]}], ['Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features .', {'entities': [(92, 105, 'B_Disease'), (112, 117, 'B_Disease'), (152, 159, 'B_Disease'), (160, 161, 'I_Disease'), (162, 170, 'I_Disease'), (187, 196, 'B_Disease')]}], ['In a double - blind 6 - week trial , 458 patients with acute schizophrenia were randomly assigned to fixed - dose treatment with asenapine at 5 mg twice daily ( BID ) , asenapine at 10 mg BID , placebo , or haloperidol at 4 mg BID ( to verify assay sensitivity ) .', {'entities': [(61, 74, 'B_Disease')]}], ['Extrapyramidal symptoms reported as AEs occurred in 15 % and 18 % , 34 % , and 10 % of the asenapine at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .', {'entities': [(0, 14, 'B_Disease'), (15, 23, 'I_Disease')]}], ['Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol ; greater contrasts were seen in AEs , especially extrapyramidal symptoms .', {'entities': [(135, 149, 'B_Disease'), (150, 158, 'I_Disease')]}], ['Salvage therapy with nelarabine , etoposide , and cyclophosphamide in relapsed / refractory paediatric T - cell lymphoblastic leukaemia and lymphoma .', {'entities': [(103, 104, 'B_Disease'), (105, 106, 'I_Disease'), (107, 111, 'I_Disease'), (112, 125, 'I_Disease'), (126, 135, 'I_Disease'), (136, 139, 'I_Disease'), (140, 148, 'I_Disease')]}], ['A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T - cell leukaemia or lymphoma .', {'entities': [(218, 219, 'B_Disease'), (220, 221, 'I_Disease'), (222, 226, 'I_Disease'), (227, 236, 'I_Disease'), (237, 239, 'I_Disease'), (240, 248, 'I_Disease')]}], ['The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain .', {'entities': [(95, 105, 'B_Disease'), (110, 125, 'B_Disease'), (126, 130, 'I_Disease')]}], ['Haematological toxicity was greater for the combination than AraG alone , although median time to neutrophil and platelet recovery was consistent with other salvage therapies .', {'entities': [(0, 14, 'B_Disease'), (15, 23, 'I_Disease')]}], ['Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide , although neurological toxicity must be closely monitored .', {'entities': [(129, 141, 'B_Disease'), (142, 150, 'I_Disease')]}], ['Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues .', {'entities': [(46, 58, 'B_Disease'), (62, 67, 'B_Disease')]}], ['Thermal enhancement of Adriamycin - mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model .', {'entities': [(82, 92, 'B_Disease'), (107, 119, 'B_Disease')]}], ['Antitumor activity was studied using a tumor growth delay assay .', {'entities': [(39, 44, 'B_Disease')]}], ['Acute normal tissue toxicities ( i . e . , leukopenia and thrombocytopenia ) and late normal tissue toxicities ( i . e . , myocardial and kidney injury ) were evaluated by functional / physiological assays and by morphological techniques .', {'entities': [(20, 30, 'B_Disease'), (43, 53, 'B_Disease'), (58, 74, 'B_Disease'), (100, 110, 'B_Disease'), (123, 133, 'B_Disease'), (134, 137, 'I_Disease'), (138, 144, 'I_Disease'), (145, 151, 'I_Disease')]}], ['Whole body hyperthermia ( 120 min at 41 . 5 degrees C ) enhanced both Adriamycin - mediated antitumor activity and toxic side effects .', {'entities': [(11, 23, 'B_Disease')]}], ['Thermal enhancement ratios estimated for \" acute \" hematological changes were 1 . 3 , whereas those estimated for \" late \" damage ( based on morphological cardiac and renal lesions ) varied between 2 . 4 and 4 . 3 .', {'entities': [(155, 162, 'B_Disease'), (163, 166, 'I_Disease'), (167, 172, 'I_Disease'), (173, 180, 'I_Disease')]}], ['Thus , while whole body hyperthermia enhances Adriamycin - mediated antitumor effect , normal tissue toxicity is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .', {'entities': [(24, 36, 'B_Disease'), (101, 109, 'B_Disease')]}], ['Permeability , ultrastructural changes , and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis .', {'entities': [(137, 146, 'B_Disease')]}], ['BACKGROUND / AIMS : It is still unclear what happens in the glomerulus when proteinuria starts .', {'entities': [(76, 87, 'B_Disease')]}], ['Using puromycin aminonucleoside nephrosis ( PAN ) rats , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules nephrin , a - actinin , dendrin , and plekhh2 , the last two of which were only recently discovered in podocytes .', {'entities': [(32, 41, 'B_Disease')]}], ['RESULTS : By day 2 , some patchy foot process effacement , but no proteinuria , appeared .', {'entities': [(66, 77, 'B_Disease')]}], ['By day 4 , foot process effacement was complete and proteinuria appeared in parallel with signs of size barrier damage .', {'entities': [(52, 63, 'B_Disease')]}], ['CONCLUSIONS : PAN glomeruli already showed significant pathology by day 4 , despite relatively mild proteinuria .', {'entities': [(100, 111, 'B_Disease')]}], ['A novel , multiple symptom model of obsessive - compulsive - like behaviors in animals .', {'entities': [(36, 45, 'B_Disease'), (46, 47, 'I_Disease'), (48, 58, 'I_Disease'), (59, 60, 'I_Disease'), (61, 65, 'I_Disease'), (66, 75, 'I_Disease')]}], ['BACKGROUND : Current animal models of obsessive - compulsive disorder ( OCD ) typically involve acute , drug - induced symptom provocation or a genetic association with stereotypies or anxiety .', {'entities': [(38, 47, 'B_Disease'), (48, 49, 'I_Disease'), (50, 60, 'I_Disease'), (61, 69, 'I_Disease'), (72, 75, 'B_Disease'), (185, 192, 'B_Disease')]}], ['None of these current models demonstrate multiple OCD - like behaviors .', {'entities': [(50, 53, 'B_Disease')]}], ['RESULTS : Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , hoarding , and corticostriatal dysfunction .', {'entities': [(127, 134, 'B_Disease'), (179, 189, 'B_Disease'), (190, 203, 'I_Disease'), (299, 305, 'B_Disease'), (306, 316, 'I_Disease'), (354, 362, 'B_Disease'), (369, 384, 'B_Disease'), (385, 396, 'I_Disease')]}], ['CONCLUSIONS : This is the first demonstration of multiple symptoms consistent with an OCD - like profile in animals .', {'entities': [(86, 89, 'B_Disease')]}], ['Moreover , these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD .', {'entities': [(120, 123, 'B_Disease')]}], ['This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease - like systems permanently , which could have implications for current and future therapeutic strategies for this and other psychiatric disorders .', {'entities': [(20, 23, 'B_Disease'), (226, 237, 'B_Disease'), (238, 247, 'I_Disease')]}], ['Elevation of ADAM10 , ADAM17 , MMP - 2 and MMP - 9 expression with media degeneration features CaCl2 - induced thoracic aortic aneurysm in a rat model .', {'entities': [(111, 119, 'B_Disease'), (120, 126, 'I_Disease'), (127, 135, 'I_Disease')]}], ['PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( CaCl ( 2 ) ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .', {'entities': [(62, 70, 'B_Disease'), (71, 77, 'I_Disease'), (78, 86, 'I_Disease'), (89, 92, 'B_Disease'), (140, 148, 'B_Disease'), (149, 155, 'I_Disease'), (320, 323, 'B_Disease')]}], ['CONCLUSION : This study establishes a TAA model by periarterial CaCl ( 2 ) exposure in rats , and demonstrates a significant elevation of expression of MMP - 2 , MMP - 9 , ADAM10 and ADAM17 in the pathogenesis of vascular remodeling .', {'entities': [(38, 41, 'B_Disease')]}], ['Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy .', {'entities': [(32, 37, 'B_Disease')]}], ['Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus ( OP ) poisons .', {'entities': [(31, 36, 'B_Disease')]}], ['Here , we present a similar incident in a severely depressed patient who received electroconvulsive therapy ( ECT ) .', {'entities': [(51, 60, 'B_Disease')]}], ['Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team .', {'entities': [(10, 15, 'B_Disease')]}], ['Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats .', {'entities': [(21, 30, 'B_Disease'), (31, 42, 'I_Disease')]}], ['The antiepileptic drugs , phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use .', {'entities': [(83, 92, 'B_Disease'), (93, 103, 'I_Disease')]}], ['The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs .', {'entities': [(98, 107, 'B_Disease'), (108, 118, 'I_Disease')]}], ['Therefore , the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone - and carbamazepine - induced cognitive impairment and oxidative stress in rats .', {'entities': [(155, 164, 'B_Disease'), (165, 175, 'I_Disease')]}], ['The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress .', {'entities': [(87, 97, 'B_Disease'), (98, 100, 'I_Disease'), (101, 109, 'I_Disease'), (110, 113, 'I_Disease'), (114, 120, 'I_Disease')]}], ['Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs .', {'entities': [(50, 59, 'B_Disease'), (60, 70, 'I_Disease')]}], ['These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations .', {'entities': [(73, 86, 'B_Disease'), (87, 89, 'I_Disease'), (90, 99, 'I_Disease'), (100, 109, 'I_Disease')]}], ['The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs .', {'entities': [(154, 163, 'B_Disease'), (164, 174, 'I_Disease')]}], ['Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia ?', {'entities': [(67, 76, 'B_Disease'), (77, 83, 'I_Disease')]}], ['BACKGROUND / AIMS : Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis .', {'entities': [(181, 190, 'B_Disease')]}], ['We aimed to investigate whether there is a relation between hemoglobin , haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia .', {'entities': [(185, 191, 'B_Disease')]}], ['METHODS : Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin .', {'entities': [(28, 39, 'B_Disease'), (40, 48, 'I_Disease'), (49, 53, 'I_Disease'), (54, 63, 'I_Disease'), (64, 65, 'I_Disease'), (66, 71, 'I_Disease')]}], ['CONCLUSION : This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation .', {'entities': [(135, 141, 'B_Disease'), (159, 168, 'B_Disease'), (169, 170, 'I_Disease')]}], ['Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization .', {'entities': [(23, 27, 'B_Disease')]}], ['Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution .', {'entities': [(37, 41, 'B_Disease')]}], ['To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection , we performed a blinded randomized study in patients undergoing cardiac catheterization .', {'entities': [(123, 127, 'B_Disease')]}], ['Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area .', {'entities': [(55, 59, 'B_Disease')]}], ['The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine ( 2 . 7 + / - 1 . 9 vs . 3 . 8 + / - 2 . 2 , P = 0 . 03 ) .', {'entities': [(9, 13, 'B_Disease')]}], ['The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues .', {'entities': [(152, 156, 'B_Disease')]}], ['Effect of L - alpha - glyceryl - phosphorylcholine on amnesia caused by scopolamine .', {'entities': [(54, 61, 'B_Disease')]}], ['The present study was carried out to test the effects of L - alpha - glycerylphosphorylcholine ( L - alpha - GFC ) on memory impairment induced by scopolamine in man .', {'entities': [(118, 124, 'B_Disease'), (125, 135, 'I_Disease')]}], ['The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine .', {'entities': [(72, 82, 'B_Disease'), (83, 85, 'I_Disease'), (86, 95, 'I_Disease'), (96, 99, 'I_Disease'), (100, 106, 'I_Disease')]}], ['IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5 - fluorouracil ( 5 - FU ) , have been the mainstay of treatment for several solid tumors , including colorectal , breast and head and neck cancers , for > 40 years .', {'entities': [(144, 150, 'B_Disease'), (163, 173, 'B_Disease'), (174, 175, 'I_Disease'), (176, 182, 'I_Disease'), (183, 186, 'I_Disease'), (187, 191, 'I_Disease'), (192, 195, 'I_Disease'), (196, 200, 'I_Disease'), (201, 208, 'I_Disease')]}], ['WHAT THE READER WILL GAIN : The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age , renal and kidney disease .', {'entities': [(156, 161, 'B_Disease'), (162, 165, 'I_Disease'), (166, 172, 'I_Disease'), (173, 180, 'I_Disease')]}], ['It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers .', {'entities': [(93, 103, 'B_Disease'), (104, 105, 'I_Disease'), (106, 112, 'I_Disease'), (113, 114, 'I_Disease'), (115, 133, 'I_Disease'), (134, 135, 'I_Disease'), (136, 143, 'I_Disease'), (144, 145, 'I_Disease'), (146, 151, 'I_Disease'), (152, 156, 'I_Disease'), (157, 160, 'I_Disease'), (161, 165, 'I_Disease'), (166, 169, 'I_Disease'), (170, 174, 'I_Disease'), (175, 182, 'I_Disease')]}], ['The most commonly reported toxic effects of capecitabine are diarrhea , nausea , vomiting , stomatitis and hand - foot syndrome .', {'entities': [(61, 69, 'B_Disease'), (72, 78, 'B_Disease'), (81, 89, 'B_Disease'), (92, 102, 'B_Disease'), (107, 111, 'B_Disease'), (112, 113, 'I_Disease'), (114, 118, 'I_Disease'), (119, 127, 'I_Disease')]}], ['Capecitabine has a well - established safety profile and can be given safely to patients with advanced age , hepatic and renal dysfunctions .', {'entities': [(109, 116, 'B_Disease'), (117, 120, 'I_Disease'), (121, 126, 'I_Disease'), (127, 139, 'I_Disease')]}], [\"Levodopa - induced dyskinesias in patients with Parkinson ' s disease : filling the bench - to - bedside gap .\", {'entities': [(19, 30, 'B_Disease'), (48, 57, 'B_Disease'), (58, 59, 'I_Disease'), (60, 61, 'I_Disease'), (62, 69, 'I_Disease')]}], [\"Levodopa is the most effective drug for the treatment of Parkinson ' s disease .\", {'entities': [(57, 66, 'B_Disease'), (67, 68, 'I_Disease'), (69, 70, 'I_Disease'), (71, 78, 'I_Disease')]}], ['However , the long - term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias .', {'entities': [(109, 120, 'B_Disease')]}], ['Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa - induced dyskinesias , their pathogenesis is still unclear .', {'entities': [(157, 168, 'B_Disease')]}], [\"In recent years , evidence from animal models of Parkinson ' s disease has provided important information to understand the effect of specific receptor and post - receptor molecular mechanisms underlying the development of dyskinetic movements .\", {'entities': [(49, 58, 'B_Disease'), (59, 60, 'I_Disease'), (61, 62, 'I_Disease'), (63, 70, 'I_Disease'), (223, 233, 'B_Disease'), (234, 243, 'I_Disease')]}], ['Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , dopamine receptor subtypes , ionotropic and metabotropic glutamate receptors , and non - dopaminergic neurotransmitter systems in the pathophysiology of levodopa - induced dyskinesias .', {'entities': [(321, 332, 'B_Disease')]}], ['Effects of pallidal neurotensin on haloperidol - induced parkinsonian catalepsy : behavioral and electrophysiological studies .', {'entities': [(57, 69, 'B_Disease'), (70, 79, 'I_Disease')]}], ['The present study aimed to investigate the effects of pallidal neurotensin on haloperidol - induced parkinsonian symptoms .', {'entities': [(100, 112, 'B_Disease'), (113, 121, 'I_Disease')]}], ['RESULTS : Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol - induced parkinsonian catalepsy in rats .', {'entities': [(101, 113, 'B_Disease'), (114, 123, 'I_Disease')]}], ['Carmofur - induced organic mental disorders .', {'entities': [(19, 26, 'B_Disease'), (27, 33, 'I_Disease'), (34, 43, 'I_Disease')]}], ['Organic mental disorder was observed in a 29 - year - old female in the prognostic period after the onset of carmofur - induced leukoencephalopathy .', {'entities': [(0, 7, 'B_Disease'), (8, 14, 'I_Disease'), (15, 23, 'I_Disease'), (128, 147, 'B_Disease')]}], ['Symptoms such as euphoria , emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM - III - R .', {'entities': [(107, 114, 'B_Disease'), (115, 126, 'I_Disease'), (127, 135, 'I_Disease')]}], ['It is referred to as a frontal lobe syndrome .', {'entities': [(23, 30, 'B_Disease'), (31, 35, 'I_Disease'), (36, 44, 'I_Disease')]}], ['Consequently , carmofur - induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state .', {'entities': [(34, 53, 'B_Disease'), (79, 86, 'B_Disease'), (87, 98, 'I_Disease'), (99, 107, 'I_Disease')]}], ['It may be attributed to the structural damage to the frontal lobe .', {'entities': [(28, 38, 'B_Disease'), (39, 45, 'I_Disease'), (46, 48, 'I_Disease'), (49, 52, 'I_Disease'), (53, 60, 'I_Disease'), (61, 65, 'I_Disease')]}], ['Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy .', {'entities': [(64, 69, 'B_Disease')]}], ['We determined the BChE activity and the BCHE genotype using molecular genetic methods , the duration of apnea , time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used .', {'entities': [(104, 109, 'B_Disease')]}], ['The duration of apnea was compared with published data on normal subjects .', {'entities': [(16, 21, 'B_Disease')]}], ['The duration of apnea was 5 - 15 min compared with 3 - 5 . 3 min from the literature .', {'entities': [(16, 21, 'B_Disease')]}], ['CONCLUSION : eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE , indicating that this is the possible reason for a prolonged period of apnea .', {'entities': [(184, 189, 'B_Disease')]}], ['Perhexiline maleate and peripheral neuropathy .', {'entities': [(24, 34, 'B_Disease'), (35, 45, 'I_Disease')]}], ['Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate , a drug widely used in France ( and in clinical trials in the United States ) for the prophylactic treatment of angina pectoris .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (204, 210, 'B_Disease'), (211, 219, 'I_Disease')]}], ['In 24 patients with this complication , the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder .', {'entities': [(143, 156, 'B_Disease'), (157, 165, 'I_Disease')]}], ['The underlying mechanism causing the neuropathy is not yet fully known , although some evidence indicates that it may be a lipid storage process .', {'entities': [(37, 47, 'B_Disease')]}], [\"A Phase I study of intravenous ( IV ) bolus 4 ' - 0 - tetrahydropyranyladriamycin ( Pirarubicin ) was done in 55 patients in good performance status with refractory tumors .\", {'entities': [(165, 171, 'B_Disease')]}], ['Twenty - six had minimal prior therapy ( good risk ) , 23 had extensive prior therapy ( poor risk ) , and six had renal and / or hepatic dysfunction .', {'entities': [(114, 119, 'B_Disease'), (120, 123, 'I_Disease'), (124, 125, 'I_Disease'), (126, 128, 'I_Disease'), (129, 136, 'I_Disease'), (137, 148, 'I_Disease')]}], ['The dose - limiting toxic effect was transient noncumulative granulocytopenia .', {'entities': [(61, 77, 'B_Disease')]}], ['Less frequent toxic effects included thrombocytopenia , anemia , nausea , mild alopecia , phlebitis , and mucositis .', {'entities': [(37, 53, 'B_Disease'), (56, 62, 'B_Disease'), (65, 71, 'B_Disease'), (79, 87, 'B_Disease'), (90, 99, 'B_Disease'), (106, 115, 'B_Disease')]}], ['Myelosuppression was more in patients with hepatic dysfunction .', {'entities': [(0, 16, 'B_Disease'), (43, 50, 'B_Disease'), (51, 62, 'I_Disease')]}], ['Activity was noted in mesothelioma , leiomyosarcoma , and basal cell carcinoma .', {'entities': [(22, 34, 'B_Disease'), (37, 51, 'B_Disease'), (58, 63, 'B_Disease'), (64, 68, 'I_Disease'), (69, 78, 'I_Disease')]}], ['Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine .', {'entities': [(0, 6, 'B_Disease'), (7, 10, 'I_Disease'), (11, 19, 'I_Disease'), (20, 28, 'I_Disease')]}], ['During an 18 - month period of study 41 hemodialyzed patients receiving desferrioxamine ( 10 - 40 mg / kg BW / 3 times weekly ) for the first time were monitored for detection of audiovisual toxicity .', {'entities': [(179, 190, 'B_Disease'), (191, 199, 'I_Disease')]}], ['6 patients presented clinical symptoms of visual or auditory toxicity .', {'entities': [(42, 48, 'B_Disease'), (49, 51, 'I_Disease'), (52, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['Visual toxicity was of retinal origin and was characterized by a tritan - type dyschromatopsy , sometimes associated with a loss of visual acuity and pigmentary retinal deposits .', {'entities': [(0, 6, 'B_Disease'), (7, 15, 'I_Disease'), (79, 93, 'B_Disease'), (122, 123, 'B_Disease'), (124, 128, 'I_Disease'), (129, 131, 'I_Disease'), (132, 138, 'I_Disease'), (139, 145, 'I_Disease'), (150, 160, 'B_Disease'), (161, 168, 'I_Disease'), (169, 177, 'I_Disease')]}], ['Auditory toxicity was characterized by a mid - to high - frequency neurosensorial hearing loss and the lesion was of the cochlear type .', {'entities': [(0, 8, 'B_Disease'), (9, 17, 'I_Disease'), (67, 81, 'B_Disease'), (82, 89, 'I_Disease'), (90, 94, 'I_Disease')]}], ['Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3 , and a complete reversal of hearing loss in 3 patients and partial recovery in 3 .', {'entities': [(146, 153, 'B_Disease'), (154, 158, 'I_Disease')]}], ['This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels .', {'entities': [(5, 13, 'B_Disease')]}], ['The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine .', {'entities': [(23, 34, 'B_Disease'), (35, 43, 'I_Disease')]}], ['Serial epilepsy caused by levodopa / carbidopa administration in two patients on hemodialysis .', {'entities': [(7, 15, 'B_Disease')]}], ['Two patients with similar clinical features are presented : both patients had chronic renal failure , on hemodialysis for many years but recently begun on a high - flux dialyzer ; both had been receiving a carbidopa / levodopa preparation ; and both had the onset of hallucinosis and recurrent seizures , which were refractory to anticonvulsants .', {'entities': [(78, 85, 'B_Disease'), (86, 91, 'I_Disease'), (92, 99, 'I_Disease'), (267, 279, 'B_Disease'), (294, 302, 'B_Disease')]}], ['Randomized , double - blind trial of mazindol in Duchenne dystrophy .', {'entities': [(49, 57, 'B_Disease'), (58, 67, 'I_Disease')]}], ['There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy .', {'entities': [(75, 83, 'B_Disease'), (87, 95, 'B_Disease'), (96, 105, 'I_Disease')]}], ['We conducted a 12 - month controlled trial of mazindol , a putative growth hormone secretion inhibitor , in 83 boys with Duchenne dystrophy .', {'entities': [(121, 129, 'B_Disease'), (130, 139, 'I_Disease')]}], ['The study was designed to have a power of greater than 0 . 90 to detect a slowing to 25 % of the expected rate of progression of weakness at P less than 0 . 05 .', {'entities': [(129, 137, 'B_Disease')]}], ['Side effects attributable to mazindol included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .', {'entities': [(47, 56, 'B_Disease'), (57, 65, 'I_Disease'), (77, 80, 'B_Disease'), (81, 86, 'I_Disease'), (131, 147, 'B_Disease'), (148, 156, 'I_Disease')]}], ['Mazindol doses not slow the progression of weakness in Duchenne dystrophy .', {'entities': [(43, 51, 'B_Disease'), (55, 63, 'B_Disease'), (64, 73, 'I_Disease')]}], ['Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial ( pre - test ) , and pre - test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .', {'entities': [(0, 7, 'B_Disease')]}], ['Similarly , pre - test scopolamine partially reversed the scopolamine - induced amnesia , but not significantly ; and pre - test cycloheximide failed to reverse the cycloheximide - induced amnesia .', {'entities': [(80, 87, 'B_Disease'), (189, 196, 'B_Disease')]}], ['In unanesthetized , spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine , 5 to 20 micrograms / kg , was inhibited or reversed by nalozone , 0 . 2 to 2 mg / kg .', {'entities': [(34, 46, 'B_Disease')]}], ['The hypotensive effect of 100 mg / kg alpha - methyldopa was also partially reversed by naloxone .', {'entities': [(4, 15, 'B_Disease')]}], ['In brain membranes from spontaneously hypertensive rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 ) M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .', {'entities': [(38, 50, 'B_Disease')]}], ['These findings indicate that in spontaneously hypertensive rats the effects of central alpha - adrenoceptor stimulation involve activation of opiate receptors .', {'entities': [(46, 58, 'B_Disease')]}], ['Neurotoxicity of halogenated hydroxyquinolines : clinical analysis of cases reported outside Japan .', {'entities': [(0, 13, 'B_Disease')]}], ['An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan .', {'entities': [(50, 60, 'B_Disease')]}], ['In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period .', {'entities': [(33, 45, 'B_Disease'), (46, 57, 'I_Disease'), (91, 105, 'B_Disease')]}], ['The most common manifestation , observed in 15 further cases , was isolated optic atrophy .', {'entities': [(76, 81, 'B_Disease'), (82, 89, 'I_Disease')]}], ['This was most frequently found in children , many of whom had received clioquinol as treatment for acrodermatitis enteropathica .', {'entities': [(99, 113, 'B_Disease'), (114, 127, 'I_Disease')]}], ['In the remaining cases , a combination of myelopathy , visual disturbance , and peripheral neuropathy was the most common manifestation .', {'entities': [(42, 52, 'B_Disease'), (55, 61, 'B_Disease'), (62, 73, 'I_Disease'), (80, 90, 'B_Disease'), (91, 101, 'I_Disease')]}], ['Isolated myelopathy or peripheral neuropathy , or these manifestations occurring together , were infrequent .', {'entities': [(9, 19, 'B_Disease'), (23, 33, 'B_Disease'), (34, 44, 'I_Disease')]}], ['The onset of all manifestations ( except toxic encephalopathy ) was usually subacute , with subsequent partial recovery .', {'entities': [(47, 61, 'B_Disease')]}], ['The full syndrome of subacute myelo - optic neuropathy was more frequent in women , but they tended to have taken greater quantities of the drug .', {'entities': [(30, 35, 'B_Disease'), (36, 37, 'I_Disease'), (38, 43, 'I_Disease'), (44, 54, 'I_Disease')]}], ['Prazosin - induced stress incontinence .', {'entities': [(19, 25, 'B_Disease'), (26, 38, 'I_Disease')]}], ['A case of genuine stress incontinence due to prazosin , a common antihypertensive drug , is presented .', {'entities': [(18, 24, 'B_Disease'), (25, 37, 'I_Disease')]}], ['Her incontinence resolved with the change of medication .', {'entities': [(4, 16, 'B_Disease')]}], ['Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery , because their incontinence may resolve spontaneously with a change in drug therapy .', {'entities': [(26, 32, 'B_Disease'), (33, 45, 'I_Disease'), (159, 171, 'B_Disease')]}], ['Myocardial infarction following sublingual administration of isosorbide dinitrate .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease')]}], ['A 78 - year - old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually .', {'entities': [(37, 45, 'B_Disease'), (67, 77, 'B_Disease'), (78, 88, 'I_Disease')]}], ['After detailing the course of events , we discuss the role of paradoxical coronary spasm and hypotension - mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency .', {'entities': [(83, 88, 'B_Disease'), (93, 104, 'B_Disease'), (116, 126, 'B_Disease'), (127, 135, 'I_Disease'), (172, 180, 'B_Disease'), (181, 189, 'I_Disease'), (190, 198, 'I_Disease'), (225, 230, 'B_Disease'), (231, 239, 'I_Disease'), (240, 253, 'I_Disease')]}], ['The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i . v . infusion of morphine ( mean 73 . 6 mg ) and five patients receiving a continuous extradural infusion of 0 . 25 % bupivacaine ( mean 192 mg ) in the 24 - h period following upper abdominal surgery .', {'entities': [(43, 49, 'B_Disease')]}], ['Both obstructive ( P less than 0 . 05 ) and central apnoea ( P less than 0 . 05 ) occurred more frequently in patients who had a morphine infusion .', {'entities': [(5, 16, 'B_Disease'), (17, 18, 'I_Disease'), (19, 20, 'I_Disease'), (21, 25, 'I_Disease'), (26, 30, 'I_Disease'), (31, 32, 'I_Disease'), (33, 34, 'I_Disease'), (35, 37, 'I_Disease'), (38, 39, 'I_Disease'), (40, 43, 'I_Disease'), (44, 51, 'I_Disease'), (52, 58, 'I_Disease')]}], ['There was also a higher incidence of tachyarrhythmias ( P less than 0 . 05 ) and ventricular ectopic beats ( P less than 0 . 05 ) in the morphine infusion group .', {'entities': [(37, 53, 'B_Disease'), (81, 92, 'B_Disease'), (93, 100, 'I_Disease'), (101, 106, 'I_Disease')]}], ['Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure .', {'entities': [(57, 68, 'B_Disease'), (69, 81, 'I_Disease'), (89, 100, 'B_Disease'), (101, 108, 'I_Disease')]}], ['Cardiac arrhythmias have frequently been reported in association with respiratory failure .', {'entities': [(0, 7, 'B_Disease'), (8, 19, 'I_Disease'), (70, 81, 'B_Disease'), (82, 89, 'I_Disease')]}], ['The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized .', {'entities': [(68, 75, 'B_Disease'), (76, 88, 'I_Disease'), (106, 117, 'B_Disease'), (118, 125, 'I_Disease')]}], ['The effects of aminophylline on the ventricular fibrillation threshold during normal acid - base conditions and during respiratory failure were studied in anesthetized open chest dogs .', {'entities': [(36, 47, 'B_Disease'), (48, 60, 'I_Disease'), (119, 130, 'B_Disease'), (131, 138, 'I_Disease')]}], ['The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle .', {'entities': [(4, 15, 'B_Disease'), (16, 28, 'I_Disease')]}], ['During the infusion of aminophylline , the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and carbon dioxide ( CO2 ) were kept within normal limits .', {'entities': [(43, 54, 'B_Disease'), (55, 67, 'I_Disease')]}], ['When respiratory failure was produced by hypoventilation ( pH 7 . 05 to 7 . 25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level .', {'entities': [(5, 16, 'B_Disease'), (17, 24, 'I_Disease'), (41, 56, 'B_Disease'), (193, 204, 'B_Disease'), (205, 217, 'I_Disease')]}], ['These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure , pharmacologic agents , particularly aminophylline , may play a significant role .', {'entities': [(98, 109, 'B_Disease'), (110, 121, 'I_Disease'), (125, 136, 'B_Disease'), (137, 144, 'I_Disease')]}], ['Pentoxifylline ( Trental ) does not inhibit dipyridamole - induced coronary hyperemia : implications for dipyridamole - thallium - 201 myocardial imaging .', {'entities': [(76, 85, 'B_Disease')]}], ['Dipyridamole - thallium - 201 imaging is often performed in patients unable to exercise because of peripheral vascular disease .', {'entities': [(99, 109, 'B_Disease'), (110, 118, 'I_Disease'), (119, 126, 'I_Disease')]}], ['Many of these patients are taking pentoxifylline ( Trental ) , a methylxanthine derivative which may improve intermittent claudication .', {'entities': [(109, 121, 'B_Disease'), (122, 134, 'I_Disease')]}], ['Whether pentoxifylline inhibits dipyridamole - induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .', {'entities': [(64, 73, 'B_Disease')]}], ['Neither dose of pentoxifylline significantly decreased the dipyridamole - induced hyperemia , while peak coronary blood flow was significantly lower after theophylline ( p less than 0 . 01 ) .', {'entities': [(82, 91, 'B_Disease')]}], ['We conclude that pentoxyifylline does not inhibit dipyridamole - induced coronary hyperemia even at high doses .', {'entities': [(82, 91, 'B_Disease')]}], [\"Cause of death among patients with Parkinson ' s disease : a rare mortality due to cerebral haemorrhage .\", {'entities': [(9, 14, 'B_Disease'), (35, 44, 'B_Disease'), (45, 46, 'I_Disease'), (47, 48, 'I_Disease'), (49, 56, 'I_Disease'), (83, 91, 'B_Disease'), (92, 103, 'I_Disease')]}], [\"Causes of death , with special reference to cerebral haemorrhage , among 240 patients with pathologically verified Parkinson ' s disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985 .\", {'entities': [(10, 15, 'B_Disease'), (44, 52, 'B_Disease'), (53, 64, 'I_Disease'), (115, 124, 'B_Disease'), (125, 126, 'I_Disease'), (127, 128, 'I_Disease'), (129, 136, 'I_Disease')]}], ['The leading causes of death were pneumonia and bronchitis ( 44 . 1 % ) , malignant neoplasms ( 11 . 6 % ) , heart diseases ( 4 . 1 % ) , cerebral infarction ( 3 . 7 % ) and septicaemia ( 3 . 3 % ) .', {'entities': [(22, 27, 'B_Disease'), (33, 42, 'B_Disease'), (47, 57, 'B_Disease'), (83, 92, 'B_Disease'), (108, 113, 'B_Disease'), (114, 122, 'I_Disease'), (137, 145, 'B_Disease'), (146, 156, 'I_Disease'), (173, 184, 'B_Disease')]}], ['Cerebral haemorrhage was the 11th most frequent cause of death , accounting for only 0 . 8 % of deaths among the patients , whereas it was the 5th most common cause of death among the Japanese general population in 1985 .', {'entities': [(0, 8, 'B_Disease'), (9, 20, 'I_Disease'), (57, 62, 'B_Disease'), (96, 102, 'B_Disease'), (168, 173, 'B_Disease')]}], [\"The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson ' s disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .\", {'entities': [(21, 29, 'B_Disease'), (30, 41, 'I_Disease'), (56, 61, 'B_Disease'), (79, 88, 'B_Disease'), (89, 90, 'I_Disease'), (91, 92, 'I_Disease'), (93, 100, 'I_Disease'), (117, 128, 'B_Disease'), (154, 165, 'B_Disease'), (219, 231, 'B_Disease')]}], ['Possible intramuscular midazolam - associated cardiorespiratory arrest and death .', {'entities': [(46, 63, 'B_Disease'), (64, 70, 'I_Disease'), (75, 80, 'B_Disease')]}], ['Although generally consisted safe when given intramuscularly , intravenous administration is known to cause respiratory and cardiovascular depression .', {'entities': [(108, 119, 'B_Disease'), (120, 123, 'I_Disease'), (124, 138, 'I_Disease'), (139, 149, 'I_Disease')]}], ['This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam .', {'entities': [(50, 67, 'B_Disease'), (68, 74, 'I_Disease'), (79, 84, 'B_Disease')]}], ['Myasthenia gravis presenting as weakness after magnesium administration .', {'entities': [(0, 10, 'B_Disease'), (11, 17, 'I_Disease')]}], ['We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia .', {'entities': [(46, 59, 'B_Disease'), (60, 67, 'I_Disease'), (89, 101, 'B_Disease'), (148, 160, 'B_Disease')]}], ['While she was weak , 2 - Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise , suggesting postsynaptic neuromuscular blockade .', {'entities': [(151, 163, 'B_Disease'), (164, 177, 'I_Disease'), (178, 186, 'I_Disease')]}], ['Although paralysis after magnesium administration has been described in patients with known myasthenia gravis , it has not previously been reported to be the initial or only manifestation of the disease .', {'entities': [(9, 18, 'B_Disease'), (92, 102, 'B_Disease'), (103, 109, 'I_Disease')]}], ['Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission .', {'entities': [(123, 131, 'B_Disease'), (132, 134, 'I_Disease'), (135, 148, 'I_Disease'), (149, 161, 'I_Disease')]}], ['No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline - supplemented diet , while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital .', {'entities': [(36, 50, 'B_Disease'), (51, 61, 'I_Disease'), (163, 177, 'B_Disease'), (178, 187, 'I_Disease')]}], ['The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10 % and 37 % , respectively , in rats fed the plain choline - devoid diet , and 17 % and 30 % , in rats fed the phenobarbital - containing choline - devoid diet .', {'entities': [(46, 60, 'B_Disease'), (61, 71, 'I_Disease')]}], ['Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone .', {'entities': [(0, 5, 'B_Disease'), (6, 17, 'I_Disease'), (22, 28, 'B_Disease'), (29, 36, 'I_Disease')]}], ['Differential effects of gamma - hexachlorocyclohexane ( lindane ) on pharmacologically - induced seizures .', {'entities': [(97, 105, 'B_Disease')]}], ['Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h after exposure to gamma - HCH ( Vohland et al . 1981 ) .', {'entities': [(126, 133, 'B_Disease'), (256, 264, 'B_Disease')]}], ['In this study , the severity of response to other seizure - inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg / kg gamma - HCH .', {'entities': [(50, 57, 'B_Disease')]}], ['One hour after the administration of gamma - HCH , the activity of seizure - inducing agents was increased , regardless of their mechanism , while 24 h after gamma - HCH a differential response was observed .', {'entities': [(67, 74, 'B_Disease')]}], ['Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .', {'entities': [(0, 7, 'B_Disease'), (91, 98, 'B_Disease')]}], ['The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma - HCH , since the response to only these two seizure - inducing agents is decreased .', {'entities': [(71, 78, 'B_Disease'), (173, 180, 'B_Disease')]}], ['The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma - HCH may be the GABA - A receptor - linked chloride channel .', {'entities': [(72, 79, 'B_Disease')]}], ['Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever .', {'entities': [(61, 70, 'B_Disease'), (71, 82, 'I_Disease'), (83, 88, 'I_Disease')]}], ['Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever ( AHF ) of more than 8 days of evolution .', {'entities': [(75, 84, 'B_Disease'), (85, 96, 'I_Disease'), (97, 102, 'I_Disease'), (105, 108, 'B_Disease')]}], ['Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers .', {'entities': [(60, 67, 'B_Disease')]}], ['The average time of death was delayed .', {'entities': [(20, 25, 'B_Disease')]}], ['A reversible anemia was the only adverse effect observed .', {'entities': [(13, 19, 'B_Disease')]}], ['From these results , we conclude that ribavirin has an antiviral effect in advanced cases of AHF , and that anemia , the only secondary reaction observed , can be easily managed .', {'entities': [(93, 96, 'B_Disease'), (108, 114, 'B_Disease')]}], ['The possible beneficial effect of ribavirin during the initial days of AHF is discussed .', {'entities': [(71, 74, 'B_Disease')]}], ['Is the treatment of scabies hazardous ?', {'entities': [(20, 27, 'B_Disease')]}], ['Treatment for scabies is usually initiated by general practitioners ; most consider lindane ( gamma benzene hexachloride ) the treatment of choice .', {'entities': [(14, 21, 'B_Disease')]}], ['Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia .', {'entities': [(45, 50, 'B_Disease'), (51, 53, 'I_Disease'), (54, 57, 'I_Disease'), (58, 65, 'I_Disease'), (66, 73, 'I_Disease'), (74, 80, 'I_Disease'), (108, 116, 'B_Disease'), (117, 124, 'I_Disease')]}], ['This literature review suggests that general practitioners should prescribe scabicides with increased caution for certain at - risk groups , and give adequate warnings regarding potential toxicity .', {'entities': [(188, 196, 'B_Disease')]}], ['The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB / C mice being the most sensitive .', {'entities': [(31, 40, 'B_Disease')]}], ['Readministration of amantadine , after a drug - free overnight period , increased motility from respective saline control in all strains with exception of the BALB / C mice where suppression of motility occurred .', {'entities': [(179, 190, 'B_Disease'), (191, 193, 'I_Disease'), (194, 202, 'I_Disease')]}], ['The biochemical results of brain biogenic amines of BALB / C mouse strain suggest a probable decrease of catecholamine turnover rate and / or metabolism by monoamine oxidase and a resulting increase in O - methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB / C mice .', {'entities': [(260, 270, 'B_Disease'), (271, 281, 'I_Disease')]}], ['Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis .', {'entities': [(227, 238, 'B_Disease'), (239, 247, 'I_Disease')]}], ['The data demonstrate that CAA after i . v . administration does not contribute to bladder damage .', {'entities': [(82, 89, 'B_Disease'), (90, 96, 'I_Disease')]}], ['Source of pain and primitive dysfunction in migraine : an identical site ?', {'entities': [(10, 14, 'B_Disease'), (44, 52, 'B_Disease')]}], ['Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin ( 10 patients ) or placebo ointment ( 10 patients ) in a double blind study .', {'entities': [(14, 22, 'B_Disease')]}], ['Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group .', {'entities': [(12, 20, 'B_Disease')]}], ['Subsequently 20 migraine patients , who developed an early onset attack with frontotemporal nitroglycerin , received the drug in a second induction test at other body areas .', {'entities': [(16, 24, 'B_Disease')]}], ['No early onset migraine was observed .', {'entities': [(15, 23, 'B_Disease')]}], ['Thus the migraine - inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .', {'entities': [(9, 17, 'B_Disease'), (115, 119, 'B_Disease'), (213, 221, 'B_Disease')]}], ['This is not consistent with a CNS origin of migraine attack .', {'entities': [(44, 52, 'B_Disease')]}], ['Hypersensitivity to carbamazepine presenting with a leukemoid reaction , eosinophilia , erythroderma , and renal failure .', {'entities': [(0, 16, 'B_Disease'), (52, 61, 'B_Disease'), (62, 70, 'I_Disease'), (73, 85, 'B_Disease'), (88, 100, 'B_Disease'), (107, 112, 'B_Disease'), (113, 120, 'I_Disease')]}], ['We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .', {'entities': [(28, 44, 'B_Disease'), (89, 101, 'B_Disease'), (113, 122, 'B_Disease'), (123, 131, 'I_Disease'), (134, 146, 'B_Disease'), (149, 161, 'B_Disease'), (168, 173, 'B_Disease'), (174, 181, 'I_Disease')]}], ['Fluoxetine - induced akathisia : clinical and theoretical implications .', {'entities': [(21, 30, 'B_Disease')]}], ['Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia .', {'entities': [(56, 65, 'B_Disease'), (66, 76, 'I_Disease'), (77, 85, 'I_Disease'), (89, 94, 'B_Disease'), (95, 105, 'I_Disease'), (116, 125, 'B_Disease')]}], ['The typical fluoxetine - induced symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia .', {'entities': [(134, 141, 'B_Disease'), (201, 210, 'B_Disease')]}], ['Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical , although somewhat milder .', {'entities': [(57, 66, 'B_Disease'), (130, 139, 'B_Disease')]}], ['Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol , dose reduction , or both .', {'entities': [(0, 9, 'B_Disease')]}], ['The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced \" jitteriness \" may be identical .', {'entities': [(46, 55, 'B_Disease'), (197, 206, 'B_Disease')]}], ['Effect of converting enzyme inhibition on the course of adriamycin - induced nephropathy .', {'entities': [(77, 88, 'B_Disease')]}], ['The effect of the converting enzyme inhibitor ( CEI ) enalapril was assessed in Munich - Wistar rats with established adriamycin nephrosis .', {'entities': [(129, 138, 'B_Disease')]}], ['Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria , blood pressure , and plasma albumin concentration .', {'entities': [(101, 112, 'B_Disease')]}], ['These short - term studies showed that enalapril reduced arterial blood pressure ( 101 + / - 2 vs . 124 + / - 3 mm Hg , group 2 vs . 1 , P less than 0 . 05 ) and glomerular capillary pressure ( 54 + / - 1 vs . 61 + / - 2 mm Hg , P less than 0 . 05 ) without reducing albuminuria ( 617 + / - 50 vs . 570 + / - 47 mg / day ) or GFR ( 1 . 03 + / - 0 . 04 vs . 1 . 04 + / - 0 . 11 ml / min ) .', {'entities': [(267, 278, 'B_Disease')]}], ['Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis .', {'entities': [(106, 111, 'B_Disease'), (112, 118, 'I_Disease'), (133, 142, 'B_Disease')]}], ['Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4 .', {'entities': [(68, 79, 'B_Disease')]}], ['Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats . ( ABSTRACT TRUNCATED AT 250 WORDS )', {'entities': [(56, 66, 'B_Disease'), (67, 76, 'I_Disease')]}], ['Clotiazepam - induced acute hepatitis .', {'entities': [(28, 37, 'B_Disease')]}], ['We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis , 7 months after the onset of administration of clotiazepam , a thienodiazepine derivative .', {'entities': [(52, 61, 'B_Disease'), (67, 76, 'B_Disease'), (77, 91, 'I_Disease'), (92, 100, 'I_Disease')]}], ['The administration of several benzodiazepines , chemically related to clotiazepam , did not interfere with recovery and did not induce any relapse of hepatitis .', {'entities': [(150, 159, 'B_Disease')]}], ['This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines .', {'entities': [(57, 66, 'B_Disease'), (103, 117, 'B_Disease')]}], ['5 - azacytidine potentiates initiation induced by carcinogens in rat liver .', {'entities': [(28, 38, 'B_Disease'), (39, 46, 'I_Disease'), (47, 49, 'I_Disease'), (50, 61, 'I_Disease')]}], ['To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process , 5 - azacytidine ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( 1 , 2 - DMH ) ( 100 mg / kg ) .', {'entities': [(98, 108, 'B_Disease'), (109, 111, 'I_Disease'), (112, 124, 'I_Disease'), (125, 132, 'I_Disease')]}], ['Antihypertensive drugs and depression : a reappraisal .', {'entities': [(27, 37, 'B_Disease')]}], ['Eighty - nine new referral hypertensive out - patients and 46 new referral non - hypertensive chronically physically ill out - patients completed a mood rating scale at regular intervals for one year .', {'entities': [(27, 39, 'B_Disease'), (81, 93, 'B_Disease')]}], ['The results showed a high prevalence of depression in both groups of patients , with no preponderance in the hypertensive group .', {'entities': [(40, 50, 'B_Disease'), (109, 121, 'B_Disease')]}], ['Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients .', {'entities': [(0, 12, 'B_Disease'), (27, 38, 'B_Disease'), (76, 86, 'B_Disease')]}], ['This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories .', {'entities': [(50, 61, 'B_Disease'), (109, 120, 'B_Disease')]}], ['Chronic active hepatitis associated with diclofenac sodium therapy .', {'entities': [(0, 7, 'B_Disease'), (8, 14, 'I_Disease'), (15, 24, 'I_Disease')]}], ['Although generally well - tolerated , asymptomatic abnormalities of liver function have been recorded and , less commonly , severe hepatitis induced by diclofenac .', {'entities': [(51, 64, 'B_Disease'), (65, 67, 'I_Disease'), (68, 73, 'I_Disease'), (74, 82, 'I_Disease'), (131, 140, 'B_Disease')]}], ['The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug , a finding not previously reported .', {'entities': [(32, 39, 'B_Disease'), (40, 46, 'I_Disease'), (47, 56, 'I_Disease')]}], ['Arterial hypertension as a complication of prolonged ketoconazole treatment .', {'entities': [(9, 21, 'B_Disease')]}], [\"Two of 14 patients with Cushing ' s syndrome treated on a long - term basis with ketoconazole developed sustained hypertension .\", {'entities': [(24, 31, 'B_Disease'), (32, 33, 'I_Disease'), (34, 35, 'I_Disease'), (36, 44, 'I_Disease'), (114, 126, 'B_Disease')]}], ['In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy , yet continuous blood pressure monitoring demonstrated hypertension 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .', {'entities': [(166, 178, 'B_Disease')]}], ['Our findings show that long - term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid - related hypertension .', {'entities': [(143, 155, 'B_Disease')]}], ['Effects of an inhibitor of angiotensin converting enzyme ( Captopril ) on pulmonary and renal insufficiency due to intravascular coagulation in the rat .', {'entities': [(74, 83, 'B_Disease'), (84, 87, 'I_Disease'), (88, 93, 'I_Disease'), (94, 107, 'I_Disease'), (115, 128, 'B_Disease'), (129, 140, 'I_Disease')]}], ['Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .', {'entities': [(13, 26, 'B_Disease'), (27, 38, 'I_Disease'), (149, 158, 'B_Disease'), (159, 162, 'I_Disease'), (163, 168, 'I_Disease'), (169, 182, 'I_Disease'), (215, 221, 'B_Disease'), (225, 231, 'B_Disease')]}], ['Injection of Captopril ( 1 mg / kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both pulmonary and renal insufficiency in this rat model .', {'entities': [(108, 117, 'B_Disease'), (118, 121, 'I_Disease'), (122, 127, 'I_Disease'), (128, 141, 'I_Disease')]}], ['Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease')]}], ['Captopril may , by the same mechanism , reduce the increase in glomerular filtration that is known to occur after an injection of thrombin , thereby diminishing the aggregation of fibrin monomers in the glomeruli , with the result that less fibrin will be deposited and thus less kidney damage will be produced .', {'entities': [(280, 286, 'B_Disease'), (287, 293, 'I_Disease')]}], ['Stroke associated with cocaine use .', {'entities': [(0, 6, 'B_Disease')]}], ['We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature .', {'entities': [(62, 68, 'B_Disease')]}], ['Stroke followed cocaine use by inhalation , intranasal , intravenous , and intramuscular routes .', {'entities': [(0, 6, 'B_Disease')]}], ['Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy ; cerebral vasculitis was present in two patients .', {'entities': [(0, 12, 'B_Disease'), (13, 22, 'I_Disease'), (26, 39, 'B_Disease'), (40, 53, 'I_Disease'), (129, 137, 'B_Disease'), (138, 148, 'I_Disease')]}], ['Cerebral infarction occurred in 10 patients ( 22 % ) , intracerebral hemorrhage in 22 ( 49 % ) , and subarachnoid hemorrhage in 13 ( 29 % ) .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease'), (55, 68, 'B_Disease'), (69, 79, 'I_Disease'), (101, 113, 'B_Disease'), (114, 124, 'I_Disease')]}], ['These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .', {'entities': [(57, 63, 'B_Disease'), (130, 136, 'B_Disease'), (178, 184, 'B_Disease'), (240, 246, 'B_Disease'), (295, 307, 'B_Disease'), (308, 317, 'I_Disease'), (322, 335, 'B_Disease'), (336, 349, 'I_Disease'), (386, 392, 'B_Disease'), (412, 424, 'B_Disease'), (425, 435, 'I_Disease'), (452, 460, 'B_Disease'), (461, 471, 'I_Disease')]}], ['A randomized comparison of labetalol and nitroprusside for induced hypotension .', {'entities': [(67, 78, 'B_Disease')]}], ['In a randomized study , labetalol - induced hypotension and nitroprusside - induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .', {'entities': [(44, 55, 'B_Disease'), (84, 95, 'B_Disease')]}], ['Each patient was subjected to an identical anesthetic protocol and similar drug - induced reductions in mean arterial blood pressure ( BP ) ( 50 to 55 mmHg ) .', {'entities': [(90, 100, 'B_Disease'), (101, 103, 'I_Disease'), (104, 108, 'I_Disease'), (109, 117, 'I_Disease'), (118, 123, 'I_Disease'), (124, 132, 'I_Disease')]}], ['Nitroprusside infusion was associated with a significant ( p less than 0 . 05 ) increase in heart rate and cardiac output ; rebound hypertension was observed in three patients after discontinuation of nitroprusside .', {'entities': [(80, 88, 'B_Disease'), (89, 91, 'I_Disease'), (92, 97, 'I_Disease'), (98, 102, 'I_Disease'), (103, 106, 'I_Disease'), (107, 114, 'I_Disease'), (115, 121, 'I_Disease'), (132, 144, 'B_Disease')]}], ['Sodium status influences chronic amphotericin B nephrotoxicity in rats .', {'entities': [(48, 62, 'B_Disease')]}], ['The nephrotoxic potential of amphotericin B ( 5 mg / kg per day intraperitoneally for 3 weeks ) has been investigated in salt - depleted , normal - salt , and salt - loaded rats .', {'entities': [(4, 15, 'B_Disease')]}], ['Flestolol produced a dose - dependent attenuation of isoproterenol - induced tachycardia .', {'entities': [(77, 88, 'B_Disease')]}], ['Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia .', {'entities': [(58, 74, 'B_Disease'), (75, 90, 'I_Disease')]}], ['In patients with unstable angina , flestolol infusion was found to be safe and effective in controlling chest pain .', {'entities': [(17, 25, 'B_Disease'), (26, 32, 'I_Disease'), (104, 109, 'B_Disease'), (110, 114, 'I_Disease')]}], ['Immunohistochemical , electron microscopic and morphometric studies of estrogen - induced rat prolactinomas after bromocriptine treatment .', {'entities': [(94, 107, 'B_Disease')]}], ['To clarify the effects of bromocriptine on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen - induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine ( 3 mg / kg of body weight ) .', {'entities': [(43, 55, 'B_Disease'), (177, 189, 'B_Disease')]}], ['Electron microscopy disclosed many secretory granules , slightly distorted rough endoplasmic reticulum , and partially dilated Golgi cisternae in the prolactinoma cells .', {'entities': [(150, 162, 'B_Disease')]}], ['The prolactinoma cells at this time were well granulated , with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae .', {'entities': [(4, 16, 'B_Disease')]}], ['Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules , Golgi cisternae , and endoplasmic reticulum of the untreated rat prolactinoma cells .', {'entities': [(179, 191, 'B_Disease')]}], ['However , only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells .', {'entities': [(127, 134, 'B_Disease')]}], ['Sulfasalazine - induced lupus erythematosus .', {'entities': [(24, 29, 'B_Disease'), (30, 43, 'I_Disease')]}], ['Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis .', {'entities': [(0, 11, 'B_Disease'), (24, 31, 'B_Disease'), (32, 41, 'I_Disease'), (74, 81, 'B_Disease'), (82, 91, 'I_Disease'), (223, 233, 'B_Disease'), (234, 241, 'I_Disease')]}], ['It is suggested that the patient had sulfasalazine - induced lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .', {'entities': [(61, 66, 'B_Disease'), (91, 100, 'B_Disease')]}], ['Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine - induced lupus syndrome .', {'entities': [(56, 68, 'B_Disease'), (69, 74, 'I_Disease'), (75, 82, 'I_Disease'), (139, 144, 'B_Disease'), (145, 153, 'I_Disease')]}], ['Chronic carbamazepine treatment in the rat : efficacy , toxicity , and effect on plasma and tissue folate concentrations .', {'entities': [(56, 64, 'B_Disease')]}], ['In the course of developing this model , a common vehicle , propylene glycol , by itself in high doses , was found to exhibit protective properties against induced seizures and inhibited weight gain .', {'entities': [(164, 172, 'B_Disease'), (187, 193, 'B_Disease'), (194, 198, 'I_Disease')]}], ['Seizures induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .', {'entities': [(0, 8, 'B_Disease'), (126, 134, 'B_Disease')]}], ['Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against HFDE - induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment .', {'entities': [(138, 146, 'B_Disease'), (186, 192, 'B_Disease'), (193, 197, 'I_Disease')]}], ['Dipyridamole - induced myocardial ischemia .', {'entities': [(23, 33, 'B_Disease'), (34, 42, 'I_Disease')]}], ['Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures .', {'entities': [(0, 6, 'B_Disease')]}], ['To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although dipyridamole - induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease .', {'entities': [(145, 155, 'B_Disease'), (156, 164, 'I_Disease'), (223, 231, 'B_Disease'), (232, 238, 'I_Disease'), (239, 246, 'I_Disease')]}], ['Epicardial coronary collateral vessels were demonstrated in all four patients ; a coronary \" steal \" phenomenon may be the mechanism of the dipyridamole - induced ischemia observed .', {'entities': [(163, 171, 'B_Disease')]}], ['Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin .', {'entities': [(303, 314, 'B_Disease'), (458, 469, 'B_Disease')]}], ['Nitroprusside - induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin - releasing factor ( irCRF ) into the hypophysial - portal circulation .', {'entities': [(24, 35, 'B_Disease')]}], ['Suppression of irCRF secretion in response to nitroprusside - induced hypotension is observed and occurs at a plasma corticosterone level between 8 - 12 micrograms / dl .', {'entities': [(70, 81, 'B_Disease')]}], ['Noradrenergic involvement in catalepsy induced by delta 9 - tetrahydrocannabinol .', {'entities': [(29, 38, 'B_Disease')]}], ['These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC , whereas dopaminergic neurons are important in catalepsy induced by haloperidol .', {'entities': [(97, 106, 'B_Disease'), (170, 179, 'B_Disease')]}], ['Reversibility of captopril - induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension .', {'entities': [(37, 42, 'B_Disease'), (43, 56, 'I_Disease'), (99, 111, 'B_Disease'), (112, 124, 'I_Disease')]}], ['We report a case of severe hypertension with an occluded renal artery to a solitary kidney , who developed sudden deterioration of renal function following treatment with captopril .', {'entities': [(27, 39, 'B_Disease'), (107, 113, 'B_Disease'), (114, 127, 'I_Disease'), (128, 130, 'I_Disease'), (131, 136, 'I_Disease'), (137, 145, 'I_Disease')]}], ['This indicates reversibility in captopril - induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition .', {'entities': [(52, 57, 'B_Disease'), (58, 65, 'I_Disease')]}], ['Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .', {'entities': [(0, 8, 'B_Disease'), (41, 54, 'B_Disease'), (87, 92, 'B_Disease'), (93, 100, 'I_Disease')]}], ['As wider use confirms their safety profile , they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences .', {'entities': [(113, 134, 'B_Disease')]}], ['By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug , including five deaths .', {'entities': [(90, 104, 'B_Disease'), (147, 153, 'B_Disease')]}], ['An analysis of the 75 cases that had been adequately followed up suggested that 16 , including three deaths , were probably related to treatment with the drug .', {'entities': [(101, 107, 'B_Disease')]}], ['The mean age of patients in the 16 probable cases was 57 . 9 , with hepatotoxicity being more common in women .', {'entities': [(68, 82, 'B_Disease')]}], ['The average duration of treatment before the onset of jaundice was 61 days .', {'entities': [(54, 62, 'B_Disease')]}], ['The results of serum liver function tests suggested hepatocellular injury in 10 ( 63 % ) ; the rest showed a mixed pattern .', {'entities': [(52, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['In contrast , the results of histological examination of the liver often showed evidence of cholestasis .', {'entities': [(92, 103, 'B_Disease')]}], ['Allergic manifestations such as rash and eosinophilia were rare .', {'entities': [(32, 36, 'B_Disease'), (41, 53, 'B_Disease')]}], ['Hepatitis was usually reversible when treatment was stopped , with the results of liver function tests returning to normal after an average of 3 . 1 months .', {'entities': [(0, 9, 'B_Disease')]}], ['In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis .', {'entities': [(20, 26, 'B_Disease'), (122, 130, 'B_Disease'), (153, 162, 'B_Disease')]}], ['Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury .', {'entities': [(73, 82, 'B_Disease'), (167, 174, 'B_Disease'), (175, 181, 'I_Disease')]}], ['Glyburide - induced hepatitis .', {'entities': [(20, 29, 'B_Disease')]}], ['Drug - induced hepatotoxicity , although common , has been reported only infrequently with sulfonylureas .', {'entities': [(15, 29, 'B_Disease')]}], ['For glyburide , a second - generation sulfonylurea , only two brief reports of hepatotoxicity exist .', {'entities': [(79, 93, 'B_Disease')]}], ['Two patients with type II diabetes mellitus developed an acute hepatitis - like syndrome soon after initiation of glyburide therapy .', {'entities': [(18, 22, 'B_Disease'), (23, 25, 'I_Disease'), (26, 34, 'I_Disease'), (35, 43, 'I_Disease'), (57, 62, 'B_Disease'), (63, 72, 'I_Disease'), (73, 74, 'I_Disease'), (75, 79, 'I_Disease'), (80, 88, 'I_Disease')]}], ['There was no serologic evidence of viral infection , and a liver biopsy sample showed a histologic pattern consistent with drug - induced hepatitis .', {'entities': [(35, 40, 'B_Disease'), (41, 50, 'I_Disease'), (123, 127, 'B_Disease'), (128, 129, 'I_Disease'), (130, 137, 'I_Disease'), (138, 147, 'I_Disease')]}], ['Glyburide can produce an acute hepatitis - like illness in some persons .', {'entities': [(25, 30, 'B_Disease'), (31, 40, 'I_Disease'), (41, 42, 'I_Disease'), (43, 47, 'I_Disease'), (48, 55, 'I_Disease')]}], ['Intracranial pressure increases during alfentanil - induced rigidity .', {'entities': [(60, 68, 'B_Disease')]}], ['Intracranial pressure ( ICP ) was measured during alfentanil - induced rigidity in rats .', {'entities': [(71, 79, 'B_Disease')]}], ['In the five rats that developed somatic rigidity , ICP and CVP increased significantly above baseline ( delta ICP 7 . 5 + / - 1 . 0 mmHg , delta CVP 5 . 9 + / - 1 . 3 mmHg ) .', {'entities': [(32, 39, 'B_Disease'), (40, 48, 'I_Disease')]}], ['These variables returned to baseline when rigidity was abolished with metocurine .', {'entities': [(42, 50, 'B_Disease')]}], ['These observations suggest that rigidity should be prevented when alfentanil , and , presumably , other opiates , are used in the anesthetic management of patients with ICP problems .', {'entities': [(32, 40, 'B_Disease')]}], ['Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram .', {'entities': [(44, 54, 'B_Disease'), (55, 65, 'I_Disease'), (71, 83, 'B_Disease')]}], ['Serious adverse effects are uncommon and mainly have been related to the depression of cardiac contractility and conduction , especially when the drug is combined with beta - blocking agents .', {'entities': [(73, 83, 'B_Disease')]}], ['We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension .', {'entities': [(26, 36, 'B_Disease'), (37, 47, 'I_Disease'), (172, 184, 'B_Disease')]}], ['Haemolytic - uraemic syndrome after treatment with metronidazole .', {'entities': [(0, 10, 'B_Disease'), (11, 12, 'I_Disease'), (13, 20, 'I_Disease'), (21, 29, 'I_Disease')]}], ['This paper describes the clinical features of six children who developed the haemolytic - uraemic syndrome after treatment with metronidazole .', {'entities': [(77, 87, 'B_Disease'), (88, 89, 'I_Disease'), (90, 97, 'I_Disease'), (98, 106, 'I_Disease')]}], ['While the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome .', {'entities': [(63, 73, 'B_Disease'), (74, 75, 'I_Disease'), (76, 83, 'I_Disease'), (84, 92, 'I_Disease'), (242, 252, 'B_Disease'), (253, 254, 'I_Disease'), (255, 262, 'I_Disease'), (263, 271, 'I_Disease'), (350, 360, 'B_Disease'), (361, 362, 'I_Disease'), (363, 370, 'I_Disease'), (371, 379, 'I_Disease')]}], ['Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and / or surgery .', {'entities': [(36, 40, 'B_Disease'), (41, 44, 'I_Disease'), (45, 49, 'I_Disease'), (50, 59, 'I_Disease'), (64, 74, 'B_Disease'), (75, 84, 'I_Disease')]}], ['In the pre - treatment evaluation , signs of cardiovascular disease were found in 33 patients ( 43 % ) .', {'entities': [(45, 59, 'B_Disease'), (60, 67, 'I_Disease')]}], ['The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre - treatment evaluation .', {'entities': [(17, 31, 'B_Disease'), (73, 87, 'B_Disease'), (88, 95, 'I_Disease')]}], ['The most common signs of cardiotoxicity were chest pain , ST - T wave changes and atrial fibrillation .', {'entities': [(25, 39, 'B_Disease'), (45, 50, 'B_Disease'), (51, 55, 'I_Disease'), (82, 88, 'B_Disease'), (89, 101, 'I_Disease')]}], ['This was followed by ventricular fibrillation in one patient and sudden death in another .', {'entities': [(21, 32, 'B_Disease'), (33, 45, 'I_Disease'), (65, 71, 'B_Disease'), (72, 77, 'I_Disease')]}], ['It is concluded that patients on 5 - FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed .', {'entities': [(133, 138, 'B_Disease'), (139, 143, 'I_Disease'), (147, 162, 'B_Disease')]}], ['Death from chemotherapy in gestational trophoblastic disease .', {'entities': [(0, 5, 'B_Disease'), (27, 38, 'B_Disease'), (39, 52, 'I_Disease'), (53, 60, 'I_Disease')]}], ['Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high - risk stage of choriocarcinoma .', {'entities': [(115, 130, 'B_Disease')]}], ['Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs , probably originating from the uterus .', {'entities': [(103, 112, 'B_Disease'), (113, 124, 'I_Disease')]}], ['Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins , which resulted in an open exchange of tumor plugs to the vascular spaces ; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli .', {'entities': [(55, 60, 'B_Disease'), (61, 69, 'B_Disease'), (163, 168, 'B_Disease'), (212, 217, 'B_Disease'), (310, 315, 'B_Disease')]}], ['In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations , such as spontaneous necrosis , must be considered less likely .', {'entities': [(103, 111, 'B_Disease'), (153, 161, 'B_Disease')]}], ['Patients with large pelvic tumor loads are , according to existing classifications , at high risk to die and to develop drug resistance .', {'entities': [(20, 26, 'B_Disease'), (27, 32, 'I_Disease')]}], ['Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside - induced hypotension .', {'entities': [(84, 95, 'B_Disease')]}], ['Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS / QT .', {'entities': [(65, 73, 'B_Disease'), (74, 76, 'I_Disease'), (77, 85, 'I_Disease'), (86, 91, 'I_Disease'), (92, 100, 'I_Disease'), (144, 153, 'B_Disease'), (154, 161, 'I_Disease'), (162, 168, 'I_Disease')]}], ['Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate , but did not change cardiac output or QS / QT .', {'entities': [(33, 42, 'B_Disease'), (43, 45, 'I_Disease'), (46, 54, 'I_Disease'), (55, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm H2O ) , while decreasing QS / QT , produce marked decreases in arterial blood pressure and cardiac output .', {'entities': [(179, 188, 'B_Disease'), (189, 191, 'I_Disease'), (192, 200, 'I_Disease'), (201, 206, 'I_Disease'), (207, 215, 'I_Disease'), (216, 219, 'I_Disease'), (220, 227, 'I_Disease'), (228, 234, 'I_Disease')]}], ['Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside - induced hypotension in ventilated dogs .', {'entities': [(46, 56, 'B_Disease'), (100, 111, 'B_Disease')]}], ['The systolic pressure variation ( SPV ) , which is the difference between the maximal and minimal values of the systolic blood pressure ( SBP ) after one positive - pressure breath , was studied in ventilated dogs subjected to hypotension .', {'entities': [(227, 238, 'B_Disease')]}], ['Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( HEM , n = 7 ) or by continuous infusion of sodium nitroprusside ( SNP , n = 7 ) .', {'entities': [(74, 84, 'B_Disease'), (87, 90, 'B_Disease')]}], ['During HEM - induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group .', {'entities': [(7, 10, 'B_Disease'), (21, 32, 'B_Disease')]}], ['The SPV during hypotension was 15 . 7 + / - 6 . 7 mm Hg in the HEM group , compared with 9 . 1 + / - 2 . 0 mm Hg in the SNP group ( P less than 0 . 02 ) .', {'entities': [(15, 26, 'B_Disease'), (63, 66, 'B_Disease')]}], ['The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20 . 3 + / - 8 . 4 and 10 . 1 + / - 3 . 8 mm Hg in the HEM and SNP groups , respectively , during hypotension ( P less than 0 . 02 ) .', {'entities': [(144, 147, 'B_Disease'), (187, 198, 'B_Disease')]}], ['It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload .', {'entities': [(85, 96, 'B_Disease')]}], ['They are thus more important during absolute hypovolemia than during deliberate hypotension .', {'entities': [(45, 56, 'B_Disease'), (80, 91, 'B_Disease')]}], ['Ventricular tachyarrhythmias during cesarean section after ritodrine therapy : interaction with anesthetics .', {'entities': [(0, 11, 'B_Disease'), (12, 28, 'I_Disease')]}], ['This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section .', {'entities': [(60, 67, 'B_Disease'), (68, 73, 'I_Disease')]}], ['Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine .', {'entities': [(40, 54, 'B_Disease'), (55, 68, 'I_Disease')]}], ['After delivery of the infant , there should be no contraindication to the use of an alpha - adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia .', {'entities': [(146, 157, 'B_Disease'), (172, 183, 'B_Disease')]}], ['Verapamil - induced carbamazepine neurotoxicity .', {'entities': [(34, 47, 'B_Disease')]}], ['Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker .', {'entities': [(41, 54, 'B_Disease')]}], ['Paracetamol - associated coma , metabolic acidosis , renal and hepatic failure .', {'entities': [(25, 29, 'B_Disease'), (32, 41, 'B_Disease'), (42, 50, 'I_Disease'), (53, 58, 'B_Disease'), (59, 62, 'I_Disease'), (63, 70, 'I_Disease'), (71, 78, 'I_Disease')]}], ['A case of metabolic acidosis , acute renal failure and hepatic failure following paracetamol ingestion is presented .', {'entities': [(10, 19, 'B_Disease'), (20, 28, 'I_Disease'), (31, 36, 'B_Disease'), (37, 42, 'I_Disease'), (43, 50, 'I_Disease'), (51, 54, 'I_Disease'), (55, 62, 'I_Disease'), (63, 70, 'I_Disease')]}], ['Sexual dysfunction among patients with arthritis .', {'entities': [(0, 6, 'B_Disease'), (7, 18, 'I_Disease'), (39, 48, 'B_Disease')]}], ['The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis , osteoarthritis and spondyloarthropathy , 130 of whom were pair - matched to controls .', {'entities': [(20, 29, 'B_Disease'), (34, 40, 'B_Disease'), (41, 52, 'I_Disease'), (94, 104, 'B_Disease'), (105, 114, 'I_Disease'), (117, 131, 'B_Disease'), (136, 155, 'B_Disease')]}], ['Assessments of marital happiness and depressed mood were also made using the CES - D and the Azrin Marital Happiness Scale ( AMHS ) .', {'entities': [(37, 46, 'B_Disease'), (47, 51, 'I_Disease')]}], ['Sexual dysfunctions were found to be common among patients and controls , the majority in both groups reporting one or more dysfunctions .', {'entities': [(0, 6, 'B_Disease'), (7, 19, 'I_Disease')]}], ['Impotence was more common among male patients than controls and was found to be associated with co - morbidity and the taking of methotrexate .', {'entities': [(0, 9, 'B_Disease')]}], ['Depressed mood was more common among patients and was associated with certain sexual difficulties , but not with impotence .', {'entities': [(0, 9, 'B_Disease'), (10, 14, 'I_Disease'), (113, 122, 'B_Disease')]}], ['Marital unhappiness , as indicated by AMHS scores , was not associated with arthritis but was associated with sexual dysfunction , sexual dissatisfaction and being female .', {'entities': [(76, 85, 'B_Disease'), (110, 116, 'B_Disease'), (117, 128, 'I_Disease')]}], ['Does paracetamol cause urothelial cancer or renal papillary necrosis ?', {'entities': [(23, 33, 'B_Disease'), (34, 40, 'I_Disease'), (44, 49, 'B_Disease'), (50, 59, 'I_Disease'), (60, 68, 'I_Disease')]}], ['The risk of developing renal papillary necrosis or cancer of the renal pelvis , ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .', {'entities': [(23, 28, 'B_Disease'), (29, 38, 'I_Disease'), (39, 47, 'I_Disease'), (51, 57, 'B_Disease'), (58, 60, 'I_Disease'), (61, 64, 'I_Disease'), (65, 70, 'I_Disease'), (71, 77, 'I_Disease'), (78, 79, 'I_Disease'), (80, 86, 'I_Disease'), (87, 89, 'I_Disease'), (90, 97, 'I_Disease')]}], ['The risk of renal papillary necrosis was increased nearly 20 - fold by consumption of phenacetin , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer .', {'entities': [(12, 17, 'B_Disease'), (18, 27, 'I_Disease'), (28, 36, 'I_Disease'), (133, 139, 'B_Disease'), (140, 142, 'I_Disease'), (143, 146, 'I_Disease'), (147, 152, 'I_Disease'), (153, 159, 'I_Disease'), (160, 163, 'I_Disease'), (164, 171, 'I_Disease'), (184, 192, 'B_Disease'), (193, 199, 'I_Disease')]}], ['By contrast , we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter .', {'entities': [(96, 101, 'B_Disease'), (102, 111, 'I_Disease'), (112, 120, 'I_Disease'), (137, 144, 'B_Disease'), (200, 206, 'B_Disease'), (207, 209, 'I_Disease'), (210, 213, 'I_Disease'), (214, 220, 'I_Disease')]}], ['Dapsone - associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait .', {'entities': [(32, 41, 'B_Disease'), (42, 48, 'I_Disease')]}], ['A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis .', {'entities': [(53, 60, 'B_Disease'), (84, 93, 'B_Disease'), (94, 100, 'I_Disease'), (185, 194, 'B_Disease')]}], ['Thus , AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo , since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals .', {'entities': [(130, 139, 'B_Disease'), (140, 146, 'I_Disease')]}], ['Given the influx of Southeast Asians into the United States , oxidant medications should be used with caution , especially if an infection is present , in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E .', {'entities': [(129, 138, 'B_Disease')]}], ['A 47 - year - old patient suffering from coronary artery disease was admitted to the CCU in shock with III .', {'entities': [(41, 49, 'B_Disease'), (50, 56, 'I_Disease'), (57, 64, 'I_Disease'), (92, 97, 'B_Disease')]}], ['AV block , severe hypotension , and impairment of ventricular function .', {'entities': [(0, 2, 'B_Disease'), (3, 8, 'I_Disease'), (18, 29, 'B_Disease'), (36, 46, 'B_Disease'), (47, 49, 'I_Disease'), (50, 61, 'I_Disease'), (62, 70, 'I_Disease')]}], ['Therefore , patients belonging to the poor - metabolizer phenotype of sparteine / debrisoquine polymorphism in drug metabolism , which constitutes 6 . 4 % of the German population , may experience adverse drug reactions when treated with standard doses of one of these drugs alone .', {'entities': [(197, 204, 'B_Disease'), (205, 209, 'I_Disease'), (210, 219, 'I_Disease')]}], ['Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms ; no other side effects were observed .', {'entities': [(41, 55, 'B_Disease'), (56, 67, 'I_Disease'), (68, 76, 'I_Disease')]}], ['In the double blind study with haloperidol , both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group .', {'entities': [(115, 124, 'B_Disease'), (125, 134, 'I_Disease'), (135, 144, 'I_Disease'), (145, 158, 'I_Disease'), (159, 161, 'I_Disease'), (162, 165, 'I_Disease'), (166, 179, 'I_Disease'), (180, 185, 'I_Disease')]}], ['Prolonged cholestasis after troleandomycin - induced acute hepatitis .', {'entities': [(10, 21, 'B_Disease'), (59, 68, 'B_Disease')]}], ['We report the case of a patient in whom troleandomycin - induced hepatitis was followed by prolonged anicteric cholestasis .', {'entities': [(65, 74, 'B_Disease'), (111, 122, 'B_Disease')]}], ['Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia .', {'entities': [(0, 8, 'B_Disease'), (92, 109, 'B_Disease')]}], ['Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities .', {'entities': [(0, 8, 'B_Disease'), (77, 88, 'B_Disease'), (99, 107, 'B_Disease')]}], ['Finally , pruritus disappeared within 19 months , and liver tests returned to normal 27 months after the onset of hepatitis .', {'entities': [(10, 18, 'B_Disease'), (114, 123, 'B_Disease')]}], ['This observation demonstrates that prolonged cholestasis can follow troleandomycin - induced acute hepatitis .', {'entities': [(45, 56, 'B_Disease'), (99, 108, 'B_Disease')]}], ['Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy .', {'entities': [(18, 26, 'B_Disease'), (27, 40, 'I_Disease')]}], ['Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion - dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine .', {'entities': [(0, 6, 'B_Disease'), (7, 10, 'I_Disease'), (11, 19, 'I_Disease'), (20, 33, 'I_Disease'), (110, 116, 'B_Disease')]}], ['Twenty - two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 Hz and in the hearing threshold levels of 30 to 100 decibels .', {'entities': [(48, 56, 'B_Disease'), (57, 67, 'I_Disease'), (68, 72, 'I_Disease'), (73, 81, 'I_Disease'), (82, 88, 'I_Disease'), (89, 91, 'I_Disease'), (92, 95, 'I_Disease'), (96, 100, 'I_Disease'), (101, 110, 'I_Disease'), (111, 116, 'I_Disease'), (117, 119, 'I_Disease'), (120, 121, 'I_Disease'), (122, 123, 'I_Disease'), (124, 127, 'I_Disease'), (128, 130, 'I_Disease'), (131, 132, 'I_Disease'), (133, 134, 'I_Disease'), (135, 138, 'I_Disease'), (139, 141, 'I_Disease')]}], ['Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability .', {'entities': [(97, 106, 'B_Disease'), (107, 117, 'I_Disease')]}], ['Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg / kg per dose , therapy was restarted with lower doses , usually 50 mg / kg per dose or less depending on the degree of auditory abnormality , and with the exception of two cases no further toxicity was demonstrated .', {'entities': [(236, 244, 'B_Disease'), (245, 256, 'I_Disease'), (306, 314, 'B_Disease')]}], ['Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving deferoxamine , respectively , provided convincing evidence for a cause - and - effect relation between deferoxamine administration and ototoxicity .', {'entities': [(249, 260, 'B_Disease')]}], ['With mild toxicity , a reduction to 30 or 40 mg / kg per dose should result in a reversal of the abnormal results to normal within four weeks .', {'entities': [(10, 18, 'B_Disease')]}], ['In those with symptoms of hearing loss , the drug should be stopped for four weeks , and when the audiogram is stable or improved , therapy should be restarted at 10 to 25 mg / kg per dose .', {'entities': [(26, 33, 'B_Disease'), (34, 38, 'I_Disease')]}], ['Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction .', {'entities': [(171, 179, 'B_Disease'), (180, 191, 'I_Disease')]}], ['Lidocaine - induced cardiac asystole .', {'entities': [(20, 27, 'B_Disease'), (28, 36, 'I_Disease')]}], ['Intravenous administration of a single 50 - mg bolus of lidocaine in a 67 - year - old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers .', {'entities': [(112, 122, 'B_Disease')]}], ['The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias ; and , thus , this probably represented a true idiosyncrasy to lidocaine .', {'entities': [(105, 121, 'B_Disease')]}], ['Flurbiprofen in the treatment of juvenile rheumatoid arthritis .', {'entities': [(33, 41, 'B_Disease'), (42, 52, 'I_Disease'), (53, 62, 'I_Disease')]}], ['Thirty - four patients with juvenile rheumatoid arthritis , who were treated with flurbiprofen at a maximum dose of 4 mg / kg / day , had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment .', {'entities': [(28, 36, 'B_Disease'), (37, 47, 'I_Disease'), (48, 57, 'I_Disease'), (193, 202, 'B_Disease')]}], ['Improvements were seen in the number of tender joints , the severity of swelling and tenderness , the time of walk 50 feet , the duration of morning stiffness and the circumference of the left knee .', {'entities': [(40, 46, 'B_Disease'), (47, 53, 'I_Disease'), (72, 80, 'B_Disease'), (85, 95, 'B_Disease'), (141, 148, 'B_Disease'), (149, 158, 'I_Disease')]}], ['The most frequently observed side effect was fecal occult blood ( 25 % of patients ) ; however , there was no other evidence of gastrointestinal ( GI ) bleeding in these patients .', {'entities': [(45, 50, 'B_Disease'), (51, 57, 'I_Disease'), (58, 63, 'I_Disease'), (128, 144, 'B_Disease'), (145, 146, 'I_Disease'), (147, 149, 'I_Disease'), (150, 151, 'I_Disease'), (152, 160, 'I_Disease')]}], ['One patient was prematurely discontinued from the study for severe headache and abdominal pain .', {'entities': [(67, 75, 'B_Disease'), (80, 89, 'B_Disease'), (90, 94, 'I_Disease')]}], ['Hyperkalemia associated with sulindac therapy .', {'entities': [(0, 12, 'B_Disease')]}], ['Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents ( NSAID ) such as indomethacin .', {'entities': [(0, 12, 'B_Disease')]}], ['We describe 4 patients in whom hyperkalemia ranging from 6 . 1 to 6 . 9 mEq / l developed within 3 to 8 days of sulindac administration .', {'entities': [(31, 43, 'B_Disease')]}], ['As no other medications known to effect serum potassium had been given concomitantly , this course of events is suggestive of a cause - and - effect relationship between sulindac and hyperkalemia .', {'entities': [(183, 195, 'B_Disease')]}], ['Drug - induced arterial spasm relieved by lidocaine .', {'entities': [(24, 29, 'B_Disease')]}], ['Following major intracranial surgery in a 35 - year - old man , sodium pentothal was intravenously infused to minimize cerebral ischaemia .', {'entities': [(119, 127, 'B_Disease'), (128, 137, 'I_Disease')]}], ['Intense vasospasm with threatened gangrene arose in the arm used for the infusion .', {'entities': [(8, 17, 'B_Disease'), (34, 42, 'B_Disease')]}], ['Since the cranial condition precluded use of more usual methods , lidocaine was given intra - arterially , with careful cardiovascular monitoring , to counteract the vasospasm .', {'entities': [(166, 175, 'B_Disease')]}], ['Regional localization of the antagonism of amphetamine - induced hyperactivity by intracerebral calcitonin injections .', {'entities': [(65, 78, 'B_Disease')]}], ['The hematologic effects of cefonicid and cefazedone in the dog : a potential model of cephalosporin hematotoxicity in man .', {'entities': [(100, 114, 'B_Disease')]}], ['Cephalosporin antibiotics cause a variety of hematologic disturbances in man , the pathogeneses and hematopathology of which remain poorly characterized .', {'entities': [(45, 56, 'B_Disease'), (57, 69, 'I_Disease')]}], ['There is a need for a well - defined animal model in which these blood dyscrasias can be studied .', {'entities': [(65, 70, 'B_Disease'), (71, 81, 'I_Disease')]}], ['In four subacute toxicity studies , the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose - dependent incidence of anemia , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .', {'entities': [(17, 25, 'B_Disease'), (148, 154, 'B_Disease'), (157, 168, 'B_Disease'), (175, 191, 'B_Disease')]}], ['A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50 % of dogs receiving 400 - 500 mg / kg cefonicid or 540 - 840 mg / kg cefazedone .', {'entities': [(18, 24, 'B_Disease'), (58, 68, 'B_Disease')]}], ['All three cytopenias were completely reversible following cessation of treatment ; the time required for recovery of the erythron ( approximately 1 month ) was considerably longer than that of the granulocytes and platelets ( hours to a few days ) .', {'entities': [(10, 20, 'B_Disease')]}], ['Upon rechallenge with either cephalosporin , the hematologic syndrome was reproduced in most dogs tested ; cefonicid ( but not cefazedone ) - treated dogs showed a substantially reduced induction period ( 15 + / - 5 days ) compared to that of the first exposure to the drug ( 61 + / - 24 days ) .', {'entities': [(49, 60, 'B_Disease'), (61, 69, 'I_Disease')]}], ['This observation , along with the rapid rate of decline in red cell mass parameters of affected dogs , suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia .', {'entities': [(119, 128, 'B_Disease'), (243, 252, 'B_Disease')]}], ['We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin - induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .', {'entities': [(96, 110, 'B_Disease'), (150, 155, 'B_Disease'), (156, 166, 'I_Disease')]}], ['Cerebral blood flow and metabolism during isoflurane - induced hypotension in patients subjected to surgery for cerebral aneurysms .', {'entities': [(63, 74, 'B_Disease'), (112, 120, 'B_Disease'), (121, 130, 'I_Disease')]}], ['Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane - induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .', {'entities': [(101, 112, 'B_Disease'), (170, 178, 'B_Disease'), (179, 187, 'I_Disease')]}], ['Flow and metabolism were measured 5 - 13 days after the subarachnoid haemorrhage by a modification of the classical Kety - Schmidt technique using xenon - 133 i . v . Anaesthesia was maintained with an inspired isoflurane concentration of 0 . 75 % ( plus 67 % nitrous oxide in oxygen ) , during which CBF and CMRO2 were 34 . 3 + / - 2 . 1 ml / 100 g min - 1 and 2 . 32 + / - 0 . 16 ml / 100 g min - 1 at PaCO2 4 . 1 + / - 0 . 1 kPa ( mean + / - SEM ) .', {'entities': [(56, 68, 'B_Disease'), (69, 80, 'I_Disease')]}], ['Controlled hypotension to an average MAP of 50 - 55 mm Hg was induced by increasing the dose of isoflurane , and maintained at an inspired concentration of 2 . 2 + / - 0 . 2 % .', {'entities': [(11, 22, 'B_Disease')]}], ['After the clipping of the aneurysm the isoflurane concentration was reduced to 0 . 75 % .', {'entities': [(26, 34, 'B_Disease')]}], ['There was a significant increase in CBF , although CMRO2 was unchanged , compared with pre - hypotensive values .', {'entities': [(93, 104, 'B_Disease')]}], ['These changes might offer protection to brain tissue during periods of induced hypotension .', {'entities': [(79, 90, 'B_Disease')]}], ['Triazolam - induced brief episodes of secondary mania in a depressed patient .', {'entities': [(48, 53, 'B_Disease'), (59, 68, 'B_Disease')]}], ['Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman .', {'entities': [(62, 67, 'B_Disease'), (73, 82, 'B_Disease')]}], ['Features of organic mental disorder ( delirium ) were not present .', {'entities': [(12, 19, 'B_Disease'), (20, 26, 'I_Disease'), (27, 35, 'I_Disease'), (38, 46, 'B_Disease')]}], ['Manic excitement was coincident with the duration of action of triazolam .', {'entities': [(0, 5, 'B_Disease')]}], ['The correlation between neurotoxic esterase inhibition and mipafox - induced neuropathic damage in rats .', {'entities': [(24, 34, 'B_Disease'), (77, 88, 'B_Disease'), (89, 95, 'I_Disease')]}], [\"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .\", {'entities': [(24, 35, 'B_Disease'), (36, 42, 'I_Disease'), (61, 71, 'B_Disease'), (84, 94, 'B_Disease'), (221, 231, 'B_Disease')]}], ['These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14 - 21 days post - exposure .', {'entities': [(63, 67, 'B_Disease'), (68, 74, 'I_Disease')]}], ['In contrast , dosages of Mipafox ( less than or equal to 5 mg / kg ) which inhibited mean NTE activity in spinal cord less than or equal to 61 % and brain less than or equal to 60 % produced this degree of cord damage in only 9 % of the animals .', {'entities': [(206, 210, 'B_Disease'), (211, 217, 'I_Disease')]}], ['These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later .', {'entities': [(141, 152, 'B_Disease'), (153, 159, 'I_Disease')]}], ['Allergic reaction to 5 - fluorouracil infusion .', {'entities': [(0, 8, 'B_Disease'), (9, 17, 'I_Disease')]}], ['An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin - induced impaired renal function .', {'entities': [(3, 11, 'B_Disease'), (12, 20, 'I_Disease'), (35, 48, 'B_Disease'), (49, 54, 'I_Disease'), (142, 151, 'B_Disease'), (152, 154, 'I_Disease'), (155, 158, 'I_Disease'), (159, 163, 'I_Disease'), (164, 170, 'I_Disease'), (173, 182, 'B_Disease'), (209, 217, 'B_Disease'), (218, 223, 'I_Disease'), (224, 232, 'I_Disease')]}], ['Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction .', {'entities': [(89, 97, 'B_Disease'), (98, 106, 'I_Disease')]}], ['Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis .', {'entities': [(0, 10, 'B_Disease'), (11, 17, 'I_Disease'), (70, 80, 'B_Disease'), (81, 90, 'I_Disease')]}], ['We have described a unique patient who had reversible and dose - related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis .', {'entities': [(73, 83, 'B_Disease'), (84, 90, 'I_Disease'), (139, 149, 'B_Disease'), (150, 159, 'I_Disease')]}], ['On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats .', {'entities': [(57, 65, 'B_Disease'), (66, 74, 'I_Disease')]}], ['The development of tolerance to the muscular rigidity produced by morphine was studied in rats .', {'entities': [(36, 44, 'B_Disease'), (45, 53, 'I_Disease')]}], ['Saline - pretreated controls given a test dose of morphine ( 20 mg / kg i . p . ) showed a pronounced rigidity recorded as tonic activity in the electromyogram .', {'entities': [(102, 110, 'B_Disease')]}], ['Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic ( A group ) .', {'entities': [(155, 163, 'B_Disease'), (258, 266, 'B_Disease')]}], ['The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped ( S ) licking and / or gnawing in presence of akinetic or hyperkinetic ( K ) behaviour ( AS / KS group ) , suggesting signs of dopaminergic activation .', {'entities': [(47, 55, 'B_Disease'), (136, 144, 'B_Disease'), (148, 160, 'B_Disease')]}], [\"The rigidity was considerably decreased in both groups after 20 days ' treatment .\", {'entities': [(4, 12, 'B_Disease')]}], ['In a further series of experiments , haloperidol ( 0 . 2 mg / kg i . p . ) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference .', {'entities': [(186, 194, 'B_Disease')]}], ['Haloperidol enhanced the rigidity in the A group .', {'entities': [(25, 33, 'B_Disease')]}], ['The results suggest that rigidity , which is assumed to be due to an action of morphine in the striatum , can be antagonized by another process leading to dopaminergic activation in the striatum .', {'entities': [(25, 33, 'B_Disease')]}], ['The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS / KS group might be due to rapid shifts in the predominance of various DA - innervated structures .', {'entities': [(26, 34, 'B_Disease')]}], ['A case of massive rhabdomyolysis following molindone administration .', {'entities': [(18, 32, 'B_Disease')]}], ['Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop .', {'entities': [(0, 14, 'B_Disease'), (53, 64, 'B_Disease')]}], ['The clinical signs and symptoms , typical laboratory features , and complications of rhabdomyolysis are presented .', {'entities': [(85, 99, 'B_Disease')]}], ['The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration .', {'entities': [(14, 27, 'B_Disease'), (70, 84, 'B_Disease'), (100, 105, 'B_Disease'), (106, 111, 'I_Disease'), (112, 119, 'I_Disease')]}], ['Compression neuropathy of the radial nerve due to pentazocine - induced fibrous myopathy .', {'entities': [(0, 11, 'B_Disease'), (12, 22, 'I_Disease'), (23, 25, 'I_Disease'), (26, 29, 'I_Disease'), (30, 36, 'I_Disease'), (37, 42, 'I_Disease'), (72, 79, 'B_Disease'), (80, 88, 'I_Disease')]}], ['Fibrous myopathy is a common , well - known side effect of repeated pentazocine injection .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease')]}], ['However , compression neuropathy due to fibrotic muscle affected by pentazocine - induced myopathy has not previously been reported .', {'entities': [(10, 21, 'B_Disease'), (22, 32, 'I_Disease'), (90, 98, 'B_Disease')]}], ['In a 37 - year - old woman with documented pentazocine - induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three - week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .', {'entities': [(65, 72, 'B_Disease'), (73, 81, 'I_Disease'), (324, 331, 'B_Disease'), (332, 340, 'I_Disease')]}], ['Recurrent reversible acute renal failure from amphotericin .', {'entities': [(21, 26, 'B_Disease'), (27, 32, 'I_Disease'), (33, 40, 'I_Disease')]}], ['A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions .', {'entities': [(27, 36, 'B_Disease'), (54, 68, 'B_Disease'), (79, 84, 'B_Disease'), (85, 90, 'I_Disease'), (91, 98, 'I_Disease')]}], ['The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction .', {'entities': [(22, 27, 'B_Disease'), (28, 35, 'I_Disease'), (124, 129, 'B_Disease'), (130, 141, 'I_Disease')]}], ['We propose that amphotericin , in the setting of reduced effective arterial volume , may activate tubuloglomerular feedback , thereby contributing to acute renal failure .', {'entities': [(150, 155, 'B_Disease'), (156, 161, 'I_Disease'), (162, 169, 'I_Disease')]}], ['Cerebral infarction with a single oral dose of phenylpropanolamine .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease')]}], ['Its prolonged use or overuse has been associated with seizures , intracerebral hemorrhage , neuropsychiatric symptoms , and nonhemorrhagic cerebral infarction .', {'entities': [(54, 62, 'B_Disease'), (65, 78, 'B_Disease'), (79, 89, 'I_Disease'), (92, 108, 'B_Disease'), (109, 117, 'I_Disease'), (139, 147, 'B_Disease'), (148, 158, 'I_Disease')]}], ['We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA .', {'entities': [(51, 59, 'B_Disease'), (60, 70, 'I_Disease')]}], ['Remission induction of meningeal leukemia with high - dose intravenous methotrexate .', {'entities': [(23, 32, 'B_Disease'), (33, 41, 'I_Disease')]}], ['Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high - dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10 ( - 5 ) mol / L without the need for concomitant intrathecal dosing .', {'entities': [(21, 26, 'B_Disease'), (27, 40, 'I_Disease'), (41, 49, 'I_Disease'), (64, 73, 'B_Disease'), (74, 81, 'I_Disease')]}], ['The most common toxicities encountered were transient serum transaminase and bilirubin elevations , neutropenia , and mucositis .', {'entities': [(16, 26, 'B_Disease'), (100, 111, 'B_Disease'), (118, 127, 'B_Disease')]}], ['One patient had focal seizures and transient hemiparesis but recovered completely .', {'entities': [(22, 30, 'B_Disease'), (35, 44, 'B_Disease'), (45, 56, 'I_Disease')]}], ['High - dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia .', {'entities': [(121, 126, 'B_Disease'), (127, 140, 'I_Disease'), (141, 149, 'I_Disease')]}], ['A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T - lymphocytic leukemia in relapse .', {'entities': [(83, 88, 'B_Disease'), (89, 90, 'I_Disease'), (91, 92, 'I_Disease'), (93, 104, 'I_Disease'), (105, 113, 'I_Disease')]}], ['The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow .', {'entities': [(109, 117, 'B_Disease'), (118, 130, 'I_Disease')]}], ['Severe side effects in terms of mental confusion and progressive hyperbilirubinemia , however , point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues .', {'entities': [(39, 48, 'B_Disease'), (65, 83, 'B_Disease'), (167, 175, 'B_Disease')]}], ['Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens .', {'entities': [(13, 22, 'B_Disease'), (40, 50, 'B_Disease'), (51, 60, 'I_Disease')]}], ['Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis .', {'entities': [(101, 111, 'B_Disease'), (112, 121, 'I_Disease')]}], ['There is evidence that all four immunosuppressive drugs can reduce synovitis , but disease activity almost always recurs after therapy is stopped .', {'entities': [(67, 76, 'B_Disease')]}], [\"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia , and both alkylating agents and azathioprine are associated with the development of non - Hodgkin ' s lymphoma .\", {'entities': [(81, 86, 'B_Disease'), (87, 101, 'I_Disease'), (102, 110, 'I_Disease'), (196, 199, 'B_Disease'), (200, 201, 'I_Disease'), (202, 209, 'I_Disease'), (210, 211, 'I_Disease'), (212, 213, 'I_Disease'), (214, 222, 'I_Disease')]}], ['Cyclophosphamide therapy increases the risk of carcinoma of the bladder .', {'entities': [(47, 56, 'B_Disease'), (57, 59, 'I_Disease'), (60, 63, 'I_Disease'), (64, 71, 'I_Disease')]}], ['There have been several long - term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased .', {'entities': [(61, 71, 'B_Disease'), (72, 81, 'I_Disease'), (169, 176, 'B_Disease')]}], ['Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly alkylating agents , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life - threatening complications .', {'entities': [(39, 49, 'B_Disease'), (53, 63, 'B_Disease'), (64, 73, 'I_Disease'), (237, 247, 'B_Disease'), (248, 257, 'I_Disease')]}], ['Warfarin - induced iliopsoas hemorrhage with subsequent femoral nerve palsy .', {'entities': [(29, 39, 'B_Disease'), (56, 63, 'B_Disease'), (64, 69, 'I_Disease'), (70, 75, 'I_Disease')]}], ['We present the case of a 28 - year - old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip .', {'entities': [(95, 101, 'B_Disease'), (102, 106, 'I_Disease'), (132, 136, 'B_Disease'), (151, 162, 'B_Disease')]}], ['Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment , resulting in a femoral nerve palsy and partial loss of quadriceps functions .', {'entities': [(43, 51, 'B_Disease'), (64, 69, 'B_Disease'), (70, 80, 'I_Disease'), (98, 105, 'B_Disease'), (106, 111, 'I_Disease'), (112, 117, 'I_Disease'), (122, 129, 'B_Disease'), (130, 134, 'I_Disease'), (135, 137, 'I_Disease'), (138, 148, 'I_Disease'), (149, 158, 'I_Disease')]}], ['Anticoagulant - induced femoral nerve palsy represents the most common form of warfarin - induced peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .', {'entities': [(24, 31, 'B_Disease'), (32, 37, 'I_Disease'), (38, 43, 'I_Disease'), (98, 108, 'B_Disease'), (109, 119, 'I_Disease'), (152, 156, 'B_Disease'), (201, 206, 'B_Disease'), (207, 210, 'I_Disease'), (211, 218, 'I_Disease'), (219, 229, 'I_Disease'), (244, 255, 'B_Disease')]}], ['Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .', {'entities': [(17, 24, 'B_Disease'), (25, 28, 'I_Disease'), (29, 40, 'I_Disease'), (41, 49, 'I_Disease'), (54, 64, 'B_Disease')]}], ['A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of supraventricular tachyarrhythmias .', {'entities': [(15, 25, 'B_Disease'), (26, 33, 'I_Disease'), (174, 190, 'B_Disease'), (191, 207, 'I_Disease')]}], ['He developed pneumonitis , pleural and pericardial effusions , and a predominantly proximal motor neuropathy .', {'entities': [(13, 24, 'B_Disease'), (27, 34, 'B_Disease'), (35, 38, 'I_Disease'), (39, 50, 'I_Disease'), (51, 60, 'I_Disease'), (83, 91, 'B_Disease'), (92, 97, 'I_Disease'), (98, 108, 'I_Disease')]}], ['Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .', {'entities': [(98, 109, 'B_Disease')]}], ['Amiodarone - induced sinoatrial block .', {'entities': [(21, 31, 'B_Disease'), (32, 37, 'I_Disease')]}], ['We observed sinoatrial block due to chronic amiodarone administration in a 5 - year - old boy with primary cardiomyopathy , Wolff - Parkinson - White syndrome and supraventricular tachycardia .', {'entities': [(12, 22, 'B_Disease'), (23, 28, 'I_Disease'), (99, 106, 'B_Disease'), (107, 121, 'I_Disease'), (124, 129, 'B_Disease'), (130, 131, 'I_Disease'), (132, 141, 'I_Disease'), (142, 143, 'I_Disease'), (144, 149, 'I_Disease'), (150, 158, 'I_Disease'), (163, 179, 'B_Disease'), (180, 191, 'I_Disease')]}], ['Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia .', {'entities': [(75, 85, 'B_Disease'), (86, 91, 'I_Disease'), (128, 133, 'B_Disease'), (134, 145, 'I_Disease')]}], ['Desipramine - induced delirium at \" subtherapeutic \" concentrations : a case report .', {'entities': [(22, 30, 'B_Disease')]}], ['An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the \" subtherapeutic \" range .', {'entities': [(65, 73, 'B_Disease')]}], ['Delirium , which may be induced by tricyclic drug therapy in the elderly , can be caused by tricyclics with low anticholinergic potency .', {'entities': [(0, 8, 'B_Disease')]}], ['Indomethacin - induced renal insufficiency : recurrence on rechallenge .', {'entities': [(23, 28, 'B_Disease'), (29, 42, 'I_Disease')]}], ['We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , ascites , and cor pulmonale after indomethacin therapy .', {'entities': [(42, 47, 'B_Disease'), (48, 55, 'I_Disease'), (61, 73, 'B_Disease'), (92, 101, 'B_Disease'), (104, 111, 'B_Disease'), (118, 121, 'B_Disease'), (122, 131, 'I_Disease')]}], ['Prompt restoration of renal function followed drug withdrawal , while re - exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria .', {'entities': [(155, 163, 'B_Disease')]}], ['Since nonsteroidal anti - inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure , they should be used with caution in such patients .', {'entities': [(103, 108, 'B_Disease'), (109, 114, 'I_Disease'), (115, 122, 'I_Disease')]}], ['Patterns of hepatic injury induced by methyldopa .', {'entities': [(12, 19, 'B_Disease'), (20, 26, 'I_Disease')]}], ['Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977 .', {'entities': [(21, 26, 'B_Disease'), (27, 34, 'I_Disease')]}], ['Jaundice with tender hepatomegaly , usually preceded by symptoms of malaise , anorexia , nausea and vomiting , and associated with upper abdominal pain , was an invariable finding in all patients .', {'entities': [(0, 8, 'B_Disease'), (21, 33, 'B_Disease'), (78, 86, 'B_Disease'), (89, 95, 'B_Disease'), (100, 108, 'B_Disease'), (137, 146, 'B_Disease'), (147, 151, 'I_Disease')]}], ['Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury , the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis .', {'entities': [(58, 66, 'B_Disease'), (117, 124, 'B_Disease'), (125, 131, 'I_Disease'), (168, 173, 'B_Disease'), (174, 180, 'I_Disease'), (206, 214, 'B_Disease'), (218, 225, 'B_Disease'), (226, 233, 'I_Disease'), (234, 242, 'I_Disease')]}], ['Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis .', {'entities': [(40, 45, 'B_Disease'), (46, 55, 'I_Disease'), (59, 66, 'B_Disease'), (67, 73, 'I_Disease'), (74, 83, 'I_Disease'), (100, 111, 'B_Disease')]}], ['One patient died , having presented in hepatic failure , and another , who had been taking methyldopa for 7 years , showed slower clinical and biochemical resolution over a period of several months .', {'entities': [(39, 46, 'B_Disease'), (47, 54, 'I_Disease')]}], ['The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa - induced hepatitis .', {'entities': [(46, 55, 'B_Disease'), (56, 65, 'I_Disease'), (162, 171, 'B_Disease')]}], ['In this latter patient , and in 2 others , the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re - exposure to the drug .', {'entities': [(90, 97, 'B_Disease'), (98, 109, 'I_Disease'), (144, 153, 'B_Disease')]}], ['Suxamethonium infusion rate and observed fasciculations .', {'entities': [(41, 55, 'B_Disease')]}], ['The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded .', {'entities': [(76, 83, 'B_Disease')]}], ['Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score .', {'entities': [(0, 14, 'B_Disease'), (88, 101, 'B_Disease')]}], ['The times to first fasciculation , twitch suppression and tetanus suppression were inversely related to the infusion rates .', {'entities': [(19, 32, 'B_Disease'), (35, 41, 'B_Disease'), (58, 65, 'B_Disease')]}], ['Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion .', {'entities': [(0, 14, 'B_Disease'), (46, 59, 'B_Disease')]}], ['Total fasciculation scores in the 30 - mg bolus group and the 5 - mg s - 1 and 20 - mg s - 1 infusion groups were not significantly different .', {'entities': [(6, 19, 'B_Disease')]}], ['Treatment of psoriasis with azathioprine .', {'entities': [(13, 22, 'B_Disease')]}], ['Azathioprine treatment benefited 19 ( 66 % ) out of 29 patients suffering from severe psoriasis .', {'entities': [(86, 95, 'B_Disease')]}], ['Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight .', {'entities': [(8, 19, 'B_Disease'), (53, 61, 'B_Disease')]}], ['Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage .', {'entities': [(113, 118, 'B_Disease'), (119, 125, 'I_Disease')]}], ['Angiosarcoma of the liver associated with diethylstilbestrol .', {'entities': [(0, 12, 'B_Disease'), (13, 15, 'I_Disease'), (16, 19, 'I_Disease'), (20, 25, 'I_Disease')]}], ['Angiosarcoma of the liver occurred in a 76 - year - old man who had been treated for a well - differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years .', {'entities': [(0, 12, 'B_Disease'), (13, 15, 'I_Disease'), (16, 19, 'I_Disease'), (20, 25, 'I_Disease'), (109, 123, 'B_Disease'), (124, 126, 'I_Disease'), (127, 130, 'I_Disease'), (131, 136, 'I_Disease')]}], ['Angiosarcoma was also present within pulmonary and renal arteries .', {'entities': [(0, 12, 'B_Disease')]}], ['The possibility that the intraarterial lesions might represent independent primary tumors is considered .', {'entities': [(25, 38, 'B_Disease'), (39, 46, 'I_Disease'), (83, 89, 'B_Disease')]}], ['Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of scopolamine ( hyoscine ) overdosage .', {'entities': [(186, 196, 'B_Disease')]}], ['Dizziness was less marked than sedation , but increased with the dose .', {'entities': [(0, 9, 'B_Disease')]}], ['There was pain on i . m . injection of flunitrazepam significantly more often than with isotonic saline .', {'entities': [(10, 14, 'B_Disease')]}], ['Three infants , born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy , were found to have major congenital anomalies .', {'entities': [(41, 53, 'B_Disease'), (54, 59, 'I_Disease'), (60, 67, 'I_Disease'), (159, 169, 'B_Disease'), (170, 179, 'I_Disease')]}], ['In the singleton pregnancy , the mother had ulcerative colitis , and the infant , a male , had coarctation of the aorta and a ventricular septal defect .', {'entities': [(44, 54, 'B_Disease'), (55, 62, 'I_Disease'), (95, 106, 'B_Disease'), (107, 109, 'I_Disease'), (110, 113, 'I_Disease'), (114, 119, 'I_Disease'), (126, 137, 'B_Disease'), (138, 144, 'I_Disease'), (145, 151, 'I_Disease')]}], [\"In the twin pregnancy , the mother had Crohn ' s disease .\", {'entities': [(39, 44, 'B_Disease'), (45, 46, 'I_Disease'), (47, 48, 'I_Disease'), (49, 56, 'I_Disease')]}], ['The first twin , a female , had a left Potter - type IIa polycystic kidney and a rudimentary left uterine cornu .', {'entities': [(39, 45, 'B_Disease'), (46, 47, 'I_Disease'), (48, 52, 'I_Disease'), (53, 56, 'I_Disease'), (57, 67, 'I_Disease'), (68, 74, 'I_Disease'), (81, 92, 'B_Disease'), (93, 97, 'I_Disease'), (98, 105, 'I_Disease'), (106, 111, 'I_Disease')]}], [\"The second twin , a male , had some features of Potter ' s facies , hypoplastic lungs , absent kidneys and ureters , and talipes equinovarus .\", {'entities': [(48, 54, 'B_Disease'), (55, 56, 'I_Disease'), (57, 58, 'I_Disease'), (59, 65, 'I_Disease'), (68, 79, 'B_Disease'), (80, 85, 'I_Disease'), (88, 94, 'B_Disease'), (95, 102, 'I_Disease'), (103, 106, 'I_Disease'), (107, 114, 'I_Disease'), (121, 128, 'B_Disease'), (129, 140, 'I_Disease')]}], ['Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy .', {'entities': [(0, 10, 'B_Disease'), (11, 26, 'I_Disease'), (31, 36, 'B_Disease'), (37, 44, 'I_Disease')]}], ['Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a vinca alkaloid .', {'entities': [(19, 28, 'B_Disease'), (39, 49, 'B_Disease'), (50, 65, 'I_Disease'), (85, 90, 'B_Disease'), (91, 104, 'I_Disease'), (107, 123, 'B_Disease'), (124, 133, 'I_Disease'), (134, 140, 'I_Disease'), (155, 171, 'B_Disease')]}], ['One patient had thrombotic thrombocytopenic purpura , three the hemolytic - uremic syndrome , and one an apparent forme fruste of one of these disorders .', {'entities': [(16, 26, 'B_Disease'), (27, 43, 'I_Disease'), (44, 51, 'I_Disease'), (64, 73, 'B_Disease'), (74, 75, 'I_Disease'), (76, 82, 'I_Disease'), (83, 91, 'I_Disease')]}], ['Histologic examination of the renal tissue showed evidence of intravascular coagulation , primarily affecting the small arteries , arterioles , and glomeruli .', {'entities': [(62, 75, 'B_Disease'), (76, 87, 'I_Disease')]}], ['Because each patient was tumor - free or had only a small tumor at the onset of this syndrome , the thrombotic microangiopathy may have been induced by chemotherapy .', {'entities': [(25, 30, 'B_Disease'), (58, 63, 'B_Disease'), (100, 110, 'B_Disease'), (111, 126, 'I_Disease')]}], ['Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug - induced bone marrow suppression .', {'entities': [(146, 151, 'B_Disease'), (152, 159, 'I_Disease'), (189, 203, 'B_Disease'), (212, 218, 'B_Disease'), (223, 239, 'B_Disease'), (258, 262, 'B_Disease'), (263, 269, 'I_Disease'), (270, 281, 'I_Disease')]}], ['Report on arrhythmia and other findings .', {'entities': [(10, 20, 'B_Disease')]}], ['The antiarrhythmic effects of the sustained release form of mexiletine ( Mexitil - Perlongets ) were evaluated in a double - blind placebo trial in 630 patients with recent documented myocardial infarction .', {'entities': [(184, 194, 'B_Disease'), (195, 205, 'I_Disease')]}], ['There were more deaths in the mexiletine group ( 7 . 6 % ) than in the placebo group ( 4 . 8 % ) ; the difference was not statistically significant .', {'entities': [(16, 22, 'B_Disease')]}], ['Previously recognized side effects , particularly tremor and gastrointestinal problems , were more frequent in the mexiletine group than in the placebo group .', {'entities': [(50, 56, 'B_Disease'), (61, 77, 'B_Disease'), (78, 86, 'I_Disease')]}], ['Changes in heart size during long - term timolol treatment after myocardial infarction .', {'entities': [(65, 75, 'B_Disease'), (76, 86, 'I_Disease')]}], ['The effect of long - term timolol treatment on heart size after myocardial infarction was evaluated by X - ray in a double - blind study including 241 patients ( placebo 126 , timolol 115 ) .', {'entities': [(64, 74, 'B_Disease'), (75, 85, 'I_Disease')]}], ['These differences may be caused by timolol - induced bradycardia and a compensatory increase in end - diastolic volume .', {'entities': [(53, 64, 'B_Disease')]}], ['In patients with cardiomegaly , the increase in heart size was similar in both groups .', {'entities': [(17, 29, 'B_Disease')]}], ['After re - infarction , heart size increased in the placebo group and remained unchanged in the timolol group .', {'entities': [(11, 21, 'B_Disease')]}], ['Vitamin D3 toxicity in dairy cows .', {'entities': [(11, 19, 'B_Disease')]}], ['Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .', {'entities': [(110, 123, 'B_Disease'), (126, 143, 'B_Disease')]}], ['None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period ; however , 22 % of the control cows developed clinical signs of milk fever during this period .', {'entities': [(57, 61, 'B_Disease'), (62, 67, 'I_Disease'), (162, 166, 'B_Disease'), (167, 172, 'I_Disease')]}], ['Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died .', {'entities': [(20, 28, 'B_Disease'), (152, 160, 'B_Disease')]}], ['Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum .', {'entities': [(23, 31, 'B_Disease'), (140, 144, 'B_Disease'), (145, 150, 'I_Disease'), (173, 177, 'B_Disease'), (178, 183, 'I_Disease'), (253, 257, 'B_Disease'), (258, 263, 'I_Disease')]}], ['Diseases of peripheral nerves as seen in the Nigerian African .', {'entities': [(0, 8, 'B_Disease'), (9, 11, 'I_Disease'), (12, 22, 'I_Disease'), (23, 29, 'I_Disease')]}], ['The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders , as seen in 358 Nigerians are presented .', {'entities': [(45, 55, 'B_Disease'), (56, 61, 'I_Disease'), (62, 69, 'I_Disease')]}], ['Sensori - motor neuropathy was the commonest presentation ( 50 % ) .', {'entities': [(0, 7, 'B_Disease'), (8, 9, 'I_Disease'), (10, 15, 'I_Disease'), (16, 26, 'I_Disease')]}], ['Guillain - Barr syndrome was the commonest identifiable cause ( 15 . 6 % ) , accounting for half of the cases with motor neuropathy .', {'entities': [(0, 8, 'B_Disease'), (9, 10, 'I_Disease'), (11, 15, 'I_Disease'), (16, 24, 'I_Disease'), (115, 120, 'B_Disease'), (121, 131, 'I_Disease')]}], ['Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (29, 40, 'B_Disease'), (41, 51, 'I_Disease'), (139, 146, 'B_Disease'), (147, 148, 'I_Disease'), (149, 154, 'I_Disease'), (155, 165, 'I_Disease')]}], ['Diabetes mellitus was the major cause of autonomic neuropathy .', {'entities': [(0, 8, 'B_Disease'), (9, 17, 'I_Disease'), (41, 50, 'B_Disease'), (51, 61, 'I_Disease')]}], ['Isoniazid was the most frequent agent in drug - induced neuropathy .', {'entities': [(56, 66, 'B_Disease')]}], ['Migraine ( 20 % ) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent ( 26 % ) .', {'entities': [(0, 8, 'B_Disease'), (47, 54, 'B_Disease'), (55, 65, 'I_Disease'), (75, 87, 'B_Disease')]}], ['In 26 . 5 % of all the cases , the aetiology of the neuropathy was undetermined .', {'entities': [(52, 62, 'B_Disease')]}], ['Heredofamilial and connective tissue disorders were rare .', {'entities': [(19, 29, 'B_Disease'), (30, 36, 'I_Disease'), (37, 46, 'I_Disease')]}], ['Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed .', {'entities': [(81, 93, 'B_Disease')]}], ['Reduction in caffeine toxicity by acetaminophen .', {'entities': [(22, 30, 'B_Disease')]}], ['Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS , attention was focused on the possibility that the presence of acetaminophen ( 52 micrograms / mL ) reduced the CNS toxicity of caffeine .', {'entities': [(214, 222, 'B_Disease')]}], ['Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .', {'entities': [(202, 213, 'B_Disease'), (332, 340, 'B_Disease')]}], ['The frequency of sound - induced seizures after 12 . 5 or 25 mg / kg caffeine was reduced from 50 to 5 % by acetaminophen .', {'entities': [(33, 41, 'B_Disease')]}], ['In the absence of caffeine , acetaminophen ( up to 300 mg / kg ) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .', {'entities': [(84, 92, 'B_Disease')]}], ['A double - blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder .', {'entities': [(103, 113, 'B_Disease'), (114, 122, 'I_Disease')]}], ['In a 6 - week double - blind parallel treatment study , dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients .', {'entities': [(132, 141, 'B_Disease')]}], ['Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness , and both were significantly superior to placebo .', {'entities': [(82, 92, 'B_Disease'), (93, 100, 'I_Disease')]}], ['The overall incidence of side effects and the frequency and severity of blurred vision , dry mouth , and drowsiness were significantly less with dothiepin than with amitriptyline .', {'entities': [(72, 79, 'B_Disease'), (80, 86, 'I_Disease'), (89, 92, 'B_Disease'), (93, 98, 'I_Disease')]}], ['Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients .', {'entities': [(138, 147, 'B_Disease')]}], ['Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia .', {'entities': [(64, 69, 'B_Disease'), (70, 78, 'I_Disease'), (83, 94, 'B_Disease')]}], ['The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double - blind , randomized and crossover design .', {'entities': [(241, 246, 'B_Disease'), (247, 256, 'I_Disease'), (261, 272, 'B_Disease')]}], ['Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol .', {'entities': [(11, 19, 'B_Disease'), (20, 29, 'I_Disease'), (30, 34, 'I_Disease'), (35, 41, 'I_Disease')]}], ['Delayed free recall was also impaired but the two drugs did not differ .', {'entities': [(0, 7, 'B_Disease'), (8, 12, 'I_Disease'), (13, 19, 'I_Disease'), (20, 23, 'I_Disease'), (24, 28, 'I_Disease'), (29, 37, 'I_Disease')]}], ['Accumulation of drugs was not reflected in prolonged behavioral impairment .', {'entities': [(53, 63, 'B_Disease'), (64, 74, 'I_Disease')]}], ['Comparison of i . v . glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children .', {'entities': [(71, 82, 'B_Disease'), (87, 98, 'B_Disease')]}], ['The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg - 1 and atropine 10 and 20 micrograms kg - 1 i . v . immediately before the induction of anaesthesia , to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children , was studied .', {'entities': [(191, 201, 'B_Disease'), (206, 217, 'B_Disease')]}], ['A frequency of bradycardia of 50 % was noted in the control group , but this was not significantly different from the frequency with the active drugs .', {'entities': [(15, 26, 'B_Disease')]}], ['Bradycardia ( defined as a decrease in heart rate to less than 50 beat min - 1 ) was prevented when the larger dose of either active drug was used .', {'entities': [(0, 11, 'B_Disease')]}], ['Veno - occlusive liver disease after dacarbazine therapy ( DTIC ) for melanoma .', {'entities': [(0, 4, 'B_Disease'), (5, 6, 'I_Disease'), (7, 16, 'I_Disease'), (17, 22, 'I_Disease'), (23, 30, 'I_Disease'), (70, 78, 'B_Disease')]}], ['A case of veno - occlusive disease of the liver with fatal outcome after dacarbazine ( DTIC ) therapy for melanoma is reported .', {'entities': [(10, 14, 'B_Disease'), (15, 16, 'I_Disease'), (17, 26, 'I_Disease'), (27, 34, 'I_Disease'), (35, 37, 'I_Disease'), (38, 41, 'I_Disease'), (42, 47, 'I_Disease'), (106, 114, 'B_Disease')]}], ['There was a fulminant clinical course from start of symptoms until death .', {'entities': [(67, 72, 'B_Disease')]}], ['At autopsy the liver was enlarged and firm with signs of venous congestion .', {'entities': [(57, 63, 'B_Disease'), (64, 74, 'I_Disease')]}], ['Small - and medium - sized hepatic veins were blocked by thrombosis .', {'entities': [(57, 67, 'B_Disease')]}], [\"Maternal lithium and neonatal Ebstein ' s anomaly : evaluation with cross - sectional echocardiography .\", {'entities': [(30, 37, 'B_Disease'), (38, 39, 'I_Disease'), (40, 41, 'I_Disease'), (42, 49, 'I_Disease')]}], [\"In one infant , Ebstein ' s anomaly of the tricuspid valve was identified .\", {'entities': [(16, 23, 'B_Disease'), (24, 25, 'I_Disease'), (26, 27, 'I_Disease'), (28, 35, 'I_Disease')]}], [\"In the other infant cross - sectional echocardiography provided reassurance that the infant did not have Ebstein ' s anomaly .\", {'entities': [(105, 112, 'B_Disease'), (113, 114, 'I_Disease'), (115, 116, 'I_Disease'), (117, 124, 'I_Disease')]}], ['Cross - sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate , noninvasive assessment of the presence or absence of lithium - induced cardiac malformations .', {'entities': [(195, 202, 'B_Disease'), (203, 216, 'I_Disease')]}], ['Effects of training on the extent of experimental myocardial infarction in aging rats .', {'entities': [(50, 60, 'B_Disease'), (61, 71, 'I_Disease')]}], ['The effects of exercise on the severity of isoproterenol - induced myocardial infarction were studied in female albino rats of 20 , 40 , 60 and 80 weeks of age .', {'entities': [(67, 77, 'B_Disease'), (78, 88, 'I_Disease')]}], ['The occurrence of infarcts were confirmed by histological methods .', {'entities': [(18, 26, 'B_Disease')]}], ['Studies dealing with myocardial infarction are more informative when dealt with age .', {'entities': [(21, 31, 'B_Disease'), (32, 42, 'I_Disease')]}], ['Effect of polyethylene glycol 400 on adriamycin toxicity in mice .', {'entities': [(48, 56, 'B_Disease')]}], ['Light microscopic analysis showed a significant protection against ADR - induced cardiac morphological alterations .', {'entities': [(81, 88, 'B_Disease'), (89, 102, 'I_Disease'), (103, 114, 'I_Disease')]}], ['Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor .', {'entities': [(62, 67, 'B_Disease'), (68, 76, 'I_Disease'), (84, 91, 'B_Disease'), (92, 99, 'I_Disease'), (100, 105, 'I_Disease')]}], ['UM - 272 ( N , N - dimethylpropranolol ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with ouabain - induced ventricular tachycardias .', {'entities': [(140, 151, 'B_Disease'), (152, 164, 'I_Disease')]}], ['Sublingual UM - 272 converted ventricular tachycardia to sinus rhythm in all 5 dogs .', {'entities': [(30, 41, 'B_Disease'), (42, 53, 'I_Disease')]}], ['Early adjuvant adriamycin in superficial bladder carcinoma .', {'entities': [(41, 48, 'B_Disease'), (49, 58, 'I_Disease')]}], ['A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder .', {'entities': [(85, 94, 'B_Disease'), (95, 97, 'I_Disease'), (98, 101, 'I_Disease'), (102, 109, 'I_Disease')]}], ['Adriamycin ( 50 mg / 50 ml ) was administered intravesically within 24 h after transurethral resection of TA - T1 ( O - A ) bladder tumors .', {'entities': [(124, 131, 'B_Disease'), (132, 138, 'I_Disease')]}], ['In 24 of these patients chemical cystitis was severe enough for them to drop out of the study .', {'entities': [(33, 41, 'B_Disease')]}], ['Of these recurrences , 27 were T1 tumors while five progressed to more highly invasive lesions .', {'entities': [(34, 40, 'B_Disease')]}], ['In patients that were free of recurrence during the first year , 80 % remained tumor - free during the 2 - to 3 - year follow - up period .', {'entities': [(79, 84, 'B_Disease')]}], ['D - penicillamine - induced angiopathy in rats .', {'entities': [(28, 38, 'B_Disease')]}], ['The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of forestomach tumors .', {'entities': [(175, 182, 'B_Disease'), (183, 193, 'I_Disease'), (225, 236, 'B_Disease'), (237, 243, 'I_Disease')]}], [\"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach , and that aspirin ' s effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .\", {'entities': [(130, 144, 'B_Disease')]}], ['A case of tardive dyskinesia caused by metoclopramide .', {'entities': [(10, 17, 'B_Disease'), (18, 28, 'I_Disease')]}], ['Abnormal involuntary movements appeared in the mouth , tongue , neck and abdomen of a 64 - year - old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days .', {'entities': [(0, 8, 'B_Disease'), (9, 20, 'I_Disease'), (21, 30, 'I_Disease'), (148, 164, 'B_Disease'), (165, 173, 'I_Disease')]}], ['When the metoclopramide administration was discontinued , the abnormal movements gradually improved to a considerable extent .', {'entities': [(62, 70, 'B_Disease'), (71, 80, 'I_Disease')]}], ['Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug .', {'entities': [(48, 55, 'B_Disease'), (56, 66, 'I_Disease')]}], ['Intra - arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system .', {'entities': [(52, 61, 'B_Disease'), (62, 69, 'I_Disease')]}], ['Because of the rapid systemic clearance of BCNU ( 1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea ) , intra - arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas .', {'entities': [(230, 239, 'B_Disease'), (240, 247, 'I_Disease')]}], ['Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy .', {'entities': [(37, 49, 'B_Disease'), (94, 99, 'B_Disease')]}], ['After two to seven cycles of chemotherapy , nine patients showed a decrease in tumor size and surrounding edema on contrast - enhanced computerized tomography scans .', {'entities': [(79, 84, 'B_Disease'), (106, 111, 'B_Disease')]}], ['Twenty - four patients with recurrent Grade I to IV astrocytomas , whose resection and irradiation therapy had failed , received two to eight courses of intra - arterial BCNU therapy .', {'entities': [(52, 64, 'B_Disease')]}], ['A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis .', {'entities': [(60, 64, 'B_Disease'), (65, 67, 'I_Disease'), (68, 74, 'I_Disease'), (90, 97, 'B_Disease'), (98, 108, 'I_Disease')]}], ['The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered .', {'entities': [(17, 23, 'B_Disease'), (24, 28, 'I_Disease')]}], ['Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy ?', {'entities': [(24, 35, 'B_Disease'), (56, 64, 'B_Disease'), (65, 74, 'I_Disease'), (75, 85, 'I_Disease')]}], ['The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 diabetic subjects with autonomic neuropathy .', {'entities': [(109, 117, 'B_Disease'), (135, 144, 'B_Disease'), (145, 155, 'I_Disease'), (164, 172, 'B_Disease'), (187, 196, 'B_Disease'), (197, 207, 'I_Disease')]}], ['The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .', {'entities': [(155, 163, 'B_Disease'), (181, 190, 'B_Disease'), (191, 201, 'I_Disease'), (310, 318, 'B_Disease'), (333, 342, 'B_Disease'), (343, 353, 'I_Disease')]}], ['It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients , particularly those with autonomic neuropathy .', {'entities': [(97, 105, 'B_Disease'), (141, 150, 'B_Disease'), (151, 161, 'I_Disease')]}], ['Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously .', {'entities': [(44, 56, 'B_Disease')]}], ['These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism .', {'entities': [(27, 39, 'B_Disease')]}], ['Characterization of estrogen - induced adenohypophyseal tumors in the Fischer 344 rat .', {'entities': [(39, 55, 'B_Disease'), (56, 62, 'I_Disease')]}], ['Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol ( DES , 8 - 10 mg ) implanted subcutaneously in silastic capsules .', {'entities': [(0, 9, 'B_Disease'), (10, 16, 'I_Disease')]}], ['The data extend the findings of other investigators , further establishing the DES - induced tumor as a model for study of PRL cellular control mechanisms .', {'entities': [(93, 98, 'B_Disease')]}], ['There was only one case of dementia possibly due to cimetidine ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1 . 25 microgram / ml .', {'entities': [(27, 35, 'B_Disease'), (161, 166, 'B_Disease'), (167, 169, 'I_Disease'), (170, 176, 'I_Disease'), (177, 184, 'I_Disease')]}], ['Thus , high cimetidine levels alone do not always induce dementia .', {'entities': [(57, 65, 'B_Disease')]}], ['A case is presented of a reversible intra - Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities .', {'entities': [(36, 41, 'B_Disease'), (42, 43, 'I_Disease'), (44, 50, 'I_Disease'), (51, 56, 'I_Disease'), (98, 104, 'B_Disease'), (105, 116, 'I_Disease'), (144, 160, 'B_Disease'), (161, 171, 'I_Disease'), (172, 185, 'I_Disease')]}], ['His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals ( 40 and 100 msec , respectively ) .', {'entities': [(32, 38, 'B_Disease'), (39, 50, 'I_Disease')]}], ['Thirty days after amiodarone discontinuation , His bundle electrograms showed atrial flutter without intra - Hisian or infra - Hisian delay .', {'entities': [(78, 84, 'B_Disease'), (85, 92, 'I_Disease')]}], ['Development of clear cell adenocarcinoma in DES - exposed offspring under observation .', {'entities': [(15, 20, 'B_Disease'), (21, 25, 'I_Disease'), (26, 40, 'I_Disease')]}], ['Two cases of clear cell adenocarcinoma of the vagina detected at follow - up in young women exposed in utero to diethylstilbestrol are reported .', {'entities': [(13, 18, 'B_Disease'), (19, 23, 'I_Disease'), (24, 38, 'I_Disease'), (39, 41, 'I_Disease'), (42, 45, 'I_Disease'), (46, 52, 'I_Disease')]}], ['One patient , aged 23 , had been followed for 2 years before carcinoma was diagnosed ; the second patient , aged 22 , had been seen on a regular basis for 5 years , 8 months .', {'entities': [(61, 70, 'B_Disease')]}], ['In both instances , suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix .', {'entities': [(49, 58, 'B_Disease')]}], ['The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated .', {'entities': [(84, 97, 'B_Disease')]}], ['Of the 20 animals that received subarachnoid injection of 2 - chloroprocaine - CE seven ( 35 % ) developed hind - limb paralysis .', {'entities': [(119, 128, 'B_Disease')]}], ['None of the animals that received bupivacaine , normal saline , or normal saline titrated to a pH 3 . 0 developed hind - limb paralysis .', {'entities': [(126, 135, 'B_Disease')]}], ['Of the 15 spinal cords of the animals that received 2 - chloroprocaine - CE , 13 showed subpial necrosis ; the nerve roots and subarachnoid vessels were normal .', {'entities': [(88, 95, 'B_Disease'), (96, 104, 'I_Disease')]}], ['Procainamide - induced polymorphous ventricular tachycardia .', {'entities': [(36, 47, 'B_Disease'), (48, 59, 'I_Disease')]}], ['Seven cases of procainamide - induced polymorphous ventricular tachycardia are presented .', {'entities': [(51, 62, 'B_Disease'), (63, 74, 'I_Disease')]}], ['In four patients , polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia .', {'entities': [(32, 43, 'B_Disease'), (44, 55, 'I_Disease'), (162, 173, 'B_Disease'), (174, 185, 'I_Disease')]}], ['In the remaining three patients , procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter .', {'entities': [(96, 105, 'B_Disease'), (106, 117, 'I_Disease'), (118, 130, 'I_Disease'), (134, 140, 'B_Disease'), (141, 148, 'I_Disease')]}], ['These patients had Q - T prolongation and recurrent syncope due to polymorphous ventricular tachycardia .', {'entities': [(19, 20, 'B_Disease'), (21, 22, 'I_Disease'), (23, 24, 'I_Disease'), (25, 37, 'I_Disease'), (52, 59, 'B_Disease'), (80, 91, 'B_Disease'), (92, 103, 'I_Disease')]}], ['In four patients , the arrhythmia was rapidly diagnosed and treated with disappearance of further episodes of the arrhythmia .', {'entities': [(23, 33, 'B_Disease'), (114, 124, 'B_Disease')]}], ['In two patients , the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died .', {'entities': [(22, 32, 'B_Disease'), (63, 74, 'B_Disease'), (75, 87, 'I_Disease')]}], ['In the seventh patient , a permanent ventricular pacemaker was inserted and , despite continuation of procainamide therapy , polymorphous ventricular tachycardia did not reoccur .', {'entities': [(138, 149, 'B_Disease'), (150, 161, 'I_Disease')]}], ['These seven cases demonstrate that procainamide can produce an acquired prolonged Q - T syndrome with polymorphous ventricular tachycardia .', {'entities': [(72, 81, 'B_Disease'), (82, 83, 'I_Disease'), (84, 85, 'I_Disease'), (86, 87, 'I_Disease'), (88, 96, 'I_Disease'), (115, 126, 'B_Disease'), (127, 138, 'I_Disease')]}], ['Phenobarbitone - induced enlargement of the liver in the rat : its relationship to carbon tetrachloride - induced cirrhosis .', {'entities': [(25, 36, 'B_Disease'), (37, 39, 'I_Disease'), (40, 43, 'I_Disease'), (44, 49, 'I_Disease'), (114, 123, 'B_Disease')]}], ['The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial \" calibrating \" dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .', {'entities': [(20, 29, 'B_Disease'), (30, 32, 'I_Disease'), (33, 36, 'I_Disease'), (37, 42, 'I_Disease'), (118, 125, 'B_Disease'), (187, 199, 'B_Disease'), (236, 243, 'B_Disease'), (519, 530, 'B_Disease'), (531, 533, 'I_Disease'), (534, 537, 'I_Disease'), (538, 543, 'I_Disease')]}], ['Triamterene nephrolithiasis complicating dyazide therapy .', {'entities': [(12, 27, 'B_Disease')]}], ['A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide - triamterene therapy for hypertension .', {'entities': [(22, 37, 'B_Disease'), (122, 134, 'B_Disease')]}], ['Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed .', {'entities': [(30, 45, 'B_Disease')]}], ['Busulfan - induced hemorrhagic cystitis .', {'entities': [(19, 30, 'B_Disease'), (31, 39, 'I_Disease')]}], ['A case of a busulfan - induced hemorrhage cystitis is reported .', {'entities': [(31, 41, 'B_Disease'), (42, 50, 'I_Disease')]}], ['The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide - induced cystitis is discussed and the world literature reviewed .', {'entities': [(62, 70, 'B_Disease'), (121, 129, 'B_Disease')]}], ['In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites , periodic urinary cytology is suggested in patients on long - term therapy .', {'entities': [(72, 81, 'B_Disease')]}], ['Variant ventricular tachycardia in desipramine toxicity .', {'entities': [(8, 19, 'B_Disease'), (20, 31, 'I_Disease'), (47, 55, 'B_Disease')]}], ['We report a case of variant ventricular tachycardia induced by desipramine toxicity .', {'entities': [(28, 39, 'B_Disease'), (40, 51, 'I_Disease'), (75, 83, 'B_Disease')]}], ['Unusual features of the arrhythmia are repetitive group beating , progressive shortening of the R - R interval , progressive widening of the QRS complex with eventual failure of intraventricular conduction , and changes in direction of the QRS axis .', {'entities': [(24, 34, 'B_Disease')]}], ['Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia .', {'entities': [(23, 34, 'B_Disease'), (35, 46, 'I_Disease'), (105, 116, 'B_Disease'), (117, 128, 'I_Disease')]}], ['Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats .', {'entities': [(8, 20, 'B_Disease')]}], ['The role of the renin - - angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ( SNP ) - induced hypotension was evaluated .', {'entities': [(153, 164, 'B_Disease')]}], ['During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr , whereas the saralasin - treated animals showed no change .', {'entities': [(71, 79, 'B_Disease'), (80, 82, 'I_Disease'), (83, 88, 'I_Disease'), (89, 97, 'I_Disease')]}], ['This demonstrates the participation of the renin - - angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP .', {'entities': [(101, 112, 'B_Disease')]}], ['Clinical nephrotoxicity of tobramycin and gentamicin .', {'entities': [(9, 23, 'B_Disease')]}], ['Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies .', {'entities': [(66, 77, 'B_Disease'), (82, 96, 'B_Disease')]}], ['In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg / kg / day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside - related renal failure , defined as at least a one - third reduction in renal function .', {'entities': [(262, 267, 'B_Disease'), (268, 275, 'I_Disease')]}], ['In these 62 patients , no other causes for renal failure could be identified .', {'entities': [(43, 48, 'B_Disease'), (49, 56, 'I_Disease')]}], ['Five of 33 ( 15 % ) of the tobramycin - treated patients and 16 of 29 ( 55 . 2 % ) of the gentamicin - treated patients had renal failure .', {'entities': [(124, 129, 'B_Disease'), (130, 137, 'I_Disease')]}], ['Thus , gentamicin was associated with renal failure more than three times as often as was tobramycin .', {'entities': [(38, 43, 'B_Disease'), (44, 51, 'I_Disease')]}], ['Metabolic involvement in adriamycin cardiotoxicity .', {'entities': [(36, 50, 'B_Disease')]}], ['The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system .', {'entities': [(4, 15, 'B_Disease')]}], ['Age - dependent sensitivity of the rat to neurotoxic effects of streptomycin .', {'entities': [(42, 52, 'B_Disease')]}], ['Abnormal movements and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to streptomycin than the site ( vestibular or central ) responsible for the dyskinesias .', {'entities': [(0, 8, 'B_Disease'), (9, 18, 'I_Disease'), (23, 31, 'B_Disease'), (353, 364, 'B_Disease')]}], ['Late , late doxorubicin cardiotoxicity .', {'entities': [(24, 38, 'B_Disease')]}], ['Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease')]}], ['Cardiomyopathy is frequent when the total dose exceeds 600 mg / m2 and occurs within one to six months after cessation of therapy .', {'entities': [(0, 14, 'B_Disease')]}], ['A patient is reported who developed progressive cardiomyopathy two and one - half years after receiving 580 mg / m2 which apparently represents late , late cardiotoxicity .', {'entities': [(48, 62, 'B_Disease'), (156, 170, 'B_Disease')]}], ['Attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride in rats .', {'entities': [(37, 45, 'B_Disease'), (46, 47, 'I_Disease'), (48, 57, 'I_Disease'), (58, 59, 'I_Disease'), (60, 64, 'I_Disease'), (65, 73, 'I_Disease')]}], ['The effect of amiloride on lithium - induced polydipsia and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .', {'entities': [(45, 55, 'B_Disease'), (60, 68, 'B_Disease')]}], ['In all the experiments , the attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .', {'entities': [(66, 74, 'B_Disease'), (75, 76, 'I_Disease'), (77, 86, 'I_Disease'), (87, 88, 'I_Disease'), (89, 93, 'I_Disease'), (94, 102, 'I_Disease')]}], ['It is concluded that acute amiloride administration to lithium - treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .', {'entities': [(97, 107, 'B_Disease'), (112, 120, 'B_Disease')]}], ['Cardiovascular complications associated with terbutaline treatment for preterm labor .', {'entities': [(0, 14, 'B_Disease'), (15, 28, 'I_Disease'), (71, 78, 'B_Disease'), (79, 84, 'I_Disease')]}], ['Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor .', {'entities': [(7, 21, 'B_Disease'), (22, 35, 'I_Disease'), (99, 106, 'B_Disease'), (107, 112, 'I_Disease')]}], ['Toxic hepatitis induced by antithyroid drugs : four cases including one with cross - reactivity between carbimazole and benzylthiouracil .', {'entities': [(0, 5, 'B_Disease'), (6, 15, 'I_Disease')]}], ['OBJECTIVE : This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs .', {'entities': [(65, 72, 'B_Disease'), (73, 80, 'I_Disease'), (81, 88, 'I_Disease')]}], ['METHODS : Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department ( in - or out - patients ) from 1986 to 1992 .', {'entities': [(71, 86, 'B_Disease')]}], ['RESULTS : Four patients ( 1 . 7 % ) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent .', {'entities': [(57, 62, 'B_Disease'), (63, 72, 'I_Disease')]}], ['Two patients had a cholestatic hepatitis induced by carbimazole ( N omercazole ) .', {'entities': [(19, 30, 'B_Disease'), (31, 40, 'I_Disease')]}], ['Two others had a mixed ( cholestatic and cytolytic ) hepatitis following carbimazole .', {'entities': [(25, 36, 'B_Disease'), (53, 62, 'B_Disease')]}], ['One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil ( Basd ne ) had replaced carbimazole .', {'entities': [(63, 72, 'B_Disease')]}], ['Biological features of hepatitis disappeared in all cases after cessation of the incriminated drug , while biliary , viral and immunological searches were negative .', {'entities': [(23, 32, 'B_Disease')]}], ['Only 2 patients of our retrospective study experienced a mild or severe neutropenia .', {'entities': [(72, 83, 'B_Disease')]}], ['CONCLUSION : Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants , as for haematological disturbances , a pre - therapeutic determination and a careful follow - up of relevant biological markers .', {'entities': [(13, 18, 'B_Disease'), (19, 28, 'I_Disease')]}], ['Moreover , hepatotoxicity may not be restricted to one class of antithyroid agents .', {'entities': [(11, 25, 'B_Disease')]}], ['Dose - dependent bradycardia induced by verapamil was potentiated by LNa , LCa , and HCa .', {'entities': [(17, 28, 'B_Disease')]}], ['Pseudo - allergic reactions to corticosteroids : diagnosis and alternatives .', {'entities': [(9, 17, 'B_Disease'), (18, 27, 'I_Disease')]}], ['A few minutes after administration of the drugs , they presented urticaria ( patients 1 and 2 ) and conjunctivitis ( patient 1 ) .', {'entities': [(65, 74, 'B_Disease'), (100, 114, 'B_Disease')]}], ['Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients ; however , a few of them were tolerated .', {'entities': [(59, 75, 'B_Disease')]}], ['To our knowledge , this is the first report of a pseudo - allergy caused by paramethasone .', {'entities': [(58, 65, 'B_Disease')]}], ['Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine .', {'entities': [(92, 100, 'B_Disease')]}], ['A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine ( ZDV ) - induced bone marrow suppression .', {'entities': [(159, 163, 'B_Disease'), (164, 170, 'I_Disease'), (171, 182, 'I_Disease')]}], ['Seventy - five human immunodeficiency virus ( HIV ) - infected patients with CD4 + cell counts < 500 / mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid ( 15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .', {'entities': [(15, 20, 'B_Disease'), (21, 37, 'I_Disease'), (38, 43, 'I_Disease'), (44, 45, 'I_Disease'), (46, 49, 'I_Disease'), (50, 51, 'I_Disease'), (52, 53, 'I_Disease'), (54, 62, 'I_Disease')]}], ['Finally , 15 patients were excluded from the study ( noncompliance 14 , death 1 ) ; thus , 60 patients ( 31 in group I and 29 in group II ) were eligible for analysis .', {'entities': [(72, 77, 'B_Disease')]}], ['Severe hematologic toxicity ( neutrophil count < 1000 / mm3 and / or hemoglobin < 8 g / dl ) occurred in 4 patients assigned to group I and 7 assigned to group II .', {'entities': [(19, 27, 'B_Disease')]}], ['There was no correlation between vitamin B12 or folate levels and development of myelosuppression .', {'entities': [(81, 97, 'B_Disease')]}], ['Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV - induced myelotoxicity in the overall treated population , although a beneficial effect in certain subgroups of patients cannot be excluded .', {'entities': [(121, 134, 'B_Disease')]}], ['Controlled study in agoraphobia with panic disorder .', {'entities': [(20, 31, 'B_Disease'), (37, 42, 'B_Disease'), (43, 51, 'I_Disease')]}], ['The efficacy of alprazolam and placebo in panic disorder with agoraphobia , and the side - effect and adverse effect profiles of both drug groups were measured .', {'entities': [(42, 47, 'B_Disease'), (48, 56, 'I_Disease'), (62, 73, 'B_Disease')]}], ['METHOD : In London and Toronto 154 patients who met DSM - III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo .', {'entities': [(75, 80, 'B_Disease'), (81, 89, 'I_Disease'), (95, 106, 'B_Disease')]}], ['Compared with placebo subjects , alprazolam patients developed more adverse reactions ( 21 % v . 0 % ) of depression , enuresis , disinhibition and aggression ; and more side - effects , particularly sedation , irritability , impaired memory , weight loss and ataxia .', {'entities': [(106, 116, 'B_Disease'), (119, 127, 'B_Disease'), (148, 158, 'B_Disease'), (211, 223, 'B_Disease'), (226, 234, 'B_Disease'), (235, 241, 'I_Disease'), (244, 250, 'B_Disease'), (251, 255, 'I_Disease'), (260, 266, 'B_Disease')]}], ['Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis .', {'entities': [(22, 40, 'B_Disease'), (91, 100, 'B_Disease'), (101, 113, 'I_Disease')]}], ['This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease .', {'entities': [(79, 97, 'B_Disease')]}], ['This patient underwent a 10 - month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .', {'entities': [(74, 83, 'B_Disease'), (84, 96, 'I_Disease'), (150, 155, 'B_Disease'), (156, 163, 'I_Disease')]}], ['Renal biopsy revealed severe glomerulonephritis with crescents , electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate .', {'entities': [(29, 47, 'B_Disease')]}], ['Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out .', {'entities': [(45, 63, 'B_Disease')]}], ['This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin .', {'entities': [(68, 86, 'B_Disease'), (116, 134, 'B_Disease')]}], ['Acute confusion induced by a high - dose infusion of 5 - fluorouracil and folinic acid .', {'entities': [(6, 15, 'B_Disease')]}], ['A 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high - dose 5 - fluorouracil ( 2 , 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma .', {'entities': [(199, 206, 'B_Disease'), (207, 221, 'I_Disease')]}], ['He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and folinic acid infusion .', {'entities': [(49, 58, 'B_Disease'), (61, 75, 'B_Disease'), (80, 92, 'B_Disease'), (123, 127, 'B_Disease')]}], ['Because folinic acid was unlikely to be associated with this condition , neurotoxicity due to high - dose 5 - fluorouracil was highly suspected .', {'entities': [(73, 86, 'B_Disease')]}], ['The pathogenesis of 5 - fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .', {'entities': [(37, 50, 'B_Disease')]}], ['High - dose 5 - fluorouracil / folinic acid infusion therapy has recently become a popular regimen for various cancers .', {'entities': [(111, 118, 'B_Disease')]}], ['Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .', {'entities': [(100, 113, 'B_Disease'), (117, 124, 'B_Disease'), (125, 134, 'I_Disease')]}], ['This change resulted within 2 - 4 weeks in the 50 - 200 % increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms .', {'entities': [(132, 146, 'B_Disease'), (147, 155, 'I_Disease')]}], ['Time course of lipid peroxidation in puromycin aminonucleoside - induced nephropathy .', {'entities': [(73, 84, 'B_Disease')]}], ['Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( PAN ) - induced nephropathy , with antioxidants significantly reducing the proteinuria .', {'entities': [(118, 129, 'B_Disease'), (177, 188, 'B_Disease')]}], ['The temporal relationship between lipid peroxidation in the kidney and proteinuria was examined in this study .', {'entities': [(71, 82, 'B_Disease')]}], ['Proteinuria was evident at day 5 , peaked at day 7 and persisted to day 27 .', {'entities': [(0, 11, 'B_Disease')]}], ['This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy .', {'entities': [(68, 79, 'B_Disease'), (80, 86, 'I_Disease'), (94, 105, 'B_Disease')]}], ['Composition of gall bladder stones associated with octreotide : response to oral ursodeoxycholic acid .', {'entities': [(15, 19, 'B_Disease'), (20, 27, 'I_Disease'), (28, 34, 'I_Disease')]}], ['Octreotide , an effective treatment for acromegaly , induces gall bladder stones in 13 - 60 % of patients .', {'entities': [(40, 50, 'B_Disease'), (61, 65, 'B_Disease'), (66, 73, 'I_Disease'), (74, 80, 'I_Disease')]}], ['Because knowledge of stone composition is essential for studies of their pathogenesis , treatment , and prevention , this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones .', {'entities': [(195, 206, 'B_Disease'), (221, 225, 'B_Disease'), (226, 232, 'I_Disease')]}], ['Chemical analysis of gall stones retrieved at cholecystectomy from two patients , showed that they contained 71 % and 87 % cholesterol by weight .', {'entities': [(21, 25, 'B_Disease'), (26, 32, 'I_Disease')]}], ['After one year of treatment , five of the remaining nine patients showed either partial ( n = 3 ) or complete ( n = 2 ) gall stone dissolution , suggesting that their stones were cholesterol rich .', {'entities': [(120, 124, 'B_Disease'), (125, 130, 'I_Disease')]}], ['This corresponds , by actuarial ( life table ) analysis , to a combined gall stone dissolution rate of 58 . 3 ( 15 . 9 % ) .', {'entities': [(72, 76, 'B_Disease'), (77, 82, 'I_Disease')]}], ['In conclusion , octreotide induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .', {'entities': [(35, 39, 'B_Disease'), (40, 46, 'I_Disease'), (139, 143, 'B_Disease'), (144, 149, 'I_Disease'), (150, 157, 'I_Disease'), (231, 235, 'B_Disease'), (236, 242, 'I_Disease')]}], ['Erythema multiforme and hypersensitivity myocarditis caused by ampicillin .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease'), (24, 40, 'B_Disease'), (41, 52, 'I_Disease')]}], ['OBJECTIVE : To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin .', {'entities': [(32, 40, 'B_Disease'), (41, 51, 'I_Disease'), (56, 72, 'B_Disease'), (73, 84, 'I_Disease')]}], ['CASE SUMMARY : A 13 - year - old boy was treated with ampicillin and gentamicin because of suspected septicemia .', {'entities': [(101, 111, 'B_Disease')]}], ['Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred .', {'entities': [(35, 43, 'B_Disease'), (44, 54, 'I_Disease'), (59, 69, 'B_Disease'), (70, 75, 'I_Disease'), (76, 83, 'I_Disease'), (94, 105, 'B_Disease')]}], ['DISCUSSION : After most infections causing erythema multiforme and myocarditis were ruled out , a drug - induced allergic reaction was suspected .', {'entities': [(24, 34, 'B_Disease'), (43, 51, 'B_Disease'), (52, 62, 'I_Disease'), (67, 78, 'B_Disease'), (98, 102, 'B_Disease'), (103, 104, 'I_Disease'), (105, 112, 'I_Disease'), (113, 121, 'I_Disease'), (122, 130, 'I_Disease')]}], ['CONCLUSIONS : Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins .', {'entities': [(14, 30, 'B_Disease'), (31, 42, 'I_Disease'), (84, 91, 'B_Disease')]}], ['Clomipramine - induced sleep disturbance does not impair its prolactin - releasing action .', {'entities': [(23, 28, 'B_Disease'), (29, 40, 'I_Disease')]}], ['The present study was undertaken to examine the role of sleep disturbance , induced by clomipramine administration , on the secretory rate of prolactin ( PRL ) in addition to the direct drug effect .', {'entities': [(56, 61, 'B_Disease'), (62, 73, 'I_Disease')]}], ['As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies ( 46 + / - 19 % vs 34 + / - 10 % ) , it can be concluded that the observed sleep disturbance did not interfere with the drug action per se .', {'entities': [(223, 228, 'B_Disease'), (229, 240, 'I_Disease')]}], ['There were 13 cases of adverse reactions ( 0 . 34 % ) , ten of which were mild reactions such as nausea , exanthema , urtication , itchiness , and urgency to defecate , and did not require treatment .', {'entities': [(97, 103, 'B_Disease'), (106, 115, 'B_Disease'), (118, 128, 'B_Disease'), (131, 140, 'B_Disease')]}], ['Also recorded were one case of pain of the vein , which required treatment , and two cases of hypotension .', {'entities': [(31, 35, 'B_Disease'), (94, 105, 'B_Disease')]}], ['The two hypotensive patients required treatment for shock .', {'entities': [(8, 19, 'B_Disease'), (52, 57, 'B_Disease')]}], ['Angioedema following the intravenous administration of metoprolol .', {'entities': [(0, 10, 'B_Disease')]}], ['A 72 - year - old woman was admitted to the hospital with \" flash \" pulmonary edema , preceded by chest pain , requiring intubation .', {'entities': [(68, 77, 'B_Disease'), (78, 83, 'I_Disease'), (98, 103, 'B_Disease'), (104, 108, 'I_Disease')]}], ['Her medical history included coronary artery disease with previous myocardial infarctions , hypertension , and diabetes mellitus .', {'entities': [(29, 37, 'B_Disease'), (38, 44, 'I_Disease'), (45, 52, 'I_Disease'), (67, 77, 'B_Disease'), (78, 89, 'I_Disease'), (92, 104, 'B_Disease'), (111, 119, 'B_Disease'), (120, 128, 'I_Disease')]}], ['A history of angioedema secondary to lisinopril therapy was elicited .', {'entities': [(13, 23, 'B_Disease')]}], ['During the first day of hospitalization ( while intubated ) , intravenous metoprolol was given , resulting in severe angioedema .', {'entities': [(117, 127, 'B_Disease')]}], ['The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride .', {'entities': [(4, 14, 'B_Disease')]}], ['The major teratogenic outcome is arthrogryposis , presumably due to nicotinic receptor blockade .', {'entities': [(33, 47, 'B_Disease')]}], ['However , coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits .', {'entities': [(40, 54, 'B_Disease')]}], ['Both compounds caused deformations and lethality in a dose - dependent manner .', {'entities': [(22, 34, 'B_Disease')]}], ['The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes .', {'entities': [(4, 16, 'B_Disease'), (66, 75, 'B_Disease'), (76, 83, 'I_Disease'), (84, 86, 'I_Disease'), (87, 96, 'I_Disease'), (97, 99, 'I_Disease'), (100, 103, 'I_Disease'), (104, 106, 'I_Disease'), (107, 111, 'I_Disease'), (112, 116, 'I_Disease')]}], ['No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group ; however , extensive cranial hemorrhage occurred in all nicotine sulfate - treated chicks .', {'entities': [(148, 155, 'B_Disease'), (156, 166, 'I_Disease')]}], ['In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .', {'entities': [(108, 122, 'B_Disease')]}], ['Immediate allergic reactions to amoxicillin .', {'entities': [(10, 18, 'B_Disease'), (19, 28, 'I_Disease')]}], ['A large group of patients with suspected allergic reactions to beta - lactam antibiotics was evaluated .', {'entities': [(41, 49, 'B_Disease'), (50, 59, 'I_Disease')]}], ['A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta - lactam antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross - reacting with other penicillin derivatives .', {'entities': [(165, 173, 'B_Disease'), (227, 235, 'B_Disease')]}], ['A total of 177 patients were diagnosed as allergic to beta - lactam antibiotics .', {'entities': [(42, 50, 'B_Disease')]}], ['We selected the 54 ( 30 . 5 % ) cases of immediate AX allergy with good tolerance of PG .', {'entities': [(54, 61, 'B_Disease')]}], ['Anaphylaxis was seen in 37 patients ( 69 % ) , the other 17 ( 31 % ) having urticaria and / or angioedema .', {'entities': [(0, 11, 'B_Disease'), (76, 85, 'B_Disease'), (95, 105, 'B_Disease')]}], ['All the patients were skin test negative to BPO ; 49 of 51 ( 96 % ) were also negative to MDM , and 44 of 46 ( 96 % ) to PG .', {'entities': [(90, 93, 'B_Disease')]}], ['Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate allergic reaction to AX , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .', {'entities': [(103, 111, 'B_Disease'), (112, 120, 'I_Disease')]}], ['We describe the largest group of AX - allergic patients who have tolerated PG reported so far .', {'entities': [(38, 46, 'B_Disease')]}], ['Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction .', {'entities': [(98, 103, 'B_Disease'), (104, 114, 'I_Disease'), (115, 125, 'I_Disease')]}], ['Nitroglycerin has been shown to reduce ST - segment elevation during acute myocardial infarction , an effect potentiated in the dog by agents that reverse nitroglycerin - induced hypotension .', {'entities': [(69, 74, 'B_Disease'), (75, 85, 'I_Disease'), (86, 96, 'I_Disease'), (179, 190, 'B_Disease')]}], ['Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin , sufficient to reduce mean arterial pressure from 107 + / - 6 to 85 + / - 6 mm Hg ( P less than 0 . 001 ) , for 60 minutes .', {'entities': [(35, 45, 'B_Disease'), (46, 57, 'I_Disease')]}], ['Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction .', {'entities': [(120, 125, 'B_Disease'), (126, 136, 'I_Disease'), (137, 147, 'I_Disease')]}], ['Acetazolamide - induced nephrolithiasis : implications for treatment of neuromuscular disorders .', {'entities': [(24, 39, 'B_Disease'), (72, 85, 'B_Disease'), (86, 95, 'I_Disease')]}], ['Carbonic anhydrase inhibitors can cause nephrolithiasis .', {'entities': [(40, 55, 'B_Disease')]}], ['We studied 20 patients receiving long - term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia .', {'entities': [(97, 106, 'B_Disease'), (111, 119, 'B_Disease')]}], ['Three patients on acetazolamide ( 15 % ) developed renal calculi .', {'entities': [(51, 56, 'B_Disease'), (57, 64, 'I_Disease')]}], ['Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another , permitting continued treatment .', {'entities': [(50, 55, 'B_Disease'), (56, 64, 'I_Disease'), (111, 119, 'B_Disease')]}], ['Nephrolithiasis is a complication of acetazolamide but does not preclude its use .', {'entities': [(0, 15, 'B_Disease')]}], ['Effects of calcium channel blockers on bupivacaine - induced toxicity .', {'entities': [(61, 69, 'B_Disease')]}], ['The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine - induced acute toxicity .', {'entities': [(118, 126, 'B_Disease')]}], ['The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine - induced convulsions ; this effect was less pronounced with bepridil .', {'entities': [(161, 172, 'B_Disease')]}], ['Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension .', {'entities': [(68, 79, 'B_Disease')]}], ['To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( TMP ) induced hypotension on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .', {'entities': [(84, 95, 'B_Disease')]}], ['The hypotensive drug was discontinued at the completion of the operative procedure .', {'entities': [(4, 15, 'B_Disease')]}], ['After starting PGE1 or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation .', {'entities': [(159, 170, 'B_Disease')]}], ['These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF .', {'entities': [(61, 72, 'B_Disease')]}], ['Dup 753 prevents the development of puromycin aminonucleoside - induced nephrosis .', {'entities': [(72, 81, 'B_Disease')]}], ['The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .', {'entities': [(18, 27, 'B_Disease'), (28, 37, 'I_Disease'), (46, 57, 'B_Disease'), (60, 75, 'B_Disease'), (78, 98, 'B_Disease')]}], ['The results suggest a possible involvement of the renin - angiotensin system in the development of puromycin aminonucleoside - induced nephrosis .', {'entities': [(135, 144, 'B_Disease')]}], ['Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss .', {'entities': [(72, 79, 'B_Disease'), (80, 84, 'I_Disease')]}], ['The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss .', {'entities': [(110, 117, 'B_Disease'), (118, 122, 'I_Disease')]}], ['The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss .', {'entities': [(100, 107, 'B_Disease'), (108, 112, 'I_Disease')]}], ['Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .', {'entities': [(30, 36, 'B_Disease'), (37, 41, 'I_Disease'), (83, 91, 'B_Disease'), (92, 103, 'I_Disease')]}], ['In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications .', {'entities': [(35, 41, 'B_Disease'), (42, 46, 'I_Disease'), (196, 202, 'B_Disease'), (203, 207, 'I_Disease')]}], ['A total of 38 consecutive patients who presented to our clinic with impotence received 0 . 2 ml . of a combination of 3 drugs : 6 mg . papaverine , 100 micrograms . phentolamine and 10 micrograms . prostaglandin E1 with ( pH 7 . 05 ) or without ( pH 4 . 17 ) the addition of sodium bicarbonate ( 0 . 03 mEq . ) .', {'entities': [(68, 77, 'B_Disease')]}], ['Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of penile pain .', {'entities': [(96, 102, 'B_Disease'), (103, 107, 'I_Disease'), (213, 219, 'B_Disease'), (220, 224, 'I_Disease')]}], ['From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication , which can be overcome by elevating the pH to a neutral level .', {'entities': [(37, 43, 'B_Disease'), (44, 48, 'I_Disease')]}], ['The use and toxicity of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT )', {'entities': [(12, 20, 'B_Disease'), (46, 49, 'B_Disease'), (50, 58, 'I_Disease'), (59, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['Seventy patients developed major opportunistic infections whilst on therapy ; this was the first AIDS diagnosis in 17 .', {'entities': [(33, 46, 'B_Disease'), (47, 57, 'I_Disease'), (97, 101, 'B_Disease')]}], ['Only minor changes in CD4 + lymphocyte subset count were observed in AIDS patients , although a more significant rise occurred in those with earlier stages of disease .', {'entities': [(69, 73, 'B_Disease')]}], ['The most common side - effect was diarrhoea , which resulted in cessation of therapy in 19 individuals .', {'entities': [(34, 43, 'B_Disease')]}], ['Peripheral neuropathy occurred in 12 patients and pancreatitis in six .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (50, 62, 'B_Disease')]}], ['Thirteen patients developed a raised serum amylase without abdominal pain .', {'entities': [(59, 68, 'B_Disease'), (69, 73, 'I_Disease')]}], ['Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild , did not require treatment and returned to normal on ceasing didanosine .', {'entities': [(25, 32, 'B_Disease'), (33, 42, 'I_Disease'), (43, 49, 'I_Disease'), (68, 76, 'B_Disease')]}], ['Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat .', {'entities': [(73, 79, 'B_Disease'), (80, 86, 'I_Disease')]}], ['Immunohistochemistry with monoclonal antibodies against neurofilament ( NF ) proteins of middle and high molecular weight class , NF - M and NF - H , was used to study axonal injury in the borderzone of focal lesions in rats .', {'entities': [(168, 174, 'B_Disease'), (175, 181, 'I_Disease')]}], ['Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion .', {'entities': [(6, 12, 'B_Disease'), (13, 15, 'I_Disease'), (16, 19, 'I_Disease'), (20, 26, 'I_Disease')]}], ['Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine - induced status epilepticus .', {'entities': [(0, 8, 'B_Disease'), (9, 11, 'I_Disease'), (12, 22, 'I_Disease'), (23, 28, 'I_Disease'), (29, 33, 'I_Disease'), (34, 44, 'I_Disease'), (92, 98, 'B_Disease'), (99, 110, 'I_Disease')]}], ['These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions .', {'entities': [(67, 73, 'B_Disease'), (74, 80, 'I_Disease'), (105, 114, 'B_Disease')]}], ['Pharmacokinetic and clinical studies in patients with cimetidine - associated mental confusion .', {'entities': [(85, 94, 'B_Disease')]}], ['15 cases of cimetidine - associated mental confusion have been reported .', {'entities': [(43, 52, 'B_Disease')]}], ['These 6 patients had both renal and liver dysfunction ( P less than 0 . 05 ) , as well as cimetidine trough - concentrations of more than 1 . 25 microgram / ml ( P less than 0 . 05 ) .', {'entities': [(26, 31, 'B_Disease'), (32, 35, 'I_Disease'), (36, 41, 'I_Disease'), (42, 53, 'I_Disease')]}], ['Patients likely to have both raised trough - concentrations and mental confusion are those with both severe renal and hepatic dysfunction .', {'entities': [(71, 80, 'B_Disease'), (108, 113, 'B_Disease'), (114, 117, 'I_Disease'), (118, 125, 'I_Disease'), (126, 137, 'I_Disease')]}], ['Prospective study of the long - term effects of somatostatin analog ( octreotide ) on gallbladder function and gallstone formation in Chinese acromegalic patients .', {'entities': [(111, 120, 'B_Disease'), (142, 153, 'B_Disease')]}], ['This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300 - 1500 micrograms / day for a mean of 24 . 2 + / - 13 . 9 months .', {'entities': [(120, 130, 'B_Disease')]}], ['During treatment with octreotide , 17 patients developed sludge , 10 had gallstones , and 1 developed acute cholecystitis requiring surgery .', {'entities': [(73, 83, 'B_Disease'), (102, 107, 'B_Disease'), (108, 121, 'I_Disease')]}], ['In 8 patients followed for 24 weeks , gallbladder contractility remained depressed throughout therapy .', {'entities': [(73, 82, 'B_Disease')]}], ['After withdrawal of octreotide in 10 patients without gallstones , 8 patients assessed had return of normal gallbladder contractility within 1 month .', {'entities': [(54, 64, 'B_Disease')]}], ['In 8 of the remaining 10 patients who developed gallstones during treatment , gallbladder contractility normalized in 5 patients ( 3 of whom has disappearance of their stones within 3 weeks ) , and remained depressed in 3 ( 2 of whom had stones present at 6 months ) .', {'entities': [(48, 58, 'B_Disease'), (207, 216, 'B_Disease')]}], ['Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and cholecystitis during octreotide therapy in Chinese acromegalic patients .', {'entities': [(128, 138, 'B_Disease'), (145, 158, 'B_Disease'), (196, 207, 'B_Disease')]}], ['It is therefore very important to follow the changes of gallbladder function during long - term octreotide therapy of acromegalic patients .', {'entities': [(118, 129, 'B_Disease')]}], ['Increase of Parkinson disability after fluoxetine medication .', {'entities': [(12, 21, 'B_Disease'), (22, 32, 'I_Disease')]}], [\"Depression is a major clinical feature of Parkinson ' s disease .\", {'entities': [(0, 10, 'B_Disease'), (42, 51, 'B_Disease'), (52, 53, 'I_Disease'), (54, 55, 'I_Disease'), (56, 63, 'I_Disease')]}], [\"We report the increased amount of motor disability in four patients with idiopathic Parkinson ' s disease after exposure to the antidepressant fluoxetine .\", {'entities': [(34, 39, 'B_Disease'), (40, 50, 'I_Disease'), (73, 83, 'B_Disease'), (84, 93, 'I_Disease'), (94, 95, 'I_Disease'), (96, 97, 'I_Disease'), (98, 105, 'I_Disease')]}], [\"The possibility of a clinically relevant dopamine - antagonistic capacity of fluoxetine in Parkinson ' s disease patients must be considered .\", {'entities': [(91, 100, 'B_Disease'), (101, 102, 'I_Disease'), (103, 104, 'I_Disease'), (105, 112, 'I_Disease')]}], ['Sinus arrest associated with continuous - infusion cimetidine .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease')]}], ['The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias .', {'entities': [(122, 138, 'B_Disease')]}], ['A 40 - year - old man with leukemia and no history of cardiac disease developed recurrent , brief episodes of apparent sinus arrest while receiving continuous - infusion cimetidine 50 mg / hour .', {'entities': [(27, 35, 'B_Disease'), (54, 61, 'B_Disease'), (62, 69, 'I_Disease'), (119, 124, 'B_Disease'), (125, 131, 'I_Disease')]}], ['The arrhythmias were temporally related to cimetidine administration , disappeared after dechallenge , and did not recur during ranitidine treatment .', {'entities': [(4, 15, 'B_Disease')]}], ['This is the first reported case of sinus arrest associated with continuous - infusion cimetidine .', {'entities': [(35, 40, 'B_Disease'), (41, 47, 'I_Disease')]}], ['Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma .', {'entities': [(44, 52, 'B_Disease'), (53, 57, 'I_Disease'), (58, 68, 'I_Disease'), (69, 78, 'I_Disease')]}], ['European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group .', {'entities': [(52, 58, 'B_Disease'), (82, 88, 'B_Disease')]}], ['PURPOSE : To evaluate the response rate and toxic effects of vinorelbine ( VNB ) administered as a single agent in metastatic squamous cell esophageal carcinoma .', {'entities': [(126, 134, 'B_Disease'), (135, 139, 'I_Disease'), (140, 150, 'I_Disease'), (151, 160, 'I_Disease')]}], ['Thirty patients without prior chemotherapy and 16 pretreated with cisplatin - based chemotherapy were assessable for toxicity and response .', {'entities': [(117, 125, 'B_Disease')]}], ['VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred .', {'entities': [(72, 80, 'B_Disease')]}], ['At least one episode of grade 3 or 4 granulocytopenia was seen in 59 % of patients .', {'entities': [(37, 53, 'B_Disease')]}], ['A grade 2 or 3 infection occurred in 16 % of patients , but no toxic deaths occurred .', {'entities': [(15, 24, 'B_Disease'), (69, 75, 'B_Disease')]}], ['Other side effects were rare , and peripheral neurotoxicity has been minor ( 26 % grade 1 ) .', {'entities': [(35, 45, 'B_Disease'), (46, 59, 'I_Disease')]}], ['CONCLUSION : These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma .', {'entities': [(75, 85, 'B_Disease'), (86, 94, 'I_Disease'), (95, 99, 'I_Disease'), (100, 109, 'I_Disease')]}], ['Given its excellent tolerance profile and low toxicity , further evaluation of VNB in combination therapy is warranted .', {'entities': [(46, 54, 'B_Disease')]}], ['The ocular hypotensive effects were statistically significant for apraclonidine - treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1 % apraclonidine .', {'entities': [(4, 10, 'B_Disease'), (11, 22, 'I_Disease')]}], ['Decreases in systolic blood pressure were statistically , but not clinically , significant .', {'entities': [(0, 9, 'B_Disease'), (10, 12, 'I_Disease'), (13, 21, 'I_Disease'), (22, 27, 'I_Disease'), (28, 36, 'I_Disease')]}], ['Conjunctival blanching and mydriasis were commonly found .', {'entities': [(0, 12, 'B_Disease'), (13, 22, 'I_Disease'), (27, 36, 'B_Disease')]}], ['While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance , one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication .', {'entities': [(175, 184, 'B_Disease'), (196, 203, 'B_Disease'), (204, 212, 'I_Disease')]}], ['Thiopentone pretreatment for propofol injection pain in ambulatory patients .', {'entities': [(48, 52, 'B_Disease')]}], ['This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia .', {'entities': [(43, 47, 'B_Disease')]}], ['Loss of consciousness occurred in 60 - 90 sec .', {'entities': [(0, 4, 'B_Disease'), (5, 7, 'I_Disease'), (8, 21, 'I_Disease')]}], ['The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction ( r = 0 . 7045 ; P < 0 . 0001 ) .', {'entities': [(29, 33, 'B_Disease')]}], ['We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity .', {'entities': [(84, 88, 'B_Disease')]}], ['Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids .', {'entities': [(11, 20, 'B_Disease')]}], ['Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid - based NMBAs such as vecuronium bromide , especially when used in conjunction with corticosteroids .', {'entities': [(22, 31, 'B_Disease')]}], ['Atracurium besylate , a short - acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent paralysis , but only when used with corticosteroids .', {'entities': [(170, 179, 'B_Disease')]}], ['We report a case of atracurium - related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids .', {'entities': [(41, 50, 'B_Disease')]}], ['A phase I / II study of paclitaxel plus cisplatin as first - line therapy for head and neck cancers : preliminary results .', {'entities': [(78, 82, 'B_Disease'), (83, 86, 'I_Disease'), (87, 91, 'I_Disease'), (92, 99, 'I_Disease')]}], ['Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy .', {'entities': [(38, 42, 'B_Disease'), (43, 46, 'I_Disease'), (47, 51, 'I_Disease'), (52, 62, 'I_Disease')]}], ['Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel / cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .', {'entities': [(203, 207, 'B_Disease'), (208, 211, 'I_Disease'), (212, 216, 'I_Disease'), (217, 223, 'I_Disease'), (355, 362, 'B_Disease'), (363, 369, 'I_Disease')]}], ['We initiated a phase I / II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed - dose cisplatin with granulocyte colony - stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma .', {'entities': [(64, 72, 'B_Disease'), (249, 253, 'B_Disease'), (254, 257, 'I_Disease'), (258, 262, 'I_Disease'), (263, 272, 'I_Disease')]}], ['Primary tumor sites were oropharynx , 10 patients ; hypopharynx , four ; larynx , two ; oral cavity , three ; unknown primary , two ; and nasal cavity and parotid gland , one each .', {'entities': [(8, 13, 'B_Disease')]}], ['Of 20 patients evaluable for toxicity , four had stage III and 16 had stage IV disease .', {'entities': [(29, 37, 'B_Disease')]}], ['The dose levels incorporate escalating paclitaxel doses , and intrapatient escalations within a given dose level are permitted if toxicity permits .', {'entities': [(130, 138, 'B_Disease')]}], ['Alopecia , paresthesias , and arthralgias / myalgias have occurred frequently , but with one exception ( a grade 3 myalgia ) they have been grade 1 or 2 .', {'entities': [(0, 8, 'B_Disease'), (11, 23, 'B_Disease'), (30, 41, 'B_Disease'), (44, 52, 'B_Disease'), (115, 122, 'B_Disease')]}], ['No dose - limiting hematologic toxicity has been seen .', {'entities': [(31, 39, 'B_Disease')]}], ['Paclitaxel / cisplatin is an effective first - line regimen for locoregionally advanced head and neck cancer and continued study is warranted .', {'entities': [(88, 92, 'B_Disease'), (93, 96, 'I_Disease'), (97, 101, 'I_Disease'), (102, 108, 'I_Disease')]}], [\"Improvement of levodopa - induced dyskinesia by propranolol in Parkinson ' s disease .\", {'entities': [(34, 44, 'B_Disease'), (63, 72, 'B_Disease'), (73, 74, 'I_Disease'), (75, 76, 'I_Disease'), (77, 84, 'I_Disease')]}], [\"Seven patients suffering from Parkinson ' s disease ( PD ) with severely disabling dyskinesia received low - dose propranolol as an adjunct to the currently used medical treatment .\", {'entities': [(30, 39, 'B_Disease'), (40, 41, 'I_Disease'), (42, 43, 'I_Disease'), (44, 51, 'I_Disease'), (54, 56, 'B_Disease'), (83, 93, 'B_Disease')]}], ['There was a significant 40 % improvement in the dyskinesia score without increase of parkinsonian motor disability .', {'entities': [(48, 58, 'B_Disease'), (85, 97, 'B_Disease'), (98, 103, 'B_Disease'), (104, 114, 'I_Disease')]}], ['Ballistic and choreic dyskinesia were markedly ameliorated , whereas dystonia was not .', {'entities': [(22, 32, 'B_Disease'), (69, 77, 'B_Disease')]}], ['This study suggests that administration of low doses of beta - blockers may improve levodopa - induced ballistic and choreic dyskinesia in PD .', {'entities': [(125, 135, 'B_Disease'), (139, 141, 'B_Disease')]}], ['Habitual use of acetaminophen as a risk factor for chronic renal failure : a comparison with phenacetin .', {'entities': [(51, 58, 'B_Disease'), (59, 64, 'I_Disease'), (65, 72, 'I_Disease')]}], ['Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end - stage renal disease ( ESRD ) , with a relative risk in the range of 4 to 19 .', {'entities': [(137, 144, 'B_Disease'), (145, 150, 'I_Disease'), (151, 158, 'I_Disease'), (163, 166, 'B_Disease'), (167, 168, 'I_Disease'), (169, 174, 'I_Disease'), (175, 180, 'I_Disease'), (181, 188, 'I_Disease'), (191, 195, 'B_Disease')]}], ['However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD , with a relative risk in the range of 2 to 4 .', {'entities': [(182, 189, 'B_Disease'), (190, 195, 'I_Disease'), (196, 203, 'I_Disease'), (208, 212, 'B_Disease')]}], ['These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD , with the risk of the latter being somewhat less than that of the former .', {'entities': [(93, 97, 'B_Disease')]}], ['This apparent difference in risk may not be due to differences in nephrotoxic potential of the drugs themselves .', {'entities': [(66, 77, 'B_Disease')]}], ['The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated , but cannot be dismissed .', {'entities': [(79, 83, 'B_Disease')]}], ['Acetaminophen - induced hypotension .', {'entities': [(24, 35, 'B_Disease')]}], ['The potential for acetaminophen to produce cardiovascular toxicities is very low .', {'entities': [(43, 57, 'B_Disease'), (58, 68, 'I_Disease')]}], ['However , acetaminophen has been demonstrated to produce symptoms of anaphylaxis , including hypotension , in sensitive individuals .', {'entities': [(69, 80, 'B_Disease'), (93, 104, 'B_Disease')]}], ['This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen .', {'entities': [(27, 37, 'B_Disease'), (38, 41, 'I_Disease'), (81, 92, 'B_Disease')]}], ['Other symptoms of allergic reactions were not clinically detectable .', {'entities': [(18, 26, 'B_Disease'), (27, 36, 'I_Disease')]}], ['The hypotensive episodes were severe enough to require vasopressor administration .', {'entities': [(4, 15, 'B_Disease')]}], ['The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin .', {'entities': [(90, 101, 'B_Disease')]}], ['Reduction of heparan sulphate - associated anionic sites in the glomerular basement membrane of rats with streptozotocin - induced diabetic nephropathy .', {'entities': [(131, 139, 'B_Disease'), (140, 151, 'I_Disease')]}], ['Heparan sulphate - associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age - adn sex - matched control rats , employing the cationic dye cuprolinic blue .', {'entities': [(129, 137, 'B_Disease')]}], ['The majority of anionic sites ( 74 % in diabetic and 81 % in control rats ) were found within the lamina rara externa of the glomerular basement membrane .', {'entities': [(40, 48, 'B_Disease')]}], ['A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna , and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane ( p < 0 . 001 and p < 0 . 01 for diabetic and control rats , respectively ) .', {'entities': [(235, 243, 'B_Disease')]}], ['Diabetic rats progressively developed albuminuria reaching 40 . 3 ( 32 . 2 - 62 . 0 ) mg / 24 h after 8 months in contrast to the control animals ( 0 . 8 ( 0 . 2 - 0 . 9 ) mg / 24 h , p < 0 . 002 ) .', {'entities': [(0, 8, 'B_Disease'), (38, 49, 'B_Disease')]}], ['We conclude that in streptozotocin - diabetic rats with an increased urinary albumin excretion , a reduced heparan sulphate charge barrier / density is found at the lamina rara externa of the glomerular basement membrane .', {'entities': [(37, 45, 'B_Disease')]}], ['Mediation of enhanced reflex vagal bradycardia by L - dopa via central dopamine formation in dogs .', {'entities': [(35, 46, 'B_Disease')]}], ['In addition , reflex bradycardia caused by injected norepinephrine was significantly enhanced by L - dopa , DL - Threo - dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .', {'entities': [(21, 32, 'B_Disease')]}], ['FLA - 63 , a dopamine - beta - oxidase inhibitor , did not have any effect on the hypotension , bradycardia or reflex - enhancing effect of L - dopa .', {'entities': [(82, 93, 'B_Disease'), (96, 107, 'B_Disease')]}], ['However , L - dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate .', {'entities': [(32, 43, 'B_Disease')]}], ['5 - HTP ( 5 mg / kg i . v . ) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine .', {'entities': [(95, 106, 'B_Disease')]}], ['It is concluded that L - dopa enhances reflex bradycardia through central alpha - receptor stimulation .', {'entities': [(46, 57, 'B_Disease')]}], ['Microangiopathic hemolytic anemia complicating FK506 ( tacrolimus ) therapy .', {'entities': [(0, 16, 'B_Disease'), (17, 26, 'I_Disease'), (27, 33, 'I_Disease')]}], ['We describe 3 episodes of microangiopathic hemolytic anemia ( MAHA ) in 2 solid organ recipients under FK506 ( tacrolimus ) therapy .', {'entities': [(26, 42, 'B_Disease'), (43, 52, 'I_Disease'), (53, 59, 'I_Disease'), (62, 66, 'B_Disease')]}], ['In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , aspirin , and dipyridamole led to resolution of MAHA .', {'entities': [(178, 182, 'B_Disease')]}], ['In one patient , reintroduction of FK506 led to rapid recurrence of MAHA .', {'entities': [(68, 72, 'B_Disease')]}], ['FK506 - associated MAHA is probably rare but physicians must be aware of this severe complication .', {'entities': [(19, 23, 'B_Disease')]}], ['In our experience and according to the literature , FK506 does not seem to cross - react with cyclosporin A ( CyA ) , an immuno - suppressive drug already known to induce MAHA .', {'entities': [(171, 175, 'B_Disease')]}], ['Effect of some anticancer drugs and combined chemotherapy on renal toxicity .', {'entities': [(61, 66, 'B_Disease'), (67, 75, 'I_Disease')]}], ['The nephrotoxic action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .', {'entities': [(4, 15, 'B_Disease')]}], ['CY caused hemorrhagic cystitis in 40 % of rats , but it did not cause this complication when combined with 5 - FU and MTX .', {'entities': [(10, 21, 'B_Disease'), (22, 30, 'I_Disease')]}], ['Our studies indicate that nephrotoxicity of MTX + 5 - FU + CY administered jointly is lower than in monotherapy .', {'entities': [(26, 40, 'B_Disease')]}], ['Compared with sham - operated controls , lesions significantly ( p < 0 . 25 ) blunted the early ( < 60 min ) free - field locomotor hypoactivity caused by nicotine ( 0 . 5 mg kg ( - 1 ) , i . m . ) , enhanced the later ( 60 - 120 min ) nicotine - induced hyperactivity , and raised spontaneous nocturnal activity .', {'entities': [(122, 131, 'B_Disease'), (132, 144, 'I_Disease'), (255, 268, 'B_Disease')]}], ['We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain .', {'entities': [(64, 74, 'B_Disease')]}], ['Lithium - associated cognitive and functional deficits reduced by a switch to divalproex sodium : a case series .', {'entities': [(21, 30, 'B_Disease'), (31, 34, 'I_Disease'), (35, 45, 'I_Disease'), (46, 54, 'I_Disease')]}], ['BACKGROUND : Lithium remains a first - line treatment for the acute and maintenance treatment of bipolar disorder .', {'entities': [(97, 104, 'B_Disease'), (105, 113, 'I_Disease')]}], ['Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .', {'entities': [(108, 116, 'B_Disease'), (121, 127, 'B_Disease'), (171, 180, 'B_Disease'), (181, 189, 'I_Disease'), (192, 196, 'B_Disease'), (197, 199, 'I_Disease'), (200, 210, 'I_Disease'), (217, 227, 'B_Disease'), (228, 239, 'I_Disease')]}], ['This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments .', {'entities': [(51, 58, 'B_Disease'), (120, 129, 'B_Disease'), (130, 133, 'I_Disease'), (134, 144, 'I_Disease'), (145, 156, 'I_Disease')]}], ['RESULTS : We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our bipolar patients .', {'entities': [(153, 162, 'B_Disease'), (163, 164, 'I_Disease'), (165, 177, 'I_Disease'), (178, 179, 'I_Disease'), (180, 182, 'I_Disease'), (183, 191, 'I_Disease'), (192, 200, 'I_Disease'), (230, 237, 'B_Disease')]}], ['CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , loss of creativity , and functional impairments .', {'entities': [(101, 108, 'B_Disease'), (131, 140, 'B_Disease'), (141, 149, 'I_Disease'), (152, 156, 'B_Disease'), (157, 159, 'I_Disease'), (160, 170, 'I_Disease'), (177, 187, 'B_Disease'), (188, 199, 'I_Disease')]}], ['Two groups of patients receiving tacrolimus were compared over a period of 1 year , one group comprising hypertensive patients who were receiving nifedipine , and the other comprising nonhypertensive patients not receiving nifedipine .', {'entities': [(105, 117, 'B_Disease')]}], ['The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population .', {'entities': [(59, 73, 'B_Disease'), (193, 205, 'B_Disease')]}], ['Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia .', {'entities': [(15, 19, 'B_Disease'), (58, 66, 'B_Disease'), (67, 74, 'I_Disease')]}], ['Four patients who were rendered comatose or stuporous by drug intoxication , but who were not hypoxic , are described .', {'entities': [(32, 40, 'B_Disease'), (44, 53, 'B_Disease')]}], ['Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms , and one took a suicidal overdose of nitrazepam .', {'entities': [(66, 76, 'B_Disease'), (77, 85, 'I_Disease'), (112, 120, 'B_Disease')]}], [\"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of ' alpha coma ' , showing non - reactive generalized or frontally predominant alpha activity in the EEG .\", {'entities': [(28, 36, 'B_Disease'), (125, 129, 'B_Disease')]}], ['All four recovered completely without neurological sequelae following the withdrawal of the offending agents .', {'entities': [(38, 50, 'B_Disease'), (51, 59, 'I_Disease')]}], ['The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed .', {'entities': [(79, 89, 'B_Disease')]}], ['It is suggested that in both situations disturbed reticulo - thalamic interactions are important in the pathogenesis of alpha coma .', {'entities': [(126, 130, 'B_Disease')]}], ['It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication , in the absence of significant hypoxaemia , a favourable outcome may be anticipated .', {'entities': [(140, 150, 'B_Disease')]}], ['Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages .', {'entities': [(50, 59, 'B_Disease'), (85, 96, 'B_Disease')]}], ['The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication .', {'entities': [(88, 98, 'B_Disease'), (99, 106, 'I_Disease')]}], ['Using linear regression we found that no correlation exists between seizure duration , elevation of phenytoin serum levels and cerebellar volume .', {'entities': [(68, 75, 'B_Disease')]}], ['We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients .', {'entities': [(27, 37, 'B_Disease'), (69, 79, 'B_Disease'), (80, 87, 'I_Disease'), (155, 165, 'B_Disease'), (166, 173, 'I_Disease')]}], ['Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders .', {'entities': [(103, 113, 'B_Disease'), (114, 123, 'I_Disease')]}], ['Late recovery of renal function in a woman with the hemolytic uremic syndrome .', {'entities': [(52, 61, 'B_Disease'), (62, 68, 'I_Disease'), (69, 77, 'I_Disease')]}], ['A case is reported of the hemolytic uremic syndrome ( HUS ) in a woman taking oral contraceptives .', {'entities': [(26, 35, 'B_Disease'), (36, 42, 'I_Disease'), (43, 51, 'I_Disease'), (54, 57, 'B_Disease')]}], ['She was treated with heparin , dipyridamole and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of anuria , dialysis treatment was stopped .', {'entities': [(171, 177, 'B_Disease')]}], ['This case emphasizes the possibility that HUS in adults is not invariably irreversible and that , despite prolonged oliguria , recovery of renal function can be obtained .', {'entities': [(42, 45, 'B_Disease'), (116, 124, 'B_Disease')]}], ['Therefore , in adult patients affected by HUS , dialysis should not be discontinued prematurely ; moreover , bilateral nephrectomy , for treatment of severe hypertension and microangiopathic hemolytic anemia , should be performed with caution .', {'entities': [(42, 45, 'B_Disease'), (157, 169, 'B_Disease'), (174, 190, 'B_Disease'), (191, 200, 'I_Disease'), (201, 207, 'I_Disease')]}], ['Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats .', {'entities': [(26, 40, 'B_Disease')]}], ['w . once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating cerebellum damage ( \" valproate encephalopathy \" ) .', {'entities': [(64, 76, 'B_Disease'), (77, 86, 'I_Disease'), (98, 108, 'B_Disease'), (109, 115, 'I_Disease'), (130, 144, 'B_Disease')]}], ['Lesions of the capillary included necrosis of endothelial cells .', {'entities': [(34, 42, 'B_Disease')]}], ['Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions .', {'entities': [(13, 21, 'B_Disease')]}], ['The possible influence of the hepatic damage , mainly hyperammonemia , upon the development of valproate encephalopathy is discussed .', {'entities': [(30, 37, 'B_Disease'), (38, 44, 'I_Disease'), (54, 68, 'B_Disease'), (105, 119, 'B_Disease')]}], ['Fatal intracranial bleeding associated with prehospital use of epinephrine .', {'entities': [(6, 18, 'B_Disease'), (19, 27, 'I_Disease')]}], ['We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing .', {'entities': [(95, 103, 'B_Disease'), (104, 112, 'I_Disease'), (126, 135, 'B_Disease'), (136, 141, 'I_Disease'), (147, 155, 'B_Disease')]}], ['The sudden onset of respiratory distress , rash , and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine .', {'entities': [(20, 31, 'B_Disease'), (32, 40, 'I_Disease'), (43, 47, 'B_Disease')]}], ['Subsequently , acute cardiac arrest and fatal subarachnoid hemorrhage occurred .', {'entities': [(21, 28, 'B_Disease'), (29, 35, 'I_Disease'), (46, 58, 'B_Disease'), (59, 69, 'I_Disease')]}], ['Epinephrine has a proven role in cardiac arrest in prehospital care ; however , use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution .', {'entities': [(33, 40, 'B_Disease'), (41, 47, 'I_Disease'), (125, 133, 'B_Disease'), (134, 142, 'I_Disease'), (154, 166, 'B_Disease')]}], ['Role of activation of bradykinin B2 receptors in disruption of the blood - brain barrier during acute hypertension .', {'entities': [(102, 114, 'B_Disease')]}], ['Cellular mechanisms which account for disruption the blood - brain barrier during acute hypertension are not clear .', {'entities': [(88, 100, 'B_Disease')]}], ['The goal of this study was to determine the role of synthesis / release of bradykinin to activate B2 receptors in disruption of the blood - brain barrier during acute hypertension .', {'entities': [(167, 179, 'B_Disease')]}], ['Permeability of the blood - brain barrier was quantitated by clearance of fluorescent - labeled dextran before and during phenylephrine - induced acute hypertension in rats treated with vehicle and Hoe - 140 ( 0 . 1 microM ) .', {'entities': [(152, 164, 'B_Disease')]}], ['These findings suggest that disruption of the blood - brain barrier during acute hypertension is not related to the synthesis / release of bradykinin to activate B2 receptors .', {'entities': [(81, 93, 'B_Disease')]}], ['Risk factors of sensorineural hearing loss in preterm infants .', {'entities': [(16, 29, 'B_Disease'), (30, 37, 'I_Disease'), (38, 42, 'I_Disease')]}], ['Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991 , 8 children ( 1 . 46 % ) developed severe progressive and bilateral sensorineural hearing loss .', {'entities': [(151, 164, 'B_Disease'), (165, 172, 'I_Disease'), (173, 177, 'I_Disease')]}], ['Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications .', {'entities': [(39, 46, 'B_Disease'), (47, 51, 'I_Disease')]}], ['Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications .', {'entities': [(48, 55, 'B_Disease'), (56, 60, 'I_Disease')]}], ['Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs , particularly aminoglycosides and furosemide .', {'entities': [(0, 11, 'B_Disease'), (92, 100, 'B_Disease')]}], ['Finally , we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe .', {'entities': [(121, 128, 'B_Disease'), (129, 133, 'I_Disease')]}], ['Seizure resulting from a venlafaxine overdose .', {'entities': [(0, 7, 'B_Disease'), (37, 45, 'B_Disease')]}], ['OBJECTIVE : To report a case of venlafaxine overdose .', {'entities': [(44, 52, 'B_Disease')]}], ['CASE SUMMARY : A 40 - year - old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt .', {'entities': [(44, 49, 'B_Disease'), (50, 60, 'I_Disease'), (69, 77, 'B_Disease')]}], ['After the ingestion of 26 venlafaxine 50 - mg tablets , the patient experienced a witnessed generalized seizure .', {'entities': [(104, 111, 'B_Disease')]}], ['DISCUSSION : To our knowledge , this is the first reported case of venlafaxine overdose that resulted in a generalized seizure .', {'entities': [(79, 87, 'B_Disease'), (119, 126, 'B_Disease')]}], ['CONCLUSIONS : The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae .', {'entities': [(30, 38, 'B_Disease'), (98, 105, 'B_Disease')]}], ['Combined effects of prolonged prostaglandin E1 - induced hypotension and haemodilution on human hepatic function .', {'entities': [(57, 68, 'B_Disease'), (73, 86, 'B_Disease')]}], ['Combined effects of prolonged prostaglandin E1 ( PGE1 ) - induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery .', {'entities': [(66, 77, 'B_Disease'), (82, 95, 'B_Disease')]}], ['The patients were randomly allocated to one of three groups ; those in group A ( n = 10 ) were subjected to controlled hypotension alone , those in group B ( n = 10 ) to haemodilution alone and those in group C ( n = 10 ) to both controlled hypotension and haemodilution .', {'entities': [(119, 130, 'B_Disease'), (170, 183, 'B_Disease'), (241, 252, 'B_Disease'), (257, 270, 'B_Disease')]}], ['Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution , and final haematocrit values were 21 or 22 % .', {'entities': [(0, 13, 'B_Disease')]}], ['Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min .', {'entities': [(11, 22, 'B_Disease')]}], ['In group C , AKBR showed a significant decrease at 120 min ( - 40 % ) and at 180 min ( - 49 % ) after the start of hypotension and at 60 min ( - 32 % ) after recovery of normotension , and SGOT , SGPT , LDH and total bilirubin showed significant increases after operation .', {'entities': [(115, 126, 'B_Disease')]}], ['The results suggest that a prolonged combination of more than 120 min of PGE1 - induced hypotension and moderate haemodilution would cause impairment of hepatic function .', {'entities': [(88, 99, 'B_Disease'), (113, 126, 'B_Disease'), (139, 149, 'B_Disease'), (150, 152, 'I_Disease'), (153, 160, 'I_Disease'), (161, 169, 'I_Disease')]}], ['Cardiovascular alterations in rat fetuses exposed to calcium channel blockers .', {'entities': [(0, 14, 'B_Disease'), (15, 26, 'I_Disease')]}], ['Preclinical toxicologic investigation suggested that a new calcium channel blocker , Ro 40 - 5967 , induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis .', {'entities': [(108, 122, 'B_Disease'), (123, 134, 'I_Disease')]}], ['The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect .', {'entities': [(109, 123, 'B_Disease'), (124, 137, 'I_Disease')]}], ['Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations .', {'entities': [(167, 181, 'B_Disease'), (182, 195, 'I_Disease')]}], ['A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers , but this incidence was statistically significant only for verapamil and nifedipine .', {'entities': [(19, 33, 'B_Disease'), (34, 47, 'I_Disease')]}], ['Atypical sensations following the use of subcutaneous sumatriptan are common , but of uncertain origin .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease')]}], ['Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn .', {'entities': [(32, 40, 'B_Disease'), (41, 43, 'I_Disease'), (44, 51, 'I_Disease'), (52, 62, 'I_Disease'), (100, 107, 'B_Disease')]}], ['Macula toxicity after intravitreal amikacin .', {'entities': [(7, 15, 'B_Disease')]}], ['BACKGROUND : Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis , macular infarction may impair full visual recovery .', {'entities': [(99, 114, 'B_Disease'), (125, 135, 'B_Disease')]}], ['METHODS : We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha - haemolytic streptococcal endophthalmitis .', {'entities': [(49, 56, 'B_Disease'), (57, 65, 'I_Disease'), (138, 151, 'B_Disease'), (152, 167, 'I_Disease')]}], ['RESULTS : Endophthalmitis resolved with improvement in visual acuity to 6 / 24 at three months .', {'entities': [(10, 25, 'B_Disease')]}], ['Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis .', {'entities': [(71, 85, 'B_Disease')]}], ['CONCLUSIONS : Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia .', {'entities': [(76, 83, 'B_Disease'), (84, 92, 'I_Disease'), (105, 114, 'B_Disease')]}], ['Treatment strategies aimed at avoiding retinal toxicity are discussed .', {'entities': [(39, 46, 'B_Disease'), (47, 55, 'I_Disease')]}], ['The role of nicotine in smoking - related cardiovascular disease .', {'entities': [(42, 56, 'B_Disease'), (57, 64, 'I_Disease')]}], ['Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease .', {'entities': [(86, 100, 'B_Disease'), (101, 108, 'I_Disease')]}], ['Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis , but evidence among humans is too inadequate to be definitive about such an effect .', {'entities': [(96, 111, 'B_Disease')]}], ['Nicotine does not appear to enhance thrombosis among humans .', {'entities': [(36, 46, 'B_Disease')]}], ['Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff - Parkinson - White syndrome and idiopathic dilated cardiomyopathy .', {'entities': [(35, 51, 'B_Disease'), (52, 61, 'I_Disease'), (62, 73, 'I_Disease'), (130, 135, 'B_Disease'), (136, 137, 'I_Disease'), (138, 147, 'I_Disease'), (148, 149, 'I_Disease'), (150, 155, 'I_Disease'), (156, 164, 'I_Disease'), (169, 179, 'B_Disease'), (180, 187, 'I_Disease'), (188, 202, 'I_Disease')]}], ['In a patient with WPW syndrome and idiopathic dilated cardiomyopathy , intractable atrioventricular reentrant tachycardia ( AVRT ) was iatrogenically induced .', {'entities': [(18, 21, 'B_Disease'), (22, 30, 'I_Disease'), (35, 45, 'B_Disease'), (46, 53, 'I_Disease'), (54, 68, 'I_Disease'), (83, 99, 'B_Disease'), (100, 109, 'I_Disease'), (110, 121, 'I_Disease'), (124, 128, 'B_Disease')]}], ['QRS without preexcitation , caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation , established frequent AVRT attack .', {'entities': [(180, 184, 'B_Disease')]}], ['Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone - sparing substitutes of chlorofluorocarbons .', {'entities': [(12, 17, 'B_Disease'), (18, 25, 'I_Disease')]}], ['Limited studies in animals indicate potential hepatotoxicity of some of these compounds .', {'entities': [(46, 60, 'B_Disease')]}], ['We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane ( HCFC 123 ) and 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane ( HCFC 124 ) .', {'entities': [(31, 36, 'B_Disease'), (37, 44, 'I_Disease')]}], ['Both compounds are metabolised in the same way as 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the hepatotoxicity of halothane .', {'entities': [(207, 221, 'B_Disease')]}], ['We aimed to test whether HCFCs 123 and 124 can result in serious liver disease .', {'entities': [(65, 70, 'B_Disease'), (71, 78, 'I_Disease')]}], ['FINDINGS : The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas ( bridging necrosis ) .', {'entities': [(57, 65, 'B_Disease'), (204, 212, 'B_Disease')]}], ['Autoantibodies against P450 2E1 or P58 , previously associated with halothane hepatitis , were detected in the serum of five affected workers .', {'entities': [(68, 77, 'B_Disease'), (78, 87, 'I_Disease')]}], ['INTERPRETATION : Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population .', {'entities': [(94, 99, 'B_Disease'), (100, 106, 'I_Disease')]}], ['Although the exact mechanism of hepatotoxicity of these agents is not known , the results suggest that trifluoroacetyl - altered liver proteins are involved .', {'entities': [(32, 46, 'B_Disease')]}], ['Bile duct hamartoma occurring in association with long - term treatment with danazol .', {'entities': [(0, 4, 'B_Disease'), (5, 9, 'I_Disease'), (10, 19, 'I_Disease')]}], ['We report a case of bile duct hamartoma which developed in a patient who had been on long - term danazol treatment .', {'entities': [(20, 24, 'B_Disease'), (25, 29, 'I_Disease'), (30, 39, 'I_Disease')]}], ['If the patient develops a liver mass , because of non - specific clinical features and imaging appearances , biopsy may be the only way to achieve a definitive diagnosis .', {'entities': [(26, 31, 'B_Disease'), (32, 36, 'I_Disease')]}], ['Endocrine screening in 1 , 022 men with erectile dysfunction : clinical significance and cost - effective strategy .', {'entities': [(40, 48, 'B_Disease'), (49, 60, 'I_Disease')]}], ['PURPOSE : We reviewed the results of serum testosterone and prolactin determination in 1 , 022 patients referred because of erectile dysfunction and compared the data with history , results of physical examination , other etiological investigations and effects of endocrine therapy to refine the rules of cost - effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities .', {'entities': [(124, 132, 'B_Disease'), (133, 144, 'I_Disease')]}], ['Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire , gynecomastia or testosterone less than 4 ng . / ml .', {'entities': [(96, 99, 'B_Disease'), (100, 106, 'I_Disease'), (107, 113, 'I_Disease'), (116, 128, 'B_Disease')]}], ['Prolactin results were compared with those of a previous personal cohort of 1 , 340 patients with erectile dysfunction and systematic prolactin determination .', {'entities': [(98, 106, 'B_Disease'), (107, 118, 'I_Disease')]}], ['Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire , small testes and gynecomastia .', {'entities': [(81, 84, 'B_Disease'), (85, 91, 'I_Disease'), (92, 98, 'I_Disease'), (118, 130, 'B_Disease')]}], ['Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia .', {'entities': [(90, 102, 'B_Disease'), (125, 143, 'B_Disease')]}], ['Two pituitary tumors were discovered after testosterone determination .', {'entities': [(4, 13, 'B_Disease'), (14, 20, 'I_Disease')]}], ['Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction ( definite improvement in only 16 of 44 [ 36 % ] after androgen therapy , normal morning or nocturnal erections in 30 % and definite vasculogenic contributions in 42 % ) .', {'entities': [(75, 87, 'B_Disease'), (88, 99, 'I_Disease'), (191, 199, 'B_Disease'), (200, 211, 'I_Disease')]}], ['Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40 % of the cases with low testosterone , including 37 % of those subsequently improved by androgen therapy .', {'entities': [(42, 45, 'B_Disease'), (46, 52, 'I_Disease'), (53, 59, 'I_Disease')]}], ['Only 1 prolactinoma was discovered .', {'entities': [(7, 19, 'B_Disease')]}], ['These data are lower than those we found during the last 2 decades ( overall prolactin greater than 20 ng . / ml . in 1 . 86 % of 1 , 821 patients , prolactinomas in 7 , 0 . 38 % ) .', {'entities': [(149, 162, 'B_Disease')]}], ['CONCLUSIONS : Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination .', {'entities': [(84, 92, 'B_Disease'), (93, 104, 'I_Disease')]}], ['However , cost - effective screening strategies recommended so far missed 40 to 50 % of cases improved with endocrine therapy and the pituitary tumors .', {'entities': [(134, 143, 'B_Disease'), (144, 150, 'I_Disease')]}], ['We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years .', {'entities': [(85, 88, 'B_Disease'), (89, 95, 'I_Disease'), (96, 102, 'I_Disease')]}], ['Prolactin should be determined only in cases of low sexual desire , gynecomastia and / or testosterone less than 4 ng . / ml .', {'entities': [(48, 51, 'B_Disease'), (52, 58, 'I_Disease'), (59, 65, 'I_Disease'), (68, 80, 'B_Disease')]}], [\"Previous clinical studies have proposed that risperidone ' s pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects ; features shared by so - called ' atypical ' neuroleptics .\", {'entities': [(126, 135, 'B_Disease'), (136, 144, 'I_Disease')]}], ['Drug - induced parkinsonism was observed in subjects treated with risperidone ( 42 % ) and haloperidol ( 29 % ) and was observed at occupancy levels above 60 % .', {'entities': [(0, 4, 'B_Disease'), (5, 6, 'I_Disease'), (7, 14, 'I_Disease'), (15, 27, 'I_Disease')]}], ['Treatment of previously treated metastatic breast cancer by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( MFL ) : low palliative benefit and high treatment - related toxicity .', {'entities': [(43, 49, 'B_Disease'), (50, 56, 'I_Disease'), (206, 214, 'B_Disease')]}], ['For previously treated advanced breast cancer , there is no standard second - line therapy .', {'entities': [(32, 38, 'B_Disease'), (39, 45, 'I_Disease')]}], ['From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy - treated metastatic breast cancer by mitoxantrone , 12 mg / m2 , on day 1 and continuous infusion of 5 - FU , 3000 mg / m2 , together with leucovorin , 300 mg / m2 , for 48 h from day 1 to 2 .', {'entities': [(110, 116, 'B_Disease'), (117, 123, 'I_Disease')]}], ['Major toxicities were cardiotoxicity and leukopenia .', {'entities': [(6, 16, 'B_Disease'), (22, 36, 'B_Disease'), (41, 51, 'B_Disease')]}], ['Eight patients were dead in the last follow - up ; two of them died of treatment - related toxicity .', {'entities': [(91, 99, 'B_Disease')]}], ['The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate .', {'entities': [(70, 78, 'B_Disease')]}], ['Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention .', {'entities': [(34, 40, 'B_Disease'), (41, 47, 'I_Disease'), (110, 118, 'B_Disease'), (119, 124, 'I_Disease'), (125, 133, 'I_Disease')]}], ['Ticlopidine - induced aplastic anemia : report of three Chinese patients and review of the literature .', {'entities': [(22, 30, 'B_Disease'), (31, 37, 'I_Disease')]}], ['In this study , three Chinese patients with ticlopidine - induced aplastic anemia were reported and another 13 patients in the English literature were reviewed .', {'entities': [(66, 74, 'B_Disease'), (75, 81, 'I_Disease')]}], ['Agranulocytosis occurred 3 - 20 weeks after initiation of ticlopidine , so frequent examination of white cell count during treatment is recommended .', {'entities': [(0, 15, 'B_Disease')]}], ['There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression .', {'entities': [(95, 99, 'B_Disease'), (100, 106, 'I_Disease'), (107, 118, 'I_Disease')]}], ['Treatment for ticlopidine - induced aplastic anemia with colony - stimulating factors seemed to have little effect .', {'entities': [(36, 44, 'B_Disease'), (45, 51, 'I_Disease')]}], ['Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium - induced diabetes insipidus rat .', {'entities': [(121, 129, 'B_Disease'), (130, 139, 'I_Disease')]}], ['The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium ( Li ) - induced polyuria , using in situ hybridization histochemistry and radioimmunoassay .', {'entities': [(168, 176, 'B_Disease')]}], ['The male Wistar rats consuming a diet that contained LiCl ( 60 mmol / kg ) for 4 weeks developed marked polyuria .', {'entities': [(104, 112, 'B_Disease')]}], ['These results suggest that dehydration and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li - induced diabetes insipidus rat .', {'entities': [(27, 38, 'B_Disease'), (224, 232, 'B_Disease'), (233, 242, 'I_Disease')]}], ['( + / - ) - PG - 9 ( 10 - 40 mg kg - 1 i . p . ) was able to prevent amnesia induced by scopolamine ( 1 mg kg - 1 i . p . ) and dicyclomine ( 2 mg kg - 1 i . p . ) in the mouse passive - avoidance test .', {'entities': [(69, 76, 'B_Disease')]}], ['Affinity profiles of ( + / - ) - PG - 9 for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4 / M1 selectivity ratio of 10 . 2 that might be responsible for the antinociception and the anti - amnesic effect induced by ( + / - ) - PG - 9 through an increase in acetylcholine extracellular levels .', {'entities': [(356, 363, 'B_Disease')]}], ['The effect of different anaesthetic agents in hearing loss following spinal anaesthesia .', {'entities': [(46, 53, 'B_Disease'), (54, 58, 'I_Disease')]}], ['The cause of hearing loss after spinal anaesthesia is unknown .', {'entities': [(13, 20, 'B_Disease'), (21, 25, 'I_Disease')]}], ['Up until now , the only factor studied has been the effect of the diameter of the spinal needle on post - operative sensorineural hearing loss .', {'entities': [(116, 129, 'B_Disease'), (130, 137, 'I_Disease'), (138, 142, 'I_Disease')]}], ['The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss .', {'entities': [(43, 50, 'B_Disease'), (51, 55, 'I_Disease'), (115, 122, 'B_Disease'), (123, 127, 'I_Disease')]}], ['Patients given prilocaine were more likely to develop hearing loss ( 10 out of 22 ) than those given bupivacaine ( 4 out of 22 ) ( P < 0 . 05 ) .', {'entities': [(54, 61, 'B_Disease'), (62, 66, 'I_Disease')]}], ['The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine .', {'entities': [(12, 19, 'B_Disease'), (20, 24, 'I_Disease')]}], ['None of the patients complained of subjective hearing loss .', {'entities': [(46, 53, 'B_Disease'), (54, 58, 'I_Disease')]}], ['A transient neurological deficit following intrathecal injection of 1 % hyperbaric bupivacaine for unilateral spinal anaesthesia .', {'entities': [(12, 24, 'B_Disease'), (25, 32, 'I_Disease')]}], ['We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1 % hyperbaric bupivacaine slowly injected through a 25 - gauge pencil - point spinal needle .', {'entities': [(32, 44, 'B_Disease'), (45, 52, 'I_Disease')]}], ['The surgery and anaesthesia were uneventful , but 3 days after surgery , the patient reported an area of hypoaesthesia over L3 - L4 dermatomes of the leg which had been operated on ( loss of pinprick sensation ) without reduction in muscular strength .', {'entities': [(183, 187, 'B_Disease'), (188, 190, 'I_Disease'), (191, 199, 'I_Disease'), (200, 209, 'I_Disease')]}], ['However , we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution ( if pencil - point needle and slow injection rate are employed ) , in order to minimize the risk of a localized high peak anaesthetic concentration , which might lead to a transient neurological deficit .', {'entities': [(331, 343, 'B_Disease'), (344, 351, 'I_Disease')]}], ['Transient neurologic symptoms after spinal anesthesia : a lower incidence with prilocaine and bupivacaine than with lidocaine .', {'entities': [(0, 9, 'B_Disease'), (10, 20, 'I_Disease'), (21, 29, 'I_Disease')]}], ['BACKGROUND : Recent evidence suggests that transient neurologic symptoms ( TNSs ) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine .', {'entities': [(43, 52, 'B_Disease'), (53, 63, 'I_Disease'), (64, 72, 'I_Disease'), (75, 79, 'B_Disease')]}], ['Accordingly , the present , prospective double - blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs .', {'entities': [(168, 172, 'B_Disease')]}], ['In the evening of postoperative day 1 , patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure .', {'entities': [(68, 72, 'B_Disease')]}], ['RESULTS : Nine of 30 patients receiving lidocaine experienced TNSs , 1 of 30 patients receiving prilocaine ( P = 0 . 03 ) had them , and none of 30 patients receiving bupivacaine had TNSs .', {'entities': [(62, 66, 'B_Disease'), (183, 187, 'B_Disease')]}], ['CONCLUSIONS : Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs .', {'entities': [(155, 159, 'B_Disease')]}], ['Suxamethonium - induced cardiac arrest and death following 5 days of immobilization .', {'entities': [(24, 31, 'B_Disease'), (32, 38, 'I_Disease'), (43, 48, 'B_Disease')]}], ['The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23 - year - old Malawian woman .', {'entities': [(39, 46, 'B_Disease'), (47, 53, 'I_Disease'), (69, 74, 'B_Disease'), (90, 103, 'B_Disease')]}], ['Five days after the onset of the symptoms of meningitis , the patient aspirated stomach contents and needed endotracheal intubation .', {'entities': [(45, 55, 'B_Disease')]}], ['Forty seconds after injection of suxamethonium , bradycardia and cardiac arrest occurred .', {'entities': [(49, 60, 'B_Disease'), (65, 72, 'B_Disease'), (73, 79, 'I_Disease')]}], [\"Apart from the reduction in the patient ' s level of consciousness , there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium .\", {'entities': [(170, 183, 'B_Disease')]}], ['It is postulated that her death was caused by hypersensitivity to suxamethonium , associated with her 5 - day immobilization .', {'entities': [(26, 31, 'B_Disease'), (46, 62, 'B_Disease')]}], ['Acute hepatitis , autoimmune hemolytic anemia , and erythroblastocytopenia induced by ceftriaxone .', {'entities': [(6, 15, 'B_Disease'), (18, 28, 'B_Disease'), (29, 38, 'I_Disease'), (39, 45, 'I_Disease'), (52, 74, 'B_Disease')]}], ['An 80 - yr - old man developed acute hepatitis shortly after ingesting oral ceftriaxone .', {'entities': [(37, 46, 'B_Disease')]}], ['Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia .', {'entities': [(209, 219, 'B_Disease'), (220, 229, 'I_Disease'), (230, 236, 'I_Disease'), (241, 263, 'B_Disease')]}], ['Thyroxine abuse : an unusual case of thyrotoxicosis in pregnancy .', {'entities': [(37, 51, 'B_Disease')]}], ['Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy .', {'entities': [(0, 6, 'B_Disease'), (7, 16, 'I_Disease'), (61, 65, 'B_Disease'), (66, 71, 'I_Disease')]}], ['This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy , including prolonged and recurrent metabolic disturbances and diuretic abuse .', {'entities': [(81, 87, 'B_Disease'), (88, 97, 'I_Disease')]}], ['In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure , thyroxine abuse should be considered and explored .', {'entities': [(94, 100, 'B_Disease'), (101, 110, 'I_Disease'), (148, 162, 'B_Disease')]}], ['In the acute experiment TRI ( given i . p . ) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5 - hydroxytryptophan head twitches in rats .', {'entities': [(80, 91, 'B_Disease')]}], ['TRI given repeatedly to rats increases the locomotor hyperactivity induced by d - amphetamine , quinpirole and ( + ) - 7 - hydroxy - dipropyloaminotetralin ( dopamine D2 and D3 effects ) .', {'entities': [(53, 66, 'B_Disease')]}], ['It increases the behaviour stimulation evoked by phenylephrine ( given intraventricularly ) in rats , evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice , both these effects being mediated by an alpha1 - adrenergic receptor .', {'entities': [(150, 164, 'B_Disease')]}], ['Pethidine - associated seizure in a healthy adolescent receiving pethidine for postoperative pain control .', {'entities': [(23, 30, 'B_Disease'), (79, 92, 'B_Disease'), (93, 97, 'I_Disease')]}], ['A healthy 17 - year - old male received standard intermittent doses of pethidine via a patient - controlled analgesia ( PCA ) pump for management of postoperative pain control .', {'entities': [(149, 162, 'B_Disease'), (163, 167, 'I_Disease')]}], ['Twenty - three h postoperatively he developed a brief self - limited seizure .', {'entities': [(69, 76, 'B_Disease')]}], ['No other risk factors for CNS toxicity were identified .', {'entities': [(30, 38, 'B_Disease')]}], [\"An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren ' s contracture .\", {'entities': [(3, 11, 'B_Disease'), (12, 14, 'I_Disease'), (15, 20, 'I_Disease'), (21, 29, 'I_Disease'), (47, 53, 'B_Disease'), (54, 66, 'I_Disease'), (69, 78, 'B_Disease'), (81, 97, 'B_Disease'), (98, 104, 'I_Disease'), (109, 113, 'B_Disease'), (114, 116, 'I_Disease'), (117, 130, 'I_Disease'), (346, 355, 'B_Disease'), (356, 357, 'I_Disease'), (358, 359, 'I_Disease'), (360, 371, 'I_Disease')]}], ['The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation .', {'entities': [(83, 89, 'B_Disease'), (90, 102, 'I_Disease')]}], ['Drug - associated acute - onset vanishing bile duct and Stevens - Johnson syndromes in a child .', {'entities': [(32, 41, 'B_Disease'), (42, 46, 'I_Disease'), (47, 51, 'I_Disease'), (56, 63, 'B_Disease'), (64, 65, 'I_Disease'), (66, 73, 'I_Disease'), (74, 83, 'I_Disease')]}], ['Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults , is most often drug or toxin related , and is of unknown pathogenesis .', {'entities': [(6, 15, 'B_Disease'), (16, 20, 'I_Disease'), (21, 25, 'I_Disease'), (82, 93, 'B_Disease')]}], ['Stevens - Johnson syndrome is a well - recognized immune complex - mediated hypersensitivity reaction that affects all age groups , is drug or infection induced , and has classic systemic , mucosal , and dermatologic manifestations .', {'entities': [(0, 7, 'B_Disease'), (8, 9, 'I_Disease'), (10, 17, 'I_Disease'), (18, 26, 'I_Disease'), (76, 92, 'B_Disease'), (143, 152, 'B_Disease')]}], ['A previously healthy child who developed acute , severe , rapidly progressive vanishing bile duct syndrome shortly after Stevens - Johnson syndrome is described ; this was temporally associated with ibuprofen use .', {'entities': [(78, 87, 'B_Disease'), (88, 92, 'I_Disease'), (93, 97, 'I_Disease'), (98, 106, 'I_Disease'), (121, 128, 'B_Disease'), (129, 130, 'I_Disease'), (131, 138, 'I_Disease'), (139, 147, 'I_Disease')]}], ['Despite therapy with ursodeoxycholic acid , prednisone , and then tacrolimus , her cholestatic disease was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .', {'entities': [(83, 94, 'B_Disease'), (95, 102, 'I_Disease'), (126, 135, 'B_Disease')]}], ['This case documents acute drug - related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens - Johnson syndrome and vanishing bile duct syndrome .', {'entities': [(41, 50, 'B_Disease'), (51, 55, 'I_Disease'), (56, 60, 'I_Disease'), (61, 69, 'I_Disease'), (163, 170, 'B_Disease'), (171, 172, 'I_Disease'), (173, 180, 'I_Disease'), (181, 189, 'I_Disease'), (194, 203, 'B_Disease'), (204, 208, 'I_Disease'), (209, 213, 'I_Disease'), (214, 222, 'I_Disease')]}], ['High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium .', {'entities': [(18, 25, 'B_Disease'), (26, 35, 'I_Disease'), (36, 48, 'I_Disease')]}], ['Primary pulmonary hypertension is a rare , progressive and incurable disease , which has been associated with the intake of appetite suppressant drugs .', {'entities': [(0, 7, 'B_Disease'), (8, 17, 'I_Disease'), (18, 30, 'I_Disease')]}], ['Thirty - five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months ( 1992 - 1994 ) in Belgium .', {'entities': [(28, 35, 'B_Disease'), (36, 45, 'I_Disease'), (46, 58, 'I_Disease')]}], ['In 8 patients the diagnosis of primary pulmonary hypertension was uncertain , 5 of them had taken appetite suppressants .', {'entities': [(31, 38, 'B_Disease'), (39, 48, 'I_Disease'), (49, 61, 'I_Disease')]}], ['A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension .', {'entities': [(106, 113, 'B_Disease'), (114, 123, 'I_Disease'), (124, 136, 'I_Disease')]}], ['Inappropriate use of carbamazepine and vigabatrin in typical absence seizures .', {'entities': [(61, 68, 'B_Disease'), (69, 77, 'I_Disease')]}], ['Carbamazepine and vigabatrin are contraindicated in typical absence seizures .', {'entities': [(60, 67, 'B_Disease'), (68, 76, 'I_Disease')]}], ['Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks , which resolved on withdrawal of carbamazepine .', {'entities': [(103, 112, 'B_Disease'), (113, 118, 'I_Disease')]}], ['Choreoathetoid movements associated with rapid adjustment to methadone .', {'entities': [(0, 14, 'B_Disease'), (15, 24, 'I_Disease')]}], ['Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates .', {'entities': [(0, 12, 'B_Disease'), (13, 26, 'I_Disease'), (54, 62, 'B_Disease'), (63, 76, 'I_Disease')]}], ['This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu - opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine .', {'entities': [(38, 52, 'B_Disease'), (53, 62, 'I_Disease')]}], ['Conventional agents are associated with unwanted central nervous system effects , including extrapyramidal symptoms ( EPS ) , tardive dyskinesia , sedation , and possible impairment of some cognitive measures , as well as cardiac effects , orthostatic hypotension , hepatic changes , anticholinergic side effects , sexual dysfunction , and weight gain .', {'entities': [(92, 106, 'B_Disease'), (107, 115, 'I_Disease'), (118, 121, 'B_Disease'), (126, 133, 'B_Disease'), (134, 144, 'I_Disease'), (240, 251, 'B_Disease'), (252, 263, 'I_Disease'), (315, 321, 'B_Disease'), (322, 333, 'I_Disease'), (340, 346, 'B_Disease'), (347, 351, 'I_Disease')]}], ['The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( clozapine only ) .', {'entities': [(47, 50, 'B_Disease'), (158, 164, 'B_Disease'), (165, 169, 'I_Disease'), (172, 178, 'B_Disease'), (179, 190, 'I_Disease'), (219, 226, 'B_Disease'), (267, 282, 'B_Disease')]}], [\"A randomized , placebo - controlled dose - comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer ' s disease .\", {'entities': [(79, 88, 'B_Disease'), (93, 103, 'B_Disease'), (104, 113, 'I_Disease'), (117, 126, 'B_Disease'), (127, 128, 'I_Disease'), (129, 130, 'I_Disease'), (131, 138, 'I_Disease')]}], [\"OBJECTIVE : The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer ' s disease .\", {'entities': [(140, 149, 'B_Disease'), (154, 164, 'B_Disease'), (165, 174, 'I_Disease'), (192, 201, 'B_Disease'), (202, 203, 'I_Disease'), (204, 205, 'I_Disease'), (206, 213, 'I_Disease')]}], [\"METHOD : In a 6 - week random - assignment , double - blind , placebo - controlled trial ( phase A ) , haloperidol , 2 - 3 mg / day ( standard dose ) , and haloperidol , 0 . 50 - 0 . 75 mg / day ( low dose ) , were compared in 71 outpatients with Alzheimer ' s disease .\", {'entities': [(247, 256, 'B_Disease'), (257, 258, 'I_Disease'), (259, 260, 'I_Disease'), (261, 268, 'I_Disease')]}], ['RESULTS : For the 60 patients who completed phase A , standard - dose haloperidol was efficacious and superior to both low - dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation .', {'entities': [(203, 212, 'B_Disease'), (227, 238, 'B_Disease'), (239, 248, 'I_Disease')]}], ['In phase A , extrapyramidal signs tended to be greater with the standard dose than in the other two conditions , primarily because of a subgroup ( 20 % ) who developed moderate to severe signs .', {'entities': [(13, 27, 'B_Disease'), (28, 33, 'I_Disease')]}], ['CONCLUSIONS : The results indicated a favorable therapeutic profile for haloperidol in doses of 2 - 3 mg / day , although a subgroup developed moderate to severe extrapyramidal signs .', {'entities': [(162, 176, 'B_Disease'), (177, 182, 'I_Disease')]}], [\"The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer ' s disease patients with psychosis and disruptive behaviors .\", {'entities': [(101, 110, 'B_Disease'), (111, 112, 'I_Disease'), (113, 114, 'I_Disease'), (115, 122, 'I_Disease'), (137, 146, 'B_Disease'), (151, 161, 'B_Disease'), (162, 171, 'I_Disease')]}], ['Effects of acetylsalicylic acid , dipyridamole , and hydrocortisone on epinephrine - induced myocardial injury in dogs .', {'entities': [(93, 103, 'B_Disease'), (104, 110, 'I_Disease')]}], ['A reproducible model for producing diffuse myocardial injury ( epinephrine infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction .', {'entities': [(43, 53, 'B_Disease'), (54, 60, 'I_Disease'), (207, 217, 'B_Disease'), (218, 228, 'I_Disease')]}], ['RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic FK506 nephropathy ( n = 9 ) , and mild - type FK506 nephropathy ( n = 11 ) .', {'entities': [(160, 163, 'B_Disease'), (164, 175, 'I_Disease'), (245, 256, 'B_Disease'), (291, 302, 'B_Disease')]}], ['Of the nonepisode biopsies , 7 and 4 biopsies showed minimal - type and mild - type chronic FK506 nephropathy , respectively .', {'entities': [(98, 109, 'B_Disease')]}], ['Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .', {'entities': [(14, 25, 'B_Disease'), (170, 175, 'B_Disease'), (176, 185, 'I_Disease'), (186, 204, 'I_Disease'), (244, 256, 'B_Disease'), (257, 265, 'I_Disease')]}], ['The serum creatinine levels of patients in the mild - type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - nephropathy group ( P < 0 . 001 ) .', {'entities': [(73, 84, 'B_Disease'), (204, 215, 'B_Disease')]}], ['CONCLUSIONS : This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function .', {'entities': [(57, 68, 'B_Disease'), (212, 223, 'B_Disease')]}], ['Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis .', {'entities': [(87, 99, 'B_Disease'), (100, 103, 'I_Disease'), (104, 116, 'I_Disease'), (117, 128, 'I_Disease')]}], ['Although hepatocyte TJs are impaired in cholestasis , attempts to localize the precise site of hepatocyte TJ damage by freeze - fracture electron microscopy have produced limited information .', {'entities': [(40, 51, 'B_Disease')]}], ['We used rat models of intrahepatic cholestasis by ethinyl estradiol ( EE ) treatment and extrahepatic cholestasis by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .', {'entities': [(22, 34, 'B_Disease'), (35, 46, 'I_Disease'), (89, 101, 'B_Disease'), (102, 113, 'I_Disease')]}], ['In the mouse passive - avoidance test , PG - 9 ( 10 - 30 mg / kg , i . p . ) , administered 20 min before the training session , prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1 - selective antagonist S - ( - ) - ET - 126 .', {'entities': [(139, 146, 'B_Disease')]}], ['In the same experimental conditions , PG - 9 ( 5 - 20 microg per mouse , i . c . v . ) was also able to prevent antimuscarine - induced amnesia , demonstrating a central localization of the activity .', {'entities': [(136, 143, 'B_Disease')]}], ['Mechanisms of FK 506 - induced hypertension in the rat .', {'entities': [(31, 43, 'B_Disease')]}], ['The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity .', {'entities': [(61, 73, 'B_Disease'), (78, 92, 'B_Disease')]}], ['To clarify the mechanisms of FK 506 - induced hypertension , we studied the chronic effects of FK 506 on the synthesis of endothelin - 1 ( ET - 1 ) , the expression of mRNA of ET - 1 and endothelin - converting enzyme - 1 ( ECE - 1 ) , the endothelial nitric oxide synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C - type natriuretic peptide ( CNP ) in rat blood vessels .', {'entities': [(46, 58, 'B_Disease')]}], ['In addition , the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506 - induced hypertension in rats was studied .', {'entities': [(109, 121, 'B_Disease')]}], ['The administration of FR 139317 ( 10 mg . kg - 1 . d - 1 ) prevented FK 506 - induced hypertension in rats .', {'entities': [(86, 98, 'B_Disease')]}]]\n",
      "lenth of the TRAIN_DATA : 2658\n"
     ]
    }
   ],
   "source": [
    "TRAIN_DATA, LABELS = load_data_spacy(\"train.tsv\")\n",
    "print(TRAIN_DATA)\n",
    "print(\"lenth of the TRAIN_DATA :\",len(TRAIN_DATA))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "SxkHc0rpx-Cu"
   },
   "source": [
    "## Test Data"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "iiPdZlfqhRSV",
    "outputId": "ed38aff2-f719-4a9d-af5a-6ca93492b43b"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[['Torsade de pointes ventricular tachycardia during low dose intermittent dobutamine treatment in a patient with dilated cardiomyopathy and congestive heart failure .', {'entities': [(0, 7, 'B_Disease'), (8, 10, 'I_Disease'), (11, 18, 'I_Disease'), (19, 30, 'B_Disease'), (31, 42, 'I_Disease'), (111, 118, 'B_Disease'), (119, 133, 'I_Disease'), (138, 148, 'B_Disease'), (149, 154, 'I_Disease'), (155, 162, 'I_Disease')]}], ['The authors describe the case of a 56 - year - old woman with chronic , severe heart failure secondary to dilated cardiomyopathy and absence of significant ventricular arrhythmias who developed QT prolongation and torsade de pointes ventricular tachycardia during one cycle of intermittent low dose ( 2 . 5 mcg / kg per min ) dobutamine .', {'entities': [(79, 84, 'B_Disease'), (85, 92, 'I_Disease'), (106, 113, 'B_Disease'), (114, 128, 'I_Disease'), (156, 167, 'B_Disease'), (168, 179, 'I_Disease'), (194, 196, 'B_Disease'), (197, 209, 'I_Disease'), (214, 221, 'B_Disease'), (222, 224, 'I_Disease'), (225, 232, 'I_Disease'), (233, 244, 'B_Disease'), (245, 256, 'I_Disease')]}], ['This report of torsade de pointes ventricular tachycardia during intermittent dobutamine supports the hypothesis that unpredictable fatal arrhythmias may occur even with low doses and in patients with no history of significant rhythm disturbances .', {'entities': [(15, 22, 'B_Disease'), (23, 25, 'I_Disease'), (26, 33, 'I_Disease'), (34, 45, 'B_Disease'), (46, 57, 'I_Disease'), (138, 149, 'B_Disease')]}], ['After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction ( dyspnea , loss of consciousness ) and delayed macro - papular rash appeared , whilst patient n degree 2 developed a generalised sensation of heat , persistent pain at the site of injection immediately and a generalised macro - papular reaction after 24 hours .', {'entities': [(109, 116, 'B_Disease'), (119, 123, 'B_Disease'), (124, 126, 'I_Disease'), (127, 140, 'I_Disease'), (155, 160, 'B_Disease'), (161, 162, 'I_Disease'), (163, 170, 'I_Disease'), (171, 175, 'I_Disease'), (268, 272, 'B_Disease')]}], ['The positive skin tests are in favour of immunological reactions and may help in diagnosis of allergy in the patients .', {'entities': [(94, 101, 'B_Disease')]}], ['Risk of transient hyperammonemic encephalopathy in cancer patients who received continuous infusion of 5 - fluorouracil with the complication of dehydration and infection .', {'entities': [(18, 32, 'B_Disease'), (33, 47, 'I_Disease'), (51, 57, 'B_Disease'), (145, 156, 'B_Disease'), (161, 170, 'B_Disease')]}], ['From 1986 to 1998 , 29 cancer patients who had 32 episodes of transient hyperammonemic encephalopathy related to continuous infusion of 5 - fluorouracil ( 5 - FU ) were identified .', {'entities': [(23, 29, 'B_Disease'), (72, 86, 'B_Disease'), (87, 101, 'I_Disease')]}], ['None of the patients had decompensated liver disease .', {'entities': [(39, 44, 'B_Disease'), (45, 52, 'I_Disease')]}], ['Onset of hyperammonemic encephalopathy varied from 0 . 5 to 5 days ( mean : 2 . 6 + / - 1 . 3 days ) after the initiation of chemotherapy .', {'entities': [(9, 23, 'B_Disease'), (24, 38, 'I_Disease')]}], ['Among the 32 episodes , 26 ( 81 % ) had various degrees of azotemia , 18 ( 56 % ) occurred during bacterial infections and 14 ( 44 % ) without infection occurred during periods of dehydration .', {'entities': [(59, 67, 'B_Disease'), (98, 107, 'B_Disease'), (108, 118, 'I_Disease'), (143, 152, 'B_Disease'), (180, 191, 'B_Disease')]}], ['Higher plasma ammonium levels and more rapid onset of hyperammonemia were seen in 18 patients with bacterial infections ( p = 0 . 003 and 0 . 0006 , respectively ) and in nine patients receiving high daily doses ( 2600 or 1800 mg / m2 ) of 5 - FU ( p = 0 . 0001 and < 0 . 0001 , respectively ) .', {'entities': [(54, 68, 'B_Disease'), (99, 108, 'B_Disease'), (109, 119, 'I_Disease')]}], ['In conclusion , hyperammonemic encephalopathy can occur in patients receiving continuous infusion of 5 - FU .', {'entities': [(16, 30, 'B_Disease'), (31, 45, 'I_Disease')]}], ['Azotemia , body fluid insufficiency and bacterial infections were frequently found in these patients .', {'entities': [(0, 8, 'B_Disease'), (40, 49, 'B_Disease'), (50, 60, 'I_Disease')]}], ['In the motor activity test measured with an Animex - activity meter neither of the K ( + ) - channel blockers affected morphine - induced hypoactivity , but both K ( + ) - channel blockers prevented morphine - induced secondary hyperactivity .', {'entities': [(138, 150, 'B_Disease'), (228, 241, 'B_Disease')]}], ['It is also suggested that the blockade of K ( + ) - channels sensitive to these blockers is not sufficient to prevent morphine - induced hypoactivity whereas morphine - induced hyperactivity seems to be connected to both quinine - and 4 - aminopyridine - sensitive K ( + ) - channels .', {'entities': [(137, 149, 'B_Disease'), (177, 190, 'B_Disease')]}], ['Nociceptin / orphanin FQ and nocistatin on learning and memory impairment induced by scopolamine in mice .', {'entities': [(43, 51, 'B_Disease'), (52, 55, 'I_Disease'), (56, 62, 'I_Disease'), (63, 73, 'I_Disease')]}], ['On the other hand , nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin - induced allodynia and hyperalgesia .', {'entities': [(122, 131, 'B_Disease'), (136, 148, 'B_Disease')]}], ['The present study was designed to investigate whether nociceptin / orphanin FQ and nocistatin could modulate impairment of learning and memory induced by scopolamine , a muscarinic cholinergic receptor antagonist , using spontaneous alternation of Y - maze and step - down type passive avoidance tasks in mice .', {'entities': [(109, 119, 'B_Disease'), (120, 122, 'I_Disease'), (123, 131, 'I_Disease'), (132, 135, 'I_Disease'), (136, 142, 'I_Disease')]}], ['Meloxicam - induced liver toxicity .', {'entities': [(20, 25, 'B_Disease'), (26, 34, 'I_Disease')]}], ['We report the case of a female patient with rheumatoid arthritis who developed acute cytolytic hepatitis due to meloxicam .', {'entities': [(44, 54, 'B_Disease'), (55, 64, 'I_Disease'), (95, 104, 'B_Disease')]}], ['The acute cytolytic hepatitis occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a hypersensitivity mechanism .', {'entities': [(20, 29, 'B_Disease'), (157, 173, 'B_Disease')]}], ['This first case of meloxicam related liver toxicity demonstrates the potential of this drug to induce hepatic damage .', {'entities': [(37, 42, 'B_Disease'), (43, 51, 'I_Disease'), (102, 109, 'B_Disease'), (110, 116, 'I_Disease')]}], ['Induction of apoptosis by remoxipride metabolites in HL60 and CD34 + / CD19 - human bone marrow progenitor cells : potential relevance to remoxipride - induced aplastic anemia .', {'entities': [(160, 168, 'B_Disease'), (169, 175, 'I_Disease')]}], ['The antipsychotic agent , remoxipride [ ( S ) - ( - ) - 3 - bromo - N - [ ( 1 - ethyl - 2 - pyrrolidinyl ) methyl ] - 2 , 6 - dimethoxybenz amide ] has been associated with acquired aplastic anemia .', {'entities': [(182, 190, 'B_Disease'), (191, 197, 'I_Disease')]}], ['No necrosis was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types , inducing apoptosis at lower concentrations and necrosis at higher concentrations .', {'entities': [(3, 11, 'B_Disease'), (155, 163, 'B_Disease')]}], ['We propose that remoxipride and benzene may induce aplastic anemia via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired aplastic anemia that has been associated with remoxipride .', {'entities': [(51, 59, 'B_Disease'), (60, 66, 'I_Disease'), (242, 250, 'B_Disease'), (251, 257, 'I_Disease')]}], ['7e exhibits a high reversal of catalepsy induced by haloperidol indicating its atypical antipsychotic nature .', {'entities': [(31, 40, 'B_Disease')]}], ['Sub - chronic inhibition of nitric - oxide synthesis modifies haloperidol - induced catalepsy and the number of NADPH - diaphorase neurons in mice .', {'entities': [(84, 93, 'B_Disease')]}], ['RATIONALE : NG - nitro - L - arginine ( L - NOARG ) , an inhibitor of nitric - oxide synthase ( NOS ) , induces catalepsy in mice .', {'entities': [(112, 121, 'B_Disease')]}], ['Neuroleptic drugs such as haloperidol , which block dopamine receptors , also cause catalepsy in rodents .', {'entities': [(84, 93, 'B_Disease')]}], ['OBJECTIVES : To investigate the effects of subchronic L - NOARG treatment in haloperidol - induced catalepsy and the number of NOS neurons in areas related to motor control .', {'entities': [(99, 108, 'B_Disease')]}], ['Catalepsy was evaluated at the beginning and the end of the treatments .', {'entities': [(0, 9, 'B_Disease')]}], ['RESULTS : L - NOARG sub - chronic administration produced tolerance of L - NOARG and of haloperidol - induced catalepsy .', {'entities': [(110, 119, 'B_Disease')]}], ['Prolonged left ventricular dysfunction occurs in patients with coronary artery disease after both dobutamine and exercise induced myocardial ischaemia .', {'entities': [(10, 14, 'B_Disease'), (15, 26, 'I_Disease'), (27, 38, 'I_Disease'), (63, 71, 'B_Disease'), (72, 78, 'I_Disease'), (79, 86, 'I_Disease'), (130, 140, 'B_Disease'), (141, 150, 'I_Disease')]}], ['OBJECTIVE : To determine whether pharmacological stress leads to prolonged but reversible left ventricular dysfunction in patients with coronary artery disease , similar to that seen after exercise .', {'entities': [(90, 94, 'B_Disease'), (95, 106, 'I_Disease'), (107, 118, 'I_Disease'), (136, 144, 'B_Disease'), (145, 151, 'I_Disease'), (152, 159, 'I_Disease')]}], ['DESIGN : A randomised crossover study of recovery time of systolic and diastolic left ventricular function after exercise and dobutamine induced ischaemia .', {'entities': [(145, 154, 'B_Disease')]}], ['SUBJECTS : 10 patients with stable angina , angiographically proven coronary artery disease , and normal left ventricular function .', {'entities': [(28, 34, 'B_Disease'), (35, 41, 'I_Disease'), (68, 76, 'B_Disease'), (77, 83, 'I_Disease'), (84, 91, 'I_Disease')]}], ['There was no difference in the maximum double product ( p = 0 . 53 ) or ST depression ( p = 0 . 63 ) with either form of stress .', {'entities': [(75, 85, 'B_Disease')]}], ['CONCLUSIONS : In patients with coronary artery disease , dobutamine induced ischaemia results in prolonged reversible left ventricular dysfunction , presumed to be myocardial stunning , similar to that seen after exercise .', {'entities': [(31, 39, 'B_Disease'), (40, 46, 'I_Disease'), (47, 54, 'I_Disease'), (76, 85, 'B_Disease'), (118, 122, 'B_Disease'), (123, 134, 'I_Disease'), (135, 146, 'I_Disease'), (164, 174, 'B_Disease'), (175, 183, 'I_Disease')]}], ['Dobutamine induced ischaemia could therefore be used to study the pathophysiology of this phenomenon further in patients with coronary artery disease .', {'entities': [(19, 28, 'B_Disease'), (126, 134, 'B_Disease'), (135, 141, 'I_Disease'), (142, 149, 'I_Disease')]}], ['Anorexigens and pulmonary hypertension in the United States : results from the surveillance of North American pulmonary hypertension .', {'entities': [(16, 25, 'B_Disease'), (26, 38, 'I_Disease'), (110, 119, 'B_Disease'), (120, 132, 'I_Disease')]}], ['BACKGROUND : The use of appetite suppressants in Europe has been associated with the development of primary pulmonary hypertension ( PPH ) .', {'entities': [(100, 107, 'B_Disease'), (108, 117, 'I_Disease'), (118, 130, 'I_Disease'), (133, 136, 'B_Disease')]}], ['MATERIALS AND METHODS : We conducted a prospective surveillance study on patients diagnosed with pulmonary hypertension at 12 large referral centers in North America .', {'entities': [(97, 106, 'B_Disease'), (107, 119, 'I_Disease')]}], ['Data collected on patients seen from September 1 , 1996 , to December 31 , 1997 , included the cause of the pulmonary hypertension and its severity .', {'entities': [(108, 117, 'B_Disease'), (118, 130, 'I_Disease')]}], ['Patients with no identifiable cause of pulmonary hypertension were classed as PPH .', {'entities': [(39, 48, 'B_Disease'), (49, 61, 'I_Disease'), (78, 81, 'B_Disease')]}], ['RESULTS : Five hundred seventy - nine patients were studied , 205 with PPH and 374 with pulmonary hypertension from other causes ( secondary pulmonary hypertension [ SPH ] ) .', {'entities': [(71, 74, 'B_Disease'), (88, 97, 'B_Disease'), (98, 110, 'I_Disease'), (141, 150, 'B_Disease'), (151, 163, 'I_Disease')]}], ['However , of the medications surveyed , only the fenfluramines had a significant preferential association with PPH as compared with SPH ( adjusted odds ratio for use > 6 months , 7 . 5 ; 95 % confidence interval , 1 . 7 to 32 . 4 ) .', {'entities': [(111, 114, 'B_Disease')]}], ['CONCLUSION : The magnitude of the association with PPH , the increase of association with increasing duration of use , and the specificity for fenfluramines are consistent with previous studies indicating that fenfluramines are causally related to PPH .', {'entities': [(51, 54, 'B_Disease'), (248, 251, 'B_Disease')]}], ['The high prevalence of anorexigen use in patients with SPH also raises the possibility that these drugs precipitate pulmonary hypertension in patients with underlying conditions associated with SPH .', {'entities': [(116, 125, 'B_Disease'), (126, 138, 'I_Disease')]}], ['Clinical aspects of heparin - induced thrombocytopenia and thrombosis and other side effects of heparin therapy .', {'entities': [(38, 54, 'B_Disease'), (59, 69, 'B_Disease')]}], ['Heparin , first used to prevent the clotting of blood in vitro , has been clinically used to treat thrombosis for more than 50 years .', {'entities': [(99, 109, 'B_Disease')]}], ['Although several new anticoagulant drugs are in development , heparin remains the anticoagulant of choice to treat acute thrombotic episodes .', {'entities': [(121, 131, 'B_Disease')]}], ['Bleeding is the primary untoward effect of heparin .', {'entities': [(0, 8, 'B_Disease')]}], ['Major bleeding is of primary concern in patients receiving heparin therapy .', {'entities': [(6, 14, 'B_Disease')]}], ['However , additional important untoward effects of heparin therapy include heparin - induced thrombocytopenia , heparin - associated osteoporosis , eosinophilia , skin reactions , allergic reactions other than thrombocytopenia , alopecia , transaminasemia , hyperkalemia , hypoaldosteronism , and priapism .', {'entities': [(93, 109, 'B_Disease'), (133, 145, 'B_Disease'), (148, 160, 'B_Disease'), (163, 167, 'B_Disease'), (168, 177, 'I_Disease'), (180, 188, 'B_Disease'), (189, 198, 'I_Disease'), (210, 226, 'B_Disease'), (229, 237, 'B_Disease'), (258, 270, 'B_Disease'), (273, 290, 'B_Disease'), (297, 305, 'B_Disease')]}], ['These side effects are relatively rare in a given individual , but given the extremely widespread use of heparin , some are quite common , particularly HITT and osteoporosis .', {'entities': [(152, 156, 'B_Disease'), (161, 173, 'B_Disease')]}], ['A case of bilateral optic neuropathy in a patient on tacrolimus ( FK506 ) therapy after liver transplantation .', {'entities': [(20, 25, 'B_Disease'), (26, 36, 'I_Disease')]}], ['PURPOSE : To report a case of bilateral optic neuropathy in a patient receiving tacrolimus ( FK 506 , Prograf ; Fujisawa USA , Inc , Deerfield , Illinois ) for immunosuppression after orthotropic liver transplantation .', {'entities': [(40, 45, 'B_Disease'), (46, 56, 'I_Disease')]}], ['RESULTS : The patient had episodic deterioration of vision in both eyes , with clinical features resembling ischemic optic neuropathies .', {'entities': [(108, 116, 'B_Disease'), (117, 122, 'I_Disease'), (123, 135, 'I_Disease')]}], ['Deterioration of vision occurred despite discontinuation of the tacrolimus .', {'entities': [(0, 13, 'B_Disease'), (14, 16, 'I_Disease'), (17, 23, 'I_Disease')]}], ['CONCLUSION : Tacrolimus and other immunosuppressive agents may be associated with optic nerve toxicity .', {'entities': [(82, 87, 'B_Disease'), (88, 93, 'I_Disease'), (94, 102, 'I_Disease')]}], ['Hypercalcemia , arrhythmia , and mood stabilizers .', {'entities': [(0, 13, 'B_Disease'), (16, 26, 'B_Disease')]}], ['Recent findings in a bipolar patient receiving maintenance lithium therapy who developed hypercalcemia and severe bradyarrhythmia prompted the authors to conduct a retrospective study of bipolar patients with lithium - associated hypercalcemia .', {'entities': [(21, 28, 'B_Disease'), (89, 102, 'B_Disease'), (114, 129, 'B_Disease'), (187, 194, 'B_Disease'), (230, 243, 'B_Disease')]}], ['A printout of all cases of hypercalcemia that presented during a 1 - year period was generated .', {'entities': [(27, 40, 'B_Disease')]}], ['After eliminating spurious hypercalcemias or those associated with intravenous fluids , the authors identified 18 non - lithium - treated patients with hypercalcemias related to malignancies and other medical conditions ( group A ) and 12 patients with lithium - associated hypercalcemia ( group B ) .', {'entities': [(27, 41, 'B_Disease'), (152, 166, 'B_Disease'), (178, 190, 'B_Disease'), (274, 287, 'B_Disease')]}], ['Thus , two control groups were generated : group C1 , which included age - and sex - comparable lithium - treated bipolar normocalcemic patients , and group C2 , which included bipolar normocalcemic patients treated with anticonvulsant mood stabilizers .', {'entities': [(114, 121, 'B_Disease'), (177, 184, 'B_Disease')]}], ['Patients with hypercalcemia resulting from medical diseases and bipolar patients with lithium - associated hypercalcemia had significantly higher frequencies of conduction defects .', {'entities': [(14, 27, 'B_Disease'), (64, 71, 'B_Disease'), (107, 120, 'B_Disease')]}], ['Attenuation of nephrotoxicity by a novel lipid nanosphere ( NS - 718 ) incorporating amphotericin B .', {'entities': [(15, 29, 'B_Disease')]}], ['NS - 718 , a lipid nanosphere incorporating amphotericin B , is effective against pathogenic fungi and has low toxicity .', {'entities': [(111, 119, 'B_Disease')]}], ['We compared the toxicity of NS - 718 with that of Fungizone ( amphotericin B - sodium deoxycholate ; D - AmB ) in vitro using renal cell cultures and in vivo by biochemical analysis , histopathological study of the kidney and pharmacokinetic study of amphotericin B following intravenous infusion of the formulation in rats .', {'entities': [(16, 24, 'B_Disease')]}], ['Histopathological examination of the kidney showed tubular necrosis in D - AmB - treated rats but no change in NS - 718 - treated rats .', {'entities': [(51, 58, 'B_Disease'), (59, 67, 'I_Disease')]}], ['Our in vitro and in vivo results suggest that incorporation of amphotericin B into lipid nanospheres of NS - 718 attenuates the nephrotoxicity of amphotericin B .', {'entities': [(128, 142, 'B_Disease')]}], ['Patterns of sulfadiazine acute nephrotoxicity .', {'entities': [(25, 30, 'B_Disease'), (31, 45, 'I_Disease')]}], ['Sulfadiazine acute nephrotoxicity is reviving specially because of its use in toxoplasmosis in HIV - positive patients .', {'entities': [(13, 18, 'B_Disease'), (19, 33, 'I_Disease'), (78, 91, 'B_Disease')]}], ['Under treatment with sulfadiazine they developed oliguria , abdominal pain , renal failure and showed multiple radiolucent renal calculi in echography .', {'entities': [(49, 57, 'B_Disease'), (60, 69, 'B_Disease'), (70, 74, 'I_Disease'), (77, 82, 'B_Disease'), (83, 90, 'I_Disease'), (123, 128, 'B_Disease'), (129, 136, 'I_Disease')]}], ['A nephrostomy tube had to be placed in one of the patients for ureteral lithiasis in a single functional kidney .', {'entities': [(63, 71, 'B_Disease'), (72, 81, 'I_Disease')]}], ['Downbeat nystagmus associated with intravenous patient - controlled administration of morphine .', {'entities': [(0, 8, 'B_Disease'), (9, 18, 'I_Disease')]}], ['IMPLICATIONS : This case documents a patient who developed dizziness with downbeating nystagmus while receiving a relatively large dose of IV patient - controlled analgesia morphine .', {'entities': [(59, 68, 'B_Disease'), (74, 85, 'B_Disease'), (86, 95, 'I_Disease')]}], ['Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction .', {'entities': [(94, 104, 'B_Disease'), (105, 115, 'I_Disease')]}], ['The hemodynamic and antiadrenergic effects of dronedarone , a noniodinated compound structurally related to amiodarone , were compared with those of amiodarone after prolonged oral administration , both at rest and during sympathetic stimulation in conscious dogs with a healed myocardial infarction .', {'entities': [(278, 288, 'B_Disease'), (289, 299, 'I_Disease')]}], ['Both dronedarone and amiodarone significantly reduced the exercise - induced tachycardia and , at the highest dose , decreased the isoproterenol - induced tachycardia .', {'entities': [(77, 88, 'B_Disease'), (155, 166, 'B_Disease')]}], ['Consequently , dronedarone might be particularly suitable for the treatment and prevention of various clinical arrhythmias , without compromising the left ventricular function .', {'entities': [(111, 122, 'B_Disease')]}], ['Phase 2 trial of liposomal doxorubicin ( 40 mg / m ( 2 ) ) in platinum / paclitaxel - refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum .', {'entities': [(97, 104, 'B_Disease'), (105, 108, 'I_Disease'), (109, 118, 'I_Disease'), (119, 123, 'I_Disease'), (124, 131, 'I_Disease'), (144, 153, 'B_Disease'), (154, 156, 'I_Disease'), (157, 160, 'I_Disease'), (161, 171, 'I_Disease')]}], ['BACKGROUND : Several studies have demonstrated liposomal doxorubicin ( Doxil ) to be an active antineoplastic agent in platinum - resistant ovarian cancer , with dose limiting toxicity of the standard dosing regimen ( 50 mg / m ( 2 ) q 4 weeks ) being severe erythrodysesthesia ( \" hand - foot syndrome \" ) and stomatitis .', {'entities': [(140, 147, 'B_Disease'), (148, 154, 'I_Disease'), (176, 184, 'B_Disease'), (259, 277, 'B_Disease'), (282, 286, 'B_Disease'), (287, 288, 'I_Disease'), (289, 293, 'I_Disease'), (294, 302, 'I_Disease'), (311, 321, 'B_Disease')]}], ['METHODS AND MATERIALS : Patients with ovarian or fallopian tube cancers or primary peritoneal carcinoma with platinum / paclitaxel - refractory disease ( stable or progressive disease following treatment with these agents or previous objective response < 3 months in duration ) were treated with liposomal doxorubicin at a dose of 40 mg / m ( 2 ) q 4 weeks .', {'entities': [(38, 45, 'B_Disease'), (46, 48, 'I_Disease'), (49, 58, 'I_Disease'), (59, 63, 'I_Disease'), (64, 71, 'I_Disease'), (83, 93, 'B_Disease'), (94, 103, 'I_Disease')]}], ['Six ( 12 % ) and 4 ( 8 % ) patients experienced grade 2 hand - foot syndrome and stomatitis , respectively ( no episodes of grade 3 ) .', {'entities': [(56, 60, 'B_Disease'), (61, 62, 'I_Disease'), (63, 67, 'I_Disease'), (68, 76, 'I_Disease'), (81, 91, 'B_Disease')]}], ['One patient developed grade 3 diarrhea requiring hospitalization for hydration .', {'entities': [(30, 38, 'B_Disease')]}], ['CONCLUSION : This modified liposomal doxorubicin regimen results in less toxicity ( stomatitis , hand - foot syndrome ) than the standard FDA - approved dose schedule .', {'entities': [(73, 81, 'B_Disease'), (84, 94, 'B_Disease'), (97, 101, 'B_Disease'), (102, 103, 'I_Disease'), (104, 108, 'I_Disease'), (109, 117, 'I_Disease')]}], ['Definite , although limited , antineoplastic activity is observed in patients with well - defined platinum - and paclitaxel - refractory ovarian cancer .', {'entities': [(137, 144, 'B_Disease'), (145, 151, 'I_Disease')]}], ['Efficacy of olanzapine in acute bipolar mania : a double - blind , placebo - controlled study .', {'entities': [(32, 39, 'B_Disease'), (40, 45, 'I_Disease')]}], ['BACKGROUND : We compared the efficacy and safety of olanzapine vs placebo for the treatment of acute bipolar mania .', {'entities': [(101, 108, 'B_Disease'), (109, 114, 'I_Disease')]}], ['A total of 115 patients with a DSM - IV diagnosis of bipolar disorder , manic or mixed , were randomized to olanzapine , 5 to 20 mg / d ( n = 55 ) , or placebo ( n = 60 ) .', {'entities': [(53, 60, 'B_Disease'), (61, 69, 'I_Disease'), (72, 77, 'B_Disease')]}], ['The primary efficacy measure was the Young - Mania Rating Scale ( Y - MRS ) total score .', {'entities': [(45, 50, 'B_Disease')]}], ['Safety was assessed using adverse events , Extrapyramidal Symptom ( EPS ) rating scales , laboratory values , electrocardiograms , vital signs , and weight change .', {'entities': [(43, 57, 'B_Disease'), (58, 65, 'I_Disease'), (68, 71, 'B_Disease')]}], ['There were no statistically significant differences in EPSs between groups .', {'entities': [(55, 59, 'B_Disease')]}], ['However , olanzapine - treated patients had a statistically significant greater mean ( + / - SD ) weight gain than placebo - treated patients ( 2 . 1 + / - 2 . 8 vs 0 . 45 + / - 2 . 3 kg , respectively ) and also experienced more treatment - emergent somnolence ( 21 patients [ 38 . 2 % ] vs 5 [ 8 . 3 % ] , respectively ) .', {'entities': [(98, 104, 'B_Disease'), (105, 109, 'I_Disease'), (251, 261, 'B_Disease')]}], ['CONCLUSION : Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated .', {'entities': [(93, 100, 'B_Disease'), (101, 106, 'I_Disease')]}], ['The effect of pupil dilation with tropicamide on vision and driving simulator performance .', {'entities': [(14, 19, 'B_Disease'), (20, 28, 'I_Disease')]}], ['PURPOSE : To assess the effect of pupil dilation on vision and driving ability .', {'entities': [(34, 39, 'B_Disease'), (40, 48, 'I_Disease')]}], ['METHODS : A series of tests on various parameters of visual function and driving simulator performance were performed on 12 healthy drivers , before and after pupil dilation using guttae tropicamide 1 % .', {'entities': [(159, 164, 'B_Disease'), (165, 173, 'I_Disease')]}], ['RESULTS : Pupillary dilation resulted in a statistically significant deterioration in CT and HCVA only .', {'entities': [(10, 19, 'B_Disease'), (20, 28, 'I_Disease')]}], ['CONCLUSIONS : Pupillary dilation may lead to a decrease in vision and daylight driving performance in young people .', {'entities': [(14, 23, 'B_Disease'), (24, 32, 'I_Disease')]}], ['A case of isotretinoin embryopathy with bilateral anotia and Taussig - Bing malformation .', {'entities': [(10, 22, 'B_Disease'), (23, 34, 'I_Disease'), (50, 56, 'B_Disease'), (61, 68, 'B_Disease'), (69, 70, 'I_Disease'), (71, 75, 'I_Disease'), (76, 88, 'I_Disease')]}], ['We report a newborn infant with multiple congenital anomalies ( anotia and Taussig - Bing malformation ) due to exposure to isotretinoin within the first trimester .', {'entities': [(64, 70, 'B_Disease'), (75, 82, 'B_Disease'), (83, 84, 'I_Disease'), (85, 89, 'I_Disease'), (90, 102, 'I_Disease')]}], ['Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence : a placebo - controlled , double - blind crossover study .', {'entities': [(73, 79, 'B_Disease'), (80, 92, 'I_Disease')]}], ['The aim of the study was to evaluate the potential role for a selective alpha1 - adrenoceptor agonist in the treatment of urinary stress incontinence .', {'entities': [(122, 129, 'B_Disease'), (130, 136, 'I_Disease'), (137, 149, 'I_Disease')]}], ['Half log incremental doses of intravenous methoxamine or placebo ( saline ) were administered to a group of women with genuine stress incontinence while measuring maximum urethral pressure ( MUP ) , blood pressure , heart rate , and symptomatic side effects .', {'entities': [(127, 133, 'B_Disease'), (134, 146, 'I_Disease')]}], ['Methoxamine evoked non - significant increases in MUP and diastolic blood pressure but caused a significant rise in systolic blood pressure and significant fall in heart rate at maximum dosage .', {'entities': [(94, 95, 'B_Disease'), (96, 107, 'I_Disease'), (108, 112, 'I_Disease'), (113, 115, 'I_Disease'), (116, 124, 'I_Disease'), (125, 130, 'I_Disease'), (131, 139, 'I_Disease')]}], ['Systemic side effects including piloerection , headache , and cold extremities were experienced in all subjects .', {'entities': [(47, 55, 'B_Disease')]}], ['The results indicate that the clinical usefulness of direct , peripherally acting sub - type - selective alpha1 - adrenoceptor agonists in the medical treatment of stress incontinence may be limited by associated piloerection and cardiovascular side effects .', {'entities': [(164, 170, 'B_Disease'), (171, 183, 'I_Disease')]}], ['Hyperglycemic effect of amino compounds structurally related to caproate in rats .', {'entities': [(0, 13, 'B_Disease')]}], ['The chronic feeding of small amounts ( 0 . 3 - 3 % of diet weight ) of certain amino derivatives of caproate resulted in hyperglycemia , an elevated glucose tolerance curve and , occasionally , glucosuria .', {'entities': [(121, 134, 'B_Disease'), (194, 204, 'B_Disease')]}], ['Toleration of high doses of angiotensin - converting enzyme inhibitors in patients with chronic heart failure : results from the ATLAS trial .', {'entities': [(96, 101, 'B_Disease'), (102, 109, 'I_Disease')]}], ['BACKGROUND : Treatment with angiotensin - converting enzyme ( ACE ) inhibitors reduces mortality and morbidity in patients with chronic heart failure ( CHF ) , but most affected patients are not receiving these agents or are being treated with doses lower than those found to be efficacious in trials , primarily because of concerns about the safety and tolerability of these agents , especially at the recommended doses .', {'entities': [(136, 141, 'B_Disease'), (142, 149, 'I_Disease'), (152, 155, 'B_Disease')]}], ['The present study examines the safety and tolerability of high - compared with low - dose lisinopril in CHF .', {'entities': [(104, 107, 'B_Disease')]}], ['Patients with New York Heart Association classes II to IV CHF and left ventricular ejection fractions of no greater than 0 . 30 ( n = 3164 ) were randomized and followed up for a median of 46 months .', {'entities': [(58, 61, 'B_Disease')]}], ['We examined the occurrence of adverse events and the need for discontinuation and dose reduction during treatment , with a focus on hypotension and renal dysfunction .', {'entities': [(132, 143, 'B_Disease'), (148, 153, 'B_Disease'), (154, 165, 'I_Disease')]}], ['RESULTS : Of 405 patients not previously receiving an ACE inhibitor , doses in only 4 . 2 % could not be titrated to the medium doses required for randomization because of symptoms possibly related to hypotension ( 2 . 0 % ) or because of renal dysfunction or hyperkalemia ( 2 . 3 % ) .', {'entities': [(201, 212, 'B_Disease'), (239, 244, 'B_Disease'), (245, 256, 'I_Disease'), (260, 272, 'B_Disease')]}], ['Subgroups presumed to be at higher risk for ACE inhibitor intolerance ( blood pressure , < 120 mm Hg ; creatinine , > or = 132 . 6 micromol / L [ > or = 1 . 5 mg / dL ] ; age , > or = 70 years ; and patients with diabetes ) generally tolerated the high - dose strategy .', {'entities': [(213, 221, 'B_Disease')]}], ['CONCLUSIONS : These findings demonstrate that ACE inhibitor therapy in most patients with CHF can be successfully titrated to and maintained at high doses , and that more aggressive use of these agents is warranted .', {'entities': [(90, 93, 'B_Disease')]}], ['Cocaine , ethanol , and cocaethylene cardiotoxity in an animal model of cocaine and ethanol abuse .', {'entities': [(37, 49, 'B_Disease'), (72, 79, 'B_Disease'), (80, 83, 'I_Disease'), (84, 91, 'I_Disease'), (92, 97, 'I_Disease')]}], ['OBJECTIVES : Simultaneous abuse of cocaine and ethanol affects 12 million Americans annually .', {'entities': [(26, 31, 'B_Disease'), (32, 34, 'I_Disease'), (35, 42, 'I_Disease'), (43, 46, 'I_Disease'), (47, 54, 'I_Disease')]}], ['Their combined cardiac toxicity may be due to independent effects of each drug ; however , they may also be due to cocaethylene ( CE ) , a cocaine metabolite formed only in the presence of ethanol .', {'entities': [(15, 22, 'B_Disease'), (23, 31, 'I_Disease')]}], ['The purpose of this study was to delineate the role of CE in the combined cardiotoxicity of cocaine and ethanol in a model simulating their abuse .', {'entities': [(74, 88, 'B_Disease')]}], ['RESULTS : Two of eight dogs in the C + E group experienced cardiovascular collapse .', {'entities': [(59, 73, 'B_Disease'), (74, 82, 'I_Disease')]}], ['Peak CE levels were associated with a 45 % ( SD + / - 22 % , 95 % CI = 22 % to 69 % ) decrease in cardiac output ( p < 0 . 05 ) , a 56 % ( SD + / - 23 % , 95 % CI = 32 % to 80 % ) decrease in dP / dt ( max ) ( p < . 006 ) , and a 23 % ( SD + / - 15 % , 95 % CI = 7 % to 49 % ) decrease in SVO ( 2 ) ( p < 0 . 025 ) .', {'entities': [(86, 94, 'B_Disease'), (95, 97, 'I_Disease'), (98, 105, 'I_Disease'), (106, 112, 'I_Disease')]}], ['Ventricular arrhythmias were primarily observed in the C + E group , in which four of eight dogs experienced ventricular tachycardia .', {'entities': [(0, 11, 'B_Disease'), (12, 23, 'I_Disease'), (109, 120, 'B_Disease'), (121, 132, 'I_Disease')]}], ['Co - administration resulted in prolonged cardiac toxicity and was dysrhythmogenic .', {'entities': [(42, 49, 'B_Disease'), (50, 58, 'I_Disease')]}], ['Peak serum cocaethylene concentrations were associated with prolonged myocardial depression .', {'entities': [(70, 80, 'B_Disease'), (81, 91, 'I_Disease')]}], ['Worsening of Parkinsonism after the use of veralipride for treatment of menopause : case report .', {'entities': [(13, 25, 'B_Disease')]}], [\"We describe a female patient with stable Parkinson ' s disease who has shown a marked worsening of her motor functions following therapy of menopause related symptoms with veralipride , as well as the improvement of her symptoms back to baseline after discontinuation of the drug .\", {'entities': [(41, 50, 'B_Disease'), (51, 52, 'I_Disease'), (53, 54, 'I_Disease'), (55, 62, 'I_Disease')]}], ['Viracept and irregular heartbeat warning .', {'entities': [(13, 22, 'B_Disease'), (23, 32, 'I_Disease')]}], ['A group of doctors in Boston warn that the protease inhibitor Viracept may cause an irregular heart beat , known as bradycardia , in people with HIV .', {'entities': [(84, 93, 'B_Disease'), (94, 99, 'I_Disease'), (100, 104, 'I_Disease'), (116, 127, 'B_Disease')]}], ['Bradycardia occurred in a 45 - year - old male patient who was Viracept in combination with other anti - HIV drugs .', {'entities': [(0, 11, 'B_Disease')]}], [\"Frequency of appearance of myeloperoxidase - antineutrophil cytoplasmic antibody ( MPO - ANCA ) in Graves ' disease patients treated with propylthiouracil and the relationship between MPO - ANCA and clinical manifestations .\", {'entities': [(99, 105, 'B_Disease'), (106, 107, 'I_Disease'), (108, 115, 'I_Disease')]}], [\"OBJECTIVE : Myeloperoxidase antineutrophil cytoplasmic antibody ( MPO - ANCA ) - positive vasculitis has been reported in patients with Graves ' disease who were treated with propylthiouracil ( PTU ) .\", {'entities': [(90, 100, 'B_Disease'), (136, 142, 'B_Disease'), (143, 144, 'I_Disease'), (145, 152, 'I_Disease')]}], [\"Nevertheless , there have been no studies on the temporal relationship between the appearance of MPO - ANCA and vasculitis during PTU therapy , or on the incidence of MPO - ANCA in untreated Graves ' disease patients .\", {'entities': [(112, 122, 'B_Disease'), (191, 197, 'B_Disease'), (198, 199, 'I_Disease'), (200, 207, 'I_Disease')]}], [\"Therefore , we sought to address these parameters in patients with Graves ' disease .\", {'entities': [(67, 73, 'B_Disease'), (74, 75, 'I_Disease'), (76, 83, 'I_Disease')]}], [\"PATIENTS : We investigated 102 untreated patients with hyperthyroidism due to Graves ' disease for the presence of MPO - ANCA , and for the development vasculitis after starting PTU therapy .\", {'entities': [(55, 70, 'B_Disease'), (78, 84, 'B_Disease'), (85, 86, 'I_Disease'), (87, 94, 'I_Disease'), (152, 162, 'B_Disease')]}], [\"RESULTS : Before treatment , the MPO - ANCA titres of all 102 untreated Graves ' disease patients were within the reference range ( below 10 U / ml ) .\", {'entities': [(72, 78, 'B_Disease'), (79, 80, 'I_Disease'), (81, 88, 'I_Disease')]}], ['In two of them , the MPO - ANCA titres transiently increased to 12 . 8 and 15 . 0 U / ml , respectively , despite continued PTU therapy , but no vasculitic disorders developed .', {'entities': [(145, 155, 'B_Disease'), (156, 165, 'I_Disease')]}], ['In the third patient , the MPO - ANCA titre increased to 204 U / ml and she developed a higher fever , oral ulcers and polyarthralgia , but the symptoms resolved 2 weeks after stopping PTU therapy , and the MPO - ANCA titre decreased to 20 . 7 U / ml by 4 months after discontinuing PTU .', {'entities': [(95, 100, 'B_Disease'), (103, 107, 'B_Disease'), (108, 114, 'I_Disease'), (119, 133, 'B_Disease')]}], ['CONCLUSIONS : PTU therapy may be related to the appearance of MPO - ANCA , but MPO - ANCA does not appear to be closely related to vasculitis .', {'entities': [(131, 141, 'B_Disease')]}], ['Prevalence of heart disease in asymptomatic chronic cocaine users .', {'entities': [(14, 19, 'B_Disease'), (20, 27, 'I_Disease')]}], ['To determine the prevalence of heart disease in outpatient young asymptomatic chronic cocaine users , 35 cocaine users and 32 age - matched controls underwent resting and exercise electrocardiography ( ECG ) and Doppler echocardiography .', {'entities': [(31, 36, 'B_Disease'), (37, 44, 'I_Disease')]}], ['Findings consistent with coronary artery disease were detected in 12 ( 34 % ) patients and 3 ( 9 % ) controls ( p = 0 . 01 ) .', {'entities': [(25, 33, 'B_Disease'), (34, 40, 'I_Disease'), (41, 48, 'I_Disease')]}], ['Finally , resting and peak exercise abnormal left ventricular filling was detected in 38 and 35 % of patients as compared to 19 and 9 % of controls , respectively ( p = 0 . 11 and 0 . 02 , respectively ) .', {'entities': [(36, 44, 'B_Disease'), (45, 49, 'I_Disease'), (50, 61, 'I_Disease'), (62, 69, 'I_Disease')]}], ['We conclude that coronary artery or myocardial disease is common ( 38 % ) in young asymptomatic chronic cocaine users .', {'entities': [(17, 25, 'B_Disease'), (26, 32, 'I_Disease'), (33, 35, 'I_Disease'), (36, 46, 'I_Disease'), (47, 54, 'I_Disease')]}], ['The cardioprotective effect of the ethanol extract of Picrorrhiza kurroa rhizomes and roots ( PK ) on isoproterenol - induced myocardial infarction in rats with respect to lipid metabolism in serum and heart tissue has been investigated .', {'entities': [(126, 136, 'B_Disease'), (137, 147, 'I_Disease')]}], ['Oral pre - treatment with PK ( 80 mg kg ( - 1 ) day ( - 1 ) for 15 days ) significantly prevented the isoproterenol - induced myocardial infarction and maintained the rats at near normal status .', {'entities': [(126, 136, 'B_Disease'), (137, 147, 'I_Disease')]}], ['Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long - QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall .', {'entities': [(62, 73, 'B_Disease'), (74, 85, 'I_Disease'), (98, 102, 'B_Disease'), (103, 104, 'I_Disease'), (105, 107, 'I_Disease'), (108, 116, 'I_Disease')]}], ['BACKGROUND : This study examined the role of phase 2 early afterdepolarization ( EAD ) in producing a trigger to initiate torsade de pointes ( TdP ) with QT prolongation induced by dl - sotalol and azimilide .', {'entities': [(122, 129, 'B_Disease'), (130, 132, 'I_Disease'), (133, 140, 'I_Disease'), (143, 146, 'B_Disease'), (154, 156, 'B_Disease'), (157, 169, 'I_Disease')]}], ['The contribution of transmural dispersion of repolarization ( TDR ) to transmural propagation of EAD and the maintenance of TdP was also evaluated .', {'entities': [(124, 127, 'B_Disease')]}], ['dl - Sotalol preferentially prolonged action potential duration ( APD ) in M cells dose - dependently ( 1 to 100 micromol / L ) , leading to QT prolongation and an increase in TDR .', {'entities': [(141, 143, 'B_Disease'), (144, 156, 'I_Disease')]}], ['Although both dl - sotalol and azimilide rarely induced EADs in canine left ventricles , they produced frequent EADs in rabbits , in which more pronounced QT prolongation was seen .', {'entities': [(155, 157, 'B_Disease'), (158, 170, 'I_Disease')]}], ['An increase in TDR by dl - sotalol facilitated transmural propagation of EADs that initiated multiple episodes of spontaneous TdP in 3 of 6 rabbit left ventricles .', {'entities': [(126, 129, 'B_Disease')]}], ['CONCLUSIONS : This study provides the first direct evidence from intracellular action potential recordings that phase 2 EAD can be generated from intact ventricular wall and produce a trigger to initiate the onset of TdP under QT prolongation .', {'entities': [(217, 220, 'B_Disease'), (227, 229, 'B_Disease'), (230, 242, 'I_Disease')]}], ['A pilot study to assess the safety of dobutamine stress echocardiography in the emergency department evaluation of cocaine - associated chest pain .', {'entities': [(136, 141, 'B_Disease'), (142, 146, 'I_Disease')]}], ['STUDY OBJECTIVE : Chest pain in the setting of cocaine use poses a diagnostic dilemma .', {'entities': [(18, 23, 'B_Disease'), (24, 28, 'I_Disease')]}], ['Dobutamine stress echocardiography ( DSE ) is a widely available and sensitive test for evaluating cardiac ischemia .', {'entities': [(107, 115, 'B_Disease')]}], ['Because of the theoretical concern regarding administration of dobutamine in the setting of cocaine use , we conducted a pilot study to assess the safety of DSE in emergency department patients with cocaine - associated chest pain .', {'entities': [(220, 225, 'B_Disease'), (226, 230, 'I_Disease')]}], ['Patients were eligible for DSE if they had used cocaine within 24 hours preceding the onset of chest pain and had a normal ECG and tropinin I level .', {'entities': [(95, 100, 'B_Disease'), (101, 105, 'I_Disease')]}], ['Patients exhibiting signs of continuing cocaine toxicity were excluded from the study .', {'entities': [(48, 56, 'B_Disease')]}], ['Two patients had inadequate resting images , one DSE was terminated because of inferior hypokinesis , another DSE was terminated because of a rate - related atrial conduction deficit , and 1 patient did not reach the target heart rate .', {'entities': [(88, 99, 'B_Disease')]}], ['None of the patients experienced signs of exaggerated adrenergic response , which was defined as a systolic blood pressure of greater than 200 mm Hg or the occurrence of tachydysrhythmias ( excluding sinus tachycardia ) .', {'entities': [(170, 187, 'B_Disease'), (200, 205, 'B_Disease'), (206, 217, 'I_Disease')]}], ['CONCLUSION : No exaggerated adrenergic response was detected when dobutamine was administered to patients with cocaine - related chest pain .', {'entities': [(129, 134, 'B_Disease'), (135, 139, 'I_Disease')]}], ['Prenatal cocaine exposure and cranial sonographic findings in preterm infants .', {'entities': [(62, 69, 'B_Disease'), (70, 77, 'I_Disease')]}], ['PURPOSE : Prenatal cocaine exposure has been linked with subependymal hemorrhage and the formation of cysts that are detectable on cranial sonography in neonates born at term .', {'entities': [(70, 80, 'B_Disease'), (102, 107, 'B_Disease')]}], ['We sought to determine if prenatal cocaine exposure increases the incidence of subependymal cysts in preterm infants .', {'entities': [(79, 91, 'B_Disease'), (92, 97, 'I_Disease'), (101, 108, 'B_Disease'), (109, 116, 'I_Disease')]}], ['METHODS : We retrospectively reviewed the medical records and cranial sonograms obtained during a 1 - year period on 122 premature ( < 36 weeks of gestation ) infants .', {'entities': [(121, 130, 'B_Disease'), (131, 132, 'I_Disease'), (133, 134, 'I_Disease'), (135, 137, 'I_Disease'), (138, 143, 'I_Disease'), (144, 146, 'I_Disease'), (147, 156, 'I_Disease'), (157, 158, 'I_Disease'), (159, 166, 'I_Disease')]}], ['Infants were assigned to the cocaine - exposed group if there was a maternal history of cocaine abuse during pregnancy or if maternal or neonatal urine toxicology results were positive at the time of delivery .', {'entities': [(88, 95, 'B_Disease'), (96, 101, 'I_Disease')]}], ['The incidence of subependymal cysts in the 117 remaining infants was 14 % ( 16 of 117 ) .', {'entities': [(17, 29, 'B_Disease'), (30, 35, 'I_Disease')]}], ['The incidence of subependymal cysts in infants exposed to cocaine prenatally was 44 % ( 8 of 18 ) compared with 8 % ( 8 of 99 ) in the unexposed group ( p < 0 . 01 ) .', {'entities': [(17, 29, 'B_Disease'), (30, 35, 'I_Disease')]}], ['CONCLUSIONS : We found an increased incidence of subependymal cyst formation in preterm infants who were exposed to cocaine prenatally .', {'entities': [(49, 61, 'B_Disease'), (62, 66, 'I_Disease'), (80, 87, 'B_Disease'), (88, 95, 'I_Disease')]}], ['Thalidomide neuropathy in patients treated for metastatic prostate cancer .', {'entities': [(12, 22, 'B_Disease'), (58, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['We prospectively evaluated thalidomide - induced neuropathy using electrodiagnostic studies .', {'entities': [(49, 59, 'B_Disease')]}], ['Sixty - seven men with metastatic androgen - independent prostate cancer in an open - label trial of oral thalidomide underwent neurologic examinations and nerve conduction studies ( NCS ) prior to and at 3 - month intervals during treatment .', {'entities': [(57, 65, 'B_Disease'), (66, 72, 'I_Disease')]}], ['Six patients developed neuropathy .', {'entities': [(23, 33, 'B_Disease')]}], ['Neuropathy may thus be a common complication of thalidomide in older patients .', {'entities': [(0, 10, 'B_Disease')]}], ['The SNAP index can be used to monitor peripheral neuropathy , but not for early detection .', {'entities': [(38, 48, 'B_Disease'), (49, 59, 'I_Disease')]}], ['Overexpression of copper / zinc - superoxide dismutase protects from kanamycin - induced hearing loss .', {'entities': [(89, 96, 'B_Disease'), (97, 101, 'I_Disease')]}], ['The participation of reactive oxygen species in aminoglycoside - induced ototoxicity has been deduced from observations that aminoglycoside - iron complexes catalyze the formation of superoxide radicals in vitro and that antioxidants attenuate ototoxicity in vivo .', {'entities': [(73, 84, 'B_Disease'), (244, 255, 'B_Disease')]}], ['We therefore hypothesized that overexpression of Cu / Zn - superoxide dismutase ( h - SOD1 ) should protect transgenic mice from ototoxicity .', {'entities': [(129, 140, 'B_Disease')]}], ['The protection by overexpression of superoxide dismutase supports the hypothesis that oxidant stress plays a significant role in aminoglycoside - induced ototoxicity .', {'entities': [(154, 165, 'B_Disease')]}], ['Fatty liver induced by tetracycline in the rat .', {'entities': [(0, 5, 'B_Disease'), (6, 11, 'I_Disease')]}], ['Dose - response relationships , biochemical mechanisms , and sex differences in the experimental fatty liver induced by tetracycline were studied in the intact rat and with the isolated perfused rat liver in vitro .', {'entities': [(97, 102, 'B_Disease'), (103, 108, 'I_Disease')]}], ['With provision of adequate oleic acid as a substrate for the isolated perfused liver , a direct relationship was observed between dose of tetracycline and both accumulation of triglyceride in the liver and depression of output of triglyceride by livers from male and female rats .', {'entities': [(206, 216, 'B_Disease')]}], ['However , livers from female , and especially pregnant female rats , were strikingly resistant to the effects of tetracycline on depression of output of triglyceride under these experimental conditions .', {'entities': [(129, 139, 'B_Disease')]}], ['Depressed hepatic secretion of triglyceride accounted only for 30 to 50 % of accumulated hepatic triglyceride , indicating that additional mechanisms must be involved in the production of the triglyceride - rich fatty liver in response to tetracycline .', {'entities': [(212, 217, 'B_Disease'), (218, 223, 'I_Disease')]}], ['Prednisone induces anxiety and glial cerebral changes in rats .', {'entities': [(19, 26, 'B_Disease')]}], ['OBJECTIVE : To assess whether prednisone ( PDN ) produces anxiety and / or cerebral glial changes in rats .', {'entities': [(58, 65, 'B_Disease')]}], ['Anxiety was assessed using an open field and elevated plus - maze devices .', {'entities': [(0, 7, 'B_Disease')]}], ['RESULTS : Anxiety was documented in both groups of PDN treated rats compared with controls .', {'entities': [(10, 17, 'B_Disease')]}], ['CONCLUSION : Subacute exposure to PDN induced anxiety and reactivity of microglia .', {'entities': [(46, 53, 'B_Disease')]}], ['Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix .', {'entities': [(83, 91, 'B_Disease'), (92, 96, 'I_Disease'), (97, 106, 'I_Disease'), (107, 109, 'I_Disease'), (110, 113, 'I_Disease'), (114, 120, 'I_Disease')]}], ['BACKGROUND : The activity of the combination of carboplatin and liposomal doxorubicin was tested in a Phase II study of patients with recurrent cervical carcinoma .', {'entities': [(144, 152, 'B_Disease'), (153, 162, 'I_Disease')]}], ['METHODS : The combination of carboplatin ( area under the concentration curve [ AUC ] , 5 ) and liposomal doxorubicin ( Doxil ; starting dose , 40 mg / m ( 2 ) ) was administered intravenously every 28 days to 37 patients with recurrent squamous cell cervical carcinoma to determine antitumor activity and toxicity profile .', {'entities': [(237, 245, 'B_Disease'), (246, 250, 'I_Disease'), (251, 259, 'I_Disease'), (260, 269, 'I_Disease'), (306, 314, 'B_Disease')]}], ['RESULTS : Twenty - nine patients were assessable for response , and 35 patients were assessable for toxicity .', {'entities': [(100, 108, 'B_Disease')]}], ['The main toxic effect was myelosuppression , with Grade 3 and 4 neutropenia in 16 patients , anemia in 12 patients , thrombocytopenia in 11 patients , and neutropenic fever in 3 patients .', {'entities': [(26, 42, 'B_Disease'), (64, 75, 'B_Disease'), (93, 99, 'B_Disease'), (117, 133, 'B_Disease'), (155, 166, 'B_Disease'), (167, 172, 'I_Disease')]}], ['Grade > or = 2 nonhematologic toxicity included nausea in 17 patients , emesis in 14 patients , fatigue in 9 patients , mucositis and / or stomatitis in 8 patients , constipation in 6 patients , weight loss in 5 patients , hand - foot syndrome in 2 patients , and skin reactions in 3 patients .', {'entities': [(30, 38, 'B_Disease'), (48, 54, 'B_Disease'), (72, 78, 'B_Disease'), (96, 103, 'B_Disease'), (120, 129, 'B_Disease'), (139, 149, 'B_Disease'), (166, 178, 'B_Disease'), (195, 201, 'B_Disease'), (202, 206, 'I_Disease'), (223, 227, 'B_Disease'), (228, 229, 'I_Disease'), (230, 234, 'I_Disease'), (235, 243, 'I_Disease'), (264, 268, 'B_Disease'), (269, 278, 'I_Disease')]}], ['CONCLUSIONS : The combination of carboplatin and liposomal doxorubicin has modest activity in patients with recurrent cervical carcinoma .', {'entities': [(118, 126, 'B_Disease'), (127, 136, 'I_Disease')]}], ['Antimicrobial - induced mania ( antibiomania ) : a review of spontaneous reports .', {'entities': [(24, 29, 'B_Disease'), (32, 44, 'B_Disease')]}], ['The authors reviewed reported cases of antibiotic - induced manic episodes by means of a MEDLINE and PsychLit search for reports of antibiotic - induced mania .', {'entities': [(60, 65, 'B_Disease'), (153, 158, 'B_Disease')]}], ['Twenty - one reports of antimicrobial - induced mania were found in the literature .', {'entities': [(48, 53, 'B_Disease')]}], ['Cotrimoxazole , metronidazole , and erythromycin were involved in 15 reported manic episodes .', {'entities': [(78, 83, 'B_Disease')]}], ['Cases reported by the FDA showed clarithromycin and ciprofloxacin to be the most frequently associated with the development of mania .', {'entities': [(127, 132, 'B_Disease')]}], ['Patients have an increased risk of developing mania while being treated with antimicrobials .', {'entities': [(46, 51, 'B_Disease')]}], ['Further research clearly is required to determine the incidence of antimicrobial - induced mania , the relative risk factors of developing an antimicrobial - induced manic episode among various demographic populations , and the incidence of patients who continue to have persistent affective disorders once the initial episode , which occurs while the patient is taking antibiotics , subsides .', {'entities': [(91, 96, 'B_Disease'), (166, 171, 'B_Disease')]}], ['The authors elected to name this syndrome \" antibiomania . \"', {'entities': [(44, 56, 'B_Disease')]}], [\"Levodopa - induced ocular dyskinesias in Parkinson ' s disease .\", {'entities': [(19, 25, 'B_Disease'), (26, 37, 'I_Disease'), (41, 50, 'B_Disease'), (51, 52, 'I_Disease'), (53, 54, 'I_Disease'), (55, 62, 'I_Disease')]}], ['Levodopa - induced ocular dyskinesias are very uncommon .', {'entities': [(19, 25, 'B_Disease'), (26, 37, 'I_Disease')]}], ['Usually they occur simultaneously with limb peak - dose choreatic dyskinesias .', {'entities': [(56, 65, 'B_Disease'), (66, 77, 'I_Disease')]}], ['We report on a patient with leftward and upward deviations of gaze during the peak effect of levodopa , and hypothesize that a severe dopaminergic denervation in the caudate nucleus is needed for the appearance of these levodopa - induce ocular dyskinesias .', {'entities': [(238, 244, 'B_Disease'), (245, 256, 'I_Disease')]}], ['A comparison of glyceryl trinitrate with diclofenac for the treatment of primary dysmenorrhea : an open , randomized , cross - over trial .', {'entities': [(81, 93, 'B_Disease')]}], ['Primary dysmenorrhea is a syndrome characterized by painful uterine contractility caused by a hypersecretion of endometrial prostaglandins ; non - steroidal anti - inflammatory drugs are the first choice for its treatment .', {'entities': [(8, 20, 'B_Disease')]}], ['The aim of the present study was to determine the efficacy of glyceryl trinitrate ( GTN ) , an NO donor , in the resolution of primary dysmenorrhea in comparison with diclofenac ( DCF ) .', {'entities': [(135, 147, 'B_Disease')]}], ['A total of 24 patients with the diagnosis of severe primary dysmenorrhea were studied during two consecutive menstrual cycles .', {'entities': [(60, 72, 'B_Disease')]}], ['The difference in pain intensity score ( DPI ) was the main outcome variable .', {'entities': [(18, 22, 'B_Disease')]}], ['However , DCF continued to be effective in reducing pelvic pain for two hours , whereas GTN scores remained more or less stable after 30 min and significantly higher than those for DFC ( after one hour : GTN , - 12 . 8 + / - 17 . 9 ; DFC , - 18 . 9 + / - 16 . 6 and after two hours : GTN , - 23 . 7 + / - 20 . 5 ; DFC , - 59 . 7 + / - 17 . 9 , p = 0 . 0001 ) .', {'entities': [(52, 58, 'B_Disease'), (59, 63, 'I_Disease')]}], ['Low back pain was also relieved by both drugs .', {'entities': [(0, 3, 'B_Disease'), (4, 8, 'I_Disease'), (9, 13, 'I_Disease')]}], ['Headache was significantly increased by GTN but not by DCF .', {'entities': [(0, 8, 'B_Disease')]}], ['Eight patients stopped using GTN because headache - - attributed to its use - - became intolerable .', {'entities': [(41, 49, 'B_Disease')]}], ['These findings indicate that GTN has a reduced efficacy and tolerability by comparison with DCF in the treatment of primary dysmenorrhea .', {'entities': [(124, 136, 'B_Disease')]}], ['Temocapril , a long - acting non - SH group angiotensin converting enzyme inhibitor , modulates glomerular injury in chronic puromycin aminonucleoside nephrosis .', {'entities': [(96, 106, 'B_Disease'), (107, 113, 'I_Disease'), (151, 160, 'B_Disease')]}], ['The purpose of the present study was to determine whether chronic administration of temocapril , a long - acting non - SH group angiotensin converting enzyme ( ACE ) inhibitor , reduced proteinuria , inhibited glomerular hypertrophy and prevented glomerulosclerosis in chronic puromycin aminonucleoside ( PAN ) - induced nephrotic rats .', {'entities': [(186, 197, 'B_Disease'), (221, 232, 'B_Disease'), (247, 265, 'B_Disease'), (321, 330, 'B_Disease')]}], ['Nephrosis was induced by injection of PAN ( 15mg / 100g body weight ) in male Sprague - Dawley ( SD ) rats .', {'entities': [(0, 9, 'B_Disease')]}], ['Temocapril did not attenuate proteinuria at 8 days , but it did markedly lower it from weeks 4 to 20 .', {'entities': [(29, 40, 'B_Disease')]}], ['The glomerulosclerosis index ( GSI ) was 6 . 21 % at 4 weeks and respectively 25 . 35 % and 30 . 49 % at 14 and 20 weeks in the PAN group .', {'entities': [(4, 22, 'B_Disease')]}], ['It appears that temocapril was effective in retarding renal progression and protected renal function in PAN neprotic rats .', {'entities': [(108, 116, 'B_Disease')]}], ['Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants .', {'entities': [(0, 9, 'B_Disease'), (10, 22, 'I_Disease')]}], ['We report three cases of severe hypoxaemia after ibuprofen administration during a randomised controlled trial of prophylactic treatment of patent ductus arteriosus with ibuprofen in premature infants born at less than 28 weeks of gestation .', {'entities': [(32, 42, 'B_Disease'), (140, 146, 'B_Disease'), (147, 153, 'I_Disease'), (154, 164, 'I_Disease')]}], ['Hypoxaemia resolved quickly on inhaled nitric oxide therapy .', {'entities': [(0, 10, 'B_Disease')]}], ['We suggest that investigators involved in similar trials pay close attention to pulmonary pressure if hypoxaemia occurs after prophylactic administration of ibuprofen .', {'entities': [(102, 112, 'B_Disease')]}], ['Hyponatremia and syndrome of inappropriate anti - diuretic hormone reported with the use of Vincristine : an over - representation of Asians ?', {'entities': [(0, 12, 'B_Disease'), (17, 25, 'B_Disease'), (26, 28, 'I_Disease'), (29, 42, 'I_Disease'), (43, 47, 'I_Disease'), (48, 49, 'I_Disease'), (50, 58, 'I_Disease'), (59, 66, 'I_Disease')]}], [\"PURPOSE : This retrospective study used a pharmaceutical company ' s global safety database to determine the reporting rate of hyponatremia and / or syndrome of inappropriate secretion of anti - diuretic hormone ( SIADH ) among vincristine - treated patients and to explore the possibility of at - risk population subgroups .\", {'entities': [(127, 139, 'B_Disease'), (149, 157, 'B_Disease'), (158, 160, 'I_Disease'), (161, 174, 'I_Disease'), (175, 184, 'I_Disease'), (185, 187, 'I_Disease'), (188, 192, 'I_Disease'), (193, 194, 'I_Disease'), (195, 203, 'I_Disease'), (204, 211, 'I_Disease'), (214, 219, 'B_Disease')]}], [\"METHOD : We searched the Eli Lilly and Company ' s computerized adverse event database for all reported cases of hyponatremia and / or SIADH as of 1 November 1999 that had been reported during the use of vincristine .\", {'entities': [(113, 125, 'B_Disease'), (135, 140, 'B_Disease')]}], ['RESULTS : A total of 76 cases of hyponatremia and / or SIADH associated with vincristine use were identified .', {'entities': [(33, 45, 'B_Disease'), (55, 60, 'B_Disease')]}], ['Approximately 75 % of the patients were receiving treatment for leukemia or lymphoma .', {'entities': [(64, 72, 'B_Disease'), (76, 84, 'B_Disease')]}], ['CONCLUSION : Our data suggest that Asian patients may be at increased risk of hyponatremia and / or SIADH associated with vincristine use .', {'entities': [(78, 90, 'B_Disease'), (100, 105, 'B_Disease')]}], ['Although the overall reported rate of SIADH associated with vincristine is very low , physicians caring for Asian oncology patients should be aware of this potential serious but reversible adverse event .', {'entities': [(38, 43, 'B_Disease')]}], ['Delayed toxicity of cyclophosphamide on the bladder of DBA / 2 and C57BL / 6 female mouse .', {'entities': [(8, 16, 'B_Disease')]}], ['Early CY toxicity caused a typical haemorrhagic cystitis in both strains that was completely repaired in about 7 - 10 days .', {'entities': [(9, 17, 'B_Disease'), (35, 47, 'B_Disease'), (48, 56, 'B_Disease')]}], ['After 30 days of CY injection ulcerous and non - ulcerous forms of chronic cystitis appeared in 86 % of DBA / 2 mice but only in 4 % of C57BL / 6 mice .', {'entities': [(75, 83, 'B_Disease')]}], ['Delayed cystitis was characterized by infiltration and transepithelial passage into the lumen of inflammatory cells and by frequent exfoliation of the urothelium .', {'entities': [(8, 16, 'B_Disease')]}], ['Delayed cystitis still persisted in DBA / 2 mice 100 days after treatment .', {'entities': [(8, 16, 'B_Disease')]}], ['These results indicate that delayed toxicity of CY in female DBA / 2 mice causes a bladder pathology that is not observed in C57BL / 6 mice .', {'entities': [(36, 44, 'B_Disease')]}], ['This pathology resembles interstitial cystitis in humans and could perhaps be used as an animal model for studies on the disease .', {'entities': [(25, 37, 'B_Disease'), (38, 46, 'I_Disease')]}], ['High - dose 5 - fluorouracil / folinic acid in combination with three - weekly mitomycin C in the treatment of advanced gastric cancer .', {'entities': [(120, 127, 'B_Disease'), (128, 134, 'I_Disease')]}], ['BACKGROUND : The 24 - hour continuous infusion of 5 - fluorouracil ( 5 - FU ) and folinic acid ( FA ) as part of several new multidrug chemotherapy regimens in advanced gastric cancer ( AGC ) has shown to be effective , with low toxicity .', {'entities': [(169, 176, 'B_Disease'), (177, 183, 'I_Disease'), (186, 189, 'B_Disease'), (229, 237, 'B_Disease')]}], ['In a previous phase II study with 3 - weekly bolus 5 - FU , FA and mitomycin C ( MMC ) we found a low toxicity rate and response rates comparable to those of regimens such as ELF , FAM or FAMTX , and a promising median overall survival .', {'entities': [(102, 110, 'B_Disease')]}], ['PATIENTS AND METHODS : From February , 1998 to September , 2000 we recruited 33 patients with AGC to receive weekly 24 - hour 5 - FU 2 , 600 mg / m ( 2 ) preceded by 2 - hour FA 500 mg / m ( 2 ) for 6 weeks , followed by a 2 - week rest period .', {'entities': [(94, 97, 'B_Disease')]}], ['18 patients had a primary AGC , and 15 showed a relapsed AGC .', {'entities': [(26, 29, 'B_Disease'), (57, 60, 'B_Disease')]}], ['The worst toxicities ( % ) observed were ( CTC - NCI 1 / 2 / 3 ) : leukopenia 45 . 5 / 18 . 2 / 6 . 1 , thrombocytopenia 33 . 3 / 9 . 1 / 6 . 1 , vomitus 24 . 2 / 9 . 1 / 0 , diarrhea 36 . 4 / 6 . 1 / 3 . 0 , stomatitis 18 . 2 / 9 . 1 / 0 , hand - foot syndrome 12 . 1 / 0 / 0 .', {'entities': [(10, 20, 'B_Disease'), (67, 77, 'B_Disease'), (104, 120, 'B_Disease'), (146, 153, 'B_Disease'), (175, 183, 'B_Disease'), (209, 219, 'B_Disease'), (241, 245, 'B_Disease'), (246, 247, 'I_Disease'), (248, 252, 'I_Disease'), (253, 261, 'I_Disease')]}], ['Two patients developed hemolytic - uremic syndrome ( HUS ) .', {'entities': [(23, 32, 'B_Disease'), (33, 34, 'I_Disease'), (35, 41, 'I_Disease'), (42, 50, 'I_Disease'), (53, 56, 'B_Disease')]}], ['CONCLUSIONS : High - dose 5 - FU / FA / MMC is an effective and well - tolerated outpatient regimen for AGC ( objective response rate 54 . 6 % ) .', {'entities': [(104, 107, 'B_Disease')]}], ['It may serve as an alternative to cisplatin - containing regimens ; however , it has to be considered that possibly HUS may occur .', {'entities': [(116, 119, 'B_Disease')]}], ['Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1 - infected children treated with indinavir .', {'entities': [(19, 31, 'B_Disease'), (51, 59, 'B_Disease'), (60, 65, 'I_Disease'), (66, 74, 'I_Disease'), (78, 83, 'B_Disease'), (84, 100, 'I_Disease'), (101, 106, 'I_Disease'), (107, 111, 'I_Disease'), (112, 113, 'I_Disease'), (114, 115, 'I_Disease'), (116, 124, 'I_Disease')]}], ['DESIGN : A prospective study to monitor indinavir - related nephrotoxicity in a cohort of 30 human immunodeficiency virus type 1 - infected children treated with indinavir .', {'entities': [(60, 74, 'B_Disease'), (93, 98, 'B_Disease'), (99, 115, 'I_Disease'), (116, 121, 'I_Disease'), (122, 126, 'I_Disease'), (127, 128, 'I_Disease'), (129, 130, 'I_Disease'), (131, 139, 'I_Disease')]}], ['RESULTS : The cumulative incidence of persistent sterile leukocyturia ( > or = 75 cells / micro L in at least 2 consecutive visits ) after 96 weeks was 53 % .', {'entities': [(57, 69, 'B_Disease')]}], ['Persistent sterile leukocyturia was frequently associated with a mild increase in the urine albumin / creatinine ratio and by microscopic hematuria .', {'entities': [(19, 31, 'B_Disease'), (138, 147, 'B_Disease')]}], ['Children with persistent sterile leukocyturia more frequently had serum creatinine levels of 50 % above normal than those children without persistent sterile leukocyturia .', {'entities': [(33, 45, 'B_Disease'), (158, 170, 'B_Disease')]}], ['In children younger than 5 . 6 years , persistent sterile leukocyturia was significantly more frequent than in older children .', {'entities': [(58, 70, 'B_Disease')]}], ['A higher cumulative incidence of persistent leukocyturia was found in children with an area under the curve > 19 mg / L x h or a peak serum level of indinavir > 12 mg / L .', {'entities': [(44, 56, 'B_Disease')]}], ['In 4 children , indinavir was discontinued because of nephrotoxicity .', {'entities': [(54, 68, 'B_Disease')]}], ['Subsequently , the serum creatinine levels decreased , the urine albumin / creatinine ratios returned to zero , and the leukocyturia disappeared within 3 months .', {'entities': [(120, 132, 'B_Disease')]}], ['CONCLUSIONS : Children treated with indinavir have a high cumulative incidence of persistent sterile leukocyturia .', {'entities': [(101, 113, 'B_Disease')]}], ['Children with persistent sterile leukocyturia more frequently had an increase in serum creatinine levels of > 50 % above normal .', {'entities': [(33, 45, 'B_Disease')]}], ['The impairment of the renal function in these children occurred in the absence of clinical symptoms of nephrolithiasis .', {'entities': [(4, 14, 'B_Disease'), (15, 17, 'I_Disease'), (18, 21, 'I_Disease'), (22, 27, 'I_Disease'), (28, 36, 'I_Disease'), (103, 118, 'B_Disease')]}], ['Indinavir - associated nephrotoxicity must be monitored closely , especially in children with risk factors such as persistent sterile leukocyturia , age < 5 . 6 years , an area under the curve of indinavir > 19 mg / L x h , and a C ( max ) > 12 mg / L .', {'entities': [(23, 37, 'B_Disease'), (134, 146, 'B_Disease')]}], ['Utility of troponin I in patients with cocaine - associated chest pain .', {'entities': [(60, 65, 'B_Disease'), (66, 70, 'I_Disease')]}], ['Baseline electrocardiogram abnormalities and market elevations not associated with myocardial necrosis make accurate diagnosis of myocardial infarction ( MI ) difficult in patients with cocaine - associated chest pain .', {'entities': [(83, 93, 'B_Disease'), (94, 102, 'I_Disease'), (130, 140, 'B_Disease'), (141, 151, 'I_Disease'), (154, 156, 'B_Disease'), (207, 212, 'B_Disease'), (213, 217, 'I_Disease')]}], ['OBJECTIVE : To assess outcomes based on troponin positivity in patients with cocaine chest pain admitted for exclusion of MI .', {'entities': [(85, 90, 'B_Disease'), (91, 95, 'I_Disease'), (122, 124, 'B_Disease')]}], ['METHODS : Outcomes were examined in patients admitted for possible MI after cocaine use .', {'entities': [(67, 69, 'B_Disease')]}], ['Outcomes included CK - MB MI ( CK - MB > or = 8 ng / mL with a relative index [ ( CK - MB x 100 ) / total CK ] > or = 4 , cardiac death , and significant coronary disease ( > or = 50 % ) .', {'entities': [(26, 28, 'B_Disease'), (122, 129, 'B_Disease'), (130, 135, 'I_Disease'), (154, 162, 'B_Disease'), (163, 170, 'I_Disease')]}], ['RESULTS : Of the 246 admitted patients , 34 ( 14 % ) met CK - MB criteria for MI and 38 ( 16 % ) had cTnI elevations .', {'entities': [(78, 80, 'B_Disease')]}], ['Three of the four patients without significant disease who had cTnI elevations met CK - MB criteria for MI , and the other had a peak CK - MB level of 13 ng / mL .', {'entities': [(104, 106, 'B_Disease')]}], ['Sensitivities , specificities , and positive and negative likelihood ratios for predicting cardiac death or significant disease were high for both CK - MB MI and cTnI and were not significantly different .', {'entities': [(91, 98, 'B_Disease'), (99, 104, 'I_Disease'), (155, 157, 'B_Disease')]}], ['CONCLUSIONS : Most patients with cTnI elevations meet CK - MB criteria for MI , as well as have a high incidence of underlying significant disease .', {'entities': [(75, 77, 'B_Disease')]}], ['Troponin appears to have an equivalent diagnostic accuracy compared with CK - MB for diagnosing necrosis in patients with cocaine - associated chest pain and suspected MI .', {'entities': [(96, 104, 'B_Disease'), (143, 148, 'B_Disease'), (149, 153, 'I_Disease'), (168, 170, 'B_Disease')]}], ['Acute interstitial nephritis due to nicergoline ( Sermion ) .', {'entities': [(6, 18, 'B_Disease'), (19, 28, 'I_Disease')]}], ['We report a case of acute interstitial nephritis ( AIN ) due to nicergoline ( Sermion ) .', {'entities': [(26, 38, 'B_Disease'), (39, 48, 'I_Disease'), (51, 54, 'B_Disease')]}], ['A 50 - year - old patient admitted to our hospital for fever and acute renal failure .', {'entities': [(55, 60, 'B_Disease'), (65, 70, 'B_Disease'), (71, 76, 'I_Disease'), (77, 84, 'I_Disease')]}], ['Before admission , he had been taking nicergoline and bendazac lysine due to retinal vein occlusion at ophthalmologic department .', {'entities': [(77, 84, 'B_Disease'), (85, 89, 'I_Disease'), (90, 99, 'I_Disease')]}], ['Thereafter , he experienced intermittent fever and skin rash .', {'entities': [(41, 46, 'B_Disease'), (51, 55, 'B_Disease'), (56, 60, 'I_Disease')]}], ['On admission , clinical symptoms ( i . e . arthralgia and fever ) and laboratory findings ( i . e . eosinophilia and renal failure ) suggested AIN , and which was confirmed by pathologic findings on renal biopsy .', {'entities': [(43, 53, 'B_Disease'), (58, 63, 'B_Disease'), (100, 112, 'B_Disease'), (117, 122, 'B_Disease'), (123, 130, 'I_Disease'), (143, 146, 'B_Disease')]}], ['To our knowledge , this is the first report of nicergoline - associated AIN .', {'entities': [(72, 75, 'B_Disease')]}], ['Neuroleptic malignant syndrome complicated by massive intestinal bleeding in a patient with chronic renal failure .', {'entities': [(0, 11, 'B_Disease'), (12, 21, 'I_Disease'), (22, 30, 'I_Disease'), (65, 73, 'B_Disease'), (92, 99, 'B_Disease'), (100, 105, 'I_Disease'), (106, 113, 'I_Disease')]}], ['A patient with chronic renal failure ( CRF ) developed neuroleptic malignant syndrome ( NMS ) after administration of risperidone and levomepromazine .', {'entities': [(15, 22, 'B_Disease'), (23, 28, 'I_Disease'), (29, 36, 'I_Disease'), (39, 42, 'B_Disease'), (55, 66, 'B_Disease'), (67, 76, 'I_Disease'), (77, 85, 'I_Disease'), (88, 91, 'B_Disease')]}], ['In addition to the typical symptoms of NMS , massive intestinal bleeding was observed during the episode .', {'entities': [(39, 42, 'B_Disease'), (64, 72, 'B_Disease')]}], ['This report suggests that NMS in a patient with CRF may be complicated by intestinal bleeding and needs special caution for this complication .', {'entities': [(26, 29, 'B_Disease'), (48, 51, 'B_Disease'), (85, 93, 'B_Disease')]}], ['Adrenaline - induced hypertension was used to destroy the BBB , which was evaluated using triphenyltetrazolium ( TTC ) staining of the brain slices just after giving adrenaline for 30 s .', {'entities': [(21, 33, 'B_Disease')]}], ['Similar results were obtained in seizure - induced breakdown of BBB .', {'entities': [(33, 40, 'B_Disease')]}], ['Carvedilol protects against doxorubicin - induced mitochondrial cardiomyopathy .', {'entities': [(64, 78, 'B_Disease')]}], ['Several cytopathic mechanisms have been suggested to mediate the dose - limiting cumulative and irreversible cardiomyopathy caused by doxorubicin .', {'entities': [(109, 123, 'B_Disease')]}], ['Recent evidence indicates that oxidative stress and mitochondrial dysfunction are key factors in the pathogenic process .', {'entities': [(52, 65, 'B_Disease'), (66, 77, 'I_Disease')]}], ['The objective of this investigation was to test the hypothesis that carvedilol , a nonselective beta - adrenergic receptor antagonist with potent antioxidant properties , protects against the cardiac and hepatic mitochondrial bioenergetic dysfunction associated with subchronic doxorubicin toxicity .', {'entities': [(290, 298, 'B_Disease')]}], ['It is concluded that this protection by carvedilol against both the structural and functional cardiac tissue damage may afford significant clinical advantage in minimizing the dose - limiting mitochondrial dysfunction and cardiomyopathy that accompanies long - term doxorubicin therapy in cancer patients .', {'entities': [(192, 205, 'B_Disease'), (206, 217, 'I_Disease'), (222, 236, 'B_Disease'), (289, 295, 'B_Disease')]}], ['Cocaine - induced hyperactivity is more influenced by adenosine receptor agonists than amphetamine - induced hyperactivity .', {'entities': [(18, 31, 'B_Disease'), (109, 122, 'B_Disease')]}], ['The influence of adenosine receptor agonists and antagonists on cocaine - and amphetamine - induced hyperactivity was examined in mice .', {'entities': [(100, 113, 'B_Disease')]}], ['All adenosine receptor agonists significantly decreased the locomotor activity in mice , and the effects were dose - dependent .', {'entities': [(46, 55, 'B_Disease'), (56, 59, 'I_Disease'), (60, 69, 'I_Disease'), (70, 78, 'I_Disease')]}], ['Similarly , all adenosine receptor agonists decreased amphetamine - induced hyperactivity , but at the higher doses than those which were active in cocaine - induced hyperactivity .', {'entities': [(76, 89, 'B_Disease'), (166, 179, 'B_Disease')]}], ['Our results have shown that all adenosine receptor agonists ( A1 and A2 ) reduce cocaine - and amphetamine - induced locomotor activity and indicate that cocaine - induced hyperactivity is more influenced by adenosine receptor agonists ( particularly A1 receptors ) than amphetamine - induced hyperactivity .', {'entities': [(172, 185, 'B_Disease'), (293, 306, 'B_Disease')]}], ['Amiodarone and the risk of bradyarrhythmia requiring permanent pacemaker in elderly patients with atrial fibrillation and prior myocardial infarction .', {'entities': [(27, 42, 'B_Disease'), (98, 104, 'B_Disease'), (105, 117, 'I_Disease'), (128, 138, 'B_Disease'), (139, 149, 'I_Disease')]}], ['OBJECTIVES : The aim of this study was to determine whether the use of amiodarone in patients with atrial fibrillation ( AF ) increases the risk of bradyarrhythmia requiring a permanent pacemaker .', {'entities': [(99, 105, 'B_Disease'), (106, 118, 'I_Disease'), (121, 123, 'B_Disease'), (148, 163, 'B_Disease')]}], [\"BACKGROUND : Reports of severe bradyarrhythmia during amiodarone therapy are infrequent and limited to studies assessing the therapy ' s use in the management of patients with ventricular arrhythmias .\", {'entities': [(31, 46, 'B_Disease'), (176, 187, 'B_Disease'), (188, 199, 'I_Disease')]}], ['METHODS : A study cohort of 8 , 770 patients age > or = 65 years with a new diagnosis of AF was identified from a provincewide database of Quebec residents with a myocardial infarction ( MI ) between 1991 and 1999 .', {'entities': [(89, 91, 'B_Disease'), (163, 173, 'B_Disease'), (174, 184, 'I_Disease'), (187, 189, 'B_Disease')]}], ['Using a nested case - control design , 477 cases of bradyarrhythmia requiring a permanent pacemaker were matched ( 1 : 4 ) to 1 , 908 controls .', {'entities': [(52, 67, 'B_Disease')]}], ['CONCLUSIONS : This study suggests that the use of amiodarone in elderly patients with AF and a previous MI increases the risk of bradyarrhythmia requiring a permanent pacemaker .', {'entities': [(86, 88, 'B_Disease'), (104, 106, 'B_Disease'), (129, 144, 'B_Disease')]}], ['Nonsteroidal anti - inflammatory drug - induced cystitis is a poorly recognized and under - reported condition .', {'entities': [(48, 56, 'B_Disease')]}], ['CONCLUSIONS : Indomethacin resulted in histopathologic findings typical of interstitial cystitis , such as leaky bladder epithelium and mucosal mastocytosis .', {'entities': [(75, 87, 'B_Disease'), (88, 96, 'I_Disease'), (144, 156, 'B_Disease')]}], ['The true incidence of nonsteroidal anti - inflammatory drug - induced cystitis in humans must be clarified by prospective clinical trials .', {'entities': [(70, 78, 'B_Disease')]}], ['An open - label phase II study of low - dose thalidomide in androgen - independent prostate cancer .', {'entities': [(83, 91, 'B_Disease'), (92, 98, 'I_Disease')]}], ['The antiangiogenic effects of thalidomide have been assessed in clinical trials in patients with various solid and haematological malignancies .', {'entities': [(115, 129, 'B_Disease'), (130, 142, 'I_Disease')]}], ['We undertook an open - label study using thalidomide 100 mg once daily for up to 6 months in 20 men with androgen - independent prostate cancer .', {'entities': [(128, 136, 'B_Disease'), (137, 143, 'I_Disease')]}], ['Adverse effects included constipation , morning drowsiness , dizziness and rash , and resulted in withdrawal from the study by three men .', {'entities': [(25, 37, 'B_Disease'), (48, 58, 'B_Disease'), (61, 70, 'B_Disease'), (75, 79, 'B_Disease')]}], ['Evidence of peripheral sensory neuropathy was found in nine of 13 men before treatment .', {'entities': [(12, 22, 'B_Disease'), (23, 30, 'I_Disease'), (31, 41, 'I_Disease')]}], ['In the seven men who completed six months on thalidomide , subclinical evidence of peripheral neuropathy was found in four before treatment , but in all seven at repeat testing .', {'entities': [(83, 93, 'B_Disease'), (94, 104, 'I_Disease')]}], ['The findings indicate that thalidomide may be an option for patients who have failed other forms of therapy , provided close follow - up is maintained for development of peripheral neuropathy .', {'entities': [(170, 180, 'B_Disease'), (181, 191, 'I_Disease')]}], ['Central nervous system toxicity following the administration of levobupivacaine for lumbar plexus block : A report of two cases .', {'entities': [(0, 7, 'B_Disease'), (8, 15, 'I_Disease'), (16, 22, 'I_Disease'), (23, 31, 'I_Disease')]}], ['BACKGROUND AND OBJECTIVES : Central nervous system and cardiac toxicity following the administration of local anesthetics is a recognized complication of regional anesthesia .', {'entities': [(28, 35, 'B_Disease'), (36, 43, 'I_Disease'), (44, 50, 'I_Disease'), (51, 54, 'I_Disease'), (55, 62, 'I_Disease'), (63, 71, 'I_Disease')]}], ['We describe 2 cases of grand mal seizures following accidental intravascular injection of levobupivacaine .', {'entities': [(23, 28, 'B_Disease'), (29, 32, 'I_Disease'), (33, 41, 'I_Disease')]}], ['Immediately after the administration of levobupivacaine 0 . 5 % with epinephrine 2 . 5 microgram / mL , the patients developed grand mal seizures , despite negative aspiration for blood and no clinical signs of intravenous epinephrine administration .', {'entities': [(127, 132, 'B_Disease'), (133, 136, 'I_Disease'), (137, 145, 'I_Disease')]}], ['The seizures were successfully treated with sodium thiopental in addition to succinylcholine in 1 patient .', {'entities': [(4, 12, 'B_Disease')]}], ['Neither patient developed signs of cardiovascular toxicity .', {'entities': [(35, 49, 'B_Disease'), (50, 58, 'I_Disease')]}], ['CONCLUSIONS : Although levobupivacaine may have a safer cardiac toxicity profile than racemic bupivacaine , if adequate amounts of levobupivacaine reach the circulation , it will result in convulsions .', {'entities': [(56, 63, 'B_Disease'), (64, 72, 'I_Disease'), (189, 200, 'B_Disease')]}], ['Plasma concentrations sufficient to result in central nervous system toxicity did not produce manifestations of cardiac toxicity in these 2 patients .', {'entities': [(46, 53, 'B_Disease'), (54, 61, 'I_Disease'), (62, 68, 'I_Disease'), (69, 77, 'I_Disease'), (112, 119, 'B_Disease'), (120, 128, 'I_Disease')]}], ['Amiodarone - induced torsade de pointes during bladder irrigation : an unusual presentation - - a case report .', {'entities': [(21, 28, 'B_Disease'), (29, 31, 'I_Disease'), (32, 39, 'I_Disease')]}], ['The authors present a case of early ( within 4 days ) development of torsade de pointes ( TdP ) associated with oral amiodarone therapy .', {'entities': [(69, 76, 'B_Disease'), (77, 79, 'I_Disease'), (80, 87, 'I_Disease'), (90, 93, 'B_Disease')]}], ['Consistent with other reports this case of TdP occurred in the context of multiple exacerbating factors including hypokalemia and digoxin excess .', {'entities': [(43, 46, 'B_Disease'), (114, 125, 'B_Disease')]}], ['Transient prolongation of the QT during bladder irrigation prompted the episode of TdP .', {'entities': [(83, 86, 'B_Disease')]}], ['It is well known that bradycardia exacerbates acquired TdP .', {'entities': [(22, 33, 'B_Disease'), (55, 58, 'B_Disease')]}], ['The authors speculate that the increased vagal tone during bladder irrigation , a vagal maneuver , in the context of amiodarone therapy resulted in amiodarone - induced proarrhythmia .', {'entities': [(169, 182, 'B_Disease')]}], ['In the absence of amiodarone therapy , a second bladder irrigation did not induce TdP despite hypokalemia and hypomagnesemia .', {'entities': [(82, 85, 'B_Disease'), (94, 105, 'B_Disease'), (110, 124, 'B_Disease')]}], ['Anaesthetic complications associated with myotonia congenita : case study and comparison with other myotonic disorders .', {'entities': [(42, 50, 'B_Disease'), (51, 60, 'I_Disease'), (100, 108, 'B_Disease'), (109, 118, 'I_Disease')]}], ['Myotonia congenita ( MC ) is caused by a defect in the skeletal muscle chloride channel function , which may cause sustained membrane depolarisation .', {'entities': [(0, 8, 'B_Disease'), (9, 18, 'I_Disease'), (21, 23, 'B_Disease'), (115, 124, 'B_Disease'), (125, 133, 'I_Disease'), (134, 148, 'I_Disease')]}], ['We describe a previously healthy 32 - year - old woman who developed a life - threatening muscle spasm and secondary ventilation difficulties following a preoperative injection of suxamethonium .', {'entities': [(90, 96, 'B_Disease'), (97, 102, 'I_Disease')]}], ['The muscle spasms disappeared spontaneously and the surgery proceeded without further problems .', {'entities': [(4, 10, 'B_Disease'), (11, 17, 'I_Disease')]}], ['When subsequently questioned , she reported minor symptoms suggesting a myotonic condition .', {'entities': [(72, 80, 'B_Disease'), (81, 90, 'I_Disease')]}], ['Myotonia was found on clinical examination and EMG .', {'entities': [(0, 8, 'B_Disease')]}], ['The diagnosis MC was confirmed genetically .', {'entities': [(14, 16, 'B_Disease')]}], ['We give a brief overview of ion channel disorders including malignant hyperthermia and their anaesthetic considerations .', {'entities': [(28, 31, 'B_Disease'), (32, 39, 'I_Disease'), (40, 49, 'I_Disease'), (60, 69, 'B_Disease'), (70, 82, 'I_Disease')]}], ['Respiratory pattern in a rat model of epilepsy .', {'entities': [(38, 46, 'B_Disease')]}], ['PURPOSE : Apnea is known to occur during seizures , but systematic studies of ictal respiratory changes in adults are few .', {'entities': [(10, 15, 'B_Disease'), (41, 49, 'B_Disease')]}], ['Here we sought to generate information with regard to the interictal period in animals with pilocarpine - induced epilepsy .', {'entities': [(114, 122, 'B_Disease')]}], ['METHODS : Twelve rats ( six chronically epileptic animals and six controls ) were anesthetized , given tracheotomies , and subjected to hyperventilation or hypoventilation conditions .', {'entities': [(40, 49, 'B_Disease'), (136, 152, 'B_Disease')]}], ['RESULTS : The hyperventilation maneuver caused a decrease in spontaneous ventilation in pilocarpine - treated and control rats .', {'entities': [(14, 30, 'B_Disease')]}], ['Although VE had a similar decrease in both groups , in the epileptic group , the decrease in VE was due to a significant ( p < 0 . 05 ) increase in TE peak in relation to that of the control animals .', {'entities': [(59, 68, 'B_Disease')]}], ['In the epileptic group , the increase in VE was mediated by a significant ( p < 0 . 05 ) decrease in TE peak compared with the control group .', {'entities': [(7, 16, 'B_Disease')]}], ['We speculate on the possible relation of the current findings on treating different epilepsy - associated conditions .', {'entities': [(84, 92, 'B_Disease')]}], ['Fatal myeloencephalopathy due to intrathecal vincristine administration .', {'entities': [(6, 25, 'B_Disease')]}], ['Vincristine was accidentally given intrathecally to a child with leukaemia , producing sensory and motor dysfunction followed by encephalopathy and death .', {'entities': [(65, 74, 'B_Disease'), (87, 94, 'B_Disease'), (95, 98, 'I_Disease'), (99, 104, 'I_Disease'), (105, 116, 'I_Disease'), (129, 143, 'B_Disease')]}], ['After determining the bupivacaine AD50 ( the concentration of bupivacaine that caused 50 % of all beating rat heart myocyte cultures to become arrhythmic ) , we determined the effect of 1 - hour progesterone HCl exposure on myocyte contractile rhythm .', {'entities': [(143, 153, 'B_Disease')]}], ['There was a significant decrease in the time to onset of arrhythmia as compared with control nonprogesterone - treated rats ( 6 . 2 + / - 1 . 3 vs . 30 . 8 + / - 2 . 5 min , mean + / - SE ) .', {'entities': [(57, 67, 'B_Disease')]}], ['Potentiation of bupivacaine arrhythmia in myocyte cultures suggests that this effect is at least partly mediated at the myocyte level .', {'entities': [(28, 38, 'B_Disease')]}], ['Increased serum soluble Fas in patients with acute liver failure due to paracetamol overdose .', {'entities': [(45, 50, 'B_Disease'), (51, 56, 'I_Disease'), (57, 64, 'I_Disease'), (84, 92, 'B_Disease')]}], ['BACKGROUND / AIMS : Experimental studies have suggested that apoptosis via the Fas / Fas Ligand signaling system may play an important role in the development of acute liver failure .', {'entities': [(162, 167, 'B_Disease'), (168, 173, 'I_Disease'), (174, 181, 'I_Disease')]}], ['The aim of the study was to investigate the soluble form of Fas in patients with acute liver failure .', {'entities': [(81, 86, 'B_Disease'), (87, 92, 'I_Disease'), (93, 100, 'I_Disease')]}], ['METHODOLOGY : Serum levels of sFas ( soluble Fas ) were measured by ELISA in 24 patients with acute liver failure and 10 normal control subjects .', {'entities': [(94, 99, 'B_Disease'), (100, 105, 'I_Disease'), (106, 113, 'I_Disease')]}], ['Serum levels of tumor necrosis factor - alpha and interferon - gamma were also determined by ELISA .', {'entities': [(16, 21, 'B_Disease'), (22, 30, 'B_Disease')]}], ['RESULTS : Serum sFas was significantly increased in patients with acute liver failure ( median , 26 . 8 U / mL ; range , 6 . 9 - 52 . 7 U / mL ) compared to the normal controls ( median , 8 . 6 U / mL ; range , 6 . 5 - 12 . 0 U / mL , P < 0 . 0001 ) .', {'entities': [(66, 71, 'B_Disease'), (72, 77, 'I_Disease'), (78, 85, 'I_Disease')]}], ['Levels were significantly greater in patients with acute liver failure due to paracetamol overdose ( median , 28 . 7 U / mL ; range , 12 . 8 - 52 . 7 U / mL , n = 17 ) than those due to non - A to E hepatitis ( median , 12 . 5 U / mL ; range , 6 . 9 - 46 . 0 U / mL , n = 7 , P < 0 . 01 ) .', {'entities': [(51, 56, 'B_Disease'), (57, 62, 'I_Disease'), (63, 70, 'I_Disease'), (90, 98, 'B_Disease'), (199, 208, 'B_Disease')]}], ['CONCLUSIONS : The increased concentration of sFas in serum of patients with acute liver failure may reflect activation of Fas - mediated apoptosis in the liver and this together with increased tumor necrosis factor - alpha may be an important factor in liver cell loss .', {'entities': [(76, 81, 'B_Disease'), (82, 87, 'I_Disease'), (88, 95, 'I_Disease'), (193, 198, 'B_Disease'), (199, 207, 'B_Disease')]}], [\"Bilateral subthalamic nucleus stimulation for Parkinson ' s disease .\", {'entities': [(46, 55, 'B_Disease'), (56, 57, 'I_Disease'), (58, 59, 'I_Disease'), (60, 67, 'I_Disease')]}], [\"High frequency stimulation of the subthalamic nucleus ( STN ) is known to ameliorate the signs and symptoms of advanced Parkinson ' s disease .\", {'entities': [(120, 129, 'B_Disease'), (130, 131, 'I_Disease'), (132, 133, 'I_Disease'), (134, 141, 'I_Disease')]}], [\"METHOD : Twenty - three patients suffering from severe Parkinson ' s disease ( Stages III - V on Hoehn and Yahr scale ) and , particularly bradykinesia , rigidity , and levodopa - induced dyskinesias underwent bilateral implantation of electrodes in the STN .\", {'entities': [(55, 64, 'B_Disease'), (65, 66, 'I_Disease'), (67, 68, 'I_Disease'), (69, 76, 'I_Disease'), (139, 151, 'B_Disease'), (154, 162, 'B_Disease'), (188, 199, 'B_Disease')]}], ['Preoperative and postoperative assessments of these patients at 1 , 3 , 6 and 12 months follow - up , in \" on \" and \" off \" drug conditions , was carried out using Unified Parkinson \\' s Disease Rating Scale , Hoehn and Yahr staging , England activities of daily living score and video recordings .', {'entities': [(172, 181, 'B_Disease'), (182, 183, 'I_Disease'), (184, 185, 'I_Disease'), (186, 193, 'I_Disease')]}], [\"RESULTS : After one year of electrical stimulation of the STN , the patients ' scores for activities of daily living and motor examination scores ( Unified Parkinson ' s Disease Rating Scale parts II and III ) off medication improved by 62 % and 61 % respectively ( p < 0 . 0005 ) .\", {'entities': [(156, 165, 'B_Disease'), (166, 167, 'I_Disease'), (168, 169, 'I_Disease'), (170, 177, 'I_Disease')]}], ['The subscores for the akinesia , rigidity , tremor and gait also improved .', {'entities': [(22, 30, 'B_Disease'), (33, 41, 'B_Disease'), (44, 50, 'B_Disease')]}], [\"CONCLUSION : Bilateral subthalamic nucleus stimulation is an effective treatment for advanced Parkinson ' s disease .\", {'entities': [(94, 103, 'B_Disease'), (104, 105, 'I_Disease'), (106, 107, 'I_Disease'), (108, 115, 'I_Disease')]}], ['The reduction in the levodopa dose is useful in controlling drug - induced dyskinesias .', {'entities': [(60, 64, 'B_Disease'), (65, 66, 'I_Disease'), (67, 74, 'I_Disease'), (75, 86, 'I_Disease')]}], ['Acute renal failure occurring during intravenous desferrioxamine therapy : recovery after haemodialysis .', {'entities': [(0, 5, 'B_Disease'), (6, 11, 'I_Disease'), (12, 19, 'I_Disease')]}], ['A patient with transfusion - dependent thalassemia was undergoing home intravenous desferrioxamine ( DFX ) treatment by means of a totally implanted system because of his poor compliance with the nightly subcutaneous therapy .', {'entities': [(39, 50, 'B_Disease')]}], ['Due to an accidental malfunctioning of the infusion pump , the patient was inadvertently administered a toxic dosage of the drug which caused renal insufficiency .', {'entities': [(142, 147, 'B_Disease'), (148, 161, 'I_Disease')]}], ['Given the progressive deterioration of the symptoms and of the laboratory values , despite adequate medical treatment , a decision was made to introduce haemodialytical therapy in order to remove the drug and therapy reduce the nephrotoxicity .', {'entities': [(228, 242, 'B_Disease')]}], ['From the results obtained , haemodialysis can therefore be suggested as a useful therapy in rare cases of progressive acute renal failure caused by desferrioxamine .', {'entities': [(118, 123, 'B_Disease'), (124, 129, 'I_Disease'), (130, 137, 'I_Disease')]}], ['Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma .', {'entities': [(68, 82, 'B_Disease')]}], ['BACKGROUND : Focal subtenon carboplatin injections have recently been used as a presumably toxicity - free adjunct to systemic chemotherapy for intraocular retinoblastoma .', {'entities': [(91, 99, 'B_Disease'), (156, 170, 'B_Disease')]}], ['OBJECTIVE : To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy .', {'entities': [(51, 59, 'B_Disease'), (60, 66, 'I_Disease'), (67, 75, 'I_Disease')]}], ['METHODS : We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin .', {'entities': [(19, 27, 'B_Disease'), (28, 34, 'I_Disease'), (35, 43, 'I_Disease'), (76, 90, 'B_Disease')]}], ['During ocular manipulation under general anesthesia , we assessed their eyes by forced duction testing , comparing ocular motility after tumor control with ocular motility at diagnosis .', {'entities': [(137, 142, 'B_Disease')]}], ['RESULTS : Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy .', {'entities': [(107, 121, 'B_Disease')]}], ['Histopathological examination revealed many lipophages in the periorbital fat surrounding the optic nerve in 1 eye , indicative of phagocytosis of previously existing fat cells and suggesting prior fat necrosis .', {'entities': [(202, 210, 'B_Disease')]}], ['The enucleations were technically difficult and hazardous for globe rupture because of extensive orbital soft tissue adhesions .', {'entities': [(68, 75, 'B_Disease')]}], ['CONCLUSIONS : Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues , leading to mechanical restriction of eye movements and making subsequent enucleation difficult .', {'entities': [(79, 87, 'B_Disease')]}], ['Subtenon carboplatin is not free of toxicity , and its use is best restricted to specific indications .', {'entities': [(36, 44, 'B_Disease')]}], ['Ethambutol and optic neuropathy .', {'entities': [(15, 20, 'B_Disease'), (21, 31, 'I_Disease')]}], ['PURPOSE : To demonstrate the association between ethambutol and optic neuropathy .', {'entities': [(64, 69, 'B_Disease'), (70, 80, 'I_Disease')]}], ['METHOD : Thirteen patients who developed optic neuropathy after being treated with ethambutol for tuberculosis of the lung or lymph node at Siriraj Hospital between 1997 and 2001 were retrospectively reviewed .', {'entities': [(41, 46, 'B_Disease'), (47, 57, 'I_Disease'), (98, 110, 'B_Disease'), (111, 113, 'I_Disease'), (114, 117, 'I_Disease'), (118, 122, 'I_Disease'), (123, 125, 'I_Disease'), (126, 131, 'I_Disease'), (132, 136, 'I_Disease')]}], ['RESULTS : All patients had optic neuropathy between 1 to 6 months ( mean = 2 . 9 months ) after starting ethambutol therapy at a dosage ranging from 13 to 20 mg / kg / day ( mean = 17 mg / kg / day ) .', {'entities': [(27, 32, 'B_Disease'), (33, 43, 'I_Disease')]}], ['Of 6 patients with irreversible visual impairment , 4 patients had diabetes mellitus , glaucoma and a history of heavy smoking .', {'entities': [(32, 38, 'B_Disease'), (39, 49, 'I_Disease'), (67, 75, 'B_Disease'), (76, 84, 'I_Disease'), (87, 95, 'B_Disease')]}], ['CONCLUSION : Early recognition of optic neuropathy should be considered in patients with ethambutol therapy .', {'entities': [(34, 39, 'B_Disease'), (40, 50, 'I_Disease')]}], ['A low dose and prompt discontinuation of the drug is recommended particularly in individuals with diabetes mellitus , glaucoma or who are heavy smokers .', {'entities': [(98, 106, 'B_Disease'), (107, 115, 'I_Disease'), (118, 126, 'B_Disease')]}], ['Treatment of compensatory gustatory hyperhidrosis with topical glycopyrrolate .', {'entities': [(26, 35, 'B_Disease'), (36, 49, 'I_Disease')]}], ['Gustatory hyperhidrosis is facial sweating usually associated with the eating of hot spicy food or even smelling this food .', {'entities': [(0, 9, 'B_Disease'), (10, 23, 'I_Disease'), (34, 42, 'B_Disease')]}], ['All patients had gustatory hyperhidrosis , which interfered with their social activities , after transthroacic endoscopic sympathectomy , and which was associated with compensatory focal hyperhidrosis .', {'entities': [(17, 26, 'B_Disease'), (27, 40, 'I_Disease'), (187, 200, 'B_Disease')]}], ['After applying topical glycopyrrolate , the subjective effect was excellent ( no sweating after eating hot spicy food ) in 10 patients ( 77 % ) , and fair ( clearly reduced sweating ) in 3 patients ( 23 % ) .', {'entities': [(81, 89, 'B_Disease'), (173, 181, 'B_Disease')]}], ['Adverse effects included a mildly dry mouth and a sore throat in 2 patients ( 2 % glycopyrrolate ) , a light headache in 1 patient ( 1 . 5 % glycopyrrolate ) .', {'entities': [(34, 37, 'B_Disease'), (38, 43, 'I_Disease'), (50, 54, 'B_Disease'), (55, 61, 'I_Disease'), (109, 117, 'B_Disease')]}], ['The topical application of a glycopyrrolate pad appeared to be safe , efficacious , well tolerated , and a convenient method of treatment for moderate to severe symptoms of gustatory hyperhidrosis in post transthoracic endoscopic sympathectomy or sympathicotomy patients , with few side effects .', {'entities': [(173, 182, 'B_Disease'), (183, 196, 'I_Disease')]}], ['Neuroleptic - associated hyperprolactinemia .', {'entities': [(25, 43, 'B_Disease')]}], ['Six stable psychiatric outpatients with hyperprolactinemia and amenorrhea / oligomenorrhea associated with their neuroleptic medications were treated with bromocriptine .', {'entities': [(40, 58, 'B_Disease'), (63, 73, 'B_Disease'), (76, 90, 'B_Disease')]}], ['Daily dosages of 5 - 10 mg corrected the hyperprolactinemia and restored menstruation in four of the six patients .', {'entities': [(41, 59, 'B_Disease')]}], ['One woman , however , developed worsened psychiatric symptoms while taking bromocriptine , and it was discontinued .', {'entities': [(41, 52, 'B_Disease'), (53, 61, 'I_Disease')]}], ['This suggests that bromocriptine should be further evaluated as potential therapy for neuroleptic - associated hyperprolactinemia and amenorrhea / galactorrhea .', {'entities': [(111, 129, 'B_Disease'), (134, 144, 'B_Disease'), (147, 159, 'B_Disease')]}], ['Ethacrynic acid - induced convulsions and brain neurotransmitters in mice .', {'entities': [(26, 37, 'B_Disease')]}], ['Intracerebroventricular injection of ethacrynic acid ( 50 % convulsive dose ; 50 micrograms / mouse ) accelerated the synthesis / turnover of 5 - hydroxytryptamine ( 5 - HT ) but suppressed the synthesis of gamma - aminobutyric acid and acetylcholine in mouse brain .', {'entities': [(60, 70, 'B_Disease')]}], ['In ethacrynic acid - induced convulsions , these neurotransmitter systems may be differentially modulated , probably through activation of glutaminergic neurons in the brain .', {'entities': [(29, 40, 'B_Disease')]}], ['Moreover , 0 . 05 mg / kg of this beta - carboline reduced markedly the increase of [ 35S ] TBPS binding and the convulsions induced by isoniazid ( 200 mg / kg s . c . ) . ( ABSTRACT TRUNCATED AT 250 WORDS )', {'entities': [(113, 124, 'B_Disease')]}], ['Recurrent myocardial infarction in a postpartum patient receiving bromocriptine .', {'entities': [(10, 20, 'B_Disease'), (21, 31, 'I_Disease')]}], ['Myocardial infarction in puerperium is infrequently reported .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease')]}], ['Spasm , coronary dissection , or atheromatous etiology has been described .', {'entities': [(0, 5, 'B_Disease')]}], ['Bromocriptine has been implicated in several previous case reports of myocardial infarction in the puerperium .', {'entities': [(70, 80, 'B_Disease'), (81, 91, 'I_Disease')]}], ['Asterixis induced by carbamazepine therapy .', {'entities': [(0, 9, 'B_Disease')]}], ['There are very few reports about asterixis as a side effect of treatment with psychopharmacologic agents .', {'entities': [(33, 42, 'B_Disease')]}], ['In this report we present four patients treated with a combination of different psychotropic drugs , in whom asterixis was triggered either by adding carbamazepine ( CBZ ) to a treatment regimen , or by increasing its dosage .', {'entities': [(109, 118, 'B_Disease')]}], ['We consider asterixis to be an easily overlooked sign of neurotoxicity , which may occur even at low or moderate dosage levels , if certain drugs as lithium or clozapine are used in combination with CBZ .', {'entities': [(12, 21, 'B_Disease'), (57, 70, 'B_Disease')]}], ['Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients .', {'entities': [(24, 35, 'B_Disease'), (58, 70, 'B_Disease')]}], ['Blood pressure effects of i . v . levodopa were examined in parkinsonian patients with stable and fluctuating responses to levodopa .', {'entities': [(60, 72, 'B_Disease')]}], ['The magnitude of the hypotensive effect of levodopa was concentration dependent and was fit to an Emax model in fluctuating responders .', {'entities': [(21, 32, 'B_Disease')]}], ['Stable responders demonstrated a small hypotensive response .', {'entities': [(39, 50, 'B_Disease')]}], ['Baseline blood pressures were higher in fluctuating patients ; a higher baseline blood pressure correlated with greater hypotensive effects .', {'entities': [(120, 131, 'B_Disease')]}], ['Phenylalanine , a large neutral amino acid ( LNAA ) competing with levodopa for transport across the blood - brain barrier , reduced the hypotensive and antiparkinsonian effects of levodopa .', {'entities': [(137, 148, 'B_Disease')]}], ['We conclude that levodopa has a central hypotensive action that parallels the motor effects in fluctuating patients .', {'entities': [(40, 51, 'B_Disease')]}], ['The hypotensive effect appears to be related to the higher baseline blood pressure we observed in fluctuating patients relative to stable patients .', {'entities': [(4, 15, 'B_Disease')]}], ['Syndrome of inappropriate secretion of antidiuretic hormone after infusional vincristine .', {'entities': [(0, 8, 'B_Disease'), (9, 11, 'I_Disease'), (12, 25, 'I_Disease'), (26, 35, 'I_Disease'), (36, 38, 'I_Disease'), (39, 51, 'I_Disease'), (52, 59, 'I_Disease')]}], ['A 77 - year - old woman with refractory multiple myeloma was treated with a 4 - day continuous intravenous infusion of vincristine and doxorubicin and 4 days of oral dexamethasone .', {'entities': [(40, 48, 'B_Disease'), (49, 56, 'I_Disease')]}], ['Nine days after her second cycle she presented with lethargy and weakness associated with hyponatremia .', {'entities': [(52, 60, 'B_Disease'), (65, 73, 'B_Disease'), (90, 102, 'B_Disease')]}], ['Evaluation revealed the syndrome of inappropriate secretion of antidiuretic hormone , which was attributed to the vincristine infusion .', {'entities': [(24, 32, 'B_Disease'), (33, 35, 'I_Disease'), (36, 49, 'I_Disease'), (50, 59, 'I_Disease'), (60, 62, 'I_Disease'), (63, 75, 'I_Disease'), (76, 83, 'I_Disease')]}], ['Heart failure : to digitalise or not ?', {'entities': [(0, 5, 'B_Disease'), (6, 13, 'I_Disease')]}], ['In patients with atrial fibrillation digoxin is beneficial for ventricular rate control .', {'entities': [(17, 23, 'B_Disease'), (24, 36, 'I_Disease')]}], ['For patients in sinus rhythm and heart failure the situation is less clear .', {'entities': [(33, 38, 'B_Disease'), (39, 46, 'I_Disease')]}], ['Also , digoxin has undesirable effects such as increasing peripheral resistance and myocardial demands , and causing arrhythmias .', {'entities': [(117, 128, 'B_Disease')]}], ['Pooled analysis of the effects of other inotropic drugs shows an excess mortality and there is a possibility that digoxin may increase mortality after myocardial infarction ( MI ) .', {'entities': [(151, 161, 'B_Disease'), (162, 172, 'I_Disease'), (175, 177, 'B_Disease')]}], ['Isradipine treatment for hypertension in general practice in Hong Kong .', {'entities': [(25, 37, 'B_Disease')]}], ['303 Chinese patients with mild to moderate hypertension entered the study .', {'entities': [(43, 55, 'B_Disease')]}], ['The main side - effects were headache , dizziness , palpitation and flushing and these were not more frequent than reported in other studies with isradipine or with placebo .', {'entities': [(29, 37, 'B_Disease'), (40, 49, 'B_Disease'), (52, 63, 'B_Disease'), (68, 76, 'B_Disease')]}], ['Similar reductions occurred in standing blood pressure and there was no evidence of postural hypotension .', {'entities': [(84, 92, 'B_Disease'), (93, 104, 'I_Disease')]}], ['The pharmacodynamic parameters assessed included induction and emergence times , respiratory and cardiovascular effects , and pain on injection .', {'entities': [(126, 130, 'B_Disease')]}], ['Owing to a high incidence of thrombophlebitis , the study was terminated prematurely and only the data of the two parallel treatment groups ( 15 patients in each group ) were analysed .', {'entities': [(29, 45, 'B_Disease')]}], ['Pain on injection ( 80 vs . 20 % , p < 0 . 01 ) and thrombophlebitis ( 93 . 3 vs . 6 . 6 % , p < 0 . 001 ) occurred more frequently with AM149 than with Disoprivan .', {'entities': [(0, 4, 'B_Disease'), (52, 68, 'B_Disease')]}], ['Although both formulations had similar pharmacokinetic and pharmacodynamic profiles the new formulation is not suitable for clinical use due to the high incidence of thrombophlebitis produced .', {'entities': [(166, 182, 'B_Disease')]}], ['Pure red cell aplasia , toxic dermatitis and lymphadenopathy in a patient taking diphenylhydantoin .', {'entities': [(0, 4, 'B_Disease'), (5, 8, 'I_Disease'), (9, 13, 'I_Disease'), (14, 21, 'I_Disease'), (24, 29, 'B_Disease'), (30, 40, 'I_Disease'), (45, 60, 'B_Disease')]}], ['A patient taking diphenylhydantoin for 3 weeks developed a generalized skin rash , lymphadenopathy and pure red cell aplasia .', {'entities': [(71, 75, 'B_Disease'), (76, 80, 'I_Disease'), (83, 98, 'B_Disease'), (103, 107, 'B_Disease'), (108, 111, 'I_Disease'), (112, 116, 'I_Disease'), (117, 124, 'I_Disease')]}], ['Skin rash is a well - known complication of diphenylhydantoin treatment as is benign and malignant lymphadenopathy .', {'entities': [(0, 4, 'B_Disease'), (5, 9, 'I_Disease'), (99, 114, 'B_Disease')]}], ['Pure red cell aplasia associated with diphenylhydantoin medication has been reported in 3 patients .', {'entities': [(0, 4, 'B_Disease'), (5, 8, 'I_Disease'), (9, 13, 'I_Disease'), (14, 21, 'I_Disease')]}], ['In this patient the time relation between the ingestion of diphenylhydantoin and the occurrence of the skin rash , lymphadenopathy and pure red cell aplasia is very suggestive of a direct connection .', {'entities': [(103, 107, 'B_Disease'), (108, 112, 'I_Disease'), (115, 130, 'B_Disease'), (135, 139, 'B_Disease'), (140, 143, 'I_Disease'), (144, 148, 'I_Disease'), (149, 156, 'I_Disease')]}], ['In order to quantify the incidence of these cardiac events , we performed a meta - analysis of clinical trials comparing VNR with other chemotherapeutic agents in the treatment of various malignancies .', {'entities': [(188, 200, 'B_Disease')]}], ['Randomized clinical trials comparing VNR with other drugs in the treatment of cancer were searched in Medline , Embase , Evidence - based Medicine Reviews databases and the Cochrane library from 1987 to 2002 .', {'entities': [(78, 84, 'B_Disease')]}], ['The risk of VNR cardiac events was similar to vindesine ( VDS ) and other cardiotoxic drugs [ fluorouracil , anthracyclines , gemcitabine ( GEM ) em leader ] .', {'entities': [(74, 85, 'B_Disease')]}], ['Even if it did not reach statistical significance because of a few number of cases , the risk was lower in trials excluding patients with cardiac history , and seemed to be higher in trials including patients with pre - existing cardiac diseases .', {'entities': [(229, 236, 'B_Disease'), (237, 245, 'I_Disease')]}], ['MRI findings of hypoxic cortical laminar necrosis in a child with hemolytic anemia crisis .', {'entities': [(41, 49, 'B_Disease'), (66, 75, 'B_Disease'), (76, 82, 'I_Disease')]}], ['We present magnetic resonance imaging findings of a 5 - year - old girl who had a rapidly installing hemolytic anemia crisis induced by trimethoprim - sulfomethoxazole , resulting in cerebral anoxia leading to permanent damage .', {'entities': [(101, 110, 'B_Disease'), (111, 117, 'I_Disease'), (183, 191, 'B_Disease'), (192, 198, 'I_Disease')]}], ['Magnetic Resonance imaging revealed cortical laminar necrosis in arterial border zones in both cerebral hemispheres , ischemic changes in subcortical white matter of left cerebral hemisphere , and in the left putamen .', {'entities': [(53, 61, 'B_Disease')]}], ['Although cortical laminar necrosis is a classic entity in adulthood related to conditions of energy depletions , there are few reports available in children .', {'entities': [(26, 34, 'B_Disease')]}], ['The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication .', {'entities': [(45, 51, 'B_Disease'), (52, 57, 'I_Disease'), (58, 65, 'I_Disease')]}], ['PURPOSE : To determine the natural history of visual field defects in a group of patients known to have Vigabatrin - associated changes who elected to continue the medication because of good seizure control .', {'entities': [(46, 52, 'B_Disease'), (53, 58, 'I_Disease'), (59, 66, 'I_Disease'), (191, 198, 'B_Disease')]}], ['Following already published methodology ( Eye 2002 ; 16 ; 567 - 571 ) monocular mean radial degrees ( MRDs ) to the I / 4e isopter on Goldmann perimetry was calculated for the right eye at the time of discovery of a visual field defect and again after not less than 18 months follow - up .', {'entities': [(216, 222, 'B_Disease'), (223, 228, 'I_Disease'), (229, 235, 'I_Disease')]}], ['Only one patient demonstrated a deterioration in visual field during the study period and discontinued treatment .', {'entities': [(32, 45, 'B_Disease'), (46, 48, 'I_Disease'), (49, 55, 'I_Disease'), (56, 61, 'I_Disease')]}], ['CONCLUSION : Established visual field defects presumed to be due to Vigabatrin therapy did not usually progress in spite of continuing use of the medication .', {'entities': [(25, 31, 'B_Disease'), (32, 37, 'I_Disease'), (38, 45, 'I_Disease')]}], ['These data give support to the hypothesis that the pathogenesis of Vigabatrin - associated visual field defects may be an idiosyncratic adverse drug reaction rather than dose - dependent toxicity .', {'entities': [(91, 97, 'B_Disease'), (98, 103, 'I_Disease'), (104, 111, 'I_Disease'), (187, 195, 'B_Disease')]}], ['Induction of rosaceiform dermatitis during treatment of facial inflammatory dermatoses with tacrolimus ointment .', {'entities': [(25, 35, 'B_Disease'), (56, 62, 'B_Disease'), (63, 75, 'I_Disease'), (76, 86, 'I_Disease')]}], ['BACKGROUND : Tacrolimus ointment is increasingly used for anti - inflammatory treatment of sensitive areas such as the face , and recent observations indicate that the treatment is effective in steroid - aggravated rosacea and perioral dermatitis .', {'entities': [(215, 222, 'B_Disease'), (227, 235, 'B_Disease'), (236, 246, 'I_Disease')]}], ['We report on rosaceiform dermatitis as a complication of treatment with tacrolimus ointment .', {'entities': [(25, 35, 'B_Disease')]}], ['OBSERVATIONS : Six adult patients with inflammatory facial dermatoses were treated with tacrolimus ointment because of the ineffectiveness of standard treatments .', {'entities': [(39, 51, 'B_Disease'), (52, 58, 'I_Disease'), (59, 69, 'I_Disease')]}], ['Within 2 to 3 weeks of initially effective and well - tolerated treatment , 3 patients with a history of rosacea and 1 with a history of acne experienced sudden worsening with pustular rosaceiform lesions .', {'entities': [(105, 112, 'B_Disease'), (137, 141, 'B_Disease')]}], ['In 1 patient with eyelid eczema , rosaceiform periocular dermatitis gradually appeared after 3 weeks of treatment .', {'entities': [(25, 31, 'B_Disease'), (46, 56, 'B_Disease'), (57, 67, 'I_Disease')]}], ['In 1 patient with atopic dermatitis , telangiectatic and papular rosacea insidiously appeared after 5 months of treatment .', {'entities': [(18, 24, 'B_Disease'), (25, 35, 'I_Disease'), (57, 64, 'B_Disease'), (65, 72, 'I_Disease')]}], ['CONCLUSIONS : Our observations suggest that the spectrum of rosaceiform dermatitis as a complication of treatment with tacrolimus ointment is heterogeneous .', {'entities': [(72, 82, 'B_Disease')]}], ['Intravascular hemolysis and acute renal failure following intermittent rifampin therapy .', {'entities': [(14, 23, 'B_Disease'), (28, 33, 'B_Disease'), (34, 39, 'I_Disease'), (40, 47, 'I_Disease')]}], ['Renal failure is a rare complication associated with the use of rifampin .', {'entities': [(0, 5, 'B_Disease'), (6, 13, 'I_Disease')]}], ['Intravascular hemolysis leading to acute renal failure following rifampin therapy is extremely rare .', {'entities': [(14, 23, 'B_Disease'), (35, 40, 'B_Disease'), (41, 46, 'I_Disease'), (47, 54, 'I_Disease')]}], ['Two patients with leprosy who developed hemolysis and acute renal failure following rifampin are reported .', {'entities': [(18, 25, 'B_Disease'), (40, 49, 'B_Disease'), (54, 59, 'B_Disease'), (60, 65, 'I_Disease'), (66, 73, 'I_Disease')]}], ['We visualize , for the first time , the profile of structural deficits in the human brain associated with chronic methamphetamine ( MA ) abuse .', {'entities': [(51, 61, 'B_Disease'), (62, 70, 'I_Disease'), (71, 73, 'I_Disease'), (74, 77, 'I_Disease'), (78, 83, 'I_Disease'), (84, 89, 'I_Disease')]}], ['Studies of human subjects who have used MA chronically have revealed deficits in dopaminergic and serotonergic systems and cerebral metabolic abnormalities .', {'entities': [(132, 141, 'B_Disease'), (142, 155, 'I_Disease')]}], ['Using magnetic resonance imaging ( MRI ) and new computational brain - mapping techniques , we determined the pattern of structural brain alterations associated with chronic MA abuse in human subjects and related these deficits to cognitive impairment .', {'entities': [(231, 240, 'B_Disease'), (241, 251, 'I_Disease')]}], ['We used high - resolution MRI and surface - based computational image analyses to map regional abnormalities in the cortex , hippocampus , white matter , and ventricles in 22 human subjects who used MA and 21 age - matched , healthy controls .', {'entities': [(95, 108, 'B_Disease'), (109, 111, 'I_Disease'), (112, 115, 'I_Disease'), (116, 122, 'I_Disease'), (123, 124, 'I_Disease'), (125, 136, 'I_Disease'), (137, 138, 'I_Disease'), (139, 144, 'I_Disease'), (145, 151, 'I_Disease'), (152, 153, 'I_Disease'), (154, 157, 'I_Disease'), (158, 168, 'I_Disease')]}], ['On average , MA abusers had 7 . 8 % smaller hippocampal volumes than control subjects ( p < 0 . 01 ; left , p = 0 . 01 ; right , p < 0 . 05 ) and significant white - matter hypertrophy ( 7 . 0 % ; p < 0 . 01 ) .', {'entities': [(173, 184, 'B_Disease')]}], ['MRI - based maps suggest that chronic methamphetamine abuse causes a selective pattern of cerebral deterioration that contributes to impaired memory performance .', {'entities': [(133, 141, 'B_Disease'), (142, 148, 'I_Disease'), (149, 160, 'I_Disease')]}], ['Prominent white - matter hypertrophy may result from altered myelination and adaptive glial changes , including gliosis secondary to neuronal damage .', {'entities': [(25, 36, 'B_Disease'), (112, 119, 'B_Disease'), (133, 141, 'B_Disease'), (142, 148, 'I_Disease')]}], ['These brain substrates may help account for the symptoms of MA abuse , providing therapeutic targets for drug - induced brain injury .', {'entities': [(120, 125, 'B_Disease'), (126, 132, 'I_Disease')]}], ['Amiodarone , an efficacious and widely used antiarrhythmic agent , has been reported to cause hepatotoxicity in some patients .', {'entities': [(94, 108, 'B_Disease')]}], ['Amiodarone induced hepatomegaly , hepatocyte microvesicular lipid accumulation , and a significant decrease in serum triglycerides and glucose .', {'entities': [(19, 31, 'B_Disease')]}], ['The absence of induction of these genes as well as hepatomegaly in PPARalpha knockout [ PPARalpha - / - ] mice indicated that the effects of amiodarone were dependent upon the presence of a functional PPARalpha gene .', {'entities': [(51, 63, 'B_Disease')]}], ['Compared to wild - type mice , treatment of PPARalpha - / - mice with amiodarone resulted in an increased rate and extent of total body weight loss .', {'entities': [(136, 142, 'B_Disease'), (143, 147, 'I_Disease')]}], ['The inability of amiodarone to directly activate either human or mouse PPARalpha transiently expressed in human HepG2 hepatoma cells indicates that the effects of amiodarone on the function of this receptor were indirect .', {'entities': [(118, 126, 'B_Disease')]}], ['These results provide important new mechanistic information regarding the hepatotoxic effects of amiodarone and indicate that PPARalpha protects against amiodarone - induced hepatotoxicity .', {'entities': [(74, 85, 'B_Disease'), (174, 188, 'B_Disease')]}], ['Niacin extended - release / lovastatin is a new combination product approved for treatment of primary hypercholesterolemia and mixed dyslipidemia .', {'entities': [(102, 122, 'B_Disease'), (133, 145, 'B_Disease')]}], ['A total of 4 , 499 patients with dyslipidemia requiring drug intervention was enrolled at 1 , 081 sites .', {'entities': [(33, 45, 'B_Disease')]}], ['Patients also received dietary counseling , educational materials , and reminders to call a toll - free number that provided further education about dyslipidemia and niacin extended - release / lovastatin .', {'entities': [(149, 161, 'B_Disease')]}], ['Primary end points were study compliance , increases in liver transaminases to > 3 times the upper limit of normal , and clinical myopathy .', {'entities': [(130, 138, 'B_Disease')]}], ['Flushing was the most common adverse event , reported by 18 % of patients and leading to discontinuation by 6 % .', {'entities': [(0, 8, 'B_Disease')]}], ['An increase of creatine phosphokinase to > 5 times the upper limit of normal occurred in 0 . 24 % of patients , and no cases of drug - induced myopathy were observed .', {'entities': [(143, 151, 'B_Disease')]}], ['Protective effect of Terminalia chebula against experimental myocardial injury induced by isoproterenol .', {'entities': [(61, 71, 'B_Disease'), (72, 78, 'I_Disease')]}], ['Cardioprotective effect of ethanolic extract of Terminalia chebula fruits ( 500 mg / kg body wt ) was examined in isoproterenol ( 200 mg / kg body wt ) induced myocardial damage in rats .', {'entities': [(160, 170, 'B_Disease'), (171, 177, 'I_Disease')]}], ['Histopathological examination was carried out to confirm the myocardial necrosis .', {'entities': [(72, 80, 'B_Disease')]}], ['A case of postoperative anxiety due to low dose droperidol used with patient - controlled analgesia .', {'entities': [(24, 31, 'B_Disease')]}], ['The diagnosis of droperidol - induced psychological disturbance was not made straight away although on subsequent close questioning the patient gave a very clear history .', {'entities': [(38, 51, 'B_Disease'), (52, 63, 'I_Disease')]}], ['Accurate patient history contributes to differentiating diabetes insipidus : a case study .', {'entities': [(56, 64, 'B_Disease'), (65, 74, 'I_Disease')]}], ['The case discussed herein initially appeared to be neurogenic diabetes insipidus ( DI ) secondary to a traumatic brain injury .', {'entities': [(51, 61, 'B_Disease'), (62, 70, 'I_Disease'), (71, 80, 'I_Disease'), (83, 85, 'B_Disease'), (103, 112, 'B_Disease'), (113, 118, 'I_Disease'), (119, 125, 'I_Disease')]}], [\"The nursing staff , by reviewing the patient ' s health history with his family , discovered a history of polydipsia and long - standing lithium use .\", {'entities': [(106, 116, 'B_Disease')]}], ['Lithium is implicated in drug - induced nephrogenic DI , and because the patient had not received lithium since being admitted to the hospital , his treatment changed to focus on nephrogenic DI .', {'entities': [(40, 51, 'B_Disease'), (52, 54, 'I_Disease'), (179, 190, 'B_Disease'), (191, 193, 'I_Disease')]}], ['By combining information from the patient history , the physical examination , and radiologic and laboratory studies , the critical care team demonstrated that the patient had been self - treating his lithium - induced nephrogenic DI and developed neurogenic DI secondary to brain trauma .', {'entities': [(219, 230, 'B_Disease'), (231, 233, 'I_Disease'), (248, 258, 'B_Disease'), (259, 261, 'I_Disease'), (275, 280, 'B_Disease'), (281, 287, 'I_Disease')]}], ['Thus successful treatment required that nephrogenic and neurogenic DI be treated concomitantly .', {'entities': [(56, 66, 'B_Disease'), (67, 69, 'I_Disease')]}], ['Factors contributing to ribavirin - induced anemia .', {'entities': [(44, 50, 'B_Disease')]}], ['BACKGROUND AND AIM : Interferon and ribavirin combination therapy for chronic hepatitis C produces hemolytic anemia .', {'entities': [(70, 77, 'B_Disease'), (78, 87, 'I_Disease'), (88, 89, 'I_Disease'), (99, 108, 'B_Disease'), (109, 115, 'I_Disease')]}], ['This study was conducted to identify the factors contributing to ribavirin - induced anemia .', {'entities': [(85, 91, 'B_Disease')]}], ['METHODS : Eighty - eight patients with chronic hepatitis C who received interferon - alpha - 2b at a dose of 6 MU administered intramuscularly for 24 weeks in combination with ribavirin administered orally at a dose of 600 mg or 800 mg participated in the study .', {'entities': [(39, 46, 'B_Disease'), (47, 56, 'I_Disease'), (57, 58, 'I_Disease')]}], ['A hemoglobin concentration of < 10 g / dL was defined as ribavirin - induced anemia .', {'entities': [(77, 83, 'B_Disease')]}], ['RESULTS : Ribavirin - induced anemia occurred in 18 ( 20 . 5 % ) patients during treatment .', {'entities': [(30, 36, 'B_Disease')]}], ['A 2 g / dL decrease in hemoglobin concentrations in patients with anemia was observed at week 2 after the start of treatment .', {'entities': [(66, 72, 'B_Disease')]}], ['A significant relationship was observed between the rate of reduction of hemoglobin concentrations at week 2 and the severity of anemia ( P < 0 . 01 ) .', {'entities': [(129, 135, 'B_Disease')]}], ['Zidovudine - induced hepatitis .', {'entities': [(21, 30, 'B_Disease')]}], ['A case of acute hepatitis induced by zidovudine in a 38 - year - old patient with AIDS is presented .', {'entities': [(16, 25, 'B_Disease'), (82, 86, 'B_Disease')]}], ['The mechanism whereby the hepatitis was induced is not known .', {'entities': [(26, 35, 'B_Disease')]}], ['Physicians caring for patients with AIDS should be aware of this hitherto rarely reported complication .', {'entities': [(36, 40, 'B_Disease')]}], ['Oxidative damage precedes nitrative damage in adriamycin - induced cardiac mitochondrial injury .', {'entities': [(75, 88, 'B_Disease'), (89, 95, 'I_Disease')]}], ['The purpose of the present study was to determine if elevated reactive oxygen ( ROS ) / nitrogen species ( RNS ) reported to be present in adriamycin ( ADR ) - induced cardiotoxicity actually resulted in cardiomyocyte oxidative / nitrative damage , and to quantitatively determine the time course and subcellular localization of these postulated damage products using an in vivo approach .', {'entities': [(168, 182, 'B_Disease')]}], ['Our data showed ADR induced 4HNE - protein adducts in mitochondria at the same time point as when mitochondrial injury initially appeared .', {'entities': [(98, 111, 'B_Disease'), (112, 118, 'I_Disease')]}], ['These results document for the first time in vivo that mitochondrial oxidative damage precedes nitrative damage .', {'entities': [(55, 68, 'B_Disease'), (69, 78, 'I_Disease'), (79, 85, 'I_Disease')]}], ['The progressive nature of mitochondrial injury suggests that mitochondria , not other subcellular organelles , are the major site of intracellular injury .', {'entities': [(26, 39, 'B_Disease'), (40, 46, 'I_Disease')]}], ['Sotalol - induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia .', {'entities': [(18, 26, 'B_Disease'), (27, 32, 'I_Disease'), (51, 58, 'B_Disease'), (59, 73, 'I_Disease'), (100, 111, 'B_Disease'), (112, 123, 'I_Disease')]}], ['A 54 - year - old man with severe left ventricular dysfunction due to dilated cardiomyopathy was referred to our hospital for symptomatic incessant sustained ventricular tachycardia ( VT ) .', {'entities': [(39, 50, 'B_Disease'), (51, 62, 'I_Disease'), (70, 77, 'B_Disease'), (78, 92, 'I_Disease'), (158, 169, 'B_Disease'), (170, 181, 'I_Disease'), (184, 186, 'B_Disease')]}], ['After the administration of nifekalant hydrochloride , sustained VT was terminated .', {'entities': [(65, 67, 'B_Disease')]}], ['An alternate class III agent , sotalol , was also effective for the prevention of VT .', {'entities': [(82, 84, 'B_Disease')]}], ['Coronary vasospasm may be induced by the non - selective beta - blocking properties of sotalol .', {'entities': [(0, 8, 'B_Disease'), (9, 18, 'I_Disease')]}], ['METHODS : The effect of pretreatment with trazodone on dexamphetamine - and apomorphine - induced oral stereotypies , on catalepsy induced by haloperidol and apomorphine ( 0 . 05 mg / kg , i . p . ) , on ergometrine - induced wet dog shake ( WDS ) behavior and fluoxetine - induced penile erections was studied in rats .', {'entities': [(98, 102, 'B_Disease'), (103, 115, 'I_Disease'), (121, 130, 'B_Disease')]}], ['We also investigated whether trazodone induces catalepsy in rats .', {'entities': [(47, 56, 'B_Disease')]}], ['RESULTS : Trazodone at 2 . 5 - 20 mg / kg i . p . did not induce catalepsy , and did not antagonize apomorphine ( 1 . 5 and 3 mg / kg ) stereotypy and apomorphine ( 0 . 05 mg / kg ) - induced catalepsy .', {'entities': [(65, 74, 'B_Disease'), (192, 201, 'B_Disease')]}], ['However , pretreatment with 5 , 10 and 20 mg / kg i . p . trazodone enhanced dexamphetamine stereotypy , and antagonized haloperidol catalepsy , ergometrine - induced WDS behavior and fluoxetine - induced penile erections .', {'entities': [(133, 142, 'B_Disease')]}], ['Trazodone at 30 , 40 and 50 mg / kg i . p . induced catalepsy and antagonized apomorphine and dexamphetamine stereotypies .', {'entities': [(52, 61, 'B_Disease')]}], ['We suggest that trazodone ( 5 , 10 and 20 mg / kg ) , by blocking the 5 - HT 2C receptors , releases the nigrostriatal DAergic neurons from tonic inhibition caused by 5 - HT , and thereby potentiates dexamphetamine stereotypy and antagonizes haloperidol catalepsy .', {'entities': [(254, 263, 'B_Disease')]}], [\"Swallowing abnormalities and dyskinesia in Parkinson ' s disease .\", {'entities': [(0, 10, 'B_Disease'), (11, 24, 'I_Disease'), (29, 39, 'B_Disease'), (43, 52, 'B_Disease'), (53, 54, 'I_Disease'), (55, 56, 'I_Disease'), (57, 64, 'I_Disease')]}], [\"Gastrointestinal abnormalities in Parkinson ' s disease ( PD ) have been known for almost two centuries , but many aspects concerning their pathophysiology have not been completely clarified .\", {'entities': [(0, 16, 'B_Disease'), (17, 30, 'I_Disease'), (34, 43, 'B_Disease'), (44, 45, 'I_Disease'), (46, 47, 'I_Disease'), (48, 55, 'I_Disease'), (58, 60, 'B_Disease')]}], ['The aim of this study was to characterize the oropharyngeal dynamics in PD patients with and without levodopa - induced dyskinesia .', {'entities': [(72, 74, 'B_Disease'), (120, 130, 'B_Disease')]}], ['Fifteen dyskinetic , 12 nondyskinetic patients , and a control group were included .', {'entities': [(8, 18, 'B_Disease')]}], [\"Patients were asked about dysphagia and evaluated with the Unified Parkinson ' s Disease Rating Scale Parts II and III and the Hoehn and Yahr scale .\", {'entities': [(26, 35, 'B_Disease'), (67, 76, 'B_Disease'), (77, 78, 'I_Disease'), (79, 80, 'I_Disease'), (81, 88, 'I_Disease')]}], ['Nondyskinetic patients , but not the dyskinetic ones , showed less oropharyngeal swallowing efficiency ( OPSE ) for liquid food than controls ( Dunnett , P = 0 . 02 ) .', {'entities': [(37, 47, 'B_Disease')]}], ['Dyskinetic patients tended to have a greater OPSE than nondyskinetic ( Dunnett , P = 0 . 06 ) .', {'entities': [(0, 10, 'B_Disease')]}], ['Neither the report of dysphagia nor any of the PD severity parameters correlated to the videofluoroscopic variables .', {'entities': [(22, 31, 'B_Disease'), (47, 49, 'B_Disease')]}], ['In the current study , dyskinetic patients performed better in swallowing function , which could be explained on the basis of a greater levodopa dose .', {'entities': [(23, 33, 'B_Disease')]}], ['Our results suggest a role for levodopa in the oral phase of deglutition and confirm that dysphagia is not a good predictor of deglutition alterations in PD .', {'entities': [(90, 99, 'B_Disease'), (154, 156, 'B_Disease')]}], ['Inhibition of nuclear factor - kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin .', {'entities': [(60, 78, 'B_Disease'), (79, 88, 'I_Disease')]}], ['BACKGROUND : Animals treated with gentamicin can show residual areas of interstitial fibrosis in the renal cortex .', {'entities': [(85, 93, 'B_Disease')]}], ['The animals killed on day 30 also presented fibrosis in the renal cortex despite the recovery of renal function .', {'entities': [(44, 52, 'B_Disease')]}], ['CONCLUSIONS : These data show that inhibition of NF - kappaB activation attenuates tubulointerstitial nephritis induced by gentamicin .', {'entities': [(83, 101, 'B_Disease'), (102, 111, 'I_Disease')]}], ['Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents : a frequently sampled intravenous glucose tolerance test and minimal model analysis .', {'entities': [(36, 49, 'B_Disease')]}], ['BACKGROUND : While the incidence of new - onset diabetes mellitus may be increasing in patients with schizophrenia treated with certain atypical antipsychotic agents , it remains unclear whether atypical agents are directly affecting glucose metabolism or simply increasing known risk factors for diabetes .', {'entities': [(48, 56, 'B_Disease'), (57, 65, 'I_Disease'), (101, 114, 'B_Disease'), (297, 305, 'B_Disease')]}], ['DESIGN : A cross - sectional design in stable , treated patients with schizophrenia evaluated using a frequently sampled intravenous glucose tolerance test and the Bergman minimal model analysis .', {'entities': [(70, 83, 'B_Disease')]}], ['Thirty - six nonobese subjects with schizophrenia or schizoaffective disorder , matched by body mass index and treated with either clozapine , olanzapine , or risperidone , were included in the analysis .', {'entities': [(36, 49, 'B_Disease'), (53, 68, 'B_Disease'), (69, 77, 'I_Disease')]}], ['MAIN OUTCOME MEASURES : Fasting plasma glucose and fasting serum insulin levels , insulin sensitivity index , homeostasis model assessment of insulin resistance , and glucose effectiveness .', {'entities': [(82, 89, 'B_Disease'), (90, 101, 'I_Disease'), (142, 149, 'B_Disease'), (150, 160, 'I_Disease')]}], ['There was a significant difference in insulin sensitivity index among groups ( F ( 33 ) = 10 . 66 ; P < . 001 ) ( clozapine < olanzapine < risperidone ) , with subjects who received clozapine and olanzapine exhibiting significant insulin resistance compared with subjects who were treated with risperidone ( clozapine vs risperidone , t ( 33 ) = - 4 . 29 ; P < . 001 ; olanzapine vs risperidone , t ( 33 ) = - 3 . 62 ; P = . 001 [ P < . 001 ] ) .', {'entities': [(38, 45, 'B_Disease'), (46, 57, 'I_Disease'), (230, 237, 'B_Disease'), (238, 248, 'I_Disease')]}], ['The homeostasis model assessment of insulin resistance also differed significantly among groups ( F ( 33 ) = 4 . 92 ; P = . 01 ) ( clozapine > olanzapine > risperidone ) ( clozapine vs risperidone , t ( 33 ) = 2 . 94 ; P = . 006 ; olanzapine vs risperidone , t ( 33 ) = 2 . 42 ; P = . 02 ) .', {'entities': [(36, 43, 'B_Disease'), (44, 54, 'I_Disease')]}], ['CONCLUSIONS : Both nonobese clozapine - and olanzapine - treated groups displayed significant insulin resistance and impairment of glucose effectiveness compared with risperidone - treated subjects .', {'entities': [(94, 101, 'B_Disease'), (102, 112, 'I_Disease')]}], ['Patients taking clozapine and olanzapine must be examined for insulin resistance and its consequences .', {'entities': [(62, 69, 'B_Disease'), (70, 80, 'I_Disease')]}], ['Thoracic hematomyelia secondary to coumadin anticoagulant therapy : a case report .', {'entities': [(0, 8, 'B_Disease'), (9, 21, 'I_Disease')]}], ['A case of thoracic hematomyelia secondary to anticoagulant therapy is presented .', {'entities': [(10, 18, 'B_Disease'), (19, 31, 'I_Disease')]}], ['Mania associated with fluoxetine treatment in adolescents .', {'entities': [(0, 5, 'B_Disease')]}], ['Fluoxetine , a selective serotonin reuptake inhibitor , is gaining increased acceptance in the treatment of adolescent depression .', {'entities': [(119, 129, 'B_Disease')]}], ['Generally safe and well tolerated by adults , fluoxetine has been reported to induce mania .', {'entities': [(85, 90, 'B_Disease')]}], ['The cases of five depressed adolescents , 14 - 16 years of age , who developed mania during pharmacotherapy with fluoxetine , are reported here .', {'entities': [(18, 27, 'B_Disease'), (79, 84, 'B_Disease')]}], ['Apparent risk factors for the development of mania or hypomania during fluoxetine pharmacotherapy in this population were the combination of attention - deficit hyperactivity disorder and affective instability ; major depression with psychotic features ; a family history of affective disorder , especially bipolar disorder ; and a diagnosis of bipolar disorder .', {'entities': [(45, 50, 'B_Disease'), (54, 63, 'B_Disease'), (141, 150, 'B_Disease'), (151, 152, 'I_Disease'), (153, 160, 'I_Disease'), (161, 174, 'I_Disease'), (175, 183, 'I_Disease'), (218, 228, 'B_Disease'), (234, 243, 'B_Disease'), (275, 284, 'B_Disease'), (285, 293, 'I_Disease'), (307, 314, 'B_Disease'), (315, 323, 'I_Disease'), (345, 352, 'B_Disease'), (353, 361, 'I_Disease')]}], ['Further study is needed to determine the optimal dosage and to identify risk factors that increase individual vulnerability to fluoxetine induced mania in adolescents .', {'entities': [(146, 151, 'B_Disease')]}], ['Acute renal insufficiency after high - dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation .', {'entities': [(0, 5, 'B_Disease'), (6, 11, 'I_Disease'), (12, 25, 'I_Disease'), (71, 78, 'B_Disease'), (79, 87, 'I_Disease'), (88, 99, 'I_Disease')]}], ['BACKGROUND : Patients with primary systemic amyloidosis ( AL ) have a poor prognosis .', {'entities': [(27, 34, 'B_Disease'), (35, 43, 'I_Disease'), (44, 55, 'I_Disease'), (58, 60, 'B_Disease')]}], ['The authors have noted the development of acute renal insufficiency immediately after melphalan conditioning .', {'entities': [(42, 47, 'B_Disease'), (48, 53, 'I_Disease'), (54, 67, 'I_Disease')]}], ['METHODS : Consecutive AL patients who underwent PBSCT were studied retrospectively .', {'entities': [(22, 24, 'B_Disease')]}], ['Acute renal insufficiency ( ARI ) after high - dose melphalan was defined by a minimum increase of 0 . 5 mg / dL ( 44 micromol / L ) in the serum creatinine level that is greater than 50 % of baseline immediately after conditioning .', {'entities': [(0, 5, 'B_Disease'), (6, 11, 'I_Disease'), (12, 25, 'I_Disease'), (28, 31, 'B_Disease')]}], ['RESULTS : Of the 80 patients studied , ARI developed in 18 . 8 % of the patients after high - dose melphalan .', {'entities': [(39, 42, 'B_Disease')]}], ['Univariate analysis identified age , hypoalbuminemia , heavy proteinuria , diuretic use , and urine sediment score ( > 3 ) as risk factors .', {'entities': [(37, 52, 'B_Disease'), (61, 72, 'B_Disease')]}], ['Patients who had ARI after high - dose melphalan underwent dialysis more often ( P = 0 . 007 ) , and had a worse 1 - year survival ( P = 0 . 03 ) .', {'entities': [(17, 20, 'B_Disease')]}], ['CONCLUSION : The timing of renal injury strongly suggests melphalan as the causative agent .', {'entities': [(27, 32, 'B_Disease'), (33, 39, 'I_Disease')]}], ['Ongoing tubular injury may be a prerequisite for renal injury by melphalan as evidenced by the active urinary sediment .', {'entities': [(8, 15, 'B_Disease'), (16, 22, 'I_Disease'), (49, 54, 'B_Disease'), (55, 61, 'I_Disease')]}], ['Development of ARI adversely affected the outcome after PBSCT .', {'entities': [(15, 18, 'B_Disease')]}], ['Effective preventive measures may help decrease the treatment mortality of PBSCT in AL patients .', {'entities': [(84, 86, 'B_Disease')]}], ['Focal cerebral ischemia in rats : effect of phenylephrine - induced hypertension during reperfusion .', {'entities': [(6, 14, 'B_Disease'), (15, 23, 'I_Disease'), (68, 80, 'B_Disease')]}], ['After 180 min of temporary middle cerebral artery occlusion in spontaneously hypertensive rats , the effect of phenylephrine - induced hypertension on ischemic brain injury and blood - brain barrier permeability was determined .', {'entities': [(27, 33, 'B_Disease'), (34, 42, 'I_Disease'), (43, 49, 'I_Disease'), (50, 59, 'I_Disease'), (77, 89, 'B_Disease'), (135, 147, 'B_Disease'), (151, 159, 'B_Disease'), (160, 165, 'I_Disease'), (166, 172, 'I_Disease')]}], ['Blood pressure was manipulated by one of the following schedules during 120 min of reperfusion : Control , normotensive reperfusion ; 90 / hypertension ( 90 / HTN ) , blood pressure was increased by 35 mm Hg during the initial 90 min of reperfusion only ; 15 / hypertension ( 15 / HTN ) , normotensive reperfusion for 30 min followed by 15 min of hypertension and 75 min of normotension .', {'entities': [(139, 151, 'B_Disease'), (159, 162, 'B_Disease'), (261, 273, 'B_Disease'), (281, 284, 'B_Disease'), (347, 359, 'B_Disease')]}], ['Part A , for eight rats in each group brain injury was evaluated by staining tissue using 2 , 3 , 5 - triphenyltetrazolium chloride and edema was evaluated by microgravimetry .', {'entities': [(38, 43, 'B_Disease'), (44, 50, 'I_Disease'), (136, 141, 'B_Disease')]}], ['Brain injury ( percentage of the ischemic hemisphere ) was less in the 15 / HTN group ( 16 + / - 6 , mean + / - SD ) versus the 90 / HTN group ( 30 + / - 6 ) , which was in turn less than the control group ( 42 + / - 5 ) .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease'), (33, 41, 'B_Disease'), (42, 52, 'I_Disease'), (76, 79, 'B_Disease'), (133, 136, 'B_Disease')]}], ['Specific gravity was greater in the 15 / HTN group ( 1 . 043 + / - 0 . 002 ) versus the 90 / HTN ( 1 . 036 + / - 0 . 003 ) and control ( 1 . 037 + / - 0 . 003 ) groups .', {'entities': [(41, 44, 'B_Disease'), (93, 96, 'B_Disease')]}], ['Evans Blue ( mug g - 1 of brain tissue ) was greater in the 90 / HTN group ( 24 . 4 + / - 6 . 0 ) versus the control group ( 12 . 3 + / - 4 . 1 ) , which was in turn greater than the 15 / HTN group ( 7 . 3 + / - 3 . 2 ) .', {'entities': [(65, 68, 'B_Disease'), (188, 191, 'B_Disease')]}], ['This study supports a hypothesis that during reperfusion , a short interval of hypertension decreases brain injury and edema ; and that sustained hypertension increases the risk of vasogenic edema .', {'entities': [(79, 91, 'B_Disease'), (102, 107, 'B_Disease'), (108, 114, 'I_Disease'), (119, 124, 'B_Disease'), (146, 158, 'B_Disease'), (181, 190, 'B_Disease'), (191, 196, 'I_Disease')]}], ['People aged over 75 in atrial fibrillation on warfarin : the rate of major hemorrhage and stroke in more than 500 patient - years of follow - up .', {'entities': [(23, 29, 'B_Disease'), (30, 42, 'I_Disease'), (75, 85, 'B_Disease'), (90, 96, 'B_Disease')]}], ['OBJECTIVES : To determine the incidence of major hemorrhage and stroke in people aged 76 and older with atrial fibrillation on adjusted - dose warfarin who had been recently been admitted to hospital .', {'entities': [(49, 59, 'B_Disease'), (64, 70, 'B_Disease'), (104, 110, 'B_Disease'), (111, 123, 'I_Disease')]}], ['PARTICIPANTS : Two hundred thirty - five patients aged 76 and older admitted to a major healthcare network between July 1 , 2001 , and June 30 , 2002 , with atrial fibrillation on warfarin were enrolled .', {'entities': [(157, 163, 'B_Disease'), (164, 176, 'I_Disease')]}], ['MEASUREMENTS : Information regarding major bleeding episodes , strokes , and warfarin use was obtained from patients , relatives , primary physicians , and medical records .', {'entities': [(43, 51, 'B_Disease'), (63, 70, 'B_Disease')]}], ['There were 53 major hemorrhages , for an annual rate of 10 . 0 % , including 24 ( 45 . 3 % ) life - threatening and five ( 9 . 4 % ) fatal bleeds .', {'entities': [(20, 31, 'B_Disease')]}], ['The annual stroke rate after initiation of warfarin was 2 . 6 % .', {'entities': [(11, 17, 'B_Disease')]}], ['CONCLUSION : The rate of major hemorrhage was high in this old , frail group , but excluding fatalities , resulted in no long - term sequelae , and the stroke rate on warfarin was low , demonstrating how effective warfarin treatment is .', {'entities': [(31, 41, 'B_Disease'), (152, 158, 'B_Disease')]}], ['Safety of celecoxib in patients with adverse skin reactions to acetaminophen ( paracetamol ) and nimesulide associated or not with common non - steroidal anti - inflammatory drugs .', {'entities': [(45, 49, 'B_Disease'), (50, 59, 'I_Disease')]}], ['The rate of adverse hypersensitivity reactions to these agents is generally low .', {'entities': [(20, 36, 'B_Disease')]}], ['OBJECTIVE : We evaluated the tolerability of CE in a group of patients with documented history of adverse cutaneous reactions to P and N associated or not to classic NSAIDs .', {'entities': [(106, 115, 'B_Disease'), (116, 125, 'I_Disease')]}], ['METHODS : We studied 9 patients with hypersensitivity to P and N with or without associated reactions to classic NSAIDs .', {'entities': [(37, 53, 'B_Disease')]}], ['The diagnosis of P and N - induced skin reactions was based in vivo challenge .', {'entities': [(35, 39, 'B_Disease'), (40, 49, 'I_Disease')]}], ['The challenge was considered positive if one or more of the following appeared : erythema , rush or urticaria - angioedema .', {'entities': [(81, 89, 'B_Disease'), (100, 109, 'B_Disease'), (112, 122, 'B_Disease')]}], ['Only one patient developed a moderate angioedema of the lips .', {'entities': [(38, 48, 'B_Disease')]}], ['CONCLUSION : Only one hypersensitivity reaction to CE was documented among 9 P and N - highly NSAIDs intolerant patients .', {'entities': [(22, 38, 'B_Disease')]}], ['Case - control study of regular analgesic and nonsteroidal anti - inflammatory use and end - stage renal disease .', {'entities': [(87, 90, 'B_Disease'), (91, 92, 'I_Disease'), (93, 98, 'I_Disease'), (99, 104, 'I_Disease'), (105, 112, 'I_Disease')]}], ['BACKGROUND : Studies on the association between the long - term use of aspirin and other analgesic and nonsteroidal anti - inflammatory drugs ( NSAIDs ) and end - stage renal disease ( ESRD ) have given conflicting results .', {'entities': [(157, 160, 'B_Disease'), (161, 162, 'I_Disease'), (163, 168, 'I_Disease'), (169, 174, 'I_Disease'), (175, 182, 'I_Disease'), (185, 189, 'B_Disease')]}], ['In order to examine this association , a case - control study with incident cases of ESRD was carried out .', {'entities': [(85, 89, 'B_Disease')]}], ['METHODS : The cases were all patients entering the local dialysis program because of ESRD in the study area between June 1 , 1995 and November 30 , 1997 .', {'entities': [(85, 89, 'B_Disease')]}], ['They were classified according to the underlying disease , which had presumably led them to ESRD .', {'entities': [(92, 96, 'B_Disease')]}], ['The risk of ESRD associated with aspirin was related to the cumulated dose and duration of use , and it was particularly high among the subset of patients with vascular nephropathy as underlying disease [ 2 . 35 ( 1 . 17 - 4 . 72 ) ] .', {'entities': [(12, 16, 'B_Disease'), (169, 180, 'B_Disease')]}], ['CONCLUSION : Our data indicate that long - term use of nonaspirin analgesic drugs and NSAIDs is not associated with an increased risk of ESRD .', {'entities': [(137, 141, 'B_Disease')]}], ['However , the chronic use of aspirin may increase the risk of ESRD .', {'entities': [(62, 66, 'B_Disease')]}], ['Two cases of amisulpride overdose : a cause for prolonged QT syndrome .', {'entities': [(25, 33, 'B_Disease'), (48, 57, 'B_Disease'), (58, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['Two cases of deliberate self - poisoning with 5 g and 3 . 6 g of amisulpride , respectively , are reported .', {'entities': [(31, 40, 'B_Disease')]}], ['In both cases , QT prolongation and hypocalcaemia were noted .', {'entities': [(16, 18, 'B_Disease'), (19, 31, 'I_Disease'), (36, 49, 'B_Disease')]}], ['The QT prolongation appeared to respond to administration of i . v . calcium gluconate .', {'entities': [(4, 6, 'B_Disease'), (7, 19, 'I_Disease')]}], ['Growth - associated protein 43 expression in hippocampal molecular layer of chronic epileptic rats treated with cycloheximide .', {'entities': [(84, 93, 'B_Disease')]}], ['PURPOSE : GAP43 has been thought to be linked with mossy fiber sprouting ( MFS ) in various experimental models of epilepsy .', {'entities': [(115, 123, 'B_Disease')]}], ['To investigate how GAP43 expression ( GAP43 - ir ) correlates with MFS , we assessed the intensity ( densitometry ) and extension ( width ) of GAP43 - ir in the inner molecular layer of the dentate gyrus ( IML ) of rats subject to status epilepticus induced by pilocarpine ( Pilo ) , previously injected or not with cycloheximide ( CHX ) , which has been shown to inhibit MFS .', {'entities': [(231, 237, 'B_Disease'), (238, 249, 'I_Disease')]}], ['Although some studies in experimental animals indicate clear pharmacological interactions between them , no studies have shown a specific interaction on anxiety responses .', {'entities': [(153, 160, 'B_Disease')]}], ['OBJECTIVES : The present study investigates the effects of nicotine on anxiety induced by caffeine and another anxiogenic drug , pentylenetetrazole , in mice .', {'entities': [(71, 78, 'B_Disease')]}], ['The elevated plus - maze ( EPM ) test was used to evaluate the effects of drugs on anxiety .', {'entities': [(83, 90, 'B_Disease')]}], ['Nicotine ( 0 . 25 mg / kg ) pretreatment blocked the caffeine - but not pentylenetetrazole - induced anxiety .', {'entities': [(101, 108, 'B_Disease')]}], ['CONCLUSIONS : Our results suggest that the antagonistic effect of nicotine on caffeine - induced anxiety is specific to caffeine , instead of a non - specific anxiolytic effect .', {'entities': [(97, 104, 'B_Disease')]}], ['BACKGROUND : Hormone therapy ( HT ) is widely used for controlling menopausal symptoms .', {'entities': [(67, 77, 'B_Disease'), (78, 86, 'I_Disease')]}], ['It has also been used for the management and prevention of cardiovascular disease , osteoporosis and dementia in older women but the evidence supporting its use for these indications is largely observational .', {'entities': [(59, 73, 'B_Disease'), (74, 81, 'I_Disease'), (84, 96, 'B_Disease'), (101, 109, 'B_Disease')]}], ['OBJECTIVES : To assess the effect of long - term HT on mortality , heart disease , venous thromboembolism , stroke , transient ischaemic attacks , breast cancer , colorectal cancer , ovarian cancer , endometrial cancer , gallbladder disease , cognitive function , dementia , fractures and quality of life .', {'entities': [(67, 72, 'B_Disease'), (73, 80, 'I_Disease'), (83, 89, 'B_Disease'), (90, 105, 'I_Disease'), (108, 114, 'B_Disease'), (117, 126, 'B_Disease'), (127, 136, 'I_Disease'), (137, 144, 'I_Disease'), (147, 153, 'B_Disease'), (154, 160, 'I_Disease'), (163, 173, 'B_Disease'), (174, 180, 'I_Disease'), (183, 190, 'B_Disease'), (191, 197, 'I_Disease'), (200, 211, 'B_Disease'), (212, 218, 'I_Disease'), (221, 232, 'B_Disease'), (233, 240, 'I_Disease'), (264, 272, 'B_Disease'), (275, 284, 'B_Disease')]}], [\"In relatively healthy women , combined continuous HT significantly increased the risk of venous thromboembolism or coronary event ( after one year ' s use ) , stroke ( after 3 years ) , breast cancer ( after 5 years ) and gallbladder disease .\", {'entities': [(89, 95, 'B_Disease'), (96, 111, 'I_Disease'), (159, 165, 'B_Disease'), (186, 192, 'B_Disease'), (193, 199, 'I_Disease'), (222, 233, 'B_Disease'), (234, 241, 'I_Disease')]}], ['Long - term oestrogen - only HT also significantly increased the risk of stroke and gallbladder disease .', {'entities': [(73, 79, 'B_Disease'), (84, 95, 'B_Disease'), (96, 103, 'I_Disease')]}], ['Overall , the only statistically significant benefits of HT were a decreased incidence of fractures and colon cancer with long - term use .', {'entities': [(90, 99, 'B_Disease'), (104, 109, 'B_Disease'), (110, 116, 'I_Disease')]}], ['Among relatively healthy women over 65 years taking continuous combined HT , there was a statistically significant increase in the incidence of dementia .', {'entities': [(144, 152, 'B_Disease')]}], ['Among women with cardiovascular disease , long - term use of combined continuous HT significantly increased the risk of venous thromboembolism .', {'entities': [(17, 31, 'B_Disease'), (32, 39, 'I_Disease'), (120, 126, 'B_Disease'), (127, 142, 'I_Disease')]}], ['The only significantly increased risk reported was for venous thromboembolism in women taking combined continuous HT ; their absolute risk remained very low .', {'entities': [(55, 61, 'B_Disease'), (62, 77, 'I_Disease')]}], [\"AUTHORS ' CONCLUSIONS : HT is not indicated for the routine management of chronic disease .\", {'entities': [(74, 81, 'B_Disease'), (82, 89, 'I_Disease')]}], ['Drug - induced liver injury : an analysis of 461 incidences submitted to the Spanish registry over a 10 - year period .', {'entities': [(0, 4, 'B_Disease'), (5, 6, 'I_Disease'), (7, 14, 'I_Disease'), (15, 20, 'I_Disease'), (21, 27, 'I_Disease')]}], ['BACKGROUND & AIMS : Progress in the understanding of susceptibility factors to drug - induced liver injury ( DILI ) and outcome predictability are hampered by the lack of systematic programs to detect bona fide cases .', {'entities': [(79, 83, 'B_Disease'), (84, 85, 'I_Disease'), (86, 93, 'I_Disease'), (94, 99, 'I_Disease'), (100, 106, 'I_Disease'), (109, 113, 'B_Disease')]}], ['METHODS : A cooperative network was created in 1994 in Spain to identify all suspicions of DILI following a prospective structured report form .', {'entities': [(91, 95, 'B_Disease')]}], ['The liver damage was characterized according to hepatocellular , cholestatic , and mixed laboratory criteria and to histologic criteria when available .', {'entities': [(4, 9, 'B_Disease'), (10, 16, 'I_Disease'), (65, 76, 'B_Disease')]}], ['RESULTS : Since April 1994 to August 2004 , 461 out of 570 submitted cases , involving 505 drugs , were deemed to be related to DILI .', {'entities': [(128, 132, 'B_Disease')]}], ['Indeed , the incidence of liver transplantation and death in this group was 11 . 7 % if patients had jaundice at presentation , whereas the corresponding figure was 3 . 8 % in nonjaundiced patients ( P < . 04 ) .', {'entities': [(101, 109, 'B_Disease')]}], ['Factors associated with the development of fulminant hepatic failure were female sex ( OR = 25 ; 95 % CI : 4 . 1 - 151 ; P < . 0001 ) , hepatocellular damage ( OR = 7 . 9 ; 95 % CI : 1 . 6 - 37 ; P < . 009 ) , and higher baseline plasma bilirubin value ( OR = 1 . 15 ; 95 % CI : 1 . 09 - 1 . 22 ; P < . 0001 ) .', {'entities': [(43, 52, 'B_Disease'), (53, 60, 'I_Disease'), (61, 68, 'I_Disease')]}], ['CONCLUSIONS : Patients with drug - induced hepatocellular jaundice have 11 . 7 % chance of progressing to death or transplantation .', {'entities': [(58, 66, 'B_Disease')]}], ['Amoxicillin - clavulanate stands out as the most common drug related to DILI .', {'entities': [(72, 76, 'B_Disease')]}], ['Morphological evaluation of the effect of d - ribose on adriamycin - evoked cardiotoxicity in rats .', {'entities': [(76, 90, 'B_Disease')]}], ['The influence of d - ribose on adriamycin - induced myocardiopathy in rats was studied .', {'entities': [(52, 66, 'B_Disease')]}], ['Adriamycin in the cumulative dose of 25 mg / kg evoked fully developed cardiac toxicity .', {'entities': [(71, 78, 'B_Disease'), (79, 87, 'I_Disease')]}], ['D - ribose in the multiple doses of 200 mg / kg did not influence ADR cardiotoxicity .', {'entities': [(70, 84, 'B_Disease')]}], ['In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin - induced nephrotoxicity : protection by erdosteine .', {'entities': [(98, 112, 'B_Disease')]}], ['The aims of this study were to examine vancomycin ( VCM ) - induced oxidative stress that promotes production of reactive oxygen species ( ROS ) and to investigate the role of erdosteine , an expectorant agent , which has also antioxidant properties , on kidney tissue against the possible VCM - induced renal impairment in rats .', {'entities': [(304, 309, 'B_Disease'), (310, 320, 'I_Disease')]}], ['VCM administration to control rats significantly increased renal malondialdehyde ( MDA ) and urinary N - acetyl - beta - d - glucosaminidase ( NAG , a marker of renal tubular injury ) excretion but decreased superoxide dismutase ( SOD ) and catalase ( CAT ) activities .', {'entities': [(161, 166, 'B_Disease'), (167, 174, 'I_Disease'), (175, 181, 'I_Disease')]}], ['Erdosteine showed histopathological protection against VCM - induced nephrotoxicity .', {'entities': [(69, 83, 'B_Disease')]}], ['There were a significant dilatation of tubular lumens , extensive epithelial cell vacuolization , atrophy , desquamation , and necrosis in VCM - treated rats more than those of the control and the erdosteine groups .', {'entities': [(98, 105, 'B_Disease'), (108, 120, 'B_Disease'), (127, 135, 'B_Disease')]}], ['It is concluded that oxidative tubular damage plays an important role in the VCM - induced nephrotoxicity and the modulation of oxidative stress with erdosteine reduces the VCM - induced kidney damage both at the biochemical and histological levels .', {'entities': [(91, 105, 'B_Disease'), (187, 193, 'B_Disease'), (194, 200, 'I_Disease')]}], ['Gemfibrozil - lovastatin therapy for primary hyperlipoproteinemias .', {'entities': [(45, 66, 'B_Disease')]}], ['The specific aim of this retrospective , observational study was to assess safety and efficacy of long - term ( 21 months / patient ) , open - label , gemfibrozil - lovastatin treatment in 80 patients with primary mixed hyperlipidemia ( 68 % of whom had atherosclerotic vascular disease ) .', {'entities': [(220, 234, 'B_Disease'), (254, 269, 'B_Disease'), (270, 278, 'I_Disease'), (279, 286, 'I_Disease')]}], ['Myositis , attributable to the drug combination and symptomatic enough to discontinue it , occurred in 3 % of patients , and in 1 % with concurrent high creatine phosphokinase ( 769 U / liter ) ; no patients had rhabdomyolysis or myoglobinuria . ( ABSTRACT TRUNCATED AT 250 WORDS )', {'entities': [(0, 8, 'B_Disease'), (212, 226, 'B_Disease'), (230, 243, 'B_Disease')]}], ['Does domperidone potentiate mirtazapine - associated restless legs syndrome ?', {'entities': [(53, 61, 'B_Disease'), (62, 66, 'I_Disease'), (67, 75, 'I_Disease')]}], ['There is now evidence to suggest a central role for the dopaminergic system in restless legs syndrome ( RLS ) .', {'entities': [(79, 87, 'B_Disease'), (88, 92, 'I_Disease'), (93, 101, 'I_Disease'), (104, 107, 'B_Disease')]}], ['For example , the symptoms of RLS can be dramatically improved by levodopa and dopamine agonists , whereas central dopamine D2 receptor antagonists can induce or aggravate RLS symptoms .', {'entities': [(30, 33, 'B_Disease'), (172, 175, 'B_Disease')]}], ['To our knowledge , there is no previous report regarding whether domperidone , a peripheral dopamine D2 receptor antagonist , can also induce or aggravate symptoms of RLS .', {'entities': [(167, 170, 'B_Disease')]}], ['Mirtazapine , the first noradrenergic and specific serotonergic antidepressant ( NaSSA ) , has been associated with RLS in several recent publications .', {'entities': [(116, 119, 'B_Disease')]}], ['The authors report here a depressed patient comorbid with postprandial dyspepsia who developed RLS after mirtazapine had been added to his domperidone therapy .', {'entities': [(58, 70, 'B_Disease'), (71, 80, 'I_Disease'), (95, 98, 'B_Disease')]}], ['Our patient started to have symptoms of RLS only after he had been treated with mirtazapine , and his RLS symptoms resolved completely upon discontinuation of his mirtazapine .', {'entities': [(40, 43, 'B_Disease'), (102, 105, 'B_Disease')]}], ['Such a temporal relationship between the use of mirtazapine and the symptoms of RLS in our patient did not support a potentiating effect of domperione on mirtazapine - associated RLS .', {'entities': [(80, 83, 'B_Disease'), (179, 182, 'B_Disease')]}], ['However , physicians should be aware of the possibility that mirtazapine can be associated with RLS in some individuals , especially those receiving concomitant dopamine D2 receptor antagonists .', {'entities': [(96, 99, 'B_Disease')]}], ['Antiandrogenic therapy can cause coronary arterial disease .', {'entities': [(33, 41, 'B_Disease'), (42, 50, 'I_Disease'), (51, 58, 'I_Disease')]}], ['AIM : To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer .', {'entities': [(87, 95, 'B_Disease'), (96, 102, 'I_Disease')]}], ['MATERIALS AND METHODS : We studied with a 2 . 5 years follow - up the changes in plasma cholesterols ( C ) , triglycerides ( TG ) , lipoproteins ( LP ) , and apolipoproteins ( Apo ) B - 100 , A - I , and A - II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer ( stage : T1cN0M0 , Gleason score : 2 - 5 ) during treatment with cyproterone acetate ( CPA ) without surgical management or radiation therapy .', {'entities': [(272, 280, 'B_Disease'), (281, 287, 'I_Disease')]}], ['After a period of 2 . 5 years on CPA treatment , four patients out of twenty - four were found to be affected by coronary heart disease .', {'entities': [(113, 121, 'B_Disease'), (122, 127, 'I_Disease'), (128, 135, 'I_Disease')]}], ['CONCLUSIONS : Ischaemic coronary arteriosclerosis with an incidence rate of 16 . 6 % as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol , Apo A - I and Apo A - II pro fi les , other than the well - known hyperglyceridemic effect caused by estrogen .', {'entities': [(24, 32, 'B_Disease'), (33, 49, 'I_Disease'), (235, 252, 'B_Disease'), (253, 259, 'I_Disease')]}], ['5 - Fluorouracil cardiotoxicity induced by alpha - fluoro - beta - alanine .', {'entities': [(17, 31, 'B_Disease')]}], ['Cardiotoxicity is a rare complication occurring during 5 - fluorouracil ( 5 - FU ) treatment for malignancies .', {'entities': [(0, 14, 'B_Disease'), (97, 109, 'B_Disease')]}], ['We herein report the case of a 70 - year - old man with 5 - FU - induced cardiotoxicity , in whom a high serum level of alpha - fluoro - beta - alanine ( FBAL ) was observed .', {'entities': [(73, 87, 'B_Disease')]}], ['The patient , who had unresectable colon cancer metastases to the liver and lung , was referred to us for chemotherapy from an affiliated hospital ; he had no cardiac history .', {'entities': [(35, 40, 'B_Disease'), (41, 47, 'I_Disease')]}], ['After admission , the patient received a continuous intravenous infusion of 5 - FU ( 1000 mg / day ) , during which precordial pain with right bundle branch block occurred concomitantly with a high serum FBAL concentration of 1955 ng / ml .', {'entities': [(116, 126, 'B_Disease'), (127, 131, 'I_Disease'), (137, 142, 'B_Disease'), (143, 149, 'I_Disease'), (150, 156, 'I_Disease'), (157, 162, 'I_Disease')]}], ['Both the precordial pain and the electrocardiographic changes disappeared spontaneously after the discontinuation of 5 - FU .', {'entities': [(9, 19, 'B_Disease'), (20, 24, 'I_Disease')]}], ['As the precordial pain in this patient was considered to have been due to 5 - FU - induced cardiotoxicity , the administration of 5 - FU was abandoned .', {'entities': [(7, 17, 'B_Disease'), (18, 22, 'I_Disease'), (91, 105, 'B_Disease')]}], ['Thereafter , no cardiac symptoms were observed .', {'entities': [(16, 23, 'B_Disease'), (24, 32, 'I_Disease')]}], ['The experience of this case , together with a review of the literature , suggests that FBAL is related to 5 - FU - induced cardiotoxicity .', {'entities': [(123, 137, 'B_Disease')]}], ['S - 1 may be administered safely to patients with 5 - FU - induced cardiotoxicity .', {'entities': [(67, 81, 'B_Disease')]}], [\"Hepatocellular carcinoma in Fanconi ' s anemia treated with androgen and corticosteroid .\", {'entities': [(0, 14, 'B_Disease'), (15, 24, 'I_Disease'), (28, 35, 'B_Disease'), (36, 37, 'I_Disease'), (38, 39, 'I_Disease'), (40, 46, 'I_Disease')]}], [\"The case of an 11 - year - old boy is reported who was known to have Fanconi ' s anemia for 3 years and was treated with androgens , corticosteroids and transfusions .\", {'entities': [(69, 76, 'B_Disease'), (77, 78, 'I_Disease'), (79, 80, 'I_Disease'), (81, 87, 'I_Disease')]}], ['Two weeks before his death he was readmitted because of aplastic crisis with septicemia and marked abnormalities in liver function and died of hemorrhagic bronchopneumonia .', {'entities': [(77, 87, 'B_Disease'), (143, 154, 'B_Disease'), (155, 171, 'I_Disease')]}], ['At autopsy peliosis and multiple hepatic tumors were found which histologically proved to be well - differentiated hepatocellular carcinoma .', {'entities': [(11, 19, 'B_Disease'), (33, 40, 'B_Disease'), (41, 47, 'I_Disease'), (115, 129, 'B_Disease'), (130, 139, 'I_Disease')]}], [\"This case contributes to the previous observations that non - metastasizing hepatic neoplasms and peliosis can develop in patients with androgen - and corticosteroid - treated Fanconi ' s anemia .\", {'entities': [(76, 83, 'B_Disease'), (84, 93, 'I_Disease'), (98, 106, 'B_Disease'), (176, 183, 'B_Disease'), (184, 185, 'I_Disease'), (186, 187, 'I_Disease'), (188, 194, 'I_Disease')]}], ['The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin - induced cardiotoxicity in mice .', {'entities': [(130, 144, 'B_Disease')]}], ['PURPOSE : Despite its well - known cardiotoxicity , the anthracyclin doxorubicin ( DOX ) continues to be an effective and widely used chemotherapeutic agent .', {'entities': [(35, 49, 'B_Disease')]}], ['DOX - induced cardiac damage presumably results from the formation of free radicals by DOX .', {'entities': [(14, 21, 'B_Disease'), (22, 28, 'I_Disease')]}], ['The semisynthetic flavonoid monohydroxyethylrutoside ( monoHER ) showed cardioprotection against DOX - induced cardiotoxicity through its radical scavenging and iron chelating properties .', {'entities': [(111, 125, 'B_Disease')]}], ['Their cardiac tissues were processed for light microscopy , after which cardiomyocyte damage was evaluated according to Billingham ( in Cancer Treat Rep 62 ( 6 ) : 865 - 872 , 1978 ) .', {'entities': [(72, 85, 'B_Disease'), (86, 92, 'I_Disease'), (136, 142, 'B_Disease')]}], ['Microscopic evaluation revealed that treatment with DOX alone induced significant cardiac damage in comparison to the saline control group ( P < 0 . 001 ) .', {'entities': [(82, 89, 'B_Disease'), (90, 96, 'I_Disease')]}], ['Clinical evaluation of adverse effects during bepridil administration for atrial fibrillation and flutter .', {'entities': [(74, 80, 'B_Disease'), (81, 93, 'I_Disease'), (94, 97, 'I_Disease'), (98, 105, 'I_Disease')]}], ['BACKGROUND : Bepridil hydrochloride ( Bpd ) has attracted attention as an effective drug for atrial fibrillation ( AF ) and atrial flutter ( AFL ) .', {'entities': [(93, 99, 'B_Disease'), (100, 112, 'I_Disease'), (115, 117, 'B_Disease'), (124, 130, 'B_Disease'), (131, 138, 'I_Disease'), (141, 144, 'B_Disease')]}], ['However , serious adverse effects , including torsade de pointes ( Tdp ) , have been reported .', {'entities': [(46, 53, 'B_Disease'), (54, 56, 'I_Disease'), (57, 64, 'I_Disease'), (67, 70, 'B_Disease')]}], ['Bpd was administered to 459 patients ( 361 males , 63 + / - 12 years old ) comprising 378 AF and 81 AFL cases .', {'entities': [(90, 92, 'B_Disease'), (100, 103, 'B_Disease')]}], ['There was marked QT prolongation greater than 0 . 55 s in 13 patients , bradycardia less than 40 beats / min in 6 patients , dizziness and general fatigue in 1 patient each .', {'entities': [(17, 19, 'B_Disease'), (20, 32, 'I_Disease'), (72, 83, 'B_Disease'), (125, 134, 'B_Disease'), (147, 154, 'B_Disease')]}], ['In 4 of 13 patients with QT prolongation , Tdp occurred .', {'entities': [(25, 27, 'B_Disease'), (28, 40, 'I_Disease'), (43, 46, 'B_Disease')]}], ['The major triggering factors of Tdp were hypokalemia and sudden decrease in heart rate .', {'entities': [(32, 35, 'B_Disease'), (41, 52, 'B_Disease')]}], ['There were no differences in the clinical backgrounds of the patients with and without Tdp other than LAD and age , which were larger and older in the patients with Tdp .', {'entities': [(87, 90, 'B_Disease'), (165, 168, 'B_Disease')]}], ['Enhanced isoproterenol - induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen .', {'entities': [(33, 40, 'B_Disease'), (41, 52, 'I_Disease')]}], ['LV hypertrophy induced by Iso treatment was significantly higher in TGR than in SD rats ( in g LV wt / 100 g body wt , 0 . 28 + / - 0 . 004 vs . 0 . 24 + / - 0 . 004 , respectively ) .', {'entities': [(0, 2, 'B_Disease'), (3, 14, 'I_Disease')]}], ['The greater LV hypertrophy in TGR rats was associated with more pronounced downregulation of beta - AR and upregulation of LV beta - AR kinase - 1 mRNA levels compared with those in SD rats .', {'entities': [(12, 14, 'B_Disease'), (15, 26, 'I_Disease')]}], ['These results indicate that TGR are more sensitive to beta - AR agonist - induced cardiac inotropic response and hypertrophy , possibly due to chronically low sympathetic outflow directed to the heart .', {'entities': [(82, 89, 'B_Disease'), (90, 99, 'I_Disease'), (113, 124, 'B_Disease')]}], ['Drug - induced long QT syndrome in injection drug users receiving methadone : high frequency in hospitalized patients and risk factors .', {'entities': [(15, 19, 'B_Disease'), (20, 22, 'I_Disease'), (23, 31, 'I_Disease')]}], ['BACKGROUND : Drug - induced long QT syndrome is a serious adverse drug reaction .', {'entities': [(28, 32, 'B_Disease'), (33, 35, 'I_Disease'), (36, 44, 'I_Disease')]}], ['In the inpatient setting , the frequency of QT interval prolongation with methadone treatment , its dose dependence , and the importance of cofactors such as drug - drug interactions remain unknown .', {'entities': [(44, 46, 'B_Disease'), (47, 55, 'I_Disease'), (56, 68, 'I_Disease')]}], ['In addition to methadone dose , 15 demographic , biological , and pharmacological variables were considered as potential risk factors for QT prolongation .', {'entities': [(138, 140, 'B_Disease'), (141, 153, 'I_Disease')]}], ['Six patients ( 3 . 6 % ) in the methadone group presented torsades de pointes .', {'entities': [(58, 66, 'B_Disease'), (67, 69, 'I_Disease'), (70, 77, 'I_Disease')]}], ['Multivariate regression analysis allowed attribution of 31 . 8 % of QTc variability to methadone dose , cytochrome P - 450 3A4 drug - drug interactions , hypokalemia , and altered liver function .', {'entities': [(154, 165, 'B_Disease')]}], ['CONCLUSIONS : QT interval prolongation in methadone maintenance patients hospitalized in a tertiary care center is a frequent finding .', {'entities': [(14, 16, 'B_Disease'), (17, 25, 'I_Disease'), (26, 38, 'I_Disease')]}], ['Methadone dose , presence of cytochrome P - 450 3A4 inhibitors , potassium level , and liver function contribute to QT prolongation .', {'entities': [(116, 118, 'B_Disease'), (119, 131, 'I_Disease')]}], ['Long QT syndrome can occur with low doses of methadone .', {'entities': [(0, 4, 'B_Disease'), (5, 7, 'I_Disease'), (8, 16, 'I_Disease')]}], ['Mechanisms of hypertension induced by nitric oxide ( NO ) deficiency : focus on venous function .', {'entities': [(14, 26, 'B_Disease')]}], ['Loss of endothelial cell - derived nitric oxide ( NO ) in hypertension is a hallmark of arterial dysfunction .', {'entities': [(58, 70, 'B_Disease'), (88, 96, 'B_Disease'), (97, 108, 'I_Disease')]}], ['Experimental hypertension created by the removal of NO , however , involves mechanisms in addition to decreased arterial vasodilator activity .', {'entities': [(13, 25, 'B_Disease')]}], ['We hypothesized that increased venous smooth muscle ( venomotor ) tone plays a role in Nomega - nitro - L - arginine ( LNNA ) hypertension through these mechanisms .', {'entities': [(126, 138, 'B_Disease')]}], ['Mean circulatory filling pressure , an in vivo measure of venomotor tone , was not elevated in LNNA hypertension at 1 or 2 weeks after LNNA .', {'entities': [(100, 112, 'B_Disease')]}], ['Similarly , ganglionic blockade with hexamethonium caused a significantly greater fall in LNNA hypertensive rats ( 76 + / - 9 mm Hg ) compared with control rats ( 35 + / - 10 mm Hg ) .', {'entities': [(95, 107, 'B_Disease')]}], ['These data suggest that while NO deficiency increases oxidative stress and sympathetic activity in both arterial and venous vessels , the impact on veins does not make a major contribution to this form of hypertension .', {'entities': [(205, 217, 'B_Disease')]}], ['Association of DRD2 polymorphisms and chlorpromazine - induced extrapyramidal syndrome in Chinese schizophrenic patients .', {'entities': [(63, 77, 'B_Disease'), (78, 86, 'I_Disease'), (98, 111, 'B_Disease')]}], ['AIM : Extrapyramidal syndrome ( EPS ) is most commonly affected by typical antipsychotic drugs that have a high affinity with the D2 receptor .', {'entities': [(6, 20, 'B_Disease'), (21, 29, 'I_Disease'), (32, 35, 'B_Disease')]}], ['Recently , many research groups have reported on the positive relationship between the genetic variations in the DRD2 gene and the therapeutic response in schizophrenia patients as a result of the role of variations in the receptor in modulating receptor expression .', {'entities': [(155, 168, 'B_Disease')]}], ['In this study , we evaluate the role DRD2 plays in chlorpromazine - induced EPS in schizophrenic patients .', {'entities': [(76, 79, 'B_Disease'), (83, 96, 'B_Disease')]}], ['METHODS : We identified seven SNP ( single nucleotide polymorphism ) ( - 141Cins > del , TaqIB , TaqID , Ser311Cys , rs6275 , rs6277 and TaqIA ) in the DRD2 gene in 146 schizophrenic inpatients ( 59 with EPS and 87 without EPS according to the Simpson - Angus Scale ) treated with chlorpromazine after 8 weeks .', {'entities': [(169, 182, 'B_Disease'), (204, 207, 'B_Disease'), (223, 226, 'B_Disease')]}], ['CONCLUSION : Our results did not lend strong support to the view that the genetic variation of the DRD2 gene plays a major role in the individually variable adverse effect induced by chlorpromazine , at least in Chinese patients with schizophrenia .', {'entities': [(234, 247, 'B_Disease')]}], ['Our results confirmed a previous study on the relationship between DRD2 and EPS in Caucasians .', {'entities': [(76, 79, 'B_Disease')]}], ['Physical training decreases susceptibility to subsequent pilocarpine - induced seizures in the rat .', {'entities': [(79, 87, 'B_Disease')]}], ['Regular motor activity has many benefits for mental and physical condition but its implications for epilepsy are still controversial .', {'entities': [(100, 108, 'B_Disease')]}], ['In order to elucidate this problem , we have studied the effect of long - term physical activity on susceptibility to subsequent seizures .', {'entities': [(129, 137, 'B_Disease')]}], ['Thereafter , seizures were induced by pilocarpine injections in trained and non - trained control groups .', {'entities': [(13, 21, 'B_Disease')]}], ['During the acute period of status epilepticus , we measured : ( 1 ) the latency of the first motor sign , ( 2 ) the intensity of seizures , ( 3 ) the time when it occurred within the 6 - h observation period , and ( 4 ) the time when the acute period ended .', {'entities': [(27, 33, 'B_Disease'), (34, 45, 'I_Disease'), (129, 137, 'B_Disease')]}], ['All these behavioral parameters showed statistically significant changes suggesting that regular physical exercises decrease susceptibility to subsequently induced seizures and ameliorate the course of experimentally induced status epilepticus .', {'entities': [(164, 172, 'B_Disease'), (225, 231, 'B_Disease'), (232, 243, 'I_Disease')]}], ['Tonic dopaminergic stimulation impairs associative learning in healthy subjects .', {'entities': [(31, 38, 'B_Disease'), (39, 50, 'I_Disease'), (51, 59, 'I_Disease')]}], ['Administration of the dopamine precursor levodopa enhances learning in healthy subjects and stroke patients .', {'entities': [(92, 98, 'B_Disease')]}], ['The dopamine agonist significantly impaired novel word learning compared to placebo .', {'entities': [(35, 43, 'B_Disease'), (44, 49, 'I_Disease'), (50, 54, 'I_Disease'), (55, 63, 'I_Disease')]}], ['Thus , phasic signaling seems to be the critical mechanism by which dopamine enhances associative learning in healthy subjects and stroke patients .', {'entities': [(131, 137, 'B_Disease')]}], ['Minocycline - induced vasculitis fulfilling the criteria of polyarteritis nodosa .', {'entities': [(22, 32, 'B_Disease'), (60, 73, 'B_Disease'), (74, 80, 'I_Disease')]}], ['A 47 - year - old man who had been taking minocycline for palmoplantar pustulosis developed fever , myalgias , polyneuropathy , and testicular pain , with elevated C - reactive protein ( CRP ) .', {'entities': [(58, 70, 'B_Disease'), (71, 81, 'I_Disease'), (92, 97, 'B_Disease'), (100, 108, 'B_Disease'), (111, 125, 'B_Disease'), (132, 142, 'B_Disease'), (143, 147, 'I_Disease')]}], ['These manifestations met the American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa .', {'entities': [(102, 115, 'B_Disease'), (116, 122, 'I_Disease')]}], ['To our knowledge , this is the second case of minocycline - induced vasculitis satisfying the criteria .', {'entities': [(68, 78, 'B_Disease')]}], ['Differential diagnosis for drug - induced disease is invaluable even for patients with classical polyarteritis nodosa .', {'entities': [(97, 110, 'B_Disease'), (111, 117, 'I_Disease')]}], ['Intramuscular hepatitis B immune globulin combined with lamivudine in prevention of hepatitis B recurrence after liver transplantation .', {'entities': [(14, 23, 'B_Disease'), (24, 25, 'I_Disease'), (84, 93, 'B_Disease'), (94, 95, 'I_Disease')]}], ['BACKGROUND : Combined hepatitis B immune globulin ( HBIg ) and lamivudine in prophylaxis of the recurrence of hepatitis B after liver transplantation has significantly improved the survival of HBsAg positive patients .', {'entities': [(22, 31, 'B_Disease'), (32, 33, 'I_Disease'), (110, 119, 'B_Disease'), (120, 121, 'I_Disease')]}], ['This study was undertaken to evaluate the outcomes of liver transplantation for patients with hepatitis B virus ( HBV ) .', {'entities': [(94, 103, 'B_Disease'), (104, 105, 'I_Disease')]}], ['METHODS : A retrospective chart analysis and a review of the organ transplant database identified 51 patients ( 43 men and 8 women ) transplanted for benign HBV - related cirrhotic diseases between June 2002 and December 2004 who had survived more than 3 months .', {'entities': [(171, 180, 'B_Disease'), (181, 189, 'I_Disease')]}], ['Anticonvulsant effect of eslicarbazepine acetate ( BIA 2 - 093 ) on seizures induced by microperfusion of picrotoxin in the hippocampus of freely moving rats .', {'entities': [(68, 76, 'B_Disease')]}], ['We have studied the effects of oral treatment with eslicarbazepine acetate on a whole - animal model in which partial seizures can be elicited repeatedly on different days without changes in threshold or seizure patterns .', {'entities': [(118, 126, 'B_Disease'), (204, 211, 'B_Disease')]}], ['In the animals treated with threshold doses of picrotoxin , the average number of seizures was 2 . 3 + / - 1 . 2 , and average seizure duration was 39 . 5 + / - 8 . 4s .', {'entities': [(82, 90, 'B_Disease'), (127, 134, 'B_Disease')]}], ['Pre - treatment with a dose of 30 mg / kg 2h before picrotoxin microperfusion prevented seizures in the 75 % of the rats .', {'entities': [(88, 96, 'B_Disease')]}], ['Lower doses ( 3 and 10mg / kg ) did not suppress seizures , however , after administration of 10mg / kg , significant reductions in seizures duration ( 24 . 3 + / - 6 . 8s ) and seizure number ( 1 . 6 + / - 0 . 34 ) were found .', {'entities': [(49, 57, 'B_Disease'), (132, 140, 'B_Disease'), (178, 185, 'B_Disease')]}], ['Acute renal failure associated with prolonged intake of slimming pills containing anthraquinones .', {'entities': [(0, 5, 'B_Disease'), (6, 11, 'I_Disease'), (12, 19, 'I_Disease')]}], ['Nephropathy caused by Chinese herbs has previously been reported , usually involving the use of aristolochic acids .', {'entities': [(0, 11, 'B_Disease')]}], ['We report a 23 - year - old woman who developed acute renal failure following prolonged use of a proprietary Chinese herbal slimming pill that contained anthraquinone derivatives , extracted from Rhizoma Rhei ( rhubarb ) .', {'entities': [(48, 53, 'B_Disease'), (54, 59, 'I_Disease'), (60, 67, 'I_Disease')]}], ['The renal injury was probably aggravated by the concomitant intake of a non - steroidal anti - inflammatory drug , diclofenac .', {'entities': [(4, 9, 'B_Disease'), (10, 16, 'I_Disease')]}], ['Renal pathology was that of hypocellular interstitial fibrosis .', {'entities': [(54, 62, 'B_Disease')]}], ['Spontaneous renal recovery occurred upon cessation of the slimming pills , but mild interstitial fibrosis and tubular atrophy was still evident histologically 4 months later .', {'entities': [(97, 105, 'B_Disease'), (118, 125, 'B_Disease')]}], ['Although a causal relationship between the use of an anthraquinone - containing herbal agent and renal injury remains to be proven , phytotherapy - associated interstitial nephropathy should be considered in patients who present with unexplained renal failure .', {'entities': [(97, 102, 'B_Disease'), (103, 109, 'I_Disease'), (172, 183, 'B_Disease'), (246, 251, 'B_Disease'), (252, 259, 'I_Disease')]}], ['Chloroacetaldehyde as a sulfhydryl reagent : the role of critical thiol groups in ifosfamide nephropathy .', {'entities': [(93, 104, 'B_Disease')]}], ['Chloroacetaldehyde ( CAA ) is a metabolite of the alkylating agent ifosfamide ( IFO ) and putatively responsible for renal damage following anti - tumor therapy with IFO .', {'entities': [(117, 122, 'B_Disease'), (123, 129, 'I_Disease'), (147, 152, 'B_Disease')]}], ['Toxicity of CAA was determined by protein content , cell number , LDH release , trypan blue exclusion assay and caspase - 3 activity .', {'entities': [(0, 8, 'B_Disease')]}], ['CAA reduced hRPTEC cell number and protein , induced a loss in free intracellular thiols and an increase in necrosis markers .', {'entities': [(108, 116, 'B_Disease')]}], ['Acidification , which slowed the reaction of CAA with thiol donors , could also attenuate effects of CAA on necrosis markers , thiol depletion and cysteine protease inhibition in living cells .', {'entities': [(108, 116, 'B_Disease')]}], ['Thus , CAA directly reacts with cellular protein and non - protein thiols , mediating its toxicity on hRPTEC .', {'entities': [(90, 98, 'B_Disease')]}], ['Therefore , urinary acidification could be an option to prevent IFO nephropathy in patients .', {'entities': [(68, 79, 'B_Disease')]}], ['Stereological methods reveal the robust size and stability of ectopic hilar granule cells after pilocarpine - induced status epilepticus in the adult rat .', {'entities': [(118, 124, 'B_Disease'), (125, 136, 'I_Disease')]}], ['Following status epilepticus in the rat , dentate granule cell neurogenesis increases greatly , and many of the new neurons appear to develop ectopically , in the hilar region of the hippocampal formation .', {'entities': [(10, 16, 'B_Disease'), (17, 28, 'I_Disease')]}], ['It has been suggested that the ectopic hilar granule cells could contribute to the spontaneous seizures that ultimately develop after status epilepticus .', {'entities': [(95, 103, 'B_Disease'), (134, 140, 'B_Disease'), (141, 152, 'I_Disease')]}], ['To quantify this population , the total number of ectopic hilar granule cells was estimated using unbiased stereology at different times after pilocarpine - induced status epilepticus .', {'entities': [(165, 171, 'B_Disease'), (172, 183, 'I_Disease')]}], ['The results indicate that the size of the hilar ectopic granule cell population after status epilepticus is substantial , and stable over time .', {'entities': [(86, 92, 'B_Disease'), (93, 104, 'I_Disease')]}], ['Interestingly , the size of the population appears to be correlated with the frequency of behavioral seizures , because animals with more ectopic granule cells in the hilus have more frequent behavioral seizures .', {'entities': [(101, 109, 'B_Disease'), (203, 211, 'B_Disease')]}], ['The results provide new insight into the potential role of ectopic hilar granule cells in the pilocarpine model of temporal lobe epilepsy .', {'entities': [(115, 123, 'B_Disease'), (124, 128, 'I_Disease'), (129, 137, 'I_Disease')]}], ['A prospective , open - label trial of galantamine in autistic disorder .', {'entities': [(53, 61, 'B_Disease'), (62, 70, 'I_Disease')]}], ['OBJECTIVE : Post - mortem studies have reported abnormalities of the cholinergic system in autism .', {'entities': [(91, 97, 'B_Disease')]}], ['The purpose of this study was to assess the use of galantamine , an acetylcholinesterase inhibitor and nicotinic receptor modulator , in the treatment of interfering behaviors in children with autism .', {'entities': [(193, 199, 'B_Disease')]}], ['METHODS : Thirteen medication - free children with autism ( mean age , 8 . 8 + / - 3 . 5 years ) participated in a 12 - week , open - label trial of galantamine .', {'entities': [(51, 57, 'B_Disease')]}], [\"RESULTS : Patients showed a significant reduction in parent - rated irritability and social withdrawal on the ABC as well as significant improvements in emotional lability and inattention on the Conners ' Parent Rating Scale - - Revised .\", {'entities': [(68, 80, 'B_Disease')]}], ['Overall , galantamine was well - tolerated , with no significant adverse effects apart from headaches in one patient .', {'entities': [(92, 101, 'B_Disease')]}], ['CONCLUSION : In this open trial , galantamine was well - tolerated and appeared to be beneficial for the treatment of interfering behaviors in children with autism , particularly aggression , behavioral dyscontrol , and inattention .', {'entities': [(157, 163, 'B_Disease'), (179, 189, 'B_Disease'), (192, 202, 'B_Disease'), (203, 213, 'I_Disease'), (220, 231, 'B_Disease')]}], ['Randomized comparison of olanzapine versus risperidone for the treatment of first - episode schizophrenia : 4 - month outcomes .', {'entities': [(92, 105, 'B_Disease')]}], ['OBJECTIVE : The authors compared 4 - month treatment outcomes for olanzapine versus risperidone in patients with first - episode schizophrenia spectrum disorders .', {'entities': [(129, 142, 'B_Disease')]}], ['METHOD : One hundred twelve subjects ( 70 % male ; mean age = 23 . 3 years [ SD = 5 . 1 ] ) with first - episode schizophrenia ( 75 % ) , schizophreniform disorder ( 17 % ) , or schizoaffective disorder ( 8 % ) were randomly assigned to treatment with olanzapine ( 2 . 5 - 20 mg / day ) or risperidone ( 1 - 6 mg / day ) .', {'entities': [(113, 126, 'B_Disease'), (138, 154, 'B_Disease'), (155, 163, 'I_Disease'), (178, 193, 'B_Disease'), (194, 202, 'I_Disease')]}], ['Negative symptom outcomes and measures of parkinsonism and akathisia did not differ between medications .', {'entities': [(42, 54, 'B_Disease'), (59, 68, 'B_Disease')]}], ['Extrapyramidal symptom severity scores were 1 . 4 ( 95 % CI = 1 . 2 - 1 . 6 ) with risperidone and 1 . 2 ( 95 % CI = 1 . 0 - 1 . 4 ) with olanzapine .', {'entities': [(0, 14, 'B_Disease'), (15, 22, 'I_Disease')]}], ['Significantly more weight gain occurred with olanzapine than with risperidone : the increase in weight at 4 months relative to baseline weight was 17 . 3 % ( 95 % CI = 14 . 2 % - 20 . 5 % ) with olanzapine and 11 . 3 % ( 95 % CI = 8 . 4 % - 14 . 3 % ) with risperidone .', {'entities': [(19, 25, 'B_Disease'), (26, 30, 'I_Disease')]}], ['Both medications caused substantial rapid weight gain , but weight gain was greater with olanzapine .', {'entities': [(42, 48, 'B_Disease'), (49, 53, 'I_Disease'), (60, 66, 'B_Disease'), (67, 71, 'I_Disease')]}], ['Early paracentral visual field loss in patients taking hydroxychloroquine .', {'entities': [(18, 24, 'B_Disease'), (25, 30, 'I_Disease'), (31, 35, 'I_Disease')]}], ['Thirty - five patients ( 13 . 4 % ) had visual field abnormalities , which were attributed to hydroxychloroquine treatment in 4 patients ( 1 . 5 % ) .', {'entities': [(40, 46, 'B_Disease'), (47, 52, 'I_Disease'), (53, 66, 'I_Disease')]}], ['CONCLUSIONS : The current study used a protocol of visual acuity and color vision assessment , funduscopy , and Humphrey 10 - 2 visual field testing and shows that visual field defects appeared before any corresponding changes in any other tested clinical parameters ; the defects were reproducible and the test parameters were reliable .', {'entities': [(164, 170, 'B_Disease'), (171, 176, 'I_Disease'), (177, 184, 'I_Disease')]}], ['Peri - operative atrioventricular block as a result of chemotherapy with epirubicin and paclitaxel .', {'entities': [(17, 33, 'B_Disease'), (34, 39, 'I_Disease')]}], ['A 47 - year - old woman presented for mastectomy and immediate latissimus dorsi flap reconstruction having been diagnosed with carcinoma of the breast 6 months previously .', {'entities': [(127, 136, 'B_Disease'), (137, 139, 'I_Disease'), (140, 143, 'I_Disease'), (144, 150, 'I_Disease')]}], ['She was found to be bradycardic at pre - operative assessment but had no cardiac symptoms .', {'entities': [(20, 31, 'B_Disease')]}], ['Second degree Mobitz type II atrioventricular block was diagnosed on electrocardiogram , and temporary transvenous ventricular pacing instituted in the peri - operative period .', {'entities': [(29, 45, 'B_Disease'), (46, 51, 'I_Disease')]}], ['We discuss how evidence - based guidelines would not have been helpful in this case , and how chemotherapy can exhibit substantial cardiotoxicity that may develop over many years .', {'entities': [(131, 145, 'B_Disease')]}], ['OBJECTIVES : The risk of acute myocardial infarction ( AMI ) with COX - 2 inhibitors may offset their gastrointestinal ( GI ) benefit compared with non - selective ( NS ) non - steroidal anti - inflammatory drugs ( NSAIDs ) .', {'entities': [(25, 30, 'B_Disease'), (31, 41, 'I_Disease'), (42, 52, 'I_Disease'), (55, 58, 'B_Disease')]}], ['We aimed to compare the risks of hospitalization for AMI and GI bleeding among elderly patients using COX - 2 inhibitors , NS - NSAIDs and acetaminophen .', {'entities': [(53, 56, 'B_Disease'), (61, 63, 'B_Disease'), (64, 72, 'I_Disease')]}], ['Among non - users of aspirin , the adjusted hazard ratios ( 95 % confidence interval ) of hospitalization for AMI / GI vs the acetaminophen ( with no aspirin ) group were : rofecoxib 1 . 27 ( 1 . 13 , 1 . 42 ) , celecoxib 0 . 93 ( 0 . 83 , 1 . 03 ) , naproxen 1 . 59 ( 1 . 31 , 1 . 93 ) , diclofenac 1 . 17 ( 0 . 99 , 1 . 38 ) and ibuprofen 1 . 05 ( 0 . 74 , 1 . 51 ) .', {'entities': [(110, 113, 'B_Disease')]}], ['CONCLUSION : Among non - users of aspirin , naproxen seemed to carry the highest risk for AMI / GI bleeding .', {'entities': [(90, 93, 'B_Disease'), (96, 98, 'B_Disease'), (99, 107, 'I_Disease')]}], ['The AMI / GI toxicity of celecoxib was similar to that of acetaminophen and seemed to be better than those of rofecoxib and NS - NSAIDs .', {'entities': [(4, 7, 'B_Disease'), (13, 21, 'B_Disease')]}], ['Quinine - induced arrhythmia in a patient with severe malaria .', {'entities': [(18, 28, 'B_Disease'), (47, 53, 'B_Disease'), (54, 61, 'I_Disease')]}], ['It was reported that there was a case of severe malaria patient with jaundice who presented with arrhythmia ( premature ventricular contraction ) while getting quinine infusion was reported .', {'entities': [(41, 47, 'B_Disease'), (48, 55, 'I_Disease'), (69, 77, 'B_Disease'), (97, 107, 'B_Disease'), (110, 119, 'B_Disease'), (120, 131, 'I_Disease'), (132, 143, 'I_Disease')]}], ['A man , 25 years old , was admitted to hospital with high fever , chill , vomiting , jaundice .', {'entities': [(58, 63, 'B_Disease'), (66, 71, 'B_Disease'), (74, 82, 'B_Disease'), (85, 93, 'B_Disease')]}], ['On admission , laboratory examination showed Plasmodium falciparum ( + + + + ) , total bilirubin 8 . 25 mg / dL , conjugated bilirubin 4 . 36 mg / dL , unconjugated bilirubin 3 . 89 mg / dL , potassium 3 . 52 meq / L Patient was diagnosed as severe malaria with jaundice and got quinine infusion in dextrose 5 % 500 mg / 8 hour .', {'entities': [(242, 248, 'B_Disease'), (249, 256, 'I_Disease'), (262, 270, 'B_Disease')]}], ['On the second day the patient had vomitus , diarrhea , tinnitus , loss of hearing .', {'entities': [(34, 41, 'B_Disease'), (44, 52, 'B_Disease'), (55, 63, 'B_Disease'), (66, 70, 'B_Disease'), (71, 73, 'I_Disease'), (74, 81, 'I_Disease')]}], ['After 30 hours of quinine infusion the patient felt palpitation and electrocardiography ( ECG ) recording showed premature ventricular contraction ( PVC ) > 5 x / minute , trigemini , constant type - - sinoatrial block , positive U wave .', {'entities': [(52, 63, 'B_Disease'), (113, 122, 'B_Disease'), (123, 134, 'I_Disease'), (135, 146, 'I_Disease'), (149, 152, 'B_Disease'), (202, 212, 'B_Disease'), (213, 218, 'I_Disease')]}], ['Three hours later the patient felt better , the frequency of PVC reduced to 4 - 5 x / minute and on the third day ECG was normal , potassium level was 3 . 34 meq / L .', {'entities': [(61, 64, 'B_Disease')]}], ['Quinine , like quinidine , is a chincona alkaloid that has anti - arrhythmic property , although it also pro - arrhythmic that can cause various arrhythmias , including severe arrhythmia such as multiple PVC .', {'entities': [(66, 76, 'B_Disease'), (111, 121, 'B_Disease'), (145, 156, 'B_Disease'), (176, 186, 'B_Disease'), (204, 207, 'B_Disease')]}], ['Administration of parenteral quinine must be done carefully and with good observation because of its pro - arrhythmic effect , especially in older patients who have heart diseases or patients with electrolyte disorder ( hypokalemia ) which frequently occurs due to vomiting and or diarrhea in malaria cases .', {'entities': [(107, 117, 'B_Disease'), (165, 170, 'B_Disease'), (171, 179, 'I_Disease'), (197, 208, 'B_Disease'), (209, 217, 'I_Disease'), (220, 231, 'B_Disease'), (265, 273, 'B_Disease'), (281, 289, 'B_Disease'), (293, 300, 'B_Disease')]}], ['Penicillamine - related lichenoid dermatitis and utility of zinc acetate in a Wilson disease patient with hepatic presentation , anxiety and SPECT abnormalities .', {'entities': [(24, 33, 'B_Disease'), (34, 44, 'I_Disease'), (78, 84, 'B_Disease'), (85, 92, 'I_Disease'), (129, 136, 'B_Disease')]}], [\"Wilson ' s disease is an autosomal recessive disorder of hepatic copper metabolism with consequent copper accumulation and toxicity in many tissues and consequent hepatic , neurologic and psychiatric disorders .\", {'entities': [(0, 6, 'B_Disease'), (7, 8, 'I_Disease'), (9, 10, 'I_Disease'), (11, 18, 'I_Disease'), (123, 131, 'B_Disease'), (163, 170, 'B_Disease'), (171, 172, 'I_Disease'), (173, 183, 'I_Disease'), (184, 187, 'I_Disease'), (188, 199, 'I_Disease'), (200, 209, 'I_Disease')]}], [\"We report a case of Wilson ' s disease with chronic liver disease ; moreover , in our patient , presenting also with high levels of state anxiety without depression , 99mTc - ECD - SPECT showed cortical hypoperfusion in frontal lobes , more marked on the left frontal lobe .\", {'entities': [(20, 26, 'B_Disease'), (27, 28, 'I_Disease'), (29, 30, 'I_Disease'), (31, 38, 'I_Disease'), (44, 51, 'B_Disease'), (52, 57, 'I_Disease'), (58, 65, 'I_Disease'), (138, 145, 'B_Disease'), (154, 164, 'B_Disease')]}], ['During the follow - up of our patient , penicillamine was interrupted after the appearance of a lichenoid dermatitis , and zinc acetate permitted to continue the successful treatment of the patient without side - effects .', {'entities': [(96, 105, 'B_Disease'), (106, 116, 'I_Disease')]}], [\"In our case the therapy with zinc acetate represented an effective treatment for a Wilson ' s disease patient in which penicillamine - related side effects appeared .\", {'entities': [(83, 89, 'B_Disease'), (90, 91, 'I_Disease'), (92, 93, 'I_Disease'), (94, 101, 'I_Disease')]}], [\"The safety of the zinc acetate allowed us to avoid other potentially toxic chelating drugs ; this observation is in line with the growing evidence on the efficacy of the drug in the treatment of Wilson ' s disease .\", {'entities': [(195, 201, 'B_Disease'), (202, 203, 'I_Disease'), (204, 205, 'I_Disease'), (206, 213, 'I_Disease')]}], [\"Since most of Wilson ' s disease penicillamine - treated patients do not seem to develop this skin lesion , it could be conceivable that a specific genetic factor is involved in drug response .\", {'entities': [(14, 20, 'B_Disease'), (21, 22, 'I_Disease'), (23, 24, 'I_Disease'), (25, 32, 'I_Disease'), (94, 98, 'B_Disease'), (99, 105, 'I_Disease')]}], [\"Further studies are needed for a better clarification of Wilson ' s disease therapy , and in particular to differentiate specific therapies for different Wilson ' s disease phenotypes .\", {'entities': [(57, 63, 'B_Disease'), (64, 65, 'I_Disease'), (66, 67, 'I_Disease'), (68, 75, 'I_Disease'), (154, 160, 'B_Disease'), (161, 162, 'I_Disease'), (163, 164, 'I_Disease'), (165, 172, 'I_Disease')]}], ['A dramatic drop in blood pressure following prehospital GTN administration .', {'entities': [(11, 15, 'B_Disease'), (16, 18, 'I_Disease'), (19, 24, 'I_Disease'), (25, 33, 'I_Disease')]}], ['A male in his sixties with no history of cardiac chest pain awoke with chest pain following an afternoon sleep .', {'entities': [(49, 54, 'B_Disease'), (55, 59, 'I_Disease'), (71, 76, 'B_Disease'), (77, 81, 'I_Disease')]}], ['Several minutes after the GTN the patient experienced a sudden drop in blood pressure and heart rate , this was rectified by atropine sulphate and a fluid challenge .', {'entities': [(63, 67, 'B_Disease'), (68, 70, 'I_Disease'), (71, 76, 'I_Disease'), (77, 85, 'I_Disease')]}], ['Prehospital care providers who are managing any patient with a syncopal episode that fails to recover within a reasonable time frame should consider the Bezold - Jarisch reflex as the cause and manage the patient accordingly .', {'entities': [(63, 71, 'B_Disease'), (72, 79, 'I_Disease')]}], ['Chronic lesion of rostral ventrolateral medulla in spontaneously hypertensive rats .', {'entities': [(65, 77, 'B_Disease')]}], ['We studied the effects of chronic selective neuronal lesion of rostral ventrolateral medulla on mean arterial pressure , heart rate , and neurogenic tone in conscious , unrestrained spontaneously hypertensive rats .', {'entities': [(196, 208, 'B_Disease')]}], ['The trimethaphan - induced hypotension was accompanied by a significant bradycardia in lesioned rats ( - 32 + / - 13 beats per minute ) but a tachycardia in sham rats ( + 33 + / - 12 beats per minute ) 1 day postlesion .', {'entities': [(27, 38, 'B_Disease'), (72, 83, 'B_Disease'), (142, 153, 'B_Disease')]}], ['Therefore , rostral ventrolateral medulla neurons appear to play a significant role in maintaining hypertension in conscious spontaneously hypertensive rats .', {'entities': [(99, 111, 'B_Disease'), (139, 151, 'B_Disease')]}], ['Spinal or suprabulbar structures could be responsible for the gradual recovery of the hypertension in the lesioned rats .', {'entities': [(86, 98, 'B_Disease')]}], ['Acute encephalopathy and cerebral vasospasm after multiagent chemotherapy including PEG - asparaginase and intrathecal cytarabine for the treatment of acute lymphoblastic leukemia .', {'entities': [(0, 5, 'B_Disease'), (6, 20, 'I_Disease'), (25, 33, 'B_Disease'), (34, 43, 'I_Disease'), (151, 156, 'B_Disease'), (157, 170, 'I_Disease'), (171, 179, 'I_Disease')]}], ['A 7 - year - old girl with an unusual reaction to induction chemotherapy for precursor B - cell acute lymphoblastic leukemia ( ALL ) is described .', {'entities': [(96, 101, 'B_Disease'), (102, 115, 'I_Disease'), (116, 124, 'I_Disease'), (127, 130, 'B_Disease')]}], ['The patient developed acute encephalopathy evidenced by behavioral changes , aphasia , incontinence , visual hallucinations , and right - sided weakness with diffuse cerebral vasospasm on magnetic resonance angiography after the administration of intrathecal cytarabine .', {'entities': [(22, 27, 'B_Disease'), (28, 42, 'I_Disease'), (77, 84, 'B_Disease'), (87, 99, 'B_Disease'), (102, 108, 'B_Disease'), (109, 123, 'I_Disease'), (144, 152, 'B_Disease'), (166, 174, 'B_Disease'), (175, 184, 'I_Disease')]}], ['Comparison of valsartan / hydrochlorothiazide combination therapy at doses up to 320 / 25 mg versus monotherapy : a double - blind , placebo - controlled study followed by long - term combination therapy in hypertensive adults .', {'entities': [(207, 219, 'B_Disease')]}], ['BACKGROUND : One third of patients treated for hypertension attain adequate blood pressure ( BP ) control , and multidrug regimens are often required .', {'entities': [(47, 59, 'B_Disease')]}], ['Given the lifelong nature of hypertension , there is a need to evaluate the long - term efficacy and tolerability of higher doses of combination anti - hypertensive therapies .', {'entities': [(29, 41, 'B_Disease'), (152, 164, 'B_Disease')]}], ['OBJECTIVE : This study investigated the efficacy and tolerability of valsartan ( VAL ) or hydrochlorothiazide ( HCTZ ) - monotherapy and higher - dose combinations in patients with essential hypertension .', {'entities': [(181, 190, 'B_Disease'), (191, 203, 'I_Disease')]}], ['Patients with essential hypertension ( mean sitting diastolic BP [ MSDBP ] , > or = 95 mm Hg and < 110 mm Hg ) were randomized to 1 of 8 treatment groups : VAL 160 or 320 mg ; HCTZ 12 . 5 or 25 mg ; VAL / HCTZ 160 / 12 . 5 , 320 / 12 . 5 , or 320 / 25 mg ; or placebo .', {'entities': [(14, 23, 'B_Disease'), (24, 36, 'I_Disease')]}], ['The incidence of hypokalemia was lower with VAL / HCTZ combinations ( 1 . 8 % - 6 . 1 % ) than with HCTZ monotherapies ( 7 . 1 % - 13 . 3 % ) .', {'entities': [(17, 28, 'B_Disease')]}], ['CONCLUSIONS : In this study population , combination therapies with VAL / HCTZ were associated with significantly greater BP reductions compared with either monotherapy , were well tolerated , and were associated with less hypokalemia than HCTZ alone .', {'entities': [(223, 234, 'B_Disease')]}], ['Succimer chelation improves learning , attention , and arousal regulation in lead - exposed rats but produces lasting cognitive impairment in the absence of lead exposure .', {'entities': [(118, 127, 'B_Disease'), (128, 138, 'I_Disease')]}], ['OBJECTIVES : The present study was designed to answer these questions , using a rodent model of early childhood Pb exposure and treatment with succimer , a widely used chelating agent for the treatment of Pb poisoning .', {'entities': [(205, 207, 'B_Disease'), (208, 217, 'I_Disease')]}], ['RESULTS : Pb exposure produced lasting impairments in learning , attention , inhibitory control , and arousal regulation , paralleling the areas of dysfunction seen in Pb - exposed children .', {'entities': [(39, 50, 'B_Disease'), (51, 53, 'I_Disease'), (54, 62, 'I_Disease'), (63, 64, 'I_Disease'), (65, 74, 'I_Disease'), (75, 76, 'I_Disease'), (77, 87, 'I_Disease'), (88, 95, 'I_Disease'), (96, 97, 'I_Disease'), (98, 101, 'I_Disease'), (102, 109, 'I_Disease'), (110, 120, 'I_Disease')]}], ['In contrast , succimer treatment of rats not previously exposed to Pb produced lasting and pervasive cognitive and affective dysfunction comparable in magnitude to that produced by the higher Pb exposure regimen .', {'entities': [(101, 110, 'B_Disease'), (111, 114, 'I_Disease'), (115, 124, 'I_Disease'), (125, 136, 'I_Disease')]}], ['CONCLUSIONS : These are the first data , to our knowledge , to show that treatment with any chelating agent can alleviate cognitive deficits due to Pb exposure .', {'entities': [(122, 131, 'B_Disease'), (132, 140, 'I_Disease')]}], ['Caffeine challenge test in panic disorder and depression with panic attacks .', {'entities': [(27, 32, 'B_Disease'), (33, 41, 'I_Disease'), (46, 56, 'B_Disease'), (62, 67, 'B_Disease'), (68, 75, 'I_Disease')]}], ['Our aim was to observe if patients with panic disorder ( PD ) and patients with major depression with panic attacks ( MDP ) ( Diagnostic and Statistical Manual of Mental Disorders , Fourth Edition criteria ) respond in a similar way to the induction of panic attacks by an oral caffeine challenge test .', {'entities': [(40, 45, 'B_Disease'), (46, 54, 'I_Disease'), (57, 59, 'B_Disease'), (80, 85, 'B_Disease'), (86, 96, 'I_Disease'), (102, 107, 'B_Disease'), (108, 115, 'I_Disease'), (118, 121, 'B_Disease'), (163, 169, 'B_Disease'), (170, 179, 'I_Disease'), (253, 258, 'B_Disease'), (259, 266, 'I_Disease')]}], ['We randomly selected 29 patients with PD , 27 with MDP , 25 with major depression without panic attacks ( MD ) , and 28 healthy volunteers .', {'entities': [(38, 40, 'B_Disease'), (51, 54, 'B_Disease'), (65, 70, 'B_Disease'), (71, 81, 'I_Disease'), (90, 95, 'B_Disease'), (96, 103, 'I_Disease'), (106, 108, 'B_Disease')]}], ['In a randomized double - blind experiment performed in 2 occasions 7 days apart , 480 mg caffeine and a caffeine - free ( placebo ) solution were administered in a coffee form and anxiety scales were applied before and after each test .', {'entities': [(180, 187, 'B_Disease')]}], ['A total of 58 . 6 % ( n = 17 ) of patients with PD , 44 . 4 % ( n = 12 ) of patients with MDP , 12 . 0 % ( n = 3 ) of patients with MD , and 7 . 1 % ( n = 2 ) of control subjects had a panic attack after the 480 - mg caffeine challenge test ( chi ( 2 ) ( 3 ) = 16 . 22 , P = . 001 ) .', {'entities': [(48, 50, 'B_Disease'), (90, 93, 'B_Disease'), (132, 134, 'B_Disease'), (185, 190, 'B_Disease'), (191, 197, 'I_Disease')]}], ['The patients with PD and MDP were more sensitive to caffeine than were patients with MD and healthy volunteers .', {'entities': [(18, 20, 'B_Disease'), (25, 28, 'B_Disease'), (85, 87, 'B_Disease')]}], ['No panic attack was observed after the caffeine - free solution intake .', {'entities': [(3, 8, 'B_Disease'), (9, 15, 'I_Disease')]}], ['The patients with MD had a lower heart rate response to the test than all the other groups ( 2 - way analysis of variance , group by time interaction with Greenhouse - Geisser correction : F ( 3 , 762 ) = 2 . 85 , P = . 026 ) .', {'entities': [(18, 20, 'B_Disease')]}], ['Our data suggest that there is an association between panic attacks , no matter if associated with PD or MDP , and hyperreactivity to an oral caffeine challenge test .', {'entities': [(54, 59, 'B_Disease'), (60, 67, 'I_Disease'), (99, 101, 'B_Disease'), (105, 108, 'B_Disease')]}], ['Mitral annuloplasty as a ventricular restoration method for the failing left ventricle : a pilot study .', {'entities': [(64, 71, 'B_Disease'), (72, 76, 'I_Disease'), (77, 86, 'I_Disease')]}], ['BACKGROUND AND AIM OF THE STUDY : Undersized mitral annuloplasty ( MAP ) is effective in patients with dilated cardiomyopathy and functional mitral regurgitation ( MR ) since , as well as addressing the MR , the MAP may also reshape the dilated left ventricular ( LV ) base .', {'entities': [(103, 110, 'B_Disease'), (111, 125, 'I_Disease'), (141, 147, 'B_Disease'), (148, 161, 'I_Disease'), (164, 166, 'B_Disease'), (203, 205, 'B_Disease')]}], ['However , the direct benefits of this possible reshaping on LV function in the absence of underlying MR remain incompletely understood .', {'entities': [(101, 103, 'B_Disease')]}], ['The study aim was to identify these benefits in a canine model of acute heart failure .', {'entities': [(72, 77, 'B_Disease'), (78, 85, 'I_Disease')]}], ['Acute heart failure was induced by propranolol and volume loading after weaning from cardiopulmonary bypass ; an absence of MR was confirmed by echocardiography .', {'entities': [(6, 11, 'B_Disease'), (12, 19, 'I_Disease'), (124, 126, 'B_Disease')]}], ['Data were acquired at baseline , after induction of acute heart failure , and after MAP .', {'entities': [(58, 63, 'B_Disease'), (64, 71, 'I_Disease')]}], ['CONCLUSION : The data acquired suggest that isolated MAP may have certain benefits on LV dimension / function in acute heart failure , even in the absence of MR .', {'entities': [(119, 124, 'B_Disease'), (125, 132, 'I_Disease'), (158, 160, 'B_Disease')]}], ['However , further investigations are warranted in a model of chronic heart failure .', {'entities': [(69, 74, 'B_Disease'), (75, 82, 'I_Disease')]}], ['Piperacillin / tazobactam - induced seizure rapidly reversed by high flux hemodialysis in a patient on peritoneal dialysis .', {'entities': [(36, 43, 'B_Disease')]}], ['Despite popular use of piperacillin , the dire neurotoxicity associated with piperacillin still goes unrecognized , leading to a delay in appropriate management .', {'entities': [(47, 60, 'B_Disease')]}], ['We report a 57 - year - old woman with end - stage renal disease receiving continuous ambulatory peritoneal dialysis ( CAPD ) , who developed slurred speech , tremor , bizarre behavior , progressive mental confusion , and 2 episodes of generalized tonic - clonic seizure ( GTCS ) after 5 doses of piperacillin / tazobactam ( 2 g / 250 mg ) were given for bronchiectasis with secondary infection .', {'entities': [(39, 42, 'B_Disease'), (43, 44, 'I_Disease'), (45, 50, 'I_Disease'), (51, 56, 'I_Disease'), (57, 64, 'I_Disease'), (159, 165, 'B_Disease'), (206, 215, 'B_Disease'), (248, 253, 'B_Disease'), (254, 255, 'I_Disease'), (256, 262, 'I_Disease'), (263, 270, 'I_Disease'), (273, 277, 'B_Disease'), (355, 369, 'B_Disease'), (375, 384, 'B_Disease'), (385, 394, 'I_Disease')]}], ['The laboratory data revealed normal plasma electrolyte and ammonia levels but leukocytosis .', {'entities': [(78, 90, 'B_Disease')]}], ['Neurologic examinations showed dysarthria and bilateral Babinski sign .', {'entities': [(31, 41, 'B_Disease')]}], ['Despite the use of antiepileptic agents , another GTCS episode recurred after the sixth dose of piperacillin / tazobactam .', {'entities': [(50, 54, 'B_Disease')]}], ['Brain magnetic resonance imaging did not demonstrate acute infarction and organic brain lesions .', {'entities': [(59, 69, 'B_Disease'), (74, 81, 'B_Disease'), (82, 87, 'I_Disease'), (88, 95, 'I_Disease')]}], ['Piperacillin - induced encephalopathy should be considered in any uremic patients with unexplained neurological manifestations .', {'entities': [(23, 37, 'B_Disease'), (66, 72, 'B_Disease')]}], ['CAPD is inefficient in removing piperacillin , whereas hemodialysis can rapidly terminate the piperacillin - induced encephalopathy .', {'entities': [(117, 131, 'B_Disease')]}], ['Frequency of transient ipsilateral vocal cord paralysis in patients undergoing carotid endarterectomy under local anesthesia .', {'entities': [(35, 40, 'B_Disease'), (41, 45, 'I_Disease'), (46, 55, 'I_Disease')]}], ['Temporary ipsilateral vocal nerve palsies due to local anesthetics have been described , however .', {'entities': [(22, 27, 'B_Disease'), (28, 33, 'I_Disease'), (34, 41, 'I_Disease')]}], ['Such complications are most important in situations where there is a pre - existing contralateral paralysis .', {'entities': [(98, 107, 'B_Disease')]}], ['Twelve patients ( 43 % ) were found to have intraoperative ipsilateral vocal cord paralysis .', {'entities': [(71, 76, 'B_Disease'), (77, 81, 'I_Disease'), (82, 91, 'I_Disease')]}], ['There were no significant differences in operating time or volume or frequency of anesthetic administration in patients with temporary vocal cord paralysis compared with those without .', {'entities': [(135, 140, 'B_Disease'), (141, 145, 'I_Disease'), (146, 155, 'I_Disease')]}], ['CONCLUSION : Local anesthesia led to temporary ipsilateral vocal cord paralysis in almost half of these patients .', {'entities': [(59, 64, 'B_Disease'), (65, 69, 'I_Disease'), (70, 79, 'I_Disease')]}], ['Because pre - existing paralysis is of a relevant frequency ( up to 3 % ) , a preoperative evaluation of vocal cord function before carotid endarterectomy under local anesthesia is recommended to avoid intraoperative bilateral paralysis .', {'entities': [(23, 32, 'B_Disease'), (227, 236, 'B_Disease')]}], ['In patients with preoperative contralateral vocal cord paralysis , surgery under general anesthesia should be considered .', {'entities': [(44, 49, 'B_Disease'), (50, 54, 'I_Disease'), (55, 64, 'I_Disease')]}], ['Impaired fear recognition in regular recreational cocaine users .', {'entities': [(0, 8, 'B_Disease'), (9, 13, 'I_Disease'), (14, 25, 'I_Disease')]}], ['RESULTS : There were no group differences in psychopathology or \" eyes task \" performance , but the RC group , who otherwise had similar illicit substance use histories to the OC group , exhibited impaired fear recognition accuracy compared to the OC and CN groups .', {'entities': [(197, 205, 'B_Disease'), (206, 210, 'I_Disease'), (211, 222, 'I_Disease')]}], ['The selective deficit in fear recognition accuracy manifested by the RC group cannot be explained by the subacute effects of cocaine , or ecstasy , because recent and less recent users of these drugs within this group were similarly impaired .', {'entities': [(14, 21, 'B_Disease'), (22, 24, 'I_Disease'), (25, 29, 'I_Disease'), (30, 41, 'I_Disease')]}], ['Possible parallels between RC users and psychopaths with respect to impaired fear recognition , amygdala dysfunction , and etiology are discussed .', {'entities': [(40, 51, 'B_Disease'), (68, 76, 'B_Disease'), (77, 81, 'I_Disease'), (82, 93, 'I_Disease'), (96, 104, 'B_Disease'), (105, 116, 'I_Disease')]}], ['Damage of substantia nigra pars reticulata during pilocarpine - induced status epilepticus in the rat : immunohistochemical study of neurons , astrocytes and serum - protein extravasation .', {'entities': [(0, 6, 'B_Disease'), (7, 9, 'I_Disease'), (10, 20, 'I_Disease'), (21, 26, 'I_Disease'), (27, 31, 'I_Disease'), (32, 42, 'I_Disease'), (72, 78, 'B_Disease'), (79, 90, 'I_Disease')]}], ['The substantia nigra has a gating function controlling the spread of epileptic seizure activity .', {'entities': [(69, 78, 'B_Disease'), (79, 86, 'I_Disease')]}], ['Additionally , in models of prolonged status epilepticus the pars reticulata of substantia nigra ( SNR ) suffers from a massive lesion which may arise from a massive metabolic derangement and hyperexcitation developing in the activated SNR .', {'entities': [(28, 37, 'B_Disease'), (38, 44, 'I_Disease'), (45, 56, 'I_Disease'), (166, 175, 'B_Disease'), (176, 187, 'I_Disease')]}], ['In this study , status epilepticus was induced by systemic injection of pilocarpine in rats .', {'entities': [(16, 22, 'B_Disease'), (23, 34, 'I_Disease')]}], ['Animals surviving 20 , 30 , 40 , 60 min , 2 , 3 , 6 hours , 1 , 2 , and 3 days after induction of status epilepticus were perfusion - fixed , and brains processed for immunohistochemical staining of SNR .', {'entities': [(98, 104, 'B_Disease'), (105, 116, 'I_Disease')]}], ['Nissl - staining and antibodies against the neuron - specific calcium - binding protein , parvalbumin , served to detect neuronal damage in SNR .', {'entities': [(121, 129, 'B_Disease'), (130, 136, 'I_Disease')]}], ['Immunohistochemical staining for serum - albumin and immunoglobulins in brain tissue was taken as indicator of blood - brain barrier disturbances and vasogenic edema formation .', {'entities': [(150, 159, 'B_Disease'), (160, 165, 'I_Disease')]}], ['Immunohistochemical staining indicated loss of GFAP - staining already at 30 min after induction of seizures in an oval focus situated in the center of SNR while sparing medial and lateral aspects .', {'entities': [(100, 108, 'B_Disease')]}], ['By 2 hours , parvalbumin - staining changed in the central SNR indicating neuronal damage , and Nissl - staining visualized some neuronal distortion .', {'entities': [(74, 82, 'B_Disease'), (83, 89, 'I_Disease')]}], ['By 6 h , vasogenic edema covered the lesioned SNR .', {'entities': [(9, 18, 'B_Disease'), (19, 24, 'I_Disease'), (37, 45, 'B_Disease'), (46, 49, 'I_Disease')]}], ['In a further group of animals surviving 1 to 5 days , conventional paraffin - sections confirmed the neuronal and glial damage of SNR .', {'entities': [(120, 126, 'B_Disease'), (127, 129, 'I_Disease'), (130, 133, 'I_Disease')]}], ['Both cell elements may suffer in common from metabolic disturbance and neurotransmitter dysfunction as occur during massive status epilepticus .', {'entities': [(71, 87, 'B_Disease'), (88, 99, 'I_Disease'), (124, 130, 'B_Disease'), (131, 142, 'I_Disease')]}], ['Neuroprotective effects of melatonin upon the offspring cerebellar cortex in the rat model of BCNU - induced cortical dysplasia .', {'entities': [(109, 117, 'B_Disease'), (118, 127, 'I_Disease')]}], ['Cortical dysplasia is a malformation characterized by defects in proliferation , migration and maturation .', {'entities': [(0, 8, 'B_Disease'), (9, 18, 'I_Disease')]}], ['This study was designed to evaluate the alterations in offspring rat cerebellum induced by maternal exposure to carmustine - [ 1 , 3 - bis ( 2 - chloroethyl ) - 1 - nitrosoure ] ( BCNU ) and to investigate the effects of exogenous melatonin upon cerebellar BCNU - induced cortical dysplasia , using histological and biochemical analyses .', {'entities': [(272, 280, 'B_Disease'), (281, 290, 'I_Disease')]}], ['Histopathologically , typical findings were observed in the cerebella from the control groups , but the findings consistent with early embryonic development were noted in BCNU - exposed cortical dysplasia group .', {'entities': [(186, 194, 'B_Disease'), (195, 204, 'I_Disease')]}], ['Reduced cardiotoxicity of doxorubicin given in the form of N - ( 2 - hydroxypropyl ) methacrylamide conjugates : and experimental study in the rat .', {'entities': [(8, 22, 'B_Disease')]}], ['A rat model was used to evaluate the general acute toxicity and the late cardiotoxicity of 4 mg / kg doxorubicin ( DOX ) given either as free drug or in the form of three N - ( 2 - hydroxypropyl ) methacrylamide ( HPMA ) copolymer conjugates .', {'entities': [(51, 59, 'B_Disease'), (73, 87, 'B_Disease')]}], ['Throughout the study ( 20 weeks ) , deaths related to cardiotoxicity were observed only in animals that received either free DOX or the mixture of HPMA copolymer and free DOX ; in these cases , histological investigations revealed marked changes in the heart that were consistent with DOX - induced cardiotoxicity .', {'entities': [(54, 68, 'B_Disease'), (299, 313, 'B_Disease')]}], ['Corneal ulcers associated with aerosolized crack cocaine use .', {'entities': [(0, 7, 'B_Disease'), (8, 14, 'I_Disease')]}], ['PURPOSE : We report 4 cases of corneal ulcers associated with drug abuse .', {'entities': [(31, 38, 'B_Disease'), (39, 45, 'I_Disease'), (62, 66, 'B_Disease'), (67, 72, 'I_Disease')]}], ['The pathogenesis of these ulcers and management of these patients are also reviewed .', {'entities': [(26, 32, 'B_Disease')]}], ['METHODS : Review of all cases of corneal ulcers associated with drug abuse seen at our institution from July 2006 to December 2006 .', {'entities': [(33, 40, 'B_Disease'), (41, 47, 'I_Disease'), (64, 68, 'B_Disease'), (69, 74, 'I_Disease')]}], ['RESULTS : Four patients with corneal ulcers associated with crack cocaine use were reviewed .', {'entities': [(29, 36, 'B_Disease'), (37, 43, 'I_Disease')]}], ['All corneal ulcers were cultured , and the patients were admitted to the hospital for intensive topical antibiotic treatment .', {'entities': [(4, 11, 'B_Disease'), (12, 18, 'I_Disease')]}], ['Each patient received comprehensive health care , including medical and substance abuse consultations .', {'entities': [(72, 81, 'B_Disease'), (82, 87, 'I_Disease')]}], ['The infections responded to antibiotic treatment .', {'entities': [(4, 14, 'B_Disease')]}], ['Two patients needed a lateral tarsorrhaphy for persistent epithelial defects .', {'entities': [(58, 68, 'B_Disease'), (69, 76, 'I_Disease')]}], ['CONCLUSIONS : Aerosolized crack cocaine use can be associated with the development of corneal ulcers .', {'entities': [(86, 93, 'B_Disease'), (94, 100, 'I_Disease')]}], ['Drug abuse provides additional challenges for management .', {'entities': [(0, 4, 'B_Disease'), (5, 10, 'I_Disease')]}], ['Not only treatment of their infections but also the overall poor health of the patients and increased risk of noncompliance need to be addressed .', {'entities': [(28, 38, 'B_Disease')]}], ['Comprehensive care may provide the patient the opportunity to discontinue their substance abuse , improve their overall health , and prevent future corneal complications .', {'entities': [(80, 89, 'B_Disease'), (90, 95, 'I_Disease')]}], ['Topical 0 . 025 % capsaicin in chronic post - herpetic neuralgia : efficacy , predictors of response and long - term course .', {'entities': [(39, 43, 'B_Disease'), (44, 45, 'I_Disease'), (46, 54, 'I_Disease'), (55, 64, 'I_Disease')]}], ['In order to evaluate the efficacy , time - course of action and predictors of response to topical capsaicin , 39 patients with chronic post - herpetic neuralgia ( PHN ) , median duration 24 months , were treated with 0 . 025 % capsaicin cream for 8 weeks .', {'entities': [(135, 139, 'B_Disease'), (140, 141, 'I_Disease'), (142, 150, 'I_Disease'), (151, 160, 'I_Disease'), (163, 166, 'B_Disease')]}], ['During therapy the patients rated their pain on a visual analogue scale ( VAS ) and a verbal outcome scale .', {'entities': [(40, 44, 'B_Disease')]}], ['Nineteen patients ( 48 . 7 % ) substantially improved after the 8 - week trial ; 5 ( 12 . 8 % ) discontinued therapy due to side - effects such as intolerable capsaicin - induced burning sensations ( 4 ) or mastitis ( 1 ) ; 15 ( 38 . 5 % ) reported no benefit .', {'entities': [(207, 215, 'B_Disease')]}], [\"Treatment effect was not dependent on patient ' s age , duration or localization of PHN ( trigeminal involvement was excluded ) , sensory disturbance or pain character .\", {'entities': [(84, 87, 'B_Disease'), (130, 137, 'B_Disease'), (138, 149, 'I_Disease'), (153, 157, 'B_Disease')]}], ['If confirmed in controlled trials , the long - term results of this open , non - randomized study might indicate that the analgesic effect of capsaicin in PHN is mediated by both interference with neuropeptide metabolism and morphological changes ( perhaps degeneration ) of nociceptive afferents .', {'entities': [(155, 158, 'B_Disease')]}], ['This study shows that MIP synthase inhibition does not replicate or augment the effects of lithium in the inositol sensitive pilocarpine - induced seizures model .', {'entities': [(147, 155, 'B_Disease')]}], ['Non - steroidal anti - inflammatory drugs - associated acute interstitial nephritis with granular tubular basement membrane deposits .', {'entities': [(61, 73, 'B_Disease'), (74, 83, 'I_Disease')]}], ['Acute tubulo - interstitial nephritis ( ATIN ) is an important cause of acute renal failure resulting from a variety of insults , including immune complex - mediated tubulo - interstitial injury , but drugs such as non - steroidal anti - inflammatory drugs ( NSAIDs ) are a far more frequent cause .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease'), (13, 14, 'I_Disease'), (15, 27, 'I_Disease'), (28, 37, 'I_Disease'), (40, 44, 'B_Disease'), (72, 77, 'B_Disease'), (78, 83, 'I_Disease'), (84, 91, 'I_Disease'), (166, 172, 'B_Disease'), (173, 174, 'I_Disease'), (175, 187, 'I_Disease'), (188, 194, 'I_Disease')]}], ['Overall , as an entity , ATIN remains under - diagnosed , as symptoms resolve spontaneously if the medication is stopped .', {'entities': [(25, 29, 'B_Disease')]}], ['We report on a 14 - year - old boy who developed acute renal failure 2 weeks after aortic valve surgery .', {'entities': [(49, 54, 'B_Disease'), (55, 60, 'I_Disease'), (61, 68, 'I_Disease')]}], ['He was put on aspirin following surgery and took ibuprofen for fever for nearly a week prior to presentation .', {'entities': [(63, 68, 'B_Disease')]}], ['A kidney biopsy showed inflammatory infiltrate consistent with ATIN .', {'entities': [(63, 67, 'B_Disease')]}], ['His renal recovery and disappearance of proteinuria took a year .', {'entities': [(40, 51, 'B_Disease')]}], ['In conclusion , this is a first report of NSAIDs - associated ATIN , showing deposits of granular immune complex present only in the TBM and not in the glomeruli .', {'entities': [(62, 66, 'B_Disease')]}], ['Rifampicin - associated segmental necrotizing glomerulonephritis in staphylococcal endocarditis .', {'entities': [(46, 64, 'B_Disease'), (68, 82, 'B_Disease'), (83, 95, 'I_Disease')]}], ['Segmental necrotising glomerulonephritis has been reported as complication of rifampicin therapy in patients receiving treatment for tuberculosis .', {'entities': [(22, 40, 'B_Disease'), (133, 145, 'B_Disease')]}], ['Changing epidemiology of infections such as infective endocarditis ( IE ) has led to an increase in the use of rifampicin for Staphylococcal infections .', {'entities': [(25, 35, 'B_Disease'), (44, 53, 'B_Disease'), (54, 66, 'I_Disease'), (69, 71, 'B_Disease'), (126, 140, 'B_Disease'), (141, 151, 'I_Disease')]}], ['We describe a case of a patient with Staphylococcal IE who developed acute renal failure secondary to a segmental necrotising glomerulonephritis while being treated with rifampicin , and review the literature regarding this complication of rifampicin therapy .', {'entities': [(37, 51, 'B_Disease'), (52, 54, 'I_Disease'), (69, 74, 'B_Disease'), (75, 80, 'I_Disease'), (81, 88, 'I_Disease'), (126, 144, 'B_Disease')]}], ['Rate of YMDD motif mutants in lamivudine - untreated Iranian patients with chronic hepatitis B virus infection .', {'entities': [(75, 82, 'B_Disease'), (83, 92, 'I_Disease'), (93, 94, 'I_Disease'), (95, 100, 'I_Disease'), (101, 110, 'I_Disease')]}], ['BACKGROUND : Lamivudine is used for the treatment of chronic hepatitis B patients .', {'entities': [(53, 60, 'B_Disease'), (61, 70, 'I_Disease'), (71, 72, 'I_Disease')]}], ['Recent studies show that the YMDD motif mutants ( resistant hepatitis B virus ) occur as natural genome variability in lamivudine - untreated chronic hepatitis B patients .', {'entities': [(60, 69, 'B_Disease'), (70, 71, 'I_Disease'), (142, 149, 'B_Disease'), (150, 159, 'I_Disease'), (160, 161, 'I_Disease')]}], ['In this study we aimed to determine the rate of YMDD motif mutants in lamivudine - untreated chronic hepatitis B patients in Iran .', {'entities': [(93, 100, 'B_Disease'), (101, 110, 'I_Disease'), (111, 112, 'I_Disease')]}], ['PATIENTS AND METHODS : A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study .', {'entities': [(37, 44, 'B_Disease'), (45, 54, 'I_Disease'), (55, 56, 'I_Disease')]}], ['CONCLUSION : Although the natural occurrence of YMDD motif mutants in lamivudine - untreated patients with chronic hepatitis B has been reported , these mutants were not detected in Iranian lamivudine - untreated chronic hepatitis B patients .', {'entities': [(107, 114, 'B_Disease'), (115, 124, 'I_Disease'), (125, 126, 'I_Disease'), (213, 220, 'B_Disease'), (221, 230, 'I_Disease'), (231, 232, 'I_Disease')]}], ['Branch retinal vein occlusion and fluoxetine .', {'entities': [(7, 14, 'B_Disease'), (15, 19, 'I_Disease'), (20, 29, 'I_Disease')]}], ['A case of branch retinal vein occlusion associated with fluoxetine - induced secondary hypertension is described .', {'entities': [(17, 24, 'B_Disease'), (25, 29, 'I_Disease'), (30, 39, 'I_Disease'), (87, 99, 'B_Disease')]}], ['Although an infrequent complication of selective serotonin reuptake inhibitor therapy , it is important that ophthalmologists are aware that these agents can cause hypertension because this class of drugs is widely prescribed .', {'entities': [(164, 176, 'B_Disease')]}], ['The differential effects of bupivacaine and lidocaine on prostaglandin E2 release , cyclooxygenase gene expression and pain in a clinical pain model .', {'entities': [(119, 123, 'B_Disease'), (138, 142, 'B_Disease')]}], ['BACKGROUND : In addition to blocking nociceptive input from surgical sites , long - acting local anesthetics might directly modulate inflammation .', {'entities': [(133, 145, 'B_Disease')]}], ['In the present study , we describe the proinflammatory effects of bupivacaine on local prostaglandin E2 ( PGE2 ) production and cyclooxygenase ( COX ) gene expression that increases postoperative pain in human subjects .', {'entities': [(182, 195, 'B_Disease'), (196, 200, 'I_Disease')]}], ['RESULTS : The bupivacaine / rofecoxib group reported significantly less pain , as assessed by a visual analog scale , compared with the other three treatment groups over the first 4 h .', {'entities': [(72, 76, 'B_Disease')]}], ['However , the bupivacaine / placebo group reported significantly more pain at 24 h and PGE2 levels during the first 4 h were significantly higher than the other three treatment groups .', {'entities': [(70, 74, 'B_Disease')]}], ['CONCLUSIONS : These results suggest that bupivacaine stimulates COX - 2 gene expression after tissue injury , which is associated with higher PGE2 production and pain after the local anesthetic effect dissipates .', {'entities': [(94, 100, 'B_Disease'), (101, 107, 'I_Disease'), (162, 166, 'B_Disease')]}], ['p75NTR expression in rat urinary bladder sensory neurons and spinal cord with cyclophosphamide - induced cystitis .', {'entities': [(105, 113, 'B_Disease')]}], ['Previous studies have examined the expression and regulation of tyrosine kinase receptors ( Trks ) in micturition reflexes with urinary bladder inflammation .', {'entities': [(128, 135, 'B_Disease'), (136, 143, 'I_Disease'), (144, 156, 'I_Disease')]}], ['The present studies examine the expression and regulation of another receptor known to bind NGF , p75 ( NTR ) , after various durations of bladder inflammation induced by cyclophosphamide ( CYP ) .', {'entities': [(139, 146, 'B_Disease'), (147, 159, 'I_Disease')]}], ['CYP - induced cystitis increased ( P < or = 0 . 001 ) p75 ( NTR ) expression in the superficial lateral and medial dorsal horn in L1 - L2 and L6 - S1 spinal segments .', {'entities': [(14, 22, 'B_Disease')]}], ['The number of p75 ( NTR ) - immunoreactive ( - IR ) cells in the lumbosacral dorsal root ganglia ( DRG ) also increased ( P < or = 0 . 05 ) with CYP - induced cystitis ( acute , intermediate , and chronic ) .', {'entities': [(159, 167, 'B_Disease')]}], ['Quantitative , real - time polymerase chain reaction also demonstrated significant increases ( P < or = 0 . 01 ) in p75 ( NTR ) mRNA in DRG with intermediate and chronic CYP - induced cystitis .', {'entities': [(184, 192, 'B_Disease')]}], ['In bladder afferent cells in DRG , p75 ( NTR ) - IR was also increased ( P < or = 0 . 01 ) with cystitis .', {'entities': [(96, 104, 'B_Disease')]}], ['These studies demonstrate that p75 ( NTR ) expression in micturition reflexes is present constitutively and modified by bladder inflammation .', {'entities': [(120, 127, 'B_Disease'), (128, 140, 'I_Disease')]}], ['The side effects of azathioprine include anemia , which has been attributed to bone marrow suppression .', {'entities': [(41, 47, 'B_Disease')]}], ['Alternatively , anemia could result from accelerated suicidal erythrocyte death or eryptosis , which is characterized by exposure of phosphatidylserine ( PS ) at the erythrocyte surface and by cell shrinkage .', {'entities': [(16, 22, 'B_Disease')]}], ['CONCLUSIONS : Azathioprine triggers suicidal erythrocyte death , an effect presumably contributing to azathioprine - induced anemia .', {'entities': [(125, 131, 'B_Disease')]}], ['Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy .', {'entities': [(78, 88, 'B_Disease'), (89, 97, 'I_Disease')]}], ['OBJECTIVE : To assess pharmacokinetics , efficacy , and tolerability of oral levetiracetam administered as an adjunct to phenobarbital treatment in cats with poorly controlled suspected idiopathic epilepsy .', {'entities': [(186, 196, 'B_Disease'), (197, 205, 'I_Disease')]}], ['ANIMALS : 12 cats suspected to have idiopathic epilepsy that was poorly controlled with phenobarbital or that had unacceptable adverse effects when treated with phenobarbital .', {'entities': [(36, 46, 'B_Disease'), (47, 55, 'I_Disease')]}], ['Seizure frequencies before and after initiation of levetiracetam treatment were compared , and adverse effects were recorded .', {'entities': [(0, 7, 'B_Disease')]}], ['Median seizure frequency prior to treatment with levetiracetam ( 2 . 1 seizures / mo ) was significantly higher than median seizure frequency after initiation of levetiracetam treatment ( 0 . 42 seizures / mo ) , and 7 of 10 cats were classified as having responded to levetiracetam treatment ( ie , reduction in seizure frequency of > or = 50 % ) .', {'entities': [(7, 14, 'B_Disease'), (71, 79, 'B_Disease'), (124, 131, 'B_Disease'), (195, 203, 'B_Disease'), (313, 320, 'B_Disease')]}], ['Two cats had transient lethargy and inappetence .', {'entities': [(23, 31, 'B_Disease'), (36, 47, 'B_Disease')]}], ['CONCLUSIONS AND CLINICAL RELEVANCE : Results suggested that levetiracetam is well tolerated in cats and may be useful as an adjunct to phenobarbital treatment in cats with idiopathic epilepsy .', {'entities': [(172, 182, 'B_Disease'), (183, 191, 'I_Disease')]}], ['Serotonin reuptake inhibitors , paranoia , and the ventral basal ganglia .', {'entities': [(32, 40, 'B_Disease')]}], ['Antidepressants have previously been associated with paranoid reactions in psychiatric patients .', {'entities': [(53, 61, 'B_Disease')]}], ['Five cases of paranoid exacerbation with the serotonin reuptake inhibitors fluoxetine and amitriptyline are reported here .', {'entities': [(14, 22, 'B_Disease')]}], ['Elements common to these cases included a history of paranoid symptomatology and the concomitant occurrence of depressive and psychotic symptoms .', {'entities': [(53, 61, 'B_Disease'), (111, 121, 'B_Disease'), (122, 125, 'I_Disease'), (126, 135, 'I_Disease'), (136, 144, 'I_Disease')]}], ['Complicated depressive disorders ( including atypicality of course and symptomatology , chronicity , psychosis , bipolarity , and secondary onset in the course of a primary psychosis ) may present particular vulnerability to paranoid exacerbations associated with serotonin reuptake inhibitors .', {'entities': [(12, 22, 'B_Disease'), (23, 32, 'I_Disease'), (101, 110, 'B_Disease'), (173, 182, 'B_Disease'), (225, 233, 'B_Disease')]}], ['Although the pharmacology and neurobiology of paranoia remain cryptic , several mechanisms , including 5HT3 receptor - mediated dopamine release , beta - noradrenergic receptor downregulation , or GABAB receptor upregulation acting in the vicinity of the ventral basal ganglia ( possibly in lateral orbitofrontal or anterior cingulate circuits ) , might apply to this phenomenon .', {'entities': [(46, 54, 'B_Disease')]}], ['These cases call attention to possible paranoid exacerbations with serotonin reuptake blockers in select patients and raise neurobiological considerations regarding paranoia .', {'entities': [(39, 47, 'B_Disease'), (165, 173, 'B_Disease')]}], ['BACKGROUND : Spinal anaesthesia is widely employed in clinical practice but has the main drawback of post - spinal block hypotension .', {'entities': [(121, 132, 'B_Disease')]}], ['RESULTS : Three patients ( 8 . 1 % ) in the unilateral group and 5 ( 13 . 5 % ) in the conventional group developed hypotension , P = 0 . 71 .', {'entities': [(116, 127, 'B_Disease')]}], ['Four ( 10 . 8 % ) patients in the conventional group and 1 ( 2 . 7 % ) in the unilateral group , P = 0 . 17 required epinephrine infusion to treat hypotension .', {'entities': [(147, 158, 'B_Disease')]}], ['Spectrum of adverse events after generic HAART in southern Indian HIV - infected patients .', {'entities': [(66, 69, 'B_Disease'), (70, 71, 'I_Disease'), (72, 80, 'I_Disease')]}], ['To determine the incidence of clinically significant adverse events after long - term , fixed - dose , generic highly active antiretroviral therapy ( HAART ) use among HIV - infected individuals in South India , we examined the experiences of 3154 HIV - infected individuals who received a minimum of 3 months of generic HAART between February 1996 and December 2006 at a tertiary HIV care referral center in South India .', {'entities': [(168, 171, 'B_Disease'), (172, 173, 'I_Disease'), (174, 182, 'I_Disease'), (248, 251, 'B_Disease'), (252, 253, 'I_Disease'), (254, 262, 'I_Disease')]}], ['The most common adverse events and median CD4 at time of event were rash ( 15 . 2 % ; CD4 , 285 cells / microL ) and peripheral neuropathy ( 9 . 0 % and 348 cells / microL ) .', {'entities': [(68, 72, 'B_Disease'), (117, 127, 'B_Disease'), (128, 138, 'I_Disease')]}], ['Clinically significant anemia ( hemoglobin < 7 g / dL ) was observed in 5 . 4 % of patients ( CD4 , 165 cells / microL ) and hepatitis ( clinical jaundice with alanine aminotransferase > 5 times upper limits of normal ) in 3 . 5 % of patients ( CD4 , 260 cells / microL ) .', {'entities': [(23, 29, 'B_Disease'), (125, 134, 'B_Disease'), (146, 154, 'B_Disease')]}], ['Women were significantly more likely to experience lactic acidosis , while men were significantly more likely to experience immune reconstitution syndrome ( p < 0 . 05 ) .', {'entities': [(51, 57, 'B_Disease'), (58, 66, 'I_Disease'), (124, 130, 'B_Disease'), (131, 145, 'I_Disease'), (146, 154, 'I_Disease')]}], ['Among the patients with 1 year of follow - up , NVP therapy was significantly associated with developing rash and d4T therapy with developing peripheral neuropathy ( p < 0 . 05 ) .', {'entities': [(105, 109, 'B_Disease'), (142, 152, 'B_Disease'), (153, 163, 'I_Disease')]}], ['Anemia and hepatitis often occur within 12 weeks of initiating generic HAART .', {'entities': [(0, 6, 'B_Disease'), (11, 20, 'B_Disease')]}], ['Frequent and early monitoring for these toxicities is warranted in developing countries where generic HAART is increasingly available .', {'entities': [(40, 50, 'B_Disease')]}], ['Thalidomide and sensory neurotoxicity : a neurophysiological study .', {'entities': [(16, 23, 'B_Disease'), (24, 37, 'I_Disease')]}], ['BACKGROUND : Recent studies confirmed a high incidence of sensory axonal neuropathy in patients treated with different doses of thalidomide .', {'entities': [(58, 65, 'B_Disease'), (66, 72, 'I_Disease'), (73, 83, 'I_Disease')]}], [\"The study ' s aims were to measure variations in sural nerve sensory action potential ( SAP ) amplitude in patients with refractory cutaneous lupus erythematosus ( CLE ) treated with thalidomide and use these findings to identify the neurotoxic potential of thalidomide and the recovery capacity of sensory fibres after discontinuation of treatment .\", {'entities': [(132, 141, 'B_Disease'), (142, 147, 'I_Disease'), (148, 161, 'I_Disease'), (164, 167, 'B_Disease'), (234, 244, 'B_Disease')]}], ['PATIENTS AND METHODS : Clinical and electrophysiological data in 12 female patients with CLE during treatment with thalidomide and up to 47 months after discontinuation of treatment were analysed .', {'entities': [(89, 92, 'B_Disease')]}], ['Five patients complained of paresthesias and leg cramps .', {'entities': [(28, 40, 'B_Disease'), (49, 55, 'B_Disease')]}], ['The threshold neurotoxic dosage is lower than previously reported .', {'entities': [(14, 24, 'B_Disease')]}], ['This electrophysiological parameter provides information about subclinical neurotoxic potential of thalidomide but is not helpful in predicting the appearance of sensory symptoms .', {'entities': [(75, 85, 'B_Disease')]}], ['Five cases of encephalitis during treatment of loiasis with diethylcarbamazine .', {'entities': [(14, 26, 'B_Disease'), (47, 54, 'B_Disease')]}], ['Five cases of encephalitis following treatment with diethylcarbamazine ( DEC ) were observed in Congolese patients with Loa loa filariasis .', {'entities': [(14, 26, 'B_Disease'), (128, 138, 'B_Disease')]}], ['The relationship between the occurrence of encephalitis and the decrease in microfilaremia is evident .', {'entities': [(43, 55, 'B_Disease'), (76, 90, 'B_Disease')]}], ['Amiodarone - related pulmonary mass and unique membranous glomerulonephritis in a patient with valvular heart disease : Diagnostic pitfall and new findings .', {'entities': [(21, 30, 'B_Disease'), (31, 35, 'I_Disease'), (47, 57, 'B_Disease'), (58, 76, 'I_Disease'), (95, 103, 'B_Disease'), (104, 109, 'I_Disease'), (110, 117, 'I_Disease')]}], ['Amiodarone is an anti - arrhythmic drug for life - threatening tachycardia , but various adverse effects have been reported .', {'entities': [(24, 34, 'B_Disease'), (63, 74, 'B_Disease')]}], ['Reported herein is an autopsy case of valvular heart disease , in a patient who developed a lung mass ( 1 . 5 cm in diameter ) and proteinuria ( 2 . 76 g / day ) after treatment with amiodarone for a long time .', {'entities': [(38, 46, 'B_Disease'), (47, 52, 'I_Disease'), (53, 60, 'I_Disease'), (92, 96, 'B_Disease'), (97, 101, 'I_Disease'), (131, 142, 'B_Disease')]}], ['The lung mass was highly suspected to be lung cancer on CT and positron emission tomography , but histologically the lesion was composed of lymphoplasmacytic infiltrates in alveolar walls and intra - alveolar accumulation of foamy macrophages containing characteristic myelinoid bodies , indicating that it was an amiodarone - related lesion .', {'entities': [(4, 8, 'B_Disease'), (9, 13, 'I_Disease'), (41, 45, 'B_Disease'), (46, 52, 'I_Disease')]}], ['In addition , the lung tissue had unevenly distributed hemosiderin deposition , and abnormally tortuous capillaries were seen in the mass and in heavily hemosiderotic lung portions outside the mass .', {'entities': [(55, 66, 'B_Disease'), (153, 166, 'B_Disease')]}], ['Autoimmune diseases , viral hepatitis , malignant neoplasms or other diseases with a known relationship to membranous glomerulonephritis were not found .', {'entities': [(0, 10, 'B_Disease'), (11, 19, 'I_Disease'), (22, 27, 'B_Disease'), (28, 37, 'I_Disease'), (50, 59, 'B_Disease'), (107, 117, 'B_Disease'), (118, 136, 'I_Disease')]}], ['The present case highlights the possibility that differential diagnosis between an amiodarone - related pulmonary lesion and a neoplasm can be very difficult radiologically , and suggests that membranous glomerulonephritis might be another possible complication of amiodarone treatment .', {'entities': [(104, 113, 'B_Disease'), (114, 120, 'I_Disease'), (127, 135, 'B_Disease'), (193, 203, 'B_Disease'), (204, 222, 'I_Disease')]}], ['Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes : a matched case - control study .', {'entities': [(8, 16, 'B_Disease'), (17, 23, 'I_Disease'), (24, 31, 'I_Disease'), (97, 101, 'B_Disease'), (102, 103, 'I_Disease'), (104, 112, 'I_Disease')]}], ['AIMS : This study sought to assess the risk of developing coronary artery disease ( CAD ) associated with initial treatment of type 2 diabetes with different sulphonylureas .', {'entities': [(58, 66, 'B_Disease'), (67, 73, 'I_Disease'), (74, 81, 'I_Disease'), (84, 87, 'B_Disease'), (127, 131, 'B_Disease'), (132, 133, 'I_Disease'), (134, 142, 'I_Disease')]}], ['METHODS : In type 2 diabetic patients , cases who developed CAD were compared retrospectively with controls that did not .', {'entities': [(13, 17, 'B_Disease'), (18, 19, 'I_Disease'), (20, 28, 'I_Disease'), (60, 63, 'B_Disease')]}], ['The 20 - year risk of CAD at diagnosis of diabetes , using the UKPDS risk engine , was used to match cases with controls .', {'entities': [(22, 25, 'B_Disease'), (42, 50, 'B_Disease')]}], ['RESULTS : The 76 cases of CAD were compared with 152 controls .', {'entities': [(26, 29, 'B_Disease')]}], ['The hazard of developing CAD ( 95 % CI ) associated with initial treatment increased by 2 . 4 - fold ( 1 . 3 - 4 . 3 , P = 0 . 004 ) with glibenclamide ; 2 - fold ( 0 . 9 - 4 . 6 , P = 0 . 099 ) with glipizide ; 2 . 9 - fold ( 1 . 6 - 5 . 1 , P = 0 . 000 ) with either , and was unchanged with metformin .', {'entities': [(25, 28, 'B_Disease')]}], ['CONCLUSIONS : Initiating treatment of type 2 diabetes with glibenclamide or glipizide is associated with increased risk of CAD in comparison to gliclazide or glimepiride .', {'entities': [(38, 42, 'B_Disease'), (43, 44, 'I_Disease'), (45, 53, 'I_Disease'), (123, 126, 'B_Disease')]}], ['Reduced progression of adriamycin nephropathy in spontaneously hypertensive rats treated by losartan .', {'entities': [(34, 45, 'B_Disease'), (63, 75, 'B_Disease')]}], ['BACKGROUND : The aim of the study was to investigate the antihypertensive effects of angiotensin II type - 1 receptor blocker , losartan , and its potential in slowing down renal disease progression in spontaneously hypertensive rats ( SHR ) with adriamycin ( ADR ) nephropathy .', {'entities': [(173, 178, 'B_Disease'), (179, 186, 'I_Disease'), (216, 228, 'B_Disease'), (266, 277, 'B_Disease')]}], ['RESULTS : Short - term losartan treatment , besides antihypertensive effect , improved glomerular filtration rate and ameliorated glomerulosclerosis resulting in decreased proteinuria .', {'entities': [(130, 148, 'B_Disease'), (172, 183, 'B_Disease')]}], ['Prolonged treatment with losartan showed further reduction of glomerulosclerosis associated with reduced progression of tubular atrophy and interstitial fibrosis , thus preventing heavy proteinuria and chronic renal failure .', {'entities': [(62, 80, 'B_Disease'), (128, 135, 'B_Disease'), (140, 152, 'B_Disease'), (153, 161, 'I_Disease'), (186, 197, 'B_Disease'), (202, 209, 'B_Disease'), (210, 215, 'I_Disease'), (216, 223, 'I_Disease')]}], ['Losartan reduced uraemia and increased urea clearance in advanced ADR nephropathy in SHR .', {'entities': [(17, 24, 'B_Disease'), (70, 81, 'B_Disease')]}], ['Histological examination showed that losartan could prevent tubular atrophy , interstitial infiltration and fibrosis in ADR nephropathy .', {'entities': [(68, 75, 'B_Disease'), (108, 116, 'B_Disease'), (124, 135, 'B_Disease')]}], ['CONCLUSION : Losartan reduces the rate of progression of ADR - induced focal segmental glomerulosclerosis to end - stage renal disease in SHR .', {'entities': [(71, 76, 'B_Disease'), (77, 86, 'I_Disease'), (87, 105, 'I_Disease'), (109, 112, 'B_Disease'), (113, 114, 'I_Disease'), (115, 120, 'I_Disease'), (121, 126, 'I_Disease'), (127, 134, 'I_Disease')]}], ['Postoperatively , a significantly higher incidence of seizures was found in Group T ( 4 . 6 % vs 1 . 2 % , P < 0 . 001 ) .', {'entities': [(54, 62, 'B_Disease')]}], ['Persistent atrial fibrillation ( 7 . 9 % vs 2 . 3 % , P = 0 . 020 ) and renal failure ( 9 . 7 % vs 1 . 7 % , P = 0 . 002 ) were also more common in Group T , in the primary valve surgery subgroup .', {'entities': [(72, 77, 'B_Disease'), (78, 85, 'I_Disease')]}], ['On the contrary , among primary coronary artery bypass surgery patients , there were more acute myocardial infarctions and renal dysfunction in Group A ( 5 . 8 % vs 2 . 0 % , P = 0 . 027 ; 22 . 5 % vs 15 . 2 % , P = 0 . 036 , respectively ) .', {'entities': [(96, 106, 'B_Disease'), (107, 118, 'I_Disease'), (123, 128, 'B_Disease'), (129, 140, 'I_Disease')]}], ['Delirium in an elderly woman possibly associated with administration of misoprostol .', {'entities': [(0, 8, 'B_Disease')]}], ['Misoprostol has been associated with adverse reactions , including gastrointestinal symptoms , gynecologic problems , and headache .', {'entities': [(122, 130, 'B_Disease')]}], ['Her delirium significantly improved after misoprostol was discontinued and her mental status returned to normal within a week .', {'entities': [(4, 12, 'B_Disease')]}], ['Because no other factors related to this patient changed significantly , the delirium experienced by this patient possibly resulted from misoprostol therapy .', {'entities': [(77, 85, 'B_Disease')]}], ['The biological properties of the optical isomers of propranolol and their effects on cardiac arrhythmias .', {'entities': [(85, 92, 'B_Disease'), (93, 104, 'I_Disease')]}], ['Both isomers of propranolol were capable of preventing adrenaline - induced cardiac arrhythmias in cats anaesthetized with halothane , but the mean dose of ( - ) - propranolol was 0 . 09 + / - 0 . 02 mg / kg whereas that of ( + ) - propranolol was 4 . 2 + / - 1 . 2 mg / kg .', {'entities': [(76, 83, 'B_Disease'), (84, 95, 'I_Disease')]}], ['Blockade of arrhythmias with both isomers was surmountable by increasing the dose of adrenaline . 7 .', {'entities': [(12, 23, 'B_Disease')]}], ['Both isomers of propranolol were also capable of reversing ventricular tachycardia caused by ouabain in anaesthetized cats and dogs .', {'entities': [(59, 70, 'B_Disease'), (71, 82, 'I_Disease')]}], ['Topotecan in combination with radiotherapy in unresectable glioblastoma : a phase 2 study .', {'entities': [(59, 71, 'B_Disease')]}], ['Improving glioblastoma multiforme ( GBM ) treatment with radio - chemotherapy remains a challenge .', {'entities': [(10, 22, 'B_Disease'), (23, 33, 'I_Disease'), (36, 39, 'B_Disease')]}], ['Topotecan is an attractive option as it exhibits growth inhibition of human glioma as well as brain penetration .', {'entities': [(76, 82, 'B_Disease')]}], ['The present study assessed the combination of radiotherapy ( 60 Gy / 30 fractions / 40 days ) and topotecan ( 0 . 9 mg / m ( 2 ) / day on days 1 - 5 on weeks 1 , 3 and 5 ) in 50 adults with histologically proven and untreated GBM .', {'entities': [(226, 229, 'B_Disease')]}], ['The incidence of non - hematological toxicities was low and grade 3 - 4 hematological toxicities were reported in 20 patients ( mainly lymphopenia and neutropenia ) .', {'entities': [(37, 47, 'B_Disease'), (86, 96, 'B_Disease'), (135, 146, 'B_Disease'), (151, 162, 'B_Disease')]}], ['However , while response and stabilization concerned one - third of the patients , the study did not show increased benefits in terms of survival in patients with unresectable GBM .', {'entities': [(176, 179, 'B_Disease')]}], ['Long - term lithium therapy leading to hyperparathyroidism : a case report .', {'entities': [(39, 58, 'B_Disease')]}], ['We examined the case of a lithium - treated patient who had recurrent hypercalcemia to better understand the disease process .', {'entities': [(70, 83, 'B_Disease')]}], ['CONCLUSION : Primary hyperparathyroidism is a rare but potentially life - threatening side effect of long - term lithium therapy .', {'entities': [(13, 20, 'B_Disease'), (21, 40, 'I_Disease')]}], ['PRACTICAL IMPLICATIONS : As much as 15 % of lithium - treated patients become hypercalcemic .', {'entities': [(78, 91, 'B_Disease')]}], ['BACKGROUND : The purpose of this study was to compare surgical conditions , including the amount of intraoperative bleeding as well as intraoperative blood pressure , during functional endoscopic sinus surgery ( FESS ) using flexible reinforced laryngeal mask airway ( FRLMA ) versus endotracheal tube ( ETT ) in maintaining controlled hypotension anesthesia induced by propofol - remifentanil total i . v . anesthesia ( TIVA ) .', {'entities': [(115, 123, 'B_Disease'), (336, 347, 'B_Disease')]}], ['METHODS : Sixty normotensive American Society of Anesthesiologists I - II adult patients undergoing FESS under controlled hypotension anesthesia caused by propofol - remifentanil - TIVA were randomly assigned into two groups : group I , FRLMA ; group II , ETT .', {'entities': [(122, 133, 'B_Disease')]}], ['Hemorrhage was measured and the visibility of the operative field was evaluated according to a six - point scale .', {'entities': [(0, 10, 'B_Disease')]}], ['RESULTS : Controlled hypotension was achieved within a shorter period using laryngeal mask using lower rates of remifentanil infusion and lower total dose of remifentanil .', {'entities': [(21, 32, 'B_Disease')]}], ['CONCLUSION : In summary , our results indicate that airway management using FRLMA during controlled hypotension anesthesia provided better surgical conditions in terms of quality of operative field and blood loss and allowed for convenient induced hypotension with low doses of remifentanil during TIVA in patients undergoing FESS .', {'entities': [(100, 111, 'B_Disease'), (248, 259, 'B_Disease')]}], ['Nonalcoholic fatty liver disease during valproate therapy .', {'entities': [(0, 12, 'B_Disease'), (13, 18, 'I_Disease'), (19, 24, 'I_Disease'), (25, 32, 'I_Disease')]}], ['Valproic acid ( VPA ) is effective for the treatment of many types of epilepsy , but its use can be associated with an increase in body weight .', {'entities': [(70, 78, 'B_Disease')]}], ['We report a case of nonalcoholic fatty liver disease ( NAFLD ) arising in a child who developed obesity during VPA treatment .', {'entities': [(20, 32, 'B_Disease'), (33, 38, 'I_Disease'), (39, 44, 'I_Disease'), (45, 52, 'I_Disease'), (55, 60, 'B_Disease'), (96, 103, 'B_Disease')]}], ['Laboratory data revealed hyperinsulinemia with insulin resistance .', {'entities': [(25, 41, 'B_Disease'), (47, 54, 'B_Disease'), (55, 65, 'I_Disease')]}], ['After the withdrawal of VPA therapy , our patient showed a significant weight loss , a decrease of body mass index , and normalization of metabolic and endocrine parameters ; moreover , ultrasound measurements showed a complete normalization .', {'entities': [(71, 77, 'B_Disease'), (78, 82, 'I_Disease')]}], ['The present case suggests that obesity , hyperinsulinemia , insulin resistance , and long - term treatment with VPA may be all associated with the development of NAFLD ; this side effect is reversible after VPA withdrawal .', {'entities': [(31, 38, 'B_Disease'), (41, 57, 'B_Disease'), (60, 67, 'B_Disease'), (68, 78, 'I_Disease'), (162, 167, 'B_Disease')]}], ['Carbimazole induced ANCA positive vasculitis .', {'entities': [(20, 24, 'B_Disease'), (25, 33, 'I_Disease'), (34, 44, 'I_Disease')]}], ['Anti - thyroid drugs , like carbimazole and propylthiouracil ( PTU ) are commonly prescribed for the treatment of hyperthyroidism .', {'entities': [(114, 129, 'B_Disease')]}], ['Antineutrophil cytoplasmic antibody ( ANCA ) - - associated vasculitis is a potentially life - threatening adverse effect of antithyroidmedications .', {'entities': [(0, 14, 'B_Disease'), (15, 26, 'I_Disease'), (27, 35, 'I_Disease'), (36, 37, 'I_Disease'), (38, 42, 'I_Disease'), (43, 44, 'I_Disease'), (45, 46, 'I_Disease'), (47, 48, 'I_Disease'), (49, 59, 'I_Disease'), (60, 70, 'I_Disease')]}], [\"We report a patient with Graves ' disease who developed ANCA positive carbimazole induced vasculitis .\", {'entities': [(25, 31, 'B_Disease'), (32, 33, 'I_Disease'), (34, 41, 'I_Disease'), (90, 100, 'B_Disease')]}], ['The episode was characterized by a vasculitic skin rash associated with large joint arthritis , pyrexia and parotiditis but no renal or pulmonary involvement .', {'entities': [(35, 45, 'B_Disease'), (46, 50, 'B_Disease'), (51, 55, 'I_Disease'), (84, 93, 'B_Disease'), (96, 103, 'B_Disease'), (108, 119, 'B_Disease')]}], ['He was referred to us for neurological evaluation because he had difficulty in getting up from squatting position and was suspected to have myositis .', {'entities': [(140, 148, 'B_Disease')]}], ['To the best of our knowledge this is the first ANCA positive carbimazole induced vasculitis case reported from India .', {'entities': [(81, 91, 'B_Disease')]}], ['BACKGROUND : Coronary heart disease and cerebrovascular disease are leading causes of death in the United States .', {'entities': [(13, 21, 'B_Disease'), (22, 27, 'I_Disease'), (28, 35, 'I_Disease'), (40, 55, 'B_Disease'), (56, 63, 'I_Disease')]}], ['Preventive Services Task Force ( USPSTF ) strongly recommended that clinicians discuss aspirin with adults who are at increased risk for coronary heart disease .', {'entities': [(137, 145, 'B_Disease'), (146, 151, 'I_Disease'), (152, 159, 'I_Disease')]}], ['PURPOSE : To determine the benefits and harms of taking aspirin for the primary prevention of myocardial infarctions , strokes , and death .', {'entities': [(94, 104, 'B_Disease'), (105, 116, 'I_Disease'), (119, 126, 'B_Disease')]}], ['STUDY SELECTION : English - language randomized , controlled trials ( RCTs ) ; case - control studies ; meta - analyses ; and systematic reviews of aspirin versus control for the primary prevention of cardiovascular disease ( CVD ) were selected to answer the following questions : Does aspirin decrease coronary heart events , strokes , death from coronary heart events or stroke , or all - cause mortality in adults without known CVD ?', {'entities': [(201, 215, 'B_Disease'), (216, 223, 'I_Disease'), (226, 229, 'B_Disease'), (328, 335, 'B_Disease'), (374, 380, 'B_Disease'), (432, 435, 'B_Disease')]}], ['Does aspirin increase gastrointestinal bleeding or hemorrhagic strokes ?', {'entities': [(22, 38, 'B_Disease'), (39, 47, 'I_Disease'), (51, 62, 'B_Disease'), (63, 70, 'I_Disease')]}], ['DATA SYNTHESIS : New evidence from 1 good - quality RCT , 1 good - quality meta - analysis , and 2 fair - quality subanalyses of RCTs demonstrates that aspirin use reduces the number of CVD events in patients without known CVD .', {'entities': [(186, 189, 'B_Disease'), (223, 226, 'B_Disease')]}], ['Men in these studies experienced fewer myocardial infarctions and women experienced fewer ischemic strokes .', {'entities': [(39, 49, 'B_Disease'), (50, 61, 'I_Disease'), (99, 106, 'B_Disease')]}], ['Aspirin does not seem to affect CVD mortality or all - cause mortality in either men or women .', {'entities': [(32, 35, 'B_Disease')]}], ['The use of aspirin for primary prevention increases the risk for major bleeding events , primarily gastrointestinal bleeding events , in both men and women .', {'entities': [(71, 79, 'B_Disease'), (99, 115, 'B_Disease'), (116, 124, 'I_Disease')]}], ['Men have an increased risk for hemorrhagic strokes with aspirin use .', {'entities': [(31, 42, 'B_Disease'), (43, 50, 'I_Disease')]}], ['A new RCT and meta - analysis suggest that the risk for hemorrhagic strokes in women is not statistically significantly increased .', {'entities': [(56, 67, 'B_Disease'), (68, 75, 'I_Disease')]}], ['LIMITATIONS : New evidence on aspirin for the primary prevention of CVD is limited .', {'entities': [(68, 71, 'B_Disease')]}], ['CONCLUSION : Aspirin reduces the risk for myocardial infarction in men and strokes in women .', {'entities': [(42, 52, 'B_Disease'), (53, 63, 'I_Disease'), (75, 82, 'B_Disease')]}], ['Aspirin use increases the risk for serious bleeding events .', {'entities': [(43, 51, 'B_Disease')]}], ['Reducing harm associated with anticoagulation : practical considerations of argatroban therapy in heparin - induced thrombocytopenia .', {'entities': [(116, 132, 'B_Disease')]}], ['Argatroban is a hepatically metabolized , direct thrombin inhibitor used for prophylaxis or treatment of thrombosis in heparin - induced thrombocytopenia ( HIT ) and for patients with or at risk of HIT undergoing percutaneous coronary intervention ( PCI ) .', {'entities': [(105, 115, 'B_Disease'), (137, 153, 'B_Disease'), (156, 159, 'B_Disease'), (198, 201, 'B_Disease')]}], ['The objective of this review is to summarize practical considerations of argatroban therapy in HIT .', {'entities': [(95, 98, 'B_Disease')]}], ['The US FDA - recommended argatroban dose in HIT is 2 microg / kg / min ( reduced in patients with hepatic impairment and in paediatric patients ) , adjusted to achieve activated partial thromboplastin times ( aPTTs ) 1 . 5 - 3 times baseline ( not > 100 seconds ) .', {'entities': [(44, 47, 'B_Disease'), (98, 105, 'B_Disease'), (106, 116, 'I_Disease')]}], ['Contemporary experiences indicate that reduced doses are also needed in patients with conditions associated with hepatic hypoperfusion , e . g . heart failure , yet are unnecessary for renal dysfunction , adult age , sex , race / ethnicity or obesity .', {'entities': [(145, 150, 'B_Disease'), (151, 158, 'I_Disease'), (185, 190, 'B_Disease'), (191, 202, 'I_Disease'), (243, 250, 'B_Disease')]}], ['For PCI , argatroban has not been investigated in hepatically impaired patients ; dose adjustment is unnecessary for adult age , sex , race / ethnicity or obesity , and lesser doses may be adequate with concurrent glycoprotein IIb / IIIa inhibition .', {'entities': [(155, 162, 'B_Disease')]}], ['Major bleeding with argatroban is 0 - 10 % in the non - interventional setting and 0 - 5 . 8 % periprocedurally .', {'entities': [(6, 14, 'B_Disease')]}], ['Improved familiarity of healthcare professionals with argatroban therapy in HIT , including in special populations and during PCI , may facilitate reduction of harm associated with HIT ( e . g . fewer thromboses ) or its treatment ( e . g . fewer argatroban medication errors ) .', {'entities': [(76, 79, 'B_Disease'), (181, 184, 'B_Disease')]}], ['Rhabdomyolysis and brain ischemic stroke in a heroin - dependent male under methadone maintenance therapy .', {'entities': [(0, 14, 'B_Disease'), (25, 33, 'B_Disease'), (34, 40, 'I_Disease')]}], ['OBJECTIVE : There are several complications associated with heroin abuse , some of which are life - threatening .', {'entities': [(60, 66, 'B_Disease'), (67, 72, 'I_Disease')]}], ['RESULTS : A 33 - year - old man presented with rhabdomyolysis and cerebral ischemic stroke after intravenous heroin .', {'entities': [(47, 61, 'B_Disease'), (75, 83, 'B_Disease'), (84, 90, 'I_Disease')]}], ['He was found unconsciousness at home and was sent to our hospital .', {'entities': [(13, 28, 'B_Disease')]}], ['In the ICU , we found rhabdomyolysis , acute renal failure and acute respiratory failure .', {'entities': [(22, 36, 'B_Disease'), (39, 44, 'B_Disease'), (45, 50, 'I_Disease'), (51, 58, 'I_Disease'), (69, 80, 'B_Disease'), (81, 88, 'I_Disease')]}], ['After transfer to an internal ward , we noted aphasia and weakness of his left limbs .', {'entities': [(46, 53, 'B_Disease'), (58, 66, 'B_Disease')]}], ['After MRI , we found cerebral ischemic infarction .', {'entities': [(21, 29, 'B_Disease'), (30, 38, 'I_Disease'), (39, 49, 'I_Disease')]}], ['CONCLUSION : Those using methadone and heroin simultaneously may increase risk of rhabdomyolysis and ischemic stroke .', {'entities': [(82, 96, 'B_Disease'), (101, 109, 'B_Disease'), (110, 116, 'I_Disease')]}], ['Hypotheses of heroin - related rhabdomyolysis and stroke in heroin abusers are discussed .', {'entities': [(31, 45, 'B_Disease'), (50, 56, 'B_Disease')]}], ['Increased vulnerability to 6 - hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors .', {'entities': [(81, 92, 'B_Disease')]}], ['Treatment with L - DOPA + benserazide ( 12 weeks ) resulted in less severe dyskinesias in CB1 KO than in WT mice .', {'entities': [(75, 86, 'B_Disease')]}], ['The results revealed that the lack of cannabinoid CB1 receptors increased the severity of motor impairment and DA lesion , and reduced L - DOPA - induced dyskinesias .', {'entities': [(154, 165, 'B_Disease')]}], ['These results suggest that activation of CB1 receptors offers neuroprotection against dopaminergic lesion and the development of L - DOPA - induced dyskinesias .', {'entities': [(148, 159, 'B_Disease')]}], ['Hepatocellular oxidant stress following intestinal ischemia - reperfusion injury .', {'entities': [(51, 59, 'B_Disease'), (62, 73, 'B_Disease'), (74, 80, 'I_Disease')]}], ['Reperfusion of ischemic intestine results in acute liver dysfunction characterized by hepatocellular enzyme release into plasma , reduction in bile flow rate , and neutrophil sequestration within the liver .', {'entities': [(15, 23, 'B_Disease'), (51, 56, 'B_Disease'), (57, 68, 'I_Disease')]}], ['The pathophysiology underlying this acute hepatic injury is unknown .', {'entities': [(42, 49, 'B_Disease'), (50, 56, 'I_Disease')]}], ['This study was undertaken to determine whether oxidants are associated with the hepatic injury and to determine the relative value of several indirect methods of assessing oxidant exposure in vivo .', {'entities': [(80, 87, 'B_Disease'), (88, 94, 'I_Disease')]}], ['Rats were subjected to a standardized intestinal ischemia - reperfusion injury .', {'entities': [(49, 57, 'B_Disease'), (60, 71, 'B_Disease'), (72, 78, 'I_Disease')]}], ['There was no change in hepatic tissue total glutathione following intestinal ischemia - reperfusion injury .', {'entities': [(77, 85, 'B_Disease'), (88, 99, 'B_Disease'), (100, 106, 'I_Disease')]}], ['Animal model of mania induced by ouabain : Evidence of oxidative stress in submitochondrial particles of the rat brain .', {'entities': [(16, 21, 'B_Disease')]}], ['The intracerebroventricular ( ICV ) administration of ouabain ( a Na ( + ) / K ( + ) - ATPase inhibitor ) in rats has been suggested to mimic some symptoms of human bipolar mania .', {'entities': [(165, 172, 'B_Disease'), (173, 178, 'I_Disease')]}], ['Clinical studies have shown that bipolar disorder may be related to mitochondrial dysfunction .', {'entities': [(33, 40, 'B_Disease'), (41, 49, 'I_Disease'), (68, 81, 'B_Disease'), (82, 93, 'I_Disease')]}], ['Our findings demonstrated that ouabain at 10 ( - 2 ) and 10 ( - 3 ) M induced hyperlocomotion in rats , and this response remained up to 7 days following a single ICV injection .', {'entities': [(78, 93, 'B_Disease')]}], ['In conclusion , ouabain - induced mania - like behavior may provide a useful animal model to test the hypothesis of the involvement of oxidative stress in bipolar disorder .', {'entities': [(34, 39, 'B_Disease'), (155, 162, 'B_Disease'), (163, 171, 'I_Disease')]}], ['Liver transplantation for acutely ill patients with fulminant liver failure carries high intraoperative and immediate postoperative risks .', {'entities': [(52, 61, 'B_Disease'), (62, 67, 'I_Disease'), (68, 75, 'I_Disease')]}], ['These are increased with the presence of concomitant acute kidney injury ( AKI ) and intraoperative dialysis is sometimes required to allow the transplant to proceed .', {'entities': [(53, 58, 'B_Disease'), (59, 65, 'I_Disease'), (66, 72, 'I_Disease'), (75, 78, 'B_Disease')]}], ['The derangements in the procoagulant and anticoagulant pathways during fulminant liver failure can lead to difficulties with anticoagulation during dialysis , especially when continued in the operating room .', {'entities': [(71, 80, 'B_Disease'), (81, 86, 'I_Disease'), (87, 94, 'I_Disease')]}], ['Systemic anticoagulation is unsafe and regional citrate anticoagulation in the absence of a functional liver carries the risk of citrate toxicity .', {'entities': [(137, 145, 'B_Disease')]}], ['We report a case of a 40 - year - old female with acetaminophen - induced fulminant liver failure with associated AKI who underwent intraoperative dialytic support during liver transplantation anticoagulated with citrate dialysate during the entire procedure .', {'entities': [(74, 83, 'B_Disease'), (84, 89, 'I_Disease'), (90, 97, 'I_Disease'), (114, 117, 'B_Disease')]}], ['The patient tolerated the procedure well without any signs of citrate toxicity and maintained adequate anticoagulation for patency of the dialysis circuit .', {'entities': [(70, 78, 'B_Disease')]}], ['Citrate dialysate is a safe alternative for intradialytic support of liver transplantation in fulminant liver failure .', {'entities': [(94, 103, 'B_Disease'), (104, 109, 'I_Disease'), (110, 117, 'I_Disease')]}], ['Delirium in a patient with toxic flecainide plasma concentrations : the role of a pharmacokinetic drug interaction with paroxetine .', {'entities': [(0, 8, 'B_Disease')]}], ['OBJECTIVE : To describe a case of flecainide - induced delirium associated with a pharmacokinetic drug interaction with paroxetine .', {'entities': [(55, 63, 'B_Disease')]}], ['CASE SUMMARY : A 69 - year - old white female presented to the emergency department with a history of confusion and paranoia over the past several days .', {'entities': [(102, 111, 'B_Disease'), (116, 124, 'B_Disease')]}], ['Flecainide had been started 2 weeks prior for atrial fibrillation .', {'entities': [(46, 52, 'B_Disease'), (53, 65, 'I_Disease')]}], ['Her delirium resolved 3 days later .', {'entities': [(4, 12, 'B_Disease')]}], ['DISCUSSION : Flecainide and pharmacologically similar agents that interact with sodium channels may cause delirium in susceptible patients .', {'entities': [(106, 114, 'B_Disease')]}], ['A MEDLINE search ( 1966 - January 2009 ) revealed one in vivo pharmacokinetic study on the interaction between flecainide , a CYP2D6 substrate , and paroxetine , a CYP2D6 inhibitor , as well as 3 case reports of flecainide - induced delirium .', {'entities': [(233, 241, 'B_Disease')]}], [\"According to the Naranjo probability scale , flecainide was the probable cause of the patient ' s delirium ; the Horn Drug Interaction Probability Scale indicates a possible pharmacokinetic drug interaction between flecainide and paroxetine .\", {'entities': [(98, 106, 'B_Disease')]}], ['CONCLUSIONS : Supratherapeutic flecainide plasma concentrations may cause delirium .', {'entities': [(74, 82, 'B_Disease')]}], ['Because toxicity may occur when flecainide is prescribed with paroxetine and other potent CYP2D6 inhibitors , flecainide plasma concentrations should be monitored closely with commencement of CYP2D6 inhibitors .', {'entities': [(8, 16, 'B_Disease')]}], ['Efficacy of everolimus ( RAD001 ) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors .', {'entities': [(60, 65, 'B_Disease')]}], ['BACKGROUND : Treatment options are scarce in pretreated advanced non - small - cell lung cancer ( NSCLC ) patients .', {'entities': [(65, 68, 'B_Disease'), (69, 70, 'I_Disease'), (71, 76, 'I_Disease'), (77, 78, 'I_Disease'), (79, 83, 'I_Disease'), (84, 88, 'I_Disease'), (89, 95, 'I_Disease'), (98, 103, 'B_Disease')]}], ['RAD001 , an oral inhibitor of the mammalian target of rapamycin ( mTOR ) , has shown phase I efficacy in NSCLC .', {'entities': [(105, 110, 'B_Disease')]}], ['METHODS : Stage IIIb or IV NSCLC patients , with two or fewer prior chemotherapy regimens , one platinum based ( stratum 1 ) or both chemotherapy and epidermal growth factor receptor tyrosine kinase inhibitors ( stratum 2 ) , received RAD001 10 mg / day until progression or unacceptable toxicity .', {'entities': [(27, 32, 'B_Disease'), (288, 296, 'B_Disease')]}], ['Analyses of markers associated with the mTOR pathway were carried out on archival tumor from a subgroup using immunohistochemistry ( IHC ) and direct mutation sequencing .', {'entities': [(82, 87, 'B_Disease')]}], ['Common > or = grade 3 events were fatigue , dyspnea , stomatitis , anemia , and thrombocytopenia .', {'entities': [(34, 41, 'B_Disease'), (44, 51, 'B_Disease'), (54, 64, 'B_Disease'), (67, 73, 'B_Disease'), (80, 96, 'B_Disease')]}], ['Pneumonitis , probably or possibly related , mainly grade 1 / 2 , occurred in 25 % .', {'entities': [(0, 11, 'B_Disease')]}], ['CONCLUSIONS : RAD001 10 mg / day was well tolerated , showing modest clinical activity in pretreated NSCLC .', {'entities': [(101, 106, 'B_Disease')]}], ['Evaluation of RAD001 plus standard therapy for metastatic NSCLC continues .', {'entities': [(58, 63, 'B_Disease')]}], ['Posttransplant anemia : the role of sirolimus .', {'entities': [(15, 21, 'B_Disease')]}], [\"Posttransplant anemia is a common problem that may hinder patients ' quality of life .\", {'entities': [(15, 21, 'B_Disease')]}], ['A variety of factors have been identified that increase the risk of posttransplant anemia , of which the level of renal function is most important .', {'entities': [(83, 89, 'B_Disease')]}], ['Sirolimus , a mammalian target of rapamycin inhibitor , has been implicated as playing a special role in posttransplant anemia .', {'entities': [(120, 126, 'B_Disease')]}], ['This review considers anemia associated with sirolimus , including its presentation , mechanisms , and management .', {'entities': [(22, 28, 'B_Disease')]}], ['Coronary computerized tomography angiography for rapid discharge of low - risk patients with cocaine - associated chest pain .', {'entities': [(114, 119, 'B_Disease'), (120, 124, 'I_Disease')]}], ['BACKGROUND : Most patients presenting to emergency departments ( EDs ) with cocaine - associated chest pain are admitted for at least 12 hours and receive a \" rule out acute coronary syndrome \" protocol , often with noninvasive testing prior to discharge .', {'entities': [(97, 102, 'B_Disease'), (103, 107, 'I_Disease'), (168, 173, 'B_Disease'), (174, 182, 'I_Disease'), (183, 191, 'I_Disease')]}], ['It is unclear whether a coronary CTA strategy would be efficacious in cocaine - associated chest pain , as coronary vasospasm may account for some of the ischemia .', {'entities': [(91, 96, 'B_Disease'), (97, 101, 'I_Disease'), (107, 115, 'B_Disease'), (116, 125, 'I_Disease'), (154, 162, 'B_Disease')]}], ['We studied whether a negative coronary CTA in patients with cocaine - associated chest pain could identify a subset safe for discharge .', {'entities': [(81, 86, 'B_Disease'), (87, 91, 'I_Disease')]}], ['METHODS : We prospectively evaluated the safety of coronary CTA for low - risk patients who presented to the ED with cocaineassociated chest pain ( self - reported or positive urine test ) .', {'entities': [(135, 140, 'B_Disease'), (141, 145, 'I_Disease')]}], ['Patients with negative coronary CTA ( maximal stenosis less than 50 % ) were discharged .', {'entities': [(46, 54, 'B_Disease')]}], ['The main outcome was 30 - day cardiovascular death or myocardial infarction .', {'entities': [(54, 64, 'B_Disease'), (65, 75, 'I_Disease')]}], ['RESULTS : A total of 59 patients with cocaine - associated chest pain were evaluated .', {'entities': [(59, 64, 'B_Disease'), (65, 69, 'I_Disease')]}], ['Six patients had coronary stenosis > or = 50 % .', {'entities': [(17, 25, 'B_Disease'), (26, 34, 'I_Disease')]}], ['During the 30 - day follow - up period , no patients died of a cardiovascular event ( 0 % ; 95 % CI , 0 - 6 . 1 % ) and no patient sustained a nonfatal myocardial infarction ( 0 % ; 95 % CI , 0 - 6 . 1 % ) .', {'entities': [(152, 162, 'B_Disease'), (163, 173, 'I_Disease')]}], ['CONCLUSIONS : Although cocaine - associated myocardial ischemia can result from coronary vasoconstriction , patients with cocaine associated chest pain , a non - ischemic ECG , and a TIMI risk score < 2 may be safely discharged from the ED after a negative coronary CTA with a low risk of 30 - day adverse events .', {'entities': [(44, 54, 'B_Disease'), (55, 63, 'I_Disease'), (141, 146, 'B_Disease'), (147, 151, 'I_Disease'), (162, 170, 'B_Disease')]}], ['Bilateral haemorrhagic infarction of the globus pallidus after cocaine and alcohol intoxication .', {'entities': [(10, 22, 'B_Disease'), (23, 33, 'I_Disease'), (34, 36, 'I_Disease'), (37, 40, 'I_Disease'), (41, 47, 'I_Disease'), (48, 56, 'I_Disease')]}], ['Cocaine is a risk factor for both ischemic and haemorrhagic stroke .', {'entities': [(34, 42, 'B_Disease'), (43, 46, 'I_Disease'), (47, 59, 'I_Disease'), (60, 66, 'I_Disease')]}], ['We present the case of a 31 - year - old man with bilateral ischemia of the globus pallidus after excessive alcohol and intranasal cocaine use .', {'entities': [(60, 68, 'B_Disease'), (69, 71, 'I_Disease'), (72, 75, 'I_Disease'), (76, 82, 'I_Disease'), (83, 91, 'I_Disease')]}], ['Drug - related globus pallidus infarctions are most often associated with heroin .', {'entities': [(15, 21, 'B_Disease'), (22, 30, 'I_Disease'), (31, 42, 'I_Disease')]}], ['Bilateral basal ganglia infarcts after the use of cocaine , without concurrent heroin use , have never been reported .', {'entities': [(10, 15, 'B_Disease'), (16, 23, 'I_Disease'), (24, 32, 'I_Disease')]}], ['In our patient , transient cardiac arrhythmia or respiratory dysfunction related to cocaine and / or ethanol use were the most likely causes of cerebral hypoperfusion .', {'entities': [(27, 34, 'B_Disease'), (35, 45, 'I_Disease'), (49, 60, 'B_Disease'), (61, 72, 'I_Disease'), (144, 152, 'B_Disease'), (153, 166, 'I_Disease')]}], ['Late fulminant posterior reversible encephalopathy syndrome after liver transplant .', {'entities': [(15, 24, 'B_Disease'), (25, 35, 'I_Disease'), (36, 50, 'I_Disease'), (51, 59, 'I_Disease')]}], ['OBJECTIVES : Posterior leukoencephalopathy due to calcineurin - inhibitor - related neurotoxicity is a rare but severe complication that results from treatment with immunosuppressive agents ( primarily those administered after a liver or kidney transplant ) .', {'entities': [(13, 22, 'B_Disease'), (23, 42, 'I_Disease'), (84, 97, 'B_Disease')]}], ['CASE : We report the case of a 46 - year - old woman who received a liver transplant in our center as treatment for alcoholic cirrhosis and in whom either a fulminant course of posterior leukoencephalopathy or posterior reversible encephalopathy syndrome developed 110 days after transplant .', {'entities': [(116, 125, 'B_Disease'), (126, 135, 'I_Disease'), (177, 186, 'B_Disease'), (187, 206, 'I_Disease'), (210, 219, 'B_Disease'), (220, 230, 'I_Disease'), (231, 245, 'I_Disease'), (246, 254, 'I_Disease')]}], ['CONCLUSIONS : Posterior reversible encephalopathy syndrome after liver transplant is rare .', {'entities': [(14, 23, 'B_Disease'), (24, 34, 'I_Disease'), (35, 49, 'I_Disease'), (50, 58, 'I_Disease')]}], ['Prolonged hypothermia as a bridge to recovery for cerebral edema and intracranial hypertension associated with fulminant hepatic failure .', {'entities': [(10, 21, 'B_Disease'), (50, 58, 'B_Disease'), (59, 64, 'I_Disease'), (69, 81, 'B_Disease'), (82, 94, 'I_Disease'), (111, 120, 'B_Disease'), (121, 128, 'I_Disease'), (129, 136, 'I_Disease')]}], ['BACKGROUND : To review evidence - based treatment options in patients with cerebral edema complicating fulminant hepatic failure ( FHF ) and discuss the potential applications of hypothermia .', {'entities': [(75, 83, 'B_Disease'), (84, 89, 'I_Disease'), (103, 112, 'B_Disease'), (113, 120, 'I_Disease'), (121, 128, 'I_Disease'), (131, 134, 'B_Disease'), (179, 190, 'B_Disease')]}], ['METHOD : Case - based observations from a medical intensive care unit ( MICU ) in a tertiary care facility in a 27 - year - old female with FHF from acetaminophen and resultant cerebral edema .', {'entities': [(140, 143, 'B_Disease'), (177, 185, 'B_Disease'), (186, 191, 'I_Disease')]}], ['RESULTS : Our patient was admitted to the MICU after being found unresponsive with presumed toxicity from acetaminophen which was ingested over a 2 - day period .', {'entities': [(92, 100, 'B_Disease')]}], ['Initial evaluation confirmed FHF from acetaminophen and cerebral edema .', {'entities': [(29, 32, 'B_Disease'), (56, 64, 'B_Disease'), (65, 70, 'I_Disease')]}], ['The patient was treated with hyperosmolar therapy , hyperventilation , sedation , and chemical paralysis .', {'entities': [(52, 68, 'B_Disease'), (95, 104, 'B_Disease')]}], ['We then initiated therapeutic hypothermia which was continued for 5 days .', {'entities': [(30, 41, 'B_Disease')]}], ['At re - warming , patient had resolution of her cerebral edema and intracranial hypertension .', {'entities': [(48, 56, 'B_Disease'), (57, 62, 'I_Disease'), (67, 79, 'B_Disease'), (80, 92, 'I_Disease')]}], ['CONCLUSION : In patients with FHF and cerebral edema from acetaminophen overdose , prolonged therapeutic hypothermia could potentially be used as a life saving therapy and a bridge to hepatic and neurological recovery .', {'entities': [(30, 33, 'B_Disease'), (38, 46, 'B_Disease'), (47, 52, 'I_Disease'), (72, 80, 'B_Disease'), (105, 116, 'B_Disease')]}], ['A clinical trial of hypothermia in patients with this condition is warranted .', {'entities': [(20, 31, 'B_Disease')]}], ['Binasal visual field defects are not specific to vigabatrin .', {'entities': [(0, 7, 'B_Disease'), (8, 14, 'I_Disease'), (15, 20, 'I_Disease'), (21, 28, 'I_Disease')]}], ['This study investigated the visual defects associated with the antiepileptic drug vigabatrin ( VGB ) .', {'entities': [(28, 34, 'B_Disease'), (35, 42, 'I_Disease')]}], ['Two hundred four people with epilepsy were grouped on the basis of antiepileptic drug therapy ( current , previous , or no exposure to VGB ) .', {'entities': [(29, 37, 'B_Disease')]}], ['Groups were matched with respect to age , gender , and seizure frequency .', {'entities': [(55, 62, 'B_Disease')]}], ['Bilateral visual field abnormalities are common in the treated epilepsy population , irrespective of drug history .', {'entities': [(0, 9, 'B_Disease'), (10, 16, 'I_Disease'), (17, 22, 'I_Disease'), (23, 36, 'I_Disease'), (63, 71, 'B_Disease')]}], ['Assessment by conventional static perimetry may neither be sufficiently sensitive nor specific to reliably identify retinal toxicity associated with VGB .', {'entities': [(116, 123, 'B_Disease'), (124, 132, 'I_Disease')]}], ['Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs .', {'entities': [(46, 49, 'B_Disease'), (50, 59, 'I_Disease')]}], ['BACKGROUND : Little is known about the possible role that smoking crack cocaine has on the incidence of HIV infection .', {'entities': [(104, 107, 'B_Disease'), (108, 117, 'I_Disease')]}], ['Given the increasing use of crack cocaine , we sought to examine whether use of this illicit drug has become a risk factor for HIV infection .', {'entities': [(127, 130, 'B_Disease'), (131, 140, 'I_Disease')]}], ['To determine whether the risk of HIV seroconversion among daily smokers of crack cocaine changed over time , we used Cox proportional hazards regression and divided the study into 3 periods : May 1 , 1996 - Nov .', {'entities': [(33, 36, 'B_Disease'), (37, 51, 'I_Disease')]}], ['Of these , 137 acquired HIV infection during follow - up .', {'entities': [(24, 27, 'B_Disease'), (28, 37, 'I_Disease')]}], ['After adjusting for potential confounders , we found that the risk of HIV seroconversion among participants who were daily smokers of crack cocaine increased over time ( period 1 : hazard ratio [ HR ] 1 . 03 , 95 % confidence interval [ CI ] 0 . 57 - 1 . 85 ; period 2 : HR 1 . 68 , 95 % CI 1 . 01 - 2 . 80 ; and period 3 : HR 2 . 74 , 95 % CI 1 . 06 - 7 . 11 ) .', {'entities': [(70, 73, 'B_Disease'), (74, 88, 'I_Disease')]}], ['INTERPRETATION : Smoking of crack cocaine was found to be an independent risk factor for HIV seroconversion among people who were injection drug users .', {'entities': [(89, 92, 'B_Disease'), (93, 107, 'I_Disease')]}], ['Fluoxetine improves the memory deficits caused by the chemotherapy agent 5 - fluorouracil .', {'entities': [(24, 30, 'B_Disease'), (31, 39, 'I_Disease')]}], ['Cancer patients who have been treated with systemic adjuvant chemotherapy have described experiencing deteriorations in cognition .', {'entities': [(0, 6, 'B_Disease')]}], ['Liver - specific ablation of integrin - linked kinase in mice results in enhanced and prolonged cell proliferation and hepatomegaly after phenobarbital administration .', {'entities': [(119, 131, 'B_Disease')]}], ['Decreased Expression of Na / K - ATPase , NHE3 , NBC1 , AQP1 and OAT in Gentamicin - induced Nephropathy .', {'entities': [(93, 104, 'B_Disease')]}], ['The present study was aimed to determine whether there is an altered regulation of tubular transporters in gentamicin - induced nephropathy .', {'entities': [(128, 139, 'B_Disease')]}], ['Gentamicin - induced nephropathy may at least in part be causally related with a decreased expression of Na ( + ) / K ( + ) - ATPase , NHE3 , NBC1 , AQP1 and OAT .', {'entities': [(21, 32, 'B_Disease')]}], ['Acute renal failure after high - dose methotrexate therapy in a patient with ileostomy .', {'entities': [(0, 5, 'B_Disease'), (6, 11, 'I_Disease'), (12, 19, 'I_Disease')]}], ['High - dose methotrexate ( HD - MTX ) is an important treatment for Burkitt lymphoma , but can cause hepatic and renal toxicity when its clearance is delayed .', {'entities': [(68, 75, 'B_Disease'), (76, 84, 'I_Disease'), (101, 108, 'B_Disease'), (109, 112, 'I_Disease'), (113, 118, 'I_Disease'), (119, 127, 'I_Disease')]}], ['We report a case of acute renal failure after HD - MTX therapy in a patient with ileostomy , The patient was a 3 - year - old boy who had received a living - related liver transplantation for congenital biliary atresia .', {'entities': [(20, 25, 'B_Disease'), (26, 31, 'I_Disease'), (32, 39, 'I_Disease'), (203, 210, 'B_Disease'), (211, 218, 'I_Disease')]}], ['At day 833 after the transplantation , he was diagnosed with PTLD ( post - transplantation lymphoproliferative disorder , Burkitt - type malignant lymphoma ) .', {'entities': [(61, 65, 'B_Disease'), (68, 72, 'B_Disease'), (73, 74, 'I_Disease'), (75, 90, 'I_Disease'), (91, 110, 'I_Disease'), (111, 119, 'I_Disease'), (122, 129, 'B_Disease'), (130, 131, 'I_Disease'), (132, 136, 'I_Disease'), (137, 146, 'I_Disease'), (147, 155, 'I_Disease')]}], ['Subsequent HD - MTX therapy caused acute renal failure that required continuous hemodialysis .', {'entities': [(35, 40, 'B_Disease'), (41, 46, 'I_Disease'), (47, 54, 'I_Disease')]}], ['We supposed that intravascular hypovolemia due to substantial drainage from the ileostoma caused acute prerenal failure .', {'entities': [(31, 42, 'B_Disease'), (97, 102, 'B_Disease'), (103, 111, 'I_Disease'), (112, 119, 'I_Disease')]}], ['Longitudinal association of alcohol use with HIV disease progression and psychological health of women with HIV .', {'entities': [(45, 48, 'B_Disease'), (49, 56, 'I_Disease')]}], ['We evaluated the association of alcohol consumption and depression , and their effects on HIV disease progression among women with HIV .', {'entities': [(56, 66, 'B_Disease'), (90, 93, 'B_Disease'), (94, 101, 'I_Disease')]}], ['The participants had physical examination , medical record extraction , and venipuncture , CD4 + T - cell counts determination , measurement of depression symptoms ( using the self - report Center for Epidemiological Studies - Depression Scale ) , and alcohol use assessment at enrollment , and semiannually until March 2000 .', {'entities': [(144, 154, 'B_Disease'), (227, 237, 'B_Disease')]}], ['The association between alcohol consumption and depression was significant ( p < 0 . 001 ) .', {'entities': [(48, 58, 'B_Disease')]}], ['Depression had a significant negative effect on CD4 + T - cell counts over time regardless of ART use .', {'entities': [(0, 10, 'B_Disease')]}], ['Our findings suggest that alcohol consumption has a direct association with depression .', {'entities': [(76, 86, 'B_Disease')]}], ['Moreover , depression is associated with HIV disease progression .', {'entities': [(11, 21, 'B_Disease'), (41, 44, 'B_Disease'), (45, 52, 'I_Disease')]}], ['Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine - induced status epilepticus .', {'entities': [(102, 108, 'B_Disease'), (109, 120, 'I_Disease')]}], ['BACKGROUND : Neuroinflammation occurs after seizures and is implicated in epileptogenesis .', {'entities': [(13, 30, 'B_Disease'), (44, 52, 'B_Disease')]}], ['CCR2 is a chemokine receptor for CCL2 and their interaction mediates monocyte infiltration in the neuroinflammatory cascade triggered in different brain pathologies .', {'entities': [(98, 115, 'B_Disease')]}], ['In this work CCR2 and CCL2 expression were examined following status epilepticus ( SE ) induced by pilocarpine injection .', {'entities': [(62, 68, 'B_Disease'), (69, 80, 'I_Disease'), (83, 85, 'B_Disease')]}], ['METHODS : SE was induced by pilocarpine injection .', {'entities': [(10, 12, 'B_Disease')]}], ['Five days after SE , CCR2 staining in neurons and glial cells was examined using imunohistochemical analyses .', {'entities': [(16, 18, 'B_Disease')]}], ['RESULTS : Increased CCR2 was observed in the hippocampus after SE .', {'entities': [(63, 65, 'B_Disease')]}], ['Seizures also resulted in alterations to the cell types expressing CCR2 .', {'entities': [(0, 8, 'B_Disease')]}], ['Increased numbers of neurons that expressed CCR2 was observed following SE .', {'entities': [(72, 74, 'B_Disease')]}], ['Microglial cells were more closely apposed to the CCR2 - labeled cells in SE rats .', {'entities': [(74, 76, 'B_Disease')]}], ['In addition , rats that experienced SE exhibited CCR2 - labeling in populations of hypertrophied astrocytes , especially in CA1 and dentate gyrus .', {'entities': [(36, 38, 'B_Disease'), (83, 96, 'B_Disease')]}], ['Examination of CCL2 expression showed that it was elevated in the hippocampus following SE .', {'entities': [(88, 90, 'B_Disease')]}], ['CONCLUSION : The data show that CCR2 and CCL2 are up - regulated in the hippocampus after pilocarpine - induced SE .', {'entities': [(112, 114, 'B_Disease')]}], ['Seizures also result in changes to CCR2 receptor expression in neurons and astrocytes .', {'entities': [(0, 8, 'B_Disease')]}], ['These changes might be involved in detrimental neuroplasticity and neuroinflammatory changes that occur following seizures .', {'entities': [(67, 84, 'B_Disease'), (114, 122, 'B_Disease')]}], ['The present study aimed to explore the effect of MT induction on carmustine ( BCNU ) - induced hippocampal cognitive dysfunction in rats .', {'entities': [(107, 116, 'B_Disease'), (117, 128, 'I_Disease')]}], ['The obtained data revealed that BCNU administration resulted in deterioration of learning and short - term memory ( STM ) , as measured by using radial arm water maze , accompanied with decreased hippocampal glutathione reductase ( GR ) activity and reduced glutathione ( GSH ) content .', {'entities': [(64, 77, 'B_Disease'), (78, 80, 'I_Disease'), (81, 89, 'I_Disease'), (90, 93, 'I_Disease'), (94, 99, 'I_Disease'), (100, 101, 'I_Disease'), (102, 106, 'I_Disease'), (107, 113, 'I_Disease')]}], ['Also , BCNU administration increased serum tumor necrosis factor - alpha ( TNFalpha ) , hippocampal MT and malondialdehyde ( MDA ) contents as well as caspase - 3 activity in addition to histological alterations .', {'entities': [(43, 48, 'B_Disease'), (49, 57, 'B_Disease')]}], ['In conclusion , MT induction halts BCNU - induced hippocampal toxicity as it prevented GR inhibition and GSH depletion and counteracted the increased levels of TNFalpha , MDA and caspase - 3 activity with subsequent preservation of cognition .', {'entities': [(62, 70, 'B_Disease')]}], ['Fatal carbamazepine induced fulminant eosinophilic ( hypersensitivity ) myocarditis : emphasis on anatomical and histological characteristics , mechanisms and genetics of drug hypersensitivity and differential diagnosis .', {'entities': [(28, 37, 'B_Disease'), (38, 50, 'I_Disease'), (53, 69, 'B_Disease'), (72, 83, 'B_Disease'), (171, 175, 'B_Disease'), (176, 192, 'I_Disease')]}], ['A frequently fatal , although exceptionally rare side effect of carbamazepine is necrotizing eosinophilic ( hypersensitivity ) myocarditis .', {'entities': [(108, 124, 'B_Disease'), (127, 138, 'B_Disease')]}], ['We report a case of hypersensitivity myocarditis secondary to administration of carbamazepine .', {'entities': [(20, 36, 'B_Disease'), (37, 48, 'B_Disease')]}], ['Acute hypersensitivity myocarditis was not suspected clinically , and the diagnosis was made post - mortem .', {'entities': [(6, 22, 'B_Disease'), (23, 34, 'B_Disease')]}], ['Clinically , death was due to cardiogenic shock .', {'entities': [(30, 41, 'B_Disease'), (42, 47, 'I_Disease')]}], ['To best of our knowledge this is the second case of fatal carbamazepine induced myocarditis reported in English literature .', {'entities': [(80, 91, 'B_Disease')]}], [\"Neuropsychiatric behaviors in the MPTP marmoset model of Parkinson ' s disease .\", {'entities': [(57, 66, 'B_Disease'), (67, 68, 'I_Disease'), (69, 70, 'I_Disease'), (71, 78, 'I_Disease')]}], [\"OBJECTIVES : Neuropsychiatric symptoms are increasingly recognised as a significant problem in patients with Parkinson ' s disease ( PD ) .\", {'entities': [(109, 118, 'B_Disease'), (119, 120, 'I_Disease'), (121, 122, 'I_Disease'), (123, 130, 'I_Disease'), (133, 135, 'B_Disease')]}], ['The levodopa - treated MPTP - lesioned marmoset was used as a model of neuropsychiatric symptoms in PD patients .', {'entities': [(71, 87, 'B_Disease'), (88, 96, 'I_Disease'), (100, 102, 'B_Disease')]}], ['Here we compare the time course of levodopa - induced motor fluctuations and neuropsychiatric - like behaviors to determine the relationship between duration of treatment and onset of symptoms .', {'entities': [(77, 93, 'B_Disease'), (94, 95, 'I_Disease'), (96, 100, 'I_Disease'), (101, 110, 'I_Disease')]}], ['METHODS : Marmosets were administered 1 - methyl - 4 - phenyl - 1 , 2 , 3 , 6 - tetrahydropyridine ( 2 . 0 mg / kg s . c . ) for five days , resulting in stable parkinsonism .', {'entities': [(161, 173, 'B_Disease')]}], ['Animals were evaluated for parkinsonian disability , dyskinesia and on - time ( motor fluctuations ) and neuropsychiatric - like behaviors on Day 0 ( prior to levodopa ) and on Days 1 , 7 , 13 , 27 and 30 of treatment using post hoc DVD analysis by a trained rater , blind to the treatment day .', {'entities': [(27, 39, 'B_Disease'), (40, 50, 'I_Disease'), (53, 63, 'B_Disease'), (105, 121, 'B_Disease'), (122, 123, 'I_Disease'), (124, 128, 'I_Disease'), (129, 138, 'I_Disease')]}], ['RESULTS : The neuropsychiatric - like behavior rating scale demonstrated high interrater reliability between three trained raters of differing professional backgrounds .', {'entities': [(14, 30, 'B_Disease'), (31, 32, 'I_Disease'), (33, 37, 'I_Disease'), (38, 46, 'I_Disease')]}], ['As anticipated , animals exhibited a progressive increase in levodopa - induced motor fluctuations , dyskinesia and wearing - off , that correlated with the duration of levodopa therapy .', {'entities': [(101, 111, 'B_Disease')]}], ['In contrast , levodopa - induced neuropsychiatric - like behaviors were present on Day 1 of levodopa treatment and their severity did not correlate with duration of treatment .', {'entities': [(33, 49, 'B_Disease'), (50, 51, 'I_Disease'), (52, 56, 'I_Disease'), (57, 66, 'I_Disease')]}], ['CONCLUSIONS : The data suggest that neuropsychiatric disorders in PD are more likely an interaction between levodopa and the disease state than a consequence of sensitisation to repeated dopaminergic therapy .', {'entities': [(36, 52, 'B_Disease'), (53, 62, 'I_Disease'), (66, 68, 'B_Disease')]}], ['Contrast medium nephrotoxicity after renal artery and coronary angioplasty .', {'entities': [(16, 30, 'B_Disease')]}], ['BACKGROUND : Renal dysfunction induced by iodinated contrast medium ( CM ) administration can minimize the benefit of the interventional procedure in patients undergoing renal angioplasty ( PTRA ) .', {'entities': [(13, 18, 'B_Disease'), (19, 30, 'I_Disease')]}], ['PURPOSE : To compare the susceptibility to nephrotoxic effect of CM in patients undergoing PTRA with that of patients submitted to percutaneous coronary intervention ( PCI ) .', {'entities': [(43, 54, 'B_Disease')]}], ['CONCLUSION : In this preliminary study patients submitted to PTRA showed a lower susceptibility to renal damage induced by CM administration than PCI patients .', {'entities': [(99, 104, 'B_Disease'), (105, 111, 'I_Disease')]}], ['The effectiveness of PTRA on renal function seems to be barely influenced by CM toxicity .', {'entities': [(80, 88, 'B_Disease')]}], ['We conclude that an H1 antagonist may be useful in preventing hypotension caused by iv cimetidine , since the vasodilating activity of cimetidine is mediated , in part , through the H1 receptor .', {'entities': [(62, 73, 'B_Disease')]}], ['Medical and psychiatric outcomes for patients transplanted for acetaminophen - induced acute liver failure : a case - control study .', {'entities': [(87, 92, 'B_Disease'), (93, 98, 'I_Disease'), (99, 106, 'I_Disease')]}], ['BACKGROUND : Acetaminophen - induced hepatotoxicity is the most common cause of acute liver failure ( ALF ) in the UK .', {'entities': [(37, 51, 'B_Disease'), (80, 85, 'B_Disease'), (86, 91, 'I_Disease'), (92, 99, 'I_Disease'), (102, 105, 'B_Disease')]}], ['AIMS AND METHODS : We compared the severity of pretransplant illness , psychiatric co - morbidity , medical and psychosocial outcomes of all patients who had undergone liver transplantation ( LT ) emergently between 1999 - 2004 for acetaminophen - induced ALF ( n = 36 ) with age - and sex - matched patients undergoing emergent LT for non - acetaminophen - induced ALF ( n = 35 ) and elective LT for chronic liver disease ( CLD , n = 34 ) .', {'entities': [(256, 259, 'B_Disease'), (366, 369, 'B_Disease'), (401, 408, 'B_Disease'), (409, 414, 'I_Disease'), (415, 422, 'I_Disease'), (425, 428, 'B_Disease')]}], ['RESULTS : Acetaminophen - induced ALF patients undergoing LT had a greater severity of pre - LT illness reflected by higher Acute Physiology and Chronic Health Evaluation II scores and requirement for organ support compared with the other two groups .', {'entities': [(34, 37, 'B_Disease')]}], ['Twenty ( 56 % ) acetaminophen - induced ALF patients had a formal psychiatric diagnosis before LT ( non - acetaminophen - induced ALF = 0 / 35 , CLD = 2 / 34 ; P < 0 . 01 for all ) and nine ( 25 % ) had a previous suicide attempt .', {'entities': [(40, 43, 'B_Disease'), (130, 133, 'B_Disease'), (145, 148, 'B_Disease')]}], ['During follow - up ( median 5 years ) , there were no significant differences in rejection ( acute and chronic ) , graft failure or survival between the groups ( acetaminophen - induced ALF 1 year 87 % , 5 years 75 % ; non - acetaminophen - induced ALF 88 % , 78 % ; CLD 93 % , 82 % : P > 0 . 6 log rank ) .', {'entities': [(186, 189, 'B_Disease'), (249, 252, 'B_Disease'), (267, 270, 'B_Disease')]}], ['Two acetaminophen - induced ALF patients reattempted suicide post - LT ( one died 8 years post - LT ) .', {'entities': [(28, 31, 'B_Disease')]}], ['CONCLUSIONS : Despite a high prevalence of psychiatric disturbance , outcomes for patients transplanted emergently for acetaminophen - induced ALF were comparable to those transplanted for non - acetaminophen - induced ALF and electively for CLD .', {'entities': [(143, 146, 'B_Disease'), (219, 222, 'B_Disease'), (242, 245, 'B_Disease')]}], ['Antithrombotic drug use , cerebral microbleeds , and intracerebral hemorrhage : a systematic review of published and unpublished studies .', {'entities': [(26, 34, 'B_Disease'), (35, 46, 'I_Disease'), (53, 66, 'B_Disease'), (67, 77, 'I_Disease')]}], ['BACKGROUND AND PURPOSE : Cerebral microbleeds ( MB ) are potential risk factors for intracerebral hemorrhage ( ICH ) , but it is unclear if they are a contraindication to using antithrombotic drugs .', {'entities': [(25, 33, 'B_Disease'), (34, 45, 'I_Disease'), (48, 50, 'B_Disease'), (84, 97, 'B_Disease'), (98, 108, 'I_Disease'), (111, 114, 'B_Disease')]}], ['Insights could be gained by pooling data on MB frequency stratified by antithrombotic use in cohorts with ICH and ischemic stroke ( IS ) / transient ischemic attack ( TIA ) .', {'entities': [(44, 46, 'B_Disease'), (106, 109, 'B_Disease'), (114, 122, 'B_Disease'), (123, 129, 'I_Disease'), (132, 134, 'B_Disease'), (139, 148, 'B_Disease'), (149, 157, 'I_Disease'), (158, 164, 'I_Disease'), (167, 170, 'B_Disease')]}], ['METHODS : We performed a systematic review of published and unpublished data from cohorts with stroke or TIA to compare the presence of MB in : ( 1 ) antithrombotic users vs nonantithrombotic users with ICH ; ( 2 ) antithrombotic users vs nonusers with IS / TIA ; and ( 3 ) ICH vs ischemic events stratified by antithrombotic use .', {'entities': [(95, 101, 'B_Disease'), (105, 108, 'B_Disease'), (136, 138, 'B_Disease'), (203, 206, 'B_Disease'), (253, 255, 'B_Disease'), (258, 261, 'B_Disease'), (274, 277, 'B_Disease'), (281, 289, 'B_Disease')]}], ['We also analyzed published and unpublished follow - up data to determine the risk of ICH in antithrombotic users with MB .', {'entities': [(85, 88, 'B_Disease'), (118, 120, 'B_Disease')]}], ['RESULTS : In a pooled analysis of 1460 ICH and 3817 IS / TIA , MB were more frequent in ICH vs IS / TIA in all treatment groups , but the excess increased from 2 . 8 ( odds ratio ; range , 2 . 3 - 3 . 5 ) in nonantithrombotic users to 5 . 7 ( range , 3 . 4 - 9 . 7 ) in antiplatelet users and 8 . 0 ( range , 3 . 5 - 17 . 8 ) in warfarin users ( P difference = 0 . 01 ) .', {'entities': [(39, 42, 'B_Disease'), (52, 54, 'B_Disease'), (57, 60, 'B_Disease'), (63, 65, 'B_Disease'), (88, 91, 'B_Disease'), (95, 97, 'B_Disease'), (100, 103, 'B_Disease')]}], ['There was also an excess of MB in warfarin users vs nonusers with ICH ( OR , 2 . 7 ; 95 % CI , 1 . 6 - 4 . 4 ; P < 0 . 001 ) but none in warfarin users with IS / TIA ( OR , 1 . 3 ; 95 % CI , 0 . 9 - 1 . 7 ; P = 0 . 33 ; P difference = 0 . 01 ) .', {'entities': [(28, 30, 'B_Disease'), (66, 69, 'B_Disease'), (157, 159, 'B_Disease'), (162, 165, 'B_Disease')]}], ['There was a smaller excess of MB in antiplatelet users vs nonusers with ICH ( OR , 1 . 7 ; 95 % CI , 1 . 3 - 2 . 3 ; P < 0 . 001 ) , but findings were similar for antiplatelet users with IS / TIA ( OR , 1 . 4 ; 95 % CI , 1 . 2 - 1 . 7 ; P < 0 . 001 ; P difference = 0 . 25 ) .', {'entities': [(30, 32, 'B_Disease'), (72, 75, 'B_Disease'), (187, 189, 'B_Disease'), (192, 195, 'B_Disease')]}], ['In pooled follow - up data for 768 antithrombotic users , presence of MB at baseline was associated with a substantially increased risk of subsequent ICH ( OR , 12 . 1 ; 95 % CI , 3 . 4 - 42 . 5 ; P < 0 . 001 ) .', {'entities': [(70, 72, 'B_Disease'), (150, 153, 'B_Disease')]}], ['CONCLUSIONS : The excess of MB in warfarin users with ICH compared to other groups suggests that MB increase the risk of warfarin - associated ICH .', {'entities': [(28, 30, 'B_Disease'), (54, 57, 'B_Disease'), (97, 99, 'B_Disease'), (143, 146, 'B_Disease')]}], ['Studies of synergy between morphine and a novel sodium channel blocker , CNSB002 , in rat models of inflammatory and neuropathic pain .', {'entities': [(117, 128, 'B_Disease'), (129, 133, 'I_Disease')]}], ['OBJECTIVE : This study determined the antihyperalgesic effect of CNSB002 , a sodium channel blocker with antioxidant properties given alone and in combinations with morphine in rat models of inflammatory and neuropathic pain .', {'entities': [(208, 219, 'B_Disease'), (220, 224, 'I_Disease')]}], ['DESIGN : Dose response curves for nonsedating doses of morphine and CNSB002 given intraperitoneally alone and together in combinations were constructed for antihyperalgesic effect using paw withdrawal from noxious heat in two rat pain models : carrageenan - induced paw inflammation and streptozotocin ( STZ ) - induced diabetic neuropathy .', {'entities': [(230, 234, 'B_Disease'), (270, 282, 'B_Disease'), (320, 328, 'B_Disease'), (329, 339, 'I_Disease')]}], ['The doses calculated to cause 50 % reversal of hyperalgesia ( ED50 ) were 7 . 54 ( 1 . 81 ) and 4 . 83 ( 1 . 54 ) in the carrageenan model and 44 . 18 ( 1 . 37 ) and 9 . 14 ( 1 . 24 ) in the STZ - induced neuropathy model for CNSB002 and morphine , respectively ( mg / kg ; mean , SEM ) .', {'entities': [(47, 59, 'B_Disease'), (205, 215, 'B_Disease')]}], ['The ED50 values for morphine when given in combination with CNSB002 ( 5 mg / kg ) were less than the maximum nonsedating dose : 0 . 56 ( 1 . 55 ) in the carrageenan model and 1 . 37 ( 1 . 23 ) in the neuropathy model ( mg / kg ; mean , SEM ) .', {'entities': [(200, 210, 'B_Disease')]}], ['The antinociception after morphine ( 3 . 2 mg / kg ) was increased by co - administration with CNSB002 from 28 . 0 and 31 . 7 % to 114 . 6 and 56 . 9 % reversal of hyperalgesia in the inflammatory and neuropathic models , respectively ( P < 0 . 01 ; one - way analysis of variance - significantly greater than either drug given alone ) .', {'entities': [(164, 176, 'B_Disease'), (201, 212, 'B_Disease')]}], ['Heparin - induced thrombocytopenia : a practical review .', {'entities': [(18, 34, 'B_Disease')]}], ['Heparin - induced thrombocytopenia ( HIT ) remains under - recognized despite its potentially devastating outcomes .', {'entities': [(18, 34, 'B_Disease'), (37, 40, 'B_Disease')]}], ['Thrombosis and thrombocytopenia that follow comprise the 2 hallmark traits of HIT , with the former largely responsible for significant vascular complications .', {'entities': [(0, 10, 'B_Disease'), (15, 31, 'B_Disease'), (78, 81, 'B_Disease')]}], ['The prevalence of HIT varies among several subgroups , with greater incidence in surgical as compared with medical populations .', {'entities': [(18, 21, 'B_Disease')]}], ['HIT must be acknowledged for its intense predilection for thrombosis and suspected whenever thrombosis occurs after heparin exposure .', {'entities': [(0, 3, 'B_Disease'), (58, 68, 'B_Disease'), (92, 102, 'B_Disease')]}], ['The treatment of HIT mandates an immediate cessation of all heparin exposure and the institution of an antithrombotic therapy , most commonly using a direct thrombin inhibitor .', {'entities': [(17, 20, 'B_Disease')]}], ['Current \" diagnostic \" tests , which primarily include functional and antigenic assays , have more of a confirmatory than diagnostic role in the management of HIT .', {'entities': [(159, 162, 'B_Disease')]}], ['Direct thrombin inhibitors are appropriate , evidence - based alternatives to heparin in patients with a history of HIT , who need to undergo percutaneous coronary intervention .', {'entities': [(116, 119, 'B_Disease')]}], ['As heparin remains one of the most frequently used medications today with potential for HIT with every heparin exposure , a close vigilance of platelet counts must be practiced whenever heparin is initiated .', {'entities': [(88, 91, 'B_Disease')]}], ['Abductor paralysis after botox injection for adductor spasmodic dysphonia .', {'entities': [(9, 18, 'B_Disease'), (45, 53, 'B_Disease'), (54, 63, 'I_Disease'), (64, 73, 'I_Disease')]}], ['OBJECTIVES / HYPOTHESIS : Botulinum toxin ( Botox ) injections into the thyroarytenoid muscles are the current standard of care for adductor spasmodic dysphonia ( ADSD ) .', {'entities': [(132, 140, 'B_Disease'), (141, 150, 'I_Disease'), (151, 160, 'I_Disease'), (163, 167, 'B_Disease')]}], ['Reported adverse effects include a period of breathiness , throat pain , and difficulty with swallowing liquids .', {'entities': [(59, 65, 'B_Disease'), (66, 70, 'I_Disease')]}], ['Here we report multiple cases of bilateral abductor paralysis following Botox injections for ADSD , a complication previously unreported .', {'entities': [(52, 61, 'B_Disease'), (93, 97, 'B_Disease')]}], ['METHODS : Patients that received Botox injections for spasmodic dysphonia between January 2000 and October 2009 were evaluated .', {'entities': [(54, 63, 'B_Disease'), (64, 73, 'I_Disease')]}], ['Patients with ADSD were identified .', {'entities': [(14, 18, 'B_Disease')]}], ['For patients with bilateral abductor paralysis , age , sex , paralytic Botox dose , prior Botox dose , and course following paralysis were noted .', {'entities': [(37, 46, 'B_Disease'), (124, 133, 'B_Disease')]}], ['RESULTS : From a database of 452 patients receiving Botox , 352 patients had been diagnosed with ADSD .', {'entities': [(97, 101, 'B_Disease')]}], ['Of these 352 patients , eight patients suffered bilateral abductor paralysis , and two suffered this complication twice .', {'entities': [(67, 76, 'B_Disease')]}], ['Most patients had received treatments prior to abductor paralysis and continued receiving after paralysis .', {'entities': [(56, 65, 'B_Disease'), (96, 105, 'B_Disease')]}], ['The incidence of abductor paralysis after Botox injection for ADSD was 0 . 34 % .', {'entities': [(26, 35, 'B_Disease'), (62, 66, 'B_Disease')]}], ['CONCLUSIONS : Bilateral abductor paralysis is a rare complication of Botox injections for ADSD , causing difficulty with breathing upon exertion .', {'entities': [(33, 42, 'B_Disease'), (90, 94, 'B_Disease')]}], ['The likely mechanism of paralysis is diffusion of Botox around the muscular process of the arytenoid to the posterior cricoarytenoid muscles .', {'entities': [(24, 33, 'B_Disease')]}], ['The paralysis is temporary , and watchful waiting with restriction of activity is the recommended management .', {'entities': [(4, 13, 'B_Disease')]}], ['Mitochondrial impairment contributes to cocaine - induced cardiac dysfunction : Prevention by the targeted antioxidant MitoQ .', {'entities': [(0, 13, 'B_Disease'), (14, 24, 'I_Disease'), (58, 65, 'B_Disease'), (66, 77, 'I_Disease')]}], ['The goal of this study was to assess mitochondrial function and ROS production in an experimental model of cocaine - induced cardiac dysfunction .', {'entities': [(125, 132, 'B_Disease'), (133, 144, 'I_Disease')]}], ['We hypothesized that cocaine abuse may lead to altered mitochondrial function that in turn may cause left ventricular dysfunction .', {'entities': [(21, 28, 'B_Disease'), (29, 34, 'I_Disease'), (101, 105, 'B_Disease'), (106, 117, 'I_Disease'), (118, 129, 'I_Disease')]}], ['This uncoupling effect on oxidative phosphorylation was not detectable after short - term exposure to cocaine , suggesting that these mitochondrial abnormalities were a late rather than a primary event in the pathological response to cocaine .', {'entities': [(134, 147, 'B_Disease'), (148, 161, 'I_Disease')]}], ['MitoQ , a mitochondrial - targeted antioxidant , was shown to completely prevent these mitochondrial abnormalities as well as cardiac dysfunction characterized here by a diastolic dysfunction studied with a conductance catheter to obtain pressure - volume data .', {'entities': [(87, 100, 'B_Disease'), (101, 114, 'I_Disease'), (126, 133, 'B_Disease'), (134, 145, 'I_Disease'), (170, 179, 'B_Disease'), (180, 191, 'I_Disease')]}], ['Taken together , these results extend previous studies and demonstrate that cocaine - induced cardiac dysfunction may be due to a mitochondrial defect .', {'entities': [(94, 101, 'B_Disease'), (102, 113, 'I_Disease'), (130, 143, 'B_Disease'), (144, 150, 'I_Disease')]}], ['Trimethoprim - induced immune hemolytic anemia in a pediatric oncology patient presenting as an acute hemolytic transfusion reaction .', {'entities': [(30, 39, 'B_Disease'), (40, 46, 'I_Disease')]}], ['A 10 - year - old male with acute leukemia presented with post - chemotherapy anemia .', {'entities': [(28, 33, 'B_Disease'), (34, 42, 'I_Disease'), (78, 84, 'B_Disease')]}], ['During red cell transfusion , he developed hemoglobinuria .', {'entities': [(43, 57, 'B_Disease')]}], ['Drug - induced immune hemolytic anemia was suspected because of positive direct antiglobulin test , negative eluate , and microspherocytes on smear pre - and post - transfusion .', {'entities': [(22, 31, 'B_Disease'), (32, 38, 'I_Disease')]}], ['Other causes of anemia should be considered in patients with worse - than - expected anemia after chemotherapy .', {'entities': [(16, 22, 'B_Disease'), (85, 91, 'B_Disease')]}], ['Furthermore , hemolysis during transfusion is not always a transfusion reaction .', {'entities': [(14, 23, 'B_Disease')]}], ['Verapamil stimulation test in hyperprolactinemia : loss of prolactin response in anatomic or functional stalk effect .', {'entities': [(30, 48, 'B_Disease')]}], ['AIM : Verapamil stimulation test was previously investigated as a tool for differential diagnosis of hyperprolactinemia , but with conflicting results .', {'entities': [(101, 119, 'B_Disease')]}], ['Macroprolactinemia was never considered in those previous studies .', {'entities': [(0, 18, 'B_Disease')]}], ['Here , we aimed to re - investigate the diagnostic value of verapamil in a population who were all screened for macroprolactinemia .', {'entities': [(112, 130, 'B_Disease')]}], ['Prolactin responses to verapamil in 65 female patients ( age : 29 . 9 + / - 8 . 1 years ) with hyperprolactinemia were tested in a descriptive , matched case - control study .', {'entities': [(95, 113, 'B_Disease')]}], ['RESULTS : Verapamil significantly increased PRL levels in healthy controls ( N . 8 , PRL : 183 % ) , macroprolactinoma ( N . 8 , PRL : 7 % ) , microprolactinoma ( N . 19 , PRL : 21 % ) , macroprolactinemia ( N . 23 , PRL : 126 % ) , but not in pseudoprolactinoma ( N . 8 , PRL : 0 . 8 % ) , and risperidone - induced hyperprolactinemia ( N . 7 , PRL : 3 % ) .', {'entities': [(101, 118, 'B_Disease'), (143, 160, 'B_Disease'), (187, 205, 'B_Disease'), (244, 262, 'B_Disease'), (317, 335, 'B_Disease')]}], ['ROC curve analysis revealed that unresponsiveness to verapamil defined as PRL < 7 % , discriminated anatomical or functional stalk effect ( sensitivity : 74 % , specificity : 73 % , AUC : 0 . 855 + / - 0 . 04 , P < 0 . 001 , CI : 0 . 768 - 0 . 942 ) associated with pseudoprolactinoma or risperidone - induced hyperprolactinemia , respectively .', {'entities': [(266, 284, 'B_Disease'), (310, 328, 'B_Disease')]}], ['CONCLUSION : Verapamil responsiveness is not a reliable finding for the differential diagnosis of hyperprolactinemia .', {'entities': [(98, 116, 'B_Disease')]}], ['However , verapamil unresponsiveness discriminates stalk effect ( i . e . , anatomically or functionally inhibited dopaminergic tonus ) from other causes of hyperprolactinemia with varying degrees of responsiveness .', {'entities': [(157, 175, 'B_Disease')]}], ['Blockade of endothelial - mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin - induced diabetic nephropathy .', {'entities': [(127, 135, 'B_Disease'), (136, 147, 'I_Disease')]}], ['OBJECTIVE : A multicenter , controlled trial showed that early blockade of the renin - angiotensin system in patients with type 1 diabetes and normoalbuminuria did not retard the progression of nephropathy , suggesting that other mechanism ( s ) are involved in the pathogenesis of early diabetic nephropathy ( diabetic nephropathy ) .', {'entities': [(123, 127, 'B_Disease'), (128, 129, 'I_Disease'), (130, 138, 'I_Disease'), (194, 205, 'B_Disease'), (288, 296, 'B_Disease'), (297, 308, 'I_Disease'), (311, 319, 'B_Disease'), (320, 331, 'I_Disease')]}], ['We have previously demonstrated that endothelial - mesenchymal - transition ( EndoMT ) contributes to the early development of renal interstitial fibrosis independently of microalbuminuria in mice with streptozotocin ( STZ ) - induced diabetes .', {'entities': [(146, 154, 'B_Disease'), (235, 243, 'B_Disease')]}], ['In the present study , we hypothesized that blocking EndoMT reduces the early development of diabetic nephropathy .', {'entities': [(93, 101, 'B_Disease'), (102, 113, 'I_Disease')]}], ['Blocking studies using receptor for AGE siRNA and a specific inhibitor of Smad3 ( SIS3 ) were performed in MMECs and in STZ - induced diabetic nephropathy in Tie2 - Cre ; Loxp - EGFP mice .', {'entities': [(134, 142, 'B_Disease'), (143, 154, 'I_Disease')]}], ['Immunoprecipitation / Western blotting showed that Smad3 was activated by AGEs but was inhibited by SIS3 in MMECs and in STZ - induced diabetic nephropathy .', {'entities': [(135, 143, 'B_Disease'), (144, 155, 'I_Disease')]}], ['Confocal microscopy and real - time PCR further demonstrated that SIS3 abrogated EndoMT , reduced renal fibrosis , and retarded progression of nephropathy .', {'entities': [(104, 112, 'B_Disease'), (143, 154, 'B_Disease')]}], ['CONCLUSIONS : EndoMT is a novel pathway leading to early development of diabetic nephropathy .', {'entities': [(72, 80, 'B_Disease'), (81, 92, 'I_Disease')]}], ['Blockade of EndoMT by SIS3 may provide a new strategy to retard the progression of diabetic nephropathy and other diabetes complications .', {'entities': [(83, 91, 'B_Disease'), (92, 103, 'I_Disease'), (114, 122, 'B_Disease'), (123, 136, 'I_Disease')]}], ['Cytostatic and anti - angiogenic effects of temsirolimus in refractory mantle cell lymphoma .', {'entities': [(71, 77, 'B_Disease'), (78, 82, 'I_Disease'), (83, 91, 'I_Disease')]}], [\"Mantle cell lymphoma ( MCL ) is a rare and aggressive type of B - cell non - Hodgkin ' s lymphoma .\", {'entities': [(0, 6, 'B_Disease'), (7, 11, 'I_Disease'), (12, 20, 'I_Disease'), (23, 26, 'B_Disease'), (62, 63, 'B_Disease'), (64, 65, 'I_Disease'), (66, 70, 'I_Disease'), (71, 74, 'I_Disease'), (75, 76, 'I_Disease'), (77, 84, 'I_Disease'), (85, 86, 'I_Disease'), (87, 88, 'I_Disease'), (89, 97, 'I_Disease')]}], ['However , a 38 % remission rate has been recently reported in refractory MCL treated with temsirolimus , a mTOR inhibitor . Here we had the opportunity to study a case of refractory MCL who had tumor regression two months after temsirolimus treatment , and a progression - free survival of 10 months .', {'entities': [(73, 76, 'B_Disease'), (182, 185, 'B_Disease'), (194, 199, 'B_Disease')]}], ['Comparison of the two biopsies showed that temsirolimus inhibited tumor cell proliferation through cell cycle arrest , but did not induce any change in the number of apoptotic tumor cells .', {'entities': [(66, 71, 'B_Disease'), (176, 181, 'B_Disease')]}], ['Apart from this cytostatic effect , temsirolimus had an antiangiogenic effect with decrease of tumor microvessel density and of VEGF expression .', {'entities': [(95, 100, 'B_Disease')]}], ['Moreover , numerous patchy , well - limited fibrotic areas , compatible with post - necrotic tissue repair , were found after 6 - month temsirolimus therapy .', {'entities': [(84, 92, 'B_Disease')]}], ['Thus , temsirolimus reduced tumor burden through associated cytostatic and anti - angiogenic effects . This dual effect of temsirolimus on tumor tissue could contribute to its recently reported efficiency in refractory MCL resistant to conventional chemotherapy .', {'entities': [(28, 33, 'B_Disease'), (139, 144, 'B_Disease'), (219, 222, 'B_Disease')]}], ['Acute renal failure due to rifampicin .', {'entities': [(0, 5, 'B_Disease'), (6, 11, 'I_Disease'), (12, 19, 'I_Disease')]}], ['A 23 - year - old male patient with bacteriologically proven pulmonary tuberculosis was treated with the various regimens of antituberculosis drugs for nearly 15 months .', {'entities': [(61, 70, 'B_Disease'), (71, 83, 'I_Disease')]}], ['Rifampicin was administered thrice as one of the 3 - 4 drug regimen and each time he developed untoward side effects like nausea , vomiting and fever with chills and rigors .', {'entities': [(122, 128, 'B_Disease'), (131, 139, 'B_Disease'), (144, 149, 'B_Disease')]}], ['Syncope caused by hyperkalemia during use of a combined therapy with the angiotensin - converting enzyme inhibitor and spironolactone .', {'entities': [(0, 7, 'B_Disease'), (18, 30, 'B_Disease')]}], ['A 76 year - old woman with a history of coronary artery bypass grafting and prior myocardial infarction was transferred to the emergency room with loss of consciousness due to marked bradycardia caused by hyperkalemia .', {'entities': [(82, 92, 'B_Disease'), (93, 103, 'I_Disease'), (147, 151, 'B_Disease'), (152, 154, 'I_Disease'), (155, 168, 'I_Disease'), (183, 194, 'B_Disease'), (205, 217, 'B_Disease')]}], ['The cause of hyperkalemia was considered to be several doses of spiranolactone , an aldosterone antagonist , in addition to the long - term intake of ramipril , an ACE inhibitor .', {'entities': [(13, 25, 'B_Disease')]}], ['Clinicians should be alert to the possibility of hyperkalemia , especially in elderly patients using ACE / ARB in combination with potassium sparing agents and who have mild renal disturbance .', {'entities': [(49, 61, 'B_Disease'), (174, 179, 'B_Disease'), (180, 191, 'I_Disease')]}], ['Diffuse skeletal pain after administration of alendronate .', {'entities': [(17, 21, 'B_Disease')]}], ['BACKGROUND : Osteoporosis is caused by bone resorption in excess of bone formation , and bisphosphonates , are used to inhibit bone resorption .', {'entities': [(13, 25, 'B_Disease')]}], ['Alendronate , a biphosphonate , is effective for both the treatment and prevention of osteoporosis in postmenopausal women .', {'entities': [(86, 98, 'B_Disease')]}], ['Musculoskeletal pain may be an important side effect in these patients .', {'entities': [(0, 15, 'B_Disease'), (16, 20, 'I_Disease')]}], ['We presented a patient admitted to our out - patient clinic with diffuse skeletal pain after three consecutive administration of alendronate .', {'entities': [(82, 86, 'B_Disease')]}], ['CONCLUSION : We conclude that patients with osteoporosis can report pain , and bisphosphonate - related pain should also be considered before ascribing this complaint to osteoporosis .', {'entities': [(44, 56, 'B_Disease'), (68, 72, 'B_Disease'), (104, 108, 'B_Disease'), (170, 182, 'B_Disease')]}], ['Cerebrospinal fluid penetration of high - dose daptomycin in suspected Staphylococcus aureus meningitis .', {'entities': [(93, 103, 'B_Disease')]}], ['OBJECTIVE : To report a case of methicillin - sensitive Staphylococcus aureus ( MSSA ) bacteremia with suspected MSSA meningitis treated with high - dose daptomycin assessed with concurrent serum and cerebrospinal fluid ( CSF ) concentrations .', {'entities': [(87, 97, 'B_Disease'), (118, 128, 'B_Disease')]}], ['CASE SUMMARY : A 54 - year - old male presented to the emergency department with generalized weakness and presumed health - care - associated pneumonia shown on chest radiograph .', {'entities': [(93, 101, 'B_Disease'), (142, 151, 'B_Disease')]}], ['On day 8 , the patient developed acute renal failure ( serum creatinine 1 . 9 mg / dL , increased from 1 . 2 mg / dL the previous day and 0 . 8 mg / dL on admission ) .', {'entities': [(33, 38, 'B_Disease'), (39, 44, 'I_Disease'), (45, 52, 'I_Disease')]}], [\"The patient ' s Glasgow Coma Score was 3 , with normal findings shown on computed tomography scan of the head 72 hours following an episode of cardiac arrest on day 10 .\", {'entities': [(143, 150, 'B_Disease'), (151, 157, 'I_Disease')]}], ['The patient experienced relapsing MSSA bacteremia on day 9 , increasing the suspicion for a central nervous system ( CNS ) infection .', {'entities': [(39, 49, 'B_Disease'), (123, 132, 'B_Disease')]}], [\"Nafcillin was discontinued and daptomycin 9 mg / kg daily was initiated for suspected meningitis and was continued until the patient ' s death on day 16 .\", {'entities': [(86, 96, 'B_Disease')]}], ['DISCUSSION : Daptomycin was initiated in our patient secondary to possible nafcillin - induced acute interstitial nephritis and relapsing bacteremia .', {'entities': [(101, 113, 'B_Disease'), (114, 123, 'I_Disease'), (138, 148, 'B_Disease')]}], ['CONCLUSIONS : High - dose daptomycin may be an alternative option for MSSA bacteremia with or without a CNS source in patients who have failed or cannot tolerate standard therapy .', {'entities': [(75, 85, 'B_Disease')]}], ['Further clinical evaluation in patients with confirmed meningitis is warranted .', {'entities': [(55, 65, 'B_Disease')]}], ['The role of nitric oxide in convulsions induced by lindane in rats .', {'entities': [(28, 39, 'B_Disease')]}], ['It evokes convulsions mainly trough the blockage of GABA ( A ) receptors .', {'entities': [(10, 21, 'B_Disease')]}], ['Nitric oxide ( NO ) , gaseous neurotransmitter , has contradictor role in epileptogenesis due to opposite effects of L - arginine , precursor of NO syntheses ( NOS ) , and L - NAME ( NOS inhibitor ) observed in different epilepsy models .', {'entities': [(221, 229, 'B_Disease')]}], ['The aim of the current study was to determine the effects of NO on the behavioral and EEG characteristics of lindane - induced epilepsy in male Wistar albino rats .', {'entities': [(127, 135, 'B_Disease')]}], ['The administration of L - arginine ( 600 , 800 and 1000 mg / kg , i . p . ) in dose - dependent manner significantly increased convulsion incidence and severity and shortened latency time to first convulsion elicited by lower lindane dose ( 4 mg / kg , i . p . ) .', {'entities': [(127, 137, 'B_Disease'), (197, 207, 'B_Disease')]}], ['On the contrary , pretreatment with L - NAME ( 500 , 700 and 900 mg / kg , i . p . ) decreased convulsion incidence and severity and prolonged latency time to convulsion following injection with a convulsive dose of lindane ( 8 mg / kg , i . p . ) .', {'entities': [(95, 105, 'B_Disease'), (159, 169, 'B_Disease'), (197, 207, 'B_Disease')]}], ['These results support the conclusion that NO plays a role of endogenous convulsant in rat model of lindane seizures .', {'entities': [(107, 115, 'B_Disease')]}], ['Severe polyneuropathy and motor loss after intrathecal thiotepa combination chemotherapy : description of two cases .', {'entities': [(7, 21, 'B_Disease')]}], ['Two cases of severe delayed neurologic toxicity related to the administration of intrathecal ( IT ) combination chemotherapy including thiotepa ( TSPA ) are presented .', {'entities': [(28, 38, 'B_Disease'), (39, 47, 'I_Disease')]}], ['Both cases developed axonal neuropathy with motor predominance in the lower extremities 1 and 6 months after IT chemotherapy was administered .', {'entities': [(21, 27, 'B_Disease'), (28, 38, 'I_Disease')]}], ['Neurologic toxicities have been described with IT - methotrexate , IT - cytosine arabinoside and IT - TSPA .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease')]}], ['To our knowledge , however , axonal neuropathy following administration of these three agents has not been previously described .', {'entities': [(29, 35, 'B_Disease'), (36, 46, 'I_Disease')]}], ['In spite of the fact that TSPA is a useful IT agent , its combination with MTX , ara - C and radiotherapy could cause severe neurotoxicity .', {'entities': [(125, 138, 'B_Disease')]}], ['Vasodilation of large and small coronary vessels and hypotension induced by cromakalim and pinacidil were not affected by prior combined beta adrenergic and muscarinic receptors blockade but drug - induced tachycardia was abolished .', {'entities': [(53, 64, 'B_Disease'), (206, 217, 'B_Disease')]}], ['Mefenamic acid - induced neutropenia and renal failure in elderly females with hypothyroidism .', {'entities': [(25, 36, 'B_Disease'), (41, 46, 'B_Disease'), (47, 54, 'I_Disease'), (79, 93, 'B_Disease')]}], ['We report mefenamic acid - induced non - oliguric renal failure and severe neutropenia occurring simultaneously in two elderly females .', {'entities': [(50, 55, 'B_Disease'), (56, 63, 'I_Disease'), (75, 86, 'B_Disease')]}], ['The neutropenia was due to maturation arrest of the myeloid series in one patient .', {'entities': [(4, 15, 'B_Disease')]}], ['Both patients were also hypothyroid , but it is not clear whether this was a predisposing factor to the development of these adverse reactions .', {'entities': [(24, 35, 'B_Disease')]}], ['However , it would seem prudent not to use mefenamic acid in hypothyroid patients until the hypothyroidism has been corrected .', {'entities': [(61, 72, 'B_Disease'), (92, 106, 'B_Disease')]}], ['Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy .', {'entities': [(12, 25, 'B_Disease')]}], ['Fourteen of 39 dialysis patients ( 36 % ) became hypercalcemic after switching to calcium carbonate as their principal phosphate binder .', {'entities': [(49, 62, 'B_Disease')]}], ['In order to identify risk factors associated with the development of hypercalcemia , indirect parameters of intestinal calcium reabsorption and bone turnover rate in these 14 patients were compared with results in 14 eucalcemic patients matched for age , sex , length of time on dialysis , and etiology of renal disease .', {'entities': [(69, 82, 'B_Disease'), (306, 311, 'B_Disease'), (312, 319, 'I_Disease')]}], ['In addition to experiencing hypercalcemic episodes with peak calcium values of 2 . 7 to 3 . 8 mmol / L ( 10 . 7 to 15 . 0 mg / dL ) , patients in the hypercalcemic group exhibited a significant increase in the mean calcium concentration obtained during 6 months before the switch , compared with the mean value obtained during the 7 months of observation after the switch ( 2 . 4 + / - 0 . 03 to 2 . 5 + / - 0 . 03 mmol / L [ 9 . 7 + / - 0 . 2 to 10 . 2 + / - 0 . 1 mg / dL ] , P = 0 . 006 ) .', {'entities': [(28, 41, 'B_Disease'), (150, 163, 'B_Disease')]}], ['Late - onset scleroderma renal crisis induced by tacrolimus and prednisolone : a case report .', {'entities': [(13, 24, 'B_Disease'), (25, 30, 'I_Disease'), (31, 37, 'I_Disease')]}], ['Scleroderma renal crisis ( SRC ) is a rare complication of systemic sclerosis ( SSc ) but can be severe enough to require temporary or permanent renal replacement therapy .', {'entities': [(0, 11, 'B_Disease'), (12, 17, 'I_Disease'), (18, 24, 'I_Disease'), (27, 30, 'B_Disease'), (59, 67, 'B_Disease'), (68, 77, 'I_Disease'), (80, 83, 'B_Disease')]}], ['Moderate to high dose corticosteroid use is recognized as a major risk factor for SRC .', {'entities': [(82, 85, 'B_Disease')]}], ['Furthermore , there have been reports of thrombotic microangiopathy precipitated by cyclosporine in patients with SSc .', {'entities': [(41, 51, 'B_Disease'), (52, 67, 'I_Disease'), (114, 117, 'B_Disease')]}], ['In this article , we report a patient with SRC induced by tacrolimus and corticosteroids .', {'entities': [(43, 46, 'B_Disease')]}], ['The aim of this work is to call attention to the risk of tacrolimus use in patients with SSc .', {'entities': [(89, 92, 'B_Disease')]}], ['Methyldopa - induced hemolytic anemia in a 15 year old presenting as near - syncope .', {'entities': [(21, 30, 'B_Disease'), (31, 37, 'I_Disease'), (76, 83, 'B_Disease')]}], ['Methyldopa causes an autoimmune hemolytic anemia in a small percentage of patients who take the drug .', {'entities': [(21, 31, 'B_Disease'), (32, 41, 'I_Disease'), (42, 48, 'I_Disease')]}], ['We report a case of methyldopa - induced hemolytic anemia in a 15 - year - old boy who presented to the emergency department with near - syncope .', {'entities': [(41, 50, 'B_Disease'), (51, 57, 'I_Disease'), (104, 113, 'B_Disease'), (114, 124, 'I_Disease'), (137, 144, 'B_Disease')]}], ['The boy had been treated with intravenous methyldopa during a trauma admission seven weeks prior to presentation .', {'entities': [(62, 68, 'B_Disease')]}], ['A brief review of autoimmune and drug - induced hemolytic anemias is provided .', {'entities': [(48, 57, 'B_Disease'), (58, 65, 'I_Disease')]}], ['The risk and associated factors of methamphetamine psychosis in methamphetamine - dependent patients in Malaysia .', {'entities': [(51, 60, 'B_Disease')]}], ['OBJECTIVE : The objective of this study was to determine the risk of lifetime and current methamphetamine - induced psychosis in patients with methamphetamine dependence .', {'entities': [(116, 125, 'B_Disease')]}], ['The association between psychiatric co - morbidity and methamphetamine - induced psychosis was also studied .', {'entities': [(81, 90, 'B_Disease')]}], ['Patients with the diagnosis of methamphetamine based on DSM - IV were interviewed using the Mini International Neuropsychiatric Interview ( M . I . N . I . ) for methamphetamine - induced psychosis and other Axis I psychiatric disorders .', {'entities': [(188, 197, 'B_Disease'), (215, 226, 'B_Disease'), (227, 236, 'I_Disease')]}], ['RESULTS : Of 292 subjects , 47 . 9 % of the subjects had a past history of psychotic symptoms and 13 . 0 % of the patients were having current psychotic symptoms .', {'entities': [(75, 84, 'B_Disease'), (85, 93, 'I_Disease'), (143, 152, 'B_Disease'), (153, 161, 'I_Disease')]}], ['Co - morbid major depressive disorder ( OR = 7 . 18 , 95 CI = 2 . 612 - 19 . 708 ) , bipolar disorder ( OR = 13 . 807 , 95 CI = 5 . 194 - 36 . 706 ) , antisocial personality disorder ( OR = 12 . 619 , 95 CI = 6 . 702 - 23 . 759 ) and heavy methamphetamine uses were significantly associated with lifetime methamphetamine - induced psychosis after adjusted for other factors .', {'entities': [(18, 28, 'B_Disease'), (29, 37, 'I_Disease'), (85, 92, 'B_Disease'), (93, 101, 'I_Disease'), (151, 161, 'B_Disease'), (162, 173, 'I_Disease'), (174, 182, 'I_Disease'), (331, 340, 'B_Disease')]}], ['Major depressive disorder ( OR = 2 . 870 , CI = 1 . 154 - 7 . 142 ) and antisocial personality disorder ( OR = 3 . 299 , 95 CI = 1 . 375 - 7 . 914 ) were the only factors associated with current psychosis .', {'entities': [(0, 5, 'B_Disease'), (6, 16, 'I_Disease'), (17, 25, 'I_Disease'), (72, 82, 'B_Disease'), (83, 94, 'I_Disease'), (95, 103, 'I_Disease'), (195, 204, 'B_Disease')]}], ['CONCLUSION : There was a high risk of psychosis in patients with methamphetamine dependence .', {'entities': [(38, 47, 'B_Disease')]}], ['It was associated with co - morbid affective disorder , antisocial personality , and heavy methamphetamine use .', {'entities': [(35, 44, 'B_Disease'), (45, 53, 'I_Disease'), (56, 66, 'B_Disease'), (67, 78, 'I_Disease')]}], ['It is recommended that all cases of methamphetamine dependence should be screened for psychotic symptoms .', {'entities': [(86, 95, 'B_Disease'), (96, 104, 'I_Disease')]}], [\"Cerebellar sensory processing alterations impact motor cortical plasticity in Parkinson ' s disease : clues from dyskinetic patients .\", {'entities': [(78, 87, 'B_Disease'), (88, 89, 'I_Disease'), (90, 91, 'I_Disease'), (92, 99, 'I_Disease'), (113, 123, 'B_Disease')]}], [\"The plasticity of primary motor cortex ( M1 ) in patients with Parkinson ' s disease ( PD ) and levodopa - induced dyskinesias ( LIDs ) is severely impaired .\", {'entities': [(63, 72, 'B_Disease'), (73, 74, 'I_Disease'), (75, 76, 'I_Disease'), (77, 84, 'I_Disease'), (87, 89, 'B_Disease'), (115, 126, 'B_Disease'), (129, 133, 'B_Disease')]}], ['This study demonstrates that the deficient sensorimotor M1 plasticity in 16 patients with LIDs could be reinstated by a single session of real inhibitory cerebellar stimulation but not sham stimulation .', {'entities': [(90, 94, 'B_Disease')]}], ['The benefit of inhibitory cerebellar stimulation on LIDs is known .', {'entities': [(52, 56, 'B_Disease')]}], ['To explore whether this benefit is linked to the restoration of sensorimotor plasticity of M1 , we conducted an additional study looking at changes in LIDs and PAS - induced plasticity after 10 sessions of either bilateral , real inhibitory cerebellar stimulation or sham stimulation .', {'entities': [(151, 155, 'B_Disease')]}], ['These results suggest that alterations in cerebellar sensory processing function , occurring secondary to abnormal basal ganglia signals reaching it , may be an important element contributing to the maladaptive sensorimotor plasticity of M1 and the emergence of abnormal involuntary movements .', {'entities': [(262, 270, 'B_Disease'), (271, 282, 'I_Disease'), (283, 292, 'I_Disease')]}], ['The long - term safety of danazol in women with hereditary angioedema .', {'entities': [(48, 58, 'B_Disease'), (59, 69, 'I_Disease')]}], ['We therefore investigated the long - term safety of danazol by performing a retrospective chart review of 60 female patients with hereditary angioedema treated with danazol for a continuous period of 6 months or longer .', {'entities': [(130, 140, 'B_Disease'), (141, 151, 'I_Disease')]}], ['Menstrual abnormalities ( 79 % ) , weight gain ( 60 % ) , muscle cramps / myalgias ( 40 % ) , and transaminase elevations ( 40 % ) were the most common adverse reactions .', {'entities': [(0, 9, 'B_Disease'), (10, 23, 'I_Disease'), (35, 41, 'B_Disease'), (42, 46, 'I_Disease'), (58, 64, 'B_Disease'), (65, 71, 'I_Disease'), (74, 82, 'B_Disease')]}], ['The function of P2X3 receptor and NK1 receptor antagonists on cyclophosphamide - induced cystitis in rats .', {'entities': [(89, 97, 'B_Disease')]}], ['PURPOSE : The purpose of the study is to explore the function of P2X3 and NK1 receptors antagonists on cyclophosphamide ( CYP ) - induced cystitis in rats .', {'entities': [(138, 146, 'B_Disease')]}], ['Spontaneous pain behaviors following the administration of CYP were observed .', {'entities': [(12, 16, 'B_Disease')]}], ['RESULTS : Cyclophosphamide treatment increased the spontaneous pain behaviors scores .', {'entities': [(63, 67, 'B_Disease')]}], [\"Histological changes evident in model and intervention groups rats ' bladder included edema , vasodilation , and infiltration of inflammatory cells .\", {'entities': [(86, 91, 'B_Disease')]}], ['CONCLUSIONS : In CYP - induced cystitis , the expression of P2X3 and NK1 receptors increased in urothelium and / or suburothelium .', {'entities': [(31, 39, 'B_Disease')]}], ['Patient tolerance study of topical chlorhexidine diphosphanilate : a new topical agent for burns .', {'entities': [(91, 96, 'B_Disease')]}], ['Effective topical antimicrobial agents decrease infection and mortality in burn patients .', {'entities': [(48, 57, 'B_Disease'), (75, 79, 'B_Disease')]}], ['Chlorhexidine phosphanilate ( CHP ) , a new broad - spectrum antimicrobial agent , has been evaluated as a topical burn wound dressing in cream form , but preliminary clinical trials reported that it was painful upon application .', {'entities': [(115, 119, 'B_Disease')]}], ['Twenty - nine burn patients , each with two similar burns which could be separately treated , were given pairs of treatments at successive 12 - h intervals over a 3 - day period .', {'entities': [(14, 18, 'B_Disease'), (52, 57, 'B_Disease')]}], ['One burn site was treated with each of four different CHP concentrations , from 0 . 25 per cent to 2 per cent , their vehicle , and 1 per cent silver sulphadiazine ( AgSD ) cream , an antimicrobial agent frequently used for topical treatment of burn wounds .', {'entities': [(4, 8, 'B_Disease'), (245, 249, 'B_Disease')]}], [\"There was a direct relationship between CHP concentration and patients ' ratings of pain on an analogue scale .\", {'entities': [(84, 88, 'B_Disease')]}], ['The 0 . 25 per cent CHP cream was closest to AgSD in pain tolerance ; however , none of the treatments differed statistically from AgSD or from each other .', {'entities': [(53, 57, 'B_Disease')]}], ['Acute hepatitis associated with clopidogrel : a case report and review of the literature .', {'entities': [(6, 15, 'B_Disease')]}], ['Drug - induced hepatotoxicity is a common cause of acute hepatitis , and the recognition of the responsible drug may be difficult .', {'entities': [(15, 29, 'B_Disease'), (57, 66, 'B_Disease')]}], ['We describe a case of clopidogrel - related acute hepatitis .', {'entities': [(50, 59, 'B_Disease')]}], ['Reports about cases of hepatotoxicity due to clopidogrel are increasing in the last few years , after the increased use of this drug .', {'entities': [(23, 37, 'B_Disease')]}], ['In conclusion , we believe that physicians should carefully consider the risk of drug - induced hepatic injury when clopidogrel is prescribed .', {'entities': [(96, 103, 'B_Disease'), (104, 110, 'I_Disease')]}], ['Bortezomib and dexamethasone as salvage therapy in patients with relapsed / refractory multiple myeloma : analysis of long - term clinical outcomes .', {'entities': [(87, 95, 'B_Disease'), (96, 103, 'I_Disease')]}], ['Bortezomib ( bort ) - dexamethasone ( dex ) is an effective therapy for relapsed / refractory ( R / R ) multiple myeloma ( MM ) .', {'entities': [(104, 112, 'B_Disease'), (113, 120, 'I_Disease'), (123, 125, 'B_Disease')]}], ['This retrospective study investigated the combination of bort ( 1 . 3 mg / m ( 2 ) on days 1 , 4 , 8 , and 11 every 3 weeks ) and dex ( 20 mg on the day of and the day after bort ) as salvage treatment in 85 patients with R / R MM after prior autologous stem cell transplantation or conventional chemotherapy .', {'entities': [(228, 230, 'B_Disease')]}], ['The most relevant adverse event was peripheral neuropathy , which occurred in 78 % of the patients ( grade II , 38 % ; grade III , 21 % ) and led to treatment discontinuation in 6 % .', {'entities': [(36, 46, 'B_Disease'), (47, 57, 'I_Disease')]}], ['Bort - dex was an effective salvage treatment for MM patients , particularly for those in first relapse .', {'entities': [(50, 52, 'B_Disease')]}], ['Pubertal exposure to Bisphenol A increases anxiety - like behavior and decreases acetylcholinesterase activity of hippocampus in adult male mice .', {'entities': [(43, 50, 'B_Disease')]}], ['Acetylcholinesterase ( AChE ) is a regulatory enzyme which is involved in anxiety - like behavior .', {'entities': [(74, 81, 'B_Disease')]}], ['Results from our behavioral phenotyping indicated that anxiety - like behavior was increased in mice exposed to BPA .', {'entities': [(55, 62, 'B_Disease')]}], ['Our findings showed that pubertal BPA exposure increased anxiety - like behavior , which may be associated with decreased AChE activity of the hippocampus in adult male mice .', {'entities': [(57, 64, 'B_Disease')]}], ['Further studies are necessary to investigate the cholinergic signaling of the hippocampus in PBE induced anxiety - like behaviors .', {'entities': [(105, 112, 'B_Disease')]}], ['Biochemical effects of Solidago virgaurea extract on experimental cardiotoxicity .', {'entities': [(66, 80, 'B_Disease')]}], ['Cardiovascular diseases ( CVDs ) are the major health problem of advanced as well as developing countries of the world .', {'entities': [(0, 14, 'B_Disease'), (15, 23, 'I_Disease'), (26, 30, 'B_Disease')]}], ['The aim of the present study was to investigate the protective effect of the Solidago virgaurea extract on isoproterenol - induced cardiotoxicity in rats .', {'entities': [(131, 145, 'B_Disease')]}], ['\" Real - world \" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed / refractory multiple myeloma who were treated according to the standard clinical practice : a study of the Greek Myeloma Study Group .', {'entities': [(122, 130, 'B_Disease'), (131, 138, 'I_Disease'), (223, 230, 'B_Disease')]}], ['Lenalidomide and dexamethasone ( RD ) is a standard of care for relapsed / refractory multiple myeloma ( RRMM ) , but there is limited published data on its efficacy and safety in the \" real world \" ( RW ) , according to the International Society of Pharmacoeconomics and Outcomes Research definition .', {'entities': [(86, 94, 'B_Disease'), (95, 102, 'I_Disease'), (105, 109, 'B_Disease')]}], ['We studied 212 RRMM patients who received RD in RW .', {'entities': [(15, 19, 'B_Disease')]}], ['Adverse events were reported in 68 . 9 % of patients ( myelosuppression in 49 . 4 % ) and 12 . 7 % of patients needed hospitalization .', {'entities': [(55, 71, 'B_Disease')]}], ['Peripheral neuropathy was observed only in 2 . 5 % of patients and deep vein thrombosis in 5 . 7 % .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (67, 71, 'B_Disease'), (72, 76, 'I_Disease'), (77, 87, 'I_Disease')]}], ['Our study confirms that RD is effective and safe in RRMM in the RW ; it produces durable responses especially in patients who continue on treatment till progression and improves humoral immunity even in patients with stable disease .', {'entities': [(52, 56, 'B_Disease')]}], ['It is characterized by its intense urotoxic action , leading to hemorrhagic cystitis .', {'entities': [(64, 75, 'B_Disease'), (76, 84, 'I_Disease')]}], [\"Mesna significantly reduces IFO ' s genotoxicity , while when administered in high concentrations it acts in an inhibitory fashion on the cytostatic action of the drug .\", {'entities': [(36, 48, 'B_Disease')]}], [\"Risk factors and predictors of levodopa - induced dyskinesia among multiethnic Malaysians with Parkinson ' s disease .\", {'entities': [(50, 60, 'B_Disease'), (95, 104, 'B_Disease'), (105, 106, 'I_Disease'), (107, 108, 'I_Disease'), (109, 116, 'I_Disease')]}], [\"Chronic pulsatile levodopa therapy for Parkinson ' s disease ( PD ) leads to the development of motor fluctuations and dyskinesia .\", {'entities': [(39, 48, 'B_Disease'), (49, 50, 'I_Disease'), (51, 52, 'I_Disease'), (53, 60, 'I_Disease'), (63, 65, 'B_Disease'), (119, 129, 'B_Disease')]}], ['We studied the prevalence and predictors of levodopa - induced dyskinesia among multiethnic Malaysian patients with PD .', {'entities': [(63, 73, 'B_Disease'), (116, 118, 'B_Disease')]}], ['METHODS : This is a cross - sectional study involving 95 patients with PD on uninterrupted levodopa therapy for at least 6 months .', {'entities': [(71, 73, 'B_Disease')]}], ['The predictors of dyskinesia were determined using multivariate logistic regression analysis .', {'entities': [(18, 28, 'B_Disease')]}], ['Dyskinesia was present in 44 % ( n = 42 ) with median levodopa therapy of 3 years .', {'entities': [(0, 10, 'B_Disease')]}], ['Eighty - one percent of patients with dyskinesia had clinical fluctuations .', {'entities': [(38, 48, 'B_Disease')]}], ['Patients with dyskinesia had lower onset age ( p < 0 . 001 ) , longer duration of levodopa therapy ( p < 0 . 001 ) , longer disease duration ( p < 0 . 001 ) , higher total daily levodopa dose ( p < 0 . 001 ) , and higher total UPDRS scores ( p = 0 . 005 ) than patients without dyskinesia .', {'entities': [(14, 24, 'B_Disease'), (278, 288, 'B_Disease')]}], ['The three significant predictors of dyskinesia were duration of levodopa therapy , onset age , and total daily levodopa dose .', {'entities': [(36, 46, 'B_Disease')]}], ['CONCLUSIONS : The prevalence of levodopa - induced dyskinesia in our patients was 44 % .', {'entities': [(51, 61, 'B_Disease')]}], ['Dose - dependent neurotoxicity of high - dose busulfan in children : a clinical and pharmacological study .', {'entities': [(17, 30, 'B_Disease')]}], ['Busulfan is known to be neurotoxic in animals and humans , but its acute neurotoxicity remains poorly characterized in children .', {'entities': [(24, 34, 'B_Disease'), (73, 86, 'B_Disease')]}], ['We report here a retrospective study of 123 children ( median age , 6 . 5 years ) receiving high - dose busulfan in combined chemotherapy before bone marrow transplantation for malignant solid tumors , brain tumors excluded .', {'entities': [(193, 199, 'B_Disease'), (202, 207, 'B_Disease'), (208, 214, 'I_Disease')]}], ['Ninety - six patients were not given anticonvulsive prophylaxis ; 7 ( 7 . 5 % ) developed seizures during the 4 days of the busulfan course or within 24 h after the last dosing .', {'entities': [(90, 98, 'B_Disease')]}], ['When the total busulfan dose was taken into account , there was a significant difference in terms of neurotoxicity incidence among patients under 16 mg / kg ( 1 of 57 , 1 . 7 % ) and patients under 600 mg / m2 ( 6 of 39 , 15 . 4 % ) ( P less than 0 . 02 ) .', {'entities': [(101, 114, 'B_Disease')]}], ['Twenty - seven patients were given a 600 - mg / m2 busulfan total dose with continuous i . v . infusion of clonazepam ; none had any neurological symptoms .', {'entities': [(133, 145, 'B_Disease'), (146, 154, 'I_Disease')]}], ['Busulfan levels were measured by a gas chromatographic - mass spectrometry assay in the plasma and cerebrospinal fluid of 9 children without central nervous system disease under 600 mg / m2 busulfan with clonazepam : busulfan cerebrospinal fluid : plasma ratio was 1 . 39 .', {'entities': [(141, 148, 'B_Disease'), (149, 156, 'I_Disease'), (157, 163, 'I_Disease'), (164, 171, 'I_Disease')]}], ['This study shows that busulfan neurotoxicity is dose - dependent in children and efficiently prevented by clonazepam .', {'entities': [(31, 44, 'B_Disease')]}], ['A busulfan dose calculated on the basis of body surface area , resulting in higher doses in young children , was followed by increased neurotoxicity , close to neurotoxicity incidence observed in adults .', {'entities': [(135, 148, 'B_Disease'), (160, 173, 'B_Disease')]}], ['An unexpected diagnosis in a renal - transplant patient with proteinuria treated with everolimus : AL amyloidosis .', {'entities': [(61, 72, 'B_Disease'), (99, 101, 'B_Disease'), (102, 113, 'B_Disease')]}], ['Proteinuria is an expected complication in transplant patients treated with mammalian target of rapamycin inhibitors ( mTOR - i ) .', {'entities': [(0, 11, 'B_Disease')]}], ['However , clinical suspicion should always be supported by histological evidence in order to investigate potential alternate diagnoses such as acute or chronic rejection , interstitial fibrosis and tubular atrophy , or recurrent or de novo glomerulopathy .', {'entities': [(185, 193, 'B_Disease'), (206, 213, 'B_Disease'), (240, 254, 'B_Disease')]}], ['In this case we report the unexpected diagnosis of amyloidosis in a renal - transplant patient with pre - transplant monoclonal gammapathy of undetermined significance who developed proteinuria after conversion from tacrolimus to everolimus .', {'entities': [(51, 62, 'B_Disease'), (182, 193, 'B_Disease')]}], ['Long - term oral galactose treatment prevents cognitive deficits in male Wistar rats treated intracerebroventricularly with streptozotocin .', {'entities': [(46, 55, 'B_Disease'), (56, 64, 'I_Disease')]}], [\"Basic and clinical research has demonstrated that dementia of sporadic Alzheimer ' s disease ( sAD ) type is associated with dysfunction of the insulin - receptor ( IR ) system followed by decreased glucose transport via glucose transporter GLUT4 and decreased glucose metabolism in brain cells .\", {'entities': [(50, 58, 'B_Disease'), (71, 80, 'B_Disease'), (81, 82, 'I_Disease'), (83, 84, 'I_Disease'), (85, 92, 'I_Disease')]}], ['Exclusively parenteral daily injections of galactose induce memory deterioration in rodents and are used to generate animal aging model , but the effects of oral galactose treatment on cognitive functions have never been tested .', {'entities': [(60, 66, 'B_Disease'), (67, 80, 'I_Disease')]}], ['We have investigated the effects of continuous daily oral galactose ( 200 mg / kg / day ) treatment on cognitive deficits in streptozotocin - induced ( STZ - icv ) rat model of sAD , tested by Morris Water Maze and Passive Avoidance test , respectively .', {'entities': [(103, 112, 'B_Disease'), (113, 121, 'I_Disease')]}], ['One month of oral galactose treatment initiated immediately after the STZ - icv administration , successfully prevented development of the STZ - icv - induced cognitive deficits .', {'entities': [(159, 168, 'B_Disease'), (169, 177, 'I_Disease')]}], ['Oral galactose exposure might have beneficial effects on learning and memory ability and could be worth investigating for improvement of cognitive deficits associated with glucose hypometabolism in AD .', {'entities': [(137, 146, 'B_Disease'), (147, 155, 'I_Disease'), (172, 179, 'B_Disease'), (180, 194, 'I_Disease'), (198, 200, 'B_Disease')]}], ['An investigation of the pattern of kidney injury in HIV - positive persons exposed to tenofovir disoproxil fumarate : an examination of a large population database ( MHRA database ) .', {'entities': [(35, 41, 'B_Disease'), (42, 48, 'I_Disease')]}], ['Reports that satisfy defined criteria were classified as acute kidney injury , kidney tubular dysfunction and Fanconi syndrome .', {'entities': [(57, 62, 'B_Disease'), (63, 69, 'I_Disease'), (70, 76, 'I_Disease'), (79, 85, 'B_Disease'), (86, 93, 'I_Disease'), (94, 105, 'I_Disease'), (110, 117, 'B_Disease'), (118, 126, 'I_Disease')]}], ['Of the 407 Yellow Card records analysed , 106 satisfied criteria for TDF - related kidney disease , of which 53 ( 50 % ) had features of kidney tubular dysfunction , 35 ( 33 % ) were found to have features of glomerular dysfunction and 18 ( 17 % ) had Fanconi syndrome .', {'entities': [(83, 89, 'B_Disease'), (90, 97, 'I_Disease'), (137, 143, 'B_Disease'), (144, 151, 'I_Disease'), (152, 163, 'I_Disease'), (209, 219, 'B_Disease'), (220, 231, 'I_Disease'), (252, 259, 'B_Disease'), (260, 268, 'I_Disease')]}], ['The incidence of hospitalisation for TDF kidney adverse effects was high , particularly amongst patients with features of Fanconi syndrome .', {'entities': [(122, 129, 'B_Disease'), (130, 138, 'I_Disease')]}], ['Incidence of postoperative delirium is high even in a population without known risk factors .', {'entities': [(13, 26, 'B_Disease'), (27, 35, 'I_Disease')]}], ['PURPOSE : Postoperative delirium is a recognized complication in populations at risk .', {'entities': [(10, 23, 'B_Disease'), (24, 32, 'I_Disease')]}], ['The aim of this study is to assess the prevalence of early postoperative delirium in a population without known risk factors admitted to the ICU for postoperative monitoring after elective major surgery .', {'entities': [(59, 72, 'B_Disease'), (73, 81, 'I_Disease')]}], ['Exclusion criteria were any preexisting predisposing factor for delirium or other potentially confounding neurological dysfunctions .', {'entities': [(64, 72, 'B_Disease'), (106, 118, 'B_Disease'), (119, 131, 'I_Disease')]}], ['Patients were assessed daily using the confusion assessment method for the ICU scale for 3 days after the surgical procedure .', {'entities': [(39, 48, 'B_Disease')]}], ['Early postoperative delirium incidence risk factors were then assessed through three different multiple regression models .', {'entities': [(6, 19, 'B_Disease'), (20, 28, 'I_Disease')]}], ['RESULTS : According to the confusion assessment method for the ICU scale , 28 % of patients were diagnosed with early postoperative delirium .', {'entities': [(118, 131, 'B_Disease'), (132, 140, 'I_Disease')]}], ['The use of thiopentone was significantly associated with an eight - fold - higher risk for delirium compared to propofol ( 57 . 1 % vs . 7 . 1 % , RR = 8 . 0 , X2 = 4 . 256 ; df = 1 ; 0 . 05 < p < 0 . 02 ) .', {'entities': [(91, 99, 'B_Disease')]}], ['CONCLUSION : In this study early postoperative delirium was found to be a very common complication after major surgery , even in a population without known risk factors .', {'entities': [(33, 46, 'B_Disease'), (47, 55, 'I_Disease')]}], ['A single neurotoxic dose of methamphetamine induces a long - lasting depressive - like behaviour in mice .', {'entities': [(9, 19, 'B_Disease'), (69, 79, 'B_Disease')]}], ['Methamphetamine ( METH ) triggers a disruption of the monoaminergic system and METH abuse leads to negative emotional states including depressive symptoms during drug withdrawal .', {'entities': [(135, 145, 'B_Disease'), (146, 154, 'I_Disease')]}], ['However , it is currently unknown if the acute toxic dosage of METH also causes a long - lasting depressive phenotype and persistent monoaminergic deficits .', {'entities': [(97, 107, 'B_Disease')]}], ['Thus , we now assessed the depressive - like behaviour in mice at early and long - term periods following a single high METH dose ( 30 mg / kg , i . p . ) .', {'entities': [(27, 37, 'B_Disease')]}], ['This depressive - like profile induced by METH was accompanied by a marked depletion of frontostriatal dopaminergic and serotonergic neurotransmission , indicated by a reduction in the levels of dopamine , DOPAC and HVA , tyrosine hydroxylase and serotonin , observed at both 3 and 49 days post - administration .', {'entities': [(5, 15, 'B_Disease')]}], ['In parallel , another neurochemical feature of depression - - astroglial dysfunction - - was unaffected in the cortex and the striatal levels of the astrocytic protein marker , glial fibrillary acidic protein , were only transiently increased at 3 days .', {'entities': [(47, 57, 'B_Disease')]}], ['These findings demonstrate for the first time that a single high dose of METH induces long - lasting depressive - like behaviour in mice associated with a persistent disruption of frontostriatal dopaminergic and serotonergic homoeostasis .', {'entities': [(101, 111, 'B_Disease')]}], ['Linezolid - induced optic neuropathy .', {'entities': [(20, 25, 'B_Disease'), (26, 36, 'I_Disease')]}], ['We describe a case of progressive loss of vision associated with linezolid therapy .', {'entities': [(34, 38, 'B_Disease'), (39, 41, 'I_Disease'), (42, 48, 'I_Disease')]}], ['A 45 - year - old male patient who was on treatment with multiple second - line anti - tuberculous drugs including linezolid and ethambutol for extensively drug - resistant tuberculosis ( XDR - TB ) presented to us with painless progressive loss of vision in both eyes .', {'entities': [(144, 155, 'B_Disease'), (156, 160, 'I_Disease'), (161, 162, 'I_Disease'), (163, 172, 'I_Disease'), (173, 185, 'I_Disease'), (188, 191, 'B_Disease'), (192, 193, 'I_Disease'), (194, 196, 'I_Disease'), (241, 245, 'B_Disease'), (246, 248, 'I_Disease'), (249, 255, 'I_Disease')]}], ['Color vision was defective and fundus examination revealed optic disc edema in both eyes .', {'entities': [(59, 64, 'B_Disease'), (65, 69, 'I_Disease'), (70, 75, 'I_Disease')]}], ['Ethambutol - induced toxic optic neuropathy was suspected and tablet ethambutol was withdrawn .', {'entities': [(21, 26, 'B_Disease'), (27, 32, 'I_Disease'), (33, 43, 'I_Disease')]}], ['Deterioration of vision occurred despite withdrawal of ethambutol .', {'entities': [(0, 13, 'B_Disease'), (14, 16, 'I_Disease'), (17, 23, 'I_Disease')]}], ['Resuscitation with lipid , epinephrine , or both in levobupivacaine - induced cardiac toxicity in newborn piglets .', {'entities': [(78, 85, 'B_Disease'), (86, 94, 'I_Disease')]}], ['BACKGROUND : The optimal dosing regimens of lipid emulsion , epinephrine , or both are not yet determined in neonates in cases of local anaesthetic systemic toxicity ( LAST ) .', {'entities': [(157, 165, 'B_Disease')]}], ['METHODS : Newborn piglets received levobupivacaine until cardiovascular collapse occurred .', {'entities': [(57, 71, 'B_Disease'), (72, 80, 'I_Disease')]}], ['Standard cardiopulmonary resuscitation was started and electrocardiogram ( ECG ) was monitored for ventricular tachycardia , fibrillation , or QRS prolongation .', {'entities': [(99, 110, 'B_Disease'), (111, 122, 'I_Disease'), (125, 137, 'B_Disease')]}], ['Incidence of heparin - induced thrombocytopenia type II and postoperative recovery of platelet count in liver graft recipients : a retrospective cohort analysis .', {'entities': [(31, 47, 'B_Disease'), (48, 52, 'I_Disease'), (53, 55, 'I_Disease')]}], ['BACKGROUND : Thrombocytopenia in patients with end - stage liver disease is a common disorder caused mainly by portal hypertension , low levels of thrombopoetin , and endotoxemia .', {'entities': [(13, 29, 'B_Disease'), (47, 50, 'B_Disease'), (51, 52, 'I_Disease'), (53, 58, 'I_Disease'), (59, 64, 'I_Disease'), (65, 72, 'I_Disease'), (111, 117, 'B_Disease'), (118, 130, 'I_Disease'), (167, 178, 'B_Disease')]}], ['The impact of immune - mediated heparin - induced thrombocytopenia type II ( HIT type II ) as a cause of thrombocytopenia after liver transplantation is not yet understood , with few literature citations reporting contradictory results .', {'entities': [(50, 66, 'B_Disease'), (67, 71, 'I_Disease'), (72, 74, 'I_Disease'), (77, 80, 'B_Disease'), (81, 85, 'I_Disease'), (86, 88, 'I_Disease'), (105, 121, 'B_Disease')]}], ['The aim of our study was to demonstrate the perioperative course of thrombocytopenia after liver transplantation and determine the occurrence of clinical HIT type II .', {'entities': [(68, 84, 'B_Disease'), (154, 157, 'B_Disease'), (158, 162, 'I_Disease'), (163, 165, 'I_Disease')]}], ['METHOD : We retrospectively evaluated the medical records of 205 consecutive adult patients who underwent full - size liver transplantation between January 2006 and December 2010 due to end - stage or malignant liver disease .', {'entities': [(186, 189, 'B_Disease'), (190, 191, 'I_Disease'), (192, 197, 'I_Disease'), (198, 200, 'I_Disease'), (201, 210, 'I_Disease'), (211, 216, 'I_Disease'), (217, 224, 'I_Disease')]}], ['Preoperative platelet count , postoperative course of platelets , and clinical signs of HIT type II were analyzed .', {'entities': [(88, 91, 'B_Disease'), (92, 96, 'I_Disease'), (97, 99, 'I_Disease')]}], ['RESULTS : A total of 155 ( 75 . 6 % ) of 205 patients had thrombocytopenia before transplantation , significantly influenced by Model of End - Stage Liver Disease score and liver cirrhosis .', {'entities': [(58, 74, 'B_Disease'), (137, 140, 'B_Disease'), (141, 142, 'I_Disease'), (143, 148, 'I_Disease'), (149, 154, 'I_Disease'), (155, 162, 'I_Disease'), (173, 178, 'B_Disease'), (179, 188, 'I_Disease')]}], ['Regarding HIT II , there were four ( 1 . 95 % ) patients with a background of HIT type II .', {'entities': [(10, 13, 'B_Disease'), (14, 16, 'I_Disease'), (78, 81, 'B_Disease'), (82, 86, 'I_Disease'), (87, 89, 'I_Disease')]}], ['CONCLUSIONS : The incidence of HIT in patients with end - stage hepatic failure is , with about 1 . 95 % , rare .', {'entities': [(31, 34, 'B_Disease'), (52, 55, 'B_Disease'), (56, 57, 'I_Disease'), (58, 63, 'I_Disease'), (64, 71, 'I_Disease'), (72, 79, 'I_Disease')]}], ['For further reduction of HIT type II , the use of intravenous heparin should be avoided and the prophylactic anticoagulation should be performed with low - molecular - weight heparin after normalization of platelet count .', {'entities': [(25, 28, 'B_Disease'), (29, 33, 'I_Disease'), (34, 36, 'I_Disease')]}], ['Takotsubo syndrome ( or apical ballooning syndrome ) secondary to Zolmitriptan .', {'entities': [(0, 9, 'B_Disease'), (10, 18, 'I_Disease'), (24, 30, 'B_Disease'), (31, 41, 'I_Disease'), (42, 50, 'I_Disease')]}], ['Takotsubo syndrome ( TS ) , also known as broken heart syndrome , is characterized by left ventricle apical ballooning with elevated cardiac biomarkers and electrocardiographic changes suggestive of an acute coronary syndrome ( ie , ST - segment elevation , T wave inversions , and pathologic Q waves ) .', {'entities': [(0, 9, 'B_Disease'), (10, 18, 'I_Disease'), (21, 23, 'B_Disease'), (42, 48, 'B_Disease'), (49, 54, 'I_Disease'), (55, 63, 'I_Disease'), (202, 207, 'B_Disease'), (208, 216, 'I_Disease'), (217, 225, 'I_Disease')]}], ['We report a case of 54 - year - old woman with medical history of mitral valve prolapse and migraines , who was admitted to the hospital for substernal chest pain and electrocardiogram demonstrated 1 / 2 mm ST - segment elevation in leads II , III , aVF , V5 , and V6 and positive troponin I .', {'entities': [(66, 72, 'B_Disease'), (73, 78, 'I_Disease'), (79, 87, 'I_Disease'), (92, 101, 'B_Disease'), (152, 157, 'B_Disease'), (158, 162, 'I_Disease')]}], ['Emergent coronary angiogram revealed normal coronary arteries with moderately reduced left ventricular ejection fraction with wall motion abnormalities consistent with TS .', {'entities': [(168, 170, 'B_Disease')]}], ['Detailed history obtained retrospectively revealed that the patient took zolmitriptan sparingly only when she had migraines .', {'entities': [(114, 123, 'B_Disease')]}], ['But before this event , she was taking zolmitriptan 2 - 3 times daily for several days because of a persistent migraine headache .', {'entities': [(111, 119, 'B_Disease'), (120, 128, 'I_Disease')]}], ['There was no evidence of any recent stress or status migrainosus .', {'entities': [(46, 52, 'B_Disease'), (53, 64, 'I_Disease')]}], ['Extensive literature search revealed multiple cases of coronary artery vasospasm secondary to zolmitriptan , but none of the cases were associated with TS .', {'entities': [(55, 63, 'B_Disease'), (64, 70, 'I_Disease'), (71, 80, 'I_Disease'), (152, 154, 'B_Disease')]}], ['Depression , impulsiveness , sleep , and memory in past and present polydrug users of 3 , 4 - methylenedioxymethamphetamine ( MDMA , ecstasy ) .', {'entities': [(0, 10, 'B_Disease'), (13, 26, 'B_Disease')]}], ['Participants completed a drug history questionnaire , Beck Depression Inventory , Barratt Impulsiveness Scale , Pittsburgh Sleep Quality Index , and Wechsler Memory Scale - Revised which , in total , provided 13 psychometric measures .', {'entities': [(59, 69, 'B_Disease'), (90, 103, 'B_Disease')]}], ['CONCLUSIONS : Given this record of impaired memory and clinically significant levels of depression , impulsiveness , and sleep disturbance , the prognosis for the current generation of ecstasy users is a major cause for concern .', {'entities': [(35, 43, 'B_Disease'), (44, 50, 'I_Disease'), (88, 98, 'B_Disease'), (101, 114, 'B_Disease'), (121, 126, 'B_Disease'), (127, 138, 'I_Disease')]}], [\"Association of common genetic variants of HOMER1 gene with levodopa adverse effects in Parkinson ' s disease patients .\", {'entities': [(87, 96, 'B_Disease'), (97, 98, 'I_Disease'), (99, 100, 'I_Disease'), (101, 108, 'I_Disease')]}], [\"Levodopa is the most effective symptomatic therapy for Parkinson ' s disease , but its chronic use could lead to chronic adverse outcomes , such as motor fluctuations , dyskinesia and visual hallucinations .\", {'entities': [(55, 64, 'B_Disease'), (65, 66, 'I_Disease'), (67, 68, 'I_Disease'), (69, 76, 'I_Disease'), (169, 179, 'B_Disease'), (184, 190, 'B_Disease'), (191, 205, 'I_Disease')]}], [\"A total of 205 patients with idiopathic Parkinson ' s disease were investigated .\", {'entities': [(29, 39, 'B_Disease'), (40, 49, 'I_Disease'), (50, 51, 'I_Disease'), (52, 53, 'I_Disease'), (54, 61, 'I_Disease')]}], ['The rs4704559 G allele was associated with a lower prevalence of dyskinesia ( prevalence ratio ( PR ) = 0 . 615 , 95 % confidence interval ( CI ) 0 . 426 - 0 . 887 , P = 0 . 009 ) and visual hallucinations ( PR = 0 . 515 , 95 % CI 0 . 295 - 0 . 899 , P = 0 . 020 ) .', {'entities': [(65, 75, 'B_Disease'), (184, 190, 'B_Disease'), (191, 205, 'I_Disease')]}], ['Crocin reduced inhibition of ERK activation and diazinon - induced hyperlipemia and increased levels of LDLr transcript .', {'entities': [(67, 79, 'B_Disease')]}], ['CONCLUSIONS : Crocin may be considered as a novel protective agent in diazinon - induced hyperlipemia through modulating of ERK pathway and increase of LDLr expression .', {'entities': [(89, 101, 'B_Disease')]}], ['GEM - P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma .', {'entities': [(60, 67, 'B_Disease'), (68, 76, 'I_Disease')]}], ['Hodgkin lymphoma ( HL ) is a relatively chemosensitive malignancy .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease'), (19, 21, 'B_Disease'), (55, 65, 'B_Disease')]}], ['Regimens commonly used often require inpatient administration and can be difficult to deliver due to toxicity .', {'entities': [(101, 109, 'B_Disease')]}], ['Gemcitabine and cisplatin have activity in HL , non - overlapping toxicity with first - line chemotherapeutics , and may be delivered in an outpatient setting .', {'entities': [(43, 45, 'B_Disease'), (66, 74, 'B_Disease')]}], ['In this retrospective single - centre analysis , patients with relapsed or refractory HL treated with gemcitabine 1 , 000 mg / m ( 2 ) day ( D ) 1 , D8 and D15 ; methylprednisolone 1 , 000 mg D1 - 5 ; and cisplatin 100 mg / m ( 2 ) D15 , every 28 days ( GEM - P ) were included .', {'entities': [(86, 88, 'B_Disease')]}], ['Demographic , survival , response and toxicity data were recorded .', {'entities': [(38, 46, 'B_Disease')]}], ['The most common grade 3 / 4 toxicities were haematological : neutropenia 54 % and thrombocytopenia 51 % .', {'entities': [(28, 38, 'B_Disease'), (61, 72, 'B_Disease'), (82, 98, 'B_Disease')]}], ['GEM - P is a salvage chemotherapy with relatively high response rates , leading to successful transplantation in appropriate patients , in the treatment of relapsed or refractory HL .', {'entities': [(179, 181, 'B_Disease')]}], ['RATIONALE : Ecstasy ( MDMA ) is a psychostimulant drug which is increasingly associated with psychobiological dysfunction .', {'entities': [(93, 109, 'B_Disease'), (110, 121, 'I_Disease')]}], ['RESULTS : Both user groups exhibited significantly greater levels of anxiety and depression than nonusers .', {'entities': [(69, 76, 'B_Disease'), (81, 91, 'B_Disease')]}], ['CONCLUSIONS : The increases in anxiety and depression are in line with previous observations in recreational ecstasy - polydrug users .', {'entities': [(31, 38, 'B_Disease'), (43, 53, 'B_Disease')]}], ['Ifosfamide related encephalopathy : the need for a timely EEG evaluation .', {'entities': [(19, 33, 'B_Disease')]}], ['BACKGROUND : Ifosfamide is an alkylating agent useful in the treatment of a wide range of cancers including sarcomas , lymphoma , gynecologic and testicular cancers .', {'entities': [(90, 97, 'B_Disease'), (108, 116, 'B_Disease'), (119, 127, 'B_Disease'), (130, 141, 'B_Disease'), (142, 145, 'I_Disease'), (146, 156, 'I_Disease'), (157, 164, 'I_Disease')]}], ['Encephalopathy has been reported in 10 - 40 % of patients receiving high - dose IV ifosfamide .', {'entities': [(0, 14, 'B_Disease')]}], ['OBJECTIVE : To highlight the role of electroencephalogram ( EEG ) in the early detection and management of ifosfamide related encephalopathy .', {'entities': [(126, 140, 'B_Disease')]}], ['METHODS : Retrospective chart review including clinical data and EEG recordings was done on five patients , admitted to MD Anderson Cancer Center between years 2009 and 2012 , who developed ifosfamide related acute encephalopathy .', {'entities': [(132, 138, 'B_Disease'), (215, 229, 'B_Disease')]}], ['RESULTS : All five patients experienced symptoms of encephalopathy soon after ( within 12 h - 2 days ) receiving ifosfamide .', {'entities': [(52, 66, 'B_Disease')]}], ['Two patients developed generalized convulsions while one patient developed continuous non - convulsive status epilepticus ( NCSE ) that required ICU admission and intubation .', {'entities': [(35, 46, 'B_Disease'), (86, 89, 'B_Disease'), (90, 91, 'I_Disease'), (92, 102, 'I_Disease'), (103, 109, 'I_Disease'), (110, 121, 'I_Disease'), (124, 128, 'B_Disease')]}], ['CONCLUSIONS : Severity of ifosfamide related encephalopathy correlates with EEG changes .', {'entities': [(45, 59, 'B_Disease')]}], ['We suggest a timely EEG evaluation for patients receiving ifosfamide who develop features of encephalopathy .', {'entities': [(93, 107, 'B_Disease')]}], ['Incidence of contrast - induced nephropathy in hospitalised patients with cancer .', {'entities': [(32, 43, 'B_Disease'), (74, 80, 'B_Disease')]}], ['OBJECTIVES : To determine the frequency of and possible factors related to contrast - induced nephropathy ( CIN ) in hospitalised patients with cancer .', {'entities': [(94, 105, 'B_Disease'), (144, 150, 'B_Disease')]}], ['Patients with risk factors for acute renal failure were excluded .', {'entities': [(31, 36, 'B_Disease'), (37, 42, 'I_Disease'), (43, 50, 'I_Disease')]}], ['CIN was significantly more after treatment with bevacizumab / irinotecan ( P = 0 . 021 ) and in patients with hypertension ( P = 0 . 044 ) .', {'entities': [(110, 122, 'B_Disease')]}], ['CIN developed 4 . 5 - times more frequently in patients with cancer who had undergone recent chemotherapy .', {'entities': [(61, 67, 'B_Disease')]}], ['Hypertension and the combination of bevacizumab / irinotecan may be additional risk factors for CIN development .', {'entities': [(0, 12, 'B_Disease')]}], ['Contrast - induced nephropathy ( CIN ) is a concern for oncological patients undergoing CT .', {'entities': [(19, 30, 'B_Disease')]}], ['. Hypertension and treatment with bevacizumab appear to be additional risk factors .', {'entities': [(2, 14, 'B_Disease')]}], ['Syndrome of inappropriate antidiuretic hormone secretion associated with desvenlafaxine .', {'entities': [(0, 8, 'B_Disease'), (9, 11, 'I_Disease'), (12, 25, 'I_Disease'), (26, 38, 'I_Disease'), (39, 46, 'I_Disease')]}], ['OBJECTIVE : To report a case of syndrome of inappropriate anti - diuretic hormone ( SIADH ) secretion associated with desvenlafaxine .', {'entities': [(32, 40, 'B_Disease'), (41, 43, 'I_Disease'), (44, 57, 'I_Disease'), (58, 62, 'I_Disease'), (63, 64, 'I_Disease'), (65, 73, 'I_Disease'), (74, 81, 'I_Disease'), (84, 89, 'B_Disease')]}], ['CASE SUMMARY : A 57 - year old female with hyponatraemia .', {'entities': [(43, 56, 'B_Disease')]}], ['Her medications included desvenlafaxine , and symptoms included nausea , anxiety and confusion .', {'entities': [(64, 70, 'B_Disease'), (73, 80, 'B_Disease'), (85, 94, 'B_Disease')]}], ['The serum sodium at this time was 120 mmol / L , serum osmolality was 263 mosmol / kg , urine osmolality 410 mosmol / kg and urine sodium 63 mmol / L , consistent with a diagnosis of SIADH .', {'entities': [(183, 188, 'B_Disease')]}], ['DISCUSSION : SIADH has been widely reported with a range of antidepressants .', {'entities': [(13, 18, 'B_Disease')]}], ['This case report suggests that desvenlafaxine might cause clinically significant hyponatremia .', {'entities': [(81, 93, 'B_Disease')]}], ['CONCLUSIONS : Clinicians should be aware of the potential for antidepressants to cause hyponatremia , and take appropriate corrective action where necessary .', {'entities': [(87, 99, 'B_Disease')]}], ['Oxidative stress on cardiotoxicity after treatment with single and multiple doses of doxorubicin .', {'entities': [(20, 34, 'B_Disease')]}], ['The mechanism of doxorubicin ( DOX ) - induced cardiotoxicity remains controversial .', {'entities': [(47, 61, 'B_Disease')]}], ['Single dose of DOX was associated with increased cardiac disarrangement , necrosis , and DNA damage ( strand breaks ( SBs ) and oxidized pyrimidines ) and decreased TAP .', {'entities': [(49, 56, 'B_Disease'), (57, 71, 'I_Disease'), (74, 82, 'B_Disease')]}], ['The chronological study showed an effect of a cumulative dose on body weight ( R = - 0 . 99 , p = 0 . 011 ) , necrosis ( R = 1 . 00 , p = 0 . 004 ) , TAP ( R = 0 . 95 , p = 0 . 049 ) , and DNA SBs ( R = - 0 . 95 , p = 0 . 049 ) .', {'entities': [(110, 118, 'B_Disease')]}], ['DNA SBs damage was negatively associated with TAP ( R = - 0 . 98 , p = 0 . 018 ) , and necrosis ( R = - 0 . 97 , p = 0 . 027 ) .', {'entities': [(87, 95, 'B_Disease')]}], ['Our results suggest that oxidative damage is associated with acute cardiotoxicity induced by a single dose of DOX only .', {'entities': [(67, 81, 'B_Disease')]}], ['Thus , different mechanisms may be involved in acute toxicity versus chronic toxicity .', {'entities': [(53, 61, 'B_Disease'), (77, 85, 'B_Disease')]}], ['Tacrolimus - related seizure after pediatric liver transplantation - - a single - center experience .', {'entities': [(21, 28, 'B_Disease')]}], ['To identify the risk factors for new - onset seizures after pediatric LT and to assess their clinical implications and long - term prognosis .', {'entities': [(45, 53, 'B_Disease')]}], ['Patients were divided into seizures group and a non - seizures group .', {'entities': [(27, 35, 'B_Disease'), (54, 62, 'B_Disease')]}], ['Seizures occurred in four children , an incidence of 14 . 8 % .', {'entities': [(0, 8, 'B_Disease')]}], ['All exhibited generalized tonic - clonic seizures within the first two wk after LT .', {'entities': [(26, 31, 'B_Disease'), (32, 33, 'I_Disease'), (34, 40, 'I_Disease'), (41, 49, 'I_Disease')]}], ['Univariate analysis showed that the risk factors associated with seizures after pediatric LT included gender , pediatric end - stage liver disease score before surgery , Child - Pugh score before surgery , serum total bilirubin after surgery , and trough TAC level .', {'entities': [(65, 73, 'B_Disease'), (121, 124, 'B_Disease'), (125, 126, 'I_Disease'), (127, 132, 'I_Disease'), (133, 138, 'I_Disease'), (139, 146, 'I_Disease')]}], ['Multivariate analysis showed that trough TAC level was the only independent risk factor associated with the seizures .', {'entities': [(108, 116, 'B_Disease')]}], ['All children who experienced seizures survived with good graft function and remained seizure - free without anti - epileptic drugs over a mean follow - up period of 33 . 7 + 14 . 6 months .', {'entities': [(29, 37, 'B_Disease'), (85, 92, 'B_Disease'), (115, 124, 'B_Disease')]}], ['High trough TAC level was the predominant factor that contributed to seizures in the early post - operative period after pediatric LT .', {'entities': [(69, 77, 'B_Disease')]}], ['High PELD and Child - Pugh scores before LT and high post - operative serum Tbil may be contributory risk factors for TAC - related seizures .', {'entities': [(132, 140, 'B_Disease')]}], ['Furthermore , apigenin did not prevent the amnesia induced by scopolamine ( 1mg / kg , i . p . , 30 min before the acquisition ) .', {'entities': [(43, 50, 'B_Disease')]}], ['In the saline treated group , the first significant decline in passive avoidance response was observed at four weeks , and complete memory loss was found five weeks after the acquisition of the passive avoidance task .', {'entities': [(132, 138, 'B_Disease'), (139, 143, 'I_Disease')]}], ['Histamine antagonists and d - tubocurarine - induced hypotension in cardiac surgical patients .', {'entities': [(53, 64, 'B_Disease')]}], ['We have previously reported that CCK - 8 significantly alleviated morphine - induced amnesia and reversed spine density decreases in the CA1 region of the hippocampus in morphine - treated animals .', {'entities': [(85, 92, 'B_Disease')]}], ['The present results demonstrate that CCK - 8 attenuates the effect of morphine on hippocampal LTP through CCK2 receptors and suggest an ameliorative function of CCK - 8 on morphine - induced memory impairment .', {'entities': [(191, 197, 'B_Disease'), (198, 208, 'I_Disease')]}], ['Glial activation and post - synaptic neurotoxicity : the key events in Streptozotocin ( ICV ) induced memory impairment in rats .', {'entities': [(37, 50, 'B_Disease'), (102, 108, 'B_Disease'), (109, 119, 'I_Disease')]}], ['In the present study the role of glial activation and post synaptic toxicity in ICV Streptozotocin ( STZ ) induced memory impaired rats was explored .', {'entities': [(68, 76, 'B_Disease'), (115, 121, 'B_Disease'), (122, 130, 'I_Disease')]}], ['In experiment set up 1 : Memory deficit was found in Morris water maze test on 14 - 16 days after STZ ( ICV ; 3mg / Kg ) administration .', {'entities': [(25, 31, 'B_Disease'), (32, 39, 'I_Disease')]}], ['STZ causes increased expression of GFAP , CD11b and TNF - a indicating glial activation and neuroinflammation .', {'entities': [(92, 109, 'B_Disease')]}], ['STZ also significantly increased the level of ROS , nitrite , Ca ( 2 + ) and reduced the mitochondrial activity in synaptosomal preparation illustrating free radical generation and excitotoxicity .', {'entities': [(181, 195, 'B_Disease')]}], ['STZ treatment showed decrease expression of post synaptic markers CaMKIIa and PSD - 95 , while , expression of pre synaptic markers ( synaptophysin and SNAP - 25 ) remains unaltered indicating selective post synaptic neurotoxicity .', {'entities': [(217, 230, 'B_Disease')]}], ['Oral treatment with Memantine ( 10mg / kg ) and Ibuprofen ( 50 mg / kg ) daily for 13 days attenuated STZ induced glial activation , apoptotic cell death and post synaptic neurotoxicity in rat brain .', {'entities': [(172, 185, 'B_Disease')]}], ['Collective data indicates that neuroinflammatory process and oxidative stress occurs earlier to apoptosis and does not affect memory function .', {'entities': [(31, 48, 'B_Disease')]}], ['Present study clearly suggests that glial activation and post synaptic neurotoxicity are the key factors in STZ induced memory impairment and neuronal cell death .', {'entities': [(71, 84, 'B_Disease'), (120, 126, 'B_Disease'), (127, 137, 'I_Disease')]}], ['Comparison of effects of isotonic sodium chloride with diltiazem in prevention of contrast - induced nephropathy .', {'entities': [(101, 112, 'B_Disease')]}], ['INTRODUCTION AND OBJECTIVE : Contrast - induced nephropathy ( CIN ) significantly increases the morbidity and mortality of patients .', {'entities': [(48, 59, 'B_Disease')]}], ['Among a total of 60 patients included in the study , 16 patients developed acute renal failure ( ARF ) on the second day after contrast material was injected ( 26 . 6 % ) .', {'entities': [(75, 80, 'B_Disease'), (81, 86, 'I_Disease'), (87, 94, 'I_Disease'), (97, 100, 'B_Disease')]}], ['The number of patients who developed ARF on the second day after the injection in the first group was five ( 25 % ) , in the second group was six ( 30 % ) and the third group was five ( 25 % ) ( p > 0 . 05 ) .', {'entities': [(37, 40, 'B_Disease')]}], ['Neurocognitive and neuroradiologic central nervous system late effects in children treated on Pediatric Oncology Group ( POG ) P9605 ( standard risk ) and P9201 ( lesser risk ) acute lymphoblastic leukemia protocols ( ACCL0131 ) : a methotrexate consequence ?', {'entities': [(177, 182, 'B_Disease'), (183, 196, 'I_Disease'), (197, 205, 'I_Disease')]}], ['Concerns about long - term methotrexate ( MTX ) neurotoxicity in the 1990s led to modifications in intrathecal ( IT ) therapy , leucovorin rescue , and frequency of systemic MTX administration in children with acute lymphoblastic leukemia .', {'entities': [(48, 61, 'B_Disease'), (210, 215, 'B_Disease'), (216, 229, 'I_Disease'), (230, 238, 'I_Disease')]}], ['In this study , neurocognitive outcomes and neuroradiologic evidence of leukoencephalopathy were compared in children treated with intense central nervous system ( CNS ) - directed therapy ( P9605 ) versus those receiving fewer CNS - directed treatment days during intensive consolidation ( P9201 ) .', {'entities': [(72, 91, 'B_Disease')]}], ['A total of 66 children from 16 Pediatric Oncology Group institutions with \" standard - risk \" acute lymphoblastic leukemia , 1 . 00 to 9 . 99 years at diagnosis , without evidence of CNS leukemia at diagnosis were enrolled on ACCL0131 : 28 from P9201 and 38 from P9605 .', {'entities': [(94, 99, 'B_Disease'), (100, 113, 'I_Disease'), (114, 122, 'I_Disease'), (187, 195, 'B_Disease')]}], ['Significantly more P9605 patients developed leukoencephalopathy compared with P9201 patients ( 68 % , 95 % confidence interval 49 % - 83 % vs . 22 % , 95 % confidence interval 5 % - 44 % ; P = 0 . 001 ) identified as late as 7 . 7 years after the end of treatment .', {'entities': [(44, 63, 'B_Disease')]}], ['Children on both studies had significant attention problems , but P9605 children scored below average on more neurocognitive measures than those treated on P9201 ( 82 % , 14 / 17 measures vs . 24 % , 4 / 17 measures ) .', {'entities': [(41, 50, 'B_Disease'), (51, 59, 'I_Disease')]}], ['Tranexamic acid overdosage - induced generalized seizure in renal failure .', {'entities': [(49, 56, 'B_Disease'), (60, 65, 'B_Disease'), (66, 73, 'I_Disease')]}], ['We report a 45 - year - old lady with chronic kidney disease stage 4 due to chronic tubulointerstial disease .', {'entities': [(38, 45, 'B_Disease'), (46, 52, 'I_Disease'), (53, 60, 'I_Disease'), (84, 100, 'B_Disease'), (101, 108, 'I_Disease')]}], ['She was admitted to our center for severe anemia due to menorrhagia and deterioration of renal function .', {'entities': [(42, 48, 'B_Disease'), (56, 67, 'B_Disease'), (72, 85, 'B_Disease'), (86, 88, 'I_Disease'), (89, 94, 'I_Disease'), (95, 103, 'I_Disease')]}], ['Tranexamic acid ( TNA ) 1 g 8 - hourly was administered to her to control bleeding per vaginum .', {'entities': [(74, 82, 'B_Disease')]}], ['Two hours after the sixth dose of TNA , she had an episode of generalized tonic clonic convulsions .', {'entities': [(74, 79, 'B_Disease'), (80, 86, 'I_Disease'), (87, 98, 'I_Disease')]}], ['Investigations of the patient revealed no biochemical or structural central nervous system abnormalities that could have provoked the convulsions .', {'entities': [(76, 83, 'B_Disease'), (84, 90, 'I_Disease'), (91, 104, 'I_Disease'), (134, 145, 'B_Disease')]}], ['She had no further episodes of convulsion till dis - charge and during the two months of follow - up .', {'entities': [(31, 41, 'B_Disease')]}], ['Thus , the precipitating cause of convulsions was believed to be an overdose of TNA .', {'entities': [(34, 45, 'B_Disease'), (68, 76, 'B_Disease')]}], ['Pre - treatment of bupivacaine - induced cardiovascular depression using different lipid formulations of propofol .', {'entities': [(41, 55, 'B_Disease'), (56, 66, 'I_Disease')]}], ['BACKGROUND : Pre - treatment with lipid emulsions has been shown to increase lethal doses of bupivacaine , and the lipid content of propofol may alleviate bupivacaine - induced cardiotoxicity .', {'entities': [(177, 191, 'B_Disease')]}], ['The aim of this study is to investigate the effects of propofol in intralipid or medialipid emulsions on bupivacaine - induced cardiotoxicity .', {'entities': [(127, 141, 'B_Disease')]}], ['We recorded time to first dysrhythmia occurrence , respective times to 25 % and 50 % reduction of the heart rate ( HR ) and mean arterial pressure , and time to asystole and total amount of bupivacaine consumption .', {'entities': [(26, 37, 'B_Disease'), (161, 169, 'B_Disease')]}], ['Blood and tissue samples were collected following asystole .', {'entities': [(50, 58, 'B_Disease')]}], ['RESULTS : The time to first dysrhythmia occurrence , time to 25 % and 50 % reductions in HR , and time to asystole were longer in Group P than the other groups .', {'entities': [(28, 39, 'B_Disease'), (106, 114, 'B_Disease')]}], ['CONCLUSION : We conclude that pre - treatment with propofol in intralipid , compared with propofol in medialipid or saline , delayed the onset of bupivacaine - induced cardiotoxic effects as well as reduced plasma bupivacaine levels .', {'entities': [(168, 179, 'B_Disease')]}], ['Drug - Induced Acute Liver Injury Within 12 Hours After Fluvastatin Therapy .', {'entities': [(0, 4, 'B_Disease'), (5, 6, 'I_Disease'), (7, 14, 'I_Disease'), (15, 20, 'I_Disease'), (21, 26, 'I_Disease'), (27, 33, 'I_Disease')]}], ['Although statins are generally well - tolerated drugs , recent cases of drug - induced liver injury associated with their use have been reported .', {'entities': [(72, 76, 'B_Disease'), (77, 78, 'I_Disease'), (79, 86, 'I_Disease'), (87, 92, 'I_Disease'), (93, 99, 'I_Disease')]}], ['A 52 - year - old Chinese man reported with liver damage , which appeared 12 hours after beginning treatment with fluvastatin .', {'entities': [(44, 49, 'B_Disease'), (50, 56, 'I_Disease')]}], ['Patient presented with complaints of increasing nausea , anorexia , and upper abdominal pain .', {'entities': [(48, 54, 'B_Disease'), (57, 65, 'B_Disease'), (78, 87, 'B_Disease'), (88, 92, 'I_Disease')]}], ['Therefore , when prescribing statins , the possibility of hepatic damage should be taken into account .', {'entities': [(58, 65, 'B_Disease'), (66, 72, 'I_Disease')]}], ['Fluconazole associated agranulocytosis and thrombocytopenia .', {'entities': [(23, 38, 'B_Disease'), (43, 59, 'B_Disease')]}], ['CASE : We describe a second case of fluconazole associated agranulocytosis with thrombocytopenia and recovery upon discontinuation of therapy .', {'entities': [(59, 74, 'B_Disease'), (80, 96, 'B_Disease')]}], ['This case highlights that drug - induced blood dyscrasias can occur unexpectedly as a result of treatment with a commonly used drug thought to be \" safe \" .', {'entities': [(41, 46, 'B_Disease'), (47, 57, 'I_Disease')]}], [\"CONCLUSION : According to Naranjo ' s algorithm the likelihood that our patient ' s agranulocytosis and thrombocytopenia occurred as a result of therapy with fluconazole is probable , with a total of six points .\", {'entities': [(84, 99, 'B_Disease'), (104, 120, 'B_Disease')]}], ['In particular the temporal relationship of bone marrow suppression to the initiation of fluconazole and the abatement of symptoms that rapidly reversed immediately following discontinuation .', {'entities': [(43, 47, 'B_Disease'), (48, 54, 'I_Disease'), (55, 66, 'I_Disease')]}], ['Two - dimensional speckle tracking echocardiography combined with high - sensitive cardiac troponin T in early detection and prediction of cardiotoxicity during epirubicine - based chemotherapy .', {'entities': [(139, 153, 'B_Disease')]}], ['AIMS : To investigate whether alterations of myocardial strain and high - sensitive cardiac troponin T ( cTnT ) could predict future cardiac dysfunction in patients after epirubicin exposure .', {'entities': [(45, 55, 'B_Disease'), (56, 62, 'I_Disease'), (133, 140, 'B_Disease'), (141, 152, 'I_Disease')]}], ['METHODS : Seventy - five patients with non - Hodgkin lymphoma treated with epirubicin were studied .', {'entities': [(39, 42, 'B_Disease'), (43, 44, 'I_Disease'), (45, 52, 'I_Disease'), (53, 61, 'I_Disease')]}], ['Cardiotoxicity was defined as a reduction of the LVEF of > 5 % to < 55 % with symptoms of heart failure or an asymptomatic reduction of the LVEF of > 10 % to < 55 % .', {'entities': [(0, 14, 'B_Disease'), (90, 95, 'B_Disease'), (96, 103, 'I_Disease')]}], ['RESULTS : Fourteen patients ( 18 . 67 % ) developed cardiotoxicity after treatment .', {'entities': [(52, 66, 'B_Disease')]}], ['A > 15 . 9 % decrease in GLS [ sensitivity , 86 % ; specificity , 75 % ; area under the curve ( AUC ) = 0 . 815 ; P = 0 . 001 ] and a > 0 . 004 ng / mL elevation in cTnT ( sensitivity , 79 % ; specificity , 64 % ; AUC = 0 . 757 ; P = 0 . 005 ) from baseline to the third cycle of chemotherapy predicted later cardiotoxicity .', {'entities': [(309, 323, 'B_Disease')]}], ['The decrease in GLS remained the only independent predictor of cardiotoxicity ( P = 0 . 000 ) .', {'entities': [(63, 77, 'B_Disease')]}], ['CONCLUSIONS : GLS combined with cTnT may provide a reliable and non - invasive method to predict cardiac dysfunction in patients receiving anthracycline - based chemotherapy .', {'entities': [(97, 104, 'B_Disease'), (105, 116, 'I_Disease')]}], ['Prevention of etomidate - induced myoclonus : which is superior : Fentanyl , midazolam , or a combination ?', {'entities': [(34, 43, 'B_Disease')]}], ['BACKGROUND : In this retrospective comparative study , we aimed to compare the effectiveness of fentanyl , midazolam , and a combination of fentanyl and midazolam to prevent etomidate - induced myoclonus .', {'entities': [(194, 203, 'B_Disease')]}], ['Myoclonic movements are evaluated , which were observed and graded according to clinical severity during the 2 minutes after etomidate injection .', {'entities': [(0, 9, 'B_Disease'), (10, 19, 'I_Disease')]}], ['The severity of pain due to etomidate injection , mean arterial pressure , heart rate , and adverse effects were also evaluated .', {'entities': [(16, 20, 'B_Disease')]}], ['RESULTS : Study results showed that myoclonus incidence was 85 % , 40 % , 70 % , and 25 % in Group NP , Group F , Group M , and Group FM , respectively , and were significantly lower in Group F and Group FM .', {'entities': [(36, 45, 'B_Disease')]}], ['CONCLUSIONS : We conclude that pretreatment with fentanyl or combination of fentanyl and midazolam was effective in preventing etomidate - induced myoclonus .', {'entities': [(147, 156, 'B_Disease')]}], ['Lindane ( gamma - hexachlorocyclohexane ) is an organochlorine insecticide with known neurotoxic effects .', {'entities': [(86, 96, 'B_Disease')]}], ['We studied the effect of lindane ( 150 mg / kg ) on the GABAergic and dopaminergic systems by measuring the concentration of GABA , dopamine and its metabolites in 7 brain areas at the onset of seizures .', {'entities': [(194, 202, 'B_Disease')]}], ['All animals suffered tonic convulsions at 18 . 3 + / - 1 . 4 min after lindane administration .', {'entities': [(27, 38, 'B_Disease')]}], ['Cholestatic presentation of yellow phosphorus poisoning .', {'entities': [(0, 11, 'B_Disease'), (46, 55, 'B_Disease')]}], ['Yellow phosphorus , a component of certain pesticide pastes and fireworks , is well known to cause hepatotoxicity .', {'entities': [(99, 113, 'B_Disease')]}], ['Poisoning with yellow phosphorus classically manifests with acute hepatitis leading to acute liver failure which may need liver transplantation .', {'entities': [(0, 9, 'B_Disease'), (60, 65, 'B_Disease'), (66, 75, 'I_Disease'), (87, 92, 'B_Disease'), (93, 98, 'I_Disease'), (99, 106, 'I_Disease')]}], ['We present a case of yellow phosphorus poisoning in which a patient presented with florid clinical features of cholestasis highlighting the fact that cholestasis can rarely be a presenting feature of yellow phosphorus hepatotoxicity .', {'entities': [(39, 48, 'B_Disease'), (111, 122, 'B_Disease'), (150, 161, 'B_Disease'), (218, 232, 'B_Disease')]}], ['Vasovagal syncope and severe bradycardia following intranasal dexmedetomidine for pediatric procedural sedation .', {'entities': [(0, 9, 'B_Disease'), (10, 17, 'I_Disease'), (29, 40, 'B_Disease')]}], ['We report syncope and bradycardia in an 11 - year - old girl following administration of intranasal dexmedetomidine for sedation for a voiding cystourethrogram .', {'entities': [(10, 17, 'B_Disease'), (22, 33, 'B_Disease')]}], ['The primary abnormality found was persistent bradycardia , and she was admitted to the hospital for telemetric observation .', {'entities': [(45, 56, 'B_Disease')]}], ['The bradycardia lasted ~ 2 h , and further cardiac workup revealed no underlying abnormality .', {'entities': [(4, 15, 'B_Disease')]}], ['Paradoxical severe agitation induced by add - on high - doses quetiapine in schizo - affective disorder .', {'entities': [(19, 28, 'B_Disease'), (76, 82, 'B_Disease'), (83, 84, 'I_Disease'), (85, 94, 'I_Disease'), (95, 103, 'I_Disease')]}], ['We report the case of a 35 - year - old patient suffering from schizo - affective disorder since the age of 19 years , treated by a combination of first - generation antipsychotics , zuclopenthixol ( 100 mg / day ) and lithium ( 1200 mg / day ) ( serum lithium = 0 . 85 mEq / l ) .', {'entities': [(63, 69, 'B_Disease'), (70, 71, 'I_Disease'), (72, 81, 'I_Disease'), (82, 90, 'I_Disease')]}], ['This patient had no associated personality disorder ( particularly no antisocial disorder ) and no substance abuse disorder .', {'entities': [(31, 42, 'B_Disease'), (43, 51, 'I_Disease'), (70, 80, 'B_Disease'), (81, 89, 'I_Disease'), (99, 108, 'B_Disease'), (109, 114, 'I_Disease'), (115, 123, 'I_Disease')]}], ['Within the 48 h following the gradual introduction of quetiapine ( up to 600 mg / day ) , the patient presented severe agitation without an environmental explanation , contrasting with the absence of a history of aggressiveness or personality disorder .', {'entities': [(119, 128, 'B_Disease'), (213, 227, 'B_Disease'), (231, 242, 'B_Disease'), (243, 251, 'I_Disease')]}], ['The diagnoses of manic shift and akathisia were dismissed .', {'entities': [(17, 22, 'B_Disease'), (33, 42, 'B_Disease')]}], ['The withdrawal and the gradual reintroduction of quetiapine 2 weeks later , which led to another severe agitation , enabled us to attribute the agitation specifically to quetiapine .', {'entities': [(104, 113, 'B_Disease'), (144, 153, 'B_Disease')]}], ['Antioxidant effects of bovine lactoferrin on dexamethasone - induced hypertension in rat .', {'entities': [(69, 81, 'B_Disease')]}], ['Dexamethasone - ( Dex - ) induced hypertension is associated with enhanced oxidative stress .', {'entities': [(34, 46, 'B_Disease')]}], ['In this study , we investigated the effect of chronic administration of LF on oxidative stress and hypertension upon Dex administration .', {'entities': [(99, 111, 'B_Disease')]}], ['LF lowered ( P < 0 . 01 ) and dose dependently prevented ( P < 0 . 001 ) Dex - induced hypertension .', {'entities': [(87, 99, 'B_Disease')]}], ['LF prevented body weight loss and significantly reduced the elevated plasma H2O2 and increased FRAP values .', {'entities': [(18, 24, 'B_Disease'), (25, 29, 'I_Disease')]}], ['Chronic administration of LF strongly reduced the blood pressure and production of ROS and improved antioxidant capacity in Dex - induced hypertension , suggesting the role of inhibition of oxidative stress as another mechanism of antihypertensive action of LF .', {'entities': [(138, 150, 'B_Disease')]}], ['The association between tranexamic acid and convulsive seizures after cardiac surgery : a multivariate analysis in 11 529 patients .', {'entities': [(44, 54, 'B_Disease'), (55, 63, 'B_Disease')]}], ['Because of a lack of contemporary data regarding seizures after cardiac surgery , we undertook a retrospective analysis of prospectively collected data from 11 529 patients in whom cardiopulmonary bypass was used from January 2004 to December 2010 .', {'entities': [(49, 57, 'B_Disease')]}], ['A convulsive seizure was defined as a transient episode of disturbed brain function characterised by abnormal involuntary motor movements .', {'entities': [(2, 12, 'B_Disease'), (13, 20, 'B_Disease'), (101, 109, 'B_Disease'), (110, 121, 'I_Disease'), (122, 127, 'I_Disease'), (128, 137, 'I_Disease')]}], ['Multivariate regression analysis was performed to identify independent predictors of postoperative seizures .', {'entities': [(99, 107, 'B_Disease')]}], ['A total of 100 ( 0 . 9 % ) patients developed postoperative convulsive seizures .', {'entities': [(60, 70, 'B_Disease'), (71, 79, 'B_Disease')]}], ['Generalised and focal seizures were identified in 68 and 32 patients , respectively .', {'entities': [(0, 11, 'B_Disease'), (12, 15, 'I_Disease'), (16, 21, 'I_Disease'), (22, 30, 'I_Disease')]}], ['The median ( IQR [ range ] ) time after surgery when the seizure occurred was 7 ( 6 - 12 [ 1 - 216 ] ) h and 8 ( 6 - 11 [ 4 - 18 ] ) h , respectively .', {'entities': [(57, 64, 'B_Disease')]}], ['Independent predictors of postoperative seizures included age , female sex , redo cardiac surgery , calcification of ascending aorta , congestive heart failure , deep hypothermic circulatory arrest , duration of aortic cross - clamp and tranexamic acid .', {'entities': [(40, 48, 'B_Disease'), (135, 145, 'B_Disease'), (146, 151, 'I_Disease'), (152, 159, 'I_Disease'), (167, 178, 'B_Disease')]}], ['When tested in a multivariate regression analysis , tranexamic acid was a strong independent predictor of seizures ( OR 14 . 3 , 95 % CI 5 . 5 - 36 . 7 ; p < 0 . 001 ) .', {'entities': [(106, 114, 'B_Disease')]}], ['Patients with convulsive seizures had 2 . 5 times higher in - hospital mortality rates and twice the length of hospital stay compared with patients without convulsive seizures .', {'entities': [(14, 24, 'B_Disease'), (25, 33, 'B_Disease'), (156, 166, 'B_Disease'), (167, 175, 'B_Disease')]}], ['Mean ( IQR [ range ] ) length of stay in the intensive care unit was 115 ( 49 - 228 [ 32 - 481 ] ) h in patients with convulsive seizures compared with 26 ( 22 - 69 [ 14 - 1080 ] ) h in patients without seizures ( p < 0 . 001 ) .', {'entities': [(118, 128, 'B_Disease'), (129, 137, 'B_Disease'), (203, 211, 'B_Disease')]}], ['Convulsive seizures are a serious postoperative complication after cardiac surgery .', {'entities': [(0, 10, 'B_Disease'), (11, 19, 'B_Disease'), (34, 47, 'B_Disease'), (48, 60, 'I_Disease')]}], ['As tranexamic acid is the only modifiable factor , its administration , particularly in doses exceeding 80 mg . kg ( - 1 ) , should be weighed against the risk of postoperative seizures .', {'entities': [(177, 185, 'B_Disease')]}], ['Dysfunctional overnight memory consolidation in ecstasy users .', {'entities': [(0, 13, 'B_Disease'), (14, 23, 'I_Disease'), (24, 30, 'I_Disease')]}], ['Previous studies indicate that ecstasy users have marked and persistent neurocognitive and sleep - related impairments .', {'entities': [(91, 96, 'B_Disease'), (97, 98, 'I_Disease'), (99, 106, 'I_Disease'), (107, 118, 'I_Disease')]}], ['Ecstasy users demonstrated impaired overnight memory consolidation , a finding that was more pronounced following associative interference .', {'entities': [(27, 35, 'B_Disease'), (36, 45, 'I_Disease'), (46, 52, 'I_Disease')]}], ['We suggest that ecstasy - associated dysfunction in fronto - temporal circuitry may underlie overnight consolidation memory impairments in regular ecstasy users .', {'entities': [(117, 123, 'B_Disease'), (124, 135, 'I_Disease')]}], ['Normoammonemic encephalopathy : solely valproate induced or multiple mechanisms ?', {'entities': [(15, 29, 'B_Disease')]}], ['A 77 - year - old woman presented with subacute onset progressive confusion , aggression , auditory hallucinations and delusions .', {'entities': [(66, 75, 'B_Disease'), (78, 88, 'B_Disease'), (91, 99, 'B_Disease'), (100, 114, 'I_Disease'), (119, 128, 'B_Disease')]}], ['In the preceding months , the patient had a number of admissions with transient unilateral hemiparesis with facial droop , and had been started on valproate for presumed hemiplegic migraine .', {'entities': [(91, 102, 'B_Disease'), (170, 180, 'B_Disease'), (181, 189, 'I_Disease')]}], ['EEG undertaken during inpatient stay showed changes consistent with encephalopathy , and low titre N - methyl - D - aspartate ( NMDA ) receptor antibodies were present in this patient .', {'entities': [(68, 82, 'B_Disease')]}], ['The possible aetiologies of valproate - induced encephalopathy and NMDA receptor - associated encephalitis present a diagnostic dilemma .', {'entities': [(48, 62, 'B_Disease'), (94, 106, 'B_Disease')]}], ['Cerebellar and oculomotor dysfunction induced by rapid infusion of pethidine .', {'entities': [(0, 10, 'B_Disease'), (11, 14, 'I_Disease'), (15, 25, 'I_Disease'), (26, 37, 'I_Disease')]}], ['Pethidine is an opioid that gains its popularity for the effective pain control through acting on the opioid - receptors .', {'entities': [(67, 71, 'B_Disease')]}], ['However , rapid pain relief sometimes brings about unfavourable side effects that largely limit its clinical utility .', {'entities': [(16, 20, 'B_Disease')]}], ['Common side effects include nausea , vomiting and hypotension .', {'entities': [(28, 34, 'B_Disease'), (37, 45, 'B_Disease'), (50, 61, 'B_Disease')]}], ['In patients with impaired renal and liver function , and those who need long - term pain control , pethidine may cause excitatory central nervous system ( CNS ) effects through its neurotoxic metabolite , norpethidine , resulting in irritability and seizure attack .', {'entities': [(17, 25, 'B_Disease'), (26, 31, 'I_Disease'), (32, 35, 'I_Disease'), (36, 41, 'I_Disease'), (42, 50, 'I_Disease'), (84, 88, 'B_Disease'), (181, 191, 'B_Disease'), (233, 245, 'B_Disease'), (250, 257, 'B_Disease')]}], [\"In this case report , we highlight opioid ' s inhibitory side effects on the cerebellar structure that causes dysmetria , dysarthria , reduced smooth pursuit gain and decreased saccadic velocity .\", {'entities': [(110, 119, 'B_Disease'), (122, 132, 'B_Disease')]}], ['Baboon syndrome induced by ketoconazole .', {'entities': [(0, 6, 'B_Disease'), (7, 15, 'I_Disease')]}], ['A 27 - year - old male patient presented with a maculopapular eruption on the flexural areas and buttocks after using oral ketoconazole .', {'entities': [(48, 61, 'B_Disease'), (62, 70, 'I_Disease')]}], ['The patient was diagnosed with drug - induced baboon syndrome based on his history , which included prior sensitivity to topical ketoconazole , a physical examination , and histopathological findings .', {'entities': [(46, 52, 'B_Disease'), (53, 61, 'I_Disease')]}], ['Baboon syndrome is a drug - or contact allergen - related maculopapular eruption that typically involves the flexural and gluteal areas .', {'entities': [(0, 6, 'B_Disease'), (7, 15, 'I_Disease'), (58, 71, 'B_Disease'), (72, 80, 'I_Disease')]}], ['To the best of our knowledge , this is the first reported case of ketoconazole - induced baboon syndrome in the English literature .', {'entities': [(89, 95, 'B_Disease'), (96, 104, 'I_Disease')]}], ['A Case of Sudden Cardiac Death due to Pilsicainide - Induced Torsades de Pointes .', {'entities': [(10, 16, 'B_Disease'), (17, 24, 'I_Disease'), (25, 30, 'I_Disease'), (61, 69, 'B_Disease'), (70, 72, 'I_Disease'), (73, 80, 'I_Disease')]}], ['An 84 - year - old male received oral pilsicainide , a pure sodium channel blocker with slow recovery kinetics , to convert his paroxysmal atrial fibrillation to a sinus rhythm ; the patient developed sudden cardiac death two days later .', {'entities': [(139, 145, 'B_Disease'), (146, 158, 'I_Disease'), (201, 207, 'B_Disease'), (208, 215, 'I_Disease'), (216, 221, 'I_Disease')]}], ['The Holter electrocardiogram , which was worn by chance , revealed torsade de pointes with gradually prolonged QT intervals .', {'entities': [(67, 74, 'B_Disease'), (75, 77, 'I_Disease'), (78, 85, 'I_Disease')]}], [\"Although the patient ' s renal function was not highly impaired and the dose of pilsicainide was low , the plasma concentration of pilsicainide may have been high , which can produce torsades de pointes in the octogenarian .\", {'entities': [(183, 191, 'B_Disease'), (192, 194, 'I_Disease'), (195, 202, 'I_Disease')]}], ['Although the oral administration of class IC drugs , including pilsicainide , is effective to terminate atrial fibrillation , careful consideration must be taken before giving these drugs to octogenarians .', {'entities': [(104, 110, 'B_Disease'), (111, 123, 'I_Disease')]}], ['All - trans retinoic acid - induced inflammatory myositis in a patient with acute promyelocytic leukemia .', {'entities': [(49, 57, 'B_Disease'), (76, 81, 'B_Disease'), (82, 95, 'I_Disease'), (96, 104, 'I_Disease')]}], ['All - trans retinoic acid ( ATRA ) , a component of standard therapy for acute promyelocytic leukemia ( APL ) , is associated with potentially serious but treatable adverse effects involving numerous organ systems , including rare skeletal muscle involvement .', {'entities': [(73, 78, 'B_Disease'), (79, 92, 'I_Disease'), (93, 101, 'I_Disease'), (104, 107, 'B_Disease')]}], ['Only a handful of cases of ATRA - induced myositis in children have been reported , and none in the radiology literature .', {'entities': [(42, 50, 'B_Disease')]}], ['We present such a case in a 15 - year - old boy with APL , where recognition of imaging findings played a crucial role in making the diagnosis and facilitated prompt , effective treatment .', {'entities': [(53, 56, 'B_Disease')]}], ['Tolerability of lomustine in combination with cyclophosphamide in dogs with lymphoma .', {'entities': [(76, 84, 'B_Disease')]}], ['This retrospective study describes toxicity associated with a protocol of lomustine ( CCNU ) and cyclophosphamide ( CTX ) in dogs with lymphoma .', {'entities': [(35, 43, 'B_Disease'), (135, 143, 'B_Disease')]}], ['Neutropenia was the principal toxic effect , and the overall frequency of grade 4 neutropenia after the first treatment of CCNU / CTX was 30 % ( 95 % confidence interval , 19 - 43 % ) .', {'entities': [(0, 11, 'B_Disease'), (82, 93, 'B_Disease')]}], ['The mean body weight of dogs with grade 4 neutropenia ( 19 . 7 kg + 13 . 4 kg ) was significantly less than the mean body weight of dogs that did not develop grade 4 neutropenia ( 31 . 7 kg + 12 . 4 kg ; P = . 005 ) .', {'entities': [(42, 53, 'B_Disease'), (166, 177, 'B_Disease')]}], ['One dog ( 3 % ) developed hematologic changes suggestive of hepatotoxicity .', {'entities': [(60, 74, 'B_Disease')]}], ['No dogs had evidence of either renal toxicity or hemorrhagic cystitis .', {'entities': [(31, 36, 'B_Disease'), (37, 45, 'I_Disease'), (49, 60, 'B_Disease'), (61, 69, 'I_Disease')]}], ['On the basis of the findings reported herein , a dose of 60 mg / m ( 2 ) of CCNU combined with 250 mg / m ( 2 ) of CTX ( divided over 5 days ) q 4 wk is tolerable in tumor - bearing dogs .', {'entities': [(166, 171, 'B_Disease')]}], ['Nelarabine neurotoxicity with concurrent intrathecal chemotherapy : Case report and review of literature .', {'entities': [(11, 24, 'B_Disease')]}], ['Severe nelarabine neurotoxicity in a patient who received concurrent intrathecal ( IT ) chemotherapy is reported .', {'entities': [(18, 31, 'B_Disease')]}], ['A 37 - year - old Caucasian woman with a history of T - cell lymphoblastic lymphoma was admitted for relapsed disease .', {'entities': [(52, 53, 'B_Disease'), (54, 55, 'I_Disease'), (56, 60, 'I_Disease'), (61, 74, 'I_Disease'), (75, 83, 'I_Disease')]}], ['She developed relapsed disease 10 months later with leukemic involvement .', {'entities': [(52, 60, 'B_Disease')]}], ['At the time of treatment , she was on continuous renal replacement therapy due to sequelae of tumor lysis syndrome ( TLS ) .', {'entities': [(94, 99, 'B_Disease'), (100, 105, 'I_Disease'), (106, 114, 'I_Disease'), (117, 120, 'B_Disease')]}], ['Predominantly sensory , though also motor and autonomic , peripheral neuropathy started in her feet , ascended proximally to the mid - thoracic region , and eventually included her distal upper extremities .', {'entities': [(58, 68, 'B_Disease'), (69, 79, 'I_Disease')]}], ['Her neuropathy stabilized and showed slight improvement and ultimately received an unrelated , reduced - intensity allogeneic transplant while in complete remission , but relapsed disease 10 weeks later .', {'entities': [(4, 14, 'B_Disease')]}], ['To our knowledge , this is the first published case report of severe neurotoxicity caused by nelarabine in a patient who received concurrent IT chemotherapy .', {'entities': [(69, 82, 'B_Disease')]}], ['Valproate - induced hyperammonemic encephalopathy in a renal transplanted patient .', {'entities': [(20, 34, 'B_Disease'), (35, 49, 'B_Disease')]}], ['Neurological complications after renal transplantation constitute an important cause of morbidity and mortality .', {'entities': [(0, 12, 'B_Disease'), (13, 26, 'I_Disease')]}], ['Valproate - induced hyperammonemic encephalopathy is an uncommon but serious effect of valproate treatment .', {'entities': [(20, 34, 'B_Disease'), (35, 49, 'B_Disease')]}], ['Here , we describe the case of a 15 - year - old girl who was on a long - term therapy with valproate due to epilepsy and revealed impaired consciousness with hyperammonemia 12 days after renal transplantation .', {'entities': [(109, 117, 'B_Disease'), (131, 139, 'B_Disease'), (140, 153, 'I_Disease'), (159, 173, 'B_Disease')]}], ['Necrotising fasciitis after bortezomib and dexamethasone - containing regimen in an elderly patient of Waldenstrom macroglobulinaemia .', {'entities': [(0, 11, 'B_Disease'), (12, 21, 'I_Disease'), (103, 114, 'B_Disease'), (115, 133, 'I_Disease')]}], ['Bortezomib and high - dose dexamethasone - containing regimens are considered to be generally tolerable with few severe bacterial infections in patients with B - cell malignancies .', {'entities': [(120, 129, 'B_Disease'), (130, 140, 'I_Disease'), (167, 179, 'B_Disease')]}], ['We report a case of a 76 - year - old man with Waldenstrom macroglobulinaemia who suffered necrotising fasciitis without neutropenia after the combination treatment with bortezomib , high - dose dexamethasone and rituximab .', {'entities': [(47, 58, 'B_Disease'), (59, 77, 'I_Disease'), (91, 102, 'B_Disease'), (103, 112, 'I_Disease'), (121, 132, 'B_Disease')]}], ['Physicians should recognise the possibility of fatal bacterial infections related to bortezomib plus high - dose dexamethasone in elderly patients , and we believe this case warrants further investigation .', {'entities': [(53, 62, 'B_Disease'), (63, 73, 'I_Disease')]}], ['An integrated characterization of serological , pathological , and functional events in doxorubicin - induced cardiotoxicity .', {'entities': [(110, 124, 'B_Disease')]}], ['Many efficacious cancer treatments cause significant cardiac morbidity , yet biomarkers or functional indices of early damage , which would allow monitoring and intervention , are lacking .', {'entities': [(17, 23, 'B_Disease')]}], ['In this study , we have utilized a rat model of progressive doxorubicin ( DOX ) - induced cardiomyopathy , applying multiple approaches , including cardiac magnetic resonance imaging ( MRI ) , to provide the most comprehensive characterization to date of the timecourse of serological , pathological , and functional events underlying this toxicity .', {'entities': [(90, 104, 'B_Disease'), (340, 348, 'B_Disease')]}], ['Electron microscopy of the myocardium revealed subcellular degeneration and marked mitochondrial changes after a single dose .', {'entities': [(47, 58, 'B_Disease'), (59, 71, 'I_Disease')]}], ['Histopathological analysis revealed progressive cardiomyocyte degeneration , hypertrophy / cytomegaly , and extensive vacuolation after two doses .', {'entities': [(48, 61, 'B_Disease'), (62, 74, 'I_Disease'), (77, 88, 'B_Disease')]}], ['Extensive replacement fibrosis ( quantified by Sirius red staining ) developed during the off - dosing period .', {'entities': [(22, 30, 'B_Disease')]}], ['Functional indices assessed by cardiac MRI ( including left ventricular ejection fraction ( LVEF ) , cardiac output , and E / A ratio ) declined progressively , reaching statistical significance after two doses and culminating in \" clinical \" LV dysfunction by 12 weeks .', {'entities': [(243, 245, 'B_Disease'), (246, 257, 'I_Disease')]}], ['Troponin I levels positively correlated with delayed and peak gadolinium contrast enhancement , histopathological grading , and diastolic dysfunction .', {'entities': [(128, 137, 'B_Disease'), (138, 149, 'I_Disease')]}], ['In summary , subcellular cardiomyocyte degeneration was the earliest marker , followed by progressive functional decline and histopathological manifestations .', {'entities': [(25, 38, 'B_Disease'), (39, 51, 'I_Disease')]}], ['However , all indices predated \" clinical \" LV dysfunction and thus warrant further evaluation as predictive biomarkers .', {'entities': [(44, 46, 'B_Disease'), (47, 58, 'I_Disease')]}], ['Intradermal glutamate and capsaicin injections : intra - and interindividual variability of provoked hyperalgesia and allodynia .', {'entities': [(101, 113, 'B_Disease'), (118, 127, 'B_Disease')]}], ['Intradermal injections of glutamate and capsaicin are attractive to use in human experimental pain models because hyperalgesia and allodynia mimic isolated aspects of clinical pain disorders .', {'entities': [(94, 98, 'B_Disease'), (114, 126, 'B_Disease'), (131, 140, 'B_Disease'), (176, 180, 'B_Disease'), (181, 190, 'I_Disease')]}], ['Magnitudes of secondary pinprick hyperalgesia and brush - evoked allodynia were investigated using von Frey filaments ( gauges 10 , 15 , 60 and 100 g ) and brush strokes .', {'entities': [(33, 45, 'B_Disease'), (65, 74, 'B_Disease')]}], ['Areas of secondary hyperalgesia and allodynia were quantified immediately after injection and after 15 , 30 and 60 min .', {'entities': [(9, 18, 'B_Disease'), (19, 31, 'I_Disease'), (36, 45, 'B_Disease')]}], ['Secondary pinprick hyperalgesia was observed as a marked increase in the visual analogue scale ( VAS ) response to von Frey gauges 60 and 100 g ( P < 0 . 001 ) after glutamate injection .', {'entities': [(19, 31, 'B_Disease')]}], ['For capsaicin , secondary pinprick hyperalgesia was detected with all von Frey gauges ( P < 0 . 001 ) .', {'entities': [(35, 47, 'B_Disease')]}], ['Capsaicin injection was reproducible for secondary hyperalgesia ( ICC > 0 . 70 ) and allodynia ( ICC > 0 . 71 ) .', {'entities': [(41, 50, 'B_Disease'), (51, 63, 'I_Disease'), (85, 94, 'B_Disease')]}], ['Intra - individual variability was generally lower for the VAS response to von Frey and brush compared with areas of secondary hyperalgesia and allodynia .', {'entities': [(117, 126, 'B_Disease'), (127, 139, 'I_Disease'), (144, 153, 'B_Disease')]}], ['In conclusion , glutamate and capsaicin yield reproducible hyperalgesic and allodynic responses , and the present model is well suited for basic research , as well as for assessing the modulation of central phenomena .', {'entities': [(59, 71, 'B_Disease'), (76, 85, 'B_Disease')]}], ['Ocular - specific ER stress reduction rescues glaucoma in murine glucocorticoid - induced glaucoma .', {'entities': [(46, 54, 'B_Disease'), (90, 98, 'B_Disease')]}], ['Administration of glucocorticoids induces ocular hypertension in some patients .', {'entities': [(42, 48, 'B_Disease'), (49, 61, 'I_Disease')]}], ['If untreated , these patients can develop a secondary glaucoma that resembles primary open - angle glaucoma ( POAG ) .', {'entities': [(54, 62, 'B_Disease'), (78, 85, 'B_Disease'), (86, 90, 'I_Disease'), (91, 92, 'I_Disease'), (93, 98, 'I_Disease'), (99, 107, 'I_Disease'), (110, 114, 'B_Disease')]}], ['The underlying pathology of glucocorticoid - induced glaucoma is not fully understood , due in part to lack of an appropriate animal model .', {'entities': [(53, 61, 'B_Disease')]}], ['Here , we developed a murine model of glucocorticoid - induced glaucoma that exhibits glaucoma features that are observed in patients .', {'entities': [(63, 71, 'B_Disease'), (86, 94, 'B_Disease')]}], ['Treatment of WT mice with topical ocular 0 . 1 % dexamethasone led to elevation of intraocular pressure ( IOP ) , functional and structural loss of retinal ganglion cells , and axonal degeneration , resembling glucocorticoid - induced glaucoma in human patients .', {'entities': [(148, 155, 'B_Disease'), (156, 164, 'I_Disease'), (177, 183, 'B_Disease'), (184, 196, 'I_Disease'), (235, 243, 'B_Disease')]}], ['Furthermore , dexamethasone - induced ocular hypertension was associated with chronic ER stress of the trabecular meshwork ( TM ) .', {'entities': [(38, 44, 'B_Disease'), (45, 57, 'I_Disease')]}], ['Dexamethasone induced the transcriptional factor CHOP , a marker for chronic ER stress , in the anterior segment tissues , and Chop deletion reduced ER stress in these tissues and prevented dexamethasone - induced ocular hypertension .', {'entities': [(214, 220, 'B_Disease'), (221, 233, 'I_Disease')]}], ['Furthermore , reduction of ER stress in the TM with sodium 4 - phenylbutyrate prevented dexamethasone - induced ocular hypertension in WT mice .', {'entities': [(112, 118, 'B_Disease'), (119, 131, 'I_Disease')]}], ['Our data indicate that ER stress contributes to glucocorticoid - induced ocular hypertension and suggest that reducing ER stress has potential as a therapeutic strategy for treating glucocorticoid - induced glaucoma .', {'entities': [(73, 79, 'B_Disease'), (80, 92, 'I_Disease'), (207, 215, 'B_Disease')]}], ['Effects of ginsenosides on opioid - induced hyperalgesia in mice .', {'entities': [(44, 56, 'B_Disease')]}], ['Opioid - induced hyperalgesia ( OIH ) is characterized by nociceptive sensitization caused by the cessation of chronic opioid use .', {'entities': [(17, 29, 'B_Disease'), (32, 35, 'B_Disease')]}], ['OIH can limit the clinical use of opioid analgesics and complicate withdrawal from opioid addiction .', {'entities': [(0, 3, 'B_Disease'), (83, 89, 'B_Disease'), (90, 99, 'I_Disease')]}], ['In this study , we investigated the effects of Re , Rg1 , and Rb1 ginsenosides , the bioactive components of ginseng , on OIH .', {'entities': [(122, 125, 'B_Disease')]}], ['OIH was achieved in mice after subcutaneous administration of morphine for 7 consecutive days three times per day .', {'entities': [(0, 3, 'B_Disease')]}], ['Re ( 300 mg / kg ) inhibited OIH in both the thermal sensitivity test and the acetic acid - induced writhing test .', {'entities': [(29, 32, 'B_Disease')]}], ['However , the Rg1 and Rb1 ginsenosides failed to prevent OIH in either test .', {'entities': [(57, 60, 'B_Disease')]}], ['Furthermore , Rg1 showed a tendency to aggravate OIH in the acetic acid - induced writhing test .', {'entities': [(49, 52, 'B_Disease')]}], ['Our data suggested that the ginsenoside Re , but not Rg1 or Rb1 , may contribute toward reversal of OIH .', {'entities': [(100, 103, 'B_Disease')]}], ['The primary outcome of this study was a composite of severe hypotension ( mean arterial pressure < 60 mm Hg ) and bradycardia ( heart rate < 50 beats / min ) during sedative infusion .', {'entities': [(60, 71, 'B_Disease'), (114, 125, 'B_Disease')]}], ['When analyzed separately , no differences could be found in the prevalence of severe hypotension or bradycardia in either the unmatched or matched cohorts .', {'entities': [(85, 96, 'B_Disease'), (100, 111, 'B_Disease')]}], ['CONCLUSIONS : Severe hypotension and bradycardia occur at similar prevalence in neurocritical care patients who receive dexmedetomidine or propofol .', {'entities': [(21, 32, 'B_Disease'), (37, 48, 'B_Disease')]}], ['Providers should similarly consider the likelihood of hypotension or bradycardia before starting either sedative .', {'entities': [(54, 65, 'B_Disease'), (69, 80, 'B_Disease')]}], ['Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin - induced cardiotoxicity in rats with breast cancer .', {'entities': [(48, 61, 'B_Disease'), (62, 73, 'I_Disease'), (99, 113, 'B_Disease'), (127, 133, 'B_Disease'), (134, 140, 'I_Disease')]}], ['Oxidative stress is involved in several processes including cancer , aging and cardiovascular disease , and has been shown to potentiate the therapeutic effect of drugs such as doxorubicin .', {'entities': [(60, 66, 'B_Disease'), (79, 93, 'B_Disease'), (94, 101, 'I_Disease')]}], ['Doxorubicin causes significant cardiotoxicity characterized by marked increases in oxidative stress and mitochondrial dysfunction .', {'entities': [(31, 45, 'B_Disease'), (104, 117, 'B_Disease'), (118, 129, 'I_Disease')]}], ['Herein , we investigate whether doxorubicin - associated chronic cardiac toxicity can be ameliorated with the antioxidant hydroxytyrosol in rats with breast cancer .', {'entities': [(65, 72, 'B_Disease'), (73, 81, 'I_Disease'), (150, 156, 'B_Disease'), (157, 163, 'I_Disease')]}], ['Thirty - six rats bearing breast tumors induced chemically were divided into 4 groups : control , hydroxytyrosol ( 0 . 5mg / kg , 5days / week ) , doxorubicin ( 1mg / kg / week ) , and doxorubicin plus hydroxytyrosol .', {'entities': [(26, 32, 'B_Disease'), (33, 39, 'I_Disease')]}], ['Cardiac disturbances at the cellular and mitochondrial level , mitochondrial electron transport chain complexes I - IV and apoptosis - inducing factor , and oxidative stress markers have been analyzed .', {'entities': [(0, 7, 'B_Disease'), (8, 20, 'I_Disease')]}], ['Hydroxytyrosol improved the cardiac disturbances enhanced by doxorubicin by significantly reducing the percentage of altered mitochondria and oxidative damage .', {'entities': [(28, 35, 'B_Disease'), (36, 48, 'I_Disease')]}], ['This study demonstrates that hydroxytyrosol protect rat heart damage provoked by doxorubicin decreasing oxidative damage and mitochondrial alterations .', {'entities': [(56, 61, 'B_Disease'), (62, 68, 'I_Disease')]}], ['Amiodarone - induced myxoedema coma .', {'entities': [(21, 30, 'B_Disease'), (31, 35, 'I_Disease')]}], ['A 62 - year - old man was found to have bradycardia , hypothermia and respiratory failure 3 weeks after initiation of amiodarone therapy for atrial fibrillation .', {'entities': [(40, 51, 'B_Disease'), (54, 65, 'B_Disease'), (70, 81, 'B_Disease'), (82, 89, 'I_Disease'), (141, 147, 'B_Disease'), (148, 160, 'I_Disease')]}], ['The only two cases of amiodarone - induced myxoedema coma in the literature report patient death despite supportive therapy and thyroid hormone replacement .', {'entities': [(43, 52, 'B_Disease'), (53, 57, 'I_Disease')]}], ['This case represents the most thoroughly investigated case of amiodarone - induced myxoedema coma with a history significant for subclinical thyroid disease .', {'entities': [(83, 92, 'B_Disease'), (93, 97, 'I_Disease'), (141, 148, 'B_Disease'), (149, 156, 'I_Disease')]}], ['Use of argatroban and catheter - directed thrombolysis with alteplase in an oncology patient with heparin - induced thrombocytopenia with thrombosis .', {'entities': [(42, 54, 'B_Disease'), (116, 132, 'B_Disease'), (138, 148, 'B_Disease')]}], ['PURPOSE : The case of an oncology patient who developed heparin - induced thrombocytopenia with thrombosis ( HITT ) and was treated with argatroban plus catheter - directed thrombolysis ( CDT ) with alteplase is presented .', {'entities': [(74, 90, 'B_Disease'), (96, 106, 'B_Disease'), (109, 113, 'B_Disease'), (173, 185, 'B_Disease')]}], ['SUMMARY : A 63 - year - old Caucasian man with renal amyloidosis undergoing peripheral blood stem cell collection for an autologous stem cell transplant developed extensive bilateral upper - extremity deep venous thrombosis ( DVT ) and pulmonary embolism secondary to heparin - induced thrombocytopenia .', {'entities': [(53, 64, 'B_Disease'), (183, 188, 'B_Disease'), (189, 190, 'I_Disease'), (191, 200, 'I_Disease'), (201, 205, 'I_Disease'), (206, 212, 'I_Disease'), (213, 223, 'I_Disease'), (226, 229, 'B_Disease'), (236, 245, 'B_Disease'), (246, 254, 'I_Disease'), (286, 302, 'B_Disease')]}], ['After one week of therapy , he was transferred to the intensive care unit with cardiopulmonary compromise related to superior vena cava ( SVC ) syndrome .', {'entities': [(117, 125, 'B_Disease'), (126, 130, 'I_Disease'), (131, 135, 'I_Disease'), (136, 137, 'I_Disease'), (138, 141, 'I_Disease'), (142, 143, 'I_Disease'), (144, 152, 'I_Disease')]}], ['A percutaneous mechanical thrombectomy and CDT with alteplase were attempted , but the procedure was aborted due to epistaxis .', {'entities': [(116, 125, 'B_Disease')]}], ['The epistaxis resolved the next day , and the patient was restarted on argatroban .', {'entities': [(4, 13, 'B_Disease')]}], ['Although the patient recovered , he experienced permanent vision and hearing loss , as well as end - stage renal disease .', {'entities': [(58, 64, 'B_Disease'), (65, 68, 'I_Disease'), (69, 76, 'I_Disease'), (77, 81, 'I_Disease'), (95, 98, 'B_Disease'), (99, 100, 'I_Disease'), (101, 106, 'I_Disease'), (107, 112, 'I_Disease'), (113, 120, 'I_Disease')]}], ['CONCLUSION : A 63 - year - old man with renal amyloidosis and SVC syndrome secondary to HITT was successfully treated with argatroban and CDT with alteplase .', {'entities': [(46, 57, 'B_Disease'), (62, 65, 'B_Disease'), (66, 74, 'I_Disease'), (88, 92, 'B_Disease')]}], ['Effects of dehydroepiandrosterone in amphetamine - induced schizophrenia models in mice .', {'entities': [(59, 72, 'B_Disease')]}], ['OBJECTIVE : To examine the effects of dehydroepiandrosterone ( DHEA ) on animal models of schizophrenia .', {'entities': [(90, 103, 'B_Disease')]}], ['Amphetamine ( 3 mg / kg ip ) induced hyper locomotion , apomorphine ( 1 . 5 mg / kg subcutaneously [ sc ] ) induced climbing , and haloperidol ( 1 . 5 mg / kg sc ) induced catalepsy tests were used as animal models of schizophrenia .', {'entities': [(37, 42, 'B_Disease'), (172, 181, 'B_Disease'), (218, 231, 'B_Disease')]}], ['Statistical analysis was carried out using Kruskal - Wallis test for hyper locomotion , and one - way ANOVA for climbing and catalepsy tests .', {'entities': [(69, 74, 'B_Disease'), (125, 134, 'B_Disease')]}], ['There was a significant difference between groups in the haloperidol - induced catalepsy test ( p < 0 . 05 ) .', {'entities': [(79, 88, 'B_Disease')]}], ['CONCLUSION : We observed that DHEA reduced locomotor activity and increased catalepsy at both doses , while it had no effect on climbing behavior .', {'entities': [(76, 85, 'B_Disease')]}], ['We suggest that DHEA displays typical neuroleptic - like effects , and may be used in the treatment of schizophrenia .', {'entities': [(103, 116, 'B_Disease')]}], ['Availability of human induced pluripotent stem cell - derived cardiomyocytes in assessment of drug potential for QT prolongation .', {'entities': [(113, 115, 'B_Disease'), (116, 128, 'I_Disease')]}], ['However , there is no report showing that this technique can be used to predict multichannel blocker potential for QT prolongation .', {'entities': [(115, 117, 'B_Disease'), (118, 130, 'I_Disease')]}], ['The aim of this study is to show that FPD from MEA ( Multielectrode array ) of hiPS - CMs can detect QT prolongation induced by multichannel blockers .', {'entities': [(101, 103, 'B_Disease'), (104, 116, 'I_Disease')]}], ['Finally , the IKr blockers , Terfenadine and Citalopram , which are reported to cause Torsade de Pointes ( TdP ) in clinical practice , produced early afterdepolarization ( EAD ) .', {'entities': [(86, 93, 'B_Disease'), (94, 96, 'I_Disease'), (97, 104, 'I_Disease'), (107, 110, 'B_Disease')]}], ['This study also shows that this assay can help detect EAD for drugs with TdP potential .', {'entities': [(73, 76, 'B_Disease')]}], ['Dermal developmental toxicity of N - phenylimide herbicides in rats .', {'entities': [(21, 29, 'B_Disease')]}], ['BACKGROUND : S - 53482 and S - 23121 are N - phenylimide herbicides and produced embryolethality , teratogenicity ( mainly ventricular septal defects and wavy ribs ) , and growth retardation in rats in conventional oral developmental toxicity studies .', {'entities': [(81, 96, 'B_Disease'), (99, 113, 'B_Disease'), (123, 134, 'B_Disease'), (135, 141, 'I_Disease'), (142, 149, 'I_Disease'), (172, 178, 'B_Disease'), (179, 190, 'I_Disease'), (234, 242, 'B_Disease')]}], ['Our objective in this study was to investigate whether the compounds induce developmental toxicity via the dermal route , which is more relevant to occupational exposure , hence better addressing human health risks .', {'entities': [(90, 98, 'B_Disease')]}], ['RESULTS : Dermal exposure of rats to S - 53482 at 300 mg / kg produced patterns of developmental toxicity similar to those resulting from oral exposure .', {'entities': [(97, 105, 'B_Disease')]}], ['Toxicity included embryolethality , teratogenicity , and growth retardation .', {'entities': [(0, 8, 'B_Disease'), (18, 33, 'B_Disease'), (36, 50, 'B_Disease'), (57, 63, 'B_Disease'), (64, 75, 'I_Disease')]}], ['Dermal administration of S - 23121 at 800 mg / kg resulted in an increased incidence of embryonic death and ventricular septal defect , but retarded fetal growth was not observed as it was following oral exposure to S - 23121 .', {'entities': [(88, 97, 'B_Disease'), (98, 103, 'I_Disease'), (108, 119, 'B_Disease'), (120, 126, 'I_Disease'), (127, 133, 'I_Disease')]}], ['CONCLUSIONS : Based on the results , S - 53482 and S - 23121 were teratogenic when administered dermally to pregnant rats as were the compounds administered orally .', {'entities': [(66, 77, 'B_Disease')]}], ['Rates of Renal Toxicity in Cancer Patients Receiving Cisplatin With and Without Mannitol .', {'entities': [(9, 14, 'B_Disease'), (15, 23, 'I_Disease'), (27, 33, 'B_Disease')]}], ['One of the major complications of cisplatin use is dose - limiting nephrotoxicity .', {'entities': [(67, 81, 'B_Disease')]}], ['There are many strategies to prevent this toxicity , including the use of mannitol as a nephroprotectant in combination with hydration .', {'entities': [(42, 50, 'B_Disease')]}], ['OBJECTIVE : We aimed to evaluate the rates of cisplatin - induced nephrotoxicity in cancer patients receiving single - agent cisplatin with and without mannitol .', {'entities': [(66, 80, 'B_Disease'), (84, 90, 'B_Disease')]}], ['Data were collected on adult cancer patients receiving single - agent cisplatin as an outpatient from January 2011 to September 2012 .', {'entities': [(29, 35, 'B_Disease')]}], ['The primary outcome was acute kidney injury ( AKI ) .', {'entities': [(24, 29, 'B_Disease'), (30, 36, 'I_Disease'), (37, 43, 'I_Disease'), (46, 49, 'B_Disease')]}], ['RESULTS : We evaluated 143 patients who received single - agent cisplatin ; 97 . 2 % of patients had head and neck cancer as their primary malignancy .', {'entities': [(101, 105, 'B_Disease'), (106, 109, 'I_Disease'), (110, 114, 'I_Disease'), (115, 121, 'I_Disease'), (139, 149, 'B_Disease')]}], ['Patients who did not receive mannitol were more likely to develop nephrotoxicity : odds ratio [ OR ] = 2 . 646 ( 95 % CI = 1 . 008 , 6 . 944 ; P = 0 . 048 ) .', {'entities': [(66, 80, 'B_Disease')]}], ['Patients who received the 100 mg / m ( 2 ) dosing and patients who had a history of hypertension also had a higher likelihood of developing nephrotoxicity : OR = 11 . 494 ( 95 % CI = 4 . 149 , 32 . 258 ; P < 0 . 0001 ) and OR = 3 . 219 ( 95 % CI = 1 . 228 , 8 . 439 ; P = 0 . 017 ) , respectively .', {'entities': [(84, 96, 'B_Disease'), (140, 154, 'B_Disease')]}], ['CONCLUSIONS : When limited quantities of mannitol are available , it should preferentially be given to patients at particularly high risk of nephrotoxicity .', {'entities': [(141, 155, 'B_Disease')]}], ['Our analysis suggests that those patients receiving the dosing schedule of 100 mg / m ( 2 ) cisplatin every 3 weeks and those with hypertension are at the greatest risk of nephrotoxicity and would benefit from the addition of mannitol .', {'entities': [(131, 143, 'B_Disease'), (172, 186, 'B_Disease')]}], ['Metformin protects against seizures , learning and memory impairments and oxidative damage induced by pentylenetetrazole - induced kindling in mice .', {'entities': [(27, 35, 'B_Disease'), (38, 46, 'B_Disease'), (47, 50, 'I_Disease'), (51, 57, 'I_Disease'), (58, 69, 'I_Disease')]}], ['Cognitive impairment , the most common and severe comorbidity of epilepsy , greatly diminishes the quality of life .', {'entities': [(0, 9, 'B_Disease'), (10, 20, 'I_Disease'), (65, 73, 'B_Disease')]}], ['However , current therapeutic interventions for epilepsy can also cause untoward cognitive effects .', {'entities': [(48, 56, 'B_Disease')]}], ['Thus , there is an urgent need for new kinds of agents targeting both seizures and cognition deficits .', {'entities': [(70, 78, 'B_Disease'), (83, 92, 'B_Disease'), (93, 101, 'I_Disease')]}], ['Oxidative stress is considered to play an important role in epileptogenesis and cognitive deficits , and antioxidants have a putative antiepileptic potential .', {'entities': [(80, 89, 'B_Disease'), (90, 98, 'I_Disease')]}], ['This study was designed to evaluate the ameliorative effects of metformin on seizures , cognitive impairment and brain oxidative stress markers observed in pentylenetetrazole - induced kindling animals .', {'entities': [(77, 85, 'B_Disease'), (88, 97, 'B_Disease'), (98, 108, 'I_Disease')]}], ['We found that metformin suppressed the progression of kindling , ameliorated the cognitive impairment and decreased brain oxidative stress .', {'entities': [(81, 90, 'B_Disease'), (91, 101, 'I_Disease')]}], ['Thus the present study concluded that metformin may be a potential agent for the treatment of epilepsy as well as a protective medicine against cognitive impairment induced by seizures .', {'entities': [(94, 102, 'B_Disease'), (144, 153, 'B_Disease'), (154, 164, 'I_Disease'), (176, 184, 'B_Disease')]}], ['P53 inhibition exacerbates late - stage anthracycline cardiotoxicity .', {'entities': [(54, 68, 'B_Disease')]}], ['AIMS : Doxorubicin ( DOX ) is an effective anti - cancer therapeutic , but is associated with both acute and late - stage cardiotoxicity .', {'entities': [(50, 56, 'B_Disease'), (122, 136, 'B_Disease')]}], ['Children are particularly sensitive to DOX - induced heart failure .', {'entities': [(53, 58, 'B_Disease'), (59, 66, 'I_Disease')]}], ['Here , the impact of p53 inhibition on acute vs . late - stage DOX cardiotoxicity was examined in a juvenile model .', {'entities': [(67, 81, 'B_Disease')]}], ['Furthermore , these data suggest an explanation as to how p53 inhibition can result in cardioprotection during drug treatment and , paradoxically , enhanced cardiotoxicity long after the cessation of drug treatment .', {'entities': [(157, 171, 'B_Disease')]}], ['Metronidazole - induced encephalopathy : an uncommon scenario .', {'entities': [(24, 38, 'B_Disease')]}], ['We present a case where a patient developed features of encephalopathy following prolonged metronidazole intake .', {'entities': [(56, 70, 'B_Disease')]}], ['The diagnosis of metronidazole toxicity was made by the MRI findings and supported clinically .', {'entities': [(31, 39, 'B_Disease')]}], ['Aconitine - induced Ca2 + overload causes arrhythmia and triggers apoptosis through p38 MAPK signaling pathway in rats .', {'entities': [(42, 52, 'B_Disease')]}], ['Emerging evidence indicates that voltage - dependent Na ( + ) channels have pivotal roles in the cardiotoxicity of aconitine .', {'entities': [(97, 111, 'B_Disease')]}], ['However , no reports are available on the role of Ca ( 2 + ) in aconitine poisoning .', {'entities': [(74, 83, 'B_Disease')]}], ['In this study , we explored the importance of pathological Ca ( 2 + ) signaling in aconitine poisoning in vitro and in vivo .', {'entities': [(93, 102, 'B_Disease')]}], ['We found that Ca ( 2 + ) overload lead to accelerated beating rhythm in adult rat ventricular myocytes and caused arrhythmia in conscious freely moving rats .', {'entities': [(114, 124, 'B_Disease')]}], ['To investigate effects of aconitine on myocardial injury , we performed cytotoxicity assay in neonatal rat ventricular myocytes ( NRVMs ) , as well as measured lactate dehydrogenase level in the culture medium of NRVMs and activities of serum cardiac enzymes in rats .', {'entities': [(39, 49, 'B_Disease'), (50, 56, 'I_Disease'), (72, 84, 'B_Disease')]}], ['The results showed that aconitine resulted in myocardial injury and reduced NRVMs viability dose - dependently .', {'entities': [(46, 56, 'B_Disease'), (57, 63, 'I_Disease')]}], ['Hence , our results suggest that aconitine significantly aggravates Ca ( 2 + ) overload and causes arrhythmia and finally promotes apoptotic development via phosphorylation of P38 mitogen - activated protein kinase .', {'entities': [(99, 109, 'B_Disease')]}], ['Chronic treatment with metformin suppresses toll - like receptor 4 signaling and attenuates left ventricular dysfunction following myocardial infarction .', {'entities': [(92, 96, 'B_Disease'), (97, 108, 'I_Disease'), (109, 120, 'I_Disease'), (131, 141, 'B_Disease'), (142, 152, 'I_Disease')]}], ['Acute treatment with metformin has a protective effect in myocardial infarction by suppression of inflammatory responses due to activation of AMP - activated protein kinase ( AMPK ) .', {'entities': [(58, 68, 'B_Disease'), (69, 79, 'I_Disease')]}], ['In the present study , the effect of chronic pre - treatment with metformin on cardiac dysfunction and toll - like receptor 4 ( TLR4 ) activities following myocardial infarction and their relation with AMPK were assessed .', {'entities': [(79, 86, 'B_Disease'), (87, 98, 'I_Disease'), (156, 166, 'B_Disease'), (167, 177, 'I_Disease')]}], ['Isoproterenol ( 100mg / kg ) was injected subcutaneously on the 13th and 14th days to induce acute myocardial infarction .', {'entities': [(93, 98, 'B_Disease'), (99, 109, 'I_Disease'), (110, 120, 'I_Disease')]}], ['The left ventricular dysfunction was significantly lower in the groups treated with 25 and 50mg / kg of metformin .', {'entities': [(4, 8, 'B_Disease'), (9, 20, 'I_Disease'), (21, 32, 'I_Disease')]}], ['Metfromin markedly lowered isoproterenol - induced elevation in the levels of TLR4 mRNA , myeloid differentiation protein 88 ( MyD88 ) , tumor necrosis factor - alpha ( TNF - a ) , and interleukin 6 ( IL - 6 ) in the heart tissues .', {'entities': [(137, 142, 'B_Disease'), (143, 151, 'B_Disease')]}], ['Chronic pre - treatment with metformin reduces post - myocardial infarction cardiac dysfunction and suppresses inflammatory responses , possibly through inhibition of TLR4 activities .', {'entities': [(54, 64, 'B_Disease'), (65, 75, 'I_Disease')]}], ['Two cases of propylthiouracil - associated acute hepatitis , one case of fatal methimazole - associated hepatocellular necrosis and one case of propylthiouracil - associated lupus - like syndrome are described .', {'entities': [(49, 58, 'B_Disease'), (104, 118, 'B_Disease'), (119, 127, 'I_Disease'), (174, 179, 'B_Disease'), (180, 181, 'I_Disease'), (182, 186, 'I_Disease'), (187, 195, 'I_Disease')]}], ['It is concluded that in most circumstances 131I is the therapy of choice for hyperthyroidism .', {'entities': [(77, 92, 'B_Disease')]}], [\"Neuroleptic malignant syndrome induced by combination therapy with tetrabenazine and tiapride in a Japanese patient with Huntington ' s disease at the terminal stage of recurrent breast cancer .\", {'entities': [(0, 11, 'B_Disease'), (12, 21, 'I_Disease'), (22, 30, 'I_Disease'), (121, 131, 'B_Disease'), (132, 133, 'I_Disease'), (134, 135, 'I_Disease'), (136, 143, 'I_Disease'), (179, 185, 'B_Disease'), (186, 192, 'I_Disease')]}], [\"We herein describe the case of an 81 - year - old Japanese woman with neuroleptic malignant syndrome that occurred 36 days after the initiation of combination therapy with tiapride ( 75 mg / day ) and tetrabenazine ( 12 . 5 mg / day ) for Huntington ' s disease .\", {'entities': [(70, 81, 'B_Disease'), (82, 91, 'I_Disease'), (92, 100, 'I_Disease'), (239, 249, 'B_Disease'), (250, 251, 'I_Disease'), (252, 253, 'I_Disease'), (254, 261, 'I_Disease')]}], ['She also had advanced breast cancer when the combination therapy was initiated .', {'entities': [(22, 28, 'B_Disease'), (29, 35, 'I_Disease')]}], ['To the best of our knowledge , the occurrence of neuroleptic malignant syndrome due to combination therapy with tetrabenazine and tiapride has not been previously reported .', {'entities': [(49, 60, 'B_Disease'), (61, 70, 'I_Disease'), (71, 79, 'I_Disease')]}], ['A metoprolol - terbinafine combination induced bradycardia .', {'entities': [(47, 58, 'B_Disease')]}], ['To report a sinus bradycardia induced by metoprolol and terbinafine drug - drug interaction and its management .', {'entities': [(12, 17, 'B_Disease'), (18, 29, 'I_Disease')]}], ['A 63 year - old Caucasian man on metoprolol 200 mg / day for stable coronary artery disease was prescribed a 90 - day course of oral terbinafine 250 mg / day for onychomycosis .', {'entities': [(68, 76, 'B_Disease'), (77, 83, 'I_Disease'), (84, 91, 'I_Disease'), (162, 175, 'B_Disease')]}], ['On the 49th day of terbinafine therapy , he was brought to the emergency room for a decrease of his global health status , confusion and falls .', {'entities': [(123, 132, 'B_Disease')]}], ['The electrocardiogram revealed a 37 beats / min sinus bradycardia .', {'entities': [(48, 53, 'B_Disease'), (54, 65, 'I_Disease')]}], [\"A score of 7 on the Naranjo adverse drug reaction probability scale indicates a probable relationship between the patient ' s sinus bradycardia and the drug interaction between metoprolol and terbinafine .\", {'entities': [(28, 35, 'B_Disease'), (36, 40, 'I_Disease'), (41, 49, 'I_Disease'), (126, 131, 'B_Disease'), (132, 143, 'I_Disease')]}], [\"By inhibiting the cytochrome P450 2D6 , terbinafine had decreased metoprolol ' s clearance , leading in metoprolol accumulation which has resulted in clinically significant sinus bradycardia .\", {'entities': [(173, 178, 'B_Disease'), (179, 190, 'I_Disease')]}], ['Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment .', {'entities': [(19, 29, 'B_Disease'), (30, 40, 'I_Disease')]}], ['Ethambutol is known to cause optic neuropathy and , more rarely , axonal polyneuropathy .', {'entities': [(29, 34, 'B_Disease'), (35, 45, 'I_Disease'), (73, 87, 'B_Disease')]}], ['We characterize the clinical , neurophysiological , and neuroimaging findings in a 72 - year - old man who developed visual loss and paresthesias after 11 weeks of exposure to a supratherapeutic dose of ethambutol .', {'entities': [(117, 123, 'B_Disease'), (124, 128, 'I_Disease'), (133, 145, 'B_Disease')]}], ['This case demonstrates the selective vulnerability of the anterior visual pathways and peripheral nerves to ethambutol toxicity .', {'entities': [(119, 127, 'B_Disease')]}], ['Testosterone ameliorates streptozotocin - induced memory impairment in male rats .', {'entities': [(50, 56, 'B_Disease'), (57, 67, 'I_Disease')]}], ['AIM : To study the effects of testosterone on streptozotocin ( STZ ) - induced memory impairment in male rats .', {'entities': [(79, 85, 'B_Disease'), (86, 96, 'I_Disease')]}], ['Administration of flutamide , letrozole or tamoxifen significantly impaired the memory in intact rats , and significantly attenuated the testosterone replacement in improving STZ - and castration - induced memory impairment .', {'entities': [(67, 75, 'B_Disease'), (76, 79, 'I_Disease'), (80, 86, 'I_Disease'), (206, 212, 'B_Disease'), (213, 223, 'I_Disease')]}], ['CONCLUSION : Testosterone administration ameliorates STZ - and castration - induced memory impairment in male Wistar rats .', {'entities': [(84, 90, 'B_Disease'), (91, 101, 'I_Disease')]}], ['Behavioral and neurochemical studies in mice pretreated with garcinielliptone FC in pilocarpine - induced seizures .', {'entities': [(106, 114, 'B_Disease')]}], ['It is widely used in folk medicine to treat skin diseases in both humans and animals as well as the seed decoction has been used to treat diarrheas and inflammatory diseases .', {'entities': [(44, 48, 'B_Disease'), (49, 57, 'I_Disease'), (138, 147, 'B_Disease'), (152, 164, 'B_Disease'), (165, 173, 'I_Disease')]}], ['The present study aimed to evaluate the GFC effects at doses of 25 , 50 or 75 mg / kg on seizure parameters to determine their anticonvulsant activity and its effects on amino acid ( r - aminobutyric acid ( GABA ) , glutamine , aspartate and glutathione ) levels as well as on acetylcholinesterase ( AChE ) activity in mice hippocampus after seizures .', {'entities': [(89, 96, 'B_Disease'), (342, 350, 'B_Disease')]}], ['GFC produced an increased latency to first seizure , at doses 25mg / kg ( 20 . 12 + 2 . 20 min ) , 50mg / kg ( 20 . 95 + 2 . 21 min ) or 75 mg / kg ( 23 . 43 + 1 . 99 min ) when compared with seized mice .', {'entities': [(43, 50, 'B_Disease')]}], ['The results indicate that GFC can exert anticonvulsant activity and reduce the frequency of installation of pilocarpine - induced status epilepticus , as demonstrated by increase in latency to first seizure and decrease in mortality rate of animals .', {'entities': [(130, 136, 'B_Disease'), (137, 148, 'I_Disease'), (199, 206, 'B_Disease')]}], ['Standard operating procedures for antibiotic therapy and the occurrence of acute kidney injury : a prospective , clinical , non - interventional , observational study .', {'entities': [(75, 80, 'B_Disease'), (81, 87, 'I_Disease'), (88, 94, 'I_Disease')]}], ['INTRODUCTION : Acute kidney injury ( AKI ) occurs in 7 % of hospitalized and 66 % of Intensive Care Unit ( ICU ) patients .', {'entities': [(15, 20, 'B_Disease'), (21, 27, 'I_Disease'), (28, 34, 'I_Disease'), (37, 40, 'B_Disease')]}], ['The aim of this study was to investigate , whether there is an association between adherence to guidelines ( standard operating procedures ( SOP ) ) for potentially nephrotoxic antibiotics and the occurrence of AKI .', {'entities': [(165, 176, 'B_Disease'), (211, 214, 'B_Disease')]}], ['AKI was defined according to RIFLE criteria .', {'entities': [(0, 3, 'B_Disease')]}], ['Development of AKI was compared between groups with exact Chi2 - test and multivariate logistic regression analysis ( two - sided P < 0 . 05 ) .', {'entities': [(15, 18, 'B_Disease')]}], ['AKI occurred significantly more often in LAG with 36 % versus 21 % in HAG ( P = 0 . 035 ) .', {'entities': [(0, 3, 'B_Disease')]}], ['Basic characteristics were comparable , except an increased rate of soft tissue infections in LAG .', {'entities': [(80, 90, 'B_Disease')]}], ['Multivariate analysis revealed an odds ratio of 2 . 5 - fold for LAG to develop AKI compared with HAG ( 95 % confidence interval 1 . 195 to 5 . 124 , P = 0 . 039 ) .', {'entities': [(80, 83, 'B_Disease')]}], ['CONCLUSION : Low adherence to SOPs for potentially nephrotoxic antibiotics was associated with a higher occurrence of AKI .', {'entities': [(51, 62, 'B_Disease'), (118, 121, 'B_Disease')]}], ['Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin .', {'entities': [(0, 14, 'B_Disease'), (20, 29, 'B_Disease'), (30, 31, 'I_Disease'), (32, 37, 'I_Disease'), (38, 46, 'I_Disease')]}], ['A 46 - year old man with a chronic hepatitis C virus infection received triple therapy with ribavirin , pegylated interferon and telaprevir .', {'entities': [(35, 44, 'B_Disease'), (45, 46, 'I_Disease'), (47, 52, 'I_Disease'), (53, 62, 'I_Disease')]}], ['One month after starting the antiviral therapy , the patient was admitted to the hospital because he developed rhabdomyolysis .', {'entities': [(111, 125, 'B_Disease')]}], ['At admission simvastatin and all antiviral drugs were discontinued because toxicity due to a drug - drug interaction was suspected .', {'entities': [(75, 83, 'B_Disease')]}], ['Simvastatin plasma concentration increased 30 times in this patient and statin induced muscle toxicity is related to the concentration of the statin in blood .', {'entities': [(87, 93, 'B_Disease'), (94, 102, 'I_Disease')]}], ['Combination of bortezomib , thalidomide , and dexamethasone ( VTD ) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients .', {'entities': [(154, 162, 'B_Disease'), (163, 170, 'I_Disease')]}], ['Consolidation therapy for patients with multiple myeloma ( MM ) has been widely adopted to improve treatment response following autologous stem cell transplantation .', {'entities': [(40, 48, 'B_Disease'), (49, 56, 'I_Disease'), (59, 61, 'B_Disease')]}], ['In this study , we retrospectively analyzed the safety and efficacy of combination regimen of bortezomib , thalidomide , and dexamethasone ( VTD ) as consolidation therapy in 24 Japanese patients with newly diagnosed MM .', {'entities': [(217, 219, 'B_Disease')]}], ['Grade 3 - 4 neutropenia and thrombocytopenia were documented in four and three patients ( 17 and 13 % ) , respectively , but drug dose reduction due to cytopenia was not required in any case .', {'entities': [(12, 23, 'B_Disease'), (28, 44, 'B_Disease'), (152, 161, 'B_Disease')]}], ['Peripheral neuropathy was common ( 63 % ) , but severe grade 3 - 4 peripheral neuropathy was not observed .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (67, 77, 'B_Disease'), (78, 88, 'I_Disease')]}], ['Conversion to sirolimus ameliorates cyclosporine - induced nephropathy in the rat : focus on serum , urine , gene , and protein renal expression biomarkers .', {'entities': [(59, 70, 'B_Disease')]}], ['Protocols of conversion from cyclosporin A ( CsA ) to sirolimus ( SRL ) have been widely used in immunotherapy after transplantation to prevent CsA - induced nephropathy , but the molecular mechanisms underlying these protocols remain nuclear .', {'entities': [(158, 169, 'B_Disease')]}], [\"Renal lesions were analyzed in hematoxylin and eosin , periodic acid - Schiff , and Masson ' s trichrome stains .\", {'entities': [(0, 5, 'B_Disease'), (6, 13, 'I_Disease')]}], ['SRL - treated rats presented proteinuria and NGAL ( serum and urinary ) as the best markers of renal impairment .', {'entities': [(29, 40, 'B_Disease'), (95, 100, 'B_Disease'), (101, 111, 'I_Disease')]}], ['Short CsA treatment presented slight or even absent kidney lesions and TGF - b , NF - kb , mTOR , PCNA , TP53 , KIM - 1 , and CTGF as relevant gene and protein changes .', {'entities': [(52, 58, 'B_Disease'), (59, 66, 'I_Disease')]}], ['Prolonged CsA exposure aggravated renal damage , without clear changes on the traditional markers , but with changes in serums TGF - b and IL - 7 , TBARs clearance , and kidney TGF - b and mTOR .', {'entities': [(34, 39, 'B_Disease'), (40, 46, 'I_Disease')]}], ['Conversion to SRL prevented CsA - induced renal damage evolution ( absent / mild grade lesions ) , while NGAL ( serum versus urine ) seems to be a feasible biomarker of CsA replacement to SRL .', {'entities': [(42, 47, 'B_Disease'), (48, 54, 'I_Disease')]}], ['Kinin B2 receptor deletion and blockage ameliorates cisplatin - induced acute renal injury .', {'entities': [(72, 77, 'B_Disease'), (78, 83, 'I_Disease'), (84, 90, 'I_Disease')]}], ['Cisplatin treatment has been adopted in some chemotherapies ; however , this drug can induce acute kidney injury due its ability to negatively affect renal function , augment serum levels of creatinine and urea , increase the acute tubular necrosis score and up - regulate cytokines ( e . g . , IL - 1b and TNF - a ) .', {'entities': [(93, 98, 'B_Disease'), (99, 105, 'I_Disease'), (106, 112, 'I_Disease'), (226, 231, 'B_Disease'), (232, 239, 'I_Disease'), (240, 248, 'I_Disease')]}], ['The kinin B2 receptor has been associated with the inflammation process , as well as the regulation of cytokine expression , and its deletion resulted in an improvement in the diabetic nephropathy status .', {'entities': [(51, 63, 'B_Disease'), (176, 184, 'B_Disease'), (185, 196, 'I_Disease')]}], ['To examine the role of the kinin B2 receptor in cisplatin - induced acute kidney injury , kinin B2 receptor knockout mice were challenged with cisplatin .', {'entities': [(68, 73, 'B_Disease'), (74, 80, 'I_Disease'), (81, 87, 'I_Disease')]}], ['B2 receptor - deficient mice were less sensitive to this drug than the WT mice , as shown by reduced weight loss , better preservation of kidney function , down regulation of inflammatory cytokines and less acute tubular necrosis .', {'entities': [(101, 107, 'B_Disease'), (108, 112, 'I_Disease'), (207, 212, 'B_Disease'), (213, 220, 'I_Disease'), (221, 229, 'I_Disease')]}], ['Thus , our data suggest that the kinin B2 receptor is involved in cisplatin - induced acute kidney injury by mediating the necrotic process and the expression of inflammatory cytokines , thus resulting in declined renal function .', {'entities': [(86, 91, 'B_Disease'), (92, 98, 'I_Disease'), (99, 105, 'I_Disease'), (123, 131, 'B_Disease')]}], ['These results highlight the kinin B2 receptor antagonist treatment in amelioration of nephrotoxicity induced by cisplatin therapy .', {'entities': [(86, 100, 'B_Disease')]}], ['Safety and efficacy of fluocinolone acetonide intravitreal implant ( 0 . 59 mg ) in birdshot retinochoroidopathy .', {'entities': [(84, 92, 'B_Disease'), (93, 112, 'I_Disease')]}], ['PURPOSE : To report the treatment outcomes of the fluocinolone acetonide intravitreal implant ( 0 . 59 mg ) in patients with birdshot retinochoroidopathy whose disease is refractory or intolerant to conventional immunomodulatory therapy .', {'entities': [(125, 133, 'B_Disease'), (134, 153, 'I_Disease')]}], ['METHODS : A retrospective case series involving 11 birdshot retinochoroidopathy patients ( 11 eyes ) .', {'entities': [(51, 59, 'B_Disease'), (60, 79, 'I_Disease')]}], ['Disease activity markers , including signs of ocular inflammation , evidence of retinal vasculitis , Swedish interactive threshold algorithm - short wavelength automated perimetry Humphrey visual field analysis , electroretinographic parameters , and optical coherence tomography were recorded .', {'entities': [(53, 65, 'B_Disease'), (80, 87, 'B_Disease'), (88, 98, 'I_Disease')]}], ['Data on occurrence of cataract and raised intraocular pressure were collected in all eyes .', {'entities': [(22, 30, 'B_Disease'), (35, 41, 'B_Disease'), (42, 53, 'I_Disease'), (54, 62, 'I_Disease')]}], ['RESULTS : Intraocular inflammation was present in 54 . 5 , 9 . 9 , 11 . 1 , and 0 % of patients at baseline , 6 months , 1 year , 2 years , 3 years , and beyond 3 years after receiving the implant , respectively .', {'entities': [(22, 34, 'B_Disease')]}], ['Active vasculitis was noted in 36 . 3 % patients at baseline and 0 % at 3 years of follow - up .', {'entities': [(7, 17, 'B_Disease')]}], ['More than 20 % ( 47 . 61 - 67 . 2 % ) reduction in central retinal thickness was noted in all patients with cystoid macular edema at 6 months , 1 year , 2 years , and 3 years postimplant .', {'entities': [(108, 115, 'B_Disease'), (116, 123, 'I_Disease'), (124, 129, 'I_Disease')]}], ['Adverse events included increased intraocular pressure ( 54 . 5 % ) and cataract formation ( 100 % ) .', {'entities': [(24, 33, 'B_Disease'), (34, 45, 'I_Disease'), (46, 54, 'I_Disease'), (72, 80, 'B_Disease')]}], ['CONCLUSION : The data suggest that fluocinolone acetonide implant ( 0 . 59 mg ) helps to control inflammation in otherwise treatment - refractory cases of birdshot retinochoroidopathy .', {'entities': [(97, 109, 'B_Disease'), (155, 163, 'B_Disease'), (164, 183, 'I_Disease')]}], ['It is associated with significant side effects of cataract and ocular hypertension requiring treatment .', {'entities': [(50, 58, 'B_Disease'), (63, 69, 'B_Disease'), (70, 82, 'I_Disease')]}], ['Optimal precurarizing dose of rocuronium to decrease fasciculation and myalgia following succinylcholine administration .', {'entities': [(53, 66, 'B_Disease'), (71, 78, 'B_Disease')]}], ['BACKGROUND : Succinylcholine commonly produces frequent adverse effects , including muscle fasciculation and myalgia .', {'entities': [(84, 90, 'B_Disease'), (91, 104, 'I_Disease'), (109, 116, 'B_Disease')]}], ['The current study identified the optimal dose of rocuronium to prevent succinylcholine - induced fasciculation and myalgia and evaluated the influence of rocuronium on the speed of onset produced by succinylcholine .', {'entities': [(97, 110, 'B_Disease'), (115, 122, 'B_Disease')]}], ['All patients received succinylcholine 1 . 5 mg / kg at 2 minutes after the precurarization , and were assessed the incidence and severity of fasciculations , while myalgia was assessed at 24 hours after surgery .', {'entities': [(141, 155, 'B_Disease'), (164, 171, 'B_Disease')]}], ['RESULTS : The incidence and severity of visible muscle fasciculation was significantly less with increasing the amount of precurarizing dose of rocuronium ( P < 0 . 001 ) .', {'entities': [(48, 54, 'B_Disease'), (55, 68, 'I_Disease')]}], ['Those of myalgia tend to decrease according to increasing the amount of precurarizing dose of rocuronium , but there was no significance ( P = 0 . 072 ) .', {'entities': [(9, 16, 'B_Disease')]}], ['CONCLUSIONS : Precurarization with 0 . 04 mg / kg rocuronium was the optimal dose considering the reduction in the incidence and severity of fasciculation and myalgia with acceptable onset time , and the safe and effective precurarization .', {'entities': [(141, 154, 'B_Disease'), (159, 166, 'B_Disease')]}], ['Absence of PKC - alpha attenuates lithium - induced nephrogenic diabetes insipidus .', {'entities': [(52, 63, 'B_Disease'), (64, 72, 'I_Disease'), (73, 82, 'I_Disease')]}], ['Lithium , an effective antipsychotic , induces nephrogenic diabetes insipidus ( NDI ) in 40 % of patients .', {'entities': [(47, 58, 'B_Disease'), (59, 67, 'I_Disease'), (68, 77, 'I_Disease'), (80, 83, 'B_Disease')]}], ['Targeting an alternative signaling pathway , such as PKC - mediated signaling , may be an effective method of treating lithium - induced polyuria .', {'entities': [(137, 145, 'B_Disease')]}], ['Our data show that ablation of PKCa preserves AQP2 and UT - A1 protein expression and localization in lithium - induced NDI , and prevents the development of the severe polyuria associated with lithium therapy .', {'entities': [(120, 123, 'B_Disease'), (169, 177, 'B_Disease')]}], ['Is Dysguesia Going to be a Rare or a Common Side - effect of Amlodipine ?', {'entities': [(3, 12, 'B_Disease')]}], ['A very rare side - effect of amlodipine is dysguesia .', {'entities': [(43, 52, 'B_Disease')]}], ['We report a case about a female with essential hypertension on drug treatment with amlodipine developed loss of taste sensation .', {'entities': [(47, 59, 'B_Disease'), (104, 108, 'B_Disease'), (109, 111, 'I_Disease'), (112, 117, 'I_Disease'), (118, 127, 'I_Disease')]}], ['We conclude that amlodipine can cause dysguesia .', {'entities': [(38, 47, 'B_Disease')]}], ['Here , we describe the clinical presentation and review the relevant literature on amlodipine and dysguesia .', {'entities': [(98, 107, 'B_Disease')]}], ['Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin .', {'entities': [(0, 14, 'B_Disease')]}], ['This particular case is of interest as rhabdomyolysis only occurred after an increase in the dose of clarithromycin .', {'entities': [(39, 53, 'B_Disease')]}], ['The patient developed raised cardiac biomarkers without any obvious cardiac issues , a phenomenon that has been linked to rhabdomyolysis previously .', {'entities': [(122, 136, 'B_Disease')]}], ['To date , there has been no reported effect of rhabdomyolysis on the structure and function of cardiac muscle .', {'entities': [(47, 61, 'B_Disease')]}], ['Clinicians need to be aware of prescribing concomitant medications that increase the risk of myopathy or inhibit the CYP3A4 enzyme .', {'entities': [(93, 101, 'B_Disease')]}], ['Our case suggests that troponin elevation could be associated with statin induced rhabdomyolysis , which may warrant further studies .', {'entities': [(82, 96, 'B_Disease')]}], ['Characterization of a novel BCHE \" silent \" allele : point mutation ( p . Val204Asp ) causes loss of activity and prolonged apnea with suxamethonium .', {'entities': [(124, 129, 'B_Disease')]}], ['Butyrylcholinesterase deficiency is characterized by prolonged apnea after the use of muscle relaxants ( suxamethonium or mivacurium ) in patients who have mutations in the BCHE gene .', {'entities': [(0, 21, 'B_Disease'), (22, 32, 'I_Disease'), (63, 68, 'B_Disease')]}], ['Delayed anemia after treatment with injectable artesunate in the Democratic Republic of the Congo : a manageable issue .', {'entities': [(8, 14, 'B_Disease')]}], ['Cases of delayed hemolytic anemia have been described after treatment with injectable artesunate , the current World Health Organization ( WHO ) - recommended first - line drug for the treatment of severe malaria .', {'entities': [(17, 26, 'B_Disease'), (27, 33, 'I_Disease'), (205, 212, 'B_Disease')]}], ['A total of 350 patients ( 215 [ 61 . 4 % ] < 5 years of age and 135 [ 38 . 6 % ] > 5 years of age ) were followed - up after treatment with injectable artesunate for severe malaria in hospitals and health centers of the Democratic Republic of the Congo .', {'entities': [(173, 180, 'B_Disease')]}], ['All cases of delayed anemia were clinically manageable and resolved within one month .', {'entities': [(21, 27, 'B_Disease')]}], ['Regulation of signal transducer and activator of transcription 3 and apoptotic pathways by betaine attenuates isoproterenol - induced acute myocardial injury in rats .', {'entities': [(140, 150, 'B_Disease'), (151, 157, 'I_Disease')]}], ['The present study was designed to investigate the cardioprotective effects of betaine on acute myocardial ischemia induced experimentally in rats focusing on regulation of signal transducer and activator of transcription 3 ( STAT3 ) and apoptotic pathways as the potential mechanism underlying the drug effect .', {'entities': [(95, 105, 'B_Disease'), (106, 114, 'I_Disease')]}], ['Acute myocardial ischemic injury was induced in rats by subcutaneous injection of isoproterenol ( 85 mg / kg ) , for two consecutive days .', {'entities': [(6, 16, 'B_Disease'), (17, 25, 'I_Disease'), (26, 32, 'I_Disease')]}], ['Oral administration of betaine ( 200 and 400 mg / kg ) significantly reduced the level of cardiac marker enzyme in the serum and prevented left ventricular remodeling .', {'entities': [(144, 155, 'B_Disease'), (156, 166, 'I_Disease')]}], ['The protective role of betaine on myocardial damage was further confirmed by histopathological examination .', {'entities': [(34, 44, 'B_Disease'), (45, 51, 'I_Disease')]}], ['In summary , our results showed that betaine pretreatment attenuated isoproterenol - induced acute myocardial ischemia via the regulation of STAT3 and apoptotic pathways .', {'entities': [(99, 109, 'B_Disease'), (110, 118, 'I_Disease')]}], ['Quetiapine - induced neutropenia in a bipolar patient with hepatocellular carcinoma .', {'entities': [(21, 32, 'B_Disease'), (38, 45, 'B_Disease'), (59, 73, 'B_Disease'), (74, 83, 'I_Disease')]}], ['OBJECTIVE : Quetiapine is a dibenzothiazepine derivative , similar to clozapine , which has the highest risk of causing blood dyscrasias , especially neutropenia .', {'entities': [(120, 125, 'B_Disease'), (126, 136, 'I_Disease'), (150, 161, 'B_Disease')]}], ['A case of a patient with hepatocellular carcinoma that developed neutropenia after treatment with quetiapine is described here .', {'entities': [(25, 39, 'B_Disease'), (40, 49, 'I_Disease'), (65, 76, 'B_Disease')]}], ['CASE REPORT : A 62 - year - old Taiwanese widow with bipolar disorder was diagnosed with hepatocellular carcinoma at age 60 .', {'entities': [(53, 60, 'B_Disease'), (61, 69, 'I_Disease'), (89, 103, 'B_Disease'), (104, 113, 'I_Disease')]}], ['She developed leucopenia after being treated with quetiapine .', {'entities': [(14, 24, 'B_Disease')]}], ['CONCLUSIONS : Although neutropenia is not a common side effect of quetiapine , physicians should be cautious about its presentation and associated risk factors .', {'entities': [(23, 34, 'B_Disease')]}], ['Hepatic dysfunction may be one of the possible risk factors , and concomitant fever may be a diagnostic marker for adverse reaction to quetiapine .', {'entities': [(0, 7, 'B_Disease'), (8, 19, 'I_Disease'), (78, 83, 'B_Disease')]}], ['Lateral antebrachial cutaneous neuropathy after steroid injection at lateral epicondyle .', {'entities': [(31, 41, 'B_Disease')]}], ['BACKGROUND AND OBJECTIVES : This report aimed to present a case of lateral antebrachial cutaneous neuropathy ( LACNP ) that occurred after a steroid injection in the lateral epicondyle to treat lateral epicondylitis in a 40 - year - old woman .', {'entities': [(98, 108, 'B_Disease'), (194, 201, 'B_Disease'), (202, 215, 'I_Disease')]}], ['MATERIAL AND METHOD : A 40 - year - old woman presented with decreased sensation and paresthesia over her right lateral forearm ; the paresthesia had occurred after a steroid injection in the right lateral epicondyle 3 months before .', {'entities': [(85, 96, 'B_Disease'), (134, 145, 'B_Disease')]}], ['Her sensation of light touch and pain was diminished over the lateral side of the right forearm and wrist area .', {'entities': [(33, 37, 'B_Disease')]}], ['CONCLUSION : This report describes the case of a woman with LACNP that developed after a steroid injection for the treatment of lateral epicondylitis .', {'entities': [(128, 135, 'B_Disease'), (136, 149, 'I_Disease')]}], ['Curcumin prevents maleate - induced nephrotoxicity : relation to hemodynamic alterations , oxidative stress , mitochondrial oxygen consumption and activity of respiratory complex I .', {'entities': [(36, 50, 'B_Disease')]}], ['The potential protective effect of the dietary antioxidant curcumin ( 120 mg / Kg / day for 6 days ) against the renal injury induced by maleate was evaluated .', {'entities': [(113, 118, 'B_Disease'), (119, 125, 'I_Disease')]}], ['Tubular proteinuria and oxidative stress were induced by a single injection of maleate ( 400 mg / kg ) in rats .', {'entities': [(8, 19, 'B_Disease')]}], ['Maleate - induced renal injury included increase in renal vascular resistance and in the urinary excretion of total protein , glucose , sodium , neutrophil gelatinase - associated lipocalin ( NGAL ) and N - acetyl b - D - glucosaminidase ( NAG ) , upregulation of kidney injury molecule ( KIM ) - 1 , decrease in renal blood flow and claudin - 2 expression besides of necrosis and apoptosis of tubular cells on 24 h .', {'entities': [(18, 23, 'B_Disease'), (24, 30, 'I_Disease'), (264, 270, 'B_Disease'), (271, 277, 'I_Disease'), (368, 376, 'B_Disease')]}], ['It is concluded that curcumin is able to attenuate in vivo maleate - induced nephropathy and in vitro cell damage .', {'entities': [(77, 88, 'B_Disease')]}], ['Anticonvulsant actions of MK - 801 on the lithium - pilocarpine model of status epilepticus in rats .', {'entities': [(73, 79, 'B_Disease'), (80, 91, 'I_Disease')]}], ['MK - 801 , a noncompetitive N - methyl - D - aspartate ( NMDA ) receptor antagonist , was tested for anticonvulsant effects in rats using two seizure models , coadministration of lithium and pilocarpine and administration of a high dose of pilocarpine alone .', {'entities': [(142, 149, 'B_Disease')]}], ['First , pretreatment with MK - 801 produced an effective and dose - dependent anticonvulsant action with the lithium - pilocarpine model but not with rats treated with pilocarpine alone , suggesting that different biochemical mechanisms control seizures in these two models .', {'entities': [(245, 253, 'B_Disease')]}], ['Second , the anticonvulsant effect of MK - 801 in the lithium - pilocarpine model only occurred after initial periods of seizure activity .', {'entities': [(121, 128, 'B_Disease')]}], ['Third , although it is relatively easy to block seizures induced by lithium and pilocarpine by administration of anticonvulsants prior to pilocarpine , it is more difficult to terminate ongoing status epilepticus and block the lethality of the seizures .', {'entities': [(48, 56, 'B_Disease'), (194, 200, 'B_Disease'), (201, 212, 'I_Disease'), (244, 252, 'B_Disease')]}], ['Administration of MK - 801 30 or 60 min after pilocarpine , i . e . , during status epilepticus , gradually reduced electrical and behavioral seizure activity and greatly enhanced the survival rate .', {'entities': [(77, 83, 'B_Disease'), (84, 95, 'I_Disease'), (142, 149, 'B_Disease')]}], ['These results suggest that activation of NMDA receptors plays an important role in status epilepticus and brain damage in the lithium - pilocarpine model .', {'entities': [(83, 89, 'B_Disease'), (90, 101, 'I_Disease'), (106, 111, 'B_Disease'), (112, 118, 'I_Disease')]}], ['This was further supported by results showing that nonconvulsive doses of NMDA and pilocarpine were synergistic , resulting in status epilepticus and subsequent mortality .', {'entities': [(127, 133, 'B_Disease'), (134, 145, 'I_Disease')]}], ['Continuous infusion tobramycin combined with carbenicillin for infections in cancer patients .', {'entities': [(63, 73, 'B_Disease'), (77, 83, 'B_Disease')]}], ['The cure rate of infections in cancer patients is adversely affected by neutropenia ( less than 1 , 000 / mm3 ) .', {'entities': [(17, 27, 'B_Disease'), (31, 37, 'B_Disease'), (72, 83, 'B_Disease')]}], ['In particular , patients with severe neutropenia ( less than 100 / mm3 ) have shown a poor response to antibiotics .', {'entities': [(37, 48, 'B_Disease')]}], ['To overcome the adverse effects of neutropenia , tobramycin was given by continuous infusion and combined with intermittent carbenicillin .', {'entities': [(35, 46, 'B_Disease')]}], ['There were 125 infectious episodes in 116 cancer patients receiving myelosuppressive chemotherapy .', {'entities': [(42, 48, 'B_Disease')]}], ['Pneumonia was the most common infection and 61 % of 59 episodes were cured .', {'entities': [(0, 9, 'B_Disease'), (30, 39, 'B_Disease')]}], ['Gram - negative bacilli were the most common causative organisms and 69 % of these infections were cured .', {'entities': [(83, 93, 'B_Disease')]}], ['The most common pathogen was Klebsiella pneumoniae and this , together with Escherichia coli and Pseudomonas aeruginosa , accounted for 74 % of all gram - negative bacillary infections .', {'entities': [(40, 50, 'B_Disease'), (148, 152, 'B_Disease'), (153, 154, 'I_Disease'), (155, 163, 'I_Disease'), (164, 173, 'I_Disease'), (174, 184, 'I_Disease')]}], ['Response was not influenced by the initial neutrophil count , with a 62 % cure rate for 39 episodes associated with severe neutropenia .', {'entities': [(123, 134, 'B_Disease')]}], ['Azotemia was the major side effect recognized , and it occurred in 11 % of episodes .', {'entities': [(0, 8, 'B_Disease')]}], ['Major azotemia ( serum creatinine greater than 2 . 5 mg / dl or BUN greater than 50 mg / dl ) occurred in only 2 % .', {'entities': [(6, 14, 'B_Disease')]}], ['Azotemia was not related to duration of therapy or serum tobramycin concentration .', {'entities': [(0, 8, 'B_Disease')]}], ['This antibiotic regimen showed both therapeutic efficacy and acceptable renal toxicity for these patients .', {'entities': [(72, 77, 'B_Disease'), (78, 86, 'I_Disease')]}], ['Incidence of solid tumours among pesticide applicators exposed to the organophosphate insecticide diazinon in the Agricultural Health Study : an updated analysis .', {'entities': [(19, 26, 'B_Disease')]}], ['OBJECTIVE : Diazinon , a common organophosphate insecticide with genotoxic properties , was previously associated with lung cancer in the Agricultural Health Study ( AHS ) cohort , but few other epidemiological studies have examined diazinon - associated cancer risk .', {'entities': [(119, 123, 'B_Disease'), (124, 130, 'I_Disease'), (255, 261, 'B_Disease')]}], ['We used updated diazinon exposure and cancer incidence information to evaluate solid tumour risk in the AHS .', {'entities': [(38, 44, 'B_Disease'), (85, 91, 'B_Disease')]}], ['METHODS : Male pesticide applicators in Iowa and North Carolina reported lifetime diazinon use at enrolment ( 1993 - 1997 ) and follow - up ( 1998 - 2005 ) ; cancer incidence was assessed through 2010 ( North Carolina ) / 2011 ( Iowa ) .', {'entities': [(158, 164, 'B_Disease')]}], ['Among applicators with usage information sufficient to evaluate exposure - response patterns , we used Poisson regression to estimate adjusted rate ratios ( RRs ) and 95 % CI for cancer sites with > 10 exposed cases for both lifetime ( LT ) exposure days and intensity - weighted ( IW ) lifetime exposure days ( accounting for factors impacting exposure ) .', {'entities': [(179, 185, 'B_Disease')]}], ['RESULTS : We observed elevated lung cancer risks ( N = 283 ) among applicators with the greatest number of LT ( RR = 1 . 60 ; 95 % CI 1 . 11 to 2 . 31 ; Ptrend = 0 . 02 ) and IW days of diazinon use ( RR = 1 . 41 ; 95 % CI 0 . 98 to 2 . 04 ; Ptrend = 0 . 08 ) .', {'entities': [(31, 35, 'B_Disease'), (36, 42, 'I_Disease')]}], ['Kidney cancer ( N = 94 ) risks were non - significantly elevated ( RRLT days = 1 . 77 ; 95 % CI 0 . 90 to 3 . 51 ; Ptrend = 0 . 09 ; RRIW days 1 . 37 ; 95 % CI 0 . 64 to 2 . 92 ; Ptrend = 0 . 50 ) , as were risks for aggressive prostate cancer ( N = 656 ) .', {'entities': [(0, 6, 'B_Disease'), (7, 13, 'I_Disease'), (228, 236, 'B_Disease'), (237, 243, 'I_Disease')]}], ['CONCLUSIONS : Our updated evaluation of diazinon provides additional evidence of an association with lung cancer risk .', {'entities': [(101, 105, 'B_Disease'), (106, 112, 'I_Disease')]}], ['Newly identified links to kidney cancer and associations with aggressive prostate cancer require further evaluation .', {'entities': [(26, 32, 'B_Disease'), (33, 39, 'I_Disease'), (73, 81, 'B_Disease'), (82, 88, 'I_Disease')]}], [\"Associations of Ozone and PM2 . 5 Concentrations With Parkinson ' s Disease Among Participants in the Agricultural Health Study .\", {'entities': [(54, 63, 'B_Disease'), (64, 65, 'I_Disease'), (66, 67, 'I_Disease'), (68, 75, 'I_Disease')]}], [\"OBJECTIVE : This study describes associations of ozone and fine particulate matter with Parkinson ' s disease observed among farmers in North Carolina and Iowa .\", {'entities': [(88, 97, 'B_Disease'), (98, 99, 'I_Disease'), (100, 101, 'I_Disease'), (102, 109, 'I_Disease')]}], [\"METHODS : We used logistic regression to determine the associations of these pollutants with self - reported , doctor - diagnosed Parkinson ' s disease .\", {'entities': [(130, 139, 'B_Disease'), (140, 141, 'I_Disease'), (142, 143, 'I_Disease'), (144, 151, 'I_Disease')]}], [\"RESULTS : We observed positive associations of Parkinson ' s disease with ozone ( odds ratio = 1 . 39 ; 95 % CI : 0 . 98 to 1 . 98 ) and fine particulate matter ( odds ratio = 1 . 34 ; 95 % CI : 0 . 93 to 1 . 93 ) in North Carolina but not in Iowa .\", {'entities': [(47, 56, 'B_Disease'), (57, 58, 'I_Disease'), (59, 60, 'I_Disease'), (61, 68, 'I_Disease')]}], [\"CONCLUSIONS : The plausibility of an effect of ambient concentrations of these pollutants on Parkinson ' s disease risk is supported by experimental data demonstrating damage to dopaminergic neurons at relevant concentrations .\", {'entities': [(93, 102, 'B_Disease'), (103, 104, 'I_Disease'), (105, 106, 'I_Disease'), (107, 114, 'I_Disease')]}], ['Low functional programming of renal AT2R mediates the developmental origin of glomerulosclerosis in adult offspring induced by prenatal caffeine exposure .', {'entities': [(78, 96, 'B_Disease')]}], ['UNASSIGNED : Our previous study has indicated that prenatal caffeine exposure ( PCE ) could induce intrauterine growth retardation ( IUGR ) of offspring .', {'entities': [(99, 111, 'B_Disease'), (112, 118, 'I_Disease'), (119, 130, 'I_Disease'), (133, 137, 'B_Disease')]}], ['Recent research suggested that IUGR is a risk factor for glomerulosclerosis .', {'entities': [(31, 35, 'B_Disease'), (57, 75, 'B_Disease')]}], ['However , whether PCE could induce glomerulosclerosis and its underlying mechanisms remain unknown .', {'entities': [(35, 53, 'B_Disease')]}], ['This study aimed to demonstrate the induction to glomerulosclerosis in adult offspring by PCE and its intrauterine programming mechanisms .', {'entities': [(49, 67, 'B_Disease')]}], ['A rat model of IUGR was established by PCE , male fetuses and adult offspring at the age of postnatal week 24 were euthanized .', {'entities': [(15, 19, 'B_Disease')]}], ['The results revealed that the adult offspring kidneys in the PCE group exhibited glomerulosclerosis as well as interstitial fibrosis , accompanied by elevated levels of serum creatinine and urine protein .', {'entities': [(81, 99, 'B_Disease'), (111, 123, 'B_Disease'), (124, 132, 'I_Disease')]}], ['These results demonstrated that PCE could induce dysplasia of fetal kidneys as well as glomerulosclerosis of adult offspring , and the low functional programming of renal AT2R might mediate the developmental origin of adult glomerulosclerosis .', {'entities': [(49, 58, 'B_Disease'), (59, 61, 'I_Disease'), (62, 67, 'I_Disease'), (68, 75, 'I_Disease'), (87, 105, 'B_Disease'), (224, 242, 'B_Disease')]}], ['1 , 3 - Butadiene , CML and the t ( 9 : 22 ) translocation : A reality check .', {'entities': [(20, 23, 'B_Disease')]}], ['UNASSIGNED : Epidemiological studies of 1 , 3 - butadiene have suggest that exposures to humans are associated with chronic myeloid leukemia ( CML ) .', {'entities': [(116, 123, 'B_Disease'), (124, 131, 'I_Disease'), (132, 140, 'I_Disease'), (143, 146, 'B_Disease')]}], ['CML has a well - documented association with ionizing radiation , but reports of associations with chemical exposures have been questioned .', {'entities': [(0, 3, 'B_Disease')]}], ['Ionizing radiation is capable of inducing the requisite CML - associated t ( 9 : 22 ) translocation ( Philadelphia chromosome ) in appropriate cells in vitro but , thus far , chemicals have not shown this capacity .', {'entities': [(56, 59, 'B_Disease'), (102, 114, 'B_Disease'), (115, 125, 'I_Disease')]}], ['Cancer incidence and metolachlor use in the Agricultural Health Study : An update .', {'entities': [(0, 6, 'B_Disease')]}], ['Environmental Protection Agency based on increased liver neoplasms in female rats .', {'entities': [(51, 56, 'B_Disease'), (57, 66, 'I_Disease')]}], ['We evaluated cancer incidence through 2010 / 2011 ( NC / IA ) for 49 , 616 applicators , 53 % of whom reported ever using metolachlor .', {'entities': [(13, 19, 'B_Disease')]}], ['We used Poisson regression to evaluate relations between two metrics of metolachlor use ( lifetime days , intensity - weighted lifetime days ) and cancer incidence .', {'entities': [(147, 153, 'B_Disease')]}], ['We saw no association between metolachlor use and incidence of all cancers combined ( n = 5 , 701 with a 5 - year lag ) or most site - specific cancers .', {'entities': [(67, 74, 'B_Disease'), (144, 151, 'B_Disease')]}], ['For liver cancer , in analyses restricted to exposed workers , elevations observed at higher categories of use were not statistically significant .', {'entities': [(4, 9, 'B_Disease'), (10, 16, 'I_Disease')]}], ['A similar pattern was observed for follicular cell lymphoma , but no other lymphoma subtypes .', {'entities': [(35, 45, 'B_Disease'), (46, 50, 'I_Disease'), (51, 59, 'I_Disease'), (75, 83, 'B_Disease')]}], ['An earlier suggestion of increased lung cancer risk at high levels of metolachlor use in this cohort was not confirmed in this update .', {'entities': [(35, 39, 'B_Disease'), (40, 46, 'I_Disease')]}], ['This suggestion of an association between metolachlor and liver cancer among pesticide applicators is a novel finding and echoes observation of increased liver neoplasms in some animal studies .', {'entities': [(58, 63, 'B_Disease'), (64, 70, 'I_Disease'), (154, 159, 'B_Disease'), (160, 169, 'I_Disease')]}], ['However , our findings for both liver cancer and follicular cell lymphoma warrant follow - up to better differentiate effects of metolachlor use from other factors .', {'entities': [(32, 37, 'B_Disease'), (38, 44, 'I_Disease'), (65, 73, 'B_Disease')]}], ['There is considerable interest in identifying the molecular mechanisms that relate early - life iAs exposure to the development of these latent diseases , particularly in relationship to cancer .', {'entities': [(187, 193, 'B_Disease')]}], ['OBJECTIVES : This work summarizes research on the molecular mechanisms that underlie the increased risk of cancer development in adulthood that is associated with early - life iAs exposure .', {'entities': [(107, 113, 'B_Disease')]}], ['DISCUSSION : Epigenetic reprogramming that imparts functional changes in gene expression , the development of cancer stem cells , and immunomodulation are plausible underlying mechanisms by which early - life iAs exposure elicits latent carcinogenic effects .', {'entities': [(110, 116, 'B_Disease')]}], ['CONCLUSIONS : Evidence is mounting that relates early - life iAs exposure and cancer development later in life .', {'entities': [(78, 84, 'B_Disease')]}], ['Nifedipine induced bradycardia in a patient with autonomic neuropathy .', {'entities': [(19, 30, 'B_Disease'), (49, 58, 'B_Disease'), (59, 69, 'I_Disease')]}], ['An 80 year old diabetic male with evidence of peripheral and autonomic neuropathy was admitted with chest pain .', {'entities': [(15, 23, 'B_Disease'), (46, 56, 'B_Disease'), (57, 60, 'I_Disease'), (61, 70, 'I_Disease'), (71, 81, 'I_Disease'), (100, 105, 'B_Disease'), (106, 110, 'I_Disease')]}], ['He was found to have atrial flutter at a ventricular rate of 70 / min which slowed down to 30 - 40 / min when nifedipine ( 60 mg ) in 3 divided doses , during which he was paced at a rate of 70 / min .', {'entities': [(21, 27, 'B_Disease'), (28, 35, 'I_Disease')]}], ['This is inconsistent with the well - established finding that nifedipine induces tachycardia in normally innervated hearts .', {'entities': [(81, 92, 'B_Disease')]}], ['However , in hearts deprived of compensatory sympathetic drive , it may lead to bradycardia .', {'entities': [(80, 91, 'B_Disease')]}], ['Haloperidol failed to prevent amphetamine - induced seizures , but did lower the mortality rate at most doses tested .', {'entities': [(52, 60, 'B_Disease')]}], ['Haloperidol decreased the incidence of cocaine - induced seizures at the two highest doses , but the lowering of the mortality rate did not reach statistical significance at any dose .', {'entities': [(57, 65, 'B_Disease')]}], ['These data suggest a protective role for the central dopamine blocker haloperidol against death from high - dose amphetamine exposure without reducing the incidence of seizures .', {'entities': [(168, 176, 'B_Disease')]}], ['In contrast , haloperidol demonstrated an ability to reduce cocaine - induced seizures without significantly reducing mortality .', {'entities': [(78, 86, 'B_Disease')]}], ['Autoradiographic evidence of estrogen binding sites in nuclei of diethylstilbesterol induced hamster renal carcinomas .', {'entities': [(101, 106, 'B_Disease'), (107, 117, 'I_Disease')]}], ['Estrogen binding sites were demonstrated by autoradiography in one transplantable and five primary diethylstilbesterol induced renal carcinomas in three hamsters .', {'entities': [(127, 132, 'B_Disease'), (133, 143, 'I_Disease')]}], ['Radiolabelling , following the in vivo injection of 3H - 17 beta estradiol , was increased only over the nuclei of tumor cells ; stereologic analysis revealed a 4 . 5 - to 6 . 7 - times higher concentration of reduced silver grains over nuclei than cytoplasm of these cells .', {'entities': [(115, 120, 'B_Disease')]}], ['This is the first published report documenting the preferential in vivo binding of estrogen to nuclei of cells in estrogen induced hamster renal carcinomas .', {'entities': [(139, 144, 'B_Disease'), (145, 155, 'I_Disease')]}], ['Bradycardia due to biperiden .', {'entities': [(0, 11, 'B_Disease')]}], ['In a 38 - year - old male patient suffering from a severe postzosteric trigeminal neuralgia , intravenous application of 10 mg biperiden lactate led to a long - lasting paradoxical reaction characterized by considerable bradycardia , dysarthria , and dysphagia .', {'entities': [(58, 70, 'B_Disease'), (71, 81, 'B_Disease'), (82, 91, 'I_Disease'), (220, 231, 'B_Disease'), (234, 244, 'B_Disease'), (251, 260, 'B_Disease')]}], ['Bradycardia induced by biperiden is attributed to the speed of injection and to a dose - related dual effect of atropine - like drugs on muscarine receptors .', {'entities': [(0, 11, 'B_Disease')]}], ['Deliberate hypotension induced by labetalol with halothane , enflurane or isoflurane for middle - ear surgery .', {'entities': [(11, 22, 'B_Disease')]}], ['The feasibility of using labetalol , an alpha - and beta - adrenergic blocking agent , as a hypotensive agent in combination with inhalation anaesthetics ( halothane , enflurane or isoflurane ) was studied in 23 adult patients undergoing middle - ear surgery .', {'entities': [(92, 103, 'B_Disease')]}], ['The mean H concentration during hypotension in the inspiratory gas was 0 . 7 + / - 0 . 1 vol % , the mean E concentration 1 . 6 + / - 0 . 2 vol % , and the mean I concentration 1 . 0 + / - 0 . 1 vol % .', {'entities': [(32, 43, 'B_Disease')]}], ['During hypotension , the heart rate was stable without tachy - or bradycardia .', {'entities': [(7, 18, 'B_Disease'), (55, 60, 'B_Disease'), (61, 62, 'I_Disease'), (63, 65, 'I_Disease'), (66, 77, 'I_Disease')]}], ['The operating conditions regarding bleeding were estimated in a double - blind manner , and did not differ significantly between the groups .', {'entities': [(35, 43, 'B_Disease')]}], ['During hypotension , the serum creatinine concentration rose significantly in all groups from the values before hypotension and returned postoperatively to the initial level in the other groups , except the isoflurane group .', {'entities': [(7, 18, 'B_Disease'), (112, 123, 'B_Disease')]}], ['After hypotension there was no rebound phenomenon in either blood pressure or heart rate .', {'entities': [(6, 17, 'B_Disease')]}], ['These results indicate that labetalol induces easily adjustable hypotension without compensatory tachycardia and rebound hypertension .', {'entities': [(64, 75, 'B_Disease'), (97, 108, 'B_Disease'), (121, 133, 'B_Disease')]}], ['Convulsion following intravenous fluorescein angiography .', {'entities': [(0, 10, 'B_Disease')]}], ['Tonic - clonic seizures followed intravenous fluorescein injection for fundus angiography in a 47 - year - old male .', {'entities': [(0, 5, 'B_Disease'), (6, 7, 'I_Disease'), (8, 14, 'I_Disease'), (15, 23, 'I_Disease')]}], ['ACC - 9653 and phenytoin sodium have equivalent anticonvulsant activity against seizures induced by maximal electroshock ( MES ) in mice following i . p . , oral , or i . v . administration .', {'entities': [(80, 88, 'B_Disease')]}], ['ACC - 9653 and phenytoin sodium have similar antiarrhythmic activity against ouabain - induced ventricular tachycardia in anesthetized dogs .', {'entities': [(95, 106, 'B_Disease'), (107, 118, 'I_Disease')]}], ['The total doses of ACC - 9653 or phenytoin sodium necessary to convert the arrhythmia to a normal sinus rhythm were 24 + / - 6 and 14 + / - 3 mg / kg , respectively .', {'entities': [(75, 85, 'B_Disease')]}], ['Only phenytoin sodium displayed in vitro antiarrhythmic activity against strophanthidin - induced arrhythmias in guinea pig right atria .', {'entities': [(98, 109, 'B_Disease')]}], ['Acute toxicity studies of ACC - 9653 and phenytoin sodium were carried out in mice , rats , rabbits , and dogs by i . v . , i . m . , and i . p . routes of administration .', {'entities': [(6, 14, 'B_Disease')]}], ['Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics .', {'entities': [(116, 126, 'B_Disease')]}], ['High doses of inhaled salbutamol produce substantial improvements in airway response in patients with asthma , and are associated with dose - dependent systemic beta - adrenoceptor responses .', {'entities': [(102, 108, 'B_Disease')]}], ['Twelve asthmatic patients ( FEV1 , 81 + / - 4 % predicted ) , requiring only occasional inhaled beta - agonists as their sole therapy , were given a 14 - day treatment with high dose inhaled salbutamol ( HDS ) , 4 , 000 micrograms daily , low dose inhaled salbutamol ( LDS ) , 800 micrograms daily , or placebo ( PI ) by metered - dose inhaler in a double - blind , randomized crossover design .', {'entities': [(7, 16, 'B_Disease')]}], ['At the end of each 14 - day treatment , a dose - response curve ( DRC ) was performed , and airway ( FEV1 , FEF25 - 75 ) chronotropic ( HR ) , tremor , and metabolic ( K , Glu ) responses were measured at each step ( from 100 to 4 , 000 micrograms ) .', {'entities': [(143, 149, 'B_Disease')]}], ['Frequency and severity of subjective adverse effects were also reduced after HDS : tremor ( p less than 0 . 001 ) , palpitations ( p less than 0 . 001 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )', {'entities': [(83, 89, 'B_Disease'), (116, 128, 'B_Disease')]}], ['Phenytoin induced fatal hepatic injury .', {'entities': [(24, 31, 'B_Disease'), (32, 38, 'I_Disease')]}], ['A 61 year old female developed fatal hepatic failure after phenytoin administration .', {'entities': [(37, 44, 'B_Disease'), (45, 52, 'I_Disease')]}], ['A typical multisystem clinical pattern precedes the manifestations of hepatic injury .', {'entities': [(70, 77, 'B_Disease'), (78, 84, 'I_Disease')]}], ['The hematologic , biochemical and pathologic features indicate a mixed hepatocellular damage due to drug hypersensitivity .', {'entities': [(71, 85, 'B_Disease'), (86, 92, 'I_Disease'), (100, 104, 'B_Disease'), (105, 121, 'I_Disease')]}], ['We studied mortality after pertussis immunization in the mouse .', {'entities': [(27, 36, 'B_Disease')]}], ['Without treatment , 73 of 92 animals ( 80 % ) died after injection of bovine serum albumin ( BSA ) on day + 7 of pertussis immunization .', {'entities': [(113, 122, 'B_Disease')]}], ['Blockade of histamine H1 receptors may reduce mortality in pertussis immunization - induced encephalopathy in mice .', {'entities': [(59, 68, 'B_Disease'), (92, 106, 'B_Disease')]}], ['Support for adrenaline - hypertension hypothesis : 18 hour pressor effect after 6 hours adrenaline infusion .', {'entities': [(25, 37, 'B_Disease')]}], ['These findings are strong support for the adrenaline - hypertension hypothesis in man .', {'entities': [(55, 67, 'B_Disease')]}], ['Effect of alkylxanthines on gentamicin - induced acute renal failure in the rat .', {'entities': [(49, 54, 'B_Disease'), (55, 60, 'I_Disease'), (61, 68, 'I_Disease')]}], ['Adenosine antagonists have been previously shown to be of benefit in some ischaemic and nephrotoxic models of acute renal failure ( ARF ) .', {'entities': [(74, 83, 'B_Disease'), (88, 99, 'B_Disease'), (110, 115, 'B_Disease'), (116, 121, 'I_Disease'), (122, 129, 'I_Disease'), (132, 135, 'B_Disease')]}], ['In the present study , the effects of three alkylxanthines with different potencies as adenosine antagonists 8 - phenyltheophylline , theophylline and enprofylline , were examined in rats developing acute renal failure after 4 daily injections of gentamicin ( 200 mg kg - 1 ) .', {'entities': [(199, 204, 'B_Disease'), (205, 210, 'I_Disease'), (211, 218, 'I_Disease')]}], ['Renal function was assessed by biochemical ( plasma urea and creatinine ) , functional ( urine analysis and [ 3H ] inulin and [ 14C ] p - aminohippuric acid clearances ) and morphological ( degree of necrosis ) indices .', {'entities': [(200, 208, 'B_Disease')]}], ['The lack of any consistent protective effect noted with the alkylxanthines tested in the present study indicates that adenosine plays little , if any , pathophysiological role in gentamicin - induced ARF .', {'entities': [(200, 203, 'B_Disease')]}], ['A total of 261 adverse ocular reactions occurred in 237 patients who received isotretinoin , a commonly used drug in the treatment of severe cystic acne .', {'entities': [(148, 152, 'B_Disease')]}], ['Blepharoconjunctivitis , subjective complaints of dry eyes , blurred vision , contact lens intolerance , and photodermatitis are reversible side effects .', {'entities': [(0, 22, 'B_Disease'), (50, 53, 'B_Disease'), (54, 58, 'I_Disease'), (61, 68, 'B_Disease'), (69, 75, 'I_Disease'), (109, 124, 'B_Disease')]}], ['More serious ocular adverse reactions include papilledema , pseudotumor cerebri , and white or gray subepithelial corneal opacities ; all of these are reversible if the drug is discontinued .', {'entities': [(46, 57, 'B_Disease'), (60, 71, 'B_Disease'), (72, 79, 'I_Disease'), (114, 121, 'B_Disease'), (122, 131, 'I_Disease')]}], ['Isotretinoin is contraindicated in pregnancy because of the many reported congenital abnormalities after maternal use ( including microphthalmos , orbital hypertelorism , and optic nerve hypoplasia ) .', {'entities': [(74, 84, 'B_Disease'), (85, 98, 'I_Disease'), (130, 144, 'B_Disease'), (155, 168, 'B_Disease'), (175, 180, 'B_Disease'), (181, 186, 'I_Disease'), (187, 197, 'I_Disease')]}], ['Procaterol and terbutaline in bronchial asthma .', {'entities': [(30, 39, 'B_Disease'), (40, 46, 'I_Disease')]}], ['Procaterol , a new beta - 2 adrenoceptor stimulant , was studied in a double - blind , placebo - controlled , cross - over trial in patients with bronchial asthma .', {'entities': [(146, 155, 'B_Disease'), (156, 162, 'I_Disease')]}], ['Both anti - asthmatic and tremorgenic effects of procaterol were dose - related .', {'entities': [(12, 21, 'B_Disease'), (26, 37, 'B_Disease')]}], ['Subacute effects of propranolol and B 24 / 76 on isoproterenol - induced rat heart hypertrophy in correlation with blood pressure .', {'entities': [(77, 82, 'B_Disease'), (83, 94, 'I_Disease')]}], ['The studies were performed using an experimental model of isoproterenol - induced heart hypertrophy in rats .', {'entities': [(82, 87, 'B_Disease'), (88, 99, 'I_Disease')]}], ['A correlation of the blood pressure was neither found in the development nor in the attempt to suppress the development of heart hypertrophy with the two beta - receptor blockers .', {'entities': [(123, 128, 'B_Disease'), (129, 140, 'I_Disease')]}], ['Both beta - blockers influenced the development of hypertrophy to a different , but not reproducible extent .', {'entities': [(51, 62, 'B_Disease')]}], ['It was possible to suppress the increased ornithine decarboxylase activity with both beta - blockers in hypertrophied hearts , but there was no effect on the heart mass .', {'entities': [(104, 117, 'B_Disease'), (118, 124, 'I_Disease')]}], ['Neither propranolol nor B 24 / 76 could stop the changes in the characteristic myosin isoenzyme pattern of the hypertrophied rat heart .', {'entities': [(111, 124, 'B_Disease')]}], ['Thus , the investigations did not provide any evidence that the beta - receptor blockers propranolol and B 24 / 76 have the potency to prevent isoproterenol from producing heart hypertrophy .', {'entities': [(172, 177, 'B_Disease'), (178, 189, 'I_Disease')]}], ['Increased anxiogenic effects of caffeine in panic disorders .', {'entities': [(44, 49, 'B_Disease'), (50, 59, 'I_Disease')]}], ['The effects of oral administration of caffeine ( 10 mg / kg ) on behavioral ratings , somatic symptoms , blood pressure and plasma levels of 3 - methoxy - 4 - hydroxyphenethyleneglycol ( MHPG ) and cortisol were determined in 17 healthy subjects and 21 patients meeting DSM - III criteria for agoraphobia with panic attacks or panic disorder .', {'entities': [(293, 304, 'B_Disease'), (310, 315, 'B_Disease'), (316, 323, 'I_Disease'), (327, 332, 'B_Disease'), (333, 341, 'I_Disease')]}], ['Caffeine produced significantly greater increases in subject - rated anxiety , nervousness , fear , nausea , palpitations , restlessness , and tremors in the patients compared with healthy subjects .', {'entities': [(69, 76, 'B_Disease'), (100, 106, 'B_Disease'), (109, 121, 'B_Disease'), (124, 136, 'B_Disease'), (143, 150, 'B_Disease')]}], ['Seventy - one percent of the patients reported that the behavioral effects of caffeine were similar to those experienced during panic attacks .', {'entities': [(128, 133, 'B_Disease'), (134, 141, 'I_Disease')]}], ['Because caffeine is an adenosine receptor antagonist , these results suggest that some panic disorder patients may have abnormalities in neuronal systems involving adenosine .', {'entities': [(87, 92, 'B_Disease'), (93, 101, 'I_Disease'), (120, 133, 'B_Disease'), (134, 136, 'I_Disease'), (137, 145, 'I_Disease'), (146, 153, 'I_Disease')]}], ['Patients with anxiety disorders may benefit by avoiding caffeine - containing foods and beverages .', {'entities': [(14, 21, 'B_Disease'), (22, 31, 'I_Disease')]}], ['Comparison of the effect of oxitropium bromide and of slow - release theophylline on nocturnal asthma .', {'entities': [(95, 101, 'B_Disease')]}], ['The effects of a new inhaled antimuscarinic drug , oxitropium bromide , and of a slow - release theophylline preparation upon nocturnal asthma were compared in a placebo - controlled double - blind study .', {'entities': [(136, 142, 'B_Disease')]}], ['No subject reported side effects of oxitropium , as compared to three subjects reporting nausea , vomiting and tremors after theophylline .', {'entities': [(89, 95, 'B_Disease'), (98, 106, 'B_Disease'), (111, 118, 'B_Disease')]}], ['Oxitropium proves to be a valuable alternative to theophylline in nocturnal asthma , since it is equally potent , safer and does not require the titration of dosage .', {'entities': [(76, 82, 'B_Disease')]}], ['Penicillin anaphylaxis .', {'entities': [(11, 22, 'B_Disease')]}], ['A case of oral penicillin anaphylaxis is described , and the terminology , occurrence , clinical manifestations , pathogenesis , prevention , and treatment of anaphylaxis are reviewed .', {'entities': [(26, 37, 'B_Disease'), (159, 170, 'B_Disease')]}], ['Emergency physicians should be aware of oral penicillin anaphylaxis in order to prevent its occurrence by prescribing the antibiotic judiciously and knowledgeably and to offer optimal medical therapy once this life - threatening reaction has begun .', {'entities': [(56, 67, 'B_Disease')]}], ['Reversible valproic acid - induced dementia : a case report .', {'entities': [(35, 43, 'B_Disease')]}], ['Reversible valproic acid - induced dementia was documented in a 21 - year - old man with epilepsy who had a 3 - year history of insidious progressive decline in global cognitive abilities documented by serial neuropsychological studies .', {'entities': [(35, 43, 'B_Disease'), (89, 97, 'B_Disease')]}], ['Possible pathophysiological mechanisms which may have been operative in this case include : a direct central nervous system ( CNS ) toxic effect of valproic acid ; a paradoxical epileptogenic effect secondary to the drug ; and an indirect CNS toxic effect mediated through valproic acid - induced hyperammonemia .', {'entities': [(297, 311, 'B_Disease')]}], ['Reversal of scopolamine - induced amnesia of passive avoidance by pre - and post - training naloxone .', {'entities': [(34, 41, 'B_Disease')]}], ['In a series of five experiments , the modulating role of naloxone on a scopolamine - induced retention deficit in a passive avoidance paradigm was investigated in mice .', {'entities': [(93, 102, 'B_Disease'), (103, 110, 'I_Disease')]}], ['Scopolamine , but not methyl scopolamine ( 1 and 3 mg / kg ) , induced an amnesia as measured by latency and duration parameters .', {'entities': [(74, 81, 'B_Disease')]}], ['Naloxone ( 0 . 3 , 1 , 3 , and 10 mg / kg ) injected prior to training attenuated the retention deficit with a peak of activity at 3 mg / kg .', {'entities': [(86, 95, 'B_Disease'), (96, 103, 'I_Disease')]}], ['Post - training administration of naloxone ( 3 mg / kg ) as a single or as a split dose also attenuated the scopolamine - induced amnesia .', {'entities': [(130, 137, 'B_Disease')]}], ['Control experiments indicated that neither an increase in pain sensitivity ( pre - training naloxone ) nor an induced aversive state ( post - training naloxone ) appear to be responsible for the influence of naloxone on the scopolamine - induced retention deficit .', {'entities': [(58, 62, 'B_Disease'), (246, 255, 'B_Disease'), (256, 263, 'I_Disease')]}], ['Electron microscopic investigations of the cyclophosphamide - induced lesions of the urinary bladder of the rat and their prevention by mesna .', {'entities': [(70, 77, 'B_Disease'), (78, 80, 'I_Disease'), (81, 84, 'I_Disease'), (85, 92, 'I_Disease'), (93, 100, 'I_Disease')]}], ['Fully developed cyclophosphamide - induced cystitis is characterized by nearly complete detachment of the urothelium , severe submucosal edema owing to damage to the microvascular bed and focal muscle necroses .', {'entities': [(43, 51, 'B_Disease'), (137, 142, 'B_Disease'), (201, 209, 'B_Disease')]}], ['Subsequent breaks in the lateral cell membranes of the superficial cells and in all the plasma membranes of the intermediate and basal cells , intercellular and intracellular edema and disintegration of the desmosomes and hemidesmosomes lead to progressive degeneration and detachment of the epithelial cells with exposure and splitting of the basal membrane .', {'entities': [(175, 180, 'B_Disease')]}], ['Increase in intragastric pressure during suxamethonium - induced muscle fasciculations in children : inhibition by alfentanil .', {'entities': [(65, 71, 'B_Disease'), (72, 86, 'I_Disease')]}], ['The incidence and intensity of muscle fasciculations caused by suxamethonium were significantly greater in the control than in the alfentanil group .', {'entities': [(31, 37, 'B_Disease'), (38, 52, 'I_Disease')]}], ['The intragastric pressure during muscle fasciculations was significantly higher in the control group ( 16 + / - 0 . 7 ( SEM ) cm H2O ) than in the alfentanil group ( 7 . 7 + / - 1 . 5 ( SEM ) cm H2O ) .', {'entities': [(33, 39, 'B_Disease'), (40, 54, 'I_Disease')]}], ['The increase in intragastric pressure was directly related to the intensity of muscle fasciculations ( regression line : y = 0 . 5 + 4 . 78x with r of 0 . 78 ) .', {'entities': [(79, 85, 'B_Disease'), (86, 100, 'I_Disease')]}], ['It is concluded that intragastric pressure increases significantly during muscle fasciculations caused by suxamethonium in healthy children .', {'entities': [(74, 80, 'B_Disease'), (81, 95, 'I_Disease')]}], ['Alfentanil 50 micrograms kg - 1 effectively inhibits the incidence and intensity of suxamethonium - induced muscle fasciculations ; moreover , intragastric pressure remains at its control value .', {'entities': [(108, 114, 'B_Disease'), (115, 129, 'I_Disease')]}], ['Acute insulin treatment normalizes the resistance to the cardiotoxic effect of isoproterenol in streptozotocin diabetic rats .', {'entities': [(57, 68, 'B_Disease'), (111, 119, 'B_Disease')]}], ['A morphometric study of isoproterenol induced myocardial fibrosis .', {'entities': [(57, 65, 'B_Disease')]}], ['The acute effect of insulin treatment on the earlier reported protective effect of streptozotocin diabetes against the cardiotoxic effect of high doses of isoproterenol ( ISO ) was investigated in rats .', {'entities': [(98, 106, 'B_Disease'), (119, 130, 'B_Disease')]}], ['Thirty to 135 min after the injection of crystalline insulin , ISO was given subcutaneously and when ISO induced fibrosis in the myocardium was morphometrically analyzed 7 days later , a highly significant correlation ( r = 0 . 83 , 2 p = 0 . 006 ) to the slope of the fall in blood glucose after insulin treatment appeared .', {'entities': [(113, 121, 'B_Disease')]}], ['The myocardial content of catecholamines was estimated in these 8 day diabetic rats .', {'entities': [(70, 78, 'B_Disease')]}], ['The rapid reversion after insulin treatment excludes the possibility that streptozotocin in itself causes the ISO resistance and points towards a direct insulin effect on myocardial catecholamine sensitivity in diabetic rats .', {'entities': [(211, 219, 'B_Disease')]}], ['The phenomenon described might elucidate pathogenetic mechanisms behind toxic myocardial cell degeneration and may possibly have relevance for acute cardiovascular complications in diabetic patients .', {'entities': [(181, 189, 'B_Disease')]}], ['Differential effects of non - steroidal anti - inflammatory drugs on seizures produced by pilocarpine in rats .', {'entities': [(69, 77, 'B_Disease')]}], ['The muscarinic cholinergic agonist pilocarpine induces in rats seizures and status epilepticus followed by widespread damage to the forebrain .', {'entities': [(63, 71, 'B_Disease'), (76, 82, 'B_Disease'), (83, 94, 'I_Disease')]}], ['The present study was designed to investigate the effect of 5 non - steroidal anti - inflammatory drugs , sodium salicylate , phenylbutazone , indomethacin , ibuprofen and mefenamic acid , on seizures produced by pilocarpine .', {'entities': [(192, 200, 'B_Disease')]}], ['Indomethacin , 1 - 10 mg / kg , and ibuprofen , 10 - 100 mg / kg , failed to modulate seizures produced by pilocarpine .', {'entities': [(86, 94, 'B_Disease')]}], ['Mefenamic acid , 26 ( 22 - 30 ) mg / kg , prevented seizures and protected rats from seizure - related brain damage induced by pilocarpine , 380 mg / kg .', {'entities': [(52, 60, 'B_Disease'), (85, 92, 'B_Disease'), (103, 108, 'B_Disease'), (109, 115, 'I_Disease')]}], ['These results indicate that non - steroidal anti - inflammatory drugs differentially modulate the threshold for pilocarpine - induced seizures .', {'entities': [(134, 142, 'B_Disease')]}], ['Acute neurologic dysfunction after high - dose etoposide therapy for malignant glioma .', {'entities': [(0, 5, 'B_Disease'), (6, 16, 'I_Disease'), (17, 28, 'I_Disease'), (69, 78, 'B_Disease'), (79, 85, 'I_Disease')]}], ['Etoposide ( VP - 16 - 213 ) has been used in the treatment of many solid tumors and hematologic malignancies .', {'entities': [(73, 79, 'B_Disease'), (84, 95, 'B_Disease'), (96, 108, 'I_Disease')]}], ['When used in high doses and in conjunction with autologous bone marrow transplantation , this agent has activity against several treatment - resistant cancers including malignant glioma .', {'entities': [(151, 158, 'B_Disease'), (169, 178, 'B_Disease'), (179, 185, 'I_Disease')]}], ['In six of eight patients ( 75 % ) who we treated for recurrent or resistant glioma , sudden severe neurologic deterioration occurred .', {'entities': [(76, 82, 'B_Disease'), (99, 109, 'B_Disease'), (110, 123, 'I_Disease')]}], ['Significant clinical manifestations have included confusion , papilledema , somnolence , exacerbation of motor deficits , and sharp increase in seizure activity .', {'entities': [(50, 59, 'B_Disease'), (62, 73, 'B_Disease'), (76, 86, 'B_Disease'), (105, 110, 'B_Disease'), (111, 119, 'I_Disease'), (144, 151, 'B_Disease')]}], ['In all patients , computerized tomographic ( CT ) brain scans demonstrated stability in tumor size and peritumor edema when compared with pretransplant scans .', {'entities': [(88, 93, 'B_Disease'), (113, 118, 'B_Disease')]}], ['This complication appears to represent a significant new toxicity of high - dose etoposide therapy for malignant glioma .', {'entities': [(57, 65, 'B_Disease'), (103, 112, 'B_Disease'), (113, 119, 'I_Disease')]}], ['Progressive bile duct injury after thiabendazole administration .', {'entities': [(12, 16, 'B_Disease'), (17, 21, 'I_Disease'), (22, 28, 'I_Disease')]}], ['A 27 - yr - old man developed jaundice 2 wk after exposure to thiabendazole .', {'entities': [(30, 38, 'B_Disease')]}], ['Cholestasis persisted for 3 yr , at which time a liver transplant was performed .', {'entities': [(0, 11, 'B_Disease')]}], ['Prominent fibrosis and hepatocellular regeneration were also present ; however , the lobular architecture was preserved .', {'entities': [(10, 18, 'B_Disease')]}], ['This case represents an example of \" idiosyncratic \" drug - induced liver damage in which the primary target of injury is the bile duct .', {'entities': [(53, 57, 'B_Disease'), (58, 59, 'I_Disease'), (60, 67, 'I_Disease'), (68, 73, 'I_Disease'), (74, 80, 'I_Disease')]}], ['An autoimmune pathogenesis of the bile duct destruction is suggested .', {'entities': [(34, 38, 'B_Disease'), (39, 43, 'I_Disease'), (44, 55, 'I_Disease')]}], ['Increasing recognition of the importance of calcium in the pathogenesis of cardiovascular disease has stimulated research into the use of calcium channel blocking agents for treatment of a variety of cardiovascular diseases .', {'entities': [(75, 89, 'B_Disease'), (90, 97, 'I_Disease'), (200, 214, 'B_Disease'), (215, 223, 'I_Disease')]}], ['As the first dihydropyridine available for use in the United States , nifedipine controls angina and hypertension with minimal depression of cardiac function .', {'entities': [(90, 96, 'B_Disease'), (101, 113, 'B_Disease')]}], ['Once or twice daily dosage possible with nitrendipine and nisoldipine offers a convenient administration schedule , which encourages patient compliance in long - term therapy of hypertension .', {'entities': [(178, 190, 'B_Disease')]}], ['The coronary vasodilating properties of nisoldipine have led to the investigation of this agent for use in angina .', {'entities': [(107, 113, 'B_Disease')]}], ['Selectivity for the cerebrovascular bed makes nimodipine potentially useful in the treatment of subarachnoid hemorrhage , migraine headache , dementia , and stroke .', {'entities': [(96, 108, 'B_Disease'), (109, 119, 'I_Disease'), (122, 130, 'B_Disease'), (131, 139, 'I_Disease'), (142, 150, 'B_Disease'), (157, 163, 'B_Disease')]}], ['In general , the dihydropyridine calcium channel blockers are usually well tolerated , with headache , facial flushing , palpitations , edema , nausea , anorexia , and dizziness being the more common adverse effects .', {'entities': [(92, 100, 'B_Disease'), (110, 118, 'B_Disease'), (121, 133, 'B_Disease'), (136, 141, 'B_Disease'), (144, 150, 'B_Disease'), (153, 161, 'B_Disease'), (168, 177, 'B_Disease')]}], ['The enhancement of aminonucleoside nephrosis by the co - administration of protamine .', {'entities': [(35, 44, 'B_Disease')]}], ['An experimental model of focal segmental glomerular sclerosis ( FSGS ) was developed in rats by the combined administration of puromycin - aminonucleoside ( AMNS ) and protamine sulfate ( PS ) .', {'entities': [(25, 30, 'B_Disease'), (31, 40, 'I_Disease'), (41, 51, 'I_Disease'), (52, 61, 'I_Disease'), (64, 68, 'B_Disease')]}], ['They developed nephrotic syndrome and finally renal failure .', {'entities': [(15, 24, 'B_Disease'), (25, 33, 'I_Disease'), (46, 51, 'B_Disease'), (52, 59, 'I_Disease')]}], ['Their glomeruli showed changes of progressive FSGS .', {'entities': [(46, 50, 'B_Disease')]}], ['Therefore , it is suggested that the administration of PS enhances the toxicity of AMNS on the glomerulus and readily produces progressive FSGS in rats resulting in the end - stage renal disease .', {'entities': [(71, 79, 'B_Disease'), (139, 143, 'B_Disease'), (169, 172, 'B_Disease'), (173, 174, 'I_Disease'), (175, 180, 'I_Disease'), (181, 186, 'I_Disease'), (187, 194, 'I_Disease')]}], ['Theophylline neurotoxicity in pregnant rats .', {'entities': [(13, 26, 'B_Disease')]}], ['The purpose of this investigation was to determine whether the neurotoxicity of theophylline is altered in advanced pregnancy .', {'entities': [(63, 76, 'B_Disease')]}], ['Sprague - Dawley rats that were 20 days pregnant and nonpregnant rats of the same age and strain received infusions of aminophylline until onset of maximal seizures which occurred after 28 and 30 minutes respectively .', {'entities': [(156, 164, 'B_Disease')]}], ['Fetal serum concentrations at onset of seizures in the mother were similar to maternal brain and CSF concentrations and correlated significantly with the former .', {'entities': [(39, 47, 'B_Disease')]}], ['It is concluded that advanced pregnancy has a negligible effect on the neurotoxic response to theophylline in rats .', {'entities': [(71, 81, 'B_Disease')]}], ['Hyperkalemia induced by indomethacin and naproxen and reversed by fludrocortisone .', {'entities': [(0, 12, 'B_Disease')]}], ['We have described a patient with severe rheumatoid arthritis and a history of mefenamic acid nephropathy in whom hyperkalemia and inappropriate hypoaldosteronism were caused by both indomethacin and naproxen , without major decline in renal function .', {'entities': [(40, 50, 'B_Disease'), (51, 60, 'I_Disease'), (93, 104, 'B_Disease'), (113, 125, 'B_Disease'), (144, 161, 'B_Disease')]}], ['It is likely that preexisting renal disease predisposed this patient to type IV renal tubular acidosis with prostaglandin synthetase inhibitors .', {'entities': [(30, 35, 'B_Disease'), (36, 43, 'I_Disease'), (72, 76, 'B_Disease'), (77, 79, 'I_Disease'), (80, 85, 'I_Disease'), (86, 93, 'I_Disease'), (94, 102, 'I_Disease')]}], ['Because he was unable to discontinue nonsteroidal anti - inflammatory drug therapy , fludrocortisone was added , correcting the hyperkalemia and allowing indomethacin therapy to be continued safely .', {'entities': [(128, 140, 'B_Disease')]}], ['Hypotension as a manifestation of cardiotoxicity in three patients receiving cisplatin and 5 - fluorouracil .', {'entities': [(0, 11, 'B_Disease'), (34, 48, 'B_Disease')]}], ['Cardiac symptoms , including hypotension , developed in three patients with advanced colorectal carcinoma while being treated with cisplatin ( CDDP ) and 5 - fluorouracil ( 5 - FU ) .', {'entities': [(29, 40, 'B_Disease'), (85, 95, 'B_Disease'), (96, 105, 'I_Disease')]}], ['In two patients , hypotension was associated with severe left ventricular dysfunction .', {'entities': [(18, 29, 'B_Disease'), (57, 61, 'B_Disease'), (62, 73, 'I_Disease'), (74, 85, 'I_Disease')]}], ['The presentation and cardiac evaluation ( hemodynamic , echocardiographic , and scintigraphic ) of these patients suggest new manifestations of 5 - FU cardiotoxicity that may be influenced by CDDP .', {'entities': [(151, 165, 'B_Disease')]}], ['Fatal aplastic anemia in a patient treated with carbamazepine .', {'entities': [(6, 14, 'B_Disease'), (15, 21, 'I_Disease')]}], ['A case of fatal aplastic anemia due to carbamazepine treatment in an epileptic woman is reported .', {'entities': [(16, 24, 'B_Disease'), (25, 31, 'I_Disease'), (69, 78, 'B_Disease')]}], ['Despite concerns of fatal bone marrow toxicity due to carbamazepine , this is only the fourth documented and published report .', {'entities': [(26, 30, 'B_Disease'), (31, 37, 'I_Disease'), (38, 46, 'I_Disease')]}], ['Participation of a bulbospinal serotonergic pathway in the rat brain in clonidine - induced hypotension and bradycardia .', {'entities': [(92, 103, 'B_Disease'), (108, 119, 'B_Disease')]}], ['The clonidine - induced hypotension was antagonized by prior spinal transection , but not bilateral vagotomy .', {'entities': [(24, 35, 'B_Disease')]}], ['On the other hand , the clonidine - induced bradycardia was antagonized by prior bilateral vagotomy , but not spinal transection .', {'entities': [(44, 55, 'B_Disease')]}], ['Furthermore , selective destruction of the spinal 5 - HT nerves , produced by bilateral spinal injection of 5 , 7 - dihydroxytryptamine , reduced the magnitude of the vasodepressor or the bradycardiac responses to clonidine microinjected into the area near the ventrolateral surface of the medulla oblongata in rats .', {'entities': [(188, 200, 'B_Disease')]}], ['The data indicate that a bulbospinal serotonergic pathway is involved in development of clonidine - induced hypotension and bradycardia .', {'entities': [(108, 119, 'B_Disease'), (124, 135, 'B_Disease')]}], ['The induced hypotension is brought about by a decrease in sympathetic efferent activity , whereas the induced bradycardia was due to an increase in vagal efferent activity .', {'entities': [(12, 23, 'B_Disease'), (110, 121, 'B_Disease')]}], ['Hypertension in neuroblastoma induced by imipramine .', {'entities': [(0, 12, 'B_Disease'), (16, 29, 'B_Disease')]}], ['Hypertension is a well - known finding in some patients with neuroblastoma .', {'entities': [(0, 12, 'B_Disease'), (61, 74, 'B_Disease')]}], ['We report the occurrence of severe hypertension ( blood pressure 190 / 160 ) in a 4 - year - old girl with neuroblastoma who was given Imipramine to control a behavior disorder .', {'entities': [(35, 47, 'B_Disease'), (107, 120, 'B_Disease'), (159, 167, 'B_Disease'), (168, 176, 'I_Disease')]}], [\"It was determined later that this patient ' s tumor was recurring at the time of her hypertensive episode .\", {'entities': [(46, 51, 'B_Disease'), (85, 97, 'B_Disease')]}], ['Since she had no blood pressure elevation at initial diagnosis and none following discontinuation of the Imipramine ( when she was in florid relapse ) , we believe that this drug rather than her underlying disease alone caused her hypertension .', {'entities': [(231, 243, 'B_Disease')]}], ['From this experience , we urge extreme caution in the use of tricyclic antidepressants in children with active neuroblastoma .', {'entities': [(111, 124, 'B_Disease')]}], ['Rechallenge of patients who developed oral candidiasis or hoarseness with beclomethasone dipropionate .', {'entities': [(38, 42, 'B_Disease'), (43, 54, 'I_Disease'), (58, 68, 'B_Disease')]}], ['Of 158 asthmatic patients who were placed on inhaled beclomethasone , 15 ( 9 . 5 % ) developed either hoarseness ( 8 ) , oral thrush ( 6 ) , or both ( 1 ) .', {'entities': [(7, 16, 'B_Disease'), (102, 112, 'B_Disease'), (126, 132, 'B_Disease')]}], ['These included five cases who developed hoarseness and three who developed Candidiasis .', {'entities': [(40, 50, 'B_Disease'), (75, 86, 'B_Disease')]}], ['Oral thrush did not recur , but 60 % ( 3 / 5 ) of patients with hoarseness had recurrence .', {'entities': [(5, 11, 'B_Disease'), (64, 74, 'B_Disease')]}], ['We conclude that patients may be restarted on inhaled beclomethasone when clinically indicated ; however , because of the high recurrence rate , patients who develop hoarseness should not be re - challenged .', {'entities': [(166, 176, 'B_Disease')]}], ['Concomitant use of oral prednisone and topical beclomethasone may increase the risk of developing hoarseness or candidiasis .', {'entities': [(98, 108, 'B_Disease'), (112, 123, 'B_Disease')]}], ['Cyclophosphamide cardiotoxicity : an analysis of dosing as a risk factor .', {'entities': [(17, 31, 'B_Disease')]}], ['At these high doses of CYA , serious cardiotoxicity may occur , but definitive risk factors for the development of such cardiotoxicity have not been described .', {'entities': [(37, 51, 'B_Disease'), (120, 134, 'B_Disease')]}], ['Since chemotherapeutic agent toxicity generally correlates with dose per body surface area , we retrospectively calculated the dose of CYA in patients transplanted at our institution to determine whether the incidence of CYA cardiotoxicity correlated with the dose per body surface area .', {'entities': [(29, 37, 'B_Disease'), (225, 239, 'B_Disease')]}], ['Eighty patients who were to receive CYA 50 mg / kg / d for four days as preparation for marrow grafting underwent a total of 84 transplants for aplastic anemia , Wiskott - Aldrich syndrome , or severe combined immunodeficiency syndrome .', {'entities': [(144, 152, 'B_Disease'), (153, 159, 'I_Disease'), (162, 169, 'B_Disease'), (170, 171, 'I_Disease'), (172, 179, 'I_Disease'), (180, 188, 'I_Disease'), (194, 200, 'B_Disease'), (201, 209, 'I_Disease'), (210, 226, 'I_Disease'), (227, 235, 'I_Disease')]}], ['Fourteen of 84 ( 17 % ) patients had symptoms and signs consistent with CYA cardiotoxicity within ten days of receiving 1 to 4 doses of CYA .', {'entities': [(76, 90, 'B_Disease')]}], ['Six of the 14 patients died with congestive heart failure .', {'entities': [(33, 43, 'B_Disease'), (44, 49, 'I_Disease'), (50, 57, 'I_Disease')]}], ['Cardiotoxicity that was thought to be related to CYA occurred in 1 / 32 ( 3 % ) of patients in Group 1 and in 13 / 52 ( 25 % ) patients in Group 2 ( P less than 0 . 025 ) .', {'entities': [(0, 14, 'B_Disease')]}], ['Congestive heart failure caused or contributed to death in 0 / 32 patients in Group 1 v 6 / 52 ( 12 % ) of patients in Group 2 ( P less than 0 . 25 ) .', {'entities': [(0, 10, 'B_Disease'), (11, 16, 'I_Disease'), (17, 24, 'I_Disease')]}], ['We conclude that the CYA cardiotoxicity correlates with CYA dosage as calculated by body surface area , and that patients with aplastic anemia and immunodeficiencies can be effectively prepared for bone marrow grafting at a CYA dose of 1 . 55 g / m2 / d for four days with a lower incidence of cardiotoxicity than patients whose CYA dosage is calculated based on weight .', {'entities': [(25, 39, 'B_Disease'), (127, 135, 'B_Disease'), (136, 142, 'I_Disease'), (147, 165, 'B_Disease'), (294, 308, 'B_Disease')]}], ['This study reaffirms the principle that drug toxicity correlates with dose per body surface area .', {'entities': [(45, 53, 'B_Disease')]}], ['Studies of risk factors for aminoglycoside nephrotoxicity .', {'entities': [(43, 57, 'B_Disease')]}], ['The epidemiology of aminoglycoside - induced nephrotoxicity is not fully understood .', {'entities': [(45, 59, 'B_Disease')]}], ['Experimental studies in healthy human volunteers indicate aminoglycosides cause proximal tubular damage in most patients , but rarely , if ever , cause glomerular or tubular dysfunction .', {'entities': [(152, 162, 'B_Disease'), (163, 165, 'I_Disease'), (166, 173, 'I_Disease'), (174, 185, 'I_Disease')]}], ['Clinical trials of aminoglycosides in seriously ill patients indicate that the relative risk for developing acute renal failure during therapy ranges from 8 to 10 and that the attributable risk is 70 % to 80 % .', {'entities': [(108, 113, 'B_Disease'), (114, 119, 'I_Disease'), (120, 127, 'I_Disease')]}], ['Further analysis of these data suggests that the duration of therapy , plasma aminoglycoside levels , liver disease , advanced age , high initial estimated creatinine clearance and , possibly , female gender all increase the risk for nephrotoxicity .', {'entities': [(102, 107, 'B_Disease'), (108, 115, 'I_Disease'), (234, 248, 'B_Disease')]}], ['Other causes of acute renal failure , such as shock , appear to have an additive effect .', {'entities': [(16, 21, 'B_Disease'), (22, 27, 'I_Disease'), (28, 35, 'I_Disease'), (46, 51, 'B_Disease')]}], ['These models may also be useful in developing insights into the pathophysiology of aminoglycoside - induced nephrotoxicity .', {'entities': [(108, 122, 'B_Disease')]}], ['The effect of clonidine , naphazoline and xylometazoline on analgesia induced by morphine , codeine , fentanyl and pentazocine , and on cataleptic effect of morphine , codine and fentanyl was studied in rats .', {'entities': [(136, 146, 'B_Disease')]}], ['It was found that three drugs stimulating central NA receptors failed to affect the analgesic ED50 of all antinociceptive agents and they enhanced catalepsy induced by morphine and fentanyl .', {'entities': [(147, 156, 'B_Disease')]}], ['Codeine catalepsy was increased by clonidine and decreased by naphazoline and xylometazoline .', {'entities': [(8, 17, 'B_Disease')]}], ['Flurothyl seizure thresholds in mice treated neonatally with a single injection of monosodium glutamate ( MSG ) : evaluation of experimental parameters in flurothyl seizure testing .', {'entities': [(10, 17, 'B_Disease'), (165, 172, 'B_Disease')]}], ['Monosodium glutamate ( MSG ) administration to neonatal rodents produces convulsions and results in numerous biochemical and behavioral deficits .', {'entities': [(73, 84, 'B_Disease')]}], ['These studies were undertaken to determine if neonatal administration of MSG produced permanent alterations in seizure susceptibility , since previous investigations were inconclusive .', {'entities': [(111, 118, 'B_Disease')]}], ['A flurothyl ether seizure screening technique was used to evaluate seizure susceptibility in adult mice that received neonatal injections of MSG ( 4 mg / g and 1 mg / g ) .', {'entities': [(18, 25, 'B_Disease'), (67, 74, 'B_Disease')]}], ['MSG treatment resulted in significant reductions in whole brain weight but did not alter seizure threshold .', {'entities': [(89, 96, 'B_Disease')]}], ['A naloxone ( 5 mg / kg ) challenge was also ineffective in altering the seizure thresholds of either control of MSG - treated mice .', {'entities': [(72, 79, 'B_Disease')]}], ['Flurothyl ether produced hypothermia which was correlated with the duration of flurothyl exposure ; however , the relationship of hypothermia to seizure induction was unclear .', {'entities': [(25, 36, 'B_Disease'), (130, 141, 'B_Disease'), (145, 152, 'B_Disease')]}], ['Flurothyl seizure testing proved to be a rapid and reliable technique with which to evaluate seizure susceptibility .', {'entities': [(10, 17, 'B_Disease'), (93, 100, 'B_Disease')]}], ['Susceptibility to seizures produced by pilocarpine in rats after microinjection of isoniazid or gamma - vinyl - GABA into the substantia nigra .', {'entities': [(18, 26, 'B_Disease')]}], ['Pilocarpine , given intraperitoneally to rats , reproduces the neuropathological sequelae of temporal lobe epilepsy and provides a relevant animal model for studying mechanisms of buildup of convulsive activity and pathways operative in the generalization and propagation of seizures within the forebrain .', {'entities': [(93, 101, 'B_Disease'), (102, 106, 'I_Disease'), (107, 115, 'I_Disease'), (191, 201, 'B_Disease'), (275, 283, 'B_Disease')]}], ['In the present study , the effects of manipulating the activity of the gamma - aminobutyric acid ( GABA ) - mediated synaptic inhibition within the substantia nigra on seizures produced by pilocarpine in rats , were investigated .', {'entities': [(168, 176, 'B_Disease')]}], ['In animals pretreated with microinjections of isoniazid , 150 micrograms , an inhibitor of activity of the GABA - synthesizing enzyme , L - glutamic acid decarboxylase , into the substantia nigra pars reticulata ( SNR ) , bilaterally , non - convulsant doses of pilocarpine , 100 and 200 mg / kg , resulted in severe motor limbic seizures and status epilepticus .', {'entities': [(330, 338, 'B_Disease'), (343, 349, 'B_Disease'), (350, 361, 'I_Disease')]}], ['Electroencephalographic and behavioral monitoring revealed a profound reduction of the threshold for pilocarpine - induced convulsions .', {'entities': [(123, 134, 'B_Disease')]}], ['Morphological analysis of frontal forebrain sections with light microscopy revealed seizure - related damage to the hippocampal formation , thalamus , amygdala , olfactory cortex , substantia nigra and neocortex , which is typically observed with pilocarpine in doses exceeding 350 mg / kg .', {'entities': [(84, 91, 'B_Disease')]}], ['Bilateral intrastriatal injections of isoniazid did not augment seizures produced by pilocarpine , 200 mg / kg .', {'entities': [(64, 72, 'B_Disease')]}], ['Application of an irreversible inhibitor of GABA transaminase , gamma - vinyl - GABA ( D , L - 4 - amino - hex - 5 - enoic acid ) , 5 micrograms , into the SNR , bilaterally , suppressed the appearance of electrographic and behavioral seizures produced by pilocarpine , 380 mg / kg .', {'entities': [(235, 243, 'B_Disease')]}], ['This treatment was also sufficient to protect animals from the occurrence of brain damage .', {'entities': [(77, 82, 'B_Disease'), (83, 89, 'I_Disease')]}], ['Microinjections of gamma - vinyl - GABA , 5 micrograms , into the dorsal striatum , bilaterally , failed to prevent the development of convulsions produced by pilocarpine , 380 mg / kg .', {'entities': [(135, 146, 'B_Disease')]}], ['The results demonstrate that the threshold for pilocarpine - induced seizures in rats is subjected to the regulation of the GABA - mediated synaptic inhibition within the substantia nigra .', {'entities': [(69, 77, 'B_Disease')]}], ['Human and canine ventricular vasoactive intestinal polypeptide : decrease with heart failure .', {'entities': [(79, 84, 'B_Disease'), (85, 92, 'I_Disease')]}], ['Myocardial levels of VIP were assayed before and after the development of heart failure in two canine models .', {'entities': [(74, 79, 'B_Disease'), (80, 87, 'I_Disease')]}], ['In the first , cobalt cardiomyopathy was induced in eight dogs ; VIP ( by radioimmunoassay ) decreased from 35 + / - 11 pg / mg protein ( mean + / - SD ) to 5 + / - 4 pg / mg protein ( P less than 0 . 05 ) .', {'entities': [(22, 36, 'B_Disease')]}], ['In six dogs with doxorubicin - induced heart failure , VIP decreased from 31 + / - 7 to 11 + / - 4 pg / mg protein ( P less than 0 . 05 ) .', {'entities': [(39, 44, 'B_Disease'), (45, 52, 'I_Disease')]}], ['In addition , VIP content of left ventricular muscle of resected failing hearts in 10 patients receiving a heart transplant was compared with the papillary muscles in 14 patients ( five with rheumatic disease , nine with myxomatous degeneration ) receiving mitral valve prostheses .', {'entities': [(191, 200, 'B_Disease'), (201, 208, 'I_Disease'), (221, 231, 'B_Disease'), (232, 244, 'I_Disease')]}], ['The lowest myocardial VIP concentration was found in the hearts of patients with coronary disease ( one patient receiving a transplant and three receiving mitral prostheses ) ( 6 . 3 + / - 1 . 9 pg / mg protein ) .', {'entities': [(81, 89, 'B_Disease'), (90, 97, 'I_Disease')]}], ['The hearts without coronary artery disease ( average ejection fraction of this group 62 % + / - 10 % ) had a VIP concentration of 14 . 1 + / - 7 . 9 pg / mg protein , and this was greater than in hearts of the patients with coronary disease and the hearts of patients receiving a transplant ( P less than 0 . 05 ) .', {'entities': [(19, 27, 'B_Disease'), (28, 34, 'I_Disease'), (35, 42, 'I_Disease'), (224, 232, 'B_Disease'), (233, 240, 'I_Disease')]}], ['Non - invasive detection of coronary artery disease by body surface electrocardiographic mapping after dipyridamole infusion .', {'entities': [(28, 36, 'B_Disease'), (37, 43, 'I_Disease'), (44, 51, 'I_Disease')]}], ['Electrocardiographic changes after dipyridamole infusion ( 0 . 568 mg / kg / 4 min ) were studied in 41 patients with coronary artery disease and compared with those after submaximal treadmill exercise by use of the body surface mapping technique .', {'entities': [(118, 126, 'B_Disease'), (127, 133, 'I_Disease'), (134, 141, 'I_Disease')]}], ['Patients were divided into three groups ; 19 patients without myocardial infarction ( non - MI group ) , 14 with anterior infarction ( ANT - MI ) and eight with inferior infarction ( INF - MI ) .', {'entities': [(62, 72, 'B_Disease'), (73, 83, 'I_Disease'), (92, 94, 'B_Disease'), (113, 121, 'B_Disease'), (122, 132, 'I_Disease'), (135, 138, 'B_Disease'), (139, 140, 'I_Disease'), (141, 143, 'I_Disease'), (161, 169, 'B_Disease'), (170, 180, 'I_Disease'), (183, 186, 'B_Disease'), (187, 188, 'I_Disease'), (189, 191, 'I_Disease')]}], ['After dipyridamole , ischemic ST - segment depression ( 0 . 05 mV or more ) was observed in 84 % of the non - MI group , 29 % of the ANT - MI group , 63 % of the INF - MI group and 61 % of the total population .', {'entities': [(21, 29, 'B_Disease'), (43, 53, 'B_Disease'), (110, 112, 'B_Disease'), (133, 136, 'B_Disease'), (137, 138, 'I_Disease'), (139, 141, 'I_Disease'), (162, 165, 'B_Disease'), (166, 167, 'I_Disease'), (168, 170, 'I_Disease')]}], ['Exercise - induced ST depression was observed in 84 % of the non - MI group , 43 % of the ANT - MI group , 38 % of the INF - MI group and 61 % of the total .', {'entities': [(22, 32, 'B_Disease'), (67, 69, 'B_Disease'), (90, 93, 'B_Disease'), (94, 95, 'I_Disease'), (96, 98, 'I_Disease'), (119, 122, 'B_Disease'), (123, 124, 'I_Disease'), (125, 127, 'I_Disease')]}], ['For individual patients , there were no obvious differences between the body surface distribution of ST depression in both tests .', {'entities': [(104, 114, 'B_Disease')]}], ['The data suggest that the dipyridamole - induced myocardial ischemia is caused by the inhomogenous distribution of myocardial blood flow .', {'entities': [(49, 59, 'B_Disease'), (60, 68, 'I_Disease')]}], ['We conclude that the dipyridamole ECG test is as useful as the exercise ECG test for the assessment of coronary artery disease .', {'entities': [(103, 111, 'B_Disease'), (112, 118, 'I_Disease'), (119, 126, 'I_Disease')]}], ['Bradycardia after high - dose intravenous methylprednisolone therapy .', {'entities': [(0, 11, 'B_Disease')]}], ['In 5 consecutive patients with rheumatoid arthritis who received intravenous high - dose methylprednisolone ( MP ) therapy ( 1 g daily for 2 or 3 consecutive days ) , a decline in pulse rate was observed , most pronounced on day 4 .', {'entities': [(31, 41, 'B_Disease'), (42, 51, 'I_Disease')]}], ['In one of the 5 patients the bradycardia was associated with complaints of substernal pressure .', {'entities': [(29, 40, 'B_Disease')]}], ['Electrocardiographic registrations showed sinus bradycardia in all cases .', {'entities': [(42, 47, 'B_Disease'), (48, 59, 'I_Disease')]}], ['High - dose MP may be contraindicated in patients with known heart disease .', {'entities': [(61, 66, 'B_Disease'), (67, 74, 'I_Disease')]}], ['Two cases of downbeat nystagmus and oscillopsia associated with carbamazepine .', {'entities': [(13, 21, 'B_Disease'), (22, 31, 'I_Disease'), (36, 47, 'B_Disease')]}], ['Downbeat nystagmus is often associated with structural lesions at the craniocervical junction , but has occasionally been reported as a manifestation of metabolic imbalance or drug intoxication .', {'entities': [(0, 8, 'B_Disease'), (9, 18, 'I_Disease')]}], ['We recorded the eye movements of two patients with reversible downbeat nystagmus related to carbamazepine therapy .', {'entities': [(62, 70, 'B_Disease'), (71, 80, 'I_Disease')]}], ['The nystagmus of both patients resolved after reduction of the serum carbamazepine levels .', {'entities': [(4, 13, 'B_Disease')]}], ['In patients with downbeat nystagmus who are taking anticonvulsant medications , consideration should be given to reduction in dose before further investigation is undertaken .', {'entities': [(17, 25, 'B_Disease'), (26, 35, 'I_Disease')]}], ['Improvement by denopamine ( TA - 064 ) of pentobarbital - induced cardiac failure in the dog heart - lung preparation .', {'entities': [(66, 73, 'B_Disease'), (74, 81, 'I_Disease')]}], ['The efficacy of denopamine , an orally active beta 1 - adrenoceptor agonist , in improving cardiac failure was assessed in dog heart - lung preparations .', {'entities': [(91, 98, 'B_Disease'), (99, 106, 'I_Disease')]}], ['No arrhythmias were induced by these doses of denopamine .', {'entities': [(3, 14, 'B_Disease')]}], ['The results warrant clinical trials of denopamine in the treatment of cardiac failure .', {'entities': [(70, 77, 'B_Disease'), (78, 85, 'I_Disease')]}], ['Clonazepam monotherapy for epilepsy in childhood .', {'entities': [(27, 35, 'B_Disease')]}], ['Sixty patients ( age - range one month to 14 years ) with other types of epilepsy than infantile spasms were treated with clonazepam .', {'entities': [(73, 81, 'B_Disease'), (87, 96, 'B_Disease'), (97, 103, 'I_Disease')]}], ['Disappearance of seizures and normalization of abnormal EEG with disappearance of seizures were recognized in 77 % and 50 % , respectively .', {'entities': [(17, 25, 'B_Disease'), (82, 90, 'B_Disease')]}], ['Seizures disappeared in 71 % of the patients with generalized seizures and 89 % of partial seizures .', {'entities': [(0, 8, 'B_Disease'), (62, 70, 'B_Disease'), (91, 99, 'B_Disease')]}], ['The incidence of side effects such as drowsiness and ataxia was only 5 % .', {'entities': [(38, 48, 'B_Disease'), (53, 59, 'B_Disease')]}], ['A postmarketing surveillance study was conducted to determine the safety and efficacy of a fixed - ratio combination containing 10 mg of timolol maleate and 25 mg of hydrochlorothiazide , administered twice daily for one month to hypertensive patients .', {'entities': [(230, 242, 'B_Disease')]}], ['The antihypertensive effect of the drug was greater in patients with more severe hypertension .', {'entities': [(81, 93, 'B_Disease')]}], ['Overall , 1 , 453 patients experienced a total of 2 , 658 adverse events , the most common being fatigue , dizziness , and weakness .', {'entities': [(97, 104, 'B_Disease'), (107, 116, 'B_Disease'), (123, 131, 'B_Disease')]}], ['Salicylate nephropathy in the Gunn rat : potential role of prostaglandins .', {'entities': [(11, 22, 'B_Disease')]}], ['We examined the potential role of prostaglandins in the development of analgesic nephropathy in the Gunn strain of rat .', {'entities': [(81, 92, 'B_Disease')]}], ['The homozygous Gunn rats have unconjugated hyperbilirubinemia due to the absence of glucuronyl transferase , leading to marked bilirubin deposition in renal medulla and papilla .', {'entities': [(43, 61, 'B_Disease')]}], ['These rats are also highly susceptible to develop papillary necrosis with analgesic administration .', {'entities': [(50, 59, 'B_Disease'), (60, 68, 'I_Disease')]}], ['The changes in renal prostaglandin synthesis were accompanied by evidence of renal damage in aspirin - treated jj but not jJ rats as evidenced by : increased incidence and severity of hematuria ( p less than 0 . 01 ) ; increased serum creatinine ( p less than 0 . 05 ) ; and increase in outer medullary histopathologic lesions ( p less than 0 . 005 compared to either sham - treated jj or aspirin - treated jJ ) .', {'entities': [(77, 82, 'B_Disease'), (83, 89, 'I_Disease'), (184, 193, 'B_Disease')]}], ['These results suggest that enhanced prostaglandin synthesis contributes to maintenance of renal function and morphological integrity , and that inhibition of prostaglandin synthesis may lead to pathological renal medullary lesions and deterioration of renal function .', {'entities': [(194, 206, 'B_Disease'), (207, 212, 'I_Disease'), (213, 222, 'I_Disease'), (223, 230, 'I_Disease'), (235, 248, 'B_Disease'), (249, 251, 'I_Disease'), (252, 257, 'I_Disease'), (258, 266, 'I_Disease')]}], ['Prophylactic lidocaine in the early phase of suspected myocardial infarction .', {'entities': [(55, 65, 'B_Disease'), (66, 76, 'I_Disease')]}], ['Four hundred two patients with suspected myocardial infarction seen within 6 hours of the onset of symptoms entered a double - blind randomized trial of lidocaine vs placebo .', {'entities': [(41, 51, 'B_Disease'), (52, 62, 'I_Disease')]}], ['During the 1 hour after administration of the drug the incidence of ventricular fibrillation or sustained ventricular tachycardia among the 204 patients with acute myocardial infarction was low , 1 . 5 % .', {'entities': [(68, 79, 'B_Disease'), (80, 92, 'I_Disease'), (106, 117, 'B_Disease'), (118, 129, 'I_Disease'), (164, 174, 'B_Disease'), (175, 185, 'I_Disease')]}], ['Lidocaine , given in a 300 mg dose intramuscularly followed by 100 mg intravenously , did not prevent sustained ventricular tachycardia , although there was a significant reduction in the number of patients with warning arrhythmias between 15 and 45 minutes after the administration of lidocaine ( p less than 0 . 05 ) .', {'entities': [(112, 123, 'B_Disease'), (124, 135, 'I_Disease'), (220, 231, 'B_Disease')]}], ['The average plasma lidocaine level 10 minutes after administration for patients without a myocardial infarction was significantly higher than that for patients with an acute infarction .', {'entities': [(90, 100, 'B_Disease'), (101, 111, 'I_Disease'), (174, 184, 'B_Disease')]}], ['During the 1 - hour study period , the incidence of central nervous system side effects was significantly greater in the lidocaine group , hypotension occurred in 11 patients , nine of whom had received lidocaine , and four patients died from asystole , three of whom had had lidocaine .', {'entities': [(139, 150, 'B_Disease'), (243, 251, 'B_Disease')]}], ['We cannot advocate the administration of lidocaine prophylactically in the early hours of suspected myocardial infarction .', {'entities': [(100, 110, 'B_Disease'), (111, 121, 'I_Disease')]}], ['Evidence for a cholinergic role in haloperidol - induced catalepsy .', {'entities': [(57, 66, 'B_Disease')]}], ['Experiments in mice tested previous evidence that activation of cholinergic systems promotes catalepsy and that cholinergic mechanisms need to be intact for full expression of neuroleptic - induced catalepsy .', {'entities': [(93, 102, 'B_Disease'), (198, 207, 'B_Disease')]}], ['Large doses of the cholinomimetic , pilocarpine , could induce catalepsy when peripheral cholinergic receptors were blocked .', {'entities': [(63, 72, 'B_Disease')]}], ['Low doses of pilocarpine caused a pronounced enhancement of the catalepsy that was induced by the dopaminergic blocker , haloperidol .', {'entities': [(64, 73, 'B_Disease')]}], ['A muscarinic receptor blocker , atropine , disrupted haloperidol - induced catalepsy .', {'entities': [(75, 84, 'B_Disease')]}], ['Intracranial injection of an acetylcholine - synthesis inhibitor , hemicholinium , prevented the catalepsy that is usually induced by haloperidol .', {'entities': [(97, 106, 'B_Disease')]}], ['These findings suggest the hypothesis that the catalepsy that is produced by neuroleptics such as haloperidol is actually mediated by intrinsic central cholinergic systems .', {'entities': [(47, 56, 'B_Disease')]}], ['Alternatively , activation of central cholinergic systems could promote catalepsy by suppression of dopaminergic systems .', {'entities': [(72, 81, 'B_Disease')]}], ['Cardiovascular dysfunction and hypersensitivity to sodium pentobarbital induced by chronic barium chloride ingestion .', {'entities': [(0, 14, 'B_Disease'), (15, 26, 'I_Disease'), (31, 47, 'B_Disease')]}], ['Barium - supplemented Long - Evans hooded rats were characterized by a persistent hypertension that was evident after 1 month of barium ( 100 micrograms / ml mineral fortified water ) treatment .', {'entities': [(82, 94, 'B_Disease')]}], ['Analysis of in vivo myocardial excitability , contractility , and metabolic characteristics at 16 months revealed other significant barium - induced disturbances within the cardiovascular system .', {'entities': [(149, 161, 'B_Disease'), (162, 168, 'I_Disease'), (169, 172, 'I_Disease'), (173, 187, 'I_Disease'), (188, 194, 'I_Disease')]}], ['The most distinctive aspect of the barium effect was a demonstrated hypersensitivity of the cardiovascular system to sodium pentobarbital .', {'entities': [(68, 84, 'B_Disease')]}], ['Overall , the altered cardiac contractility and excitability characteristics , the myocardial metabolic disturbances , and the hypersensitivity of the cardiovascular system to sodium pentobarbital suggest the existence of a heretofore undescribed cardiomyopathic disorder induced by chronic barium exposure .', {'entities': [(94, 103, 'B_Disease'), (104, 116, 'I_Disease'), (127, 143, 'B_Disease'), (247, 262, 'B_Disease'), (263, 271, 'I_Disease')]}], ['Propranolol antagonism of phenylpropanolamine - induced hypertension .', {'entities': [(56, 68, 'B_Disease')]}], ['Phenylpropanolamine ( PPA ) overdose can cause severe hypertension , intracerebral hemorrhage , and death .', {'entities': [(28, 36, 'B_Disease'), (54, 66, 'B_Disease'), (69, 82, 'B_Disease'), (83, 93, 'I_Disease')]}], ['We studied the efficacy and safety of propranolol in the treatment of PPA - induced hypertension .', {'entities': [(84, 96, 'B_Disease')]}], ['Left ventricular function ( assessed by echocardiography ) showed that PPA increased the stroke volume 30 % ( from 62 . 5 + / - 20 . 9 to 80 . 8 + / - 22 . 4 ml ) , the ejection fraction 9 % ( from 64 % + / - 10 % to 70 % + / - 7 % ) , and cardiac output 14 % ( from 3 . 6 + / - 0 . 6 to 4 . 1 + / - 1 . 0 L / min ) .', {'entities': [(89, 95, 'B_Disease')]}], ['Mesangial function and glomerular sclerosis in rats with aminonucleoside nephrosis .', {'entities': [(23, 33, 'B_Disease'), (34, 43, 'I_Disease'), (73, 82, 'B_Disease')]}], ['The possible relationship between mesangial dysfunction and development of glomerular sclerosis was studied in the puromycin aminonucleoside ( PAN ) model .', {'entities': [(34, 43, 'B_Disease'), (44, 55, 'I_Disease'), (75, 85, 'B_Disease'), (86, 95, 'I_Disease')]}], ['After 4 weeks the PAN rats were severely proteinuric ( 190 + / - 80 mg / 24 hr ) , and all rats were given colloidal carbon ( CC ) intravenously .', {'entities': [(41, 52, 'B_Disease')]}], ['At 5 months glomerular sclerosis was found in 7 . 6 + / - 3 . 4 % of the glomeruli of PAN rats ; glomeruli of the controls were normal .', {'entities': [(12, 22, 'B_Disease'), (23, 32, 'I_Disease')]}], ['Glomeruli with sclerosis contained significantly more CC than non - sclerotic glomeruli in the same kidneys .', {'entities': [(15, 24, 'B_Disease')]}], ['Since mesangial CC clearance from the mesangium did not change during chronic PAN treatment , we conclude that this preferential CC localization within the lesions is caused by an increased CC uptake shortly after injection in apparent vulnerable areas where sclerosis will develop subsequently .', {'entities': [(259, 268, 'B_Disease')]}], ['Similar to the remnant kidney model in PAN nephrosis the development of glomerular sclerosis may be related to \" mesangial overloading . \"', {'entities': [(43, 52, 'B_Disease'), (72, 82, 'B_Disease'), (83, 92, 'I_Disease')]}], ['Relationship between nicotine - induced seizures and hippocampal nicotinic receptors .', {'entities': [(40, 48, 'B_Disease')]}], ['Using mice derived from a classical F2 and backcross genetic design , a relationship between nicotine - induced seizures and alpha - bungarotoxin nicotinic receptor concentration was found .', {'entities': [(112, 120, 'B_Disease')]}], ['Mice sensitive to the convulsant effects of nicotine had greater alpha - bungarotoxin binding in the hippocampus than seizure insensitive mice .', {'entities': [(118, 125, 'B_Disease')]}], ['The binding sites from seizure sensitive and resistant mice were equally affected by treatment with dithiothreitol , trypsin or heat .', {'entities': [(23, 30, 'B_Disease')]}], ['Thus it appears that the difference between seizure sensitive and insensitive animals may be due to a difference in hippocampal nicotinic receptor concentration as measured with alpha - bungarotoxin binding .', {'entities': [(44, 51, 'B_Disease')]}], ['The role of p - aminophenol in acetaminophen - induced nephrotoxicity : effect of bis ( p - nitrophenyl ) phosphate on acetaminophen and p - aminophenol nephrotoxicity and metabolism in Fischer 344 rats .', {'entities': [(55, 69, 'B_Disease'), (153, 167, 'B_Disease')]}], ['Acetaminophen ( APAP ) produces proximal tubular necrosis in Fischer 344 ( F344 ) rats .', {'entities': [(41, 48, 'B_Disease'), (49, 57, 'I_Disease')]}], ['The purpose of this study was to determine if PAP formation is a requisite step in APAP - induced nephrotoxicity .', {'entities': [(98, 112, 'B_Disease')]}], ['Therefore , the effect of bis ( p - nitrophenyl ) phosphate ( BNPP ) , an acylamidase inhibitor , on APAP and PAP nephrotoxicity and metabolism was determined .', {'entities': [(114, 128, 'B_Disease')]}], ['Pretreatment of animals with BNPP prior to APAP or PAP administration resulted in marked reduction of APAP ( 900 mg / kg ) nephrotoxicity but not PAP nephrotoxicity .', {'entities': [(123, 137, 'B_Disease'), (150, 164, 'B_Disease')]}], ['Therefore , the BNPP - induced reduction in APAP - induced nephrotoxicity appears to be due to inhibition of APAP deacetylation .', {'entities': [(59, 73, 'B_Disease')]}], ['It is concluded that PAP formation , in vivo , accounts , at least in part , for APAP - induced renal tubular necrosis .', {'entities': [(96, 101, 'B_Disease'), (102, 109, 'I_Disease'), (110, 118, 'I_Disease')]}], ['Morphine - induced seizures in newborn infants .', {'entities': [(19, 27, 'B_Disease')]}], ['Two neonates suffered from generalized seizures during the course of intravenous morphine sulfate for post - operative analgesia .', {'entities': [(39, 47, 'B_Disease')]}], ['They received morphine in doses of 32 micrograms / kg / hr and 40 micrograms / kg / hr larger than a group of 10 neonates who received 6 - 24 micrograms / kg / hr and had no seizures .', {'entities': [(174, 182, 'B_Disease')]}], ['Other known reasons for seizures were ruled out and the convulsions stopped a few hours after cessation of morphine and did not reoccur in the subsequent 8 months .', {'entities': [(24, 32, 'B_Disease'), (56, 67, 'B_Disease')]}], ['Indomethacin induced hypotension in sodium and volume depleted rats .', {'entities': [(21, 32, 'B_Disease')]}], ['Four types of experimental arrhythmia are used - - with BaCl2 , with chloroform - adrenaline , with strophantine G and with aconitine .', {'entities': [(27, 37, 'B_Disease')]}], ['The compound manifests antiarrhythmic activity in all models of experimental arrhythmia used , causing greatest inhibition on the arrhythmia induced by chloroform - adrenaline ( in 90 per cent ) and with BaCl2 ( in 84 per cent ) .', {'entities': [(77, 87, 'B_Disease'), (130, 140, 'B_Disease')]}], ['Recurrent subarachnoid hemorrhage associated with aminocaproic acid therapy and acute renal artery thrombosis .', {'entities': [(10, 22, 'B_Disease'), (23, 33, 'I_Disease'), (80, 85, 'B_Disease'), (86, 91, 'I_Disease'), (92, 98, 'I_Disease'), (99, 109, 'I_Disease')]}], ['Epsilon aminocaproic acid ( EACA ) has been used to prevent rebleeding in patients with subarachnoid hemorrhage ( SAH ) .', {'entities': [(88, 100, 'B_Disease'), (101, 111, 'I_Disease'), (114, 117, 'B_Disease')]}], ['Although this agent does decrease the frequency of rebleeding , several reports have described thrombotic complications of EACA therapy .', {'entities': [(95, 105, 'B_Disease')]}], ['These complications have included clinical deterioration and intracranial vascular thrombosis in patients with SAH , arteriolar and capillary fibrin thrombi in patients with fibrinolytic syndromes treated with EACA , or other thromboembolic phenomena .', {'entities': [(61, 73, 'B_Disease'), (74, 82, 'I_Disease'), (83, 93, 'I_Disease'), (111, 114, 'B_Disease'), (149, 156, 'B_Disease'), (226, 240, 'B_Disease'), (241, 250, 'I_Disease')]}], ['Since intravascular fibrin thrombi are often observed in patients with fibrinolytic disorders , EACA should not be implicated in the pathogenesis of fibrin thrombi in patients with disseminated intravascular coagulation or other \" consumption coagulopathies . \" This report describes subtotal infarction of the kidney due to thrombosis of a normal renal artery .', {'entities': [(27, 34, 'B_Disease'), (156, 163, 'B_Disease'), (181, 193, 'B_Disease'), (194, 207, 'I_Disease'), (208, 219, 'I_Disease'), (231, 242, 'B_Disease'), (243, 257, 'I_Disease'), (293, 303, 'B_Disease'), (325, 335, 'B_Disease'), (336, 338, 'I_Disease'), (339, 340, 'I_Disease'), (341, 347, 'I_Disease'), (348, 353, 'I_Disease'), (354, 360, 'I_Disease')]}], ['This occlusion occurred after EACA therapy in a patient with SAH and histopathological documentation of recurrent SAH .', {'entities': [(61, 64, 'B_Disease'), (114, 117, 'B_Disease')]}], ['The corresponding clinical event was characterized by marked hypertension and abrupt neurological deterioration .', {'entities': [(61, 73, 'B_Disease')]}], ['Effect of vincristine sulfate on Pseudomonas infections in monkeys .', {'entities': [(33, 44, 'B_Disease'), (45, 55, 'I_Disease')]}], ['Leukocytosis was observed in all monkeys .', {'entities': [(0, 12, 'B_Disease')]}], ['Intravenous or intratracheal inoculation of 2 . 0 to 2 . 5 mg of vincristine sulfate was followed by leukopenia in 4 to 5 days .', {'entities': [(101, 111, 'B_Disease')]}], ['Intravenous inoculation of 4 . 2 x 10 ( 10 ) to 7 . 8 x 10 ( 10 ) pyocin type 6 Pseudomonas organisms in monkeys given vincristine sulfate 4 days previously resulted in fatal infection in 11 of 14 monkeys , whereas none of four receiving Pseudomonas alone died .', {'entities': [(175, 184, 'B_Disease')]}], ['These studies suggest that an antimetabolite - induced leukopenia predisposes to severe Pseudomonas sepsis and that such monkeys may serve as a biological model for study of comparative efficacy of antimicrobial agents .', {'entities': [(55, 65, 'B_Disease'), (100, 106, 'B_Disease')]}], ['Modification by propranolol of cardiovascular effects of induced hypoglycaemia .', {'entities': [(65, 78, 'B_Disease')]}], ['The cardiovascular effects of hypoglycaemia , with and without beta - blockade , were compared in fourteen healthy men .', {'entities': [(30, 43, 'B_Disease')]}], ['In the insulin - group the period of hypoglycaemia was associated with an increase in heart - rate and a fall in diastolic blood - pressure .', {'entities': [(37, 50, 'B_Disease')]}], ['Hypertension in diabetics prone to hypoglycaemia attacks should not be treated with beta - blockers because these drugs may cause a sharp rise in blood - pressure in such patients .', {'entities': [(0, 12, 'B_Disease'), (16, 25, 'B_Disease'), (35, 48, 'B_Disease')]}], ['We conclude that previously reported hypoglycemia , hyperbilirubinemia , polycythemia , neonatal apnea , and bradycardia are not invariable and cannot be statistically correlated with chronic propranolol therapy .', {'entities': [(37, 49, 'B_Disease'), (52, 70, 'B_Disease'), (73, 85, 'B_Disease'), (88, 96, 'B_Disease'), (97, 102, 'I_Disease'), (109, 120, 'B_Disease')]}], ['Growth retardation , however , appears to be significant in both of our series .', {'entities': [(0, 6, 'B_Disease'), (7, 18, 'I_Disease')]}], ['High doses caused an apparent central excitation , most clearly seen as clonic convulsions , superimposed on general depression .', {'entities': [(79, 90, 'B_Disease'), (117, 127, 'B_Disease')]}], ['Following a lethal dose , death was always associated with convulsions .', {'entities': [(59, 70, 'B_Disease')]}], ['Comparing the relative sensitivity to central depression and excitation revealed that rats were least likely to have convulsions at doses that did not first cause loss of consciousness , while cats most clearly showed marked central excitatory actions .', {'entities': [(46, 56, 'B_Disease'), (117, 128, 'B_Disease'), (163, 167, 'B_Disease'), (168, 170, 'I_Disease'), (171, 184, 'I_Disease')]}], ['Signs of FZP toxocity in cats included excessive salivation , extreme apprehensive behavior , retching , muscle tremors and convulsions .', {'entities': [(13, 21, 'B_Disease'), (49, 59, 'B_Disease'), (105, 111, 'B_Disease'), (112, 119, 'I_Disease'), (124, 135, 'B_Disease')]}], ['As a function of dose , FZP first protected against convulsions and death .', {'entities': [(52, 63, 'B_Disease')]}], ['At higher doses , however , convulsions again emerged .', {'entities': [(28, 39, 'B_Disease')]}], ['These doses of FZP were lower than those that would alone cause convulsions .', {'entities': [(64, 75, 'B_Disease')]}], ['These results may be relevant to the use of FZP in clinical situations in which there is increased neural excitability , such as epilepsy or sedative - hypnotic drug withdrawal .', {'entities': [(129, 137, 'B_Disease')]}], ['Use of propranolol in the treatment of idiopathic orthostatic hypotension .', {'entities': [(39, 49, 'B_Disease'), (50, 61, 'I_Disease'), (62, 73, 'I_Disease')]}], ['Five patients with idiopathic orthostatic hypotension who had physiologic and biochemical evidence of severe autonomic dysfunction were included in the study .', {'entities': [(19, 29, 'B_Disease'), (30, 41, 'I_Disease'), (42, 53, 'I_Disease')]}], ['They all exhibited markedly reduced plasma catecholamines and plasma renin activity in both recumbent and upright positions and had marked hypersensitivity to the pressor effects of infused norepinephrine .', {'entities': [(139, 155, 'B_Disease')]}], ['In 1 patient , marked hypertension was induced by propranolol and the drug had to be withdrawn .', {'entities': [(22, 34, 'B_Disease')]}], ['The studies suggest that propranolol is a useful drug in selected patients with severe idiopathic orthostatic hypotension .', {'entities': [(87, 97, 'B_Disease'), (98, 109, 'I_Disease'), (110, 121, 'I_Disease')]}], ['The investigation was discontinued after 18 patients because of the frequency and intensity of side - effects , particularly pain and myoclonia , which caused the technique to be abandoned in two cases .', {'entities': [(125, 129, 'B_Disease'), (134, 143, 'B_Disease')]}], ['It is considered unlikely that etomidate will prove to be the hypnotic of choice for a totally intravenous anesthetic technique in adults because of the high incidence of myoclonia after prolonged administration .', {'entities': [(171, 180, 'B_Disease')]}], ['We compared the effects of single doses of 50 mg atenolol ( cardioselective ) , 40 mg propranolol ( nonselective ) , and placebo on both exercise - and isoproterenol - induced tachycardia in two experiments involving nine normal subjects .', {'entities': [(176, 187, 'B_Disease')]}], ['The effects on isoproterenol tachycardia were determined before and after atropine ( 0 . 04 mg / kg IV ) .', {'entities': [(29, 40, 'B_Disease')]}], ['These data are consistent with the hypothesis that exercise - induced tachycardia results largely from beta 1 - receptor activation that is blocked by both cardioselective and nonselective drugs , whereas isoproterenol activates both beta 1 - and beta 2 - receptors so that after cardioselective blockade there remains a beta 2 - component that can be blocked with a nonselective drug .', {'entities': [(70, 81, 'B_Disease')]}], ['Hormones and risk of breast cancer .', {'entities': [(21, 27, 'B_Disease'), (28, 34, 'I_Disease')]}], ['Mastodynia was reported by 21 patients , and physical examination revealed a light increase in breast firmness in 12 women and a moderate increase in breast nodularity in 2 women .', {'entities': [(0, 10, 'B_Disease')]}], ['Themography confirmed the existence of an excessive breast stimulation in 1 women who complained of moderate mastodynia and in 5 of the 7 women who complained of severe mastodynia .', {'entities': [(109, 119, 'B_Disease'), (169, 179, 'B_Disease')]}], ['Early infections in kidney , heart , and liver transplant recipients on cyclosporine .', {'entities': [(6, 16, 'B_Disease')]}], ['Eighty - one renal , seventeen heart , and twenty - four liver transplant patients were followed for infection .', {'entities': [(101, 110, 'B_Disease')]}], ['The randomized Aza patients had more overall infections ( P less than 0 . 05 ) and more nonviral infections ( P less than 0 . 02 ) than the randomized cyclosporine patients .', {'entities': [(45, 55, 'B_Disease'), (97, 107, 'B_Disease')]}], ['Heart and liver patients had more infections than cyclosporine renal patients but fewer infections than the Aza renal patients .', {'entities': [(34, 44, 'B_Disease'), (88, 98, 'B_Disease')]}], ['There were no infectious deaths in renal transplant patients on cyclosporine or Aza , but infection played a major role in 3 out of 6 cardiac transplant deaths and in 8 out of 9 liver transplant deaths .', {'entities': [(90, 99, 'B_Disease')]}], ['Renal patients on cyclosporine had the fewest bacteremias .', {'entities': [(46, 57, 'B_Disease')]}], ['Analysis of site of infection showed a preponderance of abdominal infections in liver patients , intrathoracic infections in heart patients , and urinary tract infections in renal patients .', {'entities': [(20, 29, 'B_Disease'), (56, 65, 'B_Disease'), (66, 76, 'I_Disease'), (111, 121, 'B_Disease'), (146, 153, 'B_Disease'), (154, 159, 'I_Disease'), (160, 170, 'I_Disease')]}], ['Pulmonary infections were less common in cyclosporine - treated renal patients than in Aza - treated patients ( P less than 0 . 05 ) .', {'entities': [(10, 20, 'B_Disease')]}], ['Aza patients had significantly more staphylococcal infections than all other transplant groups ( P less than 0 . 005 ) , and systemic fungal infections occurred only in the liver transplant group .', {'entities': [(36, 50, 'B_Disease'), (51, 61, 'I_Disease'), (134, 140, 'B_Disease'), (141, 151, 'I_Disease')]}], ['Of the cyclosporine patients , 15 % had symptoms related to CMV infection .', {'entities': [(60, 63, 'B_Disease'), (64, 73, 'I_Disease')]}], ['Serological evidence for Epstein Barr Virus infection was found in 20 % of 65 cyclosporine patients studied .', {'entities': [(25, 32, 'B_Disease'), (33, 37, 'I_Disease'), (38, 43, 'I_Disease'), (44, 53, 'I_Disease')]}], ['Three had associated symptoms , and one developed a lymphoma .', {'entities': [(52, 60, 'B_Disease')]}], ['Structure - activity and dose - effect relationships of the antagonism of picrotoxin - induced seizures by cholecystokinin , fragments and analogues of cholecystokinin in mice .', {'entities': [(95, 103, 'B_Disease')]}], ['Intraperitoneal administration of cholecystokinin octapeptide sulphate ester ( CCK - 8 - SE ) and nonsulphated cholecystokinin octapeptide ( CCK - 8 - NS ) enhanced the latency of seizures induced by picrotoxin in mice .', {'entities': [(180, 188, 'B_Disease')]}], ['The peptide CCK - 5 - 8 had weak anticonvulsant activity in comparison to the octapeptides , 3 . 2 mumol / kg and larger doses of the reference drug , diazepam , totally prevented picrotoxin - induced seizures and mortality .', {'entities': [(201, 209, 'B_Disease')]}], ['Vasopressin as a possible contributor to hypertension .', {'entities': [(41, 53, 'B_Disease')]}], ['The role of vasopressin as a pressor agent to the hypertensive process was examined .', {'entities': [(50, 62, 'B_Disease')]}], ['Vasopressin plays a major role in the pathogenesis of DOCA - salt hypertension , since the elevation of blood pressure was not substantial in the rats with lithium - treated diabetes insipidus after DOCA - salt treatment .', {'entities': [(66, 78, 'B_Disease'), (174, 182, 'B_Disease'), (183, 192, 'I_Disease')]}], ['Furthermore , the pressor action of vasopressin appears to be important in the development of this model of hypertension , since the enhanced pressor responsiveness to the hormone was observed in the initial stage of hypertension .', {'entities': [(108, 120, 'B_Disease'), (217, 229, 'B_Disease')]}], ['Increased secretion of vasopressin from neurohypophysis also promotes the function of the hormone as a pathogenetic factor in hypertension .', {'entities': [(126, 138, 'B_Disease')]}], ['However , the role of vasopressin remains to be determined in human essential hypertension .', {'entities': [(78, 90, 'B_Disease')]}], ['Toxic hepatitis induced by disulfiram in a non - alcoholic .', {'entities': [(0, 5, 'B_Disease'), (6, 15, 'I_Disease')]}], ['A reversible toxic liver damage was observed in a non - alcoholic woman treated with disulfiram .', {'entities': [(13, 18, 'B_Disease'), (19, 24, 'I_Disease'), (25, 31, 'I_Disease')]}], ['Atrial thrombosis involving the heart of F - 344 rats ingesting quinacrine hydrochloride .', {'entities': [(0, 6, 'B_Disease'), (7, 17, 'I_Disease')]}], ['Rats treated with 500 ppm quinacrine hydrochloride in the diet all developed a high incidence of left atrial thrombosis .', {'entities': [(102, 108, 'B_Disease'), (109, 119, 'I_Disease')]}], ['The lesion was associated with cardiac hypertrophy and dilatation and focal myocardial degeneration .', {'entities': [(31, 38, 'B_Disease'), (39, 50, 'I_Disease'), (76, 86, 'B_Disease'), (87, 99, 'I_Disease')]}], ['Rats died from cardiac hypertrophy with severe acute and chronic congestion of the lungs , liver , and other organs .', {'entities': [(15, 22, 'B_Disease'), (23, 34, 'I_Disease')]}], ['Seventy percent of rats given 250 ppm quinacrine hydrochloride and 1 , 000 ppm sodium nitrite simultaneously in the diet had thrombosis of the atria of the heart , while untreated control rats in this laboratory did not have atrial thrombosis .', {'entities': [(125, 135, 'B_Disease'), (225, 231, 'B_Disease'), (232, 242, 'I_Disease')]}], ['Alternating sinus rhythm and intermittent sinoatrial block induced by propranolol .', {'entities': [(0, 11, 'B_Disease'), (12, 17, 'I_Disease'), (18, 24, 'I_Disease'), (42, 52, 'B_Disease'), (53, 58, 'I_Disease')]}], ['Alternating sinus rhythm and intermittent sinoatrial ( S - A ) block was observed in a 57 - year - old woman , under treatment for angina with 80 mg propranolol daily .', {'entities': [(0, 11, 'B_Disease'), (12, 17, 'I_Disease'), (18, 24, 'I_Disease'), (42, 52, 'B_Disease'), (53, 54, 'I_Disease'), (55, 56, 'I_Disease'), (57, 58, 'I_Disease'), (59, 60, 'I_Disease'), (61, 62, 'I_Disease'), (63, 68, 'I_Disease'), (131, 137, 'B_Disease')]}], ['Following these basic sinus cycles , alternating rhythm started with the longer P - P interval .', {'entities': [(37, 48, 'B_Disease'), (49, 55, 'I_Disease')]}], ['In one recording a short period of regular sinus rhythm with intermittent 2 / 1 S - A block was observed .', {'entities': [(80, 81, 'B_Disease'), (82, 83, 'I_Disease'), (84, 85, 'I_Disease'), (86, 91, 'I_Disease')]}], ['The abnormal rhythm disappeared with the withdrawal of propranolol and when the drug was restarted a 2 / 1 S - A block was seen .', {'entities': [(107, 108, 'B_Disease'), (109, 110, 'I_Disease'), (111, 112, 'I_Disease'), (113, 118, 'I_Disease')]}], ['This was accepted as evidence for propranolol being the cause of this conduction disorder .', {'entities': [(70, 80, 'B_Disease'), (81, 89, 'I_Disease')]}], ['Antitumor effect , cardiotoxicity , and nephrotoxicity of doxorubicin in the IgM solid immunocytoma - bearing LOU / M / WSL rat .', {'entities': [(19, 33, 'B_Disease'), (40, 54, 'B_Disease'), (87, 99, 'B_Disease')]}], ['Antitumor activity , cardiotoxicity , and nephrotoxicity induced by doxorubicin were studied in LOU / M / WSL inbred rats each bearing a transplantable solid IgM immunocytoma .', {'entities': [(21, 35, 'B_Disease'), (42, 56, 'B_Disease'), (162, 174, 'B_Disease')]}], ['Animals with a tumor ( diameter , 15 . 8 + / - 3 . 3 mm ) were treated with iv injections of doxorubicin on 5 consecutive days , followed by 1 weekly injection for 7 weeks ( dose range , 0 . 015 - 4 . 0 mg / kg body wt ) .', {'entities': [(15, 20, 'B_Disease')]}], ['Tumor regression was observed with 0 . 5 mg doxorubicin / kg .', {'entities': [(0, 5, 'B_Disease')]}], ['Complete disappearance of the tumor was induced with 1 . 0 mg doxorubicin / kg .', {'entities': [(30, 35, 'B_Disease')]}], ['Histologic evidence of cardiotoxicity scored as grade III was only observed at a dose of 1 . 0 mg doxorubicin / kg .', {'entities': [(23, 37, 'B_Disease')]}], ['Light microscopic evidence of renal damage was seen above a dose of 0 . 5 mg doxorubicin / kg , which resulted in albuminuria and very low serum albumin levels .', {'entities': [(30, 35, 'B_Disease'), (36, 42, 'I_Disease'), (114, 125, 'B_Disease')]}], ['Ascites and hydrothorax were observed simultaneously .', {'entities': [(0, 7, 'B_Disease'), (12, 23, 'B_Disease')]}], ['The same experiments were performed with non - tumor - bearing rats , in which no major differences were observed .', {'entities': [(47, 52, 'B_Disease')]}], ['In conclusion , antitumor activity , cardiotoxicity , and nephrotoxicity were studied simultaneously in the same LOU / M / WSL rat .', {'entities': [(37, 51, 'B_Disease'), (58, 72, 'B_Disease')]}], ['Albuminuria due to renal damage led to extremely low serum albumin levels , so ascites and hydrothorax were not necessarily a consequence of the observed cardiomyopathy .', {'entities': [(0, 11, 'B_Disease'), (19, 24, 'B_Disease'), (25, 31, 'I_Disease'), (79, 86, 'B_Disease'), (91, 102, 'B_Disease'), (154, 168, 'B_Disease')]}], ['Intraoperative bradycardia and hypotension associated with timolol and pilocarpine eye drops .', {'entities': [(15, 26, 'B_Disease'), (31, 42, 'B_Disease')]}], ['A 69 - yr - old man , who was concurrently being treated with pilocarpine nitrate and timolol maleate eye drops , developed a bradycardia and became hypotensive during halothane anaesthesia .', {'entities': [(126, 137, 'B_Disease'), (149, 160, 'B_Disease')]}], ['It is postulated that this action may have been enhanced during halothane anaesthesia with resultant bradycardia and hypotension .', {'entities': [(101, 112, 'B_Disease'), (117, 128, 'B_Disease')]}], ['Succinylcholine apnoea : attempted reversal with anticholinesterases .', {'entities': [(16, 22, 'B_Disease')]}], ['Anticholinesterases were administered in an attempt to antagonize prolonged neuromuscular blockade following the administration of succinylcholine in a patient later found to be homozygous for atypical plasma cholinesterase .', {'entities': [(76, 89, 'B_Disease'), (90, 98, 'I_Disease')]}], ['It is concluded that anticholinesterases are only partially effective in restoring neuromuscular function in succinylcholine apnoea despite muscle twitch activity typical of phase II block .', {'entities': [(125, 131, 'B_Disease')]}], ['Our findings suggest that the changes leading to an alteration of myocardial dynamic imaging with I - 131 HA are not the initiating factor in doxorubicin cardiotoxicity .', {'entities': [(154, 168, 'B_Disease')]}], ['Hemodynamics and myocardial metabolism under deliberate hypotension .', {'entities': [(56, 67, 'B_Disease')]}], ['Coronary blood flow , cardiac work and metabolism were studied in dogs under sodium nitroprusside ( SNP ) and trimetaphan ( TMP ) deliberate hypotension ( 20 % and 40 % mean pressure decrease from baseline ) .', {'entities': [(141, 152, 'B_Disease')]}], ['Regarding the effects of drug - induced hypotension on coronary blood flow , aortic and coronary sinus metabolic data ( pH , pO2 , pCO2 ) we could confirm that nitroprusside hypotension could be safely used to 30 % mean blood pressure decrease from control , trimetaphan hypotension to 20 % mean blood pressure decrease .', {'entities': [(40, 51, 'B_Disease'), (174, 185, 'B_Disease'), (271, 282, 'B_Disease')]}], ['Cardiac work was significantly reduced during SNP hypotension .', {'entities': [(50, 61, 'B_Disease')]}], ['The hyperactivity induced by D - amphetamine ( 10 mumol / kg ) was significantly reduced by DSP4 pretreatment .', {'entities': [(4, 17, 'B_Disease')]}], ['However , the increased rearings and the amphetamine - induced stereotypies were not blocked by pretreatment with DSP4 .', {'entities': [(63, 75, 'B_Disease')]}], ['The reduction of amphetamine hyperactivity induced by DSP4 was blocked by pretreatment with the noradrenaline - uptake blocking agent , desipramine , which prevents the neurotoxic action of DSP4 .', {'entities': [(29, 42, 'B_Disease'), (169, 179, 'B_Disease')]}], ['Accelerated junctional rhythms during oral verapamil therapy .', {'entities': [(0, 11, 'B_Disease'), (12, 22, 'I_Disease'), (23, 30, 'I_Disease')]}], ['This study examined the frequency of atrioventricular ( AV ) dissociation and accelerated junctional rhythms in 59 patients receiving oral verapamil .', {'entities': [(78, 89, 'B_Disease'), (90, 100, 'I_Disease'), (101, 108, 'I_Disease')]}], ['Accelerated junctional rhythms and AV dissociation were frequent in patients with supraventricular tachyarrhythmias , particularly AV nodal reentry .', {'entities': [(0, 11, 'B_Disease'), (12, 22, 'I_Disease'), (23, 30, 'I_Disease'), (82, 98, 'B_Disease'), (99, 115, 'I_Disease')]}], ['In patients with various chest pain syndromes , verapamil neither increased the frequency of junctional rhythms nor suppressed their role as escape rhythms under physiologically appropriate circumstances .', {'entities': [(25, 30, 'B_Disease'), (31, 35, 'I_Disease')]}], ['Five phenotypic characteristics - - locomotor activity , righting ability , clonic seizure induction , stress - induced lethality , death without external stress - - were scored at various caffeine doses in drug - naive animals under empirically optimized , rigidly constant experimental conditions .', {'entities': [(76, 82, 'B_Disease'), (83, 90, 'I_Disease')]}], ['In the same animals the occurrence of clonic seizures was scored as to time of onset and severity for 20 min after drug administration .', {'entities': [(38, 44, 'B_Disease'), (45, 53, 'I_Disease')]}], ['When these proceeded to tonic seizures , death occurred in less than 20 min .', {'entities': [(24, 29, 'B_Disease'), (30, 38, 'I_Disease')]}], ['Animals surviving for 20 min were immediately stressed by a swim test in 25 degrees C water , and death - producing tonic seizures were scored for 2 min .', {'entities': [(116, 121, 'B_Disease'), (122, 130, 'I_Disease')]}], ['These results indicate that behavioral toxicity testing of alkylxanthines in a single mouse strain may be misleading and suggest that toxic responses of the central nervous system to this class of compounds are genetically influenced in mammals .', {'entities': [(39, 47, 'B_Disease')]}], ['Treatment of ovarian cancer with a combination of cis - platinum , adriamycin , cyclophosphamide and hexamethylmelamine .', {'entities': [(13, 20, 'B_Disease'), (21, 27, 'I_Disease')]}], ['During the last 2 1 / 2 years , 38 patients with ovarian cancer were treated with a combination of cisplatinum ( CPDD ) , 50 mg / m2 , adriamycin , 30 mg / m2 , cyclophosphamide , 300 mg / m2 , on day 1 ; and hexamethylmelamine ( HMM ) , 6 mg / kg daily , for 14 days .', {'entities': [(49, 56, 'B_Disease'), (57, 63, 'I_Disease')]}], ['Hematologic toxicity was moderate and with reversible anemia developing in 71 % of patients .', {'entities': [(0, 11, 'B_Disease'), (12, 20, 'I_Disease'), (54, 60, 'B_Disease')]}], ['HMM gastrointestinal toxicity necessitated discontinuation of the drug in 5 patients .', {'entities': [(4, 20, 'B_Disease'), (21, 29, 'I_Disease')]}], ['Severe nephrotoxicity was observed in 2 patients but was reversible .', {'entities': [(7, 21, 'B_Disease')]}], ['Nontraumatic dissecting aneurysm of the basilar artery .', {'entities': [(13, 23, 'B_Disease'), (24, 32, 'I_Disease')]}], ['A case of nontraumatic dissecting aneurysm of the basilar artery in association with hypertension , smoke , and oral contraceptives is reported in a young female patient with a locked - in syndrome .', {'entities': [(23, 33, 'B_Disease'), (34, 42, 'I_Disease'), (85, 97, 'B_Disease'), (177, 183, 'B_Disease'), (184, 185, 'I_Disease'), (186, 188, 'I_Disease'), (189, 197, 'I_Disease')]}], ['A method for the measurement of tremor , and a comparison of the effects of tocolytic beta - mimetics .', {'entities': [(32, 38, 'B_Disease')]}], ['A method permitting measurement of finger tremor as a displacement - time curve is described , using a test system with simple amplitude calibration .', {'entities': [(42, 48, 'B_Disease')]}], ['By means of a computer program , periods and amplitudes of tremor oscillations were calculated and classified .', {'entities': [(59, 65, 'B_Disease')]}], ['At therapeutic doses both substances raised the mean tremor amplitude to about three times the control level .', {'entities': [(53, 59, 'B_Disease')]}], ['After the end of fenoterol - hydrobromide infusion , tremor amplitudes decreased significantly faster than those following ritodrin - HCl infusion .', {'entities': [(53, 59, 'B_Disease')]}], ['Propylthiouracil - induced hepatic damage .', {'entities': [(27, 34, 'B_Disease'), (35, 41, 'I_Disease')]}], ['Two cases of propylthiouracil - induced liver damage have been observed .', {'entities': [(40, 45, 'B_Disease'), (46, 52, 'I_Disease')]}], ['The first case is of an acute type of damage , proven by rechallenge ; the second presents a clinical and histologic picture resembling chronic active hepatitis , with spontaneous remission .', {'entities': [(136, 143, 'B_Disease'), (144, 150, 'I_Disease'), (151, 160, 'I_Disease')]}], ['Studies on the bradycardia induced by bepridil .', {'entities': [(15, 26, 'B_Disease')]}], ['Bepridil , a novel active compound for prophylactic treatment of anginal attacks , induced persistent bradycardia and a non - specific anti - tachycardial effect , the mechanisms of which were investigated in vitro and in vivo .', {'entities': [(65, 72, 'B_Disease'), (73, 80, 'I_Disease'), (102, 113, 'B_Disease'), (142, 154, 'B_Disease')]}], ['Hepatitis and renal tubular acidosis after anesthesia with methoxyflurane .', {'entities': [(0, 9, 'B_Disease'), (14, 19, 'B_Disease'), (20, 27, 'I_Disease'), (28, 36, 'I_Disease')]}], ['A 69 - year - old man operated for acute cholecystitis under methoxyflurane anesthesia developed postoperatively a hepatic insufficiency syndrome and renal tubular acidosis .', {'entities': [(35, 40, 'B_Disease'), (41, 54, 'I_Disease'), (115, 122, 'B_Disease'), (123, 136, 'I_Disease'), (137, 145, 'I_Disease'), (150, 155, 'B_Disease'), (156, 163, 'I_Disease'), (164, 172, 'I_Disease')]}], ['Massive bleeding appeared during surgery which lasted for six hours .', {'entities': [(8, 16, 'B_Disease')]}], ['Pituitary response to luteinizing hormone - releasing hormone during haloperidol - induced hyperprolactinemia .', {'entities': [(91, 109, 'B_Disease')]}], ['During the course of haloperidol infusions , significant hyperprolactinemia was found , together with an abolished pituitary response to LH - RH , as compared with responses of control subjects .', {'entities': [(57, 75, 'B_Disease')]}], ['Antirifampicin antibodies in acute rifampicin - associated renal failure .', {'entities': [(59, 64, 'B_Disease'), (65, 72, 'I_Disease')]}], ['5 patients with acute renal failure ( 3 with thrombopenia and hemolysis ) induced by the reintroduction of rifampicin are described .', {'entities': [(16, 21, 'B_Disease'), (22, 27, 'I_Disease'), (28, 35, 'I_Disease'), (45, 57, 'B_Disease'), (62, 71, 'B_Disease')]}], ['Antibodies suggested to be of the IgM class were detected in all 3 patients with hematological disorders .', {'entities': [(81, 94, 'B_Disease'), (95, 104, 'I_Disease')]}], ['The pattern of non - specific acute tubular necrosis found in the 2 biopsied patients , indistinguishable from that of ischemic origin , raised the possibility of a vascular - mediated damage .', {'entities': [(30, 35, 'B_Disease'), (36, 43, 'I_Disease'), (44, 52, 'I_Disease')]}], ['Cardiovascular effects of hypotension induced by adenosine triphosphate and sodium nitroprusside on dogs with denervated hearts .', {'entities': [(26, 37, 'B_Disease')]}], ['Adenosine triphosphate ( ATP ) and sodium nitroprusside ( SNP ) are administered to patients to induce and control hypotension during anesthesia .', {'entities': [(115, 126, 'B_Disease')]}], ['Before , during and after induced hypotension , we measured major cardiovascular parameters .', {'entities': [(34, 45, 'B_Disease')]}], ['Hypotension induced by ATP was accompanied by significant decreases in mean pulmonary arterial pressure ( p less than 0 . 001 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 001 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , total body oxygen consumption ( p less than 0 . 05 ) , and heart rate ( p less than 0 . 001 ) ; all these variables returned normal within 30 min after ATP was stopped .', {'entities': [(0, 11, 'B_Disease')]}], ['During hypotension produced by SNP similar decreases were observed in mean pulmonary arterial pressure ( p less than 0 . 01 ) , central venous pressure ( p less than 0 . 001 ) , left ventricular end - diastolic pressure ( p less than 0 . 01 ) , total peripheral resistance ( p less than 0 . 001 ) , rate pressure product ( p less than 0 . 001 ) , and oxygen content difference between arterial and mixed venous blood ( p less than 0 . 05 ) , while heart rate ( p less than 0 . 001 ) and cardiac output ( p less than 0 . 05 ) were increased .', {'entities': [(7, 18, 'B_Disease')]}], ['The Dimer - X group had a higher incidence of nausea and dizziness .', {'entities': [(46, 52, 'B_Disease'), (57, 66, 'B_Disease')]}], ['The Endografine group had a higher incidence of abdominal pain .', {'entities': [(48, 57, 'B_Disease'), (58, 62, 'I_Disease')]}], ['Hexabrix and Vasurix polyvidone are considered the best contrast media for hysterosalpingography and perhaps because of its low toxicity Hexabrix should be preferred .', {'entities': [(128, 136, 'B_Disease')]}], ['Post - suxamethonium pains in Nigerian surgical patients .', {'entities': [(21, 26, 'B_Disease')]}], ['Contrary to an earlier report by Coxon , scoline pain occurs in African negroes .', {'entities': [(49, 53, 'B_Disease')]}], ['About 62 % of the out - patients developed scoline pain as compared with about 26 % among the in - patients .', {'entities': [(51, 55, 'B_Disease')]}], ['The abolition of muscle fasciculations ( by 0 . 075mg / kg dose of Fazadinium ) did not influence the occurrence of scoline pain .', {'entities': [(24, 38, 'B_Disease'), (124, 128, 'B_Disease')]}], ['Neither the type of induction agent ( Althesin or Thiopentone ) nor the salt preparation of suxamethonium used ( chloride or bromide ) , affected the incidence of scoline pain .', {'entities': [(171, 175, 'B_Disease')]}], ['Invasive carcinoma of the renal pelvis following cyclophosphamide therapy for nonmalignant disease .', {'entities': [(9, 18, 'B_Disease'), (19, 21, 'I_Disease'), (22, 25, 'I_Disease'), (26, 31, 'I_Disease'), (32, 38, 'I_Disease')]}], ['A 47 - year - old woman with right hydroureteronephrosis due to ureterovesical junction obstruction had gross hematuria after being treated for five years wtih cyclophosphamide for cerebral vasculitis .', {'entities': [(35, 56, 'B_Disease'), (110, 119, 'B_Disease'), (181, 189, 'B_Disease'), (190, 200, 'I_Disease')]}], ['A right nephroureterectomy was required for control of bleeding .', {'entities': [(55, 63, 'B_Disease')]}], ['The pathology specimen contained clinically occult invasive carcinoma of the renal pelvis .', {'entities': [(60, 69, 'B_Disease'), (70, 72, 'I_Disease'), (73, 76, 'I_Disease'), (77, 82, 'I_Disease'), (83, 89, 'I_Disease')]}], ['Although the ability of cyclophosphamide to cause hemorrhagic cystitis and urine cytologic abnormalities indistinguishable from high grade carcinoma is well known , it is less widely appreciated that it is also associated with carcinoma of the urinary tract .', {'entities': [(50, 61, 'B_Disease'), (62, 70, 'I_Disease'), (139, 148, 'B_Disease'), (227, 236, 'B_Disease'), (237, 239, 'I_Disease'), (240, 243, 'I_Disease'), (244, 251, 'I_Disease'), (252, 257, 'I_Disease')]}], ['Twenty carcinomas of the urinary bladder and one carcinoma of the prostate have been reported in association with its use .', {'entities': [(7, 17, 'B_Disease'), (18, 20, 'I_Disease'), (21, 24, 'I_Disease'), (25, 32, 'I_Disease'), (33, 40, 'I_Disease'), (49, 58, 'B_Disease'), (59, 61, 'I_Disease'), (62, 65, 'I_Disease'), (66, 74, 'I_Disease')]}], ['The present case is the first carcinoma of the renal pelvis reported in association with cyclophosphamide treatment .', {'entities': [(30, 39, 'B_Disease'), (40, 42, 'I_Disease'), (43, 46, 'I_Disease'), (47, 52, 'I_Disease'), (53, 59, 'I_Disease')]}], ['It is the third urinary tract cancer reported in association with cyclophosphamide treatment for nonmalignant disease .', {'entities': [(16, 23, 'B_Disease'), (24, 29, 'I_Disease'), (30, 36, 'I_Disease')]}], ['The association of the tumor with preexisting hydroureteronephrosis suggests that stasis prolonged and intensified exposure of upper urinary tract epithelium to cyclophosphamide .', {'entities': [(23, 28, 'B_Disease'), (46, 67, 'B_Disease')]}], ['Patients who are candidates for long - term cyclophosphamide treatment should be routinely evaluated for obstructive uropathy .', {'entities': [(105, 116, 'B_Disease'), (117, 125, 'I_Disease')]}], ['Medial changes in arterial spasm induced by L - norepinephrine .', {'entities': [(27, 32, 'B_Disease')]}], ['In the media of the saphenous artery and its distal branch , vasoconstriction induced by L - norepinephrine produced many cell - to - cell hernias within 15 minutes .', {'entities': [(139, 146, 'B_Disease')]}], ['The experimental data are discussed in relation to medial changes observed in other instances of arterial spasm .', {'entities': [(106, 111, 'B_Disease')]}], ['Bilateral retinal artery and choriocapillaris occlusion following the injection of long - acting corticosteroid suspensions in combination with other drugs : I .', {'entities': [(10, 17, 'B_Disease'), (18, 24, 'I_Disease'), (25, 28, 'I_Disease'), (29, 45, 'I_Disease'), (46, 55, 'I_Disease')]}], ['Two well - documented cases of bilateral retinal artery and choriocapillaris occlusions with blindness following head and neck soft - tissue injection with methylprednisolone acetate in combination with lidocaine , epinephrine , or penicillin are reported .', {'entities': [(41, 48, 'B_Disease'), (49, 55, 'I_Disease'), (56, 59, 'I_Disease'), (60, 76, 'I_Disease'), (77, 87, 'I_Disease'), (93, 102, 'B_Disease')]}], ['The acute observations included hazy sensorium , superior gaze palsy , pupillary abnormalities , and conjunctival hemorrhages with edema .', {'entities': [(63, 68, 'B_Disease'), (71, 80, 'B_Disease'), (81, 94, 'I_Disease'), (114, 125, 'B_Disease'), (131, 136, 'B_Disease')]}], ['Follow - up changes showed marked visual loss , constricted visual fields , optic nerve pallor , vascular attenuation , and chorioretinal atrophy .', {'entities': [(34, 40, 'B_Disease'), (41, 45, 'I_Disease'), (124, 137, 'B_Disease'), (138, 145, 'I_Disease')]}], ['Abnormalities of the pupil and visual - evoked potential in quinine amblyopia .', {'entities': [(68, 77, 'B_Disease')]}], ['Total blindness with a transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials developed in a 54 - year - old man after the use of quinine sulfate for leg cramps .', {'entities': [(6, 15, 'B_Disease'), (33, 38, 'B_Disease'), (39, 48, 'I_Disease'), (203, 206, 'B_Disease'), (207, 213, 'I_Disease')]}], ['A transient tonic pupillary response , denervation supersensitivity , and abnormal visual - evoked potentials in quinine toxicity , to our knowledge , have not been previously reported .', {'entities': [(12, 17, 'B_Disease'), (18, 27, 'I_Disease'), (121, 129, 'B_Disease')]}], ['Suxamethonium - induced jaw stiffness and myalgia associated with atypical cholinesterase : case report .', {'entities': [(24, 27, 'B_Disease'), (28, 37, 'I_Disease'), (42, 49, 'B_Disease')]}], ['In response to this a marked jaw stiffness occurred which lasted for two minutes and the anaesthesia were terminated .', {'entities': [(29, 32, 'B_Disease'), (33, 42, 'I_Disease')]}], ['Four hours of apnoea ensued and he suffered generalized severe myalgia lasting for one week .', {'entities': [(14, 20, 'B_Disease'), (63, 70, 'B_Disease')]}], ['The case shows that prolonged jaw rigidity and myalgia may occur after suxamethonium in patients with atypical cholinesterase despite pretreatment with pancuronium .', {'entities': [(20, 29, 'B_Disease'), (30, 33, 'I_Disease'), (34, 42, 'I_Disease'), (47, 54, 'B_Disease')]}], ['Indomethacin - induced hyperkalemia in three patients with gouty arthritis .', {'entities': [(23, 35, 'B_Disease'), (59, 64, 'B_Disease'), (65, 74, 'I_Disease')]}], ['We describe three patients in whom severe , life - threatening hyperkalemia and renal insufficiency developed after treatment of acute gouty arthritis with indomethacin .', {'entities': [(63, 75, 'B_Disease'), (80, 85, 'B_Disease'), (86, 99, 'I_Disease'), (135, 140, 'B_Disease'), (141, 150, 'I_Disease')]}], ['This complication may result from an inhibition of prostaglandin synthesis and consequent hyporeninemic hypoaidosteronism .', {'entities': [(90, 103, 'B_Disease'), (104, 121, 'I_Disease')]}], ['Careful attention to renal function and potassium balance in patients receiving indomethacin or other nonsteroidal anti - inflammatory agents , particularly in those patients with diabetes mellitus or preexisting renal disease , will help prevent this potentially serious complication .', {'entities': [(180, 188, 'B_Disease'), (189, 197, 'I_Disease'), (213, 218, 'B_Disease'), (219, 226, 'I_Disease')]}], ['Venous pain occurred in 68 % of patients and 50 % had redness , pain or swelling related to the injection site , in some cases lasting up to three weeks after anaesthesia .', {'entities': [(7, 11, 'B_Disease'), (64, 68, 'B_Disease'), (72, 80, 'B_Disease')]}], ['Skeletal movements occurred in 50 % of patients ; 30 % experienced respiratory upset , one sufficiently severe to necessitate abandoning the technique .', {'entities': [(67, 78, 'B_Disease'), (79, 84, 'I_Disease')]}], ['Nausea and vomiting occurred in 40 % and 25 % had disturbing emergence psychoses .', {'entities': [(0, 6, 'B_Disease'), (11, 19, 'B_Disease'), (71, 80, 'B_Disease')]}], ['Levodopa - induced dyskinesias are improved by fluoxetine .', {'entities': [(19, 30, 'B_Disease')]}], [\"We evaluated the severity of motor disability and dyskinesias in seven levodopa - responsive patients with Parkinson ' s disease after an acute challenge with the mixed dopamine agonist , apomorphine , before and after the administration of fluoxetine ( 20 mg twice per day ) for 11 + / - 1 days .\", {'entities': [(29, 34, 'B_Disease'), (35, 45, 'I_Disease'), (50, 61, 'B_Disease'), (107, 116, 'B_Disease'), (117, 118, 'I_Disease'), (119, 120, 'I_Disease'), (121, 128, 'I_Disease')]}], ['After fluoxetine treatment , there was a significant 47 % improvement ( p < 0 . 05 ) of apomorphine - induced dyskinesias without modification of parkinsonian motor disability .', {'entities': [(110, 121, 'B_Disease'), (146, 158, 'B_Disease'), (159, 164, 'B_Disease'), (165, 175, 'I_Disease')]}], ['The dyskinesias were reduced predominantly in the lower limbs during the onset and disappearance of dystonic dyskinesias ( onset - and end - of - dose dyskinesias ) and in the upper limbs during choreic mid - dose dyskinesias .', {'entities': [(4, 15, 'B_Disease'), (100, 108, 'B_Disease'), (109, 120, 'I_Disease'), (151, 162, 'B_Disease'), (195, 202, 'B_Disease'), (203, 206, 'I_Disease'), (207, 208, 'I_Disease'), (209, 213, 'I_Disease'), (214, 225, 'I_Disease')]}], ['The results suggest that increased brain serotoninergic transmission with fluoxetine may reduce levodopa - or dopamine agonist - induced dyskinesias without aggravating parkinsonian motor disability .', {'entities': [(137, 148, 'B_Disease'), (169, 181, 'B_Disease'), (182, 187, 'B_Disease'), (188, 198, 'I_Disease')]}], ['A large population - based follow - up study of trimethoprim - sulfamethoxazole , trimethoprim , and cephalexin for uncommon serious drug toxicity .', {'entities': [(133, 137, 'B_Disease'), (138, 146, 'I_Disease')]}], ['We conducted a population - based 45 - day follow - up study of 232 , 390 people who were prescribed trimethoprim - sulfamethoxazole ( TMP - SMZ ) , 266 , 951 prescribed trimethoprim alone , and 196 , 397 prescribed cephalexin , to estimate the risk of serious liver , blood , skin , and renal disorders resulting in referral or hospitalization associated with these drugs .', {'entities': [(261, 266, 'B_Disease'), (267, 268, 'I_Disease'), (269, 274, 'I_Disease'), (275, 276, 'I_Disease'), (277, 281, 'I_Disease'), (282, 283, 'I_Disease'), (284, 287, 'I_Disease'), (288, 293, 'I_Disease'), (294, 303, 'I_Disease')]}], ['The risk of clinically important idiopathic liver disease was similar for persons prescribed TMP - SMZ ( 5 . 2 / 100 , 000 ) and those prescribed trimethoprim alone ( 3 . 8 / 100 , 000 ) .', {'entities': [(44, 49, 'B_Disease'), (50, 57, 'I_Disease')]}], ['Only five patients experienced blood disorders , one of whom was exposed to TMP - SMZ ; of seven with erythema multiforme and Stevens - Johnson syndrome , four were exposed to TMP - SMZ .', {'entities': [(102, 110, 'B_Disease'), (111, 121, 'I_Disease'), (126, 133, 'B_Disease'), (134, 135, 'I_Disease'), (136, 143, 'I_Disease'), (144, 152, 'I_Disease')]}], ['The one case of toxic epidermal necrolysis occurred in a patient who took cephalexin .', {'entities': [(16, 21, 'B_Disease'), (22, 31, 'I_Disease'), (32, 42, 'I_Disease')]}], ['Finally , only five cases of acute parenchymal renal disease occurred , none likely to be caused by a study drug .', {'entities': [(47, 52, 'B_Disease'), (53, 60, 'I_Disease')]}], ['Clinical safety of lidocaine in patients with cocaine - associated myocardial infarction .', {'entities': [(67, 77, 'B_Disease'), (78, 88, 'I_Disease')]}], ['STUDY OBJECTIVE : To evaluate the safety of lidocaine in the setting of cocaine - induced myocardial infarction ( MI ) .', {'entities': [(90, 100, 'B_Disease'), (101, 111, 'I_Disease'), (114, 116, 'B_Disease')]}], ['PARTICIPANTS : Patients with cocaine - associated MI who received lidocaine in the emergency department .', {'entities': [(50, 52, 'B_Disease')]}], ['RESULTS : Of 29 patients who received lidocaine in the setting of cocaine - associated MI , no patient died ; exhibited bradydysrhythmias , ventricular tachycardia , or ventricular fibrillation ; or experienced seizures after administration of lidocaine ( 95 % confidence interval , 0 % to 11 % ) .', {'entities': [(87, 89, 'B_Disease'), (120, 137, 'B_Disease'), (140, 151, 'B_Disease'), (152, 163, 'I_Disease'), (169, 180, 'B_Disease'), (181, 193, 'I_Disease'), (211, 219, 'B_Disease')]}], ['CONCLUSION : Despite theoretical concerns that lidocaine may enhance cocaine toxicity , the use of lidocaine in patients with cocaine - associated MI was not associated with significant cardiovascular or central nervous system toxicity .', {'entities': [(77, 85, 'B_Disease'), (147, 149, 'B_Disease'), (186, 200, 'B_Disease'), (201, 203, 'I_Disease'), (204, 211, 'I_Disease'), (212, 219, 'I_Disease'), (220, 226, 'I_Disease'), (227, 235, 'I_Disease')]}], ['Experimental progressive muscular dystrophy and its treatment with high doses anabolizing agents .', {'entities': [(25, 33, 'B_Disease'), (34, 43, 'I_Disease')]}], ['We are still a long way from discovering an unequivocal pathogenetic interpretation of progressive muscular dystrophy in man .', {'entities': [(99, 107, 'B_Disease'), (108, 117, 'I_Disease')]}], ['Myopathy due to lack of vitamin E and myopathy induced by certain viruses have much in common anatomically and pathologically with the human form .', {'entities': [(0, 8, 'B_Disease'), (38, 46, 'B_Disease')]}], ['The authors induced myodystrophy in the rat by giving it a diet lacking in vitamin E .', {'entities': [(20, 32, 'B_Disease')]}], ['It is thus confirmed that the histological characteristics of myopathic rat muscle induced experimentally are extraordinarily similar to those of human myopathy as confirmed during biopsies performed at the Orthopaedic Traumatological Centre , Florence .', {'entities': [(62, 71, 'B_Disease'), (152, 160, 'B_Disease')]}], ['The encouraging results obtained in various authoratative departments in myopathic patients by using anabolizing steroids have encouraged the authors to investigate the beneficial effects of one anabolizing agent ( Dianabol , CIBA ) at high doses in rats rendered myopathic by a diet deficient in vitamin E .', {'entities': [(73, 82, 'B_Disease'), (264, 273, 'B_Disease')]}], ['In this way they obtained appreciable changes in body weight ( increased from 50 to 70 g after forty days at a dose of 5 mg per day of anabolizing agent ) , but most of all they found histological changes due to \" regenerative \" changes in the muscle tissue , which however maintained its myopathic characteristics in the control animals that were not treated with the anabolizing agent .', {'entities': [(289, 298, 'B_Disease')]}], ['The authors conclude by affirming the undoubted efficacy of the anabolizing steroids in experimental myopathic disease , but they have reservations as to the transfer of the results into the human field , where high dosage cannot be carried out continuously because of the effects of the drug on virility ; because the tissue injury too often occurs at an irreversible stage vis - a - vis the \" regeneration \" of the muscle tissue ; and finally because the dystrophic injurious agent is certainly not the lack of vitamin E but something as yet unknown .', {'entities': [(101, 110, 'B_Disease'), (111, 118, 'I_Disease')]}], ['Paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) by 3 - hour infusion was combined with carboplatin in a phase I / II study directed to patients with non - small cell lung cancer .', {'entities': [(172, 175, 'B_Disease'), (176, 177, 'I_Disease'), (178, 183, 'I_Disease'), (184, 188, 'I_Disease'), (189, 193, 'I_Disease'), (194, 200, 'I_Disease')]}], ['The 225 mg / m2 level was expanded for the phase II study since the highest level achieved ( 250 mg / m2 ) required modification because of nonhematologic toxicities ( arthralgia and sensory neuropathy ) .', {'entities': [(155, 165, 'B_Disease'), (168, 178, 'B_Disease'), (183, 190, 'B_Disease'), (191, 201, 'I_Disease')]}], ['Toxicities were compared with a cohort of patients in a phase I trial of paclitaxel alone at identical dose levels .', {'entities': [(0, 10, 'B_Disease')]}], ['Carboplatin did not appear to add to the hematologic toxicities observed , and the paclitaxel / carboplatin combination could be dosed every 3 weeks .', {'entities': [(41, 52, 'B_Disease'), (53, 63, 'I_Disease')]}], ['The dose - dependent effect of misoprostol on indomethacin - induced renal dysfunction in well compensated cirrhosis .', {'entities': [(69, 74, 'B_Disease'), (75, 86, 'I_Disease'), (107, 116, 'B_Disease')]}], ['Misoprostol ( 200 micrograms ) has been shown to acutely counteract the indomethacin - induced renal dysfunction in well compensated cirrhotic patients .', {'entities': [(95, 100, 'B_Disease'), (101, 112, 'I_Disease'), (133, 142, 'B_Disease')]}], ['Parameters of renal hemodynamics and tubular sodium and water handling were assessed by clearance techniques in 26 well compensated cirrhotic patients before and after an oral combination of 50 mg of indomethacin and various doses of misoprostol .', {'entities': [(132, 141, 'B_Disease')]}], ['However , until this apparent ability of 200 micrograms of misoprostol to prevent the adverse effects of indomethacin on renal function is confirmed with chronic frequent dosing , it would be prudent to avoid nonsteroidal anti - inflammatory therapy in patients with cirrhosis .', {'entities': [(267, 276, 'B_Disease')]}], ['Increased frequency and severity of angio - oedema related to long - term therapy with angiotensin - converting enzyme inhibitor in two patients .', {'entities': [(36, 41, 'B_Disease'), (42, 43, 'I_Disease'), (44, 50, 'I_Disease')]}], ['Adverse reactions to drugs are well recognized as a cause of acute or chronic urticaria , and angio - oedema .', {'entities': [(78, 87, 'B_Disease'), (94, 99, 'B_Disease'), (100, 101, 'I_Disease'), (102, 108, 'I_Disease')]}], ['Angiotensin - converting enzyme ( ACE ) inhibitors , used to treat hypertension and congestive heart failure , were introduced in Europe in the middle of the eighties , and the use of these drugs has increased progressively .', {'entities': [(67, 79, 'B_Disease'), (84, 94, 'B_Disease'), (95, 100, 'I_Disease'), (101, 108, 'I_Disease')]}], ['Soon after the introduction of ACE inhibitors , acute bouts of angio - oedema were reported in association with the use of these drugs .', {'entities': [(63, 68, 'B_Disease'), (69, 70, 'I_Disease'), (71, 77, 'I_Disease')]}], ['We wish to draw attention to the possibility of adverse reactions to ACE inhibitors after long - term use and in patients with pre - existing angio - oedema .', {'entities': [(142, 147, 'B_Disease'), (148, 149, 'I_Disease'), (150, 156, 'I_Disease')]}], ['Myoclonus associated with lorazepam therapy in very - low - birth - weight infants .', {'entities': [(0, 9, 'B_Disease')]}], ['Three young infants , all of birth weight < 1 , 500 g , experienced myoclonus following the intravenous administration of lorazepam .', {'entities': [(68, 77, 'B_Disease')]}], ['The potential neurotoxic effects of the drug ( and its vehicle ) in this population are discussed .', {'entities': [(14, 24, 'B_Disease')]}], ['Transvenous right ventricular pacing during cardiopulmonary resuscitation of pediatric patients with acute cardiomyopathy .', {'entities': [(107, 121, 'B_Disease')]}], ['We describe the cardiopulmonary resuscitation efforts on five patients who presented in acute circulatory failure from myocardial dysfunction .', {'entities': [(94, 105, 'B_Disease'), (106, 113, 'I_Disease'), (119, 129, 'B_Disease'), (130, 141, 'I_Disease')]}], ['Three patients had acute viral myocarditis , one had a carbamazepine - induced acute eosinophilic myocarditis , and one had cardiac hemosiderosis resulting in acute cardiogenic shock .', {'entities': [(31, 42, 'B_Disease'), (85, 97, 'B_Disease'), (98, 109, 'I_Disease'), (165, 176, 'B_Disease'), (177, 182, 'I_Disease')]}], ['An introducer sheath , a pacemaker , and sterile pacing wires were made readily available for the patients , should the need arise to terminate resistant cardiac dysrhythmias .', {'entities': [(162, 174, 'B_Disease')]}], ['All patients developed cardiocirculatory arrest associated with extreme hypotension and dysrhythmias within the first 48 hours of their admission to the pediatric intensive care unit ( PICU ) .', {'entities': [(72, 83, 'B_Disease'), (88, 100, 'B_Disease')]}], ['These patients had a second event of cardiac arrest , resulting in death , within 10 to 60 minutes .', {'entities': [(37, 44, 'B_Disease'), (45, 51, 'I_Disease')]}], ['We conclude that cardiac pacing during resuscitative efforts in pediatric patients suffering from acute myocardial dysfunction may not have long - term value in and of itself ; however , if temporary hemodynamic stability is achieved by this procedure , it may provide additional time needed to institute other therapeutic modalities .', {'entities': [(104, 114, 'B_Disease'), (115, 126, 'I_Disease')]}], ['Efficacy and safety of granisetron , a selective 5 - hydroxytryptamine - 3 receptor antagonist , in the prevention of nausea and vomiting induced by high - dose cisplatin .', {'entities': [(118, 124, 'B_Disease'), (129, 137, 'B_Disease')]}], ['PURPOSE : To assess the antiemetic effects and safety profile of four different doses of granisetron ( Kytril ; SmithKline Beecham Pharmaceuticals , Philadelphia , PA ) when administered as a single intravenous ( IV ) dose for prophylaxis of cisplatin - induced nausea and vomiting .', {'entities': [(262, 268, 'B_Disease'), (273, 281, 'B_Disease')]}], ['Patients were observed on an inpatient basis for 18 to 24 hours , and vital signs , nausea , vomiting , retching , and appetite were assessed .', {'entities': [(84, 90, 'B_Disease'), (93, 101, 'B_Disease')]}], ['RESULTS : After granisetron doses of 5 , 10 , 20 , and 40 micrograms / kg , a major response ( < or = two vomiting or retching episodes , and no antiemetic rescue ) was recorded in 23 % , 57 % , 58 % , and 60 % of patients , respectively , and a complete response ( no vomiting or retching , and no antiemetic rescue ) in 18 % , 41 % , 40 % , and 47 % of patients , respectively .', {'entities': [(106, 114, 'B_Disease'), (269, 277, 'B_Disease')]}], ['There was a statistically longer time to first episode of nausea ( P = . 0015 ) and vomiting ( P = . 0001 ) , and fewer patients were administered additional antiemetic medication in the 10 - micrograms / kg dosing groups than in the 5 - micrograms / kg dosing group .', {'entities': [(58, 64, 'B_Disease'), (84, 92, 'B_Disease')]}], ['Headache was the most frequently reported adverse event ( 20 % ) .', {'entities': [(0, 8, 'B_Disease')]}], ['CONCLUSION : A single 10 - , 20 - , or 40 - micrograms / kg dose of granisetron was effective in controlling vomiting in 57 % to 60 % of patients who received cisplatin at doses greater than 81 mg / m2 and totally prevented vomiting in 40 % to 47 % of patients .', {'entities': [(109, 117, 'B_Disease'), (224, 232, 'B_Disease')]}], ['OBJECTIVE : To report two cases of a possible adverse interaction between clonidine and verapamil resulting in atrioventricular ( AV ) block in both patients and severe hypotension in one patient .', {'entities': [(111, 127, 'B_Disease'), (128, 129, 'I_Disease'), (130, 132, 'I_Disease'), (133, 134, 'I_Disease'), (135, 140, 'I_Disease'), (169, 180, 'B_Disease')]}], ['CASE SUMMARIES : A 54 - year - old woman with hyperaldosteronism was treated with verapamil 480 mg / d and spironolactone 100 mg / d .', {'entities': [(46, 64, 'B_Disease')]}], ['After the addition of a minimal dose of clonidine ( 0 . 15 mg bid ) , she developed complete AV block and severe hypotension , which resolved upon cessation of all medications .', {'entities': [(93, 95, 'B_Disease'), (96, 101, 'I_Disease'), (113, 124, 'B_Disease')]}], ['After the addition of clonidine 0 . 15 mg bid she developed complete AV block , which resolved after all therapy was stopped .', {'entities': [(69, 71, 'B_Disease'), (72, 77, 'I_Disease')]}], ['S - 312 , S - 312 - d , but not S - 312 - l , L - type calcium channel antagonists , showed anticonvulsant effects on the audiogenic tonic convulsions in DBA / 2 mice ; and their ED50 values were 18 . 4 ( 12 . 8 - 27 . 1 ) mg / kg , p . o . and 15 . 0 ( 10 . 2 - 23 . 7 ) mg / kg , p . o . , respectively , while that of flunarizine was 34 . 0 ( 26 . 0 - 44 . 8 ) mg / kg , p . o .', {'entities': [(122, 132, 'B_Disease'), (133, 138, 'I_Disease'), (139, 150, 'I_Disease')]}], ['Although moderate anticonvulsant effects of S - 312 - d in higher doses were observed against the clonic convulsions induced by pentylenetetrazole ( 85 mg / kg , s . c . ) or bemegride ( 40 mg / kg , s . c . ) , no effects were observed in convulsions induced by N - methyl - D - aspartate , picrotoxin , or electroshock in Slc : ddY mice .', {'entities': [(105, 116, 'B_Disease'), (240, 251, 'B_Disease')]}], ['S - 312 - d may be useful in the therapy of certain types of human epilepsy .', {'entities': [(67, 75, 'B_Disease')]}], ['Transmural myocardial infarction with sumatriptan .', {'entities': [(11, 21, 'B_Disease'), (22, 32, 'I_Disease')]}], ['We describe a 47 - year - old woman with an acute myocardial infarction after administration of sumatriptan 6 mg subcutaneously for cluster headache .', {'entities': [(50, 60, 'B_Disease'), (61, 71, 'I_Disease'), (132, 139, 'B_Disease'), (140, 148, 'I_Disease')]}], [\"The patient had no history of underlying ischaemic heart disease or Prinzmetal ' s angina .\", {'entities': [(41, 50, 'B_Disease'), (51, 56, 'I_Disease'), (57, 64, 'I_Disease'), (68, 78, 'B_Disease'), (79, 80, 'I_Disease'), (81, 82, 'I_Disease'), (83, 89, 'I_Disease')]}], ['Flumazenil induces seizures and death in mixed cocaine - diazepam intoxications .', {'entities': [(19, 27, 'B_Disease')]}], ['STUDY HYPOTHESIS : Administration of the benzodiazepine antagonist flumazenil may unmask seizures in mixed cocaine - benzodiazepine intoxication .', {'entities': [(89, 97, 'B_Disease')]}], ['Animal behavior , seizures ( time to and incidence ) , death ( time to and incidence ) , and cortical EEG tracings were recorded .', {'entities': [(18, 26, 'B_Disease')]}], ['This resulted in 100 % developing seizures and death .', {'entities': [(34, 42, 'B_Disease')]}], ['This resulted in no overt or EEG - detectable seizures and a 50 % incidence of death .', {'entities': [(46, 54, 'B_Disease')]}], ['This resulted in an increased incidence of seizures , 90 % ( P < . 01 ) , and death , 100 % ( P < or = . 01 ) , compared with group 4 .', {'entities': [(43, 51, 'B_Disease')]}], ['This also resulted in an increased incidence of seizures , 90 % ( P < or = . 01 ) , and death , 90 % ( P < or = . 05 ) , compared with group 4 .', {'entities': [(48, 56, 'B_Disease')]}], ['CONCLUSION : Flumazenil can unmask seizures and increase the incidence of death in a model of combined cocaine - diazepam intoxications .', {'entities': [(35, 43, 'B_Disease')]}], ['Mechanisms for protective effects of free radical scavengers on gentamicin - mediated nephropathy in rats .', {'entities': [(86, 97, 'B_Disease')]}], ['Studies were performed to examine the mechanisms for the protective effects of free radical scavengers on gentamicin ( GM ) - mediated nephropathy .', {'entities': [(135, 146, 'B_Disease')]}], ['Administration of GM at 40 mg / kg sc for 13 days to rats induced a significant reduction in renal blood flow ( RBF ) and inulin clearance ( CIn ) as well as marked tubular damage .', {'entities': [(165, 172, 'B_Disease'), (173, 179, 'I_Disease')]}], [\"A significant reduction in urinary guanosine 3 ' , 5 ' - cyclic monophosphate ( cGMP ) excretion and a significant increase in renal cortical renin and endothelin - 1 contents were also observed in GM - mediated nephropathy .\", {'entities': [(212, 223, 'B_Disease')]}], ['SOD did not attenuate the tubular damage .', {'entities': [(26, 33, 'B_Disease'), (34, 40, 'I_Disease')]}], ['In contrast , DMTU significantly reduced the tubular damage and lipid peroxidation , but it did not affect renal hemodynamics and vasoactive substances .', {'entities': [(45, 52, 'B_Disease'), (53, 59, 'I_Disease')]}], ['These results suggest that 1 ) both SOD and DMTU have protective effects on GM - mediated nephropathy , 2 ) the mechanisms for the protective effects differ for SOD and DMTU , and 3 ) superoxide anions play a critical role in GM - induced renal vasoconstriction .', {'entities': [(90, 101, 'B_Disease')]}], ['Cephalothin - induced immune hemolytic anemia .', {'entities': [(29, 38, 'B_Disease'), (39, 45, 'I_Disease')]}], ['A patient with renal disease developed Coombs - positive hemolytic anemia while receiving cephalothin therapy .', {'entities': [(15, 20, 'B_Disease'), (21, 28, 'I_Disease'), (57, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['Careful investigation of drug - induced hemolytic anemias reveals the complexity of the immune mechanisms involved .', {'entities': [(40, 49, 'B_Disease'), (50, 57, 'I_Disease')]}], ['Assessment of cardiomyocyte DNA synthesis during hypertrophy in adult mice .', {'entities': [(49, 60, 'B_Disease')]}], ['The ability of cardiomyocytes to synthesize DNA in response to experimentally induced cardiac hypertrophy was assessed in adult mice .', {'entities': [(86, 93, 'B_Disease'), (94, 105, 'I_Disease')]}], ['No DNA synthesis , as assessed by autoradiographic analysis of isolated cardiomyocytes , was observed in control or hypertrophic hearts .', {'entities': [(116, 128, 'B_Disease'), (129, 135, 'I_Disease')]}], ['To determine whether the capacity for reactive DNA synthesis was also subject to genetic regulation , cardiac hypertrophy was induced in the strains of mice comprising the extremes of the nuclear number survey .', {'entities': [(102, 109, 'B_Disease'), (110, 121, 'I_Disease')]}], ['These data indicate that adult mouse atrial and ventricular cardiomyocytes do not synthesize DNA in response to isoproterenol - induced cardiac hypertrophy .', {'entities': [(136, 143, 'B_Disease'), (144, 155, 'I_Disease')]}], ['Central cardiovascular effects of AVP and ANP in normotensive and spontaneously hypertensive rats .', {'entities': [(80, 92, 'B_Disease')]}], ['The purpose of the present study was to compare influence of central arginine vasopressin ( AVP ) and of atrial natriuretic peptide ( ANP ) on control of arterial blood pressure ( MAP ) and heart rate ( HR ) in normotensive ( WKY ) and spontaneously hypertensive ( SHR ) rats .', {'entities': [(250, 262, 'B_Disease')]}], ['Sensitivity of cardiac component of baroreflex ( CCB ) , expressed as a slope of the regression line was determined from relationships between systolic arterial pressure ( SAP ) and HR period ( HRp ) during phenylephrine ( Phe ) - induced hypertension and sodium nitroprusside ( SN ) - induced hypotension .', {'entities': [(239, 251, 'B_Disease'), (294, 305, 'B_Disease')]}], ['CCB was reduced in WKY and SHR after LV administration of AVP during SN - induced hypotension .', {'entities': [(82, 93, 'B_Disease')]}], ['Cutaneous exposure to warfarin - like anticoagulant causing an intracerebral hemorrhage : a case report .', {'entities': [(63, 76, 'B_Disease'), (77, 87, 'I_Disease')]}], ['A case of intercerebral hematoma due to warfarin - induced coagulopathy is presented .', {'entities': [(24, 32, 'B_Disease'), (59, 71, 'B_Disease')]}], ['Percutaneous absorption of warfarin causing coagulopathy , reported three times in the past , is a significant risk if protective measures , such as gloves , are not used .', {'entities': [(44, 56, 'B_Disease')]}], ['An adverse drug interaction with piroxicam , which she took occasionally , may have exacerbated the coagulopathy .', {'entities': [(100, 112, 'B_Disease')]}], ['Indications for transplantation were idiopathic cardiomyopathy ( 52 % ) , congenital heart disease ( 35 % ) with and without prior repair ( 71 % and 29 % , respectively ) , hypertrophic cardiomyopathy ( 5 % ) , valvular heart disease ( 3 % ) , and doxorubicin cardiomyopathy ( 5 % ) .', {'entities': [(37, 47, 'B_Disease'), (48, 62, 'I_Disease'), (74, 84, 'B_Disease'), (85, 90, 'I_Disease'), (91, 98, 'I_Disease'), (173, 185, 'B_Disease'), (186, 200, 'I_Disease'), (211, 219, 'B_Disease'), (220, 225, 'I_Disease'), (226, 233, 'I_Disease'), (260, 274, 'B_Disease')]}], ['There have been no deaths related to rejection or infection .', {'entities': [(50, 59, 'B_Disease')]}], ['Freedom from serious infections was 83 % at 1 month and 65 % at 1 year .', {'entities': [(21, 31, 'B_Disease')]}], ['Cytomegalovirus infections were treated successfully with ganciclovir in 11 patients .', {'entities': [(0, 15, 'B_Disease'), (16, 26, 'I_Disease')]}], ['Twenty - one patients ( 60 % ) have undergone annual catheterizations and no sign of graft atherosclerosis has been observed .', {'entities': [(91, 106, 'B_Disease')]}], ['Seizures occurred in five patients ( 14 % ) and hypertension was treated in 10 patients ( 28 % ) .', {'entities': [(0, 8, 'B_Disease'), (48, 60, 'B_Disease')]}], ['No patient was disabled and no lymphoproliferative disorder was observed . ( ABSTRACT TRUNCATED AT 250 WORDS )', {'entities': [(31, 50, 'B_Disease'), (51, 59, 'I_Disease')]}], ['Delirium during fluoxetine treatment .', {'entities': [(0, 8, 'B_Disease')]}], ['In some cases , a high serum concentration of citalopram ( > 600 nmol / L ) in elderly patients has been associated with increased somnolence and movement difficulties .', {'entities': [(131, 141, 'B_Disease'), (146, 154, 'B_Disease'), (155, 167, 'I_Disease')]}], ['Widespread cognitive disorders , such as delirium , have not been previously linked with high blood levels of SSRIs .', {'entities': [(11, 20, 'B_Disease'), (21, 30, 'I_Disease'), (41, 49, 'B_Disease')]}], ['In this report , we describe a patient with acute hyperkinetic delirium connected with a high serum total fluoxetine ( fluoxetine plus desmethylfluoxetine ) concentration .', {'entities': [(50, 62, 'B_Disease'), (63, 71, 'B_Disease')]}], ['Pulmonary edema and shock after high - dose aracytine - C for lymphoma ; possible role of TNF - alpha and PAF .', {'entities': [(0, 9, 'B_Disease'), (10, 15, 'I_Disease'), (20, 25, 'B_Disease'), (62, 70, 'B_Disease')]}], ['Four out of 23 consecutive patients treated with high - dose Ara - C for lymphomas in our institution developed a strikingly similar syndrome during the perfusion .', {'entities': [(73, 82, 'B_Disease')]}], ['It was characterized by the onset of fever , diarrhea , shock , pulmonary edema , acute renal failure , metabolic acidosis , weight gain and leukocytosis .', {'entities': [(37, 42, 'B_Disease'), (45, 53, 'B_Disease'), (56, 61, 'B_Disease'), (64, 73, 'B_Disease'), (74, 79, 'I_Disease'), (82, 87, 'B_Disease'), (88, 93, 'I_Disease'), (94, 101, 'I_Disease'), (104, 113, 'B_Disease'), (114, 122, 'I_Disease'), (125, 131, 'B_Disease'), (132, 136, 'I_Disease'), (141, 153, 'B_Disease')]}], ['Thorough bacteriological screening failed to provide evidence of infection .', {'entities': [(65, 74, 'B_Disease')]}], ['As TNF and PAF are thought to be involved in the development of septic shock and adult respiratory distress syndrome , we hypothesize that high - dose Ara - C may be associated with cytokine release .', {'entities': [(71, 76, 'B_Disease'), (81, 86, 'B_Disease'), (87, 98, 'I_Disease'), (99, 107, 'I_Disease'), (108, 116, 'I_Disease')]}], ['Protective effect of clentiazem against epinephrine - induced cardiac injury in rats .', {'entities': [(62, 69, 'B_Disease'), (70, 76, 'I_Disease')]}], ['We investigated the effects of clentiazem , a 1 , 5 - benzothiazepine calcium antagonist , on epinephrine - induced cardiomyopathy in rats .', {'entities': [(116, 130, 'B_Disease')]}], ['With 2 - week chronic epinephrine infusion , 16 of 30 rats died within 4 days , and severe ischemic lesions and fibrosis of the left ventricles were observed .', {'entities': [(91, 99, 'B_Disease'), (100, 107, 'I_Disease'), (112, 120, 'B_Disease')]}], ['Treatment with clentiazem prevented epinephrine - induced death ( P < . 05 ) , and attenuated the ventricular ischemic lesions and fibrosis , in a dose - dependent manner .', {'entities': [(110, 118, 'B_Disease'), (119, 126, 'I_Disease'), (131, 139, 'B_Disease')]}], ['In conclusion , clentiazem attenuated epinephrine - induced cardiac injury , possibly through its effect on the adrenergic pathway .', {'entities': [(60, 67, 'B_Disease'), (68, 74, 'I_Disease')]}], ['Kaliuretic effect of L - dopa treatment in parkinsonian patients .', {'entities': [(43, 55, 'B_Disease')]}], ['Hypokalemia , sometimes severe , was observed in some L - dopa - treated parkinsonian patients .', {'entities': [(0, 11, 'B_Disease'), (73, 85, 'B_Disease')]}], ['The influence of L - dopa on the renal excretion of potassium was studied in 3 patients with hypokalemia and in 5 normokalemic patients by determination of renal plasma flow , glomerular filtration rate , plasma concentration of potassium and sodium as well as urinary excretion of potassium , sodium and aldosterone .', {'entities': [(93, 104, 'B_Disease')]}], ['Cocaine induced myocardial ischemia .', {'entities': [(16, 26, 'B_Disease'), (27, 35, 'I_Disease')]}], ['We report a case of myocardial ischemia induced by cocaine .', {'entities': [(20, 30, 'B_Disease'), (31, 39, 'I_Disease')]}], ['The ischemia probably induced by coronary artery spasm was reversed by nitroglycerin and calcium blocking agents .', {'entities': [(4, 12, 'B_Disease'), (33, 41, 'B_Disease'), (42, 48, 'I_Disease'), (49, 54, 'I_Disease')]}], ['Doxorubicin - induced cardiotoxicity monitored by ECG in freely moving mice .', {'entities': [(22, 36, 'B_Disease')]}], ['In laboratory animals , histology is most commonly used to study doxorubicin - induced cardiotoxicity .', {'entities': [(87, 101, 'B_Disease')]}], ['After sacrifice the hearts of doxorubicin - treated animals were enlarged and the atria were hypertrophic .', {'entities': [(93, 105, 'B_Disease')]}], ['As this schedule exerted more toxicity than needed to investigate protective agents , the protection of ICRF - 187 was determined using a dose schedule with lower general toxicity ( 6 weekly doses of 4 mg / kg doxorubicin given i . v . plus 2 weeks of observation ) .', {'entities': [(30, 38, 'B_Disease'), (171, 179, 'B_Disease')]}], ['The results indicate that this new model is very sensitive and enables monitoring of the development of cardiotoxicity with time .', {'entities': [(104, 118, 'B_Disease')]}], ['These findings result in a model that allows the testing of protectors against doxorubicin - induced cardiotoxicity as demonstrated by the protection provided by ICRF - 187 .', {'entities': [(101, 115, 'B_Disease')]}], ['Since bupivacaine and epinephrine may both precipitate dysrhythmias , circulating bupivacaine during regional anesthesia could potentiate dysrhythmogenic effects of epinephrine .', {'entities': [(55, 67, 'B_Disease')]}], ['We therefore examined whether bupivacaine alters the dysrhythmogenicity of subsequent administration of epinephrine in conscious , healthy dogs and in anesthetized dogs with myocardial infarction .', {'entities': [(174, 184, 'B_Disease'), (185, 195, 'I_Disease')]}], ['Seventeen animals responded with ventricular tachycardia ( VT ) within 3 min .', {'entities': [(33, 44, 'B_Disease'), (45, 56, 'I_Disease'), (59, 61, 'B_Disease')]}], ['VT appeared in fewer dogs and at a later time , and there were more sinoatrial beats and less ectopies .', {'entities': [(0, 2, 'B_Disease')]}], ['One day after experimental myocardial infarction , six additional halothane - anesthetized dogs received 4 micrograms . kg - 1 . min - 1 epinephrine until VT appeared .', {'entities': [(27, 37, 'B_Disease'), (38, 48, 'I_Disease'), (155, 157, 'B_Disease')]}], ['Bupivacaine antagonizes epinephrine dysrhythmogenicity in conscious dogs susceptible to VT and in anesthetized dogs with spontaneous postinfarct dysrhythmias .', {'entities': [(88, 90, 'B_Disease'), (145, 157, 'B_Disease')]}], ['Milk - alkali syndrome induced by 1 , 25 ( OH ) 2D in a patient with hypoparathyroidism .', {'entities': [(0, 4, 'B_Disease'), (5, 6, 'I_Disease'), (7, 13, 'I_Disease'), (14, 22, 'I_Disease'), (69, 87, 'B_Disease')]}], ['Milk - alkali syndrome was first described 70 years ago in the context of the treatment of peptic ulcer disease with large amounts of calcium and alkali .', {'entities': [(0, 4, 'B_Disease'), (5, 6, 'I_Disease'), (7, 13, 'I_Disease'), (14, 22, 'I_Disease'), (91, 97, 'B_Disease'), (98, 103, 'I_Disease'), (104, 111, 'I_Disease')]}], ['Although with current ulcer therapy ( H - 2 blockers , omeprazole , and sucralfate ) , the frequency of milk - alkali syndrome has decreased significantly , the classic triad of hypercalcemia , alkalosis , and renal impairment remains the hallmark of the syndrome .', {'entities': [(22, 27, 'B_Disease'), (104, 108, 'B_Disease'), (109, 110, 'I_Disease'), (111, 117, 'I_Disease'), (118, 126, 'I_Disease'), (178, 191, 'B_Disease'), (194, 203, 'B_Disease'), (210, 215, 'B_Disease'), (216, 226, 'I_Disease')]}], ['Milk - alkali syndrome can present serious and occasionally life - threatening illness unless diagnosed and treated appropriately .', {'entities': [(0, 4, 'B_Disease'), (5, 6, 'I_Disease'), (7, 13, 'I_Disease'), (14, 22, 'I_Disease')]}], ['This article presents a patient with hypoparathyroidism who was treated with calcium carbonate and calcitriol resulting in two admissions to the hospital for milk - alkali syndrome .', {'entities': [(37, 55, 'B_Disease'), (158, 162, 'B_Disease'), (163, 164, 'I_Disease'), (165, 171, 'I_Disease'), (172, 180, 'I_Disease')]}], ['This illustrates intravenous pamidronate as a valuable therapeutic tool when milk - alkali syndrome presents as hypercalcemic emergency .', {'entities': [(77, 81, 'B_Disease'), (82, 83, 'I_Disease'), (84, 90, 'I_Disease'), (91, 99, 'I_Disease'), (112, 125, 'B_Disease'), (126, 135, 'I_Disease')]}], ['Famotidine - associated delirium .', {'entities': [(24, 32, 'B_Disease')]}], ['Famotidine is a histamine H2 - receptor antagonist used in inpatient settings for prevention of stress ulcers and is showing increasing popularity because of its low cost .', {'entities': [(103, 109, 'B_Disease')]}], ['Although all of the currently available H2 - receptor antagonists have shown the propensity to cause delirium , only two previously reported cases have been associated with famotidine .', {'entities': [(101, 109, 'B_Disease')]}], ['The authors report on six cases of famotidine - associated delirium in hospitalized patients who cleared completely upon removal of famotidine .', {'entities': [(59, 67, 'B_Disease')]}], ['Encephalopathy during amitriptyline therapy : are neuroleptic malignant syndrome and serotonin syndrome spectrum disorders ?', {'entities': [(0, 14, 'B_Disease'), (50, 61, 'B_Disease'), (62, 71, 'I_Disease'), (72, 80, 'I_Disease'), (85, 94, 'B_Disease'), (95, 103, 'I_Disease')]}], ['This report describes a case of encephalopathy developed in the course of amitriptyline therapy , during a remission of unipolar depression .', {'entities': [(32, 46, 'B_Disease'), (120, 128, 'B_Disease'), (129, 139, 'I_Disease')]}], ['This patient could have been diagnosed as having either neuroleptic malignant syndrome ( NMS ) or serotonin syndrome ( SS ) .', {'entities': [(56, 67, 'B_Disease'), (68, 77, 'I_Disease'), (78, 86, 'I_Disease'), (89, 92, 'B_Disease'), (98, 107, 'B_Disease'), (108, 116, 'I_Disease'), (119, 121, 'B_Disease')]}], ['The NMS - like encephalopathy that develops in association with the use of antidepressants indicates that NMS and SS are spectrum disorders induced by drugs with both antidopaminergic and serotonergic effects .', {'entities': [(4, 7, 'B_Disease'), (15, 29, 'B_Disease'), (106, 109, 'B_Disease'), (114, 116, 'B_Disease')]}], ['Genetic separation of tumor growth and hemorrhagic phenotypes in an estrogen - induced tumor .', {'entities': [(22, 27, 'B_Disease'), (39, 50, 'B_Disease'), (87, 92, 'B_Disease')]}], ['Chronic administration of estrogen to the Fischer 344 ( F344 ) rat induces growth of large , hemorrhagic pituitary tumors .', {'entities': [(93, 104, 'B_Disease'), (105, 114, 'B_Disease'), (115, 121, 'I_Disease')]}], ['Ten weeks of diethylstilbestrol ( DES ) treatment caused female F344 rat pituitaries to grow to an average of 109 . 2 + / - 6 . 3 mg ( mean + / - SE ) versus 11 . 3 + / - 1 . 4 mg for untreated rats , and to become highly hemorrhagic .', {'entities': [(222, 233, 'B_Disease')]}], ['Surprisingly , the F1 hybrid tumors were not hemorrhagic and had hemoglobin content and outward appearance identical to that of BN .', {'entities': [(29, 35, 'B_Disease'), (45, 56, 'B_Disease')]}], ['However , while DES - induced pituitary growth exhibited quantitative , additive inheritance , the hemorrhagic phenotype exhibited recessive , epistatic inheritance .', {'entities': [(99, 110, 'B_Disease')]}], ['Only 5 of the 160 F2 pituitaries exhibited the hemorrhagic phenotype ; 36 of the 160 F2 pituitaries were in the F344 range of mass , but 31 of these were not hemorrhagic , indicating that the hemorrhagic phenotype is not merely a consequence of extensive growth .', {'entities': [(47, 58, 'B_Disease'), (158, 169, 'B_Disease'), (192, 203, 'B_Disease')]}], ['The hemorrhagic F2 pituitaries were all among the most massive , indicating that some of the genes regulate both phenotypes .', {'entities': [(4, 15, 'B_Disease')]}], ['Increased expression of neuronal nitric oxide synthase in bladder afferent pathways following chronic bladder irritation .', {'entities': [(102, 109, 'B_Disease'), (110, 120, 'I_Disease')]}], ['Immunocytochemical techniques were used to examine alterations in the expression of neuronal nitric oxide synthase ( NOS ) in bladder pathways following acute and chronic irritation of the urinary tract of the rat .', {'entities': [(171, 181, 'B_Disease'), (182, 184, 'I_Disease'), (185, 188, 'I_Disease'), (189, 196, 'I_Disease'), (197, 202, 'I_Disease')]}], ['Chemical cystitis was induced by cyclophosphamide ( CYP ) which is metabolized to acrolein , an irritant eliminated in the urine .', {'entities': [(9, 17, 'B_Disease')]}], ['Effects of a new calcium antagonist , CD - 832 , on isoproterenol - induced myocardial ischemia in dogs with partial coronary stenosis .', {'entities': [(76, 86, 'B_Disease'), (87, 95, 'I_Disease'), (117, 125, 'B_Disease'), (126, 134, 'I_Disease')]}], ['Effects of CD - 832 on isoproterenol ( ISO ) - induced myocardial ischemia were studied in dogs with partial coronary stenosis of the left circumflex coronary artery and findings were compared with those for nifedipine or diltiazem .', {'entities': [(55, 65, 'B_Disease'), (66, 74, 'I_Disease'), (109, 117, 'B_Disease'), (118, 126, 'I_Disease')]}], ['In the presence of coronary artery stenosis , 3 - min periods of intracoronary ISO infusion ( 10 ng / kg / min ) increased heart rate and maximal rate of left ventricular pressure rise , which resulted in a decrease in percentage segmental shortening and ST - segment elevation of the epicardial electrocardiogram .', {'entities': [(19, 27, 'B_Disease'), (28, 34, 'I_Disease'), (35, 43, 'I_Disease')]}], ['After the control ISO infusion with stenosis was performed , equihypotensive doses of CD - 832 ( 3 and 10 micrograms / kg / min , n = 7 ) , nifedipine ( 1 and 3 micrograms / kg / min , n = 9 ) or diltiazem ( 10 and 30 micrograms / kg / min , n = 7 ) were infused 5 min before and during the second and third ISO infusion .', {'entities': [(36, 44, 'B_Disease')]}], ['In contrast to nifedipine , CD - 832 ( 10 micrograms / kg / min ) prevented the decrease in percentage segmental shortening from 32 + / - 12 % to 115 + / - 26 % of the control value ( P < . 01 ) and ST - segment elevation from 5 . 6 + / - 1 . 0 mV to 1 . 6 + / - 1 . 3 mV ( P < . 01 ) at 3 min after ISO infusion with stenosis .', {'entities': [(318, 326, 'B_Disease')]}], ['Diltiazem ( 30 micrograms / kg / min ) also prevented the decrease in percentage segmental shortening from 34 + / - 14 % to 63 + / - 18 % of the control value ( P < . 05 ) and ST - segment elevation from 4 . 7 + / - 0 . 7 mV to 2 . 1 + / - 0 . 7 mV ( P < . 01 ) at 3 min after ISO infusion with stenosis .', {'entities': [(295, 303, 'B_Disease')]}], ['These data show that CD - 832 improves myocardial ischemia during ISO infusion with stenosis and suggest that the negative chronotropic property of CD - 832 plays a major role in the beneficial effects of CD - 832 .', {'entities': [(39, 49, 'B_Disease'), (50, 58, 'I_Disease'), (84, 92, 'B_Disease')]}], ['The effect of recombinant human insulin - like growth factor - I on chronic puromycin aminonucleoside nephropathy in rats .', {'entities': [(102, 113, 'B_Disease')]}], ['We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside ( PAN ) nephropathy , an experimental model of glomerular disease .', {'entities': [(142, 153, 'B_Disease'), (181, 191, 'B_Disease'), (192, 199, 'I_Disease')]}], ['Therefore , we examined whether recombinant human ( rh ) IGF - I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy .', {'entities': [(109, 115, 'B_Disease'), (116, 123, 'I_Disease'), (149, 160, 'B_Disease')]}], ['The glomerulopathy was induced by seven serial injections of PAN over 12 wk .', {'entities': [(4, 18, 'B_Disease')]}], ['rhIGF - I improved weight gain by 14 % ( p < 0 . 05 ) , without altering hematocrit or blood pressure in rats with renal disease .', {'entities': [(115, 120, 'B_Disease'), (121, 128, 'I_Disease')]}], ['Urinary protein excretion was unaltered by rhIGF - I treatment in rats with chronic PAN nephropathy .', {'entities': [(88, 99, 'B_Disease')]}], ['After 12 wk , the inulin clearance was higher in rhIGF - I - treated rats , 0 . 48 + / - 0 . 08 versus 0 . 24 + / - 0 . 06 mL / min / 100 g of body weight in untreated PAN nephropathy animals , p < 0 . 05 .', {'entities': [(172, 183, 'B_Disease')]}], ['The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis , tubulointerstitial injury , or renal cortical malondialdehyde content .', {'entities': [(56, 66, 'B_Disease'), (67, 78, 'I_Disease'), (102, 120, 'B_Disease'), (123, 141, 'B_Disease'), (142, 148, 'I_Disease')]}], ['In rats with PAN nephropathy , administration of rhIGF - I increased IGF - I and GH receptor gene expression , without altering the steady state level of IGF - I receptor mRNA .', {'entities': [(17, 28, 'B_Disease')]}], ['In normal rats with intact kidneys , rhIGF - I administration ( n = 4 ) did not alter weight gain , blood pressure , proteinuria , GFR , glomerular planar area , renal cortical malondialdehyde content , or glomerular or tubulointerstitial damage , compared with untreated animals ( n = 4 ) .', {'entities': [(117, 128, 'B_Disease'), (220, 238, 'B_Disease'), (239, 245, 'I_Disease')]}], ['We conclude that : 1 ) administration of rhIGF - I improves growth and GFR in rats with chronic PAN nephropathy and 2 ) unlike rhGH , long - term use of rhIGF - I does not worsen renal functional and structural injury in this disease model .', {'entities': [(100, 111, 'B_Disease')]}], ['Nefiracetam ( DM - 9384 ) reverses apomorphine - induced amnesia of a passive avoidance response : delayed emergence of the memory retention effects .', {'entities': [(57, 64, 'B_Disease')]}], ['Nefiracetam is a novel pyrrolidone derivative which attenuates scopolamine - induced learning and post - training consolidation deficits .', {'entities': [(85, 93, 'B_Disease'), (94, 97, 'I_Disease'), (98, 102, 'I_Disease'), (103, 104, 'I_Disease'), (105, 113, 'I_Disease'), (114, 127, 'I_Disease'), (128, 136, 'I_Disease')]}], ['Given that apomorphine inhibits passive avoidance retention when given during training or in a defined 10 - 12h post - training period , we evaluated the ability of nefiracetam to attenuate amnesia induced by dopaminergic agonism .', {'entities': [(190, 197, 'B_Disease')]}], ['However , administration of nefiracetam during training completely reversed the amnesia induced by apomorphine at the 10h post - training time and the converse was also true .', {'entities': [(80, 87, 'B_Disease')]}], ['Phenytoin encephalopathy as probable idiosyncratic reaction : case report .', {'entities': [(10, 24, 'B_Disease')]}], ['A case of phenytoin ( DPH ) encephalopathy with increasing seizures and EEG and mental changes is described .', {'entities': [(28, 42, 'B_Disease'), (59, 67, 'B_Disease')]}], ['The encephalopathy was probably an idiosyncratic and not toxic or allergic reaction .', {'entities': [(4, 18, 'B_Disease')]}], ['In fact the concentration of free DPH was normal , the patient presented a retarded morbilliform rash during DPH treatment , the protidogram was normal , and an intradermic DPH injection had no local effect .', {'entities': [(97, 101, 'B_Disease')]}], ['The authors conclude that in a patient starting DPH treatment an unexpected increase in seizures , with EEG and mental changes occurring simultaneously , should alert the physician to the possible need for eliminating DPH from the therapeutic regimen , even if plasma concentrations are low .', {'entities': [(88, 96, 'B_Disease')]}], ['Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy .', {'entities': [(28, 39, 'B_Disease'), (40, 47, 'I_Disease')]}], ['The treatment regimens are described in 74 patients with endometrial disease among 850 climacteric women receiving oestrogen therapy .', {'entities': [(57, 68, 'B_Disease'), (69, 76, 'I_Disease')]}], ['Cystic hyperplasia was associated with unopposed oestrogen therapy without progestagen .', {'entities': [(7, 18, 'B_Disease')]}], ['Two courses of 21 days of 5 mg norethisterone daily caused reversion to normal in all 57 cases of cystic hyperplasia and 6 of the 8 cases of atypical hyperplasia .', {'entities': [(105, 116, 'B_Disease'), (150, 161, 'B_Disease')]}], ['4 cases of endometrial carcinoma referred from elsewhere demonstrated the problems of inappropriate and unsupervised unopposed oestrogen therapy and the difficulty in distinguishing severe hyperplasia from malignancy .', {'entities': [(11, 22, 'B_Disease'), (23, 32, 'I_Disease'), (189, 200, 'B_Disease'), (206, 216, 'B_Disease')]}], ['Cyclical low - dose oestrogen therapy with 7 - - 13 days of progestagen does not seem to increase the risk of endometrial hyperplasia or carcinoma .', {'entities': [(110, 121, 'B_Disease'), (122, 133, 'I_Disease'), (137, 146, 'B_Disease')]}], ['Effects of exercise on the severity of isoproterenol - induced myocardial infarction .', {'entities': [(63, 73, 'B_Disease'), (74, 84, 'I_Disease')]}], ['The effect of exercise on the severity of isoproterenol - induced myocardial infarction was studied in male rats .', {'entities': [(66, 76, 'B_Disease'), (77, 87, 'I_Disease')]}], ['The results indicated that exercise reduced the mortality associated with the effects of large dosages of isoproterenol but had little on the severity of the infarction .', {'entities': [(158, 168, 'B_Disease')]}], ['Human corticotropin - releasing hormone and thyrotropin - releasing hormone modulate the hypercapnic ventilatory response in humans .', {'entities': [(89, 100, 'B_Disease')]}], ['The results indicate an additive effect of both releasing hormones on the hypercapnic ventilatory response in humans , presumably independent of central chemosensitivity .', {'entities': [(74, 85, 'B_Disease')]}], ['Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers : a placebo - controlled trial .', {'entities': [(39, 48, 'B_Disease'), (49, 50, 'I_Disease')]}], [\"Lamivudine is a novel 2 ' , 3 ' - dideoxy cytosine analogue that has potent inhibitory effects on hepatitis B virus replication in vitro and in vivo .\", {'entities': [(98, 107, 'B_Disease'), (108, 109, 'I_Disease')]}], ['All 36 patients receiving lamivudine had a decrease in hepatitis B virus ( HBV ) DNA values of > 90 % ( P < . 001 compared with placebo ) .', {'entities': [(55, 64, 'B_Disease'), (65, 66, 'I_Disease')]}], ['There was no change in the hepatitis B e antigen status or in aminotransferase levels .', {'entities': [(27, 36, 'B_Disease'), (37, 38, 'I_Disease')]}], ['Population - based study of risk of venous thromboembolism associated with various oral contraceptives .', {'entities': [(36, 42, 'B_Disease'), (43, 58, 'I_Disease')]}], ['BACKGROUND : Four studies published since December , 1995 , reported that the incidence of venous thromboembolism ( VTE ) was higher in women who used oral contraceptives ( OCs ) containing the third - generation progestagens gestodene or desogestrel than in users of OCs containing second - generation progestagens .', {'entities': [(91, 97, 'B_Disease'), (98, 113, 'I_Disease'), (116, 119, 'B_Disease')]}], ['The aim of our study was to re - examine the association between risk of VTE and OC use with a different study design and analysis to avoid some of the bias and confounding of the earlier studies .', {'entities': [(73, 76, 'B_Disease')]}], ['All women who had a recorded diagnosis of deep - vein thrombosis , venous thrombosis not otherwise specified , or pulmonary embolus during the study period , and who had been treated with an anticoagulant were identified as potential cases of VTE .', {'entities': [(42, 46, 'B_Disease'), (47, 48, 'I_Disease'), (49, 53, 'I_Disease'), (54, 64, 'I_Disease'), (67, 73, 'B_Disease'), (74, 84, 'I_Disease'), (243, 246, 'B_Disease')]}], ['We did a cohort analysis to estimate and compare incidence of VTE in users of the main OC preparations , and a nested case - control study to calculate the odds ratios of VTE associated with use of different types of OC , after adjustment for potential confounding factors .', {'entities': [(62, 65, 'B_Disease'), (171, 174, 'B_Disease')]}], ['FINDINGS : 85 women met the inclusion criteria for VTE , two of whom were users of progestagen - only OCs .', {'entities': [(51, 54, 'B_Disease')]}], ['Of the 83 cases of VTE associated with use of combined OCs , 43 were recorded as deep - vein thrombosis , 35 as pulmonary thrombosis , and five as venous thrombosis not otherwise specified .', {'entities': [(19, 22, 'B_Disease'), (81, 85, 'B_Disease'), (86, 87, 'I_Disease'), (88, 92, 'I_Disease'), (93, 103, 'I_Disease'), (122, 132, 'B_Disease'), (147, 153, 'B_Disease'), (154, 164, 'I_Disease')]}], ['The crude rate of VTE per 10 , 000 woman - years was 4 . 10 in current users of any OC , 3 . 10 in users of second - generation OCs , and 4 . 96 in users of third - generation preparations .', {'entities': [(18, 21, 'B_Disease')]}], ['After adjustment for age , the rate ratio of VTE in users of third - generation relative to second - generation OCs was 1 . 68 ( 95 % CI 1 . 04 - 2 . 75 ) .', {'entities': [(45, 48, 'B_Disease')]}], ['Logistic regression showed no significant difference in the risk of VTE between users of third - generation and second - generation OCs .', {'entities': [(68, 71, 'B_Disease')]}], ['Among users of third - generation progestagens , the risk of VTE was higher in users of desogestrel with 20 g ethinyloestradiol than in users of gestodene or desogestrel with 30 g ethinyloestradiol .', {'entities': [(61, 64, 'B_Disease')]}], ['With all second - generation OCs as the reference , the odds ratios for VTE were 3 . 49 ( 1 . 21 - 10 . 12 ) for desogestrel plus 20 g ethinyloestradiol and 1 . 18 ( 0 . 66 - 2 . 17 ) for the other third - generation progestagens .', {'entities': [(72, 75, 'B_Disease')]}], ['MK - 801 augments pilocarpine - induced electrographic seizure but protects against brain damage in rats .', {'entities': [(55, 62, 'B_Disease'), (84, 89, 'B_Disease'), (90, 96, 'I_Disease')]}], ['The authors examined the anticonvulsant effects of MK - 801 on the pilocarpine - induced seizure model .', {'entities': [(89, 96, 'B_Disease')]}], ['Intraperitoneal injection of pilocarpine ( 400 mg / kg ) induced tonic and clonic seizure .', {'entities': [(65, 70, 'B_Disease'), (71, 74, 'I_Disease'), (75, 81, 'I_Disease'), (82, 89, 'I_Disease')]}], ['Scopolamine ( 10 mg / kg ) and pentobarbital ( 5 mg / kg ) prevented development of pilocarpine - induced behavioral seizure but MK - 801 ( 0 . 5 mg / kg ) did not .', {'entities': [(117, 124, 'B_Disease')]}], ['An electrical seizure measured with hippocampal EEG appeared in the pilocarpine - treated group .', {'entities': [(14, 21, 'B_Disease')]}], ['Scopolamine and pentobarbital blocked the pilocarpine - induced electrographic seizure , MK - 801 treatment augmented the electrographic seizure induced by pilocarpine .', {'entities': [(79, 86, 'B_Disease'), (137, 144, 'B_Disease')]}], ['Brain damage was assessed by examining the hippocampus microscopically .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease')]}], ['Pilocarpine produced neuronal death in the hippocampus , which showed pyknotic changes .', {'entities': [(21, 29, 'B_Disease'), (30, 35, 'I_Disease')]}], ['Pentobarbital , scopolamine and MK - 801 protected the brain damage by pilocarpine , though in the MK - 801 - treated group , the pyramidal cells of hippocampus appeared darker than normal .', {'entities': [(55, 60, 'B_Disease'), (61, 67, 'I_Disease')]}], ['These results indicate that status epilepticus induced by pilocarpine is initiated by cholinergic overstimulation and propagated by glutamatergic transmission , the elevation of which may cause brain damage through an excitatory NMDA receptor - mediated mechanism .', {'entities': [(28, 34, 'B_Disease'), (35, 46, 'I_Disease'), (194, 199, 'B_Disease'), (200, 206, 'I_Disease')]}], ['Paclitaxel , 5 - fluorouracil , and folinic acid in metastatic breast cancer : BRE - 26 , a phase II trial .', {'entities': [(63, 69, 'B_Disease'), (70, 76, 'I_Disease')]}], ['5 - Fluorouracil plus folinic acid and paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) are effective salvage therapies for metastatic breast cancer patients .', {'entities': [(157, 163, 'B_Disease'), (164, 170, 'I_Disease')]}], ['Paclitaxel and 5 - fluorouracil have additive cytotoxicity in MCF - 7 cell lines .', {'entities': [(46, 58, 'B_Disease')]}], ['We performed a phase II trial of paclitaxel 175 mg / m2 over 3 hours on day I followed by folinic acid 300 mg over 1 hour before 5 - fluorouracil 350 mg / m2 on days 1 to 3 every 28 days ( TFL ) in women with metastatic breast cancer .', {'entities': [(220, 226, 'B_Disease'), (227, 233, 'I_Disease')]}], ['Analysis is reported on 37 patients with a minimum of 6 months follow - up who received a total of 192 cycles of TFL : nine cycles ( 5 % ) were associated with grade 3 / 4 neutropenia requiring hospitalization ; seven ( 4 % ) cycles in two patients required granulocyte colony - stimulating factor due to neutropenia ; no patient required platelet transfusions .', {'entities': [(172, 183, 'B_Disease'), (305, 316, 'B_Disease')]}], ['Grade 3 / 4 nonhematologic toxicities were uncommon .', {'entities': [(27, 37, 'B_Disease')]}], ['TFL is an active , well - tolerated regimen in metastatic breast cancer .', {'entities': [(58, 64, 'B_Disease'), (65, 71, 'I_Disease')]}], ['Efficacy and proarrhythmia with the use of d , l - sotalol for sustained ventricular tachyarrhythmias .', {'entities': [(13, 26, 'B_Disease'), (73, 84, 'B_Disease'), (85, 101, 'I_Disease')]}], ['This study prospectively evaluated the clinical efficacy , the incidence of torsades de pointes , and the presumable risk factors for torsades de pointes in patients treated with d , l - sotalol for sustained ventricular tachyarrhythmias .', {'entities': [(76, 84, 'B_Disease'), (85, 87, 'I_Disease'), (88, 95, 'I_Disease'), (134, 142, 'B_Disease'), (143, 145, 'I_Disease'), (146, 153, 'I_Disease'), (209, 220, 'B_Disease'), (221, 237, 'I_Disease')]}], ['Eighty - one consecutive patients ( 54 with coronary artery disease , and 20 with dilated cardiomyopathy ) with inducible sustained ventricular tachycardia or ventricular fibrillation received oral d , l - sotalol to prevent induction of the ventricular tachyarrhythmia .', {'entities': [(44, 52, 'B_Disease'), (53, 59, 'I_Disease'), (60, 67, 'I_Disease'), (82, 89, 'B_Disease'), (90, 104, 'I_Disease'), (132, 143, 'B_Disease'), (144, 155, 'I_Disease'), (159, 170, 'B_Disease'), (171, 183, 'I_Disease'), (242, 253, 'B_Disease'), (254, 269, 'I_Disease')]}], ['Those patients in whom d , l - sotalol prevented induction of ventricular tachycardia or ventricular fibrillation were discharged with the drug and followed up on an outpatient basis for 21 + / - 18 months .', {'entities': [(62, 73, 'B_Disease'), (74, 85, 'I_Disease'), (89, 100, 'B_Disease'), (101, 113, 'I_Disease')]}], ['Induction of the ventricular tachyarrhythmia was prevented by oral d , l - sotalol in 35 ( 43 % ) patients ; the ventricular tachyarrhythmia remained inducible in 40 ( 49 % ) patients ; and two ( 2 . 5 % ) patients did not tolerate even 40 mg of d , l - sotalol once daily .', {'entities': [(17, 28, 'B_Disease'), (29, 44, 'I_Disease'), (113, 124, 'B_Disease'), (125, 140, 'I_Disease')]}], ['Four ( 5 % ) patients had from torsades de pointes during the initial oral treatment with d , l - sotalol .', {'entities': [(31, 39, 'B_Disease'), (40, 42, 'I_Disease'), (43, 50, 'I_Disease')]}], ['Neither ECG [ sinus - cycle length ( SCL ) , QT or QTc interval , or U wave ] nor clinical parameters identified patients at risk for torsades de pointes .', {'entities': [(134, 142, 'B_Disease'), (143, 145, 'I_Disease'), (146, 153, 'I_Disease')]}], ['However , the oral dose of d , l - sotalol was significantly lower in patients with torsades de pointes ( 200 + / - 46 vs . 328 + / - 53 mg / day ; p = 0 . 0017 ) .', {'entities': [(84, 92, 'B_Disease'), (93, 95, 'I_Disease'), (96, 103, 'I_Disease')]}], ['Risk factors associated with the development of torsades de pointes were the appearance of an U wave ( p = 0 . 049 ) , female gender ( p = 0 . 015 ) , and significant dose - corrected changes of SCL , QT interval , and QTc interval ( p < 0 . 05 ) .', {'entities': [(48, 56, 'B_Disease'), (57, 59, 'I_Disease'), (60, 67, 'I_Disease')]}], ['During follow - up , seven ( 20 % ) patients had a nonfatal ventricular tachycardia recurrence , and two ( 6 % ) patients died suddenly .', {'entities': [(60, 71, 'B_Disease'), (72, 83, 'I_Disease')]}], ['One female patient with stable cardiac disease had recurrent torsades de pointes after 2 years of successful treatment with d , l - sotalol .', {'entities': [(31, 38, 'B_Disease'), (39, 46, 'I_Disease'), (61, 69, 'B_Disease'), (70, 72, 'I_Disease'), (73, 80, 'I_Disease')]}], ['Torsades de pointes occurred early during treatment even with low doses of oral d , l - sotalol .', {'entities': [(0, 8, 'B_Disease'), (9, 11, 'I_Disease'), (12, 19, 'I_Disease')]}], ['Pronounced changes in the surface ECG ( cycle length , QT , and QTc ) in relation to the dose of oral d , l - sotalol might identify a subgroup of patients with an increased risk for torsades de pointes .', {'entities': [(183, 191, 'B_Disease'), (192, 194, 'I_Disease'), (195, 202, 'I_Disease')]}], ['Other ECG parameters before the application of d , l - sotalol did not identify patients at increased risk for torsades de pointes .', {'entities': [(111, 119, 'B_Disease'), (120, 122, 'I_Disease'), (123, 130, 'I_Disease')]}], ['Recurrence rates of ventricular tachyarrhythmias are high despite complete suppression of the arrhythmia during programmed stimulation .', {'entities': [(20, 31, 'B_Disease'), (32, 48, 'I_Disease'), (94, 104, 'B_Disease')]}], ['Chronic hyperprolactinemia and changes in dopamine neurons .', {'entities': [(8, 26, 'B_Disease')]}], ['The purpose of this study was to induce hyperprolactinemia in rats for extended periods of time and examine its effects on dopaminergic systems in the brain .', {'entities': [(40, 58, 'B_Disease')]}], [\"Hyperprolactinemia was induced by treatment with haloperidol , a dopamine receptor antagonist , and Palkovits ' microdissection technique in combination with high - performance liquid chromatography was used to measure neurotransmitter concentrations in several areas of the brain .\", {'entities': [(0, 18, 'B_Disease')]}], ['After 6 months of hyperprolactinemia , dopamine ( DA ) concentrations in the median eminence ( ME ) increased by 84 % over the control group .', {'entities': [(18, 36, 'B_Disease')]}], ['Nine months of hyperprolactinemia produced a 50 % increase in DA concentrations in the ME over the control group .', {'entities': [(15, 33, 'B_Disease')]}], ['However , DA response was lost if a 9 - month long haloperidol - induced hyperprolactinemia was followed by a 1 1 / 2 month - long extremely high increase in serum PRL levels produced by implantation of MMQ cells under the kidney capsule .', {'entities': [(73, 91, 'B_Disease')]}], ['There was no change in the levels of DA , norepinephrine ( NE ) , serotonin ( 5 - HT ) , or their metabolites in the arcuate nucleus ( AN ) , medial preoptic area ( MPA ) , caudate putamen ( CP ) , substantia nigra ( SN ) , and zona incerta ( ZI ) , except for a decrease in 5 - hydroxyindoleacetic acid ( 5 - HIAA ) in the AN after 6 - months of hyperprolactinemia and an increase in DA concentrations in the AN after 9 - months of hyperprolactinemia .', {'entities': [(347, 365, 'B_Disease'), (433, 451, 'B_Disease')]}], ['These results demonstrate that hyperprolactinemia specifically affects TIDA neurons and these effects vary , depending on the duration and intensity of hyperprolactinemia .', {'entities': [(31, 49, 'B_Disease'), (152, 170, 'B_Disease')]}], ['Treatment - related disseminated necrotizing leukoencephalopathy with characteristic contrast enhancement of the white matter .', {'entities': [(45, 64, 'B_Disease')]}], ['This report describes unique contrast enhancement of the white matter on T1 - weighted magnetic resonance images of two patients with disseminated necrotizing leukoencephalopathy , which developed from acute lymphoblastic leukemia treated with high - dose methotrexate .', {'entities': [(159, 178, 'B_Disease'), (202, 207, 'B_Disease'), (208, 221, 'I_Disease'), (222, 230, 'I_Disease')]}], ['Necropsy of the first case revealed loss of myelination and necrosis of the white matter .', {'entities': [(36, 40, 'B_Disease'), (41, 43, 'I_Disease'), (44, 55, 'I_Disease'), (60, 68, 'B_Disease')]}], ['Possible mechanisms causing such a leukoencephalopathy are discussed .', {'entities': [(35, 54, 'B_Disease')]}], ['Thrombotic complications in acute promyelocytic leukemia during all - trans - retinoic acid therapy .', {'entities': [(0, 10, 'B_Disease'), (28, 33, 'B_Disease'), (34, 47, 'I_Disease'), (48, 56, 'I_Disease')]}], ['A case of acute renal failure , due to occlusion of renal vessels in a patient with acute promyelocytic leukemia ( APL ) treated with all - trans - retinoic acid ( ATRA ) and tranexamic acid has been described recently .', {'entities': [(10, 15, 'B_Disease'), (16, 21, 'I_Disease'), (22, 29, 'I_Disease'), (39, 48, 'B_Disease'), (49, 51, 'I_Disease'), (52, 57, 'I_Disease'), (58, 65, 'I_Disease'), (84, 89, 'B_Disease'), (90, 103, 'I_Disease'), (104, 112, 'I_Disease'), (115, 118, 'B_Disease')]}], ['We report a case of acute renal failure in an APL patient treated with ATRA alone .', {'entities': [(20, 25, 'B_Disease'), (26, 31, 'I_Disease'), (32, 39, 'I_Disease'), (46, 49, 'B_Disease')]}], ['This case further supports the concern about thromboembolic complications associated with ATRA therapy in APL patients .', {'entities': [(45, 59, 'B_Disease'), (106, 109, 'B_Disease')]}], ['The patients , a 43 - year - old man , presented all the signs and symptoms of APL and was included in a treatment protocol with ATRA .', {'entities': [(79, 82, 'B_Disease')]}], ['After 10 days of treatment , he developed acute renal failure that was completely reversible after complete remission of APL was achieved and therapy discontinued .', {'entities': [(42, 47, 'B_Disease'), (48, 53, 'I_Disease'), (54, 61, 'I_Disease'), (121, 124, 'B_Disease')]}], ['We conclude that ATRA is a valid therapeutic choice for patients with APL , although the procoagulant tendency is not completely corrected .', {'entities': [(70, 73, 'B_Disease')]}], ['Thrombotic events , however , could be avoided by using low - dose heparin .', {'entities': [(0, 10, 'B_Disease')]}], ['Pupillary changes associated with the development of stimulant - induced mania : a case report .', {'entities': [(73, 78, 'B_Disease')]}], ['A 30 - year - old cocaine - dependent man who was a subject in a study evaluating the anticraving efficacy of the stimulant medication diethylpropion ( DEP ) became manic during his second week on the study drug .', {'entities': [(165, 170, 'B_Disease')]}], ['Pupillometric changes while on DEP , especially changes in the total power of pupillary oscillation , were dramatically different than those observed in the eight other study subjects who did not become manic .', {'entities': [(78, 87, 'B_Disease'), (88, 99, 'I_Disease'), (203, 208, 'B_Disease')]}], ['The large changes in total power of pupillary oscillation occurred a few days before the patient became fully manic .', {'entities': [(36, 45, 'B_Disease'), (46, 57, 'I_Disease'), (110, 115, 'B_Disease')]}], ['Such medication - associated changes in the total power of pupillary oscillation might be of utility in identifying persons at risk for manic - like adverse effects during the medical use of psychomotor stimulants or sympathomimetic agents .', {'entities': [(59, 68, 'B_Disease'), (69, 80, 'I_Disease'), (136, 141, 'B_Disease')]}], ['The baby died of cerebral and pulmonary hemorrhage .', {'entities': [(17, 25, 'B_Disease'), (26, 29, 'I_Disease'), (30, 39, 'I_Disease'), (40, 50, 'I_Disease')]}], ['The baby showed warfarin - induced embryopathy with nasal hypoplasia and stippled epiphyses ( chondrodysplasia punctata ) .', {'entities': [(35, 46, 'B_Disease'), (52, 57, 'B_Disease'), (58, 68, 'I_Disease'), (73, 81, 'B_Disease'), (82, 91, 'I_Disease'), (94, 110, 'B_Disease'), (111, 119, 'I_Disease')]}], ['Nasal hypoplasia with or without stippled epiphyses has now been reported in 11 infants born to mothers treated with warfarin during the first trimester , and a causal association is probable .', {'entities': [(0, 5, 'B_Disease'), (6, 16, 'I_Disease'), (33, 41, 'B_Disease'), (42, 51, 'I_Disease')]}], ['OBJECTIVE : We wanted to test whether assessment of both a central pain - related signal ( chemo - somatosensory evoked potential , CSSEP ) and a concomitantly recorded peripheral signal ( negative mucosal potential , NMP ) allows for separation of central and peripheral effects of NSAIDs .', {'entities': [(67, 71, 'B_Disease')]}], ['For this purpose , experimental conditions were created in which NSAIDs had previously been observed to produce effects on phasic and tonic pain by either central or peripheral mechanisms .', {'entities': [(140, 144, 'B_Disease')]}], ['Phasic pain was applied by means of short pulses of CO2 to the nasal mucosa ( stimulus duration 500 ms , interval approximately 60 s ) , and tonic pain was induced in the nasal cavity by means of dry air of controlled temperature , humidity and flow rate ( 22 degrees C , 0 % relative humidity , 145 ml . s - 1 ) .', {'entities': [(7, 11, 'B_Disease'), (147, 151, 'B_Disease')]}], ['Both CSSEPs as central and NMPs as peripheral correlates of pain were obtained in response to the CO2 stimuli .', {'entities': [(60, 64, 'B_Disease')]}], ['Additionally , the subjects rated the intensity of both phasic and tonic pain by means of visual analogue scales .', {'entities': [(73, 77, 'B_Disease')]}], ['RESULTS : As described earlier , administration of ibuprofen was followed by a decrease in tonic pain but - relative to placebo - an increase in correlates of phasic pain , indicating a specific effect of ibuprofen on the interaction between the pain stimuli under these special experimental conditions .', {'entities': [(97, 101, 'B_Disease'), (166, 170, 'B_Disease'), (246, 250, 'B_Disease')]}], ['The major advantage of this pain model is the possibility of obtaining peripheral pain - related activity directly using a non - invasive technique in humans .', {'entities': [(28, 32, 'B_Disease'), (82, 86, 'B_Disease')]}], ['Effect of D - Glucarates on basic antibiotic - induced renal damage in rats .', {'entities': [(55, 60, 'B_Disease'), (61, 67, 'I_Disease')]}], ['Dehydrated rats regularly develop acute renal failure following single injection of aminoglycoside antibiotics combined with dextran or of antibiotics only .', {'entities': [(0, 10, 'B_Disease'), (34, 39, 'B_Disease'), (40, 45, 'I_Disease'), (46, 53, 'I_Disease')]}], ['Oral administration of 2 , 5 - di - O - acetyl - D - glucaro - 1 , 4 - 6 , 3 - dilactone protected rats against renal failure induced by kanamycin - dextran .', {'entities': [(112, 117, 'B_Disease'), (118, 125, 'I_Disease')]}], ['D - Glucarates were effective against renal damage induced by peptide antibiotics as well as various aminoglycoside antibitocis .', {'entities': [(38, 43, 'B_Disease'), (44, 50, 'I_Disease')]}], ['With a D - glucarate of a fixed size of dose , approximately the same degree of protection was obtained against renal damages induced by different basic antibiotics despite large disparities in administration doses of different antibiotics .', {'entities': [(112, 117, 'B_Disease'), (118, 125, 'I_Disease')]}], ['D - Glucarates had the ability to prevent renal damage but not to cure it .', {'entities': [(42, 47, 'B_Disease'), (48, 54, 'I_Disease')]}], ['Rats excreted acidic urine when they were spared from renal lesions by monosaccharides .', {'entities': [(54, 59, 'B_Disease'), (60, 67, 'I_Disease')]}], ['The reduction effect of D - glucarates against nephrotoxicity of basic antibiotics was discussed .', {'entities': [(47, 61, 'B_Disease')]}], ['Acute severe depression following peri - operative ondansetron .', {'entities': [(13, 23, 'B_Disease')]}], ['A 41 - year - old woman with a strong history of postoperative nausea and vomiting presented for abdominal hysterectomy 3 months after a previous anaesthetic where ondansetron prophylaxis had been used .', {'entities': [(49, 62, 'B_Disease'), (63, 69, 'I_Disease'), (70, 73, 'I_Disease'), (74, 82, 'I_Disease')]}], ['She had developed a severe acute major depression disorder almost immediately thereafter , possibly related to the use of a serotonin antagonist .', {'entities': [(33, 38, 'B_Disease'), (39, 49, 'I_Disease'), (50, 58, 'I_Disease')]}], ['Nine years before she had experienced a self - limited puerperal depressive episode .', {'entities': [(65, 75, 'B_Disease'), (76, 83, 'I_Disease')]}], ['Anaesthesia with a propofol infusion and avoidance of serotonin antagonists provided a nausea - free postoperative course without exacerbation of the depression disorder .', {'entities': [(87, 93, 'B_Disease'), (150, 160, 'B_Disease'), (161, 169, 'I_Disease')]}], ['Hypertensive response during dobutamine stress echocardiography .', {'entities': [(0, 12, 'B_Disease')]}], ['Among 3 , 129 dobutamine stress echocardiographic studies , a hypertensive response , defined as systolic blood pressure ( BP ) > or = 220 mm Hg and / or diastolic BP > or = 110 mm Hg , occurred in 30 patients ( 1 % ) .', {'entities': [(62, 74, 'B_Disease')]}], ['Patients with this response more often had a history of hypertension and had higher resting systolic and diastolic BP before dobutamine infusion .', {'entities': [(56, 68, 'B_Disease')]}], ['Continuously nebulized albuterol in severe exacerbations of asthma in adults : a case - controlled study .', {'entities': [(60, 66, 'B_Disease')]}], ['A retrospective , case - controlled analysis comparing patients admitted to a medical intensive care unit with severe exacerbations of asthma who received continuously nebulized albuterol ( CNA ) versus intermittent albuterol ( INA ) treatments is reported .', {'entities': [(135, 141, 'B_Disease')]}], ['Forty matched pairs of patients with asthma are compared .', {'entities': [(37, 43, 'B_Disease')]}], ['The incidence of cardiac dysrhythmias was similar between groups .', {'entities': [(17, 24, 'B_Disease'), (25, 37, 'I_Disease')]}], ['Symptomatic hypokalemia did not occur .', {'entities': [(12, 23, 'B_Disease')]}], ['Paraplegia following intrathecal methotrexate : report of a case and review of the literature .', {'entities': [(0, 10, 'B_Disease')]}], ['A patient who developed paraplegia following the intrathecal instillation of methotrexate is discribed .', {'entities': [(24, 34, 'B_Disease')]}], ['The following factors appear to predispose to the development of this complication : abnormal cerebrospinal dynamics related to the presence of central nervous system leukemia , and epidural cerebrospinal leakage ; elevated cerebrospinal fluid methothexate concentration related to abnormal cerebrospinal fluid dynamics and to inappropriately high methotrexate doses based on body surface area calculations in older children and adults ; the presence of neurotoxic preservatives in commercially available methotrexate preparations and diluents ; and the use of methotrexate diluents of unphysiologic pH , ionic content and osmolarity .', {'entities': [(144, 151, 'B_Disease'), (152, 159, 'I_Disease'), (160, 166, 'I_Disease'), (167, 175, 'I_Disease'), (454, 464, 'B_Disease')]}], ['The role of methotrexate contaminants , local folate deficiency , and cranial irradiation in the pathogenesis of intrathecal methotrexate toxicity is unclear .', {'entities': [(46, 52, 'B_Disease'), (53, 63, 'I_Disease'), (138, 146, 'B_Disease')]}], ['The incidence of neurotoxicity may be reduced by employing lower doses of methotrexate in the presence of central nervous system leukemia , in older children and adults , and in the presence of epidural leakage .', {'entities': [(17, 30, 'B_Disease'), (106, 113, 'B_Disease'), (114, 121, 'I_Disease'), (122, 128, 'I_Disease'), (129, 137, 'I_Disease')]}], ['Periodic monitoring of cerebruspinal fluid methotrexate levels may be predictive of the development of serious neurotoxicity .', {'entities': [(111, 124, 'B_Disease')]}], ['Hyperosmolar nonketotic coma precipitated by lithium - induced nephrogenic diabetes insipidus .', {'entities': [(0, 12, 'B_Disease'), (13, 23, 'I_Disease'), (24, 28, 'I_Disease'), (63, 74, 'B_Disease'), (75, 83, 'I_Disease'), (84, 93, 'I_Disease')]}], ['A 45 - year - old man , with a 10 - year history of manic depression treated with lithium , was admitted with hyperosmolar , nonketotic coma .', {'entities': [(52, 57, 'B_Disease'), (58, 68, 'I_Disease'), (110, 122, 'B_Disease'), (123, 124, 'I_Disease'), (125, 135, 'I_Disease'), (136, 140, 'I_Disease')]}], ['He gave a five - year history of polyuria and polydipsia , during which time urinalysis had been negative for glucose .', {'entities': [(33, 41, 'B_Disease'), (46, 56, 'B_Disease')]}], ['After recovery from hyperglycaemia , he remained polyuric despite normal blood glucose concentrations ; water deprivation testing indicated nephrogenic diabetes insipidus , likely to be lithium - induced .', {'entities': [(20, 34, 'B_Disease'), (49, 57, 'B_Disease'), (140, 151, 'B_Disease'), (152, 160, 'I_Disease'), (161, 170, 'I_Disease')]}], ['We hypothesize that when this man developed type 2 diabetes , chronic polyuria due to nephrogenic diabetes insipidus was sufficient to precipitate hyperosmolar dehydration .', {'entities': [(44, 48, 'B_Disease'), (49, 50, 'I_Disease'), (51, 59, 'I_Disease'), (70, 78, 'B_Disease'), (86, 97, 'B_Disease'), (98, 106, 'I_Disease'), (107, 116, 'I_Disease'), (160, 171, 'B_Disease')]}], ['BACKGROUND : In dogs , a large amount of intravenous cocaine causes a profound deterioration of left ventricular ( LV ) systolic function and an increase in LV end - diastolic pressure .', {'entities': [(79, 92, 'B_Disease'), (93, 95, 'I_Disease'), (96, 100, 'I_Disease'), (101, 112, 'I_Disease'), (113, 114, 'I_Disease'), (115, 117, 'I_Disease'), (118, 119, 'I_Disease'), (120, 128, 'I_Disease'), (129, 137, 'I_Disease')]}], ['METHODS AND RESULTS : In 20 patients ( 14 men and 6 women aged 39 to 72 years ) referred for cardiac catheterization for the evaluation of chest pain , we measured heart rate , systemic arterial pressure , LV pressure and its first derivative ( dP / dt ) , and LV volumes and ejection fraction before and during the final 2 to 3 minutes of a 15 - minute intracoronary infusion of saline ( n = 10 , control subjects ) or cocaine hydrochloride 1 mg / min ( n = 10 ) .', {'entities': [(139, 144, 'B_Disease'), (145, 149, 'I_Disease')]}], ['CONCLUSIONS : In humans , the intracoronary infusion of cocaine sufficient in amount to achieve a high drug concentration in coronary sinus blood causes a deterioration of LV systolic and diastolic performance .', {'entities': [(155, 168, 'B_Disease'), (169, 171, 'I_Disease'), (172, 174, 'I_Disease'), (175, 183, 'I_Disease'), (184, 187, 'I_Disease'), (188, 197, 'I_Disease'), (198, 209, 'I_Disease')]}], ['Recorded were dose - limiting adverse events : hyper - or hypotension ( three ) , severe abdominal pain ( 0 ) , vomiting ( 0 ) and retained placenta ( four ) .', {'entities': [(47, 52, 'B_Disease'), (53, 54, 'I_Disease'), (55, 57, 'I_Disease'), (58, 69, 'I_Disease'), (89, 98, 'B_Disease'), (99, 103, 'I_Disease'), (112, 120, 'B_Disease'), (131, 139, 'B_Disease'), (140, 148, 'I_Disease')]}], ['Serious adverse events occurred in seven women : six cases with blood loss > or = 1000 ml , four cases of manual placenta removal , five cases of additional oxytocics administration and five cases of blood transfusion .', {'entities': [(64, 69, 'B_Disease'), (70, 74, 'I_Disease')]}], ['Maximum blood loss was greatest at the upper and lower dose levels , and lowest in the 70 - 125 microg dose range .', {'entities': [(8, 13, 'B_Disease'), (14, 18, 'I_Disease')]}], ['Four out of six cases with blood loss > or = 1000 ml occurred in the 200 microg group .', {'entities': [(27, 32, 'B_Disease'), (33, 37, 'I_Disease')]}], ['Heparin - induced thrombocytopenia , paradoxical thromboembolism , and other side effects of heparin therapy .', {'entities': [(18, 34, 'B_Disease'), (49, 64, 'B_Disease')]}], ['Important untoward effects of heparin therapy including heparin - induced thrombocytopenia , heparin - associated osteoporosis , eosinophilia , skin reactions , allergic reactions other than thrombocytopenia and alopecia will be discussed in this article .', {'entities': [(74, 90, 'B_Disease'), (114, 126, 'B_Disease'), (129, 141, 'B_Disease'), (144, 148, 'B_Disease'), (149, 158, 'I_Disease'), (161, 169, 'B_Disease'), (170, 179, 'I_Disease'), (191, 207, 'B_Disease'), (212, 220, 'B_Disease')]}], ['Nonopaque crystal deposition causing ureteric obstruction in patients with HIV undergoing indinavir therapy .', {'entities': [(37, 45, 'B_Disease'), (46, 57, 'I_Disease')]}], ['OBJECTIVE : We describe the unique CT features of ureteric calculi in six HIV - infected patients receiving indinavir , the most commonly used HIV protease inhibitor , which is associated with an increased incidence of urolithiasis .', {'entities': [(50, 58, 'B_Disease'), (59, 66, 'I_Disease'), (74, 77, 'B_Disease'), (78, 79, 'I_Disease'), (80, 88, 'I_Disease'), (219, 231, 'B_Disease')]}], ['CONCLUSION : Ureteric obstruction caused by precipitated indinavir crystals may be difficult to diagnose with unenhanced CT .', {'entities': [(13, 21, 'B_Disease'), (22, 33, 'I_Disease')]}], ['Images may need to be obtained using i . v . contrast material to enable diagnosis of ureteric stones or obstruction in patients with HIV infection who receive indinavir therapy .', {'entities': [(86, 94, 'B_Disease'), (95, 101, 'I_Disease'), (102, 104, 'I_Disease'), (105, 116, 'I_Disease'), (134, 137, 'B_Disease'), (138, 147, 'I_Disease')]}], ['Ischemic colitis and sumatriptan use .', {'entities': [(0, 8, 'B_Disease'), (9, 16, 'I_Disease')]}], ['Cases have been published of coronary vasospasm , myocardial ischemia , and myocardial infarction occurring after sumatriptan use .', {'entities': [(29, 37, 'B_Disease'), (38, 47, 'I_Disease'), (50, 60, 'B_Disease'), (61, 69, 'I_Disease'), (76, 86, 'B_Disease'), (87, 97, 'I_Disease')]}], ['We report on the development of 8 serious cases of ischemic colitis in patients with migraine treated with sumatriptan .', {'entities': [(51, 59, 'B_Disease'), (60, 67, 'I_Disease'), (85, 93, 'B_Disease')]}], [\"51 patients with medically refractory Parkinson ' s disease underwent stereotactic posteromedial pallidotomy between August 1993 and February 1997 for treatment of bradykinesia , rigidity , and L - DOPA - induced dyskinesias .\", {'entities': [(38, 47, 'B_Disease'), (48, 49, 'I_Disease'), (50, 51, 'I_Disease'), (52, 59, 'I_Disease'), (164, 176, 'B_Disease'), (179, 187, 'B_Disease'), (213, 224, 'B_Disease')]}], [\"Clinical assessment as well as blinded ratings of Unified Parkinson ' s Disease Rating Scale ( UPDRS ) scores were carried out pre - and postoperatively .\", {'entities': [(58, 67, 'B_Disease'), (68, 69, 'I_Disease'), (70, 71, 'I_Disease'), (72, 79, 'I_Disease')]}], ['85 percent of patients with dyskinesias were relieved of symptoms , regardless of whether the pallidotomies were performed with the Gamma Knife or radiofrequency methods .', {'entities': [(28, 39, 'B_Disease')]}], ['About 2 / 3 of the patients in both Gamma Knife and radiofrequency groups showed improvements in bradykinesia and rigidity , although when considered as a group neither the Gamma Knife nor the radiofrequency group showed statistically significant improvements in UPDRS scores .', {'entities': [(97, 109, 'B_Disease'), (114, 122, 'B_Disease')]}], ['One patient in the Gamma Knife group ( 3 . 4 % ) developed a homonymous hemianopsia 9 months following treatment and 5 patients ( 27 . 7 % ) in the radiofrequency group became transiently confused postoperatively .', {'entities': [(61, 71, 'B_Disease'), (72, 83, 'I_Disease')]}], [\"Gamma Knife pallidotomy is as effective as radiofrequency pallidotomy in controlling certain of the symptoms of Parkinson ' s disease .\", {'entities': [(112, 121, 'B_Disease'), (122, 123, 'I_Disease'), (124, 125, 'I_Disease'), (126, 133, 'I_Disease')]}], ['It may be the only practical technique available in certain patients , such as those who take anticoagulants , have bleeding diatheses or serious systemic medical illnesses .', {'entities': [(116, 124, 'B_Disease')]}], ['This response was significantly reduced by the intravenous ( i . v . ) injection of guanethidine ( 5 mg ) , hexamethonium ( 10 mg ) or phentolamine ( 5 mg ) , and conversely , potentiated by i . v . desmethylimipramine ( 0 . 3 mg ) , while propranolol ( 0 . 5 mg ) i . v . selectively inhibited the enlargement of pulse pressure and the tachycardia following i . c . carbachol ( 1 mug ) .', {'entities': [(299, 310, 'B_Disease'), (311, 313, 'I_Disease'), (314, 319, 'I_Disease'), (320, 328, 'I_Disease'), (337, 348, 'B_Disease')]}], ['Neuroleptic malignant syndrome and methylphenidate .', {'entities': [(0, 11, 'B_Disease'), (12, 21, 'I_Disease'), (22, 30, 'I_Disease')]}], ['A 1 - year - old female presented with neuroleptic malignant syndrome probably caused by methylphenidate .', {'entities': [(39, 50, 'B_Disease'), (51, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['She had defects in the supratentorial brain including the basal ganglia and the striatum ( multicystic encephalomalacia ) due to severe perinatal hypoxic - ischemic encephalopathy , which was considered to be a possible predisposing factor causing neuroleptic malignant syndrome .', {'entities': [(91, 102, 'B_Disease'), (103, 119, 'I_Disease'), (146, 153, 'B_Disease'), (154, 155, 'I_Disease'), (156, 164, 'I_Disease'), (165, 179, 'I_Disease'), (248, 259, 'B_Disease'), (260, 269, 'I_Disease'), (270, 278, 'I_Disease')]}], ['This is the first reported patient with neuroleptic malignant syndrome probably caused by methylphenidate .', {'entities': [(40, 51, 'B_Disease'), (52, 61, 'I_Disease'), (62, 70, 'I_Disease')]}], ['This study shows that 17alpha - ethinylestradiol ( EE ) - induced intrahepatic cholestasis in rats is associated with selective inhibition of the neutral pathway of bile salt ( BS ) synthesis .', {'entities': [(66, 78, 'B_Disease'), (79, 90, 'I_Disease')]}], ['Glibenclamide - sensitive hypotension produced by helodermin assessed in the rat .', {'entities': [(26, 37, 'B_Disease')]}], ['Helodermin produced hypotension in a dose - dependent manner with approximately similar potency and duration to VIP .', {'entities': [(20, 31, 'B_Disease')]}], ['Hypotension induced by both peptides was significantly attenuated by glibenclamide , which abolished a levcromakalim - produced decrease in arterial blood pressure .', {'entities': [(0, 11, 'B_Disease')]}], ['Oxyhemoglobin did not affect helodermin - induced hypotension , whereas it shortened the duration of acetylcholine ( ACh ) - produced hypotension .', {'entities': [(50, 61, 'B_Disease'), (134, 145, 'B_Disease')]}], ['These findings suggest that helodermin - produced hypotension is partly attributable to the activation of glibenclamide - sensitive K + channels ( K ( ATP ) channels ) , which presumably exist on arterial smooth muscle cells .', {'entities': [(50, 61, 'B_Disease')]}], ['EDRF ( endothelium - derived relaxing factor ) / nitric oxide does not seem to play an important role in the peptide - produced hypotension .', {'entities': [(128, 139, 'B_Disease')]}], ['Long - term efficacy and adverse event of nifedipine sustained - release tablets for cyclosporin A - induced hypertension in patients with psoriasis .', {'entities': [(109, 121, 'B_Disease'), (139, 148, 'B_Disease')]}], ['Thirteen psoriatic patients with hypertension during the course of cyclosporin A therapy were treated for 25 months with a calcium channel blocker , sustained - release nifedipine , to study the clinical antihypertensive effects and adverse events during treatment with both drugs .', {'entities': [(9, 18, 'B_Disease'), (33, 45, 'B_Disease')]}], ['Seven of the 13 patients had exhibited a subclinical hypertensive state before cyclosporin A therapy .', {'entities': [(53, 65, 'B_Disease')]}], ['The adverse events during combined therapy with cyclosporin A and nifedipine included an increase in blood urea nitrogen levels in 9 of the 13 patients and development of gingival hyperplasia in 2 of the 13 patients .', {'entities': [(171, 179, 'B_Disease'), (180, 191, 'I_Disease')]}], ['Our findings indicate that sustained - release nifedipine is useful for hypertensive psoriatic patients under long - term treatment with cyclosporin A , but that these patients should be monitored for gingival hyperplasia .', {'entities': [(72, 84, 'B_Disease'), (85, 94, 'B_Disease'), (201, 209, 'B_Disease'), (210, 221, 'I_Disease')]}]]\n",
      "lenth of the TRAIN_DATA : 2842\n"
     ]
    }
   ],
   "source": [
    "TEST_DATA, _ = load_data_spacy(\"test.tsv\")\n",
    "print(TEST_DATA)\n",
    "print(\"lenth of the TRAIN_DATA :\",len(TEST_DATA))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "TzFvy1F8hc5h",
    "outputId": "a66d9513-caf0-4dd5-acb6-7c87b628edc5"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "[[\"Selegiline - induced postural hypotension in Parkinson ' s disease : a longitudinal study on the effects of drug withdrawal .\", {'entities': [(21, 29, 'B_Disease'), (30, 41, 'I_Disease'), (45, 54, 'B_Disease'), (55, 56, 'I_Disease'), (57, 58, 'I_Disease'), (59, 66, 'I_Disease')]}], [\"OBJECTIVES : The United Kingdom Parkinson ' s Disease Research Group ( UKPDRG ) trial found an increased mortality in patients with Parkinson ' s disease ( PD ) randomized to receive 10 mg selegiline per day and L - dopa compared with those taking L - dopa alone .\", {'entities': [(32, 41, 'B_Disease'), (42, 43, 'I_Disease'), (44, 45, 'I_Disease'), (46, 53, 'I_Disease'), (132, 141, 'B_Disease'), (142, 143, 'I_Disease'), (144, 145, 'I_Disease'), (146, 153, 'I_Disease'), (156, 158, 'B_Disease')]}], ['Recently , we found that therapy with selegiline and L - dopa was associated with selective systolic orthostatic hypotension which was abolished by withdrawal of selegiline .', {'entities': [(92, 100, 'B_Disease'), (101, 112, 'I_Disease'), (113, 124, 'I_Disease')]}], ['The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension .', {'entities': [(274, 285, 'B_Disease'), (286, 297, 'I_Disease')]}], ['METHODS : The cardiovascular responses to standing and head - up tilt were studied repeatedly in PD patients receiving selegiline and as the drug was withdrawn .', {'entities': [(97, 99, 'B_Disease')]}], ['RESULTS : Head - up tilt caused systolic orthostatic hypotension which was marked in six of 20 PD patients on selegiline , one of whom lost consciousness with unrecordable blood pressures .', {'entities': [(32, 40, 'B_Disease'), (41, 52, 'I_Disease'), (53, 64, 'I_Disease'), (95, 97, 'B_Disease')]}], ['A lesser degree of orthostatic hypotension occurred with standing .', {'entities': [(19, 30, 'B_Disease'), (31, 42, 'I_Disease')]}], ['Orthostatic hypotension was ameliorated 4 days after withdrawal of selegiline and totally abolished 7 days after discontinuation of the drug .', {'entities': [(0, 11, 'B_Disease'), (12, 23, 'I_Disease')]}], ['Stopping selegiline also significantly reduced the supine systolic and diastolic blood pressures consistent with a previously undescribed supine pressor action .', {'entities': [(39, 46, 'B_Disease'), (47, 50, 'I_Disease'), (51, 57, 'I_Disease'), (58, 66, 'I_Disease'), (67, 70, 'I_Disease'), (71, 80, 'I_Disease'), (81, 86, 'I_Disease'), (87, 96, 'I_Disease')]}], ['CONCLUSION : This study confirms our previous finding that selegiline in combination with L - dopa is associated with selective orthostatic hypotension .', {'entities': [(128, 139, 'B_Disease'), (140, 151, 'I_Disease')]}], ['The results have shown that the degradation product p - choloroaniline is not a significant factor in chlorhexidine - digluconate associated erosive cystitis .', {'entities': [(149, 157, 'B_Disease')]}], ['A high percentage of kanamycin - colistin and povidone - iodine irrigations were associated with erosive cystitis and suggested a possible complication with human usage .', {'entities': [(105, 113, 'B_Disease')]}], ['Picloxydine irrigations appeared to have a lower incidence of erosive cystitis but further studies would have to be performed before it could be recommended for use in urological procedures .', {'entities': [(70, 78, 'B_Disease')]}], ['Effects of tetrandrine and fangchinoline on experimental thrombosis in mice and human platelet aggregation .', {'entities': [(57, 67, 'B_Disease'), (86, 94, 'B_Disease'), (95, 106, 'I_Disease')]}], ['The present study was undertaken to investigate the effects of TET and FAN on the experimental thrombosis induced by collagen plus epinephrine ( EP ) in mice , and platelet aggregation and blood coagulation in vitro .', {'entities': [(95, 105, 'B_Disease'), (164, 172, 'B_Disease'), (173, 184, 'I_Disease'), (189, 194, 'B_Disease'), (195, 206, 'I_Disease')]}], ['In the in vivo study , the administration ( 50 mg / kg , i . p . ) of TET and FAN in mice showed the inhibition of thrombosis by 55 % and 35 % , respectively , while acetylsalicylic acid ( ASA , 50 mg / kg , i . p . ) , a positive control , showed only 30 % inhibition .', {'entities': [(115, 125, 'B_Disease')]}], ['In the vitro human platelet aggregations induced by the agonists used in tests , TET and FAN showed the inhibitions dose dependently .', {'entities': [(19, 27, 'B_Disease'), (28, 40, 'I_Disease')]}], ['Angioedema due to ACE inhibitors : common and inadequately diagnosed .', {'entities': [(0, 10, 'B_Disease')]}], ['The estimated incidence of angioedema during angiotensin - converting enzyme ( ACE ) inhibitor treatment is between 1 and 7 per thousand patients .', {'entities': [(27, 37, 'B_Disease')]}], ['Cocaine - induced mood disorder : prevalence rates and psychiatric symptoms in an outpatient cocaine - dependent sample .', {'entities': [(18, 22, 'B_Disease'), (23, 31, 'I_Disease'), (55, 66, 'B_Disease')]}], ['This paper attempts to examine and compare prevalence rates and symptom patterns of DSM substance - induced and other mood disorders .', {'entities': [(118, 122, 'B_Disease'), (123, 132, 'I_Disease')]}], ['243 cocaine - dependent outpatients with cocaine - induced mood disorder ( CIMD ) , other mood disorders , or no mood disorder were compared on measures of psychiatric symptoms .', {'entities': [(59, 63, 'B_Disease'), (64, 72, 'I_Disease'), (75, 79, 'B_Disease'), (90, 94, 'B_Disease'), (95, 104, 'I_Disease'), (113, 117, 'B_Disease'), (118, 126, 'I_Disease'), (156, 167, 'B_Disease')]}], ['The prevalence rate for CIMD was 12 % at baseline .', {'entities': [(24, 28, 'B_Disease')]}], ['Introduction of the DSM - IV diagnosis of CIMD did not substantially affect rates of the other depressive disorders .', {'entities': [(42, 46, 'B_Disease'), (95, 105, 'B_Disease'), (106, 115, 'I_Disease')]}], ['Patients with CIMD had symptom severity levels between those of patients with and without a mood disorder .', {'entities': [(14, 18, 'B_Disease'), (92, 96, 'B_Disease'), (97, 105, 'I_Disease')]}], ['These findings suggest some validity for the new DSM - IV diagnosis of CIMD , but also suggest that it requires further specification and replication .', {'entities': [(71, 75, 'B_Disease')]}], ['Effect of fucoidan treatment on collagenase - induced intracerebral hemorrhage in rats .', {'entities': [(54, 67, 'B_Disease'), (68, 78, 'I_Disease')]}], ['Inflammatory cells are postulated to mediate some of the brain damage following ischemic stroke .', {'entities': [(57, 62, 'B_Disease'), (63, 69, 'I_Disease'), (80, 88, 'B_Disease'), (89, 95, 'I_Disease')]}], ['Intracerebral hemorrhage is associated with more inflammation than ischemic stroke .', {'entities': [(0, 13, 'B_Disease'), (14, 24, 'I_Disease'), (49, 61, 'B_Disease'), (67, 75, 'B_Disease'), (76, 82, 'I_Disease')]}], ['We tested the sulfated polysaccharide fucoidan , which has been reported to reduce inflammatory brain damage , in a rat model of intracerebral hemorrhage induced by injection of bacterial collagenase into the caudate nucleus .', {'entities': [(96, 101, 'B_Disease'), (102, 108, 'I_Disease'), (129, 142, 'B_Disease'), (143, 153, 'I_Disease')]}], ['The hematoma was assessed in vivo by magnetic resonance imaging .', {'entities': [(4, 12, 'B_Disease')]}], ['Fucoidan - treated rats exhibited evidence of impaired blood clotting and hemodilution , had larger hematomas , and tended to have less inflammation in the vicinity of the hematoma after three days .', {'entities': [(46, 54, 'B_Disease'), (55, 60, 'I_Disease'), (61, 69, 'I_Disease'), (74, 86, 'B_Disease'), (100, 109, 'B_Disease'), (136, 148, 'B_Disease'), (172, 180, 'B_Disease')]}], ['They showed significantly more rapid improvement of motor function in the first week following hemorrhage and better memory retention in the passive avoidance test .', {'entities': [(95, 105, 'B_Disease')]}], ['Acute white matter edema and eventual neuronal loss in the striatum adjacent to the hematoma did not differ between the two groups .', {'entities': [(6, 11, 'B_Disease'), (12, 18, 'I_Disease'), (19, 24, 'I_Disease'), (38, 46, 'B_Disease'), (47, 51, 'I_Disease'), (84, 92, 'B_Disease')]}], ['Investigation of more specific anti - inflammatory agents and hemodiluting agents are warranted in intracerebral hemorrhage .', {'entities': [(99, 112, 'B_Disease'), (113, 123, 'I_Disease')]}], ['A respiratory arrest with severe desaturation and bradycardia occurred .', {'entities': [(2, 13, 'B_Disease'), (14, 20, 'I_Disease'), (33, 45, 'B_Disease'), (50, 61, 'B_Disease')]}], ['Circumstances leading to this event and the mechanisms enabling a neuromuscular blockade to occur , following the administration of a small dose of relaxant , are discussed .', {'entities': [(66, 79, 'B_Disease'), (80, 88, 'I_Disease')]}], ['We investigated the safety and efficacy of adding different doses of ephedrine to propofol in order to obtund the hypotensive response .', {'entities': [(114, 125, 'B_Disease')]}], ['The addition of ephedrine to propofol appears to be an effective method of obtunding the hypotensive response to propofol at all doses used in this study .', {'entities': [(89, 100, 'B_Disease')]}], ['However , marked tachycardia associated with the use of ephedrine in combination with propofol occurred in the majority of patients , occasionally reaching high levels in individual patients .', {'entities': [(17, 28, 'B_Disease')]}], ['Due to the risk of this tachycardia inducing myocardial ischemia , we would not recommend the use in elderly patients of any of the ephedrine / propofol / mixtures studied .', {'entities': [(24, 35, 'B_Disease'), (45, 55, 'B_Disease'), (56, 64, 'I_Disease')]}], ['Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin .', {'entities': [(32, 40, 'B_Disease'), (41, 45, 'I_Disease'), (46, 50, 'I_Disease'), (51, 60, 'I_Disease')]}], ['BACKGROUND : Although the prevalence of nonsmall cell lung carcinoma ( NSCLC ) is high among elderly patients , few data are available regarding the efficacy and toxicity of chemotherapy in this group of patients .', {'entities': [(40, 48, 'B_Disease'), (49, 53, 'I_Disease'), (54, 58, 'I_Disease'), (59, 68, 'I_Disease'), (71, 76, 'B_Disease'), (162, 170, 'B_Disease')]}], ['Recent reports indicate that single agent therapy with vinorelbine ( VNB ) or gemcitabine ( GEM ) may obtain a response rate of 20 - 30 % in elderly patients , with acceptable toxicity and improvement in symptoms and quality of life .', {'entities': [(176, 184, 'B_Disease')]}], ['In the current study the efficacy and toxicity of the combination of GEM and VNB in elderly patients with advanced NSCLC or those with some contraindication to receiving cisplatin were assessed .', {'entities': [(38, 46, 'B_Disease'), (115, 120, 'B_Disease')]}], ['METHODS : Forty - nine patients with advanced NSCLC were included , 38 of whom were age > / = 70 years and 11 were age < 70 years but who had some contraindication to receiving cisplatin .', {'entities': [(46, 51, 'B_Disease')]}], ['All patients were evaluable for response and toxicity .', {'entities': [(45, 53, 'B_Disease')]}], ['Toxicity was mild .', {'entities': [(0, 8, 'B_Disease')]}], ['Six patients ( 12 % ) had World Health Organization Grade 3 - 4 neutropenia , 2 patients ( 4 % ) had Grade 3 - 4 thrombocytopenia , and 2 patients ( 4 % ) had Grade 3 neurotoxicity .', {'entities': [(64, 75, 'B_Disease'), (113, 129, 'B_Disease'), (167, 180, 'B_Disease')]}], ['Three patients with severe neutropenia ( 6 % ) died of sepsis .', {'entities': [(27, 38, 'B_Disease'), (55, 61, 'B_Disease')]}], ['The median age of those patients developing Grade 3 - 4 neutropenia was significantly higher than that of the remaining patients ( 75 years vs . 72 years ; P = 0 . 047 ) .', {'entities': [(56, 67, 'B_Disease')]}], ['This age group had an increased risk of myelosuppression .', {'entities': [(40, 56, 'B_Disease')]}], ['New chemotherapy combinations with higher activity and lower toxicity are needed for elderly patients with advanced NSCLC .', {'entities': [(61, 69, 'B_Disease'), (116, 121, 'B_Disease')]}], ['NRA0160 and clozapine antagonized locomotor hyperactivity induced by methamphetamine ( MAP ) in mice .', {'entities': [(44, 57, 'B_Disease')]}], ['NRA0160 and clozapine significantly induced catalepsy in rats , although their effects did not exceed 50 % induction even at the highest dose given .', {'entities': [(44, 53, 'B_Disease')]}], ['Warfarin - induced artery calcification is accelerated by growth and vitamin D .', {'entities': [(19, 25, 'B_Disease'), (26, 39, 'I_Disease')]}], ['The present studies demonstrate that growth and vitamin D treatment enhance the extent of artery calcification in rats given sufficient doses of Warfarin to inhibit gamma - carboxylation of matrix Gla protein , a calcification inhibitor known to be expressed by smooth muscle cells and macrophages in the artery wall .', {'entities': [(90, 96, 'B_Disease'), (97, 110, 'I_Disease'), (213, 226, 'B_Disease')]}], ['The first series of experiments examined the influence of age and growth status on artery calcification in Warfarin - treated rats .', {'entities': [(83, 89, 'B_Disease'), (90, 103, 'I_Disease')]}], ['Treatment for 2 weeks with Warfarin caused massive focal calcification of the artery media in 20 - day - old rats and less extensive focal calcification in 42 - day - old rats .', {'entities': [(57, 70, 'B_Disease'), (71, 73, 'I_Disease'), (74, 77, 'I_Disease'), (78, 84, 'I_Disease'), (139, 152, 'B_Disease')]}], ['In contrast , no artery calcification could be detected in 10 - month - old adult rats even after 4 weeks of Warfarin treatment .', {'entities': [(17, 23, 'B_Disease'), (24, 37, 'I_Disease')]}], ['To directly examine the importance of growth to Warfarin - induced artery calcification in animals of the same age , 20 - day - old rats were fed for 2 weeks either an ad libitum diet or a 6 - g / d restricted diet that maintains weight but prevents growth .', {'entities': [(67, 73, 'B_Disease'), (74, 87, 'I_Disease')]}], ['Concurrent treatment of both dietary groups with Warfarin produced massive focal calcification of the artery media in the ad libitum - fed rats but no detectable artery calcification in the restricted - diet , growth - inhibited group .', {'entities': [(81, 94, 'B_Disease'), (95, 97, 'I_Disease'), (98, 101, 'I_Disease'), (102, 108, 'I_Disease'), (162, 168, 'B_Disease'), (169, 182, 'I_Disease')]}], ['Although the explanation for the association between artery calcification and growth status cannot be determined from the present study , there was a relationship between higher serum phosphate and susceptibility to artery calcification , with 30 % higher levels of serum phosphate in young , ad libitum - fed rats compared with either of the groups that was resistant to Warfarin - induced artery calcification , ie , the 10 - month - old rats and the restricted - diet , growth - inhibited young rats .', {'entities': [(53, 59, 'B_Disease'), (60, 73, 'I_Disease'), (216, 222, 'B_Disease'), (223, 236, 'I_Disease'), (391, 397, 'B_Disease'), (398, 411, 'I_Disease')]}], ['This observation suggests that increased susceptibility to Warfarin - induced artery calcification could be related to higher serum phosphate levels .', {'entities': [(78, 84, 'B_Disease'), (85, 98, 'I_Disease')]}], ['The second set of experiments examined the possible synergy between vitamin D and Warfarin in artery calcification .', {'entities': [(94, 100, 'B_Disease'), (101, 114, 'I_Disease')]}], ['High doses of vitamin D are known to cause calcification of the artery media in as little as 3 to 4 days .', {'entities': [(43, 56, 'B_Disease'), (57, 59, 'I_Disease'), (60, 63, 'I_Disease'), (64, 70, 'I_Disease')]}], ['High doses of the vitamin K antagonist Warfarin are also known to cause calcification of the artery media , but at treatment times of 2 weeks or longer yet not at 1 week .', {'entities': [(72, 85, 'B_Disease'), (86, 88, 'I_Disease'), (89, 92, 'I_Disease'), (93, 99, 'I_Disease')]}], ['In the current study , we investigated the synergy between these 2 treatments and found that concurrent Warfarin administration dramatically increased the extent of calcification in the media of vitamin D - treated rats at 3 and 4 days .', {'entities': [(165, 178, 'B_Disease')]}], ['There was a close parallel between the effect of vitamin D dose on artery calcification and the effect of vitamin D dose on the elevation of serum calcium , which suggests that vitamin D may induce artery calcification through its effect on serum calcium .', {'entities': [(67, 73, 'B_Disease'), (74, 87, 'I_Disease'), (198, 204, 'B_Disease'), (205, 218, 'I_Disease')]}], ['Because Warfarin treatment had no effect on the elevation in serum calcium produced by vitamin D , the synergy between Warfarin and vitamin D is probably best explained by the hypothesis that Warfarin inhibits the activity of matrix Gla protein as a calcification inhibitor .', {'entities': [(250, 263, 'B_Disease')]}], ['High levels of matrix Gla protein are found at sites of artery calcification in rats treated with vitamin D plus Warfarin , and chemical analysis showed that the protein that accumulated was indeed not gamma - carboxylated .', {'entities': [(56, 62, 'B_Disease'), (63, 76, 'I_Disease')]}], ['These observations indicate that although the gamma - carboxyglutamate residues of matrix Gla protein are apparently required for its function as a calcification inhibitor , they are not required for its accumulation at calcification sites .', {'entities': [(148, 161, 'B_Disease'), (220, 233, 'B_Disease')]}], ['Apomorphine , a nonselective dopamine agonist , was selected due to its biphasic behavioral effects , its ability to induce hypothermia , and to produce distinct changes to dopamine turnover in the rodent brain .', {'entities': [(124, 135, 'B_Disease')]}], ['In rats , detection of apomorphine - induced hyperactivity was facilitated by a period of acclimatization to the test conditions .', {'entities': [(45, 58, 'B_Disease')]}], ['Moreover , test conditions can impact upon other physiological responses to apomorphine such as drug - induced hypothermia .', {'entities': [(111, 122, 'B_Disease')]}], ['Hemolysis of human erythrocytes induced by tamoxifen is related to disruption of membrane structure .', {'entities': [(0, 9, 'B_Disease')]}], ['Tamoxifen ( TAM ) , the antiestrogenic drug most widely prescribed in the chemotherapy of breast cancer , induces changes in normal discoid shape of erythrocytes and hemolytic anemia .', {'entities': [(90, 96, 'B_Disease'), (97, 103, 'I_Disease'), (166, 175, 'B_Disease'), (176, 182, 'I_Disease')]}], ['This work evaluates the effects of TAM on isolated human erythrocytes , attempting to identify the underlying mechanisms on TAM - induced hemolytic anemia and the involvement of biomembranes in its cytostatic action mechanisms .', {'entities': [(138, 147, 'B_Disease'), (148, 154, 'I_Disease')]}], ['TAM induces hemolysis of erythrocytes as a function of concentration .', {'entities': [(12, 21, 'B_Disease')]}], ['The extension of hemolysis is variable with erythrocyte samples , but 12 . 5 microM TAM induces total hemolysis of all tested suspensions .', {'entities': [(17, 26, 'B_Disease'), (102, 111, 'B_Disease')]}], ['The hemolytic effect of TAM is prevented by low concentrations of alpha - tocopherol ( alpha - T ) and alpha - tocopherol acetate ( alpha - TAc ) ( inactivated functional hydroxyl ) indicating that TAM - induced hemolysis is not related to oxidative membrane damage .', {'entities': [(4, 13, 'B_Disease'), (212, 221, 'B_Disease')]}], ['This was further evidenced by absence of oxygen consumption and hemoglobin oxidation both determined in parallel with TAM - induced hemolysis .', {'entities': [(132, 141, 'B_Disease')]}], ['Hemolysis caused by TAM was not preceded by the leakage of K ( + ) from the cells , also excluding a colloid - osmotic type mechanism of hemolysis , according to the effects on osmotic fragility curves .', {'entities': [(0, 9, 'B_Disease'), (137, 146, 'B_Disease')]}], ['These effects suggest that the protection from hemolysis by tocopherols is related to a decreased TAM incorporation in condensed membranes and the structural damage of the erythrocyte membrane is consequently avoided .', {'entities': [(47, 56, 'B_Disease')]}], ['Therefore , TAM - induced hemolysis results from a structural perturbation of red cell membrane , leading to changes in the framework of the erythrocyte membrane and its cytoskeleton caused by its high partition in the membrane .', {'entities': [(26, 35, 'B_Disease')]}], ['These defects explain the abnormal erythrocyte shape and decreased mechanical stability promoted by TAM , resulting in hemolytic anemia .', {'entities': [(119, 128, 'B_Disease'), (129, 135, 'I_Disease')]}], ['Changes of sodium and ATP affinities of the cardiac ( Na , K ) - ATPase during and after nitric oxide deficient hypertension .', {'entities': [(112, 124, 'B_Disease')]}], ['Inhibition of NO synthesis induces sustained hypertension .', {'entities': [(45, 57, 'B_Disease')]}], ['In several models of hypertension , elevation of intracellular sodium level was documented in cardiac tissue .', {'entities': [(21, 33, 'B_Disease')]}], ['To assess the molecular basis of disturbances in transmembraneous transport of Na + , we studied the response of cardiac ( Na , K ) - ATPase to NO - deficient hypertension induced in rats by NO - synthase inhibition with 40 mg / kg / day N ( G ) - nitro - L - arginine methyl ester ( L - NAME ) for 4 four weeks .', {'entities': [(159, 171, 'B_Disease')]}], ['After recovery from hypertension , the activity of ( Na , K ) - ATPase increased , due to higher affinity of the ATP - binding site , as revealed from the lowered Km value for ATP .', {'entities': [(20, 32, 'B_Disease')]}], ['Inhibition of NO - synthase induced a reversible hypertension accompanied by depressed Na + - extrusion from cardiac cells as a consequence of deteriorated Na + - binding properties of the ( Na , K ) - ATPase .', {'entities': [(49, 61, 'B_Disease'), (77, 86, 'B_Disease')]}], ['Effects of long - term pretreatment with isoproterenol on bromocriptine - induced tachycardia in conscious rats .', {'entities': [(82, 93, 'B_Disease')]}], ['It has been shown that bromocriptine - induced tachycardia , which persisted after adrenalectomy , is ( i ) mediated by central dopamine D2 receptor activation and ( ii ) reduced by 5 - day isoproterenol pretreatment , supporting therefore the hypothesis that this effect is dependent on sympathetic outflow to the heart .', {'entities': [(47, 58, 'B_Disease')]}], ['This study was conducted to examine whether prolonged pretreatment with isoproterenol could abolish bromocriptine - induced tachycardia in conscious rats .', {'entities': [(124, 135, 'B_Disease')]}], ['Isoproterenol pretreatment for 15 days caused cardiac hypertrophy without affecting baseline blood pressure and heart rate .', {'entities': [(46, 53, 'B_Disease'), (54, 65, 'I_Disease')]}], ['In control rats , intravenous bromocriptine ( 150 microg / kg ) induced significant hypotension and tachycardia .', {'entities': [(84, 95, 'B_Disease'), (100, 111, 'B_Disease')]}], ['Bromocriptine - induced hypotension was unaffected by isoproterenol pretreatment , while tachycardia was reversed to significant bradycardia , an effect that was partly reduced by i . v . domperidone ( 0 . 5 mg / kg ) .', {'entities': [(24, 35, 'B_Disease'), (89, 100, 'B_Disease'), (129, 140, 'B_Disease')]}], ['These results show that 15 - day isoproterenol pretreatment not only abolished but reversed bromocriptine - induced tachycardia to bradycardia , an effect that is mainly related to further cardiac beta - adrenoceptor desensitization rather than to impairment of autonomic regulation of the heart .', {'entities': [(116, 127, 'B_Disease'), (131, 142, 'B_Disease')]}], ['They suggest that , in normal conscious rats , the central tachycardia of bromocriptine appears to predominate and to mask the bradycardia of this agonist at peripheral dopamine D2 receptors .', {'entities': [(59, 70, 'B_Disease'), (127, 138, 'B_Disease')]}], [\"Given that sympathetic neural dominance exhibits a similar developmental pattern , and given that clonidine induces sympathetic withdrawal and bradycardia , we hypothesized that clonidine ' s developmental effects on cardiac rate and ultrasound production would mirror each other .\", {'entities': [(143, 154, 'B_Disease')]}], ['Age - related changes in ultrasound production corresponded with changes in cardiovascular variables , including baseline cardiac rate and clonidine - induced bradycardia .', {'entities': [(159, 170, 'B_Disease')]}], ['Recurrent use of newer oral contraceptives and the risk of venous thromboembolism .', {'entities': [(59, 65, 'B_Disease'), (66, 81, 'I_Disease')]}], ['The epidemiological studies that assessed the risk of venous thromboembolism ( VTE ) associated with newer oral contraceptives ( OC ) did not distinguish between patterns of OC use , namely first - time users , repeaters and switchers .', {'entities': [(54, 60, 'B_Disease'), (61, 76, 'I_Disease'), (79, 82, 'B_Disease')]}], ['Data from a Transnational case - control study were used to assess the risk of VTE for the latter patterns of use , while accounting for duration of use .', {'entities': [(79, 82, 'B_Disease')]}], ['Over the period 1993 - 1996 , 551 cases of VTE were identified in Germany and the UK along with 2066 controls .', {'entities': [(43, 46, 'B_Disease')]}], ['The adjusted rate ratio of VTE for repeat users of third generation OC was 0 . 6 ( 95 % CI : 0 . 3 - 1 . 2 ) relative to repeat users of second generation pills , whereas it was 1 . 3 ( 95 % CI : 0 . 7 - 2 . 4 ) for switchers from second to third generation pills relative to switchers from third to second generation pills .', {'entities': [(27, 30, 'B_Disease')]}], ['We conclude that second and third generation agents are associated with equivalent risks of VTE when the same agent is used repeatedly after interruption periods or when users are switched between the two generations of pills .', {'entities': [(92, 95, 'B_Disease')]}], ['Differential effects of systemically administered ketamine and lidocaine on dynamic and static hyperalgesia induced by intradermal capsaicin in humans .', {'entities': [(95, 107, 'B_Disease')]}], ['We have examined the effect of systemic administration of ketamine and lidocaine on brush - evoked ( dynamic ) pain and punctate - evoked ( static ) hyperalgesia induced by capsaicin .', {'entities': [(111, 115, 'B_Disease'), (149, 161, 'B_Disease')]}], ['The following were measured : spontaneous pain , pain evoked by punctate and brush stimuli ( VAS ) , and areas of brush - evoked and punctate - evoked hyperalgesia .', {'entities': [(42, 46, 'B_Disease'), (49, 53, 'B_Disease'), (151, 163, 'B_Disease')]}], ['Ketamine reduced both the area of brush - evoked and punctate - evoked hyperalgesia significantly and it tended to reduce brush - evoked pain .', {'entities': [(71, 83, 'B_Disease'), (137, 141, 'B_Disease')]}], ['Lidocaine reduced the area of punctate - evoked hyperalgesia significantly .', {'entities': [(48, 60, 'B_Disease')]}], ['It tended to reduce VAS scores of spontaneous pain but had no effect on evoked pain .', {'entities': [(46, 50, 'B_Disease'), (79, 83, 'B_Disease')]}], ['The differential effects of ketamine and lidocaine on static and dynamic hyperalgesia suggest that the two types of hyperalgesia are mediated by separate mechanisms and have a distinct pharmacology .', {'entities': [(73, 85, 'B_Disease'), (116, 128, 'B_Disease')]}], ['Development of apomorphine - induced aggressive behavior : comparison of adult male and female Wistar rats .', {'entities': [(37, 47, 'B_Disease'), (48, 56, 'I_Disease')]}], ['The development of apomorphine - induced ( 1 . 0 mg / kg s . c . once daily ) aggressive behavior of adult male and female Wistar rats obtained from the same breeder was studied in two consecutive sets .', {'entities': [(78, 88, 'B_Disease'), (89, 97, 'I_Disease')]}], ['In male animals , repeated apomorphine treatment induced a gradual development of aggressive behavior as evidenced by the increased intensity of aggressiveness and shortened latency before the first attack toward the opponent .', {'entities': [(82, 92, 'B_Disease'), (93, 101, 'I_Disease'), (145, 159, 'B_Disease')]}], ['In female rats , only a weak tendency toward aggressiveness was found .', {'entities': [(45, 59, 'B_Disease')]}], ['In conclusion , the present study demonstrates gender differences in the development of the apomorphine - induced aggressive behavior and indicates that the female rats do not fill the validation criteria for use in this method .', {'entities': [(114, 124, 'B_Disease'), (125, 133, 'I_Disease')]}], ['Intracranial aneurysms and cocaine abuse : analysis of prognostic indicators .', {'entities': [(0, 12, 'B_Disease'), (13, 22, 'I_Disease'), (27, 34, 'B_Disease'), (35, 40, 'I_Disease')]}], ['OBJECTIVE : The outcome of subarachnoid hemorrhage associated with cocaine abuse is reportedly poor .', {'entities': [(27, 39, 'B_Disease'), (40, 50, 'I_Disease'), (67, 74, 'B_Disease'), (75, 80, 'I_Disease')]}], ['METHODS : A review of admissions during a 6 - year period revealed 14 patients with cocaine - related aneurysms .', {'entities': [(102, 111, 'B_Disease')]}], ['This group was compared with a control group of 135 patients with ruptured aneurysms and no history of cocaine abuse .', {'entities': [(66, 74, 'B_Disease'), (75, 84, 'I_Disease'), (103, 110, 'B_Disease'), (111, 116, 'I_Disease')]}], ['Age at presentation , time of ictus after intoxication , Hunt and Hess grade of subarachnoid hemorrhage , size of the aneurysm , location of the aneurysm , and the Glasgow Outcome Scale score were assessed and compared .', {'entities': [(80, 92, 'B_Disease'), (93, 103, 'I_Disease'), (118, 126, 'B_Disease'), (145, 153, 'B_Disease')]}], ['In patients in the study group , all aneurysms were located in the anterior circulation .', {'entities': [(37, 46, 'B_Disease')]}], ['The majority of these aneurysms were smaller than those of the control group ( 8 + / - 6 . 08 mm versus 11 + / - 5 . 4 mm ; P = 0 . 05 ) .', {'entities': [(22, 31, 'B_Disease')]}], ['Hunt and Hess grade ( P < 0 . 005 ) and age ( P < 0 . 007 ) were significant predictors of outcome for the patients with cocaine - related aneurysms .', {'entities': [(139, 148, 'B_Disease')]}], ['CONCLUSION : Cocaine use predisposed aneurysmal rupture at a significantly earlier age and in much smaller aneurysms .', {'entities': [(37, 47, 'B_Disease'), (48, 55, 'I_Disease'), (107, 116, 'B_Disease')]}], ['Effect of intravenous nimodipine on blood pressure and outcome after acute stroke .', {'entities': [(69, 74, 'B_Disease'), (75, 81, 'I_Disease')]}], ['BACKGROUND AND PURPOSE : The Intravenous Nimodipine West European Stroke Trial ( INWEST ) found a correlation between nimodipine - induced reduction in blood pressure ( BP ) and an unfavorable outcome in acute stroke .', {'entities': [(66, 72, 'B_Disease'), (139, 148, 'B_Disease'), (149, 151, 'I_Disease'), (152, 157, 'I_Disease'), (158, 166, 'I_Disease'), (204, 209, 'B_Disease'), (210, 216, 'I_Disease')]}], ['We sought to confirm this correlation with and without adjustment for prognostic variables and to investigate outcome in subgroups with increasing levels of BP reduction .', {'entities': [(157, 159, 'B_Disease'), (160, 169, 'I_Disease')]}], ['METHODS : Patients with a clinical diagnosis of ischemic stroke ( within 24 hours ) were consecutively allocated to receive placebo ( n = 100 ) , 1 mg / h ( low - dose ) nimodipine ( n = 101 ) , or 2 mg / h ( high - dose ) nimodipine ( n = 94 ) .', {'entities': [(48, 56, 'B_Disease'), (57, 63, 'I_Disease')]}], ['Nimodipine treatment resulted in a statistically significant reduction in systolic BP ( SBP ) and diastolic BP ( DBP ) from baseline compared with placebo during the first few days .', {'entities': [(61, 70, 'B_Disease'), (71, 73, 'I_Disease'), (74, 82, 'I_Disease'), (83, 85, 'I_Disease')]}], ['In multivariate analysis , a significant correlation between DBP reduction and worsening of the neurological score was found for the high - dose group ( beta = 0 . 49 , P = 0 . 048 ) .', {'entities': [(61, 64, 'B_Disease'), (65, 74, 'I_Disease')]}], ['Patients with a DBP reduction of > or = 20 % in the high - dose group had a significantly increased adjusted OR for the compound outcome variable death or dependency ( Barthel Index < 60 ) ( n / N = 25 / 26 , OR 10 . 16 , 95 % CI 1 . 02 to 101 . 74 ) and death alone ( n / N = 9 / 26 , OR 4 . 336 , 95 % CI 1 . 131 16 . 619 ) compared with all placebo patients ( n / N = 62 / 92 and 14 / 92 , respectively ) .', {'entities': [(16, 19, 'B_Disease'), (20, 29, 'I_Disease'), (146, 151, 'B_Disease'), (255, 260, 'B_Disease')]}], ['CONCLUSIONS : DBP , but not SBP , reduction was associated with neurological worsening after the intravenous administration of high - dose nimodipine after acute stroke .', {'entities': [(156, 161, 'B_Disease'), (162, 168, 'I_Disease')]}], ['Neonatal pyridoxine responsive convulsions due to isoniazid therapy .', {'entities': [(31, 42, 'B_Disease')]}], ['A 17 - day - old infant on isoniazid therapy 13 mg / kg daily from birth because of maternal tuberculosis was admitted after 4 days of clonic fits .', {'entities': [(93, 105, 'B_Disease'), (135, 141, 'B_Disease'), (142, 146, 'I_Disease')]}], ['The fits ceased within 4 hours of administering intramuscular pyridoxine , suggesting an aetiology of pyridoxine deficiency secondary to isoniazid medication .', {'entities': [(4, 8, 'B_Disease')]}], [\"Ketamine sedation for the reduction of children ' s fractures in the emergency department .\", {'entities': [(52, 61, 'B_Disease')]}], [\"The purpose of the present study was to examine the safety and efficacy of ketamine for sedation in the treatment of children ' s fractures in the emergency department .\", {'entities': [(130, 139, 'B_Disease')]}], ['METHODS : One hundred and fourteen children ( average age , 5 . 3 years ; range , twelve months to ten years and ten months ) who underwent closed reduction of an isolated fracture or dislocation in the emergency department at a level - I trauma center were prospectively evaluated .', {'entities': [(172, 180, 'B_Disease'), (184, 195, 'B_Disease'), (239, 245, 'B_Disease')]}], [\"Any pain during the reduction was rated by the orthopaedic surgeon treating the patient according to the Children ' s Hospital of Eastern Ontario Pain Scale ( CHEOPS ) .\", {'entities': [(4, 8, 'B_Disease'), (146, 150, 'B_Disease')]}], ['RESULTS : The average time from intravenous administration of ketamine to manipulation of the fracture or dislocation was one minute and thirty - six seconds ( range , twenty seconds to five minutes ) , and the average time from intramuscular administration to manipulation was four minutes and forty - two seconds ( range , sixty seconds to fifteen minutes ) .', {'entities': [(94, 102, 'B_Disease'), (106, 117, 'B_Disease')]}], [\"The average score according to the Children ' s Hospital of Eastern Ontario Pain Scale was 6 . 4 points ( range , 5 to 10 points ) , reflecting minimal or no pain during fracture reduction .\", {'entities': [(76, 80, 'B_Disease'), (158, 162, 'B_Disease'), (170, 178, 'B_Disease')]}], ['Adequate fracture reduction was obtained in 111 of the children .', {'entities': [(9, 17, 'B_Disease')]}], ['Minor side effects included nausea ( thirteen patients ) , emesis ( eight of the thirteen patients with nausea ) , clumsiness ( evident as ataxic movements in ten patients ) , and dysphoric reaction ( one patient ) .', {'entities': [(28, 34, 'B_Disease'), (59, 65, 'B_Disease'), (104, 110, 'B_Disease'), (115, 125, 'B_Disease'), (139, 145, 'B_Disease'), (146, 155, 'I_Disease'), (180, 189, 'B_Disease'), (190, 198, 'I_Disease')]}], ['No long - term sequelae were noted , and no patients had hallucinations or nightmares .', {'entities': [(57, 71, 'B_Disease')]}], [\"CONCLUSIONS : Ketamine reliably , safely , and quickly provided adequate sedation to effectively facilitate the reduction of children ' s fractures in the emergency department at our institution .\", {'entities': [(138, 147, 'B_Disease')]}], ['Cyclosporine and tacrolimus - associated thrombotic microangiopathy .', {'entities': [(41, 51, 'B_Disease'), (52, 67, 'I_Disease')]}], ['The development of thrombotic microangiopathy ( TMA ) associated with the use of cyclosporine has been well documented .', {'entities': [(19, 29, 'B_Disease'), (30, 45, 'I_Disease'), (48, 51, 'B_Disease')]}], ['As a result , switching to tacrolimus has been reported to be a viable therapeutic option in the setting of cyclosporine - induced TMA .', {'entities': [(131, 134, 'B_Disease')]}], ['With the more widespread application of tacrolimus in organ transplantation , tacrolimus - associated TMA has also been recognized .', {'entities': [(102, 105, 'B_Disease')]}], ['However , literature regarding the incidence of the recurrence of TMA in patients exposed sequentially to cyclosporine and tacrolimus is limited .', {'entities': [(66, 69, 'B_Disease')]}], ['We report a case of a living donor renal transplant recipient who developed cyclosporine - induced TMA that responded to the withdrawal of cyclosporine in conjunction with plasmapheresis and fresh frozen plasma replacement therapy .', {'entities': [(99, 102, 'B_Disease')]}], ['Introduction of tacrolimus as an alternative immunosuppressive agent resulted in the recurrence of TMA and the subsequent loss of the renal allograft .', {'entities': [(99, 102, 'B_Disease')]}], ['Patients who are switched from cyclosporine to tacrolimus or vice versa should be closely monitored for the signs and symptoms of recurrent TMA .', {'entities': [(140, 143, 'B_Disease')]}], ['Analgesic effect of intravenous ketamine in cancer patients on morphine therapy : a randomized , controlled , double - blind , crossover , double - dose study .', {'entities': [(44, 50, 'B_Disease')]}], ['Pain not responsive to morphine is often problematic .', {'entities': [(0, 4, 'B_Disease')]}], ['Animal and clinical studies have suggested that N - methyl - D - aspartate ( NMDA ) antagonists , such as ketamine , may be effective in improving opioid analgesia in difficult pain syndromes , such as neuropathic pain .', {'entities': [(177, 181, 'B_Disease'), (202, 213, 'B_Disease'), (214, 218, 'I_Disease')]}], ['A slow bolus of subhypnotic doses of ketamine ( 0 . 25 mg / kg or 0 . 50 mg / kg ) was given to 10 cancer patients whose pain was unrelieved by morphine in a randomized , double - blind , crossover , double - dose study .', {'entities': [(99, 105, 'B_Disease'), (121, 125, 'B_Disease')]}], ['Pain intensity on a 0 to 10 numerical scale ; nausea and vomiting , drowsiness , confusion , and dry mouth , using a scale from 0 to 3 ( not at all , slight , a lot , awful ) ; Mini - Mental State Examination ( MMSE ) ( 0 - 30 ) ; and arterial pressure were recorded before administration of drugs ( T0 ) and after 30 minutes ( T30 ) , 60 minutes ( T60 ) , 120 minutes ( T120 ) , and 180 minutes ( T180 ) .', {'entities': [(0, 4, 'B_Disease'), (46, 52, 'B_Disease'), (57, 65, 'B_Disease'), (81, 90, 'B_Disease'), (97, 100, 'B_Disease'), (101, 106, 'I_Disease')]}], ['Ketamine , but not saline solution , significantly reduced the pain intensity in almost all the patients at both doses .', {'entities': [(63, 67, 'B_Disease')]}], ['Hallucinations occurred in 4 patients , and an unpleasant sensation ( \" empty head \" ) was also reported by 2 patients .', {'entities': [(0, 14, 'B_Disease')]}], ['Ketamine can improve morphine analgesia in difficult pain syndromes , such as neuropathic pain .', {'entities': [(53, 57, 'B_Disease'), (78, 89, 'B_Disease'), (90, 94, 'I_Disease')]}], ['Paclitaxel , cisplatin , and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma .', {'entities': [(128, 136, 'B_Disease'), (137, 141, 'I_Disease'), (142, 146, 'I_Disease'), (147, 156, 'I_Disease')]}], ['BACKGROUND : Cisplatin - based chemotherapy combinations improve quality of life and survival in advanced nonsmall cell lung carcinoma ( NSCLC ) .', {'entities': [(106, 114, 'B_Disease'), (115, 119, 'I_Disease'), (120, 124, 'I_Disease'), (125, 134, 'I_Disease'), (137, 142, 'B_Disease')]}], ['METHODS : The objective of this study was to determine the feasibility , response rate , and toxicity of a paclitaxel , cisplatin , and gemcitabine combination to treat metastatic NSCLC .', {'entities': [(93, 101, 'B_Disease'), (180, 185, 'B_Disease')]}], ['Thirty - five consecutive chemotherapy - naive patients with Stage IV NSCLC and an Eastern Cooperative Oncology Group performance status of 0 - 2 were treated with a combination of paclitaxel ( 135 mg / m ( 2 ) given intravenously in 3 hours ) on Day 1 , cisplatin ( 120 mg / m ( 2 ) given intravenously in 6 hours ) on Day 1 , and gemcitabine ( 800 mg / m ( 2 ) given intravenously in 30 minutes ) on Days 1 and 8 , every 4 weeks .', {'entities': [(70, 75, 'B_Disease')]}], ['Although responding patients were scheduled to receive consolidation radiotherapy and 24 patients received preplanned second - line chemotherapy after disease progression , the response and toxicity rates reported refer only to the chemotherapy regimen given .', {'entities': [(190, 198, 'B_Disease')]}], ['RESULTS : All the patients were examined for toxicity ; 34 were examinable for response .', {'entities': [(45, 53, 'B_Disease')]}], ['World Health Organization Grade 3 - 4 neutropenia and thrombocytopenia occurred in 39 . 9 % and 11 . 4 % of patients , respectively .', {'entities': [(38, 49, 'B_Disease'), (54, 70, 'B_Disease')]}], ['There was one treatment - related death .', {'entities': [(34, 39, 'B_Disease')]}], ['Nonhematologic toxicities were mild .', {'entities': [(15, 25, 'B_Disease')]}], ['CONCLUSIONS : The combination of paclitaxel , cisplatin , and gemcitabine is well tolerated and shows high activity in metastatic NSCLC .', {'entities': [(130, 135, 'B_Disease')]}], ['Serotonergic antidepressants and urinary incontinence .', {'entities': [(33, 40, 'B_Disease'), (41, 53, 'I_Disease')]}], ['Although urinary incontinence is listed as one side effect of these drugs in their package inserts there is only one report in the literature .', {'entities': [(9, 16, 'B_Disease'), (17, 29, 'I_Disease')]}], ['This concerns 2 male patients who experienced incontinence while taking venlafaxine .', {'entities': [(46, 58, 'B_Disease')]}], ['In the present paper the authors describe 2 female patients who developed incontinence secondary to the selective serotonin reuptake inhibitors paroxetine and sertraline , as well as a third who developed this side effect on venlafaxine .', {'entities': [(74, 86, 'B_Disease')]}], ['In 2 of the 3 cases the patients were also taking lithium carbonate and beta - blockers , both of which could have contributed to the incontinence .', {'entities': [(134, 146, 'B_Disease')]}], ['Animal studies suggest that incontinence secondary to serotonergic antidepressants could be mediated by the 5HT4 receptors found on the bladder .', {'entities': [(28, 40, 'B_Disease')]}], ['Acute cocaine - induced seizures : differential sensitivity of six inbred mouse strains .', {'entities': [(24, 32, 'B_Disease')]}], ['Mature male and female mice from six inbred stains were tested for susceptibility to behavioral seizures induced by a single injection of cocaine .', {'entities': [(96, 104, 'B_Disease')]}], ['Seizure end points included latency to forelimb or hindlimb clonus , latency to clonic running seizure and latency to jumping bouncing seizure .', {'entities': [(0, 7, 'B_Disease'), (95, 102, 'B_Disease'), (135, 142, 'B_Disease')]}], ['Additional studies of these murine strains may be useful for investigating genetic influences on cocaine - induced seizures .', {'entities': [(115, 123, 'B_Disease')]}], ['Hypotension following the initiation of tizanidine in a patient treated with an angiotensin converting enzyme inhibitor for chronic hypertension .', {'entities': [(0, 11, 'B_Disease'), (132, 144, 'B_Disease')]}], ['Centrally acting alpha - 2 adrenergic agonists are one of several pharmacologic agents used in the treatment of spasticity related to disorders of the central nervous system .', {'entities': [(112, 122, 'B_Disease'), (134, 143, 'B_Disease'), (144, 146, 'I_Disease'), (147, 150, 'I_Disease'), (151, 158, 'I_Disease'), (159, 166, 'I_Disease'), (167, 173, 'I_Disease')]}], ['In addition to their effects on spasticity , certain adverse cardiorespiratory effects have been reported .', {'entities': [(32, 42, 'B_Disease')]}], ['Adults chronically treated with angiotensin converting enzyme inhibitors may have a limited ability to respond to hypotension when the sympathetic response is simultaneously blocked .', {'entities': [(114, 125, 'B_Disease')]}], ['The authors present a 10 - year - old boy chronically treated with lisinopril , an angiotensin converting enzyme inhibitor , to control hypertension who developed hypotension following the addition of tizanidine , an alpha - 2 agonist , for the treatment of spasticity .', {'entities': [(136, 148, 'B_Disease'), (163, 174, 'B_Disease'), (258, 268, 'B_Disease')]}], ['The possible interaction of tizanidine and other antihypertensive agents should be kept in mind when prescribing therapy to treat either hypertension or spasticity in such patients .', {'entities': [(137, 149, 'B_Disease'), (153, 163, 'B_Disease')]}], ['Two mouse lines selected for differential sensitivities to beta - carboline - induced seizures are also differentially sensitive to various pharmacological effects of other GABA ( A ) receptor ligands .', {'entities': [(86, 94, 'B_Disease')]}], ['Two mouse lines were selectively bred according to their sensitivity ( BS line ) or resistance ( BR line ) to seizures induced by a single i . p . injection of methyl beta - carboline - 3 - carboxylate ( beta - CCM ) , an inverse agonist of the GABA ( A ) receptor benzodiazepine site .', {'entities': [(110, 118, 'B_Disease')]}], ['We measured diazepam - induced anxiolysis with the elevated plus - maze test , diazepam - induced sedation by recording the vigilance states , and picrotoxin - and pentylenetetrazol - induced seizures after i . p . injections .', {'entities': [(192, 200, 'B_Disease')]}], ['Propylthiouracil - induced perinuclear - staining antineutrophil cytoplasmic autoantibody - positive vasculitis in conjunction with pericarditis .', {'entities': [(101, 111, 'B_Disease'), (132, 144, 'B_Disease')]}], ['OBJECTIVE : To describe a case of propylthiouracil - induced vasculitis manifesting with pericarditis .', {'entities': [(61, 71, 'B_Disease'), (89, 101, 'B_Disease')]}], ['METHODS : We present the first case report of a woman with hyperthyroidism treated with propylthiouracil in whom a syndrome of pericarditis , fever , and glomerulonephritis developed .', {'entities': [(59, 74, 'B_Disease'), (127, 139, 'B_Disease'), (142, 147, 'B_Disease'), (154, 172, 'B_Disease')]}], [\"RESULTS : A 25 - year - old woman with Graves ' disease had a febrile illness and evidence of pericarditis , which was confirmed by biopsy .\", {'entities': [(39, 45, 'B_Disease'), (46, 47, 'I_Disease'), (48, 55, 'I_Disease'), (62, 69, 'B_Disease'), (70, 77, 'I_Disease'), (94, 106, 'B_Disease')]}], ['A literature review revealed no prior reports of pericarditis in anti - MPO pANCA - positive vasculitis associated with propylthio - uracil therapy .', {'entities': [(49, 61, 'B_Disease'), (93, 103, 'B_Disease')]}], ['CONCLUSION : Pericarditis may be the initial manifestation of drug - induced vasculitis attributable to propylthio - uracil therapy .', {'entities': [(13, 25, 'B_Disease'), (77, 87, 'B_Disease')]}], ['Repeated transient anuria following losartan administration in a patient with a solitary kidney .', {'entities': [(19, 25, 'B_Disease')]}], ['We report the case of a 70 - year - old hypertensive man with a solitary kidney and chronic renal insufficiency who developed two episodes of transient anuria after losartan administration .', {'entities': [(40, 52, 'B_Disease'), (84, 91, 'B_Disease'), (92, 97, 'I_Disease'), (98, 111, 'I_Disease'), (152, 158, 'B_Disease')]}], ['He was hospitalized for a myocardial infarction with pulmonary edema , treated with high - dose diuretics .', {'entities': [(26, 36, 'B_Disease'), (37, 47, 'I_Disease'), (53, 62, 'B_Disease'), (63, 68, 'I_Disease')]}], ['Due to severe systolic dysfunction losartan was prescribed .', {'entities': [(14, 22, 'B_Disease'), (23, 34, 'I_Disease')]}], ['Surprisingly , the first dose of 50 mg of losartan resulted in a sudden anuria , which lasted eight hours despite high - dose furosemide and amine infusion .', {'entities': [(72, 78, 'B_Disease')]}], ['One week later , by mistake , losartan was prescribed again and after the second dose of 50 mg , the patient developed a second episode of transient anuria lasting 10 hours .', {'entities': [(149, 155, 'B_Disease')]}], ['During these two episodes , his blood pressure diminished but no severe hypotension was noted .', {'entities': [(72, 83, 'B_Disease')]}], ['Ultimately , an arteriography showed a 70 - 80 % renal artery stenosis .', {'entities': [(49, 54, 'B_Disease'), (55, 61, 'I_Disease'), (62, 70, 'I_Disease')]}], ['In this patient , renal artery stenosis combined with heart failure and diuretic therapy certainly resulted in a strong activation of the renin - angiotensin system ( RAS ) .', {'entities': [(18, 23, 'B_Disease'), (24, 30, 'I_Disease'), (31, 39, 'I_Disease'), (54, 59, 'B_Disease'), (60, 67, 'I_Disease')]}], ['This case report highlights the fact that the angiotensin II receptor antagonist losartan can cause serious unexpected complications in patients with renovascular disease and should be used with extreme caution in this setting .', {'entities': [(150, 162, 'B_Disease'), (163, 170, 'I_Disease')]}], ['Calcineurin - inhibitor induced pain syndrome ( CIPS ) : a severe disabling complication after organ transplantation .', {'entities': [(32, 36, 'B_Disease'), (48, 52, 'B_Disease')]}], ['Bone pain after transplantation is a frequent complication that can be caused by several diseases .', {'entities': [(5, 9, 'B_Disease')]}], ['Treatment strategies depend on the correct diagnosis of the pain .', {'entities': [(60, 64, 'B_Disease')]}], ['Nine patients with severe pain in their feet , which was registered after transplantation , were investigated .', {'entities': [(26, 30, 'B_Disease')]}], ['Magnetic resonance imaging demonstrated bone marrow oedema in the painful bones .', {'entities': [(40, 44, 'B_Disease'), (45, 51, 'I_Disease'), (52, 58, 'I_Disease')]}], [\"Pain was not explained by other diseases causing foot pain , like reflex sympathetic dystrophy , polyneuropathy , Morton ' s neuralgia , gout , osteoporosis , avascular necrosis , intermittent claudication , orthopaedic foot deformities , stress fractures , and hyperparathyroidism .\", {'entities': [(0, 4, 'B_Disease'), (54, 58, 'B_Disease'), (66, 72, 'B_Disease'), (73, 84, 'I_Disease'), (85, 94, 'I_Disease'), (97, 111, 'B_Disease'), (114, 120, 'B_Disease'), (121, 122, 'I_Disease'), (123, 124, 'I_Disease'), (125, 134, 'I_Disease'), (137, 141, 'B_Disease'), (144, 156, 'B_Disease'), (159, 168, 'B_Disease'), (169, 177, 'I_Disease'), (180, 192, 'B_Disease'), (193, 205, 'I_Disease'), (220, 224, 'B_Disease'), (225, 236, 'I_Disease'), (239, 245, 'B_Disease'), (246, 255, 'I_Disease'), (262, 281, 'B_Disease')]}], ['The reduction of cyclosporine - or tacrolimus trough levels and the administration of calcium channel blockers led to relief of pain .', {'entities': [(128, 132, 'B_Disease')]}], ['The Calcineurin - inhibitor Induced Pain Syndrome ( CIPS ) is a rare but severe side effect of cyclosporine or tacrolimus and is accurately diagnosed by its typical presentation , magnetic resonance imaging and bone scans .', {'entities': [(36, 40, 'B_Disease'), (52, 56, 'B_Disease')]}], ['Incorrect diagnosis of the syndrome will lead to a significant reduction of life quality in patients suffering from CIPS .', {'entities': [(116, 120, 'B_Disease')]}], ['Brain natriuretic peptide is a predictor of anthracycline - induced cardiotoxicity .', {'entities': [(68, 82, 'B_Disease')]}], ['Anthracyclines are effective antineoplastic drugs , but they frequently cause dose - related cardiotoxicity .', {'entities': [(93, 107, 'B_Disease')]}], ['The cardiotoxicity of conventional anthracycline therapy highlights a need to search for methods that are highly sensitive and capable of predicting cardiac dysfunction .', {'entities': [(4, 18, 'B_Disease'), (149, 156, 'B_Disease'), (157, 168, 'I_Disease')]}], ['We measured the plasma level of brain natriuretic peptide ( BNP ) to determine whether BNP might serve as a simple diagnostic indicator of anthracycline - induced cardiotoxicity in patients with acute leukemia treated with a daunorubicin ( DNR ) - containing regimen .', {'entities': [(163, 177, 'B_Disease'), (195, 200, 'B_Disease'), (201, 209, 'I_Disease')]}], ['Thirteen patients with acute leukemia were treated with a DNR - containing regimen .', {'entities': [(23, 28, 'B_Disease'), (29, 37, 'I_Disease')]}], ['Three patients developed congestive heart failure after the completion of chemotherapy .', {'entities': [(25, 35, 'B_Disease'), (36, 41, 'I_Disease'), (42, 49, 'I_Disease')]}], ['Five patients were diagnosed as having subclinical heart failure after the completion of chemotherapy .', {'entities': [(51, 56, 'B_Disease'), (57, 64, 'I_Disease')]}], ['The plasma levels of BNP in all the patients with clinical and subclinical heart failure increased above the normal limit ( 40 pg / ml ) before the detection of clinical or subclinical heart failure by radionuclide angiography .', {'entities': [(75, 80, 'B_Disease'), (81, 88, 'I_Disease'), (185, 190, 'B_Disease'), (191, 198, 'I_Disease')]}], ['On the other hand , BNP did not increase in the patients without heart failure given DNR , even at more than 700 mg / m ( 2 ) .', {'entities': [(65, 70, 'B_Disease'), (71, 78, 'I_Disease')]}], ['The plasma level of ANP did not always increase in all the patients with clinical and subclinical heart failure .', {'entities': [(98, 103, 'B_Disease'), (104, 111, 'I_Disease')]}], ['These preliminary results suggest that BNP may be useful as an early and sensitive indicator of anthracycline - induced cardiotoxicity .', {'entities': [(120, 134, 'B_Disease')]}], ['Nephrotoxicity of combined cephalothin - gentamicin regimen .', {'entities': [(0, 14, 'B_Disease')]}], ['Two patients developed acute tubular necrosis , characterized clinically by acute oliguric renal failure , while they were receiving a combination of cephalothin sodium and gentamicin sulfate therapy .', {'entities': [(23, 28, 'B_Disease'), (29, 36, 'I_Disease'), (37, 45, 'I_Disease'), (82, 90, 'B_Disease'), (91, 96, 'I_Disease'), (97, 104, 'I_Disease')]}], ['Patients who are given this drug regimen should be observed very carefully for early signs of nephrotoxicity .', {'entities': [(94, 108, 'B_Disease')]}], ['Patients with renal insufficiency should not be given this regimen .', {'entities': [(14, 19, 'B_Disease'), (20, 33, 'I_Disease')]}], ['In vivo protection of dna damage associated apoptotic and necrotic cell deaths during acetaminophen - induced nephrotoxicity , amiodarone - induced lung toxicity and doxorubicin - induced cardiotoxicity by a novel IH636 grape seed proanthocyanidin extract .', {'entities': [(58, 66, 'B_Disease'), (110, 124, 'B_Disease'), (148, 152, 'B_Disease'), (153, 161, 'I_Disease'), (188, 202, 'B_Disease')]}], ['This study assessed the ability of IH636 grape seed proanthocyanidin extract ( GSPE ) to prevent acetaminophen ( AAP ) - induced nephrotoxicity , amiodarone ( AMI ) - induced lung toxicity , and doxorubicin ( DOX ) - induced cardiotoxicity in mice .', {'entities': [(129, 143, 'B_Disease'), (175, 179, 'B_Disease'), (180, 188, 'I_Disease'), (225, 239, 'B_Disease')]}], ['Histopathological examination of kidney , heart and lung sections revealed moderate to massive tissue damage with a variety of morphological aberrations by all the three drugs in the absence of GSPE preexposure than in its presence .', {'entities': [(95, 101, 'B_Disease'), (102, 108, 'I_Disease')]}], ['Interestingly , all the drugs , such as , AAP , AMI and DOX induced apoptotic death in addition to necrosis in the respective organs which was very effectively blocked by GSPE .', {'entities': [(99, 107, 'B_Disease')]}], ['Antidepressant - induced mania in bipolar patients : identification of risk factors .', {'entities': [(25, 30, 'B_Disease'), (34, 41, 'B_Disease')]}], ['BACKGROUND : Concerns about possible risks of switching to mania associated with antidepressants continue to interfere with the establishment of an optimal treatment paradigm for bipolar depression .', {'entities': [(59, 64, 'B_Disease'), (179, 186, 'B_Disease'), (187, 197, 'I_Disease')]}], ['METHOD : The response of 44 patients meeting DSM - IV criteria for bipolar disorder to naturalistic treatment was assessed for at least 6 weeks using the Montgomery - Asberg Depression Rating Scale and the Bech - Rafaelson Mania Rating Scale .', {'entities': [(67, 74, 'B_Disease'), (75, 83, 'I_Disease')]}], ['Patients who experienced a manic or hypomanic switch were compared with those who did not on several variables including age , sex , diagnosis ( DSM - IV bipolar I vs . bipolar II ) , number of previous manic episodes , type of antidepressant therapy used ( electroconvulsive therapy vs . antidepressant drugs and , more particularly , selective serotonin reuptake inhibitors [ SSRIs ] ) , use and type of mood stabilizers ( lithium vs . anticonvulsants ) , and temperament of the patient , assessed during a normothymic period using the hyperthymia component of the Semi - structured Affective Temperament Interview .', {'entities': [(27, 32, 'B_Disease'), (36, 45, 'B_Disease'), (145, 148, 'B_Disease'), (149, 150, 'I_Disease'), (151, 153, 'I_Disease'), (154, 161, 'I_Disease'), (162, 163, 'I_Disease'), (169, 176, 'B_Disease'), (177, 179, 'I_Disease'), (203, 208, 'B_Disease')]}], ['RESULTS : Switches to hypomania or mania occurred in 27 % of all patients ( N = 12 ) ( and in 24 % of the subgroup of patients treated with SSRIs [ 8 / 33 ] ) ; 16 % ( N = 7 ) experienced manic episodes , and 11 % ( N = 5 ) experienced hypomanic episodes .', {'entities': [(22, 31, 'B_Disease'), (35, 40, 'B_Disease'), (188, 193, 'B_Disease'), (236, 245, 'B_Disease')]}], ['Sex , age , diagnosis ( bipolar I vs . bipolar II ) , and additional treatment did not affect the risk of switching .', {'entities': [(24, 31, 'B_Disease'), (32, 33, 'I_Disease'), (39, 46, 'B_Disease'), (47, 49, 'I_Disease')]}], ['The number of previous manic episodes did not affect the probability of switching , whereas a high score on the hyperthymia component of the Semistructured Affective Temperament Interview was associated with a greater risk of switching ( p = . 008 ) .', {'entities': [(23, 28, 'B_Disease')]}], ['Peritubular capillary basement membrane reduplication in allografts and native kidney disease : a clinicopathologic study of 278 consecutive renal specimens .', {'entities': [(79, 85, 'B_Disease'), (86, 93, 'I_Disease')]}], ['BACKGROUND : An association has been found between transplant glomerulopathy ( TG ) and reduplication of peritubular capillary basement membranes ( PTCR ) .', {'entities': [(51, 61, 'B_Disease'), (62, 76, 'I_Disease'), (79, 81, 'B_Disease')]}], ['In addition to renal allografts with TG , we also examined grafts with acute rejection , recurrent glomerulonephritis , chronic allograft nephropathy and stable grafts ( \" protocol biopsies \" ) .', {'entities': [(37, 39, 'B_Disease'), (99, 117, 'B_Disease'), (120, 127, 'B_Disease'), (128, 137, 'I_Disease'), (138, 149, 'I_Disease')]}], ['Native kidney specimens included a wide range of glomerulopathies as well as cases of thrombotic microangiopathy , malignant hypertension , acute interstitial nephritis , and acute tubular necrosis .', {'entities': [(49, 65, 'B_Disease'), (86, 96, 'B_Disease'), (97, 112, 'I_Disease'), (115, 124, 'B_Disease'), (125, 137, 'I_Disease'), (146, 158, 'B_Disease'), (159, 168, 'I_Disease'), (175, 180, 'B_Disease'), (181, 188, 'I_Disease'), (189, 197, 'I_Disease')]}], ['RESULTS : We found PTCR in 14 of 15 cases of TG , in 7 transplant biopsy specimens without TG , and in 13 of 143 native kidney biopsy specimens .', {'entities': [(45, 47, 'B_Disease'), (91, 93, 'B_Disease')]}], ['These 13 included cases of malignant hypertension , thrombotic microangiopathy , lupus nephritis , Henoch - Schonlein nephritis , crescentic glomerulonephritis , and cocaine - related acute renal failure .', {'entities': [(27, 36, 'B_Disease'), (37, 49, 'I_Disease'), (52, 62, 'B_Disease'), (63, 78, 'I_Disease'), (81, 86, 'B_Disease'), (87, 96, 'I_Disease'), (99, 105, 'B_Disease'), (106, 107, 'I_Disease'), (108, 117, 'I_Disease'), (118, 127, 'I_Disease'), (141, 159, 'B_Disease'), (184, 189, 'B_Disease'), (190, 195, 'I_Disease'), (196, 203, 'I_Disease')]}], ['Mild PTCR in allografts without TG did not predict renal failure or significant proteinuria after follow - up periods of between 3 months and 1 year .', {'entities': [(32, 34, 'B_Disease'), (51, 56, 'B_Disease'), (57, 64, 'I_Disease'), (80, 91, 'B_Disease')]}], ['CONCLUSIONS : We conclude that in transplants , there is a strong association between well - developed PTCR and TG , while the significance of mild PTCR and its predictive value in the absence of TG is unclear .', {'entities': [(112, 114, 'B_Disease'), (196, 198, 'B_Disease')]}], ['PTCR also occurs in certain native kidney diseases , though the association is not as strong as that for TG .', {'entities': [(35, 41, 'B_Disease'), (42, 50, 'I_Disease'), (105, 107, 'B_Disease')]}], ['We suggest that repeated endothelial injury , including immunologic injury , may be the cause of this lesion both in allografts and native kidneys .', {'entities': [(25, 36, 'B_Disease'), (37, 43, 'I_Disease'), (56, 67, 'B_Disease'), (68, 74, 'I_Disease')]}], ['Caffeine - induced cardiac arrhythmia : an unrecognised danger of healthfood products .', {'entities': [(19, 26, 'B_Disease'), (27, 37, 'I_Disease')]}], ['We describe a 25 - year - old woman with pre - existing mitral valve prolapse who developed intractable ventricular fibrillation after consuming a \" natural energy \" guarana health drink containing a high concentration of caffeine .', {'entities': [(56, 62, 'B_Disease'), (63, 68, 'I_Disease'), (69, 77, 'I_Disease'), (104, 115, 'B_Disease'), (116, 128, 'I_Disease')]}], ['In behavioral studies , pre - treatment of mice with BD1018 , BD1063 , or LR132 significantly attenuated cocaine - induced convulsions and lethality .', {'entities': [(123, 134, 'B_Disease')]}], ['In contrast to the protection provided by the putative antagonists , the well - characterized sigma receptor agonist di - o - tolylguanidine ( DTG ) and the novel sigma receptor agonist BD1031 ( 3R - 1 - [ 2 - ( 3 , 4 - dichlorophenyl ) ethyl ] - 1 , 4 - diazabicyclo [ 4 . 3 . 0 ] nonane ) each worsened the behavioral toxicity of cocaine .', {'entities': [(320, 328, 'B_Disease')]}], ['To further validate the hypothesis that the anti - cocaine effects of the novel ligands involved antagonism of sigma receptors , an antisense oligodeoxynucleotide against sigma1 receptors was also shown to significantly attenuate the convulsive and locomotor stimulatory effects of cocaine .', {'entities': [(234, 244, 'B_Disease')]}], ['Ranitidine - induced acute interstitial nephritis in a cadaveric renal allograft .', {'entities': [(27, 39, 'B_Disease'), (40, 49, 'I_Disease')]}], ['This drug occasionally has been associated with acute interstitial nephritis in native kidneys .', {'entities': [(54, 66, 'B_Disease'), (67, 76, 'I_Disease')]}], ['We report a case of ranitidine - induced acute interstitial nephritis in a recipient of a cadaveric renal allograft presenting with acute allograft dysfunction within 48 hours of exposure to the drug .', {'entities': [(47, 59, 'B_Disease'), (60, 69, 'I_Disease')]}], ['Liver disease caused by propylthiouracil .', {'entities': [(0, 5, 'B_Disease'), (6, 13, 'I_Disease')]}], ['This report presents the clinical , laboratory , and light and electron microscopic observations on a patient with chronic active ( aggressive ) hepatitis caused by the administration of propylthiouracil .', {'entities': [(115, 122, 'B_Disease'), (123, 129, 'I_Disease'), (130, 131, 'I_Disease'), (132, 142, 'I_Disease'), (143, 144, 'I_Disease'), (145, 154, 'I_Disease')]}], ['This is an addition to the list of drugs that must be considered in the evaluation of chronic liver disease .', {'entities': [(94, 99, 'B_Disease'), (100, 107, 'I_Disease')]}], ['Withdrawal - emergent rabbit syndrome during dose reduction of risperidone .', {'entities': [(0, 10, 'B_Disease'), (11, 12, 'I_Disease'), (13, 21, 'I_Disease'), (22, 28, 'I_Disease'), (29, 37, 'I_Disease')]}], ['Rabbit syndrome ( RS ) is a rare extrapyramidal side effect caused by prolonged neuroleptic medication .', {'entities': [(0, 6, 'B_Disease'), (7, 15, 'I_Disease'), (18, 20, 'B_Disease')]}], ['Here we present a case of withdrawal - emergent RS , which is the first of its kind to be reported .', {'entities': [(26, 36, 'B_Disease'), (37, 38, 'I_Disease'), (39, 47, 'I_Disease'), (48, 50, 'I_Disease')]}], ['The patient developed RS during dose reduction of risperidone .', {'entities': [(22, 24, 'B_Disease')]}], ['The underlying mechanism of withdrawal - emergent RS in the present case may have been related to the pharmacological profile of risperidone , a serotonin - dopamine antagonist , suggesting the pathophysiologic influence of the serotonin system in the development of RS .', {'entities': [(28, 38, 'B_Disease'), (39, 40, 'I_Disease'), (41, 49, 'I_Disease'), (50, 52, 'I_Disease'), (267, 269, 'B_Disease')]}], ['Torsades de pointes ( TDP ) is a potentially fatal ventricular tachycardia associated with increases in QT interval and monophasic action potential duration ( MAPD ) .', {'entities': [(0, 8, 'B_Disease'), (9, 11, 'I_Disease'), (12, 19, 'I_Disease'), (22, 25, 'B_Disease'), (51, 62, 'B_Disease'), (63, 74, 'I_Disease')]}], ['TDP is a side - effect that has led to withdrawal of several drugs from the market ( e . g . terfenadine and terodiline ) .', {'entities': [(0, 3, 'B_Disease')]}], ['The potential of compounds to cause TDP was evaluated by monitoring their effects on MAPD in dog .', {'entities': [(36, 39, 'B_Disease')]}], ['Four compounds known to increase QT interval and cause TDP were investigated : terfenadine , terodiline , cisapride and E4031 .', {'entities': [(55, 58, 'B_Disease')]}], ['For compounds that have shown TDP in the clinic ( terfenadine , terodiline , cisapride ) there is little differentiation between the dog ED50 and the efficacious free plasma concentrations in man ( < 10 - fold ) reflecting their limited safety margins .', {'entities': [(30, 33, 'B_Disease')]}], ['These data underline the need to maximize the therapeutic ratio with respect to TDP in potential development candidates and the importance of using free drug concentrations in pharmacokinetic / pharmacodynamic studies .', {'entities': [(80, 83, 'B_Disease')]}], ['Bladder retention of urine as a result of continuous intravenous infusion of fentanyl : 2 case reports .', {'entities': [(8, 17, 'B_Disease'), (18, 20, 'I_Disease'), (21, 26, 'I_Disease')]}], ['Sedation has been commonly used in the neonate to decrease the stress and pain from the noxious stimuli and invasive procedures in the neonatal intensive care unit , as well as to facilitate synchrony between ventilator and spontaneous breaths .', {'entities': [(74, 78, 'B_Disease')]}], ['Various reported side effects of fentanyl administration include chest wall rigidity , hypotension , respiratory depression , and bradycardia .', {'entities': [(65, 70, 'B_Disease'), (71, 75, 'I_Disease'), (76, 84, 'I_Disease'), (87, 98, 'B_Disease'), (101, 112, 'B_Disease'), (113, 123, 'I_Disease'), (130, 141, 'B_Disease')]}], ['Here , 2 cases of urinary bladder retention leading to renal pelvocalyceal dilatation mimicking hydronephrosis as a result of continuous infusion of fentanyl are reported .', {'entities': [(18, 25, 'B_Disease'), (26, 33, 'I_Disease'), (34, 43, 'I_Disease'), (96, 110, 'B_Disease')]}], ['Fatal myeloencephalopathy due to accidental intrathecal vincristin administration : a report of two cases .', {'entities': [(6, 25, 'B_Disease')]}], ['We report on two fatal cases of accidental intrathecal vincristine instillation in a 5 - year old girl with recurrent acute lymphoblastic leucemia and a 57 - year old man with lymphoblastic lymphoma .', {'entities': [(118, 123, 'B_Disease'), (124, 137, 'I_Disease'), (138, 146, 'I_Disease'), (176, 189, 'B_Disease'), (190, 198, 'I_Disease')]}], ['Clinically , the onset was characterized by the signs of opistothonus , sensory and motor dysfunction and ascending paralysis .', {'entities': [(57, 69, 'B_Disease'), (70, 71, 'I_Disease'), (72, 79, 'I_Disease'), (80, 83, 'I_Disease'), (84, 89, 'I_Disease'), (90, 101, 'I_Disease'), (116, 125, 'B_Disease')]}], ['Histological and immunohistochemical investigations ( HE - LFB , CD - 68 , Neurofilament ) revealed degeneration of myelin and axons as well as pseudocystic transformation in areas exposed to vincristine , accompanied by secondary changes with numerous prominent macrophages .', {'entities': [(100, 112, 'B_Disease'), (113, 115, 'I_Disease'), (116, 122, 'I_Disease'), (123, 126, 'I_Disease'), (127, 132, 'I_Disease'), (144, 156, 'B_Disease'), (157, 171, 'I_Disease')]}], ['Palpebral twitching in a depressed adolescent on citalopram .', {'entities': [(0, 9, 'B_Disease'), (10, 19, 'I_Disease'), (25, 34, 'B_Disease')]}], ['Current estimates suggest that between 0 . 4 % and 8 . 3 % of children and adolescents are affected by major depression .', {'entities': [(103, 108, 'B_Disease'), (109, 119, 'I_Disease')]}], ['We report a favorable response to treatment with citalopram by a 15 - year - old boy with major depression who exhibited palpebral twitching during his first 2 weeks of treatment .', {'entities': [(90, 95, 'B_Disease'), (96, 106, 'I_Disease'), (121, 130, 'B_Disease'), (131, 140, 'I_Disease')]}], ['A 34 - year - old lady developed a constellation of dermatitis , fever , lymphadenopathy and hepatitis , beginning on the 17th day of a course of oral sulphasalazine for sero - negative rheumatoid arthritis .', {'entities': [(52, 62, 'B_Disease'), (65, 70, 'B_Disease'), (73, 88, 'B_Disease'), (93, 102, 'B_Disease'), (186, 196, 'B_Disease'), (197, 206, 'I_Disease')]}], ['Cervical and inguinal lymph node biopsies showed the features of severe necrotising lymphadenitis , associated with erythrophagocytosis and prominent eosinophilic infiltrates , without viral inclusion bodies , suggestive of an adverse drug reaction . A week later , fulminant drug - induced hepatitis , associated with the presence of anti - nuclear autoantibodies ( but not with other markers of autoimmunity ) , and accompanied by multi - organ failure and sepsis , supervened .', {'entities': [(84, 97, 'B_Disease'), (227, 234, 'B_Disease'), (235, 239, 'I_Disease'), (240, 248, 'I_Disease'), (276, 280, 'B_Disease'), (281, 282, 'I_Disease'), (283, 290, 'I_Disease'), (291, 300, 'I_Disease'), (397, 409, 'B_Disease'), (433, 438, 'B_Disease'), (439, 440, 'I_Disease'), (441, 446, 'I_Disease'), (447, 454, 'I_Disease'), (459, 465, 'B_Disease')]}], ['She subsequently died some 5 weeks after the commencement of her drug therapy . Post - mortem examination showed evidence of massive hepatocellular necrosis , acute hypersensitivity myocarditis , focal acute tubulo - interstitial nephritis and extensive bone marrow necrosis , with no evidence of malignancy .', {'entities': [(125, 132, 'B_Disease'), (133, 147, 'I_Disease'), (148, 156, 'I_Disease'), (182, 193, 'B_Disease'), (230, 239, 'B_Disease'), (254, 258, 'B_Disease'), (259, 265, 'I_Disease'), (266, 274, 'I_Disease'), (297, 307, 'B_Disease')]}], ['Intravenous administration of prochlorperazine by 15 - minute infusion versus 2 - minute bolus does not affect the incidence of akathisia : a prospective , randomized , controlled trial .', {'entities': [(128, 137, 'B_Disease')]}], ['STUDY OBJECTIVE : We sought to compare the rate of akathisia after administration of intravenous prochlorperazine as a 2 - minute bolus or 15 - minute infusion .', {'entities': [(51, 60, 'B_Disease')]}], ['Patients aged 18 years or older treated with prochlorperazine for headache , nausea , or vomiting were eligible for inclusion .', {'entities': [(66, 74, 'B_Disease'), (77, 83, 'B_Disease'), (89, 97, 'B_Disease')]}], ['The main outcome was the number of study participants experiencing akathisia within 60 minutes of administration .', {'entities': [(67, 76, 'B_Disease')]}], ['Akathisia was defined as either a spontaneous report of restlessness or agitation or a change of 2 or more in the patient - reported akathisia rating scale and a change of at least 1 in the investigator - observed akathisia rating scale .', {'entities': [(72, 81, 'B_Disease'), (133, 142, 'B_Disease'), (214, 223, 'B_Disease')]}], ['The intensity of headache and nausea was measured with a 100 - mm visual analog scale .', {'entities': [(17, 25, 'B_Disease'), (30, 36, 'B_Disease')]}], ['Seventy - three percent ( 73 / 99 ) of the study participants were treated for headache and 70 % ( 70 / 99 ) for nausea .', {'entities': [(79, 87, 'B_Disease'), (113, 119, 'B_Disease')]}], ['In the bolus group , 26 . 0 % ( 13 / 50 ) had akathisia compared with 32 . 7 % ( 16 / 49 ) in the infusion group ( Delta = - 6 . 7 % ; 95 % confidence interval [ CI ] - 24 . 6 % to 11 . 2 % ) .', {'entities': [(46, 55, 'B_Disease')]}], ['The difference between the bolus and infusion groups in the percentage of participants who saw a 50 % reduction in their headache intensity within 30 minutes was 11 . 8 % ( 95 % CI - 9 . 6 % to 33 . 3 % ) .', {'entities': [(121, 129, 'B_Disease')]}], ['The difference in the percentage of patients with a 50 % reduction in their nausea was 12 . 6 % ( 95 % CI - 4 . 6 % to 29 . 8 % ) .', {'entities': [(76, 82, 'B_Disease')]}], ['CONCLUSION : A 50 % reduction in the incidence of akathisia when prochlorperazine was administered by means of 15 - minute intravenous infusion versus a 2 - minute intravenous push was not detected .', {'entities': [(50, 59, 'B_Disease')]}], ['The efficacy of prochlorperazine in the treatment of headache and nausea likewise did not appear to be affected by the rate of administration , although no formal statistical comparisons were made .', {'entities': [(53, 61, 'B_Disease'), (66, 72, 'B_Disease')]}], ['Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice .', {'entities': [(39, 53, 'B_Disease'), (96, 100, 'B_Disease')]}], ['Highly active antiretroviral therapy ( HAART ) is implicated in cardiomyopathy ( CM ) and in elevated plasma lactate ( LA ) in AIDS through mechanisms of mitochondrial dysfunction .', {'entities': [(64, 78, 'B_Disease'), (81, 83, 'B_Disease'), (127, 131, 'B_Disease'), (154, 167, 'B_Disease'), (168, 179, 'I_Disease')]}], ['To determine mitochondrial events from HAART in vivo , 8 - week - old hemizygous transgenic AIDS mice ( NL4 - 3Delta gag / pol ; TG ) and wild - type FVB / n littermates were treated with the HAART combination of zidovudine , lamivudine , and indinavir or vehicle control for 10 days or 35 days .', {'entities': [(92, 96, 'B_Disease')]}], ['At termination of the experiments , mice underwent echocardiography , quantitation of abundance of molecular markers of CM ( ventricular mRNA encoding atrial natriuretic factor [ ANF ] and sarcoplasmic calcium ATPase [ SERCA2 ] ) , and determination of plasma LA .', {'entities': [(120, 122, 'B_Disease')]}], ['Results show that cumulative HAART caused mitochondrial CM with elevated LA in AIDS transgenic mice .', {'entities': [(56, 58, 'B_Disease'), (79, 83, 'B_Disease')]}], ['A Phase II trial of cisplatin plus WR - 2721 ( amifostine ) for metastatic breast carcinoma : an Eastern Cooperative Oncology Group Study ( E8188 ) .', {'entities': [(75, 81, 'B_Disease'), (82, 91, 'I_Disease')]}], ['BACKGROUND : Cisplatin has minimal antitumor activity when used as second - or third - line treatment of metastatic breast carcinoma .', {'entities': [(116, 122, 'B_Disease'), (123, 132, 'I_Disease')]}], ['Although a dose - response effect has been observed with cisplatin , the dose - limiting toxicities associated with cisplatin ( e . g . , nephrotoxicity , ototoxicity , and neurotoxicity ) have limited its use as a treatment for breast carcinoma .', {'entities': [(89, 99, 'B_Disease'), (138, 152, 'B_Disease'), (155, 166, 'B_Disease'), (173, 186, 'B_Disease'), (229, 235, 'B_Disease'), (236, 245, 'I_Disease')]}], ['Early trials of cisplatin and amifostine also suggested that the incidence and severity of cisplatin - induced nephrotoxicity , ototoxicity , and neuropathy were reduced .', {'entities': [(111, 125, 'B_Disease'), (128, 139, 'B_Disease'), (146, 156, 'B_Disease')]}], ['METHODS : A Phase II study of the combination of cisplatin plus amifostine was conducted in patients with progressive metastatic breast carcinoma who had received one , but not more than one , chemotherapy regimen for metastatic disease .', {'entities': [(129, 135, 'B_Disease'), (136, 145, 'I_Disease')]}], ['Neurologic toxicity was reported in 52 % of patients .', {'entities': [(0, 10, 'B_Disease'), (11, 19, 'I_Disease')]}], ['Seven different life - threatening toxicities were observed in patients while receiving treatment .', {'entities': [(35, 45, 'B_Disease')]}], ['Neither a tumor - protective effect nor reduced toxicity to normal tissues was observed with the addition of amifostine to cisplatin in this trial .', {'entities': [(10, 15, 'B_Disease'), (48, 56, 'B_Disease')]}], ['Oral contraceptives and the risk of myocardial infarction .', {'entities': [(36, 46, 'B_Disease'), (47, 57, 'I_Disease')]}], ['BACKGROUND : An association between the use of oral contraceptives and the risk of myocardial infarction has been found in some , but not all , studies .', {'entities': [(83, 93, 'B_Disease'), (94, 104, 'I_Disease')]}], ['We investigated this association , according to the type of progestagen included in third - generation ( i . e . , desogestrel or gestodene ) and second - generation ( i . e . , levonorgestrel ) oral contraceptives , the dose of estrogen , and the presence or absence of prothrombotic mutations METHODS : In a nationwide , population - based , case - control study , we identified and enrolled 248 women 18 through 49 years of age who had had a first myocardial infarction between 1990 and 1995 and 925 control women who had not had a myocardial infarction and who were matched for age , calendar year of the index event , and area of residence .', {'entities': [(451, 461, 'B_Disease'), (462, 472, 'I_Disease'), (535, 545, 'B_Disease'), (546, 556, 'I_Disease')]}], ['An analysis for factor V Leiden and the G20210A mutation in the prothrombin gene was conducted in 217 patients and 763 controls RESULTS : The odds ratio for myocardial infarction among women who used any type of combined oral contraceptive , as compared with nonusers , was 2 . 0 ( 95 percent confidence interval , 1 . 5 to 2 . 8 ) .', {'entities': [(157, 167, 'B_Disease'), (168, 178, 'I_Disease')]}], ['Among women who used oral contraceptives , the odds ratio was 2 . 1 ( 95 percent confidence interval , 1 . 5 to 3 . 0 ) for those without a prothrombotic mutation and 1 . 9 ( 95 percent confidence interval , 0 . 6 to 5 . 5 ) for those with a mutation CONCLUSIONS : The risk of myocardial infarction was increased among women who used second - generation oral contraceptives .', {'entities': [(277, 287, 'B_Disease'), (288, 298, 'I_Disease')]}], ['The risk of myocardial infarction was similar among women who used oral contraceptives whether or not they had a prothrombotic mutation .', {'entities': [(12, 22, 'B_Disease'), (23, 33, 'I_Disease')]}], ['End - stage renal disease ( ESRD ) after orthotopic liver transplantation ( OLTX ) using calcineurin - based immunotherapy : risk of development and treatment .', {'entities': [(0, 3, 'B_Disease'), (4, 5, 'I_Disease'), (6, 11, 'I_Disease'), (12, 17, 'I_Disease'), (18, 25, 'I_Disease'), (28, 32, 'B_Disease')]}], ['BACKGROUND : The calcineurin inhibitors cyclosporine and tacrolimus are both known to be nephrotoxic .', {'entities': [(89, 100, 'B_Disease')]}], ['Recently , however , we have had an increase of patients who are presenting after OLTX with end - stage renal disease ( ESRD ) .', {'entities': [(92, 95, 'B_Disease'), (96, 97, 'I_Disease'), (98, 103, 'I_Disease'), (104, 109, 'I_Disease'), (110, 117, 'I_Disease'), (120, 124, 'B_Disease')]}], ['This retrospective study examines the incidence and treatment of ESRD and chronic renal failure ( CRF ) in OLTX patients .', {'entities': [(65, 69, 'B_Disease'), (74, 81, 'B_Disease'), (82, 87, 'I_Disease'), (88, 95, 'I_Disease'), (98, 101, 'B_Disease')]}], ['Patients were divided into three groups : Controls , no CRF or ESRD , n = 748 ; CRF , sustained serum creatinine > 2 . 5 mg / dl , n = 41 ; and ESRD , n = 45 .', {'entities': [(56, 59, 'B_Disease'), (63, 67, 'B_Disease'), (80, 83, 'B_Disease'), (144, 148, 'B_Disease')]}], ['Groups were compared for preoperative laboratory variables , diagnosis , postoperative variables , survival , type of ESRD therapy , and survival from onset of ESRD .', {'entities': [(118, 122, 'B_Disease'), (160, 164, 'B_Disease')]}], ['RESULTS : At 13 years after OLTX , the incidence of severe renal dysfunction was 18 . 1 % ( CRF 8 . 6 % and ESRD 9 . 5 % ) .', {'entities': [(59, 64, 'B_Disease'), (65, 76, 'I_Disease'), (92, 95, 'B_Disease'), (108, 112, 'B_Disease')]}], ['Compared with control patients , CRF and ESRD patients had higher preoperative serum creatinine levels , a greater percentage of patients with hepatorenal syndrome , higher percentage requirement for dialysis in the first 3 months postoperatively , and a higher 1 - year serum creatinine .', {'entities': [(33, 36, 'B_Disease'), (41, 45, 'B_Disease'), (143, 154, 'B_Disease'), (155, 163, 'I_Disease')]}], ['Multivariate stepwise logistic regression analysis using preoperative and postoperative variables identified that an increase of serum creatinine compared with average at 1 year , 3 months , and 4 weeks postoperatively were independent risk factors for the development of CRF or ESRD with odds ratios of 2 . 6 , 2 . 2 , and 1 . 6 , respectively .', {'entities': [(272, 275, 'B_Disease'), (279, 283, 'B_Disease')]}], ['Overall survival from the time of OLTX was not significantly different among groups , but by year 13 , the survival of the patients who had ESRD was only 28 . 2 % compared with 54 . 6 % in the control group .', {'entities': [(140, 144, 'B_Disease')]}], ['Patients developing ESRD had a 6 - year survival after onset of ESRD of 27 % for the patients receiving hemodialysis versus 71 . 4 % for the patients developing ESRD who subsequently received kidney transplants .', {'entities': [(20, 24, 'B_Disease'), (64, 68, 'B_Disease'), (161, 165, 'B_Disease')]}], ['CONCLUSIONS : Patients who are more than 10 years post - OLTX have CRF and ESRD at a high rate .', {'entities': [(67, 70, 'B_Disease'), (75, 79, 'B_Disease')]}], ['The development of ESRD decreases survival , particularly in those patients treated with dialysis only .', {'entities': [(19, 23, 'B_Disease')]}], ['Patients who develop ESRD have a higher preoperative and 1 - year serum creatinine and are more likely to have hepatorenal syndrome .', {'entities': [(21, 25, 'B_Disease'), (111, 122, 'B_Disease'), (123, 131, 'I_Disease')]}], ['However , an increase of serum creatinine at various times postoperatively is more predictive of the development of CRF or ESRD .', {'entities': [(116, 119, 'B_Disease'), (123, 127, 'B_Disease')]}], ['Epileptic seizures following cortical application of fibrin sealants containing tranexamic acid in rats .', {'entities': [(0, 9, 'B_Disease'), (10, 18, 'I_Disease')]}], ['However , tAMCA has been shown to cause epileptic seizures .', {'entities': [(40, 49, 'B_Disease'), (50, 58, 'I_Disease')]}], ['We wanted to study whether tAMCA retains its convulsive action if incorporated into a FS .', {'entities': [(45, 55, 'B_Disease')]}], ['FINDINGS : FS containing tAMCA caused paroxysmal brain activity which was associated with distinct convulsive behaviours .', {'entities': [(99, 109, 'B_Disease')]}], ['The degree of these seizures increased with increasing concentration of tAMCA .', {'entities': [(20, 28, 'B_Disease')]}], ['Thus , FS containing 47 . 5 mg / ml tAMCA evoked generalized seizures in all tested rats ( n = 6 ) while the lowest concentration of tAMCA ( 0 . 5 mg / ml ) only evoked brief episodes of jerk - correlated convulsive potentials in 1 of 6 rats .', {'entities': [(49, 60, 'B_Disease'), (61, 69, 'I_Disease'), (205, 215, 'B_Disease')]}], ['INTERPRETATION : Tranexamic acid retains its convulsive action within FS .', {'entities': [(45, 55, 'B_Disease')]}], ['Sequential observations of exencephaly and subsequent morphological changes by mouse exo utero development system : analysis of the mechanism of transformation from exencephaly to anencephaly .', {'entities': [(27, 38, 'B_Disease'), (165, 176, 'B_Disease'), (180, 191, 'B_Disease')]}], ['Anencephaly has been suggested to develop from exencephaly ; however , there is little direct experimental evidence to support this , and the mechanism of transformation remains unclear .', {'entities': [(0, 11, 'B_Disease'), (47, 58, 'B_Disease')]}], ['We observed the exencephaly induced by 5 - azacytidine at embryonic day 13 . 5 ( E13 . 5 ) , let the embryos develop exo utero until E18 . 5 , and re - observed the same embryos at E18 . 5 .', {'entities': [(16, 27, 'B_Disease')]}], ['We confirmed several cases of transformation from exencephaly to anencephaly .', {'entities': [(50, 61, 'B_Disease'), (65, 76, 'B_Disease')]}], ['However , in many cases , the exencephalic brain tissue was preserved with more or less reduction during this period .', {'entities': [(30, 42, 'B_Disease')]}], ['To analyze the transformation patterns , we classified the exencephaly by size and shape of the exencephalic tissue into several types at E13 . 5 and E18 . 5 .', {'entities': [(59, 70, 'B_Disease'), (96, 108, 'B_Disease')]}], ['It was found that the transformation of exencephalic tissue was not simply size - dependent , and all cases of anencephaly at E18 . 5 resulted from embryos with a large amount of exencephalic tissue at E13 . 5 .', {'entities': [(40, 52, 'B_Disease'), (111, 122, 'B_Disease'), (179, 191, 'B_Disease')]}], ['Microscopic observation showed the configuration of exencephaly at E13 . 5 , frequent hemorrhaging and detachment of the neural plate from surface ectoderm in the exencephalic head at E15 . 5 , and multiple modes of reduction in the exencephalic tissue at E18 . 5 .', {'entities': [(52, 63, 'B_Disease'), (86, 98, 'B_Disease'), (163, 175, 'B_Disease'), (233, 245, 'B_Disease')]}], ['From observations of the vasculature , altered distribution patterns of vessels were identified in the exencephalic head .', {'entities': [(103, 115, 'B_Disease')]}], ['These findings suggest that overgrowth of the exencephalic neural tissue causes the altered distribution patterns of vessels , subsequent peripheral circulatory failure and / or hemorrhaging in various parts of the exencephalic head , leading to the multiple modes of tissue reduction during transformation from exencephaly to anencephaly .', {'entities': [(46, 58, 'B_Disease'), (149, 160, 'B_Disease'), (161, 168, 'I_Disease'), (178, 190, 'B_Disease'), (215, 227, 'B_Disease'), (312, 323, 'B_Disease'), (327, 338, 'B_Disease')]}], ['99mTc - glucarate for detection of isoproterenol - induced myocardial infarction in rats .', {'entities': [(59, 69, 'B_Disease'), (70, 80, 'I_Disease')]}], ['Infarct - avid radiopharmaceuticals are necessary for rapid and timely diagnosis of acute myocardial infarction .', {'entities': [(0, 7, 'B_Disease'), (90, 100, 'B_Disease'), (101, 111, 'I_Disease')]}], ['The animal model used to produce infarction implies artery ligation but chemical induction can be easily obtained with isoproterenol .', {'entities': [(33, 43, 'B_Disease')]}], ['A new infarct - avid radiopharmaceutical based on glucaric acid was prepared in the hospital radiopharmacy of the INCMNSZ .', {'entities': [(6, 13, 'B_Disease')]}], ['99mTc - glucarate was easy to prepare , stable for 96 h and was used to study its biodistribution in rats with isoproterenol - induced acute myocardial infarction .', {'entities': [(141, 151, 'B_Disease'), (152, 162, 'I_Disease')]}], ['Histological studies demonstrated that the rats developed an infarct 18 h after isoproterenol administration .', {'entities': [(61, 68, 'B_Disease')]}], ['The high image quality suggests that high contrast images can be obtained in humans and the 96 h stability makes it an ideal agent to detect , in patients , early cardiac infarction .', {'entities': [(163, 170, 'B_Disease'), (171, 181, 'I_Disease')]}], ['Bupropion ( Zyban ) toxicity .', {'entities': [(20, 28, 'B_Disease')]}], [\"In the initial 6 months since it ' s introduction , 12 overdose cases have been reported to The National Poisons Information Centre .\", {'entities': [(55, 63, 'B_Disease')]}], ['8 patients developed symptoms of toxicity .', {'entities': [(33, 41, 'B_Disease')]}], ['Common features included tachycardia , drowsiness , hallucinations and convulsions .', {'entities': [(25, 36, 'B_Disease'), (52, 66, 'B_Disease'), (71, 82, 'B_Disease')]}], ['Two patients developed severe cardiac arrhythmias , including one patient who was resuscitated following a cardiac arrest .', {'entities': [(30, 37, 'B_Disease'), (38, 49, 'I_Disease'), (107, 114, 'B_Disease'), (115, 121, 'I_Disease')]}], ['Recurrent seizures were treated with diazepam and broad complex tachycardia was successfully treated with adenosine .', {'entities': [(10, 18, 'B_Disease'), (64, 75, 'B_Disease')]}], ['Zyban caused significant neurological and cardiovascular toxicity in overdose .', {'entities': [(25, 37, 'B_Disease'), (38, 41, 'I_Disease'), (42, 56, 'I_Disease'), (57, 65, 'I_Disease'), (69, 77, 'B_Disease')]}], ['GLEPP1 receptor tyrosine phosphatase ( Ptpro ) in rat PAN nephrosis .', {'entities': [(58, 67, 'B_Disease')]}], ['To better understand the utility of GLEPP1 as a marker of glomerular injury , the amount and distribution of GLEPP1 protein and mRNA were examined by immunohistochemistry , Western blot and RNase protection assay in a model of podocyte injury in the rat .', {'entities': [(58, 68, 'B_Disease'), (69, 75, 'I_Disease')]}], ['Puromycin aminonucleoside nephrosis was induced by single intraperitoneal injection of puromycin aminonucleoside ( PAN , 20 mg / 100g BW ) .', {'entities': [(26, 35, 'B_Disease')]}], ['Tissues were analyzed at 0 , 5 , 7 , 11 , 21 , 45 , 80 and 126 days after PAN injection so as to include both the acute phase of proteinuria associated with foot process effacement ( days 5 - 11 ) and the chronic phase of proteinuria associated with glomerulosclerosis ( days 45 - 126 ) .', {'entities': [(129, 140, 'B_Disease'), (222, 233, 'B_Disease'), (250, 268, 'B_Disease')]}], ['Antithymocyte globulin in the treatment of D - penicillamine - induced aplastic anemia .', {'entities': [(71, 79, 'B_Disease'), (80, 86, 'I_Disease')]}], ['A patient who received antithymocyte globulin therapy for aplastic anemia due to D - penicillamine therapy is described .', {'entities': [(58, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['Use of antithymocyte globulin may be the optimal treatment of D - penicillamine - induced aplastic anemia .', {'entities': [(90, 98, 'B_Disease'), (99, 105, 'I_Disease')]}], ['Metamizol potentiates morphine antinociception but not constipation after chronic treatment .', {'entities': [(55, 67, 'B_Disease')]}], ['This work evaluates the antinociceptive and constipating effects of the combination of 3 . 2 mg / kg s . c . morphine with 177 . 8 mg / kg s . c . metamizol in acutely and chronically treated ( once a day for 12 days ) rats .', {'entities': [(44, 56, 'B_Disease')]}], ['On the 13th day , antinociceptive effects were assessed using a model of inflammatory nociception , pain - induced functional impairment model , and the charcoal meal test was used to evaluate the intestinal transit .', {'entities': [(100, 104, 'B_Disease')]}], ['In independent groups , morphine inhibited the intestinal transit in 48 + / - 4 % and 38 + / - 4 % after acute and chronic treatment , respectively , suggesting that tolerance did not develop to the constipating effects .', {'entities': [(199, 211, 'B_Disease')]}], ['The combination inhibited intestinal transit similar to that produced by morphine regardless of the time of treatment , suggesting that metamizol did not potentiate morphine - induced constipation .', {'entities': [(184, 196, 'B_Disease')]}], ['These findings show a significant interaction between morphine and metamizol in chronically treated rats , suggesting that this combination could be useful for the treatment of chronic pain .', {'entities': [(177, 184, 'B_Disease'), (185, 189, 'I_Disease')]}], ['Ifosfamide encephalopathy presenting with asterixis .', {'entities': [(11, 25, 'B_Disease'), (42, 51, 'B_Disease')]}], ['We report a case of a 51 - year - old man who developed severe , disabling negative myoclonus of the upper and lower extremities after the infusion of ifosfamide for plasmacytoma .', {'entities': [(84, 93, 'B_Disease'), (166, 178, 'B_Disease')]}], ['Cranial magnetic resonance imaging and extensive laboratory studies failed to reveal structural lesions of the brain and metabolic abnormalities .', {'entities': [(85, 95, 'B_Disease'), (96, 103, 'I_Disease'), (104, 106, 'I_Disease'), (107, 110, 'I_Disease'), (111, 116, 'I_Disease'), (121, 130, 'B_Disease'), (131, 144, 'I_Disease')]}], ['An electroencephalogram showed continuous , generalized irregular slowing with admixed periodic triphasic waves indicating symptomatic encephalopathy .', {'entities': [(135, 149, 'B_Disease')]}], ['The administration of ifosfamide was discontinued and within 12 h the asterixis resolved completely .', {'entities': [(70, 79, 'B_Disease')]}], ['In the patient described , the presence of asterixis during infusion of ifosfamide , normal laboratory findings and imaging studies and the resolution of symptoms following the discontinuation of the drug suggest that negative myoclonus is associated with the use of IFX .', {'entities': [(43, 52, 'B_Disease'), (227, 236, 'B_Disease')]}], ['Antagonism between interleukin 3 and erythropoietin in mice with azidothymidine - induced anemia and in bone marrow endothelial cells .', {'entities': [(90, 96, 'B_Disease')]}], ['Azidothymidine ( AZT ) - induced anemia in mice can be reversed by the administration of IGF - IL - 3 ( fusion protein of insulin - like growth factor II ( IGF II ) and interleukin 3 ) .', {'entities': [(33, 39, 'B_Disease')]}], ['The relationship between hippocampal acetylcholine release and cholinergic convulsant sensitivity in withdrawal seizure - prone and withdrawal seizure - resistant selected mouse lines .', {'entities': [(112, 119, 'B_Disease'), (143, 150, 'B_Disease')]}], ['METHODS : Cholinergic convulsant sensitivity was examined in alcohol - na ve Withdrawal Seizure - Prone ( WSP ) and - Resistant ( WSR ) mice .', {'entities': [(88, 95, 'B_Disease')]}], ['Animals were administered nicotine , carbachol , or neostigmine via timed tail vein infusion , and the latencies to onset of tremor and clonus were recorded and converted to threshold dose .', {'entities': [(125, 131, 'B_Disease')]}], ['Hippocampal ACh also was measured during testing for handling - induced convulsions .', {'entities': [(72, 83, 'B_Disease')]}], ['RESULTS : Sensitivity to several convulsion endpoints induced by nicotine , carbachol , and neostigmine were significantly greater in WSR versus WSP mice .', {'entities': [(33, 43, 'B_Disease')]}], ['When hippocampal ACh was measured during testing for handling - induced convulsions , extracellular ACh was significantly elevated ( 192 % ) in WSP mice , but was nonsignificantly elevated ( 59 % ) in WSR mice .', {'entities': [(72, 83, 'B_Disease')]}], ['CONCLUSIONS : These results suggest that differences in cholinergic activity and postsynaptic sensitivity to cholinergic convulsants may be associated with ethanol withdrawal severity and implicate cholinergic mechanisms in alcohol withdrawal .', {'entities': [(121, 132, 'B_Disease')]}], ['Specifically , WSP mice may have lower sensitivity to cholinergic convulsants compared with WSR because of postsynaptic receptor desensitization brought on by higher activity of cholinergic neurons .', {'entities': [(66, 77, 'B_Disease')]}], ['Capsaicin - induced muscle pain alters the excitability of the human jaw - stretch reflex .', {'entities': [(20, 26, 'B_Disease'), (27, 31, 'I_Disease')]}], ['The pathophysiology of painful temporomandibular disorders is not fully understood , but evidence suggests that muscle pain modulates motor function in characteristic ways .', {'entities': [(31, 48, 'B_Disease'), (49, 58, 'I_Disease'), (112, 118, 'B_Disease'), (119, 123, 'I_Disease')]}], ['This study tested the hypothesis that activation of nociceptive muscle afferent fibers would be linked to an increased excitability of the human jaw - stretch reflex and whether this process would be sensitive to length and velocity of the stretch .', {'entities': [(52, 63, 'B_Disease'), (64, 70, 'I_Disease')]}], ['Capsaicin ( 10 micro g ) was injected into the masseter muscle to induce pain in 11 healthy volunteers .', {'entities': [(73, 77, 'B_Disease')]}], ['Short - latency reflex responses were evoked in the masseter and temporalis muscles by a stretch device with different velocities and displacements before , during , and after the pain .', {'entities': [(180, 184, 'B_Disease')]}], ['The normalized reflex amplitude was significantly higher during pain , but only at faster stretches in the painful muscle .', {'entities': [(64, 68, 'B_Disease'), (107, 114, 'B_Disease'), (115, 121, 'I_Disease')]}], ['Increased sensitivity of the fusimotor system during acute muscle pain could be one likely mechanism to explain the findings .', {'entities': [(59, 65, 'B_Disease'), (66, 70, 'I_Disease')]}], ['Effects of 5 - HT1B receptor ligands microinjected into the accumbal shell or core on the cocaine - induced locomotor hyperactivity in rats .', {'entities': [(108, 117, 'B_Disease'), (118, 131, 'I_Disease')]}], ['The present study was designed to examine the effect of 5 - HT1B receptor ligands microinjected into the subregions of the nucleus accumbens ( the shell and the core ) on the locomotor hyperactivity induced by cocaine in rats .', {'entities': [(175, 184, 'B_Disease'), (185, 198, 'I_Disease')]}], ['GR 55562 ( 0 . 1 - 10 microg / side ) , administered intra - accumbens shell prior to cocaine , dose - dependently attenuated the psychostimulant - induced locomotor hyperactivity .', {'entities': [(156, 165, 'B_Disease'), (166, 179, 'I_Disease')]}], ['Our findings indicate that cocaine induced hyperlocomotion is modified by 5 - HT1B receptor ligands microinjected into the accumbens shell , but not core , this modification consisting in inhibitory and facilitatory effects of the 5 - HT1B receptor antagonist ( GR 55562 ) and agonist ( CP 93129 ) , respectively .', {'entities': [(43, 58, 'B_Disease')]}], ['Cocaine related chest pain : are we seeing the tip of an iceberg ?', {'entities': [(16, 21, 'B_Disease'), (22, 26, 'I_Disease')]}], ['In particular , the tendency of cocaine to produce chest pain ought to be in the mind of the emergency nurse when faced with a young victim of chest pain who is otherwise at low risk .', {'entities': [(51, 56, 'B_Disease'), (57, 61, 'I_Disease'), (143, 148, 'B_Disease'), (149, 153, 'I_Disease')]}], ['The mechanism of chest pain related to cocaine use is discussed and treatment dilemmas are discussed .', {'entities': [(17, 22, 'B_Disease'), (23, 27, 'I_Disease')]}], ['Crossover comparison of efficacy and preference for rizatriptan 10 mg versus ergotamine / caffeine in migraine .', {'entities': [(102, 110, 'B_Disease')]}], ['Rizatriptan is a selective 5 - HT ( 1B / 1D ) receptor agonist with rapid oral absorption and early onset of action in the acute treatment of migraine .', {'entities': [(142, 150, 'B_Disease')]}], ['This randomized double - blind crossover outpatient study assessed the preference for 1 rizatriptan 10 mg tablet to 2 ergotamine 1 mg / caffeine 100 mg tablets in 439 patients treating a single migraine attack with each therapy .', {'entities': [(194, 202, 'B_Disease')]}], ['Faster relief of headache was the most important reason for preference , cited by 67 . 3 % of patients preferring rizatriptan and 54 . 2 % of patients who preferred ergotamine / caffeine .', {'entities': [(17, 25, 'B_Disease')]}], ['The co - primary endpoint of being pain free at 2 h was also in favor of rizatriptan .', {'entities': [(35, 39, 'B_Disease')]}], ['Forty - nine percent of patients were pain free 2 h after rizatriptan , compared with 24 . 3 % treated with ergotamine / caffeine ( p < or = 0 . 001 ) , rizatriptan being superior within 1 h of treatment .', {'entities': [(38, 42, 'B_Disease')]}], ['Headache relief at 2 h was 75 . 9 % for rizatriptan and 47 . 3 % for ergotamine / caffeine ( p < or = 0 . 001 ) , with rizatriptan being superior to ergotamine / caffeine within 30 min of dosing .', {'entities': [(0, 8, 'B_Disease')]}], ['Almost 36 % of patients taking rizatriptan were pain free at 2 h and had no recurrence or need for additional medication within 24 h , compared to 20 % of patients on ergotamine / caffeine ( p < or = 0 . 001 ) .', {'entities': [(48, 52, 'B_Disease')]}], ['Rizatriptan was also superior to ergotamine / caffeine in the proportions of patients with no nausea , vomiting , phonophobia or photophobia and for patients with normal function 2 h after drug intake ( p < or = 0 . 001 ) .', {'entities': [(94, 100, 'B_Disease'), (103, 111, 'B_Disease'), (114, 125, 'B_Disease'), (129, 140, 'B_Disease')]}], ['The most common adverse events ( incidence > or = 5 % in one group ) after rizatriptan and ergotamine / caffeine , respectively , were dizziness ( 6 . 7 and 5 . 3 % ) , nausea ( 4 . 2 and 8 . 5 % ) and somnolence ( 5 . 5 and 2 . 3 % ) .', {'entities': [(135, 144, 'B_Disease'), (169, 175, 'B_Disease'), (202, 212, 'B_Disease')]}], ['Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas .', {'entities': [(7, 13, 'B_Disease'), (14, 17, 'I_Disease'), (18, 25, 'I_Disease'), (26, 34, 'I_Disease'), (93, 106, 'B_Disease')]}], ['BACKGROUND : Glioblastoma is a malignant tumor that occurs in the cerebrum during adulthood .', {'entities': [(13, 25, 'B_Disease'), (31, 40, 'B_Disease'), (41, 46, 'I_Disease')]}], ['Therefore , patients with glioblastoma sometimes have intracarotid injection of carcinostatics added to the treatment regimen .', {'entities': [(26, 38, 'B_Disease')]}], ['Generally , carboplatin is said to have milder side effects than cisplatin , whose ocular and orbital toxicity are well known .', {'entities': [(83, 89, 'B_Disease'), (90, 93, 'I_Disease'), (94, 101, 'I_Disease'), (102, 110, 'I_Disease')]}], ['However , we experienced a case of severe ocular and orbital toxicity after intracarotid injection of carboplatin , which is infrequently reported .', {'entities': [(42, 48, 'B_Disease'), (49, 52, 'I_Disease'), (53, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['CASE : A 58 - year - old man received an intracarotid injection of carboplatin for recurrent glioblastomas in his left temporal lobe .', {'entities': [(93, 106, 'B_Disease')]}], ['He complained of pain and visual disturbance in the ipsilateral eye 30 h after the injection .', {'entities': [(17, 21, 'B_Disease'), (22, 25, 'I_Disease'), (26, 32, 'I_Disease'), (33, 44, 'I_Disease'), (45, 47, 'I_Disease'), (48, 51, 'I_Disease'), (52, 63, 'I_Disease'), (64, 67, 'I_Disease')]}], ['Various ocular symptoms and findings caused by carboplatin toxicity were seen .', {'entities': [(59, 67, 'B_Disease')]}], ['Although the intraocular pressure elevation caused by secondary acute angle - closure glaucoma decreased and ocular pain diminished , inexorable papilledema and exudative retinal detachment continued for 3 weeks .', {'entities': [(86, 94, 'B_Disease'), (109, 115, 'B_Disease'), (116, 120, 'I_Disease'), (145, 156, 'B_Disease'), (171, 178, 'B_Disease'), (179, 189, 'I_Disease')]}], ['Finally , 6 weeks later , diffuse chorioretinal atrophy with optic atrophy occurred and the vision in his left eye was lost .', {'entities': [(34, 47, 'B_Disease'), (48, 55, 'I_Disease'), (61, 66, 'B_Disease'), (67, 74, 'I_Disease')]}], ['CONCLUSION : When performing intracarotid injection of carboplatin , we must be aware of its potentially blinding ocular toxicity .', {'entities': [(114, 120, 'B_Disease'), (121, 129, 'I_Disease')]}], ['Visual hallucinations associated with zonisamide .', {'entities': [(0, 6, 'B_Disease'), (7, 21, 'I_Disease')]}], ['Zonisamide is a broad - spectrum antiepileptic drug used to treat various types of seizures .', {'entities': [(83, 91, 'B_Disease')]}], ['Although visual hallucinations have not been reported as an adverse effect of this agent , we describe three patients who experienced complex visual hallucinations and altered mental status after zonisamide treatment was begun or its dosage increased .', {'entities': [(9, 15, 'B_Disease'), (16, 30, 'I_Disease'), (142, 148, 'B_Disease'), (149, 163, 'I_Disease')]}], ['All three had been diagnosed earlier with epilepsy , and their electroencephalogram ( EEG ) findings were abnormal .', {'entities': [(42, 50, 'B_Disease')]}], ['During monitoring , visual hallucinations did not correlate with EEG readings , nor did video recording capture any of the described events .', {'entities': [(20, 26, 'B_Disease'), (27, 41, 'I_Disease')]}], ['None of the patients had experienced visual hallucinations before this event .', {'entities': [(37, 43, 'B_Disease'), (44, 58, 'I_Disease')]}], ['Anti - epileptic drugs - induced de novo absence seizures .', {'entities': [(7, 16, 'B_Disease'), (41, 48, 'B_Disease'), (49, 57, 'I_Disease')]}], ['The authors present three patients with de novo absence epilepsy after administration of carbamazepine and vigabatrin .', {'entities': [(48, 55, 'B_Disease'), (56, 64, 'I_Disease')]}], ['Despite the underlying diseases , the prognosis for drug - induced de novo absence seizure is good because it subsides rapidly after discontinuing the use of the offending drugs .', {'entities': [(75, 82, 'B_Disease'), (83, 90, 'I_Disease')]}], ['The gamma - aminobutyric acid - transmitted thalamocortical circuitry accounts for a major part of the underlying neurophysiology of the absence epilepsy .', {'entities': [(137, 144, 'B_Disease'), (145, 153, 'I_Disease')]}], ['Because drug - induced de novo absence seizure is rare , pro - absence drugs can only be considered a promoting factor .', {'entities': [(31, 38, 'B_Disease'), (39, 46, 'I_Disease')]}], ['The underlying epileptogenecity of the patients or the synergistic effects of the accompanying drugs is required to trigger the de novo absence seizure .', {'entities': [(136, 143, 'B_Disease'), (144, 151, 'I_Disease')]}], ['The possibility of drug - induced aggravation should be considered whenever an unexpected increase in seizure frequency and / or new seizure types appear following a change in drug treatment .', {'entities': [(102, 109, 'B_Disease'), (133, 140, 'B_Disease')]}], ['By understanding the underlying mechanism of absence epilepsy , we can avoid the inappropriate use of anticonvulsants in children with epilepsy and prevent drug - induced absence seizures .', {'entities': [(45, 52, 'B_Disease'), (53, 61, 'I_Disease'), (135, 143, 'B_Disease'), (171, 178, 'B_Disease'), (179, 187, 'I_Disease')]}], ['Prenatal dexamethasone programs hypertension and renal injury in the rat .', {'entities': [(32, 44, 'B_Disease'), (49, 54, 'B_Disease'), (55, 61, 'I_Disease')]}], ['The purpose of the present study was to determine if prenatal dexamethasone programmed a progressive increase in blood pressure and renal injury in rats .', {'entities': [(101, 109, 'B_Disease'), (110, 112, 'I_Disease'), (113, 118, 'I_Disease'), (119, 127, 'I_Disease'), (132, 137, 'B_Disease'), (138, 144, 'I_Disease')]}], ['Offspring of rats administered dexamethasone on days 15 and 16 gestation had a 20 % reduction in glomerular number compared with control at 6 to 9 months of age ( 22 527 + / - 509 versus 28 050 + / - 561 , P < 0 . 05 ) , which was comparable to the percent reduction in glomeruli measured at 3 weeks of age .', {'entities': [(84, 93, 'B_Disease'), (94, 96, 'I_Disease'), (97, 107, 'I_Disease'), (108, 114, 'I_Disease')]}], ['Male rats that received prenatal dexamethasone on days 15 and 16 , 17 and 18 , and 13 and 14 of gestation had elevated blood pressures at 6 months of age ; the latter group did not have a reduction in glomerular number .', {'entities': [(110, 118, 'B_Disease'), (119, 124, 'I_Disease'), (125, 134, 'I_Disease'), (188, 197, 'B_Disease'), (198, 200, 'I_Disease'), (201, 211, 'I_Disease'), (212, 218, 'I_Disease')]}], ['Adult rats given dexamethasone on days 15 and 16 of gestation had more glomeruli with glomerulosclerosis than control rats .', {'entities': [(86, 104, 'B_Disease')]}], ['This study shows that prenatal dexamethasone in rats results in a reduction in glomerular number , glomerulosclerosis , and hypertension when administered at specific points during gestation .', {'entities': [(66, 75, 'B_Disease'), (76, 78, 'I_Disease'), (79, 89, 'I_Disease'), (90, 96, 'I_Disease'), (99, 117, 'B_Disease'), (124, 136, 'B_Disease')]}], ['Hypertension was observed in animals that had a reduction in glomeruli as well as in a group that did not have a reduction in glomerular number , suggesting that a reduction in glomerular number is not the sole cause for the development of hypertension .', {'entities': [(0, 12, 'B_Disease'), (113, 122, 'B_Disease'), (123, 125, 'I_Disease'), (126, 136, 'I_Disease'), (137, 143, 'I_Disease'), (164, 173, 'B_Disease'), (174, 176, 'I_Disease'), (177, 187, 'I_Disease'), (188, 194, 'I_Disease'), (240, 252, 'B_Disease')]}], ['These are nephrotoxic , but SRL seems to act differently displaying only minor nephrotoxic effects , although this question is still open .', {'entities': [(10, 21, 'B_Disease'), (79, 90, 'B_Disease')]}], ['In a number of treatment protocols where SRL was combined with a calcineurin inhibitor indications of a synergistic nephrotoxic effect were described .', {'entities': [(116, 127, 'B_Disease')]}], ['The morphological analysis of the kidneys included a semi - quantitative scoring system analysing the degree of striped fibrosis , subcapsular fibrosis and the number of basophilic tubules , plus an additional stereological analysis of the total grade of fibrosis in the cortex stained with Sirius Red .', {'entities': [(120, 128, 'B_Disease'), (143, 151, 'B_Disease'), (255, 263, 'B_Disease')]}], ['The semi - quantitative scoring was significantly worst in the group treated with CsA plus SRL ( P < 0 . 001 compared with controls ) and the analysis of the total grade of fibrosis also showed the highest proportion in the same group and was significantly different from controls ( P < 0 . 02 ) .', {'entities': [(173, 181, 'B_Disease')]}], ['The FK506 plus SRL combination showed only a marginally higher degree of fibrosis as compared with controls ( P = 0 . 05 ) .', {'entities': [(73, 81, 'B_Disease')]}], ['CONCLUSION : This rat study demonstrated a synergistic nephrotoxic effect of CsA plus SRL , whereas FK506 plus SRL was better tolerated .', {'entities': [(55, 66, 'B_Disease')]}], ['Evaluation of cardiac troponin I and T levels as markers of myocardial damage in doxorubicin - induced cardiomyopathy rats , and their relationship with echocardiographic and histological findings .', {'entities': [(60, 70, 'B_Disease'), (71, 77, 'I_Disease'), (103, 117, 'B_Disease')]}], ['BACKGROUND : Cardiac troponins I ( cTnI ) and T ( cTnT ) have been shown to be highly sensitive and specific markers of myocardial cell injury .', {'entities': [(120, 130, 'B_Disease'), (131, 135, 'I_Disease'), (136, 142, 'I_Disease')]}], ['We investigated the diagnostic value of cTnI and cTnT for the diagnosis of myocardial damage in a rat model of doxorubicin ( DOX ) - induced cardiomyopathy , and we examined the relationship between serial cTnI and cTnT with the development of cardiac disorders monitored by echocardiography and histological examinations in this model .', {'entities': [(75, 85, 'B_Disease'), (86, 92, 'I_Disease'), (141, 155, 'B_Disease'), (244, 251, 'B_Disease'), (252, 261, 'I_Disease')]}], ['RESULTS : Eighteen of the DOX rats died prematurely of general toxicity during the 9 - week period .', {'entities': [(63, 71, 'B_Disease')]}], ['Histological evaluation of hearts from all rats given DOX revealed significant slight degrees of perivascular and interstitial fibrosis .', {'entities': [(127, 135, 'B_Disease')]}], ['Only five of the controls exhibited evidence of very slight perivascular fibrosis .', {'entities': [(73, 81, 'B_Disease')]}], ['CONCLUSIONS : Among markers of ischemic injury after DOX in rats , cTnT showed the greatest ability to detect myocardial damage assessed by echocardiographic detection and histological changes .', {'entities': [(31, 39, 'B_Disease'), (40, 46, 'I_Disease'), (110, 120, 'B_Disease'), (121, 127, 'I_Disease')]}], ['Although there was a discrepancy between the amount of cTnI and cTnT after DOX , probably due to heterogeneity in cross - reactivities of mAbs to various cTnI and cTnT forms , it is likely that cTnT in rats after DOX indicates cell damage determined by the magnitude of injury induced and that cTnT should be a useful marker for the prediction of experimentally induced cardiotoxicity and possibly for cardioprotective experiments .', {'entities': [(370, 384, 'B_Disease')]}], ['Octreotide - induced hypoxemia and pulmonary hypertension in premature neonates .', {'entities': [(21, 30, 'B_Disease'), (35, 44, 'B_Disease'), (45, 57, 'I_Disease')]}], ['The authors report 2 cases of premature neonates who had enterocutaneous fistula complicating necrotizing enterocolitis .', {'entities': [(73, 80, 'B_Disease'), (94, 105, 'B_Disease'), (106, 119, 'I_Disease')]}], ['Pulmonary hypertension developed after administration of a somatostatin analogue , octreotide , to enhance resolution of the fistula .', {'entities': [(0, 9, 'B_Disease'), (10, 22, 'I_Disease'), (125, 132, 'B_Disease')]}], ['The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol : a nested cohort analysis and case - control study .', {'entities': [(12, 18, 'B_Disease'), (19, 34, 'I_Disease')]}], ['BACKGROUND : Cyproterone acetate combined with ethinyl estradiol ( CPA / EE ) is licensed in the UK for the treatment of women with acne and hirsutism and is also a treatment option for polycystic ovary syndrome ( PCOS ) .', {'entities': [(132, 136, 'B_Disease'), (141, 150, 'B_Disease'), (186, 196, 'B_Disease'), (197, 202, 'I_Disease'), (203, 211, 'I_Disease'), (214, 218, 'B_Disease')]}], ['Previous studies have demonstrated an increased risk of venous thromboembolism ( VTE ) associated with CPA / EE compared with conventional combined oral contraceptives ( COCs ) .', {'entities': [(56, 62, 'B_Disease'), (63, 78, 'I_Disease'), (81, 84, 'B_Disease')]}], ['METHODS : Using the General Practice Research Database we conducted a cohort analysis and case - control study nested within a population of women aged between 15 and 39 years with acne , hirsutism or PCOS to estimate the risk of VTE associated with CPA / EE .', {'entities': [(181, 185, 'B_Disease'), (188, 197, 'B_Disease'), (201, 205, 'B_Disease'), (230, 233, 'B_Disease')]}], ['CONCLUSIONS : We have demonstrated an increased risk of VTE associated with the use of CPA / EE in women with acne , hirsutism or PCOS although residual confounding by indication cannot be excluded .', {'entities': [(56, 59, 'B_Disease'), (110, 114, 'B_Disease'), (117, 126, 'B_Disease'), (130, 134, 'B_Disease')]}], ['The effect of treatment with gum Arabic on gentamicin nephrotoxicity in rats : a preliminary study .', {'entities': [(54, 68, 'B_Disease')]}], ['In the present work we assessed the effect of treatment of rats with gum Arabic on acute renal failure induced by gentamicin ( GM ) nephrotoxicity .', {'entities': [(83, 88, 'B_Disease'), (89, 94, 'I_Disease'), (95, 102, 'I_Disease'), (132, 146, 'B_Disease')]}], ['Nephrotoxicity was assessed by measuring the concentrations of creatinine and urea in the plasma and reduced glutathione ( GSH ) in the kidney cortex , and by light microscopic examination of kidney sections .', {'entities': [(0, 14, 'B_Disease')]}], ['The results indicated that concomitant treatment with gum Arabic and GM significantly increased creatinine and urea by about 183 and 239 % , respectively ( compared to 432 and 346 % , respectively , in rats treated with cellulose and GM ) , and decreased that of cortical GSH by 21 % ( compared to 27 % in the cellulose plus GM group ) The GM - induced proximal tubular necrosis appeared to be slightly less severe in rats given GM together with gum Arabic than in those given GM and cellulose .', {'entities': [(362, 369, 'B_Disease'), (370, 378, 'I_Disease')]}], ['It could be inferred that gum Arabic treatment has induced a modest amelioration of some of the histological and biochemical indices of GM nephrotoxicity .', {'entities': [(139, 153, 'B_Disease')]}], ['Further work is warranted on the effect of the treatments on renal functional aspects in models of chronic renal failure , and on the mechanism ( s ) involved .', {'entities': [(99, 106, 'B_Disease'), (107, 112, 'I_Disease'), (113, 120, 'I_Disease')]}], ['Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen - independent prostate cancer .', {'entities': [(23, 29, 'B_Disease'), (30, 45, 'I_Disease'), (147, 155, 'B_Disease'), (156, 162, 'I_Disease')]}], ['STUDY OBJECTIVE : To evaluate the frequency of venous thromboembolism ( VTE ) in patients with advanced androgen - independent prostate cancer who were treated with docetaxel alone or in combination with thalidomide .', {'entities': [(47, 53, 'B_Disease'), (54, 69, 'I_Disease'), (72, 75, 'B_Disease'), (127, 135, 'B_Disease'), (136, 142, 'I_Disease')]}], ['PATIENTS : Seventy men , aged 50 - 80 years , with advanced androgen - independent prostate cancer .', {'entities': [(83, 91, 'B_Disease'), (92, 98, 'I_Disease')]}], ['This 4 - week cycle was repeated until there was evidence of excessive toxicity or disease progression .', {'entities': [(71, 79, 'B_Disease')]}], ['MEASUREMENTS AND MAIN RESULTS : None of 23 patients who received docetaxel alone developed VTE , whereas 9 of 47 patients ( 19 % ) who received docetaxel plus thalidomide developed VTE ( p = 0 . 025 ) .', {'entities': [(91, 94, 'B_Disease'), (181, 184, 'B_Disease')]}], ['CONCLUSION : The addition of thalidomide to docetaxel in the treatment of prostate cancer significantly increases the frequency of VTE .', {'entities': [(74, 82, 'B_Disease'), (83, 89, 'I_Disease'), (131, 134, 'B_Disease')]}], ['Ticlopidine - induced cholestatic hepatitis .', {'entities': [(22, 33, 'B_Disease'), (34, 43, 'I_Disease')]}], ['OBJECTIVE : To report 2 cases of ticlopidine - induced cholestatic hepatitis , investigate its mechanism , and compare the observed main characteristics with those of the published cases .', {'entities': [(55, 66, 'B_Disease'), (67, 76, 'I_Disease')]}], ['CASE SUMMARIES : Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angioplasty , with complete remission during the follow - up period .', {'entities': [(50, 61, 'B_Disease'), (62, 71, 'I_Disease')]}], ['DISCUSSION : Cholestatic hepatitis is a rare complication of the antiplatelet agent ticlopidine ; several cases have been reported but few in the English literature .', {'entities': [(13, 24, 'B_Disease'), (25, 34, 'I_Disease')]}], ['Our patients developed jaundice following treatment with ticlopidine and showed the clinical and laboratory characteristics of cholestatic hepatitis , which resolved after discontinuation of the drug .', {'entities': [(23, 31, 'B_Disease'), (127, 138, 'B_Disease'), (139, 148, 'I_Disease')]}], ['Hepatitis may develop weeks after discontinuation of the drug and may run a prolonged course , but complete remission was observed in all reported cases .', {'entities': [(0, 9, 'B_Disease')]}], ['The mechanisms of this ticlopidine - induced cholestasis are unclear .', {'entities': [(45, 56, 'B_Disease')]}], [\"Immune mechanisms may be involved in the drug ' s hepatotoxicity , as suggested by the T - cell stimulation study reported here .\", {'entities': [(50, 64, 'B_Disease')]}], ['CONCLUSIONS : Cholestatic hepatitis is a rare adverse effect of ticlopidine that may be immune mediated .', {'entities': [(14, 25, 'B_Disease'), (26, 35, 'I_Disease')]}], ['Epithelial sodium channel ( ENaC ) subunit mRNA and protein expression in rats with puromycin aminonucleoside - induced nephrotic syndrome .', {'entities': [(120, 129, 'B_Disease'), (130, 138, 'I_Disease')]}], ['In experimental nephrotic syndrome , urinary sodium excretion is decreased during the early phase of the disease .', {'entities': [(16, 25, 'B_Disease'), (26, 34, 'I_Disease')]}], ['We examined the abundance of ENaC subunit mRNAs and proteins in puromycin aminonucleoside ( PAN ) - induced nephrotic syndrome .', {'entities': [(108, 117, 'B_Disease'), (118, 126, 'I_Disease')]}], ['The time courses of urinary sodium excretion , plasma aldosterone concentration and proteinuria were studied in male Sprague - Dawley rats treated with a single dose of either PAN or vehicle .', {'entities': [(84, 95, 'B_Disease')]}], ['The kinetics of urinary sodium excretion and the appearance of proteinuria were comparable with those reported previously .', {'entities': [(63, 74, 'B_Disease')]}], ['In conclusion , ENaC mRNA expression , especially alphaENaC , is increased in the very early phase of the experimental model of PAN - induced nephrotic syndrome in rats , but appears to escape from the regulation by aldosterone after day 3 .', {'entities': [(142, 151, 'B_Disease'), (152, 160, 'I_Disease')]}], ['OBJECTIVES : Given its preclinical success for treating substance abuse and the increased risk of visual field defects ( VFD ) associated with cumulative lifetime exposure , we explored the effects of sub - chronic low dose GVG on cocaine - induced increases in nucleus accumbens ( NAcc ) dopamine ( DA ) .', {'entities': [(56, 65, 'B_Disease'), (66, 71, 'I_Disease'), (98, 104, 'B_Disease'), (105, 110, 'I_Disease'), (111, 118, 'I_Disease'), (121, 124, 'B_Disease')]}], ['MR imaging with quantitative diffusion mapping of tacrolimus - induced neurotoxicity in organ transplant patients .', {'entities': [(71, 84, 'B_Disease')]}], ['Brain MR studies , including DW imaging , were prospectively performed in 14 organ transplant patients receiving tacrolimus who developed neurologic complications .', {'entities': [(138, 148, 'B_Disease'), (149, 162, 'I_Disease')]}], ['Of the 14 patients , 5 ( 35 . 7 % ) had white matter abnormalities , 1 ( 7 . 1 % ) had putaminal hemorrhage , and 8 ( 57 . 1 % ) had normal findings on initial MR images .', {'entities': [(40, 45, 'B_Disease'), (46, 52, 'I_Disease'), (53, 66, 'I_Disease'), (87, 96, 'B_Disease'), (97, 107, 'I_Disease')]}], ['Among the 5 patients with white matter abnormalities , 4 patients ( 80 . 0 % ) showed higher than normal ADC values on initial MR images , and all showed complete resolution on follow - up images .', {'entities': [(26, 31, 'B_Disease'), (32, 38, 'I_Disease'), (39, 52, 'I_Disease')]}], ['The remaining 1 patient ( 20 . 0 % ) showed lower than normal ADC value and showed incomplete resolution with cortical laminar necrosis .', {'entities': [(110, 118, 'B_Disease'), (119, 126, 'I_Disease'), (127, 135, 'I_Disease')]}], ['Diffusion - weighted imaging may be useful in predicting the outcomes of the lesions of tacrolimus - induced neurotoxicity .', {'entities': [(109, 122, 'B_Disease')]}], ['L - arginine transport in humans with cortisol - induced hypertension .', {'entities': [(57, 69, 'B_Disease')]}], ['A deficient L - arginine - nitric oxide system is implicated in cortisol - induced hypertension .', {'entities': [(83, 95, 'B_Disease')]}], ['We conclude that cortisol - induced increases in blood pressure are not associated with abnormalities in the l - arginine transport system .', {'entities': [(36, 45, 'B_Disease'), (46, 48, 'I_Disease'), (49, 54, 'I_Disease'), (55, 63, 'I_Disease')]}], ['Amount of bleeding and hematoma size in the collagenase - induced intracerebral hemorrhage rat model .', {'entities': [(10, 18, 'B_Disease'), (23, 31, 'B_Disease'), (66, 79, 'B_Disease'), (80, 90, 'I_Disease')]}], ['The aggravated risk on intracerebral hemorrhage ( ICH ) with drugs used for stroke patients should be estimated carefully .', {'entities': [(23, 36, 'B_Disease'), (37, 47, 'I_Disease'), (50, 53, 'B_Disease'), (76, 82, 'B_Disease')]}], ['We therefore established sensitive quantification methods and provided a rat ICH model for detection of ICH deterioration .', {'entities': [(77, 80, 'B_Disease'), (104, 107, 'B_Disease')]}], ['In ICH intrastriatally induced by 0 . 014 - unit , 0 . 070 - unit , and 0 . 350 - unit collagenase , the amount of bleeding was measured using a hemoglobin assay developed in the present study and was compared with the morphologically determined hematoma volume .', {'entities': [(3, 6, 'B_Disease'), (115, 123, 'B_Disease'), (246, 254, 'B_Disease')]}], ['The blood amounts and hematoma volumes were significantly correlated , and the hematoma induced by 0 . 014 - unit collagenase was adequate to detect ICH deterioration .', {'entities': [(22, 30, 'B_Disease'), (79, 87, 'B_Disease'), (149, 152, 'B_Disease')]}], ['In ICH induction using 0 . 014 - unit collagenase , heparin enhanced the hematoma volume 3 . 4 - fold over that seen in control ICH animals and the bleeding 7 . 6 - fold .', {'entities': [(3, 6, 'B_Disease'), (73, 81, 'B_Disease'), (128, 131, 'B_Disease'), (148, 156, 'B_Disease')]}], ['Data suggest that this sensitive hemoglobin assay is useful for ICH detection , and that a model with a small ICH induced with a low - dose collagenase should be used for evaluation of drugs that may affect ICH .', {'entities': [(64, 67, 'B_Disease'), (110, 113, 'B_Disease'), (207, 210, 'B_Disease')]}], ['Estradiol reduces seizure - induced hippocampal injury in ovariectomized female but not in male rats .', {'entities': [(18, 25, 'B_Disease'), (36, 47, 'B_Disease'), (48, 54, 'I_Disease')]}], ['Estrogens protect ovariectomized rats from hippocampal injury induced by kainic acid - induced status epilepticus ( SE ) .', {'entities': [(43, 54, 'B_Disease'), (55, 61, 'I_Disease'), (95, 101, 'B_Disease'), (102, 113, 'I_Disease'), (116, 118, 'B_Disease')]}], ['We compared the effects of 17beta - estradiol in adult male and ovariectomized female rats subjected to lithium - pilocarpine - induced SE .', {'entities': [(136, 138, 'B_Disease')]}], ['SE was induced 20 h following the second injection and terminated 3 h later .', {'entities': [(0, 2, 'B_Disease')]}], ['The extent of silver - stained CA3 and CA1 hippocampal neurons was evaluated 2 days after SE .', {'entities': [(90, 92, 'B_Disease')]}], ['These findings suggest that the effects of estradiol on seizure threshold and damage may be altered by sex - related differences in the hormonal environment .', {'entities': [(56, 63, 'B_Disease')]}], ['Pseudoacromegaly induced by the long - term use of minoxidil .', {'entities': [(0, 16, 'B_Disease')]}], ['Acromegaly is an endocrine disorder caused by chronic excessive growth hormone secretion from the anterior pituitary gland .', {'entities': [(0, 10, 'B_Disease'), (17, 26, 'B_Disease'), (27, 35, 'I_Disease')]}], ['Significant disfiguring changes occur as a result of bone , cartilage , and soft tissue hypertrophy , including the thickening of the skin , coarsening of facial features , and cutis verticis gyrata .', {'entities': [(88, 99, 'B_Disease'), (177, 182, 'B_Disease'), (183, 191, 'I_Disease'), (192, 198, 'I_Disease')]}], ['Pseudoacromegaly , on the other hand , is the presence of similar acromegaloid features in the absence of elevated growth hormone or insulin - like growth factor levels .', {'entities': [(0, 16, 'B_Disease')]}], ['We present a patient with pseudoacromegaly that resulted from the long - term use of minoxidil at an unusually high dose .', {'entities': [(26, 42, 'B_Disease')]}], ['This is the first case report of pseudoacromegaly as a side effect of minoxidil use .', {'entities': [(33, 49, 'B_Disease')]}], ['Combined androgen blockade - induced anemia in prostate cancer patients without bone involvement .', {'entities': [(37, 43, 'B_Disease'), (47, 55, 'B_Disease'), (56, 62, 'I_Disease')]}], ['BACKGROUND : To determine the onset and extent of combined androgen blockade ( CAB ) - induced anemia in prostate cancer patients without bone involvement .', {'entities': [(95, 101, 'B_Disease'), (105, 113, 'B_Disease'), (114, 120, 'I_Disease')]}], ['PATIENTS AND METHODS : Forty - two patients with biopsy - proven prostatic adenocarcinoma [ 26 with stage C ( T3N0M0 ) and 16 with stage D1 ( T3N1M0 ) ] were included in this study .', {'entities': [(65, 74, 'B_Disease'), (75, 89, 'I_Disease')]}], ['All patients received CAB [ leuprolide acetate ( LHRH - A ) 3 . 75 mg , intramuscularly , every 28 days plus 250 mg flutamide , tid , per Os ] and were evaluated for anemia by physical examination and laboratory tests at baseline and 4 subsequent intervals ( 1 , 2 , 3 and 6 months post - CAB ) .', {'entities': [(166, 172, 'B_Disease')]}], ['Severe and clinically evident anemia of Hb < 11 g / dl with clinical symptoms was detected in 6 patients ( 14 . 3 % ) .', {'entities': [(30, 36, 'B_Disease')]}], ['This CAB - induced anemia was normochromic and normocytic .', {'entities': [(19, 25, 'B_Disease')]}], ['At six months post - CAB , patients with severe anemia had a Hb mean value of 10 . 2 + / - 0 . 1 g / dl ( X + / - SE ) , whereas the other patients had mild anemia with Hb mean value of 13 . 2 + / - 0 . 17 ( X + / - SE ) .', {'entities': [(48, 54, 'B_Disease'), (157, 163, 'B_Disease')]}], ['The development of severe anemia at 6 months post - CAB was predictable by the reduction of Hb baseline value of more than 2 . 5 g / dl after 3 months of CAB ( p = 0 . 01 ) .', {'entities': [(26, 32, 'B_Disease')]}], ['The development of severe CAB - induced anemia in prostate cancer patients did not correlate with T baseline values ( T < 3 ng / ml versus T > or = 3 ng / ml ) , with age ( < 76 yrs versus > or = 76 yrs ) , and clinical stage ( stage C versus stage D1 ) .', {'entities': [(40, 46, 'B_Disease'), (50, 58, 'B_Disease'), (59, 65, 'I_Disease')]}], ['Severe and clinically evident anemia was easily corrected by subcutaneous injections ( 3 times / week for 1 month ) of recombinant erythropoietin ( rHuEPO - beta ) .', {'entities': [(30, 36, 'B_Disease')]}], ['CONCLUSION : Our data suggest that rHuEPO - beta correctable CAB - induced anemia occurs in 14 . 3 % of prostate cancer patients after 6 months of therapy .', {'entities': [(75, 81, 'B_Disease'), (104, 112, 'B_Disease'), (113, 119, 'I_Disease')]}], ['Delirium during clozapine treatment : incidence and associated risk factors .', {'entities': [(0, 8, 'B_Disease')]}], ['BACKGROUND : Incidence and risk factors for delirium during clozapine treatment require further clarification .', {'entities': [(44, 52, 'B_Disease')]}], ['METHODS : We used computerized pharmacy records to identify all adult psychiatric inpatients treated with clozapine ( 1995 - 96 ) , reviewed their medical records to score incidence and severity of delirium , and tested associations with potential risk factors .', {'entities': [(70, 81, 'B_Disease'), (198, 206, 'B_Disease')]}], ['Delirium was diagnosed in 14 ( 10 . 1 % incidence , or 1 . 48 cases / person - years of exposure ) ; 71 . 4 % of cases were moderate or severe .', {'entities': [(0, 8, 'B_Disease')]}], ['CONCLUSIONS : Delirium was found in 10 % of clozapine - treated inpatients , particularly in older patients exposed to other central anticholinergics .', {'entities': [(14, 22, 'B_Disease')]}], ['Delirium was inconsistently recognized clinically in milder cases and was associated with increased length - of - stay and higher costs , and inferior clinical outcome .', {'entities': [(0, 8, 'B_Disease')]}], ['Neuroprotective action of MPEP , a selective mGluR5 antagonist , in methamphetamine - induced dopaminergic neurotoxicity is associated with a decrease in dopamine outflow and inhibition of hyperthermia in rats .', {'entities': [(107, 120, 'B_Disease'), (189, 201, 'B_Disease')]}], ['Moreover , it transiently diminished the methamphetamine ( 10 mg / kg sc ) - induced hyperthermia and reduced basal body temperature .', {'entities': [(85, 97, 'B_Disease')]}], ['The results of this study suggest that the blockade of mGluR5 by MPEP may protect dopaminergic neurones against methamphetamine - induced toxicity .', {'entities': [(138, 146, 'B_Disease')]}], ['Neuroprotection rendered by MPEP may be associated with the reduction of the methamphetamine - induced dopamine efflux in the striatum due to the blockade of extrastriatal mGluR5 , and with a decrease in hyperthermia .', {'entities': [(204, 216, 'B_Disease')]}], ['Protective efficacy of neuroactive steroids against cocaine kindled - seizures in mice .', {'entities': [(70, 78, 'B_Disease')]}], ['Neuroactive steroids demonstrate pharmacological actions that have relevance for a host of neurological and psychiatric disorders .', {'entities': [(91, 103, 'B_Disease'), (104, 107, 'I_Disease'), (108, 119, 'I_Disease'), (120, 129, 'I_Disease')]}], ['They offer protection against seizures in a range of models and seem to inhibit certain stages of drug dependence in preclinical assessments .', {'entities': [(30, 38, 'B_Disease'), (98, 102, 'B_Disease'), (103, 113, 'I_Disease')]}], ['The present study was designed to evaluate two endogenous and one synthetic neuroactive steroid that positively modulate the gamma - aminobutyric acid ( GABA ( A ) ) receptor against the increase in sensitivity to the convulsant effects of cocaine engendered by repeated cocaine administration ( seizure kindling ) .', {'entities': [(296, 303, 'B_Disease')]}], ['Allopregnanolone ( 3alpha - hydroxy - 5alpha - pregnan - 20 - one ) , pregnanolone ( 3alpha - hydroxy - 5beta - pregnan - 20 - one ) and ganaxolone ( a synthetic derivative of allopregnanolone 3alpha - hydroxy - 3beta - methyl - 5alpha - pregnan - 20 - one ) were tested for their ability to suppress the expression ( anticonvulsant effect ) and development ( antiepileptogenic effect ) of cocaine - kindled seizures in male , Swiss - Webster mice .', {'entities': [(408, 416, 'B_Disease')]}], ['Kindled seizures were induced by daily administration of 60 mg / kg cocaine for 5 days .', {'entities': [(8, 16, 'B_Disease')]}], ['All of these positive GABA ( A ) modulators suppressed the expression of kindled seizures , whereas only allopregnanolone and ganaxolone inhibited the development of kindling .', {'entities': [(81, 89, 'B_Disease')]}], ['Effect of humoral modulators of morphine - induced increase in locomotor activity of mice .', {'entities': [(51, 59, 'B_Disease'), (60, 62, 'I_Disease'), (63, 72, 'I_Disease'), (73, 81, 'I_Disease')]}], ['The effect of humoral modulators on the morphine - induced increase in locomotor activity of mice was studied .', {'entities': [(59, 67, 'B_Disease'), (68, 70, 'I_Disease'), (71, 80, 'I_Disease'), (81, 89, 'I_Disease')]}], ['The subcutaneous administration of 10 mg / kg of morphine - HC1 produced a marked increase in locomotor activity in mice .', {'entities': [(82, 90, 'B_Disease'), (91, 93, 'I_Disease'), (94, 103, 'I_Disease'), (104, 112, 'I_Disease')]}], ['The morphine - induced hyperactivity was potentiated by scopolamine and attenuated by physostigmine .', {'entities': [(23, 36, 'B_Disease')]}], ['In contrast , both methscopolamine and neostigmine , which do not penetrate the blood - brain barrier , had no effect on the hyperactivity produced by morphine .', {'entities': [(125, 138, 'B_Disease')]}], ['On the other hand , pretreatment with p - chlorophenylalamine ( 3 X 320 mg / kg i . p . , 24 hr ) , a serotonin depletor , caused no significant change in the hyperactivity .', {'entities': [(159, 172, 'B_Disease')]}], ['Effects of uninephrectomy and high protein feeding on lithium - induced chronic renal failure in rats .', {'entities': [(72, 79, 'B_Disease'), (80, 85, 'I_Disease'), (86, 93, 'I_Disease')]}], ['Rats with lithium - induced nephropathy were subjected to high protein ( HP ) feeding , uninephrectomy ( NX ) or a combination of these , in an attempt to induce glomerular hyperfiltration and further progression of renal failure .', {'entities': [(28, 39, 'B_Disease'), (216, 221, 'B_Disease'), (222, 229, 'I_Disease')]}], ['Lithium also caused proteinuria and systolic hypertension in absence of glomerulosclerosis .', {'entities': [(20, 31, 'B_Disease'), (45, 57, 'B_Disease'), (72, 90, 'B_Disease')]}], ['HP failed to accentuante progression of renal failure and in fact tended to increase GFR and decrease plasma creatinine levels in lithium pretreated rats .', {'entities': [(40, 45, 'B_Disease'), (46, 53, 'I_Disease')]}], ['The results indicate that Li - induced nephropathy , even when the GFR is only modestly reduced , is associated with proteinuria and arterial systolic hypertension .', {'entities': [(39, 50, 'B_Disease'), (117, 128, 'B_Disease'), (151, 163, 'B_Disease')]}], ['In this model of chronic renal failure the decline in GFR is not accompanied by a corresponding fall in effective renal plasma flow , which may be the functional expression of the formation of nonfiltrating atubular glomeruli .', {'entities': [(17, 24, 'B_Disease'), (25, 30, 'I_Disease'), (31, 38, 'I_Disease')]}], [\"Treatment of Crohn ' s disease with fusidic acid : an antibiotic with immunosuppressive properties similar to cyclosporin .\", {'entities': [(13, 18, 'B_Disease'), (19, 20, 'I_Disease'), (21, 22, 'I_Disease'), (23, 30, 'I_Disease')]}], [\"Because of the need for the development of new treatments for Crohn ' s disease , a pilot study was undertaken to estimate the pharmacodynamics and tolerability of fusidic acid treatment in chronic active , therapy - resistant patients .\", {'entities': [(62, 67, 'B_Disease'), (68, 69, 'I_Disease'), (70, 71, 'I_Disease'), (72, 79, 'I_Disease')]}], [\"Eight Crohn ' s disease patients were included .\", {'entities': [(6, 11, 'B_Disease'), (12, 13, 'I_Disease'), (14, 15, 'I_Disease'), (16, 23, 'I_Disease')]}], ['There were no serious clinical side effects , but dose reduction was required in two patients because of nausea .', {'entities': [(105, 111, 'B_Disease')]}], [\"The results of this pilot study suggest that fusidic acid may be of benefit in selected chronic active Crohn ' s disease patients in whom conventional treatment is ineffective .\", {'entities': [(103, 108, 'B_Disease'), (109, 110, 'I_Disease'), (111, 112, 'I_Disease'), (113, 120, 'I_Disease')]}], ['Because there seems to exist a scientific rationale for the use of fusidic acid at the cytokine level in inflammatory bowel disease , we suggest that the role of this treatment should be further investigated .', {'entities': [(105, 117, 'B_Disease'), (118, 123, 'I_Disease'), (124, 131, 'I_Disease')]}], ['Changes in depressive status associated with topical beta - blockers .', {'entities': [(11, 21, 'B_Disease')]}], ['Depression and sexual dysfunction have been related to side effects of topical beta - blockers .', {'entities': [(0, 10, 'B_Disease'), (15, 21, 'B_Disease'), (22, 33, 'I_Disease')]}], ['Eight glaucomatous patients chronically treated with timolol 0 . 5 % / 12h , suffering from depression diagnosed through DMS - III - R criteria , were included in the study .', {'entities': [(6, 18, 'B_Disease'), (92, 102, 'B_Disease')]}], ['During the six - month follow up , depression was quantified through the Beck and Zung - Conde scales every two months .', {'entities': [(35, 45, 'B_Disease')]}], ['In a double blind cross - over study with control group , the patients under timolol treatment presented higher depression values measured through the Beck and the Zung - Conde scales ( p < 0 . 001 vs control ) .', {'entities': [(112, 122, 'B_Disease')]}], ['These results suggest that betaxolol could be less of a depression - inducer than timolol in predisposed patients .', {'entities': [(56, 66, 'B_Disease')]}], ['Protection against amphetamine - induced neurotoxicity toward striatal dopamine neurons in rodents by LY274614 , an excitatory amino acid antagonist .', {'entities': [(41, 54, 'B_Disease')]}], ['The data strengthen the evidence that the neurotoxic effect of amphetamine and related compounds toward nigrostriatal dopamine neurons involves NMDA receptors and that LY274614 is an NMDA receptor antagonist with long - lasting in vivo effects in rats .', {'entities': [(42, 52, 'B_Disease')]}], ['Ketoconazole - induced neurologic sequelae .', {'entities': [(23, 33, 'B_Disease'), (34, 42, 'I_Disease')]}], ['A 77 - y - old patient developed weakness of extremities , legs paralysis , dysarthria and tremor 1 h after ingestion of 200 mg ketoconazole for the first time in his life .', {'entities': [(33, 41, 'B_Disease'), (42, 44, 'I_Disease'), (45, 56, 'I_Disease'), (59, 63, 'B_Disease'), (64, 73, 'I_Disease'), (76, 86, 'B_Disease'), (91, 97, 'B_Disease')]}], ['This case illustrates the need for close vigilance in adverse drug reactions , particularly in the elderly .', {'entities': [(54, 61, 'B_Disease'), (62, 66, 'I_Disease'), (67, 76, 'I_Disease')]}], ['Development of levodopa - induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and / or duration of symptoms .', {'entities': [(34, 45, 'B_Disease'), (49, 61, 'B_Disease')]}], [\"Levodopa - induced dyskinesias ( LIDs ) present a major problem for the long - term management of Parkinson ' s disease ( PD ) patients .\", {'entities': [(19, 30, 'B_Disease'), (33, 37, 'B_Disease'), (98, 107, 'B_Disease'), (108, 109, 'I_Disease'), (110, 111, 'I_Disease'), (112, 119, 'I_Disease'), (122, 124, 'B_Disease')]}], ['Due to the interdependence of risk factors in clinical populations , it is difficult to independently examine factors that may influence the development of LIDs .', {'entities': [(156, 160, 'B_Disease')]}], ['Using macaque monkeys with different types of MPTP - induced parkinsonism , the current study evaluated the degree to which rate of symptom progression , symptom severity , and response to and duration of levodopa therapy may be involved in the development of LIDs .', {'entities': [(61, 73, 'B_Disease'), (260, 264, 'B_Disease')]}], ['Monkeys with acute ( short - term ) MPTP exposure , rapid symptom onset and short symptom duration prior to initiation of levodopa therapy developed dyskinesia between 11 and 24 days of daily levodopa administration .', {'entities': [(149, 159, 'B_Disease')]}], ['In contrast , monkeys with long - term MPTP exposure , slow symptom progression and / or long symptom duration prior to initiation of levodopa therapy were more resistant to developing LIDs ( e . g . , dyskinesia developed no sooner than 146 days of chronic levodopa administration ) .', {'entities': [(185, 189, 'B_Disease'), (202, 212, 'B_Disease')]}], ['These data suggest distinct differences in the propensity to develop LIDs in monkeys with different rates of symptom progression or symptom durations prior to levodopa and demonstrate the value of these models for further studying the pathophysiology of LIDs .', {'entities': [(69, 73, 'B_Disease'), (254, 258, 'B_Disease')]}], ['A diet promoting sugar dependency causes behavioral cross - sensitization to a low dose of amphetamine .', {'entities': [(17, 22, 'B_Disease'), (23, 33, 'I_Disease'), (41, 51, 'B_Disease'), (52, 57, 'I_Disease'), (58, 59, 'I_Disease'), (60, 73, 'I_Disease')]}], ['Previous research in this laboratory has shown that a diet of intermittent excessive sugar consumption produces a state with neurochemical and behavioral similarities to drug dependency .', {'entities': [(170, 174, 'B_Disease'), (175, 185, 'I_Disease')]}], ['The present study examined whether female rats on various regimens of sugar access would show behavioral cross - sensitization to a low dose of amphetamine .', {'entities': [(94, 104, 'B_Disease'), (105, 110, 'I_Disease'), (111, 112, 'I_Disease'), (113, 126, 'I_Disease')]}], ['The animals that had experienced cyclic sucrose and chow were hyperactive in response to amphetamine compared with four control groups ( ad libitum 10 % sucrose and chow followed by amphetamine injection , cyclic chow followed by amphetamine injection , ad libitum chow with amphetamine , or cyclic 10 % sucrose and chow with a saline injection ) .', {'entities': [(62, 73, 'B_Disease')]}], ['Reversible dilated cardiomyopathy related to amphotericin B therapy .', {'entities': [(11, 18, 'B_Disease'), (19, 33, 'I_Disease')]}], ['We describe a patient who developed dilated cardiomyopathy and clinical congestive heart failure after 2 months of therapy with amphotericin B ( AmB ) for disseminated coccidioidomycosis .', {'entities': [(36, 43, 'B_Disease'), (44, 58, 'I_Disease'), (83, 88, 'B_Disease'), (89, 96, 'I_Disease'), (168, 186, 'B_Disease')]}], ['His echocardiographic abnormalities and heart failure resolved after posaconazole was substituted for AmB .', {'entities': [(40, 45, 'B_Disease'), (46, 53, 'I_Disease')]}], ['It is important to recognize the rare and potentially reversible toxicity of AmB .', {'entities': [(65, 73, 'B_Disease')]}], ['NO - induced migraine attack : strong increase in plasma calcitonin gene - related peptide ( CGRP ) concentration and negative correlation with platelet serotonin release .', {'entities': [(13, 21, 'B_Disease')]}], ['The aim of the present study was to investigate changes in the plasma calcitonin gene - related peptide ( CGRP ) concentration and platelet serotonin ( 5 - hydroxytriptamine , 5 - HT ) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin .', {'entities': [(214, 222, 'B_Disease'), (247, 255, 'B_Disease')]}], ['Fifteen female migraineurs ( without aura ) and eight controls participated in the study .', {'entities': [(15, 26, 'B_Disease'), (27, 28, 'I_Disease'), (29, 36, 'I_Disease'), (37, 41, 'I_Disease'), (42, 43, 'I_Disease')]}], ['Blood was collected from the antecubital vein four times : 60 min before and after the nitroglycerin application , and 60 and 120 min after the beginning of the migraine attack ( mean 344 and 404 min ; 12 subjects ) .', {'entities': [(161, 169, 'B_Disease')]}], ['In those subjects who had no migraine attack ( 11 subjects ) a similar time schedule was used .', {'entities': [(29, 37, 'B_Disease')]}], ['Plasma CGRP concentration increased significantly ( P < 0 . 01 ) during the migraine attack and returned to baseline after the cessation of the migraine .', {'entities': [(76, 84, 'B_Disease'), (144, 152, 'B_Disease')]}], ['In addition , both change and peak , showed significant positive correlations with migraine headache intensity ( P < 0 . 001 ) .', {'entities': [(83, 91, 'B_Disease'), (92, 100, 'B_Disease')]}], ['However , plasma CGRP concentrations failed to change during immediate headache and in the subjects with no migraine attack .', {'entities': [(71, 79, 'B_Disease'), (108, 116, 'B_Disease')]}], ['Basal CGRP concentration was significantly higher and platelet 5 - HT content tended to be lower in subjects who experienced a migraine attack .', {'entities': [(127, 135, 'B_Disease')]}], ['Platelet serotonin content decreased significantly ( P < 0 . 01 ) after nitroglycerin in subjects with no migraine attack but no consistent change was observed in patients with migraine attack .', {'entities': [(106, 114, 'B_Disease'), (177, 185, 'B_Disease')]}], ['In conclusion , the fact that plasma CGRP concentration correlates with the timing and severity of a migraine headache suggests a direct relationship between CGRP and migraine .', {'entities': [(101, 109, 'B_Disease'), (110, 118, 'B_Disease'), (167, 175, 'B_Disease')]}], ['In contrast , serotonin release from platelets does not provoke migraine , it may even counteract the headache and the concomitant CGRP release in this model .', {'entities': [(64, 72, 'B_Disease'), (102, 110, 'B_Disease')]}], ['Hyperbaric oxygen therapy for control of intractable cyclophosphamide - induced hemorrhagic cystitis .', {'entities': [(80, 91, 'B_Disease'), (92, 100, 'I_Disease')]}], [\"We report a case of intractable hemorrhagic cystitis due to cyclophosphamide therapy for Wegener ' s granulomatosis .\", {'entities': [(32, 43, 'B_Disease'), (44, 52, 'I_Disease'), (89, 96, 'B_Disease'), (97, 98, 'I_Disease'), (99, 100, 'I_Disease'), (101, 115, 'I_Disease')]}], ['Conservative treatment , including bladder irrigation with physiological saline and instillation of prostaglandin F2 alpha , failed to totally control hemorrhage .', {'entities': [(151, 161, 'B_Disease')]}], ['The bleeding ceased completely by the end of treatment and the patient remained free of hematuria thereafter .', {'entities': [(4, 12, 'B_Disease'), (88, 97, 'B_Disease')]}], ['In future , this form of therapy can offer a safe alternative in the treatment of cyclophosphamide - induced hemorrhagic cystitis .', {'entities': [(109, 120, 'B_Disease'), (121, 129, 'I_Disease')]}], ['Acute psychosis due to treatment with phenytoin in a nonepileptic patient .', {'entities': [(0, 5, 'B_Disease'), (6, 15, 'I_Disease')]}], ['The development of psychosis related to antiepileptic drug treatment is usually attributed to the interaction between the epileptic brain substratum and the antiepileptic drugs .', {'entities': [(19, 28, 'B_Disease'), (122, 131, 'B_Disease')]}], ['The case of a nonepileptic patient who developed psychosis following phenytoin treatment for trigeminal neuralgia is described .', {'entities': [(49, 58, 'B_Disease'), (93, 103, 'B_Disease'), (104, 113, 'I_Disease')]}], ['This case suggests that the psychotic symptoms that occur following phenytoin treatment in some epileptic patients may be the direct result of medication , unrelated to seizures .', {'entities': [(28, 37, 'B_Disease'), (38, 46, 'I_Disease'), (96, 105, 'B_Disease'), (169, 177, 'B_Disease')]}], ['Although the United States Food and Drug Administration banned its use for nocturnal leg cramps due to lack of safety and efficacy , quinine is widely available in beverages including tonic water and bitter lemon .', {'entities': [(75, 84, 'B_Disease'), (85, 88, 'I_Disease'), (89, 95, 'I_Disease')]}], ['Numerous anecdotal reports suggest that products containing quinine may produce neurological complications , including confusion , altered mental status , seizures , and coma , particularly in older women .', {'entities': [(80, 92, 'B_Disease'), (93, 106, 'I_Disease'), (119, 128, 'B_Disease'), (155, 163, 'B_Disease'), (170, 174, 'B_Disease')]}], [\"Transient platypnea - orthodeoxia - like syndrome induced by propafenone overdose in a young woman with Ebstein ' s anomaly .\", {'entities': [(10, 19, 'B_Disease'), (20, 21, 'I_Disease'), (22, 33, 'I_Disease'), (34, 35, 'I_Disease'), (36, 40, 'I_Disease'), (41, 49, 'I_Disease'), (73, 81, 'B_Disease'), (104, 111, 'B_Disease'), (112, 113, 'I_Disease'), (114, 115, 'I_Disease'), (116, 123, 'I_Disease')]}], [\"In this report we describe the case of a 37 - year - old white woman with Ebstein ' s anomaly , who developed a rare syndrome called platypnea - orthodeoxia , characterized by massive right - to - left interatrial shunting with transient profound hypoxia and cyanosis .\", {'entities': [(74, 81, 'B_Disease'), (82, 83, 'I_Disease'), (84, 85, 'I_Disease'), (86, 93, 'I_Disease'), (133, 142, 'B_Disease'), (143, 144, 'I_Disease'), (145, 156, 'I_Disease'), (247, 254, 'B_Disease'), (259, 267, 'B_Disease')]}], ['This shunt of blood via a patent foramen ovale occurred in the presence of a normal pulmonary artery pressure , and was probably precipitated by a propafenone overdose .', {'entities': [(26, 32, 'B_Disease'), (33, 40, 'I_Disease'), (41, 46, 'I_Disease'), (159, 167, 'B_Disease')]}], ['This drug caused biventricular dysfunction , due to its negative inotropic effect , and hypotension , due to its peripheral vasodilatory effect .', {'entities': [(17, 30, 'B_Disease'), (31, 42, 'I_Disease'), (88, 99, 'B_Disease')]}], ['Noxious chemical stimulation of rat facial mucosa increases intracranial blood flow through a trigemino - parasympathetic reflex - - an experimental model for vascular dysfunctions in cluster headache .', {'entities': [(159, 167, 'B_Disease'), (168, 180, 'I_Disease'), (184, 191, 'B_Disease'), (192, 200, 'I_Disease')]}], ['Cluster headache is characterized by typical autonomic dysfunctions including facial and intracranial vascular disturbances .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease'), (89, 101, 'B_Disease'), (102, 110, 'I_Disease'), (111, 123, 'I_Disease')]}], ['Capsaicin ( 0 . 01 - 1 mm ) applied to oral or nasal mucosa induced increases in dural and cortical blood flow and provoked lacrimation .', {'entities': [(68, 77, 'B_Disease'), (78, 80, 'I_Disease'), (81, 86, 'I_Disease'), (87, 90, 'I_Disease'), (91, 99, 'I_Disease'), (100, 105, 'I_Disease'), (106, 110, 'I_Disease')]}], ['The evoked increases in dural blood flow were also abolished by topical pre - administration of atropine ( 1 mm ) and [ Lys1 , Pro2 , 5 , Arg3 , 4 , Tyr6 ] - VIP ( 0 . 1 mm ) , a vasoactive intestinal polypeptide ( VIP ) antagonist , onto the exposed dura mater .', {'entities': [(11, 20, 'B_Disease'), (21, 23, 'I_Disease'), (24, 29, 'I_Disease'), (30, 35, 'I_Disease'), (36, 40, 'I_Disease')]}], ['Similar mechanisms may be involved in the pathogenesis of cluster headache .', {'entities': [(58, 65, 'B_Disease'), (66, 74, 'I_Disease')]}], ['Organophosphate - induced convulsions and prevention of neuropathological damages .', {'entities': [(26, 37, 'B_Disease'), (56, 73, 'B_Disease'), (74, 81, 'I_Disease')]}], ['The acute toxicity of OPs is the result of their irreversible binding with AChEs in the central nervous system ( CNS ) , which elevates acetylcholine ( ACh ) levels .', {'entities': [(10, 18, 'B_Disease')]}], ['The rats treated with DFP - atropine showed severe typical OP - induced toxicity signs .', {'entities': [(72, 80, 'B_Disease')]}], ['When CPA , diazepam or 2PAM was given immediately after DFP - atropine , these treatments prevented , delayed or shortened the occurrence of serious signs of poisoning .', {'entities': [(158, 167, 'B_Disease')]}], ['Atropine - MK801 did not offer any additional protection against DFP toxicity .', {'entities': [(69, 77, 'B_Disease')]}], ['In conclusion , CPA , diazepam and 2PAM in combination with atropine prevented the occurrence of serious signs of poisoning and thus reduced the toxicity of DFP in rat .', {'entities': [(114, 123, 'B_Disease'), (145, 153, 'B_Disease')]}], ['A pyridoxine - dependent behavioral disorder unmasked by isoniazid .', {'entities': [(25, 35, 'B_Disease'), (36, 44, 'I_Disease')]}], ['A 3 - year - old girl had behavioral deterioration , with hyperkinesis , irritability , and sleeping difficulties after the therapeutic administration of isoniazid .', {'entities': [(26, 36, 'B_Disease'), (37, 50, 'I_Disease'), (58, 70, 'B_Disease'), (73, 85, 'B_Disease'), (92, 100, 'B_Disease'), (101, 113, 'I_Disease')]}], ['Periodic withdrawal of pyridoxine was associated with return of the hyperkinesis .', {'entities': [(68, 80, 'B_Disease')]}], ['Recurrent excitation in the dentate gyrus of a murine model of temporal lobe epilepsy .', {'entities': [(63, 71, 'B_Disease'), (72, 76, 'I_Disease'), (77, 85, 'I_Disease')]}], ['Similar to rats , systemic pilocarpine injection causes status epilepticus ( SE ) and the eventual development of spontaneous seizures and mossy fiber sprouting in C57BL / 6 and CD1 mice , but the physiological correlates of these events have not been identified in mice .', {'entities': [(56, 62, 'B_Disease'), (63, 74, 'I_Disease'), (77, 79, 'B_Disease'), (126, 134, 'B_Disease')]}], ['In Mg ( 2 + ) - free bathing medium containing bicuculline , conditions designed to increase excitability in the slices , electrical stimulation of the hilus resulted in a single population spike in granule cells from control mice and pilocarpine - treated mice that did not experience SE .', {'entities': [(286, 288, 'B_Disease')]}], ['In SE survivors , similar stimulation resulted in a population spike followed , at a variable latency , by negative DC shifts and repetitive afterdischarges of 3 - 60 s duration , which were blocked by ionotropic glutamate receptor antagonists .', {'entities': [(3, 5, 'B_Disease')]}], ['Focal glutamate photostimulation of the granule cell layer at sites distant from the recording pipette resulted in population responses of 1 - 30 s duration in slices from SE survivors but not other groups .', {'entities': [(172, 174, 'B_Disease')]}], ['These data support the hypothesis that SE - induced mossy fiber sprouting and synaptic reorganization are relevant characteristics of seizure development in these murine strains , resembling rat models of human temporal lobe epilepsy .', {'entities': [(39, 41, 'B_Disease'), (134, 141, 'B_Disease'), (211, 219, 'B_Disease'), (220, 224, 'I_Disease'), (225, 233, 'I_Disease')]}], [\"Urinary bladder cancer in Wegener ' s granulomatosis : risks and relation to cyclophosphamide .\", {'entities': [(0, 7, 'B_Disease'), (8, 15, 'I_Disease'), (16, 22, 'I_Disease'), (26, 33, 'B_Disease'), (34, 35, 'I_Disease'), (36, 37, 'I_Disease'), (38, 52, 'I_Disease')]}], [\"OBJECTIVE : To assess and characterise the risk of bladder cancer , and its relation to cyclophosphamide , in patients with Wegener ' s granulomatosis .\", {'entities': [(51, 58, 'B_Disease'), (59, 65, 'I_Disease'), (124, 131, 'B_Disease'), (132, 133, 'I_Disease'), (134, 135, 'I_Disease'), (136, 150, 'I_Disease')]}], [\"METHODS : In the population based , nationwide Swedish Inpatient Register a cohort of 1065 patients with Wegener ' s granulomatosis , 1969 - 95 , was identified .\", {'entities': [(105, 112, 'B_Disease'), (113, 114, 'I_Disease'), (115, 116, 'I_Disease'), (117, 131, 'I_Disease')]}], ['Through linkage with the Swedish Cancer Register , all subjects in this cohort diagnosed with bladder cancer were identified .', {'entities': [(33, 39, 'B_Disease'), (94, 101, 'B_Disease'), (102, 108, 'I_Disease')]}], ['Nested within the cohort , a matched case - control study was performed to estimate the association between cyclophosphamide and bladder cancer using odds ratios ( ORs ) as relative risk .', {'entities': [(129, 136, 'B_Disease'), (137, 143, 'I_Disease')]}], [\"In the cohort the cumulative risk of bladder cancer after Wegener ' s granulomatosis , and the relative prevalence of a history of bladder cancer at the time of diagnosis of Wegener ' s granulomatosis , were also estimated .\", {'entities': [(37, 44, 'B_Disease'), (45, 51, 'I_Disease'), (58, 65, 'B_Disease'), (66, 67, 'I_Disease'), (68, 69, 'I_Disease'), (70, 84, 'I_Disease'), (131, 138, 'B_Disease'), (139, 145, 'I_Disease'), (174, 181, 'B_Disease'), (182, 183, 'I_Disease'), (184, 185, 'I_Disease'), (186, 200, 'I_Disease')]}], ['The risk of bladder cancer doubled for every 10 g increment in cyclophosphamide ( OR = 2 . 0 , 95 % confidence interval ( CI ) 0 . 8 to 4 . 9 ) .', {'entities': [(12, 19, 'B_Disease'), (20, 26, 'I_Disease')]}], [\"The absolute risk for bladder cancer in the cohort reached 10 % 16 years after diagnosis of Wegener ' s granulomatosis , and a history of bladder cancer was ( non - significantly ) twice as common as expected at the time of diagnosis of Wegener ' s granulomatosis .\", {'entities': [(22, 29, 'B_Disease'), (30, 36, 'I_Disease'), (92, 99, 'B_Disease'), (100, 101, 'I_Disease'), (102, 103, 'I_Disease'), (104, 118, 'I_Disease'), (138, 145, 'B_Disease'), (146, 152, 'I_Disease'), (237, 244, 'B_Disease'), (245, 246, 'I_Disease'), (247, 248, 'I_Disease'), (249, 263, 'I_Disease')]}], [\"CONCLUSION : The results indicate a dose - response relationship between cyclophosphamide and the risk of bladder cancer , high cumulative risks in the entire cohort , and also the possibility of risk factors operating even before Wegener ' s granulomatosis .\", {'entities': [(106, 113, 'B_Disease'), (114, 120, 'I_Disease'), (231, 238, 'B_Disease'), (239, 240, 'I_Disease'), (241, 242, 'I_Disease'), (243, 257, 'I_Disease')]}], ['Differential modulation by estrogen of alpha2 - adrenergic and I1 - imidazoline receptor - mediated hypotension in female rats .', {'entities': [(100, 111, 'B_Disease')]}], ['We have recently shown that estrogen negatively modulates the hypotensive effect of clonidine ( mixed alpha2 - / I1 - receptor agonist ) in female rats and implicates the cardiovascular autonomic control in this interaction .', {'entities': [(62, 73, 'B_Disease')]}], ['In sham - operated rats , rilmenidine or alpha - methyldopa elicited similar hypotension that lasted at least 5 h and was associated with reductions in standard deviation of mean arterial pressure .', {'entities': [(77, 88, 'B_Disease')]}], ['Ovx significantly enhanced the hypotensive response to alpha - methyldopa , in contrast to no effect on rilmenidine hypotension .', {'entities': [(31, 42, 'B_Disease'), (116, 127, 'B_Disease')]}], ['The enhanced alpha - methyldopa hypotension in Ovx rats was paralleled with further reduction in SDRR and a reduced locomotor activity .', {'entities': [(32, 43, 'B_Disease'), (106, 107, 'B_Disease'), (108, 115, 'I_Disease'), (116, 125, 'I_Disease'), (126, 134, 'I_Disease')]}], ['These findings suggest that estrogen downregulates alpha2 - but not I1 - receptor - mediated hypotension and highlight a role for the cardiac autonomic control in alpha - methyldopa - estrogen interaction .', {'entities': [(93, 104, 'B_Disease')]}], ['Severe reversible left ventricular systolic and diastolic dysfunction due to accidental iatrogenic epinephrine overdose .', {'entities': [(18, 22, 'B_Disease'), (23, 34, 'I_Disease'), (35, 43, 'I_Disease'), (44, 47, 'I_Disease'), (48, 57, 'I_Disease'), (58, 69, 'I_Disease'), (111, 119, 'B_Disease')]}], ['Catecholamine - induced cardiomyopathy due to chronic excess of endogenous catecholamines has been recognized for decades as a clinical phenomenon .', {'entities': [(24, 38, 'B_Disease')]}], ['In contrast , reports of myocardial dysfunction due to acute iatrogenic overdose are rare .', {'entities': [(25, 35, 'B_Disease'), (36, 47, 'I_Disease'), (72, 80, 'B_Disease')]}], ['A 35 - year - old woman whose cervix uteri was inadvertently injected with 8 mg of epinephrine developed myocardial stunning that was characterized by severe hemodynamic compromise , profound , albeit transient , left ventricular systolic and diastolic dysfunction , and only modestly elevated biochemical markers of myocardial necrosis .', {'entities': [(105, 115, 'B_Disease'), (116, 124, 'I_Disease'), (213, 217, 'B_Disease'), (218, 229, 'I_Disease'), (230, 238, 'I_Disease'), (239, 242, 'I_Disease'), (243, 252, 'I_Disease'), (253, 264, 'I_Disease'), (317, 327, 'B_Disease'), (328, 336, 'I_Disease')]}], ['Cardioprotective effect of tincture of Crataegus on isoproterenol - induced myocardial infarction in rats .', {'entities': [(76, 86, 'B_Disease'), (87, 97, 'I_Disease')]}], ['The present study was done to investigate the protective effect of TCR on experimentally induced myocardial infarction in rats .', {'entities': [(97, 107, 'B_Disease'), (108, 118, 'I_Disease')]}], ['Treatment of tinnitus by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through ventilation tubes .', {'entities': [(13, 21, 'B_Disease')]}], ['Idiopathic subjective tinnitus ( IST ) is one of the most obscure otological pathologies .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (22, 30, 'I_Disease'), (33, 36, 'B_Disease')]}], ['This paper presents the results of treating IST by intratympanic instillation of lignocaine ( lidocaine ) 2 per cent through a grommet , for five weekly courses .', {'entities': [(44, 47, 'B_Disease')]}], ['Fifty - two patients suffering from intractable tinnitus entered this therapeutic trial , but only nine finished all five courses .', {'entities': [(48, 56, 'B_Disease')]}], ['In one patient , the tinnitus was almost completely abolished , but in all the nine patients the decompensated tinnitus changed to a compensated one .', {'entities': [(21, 29, 'B_Disease'), (111, 119, 'B_Disease')]}], ['Patients should be warned about the side effects of vertigo and vomiting , which subsides gradually with every new instillation , and that the tinnitus may not disappear but will be alleviated , enabling them to cope more easily with the disease and lead a more normal life .', {'entities': [(52, 59, 'B_Disease'), (64, 72, 'B_Disease'), (143, 151, 'B_Disease')]}], ['The alpha3 and beta4 nicotinic acetylcholine receptor subunits are necessary for nicotine - induced seizures and hypolocomotion in mice .', {'entities': [(100, 108, 'B_Disease'), (113, 127, 'B_Disease')]}], ['Binding of nicotine to nicotinic acetylcholine receptors ( nAChRs ) elicits a series of dose - dependent behaviors that go from altered exploration , sedation , and tremors , to seizures and death .', {'entities': [(165, 172, 'B_Disease'), (178, 186, 'B_Disease'), (191, 196, 'B_Disease')]}], ['We examined the role of the beta4 subunits in nicotine - induced seizures and hypolocomotion in beta4 homozygous null ( beta4 - / - ) and alpha3 heterozygous ( + / - ) mice .', {'entities': [(65, 73, 'B_Disease'), (78, 92, 'B_Disease')]}], ['beta4 - / - mice were less sensitive to the effects of nicotine both at low doses , measured as decreased exploration in an open field , and at high doses , measured as sensitivity to nicotine - induced seizures .', {'entities': [(203, 211, 'B_Disease')]}], ['alpha3 + / - mice were partially resistant to nicotine - induced seizures when compared to wild - type littermates .', {'entities': [(65, 73, 'B_Disease')]}], ['Together , these results suggest that the beta4 and the alpha3 subunits are mediators of nicotine - induced seizures and hypolocomotion .', {'entities': [(108, 116, 'B_Disease'), (121, 135, 'B_Disease')]}], ['The effects of sevoflurane on lidocaine - induced convulsions .', {'entities': [(50, 61, 'B_Disease')]}], ['The influence of sevoflurane on lidocaine - induced convulsions was studied in cats .', {'entities': [(52, 63, 'B_Disease')]}], ['The convulsive threshold ( mean + / - SD ) was 41 . 4 + / - 6 . 5 mg .', {'entities': [(4, 14, 'B_Disease')]}], ['There was no significant difference in the convulsive threshold between sevoflurane and enflurane .', {'entities': [(43, 53, 'B_Disease')]}], ['The rise in blood pressure became less marked when higher concentrations of sevoflurane or enflurane were administered and the blood pressure at convulsions decreased significantly in 1 . 6 % sevoflurane , and in 0 . 8 % and 1 . 6 % enflurane .', {'entities': [(145, 156, 'B_Disease')]}], ['Apamin ( 10 ng ) had a tendency to decrease the convulsive threshold ( 21 . 6 + / - 2 . 2 to 19 . 9 + / - 2 . 5 mg . l ( - 1 ) ) but this was not statistically significant .', {'entities': [(48, 58, 'B_Disease')]}], ['It is suggested that sevoflurane reduces the convulsive effect of lidocaine toxicity but carries some risk due to circulatory depression .', {'entities': [(45, 55, 'B_Disease'), (76, 84, 'B_Disease'), (126, 136, 'B_Disease')]}], ['Cardiac toxicity observed in association with high - dose cyclophosphamide - based chemotherapy for metastatic breast cancer .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease'), (111, 117, 'B_Disease'), (118, 124, 'I_Disease')]}], ['In high doses , its nonhematological dose - limiting toxicity is cardiomyopathy .', {'entities': [(53, 61, 'B_Disease'), (65, 79, 'B_Disease')]}], ['STUDY DESIGN : We combined paclitaxel , melphalan and high - dose cyclophosphamide , thiotepa , and carboplatin in a triple sequential high - dose regimen for patients with metastatic breast cancer .', {'entities': [(184, 190, 'B_Disease'), (191, 197, 'I_Disease')]}], ['Analysis was performed on 61 women with chemotherapy - responsive metastatic breast cancer receiving 96 - h infusional cyclophosphamide as part of a triple sequential high - dose regimen to assess association between presence of peritransplant congestive heart failure ( CHF ) and the following pretreatment characteristics : presence of electrocardiogram ( EKG ) abnormalities , age , hypertension , prior cardiac history , smoking , diabetes mellitus , prior use of anthracyclines , and left - sided chest irradiation .', {'entities': [(77, 83, 'B_Disease'), (84, 90, 'I_Disease'), (244, 254, 'B_Disease'), (255, 260, 'I_Disease'), (261, 268, 'I_Disease'), (271, 274, 'B_Disease'), (386, 398, 'B_Disease'), (435, 443, 'B_Disease'), (444, 452, 'I_Disease')]}], ['RESULTS : Six of 61 women ( 10 % ) developed clinically reversible grade 3 CHF following infusional cyclophosphamide with a median percent decline in ejection fraction of 31 % .', {'entities': [(75, 78, 'B_Disease')]}], ['Incidence of transient cyclophosphamide - related cardiac toxicity ( 10 % ) is comparable to previous recorded literature .', {'entities': [(50, 57, 'B_Disease'), (58, 66, 'I_Disease')]}], ['Older age was significantly correlated with the CHF development ; with median ages for the entire group and for patients developing CHF of 45 and 59 , respectively .', {'entities': [(48, 51, 'B_Disease'), (132, 135, 'B_Disease')]}], ['Routine EKG monitoring during infusional cyclophosphamide did not predict CHF development .', {'entities': [(74, 77, 'B_Disease')]}], ['Tremor side effects of salbutamol , quantified by a laser pointer technique .', {'entities': [(0, 6, 'B_Disease')]}], ['OBJECTIVE : To study tremor side effects of salbutamol an easily applicable , quick and low - priced method is needed .', {'entities': [(21, 27, 'B_Disease')]}], ['METHODS : Tremor was measured using a laser pointer technique .', {'entities': [(10, 16, 'B_Disease')]}], ['To determine sensitivity we assessed tremor in 44 patients with obstructive lung disease after administration of cumulative doses of salbutamol .', {'entities': [(37, 43, 'B_Disease'), (64, 75, 'B_Disease'), (76, 80, 'I_Disease'), (81, 88, 'I_Disease')]}], ['In another series of measurements , reproducibility and reference values of the tremor was assessed in 65 healthy subjects in three sessions , at 9 a . m . , 4 p . m . and 9 a . m . , respectively , 1 week later .', {'entities': [(80, 86, 'B_Disease')]}], ['Postural tremor was measured with the arm horizontally outstretched rest tremor with the arm supported by an armrest and finally tremor was measured after holding a 2 - kg weight until exhaustion .', {'entities': [(9, 15, 'B_Disease'), (73, 79, 'B_Disease'), (129, 135, 'B_Disease')]}], ['Tremor was measured simultaneously by two independent observers .', {'entities': [(0, 6, 'B_Disease')]}], ['RESULTS : Salbutamol significantly increased tremor severity in patients in a dose - dependent way .', {'entities': [(45, 51, 'B_Disease')]}], ['There was no agreement between the questionnaire and tremor severity ( r = 0 . 093 ; P = 0 . 53 ) .', {'entities': [(53, 59, 'B_Disease')]}], ['Postural tremor showed no significant difference between the first and third session ( P = 0 . 07 ) .', {'entities': [(9, 15, 'B_Disease')]}], ['Support of the arm decreased tremor severity , exhaustion increased tremor severity significantly .', {'entities': [(29, 35, 'B_Disease'), (68, 74, 'B_Disease')]}], ['DISCUSSION : Quantifying tremor by using an inexpensive laser pointer is , with the exception of children ( < 12 years ) a sensitive and reproducible method .', {'entities': [(25, 31, 'B_Disease')]}], ['METHODS : The Multiple Outcomes of Raloxifene Evaluation , a multicenter , randomized , double - blind trial , enrolled 7 , 705 postmenopausal women with osteoporosis .', {'entities': [(154, 166, 'B_Disease')]}], ['Outcomes included venous thromboembolism , cataracts , gallbladder disease , and endometrial hyperplasia or cancer .', {'entities': [(18, 24, 'B_Disease'), (25, 40, 'I_Disease'), (43, 52, 'B_Disease'), (55, 66, 'B_Disease'), (67, 74, 'I_Disease'), (81, 92, 'B_Disease'), (93, 104, 'I_Disease'), (105, 107, 'I_Disease'), (108, 114, 'I_Disease')]}], ['RESULTS : During a mean follow - up of 3 . 3 years , raloxifene was associated with an increased risk for venous thromboembolism ( relative risk [ RR ] 2 . 1 ; 95 % confidence interval [ CI ] 1 . 2 - 3 . 8 ) .', {'entities': [(106, 112, 'B_Disease'), (113, 128, 'I_Disease')]}], ['Raloxifene did not increase risk for cataracts ( RR 0 . 9 ; 95 % CI 0 . 8 - 1 . 1 ) , gallbladder disease ( RR 1 . 0 ; 95 % CI 0 . 7 - 1 . 3 ) , endometrial hyperplasia ( RR 1 . 3 ; 95 % CI 0 . 4 - 5 . 1 ) , or endometrial cancer ( RR 0 . 9 ; 95 % CI 0 . 3 - 2 . 7 ) .', {'entities': [(37, 46, 'B_Disease'), (86, 97, 'B_Disease'), (98, 105, 'I_Disease'), (145, 156, 'B_Disease'), (157, 168, 'I_Disease'), (211, 222, 'B_Disease'), (223, 229, 'I_Disease')]}], ['CONCLUSION : Raloxifene was associated with an increased risk for venous thromboembolism , but there was no increased risk for cataracts , gallbladder disease , endometrial hyperplasia , or endometrial cancer .', {'entities': [(66, 72, 'B_Disease'), (73, 88, 'I_Disease'), (127, 136, 'B_Disease'), (139, 150, 'B_Disease'), (151, 158, 'I_Disease'), (161, 172, 'B_Disease'), (173, 184, 'I_Disease'), (190, 201, 'B_Disease'), (202, 208, 'I_Disease')]}], ['While there is no single correct starting dose for levodopa therapy , many individuals can be started on either the 25 / 100 or controlled - release formula , following the general rule not to attempt to titrate carbidopa - levodopa to the point of \" normality , \" which can lead to toxicity .', {'entities': [(283, 291, 'B_Disease')]}], ['Other possible adverse effects - - such as gastrointestinal disorders , orthostatic hypotension , levodopa - induced psychosis , sleep disturbances or parasomnias , or drug interactions - - also require carefully monitored individual treatment .', {'entities': [(43, 59, 'B_Disease'), (60, 69, 'I_Disease'), (72, 83, 'B_Disease'), (84, 95, 'I_Disease'), (117, 126, 'B_Disease'), (129, 134, 'B_Disease'), (135, 147, 'I_Disease'), (151, 162, 'B_Disease')]}], [\"Nonpharmacologic concerns can help the Parkinson ' s disease patient achieve and maintain optimal functioning , including daily exercise , physical therapy , and involvement with support groups .\", {'entities': [(39, 48, 'B_Disease'), (49, 50, 'I_Disease'), (51, 52, 'I_Disease'), (53, 60, 'I_Disease')]}], ['Long term audiological evaluation of beta - thalassemic patients .', {'entities': [(37, 41, 'B_Disease'), (42, 43, 'I_Disease'), (44, 55, 'I_Disease')]}], ['OBJECTIVE : The objective of this study was to identify the incidence and to monitor the progression of hearing loss in children and young adults with beta - thalassemia major .', {'entities': [(104, 111, 'B_Disease'), (112, 116, 'I_Disease'), (151, 155, 'B_Disease'), (156, 157, 'I_Disease'), (158, 169, 'I_Disease')]}], ['RESULTS : Overall , 21 out of 104 patients ( 20 . 2 % ) presented with high frequency sensorineural hearing loss ( SNHL ) , either unilateral or bilateral .', {'entities': [(86, 99, 'B_Disease'), (100, 107, 'I_Disease'), (108, 112, 'I_Disease'), (115, 119, 'B_Disease')]}], ['No ototoxic factor , other than DFO , was present in any of the patients .', {'entities': [(3, 11, 'B_Disease')]}], ['Patients with SNHL presented with relatively lower serum ferritin levels than those with normal hearing , however , no statistically significant difference was observed .', {'entities': [(14, 18, 'B_Disease')]}], ['Subjects with SNHL were submitted to DFO reduction or temporary withdrawal .', {'entities': [(14, 18, 'B_Disease')]}], [\"CONCLUSION : The findings are indicative of DFO ' s contributing role in the development of hearing impairment .\", {'entities': [(92, 99, 'B_Disease'), (100, 110, 'I_Disease')]}], ['Regular audiologic evaluation is imperative in all thalassemic patients so that early changes may be recognized and treatment may be judiciously adjusted in order to prevent or reverse hearing impairment .', {'entities': [(51, 62, 'B_Disease'), (185, 192, 'B_Disease'), (193, 203, 'I_Disease')]}], ['Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin - induced renal damage .', {'entities': [(108, 113, 'B_Disease'), (114, 120, 'I_Disease')]}], ['Therefore , we studied the predictive effect of renal ACE activity for the severity of renal damage induced by a single injection of adriamycin in rats .', {'entities': [(87, 92, 'B_Disease'), (93, 99, 'I_Disease')]}], ['After 1 week of recovery , proteinuria was induced by adriamycin [ 1 . 5 mg / kg intravenously ( i . v . ) n = 18 ; controls , saline i . v . n = 9 ] .', {'entities': [(27, 38, 'B_Disease')]}], ['Proteinuria was measured every 2 weeks .', {'entities': [(0, 11, 'B_Disease')]}], ['RESULTS : As anticipated , adriamycin elicited nephrotic range proteinuria , renal interstitial damage and mild focal glomerulosclerosis .', {'entities': [(47, 56, 'B_Disease'), (63, 74, 'B_Disease'), (77, 82, 'B_Disease'), (83, 95, 'I_Disease'), (96, 102, 'I_Disease'), (112, 117, 'B_Disease'), (118, 136, 'I_Disease')]}], ['Baseline renal ACE positively correlated with the relative rise in proteinuria after adriamycin ( r = 0 . 62 , P < 0 . 01 ) , renal interstitial alpha - smooth muscle actin ( r = 0 . 49 , P < 0 . 05 ) , interstitial macrophage influx ( r = 0 . 56 , P < 0 . 05 ) , interstitial collagen III ( r = 0 . 53 , P < 0 . 05 ) , glomerular alpha - smooth muscle actin ( r = 0 . 74 , P < 0 . 01 ) and glomerular desmin ( r = 0 . 48 , P < 0 . 05 ) .', {'entities': [(67, 78, 'B_Disease')]}], ['Baseline renal ACE did not correlate with focal glomerulosclerosis ( r = 0 . 22 , NS ) .', {'entities': [(42, 47, 'B_Disease'), (48, 66, 'I_Disease')]}], ['CONCLUSION : Individual differences in renal ACE activity predict the severity of adriamycin - induced renal damage in this outbred rat strain .', {'entities': [(103, 108, 'B_Disease'), (109, 115, 'I_Disease')]}], ['This supports the assumption that differences in renal ACE activity predispose to a less favourable course of renal damage .', {'entities': [(110, 115, 'B_Disease'), (116, 122, 'I_Disease')]}], ['Recurrent acute interstitial nephritis induced by azithromycin .', {'entities': [(16, 28, 'B_Disease'), (29, 38, 'I_Disease')]}], ['A 14 - year - old girl is reported with recurrent , azithromycin - induced , acute interstitial nephritis .', {'entities': [(83, 95, 'B_Disease'), (96, 105, 'I_Disease')]}], ['Although most cases of antibiotic induced acute interstitial nephritis are benign and self - limited , some patients are at risk for permanent renal injury .', {'entities': [(48, 60, 'B_Disease'), (61, 70, 'I_Disease'), (143, 148, 'B_Disease'), (149, 155, 'I_Disease')]}], ['Spironolactone - induced renal insufficiency and hyperkalemia in patients with heart failure .', {'entities': [(25, 30, 'B_Disease'), (31, 44, 'I_Disease'), (49, 61, 'B_Disease'), (79, 84, 'B_Disease'), (85, 92, 'I_Disease')]}], ['BACKGROUND : A previous randomized controlled trial evaluating the use of spironolactone in heart failure patients reported a low risk of hyperkalemia ( 2 % ) and renal insufficiency ( 0 % ) .', {'entities': [(92, 97, 'B_Disease'), (98, 105, 'I_Disease'), (138, 150, 'B_Disease'), (163, 168, 'B_Disease'), (169, 182, 'I_Disease')]}], ['Because treatments for heart failure have changed since the benefits of spironolactone were reported , the prevalence of these complications may differ in current clinical practice .', {'entities': [(23, 28, 'B_Disease'), (29, 36, 'I_Disease')]}], ['We therefore sought to determine the prevalence and clinical associations of hyperkalemia and renal insufficiency in heart failure patients treated with spironolactone .', {'entities': [(77, 89, 'B_Disease'), (94, 99, 'B_Disease'), (100, 113, 'I_Disease'), (117, 122, 'B_Disease'), (123, 130, 'I_Disease')]}], ['METHODS : We performed a case control study of heart failure patients treated with spironolactone in our clinical practice .', {'entities': [(47, 52, 'B_Disease'), (53, 60, 'I_Disease')]}], ['Cases were patients who developed hyperkalemia ( K ( + ) > 5 . 0 mEq / L ) or renal insufficiency ( Cr > or = 2 . 5 mg / dL ) , and they were compared to 2 randomly selected controls per case .', {'entities': [(34, 46, 'B_Disease'), (78, 83, 'B_Disease'), (84, 97, 'I_Disease')]}], ['RESULTS : Sixty - seven of 926 patients ( 7 . 2 % ) required discontinuation of spironolactone due to hyperkalemia ( n = 33 ) or renal failure ( n = 34 ) .', {'entities': [(102, 114, 'B_Disease'), (129, 134, 'B_Disease'), (135, 142, 'I_Disease')]}], ['Patients who developed hyperkalemia were older and more likely to have diabetes , had higher baseline serum potassium levels and lower baseline potassium supplement doses , and were more likely to be treated with beta - blockers than controls ( n = 134 ) .', {'entities': [(23, 35, 'B_Disease'), (71, 79, 'B_Disease')]}], ['Patients who developed renal insufficiency had lower baseline body weight and higher baseline serum creatinine , required higher doses of loop diuretics , and were more likely to be treated with thiazide diuretics than controls .', {'entities': [(23, 28, 'B_Disease'), (29, 42, 'I_Disease')]}], ['CONCLUSIONS : Spironolactone - induced hyperkalemia and renal insufficiency are more common in our clinical experience than reported previously .', {'entities': [(39, 51, 'B_Disease'), (56, 61, 'B_Disease'), (62, 75, 'I_Disease')]}], ['Acute reserpine and subchronic haloperidol treatments change synaptosomal brain glutamate uptake and elicit orofacial dyskinesia in rats .', {'entities': [(108, 117, 'B_Disease'), (118, 128, 'I_Disease')]}], ['Reserpine - and haloperidol - induced orofacial dyskinesia are putative animal models of tardive dyskinesia ( TD ) whose pathophysiology has been related to free radical generation and oxidative stress .', {'entities': [(38, 47, 'B_Disease'), (48, 58, 'I_Disease'), (89, 96, 'B_Disease'), (97, 107, 'I_Disease'), (110, 112, 'B_Disease')]}], ['In the present study , the authors induced orofacial dyskinesia by acute reserpine and subchronic haloperidol administration to rats .', {'entities': [(43, 52, 'B_Disease'), (53, 63, 'I_Disease')]}], ['Importantly , a decrease in glutamate uptake correlates negatively with an increase in the incidence of orofacial diskinesia .', {'entities': [(104, 113, 'B_Disease'), (114, 124, 'I_Disease')]}], ['Ceftriaxone - associated biliary pseudolithiasis in paediatric surgical patients .', {'entities': [(25, 32, 'B_Disease'), (33, 48, 'I_Disease')]}], ['It is well known that ceftriaxone leads to pseudolithiasis in some patients .', {'entities': [(43, 58, 'B_Disease')]}], ['Clinical and experimental studies also suggest that situations causing gallbladder dysfunction , such as fasting , may have a role for the development of pseudolithiasis .', {'entities': [(71, 82, 'B_Disease'), (83, 94, 'I_Disease'), (154, 169, 'B_Disease')]}], ['In this study , we prospectively evaluated the incidence and clinical importance of pseudolithiasis in paediatric surgical patients receiving ceftriaxone treatment , who often had to fast in the post - operative period .', {'entities': [(84, 99, 'B_Disease')]}], ['Comparison of the patients with or without pseudolithiasis revealed no significant difference with respect to age , sex , duration of the treatment and starvation variables .', {'entities': [(43, 58, 'B_Disease')]}], ['After cessation of the treatment , pseudolithiasis resolved spontaneously within a short period .', {'entities': [(35, 50, 'B_Disease')]}], ['The incidence of pseudolithiasis is not affected by fasting .', {'entities': [(17, 32, 'B_Disease')]}], ['Coronary aneurysm after implantation of a paclitaxel - eluting stent .', {'entities': [(0, 8, 'B_Disease'), (9, 17, 'I_Disease')]}], ['Formation of coronary aneurysm is a rare complication of stenting with bare metal stents , but based on experimental studies drug - eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition , aneurysm formation and with the potential of stent thrombosis or vessel rupture .', {'entities': [(13, 21, 'B_Disease'), (22, 30, 'I_Disease'), (226, 234, 'B_Disease'), (277, 287, 'B_Disease'), (291, 297, 'B_Disease'), (298, 305, 'I_Disease')]}], ['We present a 43 - year - old man who developed a coronary aneurysm in the right coronary artery 6 months after receiving a paclitaxel - eluting stent .', {'entities': [(49, 57, 'B_Disease'), (58, 66, 'I_Disease')]}], ['The patient was asymptomatic and the aneurysm was detected in a routine control .', {'entities': [(37, 45, 'B_Disease')]}], ['Angiography and intracoronary ultrasound demonstrated lack of contact between stent and vessel wall in a 15 - mm long segment with maximal aneurysm diameter of 6 . 0 mm .', {'entities': [(139, 147, 'B_Disease')]}], ['Causes of acute thrombotic microangiopathy in patients receiving kidney transplantation .', {'entities': [(16, 26, 'B_Disease'), (27, 42, 'I_Disease')]}], ['OBJECTIVES : Thrombotic microangiopathy is a well - known problem in patients following renal transplantation .', {'entities': [(13, 23, 'B_Disease'), (24, 39, 'I_Disease')]}], ['In postrenal transplantation , thrombotic microangiopathy is often a reflection of hemolytic uremic syndrome .', {'entities': [(31, 41, 'B_Disease'), (42, 57, 'I_Disease'), (83, 92, 'B_Disease'), (93, 99, 'I_Disease'), (100, 108, 'I_Disease')]}], ['We aimed to determine the causes of thrombotic microangiopathy in a population of renal transplantation recipients and discuss the literature .', {'entities': [(36, 46, 'B_Disease'), (47, 62, 'I_Disease')]}], ['MATERIALS AND METHODS : We investigated the causes of thrombotic microangiopathy during a 1 - year period , from June 2003 to June 2004 , at the King Fahad National Guard Hospital in Riyadh , Saudi Arabia , by reviewing the slides of all transplant biopsies ( n = 25 ) performed during this interval .', {'entities': [(54, 64, 'B_Disease'), (65, 80, 'I_Disease')]}], ['RESULTS : Five cases of thrombotic microangiopathy were found .', {'entities': [(24, 34, 'B_Disease'), (35, 50, 'I_Disease')]}], ['The fifth case had features of thrombotic microangiopathy related to an antiphospholipid syndrome in a patient with systemic lupus erythematosus .', {'entities': [(31, 41, 'B_Disease'), (42, 57, 'I_Disease'), (72, 88, 'B_Disease'), (89, 97, 'I_Disease'), (116, 124, 'B_Disease'), (125, 130, 'I_Disease'), (131, 144, 'I_Disease')]}], ['CONCLUSIONS : In the literature , the most - frequent cause of hemolytic uremic syndrome in patients following renal transplantation is recurrence of the hemolytic uremic syndrome .', {'entities': [(63, 72, 'B_Disease'), (73, 79, 'I_Disease'), (80, 88, 'I_Disease'), (154, 163, 'B_Disease'), (164, 170, 'I_Disease'), (171, 179, 'I_Disease')]}], ['Other causes include drug - related ( cyclosporine , tacrolimus ) toxicity , procoagulant status , and antibody - mediated rejection .', {'entities': [(66, 74, 'B_Disease')]}], ['We found that the most - frequent cause of thrombotic microangiopathy was drug related , secondary mainly to cyclosporine .', {'entities': [(43, 53, 'B_Disease'), (54, 69, 'I_Disease')]}], ['In the current study , the frequency of thrombotic microangiopathy was similar to the percentage reported in the literature ( 20 % ) .', {'entities': [(40, 50, 'B_Disease'), (51, 66, 'I_Disease')]}], ['Comparison of developmental toxicity of selective and non - selective cyclooxygenase - 2 inhibitors in CRL : ( WI ) WUBR Wistar rats - - DFU and piroxicam study .', {'entities': [(28, 36, 'B_Disease')]}], ['Unlike general toxicity data , their prenatal toxic effects were not extensively studied before .', {'entities': [(15, 23, 'B_Disease')]}], ['The aim of the experiment was to evaluate the developmental toxicity of the non - selective ( piroxicam ) and selective ( DFU ; 5 , 5 - dimethyl - 3 - ( 3 - fluorophenyl ) - 4 - ( 4 - methylsulphonyl ) phenyl - 2 ( 5H ) - furanon ) COX - 2 inhibitors .', {'entities': [(60, 68, 'B_Disease')]}], ['The pooled statistical analysis for ventricular septal ( VSD ) and midline ( MD ) defects was performed for rat fetuses exposed to piroxicam , selective and non - selective COX - 2 inhibitor based on present and historic data .', {'entities': [(36, 47, 'B_Disease'), (48, 54, 'I_Disease'), (55, 56, 'I_Disease'), (57, 60, 'I_Disease'), (61, 62, 'I_Disease'), (63, 66, 'I_Disease'), (67, 74, 'I_Disease'), (75, 76, 'I_Disease'), (77, 79, 'I_Disease'), (80, 81, 'I_Disease'), (82, 89, 'I_Disease')]}], ['RESULTS : Maternal toxicity , intrauterine growth retardation , and increase of external and skeletal variations were found in rats treated with the highest dose of piroxicam .', {'entities': [(19, 27, 'B_Disease'), (30, 42, 'B_Disease'), (43, 49, 'I_Disease'), (50, 61, 'I_Disease'), (68, 76, 'B_Disease'), (77, 79, 'I_Disease'), (80, 88, 'I_Disease'), (89, 92, 'I_Disease'), (93, 101, 'I_Disease'), (102, 112, 'I_Disease')]}], ['Decrease of fetal length was the only signs of the DFU developmental toxicity observed in pups exposed to the highest compound dose .', {'entities': [(69, 77, 'B_Disease')]}], ['Prenatal exposure to selective COX - 2 inhibitors does not increase the risk of ventricular septal and midline defects in rat when compared to non - selective drugs and historic control .', {'entities': [(80, 91, 'B_Disease'), (92, 98, 'I_Disease'), (99, 102, 'I_Disease'), (103, 110, 'I_Disease'), (111, 118, 'I_Disease')]}], ['Lone atrial fibrillation associated with creatine monohydrate supplementation .', {'entities': [(5, 11, 'B_Disease'), (12, 24, 'I_Disease')]}], ['Atrial fibrillation in young patients without structural heart disease is rare .', {'entities': [(0, 6, 'B_Disease'), (7, 19, 'I_Disease'), (57, 62, 'B_Disease'), (63, 70, 'I_Disease')]}], ['Therefore , when the arrhythmia is present in this population , reversible causes must be identified and resolved .', {'entities': [(21, 31, 'B_Disease')]}], ['Thyroid disorders , illicit drug or stimulant use , and acute alcohol intoxication are among these causes .', {'entities': [(0, 7, 'B_Disease'), (8, 17, 'I_Disease'), (56, 61, 'B_Disease'), (62, 69, 'I_Disease'), (70, 82, 'I_Disease')]}], ['We report the case of a 30 - year - old Caucasian man who came to the emergency department in atrial fibrillation with rapid ventricular response .', {'entities': [(94, 100, 'B_Disease'), (101, 113, 'I_Disease')]}], ['His medical history was unremarkable , except for minor fractures of the fingers and foot .', {'entities': [(56, 65, 'B_Disease')]}], ['Previous anecdotal reports have linked creatine to the development of arrhythmia .', {'entities': [(70, 80, 'B_Disease')]}], ['Seizures induced by the cocaine metabolite benzoylecgonine in rats .', {'entities': [(0, 8, 'B_Disease')]}], ['The half - life ( t1 / 2 ) of cocaine is relatively short , but some of the consequences of its use , such as seizures and strokes , can occur hours after exposure .', {'entities': [(110, 118, 'B_Disease'), (123, 130, 'B_Disease')]}], ['We evaluated the potential of the major metabolite of cocaine , benzoylecgonine ( BE ) , to cause seizures .', {'entities': [(98, 106, 'B_Disease')]}], ['Treated rats were then evaluated for incidence , latency , and seizure pattern or for locomotor activity in animals without seizures .', {'entities': [(63, 70, 'B_Disease'), (124, 132, 'B_Disease')]}], ['BE - Induced seizures occurred more frequently and had significantly longer latencies than those induced by equimolar amounts of cocaine .', {'entities': [(13, 21, 'B_Disease')]}], ['Whereas cocaine - induced seizures were best characterized as brief , generalized , and tonic and resulted in death , those induced by BE were prolonged , often multiple and mixed in type , and rarely resulted in death .', {'entities': [(26, 34, 'B_Disease'), (110, 115, 'B_Disease'), (213, 218, 'B_Disease')]}], ['Electrical recordings from the hippocampus showed a rhythmic progression in EEG frequency and voltage with clinical seizure expression .', {'entities': [(116, 123, 'B_Disease')]}], ['BE - Injected rats that did not have seizures had significantly more locomotor activity than cocaine - injected animals without seizures .', {'entities': [(37, 45, 'B_Disease'), (128, 136, 'B_Disease')]}], ['The finding that cocaine - and BE - induced seizures differ in several respects suggests more than one mechanism for cocaine - induced seizures and emphasizes the importance of a cocaine metabolite , BE .', {'entities': [(44, 52, 'B_Disease'), (135, 143, 'B_Disease')]}], ['The selective 5 - HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat .', {'entities': [(122, 128, 'B_Disease'), (129, 139, 'I_Disease')]}], ['Both , Ro4368554 ( 3 and 10 mg / kg , intraperitoneally ( i . p . ) ) and metrifonate ( 10 mg / kg , p . o . , respectively ) reversed memory deficits induced by scopolamine and TRP depletion ( 10 mg / kg , i . p . , and 3 mg / kg , p . o . , respectively ) .', {'entities': [(135, 141, 'B_Disease'), (142, 150, 'I_Disease')]}], ['In conclusion , although Ro4368554 did not improve a time - related retention deficit , it reversed a cholinergic and a serotonergic memory deficit , suggesting that both mechanisms may be involved in the facilitation of object memory by Ro4368554 and , possibly , other 5 - HT ( 6 ) receptor antagonists .', {'entities': [(133, 139, 'B_Disease'), (140, 147, 'I_Disease')]}], ['Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose .', {'entities': [(82, 89, 'B_Disease'), (90, 98, 'I_Disease')]}], ['The illicit use of cocaine continues in epidemic proportions and treatment for cocaine overdose remains elusive .', {'entities': [(79, 86, 'B_Disease'), (87, 95, 'I_Disease')]}], ['The therapeutic potential of the anticocaine antibody GNC92H2 was examined using a model of cocaine overdose .', {'entities': [(92, 99, 'B_Disease'), (100, 108, 'I_Disease')]}], ['Significant blockade of cocaine toxicity was observed with the higher dose of GNC92H2 ( 190 mg / kg ) , where premorbid behaviors were reduced up to 40 % , seizures up to 77 % and death by 72 % .', {'entities': [(32, 40, 'B_Disease'), (156, 164, 'B_Disease'), (180, 185, 'B_Disease')]}], ['Importantly , GNC92H2 prevented death even post - cocaine injection .', {'entities': [(32, 37, 'B_Disease')]}], ['The results support the important potential of GNC92H2 as a therapeutic tool against cocaine overdose .', {'entities': [(85, 92, 'B_Disease'), (93, 101, 'I_Disease')]}], ['Electrocardiographic evidence of myocardial injury in psychiatrically hospitalized cocaine abusers .', {'entities': [(33, 43, 'B_Disease'), (44, 50, 'I_Disease')]}], ['The electrocardiograms ( ECG ) of 99 cocaine - abusing patients were compared with the ECGs of 50 schizophrenic controls .', {'entities': [(98, 111, 'B_Disease')]}], ['Eleven of the cocaine abusers and none of the controls had ECG evidence of significant myocardial injury defined as myocardial infarction , ischemia , and bundle branch block .', {'entities': [(87, 97, 'B_Disease'), (98, 104, 'I_Disease'), (116, 126, 'B_Disease'), (127, 137, 'I_Disease'), (140, 148, 'B_Disease'), (155, 161, 'B_Disease'), (162, 168, 'I_Disease'), (169, 174, 'I_Disease')]}], ['Intracerebroventricular ( i . c . v . ) injection of U - II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion .', {'entities': [(67, 79, 'B_Disease'), (84, 95, 'B_Disease')]}], ['Whatever was the dose , the central administration of U - II had no effect on body temperature , nociception , apomorphine - induced penile erection and climbing behavior , and stress - induced plasma corticosterone level .', {'entities': [(133, 139, 'B_Disease'), (140, 148, 'I_Disease')]}], ['These data suggest that U - II may be involved in some aspects of psychiatric disorders .', {'entities': [(66, 77, 'B_Disease'), (78, 87, 'I_Disease')]}], ['Learning of rats under amnesia caused by pentobarbital .', {'entities': [(23, 30, 'B_Disease')]}], ['Dissociated learning of rats in the normal state and the state of amnesia produced by pentobarbital ( 15 mg / kg , ip ) was carried out .', {'entities': [(66, 73, 'B_Disease')]}], ['It was shown that memory dissociation occurred in both groups .', {'entities': [(18, 24, 'B_Disease'), (25, 37, 'I_Disease')]}], ['METHODS : Thirty - nine postmenopausal women with osteopenia or osteoporosis were included in this prospective , controlled clinical study .', {'entities': [(50, 60, 'B_Disease'), (64, 76, 'B_Disease')]}], ['A significant correlation was found between baseline TAFI antigen concentrations and the duration of amenorrhea ( P < 0 . 05 ; r = 0 . 33 ) .', {'entities': [(101, 111, 'B_Disease')]}], ['CONCLUSION : We suggest that the increased risk of venous thromboembolism due to raloxifene treatment may be related to increased tPA levels , but not TAFI levels .', {'entities': [(51, 57, 'B_Disease'), (58, 73, 'I_Disease')]}], ['Valproate - induced encephalopathy .', {'entities': [(20, 34, 'B_Disease')]}], ['Valproate - induced encephalopathy is a rare syndrome that may manifest in otherwise normal epileptic individuals .', {'entities': [(20, 34, 'B_Disease'), (92, 101, 'B_Disease')]}], ['It is usually but not necessarily associated with hyperammonemia .', {'entities': [(50, 64, 'B_Disease')]}], ['A case of valproate - induced encephalopathy is presented .', {'entities': [(30, 44, 'B_Disease')]}], ['Recurrent dysphonia and acitretin .', {'entities': [(10, 19, 'B_Disease')]}], ['We report the case of a woman complaining of dysphonia while she was treated by acitretin .', {'entities': [(45, 54, 'B_Disease')]}], ['To our knowledge , this is the first case of acitretin - induced dysphonia .', {'entities': [(65, 74, 'B_Disease')]}], ['Nitro - L - arginine methyl ester : a potential protector against gentamicin ototoxicity .', {'entities': [(77, 88, 'B_Disease')]}], ['The nitric oxide ( NO ) inhibitor nitro - L - arginine methyl ester ( L - NAME ) may act as an otoprotectant against high - frequency hearing loss caused by gentamicin , but further studies are needed to confirm this . Aminoglycoside antibiotics are still widely used by virtue of their efficacy and low cost .', {'entities': [(117, 121, 'B_Disease'), (122, 123, 'I_Disease'), (124, 133, 'I_Disease'), (134, 141, 'I_Disease'), (142, 146, 'I_Disease')]}], ['Their ototoxicity is a serious health problem and , as their ototoxic mechanism involves the production of NO , we need to assess the use of NO inhibitors for the prevention of aminoglycoside - induced sensorineural hearing loss .', {'entities': [(6, 17, 'B_Disease'), (61, 69, 'B_Disease'), (202, 215, 'B_Disease'), (216, 223, 'I_Disease'), (224, 228, 'I_Disease')]}], ['Its effect was determined in terms of attenuation of hearing loss , measured by shifts in the auditory brainstem response threshold .', {'entities': [(53, 60, 'B_Disease'), (61, 65, 'I_Disease')]}], ['L - NAME reduced gentamicin - induced hearing loss in the high - frequency range , but gave no protection in the middle or low frequencies .', {'entities': [(38, 45, 'B_Disease'), (46, 50, 'I_Disease')]}], ['METHODS : This was a multicenter , randomized , open - label study in adult smokers with heart disease , hypertension not controlled by medication , and / or diabetes mellitus .', {'entities': [(89, 94, 'B_Disease'), (95, 102, 'I_Disease'), (105, 117, 'B_Disease'), (158, 166, 'B_Disease'), (167, 175, 'I_Disease')]}], ['The most common adverse events were nausea ( 17 . 2 % and 16 . 1 % ; 95 % CI , - 3 . 7 to 6 . 0 ) , hiccups ( 10 . 7 % and 6 . 6 % ; 95 % CI , 0 . 5 to 7 . 8 ) , and headache ( 8 . 7 % and 9 . 9 % ; 95 % Cl , - 5 . 0 to 2 . 6 ) .', {'entities': [(36, 42, 'B_Disease'), (100, 107, 'B_Disease'), (166, 174, 'B_Disease')]}], ['Pharmacological modulation of pain - related brain activity during normal and central sensitization states in humans .', {'entities': [(30, 34, 'B_Disease')]}], ['Abnormal processing of somatosensory inputs in the central nervous system ( central sensitization ) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury ( secondary hyperalgesia ) .', {'entities': [(145, 149, 'B_Disease'), (186, 192, 'B_Disease'), (193, 199, 'I_Disease'), (202, 211, 'B_Disease'), (212, 224, 'I_Disease')]}], ['Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients with neuropathic pain .', {'entities': [(0, 9, 'B_Disease'), (10, 22, 'I_Disease'), (60, 70, 'B_Disease'), (71, 83, 'I_Disease'), (101, 112, 'B_Disease'), (113, 117, 'I_Disease')]}], ['Abnormal brain responses to somatosensory stimuli have been found in patients with hyperalgesia as well as in normal subjects during experimental central sensitization .', {'entities': [(83, 95, 'B_Disease')]}], ['The aim of this study was to assess the effects of gabapentin , a drug effective in neuropathic pain patients , on brain processing of nociceptive information in normal and central sensitization states .', {'entities': [(84, 95, 'B_Disease'), (96, 100, 'I_Disease')]}], ['Using functional magnetic resonance imaging ( fMRI ) in normal volunteers , we studied the gabapentin - induced modulation of brain activity in response to nociceptive mechanical stimulation of normal skin and capsaicin - induced secondary hyperalgesia .', {'entities': [(230, 239, 'B_Disease'), (240, 252, 'I_Disease')]}], ['Investigation of mitochondrial involvement in the experimental model of epilepsy induced by pilocarpine .', {'entities': [(72, 80, 'B_Disease')]}], ['Mitochondrial abnormalities have been associated with several aspects of epileptogenesis , such as energy generation , control of cell death , neurotransmitter synthesis , and free radical ( FR ) production .', {'entities': [(0, 13, 'B_Disease'), (14, 27, 'I_Disease'), (135, 140, 'B_Disease')]}], ['In this study , we investigated whether increased generation of FR during status epilepticus would be sufficient to provoke abnormalities in mtDNA and in the expression and activity of cytochrome c oxidase ( CCO ) , complex IV of the respiratory chain , in the chronic phase of the pilocarpine model of temporal lobe epilepsy .', {'entities': [(74, 80, 'B_Disease'), (81, 92, 'I_Disease'), (303, 311, 'B_Disease'), (312, 316, 'I_Disease'), (317, 325, 'I_Disease')]}], ['Although evidences of mitochondrial abnormalities were found in previously published studies , our results do not suggest that the FRs , generated during the acute phase , determined important abnormalities in mtDNA , in expression of CCO - I , and in CCO activity .', {'entities': [(22, 35, 'B_Disease'), (36, 49, 'I_Disease')]}], ['Adverse effect of the calcium channel blocker nitrendipine on nephrosclerosis in rats with renovascular hypertension .', {'entities': [(62, 77, 'B_Disease'), (91, 103, 'B_Disease'), (104, 116, 'I_Disease')]}], ['The effect of a 6 - week treatment with the calcium channel blocker nitrendipine or the angiotensin converting enzyme inhibitor enalapril on blood pressure , albuminuria , renal hemodynamics , and morphology of the nonclipped kidney was studied in rats with two - kidney , one clip renovascular hypertension .', {'entities': [(158, 169, 'B_Disease'), (282, 294, 'B_Disease'), (295, 307, 'I_Disease')]}], ['Six weeks after clipping of one renal artery , hypertensive rats ( 178 + / - 4 mm Hg ) were randomly assigned to three groups : untreated hypertensive controls ( n = 8 ) , enalapril - treated ( n = 8 ) , or nitrendipine - treated ( n = 10 ) .', {'entities': [(47, 59, 'B_Disease'), (138, 150, 'B_Disease')]}], ['Renal plasma flow increased , but albumin excretion and glomerulosclerosis did not change after enalapril treatment .', {'entities': [(56, 74, 'B_Disease')]}], ['In contrast , in the nitrendipine - treated group albuminuria increased from 12 . 8 + / - 2 progressively to 163 + / - 55 compared with 19 . 2 + / - 9 mg / 24 hr in the hypertensive controls .', {'entities': [(50, 61, 'B_Disease'), (169, 181, 'B_Disease')]}], ['Furthermore , glomerulosclerosis index was significantly increased in the nitrendipine - treated group compared with the hypertensive controls ( 0 . 38 + / - 0 . 1 versus 0 . 13 + / - 0 . 04 ) .', {'entities': [(14, 32, 'B_Disease'), (121, 133, 'B_Disease')]}], ['In addition , glomerular size was higher in the nitrendipine - treated group ( 14 . 9 + / - 0 . 17 10 ( - 3 ) mm2 ) but lower in the enalapril - treated group ( 11 . 5 + / - 0 . 15 10 ( - 3 ) mm2 ) compared with the hypertensive controls ( 12 . 1 + / - 0 . 17 10 ( - 3 ) mm2 ) . ( ABSTRACT TRUNCATED AT 250 WORDS )', {'entities': [(216, 228, 'B_Disease')]}], ['Ketoconazole induced torsades de pointes without concomitant use of QT interval - prolonging drug .', {'entities': [(21, 29, 'B_Disease'), (30, 32, 'I_Disease'), (33, 40, 'I_Disease')]}], ['We report a woman with coronary artery disease who developed a markedly prolonged QT interval and torsades de pointes ( TdP ) after taking ketoconazole for treatment of fungal infection .', {'entities': [(23, 31, 'B_Disease'), (32, 38, 'I_Disease'), (39, 46, 'I_Disease'), (72, 81, 'B_Disease'), (82, 84, 'I_Disease'), (85, 93, 'I_Disease'), (98, 106, 'B_Disease'), (107, 109, 'I_Disease'), (110, 117, 'I_Disease'), (120, 123, 'B_Disease'), (169, 175, 'B_Disease'), (176, 185, 'I_Disease')]}], ['We postulate that by virtue of its direct blocking action on IKr , ketoconazole alone may prolong QT interval and induce TdP .', {'entities': [(121, 124, 'B_Disease')]}], ['This calls for attention when ketoconazole is administered to patients with risk factors for acquired long QT syndrome .', {'entities': [(102, 106, 'B_Disease'), (107, 109, 'I_Disease'), (110, 118, 'I_Disease')]}], ['Cerebral vasculitis following oral methylphenidate intake in an adult : a case report .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease')]}], ['Cerebral vasculitis associated with amphetamine abuse is well documented , and in rare cases ischaemic stroke has been reported after methylphenidate intake in children .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease'), (36, 47, 'B_Disease'), (48, 53, 'I_Disease'), (93, 102, 'B_Disease'), (103, 109, 'I_Disease')]}], ['We report the case of a 63 - year - old female who was treated with methylphenidate due to hyperactivity and suffered from multiple ischaemic strokes .', {'entities': [(91, 104, 'B_Disease'), (132, 141, 'B_Disease'), (142, 149, 'I_Disease')]}], ['We consider drug - induced cerebral vasculitis as the most likely cause of recurrent ischaemic strokes in the absence of any pathological findings during the diagnostic work - up .', {'entities': [(27, 35, 'B_Disease'), (36, 46, 'I_Disease'), (85, 94, 'B_Disease'), (95, 102, 'I_Disease')]}], ['We conclude that methylphenidate mediated vasculitis should be considered in patients with neurological symptoms and a history of methylphenidate therapy .', {'entities': [(42, 52, 'B_Disease')]}], ['MDMA polydrug users show process - specific central executive impairments coupled with impaired social and emotional judgement processes .', {'entities': [(87, 95, 'B_Disease'), (96, 102, 'I_Disease'), (103, 106, 'I_Disease'), (107, 116, 'I_Disease'), (117, 126, 'I_Disease'), (127, 136, 'I_Disease')]}], ['In recent years working memory deficits have been reported in users of MDMA ( 3 , 4 - methylenedioxymethamphetamine , ecstasy ) .', {'entities': [(24, 30, 'B_Disease'), (31, 39, 'I_Disease')]}], ['Phase II study of the amsacrine analogue CI - 921 ( NSC 343499 ) in non - small cell lung cancer .', {'entities': [(68, 71, 'B_Disease'), (72, 73, 'I_Disease'), (74, 79, 'I_Disease'), (80, 84, 'I_Disease'), (85, 89, 'I_Disease'), (90, 96, 'I_Disease')]}], ['It was administered by 15 min infusion to 16 evaluable patients with non - small cell lung cancer ( NSCLC ) ( 7 with no prior treatment , 9 patients in relapse following surgery / radiotherapy ) at a dose ( 648 mg / m2 divided over 3 days , repeated every 3 weeks ) determined by phase I trial .', {'entities': [(69, 72, 'B_Disease'), (73, 74, 'I_Disease'), (75, 80, 'I_Disease'), (81, 85, 'I_Disease'), (86, 90, 'I_Disease'), (91, 97, 'I_Disease'), (100, 105, 'B_Disease')]}], ['The histology comprised squamous carcinoma ( 11 ) , adenocarcinoma ( 1 ) , mixed histology ( 2 ) , bronchio - alveolar carcinoma ( 1 ) and large cell undifferentiated carcinoma ( 1 ) .', {'entities': [(24, 32, 'B_Disease'), (33, 42, 'I_Disease'), (52, 66, 'B_Disease'), (99, 107, 'B_Disease'), (108, 109, 'I_Disease'), (110, 118, 'I_Disease'), (119, 128, 'I_Disease'), (150, 166, 'B_Disease'), (167, 176, 'I_Disease')]}], ['Neutropenia grade greater than or equal to 3 was seen in 15 patients , infections with recovery in 3 , and grand mal seizures in 1 patient .', {'entities': [(0, 11, 'B_Disease'), (71, 81, 'B_Disease'), (117, 125, 'B_Disease')]}], ['Grade less than or equal to 2 nausea and vomiting occurred in 66 % courses and phlebitis in the infusion arm in 37 % .', {'entities': [(30, 36, 'B_Disease'), (41, 49, 'B_Disease'), (79, 88, 'B_Disease')]}], ['1 patient with squamous cell carcinoma achieved a partial response lasting 5 months .', {'entities': [(15, 23, 'B_Disease'), (24, 28, 'I_Disease'), (29, 38, 'I_Disease')]}], ['Further testing in this and other tumour types using multiple daily schedules is warranted .', {'entities': [(34, 40, 'B_Disease')]}], ['Fewer subjects reported adverse events following treatment with desipramine alone than when receiving desipramine with cinacalcet ( 33 versus 86 % ) , the most frequent of which ( nausea and headache ) have been reported for patients treated with either desipramine or cinacalcet .', {'entities': [(180, 186, 'B_Disease'), (191, 199, 'B_Disease')]}], ['We report an interesting case investigating a ( near ) fatal poisoning .', {'entities': [(61, 70, 'B_Disease')]}], [\"METHODS : The son of an 84 - year - old male discovered a newspaper report stating clinical success with plant extracts in Alzheimer ' s disease .\", {'entities': [(123, 132, 'B_Disease'), (133, 134, 'I_Disease'), (135, 136, 'I_Disease'), (137, 144, 'I_Disease')]}], ['RESULTS : Minutes after oral administration , the patient developed nausea , sweating and hypotension , and finally collapsed .', {'entities': [(68, 74, 'B_Disease'), (90, 101, 'B_Disease')]}], ['Bradycardia , cholinergic symptoms and asystole occurred .', {'entities': [(0, 11, 'B_Disease'), (39, 47, 'B_Disease')]}], ['Further signs were hyperhidrosis , hypersalivation , bronchorrhoea , and severe miosis ; the electrocardiographic finding was atrio - ventricular dissociation .', {'entities': [(19, 32, 'B_Disease'), (35, 50, 'B_Disease'), (53, 66, 'B_Disease'), (80, 86, 'B_Disease'), (126, 131, 'B_Disease'), (132, 133, 'I_Disease'), (134, 145, 'I_Disease'), (146, 158, 'I_Disease')]}], ['However , increased dyspnoea and bronchospasm necessitated reintubation .', {'entities': [(20, 28, 'B_Disease'), (33, 45, 'B_Disease')]}], ['Respiratory insufficiency was further worsened by Proteus mirabilis infection and severe bronchoconstriction .', {'entities': [(0, 11, 'B_Disease'), (12, 25, 'I_Disease'), (50, 57, 'B_Disease'), (58, 67, 'I_Disease'), (68, 77, 'I_Disease')]}], ['On the next day he died , probably as a result of heart failure .', {'entities': [(50, 55, 'B_Disease'), (56, 63, 'I_Disease')]}], ['Especially in old patients , intensivists should consider intoxications ( with cholinergics ) as a cause of acute cardiovascular failure .', {'entities': [(108, 113, 'B_Disease'), (114, 128, 'I_Disease'), (129, 136, 'I_Disease')]}], ['Pharmacological evidence for the potential of Daucus carota in the management of cognitive dysfunctions .', {'entities': [(81, 90, 'B_Disease'), (91, 103, 'I_Disease')]}], ['Diazepam - , scopolamine - and ageing - induced amnesia served as the interoceptive behavioral models .', {'entities': [(48, 55, 'B_Disease')]}], ['Furthermore , DCE reversed the amnesia induced by scopolamine ( 0 . 4 mg / kg , i . p . ) and diazepam ( 1 mg / kg , i . p . ) .', {'entities': [(31, 38, 'B_Disease')]}], ['Therefore , DCE may prove to be a useful remedy for the management of cognitive dysfunctions on account of its multifarious beneficial effects such as , memory improving property , cholesterol lowering property and anticholinesterase activity .', {'entities': [(70, 79, 'B_Disease'), (80, 92, 'I_Disease')]}], ['Valproic acid induced encephalopathy - - 19 new cases in Germany from 1994 to 2003 - - a side effect associated to VPA - therapy not only in young children .', {'entities': [(22, 36, 'B_Disease')]}], ['Rare serious complications may occur in some patients , including haemorrhagic pancreatitis , bone marrow suppression , VPA - induced hepatotoxicity and VPA - induced encephalopathy .', {'entities': [(79, 91, 'B_Disease'), (94, 98, 'B_Disease'), (99, 105, 'I_Disease'), (106, 117, 'I_Disease'), (134, 148, 'B_Disease'), (167, 181, 'B_Disease')]}], ['The typical signs of VPA - induced encephalopathy are impaired consciousness , sometimes marked EEG background slowing , increased seizure frequency , with or without hyperammonemia .', {'entities': [(35, 49, 'B_Disease'), (54, 62, 'B_Disease'), (63, 76, 'I_Disease'), (131, 138, 'B_Disease'), (167, 181, 'B_Disease')]}], ['There is still no proof of causative effect of VPA in patients with encephalopathy , but only of an association with an assumed causal relation .', {'entities': [(68, 82, 'B_Disease')]}], ['We report 19 patients with VPA - associated encephalopathy in Germany from the years 1994 to 2003 , none of whom had been published previously .', {'entities': [(44, 58, 'B_Disease')]}], ['Cerebral haemorrhage induced by warfarin - the influence of drug - drug interactions .', {'entities': [(0, 8, 'B_Disease'), (9, 20, 'I_Disease')]}], ['PURPOSE : To evaluate the frequency , severity and preventability of warfarin - induced cerebral haemorrhages due to warfarin and warfarin - drug interactions in patients living in the county of Osterg tland , Sweden .', {'entities': [(88, 96, 'B_Disease'), (97, 109, 'I_Disease')]}], ['METHODS : All patients with a diagnosed cerebral haemorrhage at three hospitals during the period 2000 - 2002 were identified .', {'entities': [(40, 48, 'B_Disease'), (49, 60, 'I_Disease')]}], ['Medical records were studied retrospectively to evaluate whether warfarin and warfarin - drug interactions could have caused the cerebral haemorrhage .', {'entities': [(129, 137, 'B_Disease'), (138, 149, 'I_Disease')]}], ['RESULTS : Among 593 patients with cerebral haemorrhage , 59 ( 10 % ) were assessed as related to warfarin treatment .', {'entities': [(34, 42, 'B_Disease'), (43, 54, 'I_Disease')]}], ['A warfarin - drug interaction could have contributed to the haemorrhage in 24 ( 41 % ) of the warfarin patients and in 7 of these ( 12 % ) the bleeding complication was considered being possible to avoid .', {'entities': [(60, 71, 'B_Disease'), (143, 151, 'B_Disease')]}], ['CONCLUSIONS : Warfarin - induced cerebral haemorrhages are a major clinical problem with a high fatality rate .', {'entities': [(33, 41, 'B_Disease'), (42, 54, 'I_Disease')]}], ['A significant proportion of warfarin - related cerebral haemorrhages might have been prevented if greater caution had been taken when prescribing drugs known to interact with warfarin .', {'entities': [(47, 55, 'B_Disease'), (56, 68, 'I_Disease')]}], ['Experimental and clinical evidence points to a role of central histaminergic system in the pathogenesis of schizophrenia .', {'entities': [(107, 120, 'B_Disease')]}], ['The present study was designed to study the effect of histamine H ( 3 ) - receptor ligands on neuroleptic - induced catalepsy , apomorphine - induced climbing behavior and amphetamine - induced locomotor activities in mice .', {'entities': [(116, 125, 'B_Disease')]}], ['Catalepsy was induced by haloperidol ( 2 mg / kg p . o . ) , while apomorphine ( 1 . 5 mg / kg s . c . ) and amphetamine ( 2 mg / kg s . c . ) were used for studying climbing behavior and locomotor activities , respectively .', {'entities': [(0, 9, 'B_Disease')]}], ['( R ) - alpha - methylhistamine ( RAMH ) ( 5 microg i . c . v . ) and thioperamide ( THP ) ( 15 mg / kg i . p . ) , per se did not cause catalepsy .', {'entities': [(137, 146, 'B_Disease')]}], ['Administration of THP ( 3 . 75 , 7 . 5 and 15 mg / kg i . p . ) 1 h prior to haloperidol resulted in a dose - dependent increase in the catalepsy times ( P < 0 . 05 ) .', {'entities': [(136, 145, 'B_Disease')]}], ['On amphetamine - induced hyperactivity , THP ( 3 . 75 and 7 . 5 mg / kg i . p . ) reduced locomotor time , distance traveled and average speed ( P < 0 . 05 ) .', {'entities': [(25, 38, 'B_Disease')]}], ['THP exhibited an antipsychotic - like profile by potentiating haloperidol - induced catalepsy , reducing amphetamine - induced hyperactivity and reducing apomorphine - induced climbing in mice .', {'entities': [(84, 93, 'B_Disease'), (127, 140, 'B_Disease')]}], ['Findings suggest a potential for H ( 3 ) - receptor antagonists in improving the refractory cases of schizophrenia .', {'entities': [(101, 114, 'B_Disease')]}], ['Cauda equina syndrome after epidural steroid injection : a case report .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease'), (13, 21, 'I_Disease')]}], ['OBJECTIVE : Conventional treatment methods of lumbusacral radiculopathy are physical therapy , epidural steroid injections , oral medications , and spinal manipulative therapy .', {'entities': [(58, 71, 'B_Disease')]}], ['Cauda equina syndrome is a rare complication of epidural anesthesia .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease'), (13, 21, 'I_Disease')]}], ['The following case is a report of cauda equina syndrome possibly caused by epidural injection of triamcinolone and bupivacaine .', {'entities': [(34, 39, 'B_Disease'), (40, 46, 'I_Disease'), (47, 55, 'I_Disease')]}], ['CLINICAL FEATURES : A 50 - year - old woman with low back and right leg pain was scheduled for epidural steroid injection .', {'entities': [(49, 52, 'B_Disease'), (53, 57, 'I_Disease'), (58, 61, 'I_Disease'), (62, 67, 'I_Disease'), (68, 71, 'I_Disease'), (72, 76, 'I_Disease')]}], ['Three hours later , she complained of perineal numbness and lower extremity weakness .', {'entities': [(47, 55, 'B_Disease'), (60, 65, 'B_Disease'), (66, 75, 'I_Disease'), (76, 84, 'I_Disease')]}], ['The neurologic evaluation revealed loss of sensation in the saddle area and medial aspect of her right leg .', {'entities': [(35, 39, 'B_Disease'), (40, 42, 'I_Disease'), (43, 52, 'I_Disease')]}], ['Clinical examination and continued vigilance for neurologic deterioration after epidural steroid injections is important .', {'entities': [(49, 59, 'B_Disease'), (60, 73, 'I_Disease')]}], ['High - dose testosterone is associated with atherosclerosis in postmenopausal women .', {'entities': [(44, 59, 'B_Disease')]}], ['OBJECTIVES : To study the long - term effects of androgen treatment on atherosclerosis in postmenopausal women .', {'entities': [(71, 86, 'B_Disease')]}], ['METHODS : In a population - based study in 513 naturally postmenopausal women aged 54 - 67 years , we studied the association between self - reported intramuscularly administered high - dose estrogen - testosterone therapy ( estradiol - and testosterone esters ) and aortic atherosclerosis .', {'entities': [(274, 289, 'B_Disease')]}], ['Aortic atherosclerosis was diagnosed by radiographic detection of calcified deposits in the abdominal aorta , which have been shown to reflect intima atherosclerosis .', {'entities': [(7, 22, 'B_Disease'), (150, 165, 'B_Disease')]}], ['In almost half of these women severe atherosclerosis of the aorta was present ( n = 11 ) , while in women without hormone use severe atherosclerosis of the aorta was present in less than 20 % ( OR 3 . 1 ; 95 % CI , 1 . 1 - 8 . 5 , adjusted for age , years since menopause , smoking , and body mass index ) .', {'entities': [(37, 52, 'B_Disease'), (133, 148, 'B_Disease')]}], ['The association remained after additional adjustment for diabetes , cholesterol level , systolic blood pressure , or alcohol use .', {'entities': [(57, 65, 'B_Disease')]}], ['CONCLUSION : Our results suggest that high - dose testosterone therapy may adversely affect atherosclerosis in postmenopausal women and indicate that androgen replacement in these women may not be harmless .', {'entities': [(92, 107, 'B_Disease')]}], ['Optimising stroke prevention in non - valvular atrial fibrillation .', {'entities': [(11, 17, 'B_Disease'), (47, 53, 'B_Disease'), (54, 66, 'I_Disease')]}], ['Atrial fibrillation is associated with substantial morbidity and mortality .', {'entities': [(0, 6, 'B_Disease'), (7, 19, 'I_Disease')]}], ['Pooled data from trials comparing antithrombotic treatment with placebo have shown that warfarin reduces the risk of stroke by 62 % , and that aspirin alone reduces the risk by 22 % .', {'entities': [(117, 123, 'B_Disease')]}], ['Overall , in high - risk patients , warfarin is superior to aspirin in preventing strokes , with a relative risk reduction of 36 % .', {'entities': [(82, 89, 'B_Disease')]}], ['Ximelagatran , an oral direct thrombin inhibitor , was found to be as efficient as vitamin K antagonist drugs in the prevention of embolic events , but has been recently withdrawn because of abnormal liver function tests .', {'entities': [(131, 138, 'B_Disease'), (139, 145, 'I_Disease'), (191, 199, 'B_Disease'), (200, 205, 'I_Disease'), (206, 214, 'I_Disease')]}], ['The ACTIVE - W ( Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events ) study has demonstrated that warfarin is superior to platelet therapy ( clopidogrel plus aspirin ) in the prevention af embolic events .', {'entities': [(17, 23, 'B_Disease'), (24, 36, 'I_Disease'), (226, 233, 'B_Disease'), (234, 240, 'I_Disease')]}], ['Idraparinux , a Factor Xa inhibitor , is being evaluated in patients with atrial fibrillation .', {'entities': [(74, 80, 'B_Disease'), (81, 93, 'I_Disease')]}], ['Angiotensin - converting enzyme inhibitors and angiotensin II receptor - blocking drugs hold promise in atrial fibrillation through cardiac remodelling .', {'entities': [(104, 110, 'B_Disease'), (111, 123, 'I_Disease'), (132, 139, 'B_Disease'), (140, 151, 'I_Disease')]}], ['Anti - oxidant effects of atorvastatin in dexamethasone - induced hypertension in the rat .', {'entities': [(66, 78, 'B_Disease')]}], ['Dexamethasone ( Dex ) - induced hypertension is characterized by endothelial dysfunction associated with nitric oxide ( NO ) deficiency and increased superoxide ( O2 - ) production .', {'entities': [(32, 44, 'B_Disease')]}], ['Atorvastatin ( Ato ) possesses pleiotropic properties that have been reported to improve endothelial function through increased availability of NO and reduced O2 - production in various forms of hypertension .', {'entities': [(195, 207, 'B_Disease')]}], ['Severe citrate toxicity complicating volunteer apheresis platelet donation .', {'entities': [(15, 23, 'B_Disease')]}], ['We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection .', {'entities': [(35, 43, 'B_Disease')]}], ['Past medical history was remarkable for hypertension , hyperlipidemia , and depression .', {'entities': [(40, 52, 'B_Disease'), (55, 69, 'B_Disease'), (76, 86, 'B_Disease')]}], ['She then very rapidly developed acute onset of severe facial and extremity tetany .', {'entities': [(75, 81, 'B_Disease')]}], ['Empirical treatment with intravenous calcium gluconate was initiated , and muscle contractions slowly subsided over approximately 10 to 15 minutes .', {'entities': [(75, 81, 'B_Disease'), (82, 94, 'I_Disease')]}], ['The events are consistent with a severe reaction to calcium chelation by sodium citrate anticoagulant resulting in symptomatic systemic hypocalcemia .', {'entities': [(136, 148, 'B_Disease')]}], ['Upon additional retrospective analysis , it was noted that bumetanide is a loop diuretic that may cause significant hypocalcemia .', {'entities': [(116, 128, 'B_Disease')]}], ['We conclude that careful screening for medications and underlying conditions predisposing to hypocalcemia is recommended to help prevent severe reactions due to citrate toxicity .', {'entities': [(93, 105, 'B_Disease'), (169, 177, 'B_Disease')]}], ['Sirolimus - associated proteinuria and renal dysfunction .', {'entities': [(23, 34, 'B_Disease'), (39, 44, 'B_Disease'), (45, 56, 'I_Disease')]}], ['Sirolimus represents a major therapeutic advance in the prevention of acute renal allograft rejection and chronic allograft nephropathy .', {'entities': [(124, 135, 'B_Disease')]}], ['Its role in the therapy of glomerulonephritis , autoimmunity , cystic renal diseases and renal cancer is under investigation .', {'entities': [(27, 45, 'B_Disease'), (48, 60, 'B_Disease'), (63, 69, 'B_Disease'), (70, 75, 'I_Disease'), (76, 84, 'I_Disease'), (89, 94, 'B_Disease'), (95, 101, 'I_Disease')]}], [\"Because sirolimus does not share the vasomotor renal adverse effects exhibited by calcineurin inhibitors , it has been designated a ' non - nephrotoxic drug ' .\", {'entities': [(140, 151, 'B_Disease')]}], ['However , clinical reports suggest that , under some circumstances , sirolimus is associated with proteinuria and acute renal dysfunction .', {'entities': [(98, 109, 'B_Disease'), (114, 119, 'B_Disease'), (120, 125, 'I_Disease'), (126, 137, 'I_Disease')]}], ['A common risk factor appears to be presence of pre - existing chronic renal damage .', {'entities': [(62, 69, 'B_Disease'), (70, 75, 'I_Disease'), (76, 82, 'I_Disease')]}], ['The mechanisms of sirolimus - associated proteinuria are multifactorial and may be due to an increase in glomerular capillary pressure following calcineurin inhibitor withdrawal .', {'entities': [(41, 52, 'B_Disease')]}], ['The acute renal dysfunction associated with sirolimus ( such as in delayed graft function ) may be due to suppression of compensatory renal cell proliferation and survival / repair processes .', {'entities': [(4, 9, 'B_Disease'), (10, 15, 'I_Disease'), (16, 27, 'I_Disease')]}], ['Although these adverse effects occur in some patients , their occurrence could be minimised by knowledge of the molecular effects of sirolimus on the kidney , the use of sirolimus in appropriate patient populations , close monitoring of proteinuria and renal function , use of angiotensin - converting enzyme inhibitors or angiotensin II receptor blockers if proteinuria occurs and withdrawal if needed .', {'entities': [(237, 248, 'B_Disease'), (359, 370, 'B_Disease')]}], ['Proteinuria after conversion to sirolimus in renal transplant recipients .', {'entities': [(0, 11, 'B_Disease')]}], ['More recently , proteinuria has been reported as a consequence of sirolimus therapy , although the mechanism has remained unclear .', {'entities': [(16, 27, 'B_Disease')]}], ['We retrospectively examined the records of 25 renal transplant patients , who developed or displayed increased proteinuria after SRL conversion .', {'entities': [(111, 122, 'B_Disease')]}], [\"The patient cohort ( 14 men , 11 women ) was treated with SRL as conversion therapy , due to chronic allograft nephropathy ( CAN ) ( n = 15 ) neoplasia ( n = 8 ) ; Kaposi ' s sarcoma , Four skin cancers , One intestinal tumors , One renal cell carsinom ) or BK virus nephropathy ( n = 2 ) .\", {'entities': [(93, 100, 'B_Disease'), (101, 110, 'I_Disease'), (111, 122, 'I_Disease'), (125, 128, 'B_Disease'), (142, 151, 'B_Disease'), (164, 170, 'B_Disease'), (171, 172, 'I_Disease'), (173, 174, 'I_Disease'), (175, 182, 'I_Disease'), (190, 194, 'B_Disease'), (195, 202, 'I_Disease'), (209, 219, 'B_Disease'), (220, 226, 'I_Disease'), (233, 238, 'B_Disease'), (239, 243, 'I_Disease'), (244, 252, 'I_Disease'), (267, 278, 'B_Disease')]}], ['Proteinuria increased from 0 . 445 ( 0 to 1 . 5 ) g / d before conversion to 3 . 2 g / dL ( 0 . 2 to 12 ) after conversion ( P = 0 . 001 ) .', {'entities': [(0, 11, 'B_Disease')]}], ['Before conversion 8 ( 32 % ) patients had no proteinuria , whereas afterwards all patients had proteinuria .', {'entities': [(45, 56, 'B_Disease'), (95, 106, 'B_Disease')]}], ['In 28 % of patients proteinuria remained unchanged , whereas it increased in 68 % of patients .', {'entities': [(20, 31, 'B_Disease')]}], ['Twenty - eight percent of patients showed increased proteinuria to the nephrotic range .', {'entities': [(52, 63, 'B_Disease'), (71, 80, 'B_Disease')]}], ['Biopsies performed in five patients revealed new pathological changes : One membranoproliferative glomerulopathy and interstitial nephritis .', {'entities': [(76, 97, 'B_Disease'), (98, 112, 'I_Disease'), (117, 129, 'B_Disease'), (130, 139, 'I_Disease')]}], [\"Five patients displayed CAN and Kaposi ' s sarcoma .\", {'entities': [(24, 27, 'B_Disease'), (32, 38, 'B_Disease'), (39, 40, 'I_Disease'), (41, 42, 'I_Disease'), (43, 50, 'I_Disease')]}], ['Heavy proteinuria was common after the use of SRL as rescue therapy for renal transplantation .', {'entities': [(6, 17, 'B_Disease')]}], ['Therefore , conversion should be considered for patients who have not developed advanced CAN and proteinuria .', {'entities': [(89, 92, 'B_Disease'), (97, 108, 'B_Disease')]}], ['Long - term follow - up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors : an International Society of Pediatric Oncology report .', {'entities': [(38, 43, 'B_Disease'), (44, 52, 'I_Disease'), (77, 86, 'B_Disease'), (87, 98, 'I_Disease'), (99, 105, 'I_Disease')]}], ['The renal function of 74 children with malignant mesenchymal tumors in complete remission and who have received the same ifosfamide chemotherapy protocol ( International Society of Pediatric Oncology Malignant Mesenchymal Tumor Study 84 [ SIOP MMT 84 ] ) were studied 1 year after the completion of treatment .', {'entities': [(39, 48, 'B_Disease'), (49, 60, 'I_Disease'), (61, 67, 'I_Disease'), (200, 209, 'B_Disease'), (210, 221, 'I_Disease'), (222, 227, 'I_Disease')]}], ['The most common primary tumor site was the head and neck .', {'entities': [(24, 29, 'B_Disease')]}], ['Renal function was investigated by measuring plasma and urinary electrolytes , glucosuria , proteinuria , aminoaciduria , urinary pH , osmolarity , creatinine clearance , phosphate tubular reabsorption , beta 2 microglobulinuria , and lysozymuria .', {'entities': [(79, 89, 'B_Disease'), (92, 103, 'B_Disease'), (106, 119, 'B_Disease')]}], ['Fifty - eight patients ( 78 % ) had normal renal tests , whereas 16 patients ( 22 % ) had renal abnormalities .', {'entities': [(90, 95, 'B_Disease'), (96, 109, 'I_Disease')]}], [\"Two subsets of patients were identified from this latter group : the first included four patients ( 5 % of the total population ) who developed major toxicity resulting in Fanconi ' s syndrome ( TDFS ) ; and the second group included five patients with elevated beta 2 microglobulinuria and low phosphate reabsorption .\", {'entities': [(150, 158, 'B_Disease'), (172, 179, 'B_Disease'), (180, 181, 'I_Disease'), (182, 183, 'I_Disease'), (184, 192, 'I_Disease'), (195, 199, 'B_Disease')]}], ['Severe toxicity was correlated with the higher cumulative dose of 60 g / m2 of ifosfamide , a younger age ( less than 2 1 / 2 years old ) , and a predominance of vesicoprostatic tumor involvement .', {'entities': [(7, 15, 'B_Disease'), (178, 183, 'B_Disease')]}], ['This low percentage ( 5 % ) of TDFS must be evaluated with respect to the efficacy of ifosfamide in the treatment of mesenchymal tumors in children .', {'entities': [(117, 128, 'B_Disease'), (129, 135, 'I_Disease')]}], ['Progressive myopathy with up - regulation of MHC - I associated with statin therapy .', {'entities': [(12, 20, 'B_Disease')]}], ['Statins can cause a necrotizing myopathy and hyperCKaemia which is reversible on cessation of the drug .', {'entities': [(32, 40, 'B_Disease'), (45, 57, 'B_Disease')]}], ['What is less well known is a phenomenon whereby statins may induce a myopathy , which persists or may progress after stopping the drug .', {'entities': [(69, 77, 'B_Disease')]}], ['All had myofibre necrosis but only 3 had an inflammatory infiltrate .', {'entities': [(17, 25, 'B_Disease')]}], ['In all cases there was diffuse or multifocal up - regulation of MHC - I expression even in non - necrotic fibres .', {'entities': [(97, 105, 'B_Disease')]}], ['These observations suggest that statins may initiate an immune - mediated myopathy that persists after withdrawal of the drug and responds to immunosuppressive therapy .', {'entities': [(74, 82, 'B_Disease')]}], ['The mechanism of this myopathy is uncertain but may involve the induction by statins of an endoplasmic reticulum stress response with associated up - regulation of MHC - I expression and antigen presentation by muscle fibres .', {'entities': [(22, 30, 'B_Disease')]}], ['Use of chromosome substitution strains to identify seizure susceptibility loci in mice .', {'entities': [(51, 58, 'B_Disease')]}], ['Seizure susceptibility varies among inbred mouse strains .', {'entities': [(0, 7, 'B_Disease')]}], ['Chromosome substitution strains ( CSS ) , in which a single chromosome from one inbred strain ( donor ) has been transferred onto a second strain ( host ) by repeated backcrossing , may be used to identify quantitative trait loci ( QTLs ) that contribute to seizure susceptibility .', {'entities': [(258, 265, 'B_Disease')]}], ['QTLs for susceptibility to pilocarpine - induced seizures , a model of temporal lobe epilepsy , have not been reported , and CSS have not previously been used to localize seizure susceptibility genes .', {'entities': [(49, 57, 'B_Disease'), (71, 79, 'B_Disease'), (80, 84, 'I_Disease'), (85, 93, 'I_Disease'), (171, 178, 'B_Disease')]}], ['We report QTLs identified using a B6 ( host ) x A / J ( donor ) CSS panel to localize genes involved in susceptibility to pilocarpine - induced seizures .', {'entities': [(144, 152, 'B_Disease')]}], ['Three hundred fifty - five adult male CSS mice , 58 B6 , and 39 A / J were tested for susceptibility to pilocarpine - induced seizures .', {'entities': [(126, 134, 'B_Disease')]}], ['B6 mice were resistant to seizures and slower to reach stages compared to A / J mice .', {'entities': [(26, 34, 'B_Disease')]}], ['CSS mapping suggests seizure susceptibility loci on mouse Chromosomes 10 and 18 .', {'entities': [(21, 28, 'B_Disease')]}], ['This approach provides a framework for identifying potentially novel homologous candidate genes for human temporal lobe epilepsy .', {'entities': [(106, 114, 'B_Disease'), (115, 119, 'I_Disease'), (120, 128, 'I_Disease')]}], ['In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide - induced cystitis in the rat .', {'entities': [(101, 109, 'B_Disease')]}], ['In cyclophosphamide - induced cystitis in the rat , detrusor function is impaired and the expression and effects of muscarinic receptors altered .', {'entities': [(30, 38, 'B_Disease')]}], ['Whether or not the neuronal transmission may be affected by cystitis was presently investigated .', {'entities': [(60, 68, 'B_Disease')]}], ['Thus , in cystitis substantial changes of the efferent functional responses occur .', {'entities': [(10, 18, 'B_Disease')]}], ['BACKGROUND : Inhibition of cardiac sympathetic tone represents an important strategy for treatment of cardiovascular disease , including arrhythmia , coronary heart disease , and chronic heart failure .', {'entities': [(102, 116, 'B_Disease'), (117, 124, 'I_Disease'), (137, 147, 'B_Disease'), (150, 158, 'B_Disease'), (159, 164, 'I_Disease'), (165, 172, 'I_Disease'), (187, 192, 'B_Disease'), (193, 200, 'I_Disease')]}], ['Clonidine - induced bradycardia in conscious alpha2ABC - / - mice was 32 . 3 % ( 10 microg / kg ) and 26 . 6 % ( 100 microg / kg ) of the effect in wild - type mice .', {'entities': [(20, 31, 'B_Disease')]}], ['Granulomatous hepatitis due to combination of amoxicillin and clavulanic acid .', {'entities': [(0, 13, 'B_Disease'), (14, 23, 'I_Disease')]}], ['We report the case of a patient with amoxicillin - clavulanic acid - induced hepatitis with histologic multiple granulomas .', {'entities': [(77, 86, 'B_Disease'), (112, 122, 'B_Disease')]}], ['This type of lesion broadens the spectrum of liver injury due to this drug combination , mainly represented by a benign cholestatic syndrome .', {'entities': [(45, 50, 'B_Disease'), (51, 57, 'I_Disease'), (120, 131, 'B_Disease'), (132, 140, 'I_Disease')]}], ['The association of granulomas and eosinophilia favor an immunoallergic mechanism .', {'entities': [(19, 29, 'B_Disease'), (34, 46, 'B_Disease')]}], ['Dobutamine stress echocardiography : a sensitive indicator of diminished myocardial function in asymptomatic doxorubicin - treated long - term survivors of childhood cancer .', {'entities': [(166, 172, 'B_Disease')]}], ['Doxorubicin is an effective anticancer chemotherapeutic agent known to cause acute and chronic cardiomyopathy .', {'entities': [(95, 109, 'B_Disease')]}], ['To develop a more sensitive echocardiographic screening test for cardiac damage due to doxorubicin , a cohort study was performed using dobutamine infusion to differentiate asymptomatic long - term survivors of childhood cancer treated with doxorubicin from healthy control subjects .', {'entities': [(65, 72, 'B_Disease'), (73, 79, 'I_Disease'), (221, 227, 'B_Disease')]}], ['The influence of smoking during pregnancy on the developing cochlea has not been estimated , although smoking has been positively associated with hearing loss in adults .', {'entities': [(146, 153, 'B_Disease'), (154, 158, 'I_Disease')]}], ['METHODS : This study was undertaken as part of neonatal screening for hearing impairment and involved both ears of 200 newborns .', {'entities': [(70, 77, 'B_Disease'), (78, 88, 'I_Disease')]}], ['However , by comparing each subgroup to control group , we found statistically significant decreases of TEOAEs amplitudes at 4000Hz for all three groups .', {'entities': [(91, 100, 'B_Disease'), (101, 103, 'I_Disease'), (104, 110, 'I_Disease'), (111, 121, 'I_Disease')]}], ['Simvastatin - induced bilateral leg compartment syndrome and myonecrosis associated with hypothyroidism .', {'entities': [(36, 47, 'B_Disease'), (48, 56, 'I_Disease'), (61, 72, 'B_Disease'), (89, 103, 'B_Disease')]}], ['A 54 - year - old hypothyroid male taking thyroxine and simvastatin presented with bilateral leg compartment syndrome and myonecrosis .', {'entities': [(18, 29, 'B_Disease'), (97, 108, 'B_Disease'), (109, 117, 'I_Disease'), (122, 133, 'B_Disease')]}], ['It is likely that this complication will be seen more often with the increased worldwide use of this drug and its approval for all arteriopathic patients .', {'entities': [(131, 144, 'B_Disease')]}], ['Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats : implications for autism .', {'entities': [(0, 17, 'B_Disease'), (22, 32, 'B_Disease'), (33, 46, 'I_Disease'), (111, 117, 'B_Disease')]}], ['Autism is a neurodevelopmental disorder presenting before 3 years of age with deficits in communication and social skills and repetitive behaviors .', {'entities': [(0, 6, 'B_Disease'), (12, 30, 'B_Disease'), (31, 39, 'I_Disease'), (78, 86, 'B_Disease'), (87, 89, 'I_Disease'), (90, 103, 'I_Disease'), (104, 107, 'I_Disease'), (108, 114, 'I_Disease'), (115, 121, 'I_Disease'), (126, 136, 'B_Disease'), (137, 146, 'I_Disease')]}], ['In addition to genetic influences , recent studies suggest that prenatal drug or chemical exposures are risk factors for autism .', {'entities': [(121, 127, 'B_Disease')]}], ['Terbutaline , a beta2 - adrenoceptor agonist used to arrest preterm labor , has been associated with increased concordance for autism in dizygotic twins .', {'entities': [(60, 67, 'B_Disease'), (68, 73, 'I_Disease'), (127, 133, 'B_Disease')]}], ['Our findings indicate that beta2 - adrenoceptor overstimulation during an early critical period results in microglial activation associated with innate neuroinflammatory pathways and behavioral abnormalities , similar to those described in autism .', {'entities': [(183, 193, 'B_Disease'), (194, 207, 'I_Disease'), (240, 246, 'B_Disease')]}], ['This study provides a useful animal model for understanding the neuropathological processes underlying autism spectrum disorders .', {'entities': [(103, 109, 'B_Disease'), (110, 118, 'I_Disease'), (119, 128, 'I_Disease')]}], ['Upregulation of brain expression of P - glycoprotein in MRP2 - deficient TR ( - ) rats resembles seizure - induced up - regulation of this drug efflux transporter in normal rats .', {'entities': [(97, 104, 'B_Disease')]}], ['A comparable overexpression of Pgp in the BBB was obtained after pilocarpine - induced seizures in wild - type Wistar rats .', {'entities': [(87, 95, 'B_Disease')]}], ['Because such a compensatory mechanism most likely occurs to reduce injury to the brain from cytotoxic compounds , the present data substantiate the concept that MRP2 performs a protective role in the BBB .', {'entities': [(67, 73, 'B_Disease'), (74, 76, 'I_Disease'), (77, 80, 'I_Disease'), (81, 86, 'I_Disease')]}], ['Furthermore , our data suggest that TR ( - ) rats are an interesting tool to study consequences of overexpression of Pgp in the BBB on access of drugs in the brain , without the need of inducing seizures or other Pgp - enhancing events for this purpose .', {'entities': [(195, 203, 'B_Disease')]}], ['Role of xanthine oxidase in dexamethasone - induced hypertension in rats .', {'entities': [(52, 64, 'B_Disease')]}], ['Glucocorticoid - induced hypertension ( GC - HT ) in the rat is associated with nitric oxide - redox imbalance .', {'entities': [(25, 37, 'B_Disease'), (45, 47, 'B_Disease')]}], ['We studied the role of xanthine oxidase ( XO ) , which is implicated in the production of reactive oxygen species , in dexamethasone - induced hypertension ( dex - HT ) .', {'entities': [(143, 155, 'B_Disease'), (164, 166, 'B_Disease')]}], ['Dex increased SBP ( 110 + / - 2 - 126 + / - 3 mmHg ; P < 0 . 001 ) and decreased thymus ( P < 0 . 001 ) and bodyweights ( P \" < 0 . 01 ) .', {'entities': [(4, 13, 'B_Disease'), (14, 17, 'I_Disease'), (71, 80, 'B_Disease'), (81, 87, 'I_Disease'), (88, 89, 'I_Disease'), (90, 91, 'I_Disease'), (92, 93, 'I_Disease'), (94, 95, 'I_Disease'), (96, 97, 'I_Disease'), (98, 101, 'I_Disease'), (102, 103, 'I_Disease'), (104, 107, 'I_Disease'), (108, 119, 'I_Disease')]}], ['Allopurinol did not prevent dex - HT .', {'entities': [(34, 36, 'B_Disease')]}], ['This , together with our previous findings that allopurinol failed to prevent adrenocorticotrophic hormone induced hypertension , suggests that XO activity is not a major determinant of GC - HT in the rat .', {'entities': [(115, 127, 'B_Disease'), (191, 193, 'B_Disease')]}], [\"PURPOSE : To assess the incidence of postoperative emetic side effects after the administration of methylprednisolone and gentamicin into the posterior sub - Tenon ' s space at the end of routine cataract surgery .\", {'entities': [(196, 204, 'B_Disease')]}], ['Postoperatively , all patients were assessed for symptoms of nausea , vomiting , and headache .', {'entities': [(61, 67, 'B_Disease'), (68, 69, 'I_Disease'), (70, 78, 'I_Disease'), (85, 93, 'B_Disease')]}], ['RESULTS : Sixty percent in Group A developed postoperative emetic symptoms , headache , or both ; 1 patient in Group B developed symptoms .', {'entities': [(45, 58, 'B_Disease'), (59, 65, 'I_Disease'), (66, 74, 'I_Disease'), (77, 85, 'B_Disease')]}], [\"CONCLUSIONS : The administration of methylprednisolone and gentamicin in the posterior sub - Tenon ' s space was related to a high incidence of side effects including nausea , vomiting , and headache .\", {'entities': [(167, 173, 'B_Disease'), (174, 175, 'I_Disease'), (176, 184, 'I_Disease'), (191, 199, 'B_Disease')]}], ['Assessment of a new non - invasive index of cardiac performance for detection of dobutamine - induced myocardial ischemia .', {'entities': [(102, 112, 'B_Disease'), (113, 121, 'I_Disease')]}], ['BACKGROUND : Electrocardiography has a very low sensitivity in detecting dobutamine - induced myocardial ischemia .', {'entities': [(94, 104, 'B_Disease'), (105, 113, 'I_Disease')]}], ['OBJECTIVES : To assess the added diagnostic value of a new cardiac performance index ( dP / dtejc ) measurement , based on brachial artery flow changes , as compared to standard 12 - lead ECG , for detecting dobutamine - induced myocardial ischemia , using Tc99m - Sestamibi single - photon emission computed tomography as the gold standard of comparison to assess the presence or absence of ischemia .', {'entities': [(229, 239, 'B_Disease'), (240, 248, 'I_Disease'), (392, 400, 'B_Disease')]}], ['In 19 of the 40 patients perfusion defects compatible with ischemia were detected on SPECT .', {'entities': [(59, 67, 'B_Disease')]}], ['CONCLUSIONS : If ECG alone is used for specificity , the combination with dP / dtejc improved the sensitivity of the test and could be a cost - savings alternative to cardiac imaging or perfusion studies to detect myocardial ischemia , especially in patients unable to exercise .', {'entities': [(214, 224, 'B_Disease'), (225, 233, 'I_Disease')]}], ['Cocaine - induced myocardial infarction : clinical observations and pathogenetic considerations .', {'entities': [(18, 28, 'B_Disease'), (29, 39, 'I_Disease')]}], ['Clinical and experimental data published to date suggest several possible mechanisms by which cocaine may result in acute myocardial infarction .', {'entities': [(116, 121, 'B_Disease'), (122, 132, 'I_Disease'), (133, 143, 'I_Disease')]}], ['In individuals with preexisting , high - grade coronary arterial narrowing , acute myocardial infarction may result from an increase in myocardial oxygen demand associated with cocaine - induced increase in rate - pressure product .', {'entities': [(77, 82, 'B_Disease'), (83, 93, 'I_Disease'), (94, 104, 'I_Disease')]}], ['In other individuals with no underlying atherosclerotic obstruction , coronary occlusion may be due to spasm , thrombus , or both .', {'entities': [(40, 55, 'B_Disease'), (56, 67, 'I_Disease'), (70, 78, 'B_Disease'), (79, 88, 'I_Disease'), (103, 108, 'B_Disease'), (111, 119, 'B_Disease')]}], ['With regard to spasm , the clinical findings are largely circumstantial , and the locus of cocaine - induced vasoconstriction remains speculative .', {'entities': [(15, 20, 'B_Disease')]}], ['Although certain clinical and experimental findings support the hypothesis that spasm involves the epicardial , medium - size vessels , other data suggest intramural vasoconstriction .', {'entities': [(80, 85, 'B_Disease')]}], ['Diffuse intramural vasoconstriction is not consistent with reports of segmental , discrete infarction .', {'entities': [(91, 101, 'B_Disease')]}], ['Finally , the contribution of a primary , thrombotic effect of cocaine has not been excluded .', {'entities': [(42, 52, 'B_Disease')]}], ['Proteomic analysis of striatal proteins in the rat model of L - DOPA - induced dyskinesia .', {'entities': [(79, 89, 'B_Disease')]}], [\"L - DOPA - induced dyskinesia ( LID ) is among the motor complications that arise in Parkinson ' s disease ( PD ) patients after a prolonged treatment with L - DOPA .\", {'entities': [(19, 29, 'B_Disease'), (32, 35, 'B_Disease'), (85, 94, 'B_Disease'), (95, 96, 'I_Disease'), (97, 98, 'I_Disease'), (99, 106, 'I_Disease'), (109, 111, 'B_Disease')]}], ['To this day , transcriptome analysis has been performed in a rat model of LID [ Neurobiol . Dis . , 17 ( 2004 ) , 219 ] but information regarding the proteome is still lacking .', {'entities': [(74, 77, 'B_Disease')]}], ['In the present study , we investigated the changes occurring at the protein level in striatal samples obtained from the unilaterally 6 - hydroxydopamine - lesion rat model of PD treated with saline , L - DOPA or bromocriptine using two - dimensional difference gel electrophoresis and mass spectrometry ( MS ) .', {'entities': [(175, 177, 'B_Disease')]}], ['Rats treated with L - DOPA were allocated to two groups based on the presence or absence of LID .', {'entities': [(92, 95, 'B_Disease')]}], ['Out of these 67 proteins , LID significantly changed the expression level of five proteins : alphabeta - crystalin , gamma - enolase , guanidoacetate methyltransferase , vinculin , and proteasome alpha - 2 subunit .', {'entities': [(27, 30, 'B_Disease')]}], ['In conclusion , this study provides new insights into the protein changes occurring in LID .', {'entities': [(87, 90, 'B_Disease')]}], ['Cardiac Angiography in Renally Impaired Patients ( CARE ) study : a randomized double - blind trial of contrast - induced nephropathy in patients with chronic kidney disease .', {'entities': [(122, 133, 'B_Disease'), (151, 158, 'B_Disease'), (159, 165, 'I_Disease'), (166, 173, 'I_Disease')]}], ['METHODS AND RESULTS : The present study is a multicenter , randomized , double - blind comparison of iopamidol and iodixanol in patients with chronic kidney disease ( estimated glomerular filtration rate , 20 to 59 mL / min ) who underwent cardiac angiography or percutaneous coronary interventions .', {'entities': [(142, 149, 'B_Disease'), (150, 156, 'I_Disease'), (157, 164, 'I_Disease')]}], ['In 414 patients , contrast volume , presence of diabetes mellitus , use of N - acetylcysteine , mean baseline SCr , and estimated glomerular filtration rate were comparable in the 2 groups .', {'entities': [(48, 56, 'B_Disease'), (57, 65, 'I_Disease')]}], ['In patients with diabetes , SCr increases > or = 0 . 5 mg / dL were 5 . 1 % ( 4 of 78 patients ) with iopamidol and 13 . 0 % ( 12 of 92 patients ) with iodixanol ( P = 0 . 11 ) , whereas SCr increases > or = 25 % were 10 . 3 % and 15 . 2 % , respectively ( P = 0 . 37 ) .', {'entities': [(17, 25, 'B_Disease')]}], ['Mean post - SCr increases were significantly less with iopamidol ( all patients : 0 . 07 versus 0 . 12 mg / dL , 6 . 2 versus 10 . 6 micromol / L , P = 0 . 03 ; patients with diabetes : 0 . 07 versus 0 . 16 mg / dL , 6 . 2 versus 14 . 1 micromol / L , P = 0 . 01 ) .', {'entities': [(175, 183, 'B_Disease')]}], ['CONCLUSIONS : The rate of contrast - induced nephropathy , defined by multiple end points , is not statistically different after the intraarterial administration of iopamidol or iodixanol to high - risk patients , with or without diabetes mellitus .', {'entities': [(45, 56, 'B_Disease'), (230, 238, 'B_Disease'), (239, 247, 'I_Disease')]}], ['A novel compound , maltolyl p - coumarate , attenuates cognitive deficits and shows neuroprotective effects in vitro and in vivo dementia models .', {'entities': [(55, 64, 'B_Disease'), (65, 73, 'I_Disease'), (129, 137, 'B_Disease')]}], ['In the present study , we investigated whether maltolyl p - coumarate could improve cognitive decline in scopolamine - injected rats and in amyloid beta peptide ( 1 - 42 ) - infused rats .', {'entities': [(84, 93, 'B_Disease'), (94, 101, 'I_Disease')]}], ['Maltolyl p - coumarate was found to attenuate cognitive deficits in both rat models using passive avoidance test and to reduce apoptotic cell death observed in the hippocampus of the amyloid beta peptide ( 1 - 42 ) - infused rats .', {'entities': [(46, 55, 'B_Disease'), (56, 64, 'I_Disease')]}], [\"Taking these in vitro and in vivo results together , our study suggests that maltolyl p - coumarate is a potentially effective candidate against Alzheimer ' s disease that is characterized by wide spread neuronal death and progressive decline of cognitive function .\", {'entities': [(145, 154, 'B_Disease'), (155, 156, 'I_Disease'), (157, 158, 'I_Disease'), (159, 166, 'I_Disease'), (204, 212, 'B_Disease'), (213, 218, 'I_Disease'), (235, 242, 'B_Disease'), (243, 245, 'I_Disease'), (246, 255, 'I_Disease'), (256, 264, 'I_Disease')]}], ['Attenuation of methamphetamine - induced nigrostriatal dopaminergic neurotoxicity in mice by lipopolysaccharide pretreatment .', {'entities': [(68, 81, 'B_Disease')]}], ['Immunological activation has been proposed to play a role in methamphetamine - induced dopaminergic terminal damage .', {'entities': [(87, 99, 'B_Disease'), (100, 108, 'I_Disease'), (109, 115, 'I_Disease')]}], ['In this study , we examined the roles of lipopolysaccharide , a pro - inflammatory and inflammatory factor , treatment in modulating the methamphetamine - induced nigrostriatal dopamine neurotoxicity .', {'entities': [(186, 199, 'B_Disease')]}], ['Lipopolysaccharide pretreatment did not affect the basal body temperature or methamphetamine - elicited hyperthermia three days later .', {'entities': [(104, 116, 'B_Disease')]}], ['We concluded a critical time window for systemic lipopolysaccharide pretreatment in exerting effective protection against methamphetamine - induced nigrostriatal dopamine neurotoxicity .', {'entities': [(171, 184, 'B_Disease')]}], ['Acute myocarditis associated with clozapine .', {'entities': [(6, 17, 'B_Disease')]}], ['OBJECTIVE : A case of acute myocarditis associated with the commencement of clozapine is described , highlighting the onset , course and possible contributing factors .', {'entities': [(28, 39, 'B_Disease')]}], ['RESULTS : A 20 - year - old male with schizophrenia developed a sudden onset of myocarditis after commencement of clozapine .', {'entities': [(38, 51, 'B_Disease'), (80, 91, 'B_Disease')]}], ['CONCLUSIONS : Myocarditis is an increasingly recognized complication associated with the use of clozapine .', {'entities': [(14, 25, 'B_Disease')]}], ['Considering that clozapine remains the gold standard in treatment of resistant psychosis , there is an urgent need to raise awareness among medical and paramedical staff involved in the care of these patients .', {'entities': [(79, 88, 'B_Disease')]}], ['Severe rhabdomyolysis and acute renal failure secondary to concomitant use of simvastatin , amiodarone , and atazanavir .', {'entities': [(7, 21, 'B_Disease'), (26, 31, 'B_Disease'), (32, 37, 'I_Disease'), (38, 45, 'I_Disease')]}], ['OBJECTIVE : To report a case of a severe interaction between simvastatin , amiodarone , and atazanavir resulting in rhabdomyolysis and acute renal failure .', {'entities': [(116, 130, 'B_Disease'), (135, 140, 'B_Disease'), (141, 146, 'I_Disease'), (147, 154, 'I_Disease')]}], ['BACKGROUND : A 72 - year - old white man with underlying human immunodeficiency virus , atrial fibrillation , coronary artery disease , and hyperlipidemia presented with generalized pain , fatigue , and dark orange urine for 3 days .', {'entities': [(57, 62, 'B_Disease'), (63, 79, 'I_Disease'), (80, 85, 'I_Disease'), (88, 94, 'B_Disease'), (95, 107, 'I_Disease'), (110, 118, 'B_Disease'), (119, 125, 'I_Disease'), (126, 133, 'I_Disease'), (140, 154, 'B_Disease'), (182, 186, 'B_Disease'), (189, 196, 'B_Disease')]}], [\"Simvastatin , amiodarone , and the patient ' s human immunodeficiency virus medications were all temporarily discontinued and the patient was given forced alkaline diuresis and started on dialysis .\", {'entities': [(47, 52, 'B_Disease'), (53, 69, 'I_Disease'), (70, 75, 'I_Disease')]}], ['DISCUSSION : The risk of rhabdomyolysis is increased in the presence of concomitant drugs that inhibit simvastatin metabolism .', {'entities': [(25, 39, 'B_Disease')]}], ['We report 3 cases of serious bleeding complications that appear to be the result of the interaction between warfarin and levofloxacin .', {'entities': [(29, 37, 'B_Disease')]}], ['Mutations associated with lamivudine - resistance in therapy - na ve hepatitis B virus ( HBV ) infected patients with and without HIV co - infection : implications for antiretroviral therapy in HBV and HIV co - infected South African patients .', {'entities': [(69, 78, 'B_Disease'), (79, 80, 'I_Disease'), (81, 86, 'I_Disease'), (87, 88, 'I_Disease'), (89, 92, 'I_Disease'), (93, 94, 'I_Disease'), (95, 103, 'I_Disease'), (130, 133, 'B_Disease'), (134, 136, 'I_Disease'), (137, 138, 'I_Disease'), (139, 148, 'I_Disease'), (194, 197, 'B_Disease'), (198, 201, 'I_Disease'), (202, 205, 'I_Disease'), (206, 208, 'I_Disease'), (209, 210, 'I_Disease'), (211, 219, 'I_Disease')]}], ['This was an exploratory study to investigate lamivudine - resistant hepatitis B virus ( HBV ) strains in selected lamivudine - na ve HBV carriers with and without human immunodeficiency virus ( HIV ) co - infection in South African patients .', {'entities': [(68, 77, 'B_Disease'), (78, 79, 'I_Disease'), (163, 168, 'B_Disease'), (169, 185, 'I_Disease'), (186, 191, 'I_Disease'), (192, 193, 'I_Disease'), (194, 197, 'I_Disease'), (198, 199, 'I_Disease'), (200, 202, 'I_Disease'), (203, 204, 'I_Disease'), (205, 214, 'I_Disease')]}], ['Thirty - five lamivudine - na ve HBV infected patients with or without HIV co - infection were studied : 15 chronic HBV mono - infected patients and 20 HBV - HIV co - infected patients .', {'entities': [(33, 36, 'B_Disease'), (37, 45, 'I_Disease'), (71, 74, 'B_Disease'), (75, 77, 'I_Disease'), (78, 79, 'I_Disease'), (80, 89, 'I_Disease'), (116, 119, 'B_Disease'), (120, 124, 'I_Disease'), (125, 126, 'I_Disease'), (127, 135, 'I_Disease'), (152, 155, 'B_Disease'), (156, 157, 'I_Disease'), (158, 161, 'I_Disease'), (162, 164, 'I_Disease'), (165, 166, 'I_Disease'), (167, 175, 'I_Disease')]}], ['HBV lamivudine - resistant strains were detected in 3 of 15 mono - infected chronic hepatitis B patients and 10 of 20 HBV - HIV co - infected patients .', {'entities': [(84, 93, 'B_Disease'), (94, 95, 'I_Disease'), (118, 121, 'B_Disease'), (122, 123, 'I_Disease'), (124, 127, 'I_Disease'), (128, 130, 'I_Disease'), (131, 132, 'I_Disease'), (133, 141, 'I_Disease')]}], ['To the best of our knowledge , this constitutes the first report of HBV lamivudine - resistant strains in therapy - na ve HBV - HIV co - infected patients .', {'entities': [(122, 125, 'B_Disease'), (126, 127, 'I_Disease'), (128, 131, 'I_Disease'), (132, 134, 'I_Disease'), (135, 136, 'I_Disease'), (137, 145, 'I_Disease')]}], ['It remains to be seen whether such pre - existing antiviral mutations could result in widespread emergence of HBV resistant strains when lamivudine - containing highly active antiretroviral ( ARV ) treatment ( HAART ) regimens become widely applied in South Africa , as this is likely to have potential implications in the management of HBV - HIV co - infected patients .', {'entities': [(337, 340, 'B_Disease'), (341, 342, 'I_Disease'), (343, 346, 'I_Disease'), (347, 349, 'I_Disease'), (350, 351, 'I_Disease'), (352, 360, 'I_Disease')]}], ['Rabbit syndrome , antidepressant use , and cerebral perfusion SPECT scan findings .', {'entities': [(0, 6, 'B_Disease'), (7, 15, 'I_Disease')]}], ['The rabbit syndrome is an extrapyramidal side effect associated with chronic neuroleptic therapy .', {'entities': [(4, 10, 'B_Disease'), (11, 19, 'I_Disease')]}], ['Repeated cerebral perfusion SPECT scans revealed decreased basal ganglia perfusion while the movement disorder was present , and a return to normal perfusion when the rabbit syndrome resolved .', {'entities': [(49, 58, 'B_Disease'), (59, 64, 'I_Disease'), (65, 72, 'I_Disease'), (73, 82, 'I_Disease'), (93, 101, 'B_Disease'), (102, 110, 'I_Disease'), (167, 173, 'B_Disease'), (174, 182, 'I_Disease')]}], ['Many patients , however , develop negative long - term side effects such as premature atherosclerosis .', {'entities': [(76, 85, 'B_Disease'), (86, 101, 'I_Disease')]}], ['We have previously demonstrated that ritonavir treatment increases atherosclerotic lesion formation in male mice to a greater extent than in female mice .', {'entities': [(67, 82, 'B_Disease'), (83, 89, 'I_Disease')]}], ['Acute hepatitis attack after exposure to telithromycin .', {'entities': [(6, 15, 'B_Disease')]}], ['INTRODUCTION : Antibiotic - associated hepatotoxicity is rare .', {'entities': [(39, 53, 'B_Disease')]}], ['With widespread use of antimicrobial agents , however , hepatic injury occurs frequently , and among adverse drug reactions , idiosyncratic reactions are the most serious .', {'entities': [(56, 63, 'B_Disease'), (64, 70, 'I_Disease'), (101, 108, 'B_Disease'), (109, 113, 'I_Disease'), (114, 123, 'I_Disease')]}], [\"CASE SUMMARY : A 25 - year - old male patient , with a height of 175 cm and weight of 72 kg presented to Marmara University Hospital Emergency Department , Istanbul , Turkey , with 5 days ' history of jaundice , malaise , nausea , and vomiting .\", {'entities': [(201, 209, 'B_Disease'), (222, 228, 'B_Disease'), (235, 243, 'B_Disease')]}], ['He had been prescribed telithromycin 400 mg / d PO to treat an upper respiratory tract infection 7 days prior .', {'entities': [(63, 68, 'B_Disease'), (69, 80, 'I_Disease'), (81, 86, 'I_Disease'), (87, 96, 'I_Disease')]}], ['The patient had suffered a previous episode of \" acute hepatitis of unknown origin , \" that occurred after telithromycin usage .', {'entities': [(55, 64, 'B_Disease')]}], ['It has been associated with infrequent and usually reversible severe hepatic dysfunction .', {'entities': [(69, 76, 'B_Disease'), (77, 88, 'I_Disease')]}], ['Based on a score of 8 on the Naranjo adverse drug reaction probability scale , telithromycin was the probable cause of acute hepatitis in this patient , and pathological findings suggested drug - induced toxic hepatitis .', {'entities': [(37, 44, 'B_Disease'), (45, 49, 'I_Disease'), (50, 58, 'I_Disease'), (125, 134, 'B_Disease'), (204, 209, 'B_Disease'), (210, 219, 'I_Disease')]}], ['Recurrence of hepatitis attack might have been avoided if the initial incident had been communicated to the attending physician who prescribed telithromycin the second time .', {'entities': [(14, 23, 'B_Disease')]}], ['CONCLUSION : Here we report a case of acute hepatitis probably associated with the administration of telithromycin .', {'entities': [(44, 53, 'B_Disease')]}], ['A study on the effect of the duration of subcutaneous heparin injection on bruising and pain .', {'entities': [(75, 83, 'B_Disease'), (88, 92, 'B_Disease')]}], ['AIM : This study was carried out to determine the effect of injection duration on bruising and pain following the administration of the subcutaneous injection of heparin .', {'entities': [(82, 90, 'B_Disease'), (95, 99, 'B_Disease')]}], ['BACKGROUND : Although different methods to prevent bruising and pain following the subcutaneous injection of heparin have been widely studied and described , the effect of injection duration on the occurrence of bruising and pain is little documented .', {'entities': [(51, 59, 'B_Disease'), (64, 68, 'B_Disease'), (212, 220, 'B_Disease'), (225, 229, 'B_Disease')]}], ['Injections areas were assessed for the presence of bruising at 48 and 72 hours after each injection .', {'entities': [(51, 59, 'B_Disease')]}], ['Dimensions of the bruising on the heparin applied areas were measured using transparent millimetric measuring paper .', {'entities': [(18, 26, 'B_Disease')]}], ['The visual analog scale ( VAS ) was used to measure pain intensity and a stop - watch was used to time the pain period .', {'entities': [(52, 56, 'B_Disease'), (107, 111, 'B_Disease')]}], ['RESULTS : The percentage of bruising occurrence was 64 % with the injection of 10 seconds duration and 42 % in the 30 - second injection .', {'entities': [(28, 36, 'B_Disease')]}], ['It was determined that the size of the bruising was smaller in the 30 - second injection .', {'entities': [(39, 47, 'B_Disease')]}], ['Pain intensity and pain period were statistically significantly lower for the 30 - second injection than for the 10 - second injection .', {'entities': [(0, 4, 'B_Disease'), (19, 23, 'B_Disease')]}], ['CONCLUSIONS : It was determined that injection duration had an effect on bruising and pain following the subcutaneous administration of heparin .', {'entities': [(73, 81, 'B_Disease'), (86, 90, 'B_Disease')]}], ['Acute liver failure in two patients with regular alcohol consumption ingesting paracetamol at therapeutic dosage .', {'entities': [(0, 5, 'B_Disease'), (6, 11, 'I_Disease'), (12, 19, 'I_Disease')]}], ['BACKGROUND : The possible role of alcohol in the development of hepatotoxicity associated with therapeutic doses of paracetamol ( acetaminophen ) is currently debated .', {'entities': [(64, 78, 'B_Disease')]}], ['CASE REPORT : We describe 2 patients who were regular consumers of alcohol and who developed liver failure within 3 - 5 days after hospitalization and stopping alcohol consumption while being treated with 4 g paracetamol / day .', {'entities': [(93, 98, 'B_Disease'), (99, 106, 'I_Disease')]}], ['Possible risk factors for the development of hepatotoxicity in patients treated with therapeutic doses of paracetamol are discussed .', {'entities': [(45, 59, 'B_Disease')]}], ['CONCLUSION : In patients with risk factors , e . g . regular consumption of alcohol , liver failure is possible when therapeutic doses are ingested .', {'entities': [(86, 91, 'B_Disease'), (92, 99, 'I_Disease')]}], ['Long - term use of these drugs was associated with female sex and use of a higher number of drugs with effects on the CNS , which tended to be related to diagnosed dementia .', {'entities': [(164, 172, 'B_Disease')]}], ['However , use of BZDs / RDs was associated with dizziness , inability to sleep after awaking at night and tiredness in the mornings during the week prior to admission and with stronger depressive symptoms measured at the beginning of the hospital stay .', {'entities': [(48, 57, 'B_Disease'), (60, 69, 'B_Disease'), (70, 72, 'I_Disease'), (73, 78, 'I_Disease'), (106, 115, 'B_Disease'), (185, 195, 'B_Disease'), (196, 204, 'I_Disease')]}], ['Acute vocal fold palsy after acute disulfiram intoxication .', {'entities': [(6, 11, 'B_Disease'), (12, 16, 'I_Disease'), (17, 22, 'I_Disease')]}], ['Acute peripheral neuropathy caused by a disulfiram overdose is very rare and there is no report of it leading to vocal fold palsy .', {'entities': [(6, 16, 'B_Disease'), (17, 27, 'I_Disease'), (51, 59, 'B_Disease'), (113, 118, 'B_Disease'), (119, 123, 'I_Disease'), (124, 129, 'I_Disease')]}], ['A 49 - year - old woman was transferred to our department because of quadriparesis , lancinating pain , sensory loss , and paresthesia of the distal limbs .', {'entities': [(69, 82, 'B_Disease'), (97, 101, 'B_Disease'), (104, 111, 'B_Disease'), (112, 116, 'I_Disease'), (123, 134, 'B_Disease')]}], ['For the first few days after ingestion , she was in a confused state and had mild to moderate ataxia and giddiness .', {'entities': [(94, 100, 'B_Disease'), (105, 114, 'B_Disease')]}], ['She noticed hoarseness and distally accentuated motor and sensory dysfunction after she had recovered from this state .', {'entities': [(12, 22, 'B_Disease')]}], ['A nerve conduction study was consistent with severe sensorimotor axonal polyneuropathy .', {'entities': [(72, 86, 'B_Disease')]}], ['This was a case of acute palsy of the recurrent laryngeal nerve and superimposed severe acute sensorimotor axonal polyneuropathy caused by high - dose disulfiram intoxication .', {'entities': [(25, 30, 'B_Disease'), (114, 128, 'B_Disease')]}], ['Encephalopathy induced by levetiracetam added to valproate .', {'entities': [(0, 14, 'B_Disease')]}], ['BACKGROUND : We report on the manifestation of a levetiracetam ( LEV ) - induced encephalopathy .', {'entities': [(81, 95, 'B_Disease')]}], ['FINDINGS : A 28 - year - old man suffering from idiopathic epilepsy with generalized seizures was treated with LEV ( 3000 mg ) added to valproate ( VPA ) ( 2000 mg ) .', {'entities': [(48, 58, 'B_Disease'), (59, 67, 'I_Disease'), (85, 93, 'B_Disease')]}], ['Frequency of generalized tonic - clonic seizures increased from one per 6 months to two per month .', {'entities': [(25, 30, 'B_Disease'), (31, 32, 'I_Disease'), (33, 39, 'I_Disease'), (40, 48, 'I_Disease')]}], ['Neuropsychological testing showed impaired word fluency , psychomotor speed and working memory .', {'entities': [(34, 42, 'B_Disease'), (43, 47, 'I_Disease'), (48, 55, 'I_Disease'), (56, 57, 'I_Disease'), (58, 69, 'I_Disease'), (70, 75, 'I_Disease'), (76, 79, 'I_Disease'), (80, 87, 'I_Disease'), (88, 94, 'I_Disease')]}], ['OUTCOME : Following discontinuation of LEV , EEG and neuropsychological findings improved and seizure frequency decreased .', {'entities': [(94, 101, 'B_Disease')]}], ['Norepinephrine signaling through beta - adrenergic receptors is critical for expression of cocaine - induced anxiety .', {'entities': [(109, 116, 'B_Disease')]}], [\"While the mechanisms underlying cocaine ' s rewarding effects have been studied extensively , less attention has been paid to the unpleasant behavioral states induced by cocaine , such as anxiety .\", {'entities': [(188, 195, 'B_Disease')]}], ['METHODS : In this study , we evaluated the performance of dopamine beta - hydroxylase knockout ( Dbh - / - ) mice , which lack norepinephrine ( NE ) , in the elevated plus maze ( EPM ) to examine the contribution of noradrenergic signaling to cocaine - induced anxiety .', {'entities': [(261, 268, 'B_Disease')]}], ['RESULTS : We found that cocaine dose - dependently increased anxiety - like behavior in control ( Dbh + / - ) mice , as measured by a decrease in open arm exploration .', {'entities': [(61, 68, 'B_Disease')]}], ['Cocaine - induced anxiety was also attenuated in Dbh + / - mice following administration of disulfiram , a dopamine beta - hydroxylase ( DBH ) inhibitor .', {'entities': [(18, 25, 'B_Disease')]}], ['In experiments using specific adrenergic antagonists , we found that pretreatment with the beta - adrenergic receptor antagonist propranolol blocked cocaine - induced anxiety - like behavior in Dbh + / - and wild - type C57BL6 / J mice , while the alpha ( 1 ) antagonist prazosin and the alpha ( 2 ) antagonist yohimbine had no effect .', {'entities': [(167, 174, 'B_Disease')]}], ['CONCLUSIONS : These results indicate that noradrenergic signaling via beta - adrenergic receptors is required for cocaine - induced anxiety in mice .', {'entities': [(132, 139, 'B_Disease')]}], ['Hypothalamic prolactin receptor messenger ribonucleic acid levels , prolactin signaling , and hyperprolactinemic inhibition of pulsatile luteinizing hormone secretion are dependent on estradiol .', {'entities': [(94, 112, 'B_Disease')]}], ['Hyperprolactinemia can reduce fertility and libido .', {'entities': [(0, 18, 'B_Disease')]}], ['We first tested whether chronic hyperprolactinemia inhibited two neuroendocrine parameters necessary for female fertility : pulsatile LH secretion and the estrogen - induced LH surge .', {'entities': [(32, 50, 'B_Disease')]}], ['Chronic hyperprolactinemia induced by the dopamine antagonist sulpiride caused a 40 % reduction LH pulse frequency in ovariectomized rats , but only in the presence of chronic low levels of estradiol .', {'entities': [(8, 26, 'B_Disease')]}], ['These data show that GnRH pulse frequency is inhibited by chronic hyperprolactinemia in a steroid - dependent manner .', {'entities': [(66, 84, 'B_Disease')]}], ['Clonidine for attention - deficit / hyperactivity disorder : II .', {'entities': [(14, 23, 'B_Disease'), (24, 25, 'I_Disease'), (26, 33, 'I_Disease'), (34, 35, 'I_Disease'), (36, 49, 'I_Disease'), (50, 58, 'I_Disease')]}], ['OBJECTIVE : To examine the safety and tolerability of clonidine used alone or with methylphenidate in children with attention - deficit / hyperactivity disorder ( ADHD ) .', {'entities': [(116, 125, 'B_Disease'), (126, 127, 'I_Disease'), (128, 135, 'I_Disease'), (136, 137, 'I_Disease'), (138, 151, 'I_Disease'), (152, 160, 'I_Disease'), (163, 167, 'B_Disease')]}], ['METHOD : In a 16 - week multicenter , double - blind trial , 122 children with ADHD were randomly assigned to clonidine ( n = 31 ) , methylphenidate ( n = 29 ) , clonidine and methylphenidate ( n = 32 ) , or placebo ( n = 30 ) .', {'entities': [(79, 83, 'B_Disease')]}], ['RESULTS : There were more incidents of bradycardia in subjects treated with clonidine compared with those not treated with clonidine ( 17 . 5 % versus 3 . 4 % ; p = . 02 ) , but no other significant group differences regarding electrocardiogram and other cardiovascular outcomes .', {'entities': [(39, 50, 'B_Disease')]}], ['Drowsiness was common on clonidine , but generally resolved by 6 to 8 weeks .', {'entities': [(0, 10, 'B_Disease')]}], ['CONCLUSIONS : Clonidine , used alone or with methylphenidate , appears safe and well tolerated in childhood ADHD .', {'entities': [(108, 112, 'B_Disease')]}], ['Physicians prescribing clonidine should monitor for bradycardia and advise patients about the high likelihood of initial drowsiness .', {'entities': [(52, 63, 'B_Disease'), (121, 131, 'B_Disease')]}], ['Renal Fanconi syndrome and myopathy after liver transplantation : drug - related mitochondrial cytopathy ?', {'entities': [(0, 5, 'B_Disease'), (6, 13, 'I_Disease'), (14, 22, 'I_Disease'), (27, 35, 'B_Disease'), (81, 94, 'B_Disease'), (95, 104, 'I_Disease')]}], [\"We describe a 15 - yr - old girl who had orthotopic liver transplantation because of Wilson ' s disease .\", {'entities': [(85, 91, 'B_Disease'), (92, 93, 'I_Disease'), (94, 95, 'I_Disease'), (96, 103, 'I_Disease')]}], ['Lamivudine was added because of de nova hepatitis B infection during her follow - up .', {'entities': [(40, 49, 'B_Disease'), (50, 51, 'I_Disease'), (52, 61, 'I_Disease')]}], ['Three yr after transplantation she developed renal Fanconi syndrome with severe metabolic acidosis , hypophosphatemia , glycosuria , and aminoaciduria .', {'entities': [(45, 50, 'B_Disease'), (51, 58, 'I_Disease'), (59, 67, 'I_Disease'), (80, 89, 'B_Disease'), (90, 98, 'I_Disease'), (101, 117, 'B_Disease'), (120, 130, 'B_Disease'), (137, 150, 'B_Disease')]}], ['Although tacrolimus was suspected to be the cause of late post - transplant renal acidosis and was replaced by sirolimus , acidosis , and electrolyte imbalance got worse .', {'entities': [(82, 90, 'B_Disease'), (123, 131, 'B_Disease')]}], ['Proximal muscle weakness has developed during her follow - up .', {'entities': [(9, 15, 'B_Disease'), (16, 24, 'I_Disease')]}], ['Fanconi syndrome , as well as myopathy , is well recognized in patients with mitochondrial disorders and caused by depletion of mtDNA .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease'), (30, 38, 'B_Disease'), (77, 90, 'B_Disease'), (91, 100, 'I_Disease')]}], [\"We suggest that our patient ' s tubular dysfunction and myopathy may have resulted from mitochondrial dysfunction which is triggered by tacrolimus and augmented by lamivudine .\", {'entities': [(32, 39, 'B_Disease'), (40, 51, 'I_Disease'), (56, 64, 'B_Disease'), (88, 101, 'B_Disease'), (102, 113, 'I_Disease')]}], ['Higher optical density of an antigen assay predicts thrombosis in patients with heparin - induced thrombocytopenia .', {'entities': [(52, 62, 'B_Disease'), (98, 114, 'B_Disease')]}], ['OBJECTIVES : To correlate optical density and percent inhibition of a two - step heparin - induced thrombocytopenia ( HIT ) antigen assay with thrombosis ; the assay utilizes reaction inhibition characteristics of a high heparin concentration .', {'entities': [(99, 115, 'B_Disease'), (118, 121, 'B_Disease'), (143, 153, 'B_Disease')]}], ['PATIENTS AND METHODS : Patients with more than 50 % decrease in platelet count or thrombocytopenia ( < 150 x 10 ( 9 ) / L ) after exposure to heparin , who had a positive two - step antigen assay [ optical density ( OD ) > 0 . 4 and > 50 inhibition with high concentration of heparin ] were included in the study .', {'entities': [(82, 98, 'B_Disease')]}], ['RESULTS : Forty of 94 HIT patients had thrombosis at diagnosis ; 54 / 94 had isolated - HIT without thrombosis .', {'entities': [(22, 25, 'B_Disease'), (39, 49, 'B_Disease'), (88, 91, 'B_Disease'), (100, 110, 'B_Disease')]}], ['Eight of the isolated - HIT patients developed thrombosis within the next 30 d ; thus , a total of 48 patients had thrombosis at day 30 .', {'entities': [(24, 27, 'B_Disease'), (47, 57, 'B_Disease'), (115, 125, 'B_Disease')]}], ['At diagnosis there was no significant difference in OD between HIT patients with thrombosis and those with isolated - HIT .', {'entities': [(63, 66, 'B_Disease'), (81, 91, 'B_Disease'), (118, 121, 'B_Disease')]}], ['However , OD was significantly higher in all patients with thrombosis ( n = 48 , 1 . 34 + / - 0 . 89 ) , including isolated - HIT patients who later developed thrombosis within 30 d ( n = 8 , 1 . 84 + / - 0 . 64 ) as compared to isolated - HIT patients who did not develop thrombosis ( 0 . 96 + / - 0 . 75 ; P = 0 . 011 and P = 0 . 008 ) .', {'entities': [(59, 69, 'B_Disease'), (126, 129, 'B_Disease'), (159, 169, 'B_Disease'), (240, 243, 'B_Disease'), (273, 283, 'B_Disease')]}], ['The Receiver Operative Characteristic Curve showed that OD > 1 . 27 in the isolated - HIT group had a significantly higher chance of developing thrombosis by day 30 .', {'entities': [(86, 89, 'B_Disease'), (144, 154, 'B_Disease')]}], ['Multivariate analysis showed a 2 . 8 - fold increased risk of thrombosis in females .', {'entities': [(62, 72, 'B_Disease')]}], ['Similarly , thrombotic risk increased with age and OD values .', {'entities': [(12, 22, 'B_Disease')]}], ['CONCLUSION : Higher OD is associated with significant risk of subsequent thrombosis in patients with isolated - HIT ; percent inhibition , however , was not predictive .', {'entities': [(73, 83, 'B_Disease'), (112, 115, 'B_Disease')]}], ['Thalidomide has limited single - agent activity in relapsed or refractory indolent non - Hodgkin lymphomas : a phase II trial of the Cancer and Leukemia Group B .', {'entities': [(83, 86, 'B_Disease'), (87, 88, 'I_Disease'), (89, 96, 'I_Disease'), (97, 106, 'I_Disease'), (133, 139, 'B_Disease'), (144, 152, 'B_Disease')]}], ['Thalidomide is an immunomodulatory agent with demonstrated activity in multiple myeloma , mantle cell lymphoma and lymphoplasmacytic lymphoma .', {'entities': [(71, 79, 'B_Disease'), (80, 87, 'I_Disease'), (90, 96, 'B_Disease'), (97, 101, 'I_Disease'), (102, 110, 'I_Disease'), (115, 132, 'B_Disease'), (133, 141, 'I_Disease')]}], ['Its activity is believed to be due modulation of the tumour milieu , including downregulation of angiogenesis and inflammatory cytokines .', {'entities': [(53, 59, 'B_Disease')]}], ['Between July 2001 and April 2004 , 24 patients with relapsed / refractory indolent lymphomas received thalidomide 200 mg daily with escalation by 100 mg daily every 1 - 2 weeks as tolerated , up to a maximum of 800 mg daily .', {'entities': [(83, 92, 'B_Disease')]}], ['Grade 3 - 4 adverse effects included myelosuppression , fatigue , somnolence / depressed mood , neuropathy and dyspnea .', {'entities': [(37, 53, 'B_Disease'), (56, 63, 'B_Disease'), (66, 76, 'B_Disease'), (79, 88, 'B_Disease'), (89, 93, 'I_Disease'), (96, 106, 'B_Disease'), (111, 118, 'B_Disease')]}], ['Of concern was the occurrence of four thromboembolic events .', {'entities': [(38, 52, 'B_Disease')]}], ['Our results failed to demonstrate an important response rate to single agent thalidomide in indolent lymphomas and contrast with the higher activity level reported with the second generation immunomodulatory agent , lenalidomide .', {'entities': [(101, 110, 'B_Disease')]}], ['Sex differences in NMDA antagonist enhancement of morphine antihyperalgesia in a capsaicin model of persistent pain : comparisons to two models of acute pain .', {'entities': [(111, 115, 'B_Disease'), (147, 152, 'B_Disease'), (153, 157, 'I_Disease')]}], ['In acute pain models , N - methyl - D - aspartate ( NMDA ) antagonists enhance the antinociceptive effects of morphine to a greater extent in males than females .', {'entities': [(3, 8, 'B_Disease'), (9, 13, 'I_Disease')]}], ['The purpose of this investigation was to extend these findings to a persistent pain model which could be distinguished from acute pain models on the basis of the nociceptive fibers activated , neurochemical substrates , and duration of the nociceptive stimulus .', {'entities': [(79, 83, 'B_Disease'), (124, 129, 'B_Disease'), (130, 134, 'I_Disease')]}], ['To this end , persistent hyperalgesia was induced by administration of capsaicin in the tail of gonadally intact F344 rats , following which the tail was immersed in a mildly noxious thermal stimulus , and tail - withdrawal latencies measured .', {'entities': [(25, 37, 'B_Disease')]}], ['For comparison , tests were conducted in two acute pain models , the hotplate and warm water tail - withdrawal procedures .', {'entities': [(45, 50, 'B_Disease'), (51, 55, 'I_Disease')]}], ['Enhancement of morphine antinociception by dextromethorphan was seen in both males and females in the acute pain models , with the magnitude of this effect being greater in males .', {'entities': [(102, 107, 'B_Disease'), (108, 112, 'I_Disease')]}], ['These findings demonstrate a sexually - dimorphic interaction between NMDA antagonists and morphine in a persistent pain model that can be distinguished from those observed in acute pain models .', {'entities': [(116, 120, 'B_Disease'), (176, 181, 'B_Disease'), (182, 186, 'I_Disease')]}], ['Development of proteinuria after switch to sirolimus - based immunosuppression in long - term cardiac transplant patients .', {'entities': [(15, 26, 'B_Disease')]}], ['Calcineurin - inhibitor therapy can lead to renal dysfunction in heart transplantation patients .', {'entities': [(44, 49, 'B_Disease'), (50, 61, 'I_Disease')]}], ['The novel immunosuppressive ( IS ) drug sirolmus ( Srl ) lacks nephrotoxic effects ; however , proteinuria associated with Srl has been reported following renal transplantation .', {'entities': [(63, 74, 'B_Disease'), (95, 106, 'B_Disease')]}], ['In cardiac transplantation , the incidence of proteinuria associated with Srl is unknown .', {'entities': [(46, 57, 'B_Disease')]}], ['Before the switch , 11 . 5 % of patients had high - grade proteinuria ( > 1 . 0 g / day ) ; this increased to 22 . 9 % postswitch ( p = 0 . 006 ) .', {'entities': [(58, 69, 'B_Disease')]}], ['ACE inhibitor and angiotensin - releasing blocker ( ARB ) therapy reduced proteinuria development .', {'entities': [(74, 85, 'B_Disease')]}], ['Patients without proteinuria had increased renal function ( median 42 . 5 vs . 64 . 1 , p = 0 . 25 ) , whereas patients who developed high - grade proteinuria showed decreased renal function at the end of follow - up ( median 39 . 6 vs . 29 . 2 , p = 0 . 125 ) .', {'entities': [(17, 28, 'B_Disease'), (147, 158, 'B_Disease')]}], ['Thus , proteinuria may develop in cardiac transplant patients after switch to Srl , which may have an adverse effect on renal function in these patients .', {'entities': [(7, 18, 'B_Disease')]}], ['Srl should be used with ACEi / ARB therapy and patients monitored for proteinuria and increased renal dysfunction .', {'entities': [(70, 81, 'B_Disease'), (96, 101, 'B_Disease'), (102, 113, 'I_Disease')]}], ['Ginsenoside Rg1 restores the impairment of learning induced by chronic morphine administration in rats .', {'entities': [(29, 39, 'B_Disease'), (40, 42, 'I_Disease'), (43, 51, 'I_Disease')]}], ['Rg1 , as a ginsenoside extracted from Panax ginseng , could ameliorate spatial learning impairment .', {'entities': [(79, 87, 'B_Disease'), (88, 98, 'I_Disease')]}], ['The aim of this study was to investigate the effect of Rg1 on learning impairment by chronic morphine administration and the mechanism responsible for this effect .', {'entities': [(62, 70, 'B_Disease'), (71, 81, 'I_Disease')]}], [\"SAR studies led to compound 14 with excellent potency ( K ( i ) = 0 . 4 nM ) , selectivity ( A ( 1 ) / A ( 2A ) > 100 ) , and efficacy ( MED 10 mg / kg p . o . ) in the rat haloperidol - induced catalepsy model for Parkinson ' s disease .\", {'entities': [(195, 204, 'B_Disease'), (215, 224, 'B_Disease'), (225, 226, 'I_Disease'), (227, 228, 'I_Disease'), (229, 236, 'I_Disease')]}], ['Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine - induced hyperactivity in rats .', {'entities': [(92, 105, 'B_Disease')]}], ['Nicotine ( 1 . 0 mg / kg ) caused a significant increase in locomotor activity in rats that were habituated to the test environment , but had only a weak and delayed stimulant action in rats that were unfamiliar with the test environment .', {'entities': [(48, 56, 'B_Disease'), (57, 59, 'I_Disease'), (60, 69, 'I_Disease'), (70, 78, 'I_Disease')]}], ['Nicotine - induced hyperactivity was blocked by the selective D1 antagonist SCH 23390 , the selective D2 antagonist raclopride and the D1 / D2 antagonist fluphenazine .', {'entities': [(19, 32, 'B_Disease')]}], ['Pretreatment with the D2 agonist PHNO enhanced nicotine - induced hyperactivity , whereas the D1 agonist SKF 38393 had no effect .', {'entities': [(66, 79, 'B_Disease')]}], ['The results indicate that acute nicotine injection induces a pronounced hyperactivity in rats habituated to the test environment .', {'entities': [(72, 85, 'B_Disease')]}], ['Central retinal vein occlusion associated with clomiphene - induced ovulation .', {'entities': [(8, 15, 'B_Disease'), (16, 20, 'I_Disease'), (21, 30, 'I_Disease')]}], ['OBJECTIVE : To report a case of central retinal vein occlusion associated with clomiphene citrate ( CC ) .', {'entities': [(40, 47, 'B_Disease'), (48, 52, 'I_Disease'), (53, 62, 'I_Disease')]}], ['PATIENT ( S ) : A 36 - year - old woman referred from the infertility clinic for blurred vision .', {'entities': [(58, 69, 'B_Disease'), (81, 88, 'B_Disease'), (89, 95, 'I_Disease')]}], ['MAIN OUTCOME MEASURE ( S ) : Central retinal vein occlusion after ovulation induction with CC .', {'entities': [(37, 44, 'B_Disease'), (45, 49, 'I_Disease'), (50, 59, 'I_Disease')]}], ['RESULT ( S ) : A 36 - year - old Chinese woman developed central retinal vein occlusion after eight courses of CC .', {'entities': [(65, 72, 'B_Disease'), (73, 77, 'I_Disease'), (78, 87, 'I_Disease')]}], ['A search of the literature on the thromboembolic complications of CC does not include this severe ophthalmic complication , although mild visual disturbance after CC intake is not uncommon .', {'entities': [(34, 48, 'B_Disease'), (138, 144, 'B_Disease'), (145, 156, 'I_Disease')]}], ['CONCLUSION ( S ) : This is the first reported case of central retinal vein occlusion after treatment with CC .', {'entities': [(62, 69, 'B_Disease'), (70, 74, 'I_Disease'), (75, 84, 'I_Disease')]}], ['Extra caution is warranted in treating infertility patients with CC , and patients should be well informed of this side effect before commencement of therapy .', {'entities': [(39, 50, 'B_Disease')]}], ['Acute bronchodilating effects of ipratropium bromide and theophylline in chronic obstructive pulmonary disease .', {'entities': [(73, 80, 'B_Disease'), (81, 92, 'I_Disease'), (93, 102, 'I_Disease'), (103, 110, 'I_Disease')]}], ['The bronchodilator effects of a single dose of ipratropium bromide aerosol ( 36 micrograms ) and short - acting theophylline tablets ( dose titrated to produce serum levels of 10 - 20 micrograms / mL ) were compared in a double - blind , placebo - controlled crossover study in 21 patients with stable , chronic obstructive pulmonary disease .', {'entities': [(304, 311, 'B_Disease'), (312, 323, 'I_Disease'), (324, 333, 'I_Disease'), (334, 341, 'I_Disease')]}], ['While side effects were rare , those experienced after theophylline use did involve the cardiovascular and gastrointestinal systems .', {'entities': [(88, 102, 'B_Disease'), (103, 106, 'I_Disease'), (107, 123, 'I_Disease'), (124, 131, 'I_Disease')]}], ['These results show that ipratropium is a more potent bronchodilator than oral theophylline in patients with chronic airflow obstruction .', {'entities': [(108, 115, 'B_Disease'), (116, 123, 'I_Disease'), (124, 135, 'I_Disease')]}], ['Methamphetamine - induced neurotoxicity and microglial activation are not mediated by fractalkine receptor signaling .', {'entities': [(26, 39, 'B_Disease')]}], ['[ Nat . Neurosci . 9 ( 2006 ) , 917 ] recently identified the microglial - specific fractalkine receptor ( CX3CR1 ) as an important mediator of MPTP - induced neurodegeneration of DA neurons .', {'entities': [(159, 176, 'B_Disease')]}], ['Because the CNS damage caused by METH and MPTP is highly selective for the DA neuronal system in mouse models of neurotoxicity , we hypothesized that the CX3CR1 plays a role in METH - induced neurotoxicity and microglial activation .', {'entities': [(12, 15, 'B_Disease'), (16, 22, 'I_Disease'), (113, 126, 'B_Disease'), (192, 205, 'B_Disease')]}], ['Mice in which the CX3CR1 gene has been deleted and replaced with a cDNA encoding enhanced green fluorescent protein ( eGFP ) were treated with METH and examined for striatal neurotoxicity .', {'entities': [(174, 187, 'B_Disease')]}], ['We conclude from these studies that CX3CR1 signaling does not modulate METH neurotoxicity or microglial activation .', {'entities': [(76, 89, 'B_Disease')]}], ['Nicotine - induced nystagmus correlates with midpontine activation .', {'entities': [(19, 28, 'B_Disease')]}], ['The pathomechanism of nicotine - induced nystagmus ( NIN ) is unknown .', {'entities': [(41, 50, 'B_Disease'), (53, 56, 'B_Disease')]}], ['The aim of this study was to delineate brain structures that are involved in NIN generation .', {'entities': [(77, 80, 'B_Disease')]}], ['NIN correlated with blood oxygen level - dependent ( BOLD ) activity levels in a midpontine site in the posterior basis pontis .', {'entities': [(0, 3, 'B_Disease')]}], ['NIN - induced midpontine activation may correspond to activation of the dorsomedial pontine nuclei and the nucleus reticularis tegmenti pontis , structures known to participate in the generation of multidirectional saccades and smooth pursuit eye movements .', {'entities': [(0, 3, 'B_Disease')]}], ['Acute effects of N - ( 2 - propylpentanoyl ) urea on hippocampal amino acid neurotransmitters in pilocarpine - induced seizure in rats .', {'entities': [(119, 126, 'B_Disease')]}], ['VPU was more potent than VPA , exhibiting the median effective dose ( ED ( 50 ) ) of 49 mg / kg in protecting rats against pilocarpine - induced seizure whereas the corresponding value for VPA was 322 mg / kg .', {'entities': [(145, 152, 'B_Disease')]}], ['Based on the finding that VPU and VPA could protect the animals against pilocarpine - induced seizure it is suggested that the reduction of inhibitory amino acid neurotransmitters was comparatively minor and offset by a pronounced reduction of glutamate and aspartate .', {'entities': [(94, 101, 'B_Disease')]}], ['Therefore , like VPA , the finding that VPU could drastically reduce pilocarpine - induced increases in glutamate and aspartate should account , at least partly , for its anticonvulsant activity observed in pilocarpine - induced seizure in experimental animals .', {'entities': [(229, 236, 'B_Disease')]}], ['Protective effect of verapamil on gastric hemorrhagic ulcers in severe atherosclerotic rats .', {'entities': [(34, 41, 'B_Disease'), (42, 53, 'I_Disease'), (54, 60, 'B_Disease'), (71, 86, 'B_Disease')]}], ['Studies concerning with pathogenesis of gastric hemorrhage and mucosal ulceration produced in atherosclerotic rats are lacking .', {'entities': [(40, 47, 'B_Disease'), (48, 58, 'I_Disease'), (94, 109, 'B_Disease')]}], ['The aim of this study is to examine the role of gastric acid back - diffusion , mast cell histamine release , lipid peroxide ( LPO ) generation and mucosal microvascular permeability in modulating gastric hemorrhage and ulcer in rats with atherosclerosis induced by coadministration of vitamin D2 and cholesterol .', {'entities': [(197, 204, 'B_Disease'), (205, 215, 'I_Disease'), (220, 225, 'B_Disease'), (239, 254, 'B_Disease')]}], ['Additionally , the protective effect of verapamil on this ulcer model was evaluated .', {'entities': [(58, 63, 'B_Disease')]}], ['Male Wistar rats were challenged intragastrically once daily for 9 days with 1 . 0 ml / kg of corn oil containing vitamin D2 and cholesterol to induce atherosclerosis .', {'entities': [(151, 166, 'B_Disease')]}], ['Gastric acid back - diffusion , mucosal LPO generation , histamine concentration , microvascular permeability , luminal hemoglobin content and ulcer areas were determined .', {'entities': [(143, 148, 'B_Disease')]}], ['Elevated atherosclerotic parameters , such as serum calcium , total cholesterol and low - density lipoprotein concentration were obtained in atherosclerotic rats .', {'entities': [(9, 24, 'B_Disease'), (141, 156, 'B_Disease')]}], ['Severe gastric ulcers accompanied with increased ulcerogenic factors , including gastric acid back - diffusion , histamine release , LPO generation and luminal hemoglobin content were also observed in these rats .', {'entities': [(15, 21, 'B_Disease')]}], ['Moreover , a positive correlation of histamine to gastric hemorrhage and to ulcer was found in those atherosclerotic rats .', {'entities': [(50, 57, 'B_Disease'), (58, 68, 'I_Disease'), (76, 81, 'B_Disease'), (101, 116, 'B_Disease')]}], ['This hemorrhagic ulcer and various ulcerogenic parameters were dose - dependently ameliorated by daily intragastric verapamil .', {'entities': [(5, 16, 'B_Disease'), (17, 22, 'B_Disease')]}], ['Atherosclerosis could produce gastric hemorrhagic ulcer via aggravation of gastric acid back - diffusion , LPO generation , histamine release and microvascular permeability that could be ameliorated by verapamil in rats .', {'entities': [(0, 15, 'B_Disease'), (30, 37, 'B_Disease'), (38, 49, 'I_Disease'), (50, 55, 'B_Disease')]}], ['Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis - B surface antigen ( HBSAG ) seropositive cancer patients undergoing cytotoxic chemotherapy .', {'entities': [(33, 42, 'B_Disease'), (43, 44, 'I_Disease'), (120, 126, 'B_Disease')]}], ['Hepatitis B virus ( HBV ) is one of the major causes of chronic liver disease worldwide .', {'entities': [(0, 9, 'B_Disease'), (10, 11, 'I_Disease'), (64, 69, 'B_Disease'), (70, 77, 'I_Disease')]}], ['Cancer patients who are chronic carriers of HBV have a higher hepatic complication rate while receiving cytotoxic chemotherapy ( CT ) and this has mainly been attributed to HBV reactivation .', {'entities': [(0, 6, 'B_Disease'), (62, 69, 'B_Disease'), (70, 82, 'I_Disease')]}], ['In this study , cancer patients who have solid and hematological malignancies with chronic HBV infection received the antiviral agent lamivudine prior and during CT compared with historical control group who did not receive lamivudine .', {'entities': [(16, 22, 'B_Disease'), (51, 64, 'B_Disease'), (65, 77, 'I_Disease'), (91, 94, 'B_Disease'), (95, 104, 'I_Disease')]}], ['Of our control group ( n = 50 ) , 21 patients ( 42 % ) were established hepatitis .', {'entities': [(72, 81, 'B_Disease')]}], ['Twelve ( 24 % ) of them were evaluated as severe hepatitis .', {'entities': [(49, 58, 'B_Disease')]}], ['In the prophylactic lamivudine group severe hepatitis were observed only in 1 patient ( 2 . 7 % ) of 37 patients ( p < 0 . 006 ) .', {'entities': [(44, 53, 'B_Disease')]}], ['Our study suggests that prophylactic lamivudine significantly decreases the incidence of HBV reactivation and overall morbidity in cancer patients during and after immunosuppressive therapy .', {'entities': [(131, 137, 'B_Disease')]}], ['Recovery of tacrolimus - associated brachial neuritis after conversion to everolimus in a pediatric renal transplant recipient - - case report and review of the literature .', {'entities': [(36, 44, 'B_Disease'), (45, 53, 'I_Disease')]}], ['Neurotoxicity is a potentially serious toxic effect .', {'entities': [(0, 13, 'B_Disease')]}], ['It is characterized by encephalopathy , headaches , seizures , or neurological deficits .', {'entities': [(23, 37, 'B_Disease'), (40, 49, 'B_Disease'), (52, 60, 'B_Disease'), (66, 78, 'B_Disease'), (79, 87, 'I_Disease')]}], ['MRI demonstrated hyperintense T2 signals in the cervical cord and right brachial plexus roots indicative of both myelitis and right brachial plexitis .', {'entities': [(113, 121, 'B_Disease'), (132, 140, 'B_Disease'), (141, 149, 'I_Disease')]}], ['Omitting fentanyl reduces nausea and vomiting , without increasing pain , after sevoflurane for day surgery .', {'entities': [(26, 32, 'B_Disease'), (37, 45, 'B_Disease'), (67, 71, 'B_Disease')]}], ['BACKGROUND AND OBJECTIVE : Despite advantages of induction and maintenance of anaesthesia with sevoflurane , postoperative nausea and vomiting occurs frequently .', {'entities': [(109, 122, 'B_Disease'), (123, 129, 'I_Disease'), (130, 133, 'I_Disease'), (134, 142, 'I_Disease')]}], ['METHODS : This double - blind study examined the incidence and severity of postoperative nausea and vomiting and pain in the first 24 h after sevoflurane anaesthesia in 216 adult day surgery patients .', {'entities': [(75, 88, 'B_Disease'), (89, 95, 'I_Disease'), (96, 99, 'I_Disease'), (100, 108, 'I_Disease'), (113, 117, 'B_Disease')]}], ['RESULTS : Omission of fentanyl did not reduce the overall incidence of postoperative nausea and vomiting , but did reduce the incidence of vomiting and / or moderate to severe nausea prior to discharge from 20 % and 17 % with fentanyl and fentanyl - dexamethasone , respectively , to 5 % ( P = 0 . 013 ) .', {'entities': [(71, 84, 'B_Disease'), (85, 91, 'I_Disease'), (92, 95, 'I_Disease'), (96, 104, 'I_Disease'), (139, 147, 'B_Disease'), (176, 182, 'B_Disease')]}], ['Dexamethasone had no significant effect on the incidence or severity of postoperative nausea and vomiting .', {'entities': [(72, 85, 'B_Disease'), (86, 92, 'I_Disease'), (93, 96, 'I_Disease'), (97, 105, 'I_Disease')]}], ['Combining the two fentanyl groups revealed further significant benefits from the avoidance of opioids , reducing postoperative nausea and vomiting and nausea prior to discharge from 35 % and 33 % to 22 % and 19 % ( P = 0 . 049 and P = 0 . 035 ) , respectively , while nausea in the first 24 h was decreased from 42 % to 27 % ( P = 0 . 034 ) .', {'entities': [(113, 126, 'B_Disease'), (127, 133, 'I_Disease'), (134, 137, 'I_Disease'), (138, 146, 'I_Disease'), (151, 157, 'B_Disease'), (268, 274, 'B_Disease')]}], ['Pain severity and analgesic requirements were unaffected by the omission of fentanyl .', {'entities': [(0, 4, 'B_Disease')]}], ['Fentanyl did reduce minor intraoperative movement but had no sevoflurane - sparing effect and increased respiratory depression , hypotension and bradycardia .', {'entities': [(104, 115, 'B_Disease'), (116, 126, 'I_Disease'), (129, 140, 'B_Disease'), (145, 156, 'B_Disease')]}], ['CONCLUSION : As fentanyl exacerbated postoperative nausea and vomiting without an improvement in postoperative pain and also had adverse cardiorespiratory effects , it appears to be an unnecessary and possibly detrimental supplement to sevoflurane in day surgery .', {'entities': [(37, 50, 'B_Disease'), (51, 57, 'I_Disease'), (58, 61, 'I_Disease'), (62, 70, 'I_Disease'), (97, 110, 'B_Disease'), (111, 115, 'I_Disease')]}], [\"Valvular heart disease in patients with Parkinson ' s disease treated with pergolide .\", {'entities': [(0, 8, 'B_Disease'), (9, 14, 'I_Disease'), (15, 22, 'I_Disease'), (40, 49, 'B_Disease'), (50, 51, 'I_Disease'), (52, 53, 'I_Disease'), (54, 61, 'I_Disease')]}], [\"Valvular heart abnormalities have been reported in patients with Parkinson ' s disease ( PD ) treated with pergolide .\", {'entities': [(0, 8, 'B_Disease'), (9, 14, 'I_Disease'), (15, 28, 'I_Disease'), (65, 74, 'B_Disease'), (75, 76, 'I_Disease'), (77, 78, 'I_Disease'), (79, 86, 'I_Disease'), (89, 91, 'B_Disease')]}], ['OBJECTIVES : To estimate the frequency and severity of valvular heart abnormality and its possible reversibility after drug withdrawal in a case - control study .', {'entities': [(55, 63, 'B_Disease'), (64, 69, 'I_Disease'), (70, 81, 'I_Disease')]}], ['METHODS : All PD patients in the Amiens area treated with pergolide were invited to attend a cardiologic assessment including transthoracic echocardiography .', {'entities': [(14, 16, 'B_Disease')]}], ['Thirty PD patients participated in the study .', {'entities': [(7, 9, 'B_Disease')]}], ['Controls were age - and sex - matched non - PD patients referred to the cardiology department .', {'entities': [(44, 46, 'B_Disease')]}], ['RESULTS : Compared to controls , aortic regurgitation ( OR : 3 . 1 ; 95 % IC : 1 . 1 - 8 . 8 ) and mitral regurgitation ( OR : 10 . 7 ; 95 % IC : 2 . 1 - 53 ) were more frequent in PD patients ( tricuspid : NS ) .', {'entities': [(33, 39, 'B_Disease'), (40, 53, 'I_Disease'), (99, 105, 'B_Disease'), (106, 119, 'I_Disease'), (181, 183, 'B_Disease')]}], ['A restrictive pattern of valvular regurgitation , suggestive of the role of pergolide , was observed in 12 / 30 ( 40 % ) patients including two with heart failure .', {'entities': [(25, 33, 'B_Disease'), (34, 47, 'I_Disease'), (149, 154, 'B_Disease'), (155, 162, 'I_Disease')]}], ['Pergolide was discontinued in 10 patients with valvular heart disease , resulting in a lower regurgitation grade ( p = 0 . 01 ) at the second transthoracic echocardiography and the two patients with heart failure returned to nearly normal clinical examination .', {'entities': [(47, 55, 'B_Disease'), (56, 61, 'I_Disease'), (62, 69, 'I_Disease'), (199, 204, 'B_Disease'), (205, 212, 'I_Disease')]}], ['This study supports the high frequency of restrictive valve regurgitation in PD patients treated with pergolide and reveals that a significant improvement is usual when the treatment is converted to non - ergot dopamine agonists .', {'entities': [(54, 59, 'B_Disease'), (60, 73, 'I_Disease'), (77, 79, 'B_Disease')]}], ['Adriamycin - induced autophagic cardiomyocyte death plays a pathogenic role in a rat model of heart failure .', {'entities': [(46, 51, 'B_Disease'), (94, 99, 'B_Disease'), (100, 107, 'I_Disease')]}], ['BACKGROUND : The mechanisms underlying heart failure induced by adriamycin are very complicated and still unclear .', {'entities': [(39, 44, 'B_Disease'), (45, 52, 'I_Disease')]}], ['The aim of this study was to investigate whether autophagy was involved in the progression of heart failure induced by adriamycin , so that we can develop a novel treatment strategy for heart failure .', {'entities': [(94, 99, 'B_Disease'), (100, 107, 'I_Disease'), (186, 191, 'B_Disease'), (192, 199, 'I_Disease')]}], ['METHODS : 3 - methyladenine ( 3MA ) , a specific inhibitor on autophagy was used in a heart failure model of rats induced by adriamycin .', {'entities': [(86, 91, 'B_Disease'), (92, 99, 'I_Disease')]}], ['CONCLUSION : Autophagic cardiomyocyte death plays an important role in the pathogenesis of heart failure in rats induced by adriamycin .', {'entities': [(38, 43, 'B_Disease'), (91, 96, 'B_Disease'), (97, 104, 'I_Disease')]}], ['Mitochondrial injury may be involved in the progression of heart failure caused by adriamycin via the autophagy pathway .', {'entities': [(59, 64, 'B_Disease'), (65, 72, 'I_Disease')]}], ['mToR inhibitors - induced proteinuria : mechanisms , significance , and management .', {'entities': [(26, 37, 'B_Disease')]}], ['Massive urinary protein excretion has been observed after conversion from calcineurin inhibitors to mammalian target of rapamycin ( mToR ) inhibitors , especially sirolimus , in renal transplant recipients with chronic allograft nephropathy .', {'entities': [(211, 218, 'B_Disease'), (219, 228, 'I_Disease'), (229, 240, 'I_Disease')]}], ['Because proteinuria is a major predictive factor of poor transplantation outcome , many studies focused on this adverse event during the past years .', {'entities': [(8, 19, 'B_Disease')]}], ['Whether proteinuria was due to sirolimus or only a consequence of calcineurin inhibitors withdrawal remained unsolved until high range proteinuria has been observed during sirolimus therapy in islet transplantation and in patients who received sirolimus de novo .', {'entities': [(8, 19, 'B_Disease'), (135, 146, 'B_Disease')]}], ['Podocyte injury and focal segmental glomerulosclerosis have been related to mToR inhibition in some patients , but the pathways underlying these lesions remain hypothetic .', {'entities': [(36, 54, 'B_Disease')]}], ['We discuss herein the possible mechanisms and the significance of mToR blockade - induced proteinuria .', {'entities': [(90, 101, 'B_Disease')]}], ['Reactions consisted mainly of seizures , acute psychoses , anxiety neurosis , and major disturbances of sleep - wake rhythm .', {'entities': [(30, 38, 'B_Disease'), (47, 56, 'B_Disease'), (59, 66, 'B_Disease'), (67, 75, 'I_Disease'), (88, 100, 'B_Disease'), (101, 103, 'I_Disease'), (104, 109, 'I_Disease'), (110, 111, 'I_Disease'), (112, 116, 'I_Disease'), (117, 123, 'I_Disease')]}], ['Therefore , certain limitations for malaria prophylaxis and treatment with mefloquine are recommended .', {'entities': [(36, 43, 'B_Disease')]}], ['Epidemiological evidence indicates that prenatal nutritional deprivation may increase the risk of schizophrenia .', {'entities': [(98, 111, 'B_Disease')]}], ['The goal of these studies was to use an animal model to examine the effects of prenatal protein deprivation on behaviors and receptor binding with relevance to schizophrenia .', {'entities': [(160, 173, 'B_Disease')]}], ['No changes in haloperidol - induced catalepsy or MK - 801 - induced locomotion were seen following PD .', {'entities': [(36, 45, 'B_Disease')]}], ['This animal model may be useful to explore the mechanisms by which prenatal nutritional deficiency enhances risk for schizophrenia in humans and may also have implications for developmental processes leading to differential sensitivity to drugs of abuse .', {'entities': [(76, 87, 'B_Disease'), (88, 98, 'I_Disease'), (117, 130, 'B_Disease')]}], ['BACKGROUND : Papaverine hydrochloride is a direct - acting vasodilator used to manage vasospasm during various neurosurgical operations .', {'entities': [(86, 95, 'B_Disease')]}], ['Transient cranial nerve dysfunction has been described in a few cases with topical papaverine .', {'entities': [(10, 17, 'B_Disease'), (18, 23, 'I_Disease'), (24, 35, 'I_Disease')]}], ['METHODS : We conducted a retrospective review of 70 consecutive microvascular decompression operations and studied those patients who received topical papaverine for vasospasm .', {'entities': [(166, 175, 'B_Disease')]}], ['Topical papaverine was used as a direct therapeutic action to manage vasospasm in a total of 11 patients .', {'entities': [(69, 78, 'B_Disease')]}], ['One patient showed no recovery of later waves and a delayed profound sensorineural hearing loss .', {'entities': [(69, 82, 'B_Disease'), (83, 90, 'I_Disease'), (91, 95, 'I_Disease')]}], ['CONCLUSIONS : Topical papaverine for the treatment of vasospasm was associated with the onset of a transient disturbance in neurophysiological function of the ascending auditory brainstem pathway .', {'entities': [(54, 63, 'B_Disease')]}], ['The complete disappearance of BAEP waveforms with a consistent temporal delay suggests a possible adverse effect on the proximal eighth nerve .', {'entities': [(98, 105, 'B_Disease'), (106, 112, 'I_Disease'), (113, 115, 'I_Disease'), (116, 119, 'I_Disease'), (120, 128, 'I_Disease'), (129, 135, 'I_Disease'), (136, 141, 'I_Disease')]}], ['Recommendations to avoid potential cranial nerve deficits from papaverine are provided .', {'entities': [(35, 42, 'B_Disease'), (43, 48, 'I_Disease'), (49, 57, 'I_Disease')]}], ['Simvastatin - ezetimibe - induced hepatic failure necessitating liver transplantation .', {'entities': [(34, 41, 'B_Disease'), (42, 49, 'I_Disease')]}], ['However , hepatotoxic events have not been widely published with ezetimibe or the combination agent simvastatin - ezetimibe .', {'entities': [(10, 21, 'B_Disease')]}], ['We describe a 70 - year - old Hispanic woman who developed fulminant hepatic failure necessitating liver transplantation 10 weeks after conversion from simvastatin 40 mg / day to simvastatin 10 mg - ezetimibe 40 mg / day .', {'entities': [(59, 68, 'B_Disease'), (69, 76, 'I_Disease'), (77, 84, 'I_Disease')]}], [\"The patient ' s lipid panel had been maintained with simvastatin for 18 months before the conversion without evidence of hepatotoxicity .\", {'entities': [(121, 135, 'B_Disease')]}], ['Simvastatinezetimibe and escitalopram ( which she was taking for depression ) were discontinued , and other potential causes of hepatotoxicity were excluded .', {'entities': [(65, 75, 'B_Disease'), (128, 142, 'B_Disease')]}], ['A repeat work - up revealed further elevations in aminotransferase levels , and liver biopsy revealed evidence of moderate - to - severe drug toxicity .', {'entities': [(137, 141, 'B_Disease'), (142, 150, 'I_Disease')]}], ['Ezetimibe undergoes extensive glucuronidation by uridine diphosphate glucoronosyltransferases ( UGT ) in the intestine and liver and may have inhibited the glucuronidation of simvastatin hydroxy acid , resulting in increased simvastatin exposure and subsequent hepatotoxicity .', {'entities': [(261, 275, 'B_Disease')]}], ['To our knowledge , this is the first case report of simvastatin - ezetimibe - induced liver failure that resulted in liver transplantation .', {'entities': [(86, 91, 'B_Disease'), (92, 99, 'I_Disease')]}], ['We postulate that the mechanism of the simvastatinezetimibe - induced hepatotoxicity is the increased simvastatin exposure by ezetimibe inhibition of UGT enzymes .', {'entities': [(70, 84, 'B_Disease')]}], ['Clinicians should be aware of potential hepatotoxicity with simvastatin - ezetimibe especially in elderly patients and should carefully monitor serum aminotransferase levels when starting therapy and titrating the dosage .', {'entities': [(40, 54, 'B_Disease')]}], ['Massive proteinuria and acute renal failure after oral bisphosphonate ( alendronate ) administration in a patient with focal segmental glomerulosclerosis .', {'entities': [(8, 19, 'B_Disease'), (24, 29, 'B_Disease'), (30, 35, 'I_Disease'), (36, 43, 'I_Disease'), (119, 124, 'B_Disease'), (125, 134, 'I_Disease'), (135, 153, 'I_Disease')]}], ['A 61 - year - old Japanese man with nephrotic syndrome due to focal segmental glomerulosclerosis was initially responding well to steroid therapy .', {'entities': [(36, 45, 'B_Disease'), (46, 54, 'I_Disease'), (62, 67, 'B_Disease'), (68, 77, 'I_Disease'), (78, 96, 'I_Disease')]}], ['Within 14 days of the oral bisphosphonate ( alendronate sodium ) administration , the amount of daily urinary protein increased rapidly up to 12 . 8 g with acute renal failure .', {'entities': [(156, 161, 'B_Disease'), (162, 167, 'I_Disease'), (168, 175, 'I_Disease')]}], ['This report demonstrates that not only intravenous , but also oral bisphosphonates can aggravate proteinuria and acute renal failure .', {'entities': [(97, 108, 'B_Disease'), (113, 118, 'B_Disease'), (119, 124, 'I_Disease'), (125, 132, 'I_Disease')]}], ['Serum - and glucocorticoid - inducible kinase 1 in doxorubicin - induced nephrotic syndrome .', {'entities': [(73, 82, 'B_Disease'), (83, 91, 'I_Disease')]}], ['Doxorubicin - induced nephropathy leads to epithelial sodium channel ( ENaC ) - dependent volume retention and renal fibrosis .', {'entities': [(22, 33, 'B_Disease'), (90, 96, 'B_Disease'), (97, 106, 'I_Disease'), (117, 125, 'B_Disease')]}], ['The aldosterone - sensitive serum - and glucocorticoid - inducible kinase SGK1 has been shown to participate in the stimulation of ENaC and to mediate renal fibrosis following mineralocorticoid and salt excess .', {'entities': [(157, 165, 'B_Disease')]}], ['The present study was performed to elucidate the role of SGK1 in the volume retention and fibrosis during nephrotic syndrome .', {'entities': [(69, 75, 'B_Disease'), (76, 85, 'I_Disease'), (90, 98, 'B_Disease'), (106, 115, 'B_Disease'), (116, 124, 'I_Disease')]}], ['Doxorubicin treatment resulted in heavy proteinuria ( > 100 mg protein / mg crea ) in 15 / 44 of sgk1 ( + / + ) and 15 / 44 of sgk1 ( - / - ) mice leading to severe nephrotic syndrome with ascites , lipidemia , and hypoalbuminemia in both genotypes .', {'entities': [(40, 51, 'B_Disease'), (165, 174, 'B_Disease'), (175, 183, 'I_Disease'), (189, 196, 'B_Disease'), (199, 208, 'B_Disease'), (215, 230, 'B_Disease')]}], ['Plasma aldosterone levels increased in nephrotic mice of both genotypes and was followed by increased SGK1 protein expression in sgk1 ( + / + ) mice .', {'entities': [(39, 48, 'B_Disease')]}], ['Urinary sodium excretion reached signficantly lower values in sgk1 ( + / + ) mice ( 15 + / - 5 mumol / mg crea ) than in sgk1 ( - / - ) mice ( 35 + / - 5 mumol / mg crea ) and was associated with a significantly higher body weight gain in sgk1 ( + / + ) compared with sgk1 ( - / - ) mice ( + 6 . 6 + / - 0 . 7 vs . + 4 . 1 + / - 0 . 8 g ) .', {'entities': [(224, 230, 'B_Disease'), (231, 235, 'I_Disease')]}], ['During the course of nephrotic syndrome , serum urea concentrations increased significantly faster in sgk1 ( - / - ) mice than in sgk1 ( + / + ) mice leading to uremia and a reduced median survival in sgk1 ( - / - ) mice ( 29 vs . 40 days in sgk1 ( + / + ) mice ) .', {'entities': [(21, 30, 'B_Disease'), (31, 39, 'I_Disease'), (161, 167, 'B_Disease')]}], ['In conclusion , gene - targeted mice lacking SGK1 showed blunted volume retention , yet were not protected against renal fibrosis during experimental nephrotic syndrome .', {'entities': [(65, 71, 'B_Disease'), (72, 81, 'I_Disease'), (121, 129, 'B_Disease'), (150, 159, 'B_Disease'), (160, 168, 'I_Disease')]}], ['Severe thrombocytopenia and haemolytic anaemia associated with ciprofloxacin : a case report with fatal outcome .', {'entities': [(7, 23, 'B_Disease'), (28, 38, 'B_Disease'), (39, 46, 'I_Disease')]}], ['A 30 - year old Caucasian man reported with abdominal pain and jaundice after 3 - day administration of oral ciprofloxacin for a suspect of urinary tract infection .', {'entities': [(44, 53, 'B_Disease'), (54, 58, 'I_Disease'), (63, 71, 'B_Disease'), (140, 147, 'B_Disease'), (148, 153, 'I_Disease'), (154, 163, 'I_Disease')]}], ['Clinical evaluations suggested an initial diagnosis of severe thrombocytopenia and haemolysis .', {'entities': [(62, 78, 'B_Disease'), (83, 93, 'B_Disease')]}], ['The patient progressively developed petechiae and purpura on thorax and lower limbs .', {'entities': [(36, 45, 'B_Disease'), (50, 57, 'B_Disease')]}], ['An accurate autopsy revealed most organs with diffuse petechial haemorrhages .', {'entities': [(64, 76, 'B_Disease')]}], ['No signs of bone marrow depression were found .', {'entities': [(12, 16, 'B_Disease'), (17, 23, 'I_Disease'), (24, 34, 'I_Disease')]}], ['No thrombi or signs of microangiopathies were observed in arterial vessels .', {'entities': [(3, 10, 'B_Disease'), (23, 40, 'B_Disease')]}], ['This case report shows that ciprofloxacin may precipitate life - threatening thrombocytopenia and haemolytic anaemia , even in the early phases of treatment and without apparent previous exposures .', {'entities': [(77, 93, 'B_Disease'), (98, 108, 'B_Disease'), (109, 116, 'I_Disease')]}], ['Alpha - lipoic acid prevents mitochondrial damage and neurotoxicity in experimental chemotherapy neuropathy .', {'entities': [(29, 42, 'B_Disease'), (43, 49, 'I_Disease'), (54, 67, 'B_Disease'), (97, 107, 'B_Disease')]}], ['The study investigates if alpha - lipoic acid is neuroprotective against chemotherapy induced neurotoxicity , if mitochondrial damage plays a critical role in toxic neurodegenerative cascade , and if neuroprotective effects of alpha - lipoic acid depend on mitochondria protection .', {'entities': [(94, 107, 'B_Disease'), (113, 126, 'B_Disease'), (127, 133, 'I_Disease'), (159, 164, 'B_Disease'), (165, 182, 'I_Disease'), (183, 190, 'I_Disease')]}], ['We used an in vitro model of chemotherapy induced peripheral neuropathy that closely mimic the in vivo condition by exposing primary cultures of dorsal root ganglion ( DRG ) sensory neurons to paclitaxel and cisplatin , two widely used and highly effective chemotherapeutic drugs .', {'entities': [(50, 60, 'B_Disease'), (61, 71, 'I_Disease')]}], ['This approach allowed investigating the efficacy of alpha - lipoic acid in preventing axonal damage and apoptosis and the function and ultrastructural morphology of mitochondria after exposure to toxic agents and alpha - lipoic acid .', {'entities': [(86, 92, 'B_Disease'), (93, 99, 'I_Disease')]}], ['Our results demonstrate that both cisplatin and paclitaxel cause early mitochondrial impairment with loss of membrane potential and induction of autophagic vacuoles in neurons .', {'entities': [(71, 84, 'B_Disease'), (85, 95, 'I_Disease')]}], ['Alpha - lipoic acid exerts neuroprotective effects against chemotherapy induced neurotoxicity in sensory neurons : it rescues the mitochondrial toxicity and induces the expression of frataxin , an essential mitochondrial protein with anti - oxidant and chaperone properties .', {'entities': [(80, 93, 'B_Disease'), (130, 143, 'B_Disease'), (144, 152, 'I_Disease')]}], ['In conclusion mitochondrial toxicity is an early common event both in paclitaxel and cisplatin induced neurotoxicity .', {'entities': [(14, 27, 'B_Disease'), (28, 36, 'I_Disease'), (103, 116, 'B_Disease')]}], ['These findings suggest that alpha - lipoic acid might reduce the risk of developing peripheral nerve toxicity in patients undergoing chemotherapy and encourage further confirmatory clinical trials .', {'entities': [(84, 94, 'B_Disease'), (95, 100, 'I_Disease'), (101, 109, 'I_Disease')]}], ['Toxicity in rhesus monkeys following administration of the 8 - aminoquinoline 8 - [ ( 4 - amino - l - methylbutyl ) amino ] - 5 - ( l - hexyloxy ) - 6 - methoxy - 4 - methylquinoline ( WR242511 ) .', {'entities': [(0, 8, 'B_Disease')]}], ['INTRODUCTION : Many substances that form methemoglobin ( MHb ) effectively counter cyanide ( CN ) toxicity .', {'entities': [(98, 106, 'B_Disease')]}], ['Although MHb formers are generally applied as treatments for CN poisoning , it has been proposed that a stable , long - acting MHb former could serve as a CN pretreatment .', {'entities': [(64, 73, 'B_Disease')]}], ['RESULTS : The selected doses of WR242511 , which produced significant methemoglobinemia in beagle dogs in earlier studies conducted elsewhere , produced very little MHb ( mean < 2 . 0 % ) in the rhesus monkey .', {'entities': [(70, 87, 'B_Disease')]}], ['Furthermore , transient hemoglobinuria was noted approximately 60 minutes postinjection of WR242511 ( 3 . 5 or 7 . 0 mg / kg ) , and 2 lethalities occurred ( one IV and one PO ) following the 7 . 0 mg / kg dose .', {'entities': [(24, 38, 'B_Disease')]}], ['Myoglobinuria was also observed following the 7 . 0 mg / kg dose .', {'entities': [(0, 13, 'B_Disease')]}], ['Histopathology analyses in the 2 animals that died revealed liver and kidney toxicity , with greater severity in the orally - treated animal .', {'entities': [(60, 65, 'B_Disease'), (66, 69, 'I_Disease'), (70, 76, 'I_Disease'), (77, 85, 'I_Disease')]}], ['CONCLUSIONS : These data demonstrate direct and / or indirect drug - induced toxicity .', {'entities': [(77, 85, 'B_Disease')]}], ['It is concluded that WR242511 should not be pursued as a pretreatment for CN poisoning unless the anti - CN characteristics of this compound can be successfully dissociated from those producing undesirable toxicity .', {'entities': [(77, 86, 'B_Disease'), (206, 214, 'B_Disease')]}], [\"Repetitive transcranial magnetic stimulation for levodopa - induced dyskinesias in Parkinson ' s disease .\", {'entities': [(68, 79, 'B_Disease'), (83, 92, 'B_Disease'), (93, 94, 'I_Disease'), (95, 96, 'I_Disease'), (97, 104, 'I_Disease')]}], ['In a placebo - controlled , single - blinded , crossover study , we assessed the effect of \" real \" repetitive transcranial magnetic stimulation ( rTMS ) versus \" sham \" rTMS ( placebo ) on peak dose dyskinesias in patients with Parkinson \\' s disease ( PD ) .', {'entities': [(200, 211, 'B_Disease'), (229, 238, 'B_Disease'), (239, 240, 'I_Disease'), (241, 242, 'I_Disease'), (243, 250, 'I_Disease'), (253, 255, 'B_Disease')]}], ['Ten patients with PD and prominent dyskinesias had rTMS ( 1 , 800 pulses ; 1 Hz rate ) delivered over the motor cortex for 4 consecutive days twice , once real stimuli and once sham stimulation were used ; evaluations were done at the baseline and 1 day after the end of each of the treatment series .', {'entities': [(18, 20, 'B_Disease'), (35, 46, 'B_Disease')]}], ['Direct comparison between sham and real rTMS effects showed no significant difference in clinician - assessed dyskinesia severity .', {'entities': [(110, 120, 'B_Disease')]}], ['However , comparison with the baseline showed small but significant reduction in dyskinesia severity following real rTMS but not placebo .', {'entities': [(81, 91, 'B_Disease')]}], ['The major effect was on dystonia subscore .', {'entities': [(24, 32, 'B_Disease')]}], ['Similarly , in patient diaries , although both treatments caused reduction in subjective dyskinesia scores during the days of intervention , the effect was sustained for 3 days after the intervention for the real rTMS only .', {'entities': [(89, 99, 'B_Disease')]}], ['Following rTMS , no side effects and no adverse effects on motor function and PD symptoms were noted .', {'entities': [(78, 80, 'B_Disease')]}], ['The results suggest the existence of residual beneficial clinical aftereffects of consecutive daily applications of low - frequency rTMS on dyskinesias in PD .', {'entities': [(140, 151, 'B_Disease'), (155, 157, 'B_Disease')]}], ['Intracavernous epinephrine : a minimally invasive treatment for priapism in the emergency department .', {'entities': [(64, 72, 'B_Disease')]}], ['Priapism is the prolonged erection of the penis in the absence of sexual arousal .', {'entities': [(0, 8, 'B_Disease')]}], ['A 45 - year - old man , an admitted frequent cocaine user , presented to the Emergency Department ( ED ) on two separate occasions with a history of priapism after cocaine use .', {'entities': [(149, 157, 'B_Disease')]}], ['Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders .', {'entities': [(74, 87, 'B_Disease'), (88, 97, 'I_Disease')]}], ['The objective of this study was to report our experience concerning the effectiveness of the prophylactic administration of lamivudine in hepatitis B virus surface antigen ( HBs Ag ) positive patients with rheumatologic disease .', {'entities': [(206, 219, 'B_Disease'), (220, 227, 'I_Disease')]}], ['From June 2004 to October 2006 , 11 HBs Ag positive patients with rheumatologic diseases , who were on both immunosuppressive and prophylactic lamivudine therapies , were retrospectively assessed .', {'entities': [(66, 79, 'B_Disease'), (80, 88, 'I_Disease')]}], ['Liver function tests , hepatitis B virus ( HBV ) serologic markers , and HBV DNA levels of the patients during follow - up were obtained from hospital file records .', {'entities': [(23, 32, 'B_Disease'), (33, 34, 'I_Disease')]}], ['Shortly after treatment their tests normalized and during follow - up period none of the patients had abnormal liver function tests .', {'entities': [(102, 110, 'B_Disease'), (111, 116, 'I_Disease'), (117, 125, 'I_Disease')]}], ['Effect of green tea and vitamin E combination in isoproterenol induced myocardial infarction in rats .', {'entities': [(71, 81, 'B_Disease'), (82, 92, 'I_Disease')]}], ['The present study was aimed to investigate the combined effects of green tea and vitamin E on heart weight , body weight , serum marker enzymes , lipid peroxidation , endogenous antioxidants and membrane bound ATPases in isoproterenol ( ISO ) - induced myocardial infarction in rats .', {'entities': [(253, 263, 'B_Disease'), (264, 274, 'I_Disease')]}], ['These findings indicate the synergistic protective effect of green tea and vitamin E during ISO induced myocardial infarction in rats .', {'entities': [(104, 114, 'B_Disease'), (115, 125, 'I_Disease')]}], ['Irreversible damage to the medullary interstitium in experimental analgesic nephropathy in F344 rats .', {'entities': [(76, 87, 'B_Disease')]}], ['Renal papillary necrosis ( RPN ) and a decreased urinary concentrating ability developed during continuous long - term treatment with aspirin and paracetamol in female Fischer 344 rats .', {'entities': [(0, 5, 'B_Disease'), (6, 15, 'I_Disease'), (16, 24, 'I_Disease'), (27, 30, 'B_Disease')]}], ['This study shows that prolonged analgesic treatment in Fischer 344 rats causes progressive and irreversible damage to the interstitial matrix and type 1 interstitial cells leading to RPN .', {'entities': [(183, 186, 'B_Disease')]}], ['Testosterone - dependent hypertension and upregulation of intrarenal angiotensinogen in Dahl salt - sensitive rats .', {'entities': [(25, 37, 'B_Disease')]}], ['In this study , the hypothesis was tested that there is a sexual dimorphism in HS - induced upregulation of intrarenal angiotensinogen mediated by testosterone that also causes increases in BP and renal injury .', {'entities': [(197, 202, 'B_Disease'), (203, 209, 'I_Disease')]}], ['HS diet for 4 wk caused a progressive increase in BP , protein and albumin excretion , and glomerular sclerosis in male DS rats , which were attenuated by castration .', {'entities': [(91, 101, 'B_Disease'), (102, 111, 'I_Disease')]}], ['Testosterone replacement in castrated DS rats increased BP , renal injury , and upregulation of renal angiotensinogen associated with HS diet .', {'entities': [(61, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['Testosterone contributes to the development of hypertension and renal injury in male DS rats on HS diet possibly through upregulation of the intrarenal renin - angiotensin system .', {'entities': [(47, 59, 'B_Disease'), (64, 69, 'B_Disease'), (70, 76, 'I_Disease')]}], ['Explicit episodic memory for sensory - discriminative components of capsaicin - induced pain : immediate and delayed ratings .', {'entities': [(88, 92, 'B_Disease')]}], ['Pain memory is thought to affect future pain sensitivity and thus contribute to clinical pain conditions .', {'entities': [(0, 4, 'B_Disease'), (40, 44, 'B_Disease'), (89, 93, 'B_Disease')]}], ['Systematic investigations of the human capacity to remember sensory features of experimental pain are sparse .', {'entities': [(93, 97, 'B_Disease')]}], ['In order to address long - term pain memory , nine healthy male volunteers received intradermal injections of three doses of capsaicin ( 0 . 05 , 1 and 20 microg , separated by 15 min breaks ) , each given three times in a balanced design across three sessions at one week intervals .', {'entities': [(32, 36, 'B_Disease')]}], ['Pain rating was performed using a computerized visual analogue scale ( 0 - 100 ) digitized at 1 / s , either immediately online or one hour or one day after injection .', {'entities': [(0, 4, 'B_Disease')]}], ['Subjects also recalled their pains one week later .', {'entities': [(29, 34, 'B_Disease')]}], ['The strong burning pain decayed exponentially within a few minutes .', {'entities': [(19, 23, 'B_Disease')]}], ['Subjects were able to reliably discriminate pain magnitude and duration across capsaicin doses ( both p < 0 . 001 ) , regardless of whether first - time ratings were requested immediately , after one hour or after one day .', {'entities': [(44, 48, 'B_Disease')]}], ['Pain recall after one week was similarly precise ( magnitude : p < 0 . 01 , duration : p < 0 . 05 ) .', {'entities': [(0, 4, 'B_Disease')]}], ['These results indicate a reliable memory for magnitude and duration of experimentally induced pain .', {'entities': [(94, 98, 'B_Disease')]}], ['Severe and long lasting cholestasis after high - dose co - trimoxazole treatment for Pneumocystis pneumonia in HIV - infected patients - - a report of two cases .', {'entities': [(24, 35, 'B_Disease'), (85, 97, 'B_Disease'), (98, 107, 'I_Disease'), (111, 114, 'B_Disease'), (115, 116, 'I_Disease'), (117, 125, 'I_Disease')]}], ['Pneumocystis pneumonia ( PCP ) , a common opportunistic infection in HIV - infected individuals , is generally treated with high doses of co - trimoxazole .', {'entities': [(0, 12, 'B_Disease'), (13, 22, 'I_Disease'), (25, 28, 'B_Disease'), (42, 55, 'B_Disease'), (56, 65, 'I_Disease'), (69, 72, 'B_Disease'), (73, 74, 'I_Disease'), (75, 83, 'I_Disease')]}], ['Here , we report two cases of severely immunocompromised HIV - infected patients who developed severe intrahepatic cholestasis , and in one patient lesions mimicking liver abscess formation on radiologic exams , during co - trimoxazole treatment for PCP .', {'entities': [(57, 60, 'B_Disease'), (61, 62, 'I_Disease'), (63, 71, 'I_Disease'), (102, 114, 'B_Disease'), (115, 126, 'I_Disease'), (166, 171, 'B_Disease'), (172, 179, 'I_Disease'), (250, 253, 'B_Disease')]}], ['Bradykinin receptors antagonists and nitric oxide synthase inhibitors in vincristine and streptozotocin induced hyperalgesia in chemotherapy and diabetic neuropathy rat model .', {'entities': [(112, 124, 'B_Disease'), (145, 153, 'B_Disease'), (154, 164, 'I_Disease')]}], ['PURPOSE : The influence of an irreversible inhibitor of constitutive NO synthase ( L - NOArg ; 1 . 0 mg / kg ip ) , a relatively selective inhibitor of inducible NO synthase ( L - NIL ; 1 . 0 mg / kg ip ) and a relatively specific inhibitor of neuronal NO synthase ( 7 - NI ; 0 . 1 mg / kg ip ) , on antihyperalgesic action of selective antagonists of B2 and B1 receptors : D - Arg - [ Hyp3 , Thi5 , D - Tic7 , Oic8 ] bradykinin ( HOE 140 ; 70 nmol / kg ip ) or des Arg10 HOE 140 ( 70 nmol / kg ip ) respectively , in model of diabetic ( streptozotocin - induced ) and toxic ( vincristine - induced ) neuropathy was investigated .', {'entities': [(527, 535, 'B_Disease'), (536, 537, 'I_Disease'), (538, 552, 'I_Disease'), (553, 554, 'I_Disease'), (555, 562, 'I_Disease'), (563, 564, 'I_Disease'), (565, 568, 'I_Disease'), (569, 574, 'I_Disease'), (575, 576, 'I_Disease'), (577, 588, 'I_Disease'), (589, 590, 'I_Disease'), (591, 598, 'I_Disease'), (599, 600, 'I_Disease'), (601, 611, 'I_Disease')]}], ['METHODS : The changes in pain thresholds were determined using mechanical stimuli - - the modification of the classic paw withdrawal test described by Randall - Selitto .', {'entities': [(25, 29, 'B_Disease')]}], ['RESULTS : The results of this paper confirm that inhibition of bradykinin receptors and inducible NO synthase but not neuronal NO synthase activity reduces diabetic hyperalgesia .', {'entities': [(156, 164, 'B_Disease'), (165, 177, 'I_Disease')]}], ['It was also shown that both products of inducible NO synthase and neuronal NO synthase activation as well as bradykinin are involved in hyperalgesia produced by vincristine .', {'entities': [(136, 148, 'B_Disease')]}], ['Moreover , L - NOArg and 7 - NI but not L - NIL intensify antihyperalgesic activity of HOE 140 or des - Arg10HOE 140 in toxic neuropathy .', {'entities': [(120, 125, 'B_Disease'), (126, 136, 'I_Disease')]}], ['CONCLUSIONS : Results of these studies suggest that B1 and B2 receptors are engaged in transmission of nociceptive stimuli in both diabetic and toxic neuropathy .', {'entities': [(131, 139, 'B_Disease'), (140, 143, 'I_Disease'), (144, 149, 'I_Disease'), (150, 160, 'I_Disease')]}], ['In streptozotocin - induced hyperalgesia , inducible NO synthase participates in pronociceptive activity of bradykinin , whereas in vincristine - induced hyperalgesia bradykinin seemed to activate neuronal NO synthase pathway .', {'entities': [(28, 40, 'B_Disease'), (154, 166, 'B_Disease')]}], ['Therefore , concomitant administration of small doses of bradykinin receptor antagonists and NO synthase inhibitors can be effective in alleviation of neuropathic pain , even in hospital care .', {'entities': [(151, 162, 'B_Disease'), (163, 167, 'I_Disease')]}], ['Confusion , a rather serious adverse drug reaction with valproic acid : a review of the French Pharmacovigilance database .', {'entities': [(0, 9, 'B_Disease')]}], ['INTRODUCTION : Confusion is an adverse drug reaction frequently observed with valproic acid .', {'entities': [(15, 24, 'B_Disease')]}], ['METHODS : Using the French Pharmacovigilance database , we selected the cases of confusion reported since 1985 with valproic acid .', {'entities': [(81, 90, 'B_Disease')]}], ['RESULTS : 272 cases of confusion were reported with valproic acid : 153 women and 119 men .', {'entities': [(23, 32, 'B_Disease')]}], ['Confusion mostly occurred during the two first weeks following valproic acid exposure ( 39 . 7 % ) .', {'entities': [(0, 9, 'B_Disease')]}], ['CONCLUSION : This work shows that confusion with valproic acid is a serious , rather frequent but reversible adverse drug reaction .', {'entities': [(34, 43, 'B_Disease')]}], ['Reversible inferior colliculus lesion in metronidazole - induced encephalopathy : magnetic resonance findings on diffusion - weighted and fluid attenuated inversion recovery imaging .', {'entities': [(11, 19, 'B_Disease'), (20, 30, 'I_Disease'), (31, 37, 'I_Disease'), (65, 79, 'B_Disease')]}], ['OBJECTIVE : This is to present reversible inferior colliculus lesions in metronidazole - induced encephalopathy , to focus on the diffusion - weighted imaging ( DWI ) and fluid attenuated inversion recovery ( FLAIR ) imaging .', {'entities': [(42, 50, 'B_Disease'), (51, 61, 'I_Disease'), (62, 69, 'I_Disease'), (97, 111, 'B_Disease')]}], ['MATERIALS AND METHODS : From November 2005 to September 2007 , 8 patients ( 5 men and 3 women ) were diagnosed as having metronidazole - induced encephalopathy ( age range ; 43 - 78 years ) .', {'entities': [(145, 159, 'B_Disease')]}], ['They had been taking metronidazole ( total dosage , 45 - 120 g ; duration , 30 days to 2 months ) to treat the infection in various organs .', {'entities': [(111, 120, 'B_Disease')]}], ['All the lesions in dentate , inferior colliculus , pons , and medullas had been resolved completely on follow - up MRIs in 5 patients , but in 1 patient of them , corpus callosal lesion persisted .', {'entities': [(170, 178, 'B_Disease'), (179, 185, 'I_Disease')]}], ['CONCLUSIONS : Reversible inferior colliculus lesions could be considered as the characteristic for metronidazole - induced encephalopathy , next to the dentate nucleus involvement .', {'entities': [(25, 33, 'B_Disease'), (34, 44, 'I_Disease'), (45, 52, 'I_Disease'), (123, 137, 'B_Disease')]}], ['Clinically significant proteinuria following the administration of sirolimus to renal transplant recipients .', {'entities': [(23, 34, 'B_Disease')]}], ['BACKGROUND : Sirolimus is the latest immunosuppressive agent used to prevent rejection , and may have less nephrotoxicity than calcineurin inhibitor ( CNI ) - based regimens .', {'entities': [(107, 121, 'B_Disease')]}], ['To date there has been little documentation of clinically significant proteinuria linked with the use of sirolimus .', {'entities': [(70, 81, 'B_Disease')]}], ['We have encountered several patients who developed substantial proteinuria associated with sirolimus use .', {'entities': [(63, 74, 'B_Disease')]}], ['In each patient , the close temporal association between the commencement of sirolimus therapy and proteinuria implicated sirolimus as the most likely etiology of the proteinuria .', {'entities': [(99, 110, 'B_Disease'), (167, 178, 'B_Disease')]}], ['In these patients , the magnitude of proteinuria was assessed on morning urine samples by turbidometric measurement or random urine protein : creatinine ratios , an estimate of grams of proteinuria / day .', {'entities': [(37, 48, 'B_Disease'), (186, 197, 'B_Disease')]}], ['RESULTS : Twenty - eight patients ( 24 % ) developed increased proteinuria from baseline during their post - transplantation course .', {'entities': [(63, 74, 'B_Disease')]}], ['In 21 patients an alternative cause of proteinuria was either obvious or insufficient data was available to be conclusive .', {'entities': [(39, 50, 'B_Disease')]}], ['In 7 of the 28 patients there was a striking temporal association between the initiation of sirolimus and the development of nephrotic - range proteinuria .', {'entities': [(125, 134, 'B_Disease'), (143, 154, 'B_Disease')]}], ['Proteinuria correlated most strongly with sirolimus therapy when compared to other demographic and clinical variables .', {'entities': [(0, 11, 'B_Disease')]}], ['In most patients , discontinuation of sirolimus resulted in a decrease , but not resolution , of proteinuria .', {'entities': [(97, 108, 'B_Disease')]}], ['CONCLUSIONS : Sirolimus induces or aggravates pre - existing proteinuria in an unpredictable subset of renal allograft recipients .', {'entities': [(61, 72, 'B_Disease')]}], ['Proteinuria may improve , but does not resolve , when sirolimus is withdrawn .', {'entities': [(0, 11, 'B_Disease')]}], ['Components of lemon essential oil attenuate dementia induced by scopolamine .', {'entities': [(44, 52, 'B_Disease')]}], ['The anti - dementia effects of s - limonene and s - perillyl alcohol were observed using the passive avoidance test ( PA ) and the open field habituation test ( OFH ) .', {'entities': [(11, 19, 'B_Disease')]}], ['These lemon essential oils showed strong ability to improve memory impaired by scopolamine ; however , s - perillyl alcohol relieved the deficit of associative memory in PA only , and did not improve non - associative memory significantly in OFH .', {'entities': [(60, 66, 'B_Disease'), (67, 75, 'I_Disease'), (137, 144, 'B_Disease'), (145, 147, 'I_Disease'), (148, 159, 'I_Disease'), (160, 166, 'I_Disease')]}], ['Attentional modulation of perceived pain intensity in capsaicin - induced secondary hyperalgesia .', {'entities': [(36, 40, 'B_Disease'), (84, 96, 'B_Disease')]}], ['Perceived pain intensity is modulated by attention .', {'entities': [(10, 14, 'B_Disease')]}], ['However , it is not known that how pain intensity ratings are affected by attention in capsaicin - induced secondary hyperalgesia .', {'entities': [(35, 39, 'B_Disease'), (117, 129, 'B_Disease')]}], ['Here we show that perceived pain intensity in secondary hyperalgesia is decreased when attention is distracted away from the painful pinprick stimulus with a visual task .', {'entities': [(28, 32, 'B_Disease'), (56, 68, 'B_Disease')]}], ['Furthermore , it was found that the magnitude of attentional modulation in secondary hyperalgesia is very similar to that of capsaicin - untreated , control condition .', {'entities': [(85, 97, 'B_Disease')]}], ['Our findings , showing no interaction between capsaicin treatment and attentional modulation suggest that capsaicin - induced secondary hyperalgesia and attention might affect mechanical pain through independent mechanisms .', {'entities': [(136, 148, 'B_Disease'), (187, 191, 'B_Disease')]}], ['Cardioprotective effect of salvianolic acid A on isoproterenol - induced myocardial infarction in rats .', {'entities': [(73, 83, 'B_Disease'), (84, 94, 'I_Disease')]}], ['The present study was designed to evaluate the cardioprotective potential of salvianolic acid A on isoproterenol - induced myocardial infarction in rats .', {'entities': [(123, 133, 'B_Disease'), (134, 144, 'I_Disease')]}], ['In addition , mitochondrial respiratory dysfunction characterized by decreased respiratory control ratio and ADP / O was observed in isoproterenol - treated rats .', {'entities': [(28, 39, 'B_Disease'), (40, 51, 'I_Disease')]}], ['Administration of salvianolic acid A for a period of 8 days significantly attenuated isoproterenol - induced cardiac dysfunction and myocardial injury and improved mitochondrial respiratory function .', {'entities': [(109, 116, 'B_Disease'), (117, 128, 'I_Disease'), (133, 143, 'B_Disease'), (144, 150, 'I_Disease')]}], ['The protective role of salvianolic acid A against isoproterenol - induced myocardial damage was further confirmed by histopathological examination .', {'entities': [(74, 84, 'B_Disease'), (85, 91, 'I_Disease')]}], ['The results of our study suggest that salvianolic acid A possessing antioxidant activity has a significant protective effect against isoproterenol - induced myocardial infarction .', {'entities': [(157, 167, 'B_Disease'), (168, 178, 'I_Disease')]}], ['Long - term glutamate supplementation failed to protect against peripheral neurotoxicity of paclitaxel .', {'entities': [(64, 74, 'B_Disease'), (75, 88, 'I_Disease')]}], ['Toxic peripheral neuropathy is still a significant limiting factor for chemotherapy with paclitaxel ( PAC ) , although glutamate and its closely related amino acid glutamine were claimed to ameliorate PAC neurotoxicity .', {'entities': [(6, 16, 'B_Disease'), (17, 27, 'I_Disease'), (205, 218, 'B_Disease')]}], ['This pilot trial aimed to evaluate the role of glutamate supplementation for preventing PAC - induced peripheral neuropathy in a randomized , placebo - controlled , double - blinded clinical and electro - diagnostic study .', {'entities': [(102, 112, 'B_Disease'), (113, 123, 'I_Disease')]}], ['Forty - three ovarian cancer patients were available for analysis following six cycles of the same PAC - containing regimen : 23 had been supplemented by glutamate all along the treatment period , at a daily dose of three times 500 mg ( group G ) , and 20 had received a placebo ( group P ) .', {'entities': [(14, 21, 'B_Disease'), (22, 28, 'I_Disease')]}], ['There was no significant difference in the frequency of signs or symptoms between the two groups although neurotoxicity symptoms presented mostly with lower scores of severity in group G .', {'entities': [(106, 119, 'B_Disease')]}], ['However , this difference reached statistical significance only with regard to reported pain sensation ( P = 0 . 011 ) .', {'entities': [(88, 92, 'B_Disease')]}], ['This pilot study leads to the conclusion that glutamate supplementation at the chosen regimen fails to protect against peripheral neurotoxicity of PAC .', {'entities': [(119, 129, 'B_Disease'), (130, 143, 'I_Disease')]}], ['Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C .', {'entities': [(15, 21, 'B_Disease'), (22, 32, 'I_Disease'), (89, 96, 'B_Disease'), (97, 106, 'I_Disease'), (107, 108, 'I_Disease')]}], ['A 63 - year - old male experienced sudden diplopia after 9 weeks of administration of pegylated interferon ( IFN ) alpha - 2b and ribavirin for chronic hepatitis C ( CHC ) .', {'entities': [(42, 50, 'B_Disease'), (144, 151, 'B_Disease'), (152, 161, 'I_Disease'), (162, 163, 'I_Disease'), (166, 169, 'B_Disease')]}], ['Ophthalmologic examinations showed ptosis on the right upper lid and restricted right eye movement without any other neurological signs .', {'entities': [(35, 41, 'B_Disease'), (42, 44, 'I_Disease'), (45, 48, 'I_Disease'), (49, 54, 'I_Disease'), (55, 60, 'I_Disease'), (61, 64, 'I_Disease'), (69, 79, 'B_Disease'), (80, 85, 'I_Disease'), (86, 89, 'I_Disease'), (90, 98, 'I_Disease')]}], ['The ocular myasthenia associated with combination therapy of pegylated IFN alpha - 2b and ribavirin for CHC is very rarely reported ; therefore , we present this case with a review of the various eye complications of IFN therapy .', {'entities': [(4, 10, 'B_Disease'), (11, 21, 'I_Disease'), (104, 107, 'B_Disease')]}], ['Learning and memory deficits in ecstasy users and their neural correlates during a face - learning task .', {'entities': [(0, 8, 'B_Disease'), (9, 12, 'I_Disease'), (13, 19, 'I_Disease'), (20, 28, 'I_Disease')]}], ['It has been consistently shown that ecstasy users display impairments in learning and memory performance .', {'entities': [(58, 69, 'B_Disease'), (70, 72, 'I_Disease'), (73, 81, 'I_Disease'), (82, 85, 'I_Disease'), (86, 92, 'I_Disease')]}], ['To address the potential confounding effects of the cannabis use of the ecstasy using group , a second analysis included 14 previously tested cannabis users ( Nestor , L . , Roberts , G . , Garavan , H . , Hester , R . , 2008 . Deficits in learning and memory : parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users . Neuroimage 40 , 1328 - 1339 ) .', {'entities': [(228, 236, 'B_Disease'), (237, 239, 'I_Disease'), (240, 248, 'I_Disease'), (249, 252, 'I_Disease'), (253, 259, 'I_Disease'), (278, 291, 'B_Disease')]}], ['A conjunction analysis of the encode and recall phases of the task revealed ecstasy - specific hyperactivity in bilateral frontal regions , left temporal , right parietal , bilateral temporal , and bilateral occipital brain regions .', {'entities': [(95, 108, 'B_Disease')]}], ['These ecstasy - specific effects may be related to the vulnerability of isocortical and allocortical regions to the neurotoxic effects of ecstasy .', {'entities': [(116, 126, 'B_Disease')]}], ['In less than 1 hour after the ingestion of alcohol , he developed malaise with flushing of the face , tachycardia , and dyspnea .', {'entities': [(79, 87, 'B_Disease'), (88, 90, 'I_Disease'), (91, 94, 'I_Disease'), (95, 99, 'I_Disease'), (102, 113, 'B_Disease'), (120, 127, 'B_Disease')]}], ['Five hours after exposure , he developed disulfiram - like syndrome with flushing , tachycardia , and arterial hypotension after consuming three glasses of wine .', {'entities': [(73, 81, 'B_Disease'), (84, 95, 'B_Disease'), (102, 110, 'B_Disease'), (111, 122, 'I_Disease')]}], ['Sulpiride - induced tardive dystonia .', {'entities': [(20, 27, 'B_Disease'), (28, 36, 'I_Disease')]}], ['Although initially thought to be free of extrapyramidal side effects , sulpiride - induced tardive dyskinesia and parkinsonism have been reported occasionally .', {'entities': [(91, 98, 'B_Disease'), (99, 109, 'I_Disease'), (114, 126, 'B_Disease')]}], ['We studied a 37 - year - old man who developed persistent segmental dystonia within 2 months after starting sulpiride therapy .', {'entities': [(68, 76, 'B_Disease')]}], ['We could not find any previous reports of sulpiride - induced tardive dystonia .', {'entities': [(62, 69, 'B_Disease'), (70, 78, 'I_Disease')]}], ['This study measured the objective and subjective neurocognitive effects of a single 10 - mg dose of immediate - release oxycodone in healthy , older ( > 65 years ) , and middle - aged ( 35 to 55 years ) adults who were not suffering from chronic or significant daily pain .', {'entities': [(267, 271, 'B_Disease')]}], ['Significant declines in simple and sustained attention , working memory , and verbal memory were observed at 1 hour postdose compared to baseline for both age groups with a trend toward return to baseline by 5 hours postdose .', {'entities': [(12, 20, 'B_Disease'), (21, 23, 'I_Disease'), (24, 30, 'I_Disease'), (31, 34, 'I_Disease'), (35, 44, 'I_Disease'), (45, 54, 'I_Disease'), (55, 56, 'I_Disease'), (57, 64, 'I_Disease'), (65, 71, 'I_Disease'), (72, 73, 'I_Disease'), (74, 77, 'I_Disease'), (78, 84, 'I_Disease'), (85, 91, 'I_Disease')]}], ['This study suggests that for healthy older adults who are not suffering from chronic pain , neurocognitive and pharmacodynamic changes in response to a 10 - mg dose of immediate - release oxycodone are similar to those observed for middle - aged adults .', {'entities': [(77, 84, 'B_Disease'), (85, 89, 'I_Disease')]}], ['Schizophrenia has been initially associated with dysfunction in dopamine neurotransmission .', {'entities': [(0, 13, 'B_Disease')]}], ['However , the observation that antagonists of the glutamate N - methyl - D - aspartate ( NMDA ) receptor produce schizophrenic - like symptoms in humans has led to the idea of a dysfunctioning of the glutamatergic system via its NMDA receptor .', {'entities': [(113, 126, 'B_Disease')]}], ['This study aimed at investigating the potential antipsychotic - like properties of SSR103800 , with a particular focus on models of hyperactivity , involving either drug challenge ( ie , amphetamine and MK - 801 ) or transgenic mice ( ie , NMDA Nr1 ( neo - / - ) and DAT ( - / - ) ) .', {'entities': [(132, 145, 'B_Disease')]}], ['Results showed that SSR103800 ( 10 - 30 mg / kg p . o . ) blocked hyperactivity induced by the non - competitive NMDA receptor antagonist , MK - 801 and partially reversed spontaneous hyperactivity of NMDA Nr1 ( neo - / - ) mice .', {'entities': [(66, 79, 'B_Disease'), (184, 197, 'B_Disease')]}], ['In contrast , SSR103800 failed to affect hyperactivity induced by amphetamine or naturally observed in dopamine transporter ( DAT ( - / - ) ) knockout mice ( 10 - 30 mg / kg p . o . ) .', {'entities': [(41, 54, 'B_Disease')]}], ['Importantly , both classical ( haloperidol ) and atypical ( olanzapine , clozapine and aripiprazole ) antipsychotics were effective in all these models of hyperactivity .', {'entities': [(155, 168, 'B_Disease')]}], ['However , unlike these latter , SSR103800 did not produce catalepsy ( retention on the bar test ) up to 30 mg / kg p . o .', {'entities': [(58, 67, 'B_Disease')]}], ['Pyrrolidine dithiocarbamate protects the piriform cortex in the pilocarpine status epilepticus model .', {'entities': [(76, 82, 'B_Disease'), (83, 94, 'I_Disease')]}], ['Both , production of reactive oxygen species as well as activation of NF - kappaB have been implicated in severe neuronal damage in different sub - regions of the hippocampus as well as in the surrounding cortices .', {'entities': [(113, 121, 'B_Disease'), (122, 128, 'I_Disease')]}], ['The effect of PDTC on status epilepticus - associated cell loss in the hippocampus and piriform cortex was evaluated in the rat fractionated pilocarpine model .', {'entities': [(22, 28, 'B_Disease'), (29, 40, 'I_Disease')]}], ['Treatment with 150 mg / kg PDTC before and following status epilepticus significantly increased the mortality rate to 100 % .', {'entities': [(53, 59, 'B_Disease'), (60, 71, 'I_Disease')]}], ['Administration of 50 mg / kg PDTC ( low - dose ) did not exert major effects on the development of a status epilepticus or the mortality rate .', {'entities': [(101, 107, 'B_Disease'), (108, 119, 'I_Disease')]}], ['In vehicle - treated rats , status epilepticus caused pronounced neuronal damage in the piriform cortex comprising both pyramidal cells and interneurons .', {'entities': [(28, 34, 'B_Disease'), (35, 46, 'I_Disease'), (65, 73, 'B_Disease'), (74, 80, 'I_Disease')]}], ['A significant decrease in neuronal density of the hippocampal hilar formation was identified in vehicle - and PDTC - treated rats following status epilepticus .', {'entities': [(140, 146, 'B_Disease'), (147, 158, 'I_Disease')]}], ['In conclusion , the NF - kappaB inhibitor and antioxidant PDTC protected the piriform cortex , whereas it did not affect hilar neuronal loss .', {'entities': [(127, 135, 'B_Disease'), (136, 140, 'I_Disease')]}], ['These data might indicate that the generation of reactive oxygen species and activation of NF - kappaB plays a more central role in seizure - associated neuronal damage in the temporal cortex as compared to the hippocampal hilus .', {'entities': [(132, 139, 'B_Disease'), (153, 161, 'B_Disease'), (162, 168, 'I_Disease')]}], [\"Anaesthetists ' nightmare : masseter spasm after induction in an undiagnosed case of myotonia congenita .\", {'entities': [(28, 36, 'B_Disease'), (37, 42, 'I_Disease'), (85, 93, 'B_Disease'), (94, 103, 'I_Disease')]}], ['We report an undiagnosed case of myotonia congenita in a 24 - year - old previously healthy primigravida , who developed life threatening masseter spasm following a standard dose of intravenous suxamethonium for induction of anaesthesia .', {'entities': [(33, 41, 'B_Disease'), (42, 51, 'I_Disease'), (138, 146, 'B_Disease'), (147, 152, 'I_Disease')]}], ['Twin preterm neonates with cardiac toxicity related to lopinavir / ritonavir therapy .', {'entities': [(27, 34, 'B_Disease'), (35, 43, 'I_Disease')]}], ['We report twin neonates who were born prematurely at 32 weeks of gestation to a mother with human immunodeficiency virus infection .', {'entities': [(92, 97, 'B_Disease'), (98, 114, 'I_Disease'), (115, 120, 'I_Disease'), (121, 130, 'I_Disease')]}], ['One of the twins developed complete heart block and dilated cardiomyopathy related to lopinavir / ritonavir therapy , a boosted protease - inhibitor agent , while the other twin developed mild bradycardia .', {'entities': [(36, 41, 'B_Disease'), (42, 47, 'I_Disease'), (52, 59, 'B_Disease'), (60, 74, 'I_Disease'), (193, 204, 'B_Disease')]}], ['Twenty - three hours after heart transplantation , life - threatening acute right heart failure was diagnosed in a patient requiring continuous venovenous hemodiafiltration ( CVVHDF ) .', {'entities': [(76, 81, 'B_Disease'), (82, 87, 'I_Disease'), (88, 95, 'I_Disease')]}], ['However , a bolus of epinephrine injected through an alternative catheter provoked a hypertensive crisis .', {'entities': [(85, 97, 'B_Disease')]}], ['Lithium - induced polyuria seems to be related to extrarenal as well as to renal effects .', {'entities': [(18, 26, 'B_Disease')]}], ['Antibacterial medication use during pregnancy and risk of birth defects : National Birth Defects Prevention Study .', {'entities': [(58, 63, 'B_Disease'), (64, 71, 'I_Disease'), (83, 88, 'B_Disease'), (89, 96, 'I_Disease')]}], ['OBJECTIVE : To estimate the association between antibacterial medications and selected birth defects .', {'entities': [(87, 92, 'B_Disease'), (93, 100, 'I_Disease')]}], ['DESIGN , SETTING , AND PARTICIPANTS : Population - based , multisite , case - control study of women who had pregnancies affected by 1 of more than 30 eligible major birth defects identified via birth defect surveillance programs in 10 states ( n = 13 155 ) and control women randomly selected from the same geographical regions ( n = 4941 ) .', {'entities': [(166, 171, 'B_Disease'), (172, 179, 'I_Disease'), (195, 200, 'B_Disease'), (201, 207, 'I_Disease')]}], ['MAIN OUTCOME MEASURE : Odds ratios ( ORs ) measuring the association between antibacterial use and selected birth defects adjusted for potential confounders .', {'entities': [(108, 113, 'B_Disease'), (114, 121, 'I_Disease')]}], ['Sulfonamides were associated with anencephaly ( adjusted OR [ AOR ] = 3 . 4 ; 95 % confidence interval [ CI ] , 1 . 3 - 8 . 8 ) , hypoplastic left heart syndrome ( AOR = 3 . 2 ; 95 % CI , 1 . 3 - 7 . 6 ) , coarctation of the aorta ( AOR = 2 . 7 ; 95 % CI , 1 . 3 - 5 . 6 ) , choanal atresia ( AOR = 8 . 0 ; 95 % CI , 2 . 7 - 23 . 5 ) , transverse limb deficiency ( AOR = 2 . 5 ; 95 % CI , 1 . 0 - 5 . 9 ) , and diaphragmatic hernia ( AOR = 2 . 4 ; 95 % CI , 1 . 1 - 5 . 4 ) .', {'entities': [(34, 45, 'B_Disease'), (130, 141, 'B_Disease'), (142, 146, 'I_Disease'), (147, 152, 'I_Disease'), (153, 161, 'I_Disease'), (206, 217, 'B_Disease'), (218, 220, 'I_Disease'), (221, 224, 'I_Disease'), (225, 230, 'I_Disease'), (275, 282, 'B_Disease'), (283, 290, 'I_Disease'), (336, 346, 'B_Disease'), (347, 351, 'I_Disease'), (352, 362, 'I_Disease'), (411, 424, 'B_Disease'), (425, 431, 'I_Disease')]}], ['Nitrofurantoins were associated with anophthalmia or microphthalmos ( AOR = 3 . 7 ; 95 % CI , 1 . 1 - 12 . 2 ) , hypoplastic left heart syndrome ( AOR = 4 . 2 ; 95 % CI , 1 . 9 - 9 . 1 ) , atrial septal defects ( AOR = 1 . 9 ; 95 % CI , 1 . 1 - 3 . 4 ) , and cleft lip with cleft palate ( AOR = 2 . 1 ; 95 % CI , 1 . 2 - 3 . 9 ) .', {'entities': [(37, 49, 'B_Disease'), (53, 67, 'B_Disease'), (113, 124, 'B_Disease'), (125, 129, 'I_Disease'), (130, 135, 'I_Disease'), (136, 144, 'I_Disease'), (189, 195, 'B_Disease'), (196, 202, 'I_Disease'), (203, 210, 'I_Disease'), (259, 264, 'B_Disease'), (265, 268, 'I_Disease'), (274, 279, 'B_Disease'), (280, 286, 'I_Disease')]}], ['CONCLUSIONS : Reassuringly , penicillins , erythromycins , and cephalosporins , although used commonly by pregnant women , were not associated with many birth defects .', {'entities': [(153, 158, 'B_Disease'), (159, 166, 'I_Disease')]}], ['Sulfonamides and nitrofurantoins were associated with several birth defects , indicating a need for additional scrutiny .', {'entities': [(62, 67, 'B_Disease'), (68, 75, 'I_Disease')]}], ['Immune escape variants of the hepatitis B virus ( HBV ) represent an emerging clinical challenge , because they can be associated with vaccine escape , HBV reactivation , and failure of diagnostic tests .', {'entities': [(30, 39, 'B_Disease'), (40, 41, 'I_Disease')]}], ['Hemolytic anemia associated with the use of omeprazole .', {'entities': [(0, 9, 'B_Disease'), (10, 16, 'I_Disease')]}], ['It has been shown to be extremely effective in the treatment of peptic ulcer disease , reflux esophagitis , and the Zollinger - Ellison syndrome .', {'entities': [(64, 70, 'B_Disease'), (71, 76, 'I_Disease'), (77, 84, 'I_Disease'), (87, 93, 'B_Disease'), (94, 105, 'I_Disease'), (116, 125, 'B_Disease'), (126, 127, 'I_Disease'), (128, 135, 'I_Disease'), (136, 144, 'I_Disease')]}], ['We report the first case of a serious short - term adverse reaction with the use of omeprazole : hemolytic anemia .', {'entities': [(97, 106, 'B_Disease'), (107, 113, 'I_Disease')]}], ['The patient developed weakness , lethargy , and shortness of breath 2 days after starting therapy with omeprazole .', {'entities': [(33, 41, 'B_Disease'), (48, 57, 'B_Disease'), (58, 60, 'I_Disease'), (61, 67, 'I_Disease')]}], [\"The mechanism by which omeprazole caused the patient ' s hemolytic anemia is uncertain , but physicians should be alerted to this possible adverse effect .\", {'entities': [(57, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['Phenylephrine but not ephedrine reduces frontal lobe oxygenation following anesthesia - induced hypotension .', {'entities': [(32, 39, 'B_Disease'), (40, 47, 'I_Disease'), (48, 52, 'I_Disease'), (53, 64, 'I_Disease'), (96, 107, 'B_Disease')]}], ['BACKGROUND : Vasopressor agents are used to correct anesthesia - induced hypotension .', {'entities': [(73, 84, 'B_Disease')]}], ['We describe the effect of phenylephrine and ephedrine on frontal lobe oxygenation ( S ( c ) O ( 2 ) ) following anesthesia - induced hypotension .', {'entities': [(133, 144, 'B_Disease')]}], ['Heart rate ( HR ) , MAP , stroke volume ( SV ) , cardiac output ( CO ) , and frontal lobe oxygenation ( S ( c ) O ( 2 ) ) were registered .', {'entities': [(26, 32, 'B_Disease')]}], ['RESULTS : Induction of anesthesia was followed by a decrease in MAP , HR , SV , and CO concomitant with an elevation in S ( c ) O ( 2 ) .', {'entities': [(50, 51, 'B_Disease'), (52, 60, 'I_Disease'), (61, 63, 'I_Disease'), (64, 67, 'I_Disease'), (68, 69, 'I_Disease'), (70, 72, 'I_Disease'), (73, 74, 'I_Disease'), (75, 77, 'I_Disease'), (78, 79, 'I_Disease'), (80, 83, 'I_Disease'), (84, 86, 'I_Disease')]}], ['CONCLUSIONS : The utilization of phenylephrine to correct hypotension induced by anesthesia has a negative impact on S ( c ) O ( 2 ) while ephedrine maintains frontal lobe oxygenation potentially related to an increase in CO .', {'entities': [(58, 69, 'B_Disease')]}], ['Prolonged elevation of plasma argatroban in a cardiac transplant patient with a suspected history of heparin - induced thrombocytopenia with thrombosis .', {'entities': [(119, 135, 'B_Disease'), (141, 151, 'B_Disease')]}], ['BACKGROUND : Direct thrombin inhibitors ( DTIs ) provide an alternative method of anticoagulation for patients with a history of heparin - induced thrombocytopenia ( HIT ) or HIT with thrombosis ( HITT ) undergoing cardiopulmonary bypass ( CPB ) .', {'entities': [(147, 163, 'B_Disease'), (166, 169, 'B_Disease'), (175, 178, 'B_Disease'), (184, 194, 'B_Disease'), (197, 201, 'B_Disease')]}], ['In the following report , a 65 - year - old critically ill patient with a suspected history of HITT was administered argatroban for anticoagulation on bypass during heart transplantation .', {'entities': [(44, 54, 'B_Disease'), (55, 58, 'I_Disease'), (95, 99, 'B_Disease')]}], ['The patient required massive transfusion support ( 55 units of red blood cells , 42 units of fresh - frozen plasma , 40 units of cryoprecipitate , 40 units of platelets , and three doses of recombinant Factor VIIa ) for severe intraoperative and postoperative bleeding .', {'entities': [(227, 241, 'B_Disease'), (242, 245, 'I_Disease'), (246, 259, 'I_Disease'), (260, 268, 'I_Disease')]}], ['RESULTS : Unexpectedly high concentrations of argatroban were measured in these samples ( range , 0 - 32 microg / mL ) , and a prolonged plasma argatroban half life ( t ( 1 / 2 ) ) of 514 minutes was observed ( published elimination t ( 1 / 2 ) is 39 - 51 minutes [ < or = 181 minutes with hepatic impairment ] ) .', {'entities': [(290, 297, 'B_Disease'), (298, 308, 'I_Disease')]}], [\"CONCLUSIONS : Correlation of plasma argatroban concentration versus the patient ' s coagulation variables and clinical course suggest that prolonged elevated levels of plasma argatroban may have contributed to the patient ' s extended coagulopathy .\", {'entities': [(235, 247, 'B_Disease')]}], ['This is the first report to measure plasma argatroban concentration in the context of CPB and extended coagulopathy .', {'entities': [(103, 115, 'B_Disease')]}], ['The effects of the adjunctive bupropion on male sexual dysfunction induced by a selective serotonin reuptake inhibitor : a double - blind placebo - controlled and randomized study .', {'entities': [(48, 54, 'B_Disease'), (55, 66, 'I_Disease')]}], ['OBJECTIVE : To determine the safety and efficacy of adjunctive bupropion sustained - release ( SR ) on male sexual dysfunction ( SD ) induced by a selective serotonin reuptake inhibitor ( SSRI ) , as SD is a common side - effect of SSRIs and the most effective treatments have yet to be determined .', {'entities': [(108, 114, 'B_Disease'), (115, 126, 'I_Disease'), (129, 131, 'B_Disease'), (200, 202, 'B_Disease')]}], ['Efficacy was evaluated using the Clinical Global Impression - Sexual Function ( CGI - SF ; the primary outcome measure ) , the International Index of Erectile Function ( IIEF ) , Arizona Sexual Experience Scale ( ASEX ) , and Erectile Dysfunction Inventory of Treatment Satisfaction ( EDITS ) ( secondary outcome measures ) .', {'entities': [(226, 234, 'B_Disease'), (235, 246, 'I_Disease')]}], ['In linear regression analyses the CGI - SF score was not affected significantly by the duration of SD , type of SSRI used and age .', {'entities': [(99, 101, 'B_Disease')]}], ['CONCLUSIONS : Bupropion is an effective treatment for male SD induced by SSRIs .', {'entities': [(59, 61, 'B_Disease')]}], ['Prevention of seizures and reorganization of hippocampal functions by transplantation of bone marrow cells in the acute phase of experimental epilepsy .', {'entities': [(14, 22, 'B_Disease'), (142, 150, 'B_Disease')]}], ['In this study , we investigated the therapeutic potential of bone marrow mononuclear cells ( BMCs ) in a model of epilepsy induced by pilocarpine in rats .', {'entities': [(114, 122, 'B_Disease')]}], ['BMCs obtained from green fluorescent protein ( GFP ) transgenic mice or rats were transplanted intravenously after induction of status epilepticus ( SE ) .', {'entities': [(128, 134, 'B_Disease'), (135, 146, 'I_Disease'), (149, 151, 'B_Disease')]}], [\"Spontaneous recurrent seizures ( SRS ) were monitored using Racine ' s seizure severity scale .\", {'entities': [(0, 11, 'B_Disease'), (12, 21, 'I_Disease'), (22, 30, 'I_Disease'), (33, 36, 'B_Disease'), (71, 78, 'B_Disease')]}], ['All of the rats in the saline - treated epileptic control group developed SRS , whereas none of the BMC - treated epileptic animals had seizures in the short term ( 15 days after transplantation ) , regardless of the BMC source .', {'entities': [(40, 49, 'B_Disease'), (74, 77, 'B_Disease'), (114, 123, 'B_Disease'), (136, 144, 'B_Disease')]}], ['Over the long - term chronic phase ( 120 days after transplantation ) , only 25 % of BMC - treated epileptic animals had seizures , but with a lower frequency and duration compared to the epileptic control group .', {'entities': [(99, 108, 'B_Disease'), (121, 129, 'B_Disease'), (188, 197, 'B_Disease')]}], ['At hippocampal Schaeffer collateral - CA1 synapses , long - term potentiation was preserved in BMC - transplanted rats compared to epileptic controls .', {'entities': [(131, 140, 'B_Disease')]}], ['The donor - derived GFP ( + ) cells were rarely found in the brains of transplanted epileptic rats .', {'entities': [(84, 93, 'B_Disease')]}], ['In conclusion , treatment with BMCs can prevent the development of chronic seizures , reduce neuronal loss , and influence the reorganization of the hippocampal neuronal network .', {'entities': [(75, 83, 'B_Disease'), (93, 101, 'B_Disease'), (102, 106, 'I_Disease')]}], ['OBJECTIVE : The purpose of the present study was to determine the effect of morning - dosed modafinil on sleep and daytime sleepiness in chronic cocaine users .', {'entities': [(115, 122, 'B_Disease'), (123, 133, 'I_Disease')]}], ['Modafinil was associated with increased daytime sleep latency , as measured by the Multiple Sleep Latency Test , and a nearly significant decrease in subjective daytime sleepiness .', {'entities': [(161, 168, 'B_Disease'), (169, 179, 'I_Disease')]}], ['CONCLUSIONS : Morning - dosed modafinil promotes nocturnal sleep , normalizes sleep architecture , and decreases daytime sleepiness in abstinent cocaine users .', {'entities': [(113, 120, 'B_Disease'), (121, 131, 'I_Disease')]}], ['Uni - and multivariate analyses were used to test the influence of the clinical variables : age , sex , stroke , myocardiopathy ( MP ) , duration of the test , mitral regurgitation ( MR ) and the MZ dose .', {'entities': [(104, 110, 'B_Disease'), (113, 127, 'B_Disease'), (130, 132, 'B_Disease'), (160, 166, 'B_Disease'), (167, 180, 'I_Disease'), (183, 185, 'B_Disease')]}], ['Mild hypoxia ( SO2 < 90 % ) was the most common event ( 11 patients ) ; 3 patients ( 2 % ) presented transient hypoxia due to upper airway obstruction by probe introduction and 8 ( 5 . 8 % ) due to hypoxia caused by MZ use .', {'entities': [(5, 12, 'B_Disease'), (111, 118, 'B_Disease'), (132, 138, 'B_Disease'), (139, 150, 'I_Disease'), (198, 205, 'B_Disease')]}], ['Transient hypotension ( SAP < 90mmHg ) occurred in 1 patient ( 0 . 7 % ) .', {'entities': [(10, 21, 'B_Disease')]}], ['The multivariate analysis showed that severe MR , MP ( EF < 45 % ) and high doses of MZ ( > 5mg ) were associated with events ( p < 0 . 001 ) .', {'entities': [(45, 47, 'B_Disease'), (50, 52, 'B_Disease')]}], ['The EF was 40 % , in the group with MP and 44 % in the group with severe MR and it can be a factor associated with clinical events in the last group .', {'entities': [(36, 38, 'B_Disease'), (73, 75, 'B_Disease')]}], ['Effect of direct intracoronary administration of methylergonovine in patients with and without variant angina .', {'entities': [(95, 102, 'B_Disease'), (103, 109, 'I_Disease')]}], ['The effects of intracoronary administration of methylergonovine were studied in 21 patients with variant angina and 22 patients with atypical chest pain and in others without angina pectoris ( control group ) .', {'entities': [(97, 104, 'B_Disease'), (105, 111, 'I_Disease'), (142, 147, 'B_Disease'), (148, 152, 'I_Disease'), (175, 181, 'B_Disease'), (182, 190, 'I_Disease')]}], ['In all patients with variant angina , coronary spasm was provoked at a mean dose of 28 + / - 13 micrograms ( mean + / - SD ) .', {'entities': [(21, 28, 'B_Disease'), (29, 35, 'I_Disease'), (38, 46, 'B_Disease'), (47, 52, 'I_Disease')]}], ['In the control group neither ischemic ST change nor localized spasm occurred .', {'entities': [(62, 67, 'B_Disease')]}], ['These results suggest that spasm provocation tests , which use an intracoronary injection of a relatively low dose of methylergonovine , have a high sensitivity in variant angina and the vasoreactivity of the right coronary artery may be greater than that of the other coronary arteries .', {'entities': [(27, 32, 'B_Disease'), (164, 171, 'B_Disease'), (172, 178, 'I_Disease')]}], ['Oral manifestations of \" meth mouth \" : a case report .', {'entities': [(25, 29, 'B_Disease'), (30, 35, 'I_Disease')]}], ['AIM : The aim of the documentation of this clinical case is to make clinicians aware of \" meth mouth \" and the medical risks associated with this serious condition .', {'entities': [(90, 94, 'B_Disease'), (95, 100, 'I_Disease')]}], ['BACKGROUND : Methamphetamine is a very addictive , powerful stimulant that increases wakefulness and physical activity and can produce other effects such as cardiac dysrhythmias , hypertension , hallucinations , and violent behavior .', {'entities': [(157, 164, 'B_Disease'), (165, 177, 'I_Disease'), (180, 192, 'B_Disease'), (195, 209, 'B_Disease'), (216, 223, 'B_Disease'), (224, 232, 'I_Disease')]}], ['Dental patients abusing methamphetamine can present with poor oral hygiene , xerostomia , rampant caries ( \" meth mouth \" ) , and excessive tooth wear .', {'entities': [(77, 87, 'B_Disease'), (98, 104, 'B_Disease'), (109, 113, 'B_Disease'), (114, 119, 'I_Disease'), (140, 145, 'B_Disease'), (146, 150, 'I_Disease')]}], ['CASE DESCRIPTION : A 30 - year - old Caucasian woman presented with dental pain , bad breath , and self - reported poor esthetics .', {'entities': [(75, 79, 'B_Disease'), (82, 85, 'B_Disease'), (86, 92, 'I_Disease')]}], ['A comprehensive examination including her medical history , panoramic radiograph , and intraoral examination revealed 19 carious lesions , which is not very common for a healthy adult .', {'entities': [(121, 128, 'B_Disease'), (129, 136, 'I_Disease')]}], ['She reported her use of methamphetamine for five years and had not experienced any major carious episodes before she started using the drug .', {'entities': [(89, 96, 'B_Disease'), (97, 105, 'I_Disease')]}], ['SUMMARY : The patient \\' s medical and dental histories along with radiographic and clinical findings lead to a diagnosis of \" meth mouth . \" Although three different dental treatment modalities ( either conventional or implant - supported ) have been offered to the patient since August 2007 , the patient has yet to initiate any treatment .', {'entities': [(126, 130, 'B_Disease'), (131, 136, 'I_Disease')]}], ['CLINICAL SIGNIFICANCE : This clinical case showing oral manifestations of meth mouth was presented to help dental practitioners recognize and manage patients who may be abusing methamphetamines .', {'entities': [(74, 78, 'B_Disease'), (79, 84, 'I_Disease')]}], ['Antituberculosis therapy - induced acute liver failure : magnitude , profile , prognosis , and predictors of outcome .', {'entities': [(35, 40, 'B_Disease'), (41, 46, 'I_Disease'), (47, 54, 'I_Disease')]}], ['Antituberculosis therapy ( ATT ) - associated acute liver failure ( ATT - ALF ) is the commonest drug - induced ALF in South Asia .', {'entities': [(46, 51, 'B_Disease'), (52, 57, 'I_Disease'), (58, 65, 'I_Disease'), (74, 77, 'B_Disease'), (112, 115, 'B_Disease')]}], ['Prospective studies on ATT - ALF are lacking .', {'entities': [(29, 32, 'B_Disease')]}], ['The current study prospectively evaluated the magnitude , clinical course , outcome , and prognostic factors in ATT - ALF .', {'entities': [(118, 121, 'B_Disease')]}], ['From January 1986 to January 2009 , 1223 consecutive ALF patients were evaluated : ATT alone was the cause in 70 ( 5 . 7 % ) patients .', {'entities': [(53, 56, 'B_Disease')]}], ['Another 15 ( 1 . 2 % ) had ATT and simultaneous hepatitis virus infection .', {'entities': [(48, 57, 'B_Disease'), (58, 63, 'I_Disease'), (64, 73, 'I_Disease')]}], ['In 44 ( 62 . 8 % ) patients , ATT was prescribed empirically without definitive evidence of tuberculosis .', {'entities': [(92, 104, 'B_Disease')]}], ['ATT - ALF patients were younger ( 32 . 87 [ + / - 15 . 8 ] years ) , and 49 ( 70 % ) of them were women .', {'entities': [(6, 9, 'B_Disease')]}], ['Most had hyperacute presentation ; the median icterus encephalopathy interval was 4 . 5 ( 0 - 30 ) days .', {'entities': [(46, 53, 'B_Disease'), (54, 68, 'B_Disease')]}], ['The median duration of ATT before ALF was 30 ( 7 - 350 ) days .', {'entities': [(34, 37, 'B_Disease')]}], ['At presentation , advanced encephalopathy and cerebral edema were present in 51 ( 76 % ) and 29 ( 41 . 4 % ) patients , respectively .', {'entities': [(27, 41, 'B_Disease'), (46, 54, 'B_Disease'), (55, 60, 'I_Disease')]}], ['Gastrointestinal bleed , seizures , infection , and acute renal failure were documented in seven ( 10 % ) , five ( 7 . 1 % ) , 26 ( 37 . 1 % ) , and seven ( 10 % ) patients , respectively .', {'entities': [(0, 16, 'B_Disease'), (17, 22, 'I_Disease'), (25, 33, 'B_Disease'), (36, 45, 'B_Disease'), (52, 57, 'B_Disease'), (58, 63, 'I_Disease'), (64, 71, 'I_Disease')]}], ['Compared with hepatitis E virus ( HEV ) and non - A non - E - induced ALF , ATT - ALF patients had nearly similar presentations except for older age and less elevation of liver enzymes .', {'entities': [(14, 23, 'B_Disease'), (24, 25, 'I_Disease'), (70, 73, 'B_Disease'), (82, 85, 'B_Disease')]}], ['The mortality rate among patients with ATT - ALF was high ( 67 . 1 % , n = 47 ) , and only 23 ( 32 . 9 % ) patients recovered with medical treatment .', {'entities': [(45, 48, 'B_Disease')]}], ['In multivariate analysis , three factors independently predicted mortality : serum bilirubin ( > or = 10 . 8 mg / dL ) , prothrombin time ( PT ) prolongation ( > or = 26 seconds ) , and grade III / IV encephalopathy at presentation .', {'entities': [(201, 215, 'B_Disease')]}], ['CONCLUSION : ATT - ALF constituted 5 . 7 % of ALF at our center and had a high mortality rate .', {'entities': [(19, 22, 'B_Disease'), (46, 49, 'B_Disease')]}], ['Design and analysis of the HYPREN - trial : safety of enalapril and prazosin in the initial treatment phase of patients with congestive heart failure .', {'entities': [(125, 135, 'B_Disease'), (136, 141, 'I_Disease'), (142, 149, 'I_Disease')]}], ['Since the introduction of angiotensin converting enzyme ( ACE ) inhibitors into the adjunctive treatment of patients with congestive heart failure , cases of severe hypotension , especially on the first day of treatment , have occasionally been reported .', {'entities': [(122, 132, 'B_Disease'), (133, 138, 'I_Disease'), (139, 146, 'I_Disease'), (165, 176, 'B_Disease')]}], ['To assess the safety of the ACE inhibitor enalapril a multicenter , randomized , prazosin - controlled trial was designed that compared the incidence and severity of symptomatic hypotension on the first day of treatment .', {'entities': [(178, 189, 'B_Disease')]}], ['Patients who received enalapril experienced clinically and statistically significantly less symptomatic hypotension ( 5 . 2 % ) than the patients who received prazosin ( 12 . 9 % ) .', {'entities': [(104, 115, 'B_Disease')]}], ['Central nervous system complications during treatment of acute lymphoblastic leukemia in a single pediatric institution .', {'entities': [(0, 7, 'B_Disease'), (8, 15, 'I_Disease'), (16, 22, 'I_Disease'), (23, 36, 'I_Disease'), (57, 62, 'B_Disease'), (63, 76, 'I_Disease'), (77, 85, 'I_Disease')]}], ['Central nervous system ( CNS ) complications during treatment of childhood acute lymphoblastic leukemia ( ALL ) remain a challenging clinical problem .', {'entities': [(0, 7, 'B_Disease'), (8, 15, 'I_Disease'), (16, 22, 'I_Disease'), (23, 24, 'I_Disease'), (25, 28, 'I_Disease'), (29, 30, 'I_Disease'), (31, 44, 'I_Disease'), (75, 80, 'B_Disease'), (81, 94, 'I_Disease'), (95, 103, 'I_Disease'), (106, 109, 'B_Disease')]}], ['This study analyzed the incidence of neurological complications during ALL treatment in a single pediatric institution , focusing on clinical , radiological , and electrophysiological findings .', {'entities': [(37, 49, 'B_Disease'), (50, 63, 'I_Disease'), (71, 74, 'B_Disease')]}], ['Exclusion criteria included CNS leukemic infiltration at diagnosis , therapy - related peripheral neuropathy , late - onset encephalopathy , or long - term neurocognitive defects .', {'entities': [(32, 40, 'B_Disease'), (41, 53, 'I_Disease'), (87, 97, 'B_Disease'), (98, 108, 'I_Disease'), (124, 138, 'B_Disease'), (156, 170, 'B_Disease'), (171, 178, 'I_Disease')]}], ['During a 9 - year period , we retrospectively collected 27 neurological events ( 11 % ) in as many patients , from 253 children enrolled in the ALL front - line protocol .', {'entities': [(144, 147, 'B_Disease')]}], ['CNS complications included posterior reversible leukoencephalopathy syndrome ( n = 10 ) , stroke ( n = 5 ) , temporal lobe epilepsy ( n = 2 ) , high - dose methotrexate toxicity ( n = 2 ) , syndrome of inappropriate antidiuretic hormone secretion ( n = 1 ) , and other unclassified events ( n = 7 ) .', {'entities': [(48, 67, 'B_Disease'), (90, 96, 'B_Disease'), (109, 117, 'B_Disease'), (118, 122, 'I_Disease'), (123, 131, 'I_Disease'), (169, 177, 'B_Disease'), (202, 215, 'B_Disease'), (216, 228, 'I_Disease'), (229, 236, 'I_Disease'), (237, 246, 'I_Disease')]}], ['In conclusion , CNS complications are frequent events during ALL therapy , and require rapid detection and prompt treatment to limit permanent damage .', {'entities': [(61, 64, 'B_Disease')]}], ['Cocaine causes memory and learning impairments in rats : involvement of nuclear factor kappa B and oxidative stress , and prevention by topiramate .', {'entities': [(15, 21, 'B_Disease'), (22, 25, 'I_Disease'), (26, 34, 'I_Disease'), (35, 46, 'I_Disease')]}], ['Different mechanisms have been suggested for cocaine toxicity including an increase in oxidative stress but the association between oxidative status in the brain and cocaine induced - behaviour is poorly understood .', {'entities': [(53, 61, 'B_Disease')]}], ['Nuclear factor kappa B ( NFkappaB ) is a sensor of oxidative stress and participates in memory formation that could be involved in drug toxicity and addiction mechanisms .', {'entities': [(136, 144, 'B_Disease')]}], ['Therefore NFkappaB activity , oxidative stress , neuronal nitric oxide synthase ( nNOS ) activity , spatial learning and memory as well as the effect of topiramate , a previously proposed therapy for cocaine addiction , were evaluated in an experimental model of cocaine administration in rats .', {'entities': [(200, 207, 'B_Disease'), (208, 217, 'I_Disease')]}], ['Efficacy and safety of asenapine in a placebo - and haloperidol - controlled trial in patients with acute exacerbation of schizophrenia .', {'entities': [(122, 135, 'B_Disease')]}], ['Asenapine is approved by the Food and Drugs Administration in adults for acute treatment of schizophrenia or of manic or mixed episodes associated with bipolar I disorder with or without psychotic features .', {'entities': [(92, 105, 'B_Disease'), (112, 117, 'B_Disease'), (152, 159, 'B_Disease'), (160, 161, 'I_Disease'), (162, 170, 'I_Disease'), (187, 196, 'B_Disease')]}], ['In a double - blind 6 - week trial , 458 patients with acute schizophrenia were randomly assigned to fixed - dose treatment with asenapine at 5 mg twice daily ( BID ) , asenapine at 10 mg BID , placebo , or haloperidol at 4 mg BID ( to verify assay sensitivity ) .', {'entities': [(61, 74, 'B_Disease')]}], ['Extrapyramidal symptoms reported as AEs occurred in 15 % and 18 % , 34 % , and 10 % of the asenapine at 5 and 10 mg BID , haloperidol , and placebo groups , respectively .', {'entities': [(0, 14, 'B_Disease'), (15, 23, 'I_Disease')]}], ['Post hoc analyses indicated that efficacy was similar with asenapine and haloperidol ; greater contrasts were seen in AEs , especially extrapyramidal symptoms .', {'entities': [(135, 149, 'B_Disease'), (150, 158, 'I_Disease')]}], ['Salvage therapy with nelarabine , etoposide , and cyclophosphamide in relapsed / refractory paediatric T - cell lymphoblastic leukaemia and lymphoma .', {'entities': [(103, 104, 'B_Disease'), (105, 106, 'I_Disease'), (107, 111, 'I_Disease'), (112, 125, 'I_Disease'), (126, 135, 'I_Disease'), (136, 139, 'I_Disease'), (140, 148, 'I_Disease')]}], ['A combination of 5 d of nelarabine ( AraG ) with 5 d of etoposide ( VP ) and cyclophosphamide ( CPM ) and prophylactic intrathecal chemotherapy was used as salvage therapy in seven children with refractory or relapsed T - cell leukaemia or lymphoma .', {'entities': [(218, 219, 'B_Disease'), (220, 221, 'I_Disease'), (222, 226, 'I_Disease'), (227, 236, 'I_Disease'), (237, 239, 'I_Disease'), (240, 248, 'I_Disease')]}], ['The most common side effects attributable to the AraG included Grade 2 and 3 sensory and motor neuropathy and musculoskeletal pain .', {'entities': [(95, 105, 'B_Disease'), (110, 125, 'B_Disease'), (126, 130, 'I_Disease')]}], ['Haematological toxicity was greater for the combination than AraG alone , although median time to neutrophil and platelet recovery was consistent with other salvage therapies .', {'entities': [(0, 14, 'B_Disease'), (15, 23, 'I_Disease')]}], ['Our experience supports the safety of giving AraG as salvage therapy in synchrony with etoposide and cyclophosphamide , although neurological toxicity must be closely monitored .', {'entities': [(129, 141, 'B_Disease'), (142, 150, 'I_Disease')]}], ['Effect of adriamycin combined with whole body hyperthermia on tumor and normal tissues .', {'entities': [(46, 58, 'B_Disease'), (62, 67, 'B_Disease')]}], ['Thermal enhancement of Adriamycin - mediated antitumor activity and normal tissue toxicities by whole body hyperthermia were compared using a F344 rat model .', {'entities': [(82, 92, 'B_Disease'), (107, 119, 'B_Disease')]}], ['Antitumor activity was studied using a tumor growth delay assay .', {'entities': [(39, 44, 'B_Disease')]}], ['Acute normal tissue toxicities ( i . e . , leukopenia and thrombocytopenia ) and late normal tissue toxicities ( i . e . , myocardial and kidney injury ) were evaluated by functional / physiological assays and by morphological techniques .', {'entities': [(20, 30, 'B_Disease'), (43, 53, 'B_Disease'), (58, 74, 'B_Disease'), (100, 110, 'B_Disease'), (123, 133, 'B_Disease'), (134, 137, 'I_Disease'), (138, 144, 'I_Disease'), (145, 151, 'I_Disease')]}], ['Whole body hyperthermia ( 120 min at 41 . 5 degrees C ) enhanced both Adriamycin - mediated antitumor activity and toxic side effects .', {'entities': [(11, 23, 'B_Disease')]}], ['Thermal enhancement ratios estimated for \" acute \" hematological changes were 1 . 3 , whereas those estimated for \" late \" damage ( based on morphological cardiac and renal lesions ) varied between 2 . 4 and 4 . 3 .', {'entities': [(155, 162, 'B_Disease'), (163, 166, 'I_Disease'), (167, 172, 'I_Disease'), (173, 180, 'I_Disease')]}], ['Thus , while whole body hyperthermia enhances Adriamycin - mediated antitumor effect , normal tissue toxicity is also increased , and the potential therapeutic gain of the combined modality treatment is eroded .', {'entities': [(24, 36, 'B_Disease'), (101, 109, 'B_Disease')]}], ['Permeability , ultrastructural changes , and distribution of novel proteins in the glomerular barrier in early puromycin aminonucleoside nephrosis .', {'entities': [(137, 146, 'B_Disease')]}], ['BACKGROUND / AIMS : It is still unclear what happens in the glomerulus when proteinuria starts .', {'entities': [(76, 87, 'B_Disease')]}], ['Using puromycin aminonucleoside nephrosis ( PAN ) rats , we studied early ultrastructural and permeability changes in relation to the expression of the podocyte - associated molecules nephrin , a - actinin , dendrin , and plekhh2 , the last two of which were only recently discovered in podocytes .', {'entities': [(32, 41, 'B_Disease')]}], ['RESULTS : By day 2 , some patchy foot process effacement , but no proteinuria , appeared .', {'entities': [(66, 77, 'B_Disease')]}], ['By day 4 , foot process effacement was complete and proteinuria appeared in parallel with signs of size barrier damage .', {'entities': [(52, 63, 'B_Disease')]}], ['CONCLUSIONS : PAN glomeruli already showed significant pathology by day 4 , despite relatively mild proteinuria .', {'entities': [(100, 111, 'B_Disease')]}], ['A novel , multiple symptom model of obsessive - compulsive - like behaviors in animals .', {'entities': [(36, 45, 'B_Disease'), (46, 47, 'I_Disease'), (48, 58, 'I_Disease'), (59, 60, 'I_Disease'), (61, 65, 'I_Disease'), (66, 75, 'I_Disease')]}], ['BACKGROUND : Current animal models of obsessive - compulsive disorder ( OCD ) typically involve acute , drug - induced symptom provocation or a genetic association with stereotypies or anxiety .', {'entities': [(38, 47, 'B_Disease'), (48, 49, 'I_Disease'), (50, 60, 'I_Disease'), (61, 69, 'I_Disease'), (72, 75, 'B_Disease'), (185, 192, 'B_Disease')]}], ['None of these current models demonstrate multiple OCD - like behaviors .', {'entities': [(50, 53, 'B_Disease')]}], ['RESULTS : Clomipramine exposure in immature rats produced significant behavioral and biochemical changes that include enhanced anxiety ( elevated plus maze and marble burying ) , behavioral inflexibility ( perseveration in the spontaneous alternation task and impaired reversal learning ) , working memory impairment ( e . g . , win - shift paradigm ) , hoarding , and corticostriatal dysfunction .', {'entities': [(127, 134, 'B_Disease'), (179, 189, 'B_Disease'), (190, 203, 'I_Disease'), (299, 305, 'B_Disease'), (306, 316, 'I_Disease'), (354, 362, 'B_Disease'), (369, 384, 'B_Disease'), (385, 396, 'I_Disease')]}], ['CONCLUSIONS : This is the first demonstration of multiple symptoms consistent with an OCD - like profile in animals .', {'entities': [(86, 89, 'B_Disease')]}], ['Moreover , these behaviors are accompanied by biochemical changes in brain regions previously identified as relevant to OCD .', {'entities': [(120, 123, 'B_Disease')]}], ['This novel model of OCD demonstrates that drug exposure during a sensitive period can program disease - like systems permanently , which could have implications for current and future therapeutic strategies for this and other psychiatric disorders .', {'entities': [(20, 23, 'B_Disease'), (226, 237, 'B_Disease'), (238, 247, 'I_Disease')]}], ['Elevation of ADAM10 , ADAM17 , MMP - 2 and MMP - 9 expression with media degeneration features CaCl2 - induced thoracic aortic aneurysm in a rat model .', {'entities': [(111, 119, 'B_Disease'), (120, 126, 'I_Disease'), (127, 135, 'I_Disease')]}], ['PURPOSE : This study was designed to establish a rat model of thoracic aortic aneurysm ( TAA ) by calcium chloride ( CaCl ( 2 ) ) - induced arterial injury and to explore the potential role of a disintegrin and metalloproteinase ( ADAM ) , matrix metalloproteinases ( MMPs ) and their endogenous inhibitors ( TIMPs ) in TAA formation .', {'entities': [(62, 70, 'B_Disease'), (71, 77, 'I_Disease'), (78, 86, 'I_Disease'), (89, 92, 'B_Disease'), (140, 148, 'B_Disease'), (149, 155, 'I_Disease'), (320, 323, 'B_Disease')]}], ['CONCLUSION : This study establishes a TAA model by periarterial CaCl ( 2 ) exposure in rats , and demonstrates a significant elevation of expression of MMP - 2 , MMP - 9 , ADAM10 and ADAM17 in the pathogenesis of vascular remodeling .', {'entities': [(38, 41, 'B_Disease')]}], ['Suxamethonium induced prolonged apnea in a patient receiving electroconvulsive therapy .', {'entities': [(32, 37, 'B_Disease')]}], ['Suxamethonium causes prolonged apnea in patients in whom pseudocholinesterase enzyme gets deactivated by organophosphorus ( OP ) poisons .', {'entities': [(31, 36, 'B_Disease')]}], ['Here , we present a similar incident in a severely depressed patient who received electroconvulsive therapy ( ECT ) .', {'entities': [(51, 60, 'B_Disease')]}], ['Prolonged apnea in our case ensued because the information about suicidal attempt by OP compound was concealed from the treating team .', {'entities': [(10, 15, 'B_Disease')]}], ['Curcumin ameliorates cognitive dysfunction and oxidative damage in phenobarbitone and carbamazepine administered rats .', {'entities': [(21, 30, 'B_Disease'), (31, 42, 'I_Disease')]}], ['The antiepileptic drugs , phenobarbitone and carbamazepine are well known to cause cognitive impairment on chronic use .', {'entities': [(83, 92, 'B_Disease'), (93, 103, 'I_Disease')]}], ['The increase in free radical generation has been implicated as one of the important mechanisms of cognitive impairment by antiepileptic drugs .', {'entities': [(98, 107, 'B_Disease'), (108, 118, 'I_Disease')]}], ['Therefore , the present study was carried out to investigate the effect of chronic curcumin administration on phenobarbitone - and carbamazepine - induced cognitive impairment and oxidative stress in rats .', {'entities': [(155, 164, 'B_Disease'), (165, 175, 'I_Disease')]}], ['The administration of phenobarbitone and carbamazepine for 21days caused a significant impairment of learning and memory as well as an increased oxidative stress .', {'entities': [(87, 97, 'B_Disease'), (98, 100, 'I_Disease'), (101, 109, 'I_Disease'), (110, 113, 'I_Disease'), (114, 120, 'I_Disease')]}], ['Concomitant curcumin administration prevented the cognitive impairment and decreased the increased oxidative stress induced by these antiepileptic drugs .', {'entities': [(50, 59, 'B_Disease'), (60, 70, 'I_Disease')]}], ['These results show that curcumin has beneficial effect in mitigating the deterioration of cognitive functions and oxidative damage in rats treated with phenobarbitone and carbamazepine without significantly altering their serum concentrations .', {'entities': [(73, 86, 'B_Disease'), (87, 89, 'I_Disease'), (90, 99, 'I_Disease'), (100, 109, 'I_Disease')]}], ['The findings suggest that curcumin can be considered as a potential safe and effective adjuvant to phenobarbitone and carbamazepine therapy in preventing cognitive impairment associated with these drugs .', {'entities': [(154, 163, 'B_Disease'), (164, 174, 'I_Disease')]}], ['Can angiogenesis be a target of treatment for ribavirin associated hemolytic anemia ?', {'entities': [(67, 76, 'B_Disease'), (77, 83, 'I_Disease')]}], ['BACKGROUND / AIMS : Recently ribavirin has been found to inhibit angiogenesis and a number of angiogenesis inhibitors such as sunitinib and sorafenib have been found to cause acute hemolysis .', {'entities': [(181, 190, 'B_Disease')]}], ['We aimed to investigate whether there is a relation between hemoglobin , haptoglobin and angiogenesis soluble markers which are modifiable and can help in developing strategies against anemia .', {'entities': [(185, 191, 'B_Disease')]}], ['METHODS : Fourteen patients chronically infected with hepatitis C virus were treated by pegylated interferon alpha 2a and ribavirin .', {'entities': [(28, 39, 'B_Disease'), (40, 48, 'I_Disease'), (49, 53, 'I_Disease'), (54, 63, 'I_Disease'), (64, 65, 'I_Disease'), (66, 71, 'I_Disease')]}], ['CONCLUSION : This is the first study in the literature investigating a link between angiogenesis soluble markers and ribavirin induced anemia in patients with hepatitis C and we could not find any relation .', {'entities': [(135, 141, 'B_Disease'), (159, 168, 'B_Disease'), (169, 170, 'I_Disease')]}], ['Reduction in injection pain using buffered lidocaine as a local anesthetic before cardiac catheterization .', {'entities': [(23, 27, 'B_Disease')]}], ['Previous reports have suggested that pain associated with the injection of lidocaine is related to the acidic pH of the solution .', {'entities': [(37, 41, 'B_Disease')]}], ['To determine if the addition of a buffering solution to adjust the pH of lidocaine into the physiologic range would reduce pain during injection , we performed a blinded randomized study in patients undergoing cardiac catheterization .', {'entities': [(123, 127, 'B_Disease')]}], ['Twenty patients were asked to quantify the severity of pain after receiving standard lidocaine in one femoral area and buffered lidocaine in the opposite femoral area .', {'entities': [(55, 59, 'B_Disease')]}], ['The mean pain score for buffered lidocaine was significantly lower than the mean score for standard lidocaine ( 2 . 7 + / - 1 . 9 vs . 3 . 8 + / - 2 . 2 , P = 0 . 03 ) .', {'entities': [(9, 13, 'B_Disease')]}], ['The pH adjustment of standard lidocaine can be accomplished easily in the catheterization laboratory before injection and results in a reduction of the pain occurring during the infiltration of tissues .', {'entities': [(152, 156, 'B_Disease')]}], ['Effect of L - alpha - glyceryl - phosphorylcholine on amnesia caused by scopolamine .', {'entities': [(54, 61, 'B_Disease')]}], ['The present study was carried out to test the effects of L - alpha - glycerylphosphorylcholine ( L - alpha - GFC ) on memory impairment induced by scopolamine in man .', {'entities': [(118, 124, 'B_Disease'), (125, 135, 'I_Disease')]}], ['The findings of this study indicate that the drug is able to antagonize impairment of attention and memory induced by scopolamine .', {'entities': [(72, 82, 'B_Disease'), (83, 85, 'I_Disease'), (86, 95, 'I_Disease'), (96, 99, 'I_Disease'), (100, 106, 'I_Disease')]}], ['IMPORTANCE OF THE FIELD : Fluoropyrimidines , in particular 5 - fluorouracil ( 5 - FU ) , have been the mainstay of treatment for several solid tumors , including colorectal , breast and head and neck cancers , for > 40 years .', {'entities': [(144, 150, 'B_Disease'), (163, 173, 'B_Disease'), (174, 175, 'I_Disease'), (176, 182, 'I_Disease'), (183, 186, 'I_Disease'), (187, 191, 'I_Disease'), (192, 195, 'I_Disease'), (196, 200, 'I_Disease'), (201, 208, 'I_Disease')]}], ['WHAT THE READER WILL GAIN : The reader will gain better insight into the safety of capecitabine in special populations such as patients with advanced age , renal and kidney disease .', {'entities': [(156, 161, 'B_Disease'), (162, 165, 'I_Disease'), (166, 172, 'I_Disease'), (173, 180, 'I_Disease')]}], ['It has shown promising results alone or in combination with other chemotherapeutic agents in colorectal , breast , pancreaticobiliary , gastric , renal cell and head and neck cancers .', {'entities': [(93, 103, 'B_Disease'), (104, 105, 'I_Disease'), (106, 112, 'I_Disease'), (113, 114, 'I_Disease'), (115, 133, 'I_Disease'), (134, 135, 'I_Disease'), (136, 143, 'I_Disease'), (144, 145, 'I_Disease'), (146, 151, 'I_Disease'), (152, 156, 'I_Disease'), (157, 160, 'I_Disease'), (161, 165, 'I_Disease'), (166, 169, 'I_Disease'), (170, 174, 'I_Disease'), (175, 182, 'I_Disease')]}], ['The most commonly reported toxic effects of capecitabine are diarrhea , nausea , vomiting , stomatitis and hand - foot syndrome .', {'entities': [(61, 69, 'B_Disease'), (72, 78, 'B_Disease'), (81, 89, 'B_Disease'), (92, 102, 'B_Disease'), (107, 111, 'B_Disease'), (112, 113, 'I_Disease'), (114, 118, 'I_Disease'), (119, 127, 'I_Disease')]}], ['Capecitabine has a well - established safety profile and can be given safely to patients with advanced age , hepatic and renal dysfunctions .', {'entities': [(109, 116, 'B_Disease'), (117, 120, 'I_Disease'), (121, 126, 'I_Disease'), (127, 139, 'I_Disease')]}], [\"Levodopa - induced dyskinesias in patients with Parkinson ' s disease : filling the bench - to - bedside gap .\", {'entities': [(19, 30, 'B_Disease'), (48, 57, 'B_Disease'), (58, 59, 'I_Disease'), (60, 61, 'I_Disease'), (62, 69, 'I_Disease')]}], [\"Levodopa is the most effective drug for the treatment of Parkinson ' s disease .\", {'entities': [(57, 66, 'B_Disease'), (67, 68, 'I_Disease'), (69, 70, 'I_Disease'), (71, 78, 'I_Disease')]}], ['However , the long - term use of this dopamine precursor is complicated by highly disabling fluctuations and dyskinesias .', {'entities': [(109, 120, 'B_Disease')]}], ['Although preclinical and clinical findings suggest pulsatile stimulation of striatal postsynaptic receptors as a key mechanism underlying levodopa - induced dyskinesias , their pathogenesis is still unclear .', {'entities': [(157, 168, 'B_Disease')]}], [\"In recent years , evidence from animal models of Parkinson ' s disease has provided important information to understand the effect of specific receptor and post - receptor molecular mechanisms underlying the development of dyskinetic movements .\", {'entities': [(49, 58, 'B_Disease'), (59, 60, 'I_Disease'), (61, 62, 'I_Disease'), (63, 70, 'I_Disease'), (223, 233, 'B_Disease'), (234, 243, 'I_Disease')]}], ['Recent preclinical and clinical data from promising lines of research focus on the differential role of presynaptic versus postsynaptic mechanisms , dopamine receptor subtypes , ionotropic and metabotropic glutamate receptors , and non - dopaminergic neurotransmitter systems in the pathophysiology of levodopa - induced dyskinesias .', {'entities': [(321, 332, 'B_Disease')]}], ['Effects of pallidal neurotensin on haloperidol - induced parkinsonian catalepsy : behavioral and electrophysiological studies .', {'entities': [(57, 69, 'B_Disease'), (70, 79, 'I_Disease')]}], ['The present study aimed to investigate the effects of pallidal neurotensin on haloperidol - induced parkinsonian symptoms .', {'entities': [(100, 112, 'B_Disease'), (113, 121, 'I_Disease')]}], ['RESULTS : Bilateral infusions of neurotensin into the globus pallidus reversed haloperidol - induced parkinsonian catalepsy in rats .', {'entities': [(101, 113, 'B_Disease'), (114, 123, 'I_Disease')]}], ['Carmofur - induced organic mental disorders .', {'entities': [(19, 26, 'B_Disease'), (27, 33, 'I_Disease'), (34, 43, 'I_Disease')]}], ['Organic mental disorder was observed in a 29 - year - old female in the prognostic period after the onset of carmofur - induced leukoencephalopathy .', {'entities': [(0, 7, 'B_Disease'), (8, 14, 'I_Disease'), (15, 23, 'I_Disease'), (128, 147, 'B_Disease')]}], ['Symptoms such as euphoria , emotional lability and puerile attitude noted in the patient were diagnosed as organic personality syndrome according to the criteria defined in the DSM - III - R .', {'entities': [(107, 114, 'B_Disease'), (115, 126, 'I_Disease'), (127, 135, 'I_Disease')]}], ['It is referred to as a frontal lobe syndrome .', {'entities': [(23, 30, 'B_Disease'), (31, 35, 'I_Disease'), (36, 44, 'I_Disease')]}], ['Consequently , carmofur - induced leukoencephalopathy may uncommonly result in organic personality syndrome in the residual state .', {'entities': [(34, 53, 'B_Disease'), (79, 86, 'B_Disease'), (87, 98, 'I_Disease'), (99, 107, 'I_Disease')]}], ['It may be attributed to the structural damage to the frontal lobe .', {'entities': [(28, 38, 'B_Disease'), (39, 45, 'I_Disease'), (46, 48, 'I_Disease'), (49, 52, 'I_Disease'), (53, 60, 'I_Disease'), (61, 65, 'I_Disease')]}], ['Butyrylcholinesterase gene mutations in patients with prolonged apnea after succinylcholine for electroconvulsive therapy .', {'entities': [(64, 69, 'B_Disease')]}], ['We determined the BChE activity and the BCHE genotype using molecular genetic methods , the duration of apnea , time to sufficient spontaneous ventilation and whether neuromuscular monitoring was used .', {'entities': [(104, 109, 'B_Disease')]}], ['The duration of apnea was compared with published data on normal subjects .', {'entities': [(16, 21, 'B_Disease')]}], ['The duration of apnea was 5 - 15 min compared with 3 - 5 . 3 min from the literature .', {'entities': [(16, 21, 'B_Disease')]}], ['CONCLUSION : eleven of 13 patients with a prolonged duration of action of succinylcholine had mutations in BCHE , indicating that this is the possible reason for a prolonged period of apnea .', {'entities': [(184, 189, 'B_Disease')]}], ['Perhexiline maleate and peripheral neuropathy .', {'entities': [(24, 34, 'B_Disease'), (35, 45, 'I_Disease')]}], ['Peripheral neuropathy has been noted as a complication of therapy with perhexiline maleate , a drug widely used in France ( and in clinical trials in the United States ) for the prophylactic treatment of angina pectoris .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (204, 210, 'B_Disease'), (211, 219, 'I_Disease')]}], ['In 24 patients with this complication , the marked slowing of motor nerve conduction velocity and the electromyographic changes imply mainly a demyelinating disorder .', {'entities': [(143, 156, 'B_Disease'), (157, 165, 'I_Disease')]}], ['The underlying mechanism causing the neuropathy is not yet fully known , although some evidence indicates that it may be a lipid storage process .', {'entities': [(37, 47, 'B_Disease')]}], [\"A Phase I study of intravenous ( IV ) bolus 4 ' - 0 - tetrahydropyranyladriamycin ( Pirarubicin ) was done in 55 patients in good performance status with refractory tumors .\", {'entities': [(165, 171, 'B_Disease')]}], ['Twenty - six had minimal prior therapy ( good risk ) , 23 had extensive prior therapy ( poor risk ) , and six had renal and / or hepatic dysfunction .', {'entities': [(114, 119, 'B_Disease'), (120, 123, 'I_Disease'), (124, 125, 'I_Disease'), (126, 128, 'I_Disease'), (129, 136, 'I_Disease'), (137, 148, 'I_Disease')]}], ['The dose - limiting toxic effect was transient noncumulative granulocytopenia .', {'entities': [(61, 77, 'B_Disease')]}], ['Less frequent toxic effects included thrombocytopenia , anemia , nausea , mild alopecia , phlebitis , and mucositis .', {'entities': [(37, 53, 'B_Disease'), (56, 62, 'B_Disease'), (65, 71, 'B_Disease'), (79, 87, 'B_Disease'), (90, 99, 'B_Disease'), (106, 115, 'B_Disease')]}], ['Myelosuppression was more in patients with hepatic dysfunction .', {'entities': [(0, 16, 'B_Disease'), (43, 50, 'B_Disease'), (51, 62, 'I_Disease')]}], ['Activity was noted in mesothelioma , leiomyosarcoma , and basal cell carcinoma .', {'entities': [(22, 34, 'B_Disease'), (37, 51, 'B_Disease'), (58, 63, 'B_Disease'), (64, 68, 'I_Disease'), (69, 78, 'I_Disease')]}], ['Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine .', {'entities': [(0, 6, 'B_Disease'), (7, 10, 'I_Disease'), (11, 19, 'I_Disease'), (20, 28, 'I_Disease')]}], ['During an 18 - month period of study 41 hemodialyzed patients receiving desferrioxamine ( 10 - 40 mg / kg BW / 3 times weekly ) for the first time were monitored for detection of audiovisual toxicity .', {'entities': [(179, 190, 'B_Disease'), (191, 199, 'I_Disease')]}], ['6 patients presented clinical symptoms of visual or auditory toxicity .', {'entities': [(42, 48, 'B_Disease'), (49, 51, 'I_Disease'), (52, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['Visual toxicity was of retinal origin and was characterized by a tritan - type dyschromatopsy , sometimes associated with a loss of visual acuity and pigmentary retinal deposits .', {'entities': [(0, 6, 'B_Disease'), (7, 15, 'I_Disease'), (79, 93, 'B_Disease'), (122, 123, 'B_Disease'), (124, 128, 'I_Disease'), (129, 131, 'I_Disease'), (132, 138, 'I_Disease'), (139, 145, 'I_Disease'), (150, 160, 'B_Disease'), (161, 168, 'I_Disease'), (169, 177, 'I_Disease')]}], ['Auditory toxicity was characterized by a mid - to high - frequency neurosensorial hearing loss and the lesion was of the cochlear type .', {'entities': [(0, 8, 'B_Disease'), (9, 17, 'I_Disease'), (67, 81, 'B_Disease'), (82, 89, 'I_Disease'), (90, 94, 'I_Disease')]}], ['Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3 , and a complete reversal of hearing loss in 3 patients and partial recovery in 3 .', {'entities': [(146, 153, 'B_Disease'), (154, 158, 'I_Disease')]}], ['This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels .', {'entities': [(5, 13, 'B_Disease')]}], ['The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine .', {'entities': [(23, 34, 'B_Disease'), (35, 43, 'I_Disease')]}], ['Serial epilepsy caused by levodopa / carbidopa administration in two patients on hemodialysis .', {'entities': [(7, 15, 'B_Disease')]}], ['Two patients with similar clinical features are presented : both patients had chronic renal failure , on hemodialysis for many years but recently begun on a high - flux dialyzer ; both had been receiving a carbidopa / levodopa preparation ; and both had the onset of hallucinosis and recurrent seizures , which were refractory to anticonvulsants .', {'entities': [(78, 85, 'B_Disease'), (86, 91, 'I_Disease'), (92, 99, 'I_Disease'), (267, 279, 'B_Disease'), (294, 302, 'B_Disease')]}], ['Randomized , double - blind trial of mazindol in Duchenne dystrophy .', {'entities': [(49, 57, 'B_Disease'), (58, 67, 'I_Disease')]}], ['There is evidence that growth hormone may be related to the progression of weakness in Duchenne dystrophy .', {'entities': [(75, 83, 'B_Disease'), (87, 95, 'B_Disease'), (96, 105, 'I_Disease')]}], ['We conducted a 12 - month controlled trial of mazindol , a putative growth hormone secretion inhibitor , in 83 boys with Duchenne dystrophy .', {'entities': [(121, 129, 'B_Disease'), (130, 139, 'I_Disease')]}], ['The study was designed to have a power of greater than 0 . 90 to detect a slowing to 25 % of the expected rate of progression of weakness at P less than 0 . 05 .', {'entities': [(129, 137, 'B_Disease')]}], ['Side effects attributable to mazindol included decreased appetite ( 36 % ) , dry mouth ( 10 % ) , behavioral change ( 22 % ) , and gastrointestinal symptoms ( 18 % ) ; mazindol dosage was reduced in 43 % of patients .', {'entities': [(47, 56, 'B_Disease'), (57, 65, 'I_Disease'), (77, 80, 'B_Disease'), (81, 86, 'I_Disease'), (131, 147, 'B_Disease'), (148, 156, 'I_Disease')]}], ['Mazindol doses not slow the progression of weakness in Duchenne dystrophy .', {'entities': [(43, 51, 'B_Disease'), (55, 63, 'B_Disease'), (64, 73, 'I_Disease')]}], ['Amnesia produced by scopolamine and cycloheximide were reversed by morphine given 30 min before the test trial ( pre - test ) , and pre - test morphine also facilitated the memory retrieval in the animals administered naloxone during the training trial .', {'entities': [(0, 7, 'B_Disease')]}], ['Similarly , pre - test scopolamine partially reversed the scopolamine - induced amnesia , but not significantly ; and pre - test cycloheximide failed to reverse the cycloheximide - induced amnesia .', {'entities': [(80, 87, 'B_Disease'), (189, 196, 'B_Disease')]}], ['In unanesthetized , spontaneously hypertensive rats the decrease in blood pressure and heart rate produced by intravenous clonidine , 5 to 20 micrograms / kg , was inhibited or reversed by nalozone , 0 . 2 to 2 mg / kg .', {'entities': [(34, 46, 'B_Disease')]}], ['The hypotensive effect of 100 mg / kg alpha - methyldopa was also partially reversed by naloxone .', {'entities': [(4, 15, 'B_Disease')]}], ['In brain membranes from spontaneously hypertensive rats clonidine , 10 ( - 8 ) to 10 ( - 5 ) M , did not influence stereoselective binding of [ 3H ] - naloxone ( 8 nM ) , and naloxone , 10 ( - 8 ) to 10 ( - 4 ) M , did not influence clonidine - suppressible binding of [ 3H ] - dihydroergocryptine ( 1 nM ) .', {'entities': [(38, 50, 'B_Disease')]}], ['These findings indicate that in spontaneously hypertensive rats the effects of central alpha - adrenoceptor stimulation involve activation of opiate receptors .', {'entities': [(46, 58, 'B_Disease')]}], ['Neurotoxicity of halogenated hydroxyquinolines : clinical analysis of cases reported outside Japan .', {'entities': [(0, 13, 'B_Disease')]}], ['An analysis is presented of 220 cases of possible neurotoxic reactions to halogenated hydroxyquinolines reported from outside Japan .', {'entities': [(50, 60, 'B_Disease')]}], ['In six of the probable cases the neurological disturbance consisted of an acute reversible encephalopathy usually related to the ingestion of a high dose of clioquinol over a short period .', {'entities': [(33, 45, 'B_Disease'), (46, 57, 'I_Disease'), (91, 105, 'B_Disease')]}], ['The most common manifestation , observed in 15 further cases , was isolated optic atrophy .', {'entities': [(76, 81, 'B_Disease'), (82, 89, 'I_Disease')]}], ['This was most frequently found in children , many of whom had received clioquinol as treatment for acrodermatitis enteropathica .', {'entities': [(99, 113, 'B_Disease'), (114, 127, 'I_Disease')]}], ['In the remaining cases , a combination of myelopathy , visual disturbance , and peripheral neuropathy was the most common manifestation .', {'entities': [(42, 52, 'B_Disease'), (55, 61, 'B_Disease'), (62, 73, 'I_Disease'), (80, 90, 'B_Disease'), (91, 101, 'I_Disease')]}], ['Isolated myelopathy or peripheral neuropathy , or these manifestations occurring together , were infrequent .', {'entities': [(9, 19, 'B_Disease'), (23, 33, 'B_Disease'), (34, 44, 'I_Disease')]}], ['The onset of all manifestations ( except toxic encephalopathy ) was usually subacute , with subsequent partial recovery .', {'entities': [(47, 61, 'B_Disease')]}], ['The full syndrome of subacute myelo - optic neuropathy was more frequent in women , but they tended to have taken greater quantities of the drug .', {'entities': [(30, 35, 'B_Disease'), (36, 37, 'I_Disease'), (38, 43, 'I_Disease'), (44, 54, 'I_Disease')]}], ['Prazosin - induced stress incontinence .', {'entities': [(19, 25, 'B_Disease'), (26, 38, 'I_Disease')]}], ['A case of genuine stress incontinence due to prazosin , a common antihypertensive drug , is presented .', {'entities': [(18, 24, 'B_Disease'), (25, 37, 'I_Disease')]}], ['Her incontinence resolved with the change of medication .', {'entities': [(4, 16, 'B_Disease')]}], ['Patients who present with stress incontinence while taking prazosin should change their antihypertensive medication before considering surgery , because their incontinence may resolve spontaneously with a change in drug therapy .', {'entities': [(26, 32, 'B_Disease'), (33, 45, 'I_Disease'), (159, 171, 'B_Disease')]}], ['Myocardial infarction following sublingual administration of isosorbide dinitrate .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease')]}], ['A 78 - year - old with healed septal necrosis suffered a recurrent myocardial infarction of the anterior wall following the administration of isosorbide dinitrate 5 mg sublingually .', {'entities': [(37, 45, 'B_Disease'), (67, 77, 'B_Disease'), (78, 88, 'I_Disease')]}], ['After detailing the course of events , we discuss the role of paradoxical coronary spasm and hypotension - mediated myocardial ischemia occurring downstream to significant coronary arterial stenosis in the pathophysiology of acute coronary insufficiency .', {'entities': [(83, 88, 'B_Disease'), (93, 104, 'B_Disease'), (116, 126, 'B_Disease'), (127, 135, 'I_Disease'), (172, 180, 'B_Disease'), (181, 189, 'I_Disease'), (190, 198, 'I_Disease'), (225, 230, 'B_Disease'), (231, 239, 'I_Disease'), (240, 253, 'I_Disease')]}], ['The incidence of postoperative respiratory apnoea was compared between five patients receiving a continuous i . v . infusion of morphine ( mean 73 . 6 mg ) and five patients receiving a continuous extradural infusion of 0 . 25 % bupivacaine ( mean 192 mg ) in the 24 - h period following upper abdominal surgery .', {'entities': [(43, 49, 'B_Disease')]}], ['Both obstructive ( P less than 0 . 05 ) and central apnoea ( P less than 0 . 05 ) occurred more frequently in patients who had a morphine infusion .', {'entities': [(5, 16, 'B_Disease'), (17, 18, 'I_Disease'), (19, 20, 'I_Disease'), (21, 25, 'I_Disease'), (26, 30, 'I_Disease'), (31, 32, 'I_Disease'), (33, 34, 'I_Disease'), (35, 37, 'I_Disease'), (38, 39, 'I_Disease'), (40, 43, 'I_Disease'), (44, 51, 'I_Disease'), (52, 58, 'I_Disease')]}], ['There was also a higher incidence of tachyarrhythmias ( P less than 0 . 05 ) and ventricular ectopic beats ( P less than 0 . 05 ) in the morphine infusion group .', {'entities': [(37, 53, 'B_Disease'), (81, 92, 'B_Disease'), (93, 100, 'I_Disease'), (101, 106, 'I_Disease')]}], ['Effects of aminophylline on the threshold for initiating ventricular fibrillation during respiratory failure .', {'entities': [(57, 68, 'B_Disease'), (69, 81, 'I_Disease'), (89, 100, 'B_Disease'), (101, 108, 'I_Disease')]}], ['Cardiac arrhythmias have frequently been reported in association with respiratory failure .', {'entities': [(0, 7, 'B_Disease'), (8, 19, 'I_Disease'), (70, 81, 'B_Disease'), (82, 89, 'I_Disease')]}], ['The possible additive role of pharmacologic agents in precipitating cardiac disturbances in patients with respiratory failure has only recently been emphasized .', {'entities': [(68, 75, 'B_Disease'), (76, 88, 'I_Disease'), (106, 117, 'B_Disease'), (118, 125, 'I_Disease')]}], ['The effects of aminophylline on the ventricular fibrillation threshold during normal acid - base conditions and during respiratory failure were studied in anesthetized open chest dogs .', {'entities': [(36, 47, 'B_Disease'), (48, 60, 'I_Disease'), (119, 130, 'B_Disease'), (131, 138, 'I_Disease')]}], ['The ventricular fibrillation threshold was measured by passing a gated train of 12 constant current pulses through the ventricular myocardium during the vulnerable period of the cardiac cycle .', {'entities': [(4, 15, 'B_Disease'), (16, 28, 'I_Disease')]}], ['During the infusion of aminophylline , the ventricular fibrillation threshold was reduced by 30 to 40 percent of the control when pH and partial pressures of oxygen ( PO2 ) and carbon dioxide ( CO2 ) were kept within normal limits .', {'entities': [(43, 54, 'B_Disease'), (55, 67, 'I_Disease')]}], ['When respiratory failure was produced by hypoventilation ( pH 7 . 05 to 7 . 25 ; PC02 70 to 100 mm Hg : P02 20 to 40 mm Hg ) , infusion of aminophylline resulted in an even greater decrease in ventricular fibrillation threshold to 60 percent of the control level .', {'entities': [(5, 16, 'B_Disease'), (17, 24, 'I_Disease'), (41, 56, 'B_Disease'), (193, 204, 'B_Disease'), (205, 217, 'I_Disease')]}], ['These experiments suggest that although many factors may contribute to the increased incidence of ventricular arrhythmias in respiratory failure , pharmacologic agents , particularly aminophylline , may play a significant role .', {'entities': [(98, 109, 'B_Disease'), (110, 121, 'I_Disease'), (125, 136, 'B_Disease'), (137, 144, 'I_Disease')]}], ['Pentoxifylline ( Trental ) does not inhibit dipyridamole - induced coronary hyperemia : implications for dipyridamole - thallium - 201 myocardial imaging .', {'entities': [(76, 85, 'B_Disease')]}], ['Dipyridamole - thallium - 201 imaging is often performed in patients unable to exercise because of peripheral vascular disease .', {'entities': [(99, 109, 'B_Disease'), (110, 118, 'I_Disease'), (119, 126, 'I_Disease')]}], ['Many of these patients are taking pentoxifylline ( Trental ) , a methylxanthine derivative which may improve intermittent claudication .', {'entities': [(109, 121, 'B_Disease'), (122, 134, 'I_Disease')]}], ['Whether pentoxifylline inhibits dipyridamole - induced coronary hyperemia like other methylxanthines such as theophylline and should be stopped prior to dipyridamole - thallium - 201 imaging is unknown .', {'entities': [(64, 73, 'B_Disease')]}], ['Neither dose of pentoxifylline significantly decreased the dipyridamole - induced hyperemia , while peak coronary blood flow was significantly lower after theophylline ( p less than 0 . 01 ) .', {'entities': [(82, 91, 'B_Disease')]}], ['We conclude that pentoxyifylline does not inhibit dipyridamole - induced coronary hyperemia even at high doses .', {'entities': [(82, 91, 'B_Disease')]}], [\"Cause of death among patients with Parkinson ' s disease : a rare mortality due to cerebral haemorrhage .\", {'entities': [(9, 14, 'B_Disease'), (35, 44, 'B_Disease'), (45, 46, 'I_Disease'), (47, 48, 'I_Disease'), (49, 56, 'I_Disease'), (83, 91, 'B_Disease'), (92, 103, 'I_Disease')]}], [\"Causes of death , with special reference to cerebral haemorrhage , among 240 patients with pathologically verified Parkinson ' s disease were investigated using the Annuals of the Pathological Autopsy Cases in Japan from 1981 to 1985 .\", {'entities': [(10, 15, 'B_Disease'), (44, 52, 'B_Disease'), (53, 64, 'I_Disease'), (115, 124, 'B_Disease'), (125, 126, 'I_Disease'), (127, 128, 'I_Disease'), (129, 136, 'I_Disease')]}], ['The leading causes of death were pneumonia and bronchitis ( 44 . 1 % ) , malignant neoplasms ( 11 . 6 % ) , heart diseases ( 4 . 1 % ) , cerebral infarction ( 3 . 7 % ) and septicaemia ( 3 . 3 % ) .', {'entities': [(22, 27, 'B_Disease'), (33, 42, 'B_Disease'), (47, 57, 'B_Disease'), (83, 92, 'B_Disease'), (108, 113, 'B_Disease'), (114, 122, 'I_Disease'), (137, 145, 'B_Disease'), (146, 156, 'I_Disease'), (173, 184, 'B_Disease')]}], ['Cerebral haemorrhage was the 11th most frequent cause of death , accounting for only 0 . 8 % of deaths among the patients , whereas it was the 5th most common cause of death among the Japanese general population in 1985 .', {'entities': [(0, 8, 'B_Disease'), (9, 20, 'I_Disease'), (57, 62, 'B_Disease'), (96, 102, 'B_Disease'), (168, 173, 'B_Disease')]}], [\"The low incidence of cerebral haemorrhage as a cause of death in patients with Parkinson ' s disease may reflect the hypotensive effect of levodopa and a hypotensive mechanism due to reduced noradrenaline levels in the parkinsonian brain .\", {'entities': [(21, 29, 'B_Disease'), (30, 41, 'I_Disease'), (56, 61, 'B_Disease'), (79, 88, 'B_Disease'), (89, 90, 'I_Disease'), (91, 92, 'I_Disease'), (93, 100, 'I_Disease'), (117, 128, 'B_Disease'), (154, 165, 'B_Disease'), (219, 231, 'B_Disease')]}], ['Possible intramuscular midazolam - associated cardiorespiratory arrest and death .', {'entities': [(46, 63, 'B_Disease'), (64, 70, 'I_Disease'), (75, 80, 'B_Disease')]}], ['Although generally consisted safe when given intramuscularly , intravenous administration is known to cause respiratory and cardiovascular depression .', {'entities': [(108, 119, 'B_Disease'), (120, 123, 'I_Disease'), (124, 138, 'I_Disease'), (139, 149, 'I_Disease')]}], ['This report describes the first published case of cardiorespiratory arrest and death associated with intramuscular administration of midazolam .', {'entities': [(50, 67, 'B_Disease'), (68, 74, 'I_Disease'), (79, 84, 'B_Disease')]}], ['Myasthenia gravis presenting as weakness after magnesium administration .', {'entities': [(0, 10, 'B_Disease'), (11, 17, 'I_Disease')]}], ['We studied a patient with no prior history of neuromuscular disease who became virtually quadriplegic after parenteral magnesium administration for preeclampsia .', {'entities': [(46, 59, 'B_Disease'), (60, 67, 'I_Disease'), (89, 101, 'B_Disease'), (148, 160, 'B_Disease')]}], ['While she was weak , 2 - Hz repetitive stimulation revealed a decrement without significant facilitation at rapid rates or after exercise , suggesting postsynaptic neuromuscular blockade .', {'entities': [(151, 163, 'B_Disease'), (164, 177, 'I_Disease'), (178, 186, 'I_Disease')]}], ['Although paralysis after magnesium administration has been described in patients with known myasthenia gravis , it has not previously been reported to be the initial or only manifestation of the disease .', {'entities': [(9, 18, 'B_Disease'), (92, 102, 'B_Disease'), (103, 109, 'I_Disease')]}], ['Patients who are unusually sensitive to the neuromuscular effects of magnesium should be suspected of having an underlying disorder of neuromuscular transmission .', {'entities': [(123, 131, 'B_Disease'), (132, 134, 'I_Disease'), (135, 148, 'I_Disease'), (149, 161, 'I_Disease')]}], ['No hepatic preneoplastic nodules or hepatocellular carcinomas developed in rats fed the plain choline - supplemented diet , while one preneoplastic nodule and one hepatocellular carcinoma developed in two rats fed the same diet containing phenobarbital .', {'entities': [(36, 50, 'B_Disease'), (51, 61, 'I_Disease'), (163, 177, 'B_Disease'), (178, 187, 'I_Disease')]}], ['The incidence of preneoplastic nodules and of hepatocellular carcinomas was 10 % and 37 % , respectively , in rats fed the plain choline - devoid diet , and 17 % and 30 % , in rats fed the phenobarbital - containing choline - devoid diet .', {'entities': [(46, 60, 'B_Disease'), (61, 71, 'I_Disease')]}], ['Liver enlargement and muscle wastage occurred in Wistar rats following the subcutaneous administration of prednisolone .', {'entities': [(0, 5, 'B_Disease'), (6, 17, 'I_Disease'), (22, 28, 'B_Disease'), (29, 36, 'I_Disease')]}], ['Differential effects of gamma - hexachlorocyclohexane ( lindane ) on pharmacologically - induced seizures .', {'entities': [(97, 105, 'B_Disease')]}], ['Gamma - hexachlorocyclohexane ( gamma - HCH ) , the active ingredient of the insecticide lindane , has been shown to decrease seizure threshold to pentylenetrazol ( PTZ ) 3 h after exposure to gamma - HCH and conversely increase threshold to PTZ - induced seizures 24 h after exposure to gamma - HCH ( Vohland et al . 1981 ) .', {'entities': [(126, 133, 'B_Disease'), (256, 264, 'B_Disease')]}], ['In this study , the severity of response to other seizure - inducing agents was tested in mice 1 and 24 h after intraperitoneal administration of 80 mg / kg gamma - HCH .', {'entities': [(50, 57, 'B_Disease')]}], ['One hour after the administration of gamma - HCH , the activity of seizure - inducing agents was increased , regardless of their mechanism , while 24 h after gamma - HCH a differential response was observed .', {'entities': [(67, 74, 'B_Disease')]}], ['Seizure activity due to PTZ and picrotoxin ( PTX ) was significantly decreased ; however , seizure activity due to 3 - mercaptopropionic acid ( MPA ) , bicuculline ( BCC ) , methyl 6 , 7 - dimethoxy - 4 - ethyl - B - carboline - 3 - carboxylate ( DMCM ) , or strychnine ( STR ) was not different from control .', {'entities': [(0, 7, 'B_Disease'), (91, 98, 'B_Disease')]}], ['The pharmacological challenge data suggest that tolerance may occur to seizure activity induced by PTZ and PTX 24 h after gamma - HCH , since the response to only these two seizure - inducing agents is decreased .', {'entities': [(71, 78, 'B_Disease'), (173, 180, 'B_Disease')]}], ['The in vitro data suggest that the site responsible for the decrease in seizure activity 24 h after gamma - HCH may be the GABA - A receptor - linked chloride channel .', {'entities': [(72, 79, 'B_Disease')]}], ['Tolerance and antiviral effect of ribavirin in patients with Argentine hemorrhagic fever .', {'entities': [(61, 70, 'B_Disease'), (71, 82, 'I_Disease'), (83, 88, 'I_Disease')]}], ['Tolerance and antiviral effect of ribavirin was studied in 6 patients with Argentine hemorrhagic fever ( AHF ) of more than 8 days of evolution .', {'entities': [(75, 84, 'B_Disease'), (85, 96, 'I_Disease'), (97, 102, 'I_Disease'), (105, 108, 'B_Disease')]}], ['Administration of ribavirin resulted in a neutralization of viremia and a drop of endogenous interferon titers .', {'entities': [(60, 67, 'B_Disease')]}], ['The average time of death was delayed .', {'entities': [(20, 25, 'B_Disease')]}], ['A reversible anemia was the only adverse effect observed .', {'entities': [(13, 19, 'B_Disease')]}], ['From these results , we conclude that ribavirin has an antiviral effect in advanced cases of AHF , and that anemia , the only secondary reaction observed , can be easily managed .', {'entities': [(93, 96, 'B_Disease'), (108, 114, 'B_Disease')]}], ['The possible beneficial effect of ribavirin during the initial days of AHF is discussed .', {'entities': [(71, 74, 'B_Disease')]}], ['Is the treatment of scabies hazardous ?', {'entities': [(20, 27, 'B_Disease')]}], ['Treatment for scabies is usually initiated by general practitioners ; most consider lindane ( gamma benzene hexachloride ) the treatment of choice .', {'entities': [(14, 21, 'B_Disease')]}], ['Evidence is accumulating that lindane can be toxic to the central nervous system and may be associated with aplastic anaemia .', {'entities': [(45, 50, 'B_Disease'), (51, 53, 'I_Disease'), (54, 57, 'I_Disease'), (58, 65, 'I_Disease'), (66, 73, 'I_Disease'), (74, 80, 'I_Disease'), (108, 116, 'B_Disease'), (117, 124, 'I_Disease')]}], ['This literature review suggests that general practitioners should prescribe scabicides with increased caution for certain at - risk groups , and give adequate warnings regarding potential toxicity .', {'entities': [(188, 196, 'B_Disease')]}], ['The initial dose of amantadine depressed locomotor activity in all mouse strains studied with the BALB / C mice being the most sensitive .', {'entities': [(31, 40, 'B_Disease')]}], ['Readministration of amantadine , after a drug - free overnight period , increased motility from respective saline control in all strains with exception of the BALB / C mice where suppression of motility occurred .', {'entities': [(179, 190, 'B_Disease'), (191, 193, 'I_Disease'), (194, 202, 'I_Disease')]}], ['The biochemical results of brain biogenic amines of BALB / C mouse strain suggest a probable decrease of catecholamine turnover rate and / or metabolism by monoamine oxidase and a resulting increase in O - methylation of norepinephrine which may account for a behavioral depression caused by amantadine in the BALB / C mice .', {'entities': [(260, 270, 'B_Disease'), (271, 281, 'I_Disease')]}], ['Based on clinical data , indicating that chloroacetaldehyde ( CAA ) is an important metabolite of oxazaphosphorine cytostatics , an experimental study was carried out in order to elucidate the role of CAA in the development of hemorrhagic cystitis .', {'entities': [(227, 238, 'B_Disease'), (239, 247, 'I_Disease')]}], ['The data demonstrate that CAA after i . v . administration does not contribute to bladder damage .', {'entities': [(82, 89, 'B_Disease'), (90, 96, 'I_Disease')]}], ['Source of pain and primitive dysfunction in migraine : an identical site ?', {'entities': [(10, 14, 'B_Disease'), (44, 52, 'B_Disease')]}], ['Twenty common migraine patients received a one sided frontotemporal application of nitroglycerin ( 10 patients ) or placebo ointment ( 10 patients ) in a double blind study .', {'entities': [(14, 22, 'B_Disease')]}], ['Early onset migraine attacks were induced by nitroglycerin in seven out of 10 patients versus no patient in the placebo group .', {'entities': [(12, 20, 'B_Disease')]}], ['Subsequently 20 migraine patients , who developed an early onset attack with frontotemporal nitroglycerin , received the drug in a second induction test at other body areas .', {'entities': [(16, 24, 'B_Disease')]}], ['No early onset migraine was observed .', {'entities': [(15, 23, 'B_Disease')]}], ['Thus the migraine - inducing effect of nitroglycerin seems to depend on direct stimulation of the habitual site of pain , suggesting that the frontotemporal region is of crucial importance in the development of a migraine crisis .', {'entities': [(9, 17, 'B_Disease'), (115, 119, 'B_Disease'), (213, 221, 'B_Disease')]}], ['This is not consistent with a CNS origin of migraine attack .', {'entities': [(44, 52, 'B_Disease')]}], ['Hypersensitivity to carbamazepine presenting with a leukemoid reaction , eosinophilia , erythroderma , and renal failure .', {'entities': [(0, 16, 'B_Disease'), (52, 61, 'B_Disease'), (62, 70, 'I_Disease'), (73, 85, 'B_Disease'), (88, 100, 'B_Disease'), (107, 112, 'B_Disease'), (113, 120, 'I_Disease')]}], ['We report a patient in whom hypersensitivity to carbamazepine presented with generalized erythroderma , a severe leukemoid reaction , eosinophilia , hyponatremia , and renal failure .', {'entities': [(28, 44, 'B_Disease'), (89, 101, 'B_Disease'), (113, 122, 'B_Disease'), (123, 131, 'I_Disease'), (134, 146, 'B_Disease'), (149, 161, 'B_Disease'), (168, 173, 'B_Disease'), (174, 181, 'I_Disease')]}], ['Fluoxetine - induced akathisia : clinical and theoretical implications .', {'entities': [(21, 30, 'B_Disease')]}], ['Five patients receiving fluoxetine for the treatment of obsessive compulsive disorder or major depression developed akathisia .', {'entities': [(56, 65, 'B_Disease'), (66, 76, 'I_Disease'), (77, 85, 'I_Disease'), (89, 94, 'B_Disease'), (95, 105, 'I_Disease'), (116, 125, 'B_Disease')]}], ['The typical fluoxetine - induced symptoms of restlessness , constant pacing , purposeless movements of the feet and legs , and marked anxiety were indistinguishable from those of neuroleptic - induced akathisia .', {'entities': [(134, 141, 'B_Disease'), (201, 210, 'B_Disease')]}], ['Three patients who had experienced neuroleptic - induced akathisia in the past reported that the symptoms of fluoxetine - induced akathisia were identical , although somewhat milder .', {'entities': [(57, 66, 'B_Disease'), (130, 139, 'B_Disease')]}], ['Akathisia appeared to be a common side effect of fluoxetine and generally responded well to treatment with the beta - adrenergic antagonist propranolol , dose reduction , or both .', {'entities': [(0, 9, 'B_Disease')]}], ['The authors suggest that fluoxetine - induced akathisia may be caused by serotonergically mediated inhibition of dopaminergic neurotransmission and that the pathophysiology of fluoxetine - induced akathisia and tricyclic antidepressant - induced \" jitteriness \" may be identical .', {'entities': [(46, 55, 'B_Disease'), (197, 206, 'B_Disease')]}], ['Effect of converting enzyme inhibition on the course of adriamycin - induced nephropathy .', {'entities': [(77, 88, 'B_Disease')]}], ['The effect of the converting enzyme inhibitor ( CEI ) enalapril was assessed in Munich - Wistar rats with established adriamycin nephrosis .', {'entities': [(129, 138, 'B_Disease')]}], ['Rats were given a single dose of adriamycin and one month later divided into four groups matched for albuminuria , blood pressure , and plasma albumin concentration .', {'entities': [(101, 112, 'B_Disease')]}], ['These short - term studies showed that enalapril reduced arterial blood pressure ( 101 + / - 2 vs . 124 + / - 3 mm Hg , group 2 vs . 1 , P less than 0 . 05 ) and glomerular capillary pressure ( 54 + / - 1 vs . 61 + / - 2 mm Hg , P less than 0 . 05 ) without reducing albuminuria ( 617 + / - 50 vs . 570 + / - 47 mg / day ) or GFR ( 1 . 03 + / - 0 . 04 vs . 1 . 04 + / - 0 . 11 ml / min ) .', {'entities': [(267, 278, 'B_Disease')]}], ['Groups 3 and 4 were studied at four and at six months to assess the effect of enalapril on progression of renal injury in adriamycin nephrosis .', {'entities': [(106, 111, 'B_Disease'), (112, 118, 'I_Disease'), (133, 142, 'B_Disease')]}], ['Chronic enalapril treatment reduced blood pressure without reducing albuminuria in group 4 .', {'entities': [(68, 79, 'B_Disease')]}], ['Reduction in GFR was associated with the development of glomerular sclerosis in both treated and untreated rats . ( ABSTRACT TRUNCATED AT 250 WORDS )', {'entities': [(56, 66, 'B_Disease'), (67, 76, 'I_Disease')]}], ['Clotiazepam - induced acute hepatitis .', {'entities': [(28, 37, 'B_Disease')]}], ['We report the case of a patient who developed acute hepatitis with extensive hepatocellular necrosis , 7 months after the onset of administration of clotiazepam , a thienodiazepine derivative .', {'entities': [(52, 61, 'B_Disease'), (67, 76, 'B_Disease'), (77, 91, 'I_Disease'), (92, 100, 'I_Disease')]}], ['The administration of several benzodiazepines , chemically related to clotiazepam , did not interfere with recovery and did not induce any relapse of hepatitis .', {'entities': [(150, 159, 'B_Disease')]}], ['This observation shows that clotiazepam can induce acute hepatitis and suggests that there is no cross hepatotoxicity between clotiazepam and several benzodiazepines .', {'entities': [(57, 66, 'B_Disease'), (103, 117, 'B_Disease')]}], ['5 - azacytidine potentiates initiation induced by carcinogens in rat liver .', {'entities': [(28, 38, 'B_Disease'), (39, 46, 'I_Disease'), (47, 49, 'I_Disease'), (50, 61, 'I_Disease')]}], ['To test the validity of the hypothesis that hypomethylation of DNA plays an important role in the initiation of carcinogenic process , 5 - azacytidine ( 5 - AzC ) ( 10 mg / kg ) , an inhibitor of DNA methylation , was given to rats during the phase of repair synthesis induced by the three carcinogens , benzo [ a ] - pyrene ( 200 mg / kg ) , N - methyl - N - nitrosourea ( 60 mg / kg ) and 1 , 2 - dimethylhydrazine ( 1 , 2 - DMH ) ( 100 mg / kg ) .', {'entities': [(98, 108, 'B_Disease'), (109, 111, 'I_Disease'), (112, 124, 'I_Disease'), (125, 132, 'I_Disease')]}], ['Antihypertensive drugs and depression : a reappraisal .', {'entities': [(27, 37, 'B_Disease')]}], ['Eighty - nine new referral hypertensive out - patients and 46 new referral non - hypertensive chronically physically ill out - patients completed a mood rating scale at regular intervals for one year .', {'entities': [(27, 39, 'B_Disease'), (81, 93, 'B_Disease')]}], ['The results showed a high prevalence of depression in both groups of patients , with no preponderance in the hypertensive group .', {'entities': [(40, 50, 'B_Disease'), (109, 121, 'B_Disease')]}], ['Hypertensive patients with psychiatric histories had a higher prevalence of depression than the comparison patients .', {'entities': [(0, 12, 'B_Disease'), (27, 38, 'B_Disease'), (76, 86, 'B_Disease')]}], ['This was accounted for by a significant number of depressions occurring in methyl dopa treated patients with psychiatric histories .', {'entities': [(50, 61, 'B_Disease'), (109, 120, 'B_Disease')]}], ['Chronic active hepatitis associated with diclofenac sodium therapy .', {'entities': [(0, 7, 'B_Disease'), (8, 14, 'I_Disease'), (15, 24, 'I_Disease')]}], ['Although generally well - tolerated , asymptomatic abnormalities of liver function have been recorded and , less commonly , severe hepatitis induced by diclofenac .', {'entities': [(51, 64, 'B_Disease'), (65, 67, 'I_Disease'), (68, 73, 'I_Disease'), (74, 82, 'I_Disease'), (131, 140, 'B_Disease')]}], ['The patient described developed chronic active hepatitis after six months therapy with diclofenac sodium which progressed despite the withdrawal of the drug , a finding not previously reported .', {'entities': [(32, 39, 'B_Disease'), (40, 46, 'I_Disease'), (47, 56, 'I_Disease')]}], ['Arterial hypertension as a complication of prolonged ketoconazole treatment .', {'entities': [(9, 21, 'B_Disease')]}], [\"Two of 14 patients with Cushing ' s syndrome treated on a long - term basis with ketoconazole developed sustained hypertension .\", {'entities': [(24, 31, 'B_Disease'), (32, 33, 'I_Disease'), (34, 35, 'I_Disease'), (36, 44, 'I_Disease'), (114, 126, 'B_Disease')]}], ['In both cases normal plasma and urinary free cortisol levels had been achieved following ketoconazole therapy , yet continuous blood pressure monitoring demonstrated hypertension 31 ( patient 1 ) and 52 weeks ( patient 2 ) after treatment .', {'entities': [(166, 178, 'B_Disease')]}], ['Our findings show that long - term treatment with high doses of ketoconazole may induce enzyme blockade leading to mineralocorticoid - related hypertension .', {'entities': [(143, 155, 'B_Disease')]}], ['Effects of an inhibitor of angiotensin converting enzyme ( Captopril ) on pulmonary and renal insufficiency due to intravascular coagulation in the rat .', {'entities': [(74, 83, 'B_Disease'), (84, 87, 'I_Disease'), (88, 93, 'I_Disease'), (94, 107, 'I_Disease'), (115, 128, 'B_Disease'), (129, 140, 'I_Disease')]}], ['Induction of intravascular coagulation and inhibition of fibrinolysis by injection of thrombin and tranexamic acid ( AMCA ) in the rat gives rise to pulmonary and renal insufficiency resembling that occurring after trauma or sepsis in man .', {'entities': [(13, 26, 'B_Disease'), (27, 38, 'I_Disease'), (149, 158, 'B_Disease'), (159, 162, 'I_Disease'), (163, 168, 'I_Disease'), (169, 182, 'I_Disease'), (215, 221, 'B_Disease'), (225, 231, 'B_Disease')]}], ['Injection of Captopril ( 1 mg / kg ) , an inhibitor of angiotensin converting enzyme ( ACE ) , reduced both pulmonary and renal insufficiency in this rat model .', {'entities': [(108, 117, 'B_Disease'), (118, 121, 'I_Disease'), (122, 127, 'I_Disease'), (128, 141, 'I_Disease')]}], ['Renal damage as reflected by an increase in serum urea and in kidney weight was prevented by Captopril .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease')]}], ['Captopril may , by the same mechanism , reduce the increase in glomerular filtration that is known to occur after an injection of thrombin , thereby diminishing the aggregation of fibrin monomers in the glomeruli , with the result that less fibrin will be deposited and thus less kidney damage will be produced .', {'entities': [(280, 286, 'B_Disease'), (287, 293, 'I_Disease')]}], ['Stroke associated with cocaine use .', {'entities': [(0, 6, 'B_Disease')]}], ['We describe eight patients in whom cocaine use was related to stroke and review 39 cases from the literature .', {'entities': [(62, 68, 'B_Disease')]}], ['Stroke followed cocaine use by inhalation , intranasal , intravenous , and intramuscular routes .', {'entities': [(0, 6, 'B_Disease')]}], ['Intracranial aneurysms or arteriovenous malformations were present in 17 of 32 patients studied angiographically or at autopsy ; cerebral vasculitis was present in two patients .', {'entities': [(0, 12, 'B_Disease'), (13, 22, 'I_Disease'), (26, 39, 'B_Disease'), (40, 53, 'I_Disease'), (129, 137, 'B_Disease'), (138, 148, 'I_Disease')]}], ['Cerebral infarction occurred in 10 patients ( 22 % ) , intracerebral hemorrhage in 22 ( 49 % ) , and subarachnoid hemorrhage in 13 ( 29 % ) .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease'), (55, 68, 'B_Disease'), (69, 79, 'I_Disease'), (101, 113, 'B_Disease'), (114, 124, 'I_Disease')]}], ['These data indicate that ( 1 ) the apparent incidence of stroke related to cocaine use is increasing ; ( 2 ) cocaine - associated stroke occurs primarily in young adults ; ( 3 ) stroke may follow any route of cocaine administration ; ( 4 ) stroke after cocaine use is frequently associated with intracranial aneurysms and arteriovenous malformations ; and ( 5 ) in cocaine - associated stroke , the frequency of intracranial hemorrhage exceeds that of cerebral infarction .', {'entities': [(57, 63, 'B_Disease'), (130, 136, 'B_Disease'), (178, 184, 'B_Disease'), (240, 246, 'B_Disease'), (295, 307, 'B_Disease'), (308, 317, 'I_Disease'), (322, 335, 'B_Disease'), (336, 349, 'I_Disease'), (386, 392, 'B_Disease'), (412, 424, 'B_Disease'), (425, 435, 'I_Disease'), (452, 460, 'B_Disease'), (461, 471, 'I_Disease')]}], ['A randomized comparison of labetalol and nitroprusside for induced hypotension .', {'entities': [(67, 78, 'B_Disease')]}], ['In a randomized study , labetalol - induced hypotension and nitroprusside - induced hypotension were compared in 20 patients ( 10 in each group ) scheduled for major orthopedic procedures .', {'entities': [(44, 55, 'B_Disease'), (84, 95, 'B_Disease')]}], ['Each patient was subjected to an identical anesthetic protocol and similar drug - induced reductions in mean arterial blood pressure ( BP ) ( 50 to 55 mmHg ) .', {'entities': [(90, 100, 'B_Disease'), (101, 103, 'I_Disease'), (104, 108, 'I_Disease'), (109, 117, 'I_Disease'), (118, 123, 'I_Disease'), (124, 132, 'I_Disease')]}], ['Nitroprusside infusion was associated with a significant ( p less than 0 . 05 ) increase in heart rate and cardiac output ; rebound hypertension was observed in three patients after discontinuation of nitroprusside .', {'entities': [(80, 88, 'B_Disease'), (89, 91, 'I_Disease'), (92, 97, 'I_Disease'), (98, 102, 'I_Disease'), (103, 106, 'I_Disease'), (107, 114, 'I_Disease'), (115, 121, 'I_Disease'), (132, 144, 'B_Disease')]}], ['Sodium status influences chronic amphotericin B nephrotoxicity in rats .', {'entities': [(48, 62, 'B_Disease')]}], ['The nephrotoxic potential of amphotericin B ( 5 mg / kg per day intraperitoneally for 3 weeks ) has been investigated in salt - depleted , normal - salt , and salt - loaded rats .', {'entities': [(4, 15, 'B_Disease')]}], ['Flestolol produced a dose - dependent attenuation of isoproterenol - induced tachycardia .', {'entities': [(77, 88, 'B_Disease')]}], ['Flestolol effectively reduced heart rate in patients with supraventricular tachyarrhythmia .', {'entities': [(58, 74, 'B_Disease'), (75, 90, 'I_Disease')]}], ['In patients with unstable angina , flestolol infusion was found to be safe and effective in controlling chest pain .', {'entities': [(17, 25, 'B_Disease'), (26, 32, 'I_Disease'), (104, 109, 'B_Disease'), (110, 114, 'I_Disease')]}], ['Immunohistochemical , electron microscopic and morphometric studies of estrogen - induced rat prolactinomas after bromocriptine treatment .', {'entities': [(94, 107, 'B_Disease')]}], ['To clarify the effects of bromocriptine on prolactinoma cells in vivo , immunohistochemical , ultrastructural and morphometrical analyses were applied to estrogen - induced rat prolactinoma cells 1 h and 6 h after injection of bromocriptine ( 3 mg / kg of body weight ) .', {'entities': [(43, 55, 'B_Disease'), (177, 189, 'B_Disease')]}], ['Electron microscopy disclosed many secretory granules , slightly distorted rough endoplasmic reticulum , and partially dilated Golgi cisternae in the prolactinoma cells .', {'entities': [(150, 162, 'B_Disease')]}], ['The prolactinoma cells at this time were well granulated , with vesiculated rough endoplasmic reticulum and markedly dilated Golgi cisternae .', {'entities': [(4, 16, 'B_Disease')]}], ['Electron microscopical immunohistochemistry revealed positive reaction products noted on the secretory granules , Golgi cisternae , and endoplasmic reticulum of the untreated rat prolactinoma cells .', {'entities': [(179, 191, 'B_Disease')]}], ['However , only secretory granules showed the positive reaction products for prolactin 6 h after bromocriptine treatment of the adenoma cells .', {'entities': [(127, 134, 'B_Disease')]}], ['Sulfasalazine - induced lupus erythematosus .', {'entities': [(24, 29, 'B_Disease'), (30, 43, 'I_Disease')]}], ['Pneumonitis , bilateral pleural effusions , echocardiographic evidence of cardiac tamponade , and positive autoantibodies developed in a 43 - year - old man , who was receiving long - term sulfasalazine therapy for chronic ulcerative colitis .', {'entities': [(0, 11, 'B_Disease'), (24, 31, 'B_Disease'), (32, 41, 'I_Disease'), (74, 81, 'B_Disease'), (82, 91, 'I_Disease'), (223, 233, 'B_Disease'), (234, 241, 'I_Disease')]}], ['It is suggested that the patient had sulfasalazine - induced lupus , which manifested with serositis and pulmonary parenchymal involvement in the absence of joint symptoms .', {'entities': [(61, 66, 'B_Disease'), (91, 100, 'B_Disease')]}], ['Physicians who use sulfasalazine to treat patients with inflammatory bowel disease should be aware of the signs of sulfasalazine - induced lupus syndrome .', {'entities': [(56, 68, 'B_Disease'), (69, 74, 'I_Disease'), (75, 82, 'I_Disease'), (139, 144, 'B_Disease'), (145, 153, 'I_Disease')]}], ['Chronic carbamazepine treatment in the rat : efficacy , toxicity , and effect on plasma and tissue folate concentrations .', {'entities': [(56, 64, 'B_Disease')]}], ['In the course of developing this model , a common vehicle , propylene glycol , by itself in high doses , was found to exhibit protective properties against induced seizures and inhibited weight gain .', {'entities': [(164, 172, 'B_Disease'), (187, 193, 'B_Disease'), (194, 198, 'I_Disease')]}], ['Seizures induced by hexafluorodiethyl ether ( HFDE ) were also found to be a more sensitive measure of protection by CBZ than seizures induced by maximal electroshock ( MES ) .', {'entities': [(0, 8, 'B_Disease'), (126, 134, 'B_Disease')]}], ['Oral administration of CBZ as an aqueous suspension every 8 h at a dose of 250 mg / kg was continuously protective against HFDE - induced seizures and was minimally toxic as measured by weight gain over 8 weeks of treatment .', {'entities': [(138, 146, 'B_Disease'), (186, 192, 'B_Disease'), (193, 197, 'I_Disease')]}], ['Dipyridamole - induced myocardial ischemia .', {'entities': [(23, 33, 'B_Disease'), (34, 42, 'I_Disease')]}], ['Angina and ischemic electrocardiographic changes occurred after administration of oral dipyridamole in four patients awaiting urgent myocardial revascularization procedures .', {'entities': [(0, 6, 'B_Disease')]}], ['To our knowledge , this has not previously been reported as a side effect of preoperative dipyridamole therapy , although dipyridamole - induced myocardial ischemia has been demonstrated to occur in animals and humans with coronary artery disease .', {'entities': [(145, 155, 'B_Disease'), (156, 164, 'I_Disease'), (223, 231, 'B_Disease'), (232, 238, 'I_Disease'), (239, 246, 'I_Disease')]}], ['Epicardial coronary collateral vessels were demonstrated in all four patients ; a coronary \" steal \" phenomenon may be the mechanism of the dipyridamole - induced ischemia observed .', {'entities': [(163, 171, 'B_Disease')]}], ['Mean arterial pressure ( as a percentage of control + / - SEM ) during randomized infusions of 0 . 03 , 0 . 1 , 0 . 3 , or 1 . 0 microgram / kg / min was 99 + / - 1 , 95 + / - 1 ( p less than 0 . 05 ) , 93 + / - 1 ( p less than 0 . 01 ) , or 79 + / - 6 % ( p less than 0 . 001 ) , respectively , but no tachycardia and no augmentation of the norepinephrine release rate ( up to 0 . 3 microgram / kg / min ) were observed , which is in contrast to comparable hypotension induced by hydralazine or nitroglycerin .', {'entities': [(303, 314, 'B_Disease'), (458, 469, 'B_Disease')]}], ['Nitroprusside - induced hypotension evokes ACTH secretion which is primarily mediated by enhanced secretion of immunoreactive corticotropin - releasing factor ( irCRF ) into the hypophysial - portal circulation .', {'entities': [(24, 35, 'B_Disease')]}], ['Suppression of irCRF secretion in response to nitroprusside - induced hypotension is observed and occurs at a plasma corticosterone level between 8 - 12 micrograms / dl .', {'entities': [(70, 81, 'B_Disease')]}], ['Noradrenergic involvement in catalepsy induced by delta 9 - tetrahydrocannabinol .', {'entities': [(29, 38, 'B_Disease')]}], ['These results indicate that noradrenergic neurons have an important role in the manifestation of catalepsy induced by THC , whereas dopaminergic neurons are important in catalepsy induced by haloperidol .', {'entities': [(97, 106, 'B_Disease'), (170, 179, 'B_Disease')]}], ['Reversibility of captopril - induced renal insufficiency after prolonged use in an unusual case of renovascular hypertension .', {'entities': [(37, 42, 'B_Disease'), (43, 56, 'I_Disease'), (99, 111, 'B_Disease'), (112, 124, 'I_Disease')]}], ['We report a case of severe hypertension with an occluded renal artery to a solitary kidney , who developed sudden deterioration of renal function following treatment with captopril .', {'entities': [(27, 39, 'B_Disease'), (107, 113, 'B_Disease'), (114, 127, 'I_Disease'), (128, 130, 'I_Disease'), (131, 136, 'I_Disease'), (137, 145, 'I_Disease')]}], ['This indicates reversibility in captopril - induced renal failure even after its prolonged use and suggests that no organic damage occurs to glomerular arterioles following chronic ACE inhibition .', {'entities': [(52, 57, 'B_Disease'), (58, 65, 'I_Disease')]}], ['Myopathy , associated in some cases with myoglobinuria , and in 2 cases with transient renal failure , has been rarely reported with lovastatin , especially in patients concomitantly treated with cyclosporin , gemfibrozil or niacin .', {'entities': [(0, 8, 'B_Disease'), (41, 54, 'B_Disease'), (87, 92, 'B_Disease'), (93, 100, 'I_Disease')]}], ['As wider use confirms their safety profile , they will gain increasing importance in the therapeutic approach to hypercholesterolaemia and its consequences .', {'entities': [(113, 134, 'B_Disease')]}], ['By November 1984 the Committee on Safety of Medicines had received 82 reports of possible hepatotoxicity associated with the drug , including five deaths .', {'entities': [(90, 104, 'B_Disease'), (147, 153, 'B_Disease')]}], ['An analysis of the 75 cases that had been adequately followed up suggested that 16 , including three deaths , were probably related to treatment with the drug .', {'entities': [(101, 107, 'B_Disease')]}], ['The mean age of patients in the 16 probable cases was 57 . 9 , with hepatotoxicity being more common in women .', {'entities': [(68, 82, 'B_Disease')]}], ['The average duration of treatment before the onset of jaundice was 61 days .', {'entities': [(54, 62, 'B_Disease')]}], ['The results of serum liver function tests suggested hepatocellular injury in 10 ( 63 % ) ; the rest showed a mixed pattern .', {'entities': [(52, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], ['In contrast , the results of histological examination of the liver often showed evidence of cholestasis .', {'entities': [(92, 103, 'B_Disease')]}], ['Allergic manifestations such as rash and eosinophilia were rare .', {'entities': [(32, 36, 'B_Disease'), (41, 53, 'B_Disease')]}], ['Hepatitis was usually reversible when treatment was stopped , with the results of liver function tests returning to normal after an average of 3 . 1 months .', {'entities': [(0, 9, 'B_Disease')]}], ['In two of the three deaths probably associated with ketoconazole treatment the drug had been continued after the onset of jaundice and other symptoms of hepatitis .', {'entities': [(20, 26, 'B_Disease'), (122, 130, 'B_Disease'), (153, 162, 'B_Disease')]}], ['Clinical and biochemical monitoring at regular intervals for evidence of hepatitis is advised during long term treatment with ketoconazole to prevent possible serious hepatic injury .', {'entities': [(73, 82, 'B_Disease'), (167, 174, 'B_Disease'), (175, 181, 'I_Disease')]}], ['Glyburide - induced hepatitis .', {'entities': [(20, 29, 'B_Disease')]}], ['Drug - induced hepatotoxicity , although common , has been reported only infrequently with sulfonylureas .', {'entities': [(15, 29, 'B_Disease')]}], ['For glyburide , a second - generation sulfonylurea , only two brief reports of hepatotoxicity exist .', {'entities': [(79, 93, 'B_Disease')]}], ['Two patients with type II diabetes mellitus developed an acute hepatitis - like syndrome soon after initiation of glyburide therapy .', {'entities': [(18, 22, 'B_Disease'), (23, 25, 'I_Disease'), (26, 34, 'I_Disease'), (35, 43, 'I_Disease'), (57, 62, 'B_Disease'), (63, 72, 'I_Disease'), (73, 74, 'I_Disease'), (75, 79, 'I_Disease'), (80, 88, 'I_Disease')]}], ['There was no serologic evidence of viral infection , and a liver biopsy sample showed a histologic pattern consistent with drug - induced hepatitis .', {'entities': [(35, 40, 'B_Disease'), (41, 50, 'I_Disease'), (123, 127, 'B_Disease'), (128, 129, 'I_Disease'), (130, 137, 'I_Disease'), (138, 147, 'I_Disease')]}], ['Glyburide can produce an acute hepatitis - like illness in some persons .', {'entities': [(25, 30, 'B_Disease'), (31, 40, 'I_Disease'), (41, 42, 'I_Disease'), (43, 47, 'I_Disease'), (48, 55, 'I_Disease')]}], ['Intracranial pressure increases during alfentanil - induced rigidity .', {'entities': [(60, 68, 'B_Disease')]}], ['Intracranial pressure ( ICP ) was measured during alfentanil - induced rigidity in rats .', {'entities': [(71, 79, 'B_Disease')]}], ['In the five rats that developed somatic rigidity , ICP and CVP increased significantly above baseline ( delta ICP 7 . 5 + / - 1 . 0 mmHg , delta CVP 5 . 9 + / - 1 . 3 mmHg ) .', {'entities': [(32, 39, 'B_Disease'), (40, 48, 'I_Disease')]}], ['These variables returned to baseline when rigidity was abolished with metocurine .', {'entities': [(42, 50, 'B_Disease')]}], ['These observations suggest that rigidity should be prevented when alfentanil , and , presumably , other opiates , are used in the anesthetic management of patients with ICP problems .', {'entities': [(32, 40, 'B_Disease')]}], ['Verapamil withdrawal as a possible cause of myocardial infarction in a hypertensive woman with a normal coronary angiogram .', {'entities': [(44, 54, 'B_Disease'), (55, 65, 'I_Disease'), (71, 83, 'B_Disease')]}], ['Serious adverse effects are uncommon and mainly have been related to the depression of cardiac contractility and conduction , especially when the drug is combined with beta - blocking agents .', {'entities': [(73, 83, 'B_Disease')]}], ['We report a case in which myocardial infarction coincided with the introduction of captopril and the withdrawal of verapamil in a previously asymptomatic woman with severe hypertension .', {'entities': [(26, 36, 'B_Disease'), (37, 47, 'I_Disease'), (172, 184, 'B_Disease')]}], ['Haemolytic - uraemic syndrome after treatment with metronidazole .', {'entities': [(0, 10, 'B_Disease'), (11, 12, 'I_Disease'), (13, 20, 'I_Disease'), (21, 29, 'I_Disease')]}], ['This paper describes the clinical features of six children who developed the haemolytic - uraemic syndrome after treatment with metronidazole .', {'entities': [(77, 87, 'B_Disease'), (88, 89, 'I_Disease'), (90, 97, 'I_Disease'), (98, 106, 'I_Disease')]}], ['While the involvement of metronidazole in the aetiology of the haemolytic - uraemic syndrome is not established firmly , the action of this drug in sensitizing tissues to oxidation injury and the reported evidence of oxidation changes in the haemolytic - uraemic syndrome suggest a possible link between metronidazole treatment and some cases of the haemolytic - uraemic syndrome .', {'entities': [(63, 73, 'B_Disease'), (74, 75, 'I_Disease'), (76, 83, 'I_Disease'), (84, 92, 'I_Disease'), (242, 252, 'B_Disease'), (253, 254, 'I_Disease'), (255, 262, 'I_Disease'), (263, 271, 'I_Disease'), (350, 360, 'B_Disease'), (361, 362, 'I_Disease'), (363, 370, 'I_Disease'), (371, 379, 'I_Disease')]}], ['Survival for patients with advanced head and neck carcinoma and esophageal carcinoma is poor with radiotherapy and / or surgery .', {'entities': [(36, 40, 'B_Disease'), (41, 44, 'I_Disease'), (45, 49, 'I_Disease'), (50, 59, 'I_Disease'), (64, 74, 'B_Disease'), (75, 84, 'I_Disease')]}], ['In the pre - treatment evaluation , signs of cardiovascular disease were found in 33 patients ( 43 % ) .', {'entities': [(45, 59, 'B_Disease'), (60, 67, 'I_Disease')]}], ['The incidence of cardiotoxicity was not higher in patients with signs of cardiovascular disease than in those without in the pre - treatment evaluation .', {'entities': [(17, 31, 'B_Disease'), (73, 87, 'B_Disease'), (88, 95, 'I_Disease')]}], ['The most common signs of cardiotoxicity were chest pain , ST - T wave changes and atrial fibrillation .', {'entities': [(25, 39, 'B_Disease'), (45, 50, 'B_Disease'), (51, 55, 'I_Disease'), (82, 88, 'B_Disease'), (89, 101, 'I_Disease')]}], ['This was followed by ventricular fibrillation in one patient and sudden death in another .', {'entities': [(21, 32, 'B_Disease'), (33, 45, 'I_Disease'), (65, 71, 'B_Disease'), (72, 77, 'I_Disease')]}], ['It is concluded that patients on 5 - FU treatment should be under close supervision and that the treatment should be discontinued if chest pain or tachyarrhythmia is observed .', {'entities': [(133, 138, 'B_Disease'), (139, 143, 'I_Disease'), (147, 162, 'B_Disease')]}], ['Death from chemotherapy in gestational trophoblastic disease .', {'entities': [(0, 5, 'B_Disease'), (27, 38, 'B_Disease'), (39, 52, 'I_Disease'), (53, 60, 'I_Disease')]}], ['Multiple cytotoxic drug administration is the generally accepted treatment of patients with a high - risk stage of choriocarcinoma .', {'entities': [(115, 130, 'B_Disease')]}], ['Within 8 hours after initiation of therapy the patient died with a clinical picture resembling massive pulmonary obstruction due to choriocarcinomic tissue plugs , probably originating from the uterus .', {'entities': [(103, 112, 'B_Disease'), (113, 124, 'I_Disease')]}], ['Formation of these plugs was probably due to extensive tumor necrosis at the level of the walls of the major uterine veins , which resulted in an open exchange of tumor plugs to the vascular spaces ; decrease in tumor tissue coherence secondary to chemotherapy may have further contributed to the formation of tumor emboli .', {'entities': [(55, 60, 'B_Disease'), (61, 69, 'B_Disease'), (163, 168, 'B_Disease'), (212, 217, 'B_Disease'), (310, 315, 'B_Disease')]}], ['In view of the close time association between the start of chemotherapy and the acute onset of massive embolism other explanations , such as spontaneous necrosis , must be considered less likely .', {'entities': [(103, 111, 'B_Disease'), (153, 161, 'B_Disease')]}], ['Patients with large pelvic tumor loads are , according to existing classifications , at high risk to die and to develop drug resistance .', {'entities': [(20, 26, 'B_Disease'), (27, 32, 'I_Disease')]}], ['Pulmonary shunt and cardiovascular responses to CPAP during nitroprusside - induced hypotension .', {'entities': [(84, 95, 'B_Disease')]}], ['Ten cm H2O CPAP before nitroprusside infusion produced a further decrease in arterial blood pressure and significantly increased heart rate and decreased cardiac output and QS / QT .', {'entities': [(65, 73, 'B_Disease'), (74, 76, 'I_Disease'), (77, 85, 'I_Disease'), (86, 91, 'I_Disease'), (92, 100, 'I_Disease'), (144, 153, 'B_Disease'), (154, 161, 'I_Disease'), (162, 168, 'I_Disease')]}], ['Nitroprusside caused significant decreases in arterial blood pressure and systemic vascular resistance and increases in heart rate , but did not change cardiac output or QS / QT .', {'entities': [(33, 42, 'B_Disease'), (43, 45, 'I_Disease'), (46, 54, 'I_Disease'), (55, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['During nitroprusside infusion low levels of CPAP do not markedly alter cardiovascular dynamics , but high levels of CPAP ( 10 cm H2O ) , while decreasing QS / QT , produce marked decreases in arterial blood pressure and cardiac output .', {'entities': [(179, 188, 'B_Disease'), (189, 191, 'I_Disease'), (192, 200, 'I_Disease'), (201, 206, 'I_Disease'), (207, 215, 'I_Disease'), (216, 219, 'I_Disease'), (220, 227, 'I_Disease'), (228, 234, 'I_Disease')]}], ['Systolic pressure variation is greater during hemorrhage than during sodium nitroprusside - induced hypotension in ventilated dogs .', {'entities': [(46, 56, 'B_Disease'), (100, 111, 'B_Disease')]}], ['The systolic pressure variation ( SPV ) , which is the difference between the maximal and minimal values of the systolic blood pressure ( SBP ) after one positive - pressure breath , was studied in ventilated dogs subjected to hypotension .', {'entities': [(227, 238, 'B_Disease')]}], ['Mean arterial pressure was decreased to 50 mm Hg for 30 minutes either by hemorrhage ( HEM , n = 7 ) or by continuous infusion of sodium nitroprusside ( SNP , n = 7 ) .', {'entities': [(74, 84, 'B_Disease'), (87, 90, 'B_Disease')]}], ['During HEM - induced hypotension the cardiac output was significantly lower and systemic vascular resistance higher compared with that in the SNP group .', {'entities': [(7, 10, 'B_Disease'), (21, 32, 'B_Disease')]}], ['The SPV during hypotension was 15 . 7 + / - 6 . 7 mm Hg in the HEM group , compared with 9 . 1 + / - 2 . 0 mm Hg in the SNP group ( P less than 0 . 02 ) .', {'entities': [(15, 26, 'B_Disease'), (63, 66, 'B_Disease')]}], ['The delta down , which is the measure of decrease of SBP after a mechanical breath , was 20 . 3 + / - 8 . 4 and 10 . 1 + / - 3 . 8 mm Hg in the HEM and SNP groups , respectively , during hypotension ( P less than 0 . 02 ) .', {'entities': [(144, 147, 'B_Disease'), (187, 198, 'B_Disease')]}], ['It is concluded that increases in the SPV and the delta down are characteristic of a hypotensive state due to a predominant decrease in preload .', {'entities': [(85, 96, 'B_Disease')]}], ['They are thus more important during absolute hypovolemia than during deliberate hypotension .', {'entities': [(45, 56, 'B_Disease'), (80, 91, 'B_Disease')]}], ['Ventricular tachyarrhythmias during cesarean section after ritodrine therapy : interaction with anesthetics .', {'entities': [(0, 11, 'B_Disease'), (12, 28, 'I_Disease')]}], ['This case illustrates that patients receiving ritodrine for preterm labor may risk interactions between the residual betamimetic effects of ritodrine and the effects of anesthetics during cesarean section .', {'entities': [(60, 67, 'B_Disease'), (68, 73, 'I_Disease')]}], ['Such interactions may result in serious cardiovascular complications even after cessation of an infusion of ritodrine .', {'entities': [(40, 54, 'B_Disease'), (55, 68, 'I_Disease')]}], ['After delivery of the infant , there should be no contraindication to the use of an alpha - adrenergic vasopressor such as phenylephrine to treat hypotensive patients with tachycardia .', {'entities': [(146, 157, 'B_Disease'), (172, 183, 'B_Disease')]}], ['Verapamil - induced carbamazepine neurotoxicity .', {'entities': [(34, 47, 'B_Disease')]}], ['Two patients with signs of carbamazepine neurotoxicity after combined treatment with verapamil showed complete recovery after discontinuation of the calcium entry blocker .', {'entities': [(41, 54, 'B_Disease')]}], ['Paracetamol - associated coma , metabolic acidosis , renal and hepatic failure .', {'entities': [(25, 29, 'B_Disease'), (32, 41, 'B_Disease'), (42, 50, 'I_Disease'), (53, 58, 'B_Disease'), (59, 62, 'I_Disease'), (63, 70, 'I_Disease'), (71, 78, 'I_Disease')]}], ['A case of metabolic acidosis , acute renal failure and hepatic failure following paracetamol ingestion is presented .', {'entities': [(10, 19, 'B_Disease'), (20, 28, 'I_Disease'), (31, 36, 'B_Disease'), (37, 42, 'I_Disease'), (43, 50, 'I_Disease'), (51, 54, 'I_Disease'), (55, 62, 'I_Disease'), (63, 70, 'I_Disease')]}], ['Sexual dysfunction among patients with arthritis .', {'entities': [(0, 6, 'B_Disease'), (7, 18, 'I_Disease'), (39, 48, 'B_Disease')]}], ['The relationship of arthritis and sexual dysfunction was investigated among 169 patients with rheumatoid arthritis , osteoarthritis and spondyloarthropathy , 130 of whom were pair - matched to controls .', {'entities': [(20, 29, 'B_Disease'), (34, 40, 'B_Disease'), (41, 52, 'I_Disease'), (94, 104, 'B_Disease'), (105, 114, 'I_Disease'), (117, 131, 'B_Disease'), (136, 155, 'B_Disease')]}], ['Assessments of marital happiness and depressed mood were also made using the CES - D and the Azrin Marital Happiness Scale ( AMHS ) .', {'entities': [(37, 46, 'B_Disease'), (47, 51, 'I_Disease')]}], ['Sexual dysfunctions were found to be common among patients and controls , the majority in both groups reporting one or more dysfunctions .', {'entities': [(0, 6, 'B_Disease'), (7, 19, 'I_Disease')]}], ['Impotence was more common among male patients than controls and was found to be associated with co - morbidity and the taking of methotrexate .', {'entities': [(0, 9, 'B_Disease')]}], ['Depressed mood was more common among patients and was associated with certain sexual difficulties , but not with impotence .', {'entities': [(0, 9, 'B_Disease'), (10, 14, 'I_Disease'), (113, 122, 'B_Disease')]}], ['Marital unhappiness , as indicated by AMHS scores , was not associated with arthritis but was associated with sexual dysfunction , sexual dissatisfaction and being female .', {'entities': [(76, 85, 'B_Disease'), (110, 116, 'B_Disease'), (117, 128, 'I_Disease')]}], ['Does paracetamol cause urothelial cancer or renal papillary necrosis ?', {'entities': [(23, 33, 'B_Disease'), (34, 40, 'I_Disease'), (44, 49, 'B_Disease'), (50, 59, 'I_Disease'), (60, 68, 'I_Disease')]}], ['The risk of developing renal papillary necrosis or cancer of the renal pelvis , ureter or bladder associated with consumption of either phenacetin or paracetamol was calculated from data acquired by questionnaire from 381 cases and 808 controls .', {'entities': [(23, 28, 'B_Disease'), (29, 38, 'I_Disease'), (39, 47, 'I_Disease'), (51, 57, 'B_Disease'), (58, 60, 'I_Disease'), (61, 64, 'I_Disease'), (65, 70, 'I_Disease'), (71, 77, 'I_Disease'), (78, 79, 'I_Disease'), (80, 86, 'I_Disease'), (87, 89, 'I_Disease'), (90, 97, 'I_Disease')]}], ['The risk of renal papillary necrosis was increased nearly 20 - fold by consumption of phenacetin , which also increased the risk for cancer of the renal pelvis and bladder but not for ureteric cancer .', {'entities': [(12, 17, 'B_Disease'), (18, 27, 'I_Disease'), (28, 36, 'I_Disease'), (133, 139, 'B_Disease'), (140, 142, 'I_Disease'), (143, 146, 'I_Disease'), (147, 152, 'I_Disease'), (153, 159, 'I_Disease'), (160, 163, 'I_Disease'), (164, 171, 'I_Disease'), (184, 192, 'B_Disease'), (193, 199, 'I_Disease')]}], ['By contrast , we were unable to substantiate an increased risk from paracetamol consumption for renal papillary necrosis or any of these cancers although there was a suggestion of an association with cancer of the ureter .', {'entities': [(96, 101, 'B_Disease'), (102, 111, 'I_Disease'), (112, 120, 'I_Disease'), (137, 144, 'B_Disease'), (200, 206, 'B_Disease'), (207, 209, 'I_Disease'), (210, 213, 'I_Disease'), (214, 220, 'I_Disease')]}], ['Dapsone - associated Heinz body hemolytic anemia in a Cambodian woman with hemoglobin E trait .', {'entities': [(32, 41, 'B_Disease'), (42, 48, 'I_Disease')]}], ['A Cambodian woman with hemoglobin E trait ( AE ) and leprosy developed a Heinz body hemolytic anemia while taking a dose of dapsone ( 50 mg / day ) not usually associated with clinical hemolysis .', {'entities': [(53, 60, 'B_Disease'), (84, 93, 'B_Disease'), (94, 100, 'I_Disease'), (185, 194, 'B_Disease')]}], ['Thus , AE RBCs appear to have an increased sensitivity to oxidant stress both in vitro and in vivo , since dapsone does not cause hemolytic anemia at this dose in hematologically normal individuals .', {'entities': [(130, 139, 'B_Disease'), (140, 146, 'I_Disease')]}], ['Given the influx of Southeast Asians into the United States , oxidant medications should be used with caution , especially if an infection is present , in individuals of ethnic backgrounds that have an increased prevalence of hemoglobin E .', {'entities': [(129, 138, 'B_Disease')]}], ['A 47 - year - old patient suffering from coronary artery disease was admitted to the CCU in shock with III .', {'entities': [(41, 49, 'B_Disease'), (50, 56, 'I_Disease'), (57, 64, 'I_Disease'), (92, 97, 'B_Disease')]}], ['AV block , severe hypotension , and impairment of ventricular function .', {'entities': [(0, 2, 'B_Disease'), (3, 8, 'I_Disease'), (18, 29, 'B_Disease'), (36, 46, 'B_Disease'), (47, 49, 'I_Disease'), (50, 61, 'I_Disease'), (62, 70, 'I_Disease')]}], ['Therefore , patients belonging to the poor - metabolizer phenotype of sparteine / debrisoquine polymorphism in drug metabolism , which constitutes 6 . 4 % of the German population , may experience adverse drug reactions when treated with standard doses of one of these drugs alone .', {'entities': [(197, 204, 'B_Disease'), (205, 209, 'I_Disease'), (210, 219, 'I_Disease')]}], ['Nine patients exhibited mild to moderate extrapyramidal concomitant symptoms ; no other side effects were observed .', {'entities': [(41, 55, 'B_Disease'), (56, 67, 'I_Disease'), (68, 76, 'I_Disease')]}], ['In the double blind study with haloperidol , both substances were found to be highly effective in the treatment of psychotic syndromes belonging predominantly to the schizophrenia group .', {'entities': [(115, 124, 'B_Disease'), (125, 134, 'I_Disease'), (135, 144, 'I_Disease'), (145, 158, 'I_Disease'), (159, 161, 'I_Disease'), (162, 165, 'I_Disease'), (166, 179, 'I_Disease'), (180, 185, 'I_Disease')]}], ['Prolonged cholestasis after troleandomycin - induced acute hepatitis .', {'entities': [(10, 21, 'B_Disease'), (59, 68, 'B_Disease')]}], ['We report the case of a patient in whom troleandomycin - induced hepatitis was followed by prolonged anicteric cholestasis .', {'entities': [(65, 74, 'B_Disease'), (111, 122, 'B_Disease')]}], ['Jaundice occurred after administration of troleandomycin for 7 days and was associated with hypereosinophilia .', {'entities': [(0, 8, 'B_Disease'), (92, 109, 'B_Disease')]}], ['Jaundice disappeared within 3 months but was followed by prolonged anicteric cholestasis marked by pruritus and high levels of alkaline phosphatase and gammaglutamyltransferase activities .', {'entities': [(0, 8, 'B_Disease'), (77, 88, 'B_Disease'), (99, 107, 'B_Disease')]}], ['Finally , pruritus disappeared within 19 months , and liver tests returned to normal 27 months after the onset of hepatitis .', {'entities': [(10, 18, 'B_Disease'), (114, 123, 'B_Disease')]}], ['This observation demonstrates that prolonged cholestasis can follow troleandomycin - induced acute hepatitis .', {'entities': [(45, 56, 'B_Disease'), (99, 108, 'B_Disease')]}], ['Serial studies of auditory neurotoxicity in patients receiving deferoxamine therapy .', {'entities': [(18, 26, 'B_Disease'), (27, 40, 'I_Disease')]}], ['Visual and auditory neurotoxicity was previously documented in 42 of 89 patients with transfusion - dependent anemia who were receiving iron chelation therapy with daily subcutaneous deferoxamine .', {'entities': [(0, 6, 'B_Disease'), (7, 10, 'I_Disease'), (11, 19, 'I_Disease'), (20, 33, 'I_Disease'), (110, 116, 'B_Disease')]}], ['Twenty - two patients in the affected group had abnormal audiograms with deficits mostly in the high frequency range of 4 , 000 to 8 , 000 Hz and in the hearing threshold levels of 30 to 100 decibels .', {'entities': [(48, 56, 'B_Disease'), (57, 67, 'I_Disease'), (68, 72, 'I_Disease'), (73, 81, 'I_Disease'), (82, 88, 'I_Disease'), (89, 91, 'I_Disease'), (92, 95, 'I_Disease'), (96, 100, 'I_Disease'), (101, 110, 'I_Disease'), (111, 116, 'I_Disease'), (117, 119, 'I_Disease'), (120, 121, 'I_Disease'), (122, 123, 'I_Disease'), (124, 127, 'I_Disease'), (128, 130, 'I_Disease'), (131, 132, 'I_Disease'), (133, 134, 'I_Disease'), (135, 138, 'I_Disease'), (139, 141, 'I_Disease')]}], ['Audiograms from 15 patients remained abnormal and four patients required hearing aids because of permanent disability .', {'entities': [(97, 106, 'B_Disease'), (107, 117, 'I_Disease')]}], ['Since 18 of the 22 patients were initially receiving deferoxamine doses in excess of the commonly recommended 50 mg / kg per dose , therapy was restarted with lower doses , usually 50 mg / kg per dose or less depending on the degree of auditory abnormality , and with the exception of two cases no further toxicity was demonstrated .', {'entities': [(236, 244, 'B_Disease'), (245, 256, 'I_Disease'), (306, 314, 'B_Disease')]}], ['Auditory deterioration and improvement , demonstrated serially in individual patients receiving and not receiving deferoxamine , respectively , provided convincing evidence for a cause - and - effect relation between deferoxamine administration and ototoxicity .', {'entities': [(249, 260, 'B_Disease')]}], ['With mild toxicity , a reduction to 30 or 40 mg / kg per dose should result in a reversal of the abnormal results to normal within four weeks .', {'entities': [(10, 18, 'B_Disease')]}], ['In those with symptoms of hearing loss , the drug should be stopped for four weeks , and when the audiogram is stable or improved , therapy should be restarted at 10 to 25 mg / kg per dose .', {'entities': [(26, 33, 'B_Disease'), (34, 38, 'I_Disease')]}], ['Serial audiograms should be performed every six months in those without problems and more frequently in young patients with normal serum ferritin values and in those with auditory dysfunction .', {'entities': [(171, 179, 'B_Disease'), (180, 191, 'I_Disease')]}], ['Lidocaine - induced cardiac asystole .', {'entities': [(20, 27, 'B_Disease'), (28, 36, 'I_Disease')]}], ['Intravenous administration of a single 50 - mg bolus of lidocaine in a 67 - year - old man resulted in profound depression of the activity of the sinoatrial and atrioventricular nodal pacemakers .', {'entities': [(112, 122, 'B_Disease')]}], ['The patient had no apparent associated conditions which might have predisposed him to the development of bradyarrhythmias ; and , thus , this probably represented a true idiosyncrasy to lidocaine .', {'entities': [(105, 121, 'B_Disease')]}], ['Flurbiprofen in the treatment of juvenile rheumatoid arthritis .', {'entities': [(33, 41, 'B_Disease'), (42, 52, 'I_Disease'), (53, 62, 'I_Disease')]}], ['Thirty - four patients with juvenile rheumatoid arthritis , who were treated with flurbiprofen at a maximum dose of 4 mg / kg / day , had statistically significant decreases from baseline in 6 arthritis indices after 12 weeks of treatment .', {'entities': [(28, 36, 'B_Disease'), (37, 47, 'I_Disease'), (48, 57, 'I_Disease'), (193, 202, 'B_Disease')]}], ['Improvements were seen in the number of tender joints , the severity of swelling and tenderness , the time of walk 50 feet , the duration of morning stiffness and the circumference of the left knee .', {'entities': [(40, 46, 'B_Disease'), (47, 53, 'I_Disease'), (72, 80, 'B_Disease'), (85, 95, 'B_Disease'), (141, 148, 'B_Disease'), (149, 158, 'I_Disease')]}], ['The most frequently observed side effect was fecal occult blood ( 25 % of patients ) ; however , there was no other evidence of gastrointestinal ( GI ) bleeding in these patients .', {'entities': [(45, 50, 'B_Disease'), (51, 57, 'I_Disease'), (58, 63, 'I_Disease'), (128, 144, 'B_Disease'), (145, 146, 'I_Disease'), (147, 149, 'I_Disease'), (150, 151, 'I_Disease'), (152, 160, 'I_Disease')]}], ['One patient was prematurely discontinued from the study for severe headache and abdominal pain .', {'entities': [(67, 75, 'B_Disease'), (80, 89, 'B_Disease'), (90, 94, 'I_Disease')]}], ['Hyperkalemia associated with sulindac therapy .', {'entities': [(0, 12, 'B_Disease')]}], ['Hyperkalemia has recently been recognized as a complication of nonsteroidal antiinflammatory agents ( NSAID ) such as indomethacin .', {'entities': [(0, 12, 'B_Disease')]}], ['We describe 4 patients in whom hyperkalemia ranging from 6 . 1 to 6 . 9 mEq / l developed within 3 to 8 days of sulindac administration .', {'entities': [(31, 43, 'B_Disease')]}], ['As no other medications known to effect serum potassium had been given concomitantly , this course of events is suggestive of a cause - and - effect relationship between sulindac and hyperkalemia .', {'entities': [(183, 195, 'B_Disease')]}], ['Drug - induced arterial spasm relieved by lidocaine .', {'entities': [(24, 29, 'B_Disease')]}], ['Following major intracranial surgery in a 35 - year - old man , sodium pentothal was intravenously infused to minimize cerebral ischaemia .', {'entities': [(119, 127, 'B_Disease'), (128, 137, 'I_Disease')]}], ['Intense vasospasm with threatened gangrene arose in the arm used for the infusion .', {'entities': [(8, 17, 'B_Disease'), (34, 42, 'B_Disease')]}], ['Since the cranial condition precluded use of more usual methods , lidocaine was given intra - arterially , with careful cardiovascular monitoring , to counteract the vasospasm .', {'entities': [(166, 175, 'B_Disease')]}], ['Regional localization of the antagonism of amphetamine - induced hyperactivity by intracerebral calcitonin injections .', {'entities': [(65, 78, 'B_Disease')]}], ['The hematologic effects of cefonicid and cefazedone in the dog : a potential model of cephalosporin hematotoxicity in man .', {'entities': [(100, 114, 'B_Disease')]}], ['Cephalosporin antibiotics cause a variety of hematologic disturbances in man , the pathogeneses and hematopathology of which remain poorly characterized .', {'entities': [(45, 56, 'B_Disease'), (57, 69, 'I_Disease')]}], ['There is a need for a well - defined animal model in which these blood dyscrasias can be studied .', {'entities': [(65, 70, 'B_Disease'), (71, 81, 'I_Disease')]}], ['In four subacute toxicity studies , the intravenous administration of cefonicid or cefazedone to beagle dogs caused a dose - dependent incidence of anemia , neutropenia , and thrombocytopenia after 1 - 3 months of treatment .', {'entities': [(17, 25, 'B_Disease'), (148, 154, 'B_Disease'), (157, 168, 'B_Disease'), (175, 191, 'B_Disease')]}], ['A nonregenerative anemia was the most compromising of the cytopenias and occurred in approximately 50 % of dogs receiving 400 - 500 mg / kg cefonicid or 540 - 840 mg / kg cefazedone .', {'entities': [(18, 24, 'B_Disease'), (58, 68, 'B_Disease')]}], ['All three cytopenias were completely reversible following cessation of treatment ; the time required for recovery of the erythron ( approximately 1 month ) was considerably longer than that of the granulocytes and platelets ( hours to a few days ) .', {'entities': [(10, 20, 'B_Disease')]}], ['Upon rechallenge with either cephalosporin , the hematologic syndrome was reproduced in most dogs tested ; cefonicid ( but not cefazedone ) - treated dogs showed a substantially reduced induction period ( 15 + / - 5 days ) compared to that of the first exposure to the drug ( 61 + / - 24 days ) .', {'entities': [(49, 60, 'B_Disease'), (61, 69, 'I_Disease')]}], ['This observation , along with the rapid rate of decline in red cell mass parameters of affected dogs , suggests that a hemolytic component complicated the red cell production problem and that multiple toxicologic mechanisms contributed to the cytopenia .', {'entities': [(119, 128, 'B_Disease'), (243, 252, 'B_Disease')]}], ['We conclude that the administration of high doses of cefonicid or cefazedone to dogs can induce hematotoxicity similar to the cephalosporin - induced blood dyscrasias described in man and thus provides a useful model for studying the mechanisms of these disorders .', {'entities': [(96, 110, 'B_Disease'), (150, 155, 'B_Disease'), (156, 166, 'I_Disease')]}], ['Cerebral blood flow and metabolism during isoflurane - induced hypotension in patients subjected to surgery for cerebral aneurysms .', {'entities': [(63, 74, 'B_Disease'), (112, 120, 'B_Disease'), (121, 130, 'I_Disease')]}], ['Cerebral blood flow and cerebral metabolic rate for oxygen were measured during isoflurane - induced hypotension in 10 patients subjected to craniotomy for clipping of a cerebral aneurysm .', {'entities': [(101, 112, 'B_Disease'), (170, 178, 'B_Disease'), (179, 187, 'I_Disease')]}], ['Flow and metabolism were measured 5 - 13 days after the subarachnoid haemorrhage by a modification of the classical Kety - Schmidt technique using xenon - 133 i . v . Anaesthesia was maintained with an inspired isoflurane concentration of 0 . 75 % ( plus 67 % nitrous oxide in oxygen ) , during which CBF and CMRO2 were 34 . 3 + / - 2 . 1 ml / 100 g min - 1 and 2 . 32 + / - 0 . 16 ml / 100 g min - 1 at PaCO2 4 . 1 + / - 0 . 1 kPa ( mean + / - SEM ) .', {'entities': [(56, 68, 'B_Disease'), (69, 80, 'I_Disease')]}], ['Controlled hypotension to an average MAP of 50 - 55 mm Hg was induced by increasing the dose of isoflurane , and maintained at an inspired concentration of 2 . 2 + / - 0 . 2 % .', {'entities': [(11, 22, 'B_Disease')]}], ['After the clipping of the aneurysm the isoflurane concentration was reduced to 0 . 75 % .', {'entities': [(26, 34, 'B_Disease')]}], ['There was a significant increase in CBF , although CMRO2 was unchanged , compared with pre - hypotensive values .', {'entities': [(93, 104, 'B_Disease')]}], ['These changes might offer protection to brain tissue during periods of induced hypotension .', {'entities': [(79, 90, 'B_Disease')]}], ['Triazolam - induced brief episodes of secondary mania in a depressed patient .', {'entities': [(48, 53, 'B_Disease'), (59, 68, 'B_Disease')]}], ['Large doses of triazolam repeatedly induced brief episodes of mania in a depressed elderly woman .', {'entities': [(62, 67, 'B_Disease'), (73, 82, 'B_Disease')]}], ['Features of organic mental disorder ( delirium ) were not present .', {'entities': [(12, 19, 'B_Disease'), (20, 26, 'I_Disease'), (27, 35, 'I_Disease'), (38, 46, 'B_Disease')]}], ['Manic excitement was coincident with the duration of action of triazolam .', {'entities': [(0, 5, 'B_Disease')]}], ['The correlation between neurotoxic esterase inhibition and mipafox - induced neuropathic damage in rats .', {'entities': [(24, 34, 'B_Disease'), (77, 88, 'B_Disease'), (89, 95, 'I_Disease')]}], [\"The correlation between neuropathic damage and inhibition of neurotoxic esterase or neuropathy target enzyme ( NTE ) was examined in rats acutely exposed to Mipafox ( N , N ' - diisopropylphosphorodiamidofluoridate ) , a neurotoxic organophosphate .\", {'entities': [(24, 35, 'B_Disease'), (36, 42, 'I_Disease'), (61, 71, 'B_Disease'), (84, 94, 'B_Disease'), (221, 231, 'B_Disease')]}], ['These data were correlated with histologically scored cervical cord damage in a separate group of similarly dosed rats sampled 14 - 21 days post - exposure .', {'entities': [(63, 67, 'B_Disease'), (68, 74, 'I_Disease')]}], ['In contrast , dosages of Mipafox ( less than or equal to 5 mg / kg ) which inhibited mean NTE activity in spinal cord less than or equal to 61 % and brain less than or equal to 60 % produced this degree of cord damage in only 9 % of the animals .', {'entities': [(206, 210, 'B_Disease'), (211, 217, 'I_Disease')]}], ['These data indicate that a critical percentage of NTE inhibition in brain and spinal cord sampled shortly after Mipafox exposure can predict neuropathic damage in rats several weeks later .', {'entities': [(141, 152, 'B_Disease'), (153, 159, 'I_Disease')]}], ['Allergic reaction to 5 - fluorouracil infusion .', {'entities': [(0, 8, 'B_Disease'), (9, 17, 'I_Disease')]}], ['An allergic reaction consisting of angioneurotic edema secondary to continuous infusion 5 - fluorouracil occurred in a patient with recurrent carcinoma of the oral cavity , cirrhosis , and cisplatin - induced impaired renal function .', {'entities': [(3, 11, 'B_Disease'), (12, 20, 'I_Disease'), (35, 48, 'B_Disease'), (49, 54, 'I_Disease'), (142, 151, 'B_Disease'), (152, 154, 'I_Disease'), (155, 158, 'I_Disease'), (159, 163, 'I_Disease'), (164, 170, 'I_Disease'), (173, 182, 'B_Disease'), (209, 217, 'B_Disease'), (218, 223, 'I_Disease'), (224, 232, 'I_Disease')]}], ['Oral diphenhydramine and prednisone were ineffective in preventing the recurrence of the allergic reaction .', {'entities': [(89, 97, 'B_Disease'), (98, 106, 'I_Disease')]}], ['Myasthenia gravis caused by penicillamine and chloroquine therapy for rheumatoid arthritis .', {'entities': [(0, 10, 'B_Disease'), (11, 17, 'I_Disease'), (70, 80, 'B_Disease'), (81, 90, 'I_Disease')]}], ['We have described a unique patient who had reversible and dose - related myasthenia gravis after penicillamine and chloroquine therapy for rheumatoid arthritis .', {'entities': [(73, 83, 'B_Disease'), (84, 90, 'I_Disease'), (139, 149, 'B_Disease'), (150, 159, 'I_Disease')]}], ['On the mechanisms of the development of tolerance to the muscular rigidity produced by morphine in rats .', {'entities': [(57, 65, 'B_Disease'), (66, 74, 'I_Disease')]}], ['The development of tolerance to the muscular rigidity produced by morphine was studied in rats .', {'entities': [(36, 44, 'B_Disease'), (45, 53, 'I_Disease')]}], ['Saline - pretreated controls given a test dose of morphine ( 20 mg / kg i . p . ) showed a pronounced rigidity recorded as tonic activity in the electromyogram .', {'entities': [(102, 110, 'B_Disease')]}], ['Rats treated for 11 days with morphine and withdrawn for 36 - 40 h showed differences in the development of tolerance : about half of the animals showed a rigidity after the test dose of morphine that was not significantly less than in the controls and were akinetic ( A group ) .', {'entities': [(155, 163, 'B_Disease'), (258, 266, 'B_Disease')]}], ['The other rats showed a strong decrease in the rigidity and the occurrence of stereotyped ( S ) licking and / or gnawing in presence of akinetic or hyperkinetic ( K ) behaviour ( AS / KS group ) , suggesting signs of dopaminergic activation .', {'entities': [(47, 55, 'B_Disease'), (136, 144, 'B_Disease'), (148, 160, 'B_Disease')]}], [\"The rigidity was considerably decreased in both groups after 20 days ' treatment .\", {'entities': [(4, 12, 'B_Disease')]}], ['In a further series of experiments , haloperidol ( 0 . 2 mg / kg i . p . ) was used in order to block the dopaminergic activation and to estimate the real degree of the tolerance to the rigidity without any dopaminergic interference .', {'entities': [(186, 194, 'B_Disease')]}], ['Haloperidol enhanced the rigidity in the A group .', {'entities': [(25, 33, 'B_Disease')]}], ['The results suggest that rigidity , which is assumed to be due to an action of morphine in the striatum , can be antagonized by another process leading to dopaminergic activation in the striatum .', {'entities': [(25, 33, 'B_Disease')]}], ['The rapid alternations of rigidity and the signs of dopaminergic activation observed in the animals of the AS / KS group might be due to rapid shifts in the predominance of various DA - innervated structures .', {'entities': [(26, 34, 'B_Disease')]}], ['A case of massive rhabdomyolysis following molindone administration .', {'entities': [(18, 32, 'B_Disease')]}], ['Rhabdomyolysis is a potentially lethal syndrome that psychiatric patients seem predisposed to develop .', {'entities': [(0, 14, 'B_Disease'), (53, 64, 'B_Disease')]}], ['The clinical signs and symptoms , typical laboratory features , and complications of rhabdomyolysis are presented .', {'entities': [(85, 99, 'B_Disease')]}], ['The case of a schizophrenic patient is reported to illustrate massive rhabdomyolysis and subsequent acute renal failure following molindone administration .', {'entities': [(14, 27, 'B_Disease'), (70, 84, 'B_Disease'), (100, 105, 'B_Disease'), (106, 111, 'I_Disease'), (112, 119, 'I_Disease')]}], ['Compression neuropathy of the radial nerve due to pentazocine - induced fibrous myopathy .', {'entities': [(0, 11, 'B_Disease'), (12, 22, 'I_Disease'), (23, 25, 'I_Disease'), (26, 29, 'I_Disease'), (30, 36, 'I_Disease'), (37, 42, 'I_Disease'), (72, 79, 'B_Disease'), (80, 88, 'I_Disease')]}], ['Fibrous myopathy is a common , well - known side effect of repeated pentazocine injection .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease')]}], ['However , compression neuropathy due to fibrotic muscle affected by pentazocine - induced myopathy has not previously been reported .', {'entities': [(10, 21, 'B_Disease'), (22, 32, 'I_Disease'), (90, 98, 'B_Disease')]}], ['In a 37 - year - old woman with documented pentazocine - induced fibrous myopathy of triceps and deltoid muscles bilaterally and a three - week history of right wrist drop , electrodiagnostic examination showed a severe but partial lesion of the right radial nerve distal to the branches to the triceps , in addition to the fibrous myopathy .', {'entities': [(65, 72, 'B_Disease'), (73, 81, 'I_Disease'), (324, 331, 'B_Disease'), (332, 340, 'I_Disease')]}], ['Recurrent reversible acute renal failure from amphotericin .', {'entities': [(21, 26, 'B_Disease'), (27, 32, 'I_Disease'), (33, 40, 'I_Disease')]}], ['A patient with cryptogenic cirrhosis and disseminated sporotrichosis developed acute renal failure immediately following the administration of amphotericin B on four separate occasions .', {'entities': [(27, 36, 'B_Disease'), (54, 68, 'B_Disease'), (79, 84, 'B_Disease'), (85, 90, 'I_Disease'), (91, 98, 'I_Disease')]}], ['The abruptness of the renal failure and its reversibility within days suggests that there was a functional component to the renal dysfunction .', {'entities': [(22, 27, 'B_Disease'), (28, 35, 'I_Disease'), (124, 129, 'B_Disease'), (130, 141, 'I_Disease')]}], ['We propose that amphotericin , in the setting of reduced effective arterial volume , may activate tubuloglomerular feedback , thereby contributing to acute renal failure .', {'entities': [(150, 155, 'B_Disease'), (156, 161, 'I_Disease'), (162, 169, 'I_Disease')]}], ['Cerebral infarction with a single oral dose of phenylpropanolamine .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease')]}], ['Its prolonged use or overuse has been associated with seizures , intracerebral hemorrhage , neuropsychiatric symptoms , and nonhemorrhagic cerebral infarction .', {'entities': [(54, 62, 'B_Disease'), (65, 78, 'B_Disease'), (79, 89, 'I_Disease'), (92, 108, 'B_Disease'), (109, 117, 'I_Disease'), (139, 147, 'B_Disease'), (148, 158, 'I_Disease')]}], ['We report the case of a young woman who suffered a cerebral infarction after taking a single oral dose of PPA .', {'entities': [(51, 59, 'B_Disease'), (60, 70, 'I_Disease')]}], ['Remission induction of meningeal leukemia with high - dose intravenous methotrexate .', {'entities': [(23, 32, 'B_Disease'), (33, 41, 'I_Disease')]}], ['Twenty children with acute lymphoblastic leukemia who developed meningeal disease were treated with a high - dose intravenous methotrexate regimen that was designed to achieve and maintain CSF methotrexate concentrations of 10 ( - 5 ) mol / L without the need for concomitant intrathecal dosing .', {'entities': [(21, 26, 'B_Disease'), (27, 40, 'I_Disease'), (41, 49, 'I_Disease'), (64, 73, 'B_Disease'), (74, 81, 'I_Disease')]}], ['The most common toxicities encountered were transient serum transaminase and bilirubin elevations , neutropenia , and mucositis .', {'entities': [(16, 26, 'B_Disease'), (100, 111, 'B_Disease'), (118, 127, 'B_Disease')]}], ['One patient had focal seizures and transient hemiparesis but recovered completely .', {'entities': [(22, 30, 'B_Disease'), (35, 44, 'B_Disease'), (45, 56, 'I_Disease')]}], ['High - dose intravenous methotrexate is an effective treatment for the induction of remission after meningeal relapse in acute lymphoblastic leukemia .', {'entities': [(121, 126, 'B_Disease'), (127, 140, 'I_Disease'), (141, 149, 'I_Disease')]}], ['A synergistic effect of etoposide and cyclosporin A was observed in a patient with acute T - lymphocytic leukemia in relapse .', {'entities': [(83, 88, 'B_Disease'), (89, 90, 'I_Disease'), (91, 92, 'I_Disease'), (93, 104, 'I_Disease'), (105, 113, 'I_Disease')]}], ['The concomitant administration of etoposide and cyclosporin A resulted in eradication of hitherto refractory leukemic infiltration of bone marrow .', {'entities': [(109, 117, 'B_Disease'), (118, 130, 'I_Disease')]}], ['Severe side effects in terms of mental confusion and progressive hyperbilirubinemia , however , point to an enhancement not only of antineoplastic effects but also of toxicity in normal tissues .', {'entities': [(39, 48, 'B_Disease'), (65, 83, 'B_Disease'), (167, 175, 'B_Disease')]}], ['Incidence of neoplasms in patients with rheumatoid arthritis exposed to different treatment regimens .', {'entities': [(13, 22, 'B_Disease'), (40, 50, 'B_Disease'), (51, 60, 'I_Disease')]}], ['Immunosuppressive drugs have been used during the last 30 years in treatment of patients with severe rheumatoid arthritis .', {'entities': [(101, 111, 'B_Disease'), (112, 121, 'I_Disease')]}], ['There is evidence that all four immunosuppressive drugs can reduce synovitis , but disease activity almost always recurs after therapy is stopped .', {'entities': [(67, 76, 'B_Disease')]}], [\"Patients treated with alkylating agents have an increased risk of development of acute nonlymphocytic leukemia , and both alkylating agents and azathioprine are associated with the development of non - Hodgkin ' s lymphoma .\", {'entities': [(81, 86, 'B_Disease'), (87, 101, 'I_Disease'), (102, 110, 'I_Disease'), (196, 199, 'B_Disease'), (200, 201, 'I_Disease'), (202, 209, 'I_Disease'), (210, 211, 'I_Disease'), (212, 213, 'I_Disease'), (214, 222, 'I_Disease')]}], ['Cyclophosphamide therapy increases the risk of carcinoma of the bladder .', {'entities': [(47, 56, 'B_Disease'), (57, 59, 'I_Disease'), (60, 63, 'I_Disease'), (64, 71, 'I_Disease')]}], ['There have been several long - term studies of patients with rheumatoid arthritis treated with azathioprine and cyclophosphamide and the incidence of most of the common cancers is not increased .', {'entities': [(61, 71, 'B_Disease'), (72, 81, 'I_Disease'), (169, 176, 'B_Disease')]}], ['Data on the possible increased risk of malignancy in rheumatoid arthritis are still being collected , and until further information is available , the use of immunosuppressive drugs , particularly alkylating agents , in the treatment of rheumatoid arthritis should be reserved for patients with severe progressive disease or life - threatening complications .', {'entities': [(39, 49, 'B_Disease'), (53, 63, 'B_Disease'), (64, 73, 'I_Disease'), (237, 247, 'B_Disease'), (248, 257, 'I_Disease')]}], ['Warfarin - induced iliopsoas hemorrhage with subsequent femoral nerve palsy .', {'entities': [(29, 39, 'B_Disease'), (56, 63, 'B_Disease'), (64, 69, 'I_Disease'), (70, 75, 'I_Disease')]}], ['We present the case of a 28 - year - old man on chronic warfarin therapy who sustained a minor muscle tear and developed increasing pain and a flexure contracture of the right hip .', {'entities': [(95, 101, 'B_Disease'), (102, 106, 'I_Disease'), (132, 136, 'B_Disease'), (151, 162, 'B_Disease')]}], ['Surgical exploration revealed an iliopsoas hematoma and femoral nerve entrapment , resulting in a femoral nerve palsy and partial loss of quadriceps functions .', {'entities': [(43, 51, 'B_Disease'), (64, 69, 'B_Disease'), (70, 80, 'I_Disease'), (98, 105, 'B_Disease'), (106, 111, 'I_Disease'), (112, 117, 'I_Disease'), (122, 129, 'B_Disease'), (130, 134, 'I_Disease'), (135, 137, 'I_Disease'), (138, 148, 'I_Disease'), (149, 158, 'I_Disease')]}], ['Anticoagulant - induced femoral nerve palsy represents the most common form of warfarin - induced peripheral neuropathy ; it is characterized by severe pain in the inguinal region , varying degrees of motor and sensory impairment , and flexure contracture of the involved extremity .', {'entities': [(24, 31, 'B_Disease'), (32, 37, 'I_Disease'), (38, 43, 'I_Disease'), (98, 108, 'B_Disease'), (109, 119, 'I_Disease'), (152, 156, 'B_Disease'), (201, 206, 'B_Disease'), (207, 210, 'I_Disease'), (211, 218, 'I_Disease'), (219, 229, 'I_Disease'), (244, 255, 'B_Disease')]}], ['Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy .', {'entities': [(17, 24, 'B_Disease'), (25, 28, 'I_Disease'), (29, 40, 'I_Disease'), (41, 49, 'I_Disease'), (54, 64, 'B_Disease')]}], ['A patient with sinuatrial disease and implanted pacemaker was treated with amiodarone ( maximum dose 1000 mg , maintenance dose 800 mg daily ) for 10 months , for control of supraventricular tachyarrhythmias .', {'entities': [(15, 25, 'B_Disease'), (26, 33, 'I_Disease'), (174, 190, 'B_Disease'), (191, 207, 'I_Disease')]}], ['He developed pneumonitis , pleural and pericardial effusions , and a predominantly proximal motor neuropathy .', {'entities': [(13, 24, 'B_Disease'), (27, 34, 'B_Disease'), (35, 38, 'I_Disease'), (39, 50, 'I_Disease'), (51, 60, 'I_Disease'), (83, 91, 'B_Disease'), (92, 97, 'I_Disease'), (98, 108, 'I_Disease')]}], ['Review of this and previously reported cases indicates the need for early diagnosis of amiodarone pneumonitis , immediate withdrawal of amiodarone , and prompt but continued steroid therapy to ensure full recovery .', {'entities': [(98, 109, 'B_Disease')]}], ['Amiodarone - induced sinoatrial block .', {'entities': [(21, 31, 'B_Disease'), (32, 37, 'I_Disease')]}], ['We observed sinoatrial block due to chronic amiodarone administration in a 5 - year - old boy with primary cardiomyopathy , Wolff - Parkinson - White syndrome and supraventricular tachycardia .', {'entities': [(12, 22, 'B_Disease'), (23, 28, 'I_Disease'), (99, 106, 'B_Disease'), (107, 121, 'I_Disease'), (124, 129, 'B_Disease'), (130, 131, 'I_Disease'), (132, 141, 'I_Disease'), (142, 143, 'I_Disease'), (144, 149, 'I_Disease'), (150, 158, 'I_Disease'), (163, 179, 'B_Disease'), (180, 191, 'I_Disease')]}], ['Reduction in the dosage of amiodarone resulted in the disappearance of the sinoatrial block and the persistence of asymptomatic sinus bradycardia .', {'entities': [(75, 85, 'B_Disease'), (86, 91, 'I_Disease'), (128, 133, 'B_Disease'), (134, 145, 'I_Disease')]}], ['Desipramine - induced delirium at \" subtherapeutic \" concentrations : a case report .', {'entities': [(22, 30, 'B_Disease')]}], ['An elderly patient treated with low dose Desipramine developed a delirium while her plasma level was in the \" subtherapeutic \" range .', {'entities': [(65, 73, 'B_Disease')]}], ['Delirium , which may be induced by tricyclic drug therapy in the elderly , can be caused by tricyclics with low anticholinergic potency .', {'entities': [(0, 8, 'B_Disease')]}], ['Indomethacin - induced renal insufficiency : recurrence on rechallenge .', {'entities': [(23, 28, 'B_Disease'), (29, 42, 'I_Disease')]}], ['We have reported a case of acute oliguric renal failure with hyperkalemia in a patient with cirrhosis , ascites , and cor pulmonale after indomethacin therapy .', {'entities': [(42, 47, 'B_Disease'), (48, 55, 'I_Disease'), (61, 73, 'B_Disease'), (92, 101, 'B_Disease'), (104, 111, 'B_Disease'), (118, 121, 'B_Disease'), (122, 131, 'I_Disease')]}], ['Prompt restoration of renal function followed drug withdrawal , while re - exposure to a single dose of indomethacin caused recurrence of acute reversible oliguria .', {'entities': [(155, 163, 'B_Disease')]}], ['Since nonsteroidal anti - inflammatory agents interfere with this compensatory mechanism and may cause acute renal failure , they should be used with caution in such patients .', {'entities': [(103, 108, 'B_Disease'), (109, 114, 'I_Disease'), (115, 122, 'I_Disease')]}], ['Patterns of hepatic injury induced by methyldopa .', {'entities': [(12, 19, 'B_Disease'), (20, 26, 'I_Disease')]}], ['Twelve patients with liver disease related to methyldopa were seen between 1967 and 1977 .', {'entities': [(21, 26, 'B_Disease'), (27, 34, 'I_Disease')]}], ['Jaundice with tender hepatomegaly , usually preceded by symptoms of malaise , anorexia , nausea and vomiting , and associated with upper abdominal pain , was an invariable finding in all patients .', {'entities': [(0, 8, 'B_Disease'), (21, 33, 'B_Disease'), (78, 86, 'B_Disease'), (89, 95, 'B_Disease'), (100, 108, 'B_Disease'), (137, 146, 'B_Disease'), (147, 151, 'I_Disease')]}], ['Biochemical liver function tests indicated hepatocellular necrosis and correlated with histopathological evidence of hepatic injury , the spectrum of which ranged from fatty change and focal hepatocellular necrosis to massive hepatic necrosis .', {'entities': [(58, 66, 'B_Disease'), (117, 124, 'B_Disease'), (125, 131, 'I_Disease'), (168, 173, 'B_Disease'), (174, 180, 'I_Disease'), (206, 214, 'B_Disease'), (218, 225, 'B_Disease'), (226, 233, 'I_Disease'), (234, 242, 'I_Disease')]}], ['Most patients showed moderate to severe acute hepatitis or chronic active hepatitis with associated cholestasis .', {'entities': [(40, 45, 'B_Disease'), (46, 55, 'I_Disease'), (59, 66, 'B_Disease'), (67, 73, 'I_Disease'), (74, 83, 'I_Disease'), (100, 111, 'B_Disease')]}], ['One patient died , having presented in hepatic failure , and another , who had been taking methyldopa for 7 years , showed slower clinical and biochemical resolution over a period of several months .', {'entities': [(39, 46, 'B_Disease'), (47, 54, 'I_Disease')]}], ['The remaining patient in the series developed fulminant hepatitis when the drug was accidentally recommenced 1 year after a prior episode of methyldopa - induced hepatitis .', {'entities': [(46, 55, 'B_Disease'), (56, 65, 'I_Disease'), (162, 171, 'B_Disease')]}], ['In this latter patient , and in 2 others , the causal relationship between methyldopa and hepatic dysfunction was proved with the recurrence of hepatitis within 2 weeks of re - exposure to the drug .', {'entities': [(90, 97, 'B_Disease'), (98, 109, 'I_Disease'), (144, 153, 'B_Disease')]}], ['Suxamethonium infusion rate and observed fasciculations .', {'entities': [(41, 55, 'B_Disease')]}], ['The infusion was discontinued either when there was no muscular response to tetanic stimulation of the ulnar nerve or when Sch 120 mg was exceeded .', {'entities': [(76, 83, 'B_Disease')]}], ['Fasciculations in six areas of the body were scored from 0 to 3 and summated as a total fasciculation score .', {'entities': [(0, 14, 'B_Disease'), (88, 101, 'B_Disease')]}], ['The times to first fasciculation , twitch suppression and tetanus suppression were inversely related to the infusion rates .', {'entities': [(19, 32, 'B_Disease'), (35, 41, 'B_Disease'), (58, 65, 'B_Disease')]}], ['Fasciculations in the six areas and the total fasciculation score were related directly to the rate of infusion .', {'entities': [(0, 14, 'B_Disease'), (46, 59, 'B_Disease')]}], ['Total fasciculation scores in the 30 - mg bolus group and the 5 - mg s - 1 and 20 - mg s - 1 infusion groups were not significantly different .', {'entities': [(6, 19, 'B_Disease')]}], ['Treatment of psoriasis with azathioprine .', {'entities': [(13, 22, 'B_Disease')]}], ['Azathioprine treatment benefited 19 ( 66 % ) out of 29 patients suffering from severe psoriasis .', {'entities': [(86, 95, 'B_Disease')]}], ['Minimal cholestasis was seen in two cases and portal fibrosis of a reversible degree in eight .', {'entities': [(8, 19, 'B_Disease'), (53, 61, 'B_Disease')]}], ['Liver biopsies should be undertaken at regular intervals if azathioprine therapy is continued so that structural liver damage may be detected at an early and reversible stage .', {'entities': [(113, 118, 'B_Disease'), (119, 125, 'I_Disease')]}], ['Angiosarcoma of the liver associated with diethylstilbestrol .', {'entities': [(0, 12, 'B_Disease'), (13, 15, 'I_Disease'), (16, 19, 'I_Disease'), (20, 25, 'I_Disease')]}], ['Angiosarcoma of the liver occurred in a 76 - year - old man who had been treated for a well - differentiated adenocarcinoma of the liver with diethylstilbestrol for 13 years .', {'entities': [(0, 12, 'B_Disease'), (13, 15, 'I_Disease'), (16, 19, 'I_Disease'), (20, 25, 'I_Disease'), (109, 123, 'B_Disease'), (124, 126, 'I_Disease'), (127, 130, 'I_Disease'), (131, 136, 'I_Disease')]}], ['Angiosarcoma was also present within pulmonary and renal arteries .', {'entities': [(0, 12, 'B_Disease')]}], ['The possibility that the intraarterial lesions might represent independent primary tumors is considered .', {'entities': [(25, 38, 'B_Disease'), (39, 46, 'I_Disease'), (83, 89, 'B_Disease')]}], ['Galanthamine hydrobromide , an anticholinesterase drug capable of penetrating the blood - brain barrier , was used in a patient demonstrating central effects of scopolamine ( hyoscine ) overdosage .', {'entities': [(186, 196, 'B_Disease')]}], ['Dizziness was less marked than sedation , but increased with the dose .', {'entities': [(0, 9, 'B_Disease')]}], ['There was pain on i . m . injection of flunitrazepam significantly more often than with isotonic saline .', {'entities': [(10, 14, 'B_Disease')]}], ['Three infants , born of two mothers with inflammatory bowel disease who received treatment with sulphasalazine throughout pregnancy , were found to have major congenital anomalies .', {'entities': [(41, 53, 'B_Disease'), (54, 59, 'I_Disease'), (60, 67, 'I_Disease'), (159, 169, 'B_Disease'), (170, 179, 'I_Disease')]}], ['In the singleton pregnancy , the mother had ulcerative colitis , and the infant , a male , had coarctation of the aorta and a ventricular septal defect .', {'entities': [(44, 54, 'B_Disease'), (55, 62, 'I_Disease'), (95, 106, 'B_Disease'), (107, 109, 'I_Disease'), (110, 113, 'I_Disease'), (114, 119, 'I_Disease'), (126, 137, 'B_Disease'), (138, 144, 'I_Disease'), (145, 151, 'I_Disease')]}], [\"In the twin pregnancy , the mother had Crohn ' s disease .\", {'entities': [(39, 44, 'B_Disease'), (45, 46, 'I_Disease'), (47, 48, 'I_Disease'), (49, 56, 'I_Disease')]}], ['The first twin , a female , had a left Potter - type IIa polycystic kidney and a rudimentary left uterine cornu .', {'entities': [(39, 45, 'B_Disease'), (46, 47, 'I_Disease'), (48, 52, 'I_Disease'), (53, 56, 'I_Disease'), (57, 67, 'I_Disease'), (68, 74, 'I_Disease'), (81, 92, 'B_Disease'), (93, 97, 'I_Disease'), (98, 105, 'I_Disease'), (106, 111, 'I_Disease')]}], [\"The second twin , a male , had some features of Potter ' s facies , hypoplastic lungs , absent kidneys and ureters , and talipes equinovarus .\", {'entities': [(48, 54, 'B_Disease'), (55, 56, 'I_Disease'), (57, 58, 'I_Disease'), (59, 65, 'I_Disease'), (68, 79, 'B_Disease'), (80, 85, 'I_Disease'), (88, 94, 'B_Disease'), (95, 102, 'I_Disease'), (103, 106, 'I_Disease'), (107, 114, 'I_Disease'), (121, 128, 'B_Disease'), (129, 140, 'I_Disease')]}], ['Thrombotic microangiopathy and renal failure associated with antineoplastic chemotherapy .', {'entities': [(0, 10, 'B_Disease'), (11, 26, 'I_Disease'), (31, 36, 'B_Disease'), (37, 44, 'I_Disease')]}], ['Five patients with carcinoma developed thrombotic microangiopathy ( characterized by renal insufficiency , microangiopathic hemolytic anemia , and usually thrombocytopenia ) after treatment with cisplatin , bleomycin , and a vinca alkaloid .', {'entities': [(19, 28, 'B_Disease'), (39, 49, 'B_Disease'), (50, 65, 'I_Disease'), (85, 90, 'B_Disease'), (91, 104, 'I_Disease'), (107, 123, 'B_Disease'), (124, 133, 'I_Disease'), (134, 140, 'I_Disease'), (155, 171, 'B_Disease')]}], ['One patient had thrombotic thrombocytopenic purpura , three the hemolytic - uremic syndrome , and one an apparent forme fruste of one of these disorders .', {'entities': [(16, 26, 'B_Disease'), (27, 43, 'I_Disease'), (44, 51, 'I_Disease'), (64, 73, 'B_Disease'), (74, 75, 'I_Disease'), (76, 82, 'I_Disease'), (83, 91, 'I_Disease')]}], ['Histologic examination of the renal tissue showed evidence of intravascular coagulation , primarily affecting the small arteries , arterioles , and glomeruli .', {'entities': [(62, 75, 'B_Disease'), (76, 87, 'I_Disease')]}], ['Because each patient was tumor - free or had only a small tumor at the onset of this syndrome , the thrombotic microangiopathy may have been induced by chemotherapy .', {'entities': [(25, 30, 'B_Disease'), (58, 63, 'B_Disease'), (100, 110, 'B_Disease'), (111, 126, 'I_Disease')]}], ['Diagnosis of this potentially fatal complication may be delayed or missed if renal tissue or the peripheral blood smear is not examined , because renal failure may be ascribed to cisplatin nephrotoxicity and the anemia and thrombocytopenia to drug - induced bone marrow suppression .', {'entities': [(146, 151, 'B_Disease'), (152, 159, 'I_Disease'), (189, 203, 'B_Disease'), (212, 218, 'B_Disease'), (223, 239, 'B_Disease'), (258, 262, 'B_Disease'), (263, 269, 'I_Disease'), (270, 281, 'I_Disease')]}], ['Report on arrhythmia and other findings .', {'entities': [(10, 20, 'B_Disease')]}], ['The antiarrhythmic effects of the sustained release form of mexiletine ( Mexitil - Perlongets ) were evaluated in a double - blind placebo trial in 630 patients with recent documented myocardial infarction .', {'entities': [(184, 194, 'B_Disease'), (195, 205, 'I_Disease')]}], ['There were more deaths in the mexiletine group ( 7 . 6 % ) than in the placebo group ( 4 . 8 % ) ; the difference was not statistically significant .', {'entities': [(16, 22, 'B_Disease')]}], ['Previously recognized side effects , particularly tremor and gastrointestinal problems , were more frequent in the mexiletine group than in the placebo group .', {'entities': [(50, 56, 'B_Disease'), (61, 77, 'B_Disease'), (78, 86, 'I_Disease')]}], ['Changes in heart size during long - term timolol treatment after myocardial infarction .', {'entities': [(65, 75, 'B_Disease'), (76, 86, 'I_Disease')]}], ['The effect of long - term timolol treatment on heart size after myocardial infarction was evaluated by X - ray in a double - blind study including 241 patients ( placebo 126 , timolol 115 ) .', {'entities': [(64, 74, 'B_Disease'), (75, 85, 'I_Disease')]}], ['These differences may be caused by timolol - induced bradycardia and a compensatory increase in end - diastolic volume .', {'entities': [(53, 64, 'B_Disease')]}], ['In patients with cardiomegaly , the increase in heart size was similar in both groups .', {'entities': [(17, 29, 'B_Disease')]}], ['After re - infarction , heart size increased in the placebo group and remained unchanged in the timolol group .', {'entities': [(11, 21, 'B_Disease')]}], ['Vitamin D3 toxicity in dairy cows .', {'entities': [(11, 19, 'B_Disease')]}], ['Large parenteral doses of vitamin D3 ( 15 to 17 . 5 x 10 ( 6 ) IU vitamin D3 ) were associated with prolonged hypercalcemia , hyperphosphatemia , and large increases of vitamin D3 and its metabolites in the blood plasma of nonlactating nonpregnant and pregnant Jersey cows .', {'entities': [(110, 123, 'B_Disease'), (126, 143, 'B_Disease')]}], ['None of the cows treated with vitamin D3 showed signs of milk fever during the peripartal period ; however , 22 % of the control cows developed clinical signs of milk fever during this period .', {'entities': [(57, 61, 'B_Disease'), (62, 67, 'I_Disease'), (162, 166, 'B_Disease'), (167, 172, 'I_Disease')]}], ['Signs of vitamin D3 toxicity were not observed in nonlactating nonpregnant cows ; however , pregnant cows commonly developed severe signs of vitamin D3 toxicity and 10 of 17 cows died .', {'entities': [(20, 28, 'B_Disease'), (152, 160, 'B_Disease')]}], ['Because of the extreme toxicity of vitamin D3 in pregnant Jersey cows and the low margin of safety between doses of vitamin D3 that prevent milk fever and doses that induce milk fever , we concluded that vitamin D3 cannot be used practically to prevent milk fever when injected several weeks prepartum .', {'entities': [(23, 31, 'B_Disease'), (140, 144, 'B_Disease'), (145, 150, 'I_Disease'), (173, 177, 'B_Disease'), (178, 183, 'I_Disease'), (253, 257, 'B_Disease'), (258, 263, 'I_Disease')]}], ['Diseases of peripheral nerves as seen in the Nigerian African .', {'entities': [(0, 8, 'B_Disease'), (9, 11, 'I_Disease'), (12, 22, 'I_Disease'), (23, 29, 'I_Disease')]}], ['The anatomical and aetiological diagnoses of peripheral nerve disease excluding its primary benign and malignant disorders , as seen in 358 Nigerians are presented .', {'entities': [(45, 55, 'B_Disease'), (56, 61, 'I_Disease'), (62, 69, 'I_Disease')]}], ['Sensori - motor neuropathy was the commonest presentation ( 50 % ) .', {'entities': [(0, 7, 'B_Disease'), (8, 9, 'I_Disease'), (10, 15, 'I_Disease'), (16, 26, 'I_Disease')]}], ['Guillain - Barr syndrome was the commonest identifiable cause ( 15 . 6 % ) , accounting for half of the cases with motor neuropathy .', {'entities': [(0, 8, 'B_Disease'), (9, 10, 'I_Disease'), (11, 15, 'I_Disease'), (16, 24, 'I_Disease'), (115, 120, 'B_Disease'), (121, 131, 'I_Disease')]}], ['Peripheral neuropathy due to nutritional deficiency of thiamine and riboflavin was common ( 10 . 1 % ) and presented mainly as sensory and sensori - motor neuropathy .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (29, 40, 'B_Disease'), (41, 51, 'I_Disease'), (139, 146, 'B_Disease'), (147, 148, 'I_Disease'), (149, 154, 'I_Disease'), (155, 165, 'I_Disease')]}], ['Diabetes mellitus was the major cause of autonomic neuropathy .', {'entities': [(0, 8, 'B_Disease'), (9, 17, 'I_Disease'), (41, 50, 'B_Disease'), (51, 61, 'I_Disease')]}], ['Isoniazid was the most frequent agent in drug - induced neuropathy .', {'entities': [(56, 66, 'B_Disease')]}], ['Migraine ( 20 % ) was not an uncommon cause of cranial neuropathy although malignancies arising from the reticuloendothelial system or related structures of the head and neck were more frequent ( 26 % ) .', {'entities': [(0, 8, 'B_Disease'), (47, 54, 'B_Disease'), (55, 65, 'I_Disease'), (75, 87, 'B_Disease')]}], ['In 26 . 5 % of all the cases , the aetiology of the neuropathy was undetermined .', {'entities': [(52, 62, 'B_Disease')]}], ['Heredofamilial and connective tissue disorders were rare .', {'entities': [(19, 29, 'B_Disease'), (30, 36, 'I_Disease'), (37, 46, 'I_Disease')]}], ['Some of the factors related to the clinical presentation and pathogenesis of the neuropathies are briefly discussed .', {'entities': [(81, 93, 'B_Disease')]}], ['Reduction in caffeine toxicity by acetaminophen .', {'entities': [(22, 30, 'B_Disease')]}], ['Because salicylates have been reported to augment the stimulatory effects of caffeine on the CNS , attention was focused on the possibility that the presence of acetaminophen ( 52 micrograms / mL ) reduced the CNS toxicity of caffeine .', {'entities': [(214, 222, 'B_Disease')]}], ['Studies in DBA / 2J mice showed that : 1 ) pretreatment with acetaminophen ( 100 mg / kg ) increased the interval between the administration of caffeine ( 300 to 450 mg / kg IP ) and the onset of fatal convulsions by a factor of about two ; and 2 ) pretreatment with acetaminophen ( 75 mg / kg ) reduced the incidence of audiogenic seizures produced in the presence of caffeine ( 12 . 5 to 75 mg / kg IP ) .', {'entities': [(202, 213, 'B_Disease'), (332, 340, 'B_Disease')]}], ['The frequency of sound - induced seizures after 12 . 5 or 25 mg / kg caffeine was reduced from 50 to 5 % by acetaminophen .', {'entities': [(33, 41, 'B_Disease')]}], ['In the absence of caffeine , acetaminophen ( up to 300 mg / kg ) did not modify the seizures induced by maximal electroshock and did not alter the convulsant dose of pentylenetetrezol in mice ( tests performed by the Anticonvulsant Screening Project of NINCDS ) .', {'entities': [(84, 92, 'B_Disease')]}], ['A double - blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder .', {'entities': [(103, 113, 'B_Disease'), (114, 122, 'I_Disease')]}], ['In a 6 - week double - blind parallel treatment study , dothiepin and amitriptyline were compared to placebo in the treatment of 33 depressed outpatients .', {'entities': [(132, 141, 'B_Disease')]}], ['Dothiepin and amitriptyline were equally effective in alleviating the symptoms of depressive illness , and both were significantly superior to placebo .', {'entities': [(82, 92, 'B_Disease'), (93, 100, 'I_Disease')]}], ['The overall incidence of side effects and the frequency and severity of blurred vision , dry mouth , and drowsiness were significantly less with dothiepin than with amitriptyline .', {'entities': [(72, 79, 'B_Disease'), (80, 86, 'I_Disease'), (89, 92, 'B_Disease'), (93, 98, 'I_Disease')]}], ['Dothiepin thus was found to be an effective antidepressant drug associated with fewer side effects than amitriptyline in the treatment of depressed outpatients .', {'entities': [(138, 147, 'B_Disease')]}], ['Behavioral effects of diazepam and propranolol in patients with panic disorder and agoraphobia .', {'entities': [(64, 69, 'B_Disease'), (70, 78, 'I_Disease'), (83, 94, 'B_Disease')]}], ['The effects of oral doses of diazepam ( single dose of 10 mg and a median dose of 30 mg / day for 2 weeks ) and propranolol ( single dose of 80 mg and a median dose of 240 mg / day for 2 weeks ) on psychological performance of patients with panic disorders and agoraphobia were investigated in a double - blind , randomized and crossover design .', {'entities': [(241, 246, 'B_Disease'), (247, 256, 'I_Disease'), (261, 272, 'B_Disease')]}], ['Both drugs impaired immediate free recall but the decrease was greater for diazepam than propranolol .', {'entities': [(11, 19, 'B_Disease'), (20, 29, 'I_Disease'), (30, 34, 'I_Disease'), (35, 41, 'I_Disease')]}], ['Delayed free recall was also impaired but the two drugs did not differ .', {'entities': [(0, 7, 'B_Disease'), (8, 12, 'I_Disease'), (13, 19, 'I_Disease'), (20, 23, 'I_Disease'), (24, 28, 'I_Disease'), (29, 37, 'I_Disease')]}], ['Accumulation of drugs was not reflected in prolonged behavioral impairment .', {'entities': [(53, 63, 'B_Disease'), (64, 74, 'I_Disease')]}], ['Comparison of i . v . glycopyrrolate and atropine in the prevention of bradycardia and arrhythmias following repeated doses of suxamethonium in children .', {'entities': [(71, 82, 'B_Disease'), (87, 98, 'B_Disease')]}], ['The effectiveness of administration of glycopyrrolate 5 and 10 micrograms kg - 1 and atropine 10 and 20 micrograms kg - 1 i . v . immediately before the induction of anaesthesia , to prevent arrhythmia and bradycardia following repeated doses of suxamethonium in children , was studied .', {'entities': [(191, 201, 'B_Disease'), (206, 217, 'B_Disease')]}], ['A frequency of bradycardia of 50 % was noted in the control group , but this was not significantly different from the frequency with the active drugs .', {'entities': [(15, 26, 'B_Disease')]}], ['Bradycardia ( defined as a decrease in heart rate to less than 50 beat min - 1 ) was prevented when the larger dose of either active drug was used .', {'entities': [(0, 11, 'B_Disease')]}], ['Veno - occlusive liver disease after dacarbazine therapy ( DTIC ) for melanoma .', {'entities': [(0, 4, 'B_Disease'), (5, 6, 'I_Disease'), (7, 16, 'I_Disease'), (17, 22, 'I_Disease'), (23, 30, 'I_Disease'), (70, 78, 'B_Disease')]}], ['A case of veno - occlusive disease of the liver with fatal outcome after dacarbazine ( DTIC ) therapy for melanoma is reported .', {'entities': [(10, 14, 'B_Disease'), (15, 16, 'I_Disease'), (17, 26, 'I_Disease'), (27, 34, 'I_Disease'), (35, 37, 'I_Disease'), (38, 41, 'I_Disease'), (42, 47, 'I_Disease'), (106, 114, 'B_Disease')]}], ['There was a fulminant clinical course from start of symptoms until death .', {'entities': [(67, 72, 'B_Disease')]}], ['At autopsy the liver was enlarged and firm with signs of venous congestion .', {'entities': [(57, 63, 'B_Disease'), (64, 74, 'I_Disease')]}], ['Small - and medium - sized hepatic veins were blocked by thrombosis .', {'entities': [(57, 67, 'B_Disease')]}], [\"Maternal lithium and neonatal Ebstein ' s anomaly : evaluation with cross - sectional echocardiography .\", {'entities': [(30, 37, 'B_Disease'), (38, 39, 'I_Disease'), (40, 41, 'I_Disease'), (42, 49, 'I_Disease')]}], [\"In one infant , Ebstein ' s anomaly of the tricuspid valve was identified .\", {'entities': [(16, 23, 'B_Disease'), (24, 25, 'I_Disease'), (26, 27, 'I_Disease'), (28, 35, 'I_Disease')]}], [\"In the other infant cross - sectional echocardiography provided reassurance that the infant did not have Ebstein ' s anomaly .\", {'entities': [(105, 112, 'B_Disease'), (113, 114, 'I_Disease'), (115, 116, 'I_Disease'), (117, 124, 'I_Disease')]}], ['Cross - sectional echocardiographic screening of newborns exposed to lithium during gestation can provide highly accurate , noninvasive assessment of the presence or absence of lithium - induced cardiac malformations .', {'entities': [(195, 202, 'B_Disease'), (203, 216, 'I_Disease')]}], ['Effects of training on the extent of experimental myocardial infarction in aging rats .', {'entities': [(50, 60, 'B_Disease'), (61, 71, 'I_Disease')]}], ['The effects of exercise on the severity of isoproterenol - induced myocardial infarction were studied in female albino rats of 20 , 40 , 60 and 80 weeks of age .', {'entities': [(67, 77, 'B_Disease'), (78, 88, 'I_Disease')]}], ['The occurrence of infarcts were confirmed by histological methods .', {'entities': [(18, 26, 'B_Disease')]}], ['Studies dealing with myocardial infarction are more informative when dealt with age .', {'entities': [(21, 31, 'B_Disease'), (32, 42, 'I_Disease')]}], ['Effect of polyethylene glycol 400 on adriamycin toxicity in mice .', {'entities': [(48, 56, 'B_Disease')]}], ['Light microscopic analysis showed a significant protection against ADR - induced cardiac morphological alterations .', {'entities': [(81, 88, 'B_Disease'), (89, 102, 'I_Disease'), (103, 114, 'I_Disease')]}], ['Such treatment did not diminish the ADR antitumor activity in L1210 leukemia and in Ehrlich ascites tumor .', {'entities': [(62, 67, 'B_Disease'), (68, 76, 'I_Disease'), (84, 91, 'B_Disease'), (92, 99, 'I_Disease'), (100, 105, 'I_Disease')]}], ['UM - 272 ( N , N - dimethylpropranolol ) , a quaternary antiarrhythmic agent , was administered sublingually to dogs with ouabain - induced ventricular tachycardias .', {'entities': [(140, 151, 'B_Disease'), (152, 164, 'I_Disease')]}], ['Sublingual UM - 272 converted ventricular tachycardia to sinus rhythm in all 5 dogs .', {'entities': [(30, 41, 'B_Disease'), (42, 53, 'I_Disease')]}], ['Early adjuvant adriamycin in superficial bladder carcinoma .', {'entities': [(41, 48, 'B_Disease'), (49, 58, 'I_Disease')]}], ['A multicenter study was performed in 110 patients with superficial transitional cell carcinoma of the bladder .', {'entities': [(85, 94, 'B_Disease'), (95, 97, 'I_Disease'), (98, 101, 'I_Disease'), (102, 109, 'I_Disease')]}], ['Adriamycin ( 50 mg / 50 ml ) was administered intravesically within 24 h after transurethral resection of TA - T1 ( O - A ) bladder tumors .', {'entities': [(124, 131, 'B_Disease'), (132, 138, 'I_Disease')]}], ['In 24 of these patients chemical cystitis was severe enough for them to drop out of the study .', {'entities': [(33, 41, 'B_Disease')]}], ['Of these recurrences , 27 were T1 tumors while five progressed to more highly invasive lesions .', {'entities': [(34, 40, 'B_Disease')]}], ['In patients that were free of recurrence during the first year , 80 % remained tumor - free during the 2 - to 3 - year follow - up period .', {'entities': [(79, 84, 'B_Disease')]}], ['D - penicillamine - induced angiopathy in rats .', {'entities': [(28, 38, 'B_Disease')]}], ['The co - administration of aspirin with N - [ 4 - ( 5 - nitro - 2 - furyl ) - 2 - thiazolyl ] - formamide ( FANFT ) to rats resulted in a reduced incidence of FANFT - induced bladder carcinomas but a concomitant induction of forestomach tumors .', {'entities': [(175, 182, 'B_Disease'), (183, 193, 'I_Disease'), (225, 236, 'B_Disease'), (237, 243, 'I_Disease')]}], [\"The present results are consistent with the carcinogenicity experiment suggesting that different mechanisms are involved in FANFT carcinogenesis in the bladder and forestomach , and that aspirin ' s effect on FANFT in the forestomach is not due to an irritant effect associated with increased cell proliferation .\", {'entities': [(130, 144, 'B_Disease')]}], ['A case of tardive dyskinesia caused by metoclopramide .', {'entities': [(10, 17, 'B_Disease'), (18, 28, 'I_Disease')]}], ['Abnormal involuntary movements appeared in the mouth , tongue , neck and abdomen of a 64 - year - old male patient after he took metoclopramide for gastrointestinal disorder in a regimen of 30 mg per day for a total of about 260 days .', {'entities': [(0, 8, 'B_Disease'), (9, 20, 'I_Disease'), (21, 30, 'I_Disease'), (148, 164, 'B_Disease'), (165, 173, 'I_Disease')]}], ['When the metoclopramide administration was discontinued , the abnormal movements gradually improved to a considerable extent .', {'entities': [(62, 70, 'B_Disease'), (71, 80, 'I_Disease')]}], ['Attention to the possible induction of specific tardive dyskinesia is called for in the use of this drug .', {'entities': [(48, 55, 'B_Disease'), (56, 66, 'I_Disease')]}], ['Intra - arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system .', {'entities': [(52, 61, 'B_Disease'), (62, 69, 'I_Disease')]}], ['Because of the rapid systemic clearance of BCNU ( 1 , 3 - bis - ( 2 - chloroethyl ) - 1 - nitrosourea ) , intra - arterial administration should provide a substantial advantage over intravenous administration for the treatment of malignant gliomas .', {'entities': [(230, 239, 'B_Disease'), (240, 247, 'I_Disease')]}], ['Twelve patients with Grade III or IV astrocytomas were treated after partial resection of the tumor without prior radiation therapy .', {'entities': [(37, 49, 'B_Disease'), (94, 99, 'B_Disease')]}], ['After two to seven cycles of chemotherapy , nine patients showed a decrease in tumor size and surrounding edema on contrast - enhanced computerized tomography scans .', {'entities': [(79, 84, 'B_Disease'), (106, 111, 'B_Disease')]}], ['Twenty - four patients with recurrent Grade I to IV astrocytomas , whose resection and irradiation therapy had failed , received two to eight courses of intra - arterial BCNU therapy .', {'entities': [(52, 64, 'B_Disease')]}], ['A delayed complication in nine patients has been unilateral loss of vision secondary to a retinal vasculitis .', {'entities': [(60, 64, 'B_Disease'), (65, 67, 'I_Disease'), (68, 74, 'I_Disease'), (90, 97, 'B_Disease'), (98, 108, 'I_Disease')]}], ['The frequency of visual loss decreased after the concentration of the ethanol diluent was lowered .', {'entities': [(17, 23, 'B_Disease'), (24, 28, 'I_Disease')]}], ['Provocation of postural hypotension by nitroglycerin in diabetic autonomic neuropathy ?', {'entities': [(24, 35, 'B_Disease'), (56, 64, 'B_Disease'), (65, 74, 'I_Disease'), (75, 85, 'I_Disease')]}], ['The effect of nitroglycerin on heart rate and systolic blood pressure was compared in 5 normal subjects , 12 diabetic subjects without autonomic neuropathy , and 5 diabetic subjects with autonomic neuropathy .', {'entities': [(109, 117, 'B_Disease'), (135, 144, 'B_Disease'), (145, 155, 'I_Disease'), (164, 172, 'B_Disease'), (187, 196, 'B_Disease'), (197, 207, 'I_Disease')]}], ['The magnitude and time course of the increase in heart rate and the decrease in systolic blood pressure after nitroglycerin were similar in the normal and diabetic subjects without autonomic neuropathy , whereas a lesser increase in heart rate and a greater decrease in systolic blood pressure occurred in the diabetic subjects with autonomic neuropathy .', {'entities': [(155, 163, 'B_Disease'), (181, 190, 'B_Disease'), (191, 201, 'I_Disease'), (310, 318, 'B_Disease'), (333, 342, 'B_Disease'), (343, 353, 'I_Disease')]}], ['It is therefore suggested that caution should be exercised when prescribing vasodilator drugs in diabetic patients , particularly those with autonomic neuropathy .', {'entities': [(97, 105, 'B_Disease'), (141, 150, 'B_Disease'), (151, 161, 'I_Disease')]}], ['Intrarenal infusion of noradrenaline caused hypertension at doses which did not do so when infused intravenously .', {'entities': [(44, 56, 'B_Disease')]}], ['These results suggest that hypertension after chronic intrarenal noradrenaline infusion is produced by relatively higher levels of circulating noradrenaline and by triggering of an additional intrarenal pressor mechanism .', {'entities': [(27, 39, 'B_Disease')]}], ['Characterization of estrogen - induced adenohypophyseal tumors in the Fischer 344 rat .', {'entities': [(39, 55, 'B_Disease'), (56, 62, 'I_Disease')]}], ['Pituitary tumors were induced in F344 female rats by chronic treatment with diethylstilbestrol ( DES , 8 - 10 mg ) implanted subcutaneously in silastic capsules .', {'entities': [(0, 9, 'B_Disease'), (10, 16, 'I_Disease')]}], ['The data extend the findings of other investigators , further establishing the DES - induced tumor as a model for study of PRL cellular control mechanisms .', {'entities': [(93, 98, 'B_Disease')]}], ['There was only one case of dementia possibly due to cimetidine ( with a drug level of 1 . 9 microgram / ml 6 hr after a dose ) in a group of 13 patients without liver or kidney disease who had cimetidine levels above 1 . 25 microgram / ml .', {'entities': [(27, 35, 'B_Disease'), (161, 166, 'B_Disease'), (167, 169, 'I_Disease'), (170, 176, 'I_Disease'), (177, 184, 'I_Disease')]}], ['Thus , high cimetidine levels alone do not always induce dementia .', {'entities': [(57, 65, 'B_Disease')]}], ['A case is presented of a reversible intra - Hisian block occurring under amiodarone treatment for atrial tachycardia in a patient without clear intraventricular conduction abnormalities .', {'entities': [(36, 41, 'B_Disease'), (42, 43, 'I_Disease'), (44, 50, 'I_Disease'), (51, 56, 'I_Disease'), (98, 104, 'B_Disease'), (105, 116, 'I_Disease'), (144, 160, 'B_Disease'), (161, 171, 'I_Disease'), (172, 185, 'I_Disease')]}], ['His bundle recordings showed an atrial tachycardia with intermittent exit block and greatly prolonged BH and HV intervals ( 40 and 100 msec , respectively ) .', {'entities': [(32, 38, 'B_Disease'), (39, 50, 'I_Disease')]}], ['Thirty days after amiodarone discontinuation , His bundle electrograms showed atrial flutter without intra - Hisian or infra - Hisian delay .', {'entities': [(78, 84, 'B_Disease'), (85, 92, 'I_Disease')]}], ['Development of clear cell adenocarcinoma in DES - exposed offspring under observation .', {'entities': [(15, 20, 'B_Disease'), (21, 25, 'I_Disease'), (26, 40, 'I_Disease')]}], ['Two cases of clear cell adenocarcinoma of the vagina detected at follow - up in young women exposed in utero to diethylstilbestrol are reported .', {'entities': [(13, 18, 'B_Disease'), (19, 23, 'I_Disease'), (24, 38, 'I_Disease'), (39, 41, 'I_Disease'), (42, 45, 'I_Disease'), (46, 52, 'I_Disease')]}], ['One patient , aged 23 , had been followed for 2 years before carcinoma was diagnosed ; the second patient , aged 22 , had been seen on a regular basis for 5 years , 8 months .', {'entities': [(61, 70, 'B_Disease')]}], ['In both instances , suspicion of the presence of carcinoma was aroused by the palpation of a small nodule in the vaginal fornix .', {'entities': [(49, 58, 'B_Disease')]}], ['The possible role of low pH as well as total volume as potential factors in causing neurotoxicity was evaluated .', {'entities': [(84, 97, 'B_Disease')]}], ['Of the 20 animals that received subarachnoid injection of 2 - chloroprocaine - CE seven ( 35 % ) developed hind - limb paralysis .', {'entities': [(119, 128, 'B_Disease')]}], ['None of the animals that received bupivacaine , normal saline , or normal saline titrated to a pH 3 . 0 developed hind - limb paralysis .', {'entities': [(126, 135, 'B_Disease')]}], ['Of the 15 spinal cords of the animals that received 2 - chloroprocaine - CE , 13 showed subpial necrosis ; the nerve roots and subarachnoid vessels were normal .', {'entities': [(88, 95, 'B_Disease'), (96, 104, 'I_Disease')]}], ['Procainamide - induced polymorphous ventricular tachycardia .', {'entities': [(36, 47, 'B_Disease'), (48, 59, 'I_Disease')]}], ['Seven cases of procainamide - induced polymorphous ventricular tachycardia are presented .', {'entities': [(51, 62, 'B_Disease'), (63, 74, 'I_Disease')]}], ['In four patients , polymorphous ventricular tachycardia appeared after intravenous administration of 200 to 400 mg of procainamide for the treatment of sustained ventricular tachycardia .', {'entities': [(32, 43, 'B_Disease'), (44, 55, 'I_Disease'), (162, 173, 'B_Disease'), (174, 185, 'I_Disease')]}], ['In the remaining three patients , procainamide was administered orally for treatment of chronic premature ventricular contractions or atrial flutter .', {'entities': [(96, 105, 'B_Disease'), (106, 117, 'I_Disease'), (118, 130, 'I_Disease'), (134, 140, 'B_Disease'), (141, 148, 'I_Disease')]}], ['These patients had Q - T prolongation and recurrent syncope due to polymorphous ventricular tachycardia .', {'entities': [(19, 20, 'B_Disease'), (21, 22, 'I_Disease'), (23, 24, 'I_Disease'), (25, 37, 'I_Disease'), (52, 59, 'B_Disease'), (80, 91, 'B_Disease'), (92, 103, 'I_Disease')]}], ['In four patients , the arrhythmia was rapidly diagnosed and treated with disappearance of further episodes of the arrhythmia .', {'entities': [(23, 33, 'B_Disease'), (114, 124, 'B_Disease')]}], ['In two patients , the arrhythmia degenerated into irreversible ventricular fibrillation and both patients died .', {'entities': [(22, 32, 'B_Disease'), (63, 74, 'B_Disease'), (75, 87, 'I_Disease')]}], ['In the seventh patient , a permanent ventricular pacemaker was inserted and , despite continuation of procainamide therapy , polymorphous ventricular tachycardia did not reoccur .', {'entities': [(138, 149, 'B_Disease'), (150, 161, 'I_Disease')]}], ['These seven cases demonstrate that procainamide can produce an acquired prolonged Q - T syndrome with polymorphous ventricular tachycardia .', {'entities': [(72, 81, 'B_Disease'), (82, 83, 'I_Disease'), (84, 85, 'I_Disease'), (86, 87, 'I_Disease'), (88, 96, 'I_Disease'), (115, 126, 'B_Disease'), (127, 138, 'I_Disease')]}], ['Phenobarbitone - induced enlargement of the liver in the rat : its relationship to carbon tetrachloride - induced cirrhosis .', {'entities': [(25, 36, 'B_Disease'), (37, 39, 'I_Disease'), (40, 43, 'I_Disease'), (44, 49, 'I_Disease'), (114, 123, 'B_Disease')]}], ['The yield of severe cirrhosis of the liver ( defined as a shrunken finely nodular liver with micronodular histology , ascites greater than 30 ml , plasma albumin less than 2 . 2 g / dl , splenomegaly 2 - 3 times normal , and testicular atrophy approximately half normal weight ) after 12 doses of carbon tetrachloride given intragastrically in the phenobarbitone - primed rat was increased from 25 % to 56 % by giving the initial \" calibrating \" dose of carbon tetrachloride at the peak of the phenobarbitone - induced enlargement of the liver .', {'entities': [(20, 29, 'B_Disease'), (30, 32, 'I_Disease'), (33, 36, 'I_Disease'), (37, 42, 'I_Disease'), (118, 125, 'B_Disease'), (187, 199, 'B_Disease'), (236, 243, 'B_Disease'), (519, 530, 'B_Disease'), (531, 533, 'I_Disease'), (534, 537, 'I_Disease'), (538, 543, 'I_Disease')]}], ['Triamterene nephrolithiasis complicating dyazide therapy .', {'entities': [(12, 27, 'B_Disease')]}], ['A case of triamterene nephrolithiasis is reported in a man after 4 years of hydrochlorothiazide - triamterene therapy for hypertension .', {'entities': [(22, 37, 'B_Disease'), (122, 134, 'B_Disease')]}], ['Factors affecting triamterene nephrolithiasis are discussed and 2 previously reported cases are reviewed .', {'entities': [(30, 45, 'B_Disease')]}], ['Busulfan - induced hemorrhagic cystitis .', {'entities': [(19, 30, 'B_Disease'), (31, 39, 'I_Disease')]}], ['A case of a busulfan - induced hemorrhage cystitis is reported .', {'entities': [(31, 41, 'B_Disease'), (42, 50, 'I_Disease')]}], ['The similarity between the histologic appearances of busulfan cystitis and both radiation and cyclophosphamide - induced cystitis is discussed and the world literature reviewed .', {'entities': [(62, 70, 'B_Disease'), (121, 129, 'B_Disease')]}], ['In view of the known tendency of busulfan to induce cellular atypia and carcinoma in other sites , periodic urinary cytology is suggested in patients on long - term therapy .', {'entities': [(72, 81, 'B_Disease')]}], ['Variant ventricular tachycardia in desipramine toxicity .', {'entities': [(8, 19, 'B_Disease'), (20, 31, 'I_Disease'), (47, 55, 'B_Disease')]}], ['We report a case of variant ventricular tachycardia induced by desipramine toxicity .', {'entities': [(28, 39, 'B_Disease'), (40, 51, 'I_Disease'), (75, 83, 'B_Disease')]}], ['Unusual features of the arrhythmia are repetitive group beating , progressive shortening of the R - R interval , progressive widening of the QRS complex with eventual failure of intraventricular conduction , and changes in direction of the QRS axis .', {'entities': [(24, 34, 'B_Disease')]}], ['Recognition of variant ventricular tachycardia is important because therapy differs from that of classic ventricular tachycardia .', {'entities': [(23, 34, 'B_Disease'), (35, 46, 'I_Disease'), (105, 116, 'B_Disease'), (117, 128, 'I_Disease')]}], ['Rebound hypertensive after sodium nitroprusside prevented by saralasin in rats .', {'entities': [(8, 20, 'B_Disease')]}], ['The role of the renin - - angiotensin system in the maintenance of blood pressure during halothane anesthesia and sodium nitroprusside ( SNP ) - induced hypotension was evaluated .', {'entities': [(153, 164, 'B_Disease')]}], ['During the SNP infusion the control animals demonstrated a progressive increase in blood pressure to 61 torr , whereas the saralasin - treated animals showed no change .', {'entities': [(71, 79, 'B_Disease'), (80, 82, 'I_Disease'), (83, 88, 'I_Disease'), (89, 97, 'I_Disease')]}], ['This demonstrates the participation of the renin - - angiotensin system in antagonizing the combined hypotensive effects of halothane and SNP .', {'entities': [(101, 112, 'B_Disease')]}], ['Clinical nephrotoxicity of tobramycin and gentamicin .', {'entities': [(9, 23, 'B_Disease')]}], ['Gentamicin sulfate and tobramycin sulfate continue to demonstrate ototoxicity and nephrotoxicity in both animal and clinical studies .', {'entities': [(66, 77, 'B_Disease'), (82, 96, 'B_Disease')]}], ['In this study , 62 patients with confirmed initial normal renal function and treated with 2 to 5 mg / kg / day of gentamicin sulfate or tobramycin sulfate for a minimum of seven days were followed up prospectively for the development of aminoglycoside - related renal failure , defined as at least a one - third reduction in renal function .', {'entities': [(262, 267, 'B_Disease'), (268, 275, 'I_Disease')]}], ['In these 62 patients , no other causes for renal failure could be identified .', {'entities': [(43, 48, 'B_Disease'), (49, 56, 'I_Disease')]}], ['Five of 33 ( 15 % ) of the tobramycin - treated patients and 16 of 29 ( 55 . 2 % ) of the gentamicin - treated patients had renal failure .', {'entities': [(124, 129, 'B_Disease'), (130, 137, 'I_Disease')]}], ['Thus , gentamicin was associated with renal failure more than three times as often as was tobramycin .', {'entities': [(38, 43, 'B_Disease'), (44, 51, 'I_Disease')]}], ['Metabolic involvement in adriamycin cardiotoxicity .', {'entities': [(36, 50, 'B_Disease')]}], ['The cardiotoxic effects of adriamycin were studied in mammalian myocardial cells in culture as a model system .', {'entities': [(4, 15, 'B_Disease')]}], ['Age - dependent sensitivity of the rat to neurotoxic effects of streptomycin .', {'entities': [(42, 52, 'B_Disease')]}], ['Abnormal movements and deafness occurred only in rats treated during the preweaning period ; within this period the greatest sensitivities for these abnormalities occurred from 2 to 11 - 17 and 5 to 11 days of age , respectively , indicating that the cochlea is more sensitive to streptomycin than the site ( vestibular or central ) responsible for the dyskinesias .', {'entities': [(0, 8, 'B_Disease'), (9, 18, 'I_Disease'), (23, 31, 'B_Disease'), (353, 364, 'B_Disease')]}], ['Late , late doxorubicin cardiotoxicity .', {'entities': [(24, 38, 'B_Disease')]}], ['Cardiac toxicity is a major complication which limits the use of adriamycin as a chemotherapeutic agent .', {'entities': [(0, 7, 'B_Disease'), (8, 16, 'I_Disease')]}], ['Cardiomyopathy is frequent when the total dose exceeds 600 mg / m2 and occurs within one to six months after cessation of therapy .', {'entities': [(0, 14, 'B_Disease')]}], ['A patient is reported who developed progressive cardiomyopathy two and one - half years after receiving 580 mg / m2 which apparently represents late , late cardiotoxicity .', {'entities': [(48, 62, 'B_Disease'), (156, 170, 'B_Disease')]}], ['Attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride in rats .', {'entities': [(37, 45, 'B_Disease'), (46, 47, 'I_Disease'), (48, 57, 'I_Disease'), (58, 59, 'I_Disease'), (60, 64, 'I_Disease'), (65, 73, 'I_Disease')]}], ['The effect of amiloride on lithium - induced polydipsia and polyuria and on the lithium concentration in the plasma , brain , kidney , thyroid and red blood cells was investigated in rats , chronically treated with LiCl .', {'entities': [(45, 55, 'B_Disease'), (60, 68, 'B_Disease')]}], ['In all the experiments , the attenuation of the lithium - induced diabetes - insipidus - like syndrome by amiloride was accompanied by a reduction of the ratio between the lithium concentration in the renal medulla and its levels in the blood and an elevation in the plasma potassium level .', {'entities': [(66, 74, 'B_Disease'), (75, 76, 'I_Disease'), (77, 86, 'I_Disease'), (87, 88, 'I_Disease'), (89, 93, 'I_Disease'), (94, 102, 'I_Disease')]}], ['It is concluded that acute amiloride administration to lithium - treated patients suffering from polydipsia and polyuria might relieve these patients but prolonged amiloride supplementation would result in elevated lithium levels and might be hazardous .', {'entities': [(97, 107, 'B_Disease'), (112, 120, 'B_Disease')]}], ['Cardiovascular complications associated with terbutaline treatment for preterm labor .', {'entities': [(0, 14, 'B_Disease'), (15, 28, 'I_Disease'), (71, 78, 'B_Disease'), (79, 84, 'I_Disease')]}], ['Severe cardiovascular complications occurred in eight of 160 patients treated with terbutaline for preterm labor .', {'entities': [(7, 21, 'B_Disease'), (22, 35, 'I_Disease'), (99, 106, 'B_Disease'), (107, 112, 'I_Disease')]}], ['Toxic hepatitis induced by antithyroid drugs : four cases including one with cross - reactivity between carbimazole and benzylthiouracil .', {'entities': [(0, 5, 'B_Disease'), (6, 15, 'I_Disease')]}], ['OBJECTIVE : This study was conducted to assess the occurrence of hepatic adverse effects encountered with antithyroid drugs .', {'entities': [(65, 72, 'B_Disease'), (73, 80, 'I_Disease'), (81, 88, 'I_Disease')]}], ['METHODS : Retrospective review of medical records of 236 patients with hyperthyroidism admitted in our department ( in - or out - patients ) from 1986 to 1992 .', {'entities': [(71, 86, 'B_Disease')]}], ['RESULTS : Four patients ( 1 . 7 % ) were identified with toxic hepatitis which could reasonably be attributed to the use of antithyroid agent .', {'entities': [(57, 62, 'B_Disease'), (63, 72, 'I_Disease')]}], ['Two patients had a cholestatic hepatitis induced by carbimazole ( N omercazole ) .', {'entities': [(19, 30, 'B_Disease'), (31, 40, 'I_Disease')]}], ['Two others had a mixed ( cholestatic and cytolytic ) hepatitis following carbimazole .', {'entities': [(25, 36, 'B_Disease'), (53, 62, 'B_Disease')]}], ['One of the latter two patients further experienced a cytolytic hepatitis which appeared after Benzylthiouracil ( Basd ne ) had replaced carbimazole .', {'entities': [(63, 72, 'B_Disease')]}], ['Biological features of hepatitis disappeared in all cases after cessation of the incriminated drug , while biliary , viral and immunological searches were negative .', {'entities': [(23, 32, 'B_Disease')]}], ['Only 2 patients of our retrospective study experienced a mild or severe neutropenia .', {'entities': [(72, 83, 'B_Disease')]}], ['CONCLUSION : Toxic hepatitis is a potential adverse effect of antithyroid drugs which warrants , as for haematological disturbances , a pre - therapeutic determination and a careful follow - up of relevant biological markers .', {'entities': [(13, 18, 'B_Disease'), (19, 28, 'I_Disease')]}], ['Moreover , hepatotoxicity may not be restricted to one class of antithyroid agents .', {'entities': [(11, 25, 'B_Disease')]}], ['Dose - dependent bradycardia induced by verapamil was potentiated by LNa , LCa , and HCa .', {'entities': [(17, 28, 'B_Disease')]}], ['Pseudo - allergic reactions to corticosteroids : diagnosis and alternatives .', {'entities': [(9, 17, 'B_Disease'), (18, 27, 'I_Disease')]}], ['A few minutes after administration of the drugs , they presented urticaria ( patients 1 and 2 ) and conjunctivitis ( patient 1 ) .', {'entities': [(65, 74, 'B_Disease'), (100, 114, 'B_Disease')]}], ['Corticosteroids different from paramethasone also produced hypersensitivity reactions in these patients ; however , a few of them were tolerated .', {'entities': [(59, 75, 'B_Disease')]}], ['To our knowledge , this is the first report of a pseudo - allergy caused by paramethasone .', {'entities': [(58, 65, 'B_Disease')]}], ['Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine .', {'entities': [(92, 100, 'B_Disease')]}], ['A prospective , randomized study was conducted to evaluate the role of vitamin B12 and folinic acid supplementation in preventing zidovudine ( ZDV ) - induced bone marrow suppression .', {'entities': [(159, 163, 'B_Disease'), (164, 170, 'I_Disease'), (171, 182, 'I_Disease')]}], ['Seventy - five human immunodeficiency virus ( HIV ) - infected patients with CD4 + cell counts < 500 / mm3 were randomized to receive either ZDV ( 500 mg daily ) alone ( group I , n = 38 ) or in combination with folinic acid ( 15 mg daily ) and intramascular vitamin B12 ( 1000 micrograms monthly ) ( group II , n = 37 ) .', {'entities': [(15, 20, 'B_Disease'), (21, 37, 'I_Disease'), (38, 43, 'I_Disease'), (44, 45, 'I_Disease'), (46, 49, 'I_Disease'), (50, 51, 'I_Disease'), (52, 53, 'I_Disease'), (54, 62, 'I_Disease')]}], ['Finally , 15 patients were excluded from the study ( noncompliance 14 , death 1 ) ; thus , 60 patients ( 31 in group I and 29 in group II ) were eligible for analysis .', {'entities': [(72, 77, 'B_Disease')]}], ['Severe hematologic toxicity ( neutrophil count < 1000 / mm3 and / or hemoglobin < 8 g / dl ) occurred in 4 patients assigned to group I and 7 assigned to group II .', {'entities': [(19, 27, 'B_Disease')]}], ['There was no correlation between vitamin B12 or folate levels and development of myelosuppression .', {'entities': [(81, 97, 'B_Disease')]}], ['Vitamin B12 and folinic acid supplementation of ZDV therapy does not seem useful in preventing or reducing ZDV - induced myelotoxicity in the overall treated population , although a beneficial effect in certain subgroups of patients cannot be excluded .', {'entities': [(121, 134, 'B_Disease')]}], ['Controlled study in agoraphobia with panic disorder .', {'entities': [(20, 31, 'B_Disease'), (37, 42, 'B_Disease'), (43, 51, 'I_Disease')]}], ['The efficacy of alprazolam and placebo in panic disorder with agoraphobia , and the side - effect and adverse effect profiles of both drug groups were measured .', {'entities': [(42, 47, 'B_Disease'), (48, 56, 'I_Disease'), (62, 73, 'B_Disease')]}], ['METHOD : In London and Toronto 154 patients who met DSM - III criteria for panic disorder with agoraphobia were randomised to alprazolam or placebo .', {'entities': [(75, 80, 'B_Disease'), (81, 89, 'I_Disease'), (95, 106, 'B_Disease')]}], ['Compared with placebo subjects , alprazolam patients developed more adverse reactions ( 21 % v . 0 % ) of depression , enuresis , disinhibition and aggression ; and more side - effects , particularly sedation , irritability , impaired memory , weight loss and ataxia .', {'entities': [(106, 116, 'B_Disease'), (119, 127, 'B_Disease'), (148, 158, 'B_Disease'), (211, 223, 'B_Disease'), (226, 234, 'B_Disease'), (235, 241, 'I_Disease'), (244, 250, 'B_Disease'), (251, 255, 'I_Disease'), (260, 266, 'B_Disease')]}], ['Crescentic fibrillary glomerulonephritis associated with intermittent rifampin therapy for pulmonary tuberculosis .', {'entities': [(22, 40, 'B_Disease'), (91, 100, 'B_Disease'), (101, 113, 'I_Disease')]}], ['This case study reveals an unusual finding of rapidly proliferative crescentic glomerulonephritis in a patient treated with rifampin who had no other identifiable causes for developing this disease .', {'entities': [(79, 97, 'B_Disease')]}], ['This patient underwent a 10 - month regimen of rifampin and isoniazid for pulmonary tuberculosis and was discovered to have developed signs of severe renal failure five weeks after completion of therapy .', {'entities': [(74, 83, 'B_Disease'), (84, 96, 'I_Disease'), (150, 155, 'B_Disease'), (156, 163, 'I_Disease')]}], ['Renal biopsy revealed severe glomerulonephritis with crescents , electron dense fibrillar deposits and moderate lymphocytic interstitial infiltrate .', {'entities': [(29, 47, 'B_Disease')]}], ['Other possible causes of rapidly progressive glomerulonephritis were investigated and ruled out .', {'entities': [(45, 63, 'B_Disease')]}], ['This report documents the unusual occurrence of rapidly progressive glomerulonephritis with crescents and fibrillar glomerulonephritis in a patient treated with rifampin .', {'entities': [(68, 86, 'B_Disease'), (116, 134, 'B_Disease')]}], ['Acute confusion induced by a high - dose infusion of 5 - fluorouracil and folinic acid .', {'entities': [(6, 15, 'B_Disease')]}], ['A 61 - year - old man was treated with combination chemotherapy incorporating cisplatinum , etoposide , high - dose 5 - fluorouracil ( 2 , 250 mg / m2 / 24 hours ) and folinic acid for an inoperable gastric adenocarcinoma .', {'entities': [(199, 206, 'B_Disease'), (207, 221, 'I_Disease')]}], ['He developed acute neurologic symptoms of mental confusion , disorientation and irritability , and then lapsed into a deep coma , lasting for approximately 40 hours during the first dose ( day 2 ) of 5 - fluorouracil and folinic acid infusion .', {'entities': [(49, 58, 'B_Disease'), (61, 75, 'B_Disease'), (80, 92, 'B_Disease'), (123, 127, 'B_Disease')]}], ['Because folinic acid was unlikely to be associated with this condition , neurotoxicity due to high - dose 5 - fluorouracil was highly suspected .', {'entities': [(73, 86, 'B_Disease')]}], ['The pathogenesis of 5 - fluorouracil neurotoxicity may be due to a Krebs cycle blockade by fluoroacetate and fluorocitrate , thiamine deficiency , or dihydrouracil dehydrogenase deficiency .', {'entities': [(37, 50, 'B_Disease')]}], ['High - dose 5 - fluorouracil / folinic acid infusion therapy has recently become a popular regimen for various cancers .', {'entities': [(111, 118, 'B_Disease')]}], ['Carbamazepine was switched to its 10 - keto analogue oxcarbazepine among six difficult - to - treat schizophrenic or organic psychotic patients using concomitantly haloperidol , chlorpromazine or clozapine .', {'entities': [(100, 113, 'B_Disease'), (117, 124, 'B_Disease'), (125, 134, 'I_Disease')]}], ['This change resulted within 2 - 4 weeks in the 50 - 200 % increase in the plasma levels of these neuroleptics and the appearance of extrapyramidal symptoms .', {'entities': [(132, 146, 'B_Disease'), (147, 155, 'I_Disease')]}], ['Time course of lipid peroxidation in puromycin aminonucleoside - induced nephropathy .', {'entities': [(73, 84, 'B_Disease')]}], ['Reactive oxygen species have been implicated in the pathogenesis of acute puromycin aminonucleoside ( PAN ) - induced nephropathy , with antioxidants significantly reducing the proteinuria .', {'entities': [(118, 129, 'B_Disease'), (177, 188, 'B_Disease')]}], ['The temporal relationship between lipid peroxidation in the kidney and proteinuria was examined in this study .', {'entities': [(71, 82, 'B_Disease')]}], ['Proteinuria was evident at day 5 , peaked at day 7 and persisted to day 27 .', {'entities': [(0, 11, 'B_Disease')]}], ['This study supports the role of lipid peroxidation in mediating the proteinuric injury in PAN nephropathy .', {'entities': [(68, 79, 'B_Disease'), (80, 86, 'I_Disease'), (94, 105, 'B_Disease')]}], ['Composition of gall bladder stones associated with octreotide : response to oral ursodeoxycholic acid .', {'entities': [(15, 19, 'B_Disease'), (20, 27, 'I_Disease'), (28, 34, 'I_Disease')]}], ['Octreotide , an effective treatment for acromegaly , induces gall bladder stones in 13 - 60 % of patients .', {'entities': [(40, 50, 'B_Disease'), (61, 65, 'B_Disease'), (66, 73, 'I_Disease'), (74, 80, 'I_Disease')]}], ['Because knowledge of stone composition is essential for studies of their pathogenesis , treatment , and prevention , this was investigated by direct and indirect methods in 14 octreotide treated acromegalic patients with gall stones .', {'entities': [(195, 206, 'B_Disease'), (221, 225, 'B_Disease'), (226, 232, 'I_Disease')]}], ['Chemical analysis of gall stones retrieved at cholecystectomy from two patients , showed that they contained 71 % and 87 % cholesterol by weight .', {'entities': [(21, 25, 'B_Disease'), (26, 32, 'I_Disease')]}], ['After one year of treatment , five of the remaining nine patients showed either partial ( n = 3 ) or complete ( n = 2 ) gall stone dissolution , suggesting that their stones were cholesterol rich .', {'entities': [(120, 124, 'B_Disease'), (125, 130, 'I_Disease')]}], ['This corresponds , by actuarial ( life table ) analysis , to a combined gall stone dissolution rate of 58 . 3 ( 15 . 9 % ) .', {'entities': [(72, 76, 'B_Disease'), (77, 82, 'I_Disease')]}], ['In conclusion , octreotide induced gall stones are generally small , multiple , and cholesterol rich although , in common with spontaneous gall stone disease , at presentation some patients will have a blocked cystic duct and some gall stones containing calcium .', {'entities': [(35, 39, 'B_Disease'), (40, 46, 'I_Disease'), (139, 143, 'B_Disease'), (144, 149, 'I_Disease'), (150, 157, 'I_Disease'), (231, 235, 'B_Disease'), (236, 242, 'I_Disease')]}], ['Erythema multiforme and hypersensitivity myocarditis caused by ampicillin .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease'), (24, 40, 'B_Disease'), (41, 52, 'I_Disease')]}], ['OBJECTIVE : To report a case of erythema multiforme and hypersensitivity myocarditis caused by ampicillin .', {'entities': [(32, 40, 'B_Disease'), (41, 51, 'I_Disease'), (56, 72, 'B_Disease'), (73, 84, 'I_Disease')]}], ['CASE SUMMARY : A 13 - year - old boy was treated with ampicillin and gentamicin because of suspected septicemia .', {'entities': [(101, 111, 'B_Disease')]}], ['Medications were discontinued when erythema multiforme and congestive heart failure caused by myocarditis occurred .', {'entities': [(35, 43, 'B_Disease'), (44, 54, 'I_Disease'), (59, 69, 'B_Disease'), (70, 75, 'I_Disease'), (76, 83, 'I_Disease'), (94, 105, 'B_Disease')]}], ['DISCUSSION : After most infections causing erythema multiforme and myocarditis were ruled out , a drug - induced allergic reaction was suspected .', {'entities': [(24, 34, 'B_Disease'), (43, 51, 'B_Disease'), (52, 62, 'I_Disease'), (67, 78, 'B_Disease'), (98, 102, 'B_Disease'), (103, 104, 'I_Disease'), (105, 112, 'I_Disease'), (113, 121, 'I_Disease'), (122, 130, 'I_Disease')]}], ['CONCLUSIONS : Hypersensitivity myocarditis is a rare and dangerous manifestation of allergy to penicillins .', {'entities': [(14, 30, 'B_Disease'), (31, 42, 'I_Disease'), (84, 91, 'B_Disease')]}], ['Clomipramine - induced sleep disturbance does not impair its prolactin - releasing action .', {'entities': [(23, 28, 'B_Disease'), (29, 40, 'I_Disease')]}], ['The present study was undertaken to examine the role of sleep disturbance , induced by clomipramine administration , on the secretory rate of prolactin ( PRL ) in addition to the direct drug effect .', {'entities': [(56, 61, 'B_Disease'), (62, 73, 'I_Disease')]}], ['As the relative increase in PRL secretion expressed as a percentage of the mean did not significantly differ between the night and day time studies ( 46 + / - 19 % vs 34 + / - 10 % ) , it can be concluded that the observed sleep disturbance did not interfere with the drug action per se .', {'entities': [(223, 228, 'B_Disease'), (229, 240, 'I_Disease')]}], ['There were 13 cases of adverse reactions ( 0 . 34 % ) , ten of which were mild reactions such as nausea , exanthema , urtication , itchiness , and urgency to defecate , and did not require treatment .', {'entities': [(97, 103, 'B_Disease'), (106, 115, 'B_Disease'), (118, 128, 'B_Disease'), (131, 140, 'B_Disease')]}], ['Also recorded were one case of pain of the vein , which required treatment , and two cases of hypotension .', {'entities': [(31, 35, 'B_Disease'), (94, 105, 'B_Disease')]}], ['The two hypotensive patients required treatment for shock .', {'entities': [(8, 19, 'B_Disease'), (52, 57, 'B_Disease')]}], ['Angioedema following the intravenous administration of metoprolol .', {'entities': [(0, 10, 'B_Disease')]}], ['A 72 - year - old woman was admitted to the hospital with \" flash \" pulmonary edema , preceded by chest pain , requiring intubation .', {'entities': [(68, 77, 'B_Disease'), (78, 83, 'I_Disease'), (98, 103, 'B_Disease'), (104, 108, 'I_Disease')]}], ['Her medical history included coronary artery disease with previous myocardial infarctions , hypertension , and diabetes mellitus .', {'entities': [(29, 37, 'B_Disease'), (38, 44, 'I_Disease'), (45, 52, 'I_Disease'), (67, 77, 'B_Disease'), (78, 89, 'I_Disease'), (92, 104, 'B_Disease'), (111, 119, 'B_Disease'), (120, 128, 'I_Disease')]}], ['A history of angioedema secondary to lisinopril therapy was elicited .', {'entities': [(13, 23, 'B_Disease')]}], ['During the first day of hospitalization ( while intubated ) , intravenous metoprolol was given , resulting in severe angioedema .', {'entities': [(117, 127, 'B_Disease')]}], ['The angioedema resolved after therapy with intravenous steroids and diphenhydramine hydrochloride .', {'entities': [(4, 14, 'B_Disease')]}], ['The major teratogenic outcome is arthrogryposis , presumably due to nicotinic receptor blockade .', {'entities': [(33, 47, 'B_Disease')]}], ['However , coniine has failed to produce arthrogryposis in rats or mice and is only weakly teratogenic in rabbits .', {'entities': [(40, 54, 'B_Disease')]}], ['Both compounds caused deformations and lethality in a dose - dependent manner .', {'entities': [(22, 34, 'B_Disease')]}], ['The deformations caused by both coniine and nicotine sulfate were excessive flexion or extension of one or more toes .', {'entities': [(4, 16, 'B_Disease'), (66, 75, 'B_Disease'), (76, 83, 'I_Disease'), (84, 86, 'I_Disease'), (87, 96, 'I_Disease'), (97, 99, 'I_Disease'), (100, 103, 'I_Disease'), (104, 106, 'I_Disease'), (107, 111, 'I_Disease'), (112, 116, 'I_Disease')]}], ['No histopathological alterations or differences in bone formation were seen in the limbs or toes of any chicks from any group ; however , extensive cranial hemorrhage occurred in all nicotine sulfate - treated chicks .', {'entities': [(148, 155, 'B_Disease'), (156, 166, 'I_Disease')]}], ['In summary , the chick embryo provides a reliable and simple experimental animal model of coniine - induced arthrogryposis .', {'entities': [(108, 122, 'B_Disease')]}], ['Immediate allergic reactions to amoxicillin .', {'entities': [(10, 18, 'B_Disease'), (19, 28, 'I_Disease')]}], ['A large group of patients with suspected allergic reactions to beta - lactam antibiotics was evaluated .', {'entities': [(41, 49, 'B_Disease'), (50, 59, 'I_Disease')]}], ['A detailed clinical history , together with skin tests , RAST ( radioallergosorbent test ) , and controlled challenge tests , was used to establish whether patients allergic to beta - lactam antibiotics had selective immediate allergic responses to amoxicillin ( AX ) or were cross - reacting with other penicillin derivatives .', {'entities': [(165, 173, 'B_Disease'), (227, 235, 'B_Disease')]}], ['A total of 177 patients were diagnosed as allergic to beta - lactam antibiotics .', {'entities': [(42, 50, 'B_Disease')]}], ['We selected the 54 ( 30 . 5 % ) cases of immediate AX allergy with good tolerance of PG .', {'entities': [(54, 61, 'B_Disease')]}], ['Anaphylaxis was seen in 37 patients ( 69 % ) , the other 17 ( 31 % ) having urticaria and / or angioedema .', {'entities': [(0, 11, 'B_Disease'), (76, 85, 'B_Disease'), (95, 105, 'B_Disease')]}], ['All the patients were skin test negative to BPO ; 49 of 51 ( 96 % ) were also negative to MDM , and 44 of 46 ( 96 % ) to PG .', {'entities': [(90, 93, 'B_Disease')]}], ['Challenge tests with AX were performed in 23 subjects ( 43 % ) to establish the diagnosis of immediate allergic reaction to AX , and in 15 cases ( 28 % ) both skin test and RAST for AX were negative .', {'entities': [(103, 111, 'B_Disease'), (112, 120, 'I_Disease')]}], ['We describe the largest group of AX - allergic patients who have tolerated PG reported so far .', {'entities': [(38, 46, 'B_Disease')]}], ['Reversal by phenylephrine of the beneficial effects of intravenous nitroglycerin in patients with acute myocardial infarction .', {'entities': [(98, 103, 'B_Disease'), (104, 114, 'I_Disease'), (115, 125, 'I_Disease')]}], ['Nitroglycerin has been shown to reduce ST - segment elevation during acute myocardial infarction , an effect potentiated in the dog by agents that reverse nitroglycerin - induced hypotension .', {'entities': [(69, 74, 'B_Disease'), (75, 85, 'I_Disease'), (86, 96, 'I_Disease'), (179, 190, 'B_Disease')]}], ['Ten patients with acute transmural myocardial infarctions received intravenous nitroglycerin , sufficient to reduce mean arterial pressure from 107 + / - 6 to 85 + / - 6 mm Hg ( P less than 0 . 001 ) , for 60 minutes .', {'entities': [(35, 45, 'B_Disease'), (46, 57, 'I_Disease')]}], ['Our results suggest that addition of phenylephrine to nitroglycerin is not beneficial in the treatment of patients with acute myocardial infarction .', {'entities': [(120, 125, 'B_Disease'), (126, 136, 'I_Disease'), (137, 147, 'I_Disease')]}], ['Acetazolamide - induced nephrolithiasis : implications for treatment of neuromuscular disorders .', {'entities': [(24, 39, 'B_Disease'), (72, 85, 'B_Disease'), (86, 95, 'I_Disease')]}], ['Carbonic anhydrase inhibitors can cause nephrolithiasis .', {'entities': [(40, 55, 'B_Disease')]}], ['We studied 20 patients receiving long - term carbonic anhydrase inhibitor treatment for periodic paralysis and myotonia .', {'entities': [(97, 106, 'B_Disease'), (111, 119, 'B_Disease')]}], ['Three patients on acetazolamide ( 15 % ) developed renal calculi .', {'entities': [(51, 56, 'B_Disease'), (57, 64, 'I_Disease')]}], ['Extracorporeal lithotripsy successfully removed a renal calculus in one patient and surgery removed a staghorn calculus in another , permitting continued treatment .', {'entities': [(50, 55, 'B_Disease'), (56, 64, 'I_Disease'), (111, 119, 'B_Disease')]}], ['Nephrolithiasis is a complication of acetazolamide but does not preclude its use .', {'entities': [(0, 15, 'B_Disease')]}], ['Effects of calcium channel blockers on bupivacaine - induced toxicity .', {'entities': [(61, 69, 'B_Disease')]}], ['The purpose of this study was to investigate the influence of calcium channel blockers on bupivacaine - induced acute toxicity .', {'entities': [(118, 126, 'B_Disease')]}], ['The convulsant activity of bupivacaine was not significantly modified but calcium channel blockers decreased the time of latency to obtain bupivacaine - induced convulsions ; this effect was less pronounced with bepridil .', {'entities': [(161, 172, 'B_Disease')]}], ['Epidural blood flow during prostaglandin E1 or trimethaphan induced hypotension .', {'entities': [(68, 79, 'B_Disease')]}], ['To evaluate the effect of prostaglandin E1 ( PGE1 ) or trimethaphan ( TMP ) induced hypotension on epidural blood flow ( EBF ) during spinal surgery , EBF was measured using the heat clearance method in 30 patients who underwent postero - lateral interbody fusion under isoflurane anaesthesia .', {'entities': [(84, 95, 'B_Disease')]}], ['The hypotensive drug was discontinued at the completion of the operative procedure .', {'entities': [(4, 15, 'B_Disease')]}], ['After starting PGE1 or TMP , MAP and rate pressure product ( RPP ) decreased significantly compared with preinfusion values ( P < 0 . 01 ) , and the degree of hypotension due to PGE1 remained constant until 60 min after its discontinuation .', {'entities': [(159, 170, 'B_Disease')]}], ['These results suggest that PGE1 may be preferable to TMP for hypotensive anaesthesia in spinal surgery because TMP decreased EBF .', {'entities': [(61, 72, 'B_Disease')]}], ['Dup 753 prevents the development of puromycin aminonucleoside - induced nephrosis .', {'entities': [(72, 81, 'B_Disease')]}], ['The appearance of nephrotic syndromes such as proteinuria , hypoalbuminemia , hypercholesterolemia and increase in blood nitrogen urea , induced in rats by injection of puromycin aminonucleoside was markedly inhibited by oral administration of Dup 753 ( losartan ) , a novel angiotensin II receptor antagonist , at a dose of 1 or 2 mg / kg per day .', {'entities': [(18, 27, 'B_Disease'), (28, 37, 'I_Disease'), (46, 57, 'B_Disease'), (60, 75, 'B_Disease'), (78, 98, 'B_Disease')]}], ['The results suggest a possible involvement of the renin - angiotensin system in the development of puromycin aminonucleoside - induced nephrosis .', {'entities': [(135, 144, 'B_Disease')]}], ['Neuroplasticity of the adult primate auditory cortex following cochlear hearing loss .', {'entities': [(72, 79, 'B_Disease'), (80, 84, 'I_Disease')]}], ['The purpose of this study was to determine if changes occur in this tonotopic organization following cochlear hearing loss .', {'entities': [(110, 117, 'B_Disease'), (118, 122, 'I_Disease')]}], ['The region of cortex that represents the low frequencies was not obviously affected by the cochlear hearing loss .', {'entities': [(100, 107, 'B_Disease'), (108, 112, 'I_Disease')]}], ['Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction .', {'entities': [(30, 36, 'B_Disease'), (37, 41, 'I_Disease'), (83, 91, 'B_Disease'), (92, 103, 'I_Disease')]}], ['In an attempt to determine whether penile pain associated with intracorporeal injections could be due to the acidity of the medication , we performed a randomized study comparing the incidence of penile pain following intracorporeal injections with or without the addition of sodium bicarbonate to the intracorporeal medications .', {'entities': [(35, 41, 'B_Disease'), (42, 46, 'I_Disease'), (196, 202, 'B_Disease'), (203, 207, 'I_Disease')]}], ['A total of 38 consecutive patients who presented to our clinic with impotence received 0 . 2 ml . of a combination of 3 drugs : 6 mg . papaverine , 100 micrograms . phentolamine and 10 micrograms . prostaglandin E1 with ( pH 7 . 05 ) or without ( pH 4 . 17 ) the addition of sodium bicarbonate ( 0 . 03 mEq . ) .', {'entities': [(68, 77, 'B_Disease')]}], ['Of the 19 patients without sodium bicarbonate added to the medication 11 ( 58 % ) complained of penile pain due to the medication , while only 1 of the 19 men ( 5 % ) who received sodium bicarbonate complained of penile pain .', {'entities': [(96, 102, 'B_Disease'), (103, 107, 'I_Disease'), (213, 219, 'B_Disease'), (220, 224, 'I_Disease')]}], ['From these data we conclude that the penile pain following intracorporeal injections is most likely due to the acidity of the medication , which can be overcome by elevating the pH to a neutral level .', {'entities': [(37, 43, 'B_Disease'), (44, 48, 'I_Disease')]}], ['The use and toxicity of didanosine ( ddI ) in HIV antibody - positive individuals intolerant to zidovudine ( AZT )', {'entities': [(12, 20, 'B_Disease'), (46, 49, 'B_Disease'), (50, 58, 'I_Disease'), (59, 60, 'I_Disease'), (61, 69, 'I_Disease')]}], ['Seventy patients developed major opportunistic infections whilst on therapy ; this was the first AIDS diagnosis in 17 .', {'entities': [(33, 46, 'B_Disease'), (47, 57, 'I_Disease'), (97, 101, 'B_Disease')]}], ['Only minor changes in CD4 + lymphocyte subset count were observed in AIDS patients , although a more significant rise occurred in those with earlier stages of disease .', {'entities': [(69, 73, 'B_Disease')]}], ['The most common side - effect was diarrhoea , which resulted in cessation of therapy in 19 individuals .', {'entities': [(34, 43, 'B_Disease')]}], ['Peripheral neuropathy occurred in 12 patients and pancreatitis in six .', {'entities': [(0, 10, 'B_Disease'), (11, 21, 'I_Disease'), (50, 62, 'B_Disease')]}], ['Thirteen patients developed a raised serum amylase without abdominal pain .', {'entities': [(59, 68, 'B_Disease'), (69, 73, 'I_Disease')]}], ['Seven patients developed glucose tolerance curves characteristic of diabetes but these were mild , did not require treatment and returned to normal on ceasing didanosine .', {'entities': [(25, 32, 'B_Disease'), (33, 42, 'I_Disease'), (43, 49, 'I_Disease'), (68, 76, 'B_Disease')]}], ['Immunohistochemical studies with antibodies to neurofilament proteins on axonal damage in experimental focal lesions in rat .', {'entities': [(73, 79, 'B_Disease'), (80, 86, 'I_Disease')]}], ['Immunohistochemistry with monoclonal antibodies against neurofilament ( NF ) proteins of middle and high molecular weight class , NF - M and NF - H , was used to study axonal injury in the borderzone of focal lesions in rats .', {'entities': [(168, 174, 'B_Disease'), (175, 181, 'I_Disease')]}], ['Focal injury in the cortex was produced by infusion of lactate at acid pH or by stab caused by needle insertion .', {'entities': [(6, 12, 'B_Disease'), (13, 15, 'I_Disease'), (16, 19, 'I_Disease'), (20, 26, 'I_Disease')]}], ['Infarcts in substantia nigra pars reticulata were evoked by prolonged pilocarpine - induced status epilepticus .', {'entities': [(0, 8, 'B_Disease'), (9, 11, 'I_Disease'), (12, 22, 'I_Disease'), (23, 28, 'I_Disease'), (29, 33, 'I_Disease'), (34, 44, 'I_Disease'), (92, 98, 'B_Disease'), (99, 110, 'I_Disease')]}], ['These immunohistochemical changes of NFs can serve as a marker for axonal damage in various experimental traumatic or ischemic lesions .', {'entities': [(67, 73, 'B_Disease'), (74, 80, 'I_Disease'), (105, 114, 'B_Disease')]}], ['Pharmacokinetic and clinical studies in patients with cimetidine - associated mental confusion .', {'entities': [(85, 94, 'B_Disease')]}], ['15 cases of cimetidine - associated mental confusion have been reported .', {'entities': [(43, 52, 'B_Disease')]}], ['These 6 patients had both renal and liver dysfunction ( P less than 0 . 05 ) , as well as cimetidine trough - concentrations of more than 1 . 25 microgram / ml ( P less than 0 . 05 ) .', {'entities': [(26, 31, 'B_Disease'), (32, 35, 'I_Disease'), (36, 41, 'I_Disease'), (42, 53, 'I_Disease')]}], ['Patients likely to have both raised trough - concentrations and mental confusion are those with both severe renal and hepatic dysfunction .', {'entities': [(71, 80, 'B_Disease'), (108, 113, 'B_Disease'), (114, 117, 'I_Disease'), (118, 125, 'I_Disease'), (126, 137, 'I_Disease')]}], ['Prospective study of the long - term effects of somatostatin analog ( octreotide ) on gallbladder function and gallstone formation in Chinese acromegalic patients .', {'entities': [(111, 120, 'B_Disease'), (142, 153, 'B_Disease')]}], ['This article reports the changes in gallbladder function examined by ultrasonography in 20 Chinese patients with active acromegaly treated with sc injection of the somatostatin analog octreotide in dosages of 300 - 1500 micrograms / day for a mean of 24 . 2 + / - 13 . 9 months .', {'entities': [(120, 130, 'B_Disease')]}], ['During treatment with octreotide , 17 patients developed sludge , 10 had gallstones , and 1 developed acute cholecystitis requiring surgery .', {'entities': [(73, 83, 'B_Disease'), (102, 107, 'B_Disease'), (108, 121, 'I_Disease')]}], ['In 8 patients followed for 24 weeks , gallbladder contractility remained depressed throughout therapy .', {'entities': [(73, 82, 'B_Disease')]}], ['After withdrawal of octreotide in 10 patients without gallstones , 8 patients assessed had return of normal gallbladder contractility within 1 month .', {'entities': [(54, 64, 'B_Disease')]}], ['In 8 of the remaining 10 patients who developed gallstones during treatment , gallbladder contractility normalized in 5 patients ( 3 of whom has disappearance of their stones within 3 weeks ) , and remained depressed in 3 ( 2 of whom had stones present at 6 months ) .', {'entities': [(48, 58, 'B_Disease'), (207, 216, 'B_Disease')]}], ['Our results suggest that the suppression of gallbladder contractility is the cause of the successive formation of bile sludge , gallstones , and cholecystitis during octreotide therapy in Chinese acromegalic patients .', {'entities': [(128, 138, 'B_Disease'), (145, 158, 'B_Disease'), (196, 207, 'B_Disease')]}], ['It is therefore very important to follow the changes of gallbladder function during long - term octreotide therapy of acromegalic patients .', {'entities': [(118, 129, 'B_Disease')]}], ['Increase of Parkinson disability after fluoxetine medication .', {'entities': [(12, 21, 'B_Disease'), (22, 32, 'I_Disease')]}], [\"Depression is a major clinical feature of Parkinson ' s disease .\", {'entities': [(0, 10, 'B_Disease'), (42, 51, 'B_Disease'), (52, 53, 'I_Disease'), (54, 55, 'I_Disease'), (56, 63, 'I_Disease')]}], [\"We report the increased amount of motor disability in four patients with idiopathic Parkinson ' s disease after exposure to the antidepressant fluoxetine .\", {'entities': [(34, 39, 'B_Disease'), (40, 50, 'I_Disease'), (73, 83, 'B_Disease'), (84, 93, 'I_Disease'), (94, 95, 'I_Disease'), (96, 97, 'I_Disease'), (98, 105, 'I_Disease')]}], [\"The possibility of a clinically relevant dopamine - antagonistic capacity of fluoxetine in Parkinson ' s disease patients must be considered .\", {'entities': [(91, 100, 'B_Disease'), (101, 102, 'I_Disease'), (103, 104, 'I_Disease'), (105, 112, 'I_Disease')]}], ['Sinus arrest associated with continuous - infusion cimetidine .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease')]}], ['The administration of intermittent intravenous infusions of cimetidine is infrequently associated with the development of bradyarrhythmias .', {'entities': [(122, 138, 'B_Disease')]}], ['A 40 - year - old man with leukemia and no history of cardiac disease developed recurrent , brief episodes of apparent sinus arrest while receiving continuous - infusion cimetidine 50 mg / hour .', {'entities': [(27, 35, 'B_Disease'), (54, 61, 'B_Disease'), (62, 69, 'I_Disease'), (119, 124, 'B_Disease'), (125, 131, 'I_Disease')]}], ['The arrhythmias were temporally related to cimetidine administration , disappeared after dechallenge , and did not recur during ranitidine treatment .', {'entities': [(4, 15, 'B_Disease')]}], ['This is the first reported case of sinus arrest associated with continuous - infusion cimetidine .', {'entities': [(35, 40, 'B_Disease'), (41, 47, 'I_Disease')]}], ['Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma .', {'entities': [(44, 52, 'B_Disease'), (53, 57, 'I_Disease'), (58, 68, 'I_Disease'), (69, 78, 'I_Disease')]}], ['European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group .', {'entities': [(52, 58, 'B_Disease'), (82, 88, 'B_Disease')]}], ['PURPOSE : To evaluate the response rate and toxic effects of vinorelbine ( VNB ) administered as a single agent in metastatic squamous cell esophageal carcinoma .', {'entities': [(126, 134, 'B_Disease'), (135, 139, 'I_Disease'), (140, 150, 'I_Disease'), (151, 160, 'I_Disease')]}], ['Thirty patients without prior chemotherapy and 16 pretreated with cisplatin - based chemotherapy were assessable for toxicity and response .', {'entities': [(117, 125, 'B_Disease')]}], ['VNB was well tolerated and zero instances of WHO grade 4 nonhematologic toxicity occurred .', {'entities': [(72, 80, 'B_Disease')]}], ['At least one episode of grade 3 or 4 granulocytopenia was seen in 59 % of patients .', {'entities': [(37, 53, 'B_Disease')]}], ['A grade 2 or 3 infection occurred in 16 % of patients , but no toxic deaths occurred .', {'entities': [(15, 24, 'B_Disease'), (69, 75, 'B_Disease')]}], ['Other side effects were rare , and peripheral neurotoxicity has been minor ( 26 % grade 1 ) .', {'entities': [(35, 45, 'B_Disease'), (46, 59, 'I_Disease')]}], ['CONCLUSION : These data indicate that VNB is an active agent in metastatic esophageal squamous cell carcinoma .', {'entities': [(75, 85, 'B_Disease'), (86, 94, 'I_Disease'), (95, 99, 'I_Disease'), (100, 109, 'I_Disease')]}], ['Given its excellent tolerance profile and low toxicity , further evaluation of VNB in combination therapy is warranted .', {'entities': [(46, 54, 'B_Disease')]}], ['The ocular hypotensive effects were statistically significant for apraclonidine - treated eyes throughout the study and also statistically significant for contralateral eyes from three hours after topical administration of 1 % apraclonidine .', {'entities': [(4, 10, 'B_Disease'), (11, 22, 'I_Disease')]}], ['Decreases in systolic blood pressure were statistically , but not clinically , significant .', {'entities': [(0, 9, 'B_Disease'), (10, 12, 'I_Disease'), (13, 21, 'I_Disease'), (22, 27, 'I_Disease'), (28, 36, 'I_Disease')]}], ['Conjunctival blanching and mydriasis were commonly found .', {'entities': [(0, 12, 'B_Disease'), (13, 22, 'I_Disease'), (27, 36, 'B_Disease')]}], ['While the elevations of the upper lid margin in most subjects were not more than 2 mm and did not cause noticeable change in appearance , one subject suffered from mechanical entropion and marked corneal abrasion 3 hours after instillation of the medication .', {'entities': [(175, 184, 'B_Disease'), (196, 203, 'B_Disease'), (204, 212, 'I_Disease')]}], ['Thiopentone pretreatment for propofol injection pain in ambulatory patients .', {'entities': [(48, 52, 'B_Disease')]}], ['This study investigated propofol injection pain in patients undergoing ambulatory anaesthesia .', {'entities': [(43, 47, 'B_Disease')]}], ['Loss of consciousness occurred in 60 - 90 sec .', {'entities': [(0, 4, 'B_Disease'), (5, 7, 'I_Disease'), (8, 21, 'I_Disease')]}], ['The VAS scores for recall of pain in the recovery room were correlated with the VAS scores during induction ( r = 0 . 7045 ; P < 0 . 0001 ) .', {'entities': [(29, 33, 'B_Disease')]}], ['We conclude that lidocaine reduces the incidence and severity of propofol injection pain in ambulatory patients whereas thiopentone only reduces its severity .', {'entities': [(84, 88, 'B_Disease')]}], ['Persistent paralysis after prolonged use of atracurium in the absence of corticosteroids .', {'entities': [(11, 20, 'B_Disease')]}], ['Reports of persistent paralysis after the discontinuance of these drugs have most often involved aminosteroid - based NMBAs such as vecuronium bromide , especially when used in conjunction with corticosteroids .', {'entities': [(22, 31, 'B_Disease')]}], ['Atracurium besylate , a short - acting benzylisoquinolinium NMBA that is eliminated independently of renal or hepatic function , has also been associated with persistent paralysis , but only when used with corticosteroids .', {'entities': [(170, 179, 'B_Disease')]}], ['We report a case of atracurium - related paralysis persisting for approximately 50 hours in a patient who was not treated with corticosteroids .', {'entities': [(41, 50, 'B_Disease')]}], ['A phase I / II study of paclitaxel plus cisplatin as first - line therapy for head and neck cancers : preliminary results .', {'entities': [(78, 82, 'B_Disease'), (83, 86, 'I_Disease'), (87, 91, 'I_Disease'), (92, 99, 'I_Disease')]}], ['Improved outcomes among patients with head and neck carcinomas require investigations of new drugs for induction therapy .', {'entities': [(38, 42, 'B_Disease'), (43, 46, 'I_Disease'), (47, 51, 'I_Disease'), (52, 62, 'I_Disease')]}], ['Preliminary results of an Eastern Cooperative Oncology Group study of single - agent paclitaxel ( Taxol ; Bristol - Myers Squibb Company , Princeton , NJ ) reported a 37 % response rate in patients with head and neck cancer , and the paclitaxel / cisplatin combination has been used successfully and has significantly improved median response duration in ovarian cancer patients .', {'entities': [(203, 207, 'B_Disease'), (208, 211, 'I_Disease'), (212, 216, 'I_Disease'), (217, 223, 'I_Disease'), (355, 362, 'B_Disease'), (363, 369, 'I_Disease')]}], ['We initiated a phase I / II trial to determine the response and toxicity of escalating paclitaxel doses combined with fixed - dose cisplatin with granulocyte colony - stimulating factor support in patients with untreated locally advanced inoperable head and neck carcinoma .', {'entities': [(64, 72, 'B_Disease'), (249, 253, 'B_Disease'), (254, 257, 'I_Disease'), (258, 262, 'I_Disease'), (263, 272, 'I_Disease')]}], ['Primary tumor sites were oropharynx , 10 patients ; hypopharynx , four ; larynx , two ; oral cavity , three ; unknown primary , two ; and nasal cavity and parotid gland , one each .', {'entities': [(8, 13, 'B_Disease')]}], ['Of 20 patients evaluable for toxicity , four had stage III and 16 had stage IV disease .', {'entities': [(29, 37, 'B_Disease')]}], ['The dose levels incorporate escalating paclitaxel doses , and intrapatient escalations within a given dose level are permitted if toxicity permits .', {'entities': [(130, 138, 'B_Disease')]}], ['Alopecia , paresthesias , and arthralgias / myalgias have occurred frequently , but with one exception ( a grade 3 myalgia ) they have been grade 1 or 2 .', {'entities': [(0, 8, 'B_Disease'), (11, 23, 'B_Disease'), (30, 41, 'B_Disease'), (44, 52, 'B_Disease'), (115, 122, 'B_Disease')]}], ['No dose - limiting hematologic toxicity has been seen .', {'entities': [(31, 39, 'B_Disease')]}], ['Paclitaxel / cisplatin is an effective first - line regimen for locoregionally advanced head and neck cancer and continued study is warranted .', {'entities': [(88, 92, 'B_Disease'), (93, 96, 'I_Disease'), (97, 101, 'I_Disease'), (102, 108, 'I_Disease')]}], [\"Improvement of levodopa - induced dyskinesia by propranolol in Parkinson ' s disease .\", {'entities': [(34, 44, 'B_Disease'), (63, 72, 'B_Disease'), (73, 74, 'I_Disease'), (75, 76, 'I_Disease'), (77, 84, 'I_Disease')]}], [\"Seven patients suffering from Parkinson ' s disease ( PD ) with severely disabling dyskinesia received low - dose propranolol as an adjunct to the currently used medical treatment .\", {'entities': [(30, 39, 'B_Disease'), (40, 41, 'I_Disease'), (42, 43, 'I_Disease'), (44, 51, 'I_Disease'), (54, 56, 'B_Disease'), (83, 93, 'B_Disease')]}], ['There was a significant 40 % improvement in the dyskinesia score without increase of parkinsonian motor disability .', {'entities': [(48, 58, 'B_Disease'), (85, 97, 'B_Disease'), (98, 103, 'B_Disease'), (104, 114, 'I_Disease')]}], ['Ballistic and choreic dyskinesia were markedly ameliorated , whereas dystonia was not .', {'entities': [(22, 32, 'B_Disease'), (69, 77, 'B_Disease')]}], ['This study suggests that administration of low doses of beta - blockers may improve levodopa - induced ballistic and choreic dyskinesia in PD .', {'entities': [(125, 135, 'B_Disease'), (139, 141, 'B_Disease')]}], ['Habitual use of acetaminophen as a risk factor for chronic renal failure : a comparison with phenacetin .', {'entities': [(51, 58, 'B_Disease'), (59, 64, 'I_Disease'), (65, 72, 'I_Disease')]}], ['Six epidemiologic studies in the United States and Europe indicate that habitual use of phenacetin is associated with the development of chronic renal failure and end - stage renal disease ( ESRD ) , with a relative risk in the range of 4 to 19 .', {'entities': [(137, 144, 'B_Disease'), (145, 150, 'I_Disease'), (151, 158, 'I_Disease'), (163, 166, 'B_Disease'), (167, 168, 'I_Disease'), (169, 174, 'I_Disease'), (175, 180, 'I_Disease'), (181, 188, 'I_Disease'), (191, 195, 'B_Disease')]}], ['However , three case control studies , one each in North Carolina , northern Maryland , and West Berlin , Germany , showed that habitual use of acetaminophen is also associated with chronic renal failure and ESRD , with a relative risk in the range of 2 to 4 .', {'entities': [(182, 189, 'B_Disease'), (190, 195, 'I_Disease'), (196, 203, 'I_Disease'), (208, 212, 'B_Disease')]}], ['These studies suggest that both phenacetin and acetaminophen may contribute to the burden of ESRD , with the risk of the latter being somewhat less than that of the former .', {'entities': [(93, 97, 'B_Disease')]}], ['This apparent difference in risk may not be due to differences in nephrotoxic potential of the drugs themselves .', {'entities': [(66, 77, 'B_Disease')]}], ['The possibility that habitual use of acetaminophen alone increases the risk of ESRD has not been clearly demonstrated , but cannot be dismissed .', {'entities': [(79, 83, 'B_Disease')]}], ['Acetaminophen - induced hypotension .', {'entities': [(24, 35, 'B_Disease')]}], ['The potential for acetaminophen to produce cardiovascular toxicities is very low .', {'entities': [(43, 57, 'B_Disease'), (58, 68, 'I_Disease')]}], ['However , acetaminophen has been demonstrated to produce symptoms of anaphylaxis , including hypotension , in sensitive individuals .', {'entities': [(69, 80, 'B_Disease'), (93, 104, 'B_Disease')]}], ['This article describes two critically ill patients in whom transient episodes of hypotension reproducibly developed after administration of acetaminophen .', {'entities': [(27, 37, 'B_Disease'), (38, 41, 'I_Disease'), (81, 92, 'B_Disease')]}], ['Other symptoms of allergic reactions were not clinically detectable .', {'entities': [(18, 26, 'B_Disease'), (27, 36, 'I_Disease')]}], ['The hypotensive episodes were severe enough to require vasopressor administration .', {'entities': [(4, 15, 'B_Disease')]}], ['The reports illustrate the need for clinicians to consider acetaminophen in patients with hypotension of unknown origin .', {'entities': [(90, 101, 'B_Disease')]}], ['Reduction of heparan sulphate - associated anionic sites in the glomerular basement membrane of rats with streptozotocin - induced diabetic nephropathy .', {'entities': [(131, 139, 'B_Disease'), (140, 151, 'I_Disease')]}], ['Heparan sulphate - associated anionic sites in the glomerular basement membrane were studied in rats 8 months after induction of diabetes by streptozotocin and in age - adn sex - matched control rats , employing the cationic dye cuprolinic blue .', {'entities': [(129, 137, 'B_Disease')]}], ['The majority of anionic sites ( 74 % in diabetic and 81 % in control rats ) were found within the lamina rara externa of the glomerular basement membrane .', {'entities': [(40, 48, 'B_Disease')]}], ['A minority of anionic sites were scattered throughout the lamina densa and lamina rara interna , and were significantly smaller than those in the lamina rara externa of the glomerular basement membrane ( p < 0 . 001 and p < 0 . 01 for diabetic and control rats , respectively ) .', {'entities': [(235, 243, 'B_Disease')]}], ['Diabetic rats progressively developed albuminuria reaching 40 . 3 ( 32 . 2 - 62 . 0 ) mg / 24 h after 8 months in contrast to the control animals ( 0 . 8 ( 0 . 2 - 0 . 9 ) mg / 24 h , p < 0 . 002 ) .', {'entities': [(0, 8, 'B_Disease'), (38, 49, 'B_Disease')]}], ['We conclude that in streptozotocin - diabetic rats with an increased urinary albumin excretion , a reduced heparan sulphate charge barrier / density is found at the lamina rara externa of the glomerular basement membrane .', {'entities': [(37, 45, 'B_Disease')]}], ['Mediation of enhanced reflex vagal bradycardia by L - dopa via central dopamine formation in dogs .', {'entities': [(35, 46, 'B_Disease')]}], ['In addition , reflex bradycardia caused by injected norepinephrine was significantly enhanced by L - dopa , DL - Threo - dihydroxyphenylserine had no effect on blood pressure , heart rate or reflex responses to norepinephrine .', {'entities': [(21, 32, 'B_Disease')]}], ['FLA - 63 , a dopamine - beta - oxidase inhibitor , did not have any effect on the hypotension , bradycardia or reflex - enhancing effect of L - dopa .', {'entities': [(82, 93, 'B_Disease'), (96, 107, 'B_Disease')]}], ['However , L - dopa restored the bradycardia caused by norepinephrine in addition to decreasing blood pressure and heart rate .', {'entities': [(32, 43, 'B_Disease')]}], ['5 - HTP ( 5 mg / kg i . v . ) decreased blood pressure and heart rate and decreased the reflex bradycardia to norepinephrine .', {'entities': [(95, 106, 'B_Disease')]}], ['It is concluded that L - dopa enhances reflex bradycardia through central alpha - receptor stimulation .', {'entities': [(46, 57, 'B_Disease')]}], ['Microangiopathic hemolytic anemia complicating FK506 ( tacrolimus ) therapy .', {'entities': [(0, 16, 'B_Disease'), (17, 26, 'I_Disease'), (27, 33, 'I_Disease')]}], ['We describe 3 episodes of microangiopathic hemolytic anemia ( MAHA ) in 2 solid organ recipients under FK506 ( tacrolimus ) therapy .', {'entities': [(26, 42, 'B_Disease'), (43, 52, 'I_Disease'), (53, 59, 'I_Disease'), (62, 66, 'B_Disease')]}], ['In both cases , discontinuation of FK506 and treatment with plasma exchange , fresh frozen plasma replacement , corticosteroids , aspirin , and dipyridamole led to resolution of MAHA .', {'entities': [(178, 182, 'B_Disease')]}], ['In one patient , reintroduction of FK506 led to rapid recurrence of MAHA .', {'entities': [(68, 72, 'B_Disease')]}], ['FK506 - associated MAHA is probably rare but physicians must be aware of this severe complication .', {'entities': [(19, 23, 'B_Disease')]}], ['In our experience and according to the literature , FK506 does not seem to cross - react with cyclosporin A ( CyA ) , an immuno - suppressive drug already known to induce MAHA .', {'entities': [(171, 175, 'B_Disease')]}], ['Effect of some anticancer drugs and combined chemotherapy on renal toxicity .', {'entities': [(61, 66, 'B_Disease'), (67, 75, 'I_Disease')]}], ['The nephrotoxic action of anticancer drugs such as nitrogranulogen ( NG ) , methotrexate ( MTX ) , 5 - fluorouracil ( 5 - FU ) and cyclophosphamide ( CY ) administered alone or in combination [ MTX + 5 - FU + CY ( CMF ) ] was evaluated in experiments on Wistar rats .', {'entities': [(4, 15, 'B_Disease')]}], ['CY caused hemorrhagic cystitis in 40 % of rats , but it did not cause this complication when combined with 5 - FU and MTX .', {'entities': [(10, 21, 'B_Disease'), (22, 30, 'I_Disease')]}], ['Our studies indicate that nephrotoxicity of MTX + 5 - FU + CY administered jointly is lower than in monotherapy .', {'entities': [(26, 40, 'B_Disease')]}], ['Compared with sham - operated controls , lesions significantly ( p < 0 . 25 ) blunted the early ( < 60 min ) free - field locomotor hypoactivity caused by nicotine ( 0 . 5 mg kg ( - 1 ) , i . m . ) , enhanced the later ( 60 - 120 min ) nicotine - induced hyperactivity , and raised spontaneous nocturnal activity .', {'entities': [(122, 131, 'B_Disease'), (132, 144, 'I_Disease'), (255, 268, 'B_Disease')]}], ['We conclude that the interpeduncular nucleus mediates nicotinic depression of locomotor activity and dampens nicotinic arousal mechanisms located elsewhere in the brain .', {'entities': [(64, 74, 'B_Disease')]}], ['Lithium - associated cognitive and functional deficits reduced by a switch to divalproex sodium : a case series .', {'entities': [(21, 30, 'B_Disease'), (31, 34, 'I_Disease'), (35, 45, 'I_Disease'), (46, 54, 'I_Disease')]}], ['BACKGROUND : Lithium remains a first - line treatment for the acute and maintenance treatment of bipolar disorder .', {'entities': [(97, 104, 'B_Disease'), (105, 113, 'I_Disease')]}], ['Although much has been written about the management of the more common adverse effects of lithium , such as polyuria and tremor , more subtle lithium side effects such as cognitive deficits , loss of creativity , and functional impairments remain understudied .', {'entities': [(108, 116, 'B_Disease'), (121, 127, 'B_Disease'), (171, 180, 'B_Disease'), (181, 189, 'I_Disease'), (192, 196, 'B_Disease'), (197, 199, 'I_Disease'), (200, 210, 'I_Disease'), (217, 227, 'B_Disease'), (228, 239, 'I_Disease')]}], ['This report summarizes our experience in switching bipolar patients from lithium to divalproex sodium to alleviate such cognitive and functional impairments .', {'entities': [(51, 58, 'B_Disease'), (120, 129, 'B_Disease'), (130, 133, 'I_Disease'), (134, 144, 'I_Disease'), (145, 156, 'I_Disease')]}], ['RESULTS : We report seven cases where substitution of lithium , either fully or partially , with divalproex sodium was extremely helpful in reducing the cognitive , motivational , or creative deficits attributed to lithium in our bipolar patients .', {'entities': [(153, 162, 'B_Disease'), (163, 164, 'I_Disease'), (165, 177, 'I_Disease'), (178, 179, 'I_Disease'), (180, 182, 'I_Disease'), (183, 191, 'I_Disease'), (192, 200, 'I_Disease'), (230, 237, 'B_Disease')]}], ['CONCLUSION : In this preliminary report , divalproex sodium was a superior alternative to lithium in bipolar patients experiencing cognitive deficits , loss of creativity , and functional impairments .', {'entities': [(101, 108, 'B_Disease'), (131, 140, 'B_Disease'), (141, 149, 'I_Disease'), (152, 156, 'B_Disease'), (157, 159, 'I_Disease'), (160, 170, 'I_Disease'), (177, 187, 'B_Disease'), (188, 199, 'I_Disease')]}], ['Two groups of patients receiving tacrolimus were compared over a period of 1 year , one group comprising hypertensive patients who were receiving nifedipine , and the other comprising nonhypertensive patients not receiving nifedipine .', {'entities': [(105, 117, 'B_Disease')]}], ['The observed positive impact of nifedipine on reducing the nephrotoxicity associated with tacrolimus in liver transplant recipients should be an important factor in selecting an agent to treat hypertension in this population .', {'entities': [(59, 73, 'B_Disease'), (193, 205, 'B_Disease')]}], ['Alpha and beta coma in drug intoxication uncomplicated by cerebral hypoxia .', {'entities': [(15, 19, 'B_Disease'), (58, 66, 'B_Disease'), (67, 74, 'I_Disease')]}], ['Four patients who were rendered comatose or stuporous by drug intoxication , but who were not hypoxic , are described .', {'entities': [(32, 40, 'B_Disease'), (44, 53, 'B_Disease')]}], ['Three patients received high doses of chlormethiazole for alcohol withdrawal symptoms , and one took a suicidal overdose of nitrazepam .', {'entities': [(66, 76, 'B_Disease'), (77, 85, 'I_Disease'), (112, 120, 'B_Disease')]}], [\"The patient with nitrazepam overdose and two of those with chlormethiazole intoxication conformed to the criteria of ' alpha coma ' , showing non - reactive generalized or frontally predominant alpha activity in the EEG .\", {'entities': [(28, 36, 'B_Disease'), (125, 129, 'B_Disease')]}], ['All four recovered completely without neurological sequelae following the withdrawal of the offending agents .', {'entities': [(38, 50, 'B_Disease'), (51, 59, 'I_Disease')]}], ['The similarities between the effects of structural lesions and pharmacological depression of the brain stem reticular formation are discussed .', {'entities': [(79, 89, 'B_Disease')]}], ['It is suggested that in both situations disturbed reticulo - thalamic interactions are important in the pathogenesis of alpha coma .', {'entities': [(126, 130, 'B_Disease')]}], ['It is concluded that when this electroencephalographic and behavioural picture is seen in drug intoxication , in the absence of significant hypoxaemia , a favourable outcome may be anticipated .', {'entities': [(140, 150, 'B_Disease')]}], ['Magnetic resonance volumetry of the cerebellum in epileptic patients after phenytoin overdosages .', {'entities': [(50, 59, 'B_Disease'), (85, 96, 'B_Disease')]}], ['The aim of this study was to evaluate the relationship between phenytoin medication and cerebellar atrophy in patients who had experienced clinical intoxication .', {'entities': [(88, 98, 'B_Disease'), (99, 106, 'I_Disease')]}], ['Using linear regression we found that no correlation exists between seizure duration , elevation of phenytoin serum levels and cerebellar volume .', {'entities': [(68, 75, 'B_Disease')]}], ['We conclude that phenytoin overdosage does not necessarily result in cerebellar atrophy and it is unlikely that phenytoin medication was the only cause of cerebellar atrophy in the remaining patients .', {'entities': [(27, 37, 'B_Disease'), (69, 79, 'B_Disease'), (80, 87, 'I_Disease'), (155, 165, 'B_Disease'), (166, 173, 'I_Disease')]}], ['Quantitative morphometric studies of the cerebellum provide valuable insights into the pathogenesis of cerebellar disorders .', {'entities': [(103, 113, 'B_Disease'), (114, 123, 'I_Disease')]}], ['Late recovery of renal function in a woman with the hemolytic uremic syndrome .', {'entities': [(52, 61, 'B_Disease'), (62, 68, 'I_Disease'), (69, 77, 'I_Disease')]}], ['A case is reported of the hemolytic uremic syndrome ( HUS ) in a woman taking oral contraceptives .', {'entities': [(26, 35, 'B_Disease'), (36, 42, 'I_Disease'), (43, 51, 'I_Disease'), (54, 57, 'B_Disease')]}], ['She was treated with heparin , dipyridamole and hemodialysis ; and after more than three months , her urinary output rose above 500 ml ; and six months after the onset of anuria , dialysis treatment was stopped .', {'entities': [(171, 177, 'B_Disease')]}], ['This case emphasizes the possibility that HUS in adults is not invariably irreversible and that , despite prolonged oliguria , recovery of renal function can be obtained .', {'entities': [(42, 45, 'B_Disease'), (116, 124, 'B_Disease')]}], ['Therefore , in adult patients affected by HUS , dialysis should not be discontinued prematurely ; moreover , bilateral nephrectomy , for treatment of severe hypertension and microangiopathic hemolytic anemia , should be performed with caution .', {'entities': [(42, 45, 'B_Disease'), (157, 169, 'B_Disease'), (174, 190, 'B_Disease'), (191, 200, 'I_Disease'), (201, 207, 'I_Disease')]}], ['Morphological features of encephalopathy after chronic administration of the antiepileptic drug valproate to rats .', {'entities': [(26, 40, 'B_Disease')]}], ['w . once daily to rats for 1 , 3 , 6 , 9 and 12 months revealed neurological disorders indicating cerebellum damage ( \" valproate encephalopathy \" ) .', {'entities': [(64, 76, 'B_Disease'), (77, 86, 'I_Disease'), (98, 108, 'B_Disease'), (109, 115, 'I_Disease'), (130, 144, 'B_Disease')]}], ['Lesions of the capillary included necrosis of endothelial cells .', {'entities': [(34, 42, 'B_Disease')]}], ['Fragments of necrotic endothelial cells were in the vascular lumens and in these there was loosening and breaking of tight cellular junctions .', {'entities': [(13, 21, 'B_Disease')]}], ['The possible influence of the hepatic damage , mainly hyperammonemia , upon the development of valproate encephalopathy is discussed .', {'entities': [(30, 37, 'B_Disease'), (38, 44, 'I_Disease'), (54, 68, 'B_Disease'), (105, 119, 'B_Disease')]}], ['Fatal intracranial bleeding associated with prehospital use of epinephrine .', {'entities': [(6, 18, 'B_Disease'), (19, 27, 'I_Disease')]}], ['We present a case of paramedic misjudgment in the execution of a protocol for the treatment of allergic reaction in a case of pulmonary edema with wheezing .', {'entities': [(95, 103, 'B_Disease'), (104, 112, 'I_Disease'), (126, 135, 'B_Disease'), (136, 141, 'I_Disease'), (147, 155, 'B_Disease')]}], ['The sudden onset of respiratory distress , rash , and a history of a new medicine led the two paramedics on the scene to administer subcutaneous epinephrine .', {'entities': [(20, 31, 'B_Disease'), (32, 40, 'I_Disease'), (43, 47, 'B_Disease')]}], ['Subsequently , acute cardiac arrest and fatal subarachnoid hemorrhage occurred .', {'entities': [(21, 28, 'B_Disease'), (29, 35, 'I_Disease'), (46, 58, 'B_Disease'), (59, 69, 'I_Disease')]}], ['Epinephrine has a proven role in cardiac arrest in prehospital care ; however , use by paramedics in patients with suspected allergic reaction and severe hypertension should be viewed with caution .', {'entities': [(33, 40, 'B_Disease'), (41, 47, 'I_Disease'), (125, 133, 'B_Disease'), (134, 142, 'I_Disease'), (154, 166, 'B_Disease')]}], ['Role of activation of bradykinin B2 receptors in disruption of the blood - brain barrier during acute hypertension .', {'entities': [(102, 114, 'B_Disease')]}], ['Cellular mechanisms which account for disruption the blood - brain barrier during acute hypertension are not clear .', {'entities': [(88, 100, 'B_Disease')]}], ['The goal of this study was to determine the role of synthesis / release of bradykinin to activate B2 receptors in disruption of the blood - brain barrier during acute hypertension .', {'entities': [(167, 179, 'B_Disease')]}], ['Permeability of the blood - brain barrier was quantitated by clearance of fluorescent - labeled dextran before and during phenylephrine - induced acute hypertension in rats treated with vehicle and Hoe - 140 ( 0 . 1 microM ) .', {'entities': [(152, 164, 'B_Disease')]}], ['These findings suggest that disruption of the blood - brain barrier during acute hypertension is not related to the synthesis / release of bradykinin to activate B2 receptors .', {'entities': [(81, 93, 'B_Disease')]}], ['Risk factors of sensorineural hearing loss in preterm infants .', {'entities': [(16, 29, 'B_Disease'), (30, 37, 'I_Disease'), (38, 42, 'I_Disease')]}], ['Among 547 preterm infants of < or = 34 weeks gestation born between 1987 and 1991 , 8 children ( 1 . 46 % ) developed severe progressive and bilateral sensorineural hearing loss .', {'entities': [(151, 164, 'B_Disease'), (165, 172, 'I_Disease'), (173, 177, 'I_Disease')]}], ['Perinatal risk factors of infants with hearing loss were compared with those of two control groups matched for gestation and birth weight and for perinatal complications .', {'entities': [(39, 46, 'B_Disease'), (47, 51, 'I_Disease')]}], ['Our observations demonstrated an association of hearing loss with a higher incidence of perinatal complications .', {'entities': [(48, 55, 'B_Disease'), (56, 60, 'I_Disease')]}], ['Ototoxicity appeared closely related to a prolonged administration and higher total dose of ototoxic drugs , particularly aminoglycosides and furosemide .', {'entities': [(0, 11, 'B_Disease'), (92, 100, 'B_Disease')]}], ['Finally , we strongly recommend to prospectively and regularly perform audiologic assessment in sick preterm children as hearing loss is of delayed onset and in most cases bilateral and severe .', {'entities': [(121, 128, 'B_Disease'), (129, 133, 'I_Disease')]}], ['Seizure resulting from a venlafaxine overdose .', {'entities': [(0, 7, 'B_Disease'), (37, 45, 'B_Disease')]}], ['OBJECTIVE : To report a case of venlafaxine overdose .', {'entities': [(44, 52, 'B_Disease')]}], ['CASE SUMMARY : A 40 - year - old woman with major depression took an overdose of venlafaxine in an apparent suicide attempt .', {'entities': [(44, 49, 'B_Disease'), (50, 60, 'I_Disease'), (69, 77, 'B_Disease')]}], ['After the ingestion of 26 venlafaxine 50 - mg tablets , the patient experienced a witnessed generalized seizure .', {'entities': [(104, 111, 'B_Disease')]}], ['DISCUSSION : To our knowledge , this is the first reported case of venlafaxine overdose that resulted in a generalized seizure .', {'entities': [(79, 87, 'B_Disease'), (119, 126, 'B_Disease')]}], ['CONCLUSIONS : The venlafaxine overdose in our patient resulted in a single episode of generalized seizure but elicited no further sequelae .', {'entities': [(30, 38, 'B_Disease'), (98, 105, 'B_Disease')]}], ['Combined effects of prolonged prostaglandin E1 - induced hypotension and haemodilution on human hepatic function .', {'entities': [(57, 68, 'B_Disease'), (73, 86, 'B_Disease')]}], ['Combined effects of prolonged prostaglandin E1 ( PGE1 ) - induced hypotension and haemodilution on hepatic function were studied in 30 patients undergoing hip surgery .', {'entities': [(66, 77, 'B_Disease'), (82, 95, 'B_Disease')]}], ['The patients were randomly allocated to one of three groups ; those in group A ( n = 10 ) were subjected to controlled hypotension alone , those in group B ( n = 10 ) to haemodilution alone and those in group C ( n = 10 ) to both controlled hypotension and haemodilution .', {'entities': [(119, 130, 'B_Disease'), (170, 183, 'B_Disease'), (241, 252, 'B_Disease'), (257, 270, 'B_Disease')]}], ['Haemodilution in groups B and C was produced by withdrawing approximately 1000 mL of blood and replacing it with the same amount of dextran solution , and final haematocrit values were 21 or 22 % .', {'entities': [(0, 13, 'B_Disease')]}], ['Controlled hypotension in groups A and C was induced with PGE1 to maintain mean arterial blood pressure at 55 mmHg for 180 min .', {'entities': [(11, 22, 'B_Disease')]}], ['In group C , AKBR showed a significant decrease at 120 min ( - 40 % ) and at 180 min ( - 49 % ) after the start of hypotension and at 60 min ( - 32 % ) after recovery of normotension , and SGOT , SGPT , LDH and total bilirubin showed significant increases after operation .', {'entities': [(115, 126, 'B_Disease')]}], ['The results suggest that a prolonged combination of more than 120 min of PGE1 - induced hypotension and moderate haemodilution would cause impairment of hepatic function .', {'entities': [(88, 99, 'B_Disease'), (113, 126, 'B_Disease'), (139, 149, 'B_Disease'), (150, 152, 'I_Disease'), (153, 160, 'I_Disease'), (161, 169, 'I_Disease')]}], ['Cardiovascular alterations in rat fetuses exposed to calcium channel blockers .', {'entities': [(0, 14, 'B_Disease'), (15, 26, 'I_Disease')]}], ['Preclinical toxicologic investigation suggested that a new calcium channel blocker , Ro 40 - 5967 , induced cardiovascular alterations in rat fetuses exposed to this agent during organogenesis .', {'entities': [(108, 122, 'B_Disease'), (123, 134, 'I_Disease')]}], ['The present study was designed to investigate the hypothesis that calcium channel blockers in general induce cardiovascular malformations indicating a pharmacologic class effect .', {'entities': [(109, 123, 'B_Disease'), (124, 137, 'I_Disease')]}], ['Pregnant rats were administered one of these calcium channel blockers during the period of cardiac morphogenesis and the offspring examined on day 20 of gestation for cardiovascular malformations .', {'entities': [(167, 181, 'B_Disease'), (182, 195, 'I_Disease')]}], ['A low incidence of cardiovascular malformations was observed after exposure to each of the four calcium channel blockers , but this incidence was statistically significant only for verapamil and nifedipine .', {'entities': [(19, 33, 'B_Disease'), (34, 47, 'I_Disease')]}], ['Atypical sensations following the use of subcutaneous sumatriptan are common , but of uncertain origin .', {'entities': [(0, 8, 'B_Disease'), (9, 19, 'I_Disease')]}], ['Two patients are presented with tingling or burning sensations limited to areas of heat exposure or sunburn .', {'entities': [(32, 40, 'B_Disease'), (41, 43, 'I_Disease'), (44, 51, 'I_Disease'), (52, 62, 'I_Disease'), (100, 107, 'B_Disease')]}], ['Macula toxicity after intravitreal amikacin .', {'entities': [(7, 15, 'B_Disease')]}], ['BACKGROUND : Although intravitreal aminoglycosides have substantially improved visual prognosis in endophthalmitis , macular infarction may impair full visual recovery .', {'entities': [(99, 114, 'B_Disease'), (125, 135, 'B_Disease')]}], ['METHODS : We present a case of presumed amikacin retinal toxicity following treatment with amikacin and vancomycin for alpha - haemolytic streptococcal endophthalmitis .', {'entities': [(49, 56, 'B_Disease'), (57, 65, 'I_Disease'), (138, 151, 'B_Disease'), (152, 167, 'I_Disease')]}], ['RESULTS : Endophthalmitis resolved with improvement in visual acuity to 6 / 24 at three months .', {'entities': [(10, 25, 'B_Disease')]}], ['Fundus fluorescein angiography confirmed macular capillary closure and telangiectasis .', {'entities': [(71, 85, 'B_Disease')]}], ['CONCLUSIONS : Currently accepted intravitreal antibiotic regimens may cause retinal toxicity and macular ischaemia .', {'entities': [(76, 83, 'B_Disease'), (84, 92, 'I_Disease'), (105, 114, 'B_Disease')]}], ['Treatment strategies aimed at avoiding retinal toxicity are discussed .', {'entities': [(39, 46, 'B_Disease'), (47, 55, 'I_Disease')]}], ['The role of nicotine in smoking - related cardiovascular disease .', {'entities': [(42, 56, 'B_Disease'), (57, 64, 'I_Disease')]}], ['Nicotine activates the sympathetic nervous system and in this way could contribute to cardiovascular disease .', {'entities': [(86, 100, 'B_Disease'), (101, 108, 'I_Disease')]}], ['Animal studies and mechanistic studies indicate that nicotine could play a role in accelerating atherosclerosis , but evidence among humans is too inadequate to be definitive about such an effect .', {'entities': [(96, 111, 'B_Disease')]}], ['Nicotine does not appear to enhance thrombosis among humans .', {'entities': [(36, 46, 'B_Disease')]}], ['Iatrogenically induced intractable atrioventricular reentrant tachycardia after verapamil and catheter ablation in a patient with Wolff - Parkinson - White syndrome and idiopathic dilated cardiomyopathy .', {'entities': [(35, 51, 'B_Disease'), (52, 61, 'I_Disease'), (62, 73, 'I_Disease'), (130, 135, 'B_Disease'), (136, 137, 'I_Disease'), (138, 147, 'I_Disease'), (148, 149, 'I_Disease'), (150, 155, 'I_Disease'), (156, 164, 'I_Disease'), (169, 179, 'B_Disease'), (180, 187, 'I_Disease'), (188, 202, 'I_Disease')]}], ['In a patient with WPW syndrome and idiopathic dilated cardiomyopathy , intractable atrioventricular reentrant tachycardia ( AVRT ) was iatrogenically induced .', {'entities': [(18, 21, 'B_Disease'), (22, 30, 'I_Disease'), (35, 45, 'B_Disease'), (46, 53, 'I_Disease'), (54, 68, 'I_Disease'), (83, 99, 'B_Disease'), (100, 109, 'I_Disease'), (110, 121, 'I_Disease'), (124, 128, 'B_Disease')]}], ['QRS without preexcitation , caused by junctional escape beats after verapamil or unidirectional antegrade block of accessory pathway after catheter ablation , established frequent AVRT attack .', {'entities': [(180, 184, 'B_Disease')]}], ['Epidemic of liver disease caused by hydrochlorofluorocarbons used as ozone - sparing substitutes of chlorofluorocarbons .', {'entities': [(12, 17, 'B_Disease'), (18, 25, 'I_Disease')]}], ['Limited studies in animals indicate potential hepatotoxicity of some of these compounds .', {'entities': [(46, 60, 'B_Disease')]}], ['We investigated an epidemic of liver disease in nine industrial workers who had had repeated accidental exposure to a mixture of 1 , 1 - dichloro - 2 , 2 , 2 - trifluoroethane ( HCFC 123 ) and 1 - chloro - 1 , 2 , 2 , 2 - tetrafluoroethane ( HCFC 124 ) .', {'entities': [(31, 36, 'B_Disease'), (37, 44, 'I_Disease')]}], ['Both compounds are metabolised in the same way as 1 - bromo - 1 - chloro - 2 , 2 , 2 - trifluoroethane ( halothane ) to form reactive trifluoroacetyl halide intermediates , which have been implicated in the hepatotoxicity of halothane .', {'entities': [(207, 221, 'B_Disease')]}], ['We aimed to test whether HCFCs 123 and 124 can result in serious liver disease .', {'entities': [(65, 70, 'B_Disease'), (71, 78, 'I_Disease')]}], ['FINDINGS : The liver biopsy sample showed hepatocellular necrosis which was prominent in perivenular zone three and extended focally from portal tracts to portal tracts and centrilobular areas ( bridging necrosis ) .', {'entities': [(57, 65, 'B_Disease'), (204, 212, 'B_Disease')]}], ['Autoantibodies against P450 2E1 or P58 , previously associated with halothane hepatitis , were detected in the serum of five affected workers .', {'entities': [(68, 77, 'B_Disease'), (78, 87, 'I_Disease')]}], ['INTERPRETATION : Repeated exposure of human beings to HCFCs 123 and 124 can result in serious liver injury in a large proportion of the exposed population .', {'entities': [(94, 99, 'B_Disease'), (100, 106, 'I_Disease')]}], ['Although the exact mechanism of hepatotoxicity of these agents is not known , the results suggest that trifluoroacetyl - altered liver proteins are involved .', {'entities': [(32, 46, 'B_Disease')]}], ['Bile duct hamartoma occurring in association with long - term treatment with danazol .', {'entities': [(0, 4, 'B_Disease'), (5, 9, 'I_Disease'), (10, 19, 'I_Disease')]}], ['We report a case of bile duct hamartoma which developed in a patient who had been on long - term danazol treatment .', {'entities': [(20, 24, 'B_Disease'), (25, 29, 'I_Disease'), (30, 39, 'I_Disease')]}], ['If the patient develops a liver mass , because of non - specific clinical features and imaging appearances , biopsy may be the only way to achieve a definitive diagnosis .', {'entities': [(26, 31, 'B_Disease'), (32, 36, 'I_Disease')]}], ['Endocrine screening in 1 , 022 men with erectile dysfunction : clinical significance and cost - effective strategy .', {'entities': [(40, 48, 'B_Disease'), (49, 60, 'I_Disease')]}], ['PURPOSE : We reviewed the results of serum testosterone and prolactin determination in 1 , 022 patients referred because of erectile dysfunction and compared the data with history , results of physical examination , other etiological investigations and effects of endocrine therapy to refine the rules of cost - effective endocrine screening and to pinpoint actual responsibility for hormonal abnormalities .', {'entities': [(124, 132, 'B_Disease'), (133, 144, 'I_Disease')]}], ['Every patient was screened for testosterone and 451 were screened for prolactin on the basis of low sexual desire , gynecomastia or testosterone less than 4 ng . / ml .', {'entities': [(96, 99, 'B_Disease'), (100, 106, 'I_Disease'), (107, 113, 'I_Disease'), (116, 128, 'B_Disease')]}], ['Prolactin results were compared with those of a previous personal cohort of 1 , 340 patients with erectile dysfunction and systematic prolactin determination .', {'entities': [(98, 106, 'B_Disease'), (107, 118, 'I_Disease')]}], ['Main clinical criteria tested regarding efficiency in hormone determination were low sexual desire , small testes and gynecomastia .', {'entities': [(81, 84, 'B_Disease'), (85, 91, 'I_Disease'), (92, 98, 'I_Disease'), (118, 130, 'B_Disease')]}], ['Endocrine therapy consisted of testosterone heptylate or human chorionic gonadotropin for hypogonadism and bromocriptine for hyperprolactinemia .', {'entities': [(90, 102, 'B_Disease'), (125, 143, 'B_Disease')]}], ['Two pituitary tumors were discovered after testosterone determination .', {'entities': [(4, 13, 'B_Disease'), (14, 20, 'I_Disease')]}], ['Most of the other low testosterone levels seemed to result from nonorganic hypothalamic dysfunction because of normal serum luteinizing hormone and prolactin and to have only a small role in erectile dysfunction ( definite improvement in only 16 of 44 [ 36 % ] after androgen therapy , normal morning or nocturnal erections in 30 % and definite vasculogenic contributions in 42 % ) .', {'entities': [(75, 87, 'B_Disease'), (88, 99, 'I_Disease'), (191, 199, 'B_Disease'), (200, 211, 'I_Disease')]}], ['Determining testosterone only in cases of low sexual desire or abnormal physical examination would have missed 40 % of the cases with low testosterone , including 37 % of those subsequently improved by androgen therapy .', {'entities': [(42, 45, 'B_Disease'), (46, 52, 'I_Disease'), (53, 59, 'I_Disease')]}], ['Only 1 prolactinoma was discovered .', {'entities': [(7, 19, 'B_Disease')]}], ['These data are lower than those we found during the last 2 decades ( overall prolactin greater than 20 ng . / ml . in 1 . 86 % of 1 , 821 patients , prolactinomas in 7 , 0 . 38 % ) .', {'entities': [(149, 162, 'B_Disease')]}], ['CONCLUSIONS : Low prevalences and effects of low testosterone and high prolactin in erectile dysfunction cannot justify their routine determination .', {'entities': [(84, 92, 'B_Disease'), (93, 104, 'I_Disease')]}], ['However , cost - effective screening strategies recommended so far missed 40 to 50 % of cases improved with endocrine therapy and the pituitary tumors .', {'entities': [(134, 143, 'B_Disease'), (144, 150, 'I_Disease')]}], ['We now advocate that before age 50 years testosterone be determined only in cases of low sexual desire and abnormal physical examination but that it be measured in all men older than 50 years .', {'entities': [(85, 88, 'B_Disease'), (89, 95, 'I_Disease'), (96, 102, 'I_Disease')]}], ['Prolactin should be determined only in cases of low sexual desire , gynecomastia and / or testosterone less than 4 ng . / ml .', {'entities': [(48, 51, 'B_Disease'), (52, 58, 'I_Disease'), (59, 65, 'I_Disease'), (68, 80, 'B_Disease')]}], [\"Previous clinical studies have proposed that risperidone ' s pharmacologic profile may produce improved efficacy for negative psychotic symptoms and decreased propensity for extrapyramidal side effects ; features shared by so - called ' atypical ' neuroleptics .\", {'entities': [(126, 135, 'B_Disease'), (136, 144, 'I_Disease')]}], ['Drug - induced parkinsonism was observed in subjects treated with risperidone ( 42 % ) and haloperidol ( 29 % ) and was observed at occupancy levels above 60 % .', {'entities': [(0, 4, 'B_Disease'), (5, 6, 'I_Disease'), (7, 14, 'I_Disease'), (15, 27, 'I_Disease')]}], ['Treatment of previously treated metastatic breast cancer by mitoxantrone and 48 - hour continuous infusion of high - dose 5 - FU and leucovorin ( MFL ) : low palliative benefit and high treatment - related toxicity .', {'entities': [(43, 49, 'B_Disease'), (50, 56, 'I_Disease'), (206, 214, 'B_Disease')]}], ['For previously treated advanced breast cancer , there is no standard second - line therapy .', {'entities': [(32, 38, 'B_Disease'), (39, 45, 'I_Disease')]}], ['From October 1993 to November 1995 , we treated 13 patients with previously chemotherapy - treated metastatic breast cancer by mitoxantrone , 12 mg / m2 , on day 1 and continuous infusion of 5 - FU , 3000 mg / m2 , together with leucovorin , 300 mg / m2 , for 48 h from day 1 to 2 .', {'entities': [(110, 116, 'B_Disease'), (117, 123, 'I_Disease')]}], ['Major toxicities were cardiotoxicity and leukopenia .', {'entities': [(6, 16, 'B_Disease'), (22, 36, 'B_Disease'), (41, 51, 'B_Disease')]}], ['Eight patients were dead in the last follow - up ; two of them died of treatment - related toxicity .', {'entities': [(91, 99, 'B_Disease')]}], ['The MFL regimen achieves little palliative benefit and induces severe toxicity at a fairly high rate .', {'entities': [(70, 78, 'B_Disease')]}], ['Administration of this regimen to breast cancer patients who have been treated by chemotherapy and those with impaired heart function requires careful attention .', {'entities': [(34, 40, 'B_Disease'), (41, 47, 'I_Disease'), (110, 118, 'B_Disease'), (119, 124, 'I_Disease'), (125, 133, 'I_Disease')]}], ['Ticlopidine - induced aplastic anemia : report of three Chinese patients and review of the literature .', {'entities': [(22, 30, 'B_Disease'), (31, 37, 'I_Disease')]}], ['In this study , three Chinese patients with ticlopidine - induced aplastic anemia were reported and another 13 patients in the English literature were reviewed .', {'entities': [(66, 74, 'B_Disease'), (75, 81, 'I_Disease')]}], ['Agranulocytosis occurred 3 - 20 weeks after initiation of ticlopidine , so frequent examination of white cell count during treatment is recommended .', {'entities': [(0, 15, 'B_Disease')]}], ['There seemed to be no direct correlation between the dose or duration used and the severity of bone marrow suppression .', {'entities': [(95, 99, 'B_Disease'), (100, 106, 'I_Disease'), (107, 118, 'I_Disease')]}], ['Treatment for ticlopidine - induced aplastic anemia with colony - stimulating factors seemed to have little effect .', {'entities': [(36, 44, 'B_Disease'), (45, 51, 'I_Disease')]}], ['Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium - induced diabetes insipidus rat .', {'entities': [(121, 129, 'B_Disease'), (130, 139, 'I_Disease')]}], ['The expression of arginine vasopressin ( AVP ) gene in the paraventricular ( PVN ) and supraoptic nuclei ( SON ) was investigated in rats with lithium ( Li ) - induced polyuria , using in situ hybridization histochemistry and radioimmunoassay .', {'entities': [(168, 176, 'B_Disease')]}], ['The male Wistar rats consuming a diet that contained LiCl ( 60 mmol / kg ) for 4 weeks developed marked polyuria .', {'entities': [(104, 112, 'B_Disease')]}], ['These results suggest that dehydration and / or the activation of visceral afferent inputs may contribute to the elevation of plasma AVP and the upregulation of AVP gene expression in the PVN and the SON of the Li - induced diabetes insipidus rat .', {'entities': [(27, 38, 'B_Disease'), (224, 232, 'B_Disease'), (233, 242, 'I_Disease')]}], ['( + / - ) - PG - 9 ( 10 - 40 mg kg - 1 i . p . ) was able to prevent amnesia induced by scopolamine ( 1 mg kg - 1 i . p . ) and dicyclomine ( 2 mg kg - 1 i . p . ) in the mouse passive - avoidance test .', {'entities': [(69, 76, 'B_Disease')]}], ['Affinity profiles of ( + / - ) - PG - 9 for muscarinic receptor subtypes , determined by functional studies ( rabbit vas deferens for M1 , guinea pig atrium for M2 , guinea pig ileum for M3 and immature guinea pig uterus for putative M4 ) , have shown an M4 / M1 selectivity ratio of 10 . 2 that might be responsible for the antinociception and the anti - amnesic effect induced by ( + / - ) - PG - 9 through an increase in acetylcholine extracellular levels .', {'entities': [(356, 363, 'B_Disease')]}], ['The effect of different anaesthetic agents in hearing loss following spinal anaesthesia .', {'entities': [(46, 53, 'B_Disease'), (54, 58, 'I_Disease')]}], ['The cause of hearing loss after spinal anaesthesia is unknown .', {'entities': [(13, 20, 'B_Disease'), (21, 25, 'I_Disease')]}], ['Up until now , the only factor studied has been the effect of the diameter of the spinal needle on post - operative sensorineural hearing loss .', {'entities': [(116, 129, 'B_Disease'), (130, 137, 'I_Disease'), (138, 142, 'I_Disease')]}], ['The aim of this study was to describe this hearing loss and to investigate other factors influencing the degree of hearing loss .', {'entities': [(43, 50, 'B_Disease'), (51, 55, 'I_Disease'), (115, 122, 'B_Disease'), (123, 127, 'I_Disease')]}], ['Patients given prilocaine were more likely to develop hearing loss ( 10 out of 22 ) than those given bupivacaine ( 4 out of 22 ) ( P < 0 . 05 ) .', {'entities': [(54, 61, 'B_Disease'), (62, 66, 'I_Disease')]}], ['The average hearing loss for speech frequencies was about 10 dB after prilocaine and 15 dB after bupivacaine .', {'entities': [(12, 19, 'B_Disease'), (20, 24, 'I_Disease')]}], ['None of the patients complained of subjective hearing loss .', {'entities': [(46, 53, 'B_Disease'), (54, 58, 'I_Disease')]}], ['A transient neurological deficit following intrathecal injection of 1 % hyperbaric bupivacaine for unilateral spinal anaesthesia .', {'entities': [(12, 24, 'B_Disease'), (25, 32, 'I_Disease')]}], ['We describe a case of transient neurological deficit that occurred after unilateral spinal anaesthesia with 8 mg of 1 % hyperbaric bupivacaine slowly injected through a 25 - gauge pencil - point spinal needle .', {'entities': [(32, 44, 'B_Disease'), (45, 52, 'I_Disease')]}], ['The surgery and anaesthesia were uneventful , but 3 days after surgery , the patient reported an area of hypoaesthesia over L3 - L4 dermatomes of the leg which had been operated on ( loss of pinprick sensation ) without reduction in muscular strength .', {'entities': [(183, 187, 'B_Disease'), (188, 190, 'I_Disease'), (191, 199, 'I_Disease'), (200, 209, 'I_Disease')]}], ['However , we suggest that a low solution concentration should be preferred for unilateral spinal anaesthesia with a hyperbaric anaesthetic solution ( if pencil - point needle and slow injection rate are employed ) , in order to minimize the risk of a localized high peak anaesthetic concentration , which might lead to a transient neurological deficit .', {'entities': [(331, 343, 'B_Disease'), (344, 351, 'I_Disease')]}], ['Transient neurologic symptoms after spinal anesthesia : a lower incidence with prilocaine and bupivacaine than with lidocaine .', {'entities': [(0, 9, 'B_Disease'), (10, 20, 'I_Disease'), (21, 29, 'I_Disease')]}], ['BACKGROUND : Recent evidence suggests that transient neurologic symptoms ( TNSs ) frequently follow lidocaine spinal anesthesia but are infrequent with bupivacaine .', {'entities': [(43, 52, 'B_Disease'), (53, 63, 'I_Disease'), (64, 72, 'I_Disease'), (75, 79, 'B_Disease')]}], ['Accordingly , the present , prospective double - blind study compares prilocaine with lidocaine and bupivacaine with respect to duration of action and relative risk of TNSs .', {'entities': [(168, 172, 'B_Disease')]}], ['In the evening of postoperative day 1 , patients were evaluated for TNSs by a physician unaware of the drug administered and the details of the anesthetic procedure .', {'entities': [(68, 72, 'B_Disease')]}], ['RESULTS : Nine of 30 patients receiving lidocaine experienced TNSs , 1 of 30 patients receiving prilocaine ( P = 0 . 03 ) had them , and none of 30 patients receiving bupivacaine had TNSs .', {'entities': [(62, 66, 'B_Disease'), (183, 187, 'B_Disease')]}], ['CONCLUSIONS : Prilocaine may be preferable to lidocaine for short surgical procedures because it has a similar duration of action but a lower incidence of TNSs .', {'entities': [(155, 159, 'B_Disease')]}], ['Suxamethonium - induced cardiac arrest and death following 5 days of immobilization .', {'entities': [(24, 31, 'B_Disease'), (32, 38, 'I_Disease'), (43, 48, 'B_Disease')]}], ['The present report describes a case of cardiac arrest and subsequent death as a result of hyperkalaemia following the use of suxamethonium in a 23 - year - old Malawian woman .', {'entities': [(39, 46, 'B_Disease'), (47, 53, 'I_Disease'), (69, 74, 'B_Disease'), (90, 103, 'B_Disease')]}], ['Five days after the onset of the symptoms of meningitis , the patient aspirated stomach contents and needed endotracheal intubation .', {'entities': [(45, 55, 'B_Disease')]}], ['Forty seconds after injection of suxamethonium , bradycardia and cardiac arrest occurred .', {'entities': [(49, 60, 'B_Disease'), (65, 72, 'B_Disease'), (73, 79, 'I_Disease')]}], [\"Apart from the reduction in the patient ' s level of consciousness , there were no signs of motor neurone damage or of any of the other known predisposing conditions for hyperkalaemia following the administration of suxamethonium .\", {'entities': [(170, 183, 'B_Disease')]}], ['It is postulated that her death was caused by hypersensitivity to suxamethonium , associated with her 5 - day immobilization .', {'entities': [(26, 31, 'B_Disease'), (46, 62, 'B_Disease')]}], ['Acute hepatitis , autoimmune hemolytic anemia , and erythroblastocytopenia induced by ceftriaxone .', {'entities': [(6, 15, 'B_Disease'), (18, 28, 'B_Disease'), (29, 38, 'I_Disease'), (39, 45, 'I_Disease'), (52, 74, 'B_Disease')]}], ['An 80 - yr - old man developed acute hepatitis shortly after ingesting oral ceftriaxone .', {'entities': [(37, 46, 'B_Disease')]}], ['Although the transaminases gradually returned to baseline after withholding the beta lactam antibiotic , there was a gradual increase in serum bilirubin and a decrease in hemoglobin concentration caused by an autoimmune hemolytic anemia and erythroblastocytopenia .', {'entities': [(209, 219, 'B_Disease'), (220, 229, 'I_Disease'), (230, 236, 'I_Disease'), (241, 263, 'B_Disease')]}], ['Thyroxine abuse : an unusual case of thyrotoxicosis in pregnancy .', {'entities': [(37, 51, 'B_Disease')]}], ['Eating disorders and the associated behavioural problems and drug abuse are uncommon in pregnancy .', {'entities': [(0, 6, 'B_Disease'), (7, 16, 'I_Disease'), (61, 65, 'B_Disease'), (66, 71, 'I_Disease')]}], ['This case illustrates a number of problems that may be encountered in women with eating disorders in pregnancy , including prolonged and recurrent metabolic disturbances and diuretic abuse .', {'entities': [(81, 87, 'B_Disease'), (88, 97, 'I_Disease')]}], ['In particular it illustrates the derangements of thyroid function seen in pregnant women with eating disorders and reminds us that when a cause for thyrotoxicosis remains obscure , thyroxine abuse should be considered and explored .', {'entities': [(94, 100, 'B_Disease'), (101, 110, 'I_Disease'), (148, 162, 'B_Disease')]}], ['In the acute experiment TRI ( given i . p . ) does not antagonize the reserpine hypothermia in mice and does not potentiate the 5 - hydroxytryptophan head twitches in rats .', {'entities': [(80, 91, 'B_Disease')]}], ['TRI given repeatedly to rats increases the locomotor hyperactivity induced by d - amphetamine , quinpirole and ( + ) - 7 - hydroxy - dipropyloaminotetralin ( dopamine D2 and D3 effects ) .', {'entities': [(53, 66, 'B_Disease')]}], ['It increases the behaviour stimulation evoked by phenylephrine ( given intraventricularly ) in rats , evaluated in the open field test as well as the aggressiveness evoked by clonidine in mice , both these effects being mediated by an alpha1 - adrenergic receptor .', {'entities': [(150, 164, 'B_Disease')]}], ['Pethidine - associated seizure in a healthy adolescent receiving pethidine for postoperative pain control .', {'entities': [(23, 30, 'B_Disease'), (79, 92, 'B_Disease'), (93, 97, 'I_Disease')]}], ['A healthy 17 - year - old male received standard intermittent doses of pethidine via a patient - controlled analgesia ( PCA ) pump for management of postoperative pain control .', {'entities': [(149, 162, 'B_Disease'), (163, 167, 'I_Disease')]}], ['Twenty - three h postoperatively he developed a brief self - limited seizure .', {'entities': [(69, 76, 'B_Disease')]}], ['No other risk factors for CNS toxicity were identified .', {'entities': [(30, 38, 'B_Disease')]}], [\"An increase in blood pressure , accompanied by atrial fibrillation , agitation , incomprehensible shouts and loss of consciousness , was observed in an elderly , ASA classification group II , cardiovascularly medicated male , 12 min after performance of axillary block with mepivacaine 850 mg containing adrenaline 0 . 225 mg , for correction of Dupuytren ' s contracture .\", {'entities': [(3, 11, 'B_Disease'), (12, 14, 'I_Disease'), (15, 20, 'I_Disease'), (21, 29, 'I_Disease'), (47, 53, 'B_Disease'), (54, 66, 'I_Disease'), (69, 78, 'B_Disease'), (81, 97, 'B_Disease'), (98, 104, 'I_Disease'), (109, 113, 'B_Disease'), (114, 116, 'I_Disease'), (117, 130, 'I_Disease'), (346, 355, 'B_Disease'), (356, 357, 'I_Disease'), (358, 359, 'I_Disease'), (360, 371, 'I_Disease')]}], ['The block was successful and surgery was conducted as scheduled despite persisting atrial fibrillation .', {'entities': [(83, 89, 'B_Disease'), (90, 102, 'I_Disease')]}], ['Drug - associated acute - onset vanishing bile duct and Stevens - Johnson syndromes in a child .', {'entities': [(32, 41, 'B_Disease'), (42, 46, 'I_Disease'), (47, 51, 'I_Disease'), (56, 63, 'B_Disease'), (64, 65, 'I_Disease'), (66, 73, 'I_Disease'), (74, 83, 'I_Disease')]}], ['Acute vanishing bile duct syndrome is a rare but established cause of progressive cholestasis in adults , is most often drug or toxin related , and is of unknown pathogenesis .', {'entities': [(6, 15, 'B_Disease'), (16, 20, 'I_Disease'), (21, 25, 'I_Disease'), (82, 93, 'B_Disease')]}], ['Stevens - Johnson syndrome is a well - recognized immune complex - mediated hypersensitivity reaction that affects all age groups , is drug or infection induced , and has classic systemic , mucosal , and dermatologic manifestations .', {'entities': [(0, 7, 'B_Disease'), (8, 9, 'I_Disease'), (10, 17, 'I_Disease'), (18, 26, 'I_Disease'), (76, 92, 'B_Disease'), (143, 152, 'B_Disease')]}], ['A previously healthy child who developed acute , severe , rapidly progressive vanishing bile duct syndrome shortly after Stevens - Johnson syndrome is described ; this was temporally associated with ibuprofen use .', {'entities': [(78, 87, 'B_Disease'), (88, 92, 'I_Disease'), (93, 97, 'I_Disease'), (98, 106, 'I_Disease'), (121, 128, 'B_Disease'), (129, 130, 'I_Disease'), (131, 138, 'I_Disease'), (139, 147, 'I_Disease')]}], ['Despite therapy with ursodeoxycholic acid , prednisone , and then tacrolimus , her cholestatic disease was unrelenting , with cirrhosis shown by biopsy 6 months after presentation .', {'entities': [(83, 94, 'B_Disease'), (95, 102, 'I_Disease'), (126, 135, 'B_Disease')]}], ['This case documents acute drug - related vanishing bile duct syndrome in the pediatric age group and suggests shared immune mechanisms in the pathogenesis of both Stevens - Johnson syndrome and vanishing bile duct syndrome .', {'entities': [(41, 50, 'B_Disease'), (51, 55, 'I_Disease'), (56, 60, 'I_Disease'), (61, 69, 'I_Disease'), (163, 170, 'B_Disease'), (171, 172, 'I_Disease'), (173, 180, 'I_Disease'), (181, 189, 'I_Disease'), (194, 203, 'B_Disease'), (204, 208, 'I_Disease'), (209, 213, 'I_Disease'), (214, 222, 'I_Disease')]}], ['High incidence of primary pulmonary hypertension associated with appetite suppressants in Belgium .', {'entities': [(18, 25, 'B_Disease'), (26, 35, 'I_Disease'), (36, 48, 'I_Disease')]}], ['Primary pulmonary hypertension is a rare , progressive and incurable disease , which has been associated with the intake of appetite suppressant drugs .', {'entities': [(0, 7, 'B_Disease'), (8, 17, 'I_Disease'), (18, 30, 'I_Disease')]}], ['Thirty - five patients with primary pulmonary hypertension and 85 matched controls were recruited over 32 months ( 1992 - 1994 ) in Belgium .', {'entities': [(28, 35, 'B_Disease'), (36, 45, 'I_Disease'), (46, 58, 'I_Disease')]}], ['In 8 patients the diagnosis of primary pulmonary hypertension was uncertain , 5 of them had taken appetite suppressants .', {'entities': [(31, 38, 'B_Disease'), (39, 48, 'I_Disease'), (49, 61, 'I_Disease')]}], ['A policy of unrestricted prescription of appetite suppressants may lead to a high incidence of associated primary pulmonary hypertension .', {'entities': [(106, 113, 'B_Disease'), (114, 123, 'I_Disease'), (124, 136, 'I_Disease')]}], ['Inappropriate use of carbamazepine and vigabatrin in typical absence seizures .', {'entities': [(61, 68, 'B_Disease'), (69, 77, 'I_Disease')]}], ['Carbamazepine and vigabatrin are contraindicated in typical absence seizures .', {'entities': [(60, 67, 'B_Disease'), (68, 76, 'I_Disease')]}], ['Frequency of absences increased in four children treated with carbamazepine and two of these developed myoclonic jerks , which resolved on withdrawal of carbamazepine .', {'entities': [(103, 112, 'B_Disease'), (113, 118, 'I_Disease')]}], ['Choreoathetoid movements associated with rapid adjustment to methadone .', {'entities': [(0, 14, 'B_Disease'), (15, 24, 'I_Disease')]}], ['Choreatiform hyperkinesias are known to be occasional movement abnormalities during intoxications with cocaine but not opiates .', {'entities': [(0, 12, 'B_Disease'), (13, 26, 'I_Disease'), (54, 62, 'B_Disease'), (63, 76, 'I_Disease')]}], ['This is a case report of euphoria and choreoathetoid movements both transiently induced by rapid adjustment to the selective mu - opioid receptor agonist methadone in an inpatient previously abusing heroine and cocaine .', {'entities': [(38, 52, 'B_Disease'), (53, 62, 'I_Disease')]}], ['Conventional agents are associated with unwanted central nervous system effects , including extrapyramidal symptoms ( EPS ) , tardive dyskinesia , sedation , and possible impairment of some cognitive measures , as well as cardiac effects , orthostatic hypotension , hepatic changes , anticholinergic side effects , sexual dysfunction , and weight gain .', {'entities': [(92, 106, 'B_Disease'), (107, 115, 'I_Disease'), (118, 121, 'B_Disease'), (126, 133, 'B_Disease'), (134, 144, 'I_Disease'), (240, 251, 'B_Disease'), (252, 263, 'I_Disease'), (315, 321, 'B_Disease'), (322, 333, 'I_Disease'), (340, 346, 'B_Disease'), (347, 351, 'I_Disease')]}], ['The newer atypical agents have a lower risk of EPS , but are associated in varying degrees with sedation , cardiovascular effects , anticholinergic effects , weight gain , sexual dysfunction , hepatic effects , lowered seizure threshold ( primarily clozapine ) , and agranulocytosis ( clozapine only ) .', {'entities': [(47, 50, 'B_Disease'), (158, 164, 'B_Disease'), (165, 169, 'I_Disease'), (172, 178, 'B_Disease'), (179, 190, 'I_Disease'), (219, 226, 'B_Disease'), (267, 282, 'B_Disease')]}], [\"A randomized , placebo - controlled dose - comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer ' s disease .\", {'entities': [(79, 88, 'B_Disease'), (93, 103, 'B_Disease'), (104, 113, 'I_Disease'), (117, 126, 'B_Disease'), (127, 128, 'I_Disease'), (129, 130, 'I_Disease'), (131, 138, 'I_Disease')]}], [\"OBJECTIVE : The goal of this study was to compare the efficacy and side effects of two doses of haloperidol and placebo in the treatment of psychosis and disruptive behaviors in patients with Alzheimer ' s disease .\", {'entities': [(140, 149, 'B_Disease'), (154, 164, 'B_Disease'), (165, 174, 'I_Disease'), (192, 201, 'B_Disease'), (202, 203, 'I_Disease'), (204, 205, 'I_Disease'), (206, 213, 'I_Disease')]}], [\"METHOD : In a 6 - week random - assignment , double - blind , placebo - controlled trial ( phase A ) , haloperidol , 2 - 3 mg / day ( standard dose ) , and haloperidol , 0 . 50 - 0 . 75 mg / day ( low dose ) , were compared in 71 outpatients with Alzheimer ' s disease .\", {'entities': [(247, 256, 'B_Disease'), (257, 258, 'I_Disease'), (259, 260, 'I_Disease'), (261, 268, 'I_Disease')]}], ['RESULTS : For the 60 patients who completed phase A , standard - dose haloperidol was efficacious and superior to both low - dose haloperidol and placebo for scores on the Brief Psychiatric Rating Scale psychosis factor and on psychomotor agitation .', {'entities': [(203, 212, 'B_Disease'), (227, 238, 'B_Disease'), (239, 248, 'I_Disease')]}], ['In phase A , extrapyramidal signs tended to be greater with the standard dose than in the other two conditions , primarily because of a subgroup ( 20 % ) who developed moderate to severe signs .', {'entities': [(13, 27, 'B_Disease'), (28, 33, 'I_Disease')]}], ['CONCLUSIONS : The results indicated a favorable therapeutic profile for haloperidol in doses of 2 - 3 mg / day , although a subgroup developed moderate to severe extrapyramidal signs .', {'entities': [(162, 176, 'B_Disease'), (177, 182, 'I_Disease')]}], [\"The narrow therapeutic window observed with haloperidol may also apply to other neuroleptics used in Alzheimer ' s disease patients with psychosis and disruptive behaviors .\", {'entities': [(101, 110, 'B_Disease'), (111, 112, 'I_Disease'), (113, 114, 'I_Disease'), (115, 122, 'I_Disease'), (137, 146, 'B_Disease'), (151, 161, 'B_Disease'), (162, 171, 'I_Disease')]}], ['Effects of acetylsalicylic acid , dipyridamole , and hydrocortisone on epinephrine - induced myocardial injury in dogs .', {'entities': [(93, 103, 'B_Disease'), (104, 110, 'I_Disease')]}], ['A reproducible model for producing diffuse myocardial injury ( epinephrine infusion ) has been developed to study the cardioprotective effects of agents or maneuvers which might alter the evolution of acute myocardial infarction .', {'entities': [(43, 53, 'B_Disease'), (54, 60, 'I_Disease'), (207, 217, 'B_Disease'), (218, 228, 'I_Disease')]}], ['RESULTS : The main pathologic diagnoses ( some overlap ) were acute rejection ( AR ; n = 4 ) , chronic rejection ( CR ; n = 5 ) , AR + CR ( n = 4 ) , recurrent IgA nephropathy ( n = 5 ) , normal findings ( n = 2 ) , minimal - type chronic FK506 nephropathy ( n = 9 ) , and mild - type FK506 nephropathy ( n = 11 ) .', {'entities': [(160, 163, 'B_Disease'), (164, 175, 'I_Disease'), (245, 256, 'B_Disease'), (291, 302, 'B_Disease')]}], ['Of the nonepisode biopsies , 7 and 4 biopsies showed minimal - type and mild - type chronic FK506 nephropathy , respectively .', {'entities': [(98, 109, 'B_Disease')]}], ['Chronic FK506 nephropathy consisted of rough and foamy tubular vacuolization ( 5 biopsies ) , arteriolopathy ( angiodegeneration of the arteriolar wall ; 20 biopsies ) , focal segmental glomerulosclerosis ( 4 biopsies ) and the striped form of interstitial fibrosis ( 11 biopsies ) .', {'entities': [(14, 25, 'B_Disease'), (170, 175, 'B_Disease'), (176, 185, 'I_Disease'), (186, 204, 'I_Disease'), (244, 256, 'B_Disease'), (257, 265, 'I_Disease')]}], ['The serum creatinine levels of patients in the mild - type chronic FK506 nephropathy group , which included 7 episode biopsies , were statistically higher than those in the minimum - type chronic FK506 - nephropathy group ( P < 0 . 001 ) .', {'entities': [(73, 84, 'B_Disease'), (204, 215, 'B_Disease')]}], ['CONCLUSIONS : This study demonstrates that chronic FK506 nephropathy consists primarily of arteriolopathy manifesting as insudative hyalinosis of the arteriolar wall , and suggests that mild - type chronic FK506 nephropathy is a condition which may lead to deterioration of renal allograft function .', {'entities': [(57, 68, 'B_Disease'), (212, 223, 'B_Disease')]}], ['Different lobular distributions of altered hepatocyte tight junctions in rat models of intrahepatic and extrahepatic cholestasis .', {'entities': [(87, 99, 'B_Disease'), (100, 103, 'I_Disease'), (104, 116, 'I_Disease'), (117, 128, 'I_Disease')]}], ['Although hepatocyte TJs are impaired in cholestasis , attempts to localize the precise site of hepatocyte TJ damage by freeze - fracture electron microscopy have produced limited information .', {'entities': [(40, 51, 'B_Disease')]}], ['We used rat models of intrahepatic cholestasis by ethinyl estradiol ( EE ) treatment and extrahepatic cholestasis by bile duct ligation ( BDL ) to precisely determine the site of TJ damage .', {'entities': [(22, 34, 'B_Disease'), (35, 46, 'I_Disease'), (89, 101, 'B_Disease'), (102, 113, 'I_Disease')]}], ['In the mouse passive - avoidance test , PG - 9 ( 10 - 30 mg / kg , i . p . ) , administered 20 min before the training session , prevented amnesia induced by both the non selective antimuscarinic drug scopolamine and the M1 - selective antagonist S - ( - ) - ET - 126 .', {'entities': [(139, 146, 'B_Disease')]}], ['In the same experimental conditions , PG - 9 ( 5 - 20 microg per mouse , i . c . v . ) was also able to prevent antimuscarine - induced amnesia , demonstrating a central localization of the activity .', {'entities': [(136, 143, 'B_Disease')]}], ['Mechanisms of FK 506 - induced hypertension in the rat .', {'entities': [(31, 43, 'B_Disease')]}], ['The clinical utility of FK 506 is complicated by substantial hypertension and nephrotoxicity .', {'entities': [(61, 73, 'B_Disease'), (78, 92, 'B_Disease')]}], ['To clarify the mechanisms of FK 506 - induced hypertension , we studied the chronic effects of FK 506 on the synthesis of endothelin - 1 ( ET - 1 ) , the expression of mRNA of ET - 1 and endothelin - converting enzyme - 1 ( ECE - 1 ) , the endothelial nitric oxide synthase ( eNOS ) activity , and the expression of mRNA of eNOS and C - type natriuretic peptide ( CNP ) in rat blood vessels .', {'entities': [(46, 58, 'B_Disease')]}], ['In addition , the effect of the specific endothelin type A receptor antagonist FR 139317 on FK 506 - induced hypertension in rats was studied .', {'entities': [(109, 121, 'B_Disease')]}], ['The administration of FR 139317 ( 10 mg . kg - 1 . d - 1 ) prevented FK 506 - induced hypertension in rats .', {'entities': [(86, 98, 'B_Disease')]}], ['22 - oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure .', {'entities': [(30, 39, 'B_Disease'), (40, 59, 'I_Disease'), (77, 80, 'B_Disease'), (81, 85, 'I_Disease'), (86, 94, 'I_Disease'), (108, 113, 'B_Disease'), (114, 121, 'I_Disease')]}], ['BACKGROUND : Calcitriol therapy suppresses serum levels of parathyroid hormone ( PTH ) in patients with renal failure but has several drawbacks , including hypercalcemia and / or marked suppression of bone turnover , which may lead to adynamic bone disease .', {'entities': [(104, 109, 'B_Disease'), (110, 117, 'I_Disease'), (156, 169, 'B_Disease'), (186, 197, 'B_Disease'), (198, 200, 'I_Disease'), (201, 205, 'I_Disease'), (206, 214, 'I_Disease'), (235, 243, 'B_Disease'), (244, 248, 'I_Disease'), (249, 256, 'I_Disease')]}], ['This study was undertaken to determine the effects of OCT on serum PTH levels and bone turnover in states of normal or impaired renal function .', {'entities': [(119, 127, 'B_Disease'), (128, 133, 'I_Disease'), (134, 142, 'I_Disease')]}], ['RESULTS : In Nx dogs , OCT significantly decreased serum PTH levels soon after the induction of renal insufficiency .', {'entities': [(96, 101, 'B_Disease'), (102, 115, 'I_Disease')]}], ['In long - standing secondary hyperparathyroidism , OCT ( 0 . 03 microg / kg ) stabilized serum PTH levels during the first months .', {'entities': [(19, 28, 'B_Disease'), (29, 48, 'I_Disease')]}], ['These effects were accompanied by episodes of hypercalcemia and hyperphosphatemia .', {'entities': [(46, 59, 'B_Disease'), (64, 81, 'B_Disease')]}], ['In Nx dogs , OCT reversed abnormal bone formation , such as woven osteoid and fibrosis , but did not significantly alter the level of bone turnover .', {'entities': [(60, 65, 'B_Disease'), (66, 73, 'I_Disease'), (78, 86, 'B_Disease')]}], ['CONCLUSIONS : These results indicate that even though OCT does not completely prevent the occurrence of hypercalcemia in experimental dogs with renal insufficiency , it may be of use in the management of secondary hyperparathyroidism because it does not induce low bone turnover and , therefore , does not increase the risk of adynamic bone disease .', {'entities': [(104, 117, 'B_Disease'), (144, 149, 'B_Disease'), (150, 163, 'I_Disease'), (204, 213, 'B_Disease'), (214, 233, 'I_Disease'), (261, 264, 'B_Disease'), (265, 269, 'I_Disease'), (270, 278, 'I_Disease'), (327, 335, 'B_Disease'), (336, 340, 'I_Disease'), (341, 348, 'I_Disease')]}], ['Hypotension , bradycardia , and asystole after high - dose intravenous methylprednisolone in a monitored patient .', {'entities': [(0, 11, 'B_Disease'), (14, 25, 'B_Disease'), (32, 40, 'B_Disease')]}], ['We report a case of hypotension , bradycardia , and asystole after intravenous administration of high - dose methylprednisolone in a 73 - year - old patient who underwent electrocardiographic ( ECG ) monitoring throughout the episode .', {'entities': [(20, 31, 'B_Disease'), (34, 45, 'B_Disease'), (52, 60, 'B_Disease')]}], ['There was a history of ischemic cardiac disease 9 years earlier .', {'entities': [(23, 31, 'B_Disease'), (32, 39, 'B_Disease'), (40, 47, 'I_Disease')]}], ['The patient was admitted with a pulmonary - renal syndrome with hemoptysis , rapidly progressive renal failure , and hypoxemia that required mechanical ventilation in the intensive care unit .', {'entities': [(32, 41, 'B_Disease'), (42, 43, 'I_Disease'), (44, 49, 'I_Disease'), (50, 58, 'I_Disease'), (64, 74, 'B_Disease'), (97, 102, 'B_Disease'), (103, 110, 'I_Disease'), (117, 126, 'B_Disease')]}], ['The ECG showed a junctional rhythm without ventricular arrhythmia .', {'entities': [(43, 54, 'B_Disease'), (55, 65, 'I_Disease')]}], ['This study reviews the current proposed mechanisms of sudden death after a high dose of intravenous methylprednisolone ( IVMP ) .', {'entities': [(54, 60, 'B_Disease'), (61, 66, 'I_Disease')]}], ['Rapid infusion and underlying cardiac disease were important risk factors in the case reported here , and the authors discount ventricular arrhythmia as the main mechanism .', {'entities': [(30, 37, 'B_Disease'), (38, 45, 'I_Disease'), (127, 138, 'B_Disease'), (139, 149, 'I_Disease')]}], ['Worsening of levodopa - induced dyskinesias by motor and mental tasks .', {'entities': [(32, 43, 'B_Disease')]}], [\"Ten patients who had Parkinson ' s disease with disabling dyskinesia were included in this study to evaluate the role of mental ( mental calculation ) and motor ( flexion / extension of right fingers , flexion / extension of left fingers , flexion / extension of the neck , speaking aloud ) tasks on the worsening of peak - dose dyskinesia following administration of an effective single dose of apomorphine .\", {'entities': [(21, 30, 'B_Disease'), (31, 32, 'I_Disease'), (33, 34, 'I_Disease'), (35, 42, 'I_Disease'), (58, 68, 'B_Disease'), (329, 339, 'B_Disease')]}], ['Compared with the score at rest ( 1 . 3 + / - 0 . 3 ) , a significant aggravation of the dyskinesia score was observed during speaking aloud ( 5 . 2 + / - 1 . 1 , p < 0 . 05 ) , movements of right ( 4 . 5 + / - 1 . 0 , p < 0 . 05 ) and left ( 3 . 7 + / - 0 . 8 , p < 0 . 05 ) fingers , movements of the neck ( 5 . 1 + / - 1 . 0 , p < 0 . 05 ) , and mental calculation ( 3 . 1 + / - 1 . 0 , p < 0 . 05 ) .', {'entities': [(89, 99, 'B_Disease')]}], ['These results suggest that activation tasks such as \" speaking aloud \" could be used for objective assessment of dyskinesia severity .', {'entities': [(113, 123, 'B_Disease')]}], ['BACKGROUND : Although an indicator of renal tubular dysfunction , an increased urinary N - acetyl - beta - D - glucosaminidase ( NAG ) activity might reflect increased lysosomal activity in renal tubular cells .', {'entities': [(38, 43, 'B_Disease'), (44, 51, 'I_Disease'), (52, 63, 'I_Disease')]}], ['METHODS : Puromycin aminonucleoside ( PAN ) was administered to Sprague Dawley rats to induce proteinuria .', {'entities': [(94, 105, 'B_Disease')]}], ['Peak urine NAG activity and a change in NAG isoenzyme pattern coincided with both the peak proteinuria and the reduction in intracellular protein and NAG droplets ( day six onwards ) .', {'entities': [(91, 102, 'B_Disease')]}], ['Cauda equina syndrome after spinal anaesthesia with hyperbaric 5 % lignocaine : a review of six cases of cauda equina syndrome reported to the Swedish Pharmaceutical Insurance 1993 - 1997 .', {'entities': [(0, 5, 'B_Disease'), (6, 12, 'I_Disease'), (13, 21, 'I_Disease'), (105, 110, 'B_Disease'), (111, 117, 'I_Disease'), (118, 126, 'I_Disease')]}], ['Six cases of cauda equina syndrome with varying severity were reported to the Swedish Pharmaceutical Insurance during the period 1993 - 1997 .', {'entities': [(13, 18, 'B_Disease'), (19, 25, 'I_Disease'), (26, 34, 'I_Disease')]}], ['Three of the cases were most likely caused by direct neurotoxicity of hyperbaric 5 % lignocaine .', {'entities': [(53, 66, 'B_Disease')]}], ['In the other 3 cases , direct neurotoxicity was also probable , but unfortunately radiological investigations were not done to definitely exclude a compressive aetiology .', {'entities': [(30, 43, 'B_Disease')]}], ['All cases sustained permanent neurological deficits .', {'entities': [(30, 42, 'B_Disease'), (43, 51, 'I_Disease')]}], ['Systemic toxicity following administration of sirolimus ( formerly rapamycin ) for psoriasis : association of capillary leak syndrome with apoptosis of lesional lymphocytes .', {'entities': [(9, 17, 'B_Disease'), (83, 92, 'B_Disease'), (110, 119, 'B_Disease'), (120, 124, 'I_Disease'), (125, 133, 'I_Disease')]}], ['After 2 individuals with psoriasis developed a capillary leak syndrome following treatment with oral sirolimus lesional skin cells and activated peripheral blood cells were analyzed for induction of apoptosis .', {'entities': [(25, 34, 'B_Disease'), (47, 56, 'B_Disease'), (57, 61, 'I_Disease'), (62, 70, 'I_Disease')]}], ['OBSERVATIONS : A keratome skin specimen from 1 patient with sirolimus - induced capillary leak syndrome had a 2 . 3 - fold increase in percentage of apoptotic cells ( to 48 % ) compared with an unaffected sirolimus - treated patient with psoriasis ( 21 % ) .', {'entities': [(80, 89, 'B_Disease'), (90, 94, 'I_Disease'), (95, 103, 'I_Disease'), (238, 247, 'B_Disease')]}], ['Activated peripheral blood T cells from patients with psoriasis tended to exhibit greater spontaneous or dexamethasone - induced apoptosis than did normal T cells , particularly in the presence of sirolimus .', {'entities': [(54, 63, 'B_Disease')]}], ['CONCLUSIONS : Severe adverse effects of sirolimus include fever , anemia , and capillary leak syndrome .', {'entities': [(58, 63, 'B_Disease'), (66, 72, 'B_Disease'), (79, 88, 'B_Disease'), (89, 93, 'I_Disease'), (94, 102, 'I_Disease')]}], ['Because patients with severe psoriasis may develop capillary leak from various systemic therapies , clinical monitoring is advisable for patients with inflammatory diseases who are treated with immune modulators .', {'entities': [(29, 38, 'B_Disease'), (51, 60, 'B_Disease'), (61, 65, 'I_Disease'), (151, 163, 'B_Disease'), (164, 172, 'I_Disease')]}], ['These were evaluated with respect to the duration of lithium therapy , age , sex , and family history ( whether or not the patient had a first - degree relative with thyroid disease ) .', {'entities': [(166, 173, 'B_Disease'), (174, 181, 'I_Disease')]}], [\"PATIENTS : One hundred and one patients ( 28 men and 73 women ) with bipolar disorder receiving lithium maintenance therapy ranging from 1 year ' s to 32 years ' duration .\", {'entities': [(69, 76, 'B_Disease'), (77, 85, 'I_Disease')]}], [\"The control group consisted of 82 patients with no psychiatric or endocrinological diagnoses from the hospital ' s out - patient clinics .\", {'entities': [(51, 62, 'B_Disease')]}], ['RESULTS : Hypothyroidism developed in 40 patients , excluding 8 patients who were hypothyroid at baseline .', {'entities': [(10, 24, 'B_Disease'), (82, 93, 'B_Disease')]}], ['All patients having first - degree relatives affected by thyroid illness had accelerated onset of hypothyroidism ( 3 . 7 years after onset of lithium therapy ) compared with patients without a family history ( 8 . 6 years after onset of lithium therapy ) .', {'entities': [(57, 64, 'B_Disease'), (65, 72, 'I_Disease'), (98, 112, 'B_Disease')]}], ['Women over 60 years of age were more often affected by hypothyroidism than women under 60 years of age ( 34 . 6 % versus 31 . 9 % ) .', {'entities': [(55, 69, 'B_Disease')]}], ['CONCLUSIONS : Familial thyroid illness is a risk factor for hypothyroidism and hypercalcemia during lithium therapy .', {'entities': [(23, 30, 'B_Disease'), (31, 38, 'I_Disease'), (60, 74, 'B_Disease'), (79, 92, 'B_Disease')]}], ['Severe immune hemolytic anemia associated with prophylactic use of cefotetan in obstetric and gynecologic procedures .', {'entities': [(14, 23, 'B_Disease'), (24, 30, 'I_Disease')]}], ['Second - and third - generation cephalosporins , especially cefotetan , are increasingly associated with severe , sometimes fatal immune hemolytic anemia .', {'entities': [(137, 146, 'B_Disease'), (147, 153, 'I_Disease')]}], ['We noticed that 10 of our 35 cases of cefotetan - induced hemolytic anemias were in patients who had received cefotetan prophylactically for obstetric and gynecologic procedures .', {'entities': [(58, 67, 'B_Disease'), (68, 75, 'I_Disease')]}], ['Eight of these cases of severe immune hemolytic anemia are described .', {'entities': [(38, 47, 'B_Disease'), (48, 54, 'I_Disease')]}], ['Effects of nonsteroidal anti - inflammatory drugs on hemostasis in patients with aneurysmal subarachnoid hemorrhage .', {'entities': [(81, 91, 'B_Disease'), (92, 104, 'I_Disease'), (105, 115, 'I_Disease')]}], ['Patients with aneurysmal subarachnoid hemorrhage ( SAH ) were randomized to receive either ketoprofen , 100 mg , three times a day ( ketoprofen group , n = 9 ) or a weak NSAID , acetaminophen , 1 g , three times a day ( acetaminophen group , n = 9 ) starting immediately after the diagnosis of aneurysmal SAH .', {'entities': [(14, 24, 'B_Disease'), (25, 37, 'I_Disease'), (38, 48, 'I_Disease'), (51, 54, 'B_Disease'), (294, 304, 'B_Disease'), (305, 308, 'B_Disease')]}], ['Maximal platelet aggregation induced by 6 microM of adenosine diphosphate decreased after administration of ketoprofen .', {'entities': [(8, 16, 'B_Disease'), (17, 28, 'I_Disease')]}], ['In contrast , maximal platelet aggregation increased in the acetaminophen group on the third postoperative day as compared with the pretreatment platelet aggregation results ( P < . 05 ) .', {'entities': [(22, 30, 'B_Disease'), (31, 42, 'I_Disease'), (145, 153, 'B_Disease'), (154, 165, 'I_Disease')]}], ['One patient in the ketoprofen group developed a postoperative intracranial hematoma .', {'entities': [(75, 83, 'B_Disease')]}], ['Ketoprofen but not acetaminophen impaired platelet function in patients with SAH .', {'entities': [(77, 80, 'B_Disease')]}], ['If ketoprofen is used before surgery on cerebral artery aneurysms , it may pose an additional risk factor for hemorrhage .', {'entities': [(49, 55, 'B_Disease'), (56, 65, 'I_Disease'), (110, 120, 'B_Disease')]}], ['Nitric oxide synthase expression in the course of lead - induced hypertension .', {'entities': [(65, 77, 'B_Disease')]}], ['We recently showed elevated reactive oxygen species ( ROS ) , reduced urinary excretion of NO metabolites ( NOx ) , and increased NO sequestration as nitrotyrosine in various tissues in rats with lead - induced hypertension .', {'entities': [(211, 223, 'B_Disease')]}], ['This study was designed to discern whether the reduction in urinary NOx in lead - induced hypertension is , in part , due to depressed NO synthase ( NOS ) expression .', {'entities': [(90, 102, 'B_Disease')]}], ['Vitamin E supplementation ameliorated hypertension , lowered plasma MDA concentration , and raised urinary NOx excretion while significantly lowering vascular , but not renal , tissue eNOS and iNOS expression .', {'entities': [(38, 50, 'B_Disease')]}], ['In conclusion , lead - induced hypertension in this model was associated with a compensatory upregulation of renal and vascular eNOS and iNOS expression .', {'entities': [(31, 43, 'B_Disease')]}], ['This is , in part , due to ROS - mediated NO inactivation , lead - associated inhibition of NOS activity , and perhaps stimulatory actions of increased shear stress associated with hypertension .', {'entities': [(181, 193, 'B_Disease')]}], ['Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura .', {'entities': [(39, 47, 'B_Disease'), (48, 55, 'I_Disease'), (56, 60, 'I_Disease'), (77, 85, 'B_Disease'), (86, 90, 'I_Disease'), (91, 95, 'I_Disease')]}], ['Migraine with aura and migraine without aura have the same pain phase , thus indicating that migraine with aura and migraine without aura share a common pathway of nociception .', {'entities': [(0, 8, 'B_Disease'), (9, 13, 'I_Disease'), (14, 18, 'I_Disease'), (23, 31, 'B_Disease'), (32, 39, 'I_Disease'), (40, 44, 'I_Disease'), (59, 63, 'B_Disease'), (93, 101, 'B_Disease'), (102, 106, 'I_Disease'), (107, 111, 'I_Disease'), (116, 124, 'B_Disease'), (125, 132, 'I_Disease'), (133, 137, 'I_Disease')]}], ['In recent years , increasing evidence has suggested that the messenger molecule nitric oxide ( NO ) is involved in pain mechanisms of migraine without aura .', {'entities': [(115, 119, 'B_Disease'), (134, 142, 'B_Disease'), (143, 150, 'I_Disease'), (151, 155, 'I_Disease')]}], ['In order to clarify whether the same is true for migraine with aura , in the present study we examined the headache response to intravenous infusion of glyceryl trinitrate ( GTN ) ( 0 . 5 microg / kg / min for 20 min ) in 12 sufferers of migraine with aura .', {'entities': [(49, 57, 'B_Disease'), (58, 62, 'I_Disease'), (63, 67, 'I_Disease'), (107, 115, 'B_Disease'), (238, 246, 'B_Disease'), (247, 251, 'I_Disease'), (252, 256, 'I_Disease')]}], ['The specific aim was to elucidate whether an aura and / or an attack of migraine without aura could be induced .', {'entities': [(72, 80, 'B_Disease'), (81, 88, 'I_Disease'), (89, 93, 'I_Disease')]}], ['Headache was more severe in migraineurs than in the controls during and immediately after GTN infusion ( p = 0 . 037 ) as well as during the following 11 h ( p = 0 . 008 ) .', {'entities': [(0, 8, 'B_Disease'), (28, 39, 'B_Disease')]}], ['In the controls , the GTN - induced headache gradually disappeared , whereas in migraineurs peak headache intensity occurred at a mean time of 240 min post - infusion .', {'entities': [(36, 44, 'B_Disease'), (80, 91, 'B_Disease'), (97, 105, 'B_Disease')]}], ['At this time the induced headache in 6 of 12 migraineurs fulfilled the diagnostic criteria for migraine without aura of the International Headache Society .', {'entities': [(25, 33, 'B_Disease'), (45, 56, 'B_Disease'), (95, 103, 'B_Disease'), (104, 111, 'I_Disease'), (112, 116, 'I_Disease'), (138, 146, 'B_Disease')]}], ['The results therefore suggest that NO is involved in the pain mechanisms of migraine with aura .', {'entities': [(57, 61, 'B_Disease'), (76, 84, 'B_Disease'), (85, 89, 'I_Disease'), (90, 94, 'I_Disease')]}], ['Since cortical spreading depression has been shown to liberate NO in animals , this finding may help our understanding of the coupling between cortical spreading depression and headache in migraine with aura .', {'entities': [(25, 35, 'B_Disease'), (162, 172, 'B_Disease'), (177, 185, 'B_Disease'), (189, 197, 'B_Disease'), (198, 202, 'I_Disease'), (203, 207, 'I_Disease')]}], ['Rapid reversal of life - threatening diltiazem - induced tetany with calcium chloride .', {'entities': [(57, 63, 'B_Disease')]}], ['We describe a patient who developed tetany with sudden respiratory arrest after the infusion of intravenous diltiazem .', {'entities': [(36, 42, 'B_Disease'), (55, 66, 'B_Disease'), (67, 73, 'I_Disease')]}], [\"The administration of calcium chloride rapidly resolved the patient ' s tetany with prompt recovery of respiratory function , averting the need for more aggressive airway management and ventilatory support .\", {'entities': [(72, 78, 'B_Disease')]}], ['The emergency physician should be aware that life - threatening tetany may accompany the administration of intravenous diltiazem and that calcium chloride may be a rapid and effective remedy .', {'entities': [(64, 70, 'B_Disease')]}], ['Predictors of decreased renal function in patients with heart failure during angiotensin - converting enzyme inhibitor therapy : results from the studies of left ventricular dysfunction ( SOLVD )', {'entities': [(14, 23, 'B_Disease'), (24, 29, 'I_Disease'), (30, 38, 'I_Disease'), (56, 61, 'B_Disease'), (62, 69, 'I_Disease'), (157, 161, 'B_Disease'), (162, 173, 'I_Disease'), (174, 185, 'I_Disease')]}], ['BACKGROUND : Although angiotensin - converting enzyme inhibitor therapy reduces mortality rates in patients with congestive heart failure ( CHF ) , it may also cause decreased renal function .', {'entities': [(113, 123, 'B_Disease'), (124, 129, 'I_Disease'), (130, 137, 'I_Disease'), (140, 143, 'B_Disease'), (166, 175, 'B_Disease'), (176, 181, 'I_Disease'), (182, 190, 'I_Disease')]}], ['OBJECTIVE : To quantify specific clinical predictors of reduction in renal function in patients with CHF who are prescribed angiotensin - converting enzyme inhibitor therapy .', {'entities': [(56, 65, 'B_Disease'), (66, 68, 'I_Disease'), (69, 74, 'I_Disease'), (75, 83, 'I_Disease'), (101, 104, 'B_Disease')]}], ['METHOD : We analyzed data from the Studies of Left Ventricular Dysfunction ( SOLVD ) , a randomized , double - blind , placebo - controlled trial of enalapril for the treatment of CHF .', {'entities': [(46, 50, 'B_Disease'), (51, 62, 'I_Disease'), (63, 74, 'I_Disease'), (180, 183, 'B_Disease')]}], ['Decreased renal function was defined as a rise in serum creatinine > / = 0 . 5 mg / dL ( 44 micromol / L ) from baseline .', {'entities': [(0, 9, 'B_Disease'), (10, 15, 'I_Disease'), (16, 24, 'I_Disease')]}], ['We used time - to - event analysis to identify potential predictors of decrease in renal function including age , baseline ejection fraction , baseline creatinine , low systolic blood pressure ( < 100 mm Hg ) , history of hypertension , diabetes , and use of antiplatelet , diuretic , and beta - blocker therapy .', {'entities': [(222, 234, 'B_Disease'), (237, 245, 'B_Disease')]}], ['RESULTS : Patients randomly assigned to enalapril had a 33 % greater likelihood of decreased renal function than controls ( P = . 003 ) .', {'entities': [(83, 92, 'B_Disease'), (93, 98, 'I_Disease'), (99, 107, 'I_Disease')]}], ['By multivariate analysis , in both the placebo and enalapril groups older age , diuretic therapy , and diabetes were associated with decreased renal function , whereas beta - blocker therapy and higher ejection fraction were renoprotective .', {'entities': [(103, 111, 'B_Disease'), (133, 142, 'B_Disease'), (143, 148, 'I_Disease'), (149, 157, 'I_Disease')]}], ['Older age was associated with a greater risk of developing decreased renal function in both groups , but significantly more so in the enalapril group ( enalapril : risk ratio [ RR ] 1 . 42 per 10 years , 95 % confidence interval [ CI ] 1 . 32 - 1 . 52 with enalapril ; placebo : RR 1 . 18 , 95 % CI 1 . 12 - 1 . 25 ) .', {'entities': [(59, 68, 'B_Disease'), (69, 74, 'I_Disease'), (75, 83, 'I_Disease')]}], ['Diuretic therapy was likewise associated with a greater risk of decreased renal function in the enalapril group ( RR 1 . 89 , 95 % CI 1 . 70 - 2 . 08 ) than in the placebo group ( RR 1 . 35 , 95 % CI 1 . 09 - 1 . 66 ) .', {'entities': [(64, 73, 'B_Disease'), (74, 79, 'I_Disease'), (80, 88, 'I_Disease')]}], ['Conversely , enalapril had a relative renoprotective effect ( RR 1 . 33 , 95 % CI 1 . 13 - 1 . 53 ) compared with placebo ( RR 1 . 96 , 95 % CI 1 . 57 - 2 . 44 ) in patients with diabetes .', {'entities': [(179, 187, 'B_Disease')]}], ['A lower risk of renal impairment was seen in both groups with beta - blocker therapy ( RR 0 . 70 , 95 % CI 0 . 57 - 0 . 85 ) and higher baseline ejection fraction ( RR 0 . 93 per 5 % increment , 95 % CI 0 . 91 - 0 . 96 ) .', {'entities': [(16, 21, 'B_Disease'), (22, 32, 'I_Disease')]}], ['CONCLUSIONS : Enalapril use caused a 33 % increase in the risk of decreased renal function in patients with CHF .', {'entities': [(66, 75, 'B_Disease'), (76, 81, 'I_Disease'), (82, 90, 'I_Disease'), (108, 111, 'B_Disease')]}], ['Diabetes was associated with an increased risk of renal impairment in all patients with CHF , but this risk was reduced in the enalapril group compared with the placebo group .', {'entities': [(0, 8, 'B_Disease'), (50, 55, 'B_Disease'), (56, 66, 'I_Disease'), (88, 91, 'B_Disease')]}], ['Hypomania - like syndrome induced by olanzapine .', {'entities': [(0, 9, 'B_Disease')]}], ['We report a female patient with a diagnosis of a not otherwise specified psychotic disorder ( DSM - IV ) who developed hypomania shortly after the introduction of olanzapine treatment .', {'entities': [(73, 82, 'B_Disease'), (83, 91, 'I_Disease'), (119, 128, 'B_Disease')]}], ['Acetazolamide - induced Gerstmann syndrome .', {'entities': [(24, 33, 'B_Disease'), (34, 42, 'I_Disease')]}], ['Acute confusion induced by acetazolamide is a well known adverse drug reaction in patients with renal impairment .', {'entities': [(6, 15, 'B_Disease'), (96, 101, 'B_Disease'), (102, 112, 'I_Disease')]}], ['We report a case of acetazolamide - induced Gerstmann syndrome in a patient with normal renal function , to highlight predisposing factors that are frequently overlooked .', {'entities': [(44, 53, 'B_Disease'), (54, 62, 'I_Disease')]}], ['Vasopressin in the treatment of milrinone - induced hypotension in severe heart failure .', {'entities': [(52, 63, 'B_Disease'), (74, 79, 'B_Disease'), (80, 87, 'I_Disease')]}], ['The use of phosphodiesterase inhibitors such as milrinone in the treatment of severe heart failure is frequently restricted because they cause vasodilation and hypotension .', {'entities': [(85, 90, 'B_Disease'), (91, 98, 'I_Disease'), (160, 171, 'B_Disease')]}], ['In patients with decompensated heart failure with hypotension after treatment with milrinone , low doses of vasopressin restored blood pressure without inhibiting the inotropic effect of milrinone .', {'entities': [(31, 36, 'B_Disease'), (37, 44, 'I_Disease'), (50, 61, 'B_Disease')]}], ['Indications for early conversion were neurotoxicity ( 20 ) , ( insulin - dependent ) diabetes mellitus ( IDDM ) ( 5 ) , nephrotoxicity ( 3 ) , gastrointestinal ( GI ) toxicity ( 6 ) , and cardiomyopathy ( 1 ) , and for late conversion were neurotoxicity ( 15 ) , IDDM ( 12 ) , nephrotoxicity ( 3 ) , GI toxicity ( 5 ) , hepatotoxicity ( 6 ) , post - transplant lmphoproliferate disease ( PTLD ) ( 2 ) , cardiomyopathy ( 1 ) , hemolytic anemia ( 1 ) , and pruritus ( 1 ) .', {'entities': [(38, 51, 'B_Disease'), (61, 62, 'B_Disease'), (63, 70, 'I_Disease'), (71, 72, 'I_Disease'), (73, 82, 'I_Disease'), (83, 84, 'I_Disease'), (85, 93, 'I_Disease'), (94, 102, 'I_Disease'), (105, 109, 'B_Disease'), (120, 134, 'B_Disease'), (143, 159, 'B_Disease'), (160, 161, 'I_Disease'), (162, 164, 'I_Disease'), (165, 166, 'I_Disease'), (167, 175, 'I_Disease'), (188, 202, 'B_Disease'), (240, 253, 'B_Disease'), (263, 267, 'B_Disease'), (277, 291, 'B_Disease'), (300, 302, 'B_Disease'), (303, 311, 'I_Disease'), (320, 334, 'B_Disease'), (343, 347, 'B_Disease'), (348, 349, 'I_Disease'), (350, 360, 'I_Disease'), (361, 377, 'I_Disease'), (378, 385, 'I_Disease'), (388, 392, 'B_Disease'), (403, 417, 'B_Disease'), (426, 435, 'B_Disease'), (436, 442, 'I_Disease'), (455, 463, 'B_Disease')]}], ['Ocular manifestations of juvenile rheumatoid arthritis .', {'entities': [(25, 33, 'B_Disease'), (34, 44, 'I_Disease'), (45, 54, 'I_Disease')]}], ['We followed 210 cases of juvenile rheumatoid arthritis closely for eleven years .', {'entities': [(25, 33, 'B_Disease'), (34, 44, 'I_Disease'), (45, 54, 'I_Disease')]}], ['Thirty - six of the 210 patients ( 17 . 2 % ) developed iridocyclitis .', {'entities': [(56, 69, 'B_Disease')]}], ['Iridocyclitis was seen most frequently in young female patients ( 0 to 4 years ) with the monoarticular or pauciatricular form of the arthritis .', {'entities': [(0, 13, 'B_Disease'), (134, 143, 'B_Disease')]}], ['However , 30 % of the patients developed uveitis after 16 years of age .', {'entities': [(41, 48, 'B_Disease')]}], ['Although 61 % of patients had a noncontributory ocular history on entry , 42 % had active uveitis on entry .', {'entities': [(90, 97, 'B_Disease')]}], ['Our approach was effective in detecting uveitis in new cases and exacerbations of uveitis in established cases .', {'entities': [(40, 47, 'B_Disease'), (82, 89, 'B_Disease')]}], ['Forty - four percent of patients with uveitis had one or more identifiable signs or symptoms , such as red eye , ocular pain , decreased visual acuity , or photophobia , in order of decreasing frequency .', {'entities': [(38, 45, 'B_Disease'), (113, 119, 'B_Disease'), (120, 124, 'I_Disease'), (127, 136, 'B_Disease'), (137, 143, 'I_Disease'), (144, 150, 'I_Disease'), (156, 167, 'B_Disease')]}], ['Even after early detection and prompt treatment , 41 % of cases of uveitis did not respond to more than six months of intensive topical treatment with corticosteroids and mydriatics .', {'entities': [(67, 74, 'B_Disease')]}], ['Despite this , there was a dramatic decrease in the 50 % incidence of blinding complications of uveitis cited in earlier studies .', {'entities': [(96, 103, 'B_Disease')]}], ['Cataract and band keratopathy occurred in only 22 and 13 % of our group , respectively .', {'entities': [(0, 8, 'B_Disease'), (13, 17, 'B_Disease'), (18, 29, 'I_Disease')]}], ['We used chloroquine or hydroxychloroquine in 173 of 210 cases and found only one case of chorioretinopathy attributable to these drugs .', {'entities': [(89, 106, 'B_Disease')]}], ['Systemically administered corticosteroids were used in 75 of 210 cases ; a significant number of posterior subcapsular cataracts was found .', {'entities': [(119, 128, 'B_Disease')]}], ['Typical keratoconjunctivitis sicca developed in three of the uveitis cases .', {'entities': [(8, 28, 'B_Disease'), (61, 68, 'B_Disease')]}], ['This association with uveitis and JRA was not noted previously .', {'entities': [(22, 29, 'B_Disease')]}], ['Surgical treatment of cataracts , band keratopathy , and glaucoma achieved uniformly discouraging results .', {'entities': [(22, 31, 'B_Disease'), (34, 38, 'B_Disease'), (39, 50, 'I_Disease'), (57, 65, 'B_Disease')]}], ['Cyclophosphamide - induced cystitis in freely - moving conscious rats : behavioral approach to a new model of visceral pain .', {'entities': [(27, 35, 'B_Disease'), (110, 118, 'B_Disease'), (119, 123, 'I_Disease')]}], ['PURPOSE : To develop a model of visceral pain in rats using a behavioral approach .', {'entities': [(32, 40, 'B_Disease'), (41, 45, 'I_Disease')]}], ['Cyclophosphamide ( CP ) , an antitumoral agent known to produce toxic effects on the bladder wall through its main toxic metabolite acrolein , was used to induce cystitis .', {'entities': [(162, 170, 'B_Disease')]}], ['Morphine dose - dependently reversed these behavioral disorders .', {'entities': [(43, 53, 'B_Disease'), (54, 63, 'I_Disease')]}], ['At the time of administration of morphine , histological modifications of the bladder wall , such as chorionic and muscle layer edema , were observed .', {'entities': [(128, 133, 'B_Disease')]}], ['CONCLUSIONS : Overall , these results indicate that this experimental model of CP - induced cystitis may be an interesting new behavioral model of inflammatory visceral pain , allowing a better understanding of these painful syndromes and thus a better therapeutic approach to them .', {'entities': [(92, 100, 'B_Disease'), (160, 168, 'B_Disease'), (169, 173, 'I_Disease'), (217, 224, 'B_Disease'), (225, 234, 'I_Disease')]}], ['Prednisolone - induced muscle dysfunction is caused more by atrophy than by altered acetylcholine receptor expression .', {'entities': [(23, 29, 'B_Disease'), (30, 41, 'I_Disease'), (60, 67, 'B_Disease')]}], ['On Day 8 , the nerve - evoked peak twitch tensions , tetanic tensions , and fatigability , and the dose - response curves of d - tubocurarine in the tibialis cranialis muscle were measured in vivo and related to muscle mass or expression of AChRs .', {'entities': [(53, 60, 'B_Disease')]}], ['The evoked peak twitch and tetanic tensions were less in the P100 group than in the P10 or S groups , however , tension per milligram of muscle mass was greater in the P100 group than in the S group .', {'entities': [(27, 34, 'B_Disease')]}], ['Our results suggest that the neuromuscular dysfunction after prednisolone is dose - dependent , and derives primarily from muscle atrophy and derives less so from changes in AChR expression .', {'entities': [(29, 42, 'B_Disease'), (43, 54, 'I_Disease'), (123, 129, 'B_Disease'), (130, 137, 'I_Disease')]}], ['We suggest that the observed effects are dose - dependent and derive primarily from muscle atrophy and derive less from changes in acetylcholine receptor expression .', {'entities': [(84, 90, 'B_Disease'), (91, 98, 'I_Disease')]}], [\"Apomorphine : an underutilized therapy for Parkinson ' s disease .\", {'entities': [(43, 52, 'B_Disease'), (53, 54, 'I_Disease'), (55, 56, 'I_Disease'), (57, 64, 'I_Disease')]}], [\"Apomorphine was the first dopaminergic drug ever used to treat symptoms of Parkinson ' s disease .\", {'entities': [(75, 84, 'B_Disease'), (85, 86, 'I_Disease'), (87, 88, 'I_Disease'), (89, 96, 'I_Disease')]}], [\"While powerful antiparkinsonian effects had been observed as early as 1951 , the potential of treating fluctuating Parkinson ' s disease by subcutaneous administration of apomorphine has only recently become the subject of systematic study .\", {'entities': [(115, 124, 'B_Disease'), (125, 126, 'I_Disease'), (127, 128, 'I_Disease'), (129, 136, 'I_Disease')]}], ['In addition , there is convincing clinical evidence that monotherapy with continuous subcutaneous apomorphine infusions is associated with marked reductions of preexisting levodopa - induced dyskinesias .', {'entities': [(191, 202, 'B_Disease')]}], ['The main side effects of subcutaneous apomorphine treatment are related to cutaneous tolerability problems , whereas sedation and psychiatric complications play a lesser role .', {'entities': [(130, 141, 'B_Disease')]}], [\"Given the marked degree of efficacy of subcutaneous apomorphine treatment in fluctuating Parkinson ' s disease , this approach seems to deserve more widespread clinical use .\", {'entities': [(89, 98, 'B_Disease'), (99, 100, 'I_Disease'), (101, 102, 'I_Disease'), (103, 110, 'I_Disease')]}], [\"OBJECTIVE : The pharmacological response to drugs that act on the cholinergic system of the iris has been used to predict deficits in central cholinergic functioning due to diseases such as Alzheimer ' s disease , yet correlations between central and peripheral responses have not been properly studied .\", {'entities': [(190, 199, 'B_Disease'), (200, 201, 'I_Disease'), (202, 203, 'I_Disease'), (204, 211, 'I_Disease')]}], ['OUTCOME MEASURES : Pupil size at time points after administration of tropicamide and pilocarpine ; scopolamine - induced impairment in word recall .', {'entities': [(121, 131, 'B_Disease'), (132, 134, 'I_Disease'), (135, 139, 'I_Disease'), (140, 146, 'I_Disease')]}], ['Compared with the young group , the elderly group had greater scopolamine - induced impairment in word recall 60 , 90 and 120 minutes after administration ( p < 0 . 05 ) .', {'entities': [(84, 94, 'B_Disease'), (95, 97, 'I_Disease'), (98, 102, 'I_Disease'), (103, 109, 'I_Disease')]}], ['Pain responses in methadone - maintained opioid abusers .', {'entities': [(0, 4, 'B_Disease')]}], ['Providing pain management for known opioid abusers is a challenging clinical task , in part because little is known about their pain experience and analgesic requirements .', {'entities': [(10, 14, 'B_Disease'), (128, 132, 'B_Disease')]}], ['This study was designed to describe pain tolerance and analgesic response in a sample of opioid addicts stabilized in methadone - maintenance ( MM ) treatment ( n = 60 ) in comparison to matched nondependent control subjects ( n = 60 ) .', {'entities': [(36, 40, 'B_Disease'), (89, 95, 'B_Disease'), (96, 103, 'I_Disease')]}], ['By using a placebo - controlled , two - way factorial design , tolerance to cold - pressor ( CP ) pain was examined , both before and after oral administration of therapeutic doses of common opioid ( hydromorphone 2 mg ) and nonsteroidal anti - inflammatory ( ketorolac 10 mg ) analgesic agents .', {'entities': [(98, 102, 'B_Disease')]}], ['Results showed that MM individuals were significantly less tolerant of CP pain than control subjects , replicating previous work .', {'entities': [(74, 78, 'B_Disease')]}], ['These data indicate that MM opioid abusers represent a pain - intolerant subset of clinical patients .', {'entities': [(55, 59, 'B_Disease'), (60, 61, 'I_Disease'), (62, 72, 'I_Disease')]}], ['Their complaints of pain should be evaluated seriously and managed aggressively .', {'entities': [(20, 24, 'B_Disease')]}], ['High - dose methylprednisolone may do more harm for spinal cord injury .', {'entities': [(52, 58, 'B_Disease'), (59, 63, 'I_Disease'), (64, 70, 'I_Disease')]}], ['Because of the National Acute Spinal Cord Injury Studies ( NASCIS ) , high - dose methylprednisolone became the standard of care for the acute spinal cord injury .', {'entities': [(30, 36, 'B_Disease'), (37, 41, 'I_Disease'), (42, 48, 'I_Disease'), (143, 149, 'B_Disease'), (150, 154, 'I_Disease'), (155, 161, 'I_Disease')]}], ['In the NASCIS , there was no mention regarding the possibility of acute corticosteroid myopathy that high - dose methylprednisolone may cause .', {'entities': [(87, 95, 'B_Disease')]}], ['We hypothesize that it may cause some damage to the muscle of spinal cord injury patients .', {'entities': [(38, 44, 'B_Disease'), (45, 47, 'I_Disease'), (48, 51, 'I_Disease'), (52, 58, 'I_Disease'), (62, 68, 'B_Disease'), (69, 73, 'I_Disease'), (74, 80, 'I_Disease')]}], ['Further , steroid myopathy recovers naturally and the neurological improvement shown in the NASCIS may be just a recording of this natural motor recovery from the steroid myopathy , instead of any protection that methylprednisolone offers to the spinal cord injury .', {'entities': [(18, 26, 'B_Disease'), (171, 179, 'B_Disease'), (246, 252, 'B_Disease'), (253, 257, 'I_Disease'), (258, 264, 'I_Disease')]}], ['To our knowledge , this is the first discussion considering the possibility that the methylprednisolone recommended by NASCIS may cause acute corticosteroid myopathy .', {'entities': [(157, 165, 'B_Disease')]}], ['BACKGROUND : The aim of this study is to evaluate the effects of RAPA conversion in patients undergoing cyclosporine ( CsA ) or tacrolimus ( Tac ) toxicity .', {'entities': [(147, 155, 'B_Disease')]}], ['The indications for switch were chronic CsA or Tac nephrotoxicity ( 12 ) , acute CsA or Tac toxicity ( 3 ) , severe facial dysmorphism ( 2 ) , posttransplant lymphoproliferative disorder ( PTLD ) in remission ( 2 ) , and hepatotoxicity in 1 .', {'entities': [(51, 65, 'B_Disease'), (92, 100, 'B_Disease'), (116, 122, 'B_Disease'), (123, 134, 'I_Disease'), (143, 157, 'B_Disease'), (158, 177, 'I_Disease'), (178, 186, 'I_Disease'), (189, 193, 'B_Disease'), (221, 235, 'B_Disease')]}], ['RESULTS : In the 12 patients switched because of chronic nephrotoxicity there was a significant decrease in serum creatinine [ 233 + / - 34 to 210 + / - 56 micromol / liter ( P < 0 . 05 ) at 6 months ] .', {'entities': [(57, 71, 'B_Disease')]}], ['Facial dysmorphism improved in two patients .', {'entities': [(0, 6, 'B_Disease'), (7, 18, 'I_Disease')]}], ['No relapse of PTLD was observed .', {'entities': [(14, 18, 'B_Disease')]}], ['Five patients developed pneumonia ( two Pneumocystis carinii pneumonia , one infectious mononucleosis with polyclonal PTLD lung infiltrate ) and two had bronchiolitis obliterans .', {'entities': [(24, 33, 'B_Disease'), (40, 52, 'B_Disease'), (53, 60, 'I_Disease'), (61, 70, 'I_Disease'), (77, 87, 'B_Disease'), (88, 101, 'I_Disease'), (118, 122, 'B_Disease'), (153, 166, 'B_Disease'), (167, 177, 'I_Disease')]}], ['RAPA was discontinued in four patients , because of pneumonia in two , PTLD in one , and oral aphtous ulcers in one .', {'entities': [(52, 61, 'B_Disease'), (71, 75, 'B_Disease'), (94, 101, 'B_Disease'), (102, 108, 'I_Disease')]}], ['However , when converting patients to RAPA drug levels should be monitored to avoid over - immunosuppression and adequate antiviral and Pneumocystis carinii pneumonia prophylaxis should be given .', {'entities': [(136, 148, 'B_Disease'), (149, 156, 'I_Disease'), (157, 166, 'I_Disease')]}], ['Electro - oculography , electroretinography , visual evoked potentials , and multifocal electroretinography in patients with vigabatrin - attributed visual field constriction .', {'entities': [(149, 155, 'B_Disease'), (156, 161, 'I_Disease'), (162, 174, 'I_Disease')]}], ['PURPOSE : Symptomatic visual field constriction thought to be associated with vigabatrin has been reported .', {'entities': [(22, 28, 'B_Disease'), (29, 34, 'I_Disease'), (35, 47, 'I_Disease')]}], ['The current study investigated the visual fields and visual electrophysiology of eight patients with known vigabatrin - attributed visual field loss , three of whom were reported previously .', {'entities': [(131, 137, 'B_Disease'), (138, 143, 'I_Disease'), (144, 148, 'I_Disease')]}], ['RESULTS : Seven patients showed marked visual field constriction with some sparing of the temporal visual field .', {'entities': [(39, 45, 'B_Disease'), (46, 51, 'I_Disease'), (52, 64, 'I_Disease')]}], ['CONCLUSION : Marked visual field constriction appears to be associated with vigabatrin therapy .', {'entities': [(20, 26, 'B_Disease'), (27, 32, 'I_Disease'), (33, 45, 'I_Disease')]}], ['Myocardial ischemia due to coronary artery spasm during dobutamine stress echocardiography .', {'entities': [(0, 10, 'B_Disease'), (11, 19, 'I_Disease'), (27, 35, 'B_Disease'), (36, 42, 'I_Disease'), (43, 48, 'I_Disease')]}], ['Dobutamine stress echocardiography ( DSE ) is a useful and safe provocation test for myocardial ischemia .', {'entities': [(85, 95, 'B_Disease'), (96, 104, 'I_Disease')]}], ['Until now , the test has been focused only on the organic lesion in the coronary artery , and positive DSE has indicated the presence of significant fixed coronary artery stenosis .', {'entities': [(155, 163, 'B_Disease'), (164, 170, 'I_Disease'), (171, 179, 'I_Disease')]}], ['The aim of the present study is to examine whether myocardial ischemia due to coronary spasm is induced by dobutamine .', {'entities': [(51, 61, 'B_Disease'), (62, 70, 'I_Disease'), (78, 86, 'B_Disease'), (87, 92, 'I_Disease')]}], ['We performed DSE on 51 patients with coronary spastic angina but without significant fixed coronary artery stenosis .', {'entities': [(37, 45, 'B_Disease'), (46, 53, 'I_Disease'), (54, 60, 'I_Disease'), (91, 99, 'B_Disease'), (100, 106, 'I_Disease'), (107, 115, 'I_Disease')]}], ['All patients had anginal attacks at rest with ST elevation on the electrocardiogram ( variant angina ) .', {'entities': [(17, 24, 'B_Disease'), (86, 93, 'B_Disease'), (94, 100, 'I_Disease')]}], ['Coronary spasm was induced by intracoronary injection of acetylcholine , and no fixed coronary artery stenosis was documented on angiograms in all patients .', {'entities': [(86, 94, 'B_Disease'), (95, 101, 'I_Disease'), (102, 110, 'I_Disease')]}], ['All 7 patients ( 13 . 7 % ) had chest pain during asynergy , and both chest pain and electrocardiographic changes were preceded by asynergy .', {'entities': [(32, 37, 'B_Disease'), (38, 42, 'I_Disease'), (70, 75, 'B_Disease'), (76, 80, 'I_Disease')]}], ['These findings indicate that dobutamine can provoke coronary spasm in some patients with coronary spastic angina .', {'entities': [(52, 60, 'B_Disease'), (61, 66, 'I_Disease'), (89, 97, 'B_Disease'), (98, 105, 'I_Disease'), (106, 112, 'I_Disease')]}], ['When DSE is performed to evaluate coronary artery disease , not only fixed coronary stenosis , but also coronary spasm should be considered as a genesis of asynergy .', {'entities': [(34, 42, 'B_Disease'), (43, 49, 'I_Disease'), (50, 57, 'I_Disease'), (75, 83, 'B_Disease'), (84, 92, 'I_Disease'), (104, 112, 'B_Disease'), (113, 118, 'I_Disease')]}], ['Effect of intravenous metoprolol or intravenous metoprolol plus glucagon on dobutamine - induced myocardial ischemia .', {'entities': [(97, 107, 'B_Disease'), (108, 116, 'I_Disease')]}], ['CONCLUSION : During dobutamine stress testing , metoprolol attenuates or eliminates evidence of myocardial ischemia .', {'entities': [(96, 106, 'B_Disease'), (107, 115, 'I_Disease')]}], [\"The objective of this study was to explore the functional anatomy of the globus pallidus internus ( GPi ) by studying the effects of unilateral pallidotomy on parkinsonian ' off ' signs and levodopa - induced dyskinesias ( LID ) .\", {'entities': [(159, 171, 'B_Disease'), (209, 220, 'B_Disease'), (223, 226, 'B_Disease')]}], ['We found significant positive correlations between the preoperative levodopa responsiveness of motor signs and the levodopa responsiveness of scores in timed tests ( Core Assessment Program for Intracerebral Transplantations ) in the contralateral limbs and the improvement in these scores after surgery , whereas there was no correlation with the improvement in LID .', {'entities': [(363, 366, 'B_Disease')]}], [\"We also found a highly significant correlation ( P : < 0 . 0001 , r = 0 . 8 ) between the volume of the ventral lesion in the GPi and the improvement in LID in the contralateral limbs , whereas there was no correlation between the ventral volume and the improvement in parkinsonian ' off ' signs .\", {'entities': [(153, 156, 'B_Disease'), (269, 281, 'B_Disease')]}], [\"The volumes of the total lesion cylinder and the dorsal lesion did not correlate with the outcome of either dyskinesias or parkinsonian ' off ' signs .\", {'entities': [(108, 119, 'B_Disease'), (123, 135, 'B_Disease')]}], [\"The differential predictive value of levodopa responsiveness for the outcome of parkinsonian ' off ' signs and LID and the different correlations of ventral lesion volume with dyskinesias and parkinsonian ' off ' signs indicate that different anatomical or pathophysiological substrates may be responsible for the generation of parkinsonian ' off ' signs and dyskinesias .\", {'entities': [(80, 92, 'B_Disease'), (111, 114, 'B_Disease'), (176, 187, 'B_Disease'), (192, 204, 'B_Disease'), (328, 340, 'B_Disease'), (359, 370, 'B_Disease')]}], ['Whereas cells in a wider area of the GPi may be implicated in parkinsonism , the ventral GPi seems to be crucial for the manifestation of LID .', {'entities': [(62, 74, 'B_Disease'), (138, 141, 'B_Disease')]}], ['We suggest that our observations are additional proof of the functional somatotopy of the systems within the GPi that mediate parkinsonism and dyskinesias , especially along the dorsoventral trajectory used in pallidotomy .', {'entities': [(126, 138, 'B_Disease'), (143, 154, 'B_Disease')]}], ['Screening for stimulant use in adult emergency department seizure patients .', {'entities': [(58, 65, 'B_Disease')]}], ['OBJECTIVE : The objective of this study was to determine the prevalence of positive plasma drug screening for cocaine or amphetamine in adult emergency department seizure patients .', {'entities': [(163, 170, 'B_Disease')]}], ['METHODS : This prospective study evaluated consecutive eligible seizure patients who had a plasma sample collected as part of their clinical evaluation .', {'entities': [(64, 71, 'B_Disease')]}], ['Patient demographics , history of underlying drug or alcohol - related seizure disorder , estimated time from seizure to sample collection , history or suspicion of cocaine or amphetamine abuse , results of clinical urine testing for drugs of abuse , and assay results were recorded without patient identifiers .', {'entities': [(71, 78, 'B_Disease'), (110, 117, 'B_Disease'), (165, 172, 'B_Disease'), (173, 175, 'I_Disease'), (176, 187, 'I_Disease'), (188, 193, 'I_Disease')]}], ['Positive test results were more common in patient visits where there was a history or suspicion of cocaine or amphetamine abuse ( p < 0 . 0005 ) .', {'entities': [(99, 106, 'B_Disease'), (107, 109, 'I_Disease'), (110, 121, 'I_Disease'), (122, 127, 'I_Disease')]}], ['CONCLUSIONS : During this study period , routine plasma screening for cocaine and amphetamines in adult seizure patients had a low yield .', {'entities': [(104, 111, 'B_Disease')]}], ['As a result , routine plasma screening would yield few cases of stimulant drug in which there was neither a history nor suspicion of drug abuse in this population .', {'entities': [(133, 137, 'B_Disease'), (138, 143, 'I_Disease')]}], ['Contribution of sodium valproate to the syndrome of inappropriate secretion of antidiuretic hormone .', {'entities': [(40, 48, 'B_Disease'), (49, 51, 'I_Disease'), (52, 65, 'I_Disease'), (66, 75, 'I_Disease'), (76, 78, 'I_Disease'), (79, 91, 'I_Disease'), (92, 99, 'I_Disease')]}], ['We report the case of a 62 - year - old man who was administered sodium valproate ( VPA ) and who subsequently developed the syndrome of inappropriate secretion of antidiuretic hormone ( SIADH ) .', {'entities': [(125, 133, 'B_Disease'), (134, 136, 'I_Disease'), (137, 150, 'I_Disease'), (151, 160, 'I_Disease'), (161, 163, 'I_Disease'), (164, 176, 'I_Disease'), (177, 184, 'I_Disease'), (187, 192, 'B_Disease')]}], ['He had been taking VPA for treatment of idiopathic generalized tonic - clonic convulsions since he was 56 years old .', {'entities': [(63, 68, 'B_Disease'), (69, 70, 'I_Disease'), (71, 77, 'I_Disease'), (78, 89, 'I_Disease')]}], ['We consider this episode of SIADH to be the result of a combination of factors including a weakness of the central nervous system and the long - term administration of VPA .', {'entities': [(28, 33, 'B_Disease'), (91, 99, 'B_Disease'), (100, 102, 'I_Disease'), (103, 106, 'I_Disease'), (107, 114, 'I_Disease'), (115, 122, 'I_Disease'), (123, 129, 'I_Disease')]}], ['Association of nitric oxide production and apoptosis in a model of experimental nephropathy .', {'entities': [(80, 91, 'B_Disease')]}], ['We have studied the role of NO and its association with apoptosis in an experimental model of nephrotic syndrome induced by a single injection of adriamycin ( ADR ) .', {'entities': [(94, 103, 'B_Disease'), (104, 112, 'I_Disease')]}], ['Rats were stratified into control groups and ADR - induced nephropathy groups .', {'entities': [(59, 70, 'B_Disease')]}], ['RESULTS : Histopathological examination of the kidneys of rats treated with ADR revealed focal areas of mesangial proliferation and mild tubulointerstitial inflammation .', {'entities': [(104, 113, 'B_Disease'), (114, 127, 'I_Disease'), (137, 155, 'B_Disease'), (156, 168, 'I_Disease')]}], ['They also had significantly higher levels of proteinuria compared with control and treatment groups ( P < 0 . 05 ) .', {'entities': [(45, 56, 'B_Disease')]}], ['Urine nitrite levels were significantly increased in the ADR - nephropathy group ( P < 0 . 05 ) .', {'entities': [(63, 74, 'B_Disease')]}], ['In the IPRK phenylephrine and acetylcholine related responses were significantly impaired in the ADR - nephropathy group .', {'entities': [(103, 114, 'B_Disease')]}], ['However , in the ADR - nephropathy group , numerous apoptotic cells were identified in the tubulointerstitial areas .', {'entities': [(23, 34, 'B_Disease')]}], ['CONCLUSION : We suggest that interactions between NO and apoptosis are important in the pathogenesis of the ADR - induced nephrosis .', {'entities': [(122, 131, 'B_Disease')]}], ['Dual effects of melatonin on barbiturate - induced narcosis in rats .', {'entities': [(51, 59, 'B_Disease')]}], ['Melatonin affects the circadian sleep / wake cycle , but it is not clear whether it may influence drug - induced narcosis .', {'entities': [(113, 121, 'B_Disease')]}], ['Melatonin pre - treatment affected in a dual manner barbiturate narcosis , however , no dose - effect correlation was found .', {'entities': [(64, 72, 'B_Disease')]}], ['In particular , low doses reduced the latency to and prolonged the duration of barbiturate narcosis .', {'entities': [(91, 99, 'B_Disease')]}], ['In contrast , the highest dose of melatonin ( 50 mg / kg ) caused a paradoxical increase in the latency and produced a sustained reduction of the duration of narcosis , and a reduction in mortality rate .', {'entities': [(158, 166, 'B_Disease')]}], ['Melatonin 0 . 5 and 5 mg / kg influenced the duration but not the latency of ketamine - or diazepam - induced narcosis .', {'entities': [(110, 118, 'B_Disease')]}], ['Thus , the dual action of melatonin on pharmacological narcosis seems to be specific for the barbiturate mechanism of action .', {'entities': [(55, 63, 'B_Disease')]}], ['Reduced cardiotoxicity and preserved antitumor efficacy of liposome - encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized , multicenter trial of metastatic breast cancer .', {'entities': [(8, 22, 'B_Disease'), (226, 232, 'B_Disease'), (233, 239, 'I_Disease')]}], ['PURPOSE : To determine whether Myocet ( liposome - encapsulated doxorubicin ; The Liposome Company , Elan Corporation , Princeton , NJ ) in combination with cyclophosphamide significantly reduces doxorubicin cardiotoxicity while providing comparable antitumor efficacy in first - line treatment of metastatic breast cancer ( MBC ) .', {'entities': [(208, 222, 'B_Disease'), (309, 315, 'B_Disease'), (316, 322, 'I_Disease'), (325, 328, 'B_Disease')]}], ['PATIENTS AND METHODS : Two hundred ninety - seven patients with MBC and no prior chemotherapy for metastatic disease were randomized to receive either 60 mg / m ( 2 ) of Myocet ( M ) or conventional doxorubicin ( A ) , in combination with 600 mg / m ( 2 ) of cyclophosphamide ( C ) , every 3 weeks until disease progression or unacceptable toxicity .', {'entities': [(64, 67, 'B_Disease'), (340, 348, 'B_Disease')]}], ['Cardiotoxicity was defined by reductions in left - ventricular ejection fraction , assessed by serial multigated radionuclide angiography scans , or congestive heart failure ( CHF ) .', {'entities': [(0, 14, 'B_Disease'), (149, 159, 'B_Disease'), (160, 165, 'I_Disease'), (166, 173, 'I_Disease'), (176, 179, 'B_Disease')]}], ['Antitumor efficacy was assessed by objective tumor response rates ( World Health Organization criteria ) , time to progression , and survival .', {'entities': [(45, 50, 'B_Disease')]}], ['RESULTS : Six percent of MC patients versus 21 % ( including five cases of CHF ) of AC patients developed cardiotoxicity ( P = . 0002 ) .', {'entities': [(75, 78, 'B_Disease'), (106, 120, 'B_Disease')]}], ['MC patients also experienced less grade 4 neutropenia .', {'entities': [(42, 53, 'B_Disease')]}], ['CONCLUSION : Myocet improves the therapeutic index of doxorubicin by significantly reducing cardiotoxicity and grade 4 neutropenia and provides comparable antitumor efficacy , when used in combination with cyclophosphamide as first - line therapy for MBC .', {'entities': [(92, 106, 'B_Disease'), (119, 130, 'B_Disease'), (251, 254, 'B_Disease')]}], ['The role of nitrergic system in lidocaine - induced convulsion in the mouse .', {'entities': [(52, 62, 'B_Disease')]}], ['The effects of N - nitro - L - arginine - methyl ester ( L - NAME ) a nitric oxide ( NO ) synthase inhibitor and L - arginine , a NO precursor , were investigated on lidocaine - induced convulsions .', {'entities': [(186, 197, 'B_Disease')]}], ['L - NAME ( 100 mg / kg , i . p . ) and diazepam ( 2 mg / kg ) significantly decreased the incidence of lidocaine ( 50 mg / kg ) - induced convulsions .', {'entities': [(138, 149, 'B_Disease')]}], ['In contrast , the L - arginine treatment increased the incidence of lidocaine ( 80 mg / kg , i . p . ) - induced convulsions significantly .', {'entities': [(113, 124, 'B_Disease')]}], ['These results may suggest that NO is a proconvulsant mediator in lidocaine - induced convulsions .', {'entities': [(85, 96, 'B_Disease')]}], ['Erythropoietin restores the anemia - induced reduction in cyclophosphamide cytotoxicity in rat tumors .', {'entities': [(28, 34, 'B_Disease'), (75, 87, 'B_Disease'), (95, 101, 'B_Disease')]}], ['The aim of this study was to examine the impact of anemia prevention by recombinant human erythropoietin ( rHuEPO ) treatment on the cytotoxicity of cyclophosphamide in solid experimental tumors .', {'entities': [(51, 57, 'B_Disease'), (133, 145, 'B_Disease'), (188, 194, 'B_Disease')]}], ['Anemia was induced using a single dose of carboplatin ( 50 mg / kg i . v . ) resulting in a long - lasting reduction ( 30 % ) of the hemoglobin concentration .', {'entities': [(0, 6, 'B_Disease')]}], ['In a second group , the development of anemia was prevented by rHuEPO ( 1000 IU / kg ) administered s . c . three times / week starting 7 days before carboplatin application .', {'entities': [(39, 45, 'B_Disease')]}], ['Four days after carboplatin treatment , tumors ( DS - sarcoma of the rat ) were implanted s . c . onto the hind food dorsum .', {'entities': [(40, 46, 'B_Disease'), (54, 61, 'B_Disease')]}], ['Neither carboplatin nor rHuEPO treatment influenced tumor growth rate per se .', {'entities': [(52, 57, 'B_Disease')]}], ['When tumors were treated with a single dose of cyclophosphamide ( 60 mg / kg i . p . ) 5 days after implantation , a growth delay with a subsequent regrowth of the tumors was observed .', {'entities': [(5, 11, 'B_Disease'), (164, 170, 'B_Disease')]}], ['In the anemia group , the growth delay was significantly shorter compared with nonanemic controls ( 13 . 3 days versus 8 . 6 days ) .', {'entities': [(7, 13, 'B_Disease')]}], ['In the group where anemia was prevented by rHuEPO treatment , growth delay was comparable with that of nonanemic controls ( 13 . 3 days ) .', {'entities': [(19, 25, 'B_Disease')]}], ['These results suggest that chemotherapy - induced anemia reduces cytotoxicity of cyclophosphamide in tumors , whereas correction of anemia by rHuEPO treatment ( epoetin alpha ) increases the sensitivity , probably as a result of an improved oxygen supply to tumor tissue .', {'entities': [(50, 56, 'B_Disease'), (65, 77, 'B_Disease'), (101, 107, 'B_Disease'), (132, 138, 'B_Disease'), (258, 263, 'B_Disease')]}], ['Fatal haemorrhagic myocarditis secondary to cyclophosphamide therapy .', {'entities': [(6, 18, 'B_Disease'), (19, 30, 'I_Disease')]}], ['Haemorrhagic myocarditis is a rare but important complication of cyclophosphamide therapy .', {'entities': [(0, 12, 'B_Disease'), (13, 24, 'I_Disease')]}], ['Effects of verapamil on atrial fibrillation and its electrophysiological determinants in dogs .', {'entities': [(24, 30, 'B_Disease'), (31, 43, 'I_Disease')]}], ['BACKGROUND : Atrial tachycardia - induced remodeling promotes the occurrence and maintenance of atrial fibrillation ( AF ) and decreases L - type Ca ( 2 + ) current .', {'entities': [(13, 19, 'B_Disease'), (20, 31, 'I_Disease'), (96, 102, 'B_Disease'), (103, 115, 'I_Disease'), (118, 120, 'B_Disease')]}], ['There is also a clinical suggestion that acute L - type Ca ( 2 ) channel blockade can promote AF , consistent with an AF promoting effect of Ca ( 2 + ) channel inhibition .', {'entities': [(94, 96, 'B_Disease'), (118, 120, 'B_Disease')]}], ['METHODS : To evaluate the potential mechanisms of AF promotion by Ca ( 2 + ) channel blockers , we administered verapamil to morphine - chloralose anesthetized dogs .', {'entities': [(50, 52, 'B_Disease')]}], ['Epicardial mapping with 240 epicardial electrodes was used to evaluate activation during AF .', {'entities': [(89, 91, 'B_Disease')]}], ['RESULTS : Verapamil caused AF promotion in six dogs , increasing mean duration of AF induced by burst pacing , from 8 + / - 4 s ( mean + / - S . E . ) to 95 + / - 39 s ( P < 0 . 01 vs . control ) at a loading dose of 0 . 1 mg / kg and 228 + / - 101 s ( P < 0 . 0005 vs . control ) at a dose of 0 . 2 mg / kg .', {'entities': [(27, 29, 'B_Disease'), (82, 84, 'B_Disease')]}], ['In these experiments , verapamil shortened mean effective refractory period ( ERP ) from 122 + / - 5 to 114 + / - 4 ms ( P < 0 . 02 ) at a cycle length of 300 ms , decreased ERP heterogeneity ( from 15 + / - 1 to 10 + / - 1 % , P < 0 . 05 ) , heterogeneously accelerated atrial conduction and decreased the cycle length of AF ( 94 + / - 4 to 84 + / - 3 ms , P < 0 . 005 ) .', {'entities': [(323, 325, 'B_Disease')]}], ['Diltiazem did not affect ERP , AF cycle length or AF duration , but produced conduction acceleration similar to that caused by verapamil ( n = 5 ) .', {'entities': [(31, 33, 'B_Disease'), (50, 52, 'B_Disease')]}], ['In the presence of autonomic blockade , verapamil failed to promote AF and increased , rather than decreasing , refractoriness .', {'entities': [(68, 70, 'B_Disease')]}], ['Epicardial mapping suggested that verapamil promoted AF by increasing the number of simultaneous wavefronts reflected by separate zones of reactivation in each cycle .', {'entities': [(53, 55, 'B_Disease')]}], ['CONCLUSIONS : Verapamil promotes AF in normal dogs by promoting multiple circuit reentry , an effect dependent on intact autonomic tone and not shared by diltiazem .', {'entities': [(33, 35, 'B_Disease')]}], ['Calcitonin gene - related peptide levels during nitric oxide - induced headache in patients with chronic tension - type headache .', {'entities': [(71, 79, 'B_Disease'), (105, 112, 'B_Disease'), (113, 114, 'I_Disease'), (115, 119, 'I_Disease'), (120, 128, 'I_Disease')]}], ['It has been proposed that nitric oxide ( NO ) induced headache in primary headaches may be associated with release of calcitonin gene - related peptide ( CGRP ) .', {'entities': [(54, 62, 'B_Disease'), (66, 73, 'B_Disease'), (74, 83, 'I_Disease')]}], ['In the present study we aimed to investigate plasma levels of CGRP during headache induced by the NO donor glyceryl trinitrate ( GTN ) in 16 patients with chronic tension - type headache and 16 healthy controls .', {'entities': [(74, 82, 'B_Disease'), (163, 170, 'B_Disease'), (171, 172, 'I_Disease'), (173, 177, 'I_Disease'), (178, 186, 'I_Disease')]}], ['The subjects were randomly allocated to receive 0 . 5 microg / kg / min GTN or placebo over 20 min on two headache - free days .', {'entities': [(106, 114, 'B_Disease')]}], ['Both patients and controls developed significantly stronger immediate headache on the GTN day than on the placebo day and the headache was significantly more pronounced in patients than in controls .', {'entities': [(70, 78, 'B_Disease'), (126, 134, 'B_Disease')]}], ['The present study indicates that NO - induced immediate headache is not associated with release of CGRP .', {'entities': [(56, 64, 'B_Disease')]}], ['Fluconazole - induced torsade de pointes .', {'entities': [(22, 29, 'B_Disease'), (30, 32, 'I_Disease'), (33, 40, 'I_Disease')]}], [\"OBJECTIVE : To present a case of fluconazole - associated torsade de pointes ( TDP ) and discuss fluconazole ' s role in causing TDP .\", {'entities': [(58, 65, 'B_Disease'), (66, 68, 'I_Disease'), (69, 76, 'I_Disease'), (79, 82, 'B_Disease'), (129, 132, 'B_Disease')]}], ['CASE SUMMARY : A 68 - year - old white woman with Candida glabrata isolated from a presacral abscess developed TDP eight days after commencing oral fluconazole The patient had no other risk factors for TDP , including coronary artery disease , cardiomyopathy , congestive heart failure , and electrolyte abnormalities There was a temporal association between the initiation of fluconazole and TDP .', {'entities': [(111, 114, 'B_Disease'), (202, 205, 'B_Disease'), (218, 226, 'B_Disease'), (227, 233, 'I_Disease'), (234, 241, 'I_Disease'), (244, 258, 'B_Disease'), (261, 271, 'B_Disease'), (272, 277, 'I_Disease'), (278, 285, 'I_Disease'), (393, 396, 'B_Disease')]}], ['The TDP resolved when fluconazole was discontinued ; however , the patient continued to have premature ventricular contractions and nonsustained ventricular tachycardia ( NSVT ) until six days after drug cessation DISCUSSION : Use of the Naranjo probability scale indicates a probable relationship between the use of fluconazole and the development of TDP .', {'entities': [(4, 7, 'B_Disease'), (93, 102, 'B_Disease'), (103, 114, 'I_Disease'), (115, 127, 'I_Disease'), (145, 156, 'B_Disease'), (157, 168, 'I_Disease'), (171, 175, 'B_Disease'), (352, 355, 'B_Disease')]}], ['The possible mechanism is depression of rapidly activating delayed rectifier potassium currents .', {'entities': [(26, 36, 'B_Disease')]}], ['In our patient , there was no other etiology identified that could explain QT prolongation or TDP The complete disappearance of NSVT and premature ventricular contractions followed by normalization of QT interval after the drug was stopped strongly suggests fluconazole as the etiology .', {'entities': [(75, 77, 'B_Disease'), (78, 90, 'I_Disease'), (94, 97, 'B_Disease'), (128, 132, 'B_Disease'), (137, 146, 'B_Disease'), (147, 158, 'I_Disease'), (159, 171, 'I_Disease')]}], ['CONCLUSIONS : Clinicians should be aware that fluconazole , even at low doses , may cause prolongation of the QT interval , leading to TDP .', {'entities': [(90, 102, 'B_Disease'), (103, 105, 'I_Disease'), (106, 109, 'I_Disease'), (110, 112, 'I_Disease'), (113, 121, 'I_Disease'), (135, 138, 'B_Disease')]}], ['Serial electrocardiographic monitoring may be considered when fluconazole is administered in patients who are at risk for ventricular arrhythmias .', {'entities': [(122, 133, 'B_Disease'), (134, 145, 'I_Disease')]}], ['Cutaneous leucocytoclastic vasculitis associated with oxacillin .', {'entities': [(0, 9, 'B_Disease'), (10, 26, 'I_Disease'), (27, 37, 'I_Disease')]}], ['A 67 - year - old man who was treated with oxacillin for one week because of Staphylococcus aureus bacteremia , developed renal failure and diffuse , symmetric , palpable purpuric lesions on his feet .', {'entities': [(77, 91, 'B_Disease'), (92, 98, 'I_Disease'), (99, 109, 'I_Disease'), (122, 127, 'B_Disease'), (128, 135, 'I_Disease'), (171, 179, 'B_Disease'), (180, 187, 'I_Disease')]}], ['Necrotic blisters were noted on his fingers .', {'entities': [(0, 8, 'B_Disease'), (9, 17, 'I_Disease')]}], ['Skin biopsies showed findings diagnostic of leucocytoclastic vasculitis .', {'entities': [(44, 60, 'B_Disease'), (61, 71, 'I_Disease')]}], ['The rash disappeared after three weeks and renal function returned to normal .', {'entities': [(4, 8, 'B_Disease')]}], ['Leucocytoclastic vasculitis presents as palpable purpura of the lower extremities often accompanied by abdominal pain , arthralgia , and renal involvement .', {'entities': [(0, 16, 'B_Disease'), (17, 27, 'I_Disease'), (49, 56, 'B_Disease'), (103, 112, 'B_Disease'), (113, 117, 'I_Disease'), (120, 130, 'B_Disease'), (137, 142, 'B_Disease'), (143, 154, 'I_Disease')]}], ['Etiologic factors or associated disorders include infections , medications , collagen vascular disease and neoplasia .', {'entities': [(50, 60, 'B_Disease'), (77, 85, 'B_Disease'), (86, 94, 'I_Disease'), (95, 102, 'I_Disease'), (107, 116, 'B_Disease')]}], ['Oxacillin should be included among the drugs that can cause leucocytoclastic vasculitis .', {'entities': [(60, 76, 'B_Disease'), (77, 87, 'I_Disease')]}], ['The renal pathology in a case of lithium - induced diabetes insipidus .', {'entities': [(51, 59, 'B_Disease'), (60, 69, 'I_Disease')]}], ['A case of lithium - induced diabetes insipidus is reported .', {'entities': [(28, 36, 'B_Disease'), (37, 46, 'I_Disease')]}], ['Cholestatic jaundice associated with the use of metformin .', {'entities': [(0, 11, 'B_Disease'), (12, 20, 'I_Disease')]}], ['We report a patient who developed cholestatic jaundice shortly after initiation of treatment with metformin hydrochloride .', {'entities': [(34, 45, 'B_Disease'), (46, 54, 'I_Disease')]}], ['A percutaneous liver biopsy was obtained showing marked cholestasis , with portal edema , ductular proliferation , and acute inflammation .', {'entities': [(56, 67, 'B_Disease'), (82, 87, 'B_Disease'), (125, 137, 'B_Disease')]}], [\"Metformin hydrochloride was discontinued , and the patient ' s jaundice resolved slowly over a period of several months .\", {'entities': [(63, 71, 'B_Disease')]}], ['Given the onset of his jaundice 2 wk after the initiation of metformin , we believe that this case represents an example of metformin - associated hepatotoxicity , the first such case reported .', {'entities': [(23, 31, 'B_Disease'), (147, 161, 'B_Disease')]}], ['Systemic toxicity and resuscitation in bupivacaine - , levobupivacaine - , or ropivacaine - infused rats .', {'entities': [(9, 17, 'B_Disease')]}], ['We compared the systemic toxicity of bupivacaine , levobupivacaine , and ropivacaine in anesthetized rats .', {'entities': [(25, 33, 'B_Disease')]}], ['When asystole was recorded , drug infusion was stopped and a resuscitation sequence was begun .', {'entities': [(5, 13, 'B_Disease')]}], ['The cumulative doses of levobupivacaine and ropivacaine that produced seizures were similar and were larger than those of bupivacaine .', {'entities': [(70, 78, 'B_Disease')]}], ['The cumulative doses of levobupivacaine that produced dysrhythmias and asystole were smaller than the corresponding doses of ropivacaine , but they were larger than those of bupivacaine .', {'entities': [(54, 66, 'B_Disease'), (71, 79, 'B_Disease')]}], ['We conclude that the systemic toxicity of levobupivacaine is intermediate between that of ropivacaine and bupivacaine when administered at the same rate and that ropivacaine - induced cardiac arrest appears to be more susceptible to treatment than that induced by bupivacaine or levobupivacaine .', {'entities': [(30, 38, 'B_Disease'), (184, 191, 'B_Disease'), (192, 198, 'I_Disease')]}], ['Amphotericin B - induced seizures in a patient with AIDS .', {'entities': [(25, 33, 'B_Disease'), (52, 56, 'B_Disease')]}], ['OBJECTIVE : To report a case of multiple episodes of seizure activity in an AIDS patent following amphotericin B infusion .', {'entities': [(53, 60, 'B_Disease'), (76, 80, 'B_Disease')]}], ['CASE SUMMARY : A 46 - year - old African - American man experienced recurrent grand mal seizures during intravenous infusion of amphotericin B , then petit mal seizures as the infusion was stopped and the drug concentrations decreased with time .', {'entities': [(78, 83, 'B_Disease'), (84, 87, 'I_Disease'), (88, 96, 'I_Disease'), (160, 168, 'B_Disease')]}], ['Despite administration of phenytoin and lorazepam , the seizures persisted and occurred only during amphotercin B administration .', {'entities': [(56, 64, 'B_Disease')]}], ['DISCUSSION : AIDS and cryptococcal meningitis , both of which the patient had , can potentially cause seizures .', {'entities': [(13, 17, 'B_Disease'), (22, 34, 'B_Disease'), (35, 45, 'I_Disease'), (102, 110, 'B_Disease')]}], ['The patient had a history of alcohol abuse ; alcohol intake as well as withdrawal can also cause seizures .', {'entities': [(29, 36, 'B_Disease'), (37, 42, 'I_Disease'), (97, 105, 'B_Disease')]}], ['Didanosine also has a potential for inducing seizures .', {'entities': [(45, 53, 'B_Disease')]}], ['However , these other potential causes of seizure were ruled out .', {'entities': [(42, 49, 'B_Disease')]}], ['The time course of events suggested that amphotericin B was the cause of the seizures in this AIDS patient .', {'entities': [(77, 85, 'B_Disease'), (94, 98, 'B_Disease')]}], ['CONCLUSIONS : Amphotericin B seems to be the probable cause of the seizures .', {'entities': [(67, 75, 'B_Disease')]}], ['To date , only three cases of seizures associated with amphotericin B have been reported in the literature , but healthcare providers should be aware of the potential for this rare adverse effect .', {'entities': [(30, 38, 'B_Disease')]}], ['Although these drugs are highly effective and represent the mainstay of transplant immunosuppression , they are associated with acute and chronic nephrotoxicity .', {'entities': [(146, 160, 'B_Disease')]}], ['Acute nephrotoxicity , which occurs in the early period after transplantation , leads to a higher rate of dialysis , and chronic nephrotoxicity may eventually result in graft loss .', {'entities': [(6, 20, 'B_Disease'), (129, 143, 'B_Disease')]}], ['Acute and chronic nephrotoxicity is becoming more common as the use of marginal kidneys for transplantation increases .', {'entities': [(18, 32, 'B_Disease')]}], ['Two recently available immunosuppressive agents , mycophenolate mofetil and sirolimus ( rapamycin ) , have no nephrotoxicity .', {'entities': [(110, 124, 'B_Disease')]}], ['Tolerability of nimesulide and paracetamol in patients with NSAID - induced urticaria / angioedema .', {'entities': [(76, 85, 'B_Disease'), (88, 98, 'B_Disease')]}], ['In this study we investigated tolerability and reliability of nimesulide and paracetamol in a very large number of patients with an exclusive well - documented history of NSAID - induced urticaria / angioedema .', {'entities': [(187, 196, 'B_Disease'), (199, 209, 'B_Disease')]}], ['A single - placebo - controlled oral challenge procedure with nimesulide or paracetamol was applied to 829 patients with a history of NSAID - induced urticaria / angioedema .', {'entities': [(150, 159, 'B_Disease'), (162, 172, 'B_Disease')]}], ['Furthermore , 18 . 28 % of patients with a history of chronic urticaria and 11 . 8 % of subjects with an history of NSAID - induced urticaria / angioedema or angioedema alone ( with or without chronic urticaria ) resulted to be intolerant to alternative drugs .', {'entities': [(62, 71, 'B_Disease'), (132, 141, 'B_Disease'), (144, 154, 'B_Disease'), (158, 168, 'B_Disease'), (201, 210, 'B_Disease')]}], ['Taken together , our results confirm the good tolerability of nimesulide and paracetamol in patients who experienced urticaria / angioedema caused by NSAIDs .', {'entities': [(117, 126, 'B_Disease'), (129, 139, 'B_Disease')]}], ['However , the risk of reaction to these alternative study drugs is statistically increased by a history of chronic urticaria and , above all , by a history of NSAID - induced angioedema .', {'entities': [(115, 124, 'B_Disease'), (175, 185, 'B_Disease')]}], ['Comparison of aqueous and gellan ophthalmic timolol with placebo on the 24 - hour heart rate response in patients on treatment for glaucoma .', {'entities': [(131, 139, 'B_Disease')]}], ['PURPOSE : Topical beta - blocker treatment is routine therapy in the management of patients with glaucoma .', {'entities': [(97, 105, 'B_Disease')]}], ['DESIGN : This trial evaluated the effect of placebo , 0 . 5 % aqueous timolol ( timolol solution ) and a 0 . 5 % timolol suspension that forms a gel on application to the conjunctiva ( timolol gellan ) on the 24 - hour heart rate in patients currently being treated for glaucoma to quantify the reduction in mean heart rate .', {'entities': [(270, 278, 'B_Disease')]}], ['METHODS : Forty - three Caucasian patients with primary open - angle glaucoma or ocular hypertension with a mean ( + / - SD ) age of 63 ( + / - 8 ) years were randomized and crossed over in a double - masked manner to 14 days of treatment with placebo ( morning and evening in both eyes ) , timolol solution ( morning and evening in both eyes ) , or timolol gellan ( morning in both eyes with placebo in the evening ) .', {'entities': [(56, 60, 'B_Disease'), (61, 62, 'I_Disease'), (63, 68, 'I_Disease'), (69, 77, 'I_Disease'), (81, 87, 'B_Disease'), (88, 100, 'I_Disease')]}], ['These data quantify the modest bradycardia associated with ophthalmic beta - blocker therapy in a typical patient population on therapy for glaucoma .', {'entities': [(31, 42, 'B_Disease'), (140, 148, 'B_Disease')]}], ['Management strategies for ribavirin - induced hemolytic anemia in the treatment of hepatitis C : clinical and economic implications .', {'entities': [(46, 55, 'B_Disease'), (56, 62, 'I_Disease'), (83, 92, 'B_Disease'), (93, 94, 'I_Disease')]}], ['OBJECTIVES : Recently published studies have demonstrated increased efficacy and cost - effectiveness of combination therapy with interferon and alpha - 2b / ribavirin compared with interferon - alpha monotherapy in the treatment of chronic hepatitis C ( CHC ) .', {'entities': [(233, 240, 'B_Disease'), (241, 250, 'I_Disease'), (251, 252, 'I_Disease'), (255, 258, 'B_Disease')]}], ['Combination therapy is associated with a clinically important adverse effect : ribavirin - induced hemolytic anemia ( RIHA ) .', {'entities': [(99, 108, 'B_Disease'), (109, 115, 'I_Disease'), (118, 122, 'B_Disease')]}], ['The objective of this study was to evaluate the direct health - care costs and management of RIHA during treatment of CHC in a clinical trial setting .', {'entities': [(93, 97, 'B_Disease'), (118, 121, 'B_Disease')]}], ['METHODS : A systematic literature review was conducted to synthesize information on the incidence and management of RIHA .', {'entities': [(116, 120, 'B_Disease')]}], ['Decision - analytic techniques were used to estimate the cost of treating RIHA .', {'entities': [(74, 78, 'B_Disease')]}], ['RESULTS : RIHA , defined as a reduction in hemoglobin to less than 100 g / L , occurs in approximately 7 % to 9 % of patients treated with combination therapy .', {'entities': [(10, 14, 'B_Disease')]}], ['The standard of care for management of RIHA is reduction or discontinuation of the ribavirin dosage .', {'entities': [(39, 43, 'B_Disease')]}], ['We estimated the direct cost of treating clinically significant RIHA to be 170 per patient receiving combination therapy per 48 - week treatment course ( range 68 - 692 ) .', {'entities': [(64, 68, 'B_Disease')]}], ['CONCLUSIONS : The direct cost of treating clinically significant RIHA is 1 % ( 170 / 16 , 459 ) of drug treatment costs .', {'entities': [(65, 69, 'B_Disease')]}], ['Questions remain about the optimal dose of ribavirin and the incidence of RIHA in a real - world population .', {'entities': [(74, 78, 'B_Disease')]}], ['Despite these uncertainties , this initial evaluation of the direct cost of treating RIHA provides an estimate of the cost and management implications of this clinically important adverse effect .', {'entities': [(85, 89, 'B_Disease')]}], ['BACKGROUND : Preclinical studies of intrathecal adenosine suggest it may be effective in the treatment of acute and chronic pain in humans , and preliminary studies in volunteers and patients with a Swedish formulation of adenosine suggests it may be effective in hypersensitivity states but not with acute noxious stimulation .', {'entities': [(106, 111, 'B_Disease'), (112, 115, 'I_Disease'), (116, 123, 'I_Disease'), (124, 128, 'I_Disease'), (264, 280, 'B_Disease')]}], ['The purpose of this study was to screen for efficacy of a different formulation of adenosine marketed in the US , using both acute noxious stimulation and capsaicin - evoked mechanical hypersensitivity .', {'entities': [(185, 201, 'B_Disease')]}], ['Cerebrospinal fluid was obtained for pharmacokinetic analysis , and pain ratings in response to acute heat stimuli and areas of mechanical hyperalgesia and allodynia after intradermal capsaicin injection were determined .', {'entities': [(68, 72, 'B_Disease'), (128, 138, 'B_Disease'), (139, 151, 'I_Disease'), (156, 165, 'B_Disease')]}], ['RESULTS : Adenosine produced no effect on pain report to acute noxious thermal or chemical stimulation but reduced mechanical hyperalgesia and allodynia from intradermal capsaicin injection for at least 24 h .', {'entities': [(42, 46, 'B_Disease'), (115, 125, 'B_Disease'), (126, 138, 'I_Disease'), (143, 152, 'B_Disease')]}], ['CONCLUSIONS : These results show selective inhibition by intrathecal adenosine of hypersensitivity , presumed to reflect central sensitization in humans after peripheral capsaicin injection .', {'entities': [(82, 98, 'B_Disease')]}], ['The long - lasting effect is consistent with that observed in preliminary reports of patients with chronic neuropathic pain and is not due to prolonged residence of adenosine in cerebrospinal fluid .', {'entities': [(107, 118, 'B_Disease'), (119, 123, 'I_Disease')]}], ['Delayed - onset heparin - induced thrombocytopenia .', {'entities': [(34, 50, 'B_Disease')]}], ['BACKGROUND : Heparin - induced thrombocytopenia presents 5 to 12 days after heparin exposure , with or without arterial or venous thromboemboli .', {'entities': [(31, 47, 'B_Disease'), (111, 119, 'B_Disease'), (120, 122, 'I_Disease'), (123, 129, 'I_Disease'), (130, 143, 'I_Disease')]}], ['Delayed recognition and treatment of heparin - induced thrombocytopenia contribute to poor patient outcomes .', {'entities': [(55, 71, 'B_Disease')]}], ['OBJECTIVE : To describe and increase awareness of a clinical scenario in which the onset or manifestations of heparin - induced thrombocytopenia are delayed .', {'entities': [(128, 144, 'B_Disease')]}], ['PATIENTS : 14 patients seen over a 3 - year period in whom heparin - induced thrombocytopenia became apparent on delayed presentation with thromboembolic complications .', {'entities': [(77, 93, 'B_Disease'), (139, 153, 'B_Disease')]}], ['MEASUREMENTS : Platelet counts , onset of objectively determined thromboembolism , results of heparin - induced platelet factor 4 antibody tests , and outcomes .', {'entities': [(65, 80, 'B_Disease')]}], ['RESULTS : Patients went home after hospitalizations that had included heparin exposure - - in most cases , with no thrombocytopenia recognized - - only to return to the hospital ( median , day 14 ) with thromboembolic complications .', {'entities': [(115, 131, 'B_Disease'), (203, 217, 'B_Disease')]}], ['Thromboemboli were venous ( 12 patients , 7 with pulmonary emboli ) or arterial ( 4 patients ) or both .', {'entities': [(0, 13, 'B_Disease'), (49, 58, 'B_Disease'), (59, 65, 'I_Disease')]}], ['CONCLUSIONS : Delayed - onset heparin - induced thrombocytopenia is increasingly being recognized .', {'entities': [(48, 64, 'B_Disease')]}], ['To avoid disastrous outcomes , physicians must consider heparin - induced thrombocytopenia whenever a recently hospitalized patient returns with thromboembolism ; therapy with alternative anticoagulants , not heparin , should be initiated .', {'entities': [(74, 90, 'B_Disease'), (145, 160, 'B_Disease')]}], ['Treatment of risperidone - induced hyperprolactinemia with a dopamine agonist in children .', {'entities': [(35, 53, 'B_Disease')]}], ['BACKGROUND : Risperidone , a potent antagonist of both serotonergic ( 5HT2A ) and dopaminergic D2 receptors is associated with hyperprolactinemia in adults and children .', {'entities': [(127, 145, 'B_Disease')]}], ['Chronically elevated prolactin levels in children with prolactinomas may be associated with arrested growth and development resulting in either delayed puberty or short stature .', {'entities': [(55, 68, 'B_Disease'), (144, 151, 'B_Disease'), (152, 159, 'I_Disease')]}], ['These possibilities stress the importance of developing a safe and effective approach to drug - induced hyperprolactinemia in youth .', {'entities': [(104, 122, 'B_Disease')]}], ['We report the successful treatment of risperidone - induced hyperprolactinemia with cabergoline in youth .', {'entities': [(60, 78, 'B_Disease')]}], ['METHODS : We undertook a retrospective case review of four children with risperidone - induced hyperprolactinemia treated with cabergoline .', {'entities': [(95, 113, 'B_Disease')]}], ['RESULTS : Four males ( age 6 - 11 years ) with Diagnostic and Statistical Manual of Mental Disorders ( fourth edition ) bipolar disorder or psychoses , with risperidone - induced elevations in serum prolactin levels ( 57 . 5 - 129 ng / mL , normal 5 - 15 ng / mL ) , were treated with cabergoline ( mean dose 2 . 13 + / - 0 . 09 mg / week ) .', {'entities': [(84, 90, 'B_Disease'), (91, 100, 'I_Disease'), (120, 127, 'B_Disease'), (128, 136, 'I_Disease'), (140, 149, 'B_Disease')]}], ['CONCLUSIONS : Cabergoline may be useful for the treatment of risperidone - induced hyperprolactinemia in youth ; however , further research is needed .', {'entities': [(83, 101, 'B_Disease')]}], ['Acute cholestatic hepatitis after exposure to isoflurane .', {'entities': [(6, 17, 'B_Disease'), (18, 27, 'I_Disease')]}], ['OBJECTIVE : To report a case of acute cholestatic hepatitis following exposure to the inhalational anesthetic isoflurane .', {'entities': [(38, 49, 'B_Disease'), (50, 59, 'I_Disease')]}], ['CASE SUMMARY : A 70 - year - old healthy woman from Iraq developed acute cholestatic hepatitis 3 weeks following repair of the right rotator cuff under general anesthesia .', {'entities': [(73, 84, 'B_Disease'), (85, 94, 'I_Disease')]}], ['There was no evidence for viral , autoimmune , or metabolic causes of hepatitis .', {'entities': [(70, 79, 'B_Disease')]}], ['No other medications were involved except for dipyrone for analgesia .', {'entities': [(59, 68, 'B_Disease')]}], ['DISCUSSION : The clinical and histologic picture of this case resembles halothane hepatitis , which has a significant mortality rate .', {'entities': [(72, 81, 'B_Disease'), (82, 91, 'I_Disease')]}], ['CONCLUSIONS : Isoflurane , a common anesthetic agent , can cause severe cholestatic hepatitis .', {'entities': [(72, 83, 'B_Disease'), (84, 93, 'I_Disease')]}], ['Torsade de pointes induced by metoclopramide in an elderly woman with preexisting complete left bundle branch block .', {'entities': [(0, 7, 'B_Disease'), (8, 10, 'I_Disease'), (11, 18, 'I_Disease'), (91, 95, 'B_Disease'), (96, 102, 'I_Disease'), (103, 109, 'I_Disease'), (110, 115, 'I_Disease')]}], ['There is a growing list of drugs implicated in acquired long QT syndrome and torsade de pointes .', {'entities': [(56, 60, 'B_Disease'), (61, 63, 'I_Disease'), (64, 72, 'I_Disease'), (77, 84, 'B_Disease'), (85, 87, 'I_Disease'), (88, 95, 'I_Disease')]}], ['We report on a 92 - year - old woman with preexisting complete left bundle branch block who developed torsade de pointes after intravenous and oral administration of metoclopramide .', {'entities': [(63, 67, 'B_Disease'), (68, 74, 'I_Disease'), (75, 81, 'I_Disease'), (82, 87, 'I_Disease'), (102, 109, 'B_Disease'), (110, 112, 'I_Disease'), (113, 120, 'I_Disease')]}], ['This patient also developed torsade de pointes when cisapride and erythromycin were given simultaneously .', {'entities': [(28, 35, 'B_Disease'), (36, 38, 'I_Disease'), (39, 46, 'I_Disease')]}], ['This is the first documentation that metoclopramide provokes torsade de pointes clinically .', {'entities': [(61, 68, 'B_Disease'), (69, 71, 'I_Disease'), (72, 79, 'I_Disease')]}], ['Metoclopramide should be used cautiously in patients with a risk of torsade de pointes .', {'entities': [(68, 75, 'B_Disease'), (76, 78, 'I_Disease'), (79, 86, 'I_Disease')]}], ['Dopamine ( DA ) , through D1 / D2 receptor - mediated signaling , plays a major role in the control of epileptic seizures arising in the limbic system .', {'entities': [(103, 112, 'B_Disease'), (113, 121, 'I_Disease')]}], ['Excitotoxicity leading to neuronal cell death in the affected areas is a major consequence of seizures at the cellular level .', {'entities': [(0, 14, 'B_Disease'), (94, 102, 'B_Disease')]}], ['In this respect , little is known about the role of DA receptors in the occurrence of epilepsy - induced neuronal cell death .', {'entities': [(86, 94, 'B_Disease')]}], ['Here we analyze the occurrence of seizures and neurotoxicity in D2R - / - mice treated with the cholinergic agonist pilocarpine .', {'entities': [(34, 42, 'B_Disease'), (47, 60, 'B_Disease')]}], ['Importantly , D2R - / - mice develop seizures at doses of both drugs that are not epileptogenic for WT littermates and show greater neurotoxicity .', {'entities': [(37, 45, 'B_Disease'), (132, 145, 'B_Disease')]}], ['However , pilocarpine - induced seizures result in a more widespread neuronal death in both WT and D2R - / - brains in comparison to KA .', {'entities': [(32, 40, 'B_Disease')]}], ['Thus , the absence of D2R lowers the threshold for seizures induced by both glutamate and acetylcholine .', {'entities': [(51, 59, 'B_Disease')]}], ['Moreover , the dopaminergic control of epilepsy - induced neurodegeneration seems to be mediated by distinct interactions of D2R signaling with these two neurotransmitters .', {'entities': [(39, 47, 'B_Disease'), (58, 75, 'B_Disease')]}], ['Steroid structure and pharmacological properties determine the anti - amnesic effects of pregnenolone sulphate in the passive avoidance task in rats .', {'entities': [(70, 77, 'B_Disease')]}], ['Moreover , PREGS is able to reverse the amnesic - like effects of NMDAR and GABA ( A ) R ligands .', {'entities': [(40, 47, 'B_Disease')]}], ['The memory - enhancing effects of PREGS and its analogs were tested in the passive avoidance task using the model of scopolamine - induced amnesia .', {'entities': [(139, 146, 'B_Disease')]}], ['Moreover , enantioselectivity was demonstrated by the ability of natural PREGS to be an order of magnitude more effective than its synthetic enantiomer in reversing scopolamine - induced amnesia .', {'entities': [(187, 194, 'B_Disease')]}], ['Activation of poly ( ADP - ribose ) polymerase contributes to development of doxorubicin - induced heart failure .', {'entities': [(99, 104, 'B_Disease'), (105, 112, 'I_Disease')]}], ['Increased oxidative stress is a major factor implicated in the cardiotoxicity of doxorubicin ( DOX ) , a widely used antitumor anthracycline antibiotic .', {'entities': [(63, 77, 'B_Disease')]}], ['Thus , we hypothesized that the activation of PARP may contribute to the DOX - induced cardiotoxicity .', {'entities': [(87, 101, 'B_Disease')]}], ['Using a dual approach of PARP - 1 suppression , by genetic deletion or pharmacological inhibition with the phenanthridinone PARP inhibitor PJ34 , we now demonstrate the role of PARP in the development of cardiac dysfunction induced by DOX .', {'entities': [(204, 211, 'B_Disease'), (212, 223, 'I_Disease')]}], ['Treatment with a PJ34 significantly improved cardiac dysfunction and increased the survival of the animals .', {'entities': [(45, 52, 'B_Disease'), (53, 64, 'I_Disease')]}], ['Thus , PARP activation contributes to the cardiotoxicity of DOX .', {'entities': [(42, 56, 'B_Disease')]}], ['PARP inhibitors may exert protective effects against the development of severe cardiac complications associated with the DOX treatment .', {'entities': [(79, 86, 'B_Disease'), (87, 100, 'I_Disease')]}], ['Spironolactone : is it a novel drug for the prevention of amphotericin B - related hypokalemia in cancer patients ?', {'entities': [(83, 94, 'B_Disease'), (98, 104, 'B_Disease')]}], ['OBJECTIVE : Nephrotoxicity is the major adverse effect of amphotericin B ( AmB ) , often limiting administration of full dosage .', {'entities': [(12, 26, 'B_Disease')]}], ['Selective distal tubular epithelial toxicity seems to be responsible for the profound potassium wasting that is a major clinical side effect of treatment with AmB .', {'entities': [(36, 44, 'B_Disease')]}], ['Potassium depletion also potentiates the tubular toxicity of AmB .', {'entities': [(49, 57, 'B_Disease')]}], ['This study was designed to assess the ability of spironolactone to reduce potassium requirements and to prevent hypokalemia in neutropenic patients on AmB treatment .', {'entities': [(112, 123, 'B_Disease'), (127, 138, 'B_Disease')]}], ['METHODS : In this study 26 patients with various hematological disorders were randomized to receive either intravenous AmB alone or AmB and oral spironolactone 100 mg twice daily when developing a proven or suspected fungal infection .', {'entities': [(49, 62, 'B_Disease'), (63, 72, 'I_Disease'), (217, 223, 'B_Disease'), (224, 233, 'I_Disease')]}], ['CONCLUSION : This study showed that spironolactone can reduce potassium requirements and prevent hypokalemia by reducing urinary potassium loss in neutropenic patients on AmB treatment .', {'entities': [(97, 108, 'B_Disease'), (147, 158, 'B_Disease')]}], ['Erectile dysfunction occurs following substantia nigra lesions in the rat .', {'entities': [(0, 8, 'B_Disease'), (9, 20, 'I_Disease')]}], [\"Lesions of the substantia nigra are therefore associated with erectile dysfunction in rats and may serve as a model to study erectile dysfunction in Parkinson ' s disease .\", {'entities': [(62, 70, 'B_Disease'), (71, 82, 'I_Disease'), (125, 133, 'B_Disease'), (134, 145, 'I_Disease'), (149, 158, 'B_Disease'), (159, 160, 'I_Disease'), (161, 162, 'I_Disease'), (163, 170, 'I_Disease')]}], ['Nicotine potentiation of morphine - induced catalepsy in mice .', {'entities': [(44, 53, 'B_Disease')]}], ['In the present study , effects of nicotine on catalepsy induced by morphine in mice have been investigated .', {'entities': [(46, 55, 'B_Disease')]}], ['Morphine but not nicotine induced a dose - dependent catalepsy .', {'entities': [(53, 62, 'B_Disease')]}], ['Intraperitoneal administration of atropine , naloxone , mecamylamine , and hexamethonium to mice reduced catalepsy induced by a combination of morphine with nicotine .', {'entities': [(105, 114, 'B_Disease')]}], ['Intracerebroventricular injection of atropine , hexamethonium , and naloxone also decreased catalepsy induced by morphine plus nicotine .', {'entities': [(92, 101, 'B_Disease')]}], ['It was concluded that morphine catalepsy can be elicited by opioid and cholinergic receptors , and the potentiation of morphine induced by nicotine may also be mediated through cholinergic receptor mechanisms .', {'entities': [(31, 40, 'B_Disease')]}], [\"Force overflow and levodopa - induced dyskinesias in Parkinson ' s disease .\", {'entities': [(38, 49, 'B_Disease'), (53, 62, 'B_Disease'), (63, 64, 'I_Disease'), (65, 66, 'I_Disease'), (67, 74, 'I_Disease')]}], [\"We assessed force coordination of the hand in Parkinson ' s disease and its relationship to motor complications of levodopa therapy , particularly to levodopa - induced dyskinesias ( LID ) .\", {'entities': [(46, 55, 'B_Disease'), (56, 57, 'I_Disease'), (58, 59, 'I_Disease'), (60, 67, 'I_Disease'), (169, 180, 'B_Disease'), (183, 186, 'B_Disease')]}], [\"We studied two groups of Parkinson ' s disease patients with ( Parkinson ' s disease + LID , n = 23 ) and without levodopa - induced dyskinesias ( Parkinson ' s disease - LID , n = 10 ) , and age - matched healthy controls .\", {'entities': [(25, 34, 'B_Disease'), (35, 36, 'I_Disease'), (37, 38, 'I_Disease'), (39, 46, 'I_Disease'), (63, 72, 'B_Disease'), (73, 74, 'I_Disease'), (75, 76, 'I_Disease'), (77, 84, 'I_Disease'), (87, 90, 'B_Disease'), (133, 144, 'B_Disease'), (147, 156, 'B_Disease'), (157, 158, 'I_Disease'), (159, 160, 'I_Disease'), (161, 168, 'I_Disease'), (171, 174, 'B_Disease')]}], [\"The motor score of the Unified Parkinson ' s Disease Rating Scale , a dyskinesia score and force in a grip - lift paradigm were assessed ON and OFF levodopa .\", {'entities': [(31, 40, 'B_Disease'), (41, 42, 'I_Disease'), (43, 44, 'I_Disease'), (45, 52, 'I_Disease'), (70, 80, 'B_Disease')]}], [\"A pathological increase of forces was seen in ON - state in Parkinson ' s disease + LID only .\", {'entities': [(60, 69, 'B_Disease'), (70, 71, 'I_Disease'), (72, 73, 'I_Disease'), (74, 81, 'I_Disease'), (84, 87, 'B_Disease')]}], [\"In Parkinson ' s disease + LID , the force involved in pressing down the object before lifting was significantly increased by levodopa ( by 61 % , P < 0 . 05 ) .\", {'entities': [(3, 12, 'B_Disease'), (13, 14, 'I_Disease'), (15, 16, 'I_Disease'), (17, 24, 'I_Disease'), (27, 30, 'B_Disease')]}], [\"In contrast , no excessive force was found in Parkinson ' s disease - LID .\", {'entities': [(46, 55, 'B_Disease'), (56, 57, 'I_Disease'), (58, 59, 'I_Disease'), (60, 67, 'I_Disease'), (70, 73, 'B_Disease')]}], [\"Peak grip force in ON - state was 140 % ( P < 0 . 05 ) higher in Parkinson ' s disease + LID than in Parkinson ' s disease - LID , while static grip force was increased by 138 % ( P < 0 . 01 ) between groups .\", {'entities': [(65, 74, 'B_Disease'), (75, 76, 'I_Disease'), (77, 78, 'I_Disease'), (79, 86, 'I_Disease'), (89, 92, 'B_Disease'), (101, 110, 'B_Disease'), (111, 112, 'I_Disease'), (113, 114, 'I_Disease'), (115, 122, 'I_Disease'), (125, 128, 'B_Disease')]}], ['Severity of peak - dose dyskinesias was strongly correlated with grip force in ON - state ( r = 0 . 79 with peak force , P < 0 . 01 ) .', {'entities': [(24, 35, 'B_Disease')]}], ['Force excess was only observed in patients with LID and motor fluctuations .', {'entities': [(48, 51, 'B_Disease')]}], ['A close relationship was seen between the overshooting of forces and dyskinesias in the ON - drug condition .', {'entities': [(69, 80, 'B_Disease')]}], ['We postulate that both LID and grip force excess share common pathophysiological mechanisms related to motor fluctuations .', {'entities': [(23, 26, 'B_Disease')]}], [\"This study focuses on behavioral syndromes that may used as models for Parkinson ' s disease , or tardive dyskinesia , and its response after glutamatergic blockage .\", {'entities': [(71, 80, 'B_Disease'), (81, 82, 'I_Disease'), (83, 84, 'I_Disease'), (85, 92, 'I_Disease'), (98, 105, 'B_Disease'), (106, 116, 'I_Disease')]}], ['Reserpine ( 1 mg / kg ) , administered once every other day for 4 days , produced increases in orofacial dyskinesia , tongue protrusion and vacuous chewing in mice , which are signs indicative of tardive dyskinesia .', {'entities': [(95, 104, 'B_Disease'), (105, 115, 'I_Disease'), (196, 203, 'B_Disease'), (204, 214, 'I_Disease')]}], [\"Reserpine also produced tremor and catalepsy , which are signs suggestive of Parkinson ' s disease .\", {'entities': [(24, 30, 'B_Disease'), (35, 44, 'B_Disease'), (77, 86, 'B_Disease'), (87, 88, 'I_Disease'), (89, 90, 'I_Disease'), (91, 98, 'I_Disease')]}], ['MK - 801 ( 0 . 1 mg / kg ) , administered 30 min before the observation test , prevented the vacuous chewing movements , tongue protrusions and catalepsy induced by reserpine .', {'entities': [(144, 153, 'B_Disease')]}], ['However , MK - 801 injection produced a significant increase of tremor in reserpine - treated mice .', {'entities': [(64, 70, 'B_Disease')]}], ['Reserpine ( 1 mg / kg ) , administered 90 min before the test and followed by apomophine injection ( 0 . 1 mg / kg ) 5 min before the test , did not produce oral dyskinesia in mice .', {'entities': [(157, 161, 'B_Disease'), (162, 172, 'I_Disease')]}], ['On the other hand , reserpine induced increases in tremor and catalepsy compared to control mice .', {'entities': [(51, 57, 'B_Disease'), (62, 71, 'B_Disease')]}], ['MK - 801 ( 0 . 1 mg / kg ) administration attenuated the catalepsy and tremor induced by reserpine .', {'entities': [(57, 66, 'B_Disease'), (71, 77, 'B_Disease')]}], ['Pretreatment with reserpine ( 1 mg / kg ) 24 h before the observation test produced increases in vacuous chewing movements and tongue protrusion , as well as increases in tremor and catalepsy , whereas MK - 801 ( 0 . 1 mg / kg ) injection 90 min before the test reversed the effects of reserpine .', {'entities': [(171, 177, 'B_Disease'), (182, 191, 'B_Disease')]}], ['These results show that reserpine produces different and abnormal movements , which are related to dose and schedule employed and can be considered as parkinsonian - like and tardive dsykinesia signs .', {'entities': [(57, 65, 'B_Disease'), (66, 75, 'I_Disease'), (151, 163, 'B_Disease'), (175, 182, 'B_Disease'), (183, 193, 'I_Disease')]}], ['The glutamatergic blockage produced by NMDA can restore these signs , such as vacuous chewing movements , tongue protrusions , catalepsy and tremor according to the employed model .', {'entities': [(127, 136, 'B_Disease'), (141, 147, 'B_Disease')]}], ['Risperidone - associated , benign transient visual disturbances in schizophrenic patients with a past history of LSD abuse .', {'entities': [(44, 50, 'B_Disease'), (51, 63, 'I_Disease'), (67, 80, 'B_Disease')]}], ['Two schizophrenic patients , who had a prior history of LSD abuse and who had previously developed EPS with classic antipsychotics , were successfully treated with risperidone .', {'entities': [(4, 17, 'B_Disease'), (99, 102, 'B_Disease')]}], ['They both reported short episodes of transient visual disturbances , which appeared immediately after starting treatment with risperidone .', {'entities': [(47, 53, 'B_Disease'), (54, 66, 'I_Disease')]}], ['This imagery resembled visual disturbances previously experienced as \" flashbacks \" related to prior LSD consumption .', {'entities': [(23, 29, 'B_Disease'), (30, 42, 'I_Disease')]}], ['Risperidone administration was continued and the visual disturbances gradually wore off .', {'entities': [(49, 55, 'B_Disease'), (56, 68, 'I_Disease')]}], ['During a six - month follow - up period , there was no recurrence of visual disturbances .', {'entities': [(69, 75, 'B_Disease'), (76, 88, 'I_Disease')]}], ['Topiramate - induced nephrolithiasis .', {'entities': [(21, 36, 'B_Disease')]}]]\n",
      "lenth of the TRAIN_DATA : 3070\n"
     ]
    }
   ],
   "source": [
    "VALID_DATA, _ = load_data_spacy(\"/content/train_dev.tsv\")\n",
    "print(VALID_DATA)\n",
    "print(\"lenth of the TRAIN_DATA :\",len(VALID_DATA))"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "HZy17C-RyBpx"
   },
   "source": [
    "##Download Spacy Medium corpus"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "1XaAZawaswL8",
    "outputId": "6fbe4a50-2ded-4b4c-996e-3fdc03130a55"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Collecting en_core_web_md==2.2.5\n",
      "\u001b[?25l  Downloading https://github.com/explosion/spacy-models/releases/download/en_core_web_md-2.2.5/en_core_web_md-2.2.5.tar.gz (96.4MB)\n",
      "\u001b[K     |████████████████████████████████| 96.4MB 1.2MB/s \n",
      "\u001b[?25hRequirement already satisfied: spacy>=2.2.2 in /usr/local/lib/python3.7/dist-packages (from en_core_web_md==2.2.5) (2.2.4)\n",
      "Requirement already satisfied: catalogue<1.1.0,>=0.0.7 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (1.0.0)\n",
      "Requirement already satisfied: blis<0.5.0,>=0.4.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (0.4.1)\n",
      "Requirement already satisfied: cymem<2.1.0,>=2.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (2.0.5)\n",
      "Requirement already satisfied: thinc==7.4.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (7.4.0)\n",
      "Requirement already satisfied: numpy>=1.15.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (1.19.5)\n",
      "Requirement already satisfied: plac<1.2.0,>=0.9.6 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (1.1.3)\n",
      "Requirement already satisfied: preshed<3.1.0,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (3.0.5)\n",
      "Requirement already satisfied: murmurhash<1.1.0,>=0.28.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (1.0.5)\n",
      "Requirement already satisfied: tqdm<5.0.0,>=4.38.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (4.41.1)\n",
      "Requirement already satisfied: wasabi<1.1.0,>=0.4.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (0.8.2)\n",
      "Requirement already satisfied: requests<3.0.0,>=2.13.0 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (2.23.0)\n",
      "Requirement already satisfied: srsly<1.1.0,>=1.0.2 in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (1.0.5)\n",
      "Requirement already satisfied: setuptools in /usr/local/lib/python3.7/dist-packages (from spacy>=2.2.2->en_core_web_md==2.2.5) (57.0.0)\n",
      "Requirement already satisfied: importlib-metadata>=0.20; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from catalogue<1.1.0,>=0.0.7->spacy>=2.2.2->en_core_web_md==2.2.5) (4.6.0)\n",
      "Requirement already satisfied: idna<3,>=2.5 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.2->en_core_web_md==2.2.5) (2.10)\n",
      "Requirement already satisfied: urllib3!=1.25.0,!=1.25.1,<1.26,>=1.21.1 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.2->en_core_web_md==2.2.5) (1.24.3)\n",
      "Requirement already satisfied: chardet<4,>=3.0.2 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.2->en_core_web_md==2.2.5) (3.0.4)\n",
      "Requirement already satisfied: certifi>=2017.4.17 in /usr/local/lib/python3.7/dist-packages (from requests<3.0.0,>=2.13.0->spacy>=2.2.2->en_core_web_md==2.2.5) (2021.5.30)\n",
      "Requirement already satisfied: typing-extensions>=3.6.4; python_version < \"3.8\" in /usr/local/lib/python3.7/dist-packages (from importlib-metadata>=0.20; python_version < \"3.8\"->catalogue<1.1.0,>=0.0.7->spacy>=2.2.2->en_core_web_md==2.2.5) (3.7.4.3)\n",
      "Requirement already satisfied: zipp>=0.5 in /usr/local/lib/python3.7/dist-packages (from importlib-metadata>=0.20; python_version < \"3.8\"->catalogue<1.1.0,>=0.0.7->spacy>=2.2.2->en_core_web_md==2.2.5) (3.4.1)\n",
      "Building wheels for collected packages: en-core-web-md\n",
      "  Building wheel for en-core-web-md (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
      "  Created wheel for en-core-web-md: filename=en_core_web_md-2.2.5-cp37-none-any.whl size=98051304 sha256=8c22ebb20a2c13da7c3acd00082b8f67e763958f0ecb4d44158b30c2211c645a\n",
      "  Stored in directory: /tmp/pip-ephem-wheel-cache-bm7b5m2p/wheels/df/94/ad/f5cf59224cea6b5686ac4fd1ad19c8a07bc026e13c36502d81\n",
      "Successfully built en-core-web-md\n",
      "Installing collected packages: en-core-web-md\n",
      "Successfully installed en-core-web-md-2.2.5\n",
      "\u001b[38;5;2m✔ Download and installation successful\u001b[0m\n",
      "You can now load the model via spacy.load('en_core_web_md')\n"
     ]
    }
   ],
   "source": [
    "!python -m spacy download en_core_web_md"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "GjlxiwCoyIq0"
   },
   "source": [
    "## Load Spacy Medium"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 11,
   "metadata": {
    "id": "nvci_vZ_twke"
   },
   "outputs": [],
   "source": [
    "import en_core_web_md\n",
    "nlp = en_core_web_md.load()"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "E-Ppzt9wyOJf"
   },
   "source": [
    "## Get ner model from spacy pipeline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 12,
   "metadata": {
    "id": "EG9auAZorGR3"
   },
   "outputs": [],
   "source": [
    "if 'ner' not in nlp.pipe_names:\n",
    "  ner = nlp.create_pipe('ner')\n",
    "  nlp.add_pipe(ner)\n",
    "else:\n",
    "  ner = nlp.get_pipe(\"ner\")"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "G5MUzq9vycub"
   },
   "source": [
    "## Add entity labels to the NER pipeline"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {
    "id": "tBclPKiZsFDa"
   },
   "outputs": [],
   "source": [
    "for i in LABELS:\n",
    "  ner.add_label(i)"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "ydz7fbGXymCq"
   },
   "source": [
    "### Disable other pipelines in SpaCy to only train NER"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "metadata": {
    "id": "lHVf7SV7sV6H"
   },
   "outputs": [],
   "source": [
    "other_pipes = [pipe for pipe in nlp.pipe_names if pipe != 'ner']"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "biR9mpXWyo_0"
   },
   "source": [
    "### Define classifications metrics"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "metadata": {
    "id": "75LEAOaowb7x"
   },
   "outputs": [],
   "source": [
    "def calc_precision(pred, true):        \n",
    "    precision = len([x for x in pred if x in true]) / (len(pred) + 1e-20) # true positives / total pred\n",
    "    return precision\n",
    "\n",
    "def calc_recall(pred, true):\n",
    "    recall = len([x for x in true if x in pred]) / (len(true) + 1e-20)    # true positives / total test\n",
    "    return recall\n",
    "\n",
    "def calc_f1(precision, recall):\n",
    "    f1 = 2 * ((precision * recall) / (precision + recall + 1e-20))\n",
    "    return f1"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {
    "id": "x93u-WHay6bY"
   },
   "source": [
    "## defien evaluations function"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {
    "id": "MVJCtOafwlin"
   },
   "outputs": [],
   "source": [
    "def evaluate(ner, data ):\n",
    "    preds = [ner(x[0]) for x in data]\n",
    "\n",
    "    precisions, recalls, f1s = [], [], []\n",
    "\n",
    "    # iterate over predictions and test data and calculate precision, recall, and F1-score\n",
    "    for pred, true in zip(preds, data):\n",
    "        true = [x[2] for x in list(chain.from_iterable(true[1].values()))] \n",
    "        pred = [i.label_ for i in pred.ents] \n",
    "        precision = calc_precision(true, pred)\n",
    "        precisions.append(precision)\n",
    "        recall = calc_recall(true, pred)\n",
    "        recalls.append(recall)\n",
    "        f1s.append(calc_f1(precision, recall))\n",
    "    return {\"textcat_p\": np.mean(precisions), \"textcat_r\": np.mean(recalls), \"textcat_f\":np.mean(f1s)}"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {
    "id": "QptmEBeRvHsy"
   },
   "outputs": [],
   "source": [
    "iterations=10\n",
    "dropout=0.5\n",
    "display_freq = 1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 18,
   "metadata": {
    "id": "pSdcSQbJ1HVa"
   },
   "outputs": [],
   "source": [
    "valid_f1scores=[]\n",
    "test_f1scores=[]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 19,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/"
    },
    "id": "tNRfB2X5uqub",
    "outputId": "a8d6d42e-75d2-44f2-86fe-a6010d2f0855"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "=======================================\n",
      "Interation = 0\n",
      "Losses = {'ner': 52590.538776397705}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.0\n",
      "Precision = 0.0\n",
      "Recall = 0.0\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.0\n",
      "Precision = 0.0\n",
      "Recall = 0.0\n",
      "=======================================\n",
      "=======================================\n",
      "Interation = 1\n",
      "Losses = {'ner': 46975.105504989624}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.0\n",
      "Precision = 0.0\n",
      "Recall = 0.0\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.0\n",
      "Precision = 0.0\n",
      "Recall = 0.0\n",
      "=======================================\n",
      "=======================================\n",
      "Interation = 2\n",
      "Losses = {'ner': 46992.34825515747}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.051324055061840075\n",
      "Precision = 0.041738370207425574\n",
      "Recall = 0.07296416938110749\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.04375026470667812\n",
      "Precision = 0.03587319905053895\n",
      "Recall = 0.06192821956368754\n",
      "=======================================\n",
      "=======================================\n",
      "Interation = 3\n",
      "Losses = {'ner': 47732.297996520996}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.5907367802940711\n",
      "Precision = 0.5620224646125203\n",
      "Recall = 0.6669807662478672\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.6016855820261665\n",
      "Precision = 0.5746273704401783\n",
      "Recall = 0.6724900304949566\n",
      "=======================================\n",
      "=======================================\n",
      "Interation = 4\n",
      "Losses = {'ner': 47224.904485702515}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.6851531561091823\n",
      "Precision = 0.6686284147608156\n",
      "Recall = 0.7422033503955328\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.6982112363932332\n",
      "Precision = 0.6800290646877557\n",
      "Recall = 0.7501642036124795\n",
      "=======================================\n",
      "=======================================\n",
      "Interation = 5\n",
      "Losses = {'ner': 46696.523138046265}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.823041262393054\n",
      "Precision = 0.8139498471429372\n",
      "Recall = 0.8724181789979835\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.8468148094953989\n",
      "Precision = 0.8369685205716169\n",
      "Recall = 0.8885057471264367\n",
      "=======================================\n",
      "=======================================\n",
      "Interation = 6\n",
      "Losses = {'ner': 46636.37218666077}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.8313796337574839\n",
      "Precision = 0.8372123029494627\n",
      "Recall = 0.8586505351326198\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.8441239892905041\n",
      "Precision = 0.85063776144881\n",
      "Recall = 0.8651673313003363\n",
      "=======================================\n",
      "=======================================\n",
      "Interation = 7\n",
      "Losses = {'ner': 46046.60256576538}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.8359510702833178\n",
      "Precision = 0.8367237388534067\n",
      "Recall = 0.868710252830774\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.8499770940792177\n",
      "Precision = 0.8494867738798071\n",
      "Recall = 0.879064039408867\n",
      "=======================================\n",
      "=======================================\n",
      "Interation = 8\n",
      "Losses = {'ner': 45806.653036117554}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.8558472435996867\n",
      "Precision = 0.8587511703965501\n",
      "Recall = 0.8826306809368699\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.8596678617133351\n",
      "Precision = 0.8626616649048037\n",
      "Recall = 0.8837513823263295\n",
      "=======================================\n",
      "=======================================\n",
      "Interation = 9\n",
      "Losses = {'ner': 45506.24810218811}\n",
      "===============VALID DATA========================\n",
      "F1-score = 0.8794484382365203\n",
      "Precision = 0.8841976312827503\n",
      "Recall = 0.9042041518018715\n",
      "===============TEST DATA========================\n",
      "F1-score = 0.8795580016773666\n",
      "Precision = 0.8857835162726084\n",
      "Recall = 0.8998215542374586\n",
      "=======================================\n"
     ]
    }
   ],
   "source": [
    "with nlp.disable_pipes(*other_pipes):\n",
    "#nlp.vocab.vectors.name = 'spacy_model' # without this, spaCy throws an \"unnamed\" error\n",
    "    optimizer = nlp.begin_training()\n",
    "    for itr in range(iterations):\n",
    "      random.shuffle(TRAIN_DATA) # shuffle the training data before each iteration\n",
    "      losses = {}\n",
    "      batches = minibatch(TRAIN_DATA, size = compounding(16.0, 64.0, 1.5))\n",
    "      for batch in batches:\n",
    "        texts, annotations = zip(*batch)\n",
    "        nlp.update(texts,annotations,drop = dropout,sgd = optimizer,losses = losses)\n",
    "        scores = evaluate(nlp,VALID_DATA)\n",
    "      print('=======================================')\n",
    "      print('Interation = '+str (itr))\n",
    "      print('Losses = '+str (losses))\n",
    "      print('===============VALID DATA========================')\n",
    "            \n",
    "      print('F1-score = '+str(scores[\"textcat_f\"]))\n",
    "      print('Precision = '+str(scores[\"textcat_p\"]))\n",
    "      print('Recall = '+str(scores[\"textcat_r\"]))\n",
    "      scores = evaluate(nlp,TEST_DATA)\n",
    "      test_f1scores.append(scores[\"textcat_f\"])\n",
    "      print('===============TEST DATA========================')\n",
    "      print('F1-score = '+str(scores[\"textcat_f\"]))\n",
    "      print('Precision = '+str(scores[\"textcat_p\"]))\n",
    "      print('Recall = '+str(scores[\"textcat_r\"]))\n",
    "      print('=======================================')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {
    "id": "d8IwWtaPNaua"
   },
   "outputs": [],
   "source": [
    "nlp.to_disk(\"spacy_example\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {
    "id": "mq3hS9bWLqL9"
   },
   "outputs": [],
   "source": [
    "def load_model(model_path):\n",
    "    ''' Loads a pre-trained model for prediction on new test sentences\n",
    "   \n",
    "    model_path : directory of model saved by spacy.to_disk\n",
    "    '''\n",
    "    nlp = spacy.blank('en')\n",
    "    if 'ner' not in nlp.pipe_names:\n",
    "        ner = nlp.create_pipe('ner')\n",
    "        nlp.add_pipe(ner)\n",
    "    ner = nlp.from_disk(model_path)\n",
    "    return ner"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {
    "id": "Qk4tsSiFNp0v"
   },
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 1000
    },
    "id": "FIDGzxnBNHD4",
    "outputId": "44324d9c-a8f2-4693-8f01-f90eb703409a"
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "pointes 11 18 B_Disease\n",
      "ventricular 19 30 I_Disease\n",
      "tachycardia 31 42 I_Disease\n",
      "dilated 111 118 B_Disease\n",
      "cardiomyopathy 119 133 I_Disease\n",
      "congestive 138 148 B_Disease\n",
      "heart 149 154 I_Disease\n",
      "failure 155 162 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Torsade de \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pointes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ventricular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tachycardia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " during low dose intermittent dobutamine treatment in a patient with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dilated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiomyopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    congestive\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    heart\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "heart 79 84 B_Disease\n",
      "failure 85 92 I_Disease\n",
      "dilated 106 113 B_Disease\n",
      "cardiomyopathy 114 128 I_Disease\n",
      "ventricular 156 167 B_Disease\n",
      "arrhythmias 168 179 I_Disease\n",
      "pointes 225 232 B_Disease\n",
      "ventricular 233 244 I_Disease\n",
      "tachycardia 245 256 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The authors describe the case of a 56 - year - old woman with chronic , severe \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    heart\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    failure\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " secondary to \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dilated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiomyopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " and absence of significant \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ventricular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    arrhythmias\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " who developed QT prolongation and torsade de \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pointes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ventricular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tachycardia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " during one cycle of intermittent low dose ( 2 . 5 mcg / kg per min ) dobutamine .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "pointes 26 33 B_Disease\n",
      "ventricular 34 45 I_Disease\n",
      "tachycardia 46 57 I_Disease\n",
      "fatal 132 137 B_Disease\n",
      "arrhythmias 138 149 I_Disease\n",
      "disturbances 234 246 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">This report of torsade de \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pointes\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ventricular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    tachycardia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " during intermittent dobutamine supports the hypothesis that unpredictable \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fatal\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    arrhythmias\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " may occur even with low doses and in patients with no history of significant rhythm \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disturbances\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "dyspnea 109 116 B_Disease\n",
      "loss 119 123 B_Disease\n",
      "consciousness 127 140 B_Disease\n",
      "papular 163 170 B_Disease\n",
      "rash 171 175 I_Disease\n",
      "pain 268 272 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">After angiography by the venous route in patient n degree 1 a biphasic reaction with an immediate reaction ( \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dyspnea\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " , \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    loss\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    consciousness\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " ) and delayed macro - \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    papular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rash\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " appeared , whilst patient n degree 2 developed a generalised sensation of heat , persistent \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    pain\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " at the site of injection immediately and a generalised macro - papular reaction after 24 hours .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "allergy 94 101 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The positive skin tests are in favour of immunological reactions and may help in diagnosis of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    allergy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " in the patients .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hyperammonemic 18 32 B_Disease\n",
      "encephalopathy 33 47 I_Disease\n",
      "cancer 51 57 B_Disease\n",
      "dehydration 145 156 B_Disease\n",
      "infection 161 170 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Risk of transient \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperammonemic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    encephalopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " patients who received continuous infusion of 5 - fluorouracil with the complication of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dehydration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "cancer 23 29 B_Disease\n",
      "hyperammonemic 72 86 B_Disease\n",
      "encephalopathy 87 101 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">From 1986 to 1998 , 29 \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cancer\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " patients who had 32 episodes of transient \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperammonemic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    encephalopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " related to continuous infusion of 5 - fluorouracil ( 5 - FU ) were identified .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "decompensated 25 38 B_Disease\n",
      "liver 39 44 I_Disease\n",
      "disease 45 52 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">None of the patients had \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    decompensated\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    liver\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hyperammonemic 9 23 B_Disease\n",
      "encephalopathy 24 38 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Onset of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperammonemic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    encephalopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " varied from 0 . 5 to 5 days ( mean : 2 . 6 + / - 1 . 3 days ) after the initiation of chemotherapy .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "azotemia 59 67 B_Disease\n",
      "bacterial 98 107 B_Disease\n",
      "infections 108 118 I_Disease\n",
      "infection 143 152 B_Disease\n",
      "dehydration 180 191 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Among the 32 episodes , 26 ( 81 % ) had various degrees of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    azotemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " , 18 ( 56 % ) occurred during \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bacterial\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    infections\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " and 14 ( 44 % ) without \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    infection\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " occurred during periods of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dehydration\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hyperammonemia 54 68 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Higher plasma ammonium levels and more rapid onset of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperammonemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " were seen in 18 patients with bacterial infections ( p = 0 . 003 and 0 . 0006 , respectively ) and in nine patients receiving high daily doses ( 2600 or 1800 mg / m2 ) of 5 - FU ( p = 0 . 0001 and &lt; 0 . 0001 , respectively ) .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hyperammonemic 16 30 B_Disease\n",
      "encephalopathy 31 45 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In conclusion , \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperammonemic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    encephalopathy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " can occur in patients receiving continuous infusion of 5 - FU .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Azotemia 0 8 B_Disease\n",
      "fluid 16 21 B_Disease\n",
      "insufficiency 22 35 I_Disease\n",
      "bacterial 40 49 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Azotemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " , body \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    fluid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    insufficiency\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    bacterial\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " infections were frequently found in these patients .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hypoactivity 138 150 B_Disease\n",
      "hyperactivity 228 241 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">In the motor activity test measured with an Animex - activity meter neither of the K ( + ) - channel blockers affected morphine - induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypoactivity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " , but both K ( + ) - channel blockers prevented morphine - induced secondary \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperactivity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hypoactivity 137 149 B_Disease\n",
      "hyperactivity 177 190 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">It is also suggested that the blockade of K ( + ) - channels sensitive to these blockers is not sufficient to prevent morphine - induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypoactivity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " whereas morphine - induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperactivity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " seems to be connected to both quinine - and 4 - aminopyridine - sensitive K ( + ) - channels .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "memory 56 62 B_Disease\n",
      "impairment 63 73 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Nociceptin / orphanin FQ and nocistatin on learning and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    memory\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    impairment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " induced by scopolamine in mice .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "hyperalgesia 136 148 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">On the other hand , nocistatin is recently isolated from the same precursor as nociceptin and blocks nociceptin - induced allodynia and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hyperalgesia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "impairment 109 119 B_Disease\n",
      "memory 136 142 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The present study was designed to investigate whether nociceptin / orphanin FQ and nocistatin could modulate \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    impairment\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " of learning and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    memory\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " induced by scopolamine , a muscarinic cholinergic receptor antagonist , using spontaneous alternation of Y - maze and step - down type passive avoidance tasks in mice .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "liver 20 25 B_Disease\n",
      "toxicity 26 34 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Meloxicam - induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    liver\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    toxicity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "rheumatoid 44 54 B_Disease\n",
      "arthritis 55 64 I_Disease\n",
      "cytolytic 85 94 B_Disease\n",
      "hepatitis 95 104 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We report the case of a female patient with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    rheumatoid\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    arthritis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " who developed acute \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cytolytic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hepatitis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " due to meloxicam .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "acute 4 9 B_Disease\n",
      "cytolytic 10 19 I_Disease\n",
      "hepatitis 20 29 I_Disease\n",
      "hypersensitivity 157 173 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    acute\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cytolytic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hepatitis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " occurred rapidly after meloxicam administration and was associated with the development of antinuclear antibodies suggesting a \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypersensitivity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " mechanism .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "liver 37 42 B_Disease\n",
      "toxicity 43 51 I_Disease\n",
      "hepatic 102 109 B_Disease\n",
      "damage 110 116 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">This first case of meloxicam related \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    liver\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    toxicity\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " demonstrates the potential of this drug to induce \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hepatic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    damage\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "HL60 53 57 B_Disease\n",
      "CD34 62 66 B_Disease\n",
      "marrow 89 95 I_Disease\n",
      "aplastic 160 168 B_Disease\n",
      "anemia 169 175 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Induction of apoptosis by remoxipride metabolites in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    HL60\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    CD34\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " + / CD19 - human bone \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    marrow\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " progenitor cells : potential relevance to remoxipride - induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aplastic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "antipsychotic 4 17 B_Disease\n",
      "aplastic 182 190 B_Disease\n",
      "anemia 191 197 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">The \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    antipsychotic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " agent , remoxipride [ ( S ) - ( - ) - 3 - bromo - N - [ ( 1 - ethyl - 2 - pyrrolidinyl ) methyl ] - 2 , 6 - dimethoxybenz amide ] has been associated with acquired \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aplastic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "necrosis 3 11 B_Disease\n",
      "necrosis 155 163 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">No \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    necrosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " was observed in cells treated with NCQ436 but NCQ344 had a biphasic effect in both cell types , inducing apoptosis at lower concentrations and \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    necrosis\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " at higher concentrations .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "aplastic 51 59 B_Disease\n",
      "anemia 60 66 I_Disease\n",
      "aplastic 242 250 B_Disease\n",
      "anemia 251 257 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">We propose that remoxipride and benzene may induce \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aplastic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " via production of similar reactive metabolites and that the ability of NCQ436 and NCQ344 to induce apoptosis in HBMP cells may contribute to the mechanism underlying acquired \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    aplastic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    anemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " that has been associated with remoxipride .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "catalepsy 31 40 B_Disease\n",
      "atypical 79 87 B_Disease\n",
      "antipsychotic 88 101 I_Disease\n",
      "nature 102 108 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">7e exhibits a high reversal of \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    catalepsy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " induced by haloperidol indicating its \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    atypical\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    antipsychotic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    nature\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "catalepsy 84 93 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Sub - chronic inhibition of nitric - oxide synthesis modifies haloperidol - induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    catalepsy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " and the number of NADPH - diaphorase neurons in mice .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "catalepsy 112 121 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">RATIONALE : NG - nitro - L - arginine ( L - NOARG ) , an inhibitor of nitric - oxide synthase ( NOS ) , induces \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    catalepsy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " in mice .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Neuroleptic 0 11 B_Disease\n",
      "catalepsy 84 93 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Neuroleptic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " drugs such as haloperidol , which block dopamine receptors , also cause \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    catalepsy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " in rodents .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "catalepsy 99 108 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">OBJECTIVES : To investigate the effects of subchronic L - NOARG treatment in haloperidol - induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    catalepsy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " and the number of NOS neurons in areas related to motor control .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Catalepsy 0 9 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">\n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Catalepsy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " was evaluated at the beginning and the end of the treatments .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "catalepsy 110 119 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">RESULTS : L - NOARG sub - chronic administration produced tolerance of L - NOARG and of haloperidol - induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    catalepsy\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ventricular 15 26 B_Disease\n",
      "dysfunction 27 38 I_Disease\n",
      "coronary 63 71 B_Disease\n",
      "artery 72 78 I_Disease\n",
      "disease 79 86 I_Disease\n",
      "myocardial 130 140 B_Disease\n",
      "ischaemia 141 150 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Prolonged left \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ventricular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dysfunction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " occurs in patients with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    artery\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " after both dobutamine and exercise induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    myocardial\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ischaemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ventricular 95 106 B_Disease\n",
      "dysfunction 107 118 I_Disease\n",
      "coronary 136 144 B_Disease\n",
      "artery 145 151 I_Disease\n",
      "disease 152 159 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">OBJECTIVE : To determine whether pharmacological stress leads to prolonged but reversible left \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ventricular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dysfunction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " in patients with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    artery\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " , similar to that seen after exercise .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ventricular 86 97 B_Disease\n",
      "ischaemia 145 154 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">DESIGN : A randomised crossover study of recovery time of systolic and diastolic left \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ventricular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " function after exercise and dobutamine induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ischaemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "angina 35 41 B_Disease\n",
      "coronary 68 76 B_Disease\n",
      "artery 77 83 I_Disease\n",
      "disease 84 91 I_Disease\n",
      "ventricular 110 121 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">SUBJECTS : 10 patients with stable \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    angina\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " , angiographically proven \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    artery\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " , and normal left \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ventricular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " function .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ST 72 74 B_Disease\n",
      "depression 75 85 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">There was no difference in the maximum double product ( p = 0 . 53 ) or \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ST\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    depression\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " ( p = 0 . 63 ) with either form of stress .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "coronary 31 39 B_Disease\n",
      "artery 40 46 I_Disease\n",
      "disease 47 54 I_Disease\n",
      "ischaemia 76 85 B_Disease\n",
      "ventricular 123 134 B_Disease\n",
      "dysfunction 135 146 I_Disease\n",
      "myocardial 164 174 B_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">CONCLUSIONS : In patients with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    artery\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " , dobutamine induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ischaemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " results in prolonged reversible left \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ventricular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    dysfunction\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " , presumed to be \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    myocardial\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " stunning , similar to that seen after exercise .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "ischaemia 19 28 B_Disease\n",
      "coronary 126 134 B_Disease\n",
      "artery 135 141 I_Disease\n",
      "disease 142 149 I_Disease\n"
     ]
    },
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Dobutamine induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    ischaemia\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " could therefore be used to study the pathophysiology of this phenomenon further in patients with \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    coronary\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    artery\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " .</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "ner = load_model(\"spacy_example\")\n",
    "\n",
    "\n",
    "\n",
    "test_sentences = [x[0] for x in TEST_DATA[0:40]] # extract the sentences from [sentence, entity]\n",
    "for x in test_sentences:\n",
    "    doc = ner(x)\n",
    "    for ent in doc.ents:\n",
    "        print(ent.text, ent.start_char, ent.end_char, ent.label_)\n",
    "    displacy.render(doc,jupyter=True, style = \"ent\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {
    "colab": {
     "base_uri": "https://localhost:8080/",
     "height": 174
    },
    "id": "H41yAHP4NP1t",
    "outputId": "7df0b563-e758-4cf8-ea3c-46cd031dfac6"
   },
   "outputs": [
    {
     "data": {
      "text/html": [
       "<span class=\"tex2jax_ignore\"><div class=\"entities\" style=\"line-height: 2.5; direction: ltr\">Selegiline - induced \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    postural\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypotension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " in \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    Parkinson\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    '\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    s\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    disease\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       " : a longitudinal study on the effects of drug withdrawal.The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    cardiovascular\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    orthostatic\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">B_Disease</span>\n",
       "</mark>\n",
       " \n",
       "<mark class=\"entity\" style=\"background: #ddd; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;\">\n",
       "    hypotension\n",
       "    <span style=\"font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; text-transform: uppercase; vertical-align: middle; margin-left: 0.5rem\">I_Disease</span>\n",
       "</mark>\n",
       "</div></span>"
      ],
      "text/plain": [
       "<IPython.core.display.HTML object>"
      ]
     },
     "metadata": {
      "tags": []
     },
     "output_type": "display_data"
    }
   ],
   "source": [
    "ner = load_model(\"spacy_example\")\n",
    "doc = ner(\"Selegiline - induced postural hypotension in Parkinson ' s disease : a longitudinal study on the effects of drug withdrawal.The aims of this study were to confirm our previous findings in a separate cohort of patients and to determine the time course of the cardiovascular consequences of stopping selegiline in the expectation that this might shed light on the mechanisms by which the drug causes orthostatic hypotension\")\n",
    "displacy.render(doc,jupyter=True, style = \"ent\")"
   ]
  }
 ],
 "metadata": {
  "accelerator": "GPU",
  "colab": {
   "collapsed_sections": [],
   "name": "Custom Named Entity Recognition model with spaCy.ipynb",
   "provenance": []
  },
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.8"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 1
}
